<SEC-DOCUMENT>0001144204-13-012065.txt : 20130228
<SEC-HEADER>0001144204-13-012065.hdr.sgml : 20130228
<ACCEPTANCE-DATETIME>20130228163207
ACCESSION NUMBER:		0001144204-13-012065
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		21
CONFORMED PERIOD OF REPORT:	20121231
FILED AS OF DATE:		20130228
DATE AS OF CHANGE:		20130228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		13652605

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>v334254_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;<B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 10-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR ANNUAL AND TRANSITION REPORTS PURSUANT
TO SECTIONS 13 OR 15(d) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(Mark One) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 30.6pt"><FONT STYLE="font-family: Wingdings"><B>x</B></FONT></TD><TD><B>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt"><B>For the fiscal year ended December&nbsp;31, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OR </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 30.6pt"><FONT STYLE="font-family: Wingdings; color: black"><B>&uml;</B></FONT></TD><TD><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt"><B>For the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
to <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>001-33357 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Commission file number) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>PROTALIX
BIOTHERAPEUTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 47%; font-weight: bold; text-align: center">Florida</TD>
    <TD STYLE="width: 6%; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 47%; border-bottom: windowtext 1pt solid; font-weight: bold; text-align: center">65-0643773</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>State or other jurisdiction</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of incorporation or organization</B></P></TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(I.R.S. Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2 Snunit Street</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Science Park</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POB 455</B></P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: windowtext 1pt solid; font-weight: bold; text-align: center"><B>Carmiel, Israel</B></TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: windowtext 1pt solid; font-weight: bold; text-decoration: underline; text-align: center"><B><U>20100</U></B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Address of principal executive offices)</B></FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>972-4-988-9488</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities registered pursuant to Section&nbsp;12(b)
of the Act: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center"><B>Title of each class</B></TD>
    <TD STYLE="font-weight: bold; text-align: center"><B>Name of each exchange on which registered</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center"><B>Common stock, par value $0.001 per share</B></TD>
    <TD STYLE="font-weight: bold; text-align: center"><B>NYSE MKT</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities registered pursuant to Section&nbsp;12(g)
of the Act: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>None</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Indicate by check mark if the registrant
is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings; color: black">&uml;</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Indicate by check mark if the registrant
is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Act.&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings; color: black">&uml;</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Indicate by check mark whether the registrant
(1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject
to such filing requirements for the past 90 days.&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings; color: black">&uml;</FONT>&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt"><FONT STYLE="color: black">Indicate by
check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such
shorter period that the registrant was required to submit and post such files). </FONT>&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings; color: black">&uml;</FONT>&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Indicate by check mark if disclosure of
delinquent filers pursuant to Item&nbsp;405 of Regulation S-K is not contained herein, and will not be contained, to the best of
registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form
10-K or any amendment to this Form&nbsp;10-K.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings; color: black">&thorn;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt"><FONT STYLE="color: black">Indicate by
check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. </FONT>See definition of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting
company&rdquo; in Rule 12b-2 of the Exchange Act.&nbsp;&nbsp;(check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; text-indent: 0in">Large accelerated filer</TD>
    <TD STYLE="width: 5%; text-indent: 0in; font-family: Wingdings"><FONT STYLE="font-family: Wingdings; color: black">&uml;</FONT></TD>
    <TD STYLE="width: 35%; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 20%; text-indent: 0in">Accelerated filer</TD>
    <TD STYLE="width: 25%; text-indent: 0in; font-family: Wingdings"><FONT STYLE="font-family: Wingdings; color: black">x</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">Non-accelerated filer</TD>
    <TD STYLE="text-indent: 0in; font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="text-indent: 0in">(Do not check if a smaller reporting company)</TD>
    <TD STYLE="text-indent: 0in">Smaller reporting company</TD>
    <TD STYLE="text-indent: 0in; font-family: Wingdings"><FONT STYLE="font-family: Wingdings; color: black">&uml;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings; color: black">&uml;</FONT>&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">The aggregate market value of the voting
common equity held by non-affiliates of the Registrant, as of June 29, 2012 was approximately $359 million (based upon a per share
price equal to $5.73, the closing price for shares of the Registrant&rsquo;s common stock reported by the NYSE MKT for such date).
Shares of common stock held by each officer, director and holder of 5% or more of the outstanding common stock have been excluded
in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination
for other purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">On February 15, 2013, approximately 93,497,809
shares of the Registrant&rsquo;s common stock, par value $0.001 per share, were outstanding.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 10-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; text-decoration: none">
    <TD STYLE="width: 10%; font-weight: bold; text-align: right; padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD STYLE="width: 83%; font-weight: bold; text-align: right; padding-bottom: 1pt; text-decoration: none">&nbsp;</TD>
    <TD STYLE="width: 7%; font-weight: bold; text-decoration: none; text-align: right; border-bottom: Black 1pt solid">Page</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">PART I</TD>
    <TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD COLSPAN="2">Cautionary Statement Regarding Forward-Looking Statements</TD>
    <TD STYLE="text-align: right">1</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Item 1.</TD>
    <TD>Business</TD>
    <TD STYLE="text-align: right">3</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>Item 1A.</TD>
    <TD>Risk Factors</TD>
    <TD STYLE="text-align: right">32</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Item 1B.</TD>
    <TD>Unresolved Staff Comments</TD>
    <TD STYLE="text-align: right">52</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>Item 2.</TD>
    <TD>Properties</TD>
    <TD STYLE="text-align: right">52</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Item 3.</TD>
    <TD>Legal Proceedings</TD>
    <TD STYLE="text-align: right">52</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>Item 4.</TD>
    <TD>Mine Safety Disclosures</TD>
    <TD STYLE="text-align: right">52</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">PART II</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>Item 5.</TD>
    <TD>Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</TD>
    <TD STYLE="text-align: right">53</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Item 6.</TD>
    <TD>Selected Financial Data</TD>
    <TD STYLE="text-align: right">55</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>Item 7.</TD>
    <TD>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</TD>
    <TD STYLE="text-align: right">56</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Item 7A.</TD>
    <TD>Quantitative and Qualitative Disclosures About Market Risk</TD>
    <TD STYLE="text-align: right">65</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>Item 8.</TD>
    <TD>Financial Statements and Supplementary Data</TD>
    <TD STYLE="text-align: right">65</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Item 9.</TD>
    <TD>Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</TD>
    <TD STYLE="text-align: right">65</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>Item 9A.</TD>
    <TD>Controls and Procedures</TD>
    <TD STYLE="text-align: right">65</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Item 9B.</TD>
    <TD>Other Information</TD>
    <TD STYLE="text-align: right">67</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">PART III</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Item 10.</TD>
    <TD>Directors, Executive Officers and Corporate Governance</TD>
    <TD STYLE="text-align: right">68</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>Item 11.</TD>
    <TD>Executive Compensation</TD>
    <TD STYLE="text-align: right">71</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Item 12.</TD>
    <TD>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</TD>
    <TD STYLE="text-align: right">81</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>Item 13.</TD>
    <TD>Certain Relationships and Related Transactions, and Director Independence</TD>
    <TD STYLE="text-align: right">83</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Item 14.</TD>
    <TD>Principal Accountant Fees and Services</TD>
    <TD STYLE="text-align: right">85</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">PART IV</TD>
    <TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>Item 15.</TD>
    <TD>Exhibits and Financial Statement Schedules</TD>
    <TD STYLE="text-align: right">86</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Signatures</TD>
    <TD STYLE="text-align: right">90</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Except where the context otherwise requires, the terms, &ldquo;we,&rdquo;
&ldquo;us,&rdquo; &ldquo;our&rdquo; or &ldquo;the Company,&rdquo; refer to the business of Protalix BioTherapeutics, Inc. and its
consolidated subsidiaries, and &ldquo;Protalix&rdquo; or &ldquo;Protalix Ltd.&rdquo; refers to the business of Protalix Ltd., our
wholly-owned subsidiary and sole operating unit.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The statements set forth under the captions &ldquo;Business,&rdquo;
&ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and &ldquo;Risk Factors,&rdquo;
and other statements included elsewhere in this Annual Report on Form 10-K, which are not historical, constitute &ldquo;forward-looking
statements&rdquo; within the meanings of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section
21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including statements regarding expectations, beliefs,
intentions or strategies for the future. When used in this report, the terms &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;expect&rdquo; and &ldquo;intend&rdquo; and words or phrases of similar import, as they relate to our company or our subsidiaries
or our management, are intended to identify forward-looking statements. We intend that all forward-looking statements be subject
to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only
predictions and reflect our views as of the date they are made with respect to future events and financial performance, and we
undertake no obligation to update or revise, nor do we have a policy of updating or revising, any forward-looking statement to
reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events,
except as may be required under applicable law. Forward-looking statements are subject to many risks and uncertainties that could
cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Examples of the risks and uncertainties include, but are not
limited to, the following:</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to the commercialization efforts for taliglucerase alfa
in the United States and Israel;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the risk of significant delays in the commercial introduction of taliglucerase
alfa in the United States, Israel and other markets as planned;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to enter into supply arrangements with the Brazilian Ministry
of Health or other parties and to supply drug product pursuant to such arrangements;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the risk that we will not be able to develop a successful sales and
marketing organization for taliglucerase alfa in Israel or for any other product candidate in a timely manner, if at all;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">risks related to the acceptance and use of taliglucerase alfa or any
of our product candidates, if approved, by physicians, patients and third-party payors;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">delays in the approval or the potential rejection of any application
filed with or submitted to the regulatory authorities reviewing taliglucerase alfa outside of the United States and Israel;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to establish and maintain strategic license, collaboration
and distribution arrangements, and to manage our relationships with Pfizer Inc., or Pfizer, or any other collaborator, distributor
or partner;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">risks relating to our ability to finance our research programs, the
expansion of our manufacturing capabilities and the ongoing costs in the case of delays in regulatory approvals for taliglucerase
alfa outside of the United States and Israel;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">delays in our preparation and filing of applications for regulatory
approval of our other product candidates in the United States, the European Union and elsewhere;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the risk that products that are competitive to our product candidates
may be granted orphan drug status in certain territories and, therefore, will be subject to potential marketing and commercialization
restrictions;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the impact of development of competing therapies and/or technologies
by other companies; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any lack of progress of our research and development activities and
our clinical activities with respect to any product candidate;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the inherent risks and uncertainties in developing the types of drug
platforms and products we are developing;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">potential product liability risks, and risks of securing adequate
levels of product liability and clinical trial insurance coverage;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the possibility of infringing a third party&rsquo;s patents or other
intellectual property rights;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the uncertainty of obtaining patents covering our products and processes
and in successfully enforcing our intellectual property rights against third parties;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to biosimilar legislation and/or healthcare reform in the United States or elsewhere;<FONT STYLE="font-family: Times New Roman, Times, Serif">
and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the possible disruption of our operations due to terrorist activities
and armed conflict, including as a result of the disruption of the operations of regulatory authorities, our subsidiaries, our
manufacturing facilities and our customers, suppliers, distributors, collaborative partners, licensees and clinical trial sites.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Companies in the pharmaceutical and biotechnology industries
have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results
or preliminary findings for such clinical trials. Even if favorable testing data is generated from clinical trials of a drug product,
the U.S. Food and Drug Administration or foreign regulatory authorities may not accept or approve a marketing application filed
by a pharmaceutical or biotechnology company for the drug product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: yellow"></FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item1.&#9;&nbsp;Business </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a biopharmaceutical company focused on the development
and commercialization of recombinant therapeutic proteins based on our proprietary ProCellEx<SUP>&reg;</SUP> protein expression
system, or ProCellEx. Using our ProCellEx system, we are developing a pipeline of proprietary and biosimilar versions of recombinant
therapeutic proteins based on our plant cell-based expression technology that primarily target large, established pharmaceutical
markets and that rely upon known biological mechanisms of action. Our initial commercial focus has been on complex therapeutic
proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. We believe ProCellEx
will enable us to develop proprietary recombinant proteins that are therapeutically equivalent or superior to existing recombinant
proteins currently marketed for the same indications. Because we are primarily targeting biologically equivalent versions of highly
active, well-tolerated and commercially successful therapeutic proteins, we believe our development process is associated with
relatively less risk compared to other biopharmaceutical development processes for completely novel therapeutic proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes our current product and product
candidates and their respective stages of development as of December 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><img src="tpg06.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 1, 2012, the U.S. Food and Drug Administration, or the
FDA, approved for sale our first commercial product, taliglucerase alfa for injection, which is being marketed under the brand
name ELELYSO&trade;, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis
of type 1 Gaucher disease. The Israeli Ministry of Health, or the Israeli MOH, approved taliglucerase alfa in September 2012, and,
in November 2012, taliglucerase alfa was approved in Uruguay. Taliglucerase alfa is our proprietary, recombinant form of glucocerebrosidase
(GCD) that is produced or expressed through ProCellEx. Taliglucerase alfa is the first plant cell-based recombinant therapeutic
protein to be approved by each of the FDA and the Israeli MOH, or by the regulatory agencies with jurisdiction over any substantial
market. Gaucher disease is a rare and serious lysosomal storage disorder with severe and debilitating symptoms. Gaucher patients
suffer from mutations in or deficiencies of GCD, an enzyme that is naturally found in human cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Since May 2012, taliglucerase alfa has been marketed in the
United States by Pfizer, our commercialization partner, as provided in the exclusive license and supply agreement by and between
Protalix Ltd., our wholly-owned subsidiary, and Pfizer, which we refer to as the Pfizer Agreement. We granted Pfizer an exclusive,
worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel.
We have agreed to a specific allocation between Protalix Ltd. and Pfizer of the responsibilities for the continued development
efforts for taliglucerase alfa outside of Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are cooperating with Pfizer to obtain marketing approval
for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed
with <FONT STYLE="font-family: Times New Roman, Times, Serif">the National Sanitary Vigilance Agency, or ANVISA, an agency of the
Brazilian Ministry of Health</FONT>, or the Brazilian MOH, as well as in other countries. In November 2012, we announced that the
European Commission issued a Commission Decision refusing the marketing authorization for taliglucerase alfa in the European Union.
This decision is an endorsement of the European Medicines Agency's, or the EMA&rsquo;s, Committee for Medicinal Products for Human
Use (CHMP) June 2012 opinion recommending against the marketing authorization of taliglucerase alfa. While the CHMP gave a positive
risk-benefit assessment for taliglucerase alfa, its recommendation was based solely on the orphan market exclusivity granted to
VPRIV<SUP>&reg;</SUP>, Shire plc's, or Shire's, Gaucher disease treatment. It was not based on the safety and efficacy profile
of taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">In December 2012, we entered into
a Clinical Development Agreement with </FONT>Pfizer under which we will continue to manage, administer and sponsor current, ongoing
clinical trials relating to ELELYSO. We are currently sponsoring adult and pediatric extension studies of ELELYSO. New clinical
trials for ELELYSO<SUP> </SUP>will be conducted and sponsored by Pfizer. Under the terms of the agreement, we were eligible to
receive a milestone payment of $8.3 million upon the achievement of certain near-term clinical development milestones. The milestones
were achieved prior to the end of fiscal year 2012 and the $8.3 million milestone payment has been paid in full. This agreement
helps to maintain the continuity of the ongoing clinical trials for Gaucher patients and physicians and reinforces the companies&rsquo;
mutual commitment to the Gaucher community.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We performed a number of studies on taliglucerase alfa to supplement
the pivotal phase III clinical trial which we completed in September 2009. We initiated a double-blind, follow-on extension study
in 2008 which consisted of eligible patients who had completed nine months of treatment in the pivotal phase III clinical trial.
The patients were offered the opportunity to continue to receive taliglucerase alfa at the same dose they received in the pivotal
trial for an additional 15 months in a blinded manner. We also conducted a nine-month, worldwide, multi-center, open-label, switch-over
clinical study evaluating the safety and efficacy of switching Gaucher patients currently treated with Cerezyme<SUP>&reg;</SUP>,
which is produced by Genzyme Corporation, or Genzyme (A Sanofi-Aventis company), with taliglucerase alfa which was successfully
completed in 2011. We also conducted a 12-month clinical trial of na&iuml;ve and switchover pediatric patients which was successfully
completed in 2012. Patients in the extension trials are still being treated with taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Currently, patients are being treated with ELELYSO on a commercial
basis in the United States and in Israel. Globally, patients are being treated through our extension trials and related studies,
compassionate use programs, special access agreements, named patient provisions and other programs designed to ensure that treatments
are available to Gaucher patients in light of recent shortages of approved treatments. In France, Gaucher patients are being treated
with taliglucerase alfa through an Autorisation Temporaire d'Utilisation (ATU), or Temporary Authorization for Use, a regulatory
mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when
a genuine public health need exists. In addition to the United States and France, taliglucerase alfa is currently being provided
to Gaucher patients under special access agreements or named patient provisions in Brazil and in other countries. Hundreds of patients,
in the aggregate, have been treated with taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 10, 2010, Pfizer entered into a $30 million short-term
supply agreement with the Brazilian MOH pursuant to which Protalix and Pfizer have provided taliglucerase alfa to the Brazilian
MOH for the treatment of Gaucher patients. During the remainder of 2010 and the first quarter of 2011, we and Pfizer completed
the supply of products deliverable under the short-term supply agreement. During 2011, the Brazilian MOH requested that Pfizer
consider the replacement of certain vials that might expire during 2012. During the third quarter of 2012, we and Pfizer resupplied
a portion of the returned vials. In addition, we and the Brazilian MOH are in discussions relating to a possible long-term supply
agreement that contemplates, among other matters, providing certain components of our manufacturing technology to the Brazilian
MOH for implementation by it in Brazil. We are currently unable to assess whether these discussions will result in an agreement
and we can make no assurance that we will be able to enter into such an agreement on favorable terms, if at all. In any event,
we do not expect to supply the Brazilian MOH taliglucerase alfa until ANVISA grants marketing approval to taliglucerase alfa, if
at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to taliglucerase alfa, we are developing an innovative
product pipeline using our ProCellEx protein expression system. Our product pipeline currently includes, among other candidates:
(1) PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder in humans,
currently in a phase I/II clinical trial; (2) PRX-105, a plant cell expressed pegylated recombinant acetylcholinesterase product
candidate for biodefense and other indications, which was the subject to a completed a phase I clinical trial; (3) an orally-administered
glucocerebrosidase enzyme for the treatment of Gaucher patients utilizing oral delivery of the recombinant GCD enzyme produced
within carrot cells, for which we have performed animal studies and applied for approval to initiate a phase I clinical study;
(4) PRX-106, or pr-antiTNF, a plant cell expressed recombinant fusion protein made from the soluble form of the human TNF receptor
(TNFR) and an antibody portion, which is being developed as a treatment of certain immune diseases such as rheumatoid arthritis,
Chrohn's disease, placque psoriasis and other autoimmune disorders, for which we have performed animal studies; and (5) two additional
undisclosed therapeutic proteins, both of which are being evaluated in animal studies. We participated in a pre-investigational
new drug, or IND, meeting with respect to one of the undisclosed product candidates in the first quarter of 2012 and a pre-IND
meeting for the second candidate is planned for 2013. In March 2010, we initiated a preliminary phase I clinical trial of PRX-105
which we completed in June 2010. In our preclinical studies we utilized an analogue to nerve gas. However, we anticipate that we
will use live nerve gas rather than an analogue in the proposed additional efficacy trials in animals. In December 2012, the first
patient was treated in our phase I/II clinical study of PRX-102 in Fabry patients. We anticipate commencing a clinical trial in
the first half of 2013 in Gaucher patients designed to demonstrate safety and achieve the first ever proof in concept regarding
orally-administrated glucocerebrosidase enzyme. In December 2011, we held a pre-IND meeting with respect to PRX-106 and we expect
to submit an IND during 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except for the rights to commercialize taliglucerase alfa worldwide
(other than Israel) which we licensed to Pfizer, we hold the worldwide commercialization rights to our proprietary development
candidates. We have built an internal marketing team designed to serve the Israeli market for taliglucerase alfa and we intend
to establish internal commercialization and marketing teams for our other product candidates in North America, the European Union
and in other significant markets, including Israel, subject to required marketing approvals, as the need arises. In addition, we
continuously evaluate potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical
companies and academic research institutes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Industry Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Recombinant proteins have revolutionized the treatment of a
variety of diseases and disorders. Recombinant proteins are forms of human proteins that are produced, or expressed, using a mammalian,
plant, bacterial or yeast cell as a production engine. In the early 1970s, a number of key scientific breakthroughs, including,
among others, the demonstration of genetic engineering and genetic sequencing techniques, as well as the synthesis of genes, led
to the advancement of recombinant protein technology. As a result, the market for pharmaceutical therapeutics has undergone a transformation
as recombinant proteins and other biologic products have become an increasingly significant portion of the global drug market and
the focus of research worldwide. The IMS Institute for Healthcare Informatics reports that global biologic spending was $157 billion
in 2010 (<FONT STYLE="font-family: Times New Roman, Times, Serif">Report by the IMS Institute for Healthcare Informatics</FONT>,
July 2012).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mammalian cell-based systems are the current industry standard
for expression of recombinant therapeutic glycoproteins (complex proteins that contain sugar residues), including catalytic enzymes
and monoclonal antibodies. Mammalian cell-based systems were first introduced in the late 1980s and are currently used to produce
many of the biotechnology industry&rsquo;s largest and most successful therapeutic proteins, including Epogen<SUP>&reg;</SUP>,
Neupogen<SUP>&reg;</SUP>, Cerezyme, Rituxan<SUP>&reg;</SUP>, Enbrel, Neulasta<SUP>&reg;</SUP>, Remicade and Herceptin<SUP>&reg;</SUP>.
Mammalian cell-based expression technology is based on the introduction of a human gene encoding for a specific therapeutic protein
into the genome of a mammalian cell. The cells most often used in connection with mammalian cell-based protein expression are Chinese
hamster ovary (CHO) cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mammalian cell-based expression systems have become the dominant
system for the expression of recombinant proteins due to their capacity for sophisticated, proper protein folding (which is necessary
for proteins to carry out their intended biological activity), assembly and post-expression modification, such as glycosilation
(the addition of sugar residues to a protein which is necessary to enable specific biological activity by the protein). While bacterial
and yeast cell-based expression systems were the first protein expression systems developed by the biotechnology industry and remain
cost-effective compared to mammalian cell-based production methodologies, proteins expressed in bacterial and yeast cell-based
systems lack the capacity for sophisticated protein folding, assembly and post-expression modifications, which are key factors
of mammalian cell-based systems. Accordingly, such systems cannot be used to produce glycoproteins or other complex proteins and,
therefore, bacterial and yeast cell-based systems are limited to the expression of the most basic, simple proteins, such as insulin
and growth hormones. Due to their significant advantages, mammalian cell-based expression systems can produce proteins with superior
quality and efficacy compared to proteins expressed in bacteria and yeast cell-based systems. As a result, the majority of currently
approved therapeutic proteins, as well as those under development, are produced in mammalian cell-based systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Despite the utility and widespread use of mammalian cell-based
systems, they are subject to a number of disadvantages. CHO cells and other mammalian cells are highly sensitive and can only be
grown under near perfect conditions, requiring highly complex, expensive, stainless steel bioreactors which tightly regulate the
required temperature, pH and oxygen levels. As a result, such bioreactor systems are very costly and complicated to operate. CHO
cells and other mammalian cells are also susceptible to viral infections, including human viruses, and several cases of viral contamination
have occurred recently. The FDA and other regulatory authorities require viral inactivation and other rigorous and detailed procedures
for mammalian cell-based manufacturing processes in order to address these potential hazards, thereby increasing the cost and time
demands of such expression systems. Furthermore, the current FDA and other procedures only ensure screening for scientifically
identified, known viruses. Accordingly, compliance with current FDA and other procedures does not fully guarantee that patients
are protected against transmission of unknown or new potentially fatal viruses that may infect mammalian cells. In addition, mammalian
cell-based expression systems require large quantities of sophisticated and expensive growth medium to accelerate the expression
process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Several companies and research institutions have explored alternatives
to mammalian cell-based production technologies that overcome some of these disadvantages, focusing primarily on the expression
of human proteins in genetically-modified organisms, or GMOs, such as transgenic field-grown, whole plants and transgenic animals.
However, these alternate techniques may be restricted by regulatory and environmental risks regarding contamination of agricultural
crops and by the difficulty in applying cGMP standards of the pharmaceutical industry to these expression technologies and none
of these technologies have been approved by the regulatory agencies with jurisdiction over any substantial market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ProCellEx: Our Proprietary Protein Expression System</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ProCellEx is our proprietary production system. We have developed
ProCellEx based on our plant cell culture technology for the development, expression and manufacture of recombinant proteins. ProCellEx
consists of a comprehensive set of capabilities and proprietary technologies, including advanced genetic engineering and plant
cell culture technology, which enables us to produce complex, proprietary and biologically equivalent proteins for a variety of
human diseases. This protein expression system facilitates the creation and selection of high expressing, genetically stable cell
lines capable of expressing recombinant proteins. The entire protein expression process, from initial nucleotide cloning to large-scale
production of the protein product, occurs under cGMP-compliant, controlled processes. Our plant cell culture technology uses plant
cells, such as carrot and tobacco cells, which undergo advanced genetic engineering and are grown on an industrial scale in a flexible
bioreactor system. Cell growth, from scale up through large-scale production, takes place in flexible, sterile, polyethylene bioreactors
which are confined to a clean-room environment. Our bioreactors are well-suited for plant cell growth using a simple, inexpensive,
chemically-defined growth medium as a catalyst for growth. The reactors are custom-designed and optimized for plant cell cultures,
easy to use, entail low initial capital investment, are rapidly scalable at a low cost and require less hands-on maintenance between
cycles. Our protein expression system does not involve mammalian or animal components or transgenic field-grown, whole plants at
any point in the production process. As a result, through our ProCellEx protein expression system, we believe that we can develop
recombinant therapeutic proteins yielding substantial cost advantages, accelerated development and other competitive benefits when
compared to mammalian cell-based protein expression systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our ProCellEx system is capable of producing proteins with an
amino acid sequence and three dimensional structure practically equivalent to that of the desired human protein, and with a very
similar, although not identical, glycan, or sugar, structure, as demonstrated in our internal research and external laboratory
studies. In collaboration with the Weizmann Institute of Science, we have demonstrated that the three-dimensional structure of
a protein expressed in our proprietary plant cell-based expression system retains the same three-dimensional structure as exhibited
by the mammalian cell-based expressed version of the same protein. In addition, proteins produced by our ProCellEx system maintain
the biological activity that characterize that of the naturally-produced proteins. Based on these results, we believe that proteins
developed using our ProCellEx protein expression system have the intended composition and correct biological activity of their
human equivalent proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that the ProCellEx system will enable us, in certain
cases, to develop and commercialize recombinant proteins without infringing upon the method-based patents or other intellectual
property rights of third parties. The major elements of our ProCellEx system are patent protected in most major countries. <FONT STYLE="color: black">Moreover,
we expect to enjoy method-based patent protection for the proteins we develop using our proprietary ProCellEx protein expression
technology, although there can be no assurance that any such patents will be granted. In some cases, we may be able to obtain patent
protection for the compositions of the proteins themselves. We have filed for United States and international composition of matter
patents for taliglucerase alfa.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have successfully demonstrated the feasibility of our ProCellEx
system through: the FDA&rsquo;s approval of taliglucerase alfa; the clinical and preclinical studies we have performed to date,
including the positive efficacy and safety data in our phase III study of taliglucerase alfa, our switchover study and our extension
study; preclinical results in well-known models in our enzyme for each of Fabry disease and pr-antiTNF; extensive animal studies
for our acetylcholinesterase and PRX 106 enzymes; and by expressing, on an exploratory, research scale, many additional complex
therapeutic proteins belonging to different drug classes, such as enzymes, hormones, monoclonal antibodies, cytokines and vaccines.
The therapeutic proteins we have expressed to date in research models have produced the intended composition and similar biological
activity compared to their respective human-equivalent proteins. Moreover, several of such proteins demonstrated advantageous biological
activity when compared to the biotherapeutics currently available in the market to treat the applicable disease or disorder. We
believe that the FDA&rsquo;s approval of taliglucerase alfa represents a strong proof-of-concept of our ProCellEx system and plant
cell-based protein expression technology. We also believe that the significant benefits of our ProCellEx system, if further substantiated
in clinical trials and in the successful commercialization of taliglucerase alfa and our other product candidates, have the potential
to transform the industry standard for the development of complex therapeutic proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, our manufacturing facility, in which we utilize
our ProCellEx system was determined to be acceptable by each of the FDA, EMA, ANVISA and the Israeli MOH,
and recently by the Australian Therapeutic Goods Administration, or the TGA, after GMP inspections were performed as part of their
respective reviews for marketing approval of taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Competitive Advantages of Our ProCellEx Protein Expression
System</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">We believe that our ProCellEx protein
expression system, including our </FONT>advanced genetic engineering technology and plant cell-based protein expression methods<FONT STYLE="color: black">,
affords us a number of significant advantages over mammalian, bacterial, yeast and transgenic cell-based expression technologies,
including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Ability to Penetrate Certain Patent-Protected
Markets.</I> </B>We seek to develop recombinant proteins that we believe we can produce and commercialize without infringing upon
the method-based patents or other intellectual property rights of third parties. <FONT STYLE="color: black">Certain biotherapeutic
proteins available for commercial sale are not protected by patents that cover the compound and are available for use in the public
domain. Rather, the process of expressing the protein product in mammalian or bacterial cell systems is protected by method-based
patents. Using our plant cell-based protein expression technology, we are able to express an equivalent protein without infringing
upon these method-based patents. Moreover, we expect to enjoy method-based patent protection for the proteins we develop using
our proprietary ProCellEx protein expression technology, although there can be no assurance that any such patents will be granted.
In some cases, we may be able to obtain patent protection for the compositions of the proteins themselves. We have filed for United
States and international composition of matter patents for taliglucerase alfa, PRX-102 and certain of our other product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Significantly Lower Capital and Production
Costs.</I></B> <FONT STYLE="color: black">Plant cells have a number of dynamic qualities that make them well-suited for the production
of therapeutic proteins. Plant cells grow rapidly under a variety of conditions and are not as sensitive to temperature, pH and
oxygen levels as are mammalian cells. Our ProCellEx system, therefore, requires significantly less upfront capital expenditures
as it does not use the highly complex, expensive, stainless steel bioreactors typically used in mammalian </FONT>cell-based<FONT STYLE="color: black">
production systems to maintain very specific temperature, pH and oxygen levels. Instead, we use simple polyethylene bioreactors
that can be maintained at the room temperature of the clean-room in which they are placed. This system also reduces ongoing production
and monitoring costs typically associated with mammalian cell-based expression technologies. Furthermore, while mammalian cell-based
systems require very costly growth media at various stages of the production process to achieve target yields of proteins, plant
cells require only simple and much less expensive solutions based on sugar, water and microelements at infrequent intervals to
achieve target yields. We believe that these factors will potentially result in lower capital and production costs for the commercial
scale production of proteins by our </FONT>ProCellEx<FONT STYLE="color: black"> system thereby providing us with a competitive
advantage over competing protein expression technologies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Elimination of the Risk of Viral Transmission
or Infection by Mammalian Components.</I> </B>By <FONT STYLE="color: black">nature, plant cells do not carry the risk of infection
by human or other animal viruses. As a result, the risk of contamination of our products under development and the potential risk
of viral transmission from our products and product candidates to future patients, whether from known or unknown mammalian viruses,
is eliminated. Because our products and product candidates do not bear the risk of mammalian viral transmission, we are not required
by the FDA or other regulatory authorities to perform the constant monitoring procedures for mammalian viruses during the protein
expression process that are required in mammalian cell-based production. In addition, t</FONT>he production process of our ProCellEx
system is void of any mammalian components which are susceptible to the transmission of prions, such as those related to bovine
spongiform encephalopathy (commonly known as &ldquo;mad-cow disease&rdquo;). <FONT STYLE="color: black">These factors further reduce
the risks and operating costs of our ProCellEx system compared to mammalian cell-based expression systems.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Efficient Production Relative to Mammalian
Based Systems.</I> </B><FONT STYLE="color: black">Our ProCellEx protein expression system produces enzymes which have uniform glycosilation
patterns and therefore do not require the lengthy and expensive post-expression modifications that are required for certain proteins
produced by mammalian cell-based systems, including the proteins for the treatment of Gaucher disease. Such post-expression modifications
in mammalian cell-produced proteins are made in order to expose the terminal mannose sugar residues, which are structures on a
protein that are key elements in allowing the expressed protein to bind to a target cell and subsequently be taken into the target
cell for therapeutic benefit. For example, in the production of Cerezyme, exposing these terminal mannose sugar residues involves
a multitude of highly technical steps which add time and cost to the production process. In addition, these steps do not guarantee
the exposure of all of the required terminal mannose sugar residues, resulting in potentially lower effective yields and inconsistency
in potency from batch to batch. Our ProCellEx protein expression system, by contrast, produces taliglucerase alfa in a &ldquo;ready
to use&rdquo; form that does not require additional glycosilation or other modifications to make taliglucerase alfa suitable for
use as an ERT for Gaucher disease. We believe this quality increases the potency and consistency of the expressed proteins, and
thus, the effectiveness of the protein which presents an additional cost advantage of ProCellEx over competing protein expression
methodologies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Broad Range of Expression Capabilities.</I></B>
<FONT STYLE="color: black">Our ProCellEx protein expression system is able to produce a broad array of complex glycosilated proteins,
which differentiates our system from bacterial and yeast cell-based systems which are unable to produce complex proteins. </FONT>We
have successfully demonstrated the feasibility of our ProCellEx system by producing, on an exploratory, research scale, a variety
of therapeutic proteins belonging to different classes of recombinant drugs, such as enzymes, hormones, monoclonal antibodies,
cytokines and vaccines. We have demonstrated that the recombinant proteins we have expressed<B> </B>to date have the intended composition
and correct biological activity of their human-equivalent protein, with several of such proteins demonstrating advantageous biological
activity compared to the currently available biotherapeutics. In specific cases, we have been successful in expressing proteins
that have not been successfully expressed in other production systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">Our goal is to become a leading fully
integrated biopharmaceutical company focused on the development and commercialization of proprietary </FONT>and biosimilar<FONT STYLE="color: black">
or generic versions of recombinant therapeutic proteins. </FONT> To achieve our goal, we intend to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Facilitate the successful development
and commercialization of ELELYSO by Pfizer.</B> We intend to work closely with our commercialization partner, Pfizer, to continue
to develop and to commercialize ELELYSO. Pfizer has taken an active, collaborative role in our ATU in France and similar programs
in Brazil and other countries. We have facilitated relationships between Pfizer and the Gaucher community and third-party payors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Obtain Regulatory Approval for ELEYSO
for the Treatment of Gaucher Disease.</B> ELELYSO has been approved for marketing in the United States, Israel and Uruguay. In
addition, Pfizer has submitted marketing applications to ANVISA and to the regulatory authorities of other countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Establish Development and
Commercialization Alliances with Corporate Partners.</B> We believe that our technology and know-how has broad applicability
to many classes of proteins and can be used to develop and potentially enhance numerous existing marketed protein
therapeutics. We continuously review a broad array of product partnering, technology sharing and other strategic alternatives
and expect that such transactions will facilitate the leveraging of our technology and know-how to optimize our resources and
effectively penetrate a wider range of target diseases and therapeutic markets. In November 2009, we entered into a license
and supply agreement with Pfizer for the development and commercialization of taliglucerase alfa. We entered into an
agreement with Teva Pharmaceutical Industries Ltd., or Teva, in September 2006 for the development of two proteins.
Although programs relating to two proteins to be developed under the agreement were terminated for commercial reasons in
2009, other elements of our collaboration are still ongoing and we are exploring other potential ways to collaborate. Last,
we are engaged in confidential discussions with a number of multinational pharmaceutical companies to discuss
additional potential collaboration arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Develop PRX-102 and Oral Glucocerebrosidase.</B>
In December 2012, the first patient was treated in our phase I/II clinical trial of Fabry patients with PRX-102. We anticipate
initiating a clinical trial in Gaucher patients during the first half of 2013 designed to demonstrate safety and achieve the first
ever proof in concept regarding our orally-administrated glucocerebrosidase enzyme.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Develop a Pipeline of Innovative and
Biosimilar Versions of Recombinant Therapeutic Proteins. </B>We are leveraging our ProCellEx protein expression system to develop
a pipeline of innovative or biosimilar versions of recombinant proteins, with an emphasis on therapeutic treatments with large
market opportunities. We select additional therapeutic candidates for development through in-house testing, licensing agreements
with academic institutions and collaborations with pharmaceutical partners. We have currently identified several product candidates
that are mainly oriented towards the specialty disease and therapeutic market segments, including PRX-102, our product candidate
for Fabry disease, our orally-administered glucocerebrosidase enzyme and an acetylcholinesterase enzyme based therapy for biodefense
and nerve gas toxicity treatments. We have also identified several other product candidates that are chemical equivalents of approved
therapeutic products that will no longer be patent protected within the next couple of years, such as pr-antiTNF, our proprietary
product candidate for the treatment of certain immune diseases such as rheumatoid arthritis, Chrohn's disease, placque psoriasis
and other autoimmune disorders. In addition, we have a number of other proteins in different stages of research and development
in our pipeline. We believe our cost-effective technology will be an important asset for the commercialization of such drug candidates.
We believe that the clinical and regulatory pathway for many of our pipeline product programs candidates is already established,
which may reduce the risks and costs associated with our clinical development programs. Furthermore, established markets already
exist for the development of most of our current product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Collaborate with Third Party Pharmaceutical
Companies and Build a Targeted Sales and Marketing Infrastructure.</B> We have licensed to Pfizer the right to commercialize ELELYSO
worldwide, except in Israel. We have built our own, internal marketing team designed to serve the Israeli market for ELELYSO and
we intend to establish similar sales and marketing capabilities for our other product candidates in North America, the European
Union and in other significant markets, including Israel. We believe that the focus of our current clinical pipeline mainly on
relatively rare genetic disorders with small patient populations and a highly concentrated group of physicians focused on treating
patients with such disorders will facilitate our creation of a targeted internal sales force. In addition we are continuously evaluating
potential strategic marketing partnerships with respect to our other product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Acquire or In-License New Technologies,
Products or Companies.</B> We continuously seek attractive product candidates and innovative technologies to in-license or acquire.
We intend to focus on product candidates that would be synergistic with our ProCellEx protein expression system and expertise and
that represent large potential market opportunities. We believe that by pursuing selective acquisitions of technologies in businesses
that complement our own, we will be able to enhance our competitiveness and strengthen our market position. We are evaluating several
such products, and we engaged in confidential discussions with a number of academic and medical institutes for these matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Leverage Strength and Experience of Our
Management Team and Board of Directors. </B>Our management team has extensive experience in the biotechnology and pharmaceutical
industry. Our director, Professor Roger D. Kornberg, who heads our Scientific Advisory Board, is a renowned biochemist and laureate
of the Nobel Prize in Chemistry. We intend to continue to leverage their experience and established track record as well as their
relationships across the biotechnology and pharmaceutical industries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ELELYSO, Our First Commercial Product</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ELELYSO (taliglucerase alfa), our first commercial product,
is a plant cell expressed recombinant glucocerebrosidase enzyme (GCD) for the treatment of Gaucher disease<FONT STYLE="color: black">.
</FONT>On May 1, 2012, the FDA approved ELELYSO for injection as an enzyme replacement therapy (ERT) for the long-term treatment
of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The Israeli MOH approved taliglucerase alfa in September
2012 and it has been approved in Uruguay as well. <FONT STYLE="font-family: Times New Roman, Times, Serif">Marketing applications
for taliglucerase alfa have also been submitted with ANVISA and comparable regulatory authorities of other countries.</FONT> On
November 1, 2012, we announced that the European Commission issued a Commission Decision refusing the Marketing Authorization for
taliglucerase alfa for the treatment of Gaucher disease. The decision was an endorsement of the EMA&rsquo;s Committee for Medicinal
Products for Human Use (CHMP) recommendation not to issue a Marketing Authorization for taliglucerase alfa in the European Union.
The CHMP recommendation was not related to the safety, quality or efficacy of taliglucerase alfa, but solely to the specific requirements
of the European Union (EU) Orphan Drug Regulation, specifically the orphan drug designation and exclusivity granted by the EMA/European
Commission to VPRIV.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">We believe that taliglucerase alfa
has the potential to offer patients and healthcare payors a more effective and cost efficient treatment of Gaucher disease compared
to the currently available ERTs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Although Gaucher disease is a relatively rare disease, it represents
a substantial commercial market due to the severity of the symptoms and the chronic nature of the disease. We believe that the
approval of taliglucerase alfa as a treatment for Gaucher disease with its potentially longer acting profile and more cost-effective
development process, may lead to an increase in the number of patients who will be able to have access to and afford such treatment,
thereby expanding the size of the market for Gaucher disease treatments.<FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Gaucher Disease Background</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">Gaucher disease</FONT>, a hereditary,
genetic disorder with severe and debilitating symptoms, <FONT STYLE="color: black">is the most prevalent lysosomal storage disorder
in humans. Lysosomal storage disorders are metabolic disorders in which a lysosomal enzyme, a protein that degrades cellular substrates
in the lysosomes of cells, is mutated or deficient. Lysosomes are small membrane-bound cellular structures within cells that contain
enzymes necessary for intracellular digestion. Gaucher disease is caused by mutations or deficiencies in the gene encoding GCD,
a lysosomal enzyme that catalyzes the degradation of the fatty substrate, glucosylceramide (GlcCer). The normal degradation products
of GlcCer are glucose and ceramide, which are easily excreted by the cells through normal biological processes. Patients with Gaucher
disease lack or otherwise have dysfunctional GCD and, accordingly, are not able to break down GlcCer. The absence of an active
GCD enzyme leads to the accumulation of GlcCer in lysosomes of certain white blood cells called macrophages. Macrophages affected
by the disease become highly enlarged due to the accumulation of GlcCer and are referred to as &ldquo;Gaucher cells.&rdquo; Gaucher
cells accumulate in the spleen, liver, lungs, bone marrow and brain. Signs and symptoms of Gaucher disease may include enlarged
liver and spleen, abnormally low levels of red blood cells and platelets and skeletal complications. In some cases, the patient
may suffer an impairment of the central nervous system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Current Treatments for Gaucher Disease</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The standard of care for Gaucher disease is enzyme replacement
therapy using recombinant GCD to replace the mutated or deficient natural GCD enzyme. It is estimated that there are approximately
12,000 people suffering from Gaucher disease worldwide, but only approximately 6,000 patients are undergoing treatment. <FONT STYLE="color: black">Enzyme
replacement therapy is a medical treatment in which recombinant enzymes are injected into patients in whom the enzyme is lacking
or dysfunctional. </FONT>Cerezyme and VPRIV, enzyme replacement therapies commercialized by Genzyme and Shire, respectively, are
the only recombinant GCDs currently available on the market for the treatment of Gaucher disease. As enzyme replacement therapy
does not cure the genetic disorder, but rather provides an external source for transfusion of the missing or mutated enzyme, Gaucher
patients generally receive the treatment over their entire lifetime. According to public reports by Sanofi, consolidated sales
of Cerezyme during the year ended December 31, 2012 were &euro;633 million (or approximately $834 million), a growth of approximately
6% compared to the same period in 2011. Shire reported annual worldwide sales of VPRIV of approximately $306.6 million in 2012,
a growth of 20% compared to VPRIV&rsquo;s sales in 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cerezyme is produced through a mammalian cell-based protein
expression process in CHO cells and VPRIV is produced using a human cancer cell line. There are no known severe side effects to
the use of Cerezyme or VPRIV, and Cerezyme's approved use over the past decade suggests that it is an effective treatment of Gaucher
disease. However, Cerezyme and VPRIV are both subject to the limitations of most mammalian cell-based therapeutic proteins, including
lengthy and costly production processes and contamination risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Zavesca (miglustat), which is marketed by Actelion Ltd., or
Actelion, is a small molecule drug for the treatment of Gaucher disease. Zavesca has been approved by the FDA for use in the United
States as an oral treatment. However, it has many side effects and the FDA has approved it only for administration to those patients
who cannot be treated through ERT, and, accordingly, have no other treatment alternative. As a result, Zavesca&rsquo;s use has
been limited. Actelion has reported sales of Zavesca of approximately CHF 84.7 million (approximately $91.8 million) in 2012, an
increase of 24% compared to sales in 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Taliglucerase Alfa Development Program</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">We completed a phase I clinical trial
in 2006 and, </FONT>after discussions with the FDA, we proceeded directly with a pivotal phase III clinical trial of taliglucerase
alfa without undergoing a phase II clinical trial. We reported positive top-line results of the phase III clinical trial in October
2009 and full study results in February 2010. This study was summarized in a publication in BLOOD, the Journal of the American
Hematological Society (Zimran, <U>et</U>. <U>al</U>., September 2011).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>Phase III Clinical Trial and Related Studies</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We initiated enrollment and treatment of naive patients in our
phase III clinical trial in 2007, after having reached an agreement with the FDA regarding the design of the study through the
FDA's special protocol assessment (SPA) process. Consistent with the SPA, the phase III clinical trial was a multi-center, world-wide,
randomized, double-blind, parallel group, dose-ranging study to assess the safety and efficacy of taliglucerase alfa in 31 treatment-naive
patients suffering from Gaucher disease. In the trial, patients were selected randomly for one of two dosing arms (60 U/kg or 30
U/kg) and received intravenous infusions of taliglucerase alfa once every two weeks for a nine-month period. The primary endpoint
of the study was a 20% mean reduction from baseline in spleen volume after nine months, as measured by MRI. Major secondary endpoints
were an increase in hemoglobin, decrease in liver volume and increase in platelet count. Patients enrolled in the trial were treated
in 11 selected leading medical centers throughout Europe, Israel, North America, South America and South Africa. Enrollment was
completed in the fourth quarter of 2008 and the trial was successfully completed in September 2009.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the third quarter of<FONT STYLE="color: black"> 2008</FONT>,
we initiated a double blind, follow-on extension study as part of our phase III clinical trial. <FONT STYLE="font-family: Times New Roman, Times, Serif">Eligible
patients who successfully completed nine months of treatment in our phase III clinical trial were offered the opportunity to participate
in the extension study and to continue to receive taliglucerase alfa at the same dose they received in the phase III clinical trial
for an additional 15 months in a blinded manner. Accordingly, the extension trial included two treatment groups; one treated with
a 60 U/kg dose and the other with a 30 U/kg dose. The major endpoints of the study were spleen volume, liver volume, hemoglobin
concentration, platelet count, and chitotriosidase activity. Twenty-six patients were originally enrolled in the extension trial
which was performed in centers throughout Europe, Israel, North America, South America and South Africa. Three of the 26 patients
enrolled in the extension trial discontinued treatment; one switched to our compassionate use program, one was unable to comply
with study protocol and one had a skin reaction during month 15. We also initiated a home care treatment program for patients enrolled
in the extension study. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, in the fourth quarter of 2008, we announced the
enrollment of the first patient in a worldwide, multi-center, open-label, switch-over trial to assess the safety and efficacy of
taliglucerase alfa. The switch-over trial, which was not a prerequisite for approval, was originally designed to include 15 Gaucher
patients that were currently undergoing ERT with imiglucerase (Cerezyme). Due to the shortage of Cerezyme in 2009, after fully
enrolling 15 patients, we extended the trial to include additional patients. A total of 26 adult patients were enrolled in the
switchover trial. Patients enrolled in the trial were switched from imiglucerase (doses ranging from approximately 10-60 U/kg every
other week) to an equivalent dose using the same number of units of taliglucerase alfa over a nine-month period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
2010 we initiated a clinical trial of na&iuml;ve pediatric patients which we completed in 2012. </FONT>Eleven treatment-naive patients
with symptoms and clinical manifestations of Gaucher disease between the ages of two and eighteen were enrolled in the trial. Patients
were randomized to receive two different doses in a blinded manner; five patients were treated with a 60 U/kg dose and six patients
were treated with a 30 U/kg dose. The primary endpoint of the study was change in hemoglobin concentration, and the secondary endpoints
were change of spleen volume, liver volume, platelet count and chitotriosidase activity. Patients were enrolled in clinics in Israel,
Paraguay, and South Africa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>Results of our Phase III Clinical Trial and
Extension Trial</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We reported positive top-line results of our phase III clinical
trial of taliglucerase alfa in October 2009 and full study results in February 2010.&nbsp; In the clinical trial, taliglucerase
alfa significantly reduced mean spleen volume after nine months compared with baseline in both treatment groups, thereby meeting
the trial's primary endpoint of reduced mean spleen volume after nine months.&nbsp; In February 2013, we announced interim data
from 23 adult patients enrolled in our extension trial.&nbsp; According to the interim data, after 36 months (nine months in the
phase III clinical trial and 27 months in the extension trial), patients continued to demonstrate a significant improvement in
all parameters with a similar safety profile as seen in the phase III clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the phase III clinical trial, the 60 U/kg group demonstrated
a statistically significant mean reduction in spleen volume of 38.0% (p&lt;0.0001) and the 30 U/kg group demonstrated a significant
mean reduction in spleen volume of 26.9% (p&lt;0.0001). In addition, the primary endpoint was achieved in both treatment groups
after only six months of therapy. Patients treated with taliglucerase alfa in the extension trial continued to demonstrate a statistically
significant reduction in mean spleen volume after 36 months, compared with baseline, in both treatment groups; reductions of 62.0%
in the 60 U/kg group and of 47.0% in the 30 U/kg group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Statistically significant improvements were also observed for
the secondary endpoints of the phase III clinical trial, including increase in hemoglobin level, decrease in liver size and increase
in platelet count, after nine months when compared to baseline for the 60 U/kg dose. These improvements continued in the extension
trial. Patients in both dosage groups demonstrated mean increases in hemoglobin from baseline; mean increases from 11.4 g/DL to
13.6 g/DL (p&lt;0.0001) (22.2%) in the 60 U/kg group and from 12.2 g/DL to 14.0 g/DL (p&lt;0.0010) (14.8%). In the extension trial,
at 36 months, clinically significant mean increases in hemoglobin concentration were also demonstrated by both groups; mean increases
from baseline, from 11.0 g/DL to 14.0 g/DL (27.3%), in the 60 U/kg group and mean increases from baseline, from 12.4 g/DL to 14.3
g/DL (15.3%), in the 30 U/kg group. Patients with anemia demonstrated a mean increase from baseline in hemoglobin concentration,
from 9.5 g/DL to 13.1 g/DL (37.9%); patients with normal hemoglobin show a mean increase of 10.3% in hemoglobin, from 13.6 g/DL
at baseline to 15.0 g/DL after 36 months of treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the phase III clinical trial, patients in both dosage groups
demonstrated mean decrease (reduction) in liver volume; reductions of 11.1% (p&lt;0.0001) in the 60 U/kg group and of 10.48% (p&lt;0.0041)
in the 30 U/kg group. In the extension trial, at 36 months, both groups demonstrated clinically significant mean reductions in
liver volume; reductions of 19.0% in the 60 U/kg group and of 21.0% in the 30 U/kg group; patients with Hepatomegaly demonstrated
a reduction in liver volume of 30.0% in the 60 U/kg group and of 22.0% in the 30 U/kg group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">In the phase III clinical trial,
patients in both dosage groups demonstrated mean increases in platelet count; an increase in platelet count of 41,494 ml or 72.1%
(p=0.0031) in the 60 U/kg group, and a nominal increase of 11,427 ml or 13.7% (p=0.0460) in the 30 U/kg group. Accordingly, the
lower dose group did not meet the secondary endpoint relating to platelet count. In the extension trial, at 36 months, both groups
demonstrated clinically significant mean increases in platelet count; increases from </FONT>73,055 <FONT STYLE="color: black">to
136,027 in the 60 U/kg group and from 64,900 to 94,683 in the 30 U/kg group.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Last, 30 patients in the phase III clinical trial had chitotriosidase
measurements, a biomarker of Gaucher disease. In these patients, chitotriosidase decreased from baseline in both the 30U/kg and
60U/kg groups by 47.3% and 58.4%, respectively. In the extension trial, at 36 months, mean reductions in chitotriosidase activity
were demonstrated by both groups; a reduction of 83.0% in the 60 U/kg group and of 73.5% in the 30 U/kg group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The safety analysis for both treatment groups in the phase
III clinical trial showed that taliglucerase alfa was well tolerated and no serious or severe adverse events were reported.&nbsp;
The safety analysis in the extension trial for both treatment groups at 36 months also demonstrates that taliglucerase alfa was
well tolerated, and no drug related serious adverse events were reported.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the phase III clinical trial, no serious related adverse
event was reported and most of the adverse events were considered unrelated to taliglucerase alfa. The most frequent mild to moderate
adverse event was headache. Other mild to moderate adverse events included dizziness, muscle spasm, chest discomfort, nausea, skin
irritation and arthalgia. Adverse events in the extension trial included headache, pruritus, hypersensitivity, abdominal pain,
fixed drug eruption, arthalgia and infusion related reactions (dizziness, chills, nausea).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>Results of Our Switchover Trial; Long Term Data</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In November 2010, we announced positive preliminary data from
the first 15 patients that completed our switchover trial of taliglucerase alfa, and in February 2012 we reported full results
from 25 adult patients in the trial. &nbsp;In February 2013, we announced interim results from an extension trial related to the
switchover trial at 36 months.&nbsp; The results of the first trial demonstrate that over a nine-month treatment period of the
study, patients remained stable with regard to all of the efficacy endpoints (hemoglobin concentration, platelet count, spleen
and liver volume) and chitotriosidase activity after switching to taliglucerase alfa from imiglucerase. The safety analysis presented
for the switchover trial demonstrates that taliglucerase alfa was well tolerated, and no drug related serious adverse events were
reported.&nbsp; Additionally, all drug-related adverse effects were mild or moderate and transient in nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nineteen of the 25 patients in the switchover trial elected
to continue to be treated in an extension trial for an additional 12 months.&nbsp; Five of the six patients that did not proceed
to the extension trial continued to be treated with taliglucerase alfa through our compassionate use program; one patient was unable
to comply with the extension study protocol and therefore was unable to participate. A 24-month interim analysis of the switchover
trial demonstrates that patients remained stable with regard to all of the efficacy endpoints and chitotriosidase activity after
switching to taliglucerase alfa from imiglucerase.&nbsp; The safety analysis presented for the extended switchover trial demonstrates
that taliglucerase alfa was well tolerated, and no drug related serious adverse events were reported.&nbsp; Four of the nineteen
patients enrolled in the extension trial discontinued treatment; one switched to our compassionate use program, one enrolled in
another clinical trial, one was unable to comply with study protocol and one was not pleased with that individual&rsquo;s personal
results.&nbsp; In conclusion, the data demonstrates that taliglucerase alfa has a well-established safety profile and is an effective
alternative treatment for adult Gaucher patients previously treated with imiglucerase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>Results of Our Pediatric Trial</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In July 2012, we announced data from our clinical trial of taliglucerase
alfa in pediatric Gaucher patients.&nbsp; After 12 months of treatment with taliglucerase alfa, changes in hemoglobin concentration
were demonstrated by both dosage groups, with increases of 15.8% in the 60 U/kg group and of 13.8% in the 30 U/kg group.&nbsp;
In addition, significant improvements were also seen in all secondary endpoints.&nbsp; Spleen volumes decreased by 41.1% in patients
receiving 60 U/kg, and by 28.6% in patients receiving 30 U/kg of taliglucerase alfa.&nbsp; Similarly, liver volumes decreased by
14.0% in the 60 U/kg group and 6.3% in the 30 U/kg group.&nbsp; Both treatment groups also demonstrated improvements in platelet
counts with a 73.7% increase from baseline in the 60 U/kg group, and a 30.9% increase from baseline in the 30 U/kg group.&nbsp;
Lastly, the chitotriosidase activity decreased from baseline, with a 66.0% reduction in patients receiving 60 U/kg and a 58.0%
reduction in patients receiving 30 U/kg.&nbsp; The majority of the treatment-related adverse events were mild or moderate in intensity,
and transient in nature.&nbsp; One severe adverse event was assessed as treatment-related; gastroenteritis. The event was reported
as serious due to the need for hospitalization for rehydration. This patient continues to receive taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>Long-Term Bone Marrow Responses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As bone disease is one of the most debilitating features of
Gaucher disease, quantification of bone marrow involvement is important for monitoring the response to treatment. Therefore, our
phase III clinical trial and the extension trial included bone marrow fat fraction (Ff) measured by quantitative chemical shift
imaging (QCSI) as an exploratory parameter to evaluate bone marrow response in eight treatment na&iuml;ve Gaucher patients with
intact spleens that participated in the trials. Ff results were compared to outcomes in 15 untreated Dutch Gaucher patients with
a follow-up interval of one year. Five taliglucerase alfa treated patients had a Ff below the threshold that relates to complication
risk (&lt;0.23) at baseline (median (n=8) 0.19, range 0.11&ndash;0.35). Ff significantly increased compared to baseline (p=0.012)
and compared to untreated patients (p=0.005), already after one year of follow-up with further improvement up to 36 months. In
four patients with the lowest Ff, the higher dose resulted in increases above 0.23 within one year. All eight patients had sustained
improvements in all other parameters. There was no influence of antibodies on response parameters. This data demonstrates that
treatment with taliglucerase alfa results in significant increases in lumbar spine fat fractions, which indicates clearance of
Gaucher cells from the bone marrow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Pipeline Drug Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>PRX-102 for the Treatment of Fabry Disease</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are developing PRX-102, our proprietary plant cell expressed
chemically modified version of the recombinant alpha-GAL-A protein, a therapeutic enzyme, for the treatment of Fabry disease, a
rare genetic lysosomal storage disorder. We believe that PRX-102 has the potential to be an improved version of the currently marketed
Fabry disease enzymes, Fabrazyme<SUP>&reg;</SUP> and Replagal<SUP>&reg;</SUP>, with improved activity in the Fabry disease target
organs and significantly longer half life due to higher stability, which together can potentially lead to improved substrate clearance.
We believe that the treatment of Fabry disease is a specialty clinical niche with the potential for high growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>Fabry Disease Background</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fabry disease, an X-linked deficiency of alpha-Galactosidase-A
(alpha-GAL-A), is a progressive lysosomal storage disease that is seriously debilitating and ultimately life-threatening. The disease
is characterized by subnormal or absent enzymatic activity of alpha-GAL-A, a lysosomal enzyme which primarily catalyses the hydrolysis
of terminal alpha-galactosyl groups of glycolipids, mainly the glycosphingolipid globotriaosylceramide (Gb3). The accumulation
of Gb3 in body tissues results in Fabry disease. The ultimate consequence of glycosphingolipid deposition in the vasculature and
other tissues is end-organ failure, particularly of the kidney, but also of the heart and cerebrovascular system. In addition,
involvement of the central, peripheral and autonomic nervous systems results in episodes of pain and impaired peripheral sensation.
Fabry disease affects approximately 8,000 people globally. In PRX-102, the prh-alpha-GALA, naturally occurring as a homodimer,
is PEGylated and cross-linked to support and reinforce the homodimeric structure, which is crucial for the enzymatic activity of
this enzyme. PRX-102 has been shown to be taken up by Fabry patients&rsquo; cells where it localizes to the lysosome, in which
Gb3 accumulates. PRX-102 is characterized by higher stability under physiologically relevant conditions, and extended circulation
residence time as compared to currently ERTs for Fabry disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>Current Treatments for Fabry Disease</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Currently there are two drugs available on the market to treat
Fabry disease. Fabrazyme, marketed by Genzyme, is approved for the treatment of Fabry disease in the United States and the European
Union. Sanofi reported &euro;292&nbsp;million (approximately $385 million) in worldwide sales of Fabrazyme in 2012, a growth of
96% compared to 2011. The other approved drug for the treatment of Fabry disease in the European Union is Replagal, which is marketed
by Shire. Shire reported $497.5 million in sales of Replagal in 2012, a growth of 5% compared to 2011. According to public reports
by Shire, during 2012 Shire withdrew its Biologics License Application (BLA) for Replagal with the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>PRX-102 Development Program</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PRX-102, our proprietary plant cell expressed chemically modified
version of the recombinant alpha-GAL-A protein, has demonstrated a significantly longer circular half-life than that of Replagal,
over 40 times greater. In preclinical tests, we compared enzymatic activity of both PRX-102 and Replagal in human plasma and found
that Replagal had a 13 minute half-life compared to a half-life of 581 minutes for PRX-102. See Figure 1.</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Figure 1. Enhanced Circulatory Half-Life</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><img src="tpg17.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the significantly greater half-life, our animal
studies of PRX-102 demonstrate that the enzyme exhibits higher activity levels in target organs over time in Fabry mice after a
single injection. See Figures 2 and 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; padding-left: 9pt; font-weight: bold"><B>Figure 2. Improved In-vivo Activity in Heart</B></TD>
    <TD STYLE="width: 55%; padding-left: 0.375in; font-weight: bold">&nbsp;&nbsp;<B>Figure 3. Improved In-vivo Activity in Kidney</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><img src="tpg17a.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In August 2012, we received clearance of the IND application
we submitted to the FDA to initiate clinical trials of PRX-102. In December 2012, the first patient was treated with PRX-102 in
our phase I/II clinical trial of Fabry patients. The phase I/II clinical trial is a worldwide, multi-center, open label, dose ranging
study to evaluate the safety, tolerability, pharmacokinetics and exploratory efficacy parameters of PRX-102 in adult Fabry patients.
The trial is designed to enroll 18 adult Fabry patients, each in one of three dosing groups. Each patient will receive intravenous
infusions of PRX-102 every two weeks for 12 weeks. After the completion of the protocol, we intend to offer enrolled trial patients
the option to continue to receive PRX-102 in an open-label extension study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on the pre IND meeting we held with the FDA in 2010, our
experience with taliglucerase alfa and the experience of other companies developing ERTs for Fabry disease, we have reason to believe
that, if favorable data is accumulated in our phase I/II clinical trial, the FDA may allow us to proceed directly with a pivotal
phase III clinical trial. However, there can be no assurance that we will successfully complete our phase I/II clinical trial and
if we do, that the trial will result in favorable data. In addition, there can be no assurance that the FDA will allow us to proceed
directly with a phase III clinical trial after completion of our phase I/II clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In pre-clinical studies, PRX-102 demonstrated preliminary efficacy
in a Fabry animal model. Chemical modifications made to PRX-102 improved the enzyme&rsquo;s activity and stability resulting in
prolonged activity profiles and enhanced bioavailability in animals. The modifications also have the potential to decrease the
immunogenicity of the enzyme, which is a major drawback of currently approved therapies for Fabry disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>PRX-112; Orally Administered GCD for the Treatment
of Gaucher Disease</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are developing PRX-112, an orally-delivered glucocerebrosidase
(GCD) enzyme for the potential treatment of Gaucher disease. This represents a new method for delivering active recombinant proteins
systemically through oral administration of transgenic plant cells expressing biotherapeutic proteins. Oral GCD is a plant cell-expressed
form of GCD that is naturally encapsulated within carrot cells genetically engineered to express the GCD enzyme. Plant cells have
the unique attribute of a cellulose cell wall which makes them resistant to enzyme degradation when passing through the digestive
tract. The plant cell itself serves as a delivery vehicle to transport the enzyme in active form to the bloodstream. If proven
effective, our experimental oral GCD would be the first protein to be administered orally rather than through intravenous therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that oral delivery of GCD presents a number of advantages.
First, oral GCD consists of the same transformed genetically modified carrot plant root cells expressing prGCD from which we derive
the active drug substance taliglucerase alfa. Therefore, it has the advantage of leveraging the well-characterized mechanism of
action of our intravenously-administered taliglucerase alfa product. In addition, we believe that oral delivery of GCD may dramatically
change the treatment paradigm for Gaucher patients, compared to the intravenous delivery of taliglucerase alfa, and contribute
to increased compliance and the facilitation of treatment management. Further, oral delivery of GCD targets the disease-specific
organs without the need for lifetime dependence on repeated intravenous infusions. Last, our oral ERT does not have the unpredictable
long term untoward effects of the inhibition of other non-disease-specific compounds that are common in oral substrate reduction
therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our oral taliglucerase alfa product candidate is a recombinant
form of the GCD enzyme, not a small molecule. This differentiates our oral product candidate from other clinical stage, experimental,
small molecule, oral drugs which are being developed for the treatment of Gaucher disease by Genzyme and Amicus Therapeutics, Inc.,
or Amicus Therapeutics. Small molecule based treatments for Gaucher disease, such as Zavesca, have different mechanisms of action
than those associated with ERT, and may be associated with a number of side effects. We have filed patent applications with respect
to this new protein delivery mechanism in countries with commercially significant markets. Currently, we are the exclusive owners
of all rights to this technology. We have applied to the Israeli regulatory health authorities for the performance of a phase I
clinical trial in Gaucher patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that our oral delivery mechanism could be applied
to additional proteins and has the potential to change the method of protein administration in certain indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>PRX-112 Development Program</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have performed rodent and large animal studies of oral GCD.
To test the enzymatic activity of oral GCD, we tested the enzyme by feeding rats and pigs lyophilized carrot cells expressing GCD.
The results of the study show that, based on preliminary PK data, we can detect the enzyme in the plasma of the animals and that
active enzyme is detected in the target organs; the spleen and liver, demonstrating the ability of a plant cell's cellulose wall
to protect the enzyme against degradation in the animal's digestive tract. In addition, data from large and small animals demonstrate
active absorbance of the protein in the plasma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Figure 4. Pharmacokinetic profile of Oral GCD following oral
administration, in pigs as compared to baseline sampling</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><img src="tpg19.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Figure 5 shows the percentage of prGCD activity in rat livers
in the study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Figure 5. prGCD in Target Organs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><img src="tpg19a.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We intend to initiate a phase I clinical trial of oral GCD in
Gaucher patients in two sites in Israel during the first half of 2013. This clinical trial is designed to test safety and would
include PK data. Oral delivery of drugs is preferred to any other manner of administration <FONT STYLE="font-family: Times New Roman, Times, Serif">and
represents a longstanding goal of pharmaceutical companies.</FONT> If successful, our clinical trial could serve as a proof of
concept for an oral delivery system for enzymes, a milestone that has yet to be successfully achieved in the market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>Other Drug Candidates in Our Pipeline</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are developing other innovative recombinant therapeutic proteins
to be expressed by our ProCellEx protein expression system, with an emphasis on treatments for which there are large, established
pharmaceutical markets and where our proprietary protein expression system enables us to develop and commercialize recombinant
proteins that are patent-protected and therapeutically equivalent or superior to the existing treatments. We select additional
therapeutic candidates for development by testing candidates in-house and through collaborations with academic partners. We have
identified several product candidates oriented towards specialty disease and therapeutic market segments, including: <FONT STYLE="font-family: Times New Roman, Times, Serif">(1)
PRX-105, a plant cell expressed pegylated recombinant acetylcholinesterase product candidate for biodefense and other indications;
(2) PRX-106, or pr-antiTNF, a plant cell expressed recombinant fusion protein made from the soluble form of the human TNF receptor
(TNFR) and an antibody portion, which is being developed as a treatment of certain immune diseases such as </FONT>rheumatoid arthritis,
Chrohn's disease, placque psoriasis and other autoimmune disorders<FONT STYLE="font-family: Times New Roman, Times, Serif">; and
(3) two additional undisclosed therapeutic proteins, both of which are being evaluated in animal studies. We participated in a
pre IND meeting with respect to one of the undisclosed product candidates in the first quarter of 2012 and a pre IND meeting for
the second candidate is planned for later this year. In March 2010, we initiated a preliminary phase I clinical trial of PRX-105
which we completed in June 2010. We are currently preparing for further efficacy trials of this product candidate in larger animals.
In our preclinical studies we utilized an analogue to nerve gas. However, we anticipate that we will use live nerve gas rather
than an analogue in the proposed additional efficacy trials in animals. In December 2011 we held a pre IND meeting with respect
to PRX 106 and we expect to submit an IND around the fourth quarter of 2012. </FONT>Last, we are conducting research programs in
the fields of enzymes, monoclonal antibodies, cytokines and vaccines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Acetylcholinesterase</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">In August 2007, Protalix Ltd. licensed
the rights to certain technology under a research and license agreement with Yissum Research and Development Company, or Yissum,
and the Boyce Thompson Institute, Inc., or Boyce Thompson. Pursuant to the agreement, we are developing PRX-105, a proprietary
plant cell-based acetylcholinesterase (AChE) and its molecular variants for the use in several therapeutic and prophylactic indications,
as well as in a biodefense program and an organophosphate-based pesticide treatment program. To date, our <I>in vitro</I> experiments
of PRX-105 have shown that the acetylcholinesterase enzyme expressed in our ProCellEx protein expression system demonstrates promising
biological activity on biochemical and cellular levels. In addition, early animal studies demonstrated that the acetylcholinesterase
expressed in our ProCellEx protein expression system was able to successfully treat animals exposed to the nerve gas agent analogues,
both when injected with our acetylcholinesterase product candidate immediately before exposure or when injected after exposure.
We filed an IND with the FDA for PRX-105, our plant cell expressed pegylated recombinant acetylcholinesterase enzyme (AChE) product
candidate, during the last quarter of 2009, and in March 2010 we initiated a preliminary phase I clinical trial of PRX-105. The
trial established the pharmacokinetics of PRX-105 and demonstrated that single dose intravenous administration of PRX-105 is safe
and well tolerated. We are currently preparing for further efficacy trials of PRX-105 in larger animals. <FONT STYLE="font-family: Times New Roman, Times, Serif">In
our preclinical studies we utilized an analogue to nerve gas. However, we anticipate that we will use live nerve gas in the proposed
additional efficacy trials in animals.</FONT> In March 2010 we initiated a preliminary phase I clinical trial of PRX-105 which
we completed in June 2010. <FONT STYLE="font-family: Times New Roman, Times, Serif">In December 2010, we held a pre-investigational
new drug, or IND, meeting with the FDA with respect to PRX-105. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Under the terms of the agreement, Yissum
and Boyce Thompson granted us an exclusive, worldwide right and license to certain technology, including patents and certain patent
applications relating to AChE for the therapeutic and prophylactic indications as well as an exclusive license not limited to such
indications <FONT STYLE="color: black">with respect to certain of those patents and patent applications. As consideration for the
license, we are obligated to pay Yissum and </FONT>Boyce Thompson, collectively,<FONT STYLE="color: black"> an annual, non-refundable
initial maintenance fee of $20,000, </FONT>commencing on the fourth anniversary of the execution of the agreement, which is subject
to a 12% annual increase.<FONT STYLE="color: black"> In addition, we are obligated to make royalty payments equal to varying low,
single-digit percentages of net sales of products under the agreement. These royalty rates are evaluated on a country-by-country
basis, and are subject to reduction if a third party commercializes a competing product or commercializes an authorized generic
version of the applicable product, subject to certain conditions. We also have the right to grant sublicenses relating to the licensed
technology under the agreement, subject to the payment of sublicensing fees. The fees payable in connection with any sublicense
are equal to varying percentages, in the low-teens through the low-twenties, of the consideration we receive in connection with
the sublicense, depending on the level of clinical development of the product at the time we enter into the sublicense. Last, we
are obligated to pay Yissum and </FONT>Boyce Thompson, collectively, milestone payments equal to $700,000, in the aggregate, upon
the achievement of certain milestones under the license agreement.<FONT STYLE="color: black"> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The license agreement remains in effect until the expiration
of all obligations to <FONT STYLE="color: black">Yissum and </FONT>Boyce Thompson under the agreement, determined on a country-by-country
basis. We have the right to terminate the agreement for any reason upon 60 days&rsquo; prior written notice to <FONT STYLE="color: black">Yissum
and </FONT>Boyce Thompson. Subject to certain conditions, <FONT STYLE="color: black">Yissum and </FONT>Boyce Thompson may terminate
the agreement immediately upon written notice to us in connection with certain events relating to bankruptcy, lapses in our insurance
coverage, failures to defend against third party claims or claims we may make regarding the validity or enforceability of any licensed
patent. We or <FONT STYLE="color: black">Yissum and </FONT>Boyce Thompson may terminate the agreement within 60 days after receiving
written notice if the non-terminating party passes a resolution for a voluntary wind up, if a receiver or liquidator is appointed
for the non-terminating party, or the non-terminating party enters into an insolvency or bankruptcy proceeding. In addition, either
party may terminate the agreement due to a material breach by the other party if the breaching party is unable to cure the breach
within 60 days after receiving written notice of the breach from the non-breaching party. Any termination of the agreement will
result in a loss of our rights to the licensed technology, which will revert back to <FONT STYLE="color: black">Yissum and </FONT>Boyce
Thompson.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are currently in discussions with different U.S. civil and
military organizations regarding certain grants for which our acetylcholinesterase program is eligible. We anticipate applying
for specific U.S. grants during 2013 to support the further development of our acetylcholinesterase program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, we are researching other indications for which
PRX-105 may serve as a therapy. A paper entitled: &quot;Adaptive Alternative Splicing Correlates with Less Environmental Risk
of Parkinsonism,&quot; has been published in the Journal of Neurodegenerative Diseases (Neurodegener Dis. 2012;9(2):87-98. Epub
2011 Oct 27). The research includes an investigation of the effect of PRX-105 on alternative splicing patterns in the striatum,
which may confer protection in Parkinson's disease. The research highlights that a splice shift, either inherited or induced by
environmental factors (e.g. neurotoxins), from the more common 'synaptic form' of acetylcholinesterase (AChE-S) to the monomeric
'read-through' variant of AChE (AChE-R), is important in conferring protection against Parkinson-like symptoms. Furthermore, according
to the article, intravenous injection with PRX-105 induced a protective gene expression profile in the striatum of the brain.
We recently filed a joint PCT patent application entitled: &quot;Methods for Treating or Preventing Parkinson's Disease,&quot;
with the Hebrew University. These filings are part of our continuing collaboration with Yissum. Through our agreement with Yissum,
we are collaborating with The Hebrew University and exploring additional indications where we believe AChE may be effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>pr-antiTNF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">pr-antiTNF is an antiTNF (Tumor, Necrosis Factor) protein that
we are expressing through our proprietary ProCellEx system. We have designed this antiTNF as pr-antiTNF. pr-antiTNF is a candidate
for the treatment of certain autoimmune diseases such as rheumatoid arthritis, Chrohn's disease, placque psoriasis and other autoimmune
disorders. Our pr-antiTNF product candidate has an amino acid sequence that is similar to Enbrel which is one of the treatments
for patients of those diseases. Amgen Inc. reported total sales of Enbrel of $4.2 billion in the United States and Canada for
2012 and Pfizer has reported total sales of Enbrel outside of the United States and Canada of $3.7 billion for 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">pr-antiTNF is a plant cell-expressed recombinant fusion protein
made from the soluble form of the human TNF receptor (TNFR), fused to the Fc component of a human antibody domain. pr-antiTNF
has an identical amino acid sequence to Enbrel and our in vitro and preclinical animal studies have demonstrated that pr-antiTNF
exhibits similar activity to Enbrel. Specifically, pr-antiTNF binds TNF thereby inhibiting it from binding to cellular surface
TNF receptors and protects L929 cells from TNF-induced apoptosis in a dose-dependent manner. In a proof-of-concept <I>in vivo
</I>study using an established arthritis animal model, pr-antiTNF, when injected in mice, significantly improved the clinical
arthritis parameters associated with this accepted arthritis mouse model, including joint inflammation, swelling and tissue degradation.
We intend to conduct additional animal studies to collect additional data to form a basis for a discussion with the FDA to explore
the regulatory pathway for our antiTNF program. We expect to use our cost effective manufacturing platform to facilitate entry
into this market upon approval of our pr-antiTNF product, if at all. <FONT STYLE="font-family: Times New Roman, Times, Serif">In
December 2011, we held a pre IND meeting with respect to </FONT>pr-antiTNF, <FONT STYLE="font-family: Times New Roman, Times, Serif">and
we expect to submit an IND during 2013.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Commercialization Agreement for <FONT STYLE="font-family: Times New Roman, Times, Serif">taliglucerase
alfa</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
November&nbsp;30, 2009, Protalix Ltd. and Pfizer entered into the Pfizer Agreement pursuant to which Pfizer was granted an exclusive,
worldwide license to develop and commercialize taliglucerase alfa. Under the terms and conditions of the Pfizer Agreement, Protalix
Ltd. retained the right to commercialize taliglucerase alfa in Israel. In connection with the execution of the Pfizer Agreement,
Pfizer made an upfront payment to Protalix Ltd. of $60.0 million in connection with the execution of the agreement and subsequently
paid Protalix Ltd. an additional $5.0 million upon our filing of a proposed pediatric investigation plan to the Pediatric Committee
of the EMA. Protalix Ltd. also received a milestone payment of $25.0 million in connection with the May 2012 approval of taliglucerase
alfa by the FDA. In addition to the milestone payments, Protalix Ltd. is eligible to payments equal to 40% of the net profits
earned by Pfizer on sales of taliglucerase alfa (or share 40% of the net loss). In calculating the net profits, there are certain
agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold. Protalix
Ltd. retained the manufacturing rights to taliglucerase alfa, and Pfizer and Protalix Ltd. agreed to a specific allocation of
the responsibilities for the continued development efforts for taliglucerase alfa prior to its approval. Protalix Ltd. will manufacture
all of the taliglucerase alfa needed for all purposes under the agreement and Pfizer will purchase the taliglucerase alfa from
Protalix Ltd., subject to certain terms and conditions. </FONT>The Pfizer Agreement also provides for reimbursement by Pfizer
of certain costs to be incurred by Protalix Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">In December 2012, we entered into
a clinical development agreement with </FONT>Pfizer pursuant to which Protalix will continue to manage, administer and sponsor
current, ongoing clinical trials relating to taliglucerase alfa. Protalix is currently sponsoring adult and pediatric extension
studies of taliglucerase alfa. New clinical trials for taliglucerase alfa<SUP> </SUP>will be conducted and sponsored by Pfizer.
Protalix Ltd. received a milestone payment of $8.3 million upon the achievement of certain near-term clinical development milestones
set forth in the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the upfront and milestone payments made
under the Pfizer Agreement, Protalix Ltd. has paid a sublicense fee equal to $2.3 million to the academic institution from who
it licensed certain technology relating to taliglucerase alfa. Any future regulatory approval milestone payment due under the
Pfizer Agreement, if at all, will be subject to a 2.5% royalty, and all other revenues generated under the agreement will be subject
to a 0.35% royalty payable to the same institution until 2016, when a patent related to taliglucerase alfa licensed to us will
expire. We are also required to pay a royalty ranging between 3.0% and 6.0% of the revenues of taliglucerase alfa Pfizer records
under the Pfizer Agreement to the OCS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
August 10, 2010, Pfizer entered into a $30.0 million short-term supply agreement with the Brazilian MOH pursuant to which Protalix
and Pfizer have provided taliglucerase alfa to the Brazilian MOH for the treatment of patients with Gaucher disease. </FONT>During
the remainder of 2010 and the first quarter of 2011, we and Pfizer completed the supply of products deliverable under the short-term
supply agreement. During 2011, Pfizer recorded an allowance for sales returns in connection with the supply agreement because
the Brazilian MOH requested that Pfizer consider the replacement of certain vials that might expire during 2012. Revenue, net
of allowance for sales returns, generated from the Brazilian MOH was recorded by Pfizer, and we recorded our share of such revenues
in accordance with the terms and conditions of the Pfizer Agreement. During the third quarter of 2012, we and Pfizer resupplied
a portion of the returned vials for which an allowance for return was made during 2011 and, as a result, Pfizer reversed the allowance
related to such resupplied vials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, we and the Brazilian MOH are in discussions relating
to a possible long-term supply agreement that contemplates, among other matters, providing certain components of our manufacturing
technology to the Brazilian MOH for implementation by it in Brazil. At this time, we are unable to assess whether these discussions
will result in an agreement and there can be no assurance that we will be able to enter into such an agreement on favorable terms,
if at all. In any event, we do not expect to enter into a long-term supply agreement with the Brazilian MOH until we receive marketing
approval of taliglucerase alfa from ANVISA, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will be subject to a withholding tax on the U.S. revenue
source portion of the payments made to us for our share of Pfizer&rsquo;s in net profits under the Pfizer Agreement. Currently,
the withholding tax rate is 15%.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Strategic Collaborations</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Teva Pharmaceutical Industries</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In September 2006, we entered into a Collaboration and Licensing
Agreement with Teva for the development and manufacture of two proteins to be identified by Teva and us using our ProCellEx protein
expression system. The agreement also identifies additional matters for collaboration between Teva and us. Subsequently, two proteins
were identified to be researched and developed under the agreement but in 2009, both of the projects were terminated for commercial
reasons. Pursuant to the agreement, we have agreed to collaborate on certain additional matters regarding proteins, including
the research and development of proteins utilizing our ProCellEx protein expression system. See &ldquo;Risk Factors&mdash;Our
strategy, in certain cases, is to enter into collaboration agreements with third parties to leverage our ProCellEx system to develop
product candidates. If we fail to enter into these agreements or if we or the third parties do not perform under such agreements
or terminate or elect to discontinue the collaboration, it could have a material adverse affect on our revenues.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We maintain a proactive intellectual property strategy which
includes patent filings in multiple jurisdictions, including the United States and other commercially significant markets. As
of December 31, 2012, we hold, or have license rights to 48 patents and 97 pending patent applications with respect to various
compositions, methods of production and methods of use relating to our ProCellEx protein expression system and our proprietary
product pipeline. As of December 31, 2012, we hold, with a third party, one joint patent and one joint patent application, and
licensed rights to five patents and six patent applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our competitive position and future success depend in part
on our ability, and that of our licensees, to obtain and leverage the intellectual property covering our product candidates, know-how,
methods, processes and other technologies, to protect our trade secrets, to prevent others from using our intellectual property
and to operate without infringing the intellectual property of third parties. We seek to protect our competitive position by filing
United States, European Union, Israeli and other foreign patent applications covering our technology, including both new technology
and improvements to existing technology. Our patent strategy includes obtaining patents, where possible, on methods of production,
compositions of matter and methods of use. We also rely on know-how, continuing technological innovation, licensing and partnership
opportunities to develop and maintain our competitive position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2012, our patent portfolio consists of several
patent families (consisting of patents and/or patent applications) covering our technology, protein expression methodologies and
system and product candidates, as follows:</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>With respect
                                                                                                                 to our ProCellEx
                                                                                                                 protein expression
                                                                                                                 system, we have
                                                                                                                 been issued,
                                                                                                                 and hold licensed
                                                                                                                 rights to, 18
                                                                                                                 patents in the
                                                                                                                 United States,
                                                                                                                 Australia, the
                                                                                                                 European Union,
                                                                                                                 Israel, Canada,
                                                                                                                 the Czech Republic,
                                                                                                                 Hungary, Japan,
                                                                                                                 Poland, Mexico,
                                                                                                                 Hong Kong and
                                                                                                                 India, and to
                                                                                                                 13 pending patent
                                                                                                                 applications.&nbsp;
                                                                                                                 Among other things,
                                                                                                                 the patents cover
                                                                                                                 the methods that
                                                                                                                 we use for culturing
                                                                                                                 and harvesting
                                                                                                                 plant cells and/or
                                                                                                                 tissues in consecutive
                                                                                                                 cycles. The 13
                                                                                                                 issued patents
                                                                                                                 in this patent
                                                                                                                 family are expected
                                                                                                                 to expire in
                                                                                                                 2017 and five
                                                                                                                 issued patents
                                                                                                                 in this patent
                                                                                                                 family are expected
                                                                                                                 to expire in
                                                                                                                 2025.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>With respect
                                                                                                                 to our ProCellEx
                                                                                                                 protein expression
                                                                                                                 system, we hold
                                                                                                                 two issued patents
                                                                                                                 and 13 patent
                                                                                                                 applications
                                                                                                                 relating to the
                                                                                                                 large scale production
                                                                                                                 of proteins in
                                                                                                                 cultured plant
                                                                                                                 cells. The issued
                                                                                                                 patents and any
                                                                                                                 patents to issue
                                                                                                                 in the future
                                                                                                                 based on pending
                                                                                                                 patent applications
                                                                                                                 in this patent
                                                                                                                 family are expected
                                                                                                                 to expire in
                                                                                                                 2028.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We hold a
                                                                                                                 patent family
                                                                                                                 containing 15
                                                                                                                 granted patents
                                                                                                                 in India, South
                                                                                                                 Africa, Russia,
                                                                                                                 Australia, China,
                                                                                                                 the United States,
                                                                                                                 Ukraine, Singapore,
                                                                                                                 Japan, Europe,
                                                                                                                 Hong Kong, Mexico,
                                                                                                                 and 26 patent
                                                                                                                 applications,
                                                                                                                 relating to the
                                                                                                                 production of
                                                                                                                 recombinant glycosylated
                                                                                                                 lysosomal proteins
                                                                                                                 in our plant
                                                                                                                 culture platform
                                                                                                                 including taliglucerase
                                                                                                                 alfa and uses
                                                                                                                 of these proteins
                                                                                                                 and of cells
                                                                                                                 containing these
                                                                                                                 proteins for
                                                                                                                 the treatment
                                                                                                                 of lysosomal
                                                                                                                 disorders. The
                                                                                                                 issued patents
                                                                                                                 and any patents
                                                                                                                 to issue in the
                                                                                                                 future based
                                                                                                                 on pending patent
                                                                                                                 applications
                                                                                                                 in this patent
                                                                                                                 family are expected
                                                                                                                 to expire in
                                                                                                                 2024 and 2028.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We hold a
                                                                                                                 patent family
                                                                                                                 containing four
                                                                                                                 granted patents
                                                                                                                 relating to a
                                                                                                                 system and method
                                                                                                                 for production
                                                                                                                 of antibodies
                                                                                                                 in a plant cell
                                                                                                                 culture, and
                                                                                                                 antibodies produced
                                                                                                                 in such a system.
                                                                                                                 The patents to
                                                                                                                 issue in the
                                                                                                                 future based
                                                                                                                 on the patent
                                                                                                                 applications
                                                                                                                 in this patent
                                                                                                                 family are expected
                                                                                                                 to expire in
                                                                                                                 2025.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We hold a
                                                                                                                 patent family
                                                                                                                 containing two
                                                                                                                 issued patent
                                                                                                                 in South Africa
                                                                                                                 and Singapore
                                                                                                                 and 13 pending
                                                                                                                 patent applications
                                                                                                                 relating to a
                                                                                                                 new method for
                                                                                                                 delivering active
                                                                                                                 recombinant proteins
                                                                                                                 systemically
                                                                                                                 through oral
                                                                                                                 administration
                                                                                                                 of transgenic
                                                                                                                 plant cells.
                                                                                                                 The issued patents
                                                                                                                 and any patents
                                                                                                                 to issue in the
                                                                                                                 future based
                                                                                                                 on patent applications
                                                                                                                 in this patent
                                                                                                                 family are expected
                                                                                                                 to expire in
                                                                                                                 2026.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We hold a
                                                                                                                 patent family
                                                                                                                 containing one
                                                                                                                 granted patent
                                                                                                                 in South Africa
                                                                                                                 and six pending
                                                                                                                 patent applications
                                                                                                                 relating to saccharide
                                                                                                                 containing protein
                                                                                                                 conjugates. The
                                                                                                                 patents to issue
                                                                                                                 in the future
                                                                                                                 based on the
                                                                                                                 patent applications
                                                                                                                 in this patent
                                                                                                                 family will expire
                                                                                                                 in 2028.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We hold a
                                                                                                                 patent family
                                                                                                                 containing one
                                                                                                                 pending patent
                                                                                                                 application relating
                                                                                                                 to Nucleic Acid
                                                                                                                 construct for
                                                                                                                 expression of
                                                                                                                 alpha-galactosidase
                                                                                                                 enzyme in plants
                                                                                                                 and plant cells.
                                                                                                                 The patents to
                                                                                                                 issue in the
                                                                                                                 future based
                                                                                                                 on the patent
                                                                                                                 applications
                                                                                                                 in this patent
                                                                                                                 family will expire
                                                                                                                 in 2031.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We hold a
                                                                                                                 patent family
                                                                                                                 containing two
                                                                                                                 pending patent
                                                                                                                 applications
                                                                                                                 relating to compositions
                                                                                                                 and methods for
                                                                                                                 treating Fabry
                                                                                                                 disease. The
                                                                                                                 patents to issue
                                                                                                                 in the future
                                                                                                                 based on the
                                                                                                                 patent applications
                                                                                                                 in this patent
                                                                                                                 family will expire
                                                                                                                 in 2030.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We hold a
                                                                                                                 patent family
                                                                                                                 containing 14
                                                                                                                 pending patent
                                                                                                                 applications
                                                                                                                 relating to multimeric
                                                                                                                 protein structures
                                                                                                                 of &alpha;-galactosidase
                                                                                                                 and to uses thereof
                                                                                                                 in treating Fabry
                                                                                                                 disease. The
                                                                                                                 patents to issue
                                                                                                                 in the future
                                                                                                                 based on the
                                                                                                                 patent applications
                                                                                                                 in this patent
                                                                                                                 family will expire
                                                                                                                 in 2031.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We hold a
                                                                                                                 patent family
                                                                                                                 containing four
                                                                                                                 pending patent
                                                                                                                 applications
                                                                                                                 relating to therapeutic
                                                                                                                 proteins with
                                                                                                                 stabilized quaternary
                                                                                                                 structure. The
                                                                                                                 patents to issue
                                                                                                                 in the future
                                                                                                                 based on the
                                                                                                                 patent applications
                                                                                                                 in this patent
                                                                                                                 family will expire
                                                                                                                 in 2031.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We hold a
                                                                                                                 patent family
                                                                                                                 containing three
                                                                                                                 pending patent
                                                                                                                 applications
                                                                                                                 relating to multimeric
                                                                                                                 protein structures
                                                                                                                 of glucocerebrosidase
                                                                                                                 and to uses thereof
                                                                                                                 in treating Gaucher
                                                                                                                 disease. The
                                                                                                                 patents to issue
                                                                                                                 in the future
                                                                                                                 based on the
                                                                                                                 patent applications
                                                                                                                 in this patent
                                                                                                                 family will expire
                                                                                                                 in 2031.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our patent
                                                                                                                 portfolio includes
                                                                                                                 a patent that
                                                                                                                 we co-own that
                                                                                                                 covers human
                                                                                                                 glycoprotein
                                                                                                                 hormone and chain
                                                                                                                 splice variants,
                                                                                                                 including isolated
                                                                                                                 nucleic acids
                                                                                                                 encoding these
                                                                                                                 variants.&nbsp;
                                                                                                                 More specifically,
                                                                                                                 this patent covers
                                                                                                                 a new splice
                                                                                                                 variant of human
                                                                                                                 FSH. This patent
                                                                                                                 was issued in
                                                                                                                 the United States
                                                                                                                 and is expected
                                                                                                                 to expire in
                                                                                                                 2024.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>With respect
                                                                                                                 to taliglucerase
                                                                                                                 alfa, we have
                                                                                                                 licensed the
                                                                                                                 rights to two
                                                                                                                 patents from
                                                                                                                 Virginia Tech
                                                                                                                 Intellectual
                                                                                                                 Properties, Inc.,
                                                                                                                 or Virginia Tech,
                                                                                                                 that are expected
                                                                                                                 to expire in
                                                                                                                 2016.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>With respect
                                                                                                                 to acetylcholinesterase,
                                                                                                                 we have licensed
                                                                                                                 the rights to
                                                                                                                 three patents
                                                                                                                 issued in the
                                                                                                                 United States
                                                                                                                 that are expected
                                                                                                                 to expire in
                                                                                                                 2014, 2017 and
                                                                                                                 2021, and to
                                                                                                                 six patent applications
                                                                                                                 from Yissum.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are aware of U.S. patents, and corresponding international
counterparts of such patents, owned by third parties that contain claims covering methods of producing GCD. We do not believe
that, if any claim of infringement were to be asserted against us based upon such patents, taliglucerase alfa would be found to
infringe any valid claim under such patents. However, there can be no assurance that a court would find in our favor or that,
if we choose or are required to seek a license to any one or more of such patents, a license would be available to us on acceptable
terms or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In April 2005, Protalix Ltd. entered into a license agreement
with Icon Genetics AG, or Icon, pursuant to which we received an exclusive worldwide license to develop, test, use and commercialize
Icon&rsquo;s technology to express certain proteins in our ProCellEx protein expression system. Under the terms of the agreement,
we are also entitled to a non-exclusive worldwide license to make and have made other proteins expressed by using Icon&rsquo;s
technology in our technology. As consideration for the license, we are obligated to make <FONT STYLE="color: black">royalty payments
equal to </FONT>varying <FONT STYLE="color: black">low, single-digit percentages of net sales of products by us, our affiliates,
or any sublicensees under the agreement. </FONT>In addition, we are obligated to make milestone payments equal to $350,000, in
the aggregate, upon the achievement of certain milestones.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">Our license agreement with
Icon remains in effect until the earlier of the expiration of the last patent under the agreement or, if all of the patents under
the agreement expire, 20 years after the first commercial sale of any product under the agreement. Icon may terminate the agreement
upon written notice to us that we are in material breach of our obligations under the agreement and we are unable to remedy such
material breach within 30 days after we receive such notice. Further, Icon may terminate the agreement in connection with certain
events relating to a wind up or bankruptcy, if we make a general assignment for the benefit of our creditors, or if we cease to
conduct operations for a certain period. Icon may also terminate the exclusivity granted to us by written notice if we fail to
reach certain milestones within a designated period of time. Notwithstanding the termination date of the agreement, our obligation
to pay royalties to Icon under the agreement may expire prior to the termination of the agreement, subject to certain conditions.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2005, Protalix Ltd. entered into a license agreement
with Virginia Tech University, pursuant to which we received a non-exclusive worldwide license to make, have made, use, sell,
offer for sale and import certain of Virginia Tech&rsquo;s patents. As consideration for the license, we made a one-time license
fee payment to Virginia Tech, and we are obligated to make royalty payments equal to varying low, single-digit percentages of
net sales of licensed products by Protalix Ltd., its subsidiaries and/or their affiliates. Upon commercialization of a licensed
product, the royalty payment is subject to a low, annual minimum amount. In addition, we are obligated to make milestone payments
equal to $150,000, in the aggregate, upon the achievement of certain milestones. We have the right to grant sublicenses under
the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our license agreement with Virginia Tech remains in effect
until the earlier of the expiration of the last patent under the agreement or 10 years after the first commercial sale of any
licensed product. Virginia Tech may terminate the agreement upon written notice to us that we are in material breach of our obligations
under the agreement if we are unable to remedy such material breach within a fixed number of days after we receive such notice,
which number may be doubled if we are making good faith efforts to achieve a cure and the extension will not increase the damages
suffered by Virginia Tech. We have the right to terminate the agreement at any time upon prior written notice delivered an agreed-upon
number of days prior to the date of termination.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Manufacturing</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We are obligated to manufacture all of the
taliglucerase alfa drug product needed under the Pfizer Agreement, subject to certain terms and conditions. Our drug product candidates,
including taliglucerase alfa, must be manufactured in a sterile environment and in compliance with cGMPs set by the FDA and other
relevant foreign regulatory authorities. We use our current facility, which has approximately 20,000 sq/ft of clean rooms built
according to industry standards, to develop, process and manufacture taliglucerase alfa and other recombinant proteins We intend
to use our current manufacturing space to produce all of the taliglucerase alfa we need in the near future, included the taliglucerase
alfa to be purchased by Pfizer. In addition, we intend to use our manufacturing space to produce all of the drug substance needed
in connection with the clinical trials of PRX-102 and of our oral treatment of Gaucher disease and potentially for our other product
candidates. Current capacity of our facility can serve over 50% of the Gaucher disease patients that are currently under treatment
globally. We intend to expand our current facility in order to increase capacity for our future product candidates and to house
the laboratory space necessary for further development of other product candidates in our pipeline. Total expected cost for such
expansion is currently estimated to be approximately $25.0 million and the process is expected to be completed during 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">O</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">ur
manufacturing facilities in Carmiel, Israel, have undergone successful GMP audits by the Israeli MOH, the FDA, ANVISA, and the
</FONT>European Union<FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT>under the European Union's centralized marketing
authorization procedure,<FONT STYLE="font-family: Times New Roman, Times, Serif"> and recently by the Australian</FONT>&nbsp;TGA.</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have engaged a contract manufacturer in Europe to act as
an additional source of fill and finish activities for taliglucerase alfa. According to our agreement with Pfizer, Pfizer will
be responsible for the fill and finish activities for taliglucerase alfa.<B> </B>We have engaged other contract manufacturers
to perform fill/finish activities for PRX-102 and for our oral treatment of Gaucher disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our current facility in Israel has been granted &ldquo;Approved
Enterprise&rdquo; status, and we have elected to participate in the alternative benefits program. Our facility is located in a
Zone A location, and, therefore, our income from the Approved Enterprise will be tax exempt in Israel for a 10-year period commencing
with the year in which we first generate taxable income from the relevant Approved Enterprise. We currently anticipate that the
benefits of this program will be available to Protalix Ltd. until 2020 and, accordingly, we expect to be entitled to similar tax
benefits for a number of years thereafter. To remain eligible for these tax benefits, we must continue to meet certain conditions,
and if we increase our activities outside of Israel, for example, by future acquisitions, such increased activities generally
may not be eligible for inclusion in Israeli tax benefit programs. In addition, our technology is subject to certain restrictions
with respect to the transfer of technology and manufacturing rights. &ldquo;See Risk Factors&mdash;The manufacture of our products
is an exacting and complex process, and if we or one of our materials suppliers encounter problems manufacturing our products,
it will have a material adverse effect on our business and results of operations.&rdquo;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Raw Materials and Suppliers</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that the raw materials that we require throughout
the manufacturing process of our current and potential drug product candidates are widely available from numerous suppliers and
are generally considered to be generic industrial biological supplies. We rely on a single approved supplier for certain materials
relating to the current expression of our proprietary biotherapeutic proteins through ProCellEx. We have identified additional
suppliers for most of the materials required for the production of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Development and regulatory approval of our pharmaceutical products
are dependent upon our ability to procure active ingredients and certain packaging materials from sources approved by the FDA
and other regulatory authorities. Since the FDA and other regulatory approval processes require manufacturers to specify their
proposed suppliers of active ingredients and certain packaging materials in their applications, FDA approval of a supplemental
application to use a new supplier in connection with any drug candidate or approved product, if any, would be required if active
ingredients or such packaging materials were no longer available from the specified supplier, which could result in manufacturing
delays. From time to time, we intend to continue to identify alternative FDA-approved suppliers to ensure the continued supply
of necessary raw materials.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Competition</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The biotechnology and pharmaceutical industries are characterized
by rapidly evolving technology and significant competition. Competition from numerous existing companies and others entering the
fields in which we operate is intense and expected to increase. Most of these companies have substantially greater research and
development, manufacturing, marketing, financial, technological personnel and managerial resources than we do. In addition, many
specialized biotechnology companies have formed collaborations with large, established companies to support research, development
and commercialization of products that may be competitive with our current and future product candidates and technologies. Acquisitions
of competing companies by large pharmaceutical or biotechnology companies could further enhance such competitors&rsquo; financial,
marketing and other resources. Academic institutions, governmental agencies and other public and private research organizations
are also conducting research activities and seeking patent protection and may commercialize competitive products or technologies
on their own or through collaborations with pharmaceutical and biotechnology companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We specifically face competition from companies with approved
treatments of Gaucher disease. In addition to ELELYSO, there are two other ERTs for the treatment of Gaucher disease; Cerezyme
which is marketed by Genzyme (recently acquired by Sanofi) and VPRIV, which is marketed by Shire. To a much lesser extent, we
also compete with Actelion. In addition, we are aware of other early clinical stage, experimental, small molecule, oral drugs
which are being developed for the treatment of Gaucher disease by Genzyme. Genzyme is developing an orally-administered substrate
reduction therapy which is currently the subject of phase III clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There are two approved ERTs for the treatment of Fabry disease;
Fabrazyme which is marketed by Genzyme and Replagal, which is marketed by Shire. Fabrazyme is available in the United States and
the European Union. Replagal is available in the European Union. In 2012, Shire withdrew its BLA for Replagal in the United States.
In addition, we are aware of other clinical stage, early clinical stage and experimental drugs which are being developed for the
treatment of Fabry disease by Amicus Therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also face competition from companies that are developing
other platforms for the expression of recombinant therapeutic pharmaceuticals. We are aware of companies that are developing alternative
technologies to develop and produce therapeutic proteins in anticipation of the expiration of certain patent claims covering marketed
proteins. Competitors developing alternative expression technologies include Crucell N.V. (which was acquired by Johnson &amp;
Johnson during 2010), Shire and GlycoFi, Inc. (which was acquired by Merck &amp; Co. Inc.). Other companies are developing alternate
plant-based technologies, include Chlorogen, Inc., iBio, Inc., Medicago, Greenovation Biotech GmbH, and Symbiosys, none of which
are cell-based. Rather, such companies base their product development on transgenic plants or whole plants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Several biogeneric companies are pursuing the opportunity to
develop and commercialize follow-on versions of other currently marketed biologic products, including growth factors, hormones,
enzymes, cytokines and monoclonal antibodies, which are areas that interest us. These companies include, among others, Novartis
AG/Sandoz Pharmaceuticals, BioGeneriX AG, Stada Arzneimittel AG, BioPartners GmbH and Teva. See &ldquo;Risk Factors&mdash;Developments
by competitors may render our products or technologies obsolete or non-competitive which would have a material adverse effect
on our business, results of operations and financial condition.&rdquo;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scientific Advisory Board</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Members of our scientific advisory board, who are experts in
the fields of plant molecular and cell biology as well as Gaucher disease and various hematological and genetic disorders, consult
with our management within their professional areas of expertise; exchange strategic and business development ideas with our management;
attend scientific, medical and business meetings with our management, such as meetings with the FDA and comparable foreign regulatory
authorities, meetings with strategic or potential strategic partners and other meetings relevant to their areas of expertise;
and attend meetings of our scientific advisory board. We expect our scientific advisory board to convene at least twice annually,
and we frequently consult with the individual members of our scientific advisory board. Our scientific advisory board currently
includes the following people:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.75pt solid"><B>Name</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 69%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.75pt solid"><B>Affiliation</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: black">Roger D. Kornberg, Ph.D.</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Laureate of the Nobel Prize in Chemistry</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member, U.S. National Academy of Sciences</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Winzer Professor of Medicine, Department of Structural
        Biology at Stanford University</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2001 Welch Prize (highest award granted in the field
        of chemistry in the United States)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2002 Leopold Mayer Prize (the highest award granted
        in the field of biomedical sciences from the French Academy of Sciences)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: black">Professor Aaron Ciechanover, M.D., D.Sc.</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Laureate of the Nobel Prize in Chemistry</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Distinguished research Professor at the Cancer and
        Vascular Biology Research Center of the Rappaport Research Institute and Faculty of Medicine at the Technion, Israel&rsquo;s
        Institute of Technology</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">American Academy of Arts and Sciences, Member</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: black">Professor Gad Galili, Ph.D.</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: black">Former Chairman of the Department of Plant Sciences, The Weizmann Institute
    of Science, Rehovot, Israel</FONT><BR>
    <BR></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: black">Professor Ari Zimran, M.D.</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Director of the Gaucher Clinic, Shaare Zedek Medical
        Center, Jerusalem, Israel</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Associate Professor of Medicine, Hebrew University-Hadassah
        Medical School, Jerusalem, Israel</P></TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Government Regulation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The testing, manufacture, distribution, advertising and marketing
of drug products are subject to extensive regulation by federal, state and local governmental authorities in the United States,
including the FDA, and by similar authorities in other countries. Any product that we develop must receive all relevant regulatory
approvals or clearances, as the case may be, before it may be marketed in a particular country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The regulatory process, which includes overseeing preclinical
studies and clinical trials of each pharmaceutical compound to establish its safety and efficacy and confirmation by the FDA that
good laboratory, clinical and manufacturing practices were maintained during testing and manufacturing, can take many years, requires
the expenditure of substantial resources and gives larger companies with greater financial resources a competitive advantage over
us. Delays or terminations of clinical trials that we undertake would likely impair our development of product candidates. Delays
or terminations could result from a number of factors, including stringent enrollment criteria, slow rate of enrollment, size
of patient population, having to compete with other clinical trials for eligible patients, geographical considerations and others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The FDA review process can be lengthy and unpredictable, and
we may encounter delays or rejections of our applications when submitted. Generally, in order to gain FDA approval, we must first
conduct preclinical studies in a laboratory and in animal models to obtain preliminary information on a compound and to identify
any potential safety problems. The results of these studies are submitted as part of an IND application that the FDA must review
before human clinical trials of an investigational drug can commence. Clinical trials may be terminated by the clinical trial
site, sponsor or the FDA if toxicities appear that are either worse than expected or unexpected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Clinical trials are normally performed in three sequential
phases and generally take two to five years, or longer, to complete. Phase I consists of testing the drug product in a small number
of humans, normally healthy volunteers, to determine preliminary safety and tolerable dose range. Phase II usually involves studies
in a limited patient population to evaluate the effectiveness of the drug product in humans having the disease or medical condition
for which the product is indicated, determine dosage tolerance and optimal dosage and identify possible common adverse effects
and safety risks. Phase III consists of additional controlled testing at multiple clinical sites to establish clinical safety
and effectiveness in an expanded patient population of geographically dispersed test sites to evaluate the overall benefit-risk
relationship for administering the product and to provide an adequate basis for product labeling. Phase IV clinical trials may
be conducted after approval to gain additional experience from the treatment of patients in the intended therapeutic indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">After completion of clinical trials of a new drug product,
FDA and foreign regulatory authority marketing approval must be obtained. Assuming that the clinical data support the product&rsquo;s
safety and effectiveness for its intended use, an NDA is submitted to the FDA for its review. Generally, it takes one to three
years to obtain approval. If questions arise during the FDA review process, approval may take a significantly longer period of
time. The testing and approval processes require substantial time and effort and approval on a timely basis, if at all, or the
approval that we receive may be for a narrower indication than we had originally sought, potentially undermining the commercial
viability of the product. Even if regulatory approvals are obtained, approved products are subject to continual review and holders
of an approved product are required, for example, to report certain adverse reactions and production problems, if any, to the
FDA, and to comply with certain requirements concerning advertising and promotional labeling for the product. Also, quality control
and manufacturing procedures relating to a product must continue to conform to cGMP after approval, and the FDA periodically inspects
manufacturing facilities to assess compliance with cGMP. Accordingly, manufacturers must continue to expend time, money and effort
in the area of production and quality control to comply with cGMP and other aspects of regulatory compliance. The later discovery
of previously unknown problems or failure to comply with the applicable regulatory requirements with respect to any product may
result in restrictions on the marketing of the product or withdrawal of the product from the market as well as possible civil
or criminal sanctions. See also &ldquo;&mdash;International Regulation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Orphan Drug Act of 1983, the FDA may grant orphan
drug designation to drugs and biological products intended to treat a rare disease or condition, which is generally a disease
or condition that affects fewer than 200,000 individuals in the United States. In September 2009, we received orphan drug designation
for taliglucerase alfa for the treatment of Gaucher disease. The FDA grants orphan drug designation to drugs that may provide
a significant therapeutic advantage over existing treatments and target conditions affecting 200,000 or fewer U.S. patients per
year. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.
Among the other benefits of orphan drug designation are possible funding and tax savings to support clinical trials and for other
financial incentives and a waiver of the marketing application user fee and most likely priority review.<B> </B>If a significant
therapeutic advantage over existing treatments is shown in the marketing application, FDA may grant orphan drug approval and provide
a seven-year period of marketing exclusivity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The FDA has a fast track program that is intended to expedite
or facilitate the process for reviewing new drugs and biological products that meet certain criteria. Specifically, new drugs
and biological products are eligible for fast track designation if they are intended to treat a serious or life-threatening condition
and demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to the combination
of the product and the specific indication for which it is being studied. For a fast track product, the FDA may consider for review
on a rolling basis sections of the NDA before the complete application is submitted, if the sponsor provides a schedule for the
submission of the sections of the NDA, the FDA agrees to accept sections of the NDA as they become available and determines that
the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. We used
the rolling submission option for our taliglucerase alfa NDA, which we completed in April 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The United States federal government regulates healthcare through
various agencies, including but not limited to the following: (i) the FDA, which administers the Federal Food, Drug, and Cosmetic
Act (FDCA), as well as other relevant laws; (ii) the Center for Medicare &amp; Medicaid Services (CMS), which administers the
Medicare and Medicaid programs; (iii) the Office of Inspector General (OIG) which enforces various laws aimed at curtailing fraudulent
or abusive practices, including by way of example, the Anti-Kickback Law, the Anti-Physician Referral Law, commonly referred to
as Stark, the Anti-Inducement Law, the Civil Money Penalty Law and the laws that authorize the OIG to exclude healthcare providers
and others from participating in federal healthcare programs; and (iv) the Office of Civil Rights, which administers the privacy
aspects of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). All of the aforementioned are agencies within
the Department of Health and Human Services (HHS). Healthcare is also provided or regulated, as the case may be, by the Department
of Defense through its TriCare program, the Department of Veterans Affairs, especially through the Veterans Health Care Act of
1992, the Public Health Service within HHS under Public Health Service Act &sect; 340B (42 U.S.C. &sect; 256b), the Department
of Justice through the Federal False Claims Act and various criminal statutes, and state governments under the Medicaid and other
state sponsored or funded programs and their internal laws regulating all healthcare activities. Many states also have anti-kickback
and anti-physician referral laws that are similar to the federal laws, but may be applicable in situations where federal laws
do not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Medicare is the federal healthcare program for those who are
(i) over 65 years of age, (ii) disabled, (iii) suffering from end-stage renal disease or (iv) suffering from Lou Gehrig&rsquo;s
disease. Medicare consists of part A, which covers inpatient costs, part B, which covers services by physicians and laboratories,
durable medical equipment and certain drugs, primarily those administered by physicians, and part D, which provides drug coverage
for most prescription drugs other than those covered under part B. Medicare also offers a managed care option under part C. Medicare
is administered by CMS. In contrast, Medicaid is a state-federal healthcare program for the poor and is administered by the states
pursuant to an agreement with the Secretary of Health and Human Services. Most state Medicaid programs cover most outpatient prescription
drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In March 2010, the Patient Protection and Affordable Care Act,
as amended by the Health Care and Education Affordability Reconciliation Act, or collectively, PPACA, became law in the United
States. PPACA substantially changes the way healthcare is financed by both governmental and private insurers and significantly
affects the pharmaceutical industry. Key provisions of PPACA specific to the pharmaceutical industry, among others, include the
following:</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>An annual,
                                                                                                                 nondeductible
                                                                                                                 fee on any entity
                                                                                                                 that manufactures
                                                                                                                 or imports certain
                                                                                                                 branded prescription
                                                                                                                 drugs and biologic
                                                                                                                 agents into the
                                                                                                                 United States,
                                                                                                                 apportioned among
                                                                                                                 these entities
                                                                                                                 according to
                                                                                                                 their market
                                                                                                                 share in certain
                                                                                                                 federal government
                                                                                                                 healthcare programs
                                                                                                                 (excluding sales
                                                                                                                 of any drug or
                                                                                                                 biologic product
                                                                                                                 marketed for
                                                                                                                 an orphan indication),
                                                                                                                 beginning in
                                                                                                                 2011;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>An increase
                                                                                                                 in the rebates
                                                                                                                 a manufacturer
                                                                                                                 must pay under
                                                                                                                 the Medicaid
                                                                                                                 Drug Rebate Program,
                                                                                                                 retroactive to
                                                                                                                 January 1, 2010,
                                                                                                                 to 23.1% and
                                                                                                                 13% of the average
                                                                                                                 manufacturer
                                                                                                                 price for branded
                                                                                                                 and generic drugs,
                                                                                                                 respectively;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A new Medicare
                                                                                                                 Part D coverage
                                                                                                                 gap discount
                                                                                                                 program, in which
                                                                                                                 manufacturers
                                                                                                                 must agree to
                                                                                                                 offer 50% point-of
                                                                                                                 sale discounts
                                                                                                                 off negotiated
                                                                                                                 prices of applicable
                                                                                                                 brand drugs to
                                                                                                                 eligible beneficiaries
                                                                                                                 during their
                                                                                                                 coverage gap
                                                                                                                 period, as a
                                                                                                                 condition for
                                                                                                                 the manufacturer&rsquo;s
                                                                                                                 outpatient drugs
                                                                                                                 to be covered
                                                                                                                 under Medicare
                                                                                                                 Part D, beginning
                                                                                                                 in 2011;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Extension
                                                                                                                 of manufacturers&rsquo;
                                                                                                                 Medicaid rebate
                                                                                                                 liability to
                                                                                                                 covered drugs
                                                                                                                 dispensed to
                                                                                                                 individuals who
                                                                                                                 are enrolled
                                                                                                                 in Medicaid managed
                                                                                                                 care organizations,
                                                                                                                 effective March
                                                                                                                 23, 2010;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Expansion
                                                                                                                 of eligibility
                                                                                                                 criteria for
                                                                                                                 Medicaid programs
                                                                                                                 by, among other
                                                                                                                 things, allowing
                                                                                                                 states to offer
                                                                                                                 Medicaid coverage
                                                                                                                 to additional
                                                                                                                 individuals beginning
                                                                                                                 in April 2010
                                                                                                                 and by adding
                                                                                                                 new mandatory
                                                                                                                 eligibility categories
                                                                                                                 for certain individuals
                                                                                                                 with income at
                                                                                                                 or below 133%
                                                                                                                 of the Federal
                                                                                                                 Poverty Level
                                                                                                                 beginning in
                                                                                                                 2014, thereby
                                                                                                                 potentially increasing
                                                                                                                 both the volume
                                                                                                                 of sales and
                                                                                                                 manufacturers&rsquo;
                                                                                                                 Medicaid rebate
                                                                                                                 liability;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Expansion
                                                                                                                 of the entities
                                                                                                                 eligible for
                                                                                                                 discounts under
                                                                                                                 the Public Health
                                                                                                                 Service pharmaceutical
                                                                                                                 pricing program,
                                                                                                                 effective January
                                                                                                                 2010;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>New requirements
                                                                                                                 to report certain
                                                                                                                 financial arrangements
                                                                                                                 with physicians
                                                                                                                 and others, including
                                                                                                                 reporting any
                                                                                                                 &ldquo;transfer
                                                                                                                 of value&rdquo;
                                                                                                                 made or distributed
                                                                                                                 to prescribers
                                                                                                                 and other healthcare
                                                                                                                 providers and
                                                                                                                 reporting any
                                                                                                                 investment interests
                                                                                                                 held by physicians
                                                                                                                 and their immediate
                                                                                                                 family members
                                                                                                                 during each calendar
                                                                                                                 year beginning
                                                                                                                 in 2012, with
                                                                                                                 reporting starting
                                                                                                                 in 2013;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A new requirement
                                                                                                                 to annually report
                                                                                                                 drug samples
                                                                                                                 that manufacturers
                                                                                                                 and distributors
                                                                                                                 provide to physicians,
                                                                                                                 effective April
                                                                                                                 1, 2012;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A licensure
                                                                                                                 framework for
                                                                                                                 follow-on biologic
                                                                                                                 products; and</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A new Patient-Centered
                                                                                                                 Outcomes Research
                                                                                                                 Institute to
                                                                                                                 oversee, identify
                                                                                                                 priorities in,
                                                                                                                 and conduct comparative
                                                                                                                 clinical effectiveness
                                                                                                                 research, along
                                                                                                                 with funding
                                                                                                                 for such research.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">International Regulation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are subject to regulations and product registration requirements
in many foreign countries in which we may sell our products, including in the areas of product standards, packaging requirements,
labeling requirements, import and export restrictions and tariff regulations, duties and tax requirements. The time required to
obtain clearance required by foreign countries may be longer or shorter than that required for FDA clearance, and requirements
for licensing a product in a foreign country may differ significantly from FDA requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pharmaceutical products may not be imported into, or manufactured
or marketed in, the State of Israel absent drug registration. The three basic criteria for the registration of pharmaceuticals
in Israel is quality, safety and efficacy of the pharmaceutical product and the Israeli MOH requires pharmaceutical companies
to conform to international developments and standards. Regulatory requirements are constantly changing in accordance with scientific
advances as well as social and ethical values.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The relevant legislation of the European Union requires that
medicinal products, including generic versions of previously approved products, and new strengths, dosage forms and formulations,
of previously approved products, shall have a marketing authorization before they are placed on the market in the European Union.
Authorizations are granted after the assessment of quality, safety and efficacy by the respective health authorities. In order
to obtain an authorization, an application must be made to the competent authority of the member state concerned or in a centralized
procedure to the EMA. Besides various formal requirements, the application must contain the results of pharmaceutical (physico-chemical,
biological or microbiological) tests, of preclinical (toxicological and pharmacological) tests as well as of clinical trials.
All of these tests must have been conducted in accordance with relevant EU regulations and must allow the reviewer to evaluate
the quality, safety and efficacy of the medicinal product. Orphan drug designation in the European Union is granted to medicinal
products intended for the diagnosis, prevention and treatment of life-threatening diseases and very serious conditions that affect
not more than five in 10,000 people in the European Union. Orphan drug designation is generally given to medicinal products that
treat conditions for which no current therapy exists or are expected to bring a significant benefit to patients over existing
therapies.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Israeli Government Programs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is a summary of the current principal Israeli
tax laws applicable to us and Protalix Ltd., and of the Israeli Government programs from which Protalix Ltd. benefits. Some parts
of this discussion are based on new tax legislation that has not been subject to judicial or administrative interpretation. Therefore,
the views expressed in the discussion may not be accepted by the tax authorities in question. The discussion should not be construed
as legal or professional tax advice and does not cover all possible tax considerations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">General Corporate Tax Structure in Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Protalix Ltd.'s income, other than income from Approved Enterprises,
is taxed in Israel at the regular rate which is currently 25%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Capital gains on the sale of assets are subject to capital
gains tax according to the corporate tax rate in effect for the year the assets are sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the corporate taxes in Israel, we are subject
to a withholding tax on the U.S. revenue source portion of the payments made to us for our share of Pfizer&rsquo;s net profits
under the Pfizer Agreement. The withholding tax rate is 15%. See &ldquo;Business&mdash;Commercialization Agreement.&rdquo;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Law for the Encouragement of Capital Investments, 1959</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Law for the Encouragement of Capital Investments, 1959,
or the Investment Law, provides certain incentives for capital investments in a production facility (or other eligible assets).
Generally, an investment program that is implemented in accordance with the provisions of the Investment Law, referred to as an
&ldquo;Approved Enterprise,&rdquo; is entitled to benefits. These benefits may include cash grants from the Israeli government
and tax benefits, based upon, among other things, the location of the facility in which the investment is made and specific elections
made by the grantee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Protalix Ltd. will continue to enjoy the tax benefits under
the pre-revision provisions of the Investment Law. If any new benefits are granted to Protalix Ltd. in the future, Protalix Ltd.
will be subject to the provisions of the amended Investment Law with respect to these new benefits. Therefore, the following discussion
is a summary of the Investment Law prior to its amendment as well as the relevant changes contained in the new legislation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Investment Law prior to its amendment, a company
that wished to receive benefits had to receive approval from the &ldquo;Investment Center&rdquo; of the Israeli Ministry of Industry,
Trade and Labor, or the Investment Center. Each certificate of approval for an Approved Enterprise relates to a specific investment
program in the Approved Enterprise, delineated both by the financial scope of the investment and by the physical characteristics
of the facility or the asset, e.g., the equipment to be purchased and utilized pursuant to the program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">An Approved Enterprise may elect to forego any entitlement
to the grants otherwise available under the Investment Law and, instead, participate in an alternative benefits program under
which the undistributed income from the Approved Enterprise is fully exempt from corporate tax for a defined period of time. Under
the alternative package of benefits, a company&rsquo;s undistributed income derived from an Approved Enterprise will be exempt
from corporate tax for a period of between two and 10 years from the first year of taxable income, depending upon the geographic
location within Israel of the Approved Enterprise. Upon expiration of the exemption period, the Approved Enterprise is eligible
for the reduced tax rates otherwise applicable under the Investment Law for any remainder of the otherwise applicable benefits
period (up to an aggregate benefits period of either seven or 10 years, depending on the location of the company or its definition
as a foreign investors&rsquo; company). If a company has more than one Approved Enterprise program or if only a portion of its
capital investments are approved, its effective tax rate is the result of a weighted combination of the applicable rates. The
tax benefits from any certificate of approval relate only to taxable profits attributable to the specific Approved Enterprise.
Income from activity that is derived from different Approved Enterprises does not enjoy these tax benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A company that has an Approved Enterprise program is eligible
for further tax benefits if it qualifies as a foreign investors&rsquo; company. A foreign investors&rsquo; company eligible for
benefits is essentially a company in which more than 25% of the share capital (in terms of shares, rights to profit, voting and
appointment of directors) is owned (measured by both share capital and combined share and loan capital) by non-Israeli residents.
A company that qualifies as a foreign investors&rsquo; company and has an Approved Enterprise program is eligible for tax benefits
for a 10-year benefit period and may enjoy a reduced corporate tax rate of 10% to 25%, depending on the amount of the company&rsquo;s
shares held by non-Israeli shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If a company that has an Approved Enterprise program is a wholly
owned subsidiary of another company, the percentage of foreign investments is determined based on the percentage of foreign investment
in the parent company. The tax rates and related levels of foreign investments are set forth in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP STYLE="color: black; font-weight: bold; text-align: center">Percent of Foreign <BR>
Ownership</TD><TD NOWRAP STYLE="color: black; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="color: black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: black; font-weight: bold; text-align: center">Rate of Reduced <BR>
Tax</TD><TD NOWRAP STYLE="color: black; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 1%; color: black; text-align: left">&nbsp;</TD><TD STYLE="width: 48%; color: black; text-align: right"><FONT STYLE="color: black">0-49%</FONT></TD><TD STYLE="width: 1%; color: black; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; color: black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: black; text-align: left">&nbsp;</TD><TD STYLE="width: 47%; color: black; text-align: right">25</TD><TD STYLE="width: 1%; color: black; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right"><FONT STYLE="color: black">49-74%</FONT></TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">20</TD><TD STYLE="color: black; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right"><FONT STYLE="color: black">74-90%</FONT></TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">15</TD><TD STYLE="color: black; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right"><FONT STYLE="color: black">90-100%</FONT></TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">10</TD><TD STYLE="color: black; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our original facility in Israel has been granted &ldquo;Approved
Enterprise&rdquo; status, and it has elected to participate in the alternative benefits program. Under the terms of its Approved
Enterprise program, the facility is located in a top priority location, or &ldquo;Zone A,&rdquo; and, therefore, the income from
that Approved Enterprise will be tax exempt in Israel for a period of 10 years, commencing with the year in which taxable income
is first generated from the relevant Approved Enterprise. The current benefits program may not continue to be available and Protalix
Ltd. may not continue to qualify for its benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A company that has elected to participate in the alternative
benefits program and that subsequently pays a dividend out of the income derived from the Approved Enterprise during the tax exemption
period will be subject to corporate tax in respect of the amount distributed at the rate that would have been applicable had the
company not elected the alternative benefits program (generally 10% to 25%, depending on the extent to which non-Israeli shareholders
hold such company&rsquo;s shares). If the dividend is distributed within 12 years after the commencement of the benefits period
(or, in the case of a foreign investor&rsquo;s company, without time limitation), the dividend recipient is taxed at the reduced
withholding tax rate of 15% applicable to dividends from approved enterprises, or at the lower rate under an applicable tax treaty.
After this period, the withholding tax rate is 25%, or at the lower rate under an applicable tax treaty. In the case of a company
with a foreign investment level (as defined by the Investment Law) of 25% or more, the 12-year limitation on reduced withholding
tax on dividends does not apply. The company must withhold this tax at its source, regardless of whether the dividend is converted
into foreign currency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Investment Law also provides that an Approved Enterprise
is entitled to accelerated depreciation on its property and equipment that are included in an approved investment program. This
benefit is an incentive granted by the Israeli government regardless of whether the alternative benefits program is elected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The benefits available to an Approved Enterprise are conditioned
upon terms stipulated in the Investment Law and regulations and the criteria set forth in the applicable certificate of approval.
If Protalix Ltd. does not fulfill these conditions in whole or in part, the benefits can be canceled and Protalix Ltd. may be
required to refund the received benefits, linked to the Israeli consumer price index with the addition of interest or alternatively
with an additional penalty payment. We believe that Protalix Ltd. currently operates in compliance with all applicable conditions
and criteria, but there can be no assurance that Protalix Ltd. will continue to do so. Furthermore, there can be no assurance
that any Approved Enterprise status granted to Protalix Ltd.&rsquo;s facilities will entitle Protalix Ltd. to the same benefits
to which it is currently entitled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Investment Law, the approval of the Investment Center
is required only for Approved Enterprises that receive cash grants. Approved Enterprises that do not receive benefits in the form
of governmental cash grants, but only tax benefits, are no longer required to obtain this approval. Instead, these Approved Enterprises
are required to make certain investments as specified in the Investment Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The amended Investment Law specifies certain conditions for
an Approved Enterprise to be entitled to benefits. These conditions include:</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the Approved
                                                                                                                 Enterprise&rsquo;s
                                                                                                                 revenues from
                                                                                                                 any single country
                                                                                                                 or a separate
                                                                                                                 customs territory
                                                                                                                 may not exceed
                                                                                                                 75% of the Approved
                                                                                                                 Enterprise&rsquo;s
                                                                                                                 total revenues;
                                                                                                                 or</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at least
                                                                                                                 25% of the Approved
                                                                                                                 Enterprise&rsquo;s
                                                                                                                 revenues during
                                                                                                                 the benefits
                                                                                                                 period must be
                                                                                                                 derived from
                                                                                                                 sales into a
                                                                                                                 single country
                                                                                                                 or a separate
                                                                                                                 customs territory
                                                                                                                 with a population
                                                                                                                 of at least 12
                                                                                                                 million.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There can be no assurance that Protalix Ltd. will comply with
the above conditions in the future or that Protalix Ltd. will be entitled to any additional benefits under the Investment Law.
In addition, it is possible that Protalix Ltd. may not be able to operate in a manner that maximizes utilization of the potential
benefits available under the Investment Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From time to time, the Israeli Government has considered reducing
the benefits available to companies under the Investment Law. The termination or substantial reduction of any of the benefits
available under the Investment Law could materially impact the cost of our future investments.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Encouragement of Industrial Research and Development Law,
1984</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, Protalix Ltd. has received grants from the Office
of the Chief Scientist of the Israeli Ministry of Industry, Trade and Labor, or the OCS, for the financing of a portion of its
research and development expenditures in Israel. As of December 31, 2012, the OCS approved grants in respect of Protalix Ltd.&rsquo;s
continuing operations totaling approximately $28.1 million, measured from inception. Protalix Ltd. is required to repay up to
100% of grants actually received (plus interest at the LIBOR rate applied to the grants received on or after January 1, 1999)
to the OCS through payments of royalties at a rate of 3% to 6% of the revenues generated from an OCS-funded project, depending
on the period in which revenues were generated. As of December 31, 2012, Protalix Ltd. either paid or accrued royalties payable
of $4.4 million and Protalix Ltd.&rsquo;s contingent liability to the OCS with respect to grants received was approximately $21.3
million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Israeli Law for the Encouragement of Industrial Research
and Development, 1984, and related regulations, or the Research Law, recipients of grants from the OCS are prohibited from manufacturing
products developed using these grants outside of the State of Israel without special approvals, although the Research Law does
enable companies to seek prior approval for conducting manufacturing activities outside of Israel without being subject to increased
royalties. If Protalix Ltd. receives approval to manufacture the products developed with government grants outside of Israel,
it will be required to pay an increased total amount of royalties (possibly up to 300% of the grant amounts plus interest), depending
on the manufacturing volume that is performed outside of Israel, as well as at a possibly increased royalty rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, under the Research Law, Protalix Ltd. is prohibited
from transferring the OCS-financed technologies and related intellectual property rights outside of the State of Israel, except
under limited circumstances and only with the approval of the OCS' Research Committee. Protalix Ltd. may not receive the required
approvals for any proposed transfer and, if received, Protalix Ltd. may be required to pay the OCS a portion of the consideration
that it receives upon any sale of such technology by a non-Israeli entity. The scope of the support received, the royalties that
Protalix Ltd. has already paid to the OCS, the amount of time that has elapsed between the date on which the know-how was transferred
and the date on which the OCS grants were received and the sale price and the form of transaction will be taken into account in
order to calculate the amount of the payment to the OCS. Approval of the transfer of technology to residents of the State of Israel
is required, and may be granted in specific circumstances only if the recipient abides by the provisions of applicable laws, including
the restrictions on the transfer of know-how and the obligation to pay royalties. No assurance can be made that approval to any
such transfer, if requested, will be granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Research Law, the Research Committee to allow the
transfer outside of Israel of know-how derived from an approved program and the related manufacturing rights. In general, the
Research Committee may approve transfer of know-how in limited circumstances as follows:</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in the event
                                                                                                                 of a sale of
                                                                                                                 know-how itself
                                                                                                                 to a non affiliated
                                                                                                                 third party,
                                                                                                                 provided that
                                                                                                                 upon such sale
                                                                                                                 the owner of
                                                                                                                 the know-how
                                                                                                                 pays to the OCS
                                                                                                                 an amount, in
                                                                                                                 cash, as set
                                                                                                                 forth in the
                                                                                                                 Research Law.
                                                                                                                 In addition,
                                                                                                                 the amendment
                                                                                                                 provides that
                                                                                                                 if the purchaser
                                                                                                                 of the know-how
                                                                                                                 gives the selling
                                                                                                                 Israeli company
                                                                                                                 the right to
                                                                                                                 exploit the know-how
                                                                                                                 by way of an
                                                                                                                 exclusive, irrevocable
                                                                                                                 and unlimited
                                                                                                                 license, the
                                                                                                                 research committee
                                                                                                                 may approve such
                                                                                                                 transfer in special
                                                                                                                 cases without
                                                                                                                 requiring a cash
                                                                                                                 payment.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in the event
                                                                                                                 of a sale of
                                                                                                                 a company which
                                                                                                                 is the owner
                                                                                                                 of know-how,
                                                                                                                 pursuant to which
                                                                                                                 the company ceases
                                                                                                                 to be an Israeli
                                                                                                                 company, provided
                                                                                                                 that upon such
                                                                                                                 sale, the owner
                                                                                                                 of the know-how
                                                                                                                 makes a cash
                                                                                                                 payment to the
                                                                                                                 OCS as set forth
                                                                                                                 in the Research
                                                                                                                 Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in the event
                                                                                                                 of an exchange
                                                                                                                 of know-how such
                                                                                                                 that in exchange
                                                                                                                 for the transfer
                                                                                                                 of know-how outside
                                                                                                                 of Israel, the
                                                                                                                 recipient of
                                                                                                                 the know-how
                                                                                                                 transfers other
                                                                                                                 know-how to the
                                                                                                                 company in Israel
                                                                                                                 in a manner in
                                                                                                                 which the OCS
                                                                                                                 is convinced
                                                                                                                 that the Israeli
                                                                                                                 economy realizes
                                                                                                                 a greater, overall
                                                                                                                 benefit from
                                                                                                                 the exchange
                                                                                                                 of know-how.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Research Committee may, in special cases, approve the transfer
of manufacture or of manufacturing rights of a product developed within the framework of the approved program or which results
therefrom, outside of Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The State of Israel does not own intellectual property rights
in technology developed with OCS funding and there is no restriction on the export of products manufactured using technology developed
with OCS funding. The technology is, however, subject to transfer of technology and manufacturing rights restrictions as described
above. For a description of such restrictions, please see &ldquo;Risk Factors&mdash;Risks Relating to Our Operations in Israel.&rdquo;
OCS approval is not required for the export of any products resulting from the research or development or for the licensing of
any technology in the ordinary course of business.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Law for the Encouragement of Industry (Taxes), 1969</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that Protalix Ltd. currently qualifies as an &ldquo;Industrial
Company&rdquo; within the meaning of the Law for the Encouragement of Industry (Taxes), 1969, or the Industry Encouragement Law.
The Industry Encouragement Law defines &ldquo;Industrial Company&rdquo; as a company resident in Israel that derives 90% or more
of its income in any tax year (other than specified kinds of passive income such as capital gains, interest and dividends) from
an &ldquo;Industrial Enterprise&rdquo; that it owns. An &ldquo;Industrial Enterprise&rdquo; is defined as an enterprise whose
major activity in a given tax year is industrial production.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following corporate tax benefits, among others, are available
to Industrial Companies:</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>amortization
                                                                                                                 of the cost of
                                                                                                                 purchased know-how
                                                                                                                 and patents over
                                                                                                                 an eight-year
                                                                                                                 period for tax
                                                                                                                 purposes;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>accelerated
                                                                                                                 depreciation
                                                                                                                 rates on equipment
                                                                                                                 and buildings;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>under specified
                                                                                                                 conditions, an
                                                                                                                 election to file
                                                                                                                 consolidated
                                                                                                                 tax returns with
                                                                                                                 other related
                                                                                                                 Israeli Industrial
                                                                                                                 Companies; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>expenses
                                                                                                                 related to a
                                                                                                                 public offering
                                                                                                                 are deductible
                                                                                                                 in equal amounts
                                                                                                                 over three years.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Eligibility for the benefits under the Industry Encouragement
Law is not subject to receipt of prior approval from any governmental authority. It is possible that Protalix Ltd. may fail to
qualify or may not continue to qualify as an &ldquo;Industrial Company&rdquo; or that the benefits described above will not be
available in the future.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tax Benefits for Research and Development</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under specified conditions, Israeli tax laws allow a tax deduction
by a company for research and development expenditures, including capital expenditures, for the year in which such expenditures
are incurred. These expenditures must relate to scientific research and development projects and must be approved by the OCS.
Furthermore, the research and development projects must be for the promotion of the company and carried out by or on behalf of
the company seeking such tax deduction. However, the amount of such deductible expenditures is reduced by the sum of any funds
received through government grants for the finance of such scientific research and development projects. Expenditures not so approved
are deductible over a three-year period.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Employees</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2012, we had 266 employees, of whom 39 have
a Ph.D. or an M.D.in their respective scientific fields. We believe that our relations with these employees are good. We believe
that our success will greatly depend on our ability to identify, attract and retain capable employees. The Israeli Ministry of
Labor and Welfare is authorized to make certain industry-wide collective bargaining agreements, or Expansion Orders, that apply
to types of industries or employees including ours. These agreements affect matters such as cost of living adjustments to salaries,
length of working hours and week, recuperation, travel expenses, and pension rights. Otherwise, our employees are not represented
by a labor union or represented under a collective bargaining agreement. See &ldquo;Risk Factors&mdash;We depend upon key employees
and consultants in a competitive market for skilled personnel. If we are unable to attract and retain key personnel, it could
adversely affect our ability to develop and market our products.&rdquo;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Company Background</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our principal business address is set forth below. Our executive
offices and our main research manufacturing facility are located at that address. Our telephone number is +972-4-988-9488. We
were originally incorporated in the State of Florida in April 1992, and Protalix Ltd., our wholly-owned subsidiary and sole operating
unit, is an Israeli company and was originally incorporated in Israel on December 27, 1993. During 1999, Protalix Ltd. changed
its focus from plant secondary metabolites to the expression of recombinant therapeutic proteins in plant cells, and in April
2004 changed its name to Protalix Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ProCellEx<SUP>&reg;</SUP> is our registered trademark. Each
of the other trademarks, trade names or service marks appearing in this Annual Report on Form 10-K belongs to its respective holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Available Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our corporate website is www.protalix.com. We make available
on our website, free of charge, our Commission filings, including our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q,
Current Reports on Form 8-K and any amendments to these reports, as soon as reasonably practicable after we electronically file
these documents with, or furnish them to, the Commission. Additionally, from time to time, we provide notifications of material
news including press releases and conferences on our website. Webcasts of presentations made by our company at certain conferences
may also be available from time to time on our website, to the extent the webcasts are available. The content of our website is
not intended to be incorporated by reference into this report or in any other report or document we file and any references to
these websites are intended to be inactive textual references only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are also listed on the Tel Aviv Stock Exchange, or the TASE,
and, accordingly, we submit copies of all our filings with the Commission to the Israeli Securities Authority and the TASE. Such
copies can be retrieved electronically through the TASE&rsquo;s internet messaging system (www.maya.tase.co.il) and through the
MAGNA distribution site of the Israeli Securities Authority (www.magna.isa.gov.il).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our website also includes printable versions of our Code of
Business Conduct and Ethics and the charters for each of the Audit, Compensation and Nominating Committees of our Board of Directors.
Each of these documents is also available in print, free of charge, to any shareholder who requests a copy by addressing a request
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Protalix BioTherapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2 Snunit Street, Science Park</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">P.O. Box 455</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Carmiel 20100, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attn: Mr. Yossi Maimon, Chief Financial
Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -45pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -45pt">Item&nbsp;1A.&#9;Risk Factors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>You should carefully consider the risks described below
together with the other information included in this Annual Report on Form 10-K. Our business, financial condition or results
of operations could be adversely affected by any of these risks. If any of these risks occur, the value of our common stock could
decline.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Financial Condition and Capital Requirements
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We currently have no significant product revenues and may
need to raise additional capital to operate our business, which may not be available on favorable terms, or at all, and which
will have a dilutive effect on our shareholders.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">To date, we have not generated significant
revenues from product sales and only minimal revenues from research and development services and other fees, other than the milestone
payments we received in connection with our license and supply agreement with Pfizer. For the years ended December 31, 2012, 2011
and 2010, we had net losses of $11.6 million, $</FONT>36.5<FONT STYLE="color: black"> million and $</FONT>29.0<FONT STYLE="color: black">
million, respectively, primarily as a result of expenses incurred through a combination of research and development activities
and expenses supporting those activities, which includes share-based compensation expense. Drug development and commercialization
is very capital intensive. Our lead product has been approved for marketing by the FDA in May 2012 and by the Israeli MOH in September
2012 and is still in the early launch phase, therefore, we will have to fund all of our operations and capital expenditures from
the revenues we generate from sales of taliglucerase alfa supplemented with our cash on hand, other licensing fees and grants
and the net proceeds of any equity or debt offerings. Over the next 12 months, we expect to spend a minimum of approximately $</FONT>30.0
<FONT STYLE="color: black">million on our internal sales and marketing force for the sale of taliglucerase alfa in Israel and
on preclinical and clinical development for our products candidates. Based on our current plans and capital resources, we believe
that our cash and cash equivalents will be sufficient to enable us to meet our planned operating needs for at least 12 months.
However, changes may occur that could consume our existing capital at a faster rate than projected, including, among others, the
cost and timing of regulatory approvals, changes in the progress of our research and development efforts and the costs of protecting
our intellectual property rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may seek additional financing to implement and fund product
development, preclinical studies and clinical trials for the drugs in our pipeline, as well as additional drug candidates and
other research and development projects. If we are unable to secure additional financing in the future on acceptable terms, or
at all, we may be unable to commence or complete planned preclinical and clinical trials or obtain approval of our drug candidates
from the FDA and other regulatory authorities. In addition, we may be forced to reduce or discontinue product development or product
licensing, reduce or forego sales and marketing efforts and other commercialization activities or forego attractive business opportunities
in order to improve our liquidity and to enable us to continue operations which would have a material adverse effect on our business
and results of operations. Any additional source of financing will likely involve the issuance of our equity securities, which
will have a dilutive effect on our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to the Commercialization of taliglucerase
alfa </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We received marketing approval of taliglucerase alfa from
the FDA in May 2012; accordingly, we cannot predict our share in net income we will receive from Pfizer's sales of taliglucerase
alfa. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">Taliglucerase alfa has been approved
for marketing in the United States, Israel and Uruguay. Otherwise, we </FONT>have no other products approved for marketing<FONT STYLE="color: black">.
As we have invested a significant portion of our efforts and financial resources in the development of taliglucerase alfa, our
ability to generate product revenue depends heavily on the successful commercialization of taliglucerase alfa. In November 2009,
we granted Pfizer an exclusive worldwide license to develop and commercialize taliglucerase alfa, except in Israel. We retained
such rights in Israel. Sales of taliglucerase alfa worldwide (except Israel) are dependent upon Pfizer's sales and marketing efforts,
which we do not control and may not be able to effectively influence, and on the actions and decisions of foreign regulatory authorities.
Upon the approval of taliglucerase alfa in markets outside of the United States and Israel, if at all, Pfizer </FONT>may experience
delays in, or be unable to achieve, the commercial introduction of taliglucerase alfa in those markets, which would have a <FONT STYLE="color: black">material
adverse effect on our business, results of operations and financial condition</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our future revenues under our collaboration with Pfizer from
Pfizer's sales of taliglucerase alfa will depend on a number of factors, including:</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the number
                                                                                                                 of Gaucher patients
                                                                                                                 who will be treated
                                                                                                                 with taliglucerase
                                                                                                                 alfa;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the willingness
                                                                                                                 of Gaucher patients
                                                                                                                 to switch from
                                                                                                                 other ERTs to
                                                                                                                 taliglucerase
                                                                                                                 alfa;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>competition
                                                                                                                 from Cerezyme
                                                                                                                 and VPRIV, and
                                                                                                                 other approved
                                                                                                                 treatments of
                                                                                                                 Gaucher disease;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Pfizer's
                                                                                                                 efforts under
                                                                                                                 the Pfizer Agreement
                                                                                                                 and the effectiveness
                                                                                                                 of Pfizer's commercial
                                                                                                                 strategy and
                                                                                                                 its execution
                                                                                                                 of that strategy,
                                                                                                                 including its
                                                                                                                 pricing strategy
                                                                                                                 and the effectiveness
                                                                                                                 of its efforts
                                                                                                                 to obtain adequate
                                                                                                                 third-party reimbursements;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>obtaining
                                                                                                                 marketing approvals
                                                                                                                 from regulatory
                                                                                                                 authorities outside
                                                                                                                 of the United
                                                                                                                 States;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a continued
                                                                                                                 acceptable safety
                                                                                                                 and efficacy
                                                                                                                 profile of our
                                                                                                                 product candidates
                                                                                                                 following approval;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the successful
                                                                                                                 audit of our
                                                                                                                 facilities by
                                                                                                                 additional regulatory
                                                                                                                 authorities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>maintaining
                                                                                                                 the cGMP compliance
                                                                                                                 of our manufacturing
                                                                                                                 facility or establishing
                                                                                                                 manufacturing
                                                                                                                 arrangements
                                                                                                                 with third parties;
                                                                                                                 and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the capacity
                                                                                                                 of physicians
                                                                                                                 and health care
                                                                                                                 providers to
                                                                                                                 provide treatment
                                                                                                                 to Gaucher patients.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Over
the next several years, the revenues we generate under our collaboration with Pfizer will also depend, in part, on the receipt
of marketing approval for taliglucerase alfa in Brazil, Australia and in the rest of the world. We cannot accurately predict the
amount of revenues we will generate under our collaboration with Pfizer in future periods, if any. </FONT><FONT STYLE="color: black">Any
failure to commercialize taliglucerase alfa or the experience of significant delays in doing so will have a material adverse effect
on our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
market share and/or other indicators of market acceptance of taliglucerase alfa may not meet the expectations of investors or
public market analysts, which would have a </FONT><FONT STYLE="color: black">material adverse effect on our business, results
of operations and financial condition</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> and the market price of
our common stock would likely decline. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If safety issues regarding taliglucerase alfa that were
not known at the time of approval are discovered, or if we or Pfizer fail to comply with continuing U.S. and applicable foreign
regulations, commercialization efforts for taliglucerase alfa could be adversely affected and taliglucerase alfa could lose its
approval or its sales could be suspended. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Drug products remain subject to continuing regulatory oversight
after they are approved for marketing, including the review of additional safety information. Drugs are more widely used by patients
once approved for sale and, therefore, side-effects and other problems may be observed after approval that were not seen or anticipated,
or were not as prevalent or severe, during clinical trials or nonclinical studies. The subsequent discovery of previously unknown
problems with a product could negatively affect commercial sales of the product, result in restrictions on the product or lead
to the withdrawal of the product from the market. The reporting of adverse safety events involving taliglucerase alfa or public
speculation about such events could cause our stock price to decline or experience periods of volatility and may have a material
adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we or Pfizer fail to comply with applicable continuing regulatory
requirements, we or Pfizer may be subject to fines and/or criminal prosecutions, and taliglucerase may become subject to suspension
or withdrawal of regulatory approval, product recalls and seizures and operating restrictions. In addition, the manufacturers
we and Pfizer engage to produce taliglucerase alfa and the manufacturing facilities in which taliglucerase alfa is made are subject
to periodic review and inspection by the FDA and foreign regulatory authorities. If problems are identified during the review
or inspection of these manufacturers or manufacturing facilities, it could result in our inability to use the facility to make
our product or a determination that inventories are not safe for commercial sale, which may have a material adverse effect on
our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If physicians, patients, third party payors and others in
the medical community do not accept and use of taliglucerase alfa, or any of our other product candidates, if approved, our ability
to generate revenue from product sale will be materially impaired. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">Physicians and patients, and other
healthcare providers, may not accept and use taliglucerase alfa or any </FONT>of our other product candidates, if approved <FONT STYLE="color: black">for
marketing. Future acceptance and use of taliglucerase alfa or any </FONT>of our other product candidates, if approved, <FONT STYLE="color: black">will
depend upon a number of factors including:</FONT></P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>perceptions
                                                                                                                 by physicians,
                                                                                                                 patients, third
                                                                                                                 party payors
                                                                                                                 and others in
                                                                                                                 the medical community
                                                                                                                 about the safety
                                                                                                                 and effectiveness
                                                                                                                 of taliglucerase
                                                                                                                 alfa or our other
                                                                                                                 drug candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the willingness
                                                                                                                 of the target
                                                                                                                 patient population
                                                                                                                 to try new therapies
                                                                                                                 and of physicians
                                                                                                                 to prescribe
                                                                                                                 these therapies;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the prevalence
                                                                                                                 and severity
                                                                                                                 of any side effects,
                                                                                                                 including any
                                                                                                                 limitations or
                                                                                                                 warnings contained
                                                                                                                 in our products&rsquo;
                                                                                                                 approved labeling;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>pharmacological
                                                                                                                 benefits of taliglucerase
                                                                                                                 alfa or our other
                                                                                                                 drug candidates
                                                                                                                 relative to competing
                                                                                                                 products and
                                                                                                                 products under
                                                                                                                 development;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the efficacy
                                                                                                                 and potential
                                                                                                                 advantages relative
                                                                                                                 to competing
                                                                                                                 products and
                                                                                                                 products under
                                                                                                                 development;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>relative
                                                                                                                 convenience and
                                                                                                                 ease of administration;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>effectiveness
                                                                                                                 of education,
                                                                                                                 marketing and
                                                                                                                 distribution
                                                                                                                 efforts by us
                                                                                                                 and our licensees
                                                                                                                 and distributors,
                                                                                                                 if any;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>publicity
                                                                                                                 concerning taliglucerase
                                                                                                                 alfa or our other
                                                                                                                 drug candidates
                                                                                                                 or competing
                                                                                                                 products and
                                                                                                                 treatments;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>coverage
                                                                                                                 and reimbursement
                                                                                                                 of our products
                                                                                                                 by third party
                                                                                                                 payors; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the price
                                                                                                                 for our products
                                                                                                                 and competing
                                                                                                                 products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">Because we expect sales of taliglucerase
alfa to generate substantially all of our product revenues for the </FONT>foreseeable<FONT STYLE="color: black"> future, any lack
of market acceptance of taliglucerase alfa would have a material adverse effect on our business, results of operations and financial
condition. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If the market opportunities for taliglucerase alfa or our
other product candidates are smaller than we believe they are, our revenues may be adversely affected and our business may suffer.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, our development efforts have focused mainly on relatively
rare disorders with small patient populations, in particular Gaucher disease and Fabry disease. Currently, most reported estimates
of the prevalence of these diseases are based on studies of small subsets of the population of specific geographic areas, which
are then extrapolated to estimate the prevalence of the diseases in the broader world population. As new studies are performed,
the estimated prevalence of these diseases may change. There can be no assurance that the prevalence of Gaucher disease or Fabry
disease in the study populations, particularly in these newer studies, accurately reflect the prevalence of these diseases in
the broader world population. If the market opportunities for our current product candidates are smaller than we believe they
are, our revenues may be adversely affected and our business may suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Coverage
and reimbursement may not be available for</B></FONT><B> taliglucerase alfa or any of our other product candidates, if approved<FONT STYLE="font-family: Times New Roman, Times, Serif">,
which could diminish our sales or affect our ability to sell taliglucerase alfa or any other products profitably. </FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Market acceptance and sales of taliglucerase alfa or any of
our other product candidates, if approved, will depend on worldwide coverage and reimbursement policies. Government authorities
and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will pay
for and establish reimbursement levels. Coverage and reimbursement might not be available for taliglucerase alfa or any of our
other product candidates, if approved for marketing and sale. <FONT STYLE="color: black">Obtaining reimbursement approval for
an approved product from governments and other third party payors is a time consuming and costly process that requires our collaborators
or us, as the case may be, to provide supporting scientific, clinical and cost-effectiveness data for the use of our products,
if and when approved, to every payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage
and reimbursement or we might need to conduct post-marketing studies in order to demonstrate the cost-effectiveness of approved
products, if any, to such payors&rsquo; satisfaction. Such studies might require our collaborators or us to commit a significant
amount of management time and financial and other resources. Even if a payor determines that taliglucerase alfa, or any other
approved product, if any, is eligible for reimbursement, the payor may impose coverage limitations that preclude payment for some
uses that are approved by the FDA or other regulatory authorities. In addition, full reimbursement may not be available for high
priced products. Moreover, eligibility for coverage does not imply that any approved product will be reimbursed in all cases or
at a rate that allows us to make a profit or even cover our costs. </FONT>Also, limited reimbursement amounts may reduce the demand
for, or the price of, our product candidates. Except with respect to taliglucerase alfa, we have not commenced efforts to have
our product candidates covered and reimbursed by government or third-party payors. If coverage and reimbursement are not available
or are available only to limited levels, the sales of our products, if approved may be diminished or we may not be able to sell
such products profitably.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We and our collaborating partners may be subject, directly
or indirectly, to federal and state healthcare fraud and abuse and false claims laws and regulations. If we or our collaborating
partners are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All marketing activities associated with taliglucerase alfa
in the United States, as well as marketing activities in the United States related to any other products for which we obtain regulatory
approval, if any, will be<FONT STYLE="font-family: Times New Roman, Times, Serif">, directly or indirectly through our customers,
</FONT>subject to numerous federal and state laws governing the marketing and promotion of pharmaceutical products in the United
States<FONT STYLE="font-family: Times New Roman, Times, Serif">, including, without limitation, the federal Anti-Kickback Statute,
the federal False Claims Act and HIPAA. </FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">These laws may adversely
impact, among other things, our proposed sales, marketing and education programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, receiving, offering or paying remuneration,
directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending, or arranging for a good
or service, for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs. The
term &ldquo;remuneration&rdquo; has been broadly interpreted to include anything of value, including for example, gifts, discounts,
the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of co-payments and deductibles, ownership
interests and providing anything at less than its fair market value. The reach of the Anti-Kickback Statute was also broadened
by the </FONT><FONT STYLE="color: black">Patient Protection and Affordable Care Act, as amended by the Health Care and Education
Affordability Reconciliation Act, or the PPACA</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">, which, among other
things, amends the intent requirement of the federal Anti-Kickback Statute and the applicable criminal healthcare fraud statutes
contained within 42 U.S.C. &sect; 1320a-7b, effective March 23, 2010. Pursuant to the statutory amendment, a person or entity
no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation.
In addition, PPACA provides that the government may assert that a claim including items or services resulting from a violation
of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act (discussed
below) or the civil monetary penalties statute, which imposes penalties against any person who is determined to have presented
or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that
was not provided as claimed or is false or fraudulent. The federal Anti-Kickback Statute is broad, and despite a series of narrow
safe harbors, prohibits many arrangements and practices that are lawful in businesses outside of the healthcare industry. Penalties
for violations of the federal Anti-Kickback Statute include criminal penalties and civil sanctions such as fines, imprisonment
and possible exclusion from Medicare, Medicaid and other state or federal healthcare programs. Many states have also adopted laws
similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare items or services
reimbursed by any source, not only the Medicare and Medicaid programs, and do not contain identical safe harbors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The federal False Claims Act imposes liability on any person
who, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal healthcare
program. The &ldquo;qui tam&rdquo; provisions of the False Claims Act allow a private individual to bring civil actions on behalf
of the federal government alleging that the defendant has submitted a false claim to the federal government, and to share in any
monetary recovery. In addition, various states have enacted false claims laws analogous to the False Claims Act. Many of these
state laws apply where a claim is submitted to any third-party payer and not merely a federal healthcare program. When an entity
is determined to have violated the False Claims Act, it may be required to pay up to three times the actual damages sustained
by the government, plus civil penalties of $5,500 to $11,000 for each separate false claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Health Insurance Portability and Accountability Act of
1996, or HIPAA, created several new federal crimes, including health care fraud, and false statements relating to health care
matters. The health care fraud statute prohibits knowingly and willfully executing a scheme to defraud any health care benefit
program, including private third-party payers. The false statements statute prohibits knowingly and willfully falsifying, concealing
or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery
of or payment for health care benefits, items or services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are unable to predict whether we could be subject to actions
under any of these or other fraud and abuse laws, or the impact of such actions. Moreover, to the extent that taliglucerase alfa,
or any of our products, if approved for marketing, will be sold in a foreign country, we and our collaborators, including Pfizer,
may be subject to similar foreign laws and regulations. If we or any of our collaborators are found to be in violation of any
of the laws described above and other applicable state and federal fraud and abuse laws, we may be subject to penalties, including
civil and criminal penalties, damages, fines, exclusion from government healthcare reimbursement programs and the curtailment
or restructuring or our operations, any of which could have a material adverse effect on our business, results of operations and
financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We have a limited operating history which may limit the
ability of investors to make an informed investment decision. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Taliglucerase alfa, which has been approved for marketing in
the United States and Israel, is our first commercial product. The successful commercialization of our drug candidates will require
us to perform a variety of functions, including:</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>continuing
                                                                                                                 to undertake
                                                                                                                 preclinical development
                                                                                                                 and clinical
                                                                                                                 trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>participating
                                                                                                                 in regulatory
                                                                                                                 approval processes;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>formulating
                                                                                                                 and manufacturing
                                                                                                                 products; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>conducting
                                                                                                                 sales and marketing
                                                                                                                 activities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our operations have been limited to organizing and staffing
our company, acquiring, developing and securing our proprietary technology and undertaking, through third parties, preclinical
trials and clinical trials of our principal drug candidates. To date, we have commenced a phase III clinical trial in connection
with only one drug candidate, taliglucerase alfa, which trial was completed in August 2009. These operations provide a limited
basis for investors to assess our ability to commercialize our drug candidates and whether to invest in our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our strategy, in certain cases, is to enter into collaboration
agreements with third parties to leverage our ProCellEx system to develop product candidates. If we fail to enter into these agreements
or if we or the third parties do not perform under such agreements or terminate or elect to discontinue the collaboration, it
could have a material adverse affect on our revenues. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">Our strategy, in certain cases,
is to enter into arrangements with pharmaceutical companies to leverage our ProCellEx system to develop additional product candidates</FONT>.
<FONT STYLE="color: black">Under these arrangements, we may grant to our partners rights to license and commercialize pharmaceutical
products developed under the applicable agreements. Our partners may control key decisions relating to the development of the
products and we may depend on our partners&rsquo; expertise and dedication of sufficient resources to develop and commercialize
our product candidates. The rights of our partners limit our flexibility in considering alternatives for the commercialization
of our product candidates. If we or any of our current or future partners breach or terminate the agreements that make up such
arrangements, our partners otherwise fail to conduct their obligations under such arrangements in a timely manner, there is a
dispute about their obligations or if either party terminates the applicable agreement or elects not to continue the arrangement,
we may not enjoy the benefits of the agreements or receive a sufficient amount of royalty or milestone payments from them, if
any, which may have a material adverse effect on our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We have no experience selling, marketing or distributing
products and no internal capability to do so. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We currently have very limited sales, marketing or distribution
capabilities and no experience in building a sales force and distribution capabilities. In November 2009, we granted to Pfizer
an exclusive, worldwide right to develop and commercialize taliglucerase alfa, but retained such rights in Israel. To be able
to commercialize taliglucerase alfa in Israel, and to commercialize any of our other product candidates, we must either develop
internal sales, marketing and distribution capabilities, which will be expensive and time consuming, or make arrangements with
third parties to perform these services. If we decide to market any of our products directly, we must commit significant financial
and managerial resources to develop a marketing and sales force with technical expertise and with supporting distribution capabilities.
Factors that may inhibit our efforts to commercialize our products directly and without strategic partners include:</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the inability
                                                                                                                 to recruit and
                                                                                                                 retain adequate
                                                                                                                 numbers of effective
                                                                                                                 sales and marketing
                                                                                                                 personnel;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the inability
                                                                                                                 of sales personnel
                                                                                                                 to obtain access
                                                                                                                 to an adequate
                                                                                                                 numbers of physicians
                                                                                                                 or to pursuance
                                                                                                                 them to prescribe
                                                                                                                 our products;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the lack
                                                                                                                 of complementary
                                                                                                                 products to be
                                                                                                                 offered by sales
                                                                                                                 personnel, which
                                                                                                                 may put us at
                                                                                                                 a competitive
                                                                                                                 disadvantage
                                                                                                                 relative to companies
                                                                                                                 with more extensive
                                                                                                                 product lines;&nbsp;and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>unforeseen
                                                                                                                 costs and expenses
                                                                                                                 associated with
                                                                                                                 creating and
                                                                                                                 sustaining an
                                                                                                                 independent sales
                                                                                                                 and marketing
                                                                                                                 organization.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may not be successful in recruiting or retaining the sales
and marketing personnel necessary to sell any of our products upon approval, if at all, which would have a material adverse effect
on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We may enter into distribution arrangements and marketing
alliances for certain products and any failure to successfully identify and implement these arrangements on favorable terms, if
at all, may impair our ability to commercialize our product candidates.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">While we intend to build a sales force to market taliglucerase
alfa in Israel and other product candidates worldwide , we do not anticipate having the resources in the foreseeable future to
develop global sales and marketing capabilities for all of the products we develop. We may pursue arrangements regarding the sales
and marketing and distribution of one or more of our product candidates, such as our current license and supply agreement with
Pfizer for taliglucerase alfa, and our future revenues may depend, in part, on our ability to enter into and maintain arrangements
with other companies having sales, marketing and distribution capabilities and the ability of such companies to successfully market
and sell any such products. <FONT STYLE="color: black">Any failure to enter into such arrangements and marketing alliances on
favorable terms, if at all, could delay or impair our ability to commercialize our product candidates and could increase our costs
of commercialization. Any use of distribution arrangements and marketing alliances to commercialize our product candidates will
subject us to a number of risks, including the following: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>we may be
                                                                                                                 required to relinquish
                                                                                                                 important rights
                                                                                                                 to our products
                                                                                                                 or product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>we may not
                                                                                                                 be able to control
                                                                                                                 the amount and
                                                                                                                 timing of resources
                                                                                                                 that our distributors
                                                                                                                 or collaborators
                                                                                                                 may devote to
                                                                                                                 the commercialization
                                                                                                                 of our product
                                                                                                                 candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our distributors
                                                                                                                 or collaborators
                                                                                                                 may experience
                                                                                                                 financial difficulties;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our distributors
                                                                                                                 or collaborators
                                                                                                                 may not devote
                                                                                                                 sufficient time
                                                                                                                 to the marketing
                                                                                                                 and sales of
                                                                                                                 our products;
                                                                                                                 and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>business
                                                                                                                 combinations
                                                                                                                 or significant
                                                                                                                 changes in a
                                                                                                                 collaborator&rsquo;s
                                                                                                                 business strategy
                                                                                                                 may adversely
                                                                                                                 affect a collaborator&rsquo;s
                                                                                                                 willingness or
                                                                                                                 ability to complete
                                                                                                                 its obligations
                                                                                                                 under any arrangement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may need to enter into additional co-promotion arrangements
with third parties where our own sales force is neither well situated nor large enough to achieve maximum penetration in the market.
We may not be successful in entering into any co-promotion arrangements, and the terms of any co-promotion arrangements we enter
into may not be favorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our ProCellEx protein expression system is based on our
proprietary plant cell-based expression technology which has a limited history and any material problems with the system, which
may be unforeseen, may have a material adverse effect on our business, results of operations and financial condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our ProCellEx protein expression system is based on our proprietary
plant cell-based expression technology. The success of our business is dependent upon the successful development and approval
of our product and product candidates produced through this technology. Although taliglucerase alfa is produced through ProCellEx,
the technology remains <FONT STYLE="color: black">novel. Accordingly, the technology remains subject to certain risks. Mammalian
cell-based protein expression systems have been used in connection with recombinant therapeutic protein expression for more than
20 years and are the subject of a wealth of data; in contrast, there is not a significant amount of data generated regarding plant
cell-based protein expression and, accordingly, plant cell-based protein expression systems may be subject to unknown risks. In
addition, the protein glycosilation pattern created by our protein expression system is not identical to the natural human glycosilation
pattern and its long term effect on human patients is still unknown. Lastly, as our protein expression system is a new technology,
we cannot always rely on existing equipment; rather, there is a need to design custom-made equipment and to generate specific
growth media for the plant cells which may not be available at favorable prices, if at all. </FONT>Any material problems with
the technology underlying our plant cell-based protein expression system may have a material adverse effect on our business, results
of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We currently depend heavily on the success of taliglucerase
alfa, our first commercial product. Any failure to successfully commercialize taliglucerase alfa, or the experience of significant
delays in doing so, will have a material adverse effect on our business, results of operations and financial condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have invested a significant portion of our efforts and financial
resources in the development of taliglucerase alfa which has been approved in the United States, Israel and Uruguay. Our ability
to generate product revenue, depends heavily on the successful development and commercialization of taliglucerase alfa. In November
2009, we granted Pfizer an exclusive worldwide license to develop and commercialize taliglucerase alfa except in Israel. We retained
such rights in Israel. The successful commercialization of taliglucerase alfa will depend on several factors, including the following:</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>obtaining
                                                                                                                 marketing approvals
                                                                                                                 from additional
                                                                                                                 regulatory authorities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>successful
                                                                                                                 completion of
                                                                                                                 our ongoing studies
                                                                                                                 of taliglucerase
                                                                                                                 alfa;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the successful
                                                                                                                 audit of our
                                                                                                                 facilities by
                                                                                                                 additional regulatory
                                                                                                                 authorities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>maintaining
                                                                                                                 the cGMP compliance
                                                                                                                 of our manufacturing
                                                                                                                 facility or establishing
                                                                                                                 manufacturing
                                                                                                                 arrangements
                                                                                                                 with third parties;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Pfizer&rsquo;s
                                                                                                                 efforts under
                                                                                                                 the Pfizer Agreement;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our development
                                                                                                                 of a successful
                                                                                                                 sales and marketing
                                                                                                                 organization
                                                                                                                 for taliglucerase
                                                                                                                 in Israel;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a continued
                                                                                                                 acceptable safety
                                                                                                                 and efficacy
                                                                                                                 profile of taliglucerase
                                                                                                                 alfa;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the availability
                                                                                                                 of reimbursement
                                                                                                                 to patients from
                                                                                                                 healthcare payors
                                                                                                                 for taliglucerase
                                                                                                                 alfa; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>other risks
                                                                                                                 described in
                                                                                                                 these Risk Factors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any failure to successfully commercialize taliglucerase alfa
or the experience of significant delays in doing so will have a material adverse effect on our business, results of operations
and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If we are unable to develop and commercialize our product
candidates, our business will be adversely affected. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A key element of our strategy is to develop and commercialize
a portfolio of new products in addition to taliglucerase alfa. We are seeking to do so through our internal research programs and
strategic collaborations for the development of new products. Research programs to identify new product candidates require substantial
technical, financial and human resources, whether or not any product candidates are ultimately identified. Our research programs
may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development
for many reasons, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a product candidate is not capable of being produced in commercial quantities at an acceptable cost, or at all;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a product candidate may not be accepted by patients, the medical community or third-party payors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>competitors may develop alternatives that render our product candidates obsolete;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the research methodology used may not be successful in identifying potential product candidates; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it is
unlikely to be effective or otherwise does not meet applicable regulatory approval.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any failure to develop or commercialize any of our other product
candidates may have a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B>Clinical
trials are very expensive, time-consuming and difficult to design and implement and may result in unforeseen costs which may have
a material adverse effect on our business, results of operations and financial condition.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">Human
clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory
requirements. The clinical trial process is also time-consuming. Other than taliglucerase alfa, all of our other drug candidates
are in the clinical, preclinical or research stages and will take at least several years to complete. Preliminary and initial results
from a clinical trial do not necessarily predict final results, and failure can occur at any stage of the trials. We may encounter
problems that cause us to abandon or repeat preclinical studies or clinical trials. Companies in the pharmaceutical and biotechnology
industries have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier trials.
Data obtained from tests are susceptible to varying interpretations which may delay, limit or prevent regulatory approval. Failure
or delay in the commencement or completion of our clinical trials may be caused by several factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>unforeseen safety issues;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>determination of dosing issues;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>lack of effectiveness during clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>slower than expected rates of patient recruitment;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>inability to monitor patients adequately during or after treatment;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>lack of sufficient funding to finance the clinical trials.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any failure or delay in commencement or completion of any clinical
trials may have a material adverse effect on our business, results of operations and financial condition. In addition, we or the
FDA or other regulatory authorities may suspend any clinical trial at any time if it appears that we are exposing participants
in the trial to unacceptable safety or health risks or if the FDA or such other regulatory authorities, as applicable, find deficiencies
in our IND submissions or the conduct of the trial. Any suspension of a clinical trial may have a material adverse effect on our
business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B>If
the results of our clinical trials do not support our claims relating to any drug candidate or if serious side effects are identified,
the completion of development of such drug candidate may be significantly delayed or we may be forced to abandon development altogether,
which will significantly impair our ability to generate product revenues.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">The results of our clinical
trials with respect to any drug candidate might not support our claims of safety or efficacy, the effects of our drug candidates
may not be the desired effects or may include undesirable side effects or the drug candidates may have other unexpected characteristics.&nbsp;&nbsp;Further,
success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and the
results of later clinical trials may not replicate the results of prior clinical trials and preclinical testing.&nbsp;&nbsp;The
clinical trial process may fail to demonstrate that our drug candidates are safe for humans and effective for indicated uses.&nbsp;&nbsp;In
addition, our clinical trials may involve a specific and small patient population.&nbsp;&nbsp;Results of early clinical trials
conducted on a small patient population may not be indicative of future results.&nbsp;&nbsp;Adverse or inconclusive results may
cause us to abandon a drug candidate and may delay development of other drug candidates.&nbsp;&nbsp;Any delay in, or termination
of, our clinical trials will delay the filing of NDAs with the FDA, or other filings with other foreign regulatory authorities,
and, ultimately, significantly impair our ability to commercialize our drug candidates and generate product revenues which would
have a material adverse effect on our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B>We
may find it difficult to enroll patients in our clinical trials, which could cause significant delays in the completion of such
trials or may cause us to abandon one or more clinical trials.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">Many
of the diseases or disorders that our drug candidates are intended to treat are relatively rare and we expect only a subset of
the patients with these diseases to be eligible for our clinical trials. Our clinical trials generally mandate that a patient cannot
be involved in another clinical trial for the same indication. Therefore, subjects that participate in ongoing clinical trials
for products that are competitive with our drug candidates are not available for our clinical trials. An inability to enroll a
sufficient number of patients for any of our current or future clinical trials would result in significant delays or may require
us to abandon one or more clinical trials altogether, which will have a material adverse effect on our business, results of operations
and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B>Patients
may discontinue their participation in our clinical trials, which may negatively impact the results of these studies and extend
the timeline for completion of our development programs.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Patients enrolled in our
clinical trials may discontinue their participation at any time during the study as a result of a number of factors, including
withdrawing their consent or experiencing adverse clinical events, which may or may not be judged related to our drug candidates
under evaluation. The discontinuation of patients in any one of our studies may cause the results from that study not to be positive
or to not support a filing for regulatory approval of the applicable drug candidate, which would have a material adverse effect
on our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Because our clinical trials depend upon third-party researchers,
the results of our clinical trials and such research activities are subject to delays and other risks which are, to a certain extent,
beyond our control, which could impair our clinical development programs and our competitive position. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We depend upon independent investigators and collaborators,
such as universities and medical institutions, to conduct our preclinical and clinical trials. These collaborators are not our
employees, and we cannot control the amount or timing of resources that they devote to our clinical development programs. The investigators
may not assign as great a priority to our clinical development programs or pursue them as diligently as we would if we were undertaking
such programs directly. If outside collaborators fail to devote sufficient time and resources to our clinical development programs,
or if their performance is substandard, the approval of our NDA and other marketing applications, and our introduction of new drugs,
if any, may be delayed which could impair our clinical development programs and would have a material adverse effect on our business
and results of operations. The collaborators may also have relationships with other commercial entities, some of whom may compete
with us. If our collaborators also assist our competitors, our competitive position could be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The manufacture of our products is an exacting and complex
process, and if we or one of our materials suppliers encounter problems manufacturing our products, it will have a material adverse
effect on our business and results of operations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">The FDA and foreign regulators require
manufacturers to register manufacturing facilities. The FDA and foreign regulators also inspect these facilities to confirm compliance
with cGMP or similar requirements that the FDA or foreign regulators establish. We or our materials suppliers may face manufacturing
or quality control problems causing product production and shipment delays or a situation where we or the supplier may not be able
to maintain compliance with the FDA&rsquo;s cGMP requirements, or those of foreign regulators, necessary to continue manufacturing
our drug candidates. Any failure to comply with cGMP requirements or other FDA or foreign regulatory requirements could adversely
affect our clinical research activities an</FONT>d our ability to market and develop our products. To date, our current facility
has passed audits by the FDA, the Israeli MOH, ANVISA and the IMB on behalf of the EMA but remains subject to audit by other foreign
regulatory authorities. There can be no assurance that we will be able to comply with FDA or foreign regulatory manufacturing requirements
for our current facility or any facility we may establish in the future, which would have a material adverse effect on our business,
<FONT STYLE="color: black; background-color: white">results of operations and financial condition</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We rely on third parties for final processing of taliglucerase
alfa and our other product candidates, which exposes us to a number of risks that may delay development, regulatory approval and
commercialization of taliglucerase alfa and our other product candidates or result in higher product costs.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have no experience in the final filling and freeze drying
steps of the drug manufacturing process. We have engaged a European contract manufacturer to act as an additional source of fill
and finish activities for taliglucerase alfa and have engaged other parties for our other product candidates. We currently rely
primarily on other third-party contractors to perform the final manufacturing steps for taliglucerase alfa on a commercial scale.
We may be unable to identify manufacturers and/or replacement manufacturers on acceptable terms or at all because the number of
potential manufacturers is limited and the FDA and other regulatory authorities, as applicable, must approve any manufacturer and/or
replacement manufacturer, including us, and we or any such third party manufacturer might be unable to formulate and manufacture
our drug products in the volume and of the quality required to meet our clinical and commercial needs. If we engage any contract
manufacturers, such manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time
required to supply our clinical or commercial needs. In addition, contract manufacturers are subject to the rules and regulations
of the FDA and comparable foreign regulatory authorities and face the risk that any of those authorities may find that they are
not in compliance with applicable regulations. Each of these risks could delay our clinical trials, the approval, if any, of taliglucerase
alfa and our other potential drug candidates by the FDA and other regulatory authorities, or the commercialization of taliglucerase
alfa and our other drug candidates or could result in higher product costs or otherwise deprive us of potential product revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Developments by competitors may render our products or technologies
obsolete or non-competitive which would have a material adverse effect on our business, results of operations and financial condition.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">We compete against fully integrated
pharmaceutical companies and smaller companies that are collaborating with larger pharmaceutical companies, academic institutions,
government agencies and other public and p</FONT>rivate research organizations. Our drug candidates will have to compete with existing
therapies and therapies under development by our competitors. In addition, our commercial opportunities may be reduced or eliminated
if our competitors develop and market products that are less expensive, more effective or safer than our drug products. Other companies
have drug candidates in various stages of preclinical or clinical development to treat diseases for which we are also seeking to
develop drug products. Some of these potential competing drugs are further advanced in development than our drug candidates and
may be commercialized earlier. Even if we are successful in developing effective drugs, our products may not compete successfully
with products produced by our competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We specifically face competition from companies with approved
treatments of Gaucher disease. In addition to ELELYSO, there are two other ERTs for the treatment of Gaucher disease; Cerezyme
and VPRIV. To a much lesser extent, we also compete with Actelion. In addition, we are aware of other clinical stage, experimental,
small molecule, oral drugs which are being developed for the treatment of Gaucher disease by Genzyme.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There are two approved ERTs for the treatment of Fabry disease;
Fabrazyme and Replagal. Fabrazyme is available in the United States and the European Union. Replagal is available in the European
Union. In 2012, Shire elected to withdraw its BLA for Replagal in the United States. In addition, we are aware of other clinical
stage, early clinical stage and experimental drugs which are being developed for the treatment of Fabry disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also face competition from companies that are developing
other platforms for the expression of recombinant therapeutic pharmaceuticals. We are aware of companies that are developing alternative
technologies to develop and produce therapeutic proteins in anticipation of the expiration of certain patent claims covering marketed
proteins. Competitors developing alternative expression technologies include Crucell N.V. (which was acquired by Johnson &amp;
Johnson during 2010), Shire and GlycoFi, Inc. (which was acquired by Merck &amp; Co. Inc.). Other companies are developing alternate
plant-based technologies, include Chlorogen, Inc., iBio, Medicago, Greenovation Biotech GmbH, and Symbiosys, none of which are
cell-based. Rather, such companies base their product development on transgenic plants or whole plants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Several biogeneric companies are pursuing the opportunity to
develop and commercialize follow-on versions of other currently marketed biologic products, including growth factors, hormones,
enzymes, cytokines and monoclonal antibodies, which are areas that interest us. These companies include, among others, Novartis
AG/Sandoz Pharmaceuticals, BioGeneriX AG, Stada Arzneimittel AG, BioPartners GmbH and Teva.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Most of our competitors, either alone or together with their
collaborative partners, operate larger research and development programs, staff and facilities and have substantially greater financial
resources than we do, as well as significantly greater experience in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>developing drugs;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>undertaking preclinical testing and human clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>obtaining marketing approvals from the FDA and other regulatory authorities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>formulating and manufacturing drugs; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>launching, marketing and selling drugs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These organizations also compete with us to attract qualified
personnel, acquisitions and joint ventures candidates and for other collaborations. Activities of our competitors may impose unanticipated
costs on our business which would have a material adverse effect on our business, results of operations and financial condition.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If we in-license drug candidates, we may delay or otherwise
adversely affect the development of our existing drug candidates, which may negatively impact our business, results of operations
and financial condition. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to our own internally developed drug candidates,
we proactively seek opportunities to in-license and advance other drug candidates that are strategic and have value-creating potential
to take advantage of our development know-how and technology. If we in-license any additional drug candidate, our capital requirements
may increase significantly. In addition, in-licensing additional drug candidates may place a strain on the time of our existing
personnel, which may delay or otherwise adversely affect the development of our existing drug candidates or cause us to re-prioritize
our drug pipeline if we do not have the necessary capital resources to develop all of our drug candidates, which may delay the
development of our drug candidates and materially and adversely impact our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If we are unable to successfully manage our growth, there
could be a material adverse impact on our business, results of operations and financial condition. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have grown rapidly and expect to continue to grow. To manage
our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand
our facilities and continue to recruit and train additional qualified personnel. Due to our limited resources, we may not be able
to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our
operations may lead to significant costs and may divert our management and business development resources. Any inability on the
part of our management to manage growth could delay the execution of our business plans or disrupt our operations. If we are unable
to manage our growth effectively, we may not use our resources in an efficient manner, which may delay the development of our drug
candidates and materially and adversely impact our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If we acquire companies, products or technologies, we may
face integration risks and costs associated with those acquisitions that could negatively impact our business, results of operations
and financial condition. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we are presented with appropriate opportunities, we may acquire
or make investments in complementary companies, products or technologies. We may not realize the anticipated benefit of any acquisition
or investment. If we acquire companies or technologies, we will face risks, uncertainties and disruptions associated with the integration
process, including difficulties in the integration of the operations of an acquired company, integration of acquired technology
with our products, diversion of our management&rsquo;s attention from other business concerns, the potential loss of key employees
or customers of the acquired business and impairment charges if future acquisitions are not as successful as we originally anticipate.
In addition, our operating results may suffer because of acquisition-related costs or amortization expenses or charges relating
to acquired intangible assets.<FONT STYLE="color: black"><B> </B></FONT>Any failure to successfully integrate other companies,
products or technologies that we may acquire may have <FONT STYLE="color: black">a material adverse effect on our business and
results of operations</FONT>. Furthermore, we may have to incur debt or issue equity securities to pay for any additional future
acquisitions or investments, the issuance of which could be dilutive to our existing shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We depend upon key employees and consultants in a competitive
market for skilled personnel. If we are unable to attract and retain key personnel, it could adversely affect our ability to develop
and market our products.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">We are highly dependent upon the
</FONT>principal members of our management team, especially our President and Chief Executive Officer, David Aviezer, Ph.D., as
well as the Interim Chairman of our Board of Directors, Zeev Bronfeld, our other directors, our scientific advisory board members,
consultan<FONT STYLE="color: black">ts and collaborating scientists. Many of these people have been involved with us for many years
and have played integral roles in our progress, and we believe that they will continue to provide value to us. A loss of any of
these personnel may have a material a</FONT>dverse effect on aspects of our business, clinical development and regulatory programs.
We have employment agreements with Dr. Aviezer and five other officers that may be terminated by us or the applicable officer at
any time with varying notice periods of 60 to 90 days. <FONT STYLE="color: black">Although these employment agreements generally
include non-competition covenants, the applicable noncompetition provisions can be difficult and costly to monitor and enforce.
The loss of any of these persons&rsquo; services may adversely affect our ability to develop and market our products and obtain
necessary regulatory approvals. Further, we do not maintain key-man life insurance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also depend in part on the continued service of our key scientific
personnel and our ability to identify, hire and retain additional personnel, including marketing and sales staff. We experience
intense competition for qualified personnel, and the existence of non-competition agreements between prospective employees and
their former employers may prevent us from hiring those individuals or subject us to suit from their former employers. While we
attempt to provide competitive compensation packages to attract and retain key personnel, many of our competitors are likely to
have greater resources and more experience than we have, making it difficult for us to compete successfully for key personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our collaborations with outside scientists and consultants
may be subject to restriction and change. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">We work with medical experts, chemists,
biologists and other scientists at academic and other institutions, and consultants who assist us in our research, development,
regulatory and commercial efforts, including the members of our scientific advisory board. These scientists and consultants have
provided, and we expect that they will continue to provide, valuable advice regarding our programs. These scientists and consultants
are not our employees, may have other commitments that would limit their future availability to us and typically will not enter
into non-compete agreements with us. If a conflict of interest arises between their work for us and their work for another entity,
we may lose their services. In addition, we will be unable to prevent them from establishing competing businesses or developing
competing products. For example, if a key scientist acting as a principal investigator in any of our clinical trials identifies
a potential product or compound that is more scientifically interesting to his or her professional interests, his or her availability
to remain involved in our clinical trials could be restricted or eliminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Under current U.S. and Israeli law, we may not be able to
enforce employees&rsquo; covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the
expertise of some of our former employees.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have entered into non-competition agreements with substantially
all of our employees. These agreements prohibit our employees, if they cease working for us, from competing directly with us or
working for our competitors for a limited period. Under current U.S. and Israeli law, we may be unable to enforce these agreements
against most of our employees and it may be difficult for us to restrict our competitors from gaining the expertise our former
employees gained while working for us. <B> </B>If we cannot enforce our employees&rsquo; non-compete agreements, we may be unable
to prevent our competitors from benefiting from the expertise of our former employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If product liability claims are brought against us, it may
result in reduced demand for our products and product candidates or damages that exceed our insurance coverage.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The clinical testing, marketing and use of our products and
product candidates exposes us to product liability claims if the use or misuse of those products or product candidates cause injury
or disease, or results in adverse effects. Use of our products or product candidates, whether in clinical trials or post approval,
could result in product liability claims. We presently carry clinical trial liability insurance with coverages of up to $10.0
million per occurrence and $10.0 million in the aggregate, an amount we consider reasonable and customary. However, this insurance
coverage includes various deductibles, limitations and exclusions from coverage, and in any event might not fully cover any potential
claims. We may need to obtain additional clinical trial liability coverage prior to initiating additional clinical trials. We
expect to obtain product liability insurance coverage before commercialization of our product candidates; however, such insurance
is expensive and insurance companies may not issue this type of insurance when we need it. We may not be able to obtain adequate
insurance in the future at an acceptable cost. Any product liability claim, even one that was not in excess of our insurance coverage
or one that is meritless and/or unsuccessful, may adversely affect our cash available for other purposes, such as research and
development, which may have a material adverse effect on our business, results of operations and financial condition. Product
liability claims, even if without merit, may result in reduced demand for our products, if approved, which would have a material
adverse effect on our business, financial condition and results of operations. In addition, the existence of a product liability
claim could affect the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Reforms in the healthcare industry and the uncertainty associated
with pharmaceutical pricing, reimbursement and related matters could adversely affect the marketing, pricing and demand for our
products, if approved.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Increasing healthcare expenditures have been the subject of
considerable public attention in the United States. Both private and government entities are seeking ways to reduce or contain
healthcare costs. Numerous proposals that would affect changes in the U.S. healthcare system have been introduced or proposed in
the U.S. Congress and in some state legislatures within the United States, including reductions in the pricing of prescription
products and changes in the levels at which consumers and healthcare providers are reimbursed for purchases of pharmaceutical products.
Legislation passed in recent years has imposed certain changes to the way in which drugs, including our product candidates, are
covered and reimbursed in the United States. For example, federal legislation and regulations have implemented new reimbursement
methodologies for certain drugs, created a voluntary prescription drug benefit, Medicare Part D, and have imposed significant revisions
to the Medicaid Drug Rebate Program. The PPACA imposes yet additional changes to these programs. We believe that legislation that
reduces reimbursement for our product candidates could adversely impact how much or under what circumstances healthcare providers
will prescribe or administer our products, if approved. This could materially and adversely impact our business by reducing our
ability to generate revenue, raise capital, obtain additional collaborators and market our products, if approved. In addition,
we believe the increasing emphasis on managed care in the United States has and will continue to put pressure on the price and
usage of pharmaceutical products, which may adversely impact product sales, upon approval, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Governments outside the United States tend to impose strict
price controls and reimbursement approval policies, which may adversely affect our prospects for generating revenue.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">In some countries, particularly European
Union member states, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing
negotiations with governmental authorities can take considerable time (six to 12&nbsp;months or longer) after the receipt of marketing
approval for a product. To obtain reimbursement or pricing approval in some countries with respect to any product candidate that
achieves regulatory approval, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product
candidate to other available therapies. If reimbursement of our products upon approval, if at all, is unavailable or limited in
scope or amount, or if pricing is set at unsatisfactory levels, our prospects for generating revenue, if any, could be adversely
affected which would have a material adverse effect on our business, results of operations and financial condition. Further, if
we achieve regulatory approval of any product, we must successfully negotiate product pricing for such product in individual countries.
As a result, the pricing of our products, if approved, in different countries may vary widely, thus creating the potential for
third-party trade in our products in an attempt to exploit price differences between countries. This third-party trade of our products
could undermine our sales in markets with higher prices </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">which could
have a material adverse effect on our business, results of operations and financial condition</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our ability to utilize net operating loss carryforwards may
be limited.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The net operating loss carryforwards, or &ldquo;NOLs&rdquo;,
of the Company as of December 31, 2012, equal to approximately $13.8<FONT STYLE="background-color: white">&nbsp;</FONT>million,
may be restricted under Section 382 of the Internal Revenue Code of 1986, as amended, or the &ldquo;Code.&rdquo; Section 382 of
the Code imposes limitations on a corporation&rsquo;s ability to utilize NOLs to offset taxable income if the corporation experiences
an &ldquo;ownership change.&rdquo; In general terms, an &ldquo;ownership change&rdquo; may result from transactions increasing
the ownership of certain stockholders in the stock of a corporation by more than 50% over a three-year period. In the event that
an ownership change has occurred, or were to occur, utilization of our NOLs would be subject to an annual limitation under Section
382, which is generally the fair market value of the pre-change entity multiplied by the long-term tax exempt rate, which is published
monthly by the Internal Revenue Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>All liabilities of our company have survived the merger and
there may be undisclosed liabilities that could harm our revenues, business, prospects, financial condition and results of operations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Protalix Ltd. and its counsel conducted due diligence on us
that was customary and appropriate for the reverse merger transaction consummated on December 31, 2006. However, the due diligence
process may not have revealed all our material liabilities then existing or that could be asserted in the future against us relating
to our activities before the consummation of the merger. Any such potential liabilities survive the merger and could harm our revenues,
business, prospects, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We are a holding company with no operations of our own. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a holding company with no operations of our own. Accordingly,
our ability to conduct our operations, service any debt that we may incur in the future and pay dividends, if any, is dependent
upon the earnings from the business conducted by Protalix Ltd. The distribution of those earnings or advances or other distributions
of funds by our subsidiary to us, as well as our receipt of such funds, are contingent upon the earnings of our subsidiary and
are subject to various business considerations and U.S. and Israeli law. If Protalix Ltd. is unable to make sufficient distributions
or advances to us, or if there are limitations on our ability to receive such distributions or advances, we may not have the cash
resources necessary to conduct our corporate operations which would have a material adverse effect on our business, results of
operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Regulatory Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B>We
are subject to extensive governmental regulation including the requirement of FDA or comparable approval before our drug candidates
may be marketed.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">Both
before and after approval of our drug candidates, we, our drug candidates, our suppliers, our contract manufacturers and our contract
testing laboratories are subject to extensive regulation by the FDA or comparable foreign regulatory authorities. Failure to comply
with applicable requirements of the FDA or comparable foreign regulatory authorities could result in, among other things, any of
the following actions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>warning letters;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>fines and other monetary penalties;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>unanticipated
                                                                                                                 expenditures;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delays in the FDA&rsquo;s or other foreign regulatory authorities&rsquo; approving, or the refusal of any regulatory authority
to approve, any drug candidate;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>product recall or seizure;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>interruption of manufacturing or clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>operating restrictions;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>injunctions; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>criminal prosecutions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">In
addition to the approval requirements, other numerous and pervasive regulatory requirements apply, both before and after approval,
to us, our drug candidates, and our suppliers, contract manufacturers, and contract laboratories. These include requirements related
to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>testing;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>manufacturing;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>quality control;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>labeling;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>advertising;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>promotion;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>distribution;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>export;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>reporting to the FDA certain adverse experiences associated with use of the drug candidate; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>obtaining additional approvals for certain modifications to the drug candidate or its labeling or claims.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">We
also are subject to inspection by the FDA and comparable foreign regulatory authorities, to determine our compliance with regulatory
requirements, as are our suppliers, contract manufacturers, and contract testing laboratories, and there can be no assurance that
the FDA or any other comparable foreign regulatory authority, will not identify compliance issues that may disrupt production or
distribution, or require substantial resources to correct. We may be required to make modifications to our manufacturing operations
in response to these inspections which may require significant resources and may have a material adverse effect upon our business,
results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">The
approval process for any drug candidate may also be delayed by changes in government regulation, future legislation or administrative
action or changes in policy of the FDA and comparable foreign authorities that occur prior to or during their respective regulatory
reviews of such drug candidate. Delays in obtaining regulatory approva</FONT>ls with respect to any drug candidate may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delay commercialization of, and our ability to derive product revenues from, such drug candidate;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delay any regulatory-related milestone payments payable under outstanding collaboration agreements;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>require us to perform costly procedures with respect to such drug candidate; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>otherwise diminish any competitive advantages that we may have with respect to such drug candidate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">Delays
in the approval process for any drug candidate may have a material adverse effect upon our business, results of operations and
financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><FONT STYLE="background-color: white"><B>We
may not obtain the necessary U.S., EMA or other worldwide regulatory approvals to commercialize our drug candidates in a timely
manner, if at all, which would have a material adverse effect on our business, financial condition and results of operations.</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">We
need FDA approval to commercialize our drug candidates in the United States, EMA approval to commercialize our drug candidates
in the European Union and approvals from foreign regulators to commercialize our drug candidates elsewhere. In order to obtain
FDA approval of any of our drug candidates, we must submit to the FDA an NDA or a Biologic License Application (BLA) demonstrating
that the drug candidate is safe for humans and effective for its intended use. This demonstration requires significant research
and animal tests, which are referred to as preclinical studies, as well as human tests, which are referred to as clinical trials.
In the European Union, we must submit an MAA to the EMA. Satisfaction of the FDA&rsquo;s, the EMA's and foreign regulatory authorities&rsquo;
regulatory requirements typically takes many years, depends upon the type, complexity and novelty of the drug candidate and requires
substantial resources for research, development and testing. Taliglucerase alfa has been approved for marketing in the United States,
Israel and Uruguay, and marketing applications are outstanding in Brazil and other countries. Even if we comply with all the requests
of regulatory authorities, the authorities may ultimately reject the marketing applications filed for taliglucerase alfa or that
we file for our other product candidates in the future, if any, or we might not obtain regulatory clearance in a timely manner
for taliglucerase alfa in certain countries or for any of our other drug candidates. Companies in the pharmaceutical and biotechnology
industries have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier
trial results or in preliminary findings or other comparable authorities for such clinical trials.&nbsp;&nbsp;Further, even if
favorable testing data is generated by the clinical trials of a drug candidate, the applicable regulatory authority may not accept
or approve the marketing application filed by a pharmaceutical or biotechnology company for the drug candidate. Failure to obtain
approval of the FDA, EMA or comparable foreign authorities of any of our drug candidates in a timely manner, if at all, will severely
undermine our business, financial condition and results of operation by reducing our potential marketable products and our ability
to generate corresponding product revenues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">Our
research and clinical efforts may not result in drugs that the FDA, EMA or foreign regulatory authorities consider safe for humans
and effective for indicated uses, which would have a material adverse effect on our business, financial condition and results of
operations.&nbsp;&nbsp;After clinical trials are completed for any drug candidate, if at all, the FDA, EMA and foreign regulatory
authorities have substantial discretion in the drug approval process of the drug candidate in their respective jurisdictions and
may require us to conduct additional clinical testing or perform post-marketing studies which would cause us to incur additional
costs. Incurring such costs may have a material adverse effect on our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B>We
have only limited experience in regulatory affairs, and some of our drug candidates may be based on new technologies. These factors
may affect our ability or the time we require to obtain necessary regulatory approvals.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">We have only limited experience
in filing and prosecuting the applications necessary to gain regulatory approvals for medical devices and drug candidates. Moreover,
some of the drug candidates that are likely to result from our development programs may be based on new technologies that have
not been extensively tested in humans. The regulatory requirements governing these types of drug candidates may be less well defined
or more rigorous than for conventional products. As a result, we may experience a longer regulatory process in connection with
obtaining regulatory approvals of any products that we develop</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B>If
any of our other competitors are able to obtain orphan drug exclusivity for any products that are competitive with our products,
we may be precluded from selling or obtaining approval of our competing products by the applicable regulatory authorities for a
significant period of time.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">In
the United States, the European Union and other countries, a drug may be designated as having orphan drug status, subject to certain
conditions. There can be no assurance that a drug candidate that receives orphan drug designation will receive orphan drug marketing
exclusivity and more than one drug can have orphan designation for the same indication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: black; background-color: white">Foreign
regulations regarding orphan drugs are similar to those in the United States but there are several conceptual differences. For
example, the exclusivity period in the European Union is generally 10 years.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
The EMA/European Commission has granted orphan drug designation and exclusivity to VPRIV in the European Union. For this reason,</FONT><FONT STYLE="color: black; background-color: white">
CHMP has recommended that the EC not issue a Marketing Authorization for taliglucerase alfa in the European Union. Therefore, </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">VPRIV</FONT><FONT STYLE="color: black; background-color: white">
has orphan market exclusivity in the European Union for a 10-year period commencing on its authorization in August 2010 which may
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">have a </FONT><FONT STYLE="color: black; background-color: white">material
adverse effect on our business, results of operations and financial condition</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">From time to time, we
may apply to the FDA or any comparable foreign regulatory authority for orphan drug designation for any one or more of our drug
candidates. None of our currently developed drug candidates have been designated as an orphan drug and there is no guarantee that
the FDA or any other regulatory authority will grant such designation in the future. In addition, neither orphan drug designation
nor orphan drug exclusivity prevents competitors from developing or marketing different drugs for that indication. Even if we obtain
orphan drug exclusivity for one or more indications for one of our drug candidates, we may not be able to maintain the exclusivity.
For example, if a competitive product that is the same drug or biologic as one of our drug candidates is shown to be clinically
superior to the drug candidate, any orphan drug exclusivity granted to the drug candidate will not block the approval of the competitive
product. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Intellectual Property Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If we fail to adequately protect or enforce our intellectual
property rights or secure rights to third party patents, the value of our intellectual property rights would diminish and our business,
competitive position and results of operations would suffer.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2012, we had 90  pending patent
applications, one joint pending patent application with a third party and license rights to six pending patent applications.
However, the filing of a patent application does not mean that we will be issued a patent, or that any patent eventually
issued will be as broad as requested in the patent application or sufficient to protect our technology. Any modification
required to a current patent application may delay the approval of such patent application which would have a material
adverse effect on our business, results of operations and financial condition. In addition, there are a number of factors
that could cause our patents, if granted, to become invalid or unenforceable or that could cause our patent applications to
not be granted, including known or unknown prior art, deficiencies in the patent application or the lack of originality of
the technology. Our competitive position and future revenues will depend in part on our ability and the ability of our
licensors and collaborators to obtain and maintain patent protection for our products, methods, processes and other
technologies, to preserve our trade secrets, to prevent third parties from infringing on our proprietary rights and to
operate without infringing the proprietary rights of third parties. We have filed U.S. and international patent
applications for process patents, as well as<FONT STYLE="font-family: Times New Roman, Times, Serif"><B> </B></FONT>composition
of matter patents, for taliglucerase alfa and other product candidates. However, we cannot predict:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the degree and range of protection any patents will afford us against competitors and those who infringe upon our patents,
including whether third parties will find ways to invalidate or otherwise circumvent our licensed patents;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if and when patents will issue;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether or not others will obtain patents claiming aspects similar to those covered by our licensed patents and patent applications;
or</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether we will need to initiate litigation or administrative proceedings, which may be costly, and whether we win or lose.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">As of December 31, 2012, we hold,
or have license rights to, 48 patents (including one joint patent). If patent rights covering our products or technologies are
not sufficiently broad, they may not provide us with sufficient proprietary protection or competitive advantages against competitors
with similar products and technologies. Furthermore, if the </FONT>U.S.<FONT STYLE="color: black"> Patent and Trademark Office
or foreign patent offices issue patents to us or our licensors, others may challenge the patents or circumvent the patents, or
the patent office or the courts may invalidate the patents. Thus, any patents we own or license from or to third parties may not
provide any protection against our competitors and those who infringe upon our patents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Furthermore, the life of our patents is limited. The patents
we hold relating to our ProCellEx protein expression system will expire in 2017 and 2025. If patents issue from other currently
pending patent applications, those patents will expire between 2024 and 2031.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We rely on confidentiality agreements that could be breached
and may be difficult to enforce which could have a material adverse effect on our business and competitive position.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our policy is to enter agreements relating to the non-disclosure
of confidential information with third parties, including our contractors, consultants, advisors and research collaborators, as
well as agreements that purport to require the disclosure and assignment to us of the rights to the ideas, developments, discoveries
and inventions of our employees and consultants while we employ them. However, these agreements can be difficult and costly to
enforce. Moreover, to the extent that our contractors, consultants, advisors and research collaborators apply or independently
develop intellectual property in connection with any of our projects, disputes may arise as to the proprietary rights to the intellectual
property. If a dispute arises, a court may determine that the right belongs to a third party, and enforcement of our rights can
be costly and unpredictable. In addition, we rely on trade secrets and proprietary know-how that we seek to protect in part by
confidentiality agreements with our employees, contractors, consultants, advisors or others. Despite the protective measures we
employ, we still face the risk that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>these agreements may be breached;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>these agreements may not provide adequate remedies for the applicable type of breach; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our trade secrets or proprietary know-how will otherwise become known.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any breach of our confidentiality agreements or our failure
to effectively enforce such agreements would have a material adverse effect on our business and competitive position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If we infringe the rights of third parties we could be prevented
from selling products, forced to pay damages and required to defend against litigation which could result in substantial costs
and may have a material adverse effect on our business, results of operations and financial condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have not received to date any claims of infringement by any
third parties. However, as our drug candidates progress into clinical trials and commercialization, if at all, our public profile
and that of our drug candidates may be raised and generate such claims. Defending against such claims, and occurrence of a judgment
adverse to us, could result in unanticipated costs and may have a material adverse effect on our business and competitive position.
If our products, methods, processes and other technologies infringe the proprietary rights of other parties, we may incur substantial
costs and we may have to:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>obtain licenses, which may not be available on commercially reasonable terms, if at all;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>redesign our products or processes to avoid infringement;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>stop using the subject matter claimed in the patents held by others, which could cause us to lose the use of one or more of
our drug candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>defend litigation or administrative proceedings that may be costly whether we win or lose, and which could result in a substantial
diversion of management resources; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>pay damages.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any costs incurred in connection with such events or the inability
to sell our products may have a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If we cannot meet requirements under our license agreements,
we could lose the rights to our products, which could have a material adverse effect on our business.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">We depend on licensing agreements
with third parties to maintain the intellectual property rights to ce</FONT>rtain of our product candidates. For example, pursuant
to our agreement with the Yissum Research and Development Company, or Yissum, the technology transfer arm of the Hebrew University
of Jerusalem, Israel, and the Boyce Thompson Institute for Plant Research, at Cornell University, we have received an exclusive
worldwide right and license to certain technology, including patents and additional patent applications relating to acetylcholinesterase
(AChE), for all therapeutic and prophylactic indications as well as an exclusive license not limited to such indications with respect
to certain of these patents and patent applications. Under the agreement with Yissum, we intend to develop a proprietary plant
cell-based acetylcholinesterase (AChE) and its molecular variants for the use in several therapeutic and prophylactic indications,
including a biodefense program. In addition, we have licensed certain rights relating to our production of taliglucerase alfa from
Virginia Tech. Our license agreements require us to make payments and satisfy performance obligations in order t<FONT STYLE="color: black">o
maintain our rights under these agreements. All of these agreements last either throughout the life of the patents that are the
subject of the agreements, or with respect to other licensed technology, for a number of years after the first commercial sale
of the relevant product. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, we are responsible for the cost of filing and prosecuting
certain patent applications and maintaining certain issued patents licensed to us. If we do not meet our obligations under our
license agreements in a timely manner, we could lose the rights to our proprietary technology which could have a material adverse
effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Relating to Our Operations in Israel </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Potential political, economic and military instability in
the State of Israel, where the majority of our senior management and our research and development facilities are located, may adversely
affect our results of operations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">Our executive office and operations
are located in the State of Israel. Accordingly, political, economic and military conditions in Israel directly affect our business.
Since the State of Israel was established in 1948, a number of armed conflicts have occurred between Israel and its Arab neighbors.
Any hostilities involving Israel or the interruption or curtailment of trade between Israel and its present trading partners, or
a significant downturn in the economic or financial condition of Israel, could affect adversely our operations. </FONT>Since October
2000 there have been increasing occurrences of terrorist violence. Ongoing and revived h<FONT STYLE="color: black">ostilities or
other Israeli political or economic factors could harm our operations and product development and cause our revenues to decrease.
Furthermore, several countries, principally those in the Middle East, still restrict business with Israel and Israeli companies.
These restrictive laws and policies may limit seriously our ability to sell our products in these countries. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Although Israel has entered into various agreements with Egypt,
Jordan and the Palestinian Authority, there have been times since October 2000 when Israel has experienced an increase in unrest
and terrorist activity. The establishment in 2006 of a government in the Palestinian Authority by representatives of the Hamas
militant group has created additional unrest and uncertainty in the region. In mid-2006, there was a war between Israel and the
Hezbollah in Lebanon, resulting in thousands of rockets being fired from Lebanon up to 50 miles into Israel. Our current facilities
are located in northern Israel, are in range of rockets that were fired from Lebanon into Israel during the war and suffered minimal
damages during one of the rocket attacks. Starting in December 2008, for approximately three weeks, Israel engaged in an armed
conflict with Hamas in the Gaza Strip. An armed conflict between Israel and Hamas in the Gaza Strip occurred again in November
2012. Our insurance policies do not cover us for <FONT STYLE="color: black">the damages incurred in connection with these conflicts
or for any resulting disruption in our operations. The Israeli government, as a matter of law, provides coverage for the reinstatement
value of direct damages that are caused by terrorist attacks or acts of war; however, the government may cease providing such coverage
or the coverage might not be enough to cover potential damages. </FONT>If our facilities are damaged as a result of hostile action,
our operations may be materially adversely affected.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the foregoing, since the end of 2010, numerous
acts of protest and civil unrest have taken place in several countries in the Middle East and North Africa, many of which involved
significant violence. The civil unrest in Egypt, which borders Israel, resulted in the resignation of its president Hosni Mubarak,
and to significant changes to the country's government. In Syria, also bordering Israel, large civilian protests are continuing
to take place. The ultimate effect of these developments on the political and security situation in the Middle East and on Israel's
position within the region is not clear at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our operations may be disrupted by the obligations of our
personnel to perform military service which could have a material adverse effect on our business. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Many of our male employees in Israel, including members of senior
management, are obligated to perform up to one month (in some cases more) of annual military reserve duty until they reach the
age of 45 and, in the event of a military conflict, could be called to active duty. Our operations could be disrupted by the absence
of a significant number of our employees related to military service or the absence for extended periods of military service of
one or more of our key employees. A disruption could have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Because a certain portion of our expenses is incurred in
New Israeli Shekels, or NIS, our results of operations may be seriously harmed by currency fluctuations and inflation. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We report our financial statements in U.S. dollars, our functional
currency. Although most of our expenses are incurred in U.S. dollars, we pay a portion of our expenses in New Israeli Shekels,
or NIS, and as a result, we are exposed to risk to the extent that the inflation rate in Israel exceeds the rate of devaluation
of the NIS in relation to the U.S. dollar or if the timing of these devaluations lags behind inflation in Israel. In that event,
the U.S. dollar cost of our operations in Israel will increase and our U.S. dollar-measured results of operations will be adversely
affected. To the extent that the value of the NIS increases against the dollar, our expenses on a dollar cost basis increase. Our
operations also could be adversely affected if we are unable to guard against currency fluctuations in the future. To date, we
have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of
financial exposure from fluctuations in the exchange rate of the U.S. dollar against the NIS. These measures, however, may not
adequately protect us from material adverse effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The tax benefits available to us require that we meet several
conditions and may be terminated or reduced in the future, which would increase our taxes.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">We are</FONT> abl<FONT STYLE="color: black">e
to take advantage of tax exemptions and reductions resulting from the &ldquo;Approved Enterprise&rdquo; status of our faci</FONT>lities
in Israel. To remain eligible for these tax benefits, we must continue to meet certain conditions, including making specified investments
in property and equipment, and financing at least 30% of such investments with share capital. If we fail to meet these conditions
in the future, the tax benefits would be canceled and we may be required to refund any tax benefits we already have enjoyed. These
tax benefits are subject to investment policy by the Investment Center and may not be continued in the future at their current
levels or at any level. In recent years the Israeli government has reduced the benefits available and has indicated that it may
further reduce or eliminate some of these benefits in the future. The termination or reduction of these tax benefits or our inability
to qualify for additional &ldquo;Approved Enterprise&rdquo; approvals may increase our tax expenses in the future, which would
reduce our expected profits and adversely affect our business and results of operations. Additionally, if we increase our activities
outside of Israel, for example, by future acquisitions, such increased activities generally may not be eligible for inclusion in
Israeli tax benefit programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The Israeli government grants we have received for certain
research and development expenditures restrict our ability to manufacture products and transfer technologies outside of Israel
and require us to satisfy specified conditions. If we fail to satisfy these conditions, we may be required to refund grants previously
received together with interest and penalties which could have a material adverse effect on our business and results of operations.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our research and development efforts have been financed, in
part, through grants that we have received from the OCS. We, therefore, must comply with the requirements of the Research Law.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Research Law we are prohibited from manufacturing
products developed using these grants outside of the State of Israel without special approvals, although the Research Law does
enable companies to seek prior approval for conducting manufacturing activities outside of Israel without being subject to increased
royalties. <FONT STYLE="color: black">We may not receive the required approvals for any proposed transfer of manufacturing activities.
</FONT>Even if we do receive approval to manufacture products developed with government grants outside of Israel, we may be required
to pay an increased total amount of royalties (possibly up to 300% of the grant amounts plus interest), depending on the manufacturing
volume that is performed outside of Israel, as well as at a possibly increased royalty rate. This restriction may impair our ability
to outsource manufacturing or engage in similar arrangements for those products or technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, under the Research Law, we are prohibited from
transferring the OCS-financed technologies and related intellectual property rights outside of the State of Israel, except under
limited circumstances and only with the approval of the OCS' Research Committee. We may not receive the required approvals for
any proposed transfer and, if received, we may be required to pay the OCS a portion of the consideration that we receive upon any
sale of such technology by a non-Israeli entity. The scope of the support received, the royalties that we have already paid to
the OCS, the amount of time that has elapsed between the date on which the know-how was transferred and the date on which the OCS
grants were received and the sale price and the form of transaction will be taken into account in order to calculate the amount
of the payment to the OCS. Approval of the transfer of technology to residents of the State of Israel is required, and may be granted
in specific circumstances only if the recipient abides by the provisions of applicable laws, including the restrictions on the
transfer of know-how and the obligation to pay royalties. No assurance can be made that approval to any such transfer, if requested,
will be granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">These restrictions may impair our
ability to sell our technology assets or to outsource manufacturing outside of Israel. The restrictions will continue to apply
for a certain period of time even after we have repaid the full amount of royalties payable for the grants. </FONT>For the years
ended December 31, 2011 and 2012, we recorded grants totaling $3.3 million and $4.1 million from the OCS, respectively. The grants
represent 9% and 10.5%, respectively, of our gross research and development expenditures for the years ended December 31, 2011
and 2012. <FONT STYLE="color: black">If we fail to satisfy the conditions of the Research Law, we may be required to refund certain
grants previously received together with interest and penalties, and may become subject to criminal charges, any of which could
have a material adverse effect on our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investors may have difficulties enforcing a U.S. judgment,
including judgments based upon the civil liability provisions of the U.S. federal securities laws against us, our executive officers
and most of our directors or asserting U.S. securities laws claims in Israel. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Most of our directors and officers are not residents of the
United States and most of their assets and our assets are located outside the United States. Service of process upon our non-U.S.
resident directors and officers and enforcement of judgments obtained in the United States against us, some of our directors and
executive officers may be difficult to obtain within the United States. We have been informed by our legal counsel in Israel that
investors may find it difficult to assert claims under U.S. securities laws in original actions instituted in Israel or obtain
a judgment based on the civil liability provisions of U.S. federal securities laws against us, our officers and our directors.
Israeli courts may refuse to hear a claim based on a violation of U.S. securities laws against us or our officers and directors
because Israel is not the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a
claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the
content of applicable U.S. law must be proved as a fact which can be a time-consuming and costly process. Certain matters of procedure
will also be governed by Israeli law. There is little binding case law in Israel addressing the matters described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Israeli courts might not enforce judgments rendered outside
Israel which may make it difficult to collect on judgments rendered against us. Subject to certain time limitations, an Israeli
court may declare a foreign civil judgment enforceable only if it finds that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the judgment was rendered by a court which was, according to the laws of the state of the court, competent to render the judgment;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the judgment may no longer be appealed;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the obligation imposed by the judgment is enforceable according to the rules relating to the enforceability of judgments in
Israel and the substance of the judgment is not contrary to public policy; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the judgment is executory in the state in which it was given.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Even if these conditions are satisfied, an Israeli court will
not enforce a foreign judgment if it was given in a state whose laws do not provide for the enforcement of judgments of Israeli
courts (subject to exceptional cases) or if its enforcement is likely to prejudice the sovereignty or security of the State of
Israel. An Israeli court also will not declare a foreign judgment enforceable if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the judgment was obtained by fraud;</TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>there is a finding of lack of due process;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the judgment was rendered by a court not competent to render it according to the laws of private international law in Israel;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the judgment is at variance with another judgment that was given in the same matter between the same parties and that is still
valid; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at the time the action was brought in the foreign court, a suit in the same matter and between the same parties was pending
before a court or tribunal in Israel.<BR>
<BR>
</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Investing in Our Common Stock </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The market price of our common stock may fluctuate significantly.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The market price of our common stock may fluctuate significantly
in response to numerous factors, some of which are beyond our control, such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Pfizer's commercialization efforts for ELELYSO;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the results of our ongoing studies regarding our product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>announcements regarding partnerships or collaborations by us or our competitors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>developments concerning intellectual property rights and regulatory approvals;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the announcement of new products or product enhancements by us or our competitors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>variations in our and our competitors&rsquo; results of operations;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>changes in earnings estimates or recommendations by securities analysts;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>developments in the biotechnology industry; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>general market conditions and other factors, including factors unrelated to our operating performance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Further, stock markets in general, and the market for biotechnology
companies in particular, have recently experienced price and volume fluctuations. Continued market fluctuations could result in
extreme volatility in the price of our common stock, which could cause a decline in the value of our common stock. Price volatility
of our common stock may be worse if the trading volume of our common stock is low. We have not paid, and do not expect to pay,
any cash dividends on our common stock as any earnings generated from future operations will be used to finance our operations.
As a result, investors will not realize any income from an investment in our common stock until and unless their shares are sold
at a profit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our common stock is listed for trade on more than one stock
exchange, and this may result in price variations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is listed for trade on both the NYSE MKT and
the TASE. Dual-listing may result in price variations between the exchanges due to a number of factors. First, our common stock
is traded in U.S. dollars on the NYSE MKT and in NIS on the TASE. In addition, the exchanges are open for trade at different times
of the day and on different days. For example, the TASE opens generally during Israeli business hours, Sunday through Thursday
while the NYSE MKT opens generally during U.S. business hours, Monday through Friday. The two exchanges also have differing vacation
schedules. Differences in the trading schedules, as well as volatility in the exchange rate of the two currencies, among other
factors, may result different trading prices for our common stock on the two exchanges. Other external influences may have different
effects on the trading price of our common stock on the two exchanges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Future sales of our common stock could
reduce our stock price.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The market price of our common stock could drop significantly
if our existing shareholders sell a large number of shares of our common stock or are perceived by the market as intending to sell
them. All of our outstanding shares of our common stock are freely tradable without restriction or further registration under the
federal securities laws, unless owned by our affiliates. At December&nbsp;31, 2012, there were restricted shares and options to
purchase common stock issued and outstanding covering 7,662,796 shares of our common stock with a weighted average exercise price
of $3.55 per share. Also at December&nbsp;31, 2012, there were 176,986 shares of common stock remaining available for future for
issuance in connection with future grants of incentives under our amended 2006 stock incentive plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Directors, executive officers, principal shareholders and
affiliated entities own a significant percentage of our capital stock, and they may make decisions that an investor may not consider
to be in the best interests of our shareholders.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our directors, executive officers, principal shareholders and
affiliated entities beneficially own, in the aggregate, approximately 24% of our outstanding common stock. As a result, if some
or all of them acted together, they would have the ability to exert substantial influence over the election of our Board of Directors
and the outcome of issues requiring approval by our shareholders. This concentration of ownership may have the effect of delaying
or preventing a change in control of our company that may be favored by other shareholders. This could prevent the consummation
of transactions favorable to other shareholders, such as a transaction in which shareholders might otherwise receive a premium
for their shares over current market prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Failure to maintain effective internal controls in accordance
with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect on our business and operating results. In addition,
current and potential shareholders could lose confidence in our financial reporting, which could have a material adverse effect
on the price of our common stock. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective internal controls are necessary for us to provide
reliable financial reports and effectively prevent fraud. If we cannot provide reliable financial reports or prevent fraud, our
results of operation could be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Section 404 of the Sarbanes-Oxley Act of 2002 requires annual
management assessments of the effectiveness of our internal controls over financial reporting and a report by our independent registered
public accounting firm addressing these assessments. We continuously monitor our existing internal controls over financial reporting
systems to confirm that they are compliant with Section 404, and we may identify deficiencies that we may not be able to remediate
in time to meet the deadlines imposed by the Sarbanes-Oxley Act. This process may divert internal resources and will take a significant
amount of time and effort to complete.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If, at any time, it is determined that we are not in compliance
with Section 404, we may be required to implement new internal control procedures and reevaluate our financial reporting. We may
experience higher than anticipated operating expenses as well as increased independent auditor fees during the implementation of
these changes and thereafter. Further, we may need to hire additional qualified personnel. If we fail to maintain the adequacy
of our internal controls, as such standards are modified, supplemented or amended from time to time, we may not be able to conclude
on an ongoing basis that we have effective internal controls over financial reporting in accordance with Section 404 of the Sarbanes-Oxley
Act, which could result in our being unable to obtain an unqualified report on internal controls from our independent auditors.
Failure to maintain an effective internal control environment could also cause investors to lose confidence in our reported financial
information, which could have a material adverse effect on the price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Compliance with changing regulation of corporate governance
and public disclosure may result in additional expenses, divert management&rsquo;s attention from operating our business which
could have a material adverse effect on our business.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">There have been other changing laws,
regulations and standards relating to corporate governance and public disclosure in addition to the Sarbanes-Oxley Act, as well
as new regulations promulgated by the Commission and rules promulgated by the national securities exchanges, including the </FONT>NYSE
MKT<FONT STYLE="color: black"> and the NASDAQ. These new or changed laws, regulations and standards are subject to varying interpretations
in many cases due to their lack of specificity, and as a result, their application in practice may evolve over time as new guidance
is provided by regulatory and governing bodies, which could result in continuing uncertainty regarding compliance matters and higher
costs necessitated by ongoing revisions to disclosure and governance practices. As a result, our efforts to comply with evolving
laws, regulations and standards are likely to continue to result in increased general and administrative expenses and a diversion
of management time and attention from revenue-generating activities to compliance activities. Our board members, Chief Executive
Officer and Chief Financial Officer could face an increased risk of personal liability in connection with the performance of their
duties. As a result, we may have difficulty attracting and retaining qualified board members and executive officers, which could
have a material adverse effect on our business. If our efforts to comply with new or changed laws, regulations and standards differ
from the activities intended by regulatory or governing bodies, we may incur additional expenses to comply with standards set by
regulatory authorities or governing bodies which would have a material adverse effect on our business, results of operations and
financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The issuance of preferred stock or additional shares of common
stock could adversely affect the rights of the holders of shares of our common stock.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Board of Directors is authorized to issue up to 100,000,000
shares of preferred stock without any further action on the part of our shareholders. Our Board of Directors has the authority
to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock. Currently, we
have no shares of preferred stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Board of Directors may, at any time, authorize the issuance
of a series of preferred stock that would grant to holders the preferred right to our assets upon liquidation, the right to receive
dividend payments before dividends are distributed to the holders of common stock and the right to the redemption of the shares,
together with a premium, before the redemption of our common stock, which may have a material adverse effect on the rights of the
holders of our common stock. In addition, our Board of Directors, without further shareholder approval, may, at any time, issue
large blocks of preferred stock. In addition, the ability of our Board of Directors to issue shares of preferred stock without
any further action on the part of our shareholders may impede a takeover of our company and may prevent a transaction that is favorable
to our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the rules of the TASE, other than incentives under our
amended 2006 stock incentive plan, we were prohibited from issuing any securities of any class or series different than the common
stock that is listed on the TASE for the 12-month period immediately succeeding our initial listing, which occurred on September&nbsp;6,
2010. As of the date hereof, the rules of the TASE allow us to issue securities with preferential rights with respect to dividends
but such other securities may not include voting rights. The foregoing does not limit our liability to issue and grant options
and warrants for the purchase of shares of our common stock.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left">Item 1B.</TD><TD STYLE="text-align: justify">Unresolved Staff Comments</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left">Item 2.</TD><TD STYLE="text-align: justify">Properties</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our manufacturing facility and executive offices are located
in Carmiel, Israel. The facilities currently contain approximately 16,000 sq/ft of manufacturing space and additional 48,000 sq/ft
of laboratory, warehouse and office space and are leased at a rate of approximately $82,000 per month. In addition, we are entitled
to use an additional 13,000 sq/ft in the same facility, which we intend to utilize in connection with an anticipated expansion
of our manufacturing facilities. Our facilities are equipped with the requisite laboratory services required to conduct our business,
and we believe that the existing facilities are adequate to meet our needs for the foreseeable future. We have leased the facility
through 2017, subject to three options exercisable by us to extend the term for a five-year period, for an aggregate of 15 additional
years. Upon the exercise of each option to extend the term of the lease, if any, the then current base rent shall be increased
by 10%. We also lease an office in Ramat Gan, Israel, for approximately $2,200 per month.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">Item 3.</TD><TD STYLE="text-align: justify">Legal Proceedings</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We are not involved in any material legal
proceedings.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left; font-weight: bold"><B>Item 4.</B></TD><TD STYLE="text-align: justify; font-weight: bold"><FONT STYLE="color: black"><B>Mine
                                                                                          Safety Disclosures</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 28.05pt"><B>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">Item 5.</TD><TD STYLE="text-align: justify">Market for Registrant&rsquo;s Common Equity, Related
Stockholder Matters and Issuer Purchases of Equity Securities</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.25pt; text-indent: -38.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our common stock began trading on the NYSE
MKT (formerly, the American Stock Exchange) on March 12, 2007 under the symbol &ldquo;PLX.&rdquo; Our common stock is also listed
on the TASE under the symbol &quot;PLX.&quot; The following table sets forth the quarterly high and low closing prices for our
common stock on the NYSE MKT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 88%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-left: 0">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price Range</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-left: 0">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%; color: black; text-align: left; padding-left: 0">Fourth Quarter 2012&#9;</TD><TD STYLE="width: 1%; color: black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: black; text-align: left">$</TD><TD STYLE="width: 10%; color: black; text-align: right">5.68</TD><TD STYLE="width: 1%; color: black; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; color: black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: black; text-align: left">$</TD><TD STYLE="width: 10%; color: black; text-align: right">4.80</TD><TD STYLE="width: 1%; color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: black; text-align: left; padding-left: 0">Third Quarter 2012&#9;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">$</TD><TD STYLE="color: black; text-align: right">5.98</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">$</TD><TD STYLE="color: black; text-align: right">4.85</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="color: black; text-align: left; padding-left: 0">Second Quarter 2012&#9;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">$</TD><TD STYLE="color: black; text-align: right">7.20</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">$</TD><TD STYLE="color: black; text-align: right">5.58</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: black; text-align: left; padding-left: 0">First Quarter 2012&#9;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">$</TD><TD STYLE="color: black; text-align: right">6.51</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">$</TD><TD STYLE="color: black; text-align: right">5.00</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="color: black; text-align: left; padding-left: 0">Fourth Quarter 2011&#9;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">$</TD><TD STYLE="color: black; text-align: right">6.58</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">$</TD><TD STYLE="color: black; text-align: right">4.42</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: black; text-align: left; padding-left: 0">Third Quarter 2011&#9;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">$</TD><TD STYLE="color: black; text-align: right">6.99</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">$</TD><TD STYLE="color: black; text-align: right">4.36</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="color: black; text-align: left; padding-left: 0">Second Quarter 2011&#9;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">$</TD><TD STYLE="color: black; text-align: right">7.24</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">$</TD><TD STYLE="color: black; text-align: right">6.09</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: black; text-align: left; padding-left: 0">First Quarter 2011&#9;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">$</TD><TD STYLE="color: black; text-align: right">10.46</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">$</TD><TD STYLE="color: black; text-align: right">5.83</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">These quotations reflect prices between dealers
and do not include retained mark-ups, mark-downs and commissions and may not necessarily represent actual transactions. There were
approximately 84 holders of record of our common stock at February 15, 2013. A substantially greater number of holders of our common
stock are &ldquo;street name&rdquo; or beneficial holders, whose shares are held of record by banks, brokers and other financial
institutions. To date, we have not declared or paid any cash dividends on our common stock. We do not anticipate paying any dividends
on our common stock in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>STOCK PERFORMANCE GRAPH</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The following graph compares the cumulative
total shareholder return data for our common stock from December 31, 2007 through December 31, 2012 to the cumulative return over
such time period of (i) The NYSE MKT Composite Index and (ii) The NYSE Arca Biotechnology Index. The graph assumes an investment
of $100 on December 31, 2007 in each of our common stock, the stocks comprising the NYSE MKT Composite Index and the stocks comprising
the NYSE Arca Biotechnology Index, including dividend reinvestment, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>The stock price performance shown on
the graph below represents historical price performance and is not necessarily indicative of any future stock price performance.
Notwithstanding anything to the contrary set forth in any of our previous filings under the Securities Act or the Exchange Act,
which might incorporate future filings made by us under those statutes, this Stock Performance Graph will not be incorporated by
reference into any of those prior filings, nor will such report or graph be incorporated by reference into any future filings made
by us under those Acts.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.35pt; text-indent: -37.35pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tpg57.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">Item 6.</TD><TD STYLE="text-align: justify">Selected Financial Data</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The selected consolidated financial data below
should be read in conjunction with &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
and our consolidated financial statements and the related notes included elsewhere in this Annual Report on Form 10-K. The selected
consolidated statements of operations data for the years ended December&nbsp;31, 2012, 2011 and 2010 and the selected consolidated
balance sheet data as of December&nbsp;31, 2012 and 2011, are derived from the audited consolidated financial statements included
elsewhere in this Annual Report. The statement of operations data for the years ended December 31, 2009 and 2008 and the balance
sheet data as of December 31, 2010, 2009 and 2008 are derived from audited financial statements not included in this Annual Report.
The historical results presented below are not necessarily indicative of future results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.1in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="18" NOWRAP STYLE="font-weight: bold; text-align: center">Year Ended December&nbsp;31,</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2008</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2009</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD NOWRAP STYLE="font-style: italic">&nbsp;</TD>
    <TD COLSPAN="18" NOWRAP STYLE="font-style: italic; text-align: center">(in thousands, except share and per share amounts)</TD><TD NOWRAP STYLE="font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Consolidated Statement of Operations Data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Revenues</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">388</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,642</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">8,386</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">34,870</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify; text-indent: -9pt; padding-left: 9pt">Our share in the Collaboration Agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,602</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,418</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(446</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -9pt; padding-left: 9pt">Cost of revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,575</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,383</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,525</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,144</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify; text-indent: -9pt; padding-left: 9pt">Gross profit (loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,187</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,861</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,443</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,280</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -9pt; padding-left: 9pt">Research and development expenses, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">17,401</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,638</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,951</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,043</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,689</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify; text-indent: -9pt; padding-left: 9pt">General and administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,770</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,144</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,876</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,931</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,763</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Financial income, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,757</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">529</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">968</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2</TD><TD STYLE="padding-bottom: 1pt; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">554</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">22,414</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">31,440</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">28,998</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">36,529</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11,618</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Net loss per share of common stock, basic and <BR>diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.30</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.41</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.36</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.43</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.13</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Weighted average number of shares of common <BR>stock used in computing net loss per share of <BR>common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,890,633</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76,942,840</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80,960,300</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">84,645,364</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90,845,901</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: -9pt; padding-left: 9pt">Consolidated Balance Sheet Data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -9pt; padding-left: 9pt">Cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">42,596</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">81,266</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">35,900</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">27,001</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">52,035</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify; text-indent: -9pt; padding-left: 9pt">All other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,215</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,405</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,829</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,804</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,692</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -9pt; padding-left: 9pt">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,811</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">98,671</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,729</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">51,805</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78,727</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify; text-indent: -9pt; padding-left: 9pt">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,527</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,530</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,903</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,693</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,755</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -9pt; padding-left: 9pt">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,464</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82,788</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76,052</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">77,882</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82,084</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify; text-indent: -9pt; padding-left: 9pt">Shareholders&rsquo; equity (capital deficiency)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,347</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,883</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,323</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(26,077</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,357</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left; font-weight: bold"><B>Item 7.</B></TD><TD STYLE="text-align: justify; font-weight: bold"><B>Management&rsquo;s
                                                                                                             Discussion and Analysis
                                                                                                             of Financial Condition
                                                                                                             and Results of Operations</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>You should read the following discussion
and analysis of our financial condition and results of operations together with our consolidated financial statements and the related
notes included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis,
particularly with respect to our plans and strategy for our business and related financing, includes forward-looking statements
that involve risks and uncertainties. You should read &ldquo;Risk Factors&rdquo; in Item 1A of this Annual Report on Form 10-K
for a discussion of important factors that could cause actual results to differ materially from the results described in or implied
by the forward-looking statements contained in the following discussion and analysis. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a biopharmaceutical company focused on the development
and commercialization of recombinant therapeutic proteins based on our proprietary ProCellEx<SUP>&reg;</SUP> protein expression
system. Using our ProCellEx system, we are developing a pipeline of proprietary and biosimilar versions of recombinant therapeutic
proteins based on our plant cell-based expression technology that target large, established pharmaceutical markets and that rely
upon known biological mechanisms of action. Our initial commercial focus has been on complex therapeutic proteins, including proteins
for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. We believe ProCellEx will enable us to develop
proprietary recombinant proteins that are therapeutically equivalent or superior to existing recombinant proteins currently marketed
for the same indications. Because we are primarily targeting biologically equivalent versions of highly active, well-tolerated
and commercially successful therapeutic proteins, we believe our development process is associated with relatively less risk compared
to other biopharmaceutical development processes for completely novel therapeutic proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 1, 2012, the FDA approved our first commercial product,
ELELYSO, as an ERT for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The Israeli
MOH approved taliglucerase alfa in September 2012 and it also approved for sale in Uruguay. Taliglucerase alfa is a proprietary,
recombinant form of glucocerebrosidase (GCD) that is expressed or produced through ProCellEx. Taliglucerase alfa is the first plant
cell-based recombinant therapeutic protein to be approved by each of the FDA and the Israeli MOH. Gaucher disease is a rare and
serious lysosomal storage disorder with severe and debilitating symptoms. Gaucher patients suffer from mutations in or deficiencies
of GCD, an enzyme that is naturally found in human cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Since May 2012, taliglucerase alfa has been marketed in the
United States by Pfizer, our commercialization partner, as provided in the exclusive license and supply agreement by and between
Protalix Ltd., our wholly-owned subsidiary, and Pfizer, which we refer to as the Pfizer Agreement. We granted Pfizer an exclusive,
worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel.
We have agreed to a specific allocation between Protalix Ltd. and Pfizer of the responsibilities for the continued development
efforts for taliglucerase alfa outside of Israel. Our share in the collaboration with Pfizer for 2012 was a loss of approximately
$446,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are cooperating with Pfizer to obtain marketing approval
for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed
with <FONT STYLE="font-family: Times New Roman, Times, Serif">ANVISA </FONT>as well as in other countries. In November 2012, we
announced that the European Commission issued a Commission Decision refusing the marketing authorization for taliglucerase alfa
in the European Union. This decision is an endorsement of the CHMP&rsquo;s June 2012 opinion recommending against the marketing
authorization of taliglucerase alfa. While the CHMP gave a positive risk-benefit assessment for taliglucerase alfa, its recommendation
was based solely on the orphan market exclusivity granted to VPRIV, Shire's Gaucher disease treatment. It was not based on the
safety and efficacy profile of taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">In December 2012, we entered into
a Clinical Development Agreement with </FONT>Pfizer under which we will continue to manage, administer and sponsor current, ongoing
clinical trials relating to ELELYSO. We are currently sponsoring adult and pediatric extension studies of ELELYSO. New clinical
trials for ELELYSO<SUP> </SUP>will be conducted and sponsored by Pfizer. Under the terms of the agreement, we were eligible to
receive a milestone payment of $8.3 million upon the achievement of certain near-term clinical development milestones. The milestones
were achieved prior to the end of fiscal year 2012 and have been paid in full. The $8.3 million milestone payment we received in
connection with certain clinical development milestones will be recognized as a deduction from the relevant expenses we incur during
the relevant periods. This agreement helps to maintain the continuity of the ongoing clinical trials for Gaucher patients and physicians
and reinforces the companies&rsquo; mutual commitment to the Gaucher community.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We performed a number of studies on taliglucerase alfa to supplement
the pivotal phase III clinical trial which we completed in September 2009. We initiated a double-blind, follow-on extension study
in 2008 which consisted of eligible patients who had completed nine months of treatment in the pivotal phase III clinical trial.
The patients were offered the opportunity to continue to receive taliglucerase alfa at the same dose they received in the pivotal
trial for an additional 15 months in a blinded manner. We also conducted a nine-month, worldwide, multi-center, open-label, switch-over
clinical study evaluating the safety and efficacy of switching Gaucher patients currently treated with Cerezyme, which is produced
by Genzyme, with taliglucerase alfa which was successfully completed in 2011. We also conducted a clinical trial of na&iuml;ve
and switchover pediatric patients which we concluded in 2012. Patients in the extension trial and the switchover trial are still
being treated with taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Currently, patients are being treated with ELELYSO on a commercial
basis in the United States and in Israel shortly. Globally, patients are being treated through our extension trials and related
studies, compassionate use programs, special access agreements, named patient provisions and other programs designed to ensure
that treatments are available to Gaucher patients in light of recent shortages of approved treatments. In France, Gaucher patients
are being treated with taliglucerase alfa through an ATU. In addition to the United States and France, taliglucerase alfa is currently
being provided to Gaucher patients under special access agreements or named patient provisions in Brazil and in other countries.
Hundreds of patients, in the aggregate, have been treated with taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 10, 2010, Pfizer entered into a $30.0 million short-term
supply agreement with the Brazilian MOH pursuant to which Protalix and Pfizer have provided taliglucerase alfa to the Brazilian
MOH for the treatment of Gaucher patients. During the remainder of 2010 and the first quarter of 2011, we and Pfizer completed
the supply of products deliverable under the short-term supply agreement. During 2011, the Brazilian MOH requested that Pfizer
consider the replacement of certain vials that might expire during 2012. During the third quarter of 2012, we and Pfizer resupplied
a portion of the returned vials. In addition, we and the Brazilian MOH are in discussions relating to a possible long-term supply
agreement that contemplates, among other matters, providing certain components of our manufacturing technology to the Brazilian
MOH for implementation by it in Brazil. We are currently unable to assess whether these discussions will result in an agreement
and we can make no assurance that we will be able to enter into such an agreement on favorable terms, if at all. In any event,
we do not expect to supply the Brazilian MOH taliglucerase alfa until ANVISA grants marketing approval to taliglucerase alfa, if
at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to taliglucerase alfa, we are developing an innovative
product pipeline using our ProCellEx protein expression system. Our product pipeline currently includes, among other candidates:
(1) PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder in humans;
(2) PRX-105, a plant cell expressed pegylated recombinant acetylcholinesterase product candidate for biodefense and other indications;
(3) an orally-administered glucocerebrosidase enzyme for the treatment of Gaucher patients utilizing oral delivery of the recombinant
enzyme produced within carrot cells; (4) PRX-106, or pr-antiTNF, a plant cell expressed recombinant fusion protein made from the
soluble form of the human TNF receptor (TNFR) and an antibody portion, which is being developed as a treatment of certain immune
diseases such as rheumatoid arthritis, Chrohn's disease, placque psoriasis and other autoimmune disorders; and (5) two additional
undisclosed therapeutic proteins, both of which are being evaluated in animal studies. We participated in a pre-investigational
new drug, or IND, meeting with respect to one of the undisclosed product candidates in the first quarter of 2012 and a pre-IND
meeting for the second candidate is planned for 2013. In March 2010, we initiated a preliminary phase I clinical trial of PRX-105
which we completed in June 2010. In our preclinical studies we utilized an analogue to nerve gas. However, we anticipate that we
will use live nerve gas rather than an analogue in the proposed additional efficacy trials in animals. In December 2012, the first
patient was treated in our phase I/II clinical study of PRX-102 in Fabry patients. We anticipate commencing a clinical trial in
Gaucher patients designed to demonstrate safety and achieve the first ever proof in concept regarding orally-administrated glucocerebrosidase
enzyme during the first half of 2013. In December 2011, we held a pre-IND meeting with respect to PRX-106 and we expect to submit
an IND during 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Except for the rights to commercialize taliglucerase
alfa worldwide (other than Israel) which we licensed to Pfizer, we hold the worldwide commercialization rights to our proprietary
development candidates. We have built an internal marketing team designed to serve the Israeli market for taliglucerase alfa and
we intend to establish internal commercialization and marketing teams for our other product candidates in North America, the European
Union and in other significant markets, including Israel, subject to required marketing approvals, as the need arises. In addition,
we continuously evaluate potential strategic marketing partnerships.<FONT STYLE="background-color: yellow"> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our business is conducted by our wholly-owned
subsidiary, Protalix Ltd., which we acquired through a reverse merger transaction effective December 31, 2006. The merger transaction
was treated as a recapitalization for accounting purposes and, as such, the results of operations discussed below are those of
Protalix Ltd. Prior to the merger transaction, we had not conducted any operations for several years. Protalix Ltd. was originally
incorporated in Israel in December 1993 and, since inception, it has generated significant losses in connection with its research
and development, including the clinical development of taliglucerase alfa. We expect that our expenditures in connection with the
research and development activities will continue to represent a significant portion of our expenses for the next several years,
and will require further financial resources if the activities are successful. We believe that if taliglucerase alfa is launched
successfully, it will generate revenues to offset any such expenses. We may need to obtain additional funds for the commercialization
of taliglucerase alfa and to further develop the research and clinical development of our other programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our significant accounting policies are more fully described
in Note&nbsp;1 to our consolidated financial statements appearing at the end of this Annual Report on Form 10-K. We believe that
the accounting policies below are critical for one to fully understand and evaluate our financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The discussion and analysis of our financial condition and results
of operations is based on our financial statements, which we prepared in accordance with U.S. generally accepted accounting principles.
The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of
assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well
as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments,
including those described in greater detail below. We base our estimates on historical experience and on various other factors
that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates
under different assumptions or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Functional Currency</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">The currency of the primary economic
environment in which our operations are conducted is the U.S. dollar. </FONT>Most of the Company&rsquo;s revenues are derived in
dollars. In addition, most of the Company&rsquo;s expenses and capital expenditures are incurred in dollars, and the major source
of the Company&rsquo;s financing has been provided in dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Revenues</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Currently, our sole source of revenues comes
from sales of taliglucerase alfa pursuant to our license agreement with Pfizer, our sales of taliglucerase alfa in Israel and from
milestone payments under the Pfizer Agreement. We recognize revenue when the earnings process is complete, which is when revenue
is realized or realizable and earned, there is persuasive evidence a revenue arrangement exists, delivery of goods or services
has occurred, the sales price is fixed or determinable and collectability is reasonably assured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We recognize revenue from milestone payments
received pursuant to the Pfizer Agreement in accordance with guidance regarding revenue recognition and accounting for revenue
arrangements with multiple deliverables. Pursuant to this guidance, we determine whether our arrangement with Pfizer involves multiple
revenue-generating deliverables that should be accounted for as a combined unit of accounting or separate units of accounting for
revenue recognition purposes. If we determine that there are multiple units of accounting, the consideration from the arrangement
is allocated among the separate units based on a relative fair value allocation. If the arrangement represents a single unit of
accounting, the revenue is recognized over the performance obligation period. As the arrangement with Pfizer requires our continued
involvement with respect to the proposed commercialization of taliglucerase alfa, the non-refundable, up-front license payments
we received from Pfizer are deferred and recognized over the related performance period. We estimated the performance period of
14 years based on the date that the last relevant patent relating to taliglucerase alfa expires. The $25.0 million milestone payment
received in connection with the FDA's approval of taliglucerase alfa in the United States was considered to be a substantive milestone
for purposes of revenue recognition, and, accordingly, was recorded as revenue during the period in which the milestone was achieved.<B>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Under the terms and conditions of the Pfizer
Agreement, we are entitled to 40% of the net profits or loss from sales of taliglucerase alfa by Pfizer and reimbursement of our
certain related expenses we incur in connection with Pfizer's sales (other than those related to sales in Israel). We retained
all rights to taliglucerase alfa in Israel. We recognize our share of net profit or loss under the Pfizer Agreement based on reports
we receive from Pfizer summarizing the results of the collaborative activities under the agreement for the applicable period. Under
the terms of the Pfizer Agreement, for its subsidiaries operating outside the United States, financial information is included
based on the fiscal year ending November 30, while financial information for the U.S. entity is included based on the fiscal year
ending December 31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We recognize revenues received from the sale
of a product to Pfizer upon delivery to Pfizer. The revenues represent our cost with respect to the product sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Research and Development Expense</I> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect our research and development expense to remain our
primary expense in the near future as we continue to develop our product candidates. Research and development expense consists
of:</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 56.7pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>internal costs associated with research and development activities;&nbsp;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>payments made to third party contract research organizations, investigative/clinical sites and consultants;&nbsp;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>manufacturing development costs;&nbsp;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>personnel-related expenses, including salaries, benefits, travel, and related costs for the personnel involved in research
and development;&nbsp;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>activities relating to the advancement of product candidates through preclinical studies and clinical trials; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>facilities and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities,
as well as laboratory and other supplies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table identifies our current major research and
development projects:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 28%; border-bottom: windowtext 1pt solid; font-weight: bold"><B>Project</B></TD>
    <TD NOWRAP STYLE="width: 1%; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 30%; border-bottom: windowtext 1pt solid; font-weight: bold; text-align: center"><B>Status</B></TD>
    <TD NOWRAP STYLE="width: 1%; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 40%; border-bottom: windowtext 1pt solid; font-weight: bold; text-align: center"><B>Expected Near Term Milestones</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: black">PRX 102 &ndash; alpha-GAL-A</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Phase I/II clinical trial</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Complete enrollment</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: black">Oral Glucocerebrosidase</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Preclinical stage research Performed</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: black">Initiate phase I clinical trial</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: black">Acetylcholinesterase</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Phase I clinical trial</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: black">Additional phase I clinical trials</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: black">pr-antiTNF</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Research</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: black">Complete pre clinical development; file IND and initiate phase I clinical trials</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We anticipate incurring increasing costs in connection with
our alpha-galactosidase and oral treatment of Gaucher disease projects. In addition, we continue to incur costs in connection with
our extension studies of taliglucerase alfa, although such costs are offset by the $8.3 million payment we received in connection
with our clinical development agreement with Pfizer. Our other projects are in the early clinical, preclinical or research phases
with relatively immaterial costs. To date, most of our research and development costs were incurred in connection with our phase
III clinical trial of taliglucerase alfa. Our internal resources, employees and infrastructure are not tied to any individual research
project and are typically deployed across all of our projects. We currently do not record and maintain research and development
costs per project.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The costs and expenses of our projects are partially funded
by grants we have received from the OCS. Each grant is deducted from the related research and development expenses as the costs
are incurred. For additional information regarding the grant process, see &ldquo;Business&mdash;Israeli Government Programs&mdash;Encouragement
of Industrial Research and Development Law, 1984&rdquo; in Item 1 of this Annual Report. There can be no assurance that we will
continue to receive grants from the OCS in amounts sufficient for our operations, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At this time, due to the inherently unpredictable nature of
preclinical and clinical development processes and given the early stage of our preclinical product development programs, we are
unable to estimate with any certainty the costs we will incur in the continued development of the product candidates in our pipeline
for potential commercialization. Clinical development timelines, the probability of success and development costs can differ materially
from expectations. While we are currently focused on advancing each of our product development programs, our future research and
development expenses will depend on the clinical success of each product candidate, as well as ongoing assessments of each product
candidate&rsquo;s commercial potential. In addition, we cannot forecast with any degree of certainty which product candidates may
be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would
affect our development plans and capital requirements. See &ldquo;Risk Factors&mdash;If we are unable to develop and commercialize
our product candidates, our business will be adversely affected&rdquo; and &ldquo;&mdash;We may not obtain the necessary U.S.,
EMA or other worldwide regulatory approvals to commercialize our drug candidates in a timely manner, if at all, which would have
a material adverse effect on our business, financial condition and results of operations.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect our research and development expenses to continue
to be our primary expense in the future as we continue the advancement of our clinical trials and preclinical product development
programs for our product candidates other than taliglucerase alfa. The lengthy process of completing clinical trials and seeking
regulatory approval for our product candidates requires expenditure of substantial resources. Any failure or delay in completing
clinical trials, or in obtaining regulatory approvals, could cause a delay in generating product revenue and cause our research
and development expense to increase and, in turn, have a material adverse effect on our operations. Taliglucerase alfa has been
approved for sale in the United States, Israel and Uruguay, and marketing authorization applications are outstanding for Brazil
and other countries. Due to the factors set forth above, we are not able to estimate with any certainty when we would recognize
any net cash inflows from our projects. See &ldquo;Risk Factors&mdash;Clinical trials are very expensive, time-consuming and difficult
to design and implement and may result in unforeseen costs which may have a material adverse effect on our business, results of
operations and financial condition.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Share-Based Compensation</I> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The discussion below regarding share-based
compensation relates to share-based compensation paid by Protalix Ltd., our wholly-owned subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="color: black">In accordance with
the guidance, we record the benefit of any grant to a non-employee and remeasure the benefit in any</FONT> future vesting period
for the unvested portion of the grants, as applicable. In addition, we use the straight-line accounting method for recording the
benefit of the entire grant, unlike the graded method we use to record grants made to employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We measure share-based compensation cost for
all share-based awards at the fair value on the grant date and recognition of share-based compensation over the service period
for awards that we expect will vest. The fair value of stock options is determined based on the number of shares granted and the
price of our ordinary shares, and calculated based on the Black-Scholes valuation model. We recognize such value as expense over
the service period, net of estimated forfeitures, using the accelerated method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For purposes of determining the fair value of the restricted
shares of common stock granted to employees during the fiscal year ended December 31, 2012, our management used the fair value
of our common stock which was the closing sale price of our common stock on the NYSE MKT on the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The guidance requires companies to estimate
the expected term of the option rather than simply using the contractual term of an option. Because of lack of data on past option
exercises by employees, the expected term of the options could not be based on historic exercise patterns. Accordingly, we adopted
the simplified method, according to which companies may calculate the expected term as the average between the vesting date and
the expiration date, assuming the option was granted as a &ldquo;plain vanilla&rdquo; option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">In performing the valuation, we assumed an
expected 0% dividend yield in the previous years and in the next years. We do not have a dividend policy and given the lack of
profitability, dividends are not expected in the foreseeable future, if at all. The guidance stipulates a number of factors that
should be considered when estimating the expected volatility, including the implied volatility of traded options, historical volatility
and the period that the shares of the company are being publicly traded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
risk-free interest rate described above has been based on the implied yield of U.S. federal reserve zero&ndash;coupon government
bonds. The remaining</FONT> term of the bonds used for each valuation was equal to the expected term of the grant. This methodology
has been applied to all grants valued by us. The guidance requires the use of a risk&ndash;free interest rate based on the implied
yield currently available on zero&ndash;coupon government issues of the country in whose currency the exercise price is expressed,
with a remaining term equal to the expected life of the option being valued. This requirement has been applied for all grants valued
as part of this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Year Ended December&nbsp;31, 2012 Compared to the Year
Ended December&nbsp;31, 2011</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We recorded revenue of $34.9 million for the
year ended December&nbsp;31, 2012, an increase of $26.5 million or 315%, compared to revenue of $8.4 million for the year ended
December 31, 2011. The increase resulted primarily from the $25.0 million milestone payment we received from Pfizer in connection
with the FDA's approval of taliglucerase alfa in the United States. The increase was also due to the increase in the supply of
taliglucerase alfa vials to Pfizer during the year ended December 31, 2012. Revenues also include the amortization of the $65.0
million upfront and milestone payments received from Pfizer. The payments were recorded as deferred revenue and the amounts will
be<FONT STYLE="font-family: Times New Roman, Times, Serif"> amortized over the performance period, estimated at approximately 14
years, at a rate of approximately $1.1 million per quarter</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Our share in the Collaboration Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded a loss of $446,000 as our share in the collaboration
under the Pfizer Agreement during the year ended December&nbsp;31, 2012, a decrease of $5.0 million, or 92%, compared to the $5.4
million of loss recorded for the year ended December 31, 2011. Our share in the collaboration's loss for the year ended December
31, 2012 represents our 40% share of the net loss generated during the period, which was primarily the result of the expenses incurred
during the period mainly in connection with activities related to the U.S. launch of taliglucerase alfa which exceeded the revenues
generated by Pfizer in the United States, and resupply in Brazil. Under the terms and conditions of the Pfizer Agreement, we record
income or loss equal to 40% of the profit or loss realized from sales of taliglucerase alfa and related expenses incurred based
on reports we receive from Pfizer summarizing the results of the collaborative activities under the Pfizer Agreement for the applicable
period. Under the terms and conditions of the Pfizer Agreement, financial information of Pfizer&rsquo;s subsidiaries that operate
outside the United States is included based on the fiscal year ending November 30, while financial information for the U.S. entity
is included based on the fiscal year ending December 31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cost of Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of revenues was $8.1 million for the year ended December
31, 2012, an increase of $6.6 million, compared to the cost of revenues of $1.5 million for the year ended December 31, 2011. Cost
of revenues for the year ended December 31, 2012 includes approximately $2.2 million for royalties due to the OCS and a certain
academic institution in connection with gross sales of taliglucerase alfa during the period and $4.1 million for certain fixed
costs relating mainly to our manufacturing facility, including rent, depreciation, salary and maintenance expenses, and to a much
lesser extent, the direct cost of products delivered to Pfizer during the period. Prior to the FDA's approval of taliglucerase
alfa, manufacturing costs related to taliglucerase alfa were not capitalized; rather, such costs were expensed as research and
development expenses. Effective as of the FDA approval of taliglucerase alfa on May 1, 2012, we capitalize all manufacturing costs
associated with taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Research and Development Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses were $36.7&nbsp;million for
the year ended December&nbsp;31, 2012, a decrease of $1.1 million from $37.8&nbsp;million for the year ended December&nbsp;31,
2011. The decrease resulted primarily from a decrease of $2.6 million in expenses related to consulting and subcontractors, and
a decrease of $2.8 million in certain expenses, such as rent, depreciation and maintenance, that were classified as cost of revenues
or capitalized as inventory after the FDA's approval of taliglucerase alfa on May 1, 2012. Such decrease was partially offset by
an increase of $4.9 million in salaries expense associated with research and development activities mainly due to share-based compensation,
bonuses paid in connection with the FDA&rsquo;s approval of taliglucerase alfa and the initiation of the phase I/II clinical trial
of PRX-102 for Fabry disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We expect research and development expenses
to continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of
our product candidates<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">General and administrative expenses were $9.8&nbsp;million for
the year ended December&nbsp;31, 2012, an increase of $2.8 million, or 41%, from $6.9&nbsp;million for the year ended December&nbsp;31,
2011. The increase resulted primarily from an increase of $3.3&nbsp;million in salaries expense primarily due to bonuses paid in
connection with the FDA's approval of taliglucerase alfa on May 1, 2012 and share-based compensation. The increase was partially
offset by a decrease of $646,000 in legal and accounting expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Financial Expenses and Income</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financial income was $554,000 for the year ended December 31,
2012, an increase of $552,000 from $2,000 for the year ended December 31, 2011. The increase resulted primarily from the higher
average cash balance during the year 2012 compared to 2011 which earned interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Year Ended December&nbsp;31, 2011 Compared to the Year
Ended December&nbsp;31, 2010</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We recorded revenue of $8.4 million for the
year ended December&nbsp;31, 2011, an increase of $1.8 million, or 27%, compared to revenue of $6.6 million for the year ended
December 31, 2010. The increase resulted primarily from increases in the supply of taliglucerase alfa vials to Pfizer during the
year ended December 31, 2011. Revenues also include the amortization of the $65.0 million upfront and milestone payments received
from Pfizer. The payments were recorded as deferred revenue and the amounts will be<FONT STYLE="font-family: Times New Roman, Times, Serif">
amortized over the performance period, estimated at approximately 14 years, at a rate of approximately $1.1 million per quarter</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Our share in the Collaboration Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We recorded $5.4 million of loss as our share
in the collaboration under the Pfizer Agreement during the year ended December&nbsp;31, 2011, a decrease of $10.0 million, or 217%,
compared to the $4.6 million of income recorded for the year ended December 31, 2010. Our share in the collaboration's loss for
the year ended December 31, 2011 resulted primarily from our 40% share of the allowance for sales return of taliglucerase alfa
recorded by Pfizer in connection with the short term supply agreement between Pfizer and the Brazilian MOH. During 2011, the Brazilian
MOH requested that Pfizer consider the replacement of certain vials that might expire during 2012. As a result, Pfizer recorded
an allowance for sales return. The allowance was partially offset by our share in the income generated through sale of taliglucerase
alfa via the ATU program in France. Under the terms and conditions of the Pfizer Agreement, we record income or loss equal to 40%
of the profit or loss realized from sales of taliglucerase alfa and related expenses incurred based on reports we receive from
Pfizer summarizing the results of the collaborative activities under the Pfizer Agreement for the applicable period. Under the
terms and conditions of the Pfizer Agreement, financial information of Pfizer&rsquo;s subsidiaries that operate outside the United
States is included based on the fiscal year ending November 30, while financial information for the U.S. entity is included based
on the fiscal year ending December 31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Research and Development Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Research and development expenses were $37.8&nbsp;million
for the year ended December&nbsp;31, 2011, an increase of $127,000 from $37.7&nbsp;million for the year ended December&nbsp;31,
2010. The research and development expenses for the year ended December 31, 2011 were partially offset by grants received from
the OCS of approximately $3.3 million, and $3.4 million of reimbursements for certain expenses in accordance with the terms and
conditions of the Pfizer Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We expect research and development expenses
to continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of
our product candidates<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">General and administrative expenses were $6.9&nbsp;million for
the year ended December&nbsp;31, 2011, an increase $55,000 from $6.9&nbsp;million for the year ended December&nbsp;31, 2010. We
expect that our general and administrative expenses will increase as we become a commercial company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Financial Expenses and Income</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financial income was $2,000 for the year ended December 31,
2011, a decrease of $966,000, or 99%, from $968,000 for the year ended December 31, 2010. The decrease resulted primarily from
the devaluation of the New Israeli Shekel against the U.S. dollar and lower interest rates available for short term deposits during
the year ended December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Sources of Liquidity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">As a result of our significant research and
development expenditures and the lack of significant product sales revenue due to the recent launch of taliglucerase alfa in the
United States and Israel, we have not been profitable and have generated operating losses since our inception. To date, we have
funded our operations primarily with proceeds equal to $31.3&nbsp;million from the sale of shares of convertible preferred and
ordinary shares of Protalix Ltd., and an additional $14.1&nbsp;million in connection with the exercise of warrants issued in connection
with the sale of such shares, through December 31, 2008. In addition, on October 25, 2007, we generated gross proceeds of $50&nbsp;million
in connection with an underwritten public offering of our common stock and on each of March 23, 2011 and February 22, 2012, we
generated gross proceeds of $22.0 million and $27.2 million, respectively, in connection with underwritten public offerings of
our common stock. We believe that the funds currently available to us as are sufficient to satisfy our capital needs for at least
12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The following table summarizes our public
funding sources since 2007:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid">Security</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Year</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Number of Shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 39%; text-align: left">Common Stock</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 18%; text-align: center; text-indent: 0in">2007</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">10,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">50,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0in">2011</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">22,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0in">2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,175,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">27,168,750</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the foregoing, <FONT STYLE="font-family: Times New Roman, Times, Serif">Pfizer
paid Protalix Ltd. $60.0 million as an upfront payment in connection with the execution of the Pfizer Agreement and subsequently
paid to Protalix Ltd. an additional $5.0 million upon Protalix Ltd.'s meeting a certain milestone. Protalix Ltd. also received
a milestone payment of $25.0 in connection with the FDA's approval of taliglucerase alfa in May 2012. Protalix Ltd. is also entitled
to payments equal to 40% of the net profits earned by Pfizer on its global sales of taliglucerase alfa (except in Israel). In calculat</FONT>ing
net profits there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and
costs of goods sold. Pfizer has also paid Protalix Ltd. $8.3 million in connection with the successful achievement of certain milestones
under the Clinical Development Agreement between Pfizer and Protalix Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cash Flows </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Net cash provided by operations was $635,000
for the year ended December 31, 2012. The net loss for the year ended December 31, 2012 of $11.6 million decreased primarily due
to $7.8 million in share-based compensation and $3.7 million in depreciation and a $3.0 million increase in accounts payable, which
was partially offset by a an increase of $3.8 million in inventory. Net cash used in investing activities for the year ended December
31, 2012 was $2.3 million and consisted primarily of purchases of property and equipment. Net cash provided by financing activities
was $26.6 million, consisting primarily of net proceeds from our February 2012 underwritten public offering of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Net cash used in operations was $23.6 million
for the year ended December 31, 2011. The net loss for 2011 of $36.5 million was further increased by an increase in deferred revenues
of approximately $3.0 million. The net loss was partially offset by non-cash charges for share-based compensation of $886,000,
depreciation of $3.6 million and a decrease in accounts receivable of approximately $3.9 million and an increase in accounts payable
of $6.1 million. Net cash used in investing activities for 2011 was $5.9 million and consisted primarily of purchases of property
and equipment. Net cash provided from financing activities during 2011 was approximately $20.9 million primarily due to our underwritten
public offering of common stock in the first quarter of 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Future Funding Requirements </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We <FONT STYLE="color: black">expect to continue to incur significant
expenditures in the near future. However, we anticipate that we will generate revenues to offset such losses as Pfizer's commercialization
efforts for taliglucerase alfa progress after the FDA's approval in May 2012, and as we begin to generate revenues from the commercialization
of taliglucerase alfa in Israel after the Israeli MOH's approval in September 2012. We also anticipate that we will generate additional
revenues after additional anticipated marketing approvals of taliglucerase alfa are granted outside of the United States and Israel,
including, primarily, in Brazil. We expect to continue to incur significant research and development expenses, including expenses
related to the hiring of personnel and the advancement of PRX-102 and oral glucocerebrosidase and any other product candidates
in our pipeline into clinical trials. We expect that general and administrative expenses will marginally increase as we expand
our administrative staff, add infrastructure and incur additional costs related to the continued progression of the commercialization
of taliglucerase alfa. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We believe that our existing cash and cash
equivalents will be sufficient to enable us to fund our operating expenses and capital expenditure requirements for at least the
next 12 months. We have based this estimate on assumptions that are subject to change and may prove to be wrong, and we may be
required to use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties
associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased
capital outlays and operating expenditures associated with our current and anticipated clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our future capital requirements will depend
on many factors, including the progress of Pfizer's commercialization efforts in the United States, the progress of our commercialization
efforts in Israel<FONT STYLE="color: black"> and, if anticipated marketing approvals of taliglucerase alfa</FONT> are granted in
other jurisdictions, the progress of Pfizer's global commercialization efforts, the progress and results of our clinical trials,
the duration and cost of discovery and preclinical development and laboratory testing and clinical trials for our product candidates,
the timing and outcome of regulatory review of our product candidates, the costs involved in preparing, filing, prosecuting, maintaining,
defending and enforcing patent claims and other intellectual property rights, the number and development requirements of other
product candidates that we pursue and the costs of commercialization activities, including product marketing, sales and distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We may need to finance our future cash needs
through public or private equity offerings, debt financings, or corporate collaboration and licensing arrangements. We currently
do not have any commitments for future external funding. We may need to raise additional funds more quickly if one or more of our
assumptions prove to be incorrect or if we choose to expand our product development efforts more rapidly than we presently anticipate.
We may also decide to raise additional funds even before we need them if the conditions for raising capital are favorable. Any
sale of additional equity or debt securities will likely result in dilution to our shareholders. The incurrence of indebtedness
would result in increased fixed obligations and could also result in covenants that would restrict our operations. Additional equity
or debt financing, grants or corporate collaboration and licensing arrangements may not be available on acceptable terms, if at
all. If adequate funds are not available, we may be required to delay, reduce the scope of or eliminate our research and development
programs, reduce our planned commercialization efforts or obtain funds through arrangements with collaborators or others that may
require us to relinquish rights to certain product candidates that we might otherwise seek to develop or commercialize independently.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Effects of Inflation and Currency Fluctuations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Inflation generally affects us by increasing
our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations
during the years ended December&nbsp;31, 2010, 2011 or 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Currency fluctuations could affect us by increased
or decreased costs mainly for goods and services acquired outside of Israel. We do not believe currency fluctuations have had a
material effect on our results of operations during the years ended December&nbsp;31, 2010, 2011 or 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Off-Balance Sheet Arrangements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We have no off-balance sheet arrangements
as of December&nbsp;31, 2011 and 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recently Issued Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Contractual Obligations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The following table summarizes our significant
contractual obligations at December 31, 2012:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">(U.S. dollars in thousands)</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Total</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Less than 1 year</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">1-3 years</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">3-5 years</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">More than 5 years</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 25%; text-align: left; text-indent: 0in">Operating lease obligations</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">4,838</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1,502</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2,513</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">823</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Purchase obligations (1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,874</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,874</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: 0in">Certain clinical contract and building contractor obligations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,318</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,054</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">264</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9.35pt; padding-left: 9.35pt">Liability for employee rights upon retirement</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,016</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,016</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: 0in">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,046</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,430</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,777</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">823</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,016</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(1) Represents open purchase orders issued
to certain suppliers and other vendors mainly in connection with our research and development activities that were outstanding
as of December 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The foregoing table does not include (i) annual
license fees, which are immaterial, (ii) payments we may be required to make to certain of our licensors in the time periods set
forth above upon the achievement of agreed-upon milestones and (iii) royalty payments payable by us to certain of our licensors
in connection with the commercial sale of our product candidates, if any. If all of the contingencies with respect to milestone
payments under our research and license agreements are met, the aggregate milestone payments payable would be approximately $950,000
and would be payable, if at all, as our projects progress over the course of a number of years. The royalty payments payable in
connection with sales of each of our product candidates, if at all, shall not exceed low, single-digit percentages of net sales
of the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Selected Quarterly Financial Data (unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 8pt">
    <TD NOWRAP STYLE="font-weight: bold; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="30" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt"><FONT STYLE="font-size: 8pt">Three
    Months Ended</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 8pt">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="14" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt"><FONT STYLE="font-size: 8pt">2011</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="14" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt"><FONT STYLE="font-size: 8pt">2012</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 8pt">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="30" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt"><FONT STYLE="font-size: 8pt">(U.S.
    dollars in thousands)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 8pt">
    <TD NOWRAP STYLE="font-weight: bold; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid; font-size: 8pt"><FONT STYLE="font-size: 8pt">March
    31</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid; font-size: 8pt"><FONT STYLE="font-size: 8pt">June
    30</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid; font-size: 8pt"><FONT STYLE="font-size: 8pt">Sept.
    30</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid; font-size: 8pt"><FONT STYLE="font-size: 8pt">Dec.
    31</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid; font-size: 8pt"><FONT STYLE="font-size: 8pt">March
    31</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid; font-size: 8pt"><FONT STYLE="font-size: 8pt">June
    30</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid; font-size: 8pt"><FONT STYLE="font-size: 8pt">Sept.
    30</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid; font-size: 8pt"><FONT STYLE="font-size: 8pt">Dec.
    31</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 8pt">
    <TD STYLE="width: 28%; font-size: 8pt"><FONT STYLE="font-size: 8pt">Revenues</FONT></TD><TD STYLE="width: 1%; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">4,128</FONT></TD><TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">764</FONT></TD><TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">1,132</FONT></TD><TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">2,362</FONT></TD><TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">3,861</FONT></TD><TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">26,113</FONT></TD><TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">3,724</FONT></TD><TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">1,172</FONT></TD><TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 8pt">
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">Net profit (loss) for the period</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(5,052</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(13,689</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(8,875</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(8,913</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(5,904</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">9,642</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(5,479</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(9,877</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 8pt">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">Earnings
    (loss) per share of common stock, basic</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(0.06</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(0.16</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(0.10</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(0.10</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(0.07</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">0.11</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(0.06</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(0.11</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 8pt">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">Earnings
    (loss) per share of common stock, diluted</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(0.06</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(0.16</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(0.10</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(0.10</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(0.07</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">0.10</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(0.06</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(0.11</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Item&nbsp;7A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Quantitative and Qualitative
Disclosures about Market Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Currency Exchange Risk</B>&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The currency of the primary economic environment
in which our operations are conducted is the dollar. We are currently have no significant source of revenues; therefore we consider
the currency of the primary economic environment to be the currency in which we expend cash. Approximately 50% of our expenses
and capital expenditures are incurred in dollars, and a significant source of our financing has been provided in U.S. dollars.
Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are remeasured using
the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical exchange rates. Revenue
and expense items are remeasured at the average rate of exchange in effect during the period in which they occur. Foreign currency
translation gains or losses are recognized in the statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Approximately 35% of our costs, including salaries, expenses
and office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S. dollar cost of our operations
in Israel. If the U.S. dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations
in Israel. A revaluation of 1% of the NIS will affect our income before tax by less than 1%. The exchange rate of the U.S. dollar
to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 37%">Average rate for period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">3.733</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">3.578</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">3.856</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Rate at year-end</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.549</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.821</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.733</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, we have not engaged in hedging transactions. In the
future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange
rate of the U.S. dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due
to the impact of inflation in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Interest Rate Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our exposure to market risk is confined to
our cash and cash equivalents. We consider all short term, highly liquid investments, which include short-term deposits with original
maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible
to known amounts of cash, to be cash equivalents. The primary objective of our investment activities is to preserve principal while
maximizing the interest income we receive from our investments, without increasing risk. We invest any cash balances primarily
in bank deposits and investment grade interest-bearing instruments. We are exposed to market risks resulting from changes in interest
rates. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest gains may decline in
the future as a result of changes in the financial markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.25pt; text-indent: -38.25pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.25pt; text-indent: -38.25pt"><B>Item&nbsp;8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial
Statements and Supplementary Data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">See the Index to Consolidated Financial Statements
on Page F-1 attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.05pt; text-indent: -40.05pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.05pt; text-indent: -40.05pt"><B>Item&nbsp;9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes
in and Disagreements with Accountants on Accounting and Financial Disclosure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.95pt; text-indent: -40.95pt"><B>Item&nbsp;9A.&nbsp;&nbsp;Controls
and Procedures</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Evaluation of Disclosure Controls and Procedures</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">We conducted an evaluation of the effectiveness
of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Form 10-K. The
controls evaluation was conducted under the supervision and with the participation of management, including our Chief Executive
Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to reasonably assure
that information required to be disclosed in our reports filed under the Exchange Act, such as this Form 10-K, is recorded, processed,
summarized and reported within the time periods specified in the Commission&rsquo;s rules and forms. Disclosure controls and procedures
are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Chief
Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The evaluation of our disclosure controls
and procedures included a review of the controls&rsquo; objectives and design, our implementation of the controls and their effect
on the information generated for use in this Form 10-K. In the course of the controls evaluation, we reviewed identified data errors,
control problems or acts of fraud, and sought to confirm that appropriate corrective actions, including process improvements, were
being undertaken. This type of evaluation will be performed on a quarterly basis so that the conclusions of management, including
the Chief Executive Officer and Chief Financial Officer, concerning the effectiveness of the disclosure controls and procedures
can be reported in our periodic reports on Form 10-Q and Form 10-K. The overall goals of these various evaluation activities are
to monitor our disclosure controls and procedures, and to modify them as necessary. Our intent is to maintain the disclosure controls
and procedures as dynamic systems that change as conditions warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on the controls evaluation, our Chief Executive Officer
and Chief Financial Officer have concluded that, as of the end of the period covered by this Form 10-K, our disclosure controls
and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports
is recorded, processed, summarized and reported within the time periods specified by the Commission, and that material information
related to our company and our consolidated subsidiary is made known to management, including the Chief Executive Officer and Chief
Financial Officer, particularly during the period when our periodic reports are being prepared.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Management Report on Internal Control over Financial Reporting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our management is responsible for establishing
and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of
our financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted
accounting principles. Internal control over financial reporting includes those policies and procedures that: (i) pertain to the
maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;
(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in
accordance with U.S. generally accepted accounting principles, and that receipts and expenditures of our company are being made
only in accordance with authorizations of management and our directors; and (iii) provide reasonable assurance regarding prevention
or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Management assessed our internal control
over financial reporting as of December 31, 2012, the end of our fiscal year. Management based its assessment on criteria established
in Internal Control&mdash;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission.
Management&rsquo;s assessment included evaluation of elements such as the design and operating effectiveness of key financial reporting
controls, process documentation, accounting policies and our overall control environment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Based on our assessment, management
has concluded that our internal control over financial reporting was effective as of the end of the fiscal year to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes
in accordance with U.S. generally accepted accounting principles. We reviewed the results of management&rsquo;s assessment with
the Audit Committee of our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The effectiveness of our internal control
over financial reporting as of December 31, 2012 has been audited by Kesselman &amp; Kesselman, an independent registered public
accounting firm, as stated in their report included herein.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inherent Limitations on Effectiveness of Controls</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our management, including our Chief
Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control
over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated,
can provide only reasonable, not absolute, assurance that the control system&rsquo;s objectives will be met. The design of a control
system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their
costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance
that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company
have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns
can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion
of two or more people or by management override of the controls. The design of any system of controls is based in part on certain
assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its
stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are
subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of
compliance with policies or procedures.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Changes in internal controls</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There were no changes in our internal control over financial
reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended December 31,
2012 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Item&nbsp;9B.&#9;&nbsp;&nbsp;&nbsp;&nbsp;Other
Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On February 27, 2013, our Board of Directors
adopted Amended and Restated Bylaws in order to clarify certain voting procedures in light of recent changes to the voting rules
for brokers adopted by the New York Stock Exchange. In addition, the Amended and Restated Bylaws clarify certain matters relating
to notice procedures in the bylaws, the settlement of indemnified claims and advancement of indemnification expenses, the composition
of Board committees and other matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PART III</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 43.65pt; text-indent: -43.65pt"><B>Item&nbsp;10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Directors,
Executive Officers and Corporate Governance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our directors and executive officers, their
ages and positions as of February 15, 2013 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 96%; border-collapse: collapse; margin-left: 0.25in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; border-bottom: windowtext 1pt solid; font-weight: bold">Name</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 6%; border-bottom: windowtext 1pt solid; font-weight: bold; text-align: center">Age</TD>
    <TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 62%; border-bottom: windowtext 1pt solid; font-weight: bold">Position</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; font-weight: bold; text-indent: -0.15in">Directors</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">Zeev Bronfeld</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">61</TD>
    <TD>&nbsp;</TD>
    <TD>Interim Chairman of the Board</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">David Aviezer, Ph.D., MBA</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">48</TD>
    <TD>&nbsp;</TD>
    <TD>Director, President and Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">Yoseph Shaaltiel, Ph.D.</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">59</TD>
    <TD>&nbsp;</TD>
    <TD>Director and Executive VP, Research and Development</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">Alfred Akirov (1)(2)(3)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">72</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">Amos Bar Shalev (1)(2)(3)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">60</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">Yodfat Harel Buchris (1)(2)(3)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">40</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">Roger D. Kornberg, Ph.D.</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">65</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">Eyal Sheratzky (1)(2)(3)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">44</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; font-weight: bold; text-indent: -0.15in">Executive Officers</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">Einat Brill Almon, Ph.D.</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">53</TD>
    <TD>&nbsp;</TD>
    <TD>Senior Vice President, Product Development</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">Yossi Maimon, CPA</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">42</TD>
    <TD>&nbsp;</TD>
    <TD>Vice P<FONT STYLE="color: black">resident, </FONT>Chief Financial Officer, Treasurer and Secretary</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">Sandra L. Lauterbach</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">44</TD>
    <TD>&nbsp;</TD>
    <TD>Vice President, Sales and Commercial Affairs</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">Tzvi Palash</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">56</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Operating Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-left: 0.25in; margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">(1) Member of Nominating Committee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">(2) Member of Audit Committee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">(3) Member of Compensation Committee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black"><B>Zeev Bronfeld.</B>&nbsp;&nbsp;Mr.
Bronfeld has served as a director of Protalix Ltd. since 1996 and as our director since December 31, 2006. Mr. Bronfeld brings
to us vast experience in management and value building of biotechnology companies. Mr. Bronfeld is an experienced businessman who
is involved in a number of biotechnology companies. He is a co-founder of Biocell Ltd. (TASE:BCEL), an Israeli publicly traded
holding company specializing in biotechnology companies and has served as its Chief Executive Officer since 1986. Mr. Bronfeld
currently serves as a director of Biocell Ltd., Biomedix Incubator Ltd. (TASE:BMDX), D.N.A. Biomedical Solutions Ltd. (TASE:DNA),
and Gefen Biomed Investments Ltd. (TASE:GEFEN), all of which are public companies traded on the TASE. Mr. Bronfeld is also a director
of each of the following privately-held companies: EcoCycle Israel Ltd., Contipi Ltd., L.N. Innovative Technologies, A.T.I Ashkelon
Industries Information Technologies Ltd., The Trendlines Group, MOFET B'Yehuda &ndash; Industrial Research &amp; Development in
Judea Ltd., Incubator for Management of Technological Entrepreneurship Misgav Ltd., A.Y.M.B. Holdings and Investments Ltd., TransBiodiesel
Ltd., Entera Bio Ltd., Incubator for Management of Technological Entrepreneurship Misgav Ltd., M.B.R.T. Development and Investments
Ltd., Macrocure Ltd., Nanothera Ltd., Spearhead Investment Ltd., Stimatix G.I. Ltd. and Apifix Ltd. Mr. Bronfeld received a B.A.
in Economics from the Hebrew University in 1975. We believe Mr. Bronfeld's qualifications to serve on our Board of Directors include
his years of experience in the management of private and public Israeli companies, including life science companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black"><B>David Aviezer, Ph.D., MBA.</B>&nbsp;&nbsp;Dr.
Aviezer has served as Chief Executive Officer of Protalix Ltd. since 2002 and its director since 2005 and as our director since
December 31, 2006. On December 31, 2006, he became our President and Chief Executive Officer. Dr. Aviezer has over 15 years of
experience in biotechnology management, advancing products from early-stage research up to their regulatory approval and commercialization.
Prior to joining Protalix Ltd., from 1996 to 2002, he served as General Manager of ProChon Biotech Ltd., an Israeli company focused
on orthopedic disorders. Previously, Dr. Aviezer was a visiting scientist at the Medical Research Division of American Cyanamid,
a subsidiary of Wyeth which was subsequently acquired by Pfizer (NYSE:PFE), in New York. Since 1996, Dr. Aviezer has served as
an Adjunct Lecturer at Bar Ilan University. Dr. Aviezer is the recipient of the Clore Foundation Award and the J.F. Kennedy Scientific
Award. He holds a Ph.D. in Molecular Biology and Biochemistry from the </FONT>Weizmann Institute of Science<FONT STYLE="color: black">,
an MBA from the Bar Ilan University Business School, an M.Sc. in Biology from the </FONT>Weizmann Institute of Science<FONT STYLE="color: black">
and a B.Sc. in Biology from Bar Ilan University. We believe Dr. Aviezer's qualifications to serve on our Board of Directors include
his position as our President and Chief Executive Officer as well as his previous experience in the management of biotechnology
companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black"><B>Yoseph Shaaltiel, Ph.D.</B>&nbsp;&nbsp;Dr.
Shaaltiel founded Protalix Ltd. in 1993 and has served as a member of our Board of Directors and as our Vice President, Research
and Development since December 31, 2006. Prior to establishing Protalix Ltd., from 1988 to 1993, Dr. Shaaltiel was a Research Associate
at the MIGAL Technological Center. He also served as Deputy Head of the Biology Department of the Biological and Chemical Center
of the Israeli Defense Forces and as a Biochemist at Makor Chemicals Ltd. Dr. Shaaltiel was a Postdoctoral Fellow at the University
of California at Berkeley and at Rutgers University in New Jersey. He has co-authored over 40 articles and abstracts on plant biochemistry
and holds seven patents. Dr. Shaaltiel received his Ph.D. in Plant Biochemistry from the </FONT>Weizmann Institute of Science<FONT STYLE="color: black">,
an M.Sc. in Biochemistry from the Hebrew University and a B.Sc. in Biology from the Ben Gurion University. We believe Dr. Shaaltiel's
qualifications to serve on our Board of Directors include his role in founding our company and his continued role in the management
of our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Alfred Akirov.</B> Mr. Akirov has served as our director
since January 2008. Mr. Akirov is the founder, chairman of the Board of Directors and chief executive officer of Alrov (Israel)
Ltd. (TASE: ALRO), or Alrov Israel, an Israeli publicly-traded company listed on the TASE. Mr. Akirov founded Alrov Israel in 1978
and it is currently one of Israel's largest real-estate companies. Alrov Israel holds shares of our company directly and indirectly
through its subsidiary, Techno-Rov Holdings (1993) Ltd., of which Alrov Israel owns 80% of the outstanding capital stock. Mr. Akirov
serves in different capacities, including chairman, chief executive officer and director, for a number of private companies in
Alrov Israel's subsidiaries and the Techno-Rov portfolios. We believe Mr. Akirov's qualifications to serve on our Board of Directors
include his years of experience in the management of Israeli businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-left: white 0.25pt solid"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Amos Bar Shalev.</B> Mr. Bar Shalev has served as our director
since July 2008. Mr. Bar Shalev served as a director of Protalix Ltd. from 2005 through January 31, 2008, and as our director from
December 31, 2006 through January 31, 2008. Mr. Bar Shalev was not nominated for reelection at our annual meeting of shareholders
on January 31, 2008. On July 14, 2008, our Board of Directors appointed Mr. Bar Shalev to serve on the board, at which time he
was reappointed to the board of directors of Protalix Ltd. as well. Mr. Bar Shalev brings to us extensive experience in managing
technology companies. Currently, Mr. Bar Shalev serves as a director of Technorov Holdings (1993) Ltd. and manages its portfolio.
In addition, he has served on the board of directors of Aposense Ltd. (TASE: APOS), an Israeli publicly-traded company listed on
the TASE, since 2011, and served on the board of directors of Highcon Systems Ltd., a privately-held Israeli company, from 2010
through 2012. From 1997 through 2004, he was a Managing Director of TDA Capital Partners, a management company of the TGF (Templeton
Tadiran) Fund. From 2004 through 2007, he was the President of Win Buyer Ltd. He has served on the board of directors of many other
companies, including, among others, NESS Ltd. (acquired by BioNess Inc.), Idanit (acquired by Scitex Corporation Ltd.), Objet Geometrix,
Verisity, Scitex Vision (acquired by Hewlett Packard), Golden Wings Investment Company Ltd., the venture capital fund of the Israeli
Air Force Veterans Business Club, Win Buyer Ltd. and Sun Light Ltd. He received his B.Sc. in Electrical Engineering from the Technion,
Israel in 1978 and M.B.A. from the Tel Aviv University in 1981. He holds the highest award from the Israeli Air Force for technological
achievements. We believe Mr. Bar Shalev's qualifications to serve on our Board of Directors include his years of experience in
the management of Israeli businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Yodfat Harel Buchris.</B>&nbsp;&nbsp;Mrs. Harel Buchris has
served as our director since June 2007. Since 2006, Mrs. Harel Buchris has been a Managing Director of Tamares Capital Ltd., a
private investment group with interests in real estate, technology, manufacturing, leisure and media. At Tamares Capital, Mrs.
Harel Buchris serves as the Business Development Director and the head of the Israel office. Prior to joining Tamares Capital,
from 2004 to 2006, she was the Head of the Medical Desk of Orbotech, Ltd. (NASDAQ:ORBK), a company providing high-tech inspection
and imaging solutions for bare printed circuit board (PCB), flat panel display (FPD) and PCB assembly manufacturing worldwide.
Prior to that, from 1994 to 2003, she was a Managing Director of Harel-Hertz Investment House Ltd., a business investment company
with offices in Tel Aviv, Israel and Tokyo, Japan. In 2002, Harel-Hertz Investment House became the Israeli representative office
for ITX Corporation, a publicly-traded company in Japan. Mrs. Harel Buchris currently serves on the board of directors of Tamares
Capital, Tamares Hotels, Tamares Real Estate, Storewiz and Halman-Aldubi Provident Funds, Ltd. Mrs. Harel Buchris holds a B.A.
in Communication and Political Science from Bar Ilan University and an executive M.B.A. from Bradford University, Great Britain.
She has also completed programs in Directors' Studies and Advanced Advertising and Marketing at the Israel Management Center. We
believe Mrs. Harel Buchris' qualifications to serve on our Board of Directors include her experience in the management of Israeli
and other businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black"><B>Roger D. Kornberg, Ph.D.</B>&nbsp;&nbsp;Professor
Kornberg has served as our director since February 2008. He has served as a director of Teva Pharmaceuticals (NASDAQ:TEVA, TASE:TEVA)
since 2007 and of </FONT>OphthaliX Inc.<FONT STYLE="color: black"> (OTCBB:OPLI), since 2012. He also serves as the Chief Scientist
and a director of </FONT>Cocrystal Discovery, Inc., a privately-held biotechnology companies<FONT STYLE="color: black">. Professor
Kornberg is a member of the U.S. National Academy of Sciences and the Winzer Professor of Medicine in the Department of Structural
Biology at Stanford University, Stanford, California. He has been a member of the faculty of Stanford University since 1972. Prior
to that, he was a professor at Harvard Medical School. Professor Kornberg is a renowned biochemist and in 2006 he was awarded the
Nobel Prize in Chemistry in recognition for his studies of the molecular basis of eukaryotic transcription, the process by which
DNA is copied to RNA. Professor Kornberg is also the recipient of several awards, including the 2001 Welch Prize, the highest award
granted in the field of chemistry in the United States, and the 2002 Leopold Mayer Prize, the highest award granted in the field
of biomedical sciences from the French Academy of Sciences. He received his B.S. in Chemistry from Harvard University in 1967 and
his Ph.D. in Chemistry from Stanford University in 1972. He holds honorary degrees from universities in Europe and Israel, including
the Hebrew University in Jerusalem, where he currently is a visiting professor. We believe Professor Kornberg's qualifications
to serve on our Board of Directors include his expertise in chemistry and medicine and his experience in the academic arena.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Eyal Sheratzky.</B> Mr. Sheratzky has served as a director
of Protalix Ltd. since 2005 and as our director since December 31, 2006. Mr. Sheratzky has served as a director of Ituran Location
&amp; Control (NASDAQ:ITRN), a publicly-traded company listed on the Nasdaq, since 1995 and as a Co-Chief Executive Officer since
2003. Prior to such date, he served as an alternate Chief Executive Officer of Ituran from 2002 through 2003 and as Vice President
of Business Development from 1999 through 2002. Mr. Sheratzky serves as a director of Moked Ituran Ltd. and certain of Ituran's
other subsidiaries. From 1994 to 1999 he served as the Chief Executive Officer of Moked Services, Information and Investments Ltd.
and as legal advisor to several of Ituran's affiliated companies. Mr. Sheratzky holds LL.B and LL.M degrees from Tel Aviv University
School of Law and an Executive M.B.A. degree from Kellogg School of Management at Northwestern University. We believe Mr. Sheratzky's
qualifications to serve on our Board of Directors include his years of experience in the management of Israeli public and private
businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Einat Brill Almon, Ph.D.</B> Dr. Almon joined Protalix Ltd.
in December 2004, originally as a Senior Director and later as a Vice President and then Senior Vice President, Product Development,
and became our Senior Vice President, Product Development on December 31, 2006. Dr. Almon has many years of experience in the management
of life science projects and companies, including biotechnology and agrobiotech, with direct experience in clinical, device and
scientific software development, as well as a strong background and work experience in Intellectual Property. Prior to joining
Protalix Ltd., from 2001 to 2004, she served as Director of R&amp;D and IP of Biogenics Ltd., a company that developed an autologous
platform for tissue-based protein drug delivery. Biogenics, based in Israel, is a wholly-owned subsidiary of Medgenics Inc. Dr.
Almon has trained as a biotechnology patent agent at leading IP firms in Israel. Dr. Almon holds a Ph.D. and an M.Sc. in molecular
biology of cancer research from the Weizmann Institute of Science, a B.Sc. from the Hebrew University and has carried out Post-Doctoral
research at the Hebrew University in the area of plant molecular biology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Yossi Maimon, CPA.</B>&nbsp;&nbsp;Mr. Maimon joined Protalix
Ltd. on October 15, 2006 as its Chief Financial Officer and became our Vice President and Chief Financial Officer on December 31,
2006. Prior to joining Protalix, from 2002 to 2006, he served as the Chief Financial Officer of Colbar LifeScience Ltd., a biomaterial
company focusing on aesthetics, where he led all of the corporate finance activities, fund raisings and legal aspects of Colbar
including the sale of Colbar to Johnson and Johnson. Mr. Maimon has a B.A. in accounting from the City University of New York and
an MBA from Tel Aviv University, and he is a Certified Public Accountant in the United States (New York State) and Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Sandra L. Lauterbach.</B>&nbsp;&nbsp;Ms. Lauterbach has served
as our Vice President, Sales and Commercial Affairs since December 18, 2009. Prior to joining our company, Ms. Lauterbach was the
Vice President of Marketing, Endocrinology of EMD Serono, Inc., from July 2008 through July 2009. Prior to that, from August 2003
through July 2008, she served in a number of positions at Genzyme Corporation, the last position being the Senior Director, Global
Marketing of Fabrazyme. Ms. Lauterbach holds a B.Sc. in Molecular Biology from the University of Wisconsin&mdash;Madison and an
MBA from the University of South Florida.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Tzvi Palash.</B> Mr. Palash has served
as Protalix Ltd.&rsquo;s Chief Operating Officer since September 6, 2010. Prior to joining Protalix Ltd., from 2006 through 2010,
Mr. Palash served as a General Manager of ColBar LifeScience Ltd., a biotechnology company specializing in reconstructive medicine
and tissue engineering that was acquired by a division of Johnson &amp; Johnson in 2006. In that position, Mr. Palash served as
a member of the Global Aesthetic Management Team at the Consumer Group of Johnson &amp; Johnson. Prior to that, from 2001 through
2006, Mr. Palash served as the Vice President, Operations of ColBar LifeScience, and he has served in different positions at Teva.
Mr. Palash holds an M.Sc. in Biochemistry from the Hebrew University and a B.Sc. in Biology from the Tel Aviv University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Section 16(a) Beneficial Ownership Reporting
Compliance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 16(a) of the Exchange Act requires
our directors, executive officers and holders of more than 10% of our common stock to file with the Commission reports regarding
their ownership and changes in ownership of our equity securities. We believe that all Section&nbsp;16 filings requirements were
met by our officers and directors during 2012. In making this statement, we have relied solely upon examination of the copies of
Forms 3, 4 and 5, Schedule 13s and written representations of our former and current directors, officers and 10% shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Audit Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We require that all Audit Committee
members possess the required level of financial literacy and at least one member of the Audit Committee meet the current
standard of requisite financial management expertise as required by the NYSE Amex and applicable rules and regulations of the
Commission. Messrs. Bar Shalev, Akirov and Sheratzky, and Mrs. Harel Buchris have been appointed by the Board of Directors to
serve on the Audit Committee until their respective successors have been duly elected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our Audit Committee operates under a formal
charter that governs its duties and conduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">All members of the Audit Committee are independent
from our executive officers and management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our independent registered public accounting
firm reports directly to the Audit Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our Audit Committee meets with management
and representatives of our registered public accounting firm prior to the filing of officers&rsquo; certifications with the Commission
to receive information concerning, among other things, effectiveness of the design or operation of our internal controls over financial
reporting, as required by Section 404 of the Sarbanes-Oxley Act of 2002.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our Audit Committee has adopted a Policy for
Reporting Questionable Accounting and Auditing Practices and Policy Prohibiting Retaliation against Reporting employees to enable
confidential and anonymous reporting of improper activities to the Audit Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Messrs. Bar Shalev, Akirov and Sheratzky qualify
as &ldquo;audit committee financial experts&rdquo; under the applicable rules of the Commission. In making the determination as to these
individuals&rsquo; status as audit committee financial experts, our Board of Directors determined they have accounting and related
financial management expertise within the meaning of the aforementioned rules, as well as the listing standards of the NYSE MKT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Code of Business Conduct and Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We have adopted a Code of Business Conduct
and Ethics that includes provisions ranging from restrictions on gifts to conflicts of interest. All of our employees and directors
are bound by this Code of Business Conduct and Ethics. Violations of our Code of Business Conduct and Ethics may be reported to
the Audit Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The Code of Business Conduct and Ethics includes
provisions applicable to all of our employees, including senior financial officers and members of our Board of Directors and is
posted on our website<FONT STYLE="color: black"> (</FONT>www.protalix.com<FONT STYLE="color: black">)</FONT>. We intend to post
amendments to or waivers from any such Code of Business Conduct and Ethics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.3pt; text-indent: -42.3pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.3pt; text-indent: -42.3pt"><B>Item&nbsp;11.&nbsp;&nbsp;&nbsp;&nbsp;Executive
Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Compensation Discussion and Analysis</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The primary goals of the Compensation
Committee of our Board of Directors with respect to executive compensation are to attract and retain the most talented and dedicated
executives possible, to tie annual and long-term cash and stock incentives to achievement of specified performance objectives,
and to align executives&rsquo; incentives with shareholder value creation. To achieve these goals, the Compensation Committee implements
and maintains compensation plans that tie a portion of executives&rsquo; overall compensation to key strategic goals such as developments
in our clinical path, the establishment of key strategic collaborations, the build-up of our pipeline and the strengthening of
our financial position. The Compensation Committee evaluates individual executive performance with a goal of setting compensation
at levels the committee believes are comparable with executives in other companies of similar size and stage of development operating
in the biotechnology industry while taking into account our relative performance and our own strategic goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Elements of Compensation</B><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45pt; background-color: white">Executive compensation
consists of following elements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Base Salary.</I></B> Base salaries
for our executives are established based on the scope of their responsibilities taking into account competitive market compensation
paid by other companies for similar positions. Generally, we believe that executive base salaries should be targeted near the median
of the range of salaries for executives in similar positions with similar responsibilities at comparable companies. <FONT STYLE="color: black">The
companies reviewed by the Compensation Committee in making compensation recommendation to our Board of Directors in 2012 include,
among others, the following companies:</FONT></P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.75in; text-indent: -0.5in; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.75in; text-indent: -0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>InterMune, Inc.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Vivus, Inc.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Biomarin Pharmaceutical Inc.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Rigel Pharmaceuticals, Inc.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Momenta Pharmaceuticals, Inc.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Nektar Therapeutics</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Theravance, Inc.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Dendreon Corp.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Compensation Committee intends
to continue reviewing and revising the peer group periodically to ensure that it continues to reflect companies similar to us in
size and development stage. The Compensation Committee also reviews an executive compensation report and analysis of publicly-traded
biotechnology companies prepared by third party experts from a well known consulting firm for additional data and other information
regarding executive compensation for comparative purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Base salaries are usually reviewed
annually, and adjusted from time to time to realign salaries with market levels after taking into account individual responsibilities,
performance and experience. The base salaries of each of our President and Chief Executive Officer, our Executive Vice President,
Research and Development, our Senior Vice P<FONT STYLE="color: black">resident,</FONT> Product Development, our Vice President
and Chief Financial Officer and our Chief Operating Officer, who we refer to collectively as the &ldquo;Named Executive Officers.&rdquo;
On July 15, 2012, our Board of Directors adopted certain recommendations of the Compensation Committee regarding the compensation
of our Named Executive Officers including that the base salary component will be reviewed in 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Annual Bonus</I>.</B> The Compensation Committee has the
authority to award discretionary annual bonuses to our executive officers. The discretionary annual bonus awards were intended
to compensate officers for achieving financial, clinical, regulatory and operational goals and for achieving individual annual
performance objectives. For any given year, the compensation objectives vary, but relate generally to strategic factors such as
developments in our clinical path, the execution of a license agreement for the commercialization of product candidates, the establishment
of key strategic collaborations, the build-up of our pipeline and financial factors such as capital raising. Bonuses are awarded
generally based on corporate performance, with adjustments made within a range for individual performance, at the discretion of
the Compensation Committee. The Compensation Committee determines, on a discretionary basis, the size of the entire bonus pool
and the amount of the actual award to each Named Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Compensation Committee selects, in its discretion, the executive
officers of our company or our subsidiary who are eligible to receive bonuses for any given year. Any bonus granted by the Compensation
Committee will generally be paid in the first quarter of the year, unless such bonus was, by its terms, made payable upon the achievement
of a specific milestone. The Compensation Committee has not fixed a minimum or maximum award for any executive officer&rsquo;s
annual discretionary bonus, unless specified in the officer&rsquo;s employment agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each of our executive officers is eligible for a discretionary
annual bonus under his or her employment agreement. The Compensation Committee has not fixed a minimum or a maximum amount for
any officer&rsquo;s annual discretionary bonus, nor is any executive officer entitled to a minimum or maximum bonus amount under
his or her employment agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In 2010, the Compensation Committee established a formal bonus
plan that included, among other matters, bonuses payable to our Named Executive Officers upon the approval of taliglucerase alfa
by the FDA. Accordingly, the following bonuses were paid in 2012 in connection with the May 2012 approval of taliglucerase alfa:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Named Executive Officer</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Bonus Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 77%; text-align: left; text-indent: 0in">David Aviezer, Ph.D., MBA</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">400,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Yoseph Shaaltiel, Ph.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">140,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: 0in">Einat Brill Almon, Ph.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">140,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Yossi Maimon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">140,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: 0in; padding-left: 9pt">Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">820,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following the adoption of the 2010 bonus plan, the Compensation
Committee elected to refrain from issuing additional bonuses to our Named Executive Officers until the FDA approved taliglucerase
alfa. On July 15, 2012, our Board of Directors adopted certain recommendations of the Compensation Committee regarding the compensation
of our Named Executive Officers, including the grant of certain incentive bonuses to be paid to them upon the achievement of a
number of designated milestones, as set forth below. In addition, our Board of Directors approved the grant of restricted stock
to our Named Executive Officers, as described below, and to other members of our management team. The bonus amounts were determined
by the Compensation Committee, in its discretion after review materials regarding peer companies, review with our legal counsel
and review of materials provided by accounting firms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The bonuses adopted by the Board of Directors in 2012 are as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left; vertical-align: top">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Clinical<BR> Development<BR> Milestones<BR> per&nbsp;Clinical<BR> Product<BR> Candidate</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Other<BR> Clinical<BR> Development<BR> Milestone&nbsp;for<BR> Clinical<BR> Product<BR> Candidate</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Undisclosed<BR> Substantial<BR> Commercial<BR> Agreement</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">Entry&nbsp;into&nbsp;a<BR> Substantial<BR> Transaction</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Entry&nbsp;into&nbsp;a<BR> Change&nbsp;in<BR> Control<BR> Transaction</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 20%; text-align: left; vertical-align: top">David Aviezer, Ph.D.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">150,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">50,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">800,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: center">$900,000</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">2,980,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">Yoseph Shaaltiel, Ph.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">170,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">120,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">180,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">TBD out of $900,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,200,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; vertical-align: top">Einat Brill Almon, Ph.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">170,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">TBD out of $900,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,125,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">Yossi Maimon, CPA</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">35,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">450,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">TBD out of $900,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,125,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; vertical-align: top">Tzvi Palash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">70,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">TBD out of $900,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the bonuses granted to our Named Executive Officers,
additional members of our management team are entitled to certain incentive bonuses payable upon the achievement of designated
milestones. If we achieve agreed-upon advancements in the clinical development of each of certain designated product candidates
during an agreed-upon amount of time immediately following the Board of Director's approval of the bonuses, our Named Executive
Officers will be entitled to the amounts listed in the first two columns of the table set forth above. The amounts are payable
upon achievement of the applicable milestone if, at such time, we have available an agreed-upon minimum cash balance. If we do
not have the minimum cash balance, the bonuses will be considered earned, and will be payable when we next achieve the minimum
cash balance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The grants of restricted stock to the Named Executive Officers
in 2012 consists of 1,100,000 shares, in the aggregate, as shown in the table immediately following this paragraph. The grants
were made in accordance with the terms and conditions of our amended 2006 stock incentive plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold">Named Executive Officer</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number of Restricted Shares</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 69%; text-align: left">David Aviezer, Ph.D.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 28%; text-align: right">418,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Yoseph Shaaltiel, Ph.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">210,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Einat Brill Almon, Ph.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">185,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Yossi Maimon, CPA</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">185,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Tzvi Palash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">102,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The restricted shares detailed above vest in 16 equal, quarterly
increments over a four-year period, commencing upon the date of grant. In addition, each vested share is subject to a 24-month
lock-up period, commencing upon the applicable vesting date. Immediately and automatically in the event of a Change in Control,
all of the restricted shares listed above shall vest and the lock-up periods shall terminate, subject to certain exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Options and Share-Based Compensation.</I></B>
Our amended 2006 stock incentive plan authorizes us to grant options to purchase shares of common stock, restricted stock and other
securities to our employees, directors and consultants. Our Compensation Committee is the administrator of the stock incentive
plan. Stock option or other grants are generally made at the commencement of employment and following a significant change in job
responsibilities or to meet other special retention or performance objectives. The Compensation Committee reviews and approves
stock option and other awards to executive officers based upon a review of competitive compensation data, its assessment of individual
performance, a review of each executive&rsquo;s existing long-term incentives, and retention considerations. The exercise price
of stock options granted under our amended 2006 stock incentive plan must be equal to at least 100% of the fair market value of
our common stock on the date of grant; however, in certain circumstances, grants may be made at a lower price to Israeli grantees
who are residents of the State of Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: black"><B><I>Severance
and Change in Control Benefits.</I></B> Pursuant to the employment agreements entered into with each of our executive officers
based in Israel, the executive officer </FONT>is entitled to be insured by Protalix Ltd. under a Manager&rsquo;s Policy in lieu
of severance. The intention of such Manager&rsquo;s Policies is to provide the Israel-based officers with severance protection
of one month&rsquo;s salary for each year of employment. <FONT STYLE="color: black">In addition, </FONT>stock option and other
agreements with each of our Named Executive Officers, as amended, <FONT STYLE="color: black">provide that all of the outstanding
options and other securities granted by us to each Named Executive Officer are subject to accelerated vesting immediately upon
a change in control of our company. </FONT>As set forth above, our Board of Directors adopted certain recommendations of the Compensation
Committee on July 15, 2012, regarding the compensation of our Named Executive Officers, including cash bonuses for Named Executive
Officers if we complete a Change in Control transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Other Compensation.</I></B> Consistent
with our compensation philosophy, we intend to continue to maintain our current benefits for our executive officers; however, the
Compensation Committee in its discretion may revise, amend, or add to the officer&rsquo;s executive benefits if it deems it advisable.
As an additional benefit to all of our Israel-based Named Executive Officers and for most of our employees, we generally contribute
to certain funds amounts equaling a total of approximately 15% of their gross salaries for certain pension and other savings plans
for the benefit of the Named Executive Officers. In addition, in accordance with customary practice in Israel, our Israel-based
executives&rsquo; agreements require us to contribute towards their vocational studies, and to provide annual recreational allowances,
a company car and a company phone. We believe these benefits are currently equivalent with median competitive levels for comparable
companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Executive Compensation.</I></B>
We refer to the &ldquo;Summary Compensation Table&rdquo; set forth in Section 11 of the Annual Report on Form 10-K for information
regarding the compensation earned during the fiscal year ended December&nbsp;31, 2012 by: our President and Chief Executive Officer,
our Executive Vice President, Research and Development, our Senior Vice P<FONT STYLE="color: black">resident,</FONT> Product Development,
our Vice President and Chief Financial Officer and our Chief Operating Officer, who we refer to collectively as the &ldquo;Named
Executive Officers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Compensation Committee Report</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>The above report of the Compensation Committee
does not constitute soliciting material and shall not be deemed filed or incorporated by reference into any other filing by us
under the Securities Act of 1933 or the Securities Exchange Act of 1934.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The Compensation Committee has reviewed and
discussed the Compensation Discussion and Analysis set forth below with our management. Based on this review and discussion, the
Compensation Committee has recommended to our Board of Directors that the Compensation Discussion and Analysis be included in our
Annual Report on Form 10&ndash;K and our annual proxy statement on Schedule 14A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Respectfully submitted on February 28, 2013,
by the members of the Compensation Committee of the Board of Directors<I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt"><I>Yodfat Harel Buchris</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt"><I>Alfred Akirov</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt"><I>Amos Bar Shalev</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt"><I>Eyal Sheratzky</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Summary Compensation Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The following table sets forth a summary for
the fiscal years ended December 31, 2012, 2011 and 2010, respectively, of the cash and non-cash compensation awarded, paid or accrued
by us or Protalix Ltd. to each of our President and Chief Executive Officer, our Executive Vice President, Research and Development,
our Senior Vice P<FONT STYLE="color: black">resident,</FONT> Product Development, our Vice President and Chief Financial Officer
and our Chief Operating Officer, who we refer to collectively as the &ldquo;Named Executive Officers.&rdquo; There were no restricted
stock awards, long-term incentive plan payouts or other compensation paid during fiscal years 2012, 2011 and 2010 by us or Protalix
Ltd. to the Named Executive Officers, except as set forth below. All of the Named Executive Officers are employees of our subsidiary,
Protalix Ltd. All currency amounts are expressed in U.S. dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Name&nbsp;and&nbsp;Principal&nbsp;Position</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Salary($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Bonus&nbsp;($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock<BR> Award(s)&nbsp;($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option&nbsp;Award(s)<BR> ($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">All&nbsp;Other<BR> Compensation<BR> ($)(1)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total&nbsp;($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 44%; text-align: left">David Aviezer, Ph.D., MBA</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">2012</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; color: black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: black; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; color: black; text-align: right">493,960</TD><TD STYLE="width: 1%; color: black; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; color: black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: black; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; color: black; text-align: right">675,000</TD><TD STYLE="width: 1%; color: black; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; color: black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: black; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; color: black; text-align: right">860,963</TD><TD STYLE="width: 1%; color: black; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; color: black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: black; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; color: black; text-align: right">1,101,142</TD><TD STYLE="width: 1%; color: black; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; color: black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: black; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; color: black; text-align: right">99,080</TD><TD STYLE="width: 1%; color: black; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; color: black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: black; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; color: black; text-align: right">3,230,145</TD><TD STYLE="width: 1%; color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 9pt">President and</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">531,608</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">-</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">-</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">53,578</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">113,971</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">699,157</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 9pt">Chief Executive Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2010</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">508,868</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">-</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">-</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">145,537</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">107,972</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">762,377</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Yoseph Shaaltiel, Ph.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2012</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">283,655</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">225,000</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">409,838</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">608,826</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">67,257</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">1,594,576</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 9pt">Executive Vice President,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">305,280</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">-</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">-</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">27,830</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">80,063</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">413,173</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 9pt">Research and Development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2010</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">292,095</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">100,000</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">-</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">70,286</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">76,491</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">538,872</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Einat Brill Almon, Ph.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2012</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">244,716</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">215,000</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">361,048</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">547,846</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">67,763</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">1,436,373</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 9pt">Senior Vice President,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">263,357</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">-</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">-</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">32,557</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">71,074</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">366,988</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 9pt">Product Development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2010</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">251,940</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">20,000</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">-</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">97,007</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">66,591</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">435,538</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Yossi Maimon, CPA</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2012</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">268,618</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">157,500</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">361,048</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">544,199</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">58,231</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">1,389,596</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 9pt">Vice President,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">286,220</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">-</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">-</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">18,304</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">69,290</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">373,814</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 9pt">Chief Financial Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2010</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">268,154</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">20,000</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">-</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">63,175</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">68,156</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">419,485</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Tzvi Palash (2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2012</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">216,451</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">35,000</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">199,064</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">152,240</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">66,274</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">669,029</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 9pt">Chief Operating Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">233,452</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">-</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">-</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">339,011</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">76,490</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">648,953</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2010</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">71,956</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">-</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">-</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">207,075</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">24,094</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">303,125</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Includes employer contributions to pension and/or insurance
plans and other miscellaneous payments.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Mr. Palash joined our company in September 2010.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The following table summarizes the grant of
awards made to the Named Executive Officers during 2012 as of December 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Grants of Plan-Based Awards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">Name</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">Grant Date</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">All Other Stock Awards: <BR>Number of Shares of Stock or Units&nbsp;(#)</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Grant Date Fair Value <BR>of Stock and Option Awards&nbsp;($)</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">(a)</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">(b)</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">(i)</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">(l)</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD NOWRAP STYLE="width: 36%; text-align: left; text-indent: 0in">David Aviezer</TD><TD NOWRAP STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 17%; text-align: center; text-indent: 0in">July 16, 2012</TD><TD NOWRAP STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 20%; text-align: right">418,000</TD><TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 20%; text-align: right">2,390,960</TD><TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="text-align: left; text-indent: 0in">Yoseph Shaaltiel</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; text-indent: 0in">July 16, 2012</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">210,000</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">1,201,200</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD NOWRAP STYLE="text-align: left; text-indent: 0in">Einat Brill Almon</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; text-indent: 0in">July 16, 2012</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">185,000</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">1,058,200</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="text-align: left; text-indent: 0in">Yossi Maimon</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; text-indent: 0in">July 16, 2012</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">185,000</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">1,058,200</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD NOWRAP STYLE="text-align: left; text-indent: 0in">Tzvi Palash</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; text-indent: 0in">July 16, 2012</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">102,000</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">583,440</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Outstanding Equity Awards at Fiscal Year-End</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The following table sets forth information
with respect to the Named Executive Officers concerning equity awards as of December 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; font: 8pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 8pt">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="13" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt"><FONT STYLE="font-size: 8pt">Option&nbsp;Awards</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt"><FONT STYLE="font-size: 8pt">Stock&nbsp;Awards</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 8pt">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt"><FONT STYLE="font-size: 8pt">Name</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt"><FONT STYLE="font-size: 8pt">Number<BR>
    of&nbsp;Securities<BR> Underlying<BR> Unexercised<BR> Options<BR> Exercisable&nbsp;(#)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt"><FONT STYLE="font-size: 8pt">Number<BR>
    of&nbsp;Securities<BR> Underlying<BR> Unexercised<BR> Options<BR> Unexercisable&nbsp;(#)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt"><FONT STYLE="font-size: 8pt">Option<BR>
    Exercise<BR> Price&nbsp;($)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt"><FONT STYLE="font-size: 8pt">Option<BR>
    Expiration<BR> Date</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt"><FONT STYLE="font-size: 8pt">Number&nbsp;of&nbsp;Shares&nbsp;or<BR>
    Units&nbsp;of&nbsp;Stock&nbsp;That<BR> Have&nbsp;Not&nbsp;Vested&nbsp;(#)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt"><FONT STYLE="font-size: 8pt">Market&nbsp;Value&nbsp;of<BR>
    Shares&nbsp;or&nbsp;Units&nbsp;of<BR> Stock&nbsp;That&nbsp;Have<BR> Not&nbsp;Vested&nbsp;($)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 8pt">
    <TD STYLE="width: 14%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">David Aviezer</FONT></TD><TD STYLE="width: 1%; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">853,563</FONT></TD><TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">0.972</FONT></TD><TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 13%; text-align: center; font-size: 8pt"><FONT STYLE="font-size: 8pt">9/10/2016</FONT></TD><TD STYLE="width: 1%; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 8pt">
    <TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">600,000</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">5.00</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-size: 8pt"><FONT STYLE="font-size: 8pt">2/7/2018</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 8pt">
    <TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">100,000</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">2.65</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-size: 8pt"><FONT STYLE="font-size: 8pt">2/25/2019</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 8pt">
    <TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">41,667</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">208,333</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">6.90</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-size: 8pt"><FONT STYLE="font-size: 8pt">2/25/2020</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 8pt">
    <TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">391,875</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">2,033,831</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 8pt">
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">Yoseph Shaaltiel</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">122,162</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">(1)</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">0.001</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-size: 8pt"><FONT STYLE="font-size: 8pt">6/30/2016</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 8pt">
    <TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">263,728</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">5.00</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-size: 8pt"><FONT STYLE="font-size: 8pt">2/7/2018</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 8pt">
    <TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">50,000</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">2.65</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-size: 8pt"><FONT STYLE="font-size: 8pt">2/25/2019</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 8pt">
    <TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">24,167</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">120,833</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">6.90</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-size: 8pt"><FONT STYLE="font-size: 8pt">2/25/2020</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 8pt">
    <TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">196,875</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">1,021,781</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 8pt">
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">Einat Brill Almon</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">311,272</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">5.00</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-size: 8pt"><FONT STYLE="font-size: 8pt">2/7/2018</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 8pt">
    <TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">21,667</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">108,333</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">6.90</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-size: 8pt"><FONT STYLE="font-size: 8pt">2/25/2020</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 8pt">
    <TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">173,437</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">900,138</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 8pt">
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">Yossi Maimon</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">175,000</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">5.00</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-size: 8pt"><FONT STYLE="font-size: 8pt">2/7/2018</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 8pt">
    <TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">21,667</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">108,333</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">6.90</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-size: 8pt"><FONT STYLE="font-size: 8pt">2/25/2020</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 8pt">
    <TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">173,437</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">900,138</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 8pt">
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">Tzvi Palash</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">90,000</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">70,000</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">7.55</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-size: 8pt"><FONT STYLE="font-size: 8pt">8/29/2020</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 8pt">
    <TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">95,625</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">496,294</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">(1) Pursuant to a divorce settlement, Dr.
Shaaltiel is required to transfer 50% of these options to his former spouse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Option exercises during 2012 and vested stock
awards for Named Executive Officers as of December 31, 2012 were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Option Exercises and Stock Vested</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid">Option&nbsp;Awards</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid">Stock&nbsp;Awards</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">Name</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Number&nbsp;of&nbsp;Shares<BR> Acquired&nbsp;on&nbsp;Exercise&nbsp;(#)</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Value&nbsp;Received&nbsp;on<BR> Exercise&nbsp;($)</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Number&nbsp;of&nbsp;Shares&nbsp;Acquired<BR> on&nbsp;Vesting&nbsp;(#)</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Value&nbsp;Received&nbsp;on&nbsp;Vesting&nbsp;($)</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">(a)</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(b)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(c)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(d)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(e)</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 28%; text-align: left; text-indent: 0in">David Aviezer</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">450,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">3,049,080</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">26,125</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">137,156</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Yoseph Shaaltiel</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,125</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">68,906</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: 0in">Yossi Maimon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">125,964</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">691,786</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,563</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,706</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Einat Brill Almon</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">166,848</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">943,550</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">11,563</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">60,706</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: 0in">Tzvi Palash</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">6,375</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">33,469</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Potential Payments upon Termination or
Change-in-Control</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">Each of our Named Executive Officers
</FONT>is entitled to be insured by Protalix Ltd. under a Manager&rsquo;s Policy in lieu of severance upon termination. The intention
of such Manager&rsquo;s Policies is to provide the Israel-based officers with severance protection of one month&rsquo;s salary
for each year of employment. We do not provide any change in control benefits to our <FONT STYLE="color: black">Named Executive
Officers</FONT> except for certain cash bonuses and the acceleration of the vesting periods for <FONT STYLE="color: black">outstanding
options and restricted stock, subject to certain conditions. Since as of December 31, 2012 all options that have not been fully
vested on such date, had exercise prices higher than the closing price on that date, if we had experienced a change of control
on December 31, 2012, the value of the acceleration of the stock options held by each of Dr. Aviezer, Dr. Shaaltiel, Dr. Brill
Almon, Mr. Maimon and Mr. Palash would be zero. Had we experienced a change of control on December 31, 2012, the value of the acceleration
of the shares of restricted stock held by each of Dr. Aviezer, Dr. Shaaltiel, Dr. Brill Almon, Mr. Maimon and Mr. Palash would
be $2,033,831, $1,021,781, $900,138, $900,138 and $496,294, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Employment Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>David Aviezer, Ph.D., MBA.</B> Dr. Aviezer originally served
as Protalix Ltd.&rsquo;s Chief Executive Officer on a consultancy basis pursuant to a Consulting Services Agreement between Protalix
Ltd. and Agenda Biotechnology Ltd., a company wholly-owned by Dr. Aviezer. On September 11, 2006, Protalix Ltd. entered into an
employment agreement with Dr. Aviezer pursuant to which he agreed to be employed as Protalix Ltd.&rsquo;s President and Chief Executive
Officer, which agreement supersedes the Consultancy Services Agreement. Dr. Aviezer currently serves as our President and Chief
Executive Officer. Dr. Aviezer&rsquo;s current monthly base salary is NIS 148,000 (approximately $39,650) and he is entitled to
an annual bonus at the Board&rsquo;s discretion. The monthly salary is subject to cost of living adjustments from time to time.
Dr. Aviezer is eligible to receive a substantial bonus in the event of certain public offerings or acquisition transactions, which
bonus shall be at the discretion of the Board, and certain specified bonuses in the event Protalix achieves certain specified milestones.
In connection with the employment agreement, in addition to other options already held by Dr. Aviezer granted to Dr. Aviezer options
to purchase 16,000 ordinary shares of Protalix Ltd. at an exercise price equal to $59.40 per share, which we assumed as options
to purchase 977,297 shares of our common stock at $0.97 per share. Such options vest quarterly retroactively from June 1, 2006,
over a four-year period. In addition, in 2008 we granted to Dr. Aviezer an option to purchase 600,000 shares of our common stock
at an exercise price equal to $5.00 per share. The option vests variably over a five-year period that commenced on January 1, 2008.
In 2009, we granted Dr. Aviezer an option to purchase 100,000 shares of our common stock at an exercise price equal to $2.65 per
share. As of December 31, 2009, all of those options had fully vested. In 2010, we granted Dr. Aviezer an option to purchase 250,000
shares of our common stock at an exercise price equal to $6.90 per share, which option vests quarterly over a three-year period
commencing upon FDA approval of taliglucerase alfa, if at all, and on July 16, 2012, we granted Dr. Aviezer 418,000 restricted
shares of common stock that vest quarterly in 16 equal increments over a four-year period. Dr. Aviezer&rsquo;s employment agreement
is terminable by either party on 90 days&rsquo; written notice for any reason and we may terminate the agreement for cause without
notice. Dr. Aviezer is entitled to be insured by Protalix Ltd. under a Manager&rsquo;s Policy in lieu of severance, company contributions
towards vocational studies, annual recreational allowances, a company car and a company phone. Dr. Aviezer is entitled to 29 working
days of vacation. All stock options that have not vested as of the date of termination shall be deemed to have been forfeited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Yoseph Shaaltiel, Ph.D.</B> Dr. Shaaltiel founded Protalix
Ltd. in 1993 and currently serves as our Executive Vice President, Research and Development. Dr. Shaaltiel entered into an employment
agreement with Protalix Ltd. on September 1, 2001. Pursuant to the employment agreement, his current monthly base salary is NIS
85,000 (approximately $22,770) per month. The employment agreement is terminable by Protalix Ltd. on 90 days&rsquo; written notice
for any reason and we may terminate the agreement for cause without notice. In 2008 we granted to Dr. Shaaltiel an option to purchase
263,728 shares of our common stock at an exercise price equal to $5.00 per share. The option vests variably over a five-year period
that commenced on January 1, 2008. In 2009, we granted Dr. Shaaltiel an option to purchase 50,000 shares of our common stock at
an exercise price equal to $2.65 per share. As of December 31, 2009, all of those options had fully vested. In 2010, we granted
Dr. Shaaltiel an option to purchase 145,000 shares of our common stock at an exercise price equal to $6.90 per share, which option
vests quarterly over a three-year period commencing upon FDA approval of taliglucerase alfa, if at all, and on July 16, 2012, we
granted Dr. Shaaltiel 210,000 restricted shares of common stock that vest quarterly in 16 equal increments over a four-year period.
Dr. Shaaltiel is entitled to be insured by Protalix Ltd. under a Manager&rsquo;s Policy in lieu of severance, company contributions
towards vocational studies, annual recreational allowances, a company car and a company phone. Dr. Shaaltiel is entitled to 29
working days of vacation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Einat Brill Almon, Ph.D.</B> Dr. Brill Almon joined Protalix
Ltd. on December 19, 2004 as its Vice President, Product Development, pursuant to an employment agreement effective on December
19, 2004 by and between Protalix Ltd. and Dr. Brill Almon, and currently serves as our Senior Vice President, Product Development.
Pursuant to the employment agreement, her current monthly base salary is NIS 73,500 per month (approximately $19,690). She is also
entitled to certain specified bonuses in the event that Protalix achieves certain specified clinical development milestones within
specified timelines. In connection with the employment agreement, Protalix agreed to grant to Dr. Brill Almon options to purchase
7,919 ordinary shares of Protalix Ltd. at exercise prices equal to $24.36 and $59.40 per share, which we assumed as options to
purchase 483,701 shares of our common stock at $0.40 and $0.97 per share. The options vest over four years. In addition, in 2008
we granted to Dr. Brill Almon an option to purchase 311,272 shares of our common stock at an exercise price equal to $5.00 per
share. The option vests variably over a five-year period that commenced on January 1, 2008. In 2009, we granted to Dr. Brill Almon
an option to purchase 50,000 shares of our common stock at an exercise price equal to $2.65 per share. As of December 31, 2009,
all of those options had fully vested. In 2010, we granted Dr. Brill Almon an option to purchase 130,000 shares of our common stock
at an exercise price equal to $6.90 per share, which option vests quarterly over a three-year period commencing upon FDA approval
of taliglucerase alfa, if at all, and on July 16, 2012, we granted Dr. Brill Almon 185,000 restricted shares of common stock that
vest quarterly in 16 equal increments over a four-year period. The employment agreement is terminable by either party on 60 days&rsquo;
written notice for any reason and we may terminate the agreement for cause without notice. Dr. Brill Almon is entitled to be insured
by Protalix Ltd. under a Manager&rsquo;s Policy in lieu of severance, company contributions towards vocational studies, annual
recreational allowances, a company car and a company phone at up to NIS 1,000 per month. Dr. Brill Almon is entitled to 29 working
days of vacation. All stock options that have not vested as of the date of termination shall be deemed to have been forfeited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Yossi Maimon, CPA.</B> Mr. Maimon joined Protalix Ltd. as
its Chief Financial Officer pursuant to an employment agreement effective as of October 15, 2006 by and between Protalix Ltd. and
Mr. Maimon and currently serves as our Chief Financial Officer. Pursuant to the employment agreement, his current monthly base
salary is NIS 73,500 (approximately $19,690) and Mr. Maimon is entitled to an annual discretionary bonus and additional discretionary
bonuses in the event Protalix achieves significant financial milestones, subject to the Board&rsquo;s sole discretion. The monthly
salary is subject to cost of living adjustments from time to time. In connection with the employment agreement, Protalix agreed
to grant to Mr. Maimon options to purchase 10,150 ordinary shares of Protalix Ltd. at an exercise price equal to $59.40 per share,
which we assumed as options to purchase 619,972 shares of our common stock at $0.97 per share. The first 25% of such options shall
vest on the first anniversary of the grant date and the remainder shall vest quarterly in 12 equal increments. In addition, in
2008 we granted to Mr. Maimon an option to purchase 175,000 shares of our common stock at an exercise price equal to $5.00 per
share. The option vests variably over a five-year period that commenced on January 1, 2008. In 2009, we granted to Mr. Maimon an
option to purchase 50,000 shares of our common stock at an exercise price equal to $2.65 per share. As of December 31, 2009, all
of those options had fully vested. In 2010, we granted Mr. Maimon an option to purchase 130,000 shares of our common stock at an
exercise price equal to $6.90 per share, which option vests quarterly over a three-year period commencing upon FDA approval of
taliglucerase alfa, if at all, and on July 16, 2012, we granted Mr. Maimon 185,000 restricted shares of common stock that vest
quarterly in 16 equal increments over a four-year period. The employment agreement is terminable by either party on 60 days&rsquo;
written notice for any reason and we may terminate the agreement for cause without notice. Mr. Maimon is entitled to be insured
by Protalix Ltd. under a Manager&rsquo;s Policy in lieu of severance, company contributions towards vocational studies, annual
recreational allowances, a company car and a company phone. Mr. Maimon is entitled to 29 working days of vacation. All stock options
that have not vested as of the date of termination shall be deemed to have been forfeited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Tzvi Palash. </B>Mr. Palash joined Protalix Ltd. as its Chief
Operating Officer pursuant to an employment agreement effective September 6, 2010 and currently serves as our Chief Operating Officer.
Pursuant to the employment agreement, Mr. Palash&rsquo;s current monthly base salary is NIS 69,000 (approximately $18,480) and
Mr. Palash is entitled to an annual discretionary bonus for performance subject to the sole discretion of our compensation committee.
The monthly salary is subject to cost of living adjustments from time to time as may be required by law. In connection with the
employment agreement, we granted to Mr. Palash options to purchase 160,000 shares of our common stock with an exercise price equal
to $7.55 per share. The first 25% of such options vested on the first anniversary of the grant date and the remainder vest quarterly
in 12 equal increments. In addition, on July 16, 2012, we granted Mr. Palash 102,000 restricted shares of common stock that vest
quarterly in 16 equal increments over a four-year period. The employment agreement is terminable by either party on 60 days&rsquo;
written notice for any reason and we may terminate the agreement for cause without notice. Mr. Palash is entitled to be insured
by Protalix Ltd. under a Manager&rsquo;s Policy in lieu of severance, company contributions towards vocational studies, annual
recreational allowances, a company car, a company phone, a company laptop and lodging accommodations in the Carmiel area. Mr. Palash
is entitled to 27 working days of vacation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Amended 2006 Stock Incentive Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our Board of Directors and a majority of our
shareholders approved our 2006 Stock Incentive Plan on December 14, 2006. Our shareholders approved an amendment to the plan on June 17, 2012. There are 11,341,655
shares of our common stock reserved for issuance, in the aggregate, under the amended 2006 Stock Incentive Plan, subject to adjustment
for a stock split or any future stock dividend or other similar change in our common stock or our capital structure. As of December
31, 2012, options to acquire 176,986 shares of common stock remain available for grant under the amended 2006 Stock Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our amended 2006 Stock Incentive Plan provides
for the grant of stock options, restricted stock, restricted stock units, stock appreciation rights and dividend equivalent rights,
collectively referred to as &ldquo;awards.&rdquo; Stock options granted under the amended 2006 Stock Incentive Plan may be either
incentive stock options under the provisions of Section 422 of the Internal Revenue Code, or non-qualified stock options. Incentive
stock options may be granted only to employees. Awards other than incentive stock options may be granted to employees, directors
and consultants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The amended 2006 Stock Incentive Plan is also
designed to comply with the provisions of the Israeli Income Tax Ordinance New Version, 1961 (including as amended pursuant to
Amendment 132 thereto) (the &ldquo;tax ordinance&rdquo;) and is intended to enable us to grant awards to grantees who are Israeli
residents as follows: (i) awards to employees pursuant to Section 102 of the tax ordinance; and (ii) awards to non-employees pursuant
to Section 3(I) of the tax ordinance. For this purpose, &ldquo;employee&rdquo; refers only to employees, office holders and directors
of our company or a related entity excluding those who are considered &ldquo;Controlling Shareholders&rdquo; pursuant to, or otherwise
excluded by, the tax ordinance. In accordance with the terms and conditions imposed by the Tax Ordinance, grantees who receive
awards under the amended 2006 stock incentive plan may be afforded certain tax benefits in Israel as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our Board of Directors or the Compensation
Committee, referred to as the &ldquo;plan administrator,&rdquo; will administer our amended 2006 stock incentive plan, including
selecting the grantees, determining the number of shares to be subject to each award, determining the exercise or purchase price
of each award, and determining the vesting and exercise periods of each award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The exercise price of stock options granted
under the 2006 stock incentive plan must be equal to at least 100% of the fair market value of our common stock on the date of
grant; however, in certain circumstances, grants may be made at a lower price to Israeli grantees who are residents of the State
of Israel. If, however, incentive stock options are granted to an employee who owns stock possessing more than 10% of the voting
power of all classes of our stock or the stock of any parent or subsidiary of our company, the exercise price of any incentive
stock option granted must equal at least 110% of the fair market value on the grant date and the maximum term of these incentive
stock options must not exceed five years. The maximum term of all other awards must not exceed 10 years (or five years in the case
of an incentive stock option granted to any participant who owns stock representing more than 10% of the voting power of all classes
of our stock or the stock of any parent or subsidiary of our company). The plan administrator will determine the exercise or purchase
price (if any) of all other awards granted under the amended 2006 stock incentive plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Under the amended 2006 stock incentive plan,
incentive stock options and options to Israeli grantees may not be sold, pledged, assigned, hypothecated, transferred or disposed
of in any manner other than by will or by the laws of descent or distribution and may be exercised during the lifetime of the participant
only by the participant. Other awards shall be transferable by will or by the laws of descent or distribution and to the extent
and in the manner authorized by the plan administrator by gift or pursuant to a domestic relations order to members of the participant&rsquo;s
immediate family. The amended 2006 stock incentive plan permits the designation of beneficiaries by holders of awards, including
incentive stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">If the service of a participant in the amended
2006 stock incentive plan is terminated for any reason other than cause, the participant may exercise awards that were vested as
of the termination date for a period ending upon the earlier of 12 months from the date of termination (or such shorter or longer
period set forth in the award agreement) or the expiration date of the awards unless otherwise determined by the plan administrator.
If the service of a participant in the amended 2006 stock incentive plan is terminated for cause, the participant may exercise
awards that were vested as of the termination date for a period ending upon the earlier of 14 days from the date of termination
(or such shorter or longer period set forth in the award agreement) or the expiration date of the awards unless otherwise determined
by the plan administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">In the event of a corporate transaction, all
awards will terminate unless assumed by the successor corporation. Unless otherwise provided in a participant&rsquo;s award agreement,
in the event of a corporate transaction and with respect to the portion of each award that is assumed or replaced, then such portion
will automatically become fully vested and exercisable immediately upon termination of a participant&rsquo;s service if the participant
is terminated by the successor company or us without cause within 12 months after the corporate transaction. With respect to the
portion of each award that is not assumed or replaced, such portion will automatically become fully vested and exercisable immediately
prior to the effective date of the corporate transaction so long as the participant&rsquo;s service has not been terminated prior
to such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">In the event of a change in control, except
as otherwise provided in a participant&rsquo;s award agreement, following a change in control (other than a change in control that
also is a corporate transaction) and upon the termination of a participant&rsquo;s service without cause within 12 months after
a change in control, each award of such participant that is outstanding at such time will automatically become fully vested and
exercisable immediately upon the participant&rsquo;s termination. In addition, the stock options and shares of restricted stock
issued to each of our Named Executive Officers are subject to accelerated vesting immediately upon a change in control of our company,
as defined in our amended 2006 stock incentive plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Under our amended 2006 stock incentive plan,
a corporate transaction is generally defined as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
merger or consolidation in which we are not the surviving entity, except for the principal purpose of changing our company&rsquo;s
state of incorporation;</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
sale, transfer or other disposition of all or substantially all of our assets;</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
complete liquidation or dissolution of our company;</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
reverse merger in which we are the surviving entity but our shares of common stock outstanding immediately prior to such merger
are converted or exchanged by virtue of the merger into other property, whether in the form of securities, cash or otherwise, or
in which securities possessing more than forty percent (40%) of the total combined voting power of our outstanding securities are
transferred to a person or persons different from those who held such securities immediately prior to such merger; or</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;acquisition
in a single or series of related transactions by any person or related group of persons of beneficial ownership of securities possessing
more than fifty percent (50%) of the total combined voting power of our outstanding securities but excluding any such transaction
or series of related transactions that the plan administrator determines not to be a corporate transaction (provided however that
the plan administrator shall have no discretion in connection with a corporate transaction for the purchase of all or substantially
all of our shares unless the principal purpose of such transaction is changing our company&rsquo;s state of incorporation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt">Under our amended 2006 stock incentive
plan, a change of control is defined as:</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
direct or indirect acquisition by any person or related group of persons of beneficial ownership of securities possessing more
than fifty percent (50%) of the total combined voting power of our outstanding securities pursuant to a tender or exchange offer
made directly to our shareholders and which a majority of the members of our board (who have generally been on our board for at
least 12 months) who are not affiliates or associates of the offeror do not recommend shareholders accept the offer; or</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
change in the composition of our board over a period of 12 months or less, such that a majority of our board members ceases, by
reason of one or more contested elections for board membership, to be comprised of individuals who were previously directors of
our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Unless terminated sooner, the amended 2006
stock incentive plan will automatically terminate in 2016. Our Board of Directors has the authority to amend, suspend or terminate
our amended 2006 stock incentive plan. No amendment, suspension or termination of the amended 2006 stock incentive plan shall adversely
affect any rights under awards already granted to a participant. To the extent necessary to comply with applicable provisions of
federal securities laws, state corporate and securities laws, the Internal Revenue Code, the rules of any applicable stock exchange
or national market system, and the rules of any non-U.S. jurisdiction applicable to awards granted to residents therein (including
the Tax Ordinance), we shall obtain shareholder approval of any such amendment to the 2006 stock incentive plan in such a manner
and to such a degree as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>Impact of Israeli Tax Law</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The awards granted to employees pursuant to
Section 102 of the Tax Ordinance under the amended 2006 stock incentive plan may be designated by us as approved options under
the capital gains alternative, or as approved options under the ordinary income tax alternative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">To qualify for these benefits, certain requirements
must be met, including registration of the options in the name of a trustee. Each option, and any shares of common stock acquired
upon the exercise of the option, must be held by the trustee for a period commencing on the date of grant and deposit into trust
with the trustee and ending 24 months thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Under the terms of the capital gains alternative,
we may not deduct expenses pertaining to the options for tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Under the amended 2006 stock incentive plan,
we may also grant to employees options pursuant to Section 102(c) of the Tax Ordinance that are not required to be held in trust
by a trustee. This alternative, while facilitating immediate exercise of vested options and sale of the underlying shares, will
subject the optionee to the marginal income tax rate of up to 50% as well as payments to the National Insurance Institute and health
tax on the date of the sale of the shares or options. Under the 2006 stock incentive plan, we may also grant to non-employees options
pursuant to Section 3(I) of the Tax Ordinance. Under that section, the income tax on the benefit arising to the optionee upon the
exercise of options and the issuance of common stock is generally due at the time of exercise of the options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">These options shall be further subject to
the terms of the tax ruling that has been obtained by Protalix Ltd. from the Israeli tax authorities in connection with the merger.
Under the tax ruling, the options issued by us in connection with the assumption of Section 102 options previously issued by Protalix
Ltd. under the capital gains alternative shall be issued to a trustee, shall be designated under the capital gains alternative
and the issuance date of the original options shall be deemed the issuance date for the assumed options for the calculation of
the respective holding period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Compensation of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth information with respect to compensation
of our non-employee directors during fiscal year 2012. The fees to our current directors were paid by Protalix Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid">Name</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Fees&nbsp;Earned&nbsp;or <BR>Paid&nbsp;in&nbsp;Cash&nbsp;($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Total&nbsp;($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Current Directors</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left">Zeev Bronfeld</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">96,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">96,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Alfred Akirov</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Amos Bar Shalev</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Yodfat Harel Buchris</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Roger D. Kornberg</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Eyal Sheratzky</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Directors&rsquo; fees paid to each of Zeev
Bronfeld, Alfred Akirov, Yodfat Harel Buchris and Eyal Sheratzky are paid to the applicable director&rsquo;s employer in accordance
with arrangements between the director and the employer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our Board of Directors will review director
compensation annually and adjust it according to then current market conditions and corporate governance guidelines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Compensation Committee Interlocks and Insider
Participation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our Compensation Committee currently consists
of Messrs. Akirov, Bar Shalev and Sheratzky and Mrs. Harel Buchris. No member of our Compensation Committee or any executive officer
of our company or of Protalix Ltd. has a relationship that would constitute an interlocking relationship with executive officers
or directors of another entity. No Compensation Committee member is or was an officer or employee of ours or of Protalix Ltd. Further,
none of our executive officers serves on the board of directors or compensation committee of any entity that has one or more executive
officers serving as a member of our Board of Directors or Compensation Committee.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -45pt">&nbsp;</P>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -45pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -45pt">Item&nbsp;12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Security
Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Security Ownership of Certain Beneficial
Owners and Management</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The following table sets forth information,
as of February 15, 2013, regarding beneficial ownership of our common stock:</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>each person who is known by us to own beneficially more than 5% of our common stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>each director;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>each of our Chief Executive Officer, our Executive Vice President, Research and Development, our Senior Vice President, Product
Development, our Chief Financial Officer, our Vice President, Sales and Commercial Affairs and our Chief Operating Officer; and</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>all of our directors and executive officers collectively.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Unless otherwise noted, we believe that all
persons named in the table have sole voting and investment power with respect to all shares of our common stock beneficially owned
by each of them. For purposes of these tables, a person is deemed to be the beneficial owner of securities that can be acquired
by such person within 60 days from February 15, 2013 upon exercise of options, warrants and convertible securities. Each beneficial
owner&rsquo;s percentage ownership is determined by assuming that options, warrants and convertible securities that are held by
such person (but not those held by any other person) and that are exercisable within such 60 days from such date have been exercised.
The information set forth below is based upon information obtained from the beneficial owners, upon information in our possession
regarding their respective holdings and upon information filed by the holders with the Commission. The percentages of beneficial
ownership are based on 93,497,809 shares of our common stock outstanding as of February 15, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The address for all directors and officers
is c/o Protalix BioTherapeutics, Inc., 2 Snunit Street, Science Park, P.O. Box 455, Carmiel, Israel, 20100.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Name&nbsp;and&nbsp;Address&nbsp;of&nbsp;Beneficial&nbsp;Owner</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amount&nbsp;and&nbsp;Nature&nbsp;of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Beneficial&nbsp;Ownership</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Percentage&nbsp;of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Class</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Board of Directors and Executive Officers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left">David Aviezer, Ph.D., MBA (1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,694,439</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1.8</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Yoseph Shaaltiel, Ph.D. (2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">975,269</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Alfred Akirov (3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,086,046</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.4</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Amos Bar Shalev (4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,680</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Zeev Bronfeld (5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,466,319</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.5</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Yodfat Harel Buchris</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Roger D. Kornberg, Ph.D. (6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Eyal Sheratzky</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Einat Brill Almon, Ph.D. (7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">378,460</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Yossi Maimon (8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">242,188</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Tzvi Palash (9)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">119,125</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Sandra E. Lauterbach (10)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">123,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">All executive officers and directors as a group (12 persons) (11)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,137,275</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24.0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold">5% Holders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Biocell Ltd. (12)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,466,319</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.5</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Federated Investors Inc. (13)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,665,296</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11.4</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Al-Rov (Israel) Ltd. (14)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,086,046</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.4</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">* less than 1%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(1)</TD><TD>Consists of 1,616,064 shares of our common stock issuable upon exercise of outstanding options within 60 days of February 15,
2013 and 78,375 restricted shares of our common stock that have vested or will vest within 60 days of February 15, 2013. Does not
include 187,500 shares of common stock issuable upon exercise of outstanding options and 339,625 restricted shares of our common
stock that will not vest within 60 days of February 15, 2013.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(2)</TD><TD>Consists of 463,754 shares of our common stock held by Dr. Shaaltiel, 472,140 shares of our common stock issuable upon exercise
of outstanding options within 60 days of February 15, 2013 and 39,375 restricted shares of our, common stock that have vested or
will vest within 60 days of February 15, 2013. Does not include 108,750 shares of common stock issuable upon exercise of outstanding
options and 170,625 restricted shares of our common stock that will not vest within 60 days of February 15, 2013.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(3)</TD><TD>Consists of 4,400,000 shares of our common stock held by Al-Rov (Israel) Ltd., or Al-Rov Israel, and 686,046 shares of our
common stock held by Techno-Rov Holdings (1993) Ltd., or Techno-Rov Holdings. Al-Rov Israel owns 100% of the outstanding shares
of Al-Rov Technologies Holdings LTD, the holder of 80% of Techno-Rov Holdings. Mr. Akirov is the Chairman of Al-Rov Israel and
the Chief Executive Officer of Techno-Rov Holdings and has the power to control their respective investment decisions. Mr. Akirov
disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(4)</TD><TD>Mr. Bar Shalev is a director of Techno-Rov Holdings.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(5)</TD><TD>Consists of 14,466,319 shares of our common stock held by Biocell Ltd. Mr. Bronfeld is a director and Chief Executive Officer
of Biocell. Mr. Bronfeld disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(6)</TD><TD>Consists of 50,000 shares of our common stock issuable upon exercise of outstanding options within 60 days of February 15,
2013.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(7)</TD><TD>Consists of 343,772 shares of our common stock issuable upon exercise of outstanding options within 60 days of February 15,
2013 and 34,688 restricted shares of our common stock that have vested or will vest within 60 days of February 15, 2013. Does not
include 97,500 shares of common stock issuable upon exercise of outstanding options and 150,313 restricted shares of our common
stock that will not vest within 60 days of February 15, 2013.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(8)</TD><TD>Consists of 207,500 shares of our common stock issuable upon exercise of outstanding options within 60 days of February 15,
2013 and 34,688 restricted shares of our common stock that have vested or will vest within 60 days of February 15, 2013. Does not
include 97,500 shares of common stock issuable upon exercise of outstanding options and 150,313 restricted shares of our common
stock that will not vest within 60 days of February 15, 2013.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(9)</TD><TD>Consists of 100,000 shares of our common stock issuable upon exercise of outstanding options within 60 days of February 15,
2013 and 19,125 restricted shares of our common stock that have vested or will vest within 60 days of February 15, 2013. Does not
include 60,000 shares of common stock issuable upon exercise of outstanding options and 82,875 restricted shares of our common
stock that will not vest within 60 days of February 15, 2013.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(10)</TD><TD>Consists of 120,000 shares of our common stock issuable upon exercise of outstanding options within 60 days of February 15,
2013 and 3,750 restricted shares of our common stock that have vested or will vest within 60 days of February 15, 2013. Does not
include 40,000 shares of common stock issuable upon exercise of outstanding options and 16,250 restricted shares of our common
stock that will not vest within 60 days of February 15, 2013.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(11)</TD><TD>Consists of 2,909,476 shares of our common stock issuable upon exercise of outstanding options within 60 days of February 15,
2013 and 210,000 restricted shares of our common stock that have vested or will vest within 60 days of February 15, 2013. Does
not include 591,250 shares of common stock issuable upon exercise of outstanding options and 910,000 restricted shares of our common
stock that will not vest within 60 days of February 15, 2013.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(12)</TD><TD>The address is Moshe Aviv Tower, 7 Jabotinsky Street, Ramat Gan, Israel. Biocell Ltd.&rsquo;s investment and voting decisions
are made collectively by its board of directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(13)</TD><TD>Based solely on a Schedule 13G/A filed on February 12, 2013 by Federated Investors Inc. for December 31, 2012.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(14)</TD><TD>The address is Alrov Tower, 46 Rothschild Blvd., Tel Aviv, Israel 66883. Consists of 4,400,000 shares of our common stock held
by Al-Rov Israel directly and 686,046 shares of our common stock held by Techno-Rov Holdings. Al-Rov Israel owns 100% of the outstanding
shares of Al-Rov Technologies Holdings LTD, the holder of 80% of Techno-Rov Holdings. Mr. Akirov is the Chairman of Al-Rov Israel
and the Chief Executive Officer of Techno-Rov Holdings and has the power to control their respective investment decisions.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Equity Compensation Plan Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The following table provides information as
of December&nbsp;31, 2012 with respect to the shares of our common stock that may be issued under our existing equity compensation
plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">A</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">B</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">C</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Plan Category</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of&nbsp;Securities <BR>to be Issued <BR>Upon Exercise of <BR>Outstanding Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted&nbsp;Average <BR>Exercise Price of <BR>Outstanding&nbsp;Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of&nbsp;Securities&nbsp;Remaining <BR>Available for Future Issuance <BR>Under&nbsp;Equity&nbsp;Compensation&nbsp;Plans <BR>(Excluding Securities Reflected in <BR>Column A)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 55%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Equity Compensation Plans Approved by Shareholders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">7,030,930</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">3.27</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">176,986</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Equity Compensation Plans Not Approved by Shareholders</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">631,866</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10.24</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.3in">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,662,796</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.55</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">176,986</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-indent: -45.35pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-indent: -45.35pt">Item&nbsp;13.&nbsp;&nbsp;&nbsp;&nbsp;Certain
Relationships and Related Transactions, and Director Independence</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 14, 2006, Protalix Ltd. entered into a collaboration
and licensing agreement with Teva for the development and manufacture of two proteins using ProCellEx, our proprietary protein
expression system. Mr. Hurvitz, our former Chairman, was the chairman of Teva&rsquo;s board of directors when we entered into the
agreement. Professor Kornberg, a member of our Board of Directors also serves as a member of Teva&rsquo;s board of directors. The
agreement provides that we will collaborate with Teva on the research and development of two proteins using ProCellEx. We and Teva
identified two proteins for research and development activities under the agreement, but in 2009 both of the projects were terminated
for commercial reasons. Other elements of our collaboration with Teva are currently ongoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">All related party transactions are
reviewed and approved by the Audit Committee, as required by the Audit Committee Charter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Governance and Independent Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In compliance with the listing requirements of the NYSE MKT,
we have a comprehensive plan of corporate governance for the purpose of defining responsibilities, setting high standards of professional
and personal conduct and assuring compliance with such responsibilities and standards. We currently regularly monitor developments
in the area of corporate governance to ensure we are in compliance with the standards and regulations required by the NYSE MKT.
A summary of our corporate governance measures follows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Independent Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe a majority of the members of our Board of Directors
are independent from management. When making determinations from time to time regarding independence, the Board of Directors will
reference the listing standards adopted by the NYSE MKT as well as the independence standards set forth in the Sarbanes-Oxley Act
of 2002 and the rules and regulations promulgated by the Commission under that Act. In particular, our Audit Committee periodically evaluates
and reports to the Board of Directors on the independence of each member of the Board. We anticipate our audit committee will analyze
whether a director is independent by evaluating, among other factors, the following:</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whether
the member of the Board of Directors has any material relationship with us, either directly, or as a partner, shareholder or officer
of an organization that has a relationship with us;</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whether
the member of the Board of Directors is a current employee of our company or any of our subsidiaries, or was an employee of our
company or any of our subsidiaries within three years preceding the date of determination;</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whether
the member of the Board of Directors is, or in the three years preceding the date of determination has been, affiliated with or
employed by (i) a present internal or external auditor of our company or any affiliate of such auditor or (ii) any former internal
or external auditor of our company or any affiliate of such auditor, which performed services for us within three years preceding
the date of determination;</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0; text-indent: 28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Symbol; margin: 0pt 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whether
the member of the Board of Directors is, or in the three years preceding the date of determination has been, part of an interlocking
directorate, in which any of our executive officers serve on the Compensation Committee of another company that concurrently employs
the member as an executive officer;</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whether
the member of the Board of Directors receives any compensation from us, other than fees or compensation for service as a member
of the Board of Directors and any committee of the Board of Directors and reimbursement for reasonable expenses incurred in connection
with such service and for reasonable educational expenses associated with Board of Directors or committee membership matters;</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whether
an immediate family member of the member of the Board of Directors is a current executive officer of our company or was an executive
officer of our company within three years preceding the date of determination;</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whether
an immediate family member of the member of the Board of Directors is, or in the three years preceding the date of determination
has been, affiliated with or employed in a professional capacity by (i) a present internal or external auditor of ours or any of
our affiliates or (ii) any former internal or external auditor of our company or any affiliate of ours which performed services
for us within three years preceding the date of determination; and</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whether
an immediate family member of the member of the Board of Directors is, or in the three years preceding the date of determination
has been, part of an interlocking directorate, in which any of our executive officers serve on the Compensation Committee of another
company that concurrently employs the immediate family member of the member of the Board of Directors as an executive officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The above list is not exhaustive and we anticipate that the
Audit Committee will consider all other factors which could assist it in its determination that a director will have no material
relationship with us that could compromise that director&rsquo;s independence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under these standards, our Board of Directors has determined
that Messrs. Akirov, Bar Shalev and Sheratzky and Mrs. Harel Buchris are considered &ldquo;independent&rdquo; pursuant to the rules
of the NYSE MKT and Section 10A(m)(3) of the Exchange Act. In addition, our Board of Directors has determined that at least two
of these directors are able to read and understand fundamental financial statements and have substantial business experience that
results in their financial sophistication, qualifying them for membership on any audit committee we form. Our Board of Directors
has also determined that Messrs. Akirov, Bar Shalev, Bronfeld and Sheratzky, Mrs. Harel Buchris and Dr. Kornberg are &ldquo;independent&rdquo;
pursuant to the rules of the NYSE MKT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The position of chairman of the board is not held by our chief
executive officer at this time. The Board of Directors does not have a policy mandating the separation of these functions. We believe
it is in our best interest that Mr. Bronfeld serve as the interim chairman of the board. This decision was based on Mr. Bronfeld&rsquo;s
experience in the healthcare industry in Israel and globally and his years of experience serving on the board of directors of many
public and private companies. Our non-management directors hold formal meetings, separate from management, at least twice per year.
We have no formal policy regarding attendance by our directors at annual shareholders meetings, although we encourage such attendance
and anticipate most of our directors will attend these meetings. Messrs. Bronfeld and Bar Shalev, Dr. Aviezer, Dr. Shaaltiel, and
Mrs. Harel Buchris, attended our 2012 annual meeting of shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The Board&rsquo;s Role in Risk Oversight </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Board of Directors oversees an enterprise-wide approach
to risk management, designed to support the achievement of business objectives, including organizational and strategic objectives,
to improve long-term organizational performance and enhance shareholder value. The involvement of our Board of Directors in setting
our business strategy is a key part of its assessment of management&rsquo;s plans for risk management and its determination of
what constitutes an appropriate level of risk for the company. The participation of our Board of Directors in our risk oversight
process includes receiving regular reports from members of senior management on areas of material risk to our company, including
operational, financial, legal and regulatory, and strategic and reputational risks. While the full board has the ultimate oversight
responsibility for the risk management process, various committees of the board also have responsibility for risk management. For
example, financial risks, including internal controls, are overseen by the audit committee and risks that may be implicated by
our executive compensation programs are overseen by the compensation committee. Upon identification of a risk, the assigned board
committee or our full Board of Directors discuss or review risk management and risk mitigation strategies. Additional review or
reporting on enterprise risks is conducted as needed or as requested by our Board of Directors or a committee thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-indent: -40.55pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-indent: -40.55pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-indent: -40.55pt">Item&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;Principal
Accountant Fees and Services</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth fees billed to us by our independent
registered public accounting firm during the fiscal years ended December 31, 2012 and 2011 for: (i) services rendered for the audit
of our annual financial statements and the review of our quarterly financial statements; (ii) services by our independent registered
public accounting firm that are reasonably related to the performance of the audit or review of our financial statements and that
are not reported as Audit Fees; (iii) services rendered in connection with tax compliance, tax advice and tax planning; and (iv)
all other fees for services rendered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year&nbsp;Ended&nbsp;December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 64%; text-align: left">Audit Fees</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">252,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">252,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Audit Related Fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Tax Fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">52,767</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">44,448</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">All Other Fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">20,175</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">36,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Policy on Audit Committee Pre-Approval of Audit and Permissible
Non-Audit Services of Independent Auditors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prior to entering into the engagement letter with our independent
registered accountants, our Audit Committee approved the 2012 audit fees. For fiscal year 2013, our Audit Committee has approved
fees for certain permissible non-audit services to be rendered by our independent registered accounting firm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PART IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.75pt; text-indent: -42.75pt">Item&nbsp;15.&nbsp;&nbsp;&nbsp;Exhibits
and Financial Statement Schedules </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">The following documents are filed as part
of this Annual Report on Form 10-K:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.<I>&nbsp;&nbsp;Financial Statements</I>.
The following Consolidated Financial Statements of Protalix BioTherapeutics, Inc. are included in Item&nbsp;8 of this Annual Report
on Form 10-K:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 92%; padding-left: 0.1in; text-indent: -0.1in; text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 7%; border-bottom: windowtext 1pt solid; font-size: 10pt; font-weight: bold">Page</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.2in; text-indent: -0.2in">Report of Independent Registered Public Accounting Firm</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">F-2</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.2in; text-indent: -0.2in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.2in; text-indent: -0.2in">Consolidated Balance Sheets as of December 31, 2011 and 2012</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">F-3</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.2in; text-indent: -0.2in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.2in; text-indent: -0.2in">Consolidated Statements of Operations for the years ended December 31, 2010, 2011 and 2012</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">F-4</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.2in; text-indent: -0.2in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.2in; text-indent: -0.2in">Consolidated Statements of Changes in Shareholders&rsquo; Equity (Capital Deficiency) for the years ended December 31, 2010, 2011 and 2012</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">F-5</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.2in; text-indent: -0.2in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.2in; text-indent: -0.2in">Consolidated Statements of Cash Flows for the years ended December 31, 2010, 2011 and 2012</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">F-6</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.2in; text-indent: -0.2in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.2in; text-indent: -0.2in">Notes to Consolidated Financial Statements</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">F-8</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.<I>&nbsp;&nbsp;Financial Statement Schedule.
</I>Financial statement schedules have been omitted since they are either not required, are not applicable or the required information
is shown in the consolidated financial statements or related notes. <FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">3.<I>&nbsp;&nbsp;Exhibits.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="7" NOWRAP STYLE="border-bottom: windowtext 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom"><B>Incorporated by Reference</B></TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 10%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit<BR>
Number</B></P></TD>
    <TD NOWRAP STYLE="width: 1%; font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font-weight: bold; text-align: center; width: 32%; vertical-align: bottom">Exhibit Description</TD>
    <TD NOWRAP STYLE="width: 1%; font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font-weight: bold; text-align: center; width: 12%; vertical-align: bottom">Form</TD>
    <TD NOWRAP STYLE="width: 1%; font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 10%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>File<BR>
Number</B></P></TD>
    <TD NOWRAP STYLE="width: 1%; font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font-weight: bold; text-align: center; width: 10%; vertical-align: bottom">Exhibit</TD>
    <TD NOWRAP STYLE="width: 1%; font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font-weight: bold; text-align: center; width: 10%; vertical-align: bottom">Date</TD>
    <TD NOWRAP STYLE="width: 1%; font-weight: bold; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 10%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Filed<BR>
Herewith</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.1</TD>
    <TD>&nbsp;</TD>
    <TD>Amended and Restated Articles of Incorporation of the Company </TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">S-4</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">333-48677</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">3.4</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">March 26, 1998</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.2</TD>
    <TD>&nbsp;</TD>
    <TD>Article of Amendment to Articles of Incorporation dated June 9, 2006</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">8-A </TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">3.2</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2007</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.3</TD>
    <TD>&nbsp;</TD>
    <TD>Article of Amendment to Articles of Incorporation dated December 13, 2006</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">8-A </TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">3.3</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2007</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.4</TD>
    <TD>&nbsp;</TD>
    <TD>Article of Amendment to Articles of Incorporation dated December 26, 2006</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">8-A </TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">3.4</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2007</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.5</TD>
    <TD>&nbsp;</TD>
    <TD>Article of Amendment to Articles of Incorporation dated February 26, 2007</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">8-A </TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">3.5</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2007</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.6</TD>
    <TD>&nbsp;</TD>
    <TD>Amended and Restated Bylaws of the Company</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">10-K</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">3.1</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>4.1</TD>
    <TD>&nbsp;</TD>
    <TD>Form of Restricted Stock Agreement/Notice </TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">8-K</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">3.1</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">July 18, 2012 </TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.1</TD>
    <TD>&nbsp;</TD>
    <TD>2006 Stock Incentive Plan, as amended</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Def 14A</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Annex A</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">May 21, 2012 </TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">10.2</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 32%">Employment Agreement between Protalix Ltd. and Yoseph Shaaltiel, dated as of September 1, 2004 </TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">8-K</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">001-33357</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">10.3</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">January 8, 2007</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.3</TD>
    <TD>&nbsp;</TD>
    <TD>Employment Agreement between Protalix Ltd. and Einat Almon, dated as of December 19, 2004 </TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">8-K</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">10.3</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">January 8, 2007</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.4</TD>
    <TD>&nbsp;</TD>
    <TD>Employment Agreement between Protalix Ltd. and David Aviezer, dated as of September 11, 2006 </TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">8-K</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">10.4</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">January 8, 2007</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.5</TD>
    <TD>&nbsp;</TD>
    <TD>Employment Agreement between Protalix Ltd. and Yossi Maimon, dated as of October 15, 2006 </TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">8-K</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">10.5</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">January 8, 2007</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.6&dagger;</TD>
    <TD>&nbsp;</TD>
    <TD>License Agreement entered into as of April 12, 2005, by and between Icon Genetics AG and Protalix Ltd. </TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">8-K/A</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">10.6</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">September 20, 2007</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.7&dagger;</TD>
    <TD>&nbsp;</TD>
    <TD>Agreement between Teva Pharmaceutical Industries Ltd. and Protalix Ltd., dated September 14, 2006 </TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">8-K/A</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">10.8</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">September 20, 2007</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.8</TD>
    <TD>&nbsp;</TD>
    <TD>Lease Agreement between Protalix Ltd. and Angel Science Park (99) Ltd., dated as of October 28, 2003 as amended on April 18, 2005 </TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">8-K</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">10.9</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">January 8, 2007</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.9</TD>
    <TD>&nbsp;</TD>
    <TD>Merger Agreement and Plan of Reorganization made and entered into as of August 21, 2006, by and among the Company, Protalix Acquisition Co., Ltd. and Protalix Ltd. </TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">8-K</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">10.10</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">January 8, 2007</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.10</TD>
    <TD>&nbsp;</TD>
    <TD>Stock Option Award Agreement grant by and between the Company and Steven Rubin, dated as of December 31, 2006 </TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">10-K</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">10.13</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">March 30, 2007</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.11</TD>
    <TD>&nbsp;</TD>
    <TD>First Amendment to the December 31, 2006 Stock Option Award Agreement by and between the Company and Steven Rubin, effective as of February 28, 2007 </TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">10-K</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">10.16</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">March 30, 2007</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.12</TD>
    <TD>&nbsp;</TD>
    <TD>Scientific Advisory Board Agreement dated August 5, 2007 by and between the Company and Aaron Ciechanover, M.D. </TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">8-K</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">10.1</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">August 6, 2007</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.13&dagger;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="color: black; background-color: white">Research and License Agreement made on August&nbsp;8,&nbsp;2007, by and between Yissum Research Development Company of Jerusalem, the Boyce Thompson Institute and Protalix Ltd. </FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">10-Q</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">10.1</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">November 14, 2007</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">10.14</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 32%">Unprotected Lease Agreement</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">10-K</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">001-33357</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">10.21</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">March 17, 2008 </TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.15&dagger;</TD>
    <TD>&nbsp;</TD>
    <TD>Exclusive License and Supply Agreement dated as of November 30, 2009 between Protalix Ltd. and Pfizer Inc. </TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">10-K</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">10.16</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">February 26, 2010</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.16</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="color: black">Employment Agreement by and between the Company and Sandra Lauterbach dated as of December&nbsp;17, 2009</FONT> </TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">8-K</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">10.1</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">December 27, 2009</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.17</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="color: black">Employment Agreement by and between Protalix Ltd., and Tzvi Palash dated as of August&nbsp;29, 2010</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">8-K</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">10.1</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">September 7, 2010</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.18&dagger;</TD>
    <TD>&nbsp;</TD>
    <TD>License Agreement between Protalix BioTherapeutics Ltd. and Virginia Tech Intellectual Properties, Inc.</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">10-Q</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">10.2</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">November 8, 2010</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>21.1</TD>
    <TD>&nbsp;</TD>
    <TD>Subsidiaries </TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">10-K</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">21.1</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">February 26, 2010</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>23.1</TD>
    <TD>&nbsp;</TD>
    <TD>Consent of Kesselman &amp; Kesselman, Certified Public Accountant (Isr.), A member of PricewaterhouseCoopers International Limited, independent registered public accounting firm for the Registrant </TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>31.1</TD>
    <TD>&nbsp;</TD>
    <TD>Certification of Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>31.2</TD>
    <TD>&nbsp;</TD>
    <TD>Certification of Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>32.1</TD>
    <TD>&nbsp;</TD>
    <TD>18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>32.2</TD>
    <TD>&nbsp;</TD>
    <TD>18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.INS</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL INSTANCE FILE</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.SCH</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL SHEMA FILE</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">101.CAL</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 32%">XBRL CALCULATION FILE</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.DEF</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL DEFINITION FILE</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.LAB</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL LABEL FILE</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.PRE</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL PRESENTATION FILE</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&dagger;&nbsp;&nbsp;&nbsp;&nbsp;Portions of
this exhibit were omitted and have been filed separately with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant&rsquo;s application requesting confidential treatment under Rule 24b-2 of the Exchange Act.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of Section&nbsp;13 or 15(d) of
the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized, as of February 28, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">PROTALIX BIOTHERAPEUTICS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 55%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 41%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: windowtext 1pt solid">/s/ David Aviezer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>David Aviezer, Ph.D.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">POWER OF ATTORNEY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">KNOW ALL PERSONS BY THESE PRESENTS, that each
person whose signature appears below constitutes and appoints David Aviezer, Ph.D. and Yossi Maimon, and each of them, as his true
and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him and in his name, place and
stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with
all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said
attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite
and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby
ratifying and confirming that said attorneys-in-fact and agents, or any of them, or their or his substitute or substitutes, may
lawfully do or cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Pursuant to the requirements of the Securities
Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities
and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; border-bottom: windowtext 1pt solid; font-weight: bold; text-align: center">Signature</TD>
    <TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: windowtext 1pt solid; font-weight: bold; text-align: center">Title</TD>
    <TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 21%; border-bottom: windowtext 1pt solid; font-weight: bold; text-align: center">Date</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: windowtext 1pt solid">/s/ David Aviezer</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">President, Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">February 28, 2013</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>David Aviezer, Ph.D.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(Principal Executive Officer) and Director</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: windowtext 1pt solid">/s/ Yossi Maimon</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Chief Financial Officer, Treasurer and</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">February 28, 2013</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Yossi Maimon</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Secretary (Principal Financial</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">and Accounting Officer)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: windowtext 1pt solid">/s/ Yoseph Shaaltiel</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Executive VP, Research and Development</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">February 28, 2013</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Yoseph Shaaltiel, Ph.D.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">and Director</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: windowtext 1pt solid">/s/ Alfred Akirov</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Director</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">February 28, 2013</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Alfred Akirov</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: windowtext 1pt solid">/s/ Amos Bar Shalev</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Director</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">February 28, 2013</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Amos Bar Shalev</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: windowtext 1pt solid">/s/ Zeev Bronfeld</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Director</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">February 28, 2013</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Zeev Bronfeld</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: windowtext 1pt solid">/s/ Yodfat Harel Buchris</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Director</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">February 28, 2013</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Yodfat Harel Buchris</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: windowtext 1pt solid">/s/ Eyal Sheratzky</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Director</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">February 28, 2013</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Eyal Sheratzky</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>

</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White"><B>PROTALIX
BIOTHERAPEUTICS, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White"><B>CONSOLIDATED
FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White">TABLE
OF CONTENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 8%; font-weight: bold"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt"><B>REPORT OF INDEPENDENT REGISTERED PUBLIC</B></FONT> <FONT STYLE="font-size: 10pt"><B>ACCOUNTING
    FIRM</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">F-2</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt"><B>CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font-size: 10pt">Consolidated Balance Sheets as of December 31, 2011 and 2012</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt; text-transform: uppercase">F-3</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt">Consolidated Statements of Operations for the years ended December 31, 2010, 2011 and 2012</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt; text-transform: uppercase">F-4</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt">Consolidated Statements of Changes in Shareholders&rsquo; Equity (Capital Deficiency) for the years ended December 31, 2010, 2011 and 2012</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-size: 10pt; text-transform: uppercase">F-5</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt">Consolidated Statements of Cash Flows for the years ended December 31, 2010, 2011 and 2012</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt; text-transform: uppercase">F-6</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font-size: 10pt">Notes to Consolidated Financial Statements</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt; text-transform: uppercase">F-8</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White"><img src="tlogo.jpg"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White"><B>REPORT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">To the shareholders of</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White"><B>PROTALIX BIOTHERAPEUTICS,
INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">In our opinion, the accompanying
consolidated balance sheets and the related statements of operations, changes in shareholders&rsquo; equity (capital deficiency)
and cash flows present fairly, in all material respects, the financial position of Protalix BioTherapeutics, Inc. and its subsidiaries
at December 31, 2011 and 2012, and the results of their operations and their cash flows for each of the three years in the period
ended December 31, 2012, in conformity with accounting principles generally accepted in the United States of America. Also, in
our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December
31, 2012, based on criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations
of the Treadway Commission (COSO). The Company&rsquo;s management is responsible for these financial statements, for maintaining
effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial
reporting, included in the accompanying &ldquo;Management Report on Internal Control over Financial Reporting&rdquo; appearing
under Item 9A. Our responsibility is to express opinions on these financial statements and on the Company&rsquo;s internal control
over financial reporting based on our integrated audits. We conducted our audits in accordance with the standards of the Public
Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable
assurance about whether the financial statements are free of material misstatement and whether effective internal control over
financial reporting was maintained in all material respects. Our audits of the financial statements included examining, on a test
basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and
significant estimates made by management, and evaluating the overall financial statement presentation. Our audit of internal control
over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk
that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on
the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances.
We believe that our audits provide a reasonable basis for our opinions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">A company&rsquo;s internal
control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
A company&rsquo;s internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance
of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in
accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only
in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding
prevention or timely detection of unauthorized acquisition, use or disposition of the company&rsquo;s assets that could have a
material effect on the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">Because of its inherent
limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation
of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions,
or that the degree of compliance with the policies or procedures may deteriorate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 54%"><FONT STYLE="font-size: 10pt; background-color: White">Tel-Aviv, Israel</FONT></TD>
    <TD STYLE="width: 46%; text-align: center"><FONT STYLE="font-size: 10pt; background-color: White">/s/ Kesselman &amp; Kesselman</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt; background-color: White">February 28, 2013</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt; background-color: White">Kesselman &amp; Kesselman</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="background-color: White">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt; background-color: White">Certified Public Accountant (Isr.)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 11.55pt"><FONT STYLE="background-color: White">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt; background-color: White">A member firm of PricewaterhouseCoopers</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 11.55pt"><FONT STYLE="background-color: White">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt; background-color: White">International Limited</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">Kesselman &amp;
Kesselman, Trade Tower, 25 Hamered Street, Tel-Aviv 68125, Israel, P.O Box 452 Tel-Aviv 61003 Telephone: +972 -3- 7954555, Fax:+972
-3- 7954556, www.pwc.co.il</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">&nbsp;<B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 94; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White"><B>PROTALIX
BIOTHERAPEUTICS, INC. </B><BR>
<B>CONSOLIDATED BALANCE SHEETS </B><BR>
(U.S. dollars in thousands, except share amounts)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: center">ASSETS</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 9pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">27,001</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">52,035</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts receivable- Trade</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,374</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,410</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,837</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,686</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt">Inventories</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">279</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,039</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 27pt">Total current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">32,491</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">61,170</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in">FUNDS IN RESPECT OF EMPLOYEE RIGHTS
    UPON RETIREMENT</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,043</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,247</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">PROPERTY AND EQUIPMENT, NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,271</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16,310</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 27pt">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">51,805</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">78,727</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">LIABILITIES NET OF CAPITAL DEFICIENCY</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT LIABILITIES:</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts payable and accruals:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.25in">Trade</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,032</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,267</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in">Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,540</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,051</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Deferred revenues</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,121</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,437</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 27pt">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,693</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">25,755</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">LONG TERM LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Deferred revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,923</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,888</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Liability in connection with collaboration operation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,566</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,425</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Liability for employee rights upon retirement</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,700</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,016</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 27pt">Total long term liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">59,189</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">56,329</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 27pt">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">77,882</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">82,084</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">COMMITMENTS <FONT STYLE="font-weight: normal; font-style: normal">(Note 6)</FONT></TD><TD><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">CAPITAL DEFICIENCY:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in">Common Stock, $0.001 par value:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 27pt">Authorized - as of December 31, 2011 and 2012,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 27pt">150,000,000 shares; issued and outstanding - as of December 31, 2011 and 2012, 85,630,157 and 93,489,809 shares, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">86</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">93</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">145,814</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">180,145</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(171,977</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(183,595</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total capital deficiency</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(26,077</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,357</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Total liabilities net of capital deficiency</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">51,805</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">78,727</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="background-color: White"><B>The
accompanying notes are an integral part of the consolidated financial statements.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 95; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White"><B>PROTALIX
BIOTHERAPEUTICS, INC. </B><BR>
<B>CONSOLIDATED STATEMENTS OF OPERATIONS </B><BR>
(U.S. dollars in thousands, except shares and per share amounts)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year&nbsp;ended&nbsp;December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 61%; font-weight: bold; text-align: left">REVENUES (see Note 9(c))</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">6,642</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">8,386</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">34,870</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">COMPANY&rsquo;S SHARE IN COLLABORATION AGREEMENT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,602</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,418</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(446</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">COST OF REVENUES</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,383</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,525</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,144</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">GROSS PROFIT</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,861</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,443</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">26,280</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">RESEARCH AND DEVELOPMENT EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(37,691</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(37,818</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(36,665</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Less &ndash; grants and reimbursements</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,740</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,775</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,976</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">RESEARCH AND DEVELOPMENT EXPENSES, NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(29,951</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(31,043</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(28,689</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt; background-color: White"><B>GENERAL AND ADMINISTRATIVE <FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: black">EXPENSES</FONT></B></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,876</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,931</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(9,763</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="color: black; font-weight: bold; text-align: left">OPERATING LOSS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(29,966</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(36,531</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,172</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">FINANCIAL INCOME &ndash; NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">968</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">554</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS FOR THE YEAR</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(28,998</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(36,529</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(11,618</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="text-transform: uppercase">Net loss per
    share of common stock &ndash; basic and diluted:</FONT></TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.36</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.43</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.13</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 0.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 0.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 0.5pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 0.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 0.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 0.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 0.5pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 0.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 0.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 0.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 0.5pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 0.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="text-transform: uppercase">Weighted average
    number of shares of common stock used in computing loss per share of common stock, basic and diluted:</FONT></TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">80,960,300</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">84,645,364</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">90,845,901</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.35pt"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White"><B>The
accompanying notes are an integral part of the consolidated financial statements.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 96; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White"><B>PROTALIX
BIOTHERAPEUTICS, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White"><B>CONSOLIDATED
STATEMENT OF CHANGES IN SHAREHOLDERS&rsquo; EQUITY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White"><B>(CAPITAL
DEFICIENCY)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White">(U.S.
dollars in thousands, except share data)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Additional</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Common</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Common</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">paid&ndash;in</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Capital</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Deficit</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <BR>shares</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 35%; font-weight: bold">Balance at January 1, 2010</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">80,841,237</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">81</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">122,252</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">(106,450</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">15,883</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 9pt">Changes during 2010:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 9pt">Share-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,282</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,282</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 18.7pt">Exercise of options granted to employees and non-employees (includes net exercise)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">407,235</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">510</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">510</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt; padding-bottom: 1pt">Net Loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(28,998</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(28,998</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Balance at December 31, 2010</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">81,248,472</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">81</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">124,044</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(135,448</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(11,323</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 9pt">Changes during 2011:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -0.125in">Common stock&nbsp;&nbsp;issued for cash (net of issuance costs of $1,410)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,586</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,590</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 9pt">Share-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">886</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">886</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 18.7pt">Exercise of options granted to employees and non-employees (includes net exercise)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">381,685</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">298</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">299</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt; padding-bottom: 1pt">Net Loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(36,529</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(36,529</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Balance at December 31, 2011</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">85,630,157</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">86</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">145,814</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(171,977</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(26,077</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 9pt">Changes during 2012:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 18.7pt">Common stock&nbsp;&nbsp;issued for cash (net of issuance costs of $1,780) (see note 7c)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,175,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,383</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,388</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 18.7pt">Share-based compensation related to stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,612</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,612</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 18.7pt">Share-based compensation related to restricted stock
    award, net of forfeitures of 3,208 shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,496,792</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,138</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,139</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 18.7pt">Exercise of options granted to employees and non-employees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,187,860</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,198</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,199</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt; padding-bottom: 1pt">Net Loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(11,618</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(11,618</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2012</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">93,489,809</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">93</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">180,145</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">(183,595</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">(3,357</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">)</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="background-color: White">*
Represents an amount less than $1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5in"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White"><B>The
accompanying notes are an integral part of the consolidated financial statements.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 97; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White"><B>PROTALIX
BIOTHERAPEUTICS, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White"><B>CONSOLIDATED
STATEMENTS OF CASH FLOWS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White">(U.S.
dollars in thousands)</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year&nbsp;ended&nbsp;December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left; padding-left: 9pt">Net Loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(28,998</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(36,529</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(11,618</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 18.7pt">Adjustments required to reconcile net loss to net cash provided by (used in) operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9.35pt; padding-left: 18.7pt">Share based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,282</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">886</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,751</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 18.7pt">Depreciation and write down of fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,133</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,631</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,692</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 18.7pt">Financial expenses (income), net (mainly exchange differences)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(591</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">350</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(171</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 18.7pt">Changes in accrued liability for employee rights upon retirement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">377</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">155</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">276</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 18.7pt">Gain on amounts funded in respect of employee rights upon retirement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(26</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(14</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(36</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 18.7pt">Loss on sale of fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">8</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 18.7pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 27.35pt">Increase (decrease) in deferred revenues (including non-current portion)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,563</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,005</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,281</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 27.35pt">Decrease (increase) in accounts receivable and other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,860</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,891</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">243</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9.35pt; padding-left: 27.35pt">Decrease (Increase) in inventories</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,189</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">910</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,760</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9.35pt; padding-left: 27.35pt">Increase (decrease) in accounts payable and accruals (including long term )</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,029</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,147</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,977</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Net cash provided by (used in) operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(38,464</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(23,570</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">635</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Purchase of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(7,855</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(5,705</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2,068</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Proceeds from sale of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Investment in restricted deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(80</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Amounts funded in respect of employee rights upon retirement, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(137</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(165</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(138</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,992</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,868</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,286</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 9pt">Issuance of shares, net of issuance cost</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,650</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,328</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt">Exercise of options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">501</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">277</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,230</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">501</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20,927</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">26,558</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -9.35pt; padding-left: 9.35pt">EFFECT OF EXCHANGE RATE CHANGES ON CASH</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">589</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(388</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">127</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9.35pt; padding-left: 9.35pt">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(45,366</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,899</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,034</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -9.35pt; padding-left: 9.35pt"><FONT STYLE="font-size: 10pt; background-color: White"><B>BALANCE OF CASH AND CASH EQUIVALENTS<FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT>AT BEGINNING OF YEAR</B></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">81,266</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">35,900</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">27,001</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -9.35pt; padding-left: 9.35pt">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">35,900</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">27,001</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">52,035</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White"><B>The
accompanying notes are an integral part of the consolidated financial statements.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 98; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White"><B>PROTALIX
BIOTHERAPEUTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White"><B>CONSOLIDATED
STATEMENTS OF CASH FLOWS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White">(U.S.
dollars in thousands)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">(CONTINUED)</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -12.05pt; padding-left: 12.05pt">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left; padding-bottom: 1pt; text-indent: 8.8pt">Purchase of property and equipment</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">2,720</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">1,473</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">1,136</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 8.8pt">Issuance cost not yet paid</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">60</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 8.8pt">Exercise of options granted to employees</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">31</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="background-color: White"><B>The accompanying notes
are an integral part of the consolidated financial statements.</B></FONT></P>



<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 99; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">a.</FONT></TD><TD>General</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">1.</FONT></TD><TD>Operation</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in"><FONT STYLE="font-weight: normal">Protalix
BioTherapeutics, Inc. (collectively with its subsidiaries, the &ldquo;Company&rdquo;), and its wholly-owned subsidiary, Protalix
Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based
on the Company&rsquo;s proprietary ProCellEx<SUP>&reg;</SUP> protein expression system (&ldquo;ProCellEx&rdquo;). In September
2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with
the European Medicines Agency (&ldquo;EMA&rdquo;) application process in the European Union. The Company&rsquo;s two subsidiaries
are referred to collectively herein as the &ldquo;Subsidiaries.&rdquo;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in"><FONT STYLE="font-weight: normal">On
May 1, 2012, the U.S. Food and Drug Administration (<FONT STYLE="text-transform: uppercase">&ldquo;</FONT>FDA<FONT STYLE="text-transform: uppercase">&rdquo;</FONT>)
approved taliglucerase alfa for injection, the Company&rsquo;s first approved drug product, as an enzyme replacement therapy (ERT)
for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary,
recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by
the Israeli Ministry of Health (the &ldquo;Israeli MOH&rdquo;) in September 2012 and recently in Uruguay. Taliglucerase alfa is
the first plant cell-based recombinant therapeutic protein approved by each of the FDA and the Israeli MOH.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Taliglucerase alfa is being marketed in the United States
under the brand name ELELYSO&trade; by Pfizer Inc. (<FONT STYLE="text-transform: uppercase">&ldquo;</FONT>Pfizer<FONT STYLE="text-transform: uppercase">&rdquo;</FONT>),
the Company&rsquo;s commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix
Ltd. and Pfizer (the <FONT STYLE="text-transform: uppercase">&ldquo;</FONT>Pfizer Agreement<FONT STYLE="text-transform: uppercase">&rdquo;</FONT>).
The Company, through Protalix Ltd., markets ELELYSO in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Protalix Ltd. granted Pfizer an exclusive, worldwide
license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel. The Company
has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development
efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution
of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company
received an additional $25.0 million milestone payment in connection with the FDA&rsquo;s approval of taliglucerase alfa in the
United States, which was considered to be a substantive milestone for purposes of revenue recognition, and, accordingly, was recorded
as revenue during the period in which the milestone was achieved. The agreement provides that the Company share with Pfizer the
net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively,
except with respect to the profits or losses related to commercialization efforts in Israel, where the Company retained exclusive
marketing rights. <FONT STYLE="color: black">In calculating the net profits or losses under the agreement, there are certain agreed
upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In December 2012, Protalix Ltd. entered into a Clinical
Development Agreement with Pfizer under which Protalix Ltd. will continue to manage, administer and sponsor current, ongoing clinical
trials relating to taliglucerase alfa. According to the terms of the agreement, Protalix Ltd. was eligible to receive a payment
of $8.3 million upon the achievement of certain near-term clinical development goals. The goals were achieved, and the payment
made, in December 2012. The Company evaluated the terms of the agreement and the nature of the payment made by Pfizer and concluded
that the amount received represents an upfront funding of the anticipated costs of the Company&rsquo;s ongoing clinical trials
relating to taliglucerase alfa. Accordingly, the amount was deferred upon receipt and will be recognized as a reduction of research
and development expenses over the ongoing clinical trial period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 100; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company is cooperating with Pfizer to obtain marketing
approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have
been filed for Brazil and other countries. The European Commission (EC) issued a Commission Decision refusing the marketing authorization
for taliglucerase alfa in the European Union. This decision is an endorsement of the EMA&rsquo;s Committee for Medicinal Products
for Human Use (CHMP) June 2012 opinion recommending against the marketing authorization of taliglucerase alfa. While the CHMP gave
a positive risk-benefit assessment for taliglucerase alfa, its recommendation was based solely on the orphan market exclusivity
granted to VPRIV<SUP>&reg;</SUP>, Shire plc&rsquo;s Gaucher disease treatment. It was not based on the safety and efficacy profile
of taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In addition to taliglucerase alfa, the Company is working
on the development of certain other products using ProCellEx.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Currently, patients are being treated with taliglucerase
alfa on a commercial basis in the United States and Israel. In addition, patients are being treated globally through the Company&rsquo;s
clinical trials and related studies, compassionate use programs, special access agreements, named patient provisions and other
programs designed to ensure that treatments are available to Gaucher patients in light of recent shortages of approved treatments.
On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d&rsquo;Utilisation
(ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease. An ATU is the regulatory
mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when
a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before
marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through
government allocations to hospitals. Notwithstanding the EC&rsquo;s decision not to approve the market authorization of taliglucerase
alfa in the EU, the Company, together with Pfizer, will continue to supply taliglucerase alfa as required by physicians under the
ATU process for as long as it is authorized by the French regulatory authorities. In addition, taliglucerase alfa is currently
being provided to Gaucher patients under special access agreements or named patient provisions in Brazil and in other countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">On August 10, 2010, Pfizer entered into a short-term
supply agreement with the Ministry of Health of Brazil pursuant to which the Company and Pfizer have provided taliglucerase alfa
to the Brazilian Ministry of Health for the treatment of Gaucher patients. During the remainder of 2010 and the first quarter of
2011, the Company and Pfizer completed the supply of products deliverable under the short-term supply agreement. During 2011, Pfizer
recorded an allowance for sales returns in connection with the supply agreement because the Brazilian Ministry of Health requested
that Pfizer consider the replacement of certain vials that might expire during 2012. During the third quarter of 2012 resupply
for certain vials was completed. Revenue, net of allowance for sales returns, generated from the Brazilian Ministry of Health was
recorded by Pfizer, and the Company recorded its share of such revenues in accordance with the terms and conditions of the Pfizer
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 101; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">2.</FONT></TD><TD>Liquidity and Financial Resources</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In addition to the approval of taliglucerase alfa by
the FDA and the Israeli MOH, successful completion of the Company&rsquo;s development programs and its transition to normal operations
is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. In accordance with
the terms and conditions of the Pfizer Agreement, the Company received a $25.0 million milestone payment in connection with the
FDA&rsquo;s approval of taliglucerase alfa in the United States. A substantial amount of time may pass before the Company achieves
a level of revenues adequate to support its operations, if at all and the Company also expects to incur substantial expenditures
in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Obtaining marketing approval with respect to any product
candidate is directly dependent on the Company&rsquo;s ability to implement the necessary regulatory steps required to obtain such
approval in the United States and in other countries. The Company cannot reasonably predict the outcome of these activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Based on its current cash resources and commitments,
the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures
for at least the next 12 months, although no assurance can be given that it will not need additional funds prior to such time.
If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may
need to seek additional financing during the next 12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">b.</FONT></TD><TD>Basis of presentation</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Company&rsquo;s financial statements have been
prepared in accordance with generally accepted accounting principles in the United States (&ldquo;U.S. GAAP&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">c.</FONT></TD><TD>Use of estimates in the preparation of financial statements</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The preparation of financial statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities,
the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues
and expenses during the reporting period. Actual results may differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">d.</FONT></TD><TD>Functional currency</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The dollar is the currency of the primary economic
environment in which the operations of the Company and its Subsidiaries are conducted. Most of the Company&rsquo;s revenues are
derived in dollars. Most of the Company&rsquo;s expenses and capital expenditures are incurred in dollars, and the major source
of the Company&rsquo;s financing has been provided in dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Transactions and balances originally denominated
in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical
and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated
below) reflected in the statements of operations, the following exchange rates are used: (i) for transactions &ndash; exchange
rates at the transaction dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as
depreciation and amortization, etc.) &ndash; historical exchange rates. Currency transaction gains and losses are carried to financial
income or expenses, as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 102; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">e.</FONT></TD><TD>Cash equivalents</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Company considers all short-term, highly liquid
investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase,
that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">f.</FONT></TD><TD>Inventories</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Inventories are valued at the lower of cost or market.
Cost of raw and packaging materials and purchased products is determined using the &ldquo;moving average&rdquo; basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Cost of finished products that are capitalized is
determined as follows: the value of the raw and packaging materials component is determined primarily on a using the &ldquo;moving
average&rdquo; basis; the value of the labor and overhead component is determined on an average basis over the production period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Prior to the FDA&rsquo;s approval of taliglucerase
alfa, manufacturing costs related to taliglucerase alfa were not capitalized; rather, such costs were expensed as research and
development expenses. Effective as of the FDA approval of taliglucerase alfa on May 1, 2012, the Company capitalizes manufacturing
costs associated with taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">g.</FONT></TD><TD>Property and equipment</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">1.</FONT></TD><TD><FONT STYLE="font-weight: normal">Property and equipment are stated at cost, net of accumulated depreciation and amortization.
</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">2.</FONT></TD><TD><FONT STYLE="font-weight: normal">The Company&rsquo;s assets are depreciated by the straight-line method on the basis of their
estimated useful lives as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 65%; font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Years</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 85%; text-align: left">Laboratory equipment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">5</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Furniture</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10-15</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Computer equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 98.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Leasehold improvements are amortized by the straight-line
method over the expected lease term, which is shorter than the estimated useful life of the improvements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">h.</FONT></TD><TD>Impairment in value of long-lived assets:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Company tests long-lived assets for impairment
if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted and without
interest charges) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the
assets to their estimated fair values.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">i.</FONT></TD><TD>Income taxes</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">1.</FONT></TD><TD><FONT STYLE="font-weight: normal">Deferred income taxes</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Deferred taxes are determined utilizing the assets and
liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases
of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be
in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the
weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The
Company has provided a full valuation allowance with respect to its deferred tax assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 103; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The guidance prohibits the recognition of deferred tax
liabilities or assets that arise from differences between the financial reporting and tax bases of assets and liabilities that
are measured from the local currency into dollars using historical exchange rates, and that result from changes in exchange rates
or indexing for tax purposes. Consequently, the above mentioned differences with respect to Protalix Ltd. were not reflected in
the computation of deferred tax assets and liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">2.</FONT></TD><TD><FONT STYLE="font-weight: normal">Uncertainty in income taxes</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Tax benefits recognized in the financial statements
are those that the Company&rsquo;s management deems at least more likely than not to be sustained, based on technical merits. The
amount of benefits recorded for these tax benefits is measured as the largest benefit the Company&rsquo;s management deems more
likely than not to be sustained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">j.</FONT></TD><TD>Revenue Recognition</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Company recognizes revenue when the earnings
process is complete, which is when revenue is realized or realizable and earned, there is persuasive evidence a revenue arrangement
exists, delivery of goods or services has occurred, the sales price is fixed or determinable and collectability is reasonably assured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">1.</FONT></TD><TD><FONT STYLE="font-weight: normal">Revenues from the license and supply agreement with Pfizer</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company recognizes revenue from milestone payments
received pursuant to the Pfizer Agreement in accordance with guidance regarding revenue recognition and accounting for revenue
arrangements with multiple deliverables. As the arrangement with Pfizer requires the Company&rsquo;s continued involvement with
respect to the proposed commercialization of taliglucerase alfa, the non-refundable, up-front license payment the Company received
from Pfizer was deferred and recognized over the related performance period. The Company estimated the performance period of 14
years (commencing upon the date of the Company&rsquo;s receipt of the up-front license payment payable by Pfizer under the Pfizer
Agreement) based on the date the last relevant patent expires. See Note 2. The Company adjusts the performance periods, if appropriate,
based on the applicable facts and circumstances. Each milestone payment that is considered to be substantive for purposes of revenue
recognition is recorded as revenue during the period during which the milestone is achieved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">2.</FONT></TD><TD><FONT STYLE="font-weight: normal">Revenues from selling products to Pfizer</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company recognizes revenues from products sold to
Pfizer upon delivery, when the sales price is fixed or determinable and collectability is reasonably assured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">3.</FONT></TD><TD><FONT STYLE="font-weight: normal">Company&rsquo;s share in the collaboration agreement</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in"><FONT STYLE="font-weight: normal">Under
the terms and conditions of the Pfizer Agreement, the Company is entitled to 40% of the profits or loss from sales of taliglucerase
alfa, and related expenses incurred, except with respect to sales in Israel, where the Company retained exclusive marketing rights.
Since Pfizer bears most of the risks and rewards relating to the agreement, the Company&rsquo;s share in the profits and loss in
the agreement is recognized on a net basis. The Company recognizes its share of net profit or loss from the Pfizer Agreement based
on reports it receives from Pfizer summarizing the results of the collaborative activities under the agreement for the applicable
period. Under the terms of the Pfizer Agreement, for its subsidiaries operating outside the United States, financial information
is included based on the fiscal year ending November 30, while financial information for the U.S. entity is included based on the
fiscal year ending December 31.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 104; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">k.</FONT></TD><TD>Research and development costs</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Research and development costs are expensed as incurred
and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment
and supplies for research and development activities. Grants received by the Israeli Subsidiary from the Office of the Chief Scientist
of Israel&rsquo;s Ministry of Industry, Trade and Labor (the &ldquo;OCS&rdquo;) are recognized when the grant becomes receivable,
provided there is reasonable assurance that the Company or the Subsidiary will comply with the conditions attached to the grant
and there is reasonable assurance the grant will be received. The grant is deducted from the research and development expenses
as the applicable costs are incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Reimbursements received from Pfizer are recognized
when the reimbursements become receivable, provided there is reasonable assurance that the Company will comply with the conditions
attached to the reimbursements and there is reasonable assurance the reimbursements will be received. The reimbursements are deducted
from the research and development expenses as the applicable costs are incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">In connection with purchases of assets, amounts assigned
to intangible assets to be used in a particular research and development project that have no alternative future use are charged
to research and development costs at the purchase date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Nonrefundable advance payments for goods or services
that will be used or rendered for future research and development activities are deferred and amortized over the period that the
goods are consumed or the related services are performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">l.</FONT></TD><TD>Concentration of credit risks and trade receivable</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Financial instruments that potentially subject the
Company to concentration of credit risk consist principally of bank deposits. The Company deposits these instruments with highly
rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any
one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed
to any significant credit risk on these instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><FONT STYLE="color: black">The Company&rsquo;s trade
</FONT>receivable<FONT STYLE="color: black"> represents mainly amounts to be received from Pfizer, as the Company currently receives
most of its revenues from Pfizer. The Company does not require Pfizer to post collateral with respect to the receivables. The Company
performs periodic credit evaluations of Pfizer&rsquo;s financial condition and believes there is no significant risk with respect
to Pfizer&rsquo;s payment of the receivables.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">m.</FONT></TD><TD>Share-based compensation</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Company accounts for employee&rsquo;s share-based
payment awards classified as equity awards using the grant-date fair value method. The fair value of share-based payment transactions
is recognized as an expense over the requisite service period, net of estimated forfeitures. The Company estimates forfeitures
based on historical experience and anticipated future conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Company elected to recognize compensation cost
for an award with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option
award approach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">When stock options are granted as consideration for
services provided by consultants and other non-employees, the grant is accounted for based on the fair value of the stock options
issued. Options granted is measured on a final basis at the end of the related service period and is recognized over the related
service period using the straight-line method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>


<!-- Field: Page; Sequence: 105; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">n.</FONT></TD><TD>Net Loss per share</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Basic and diluted loss per share (&ldquo;LPS&rdquo;)
are computed by dividing net loss by the weighted average number of shares of the Company&rsquo;s Common Stock, par value $0.001
per share (the &ldquo;Common Stock&rdquo;) outstanding for each period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Diluted LPS does not include 7,761,168, 7,469,088
and 7,280,469 <FONT STYLE="color: black">shares of Common Stock underlying outstanding options and restricted shares of Common
Stock</FONT> for the fiscal years ended December 31, 2010, 2011 and 2012, respectively, because the effect would be anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 2 - LICENSE AND SUPPLY AGREEMENT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">On November&nbsp;30, 2009, Protalix Ltd.
and Pfizer entered into the Pfizer Agreement pursuant to which Pfizer was granted an exclusive, worldwide license to develop
and commercialize taliglucerase alfa, except in Israel. Under the terms and conditions of the Pfizer Agreement, Protalix
Ltd. retained the right to commercialize taliglucerase alfa in Israel. Under the Pfizer Agreement, Pfizer made an upfront
payment to Protalix Ltd. of $60.0 million in connection with the execution of the agreement and shortly thereafter paid
Protalix Ltd. an additional $5.0 million upon the Company&rsquo;s filing of a proposed pediatric investigation plan to the
Pediatric Committee of the EMA. Protalix Ltd. received a $25.0 million milestone payment in connection with the approval
of taliglucerase alfa by the FDA in May 2012. Protalix Ltd. is entitled to 40% of the results (profits or losses) earned
on Pfizer&rsquo;s sales of taliglucerase alfa. Such result (profit or loss) will be calculated while, in addition to
other adjustments, taking into account Protalix Ltd.&rsquo;s cost of goods sold and Pfizer&rsquo;s commercial expenses,
with certain expenses capped or borne solely by one party (&ldquo;Collaboration Operation&rdquo;). Of the losses incurred by
the Collaboration Operation through December 31, 2011, 40% will be deducted from the cash payments to be paid to
the Company as its share in the profits from future years, if any. This deduction will be limited to a certain percentage of
any quarterly profit. As of December 31, 2012, the Company accrued a liability in respect of these losses equal to $8.5
million, out of which $5.4 million is classified as a long term liability, and the remainder is included in accounts
payable and accruals-other.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Company has determined that the initial, non-refundable
upfront license fee payment of $60.0 million together with the first $5.0 million payment will be recognized on a straight line
basis as revenue over the estimated relationship period (approximately $4.6 million per year). The Company has estimated that the
relationship period for its arrangement with Pfizer will be approximately 14 years (commencing upon the Company&rsquo;s receipt
of the up-front license payment) based on the Company&rsquo;s last material patent relating to taliglucerase alfa to expire. The
$25.0 million milestone payment received in connection with the FDA&rsquo;s approval of taliglucerase alfa in the United States
was considered to be a substantive milestone for purposes of revenue recognition and, accordingly, was recorded as revenue during
the period in which the milestone was achieved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Company&rsquo;s deliverables under this collaboration
include an exclusive license to taliglucerase alfa as an enzyme replacement therapy for the treatment of Gaucher disease, certain
research and development services as required under the Pfizer Agreement for taliglucerase alfa and manufacturing of taliglucerase
alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">According to the terms and conditions of the Pfizer
Agreement, the Company retained manufacturing rights and sells its products to Pfizer. In addition, Pfizer is required to reimburse
the Company for certain costs it incurs in connection with certain development expenses for taliglucerase alfa. In connection with
the payments received under the Pfizer Agreement, Protalix Ltd. is obligated to pay certain royalties. See Note 6a.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 106; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 3 - PROPERTY AND EQUIPMENT</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">a.</FONT></TD><TD><FONT STYLE="font-weight: normal">Composition of property and equipment grouped by major classifications is as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">(<I>U.S. dollars in thousands)</I></FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 70%; text-align: left">Laboratory equipment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">13,079</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">14,502</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Furniture and computer equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,522</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,818</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Leasehold improvements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,705</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,447</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Equipment under construction</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,113</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">329</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 7.35pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">29,419</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">31,096</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD STYLE="font-size: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Less &ndash; accumulated depreciation and amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(11,148</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(14,786</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">18,271</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">16,310</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.3pt; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">b.</FONT></TD><TD><FONT STYLE="font-weight: normal">Depreciation and amortization in respect of property and equipment totaled approximately
$3.1 million, $3.6 million and $3.7 million for the years ended December 31, 2010, 2011 and 2012, respectively, out of which the
Company recorded a total write down of approximately $43,000, $10,000 and $0, respectively.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 4 &ndash; INVENTORIES</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">a.</FONT></TD><TD><FONT STYLE="font-weight: normal">Inventories at December&nbsp;31, 2011 and 2012 consisted of the following:</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">(<I>U.S. dollars in thousands)</I></FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 70%; text-align: left">Raw materials</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">279</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2,118</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Work in progress</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">192</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Finished goods</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 1pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,729</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total inventory</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">279</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,039</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">b.</FONT></TD><TD><FONT STYLE="font-weight: normal">During the year ended December 31, 2011 and 2012,<FONT STYLE="color: black"> the Company
recorded </FONT>approximately<FONT STYLE="color: black"> </FONT>$363,000 and $684,000 respectively, for write-down of inventory
under cost of revenues.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 5 - LIABILITY FOR EMPLOYEE RIGHTS
UPON RETIREMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Israeli Subsidiary is required to make a severance
payment upon dismissal of an employee or upon termination of employment in certain circumstances. The severance pay liability to
the employees (based upon length of service and the latest monthly salary - one month&rsquo;s salary for each year employed) is
recorded on the Company&rsquo;s balance sheets under &ldquo;Liability for employee rights upon retirement.&rdquo; The liability
is recorded as if it were payable at each balance sheet date on an undiscounted basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The liability is funded in part from the purchase
of insurance policies or by the establishment of pension funds with dedicated deposits in the funds. The amounts used to fund these
liabilities are included in the Company&rsquo;s balance sheets under &ldquo;Funds in respect of employee rights upon retirement.&rdquo;
These policies are the Company&rsquo;s assets. However, under labor agreements and subject to certain limitations, any policy may
be transferred to the ownership of the individual employee for whose benefit the funds were deposited. In the years ended December
31, 2010, 2011 and 2012, the Company deposited approximately<B> </B>$174,000, $181,000 and $177,000, respectively, with insurance
companies in connection with its severance payment obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 107; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 5 - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In accordance with the current employment agreements
with certain employees, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable
employee in order to secure the employee&rsquo;s rights upon retirement. The Company is fully relieved from any severance pay liability
with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these
employees and the amounts funded, as of the respective agreement dates, are not reflected in the Company&rsquo;s balance sheets,
as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been
irrevocably transferred to the applicable insurance companies (the &ldquo;Contribution Plans&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The amounts of severance pay expenses were approximately<B>
</B>$1.1 million, $816,000 and $1.0 million for the years ended December 31, 2010, 2011 and 2012, respectively, of which approximately<B>
</B>$531,000, $641,000 and $670,000 in the years ended December 31, 2010, 2011 and 2012, respectively, were in respect of a Contribution
Plan. Gain on amounts funded in respect of employee rights upon retirement totaled approximately<B> </B>$26,000, $14,000 and $36,000
for the years ended December 31, 2010, 2011 and 2012, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Company expects to contribute approximately $963,000
in the year ending December 31, 2013 to insurance companies in connection with its severance liabilities for its operations for
that year, approximately<B> </B>$773,000 of which will be contributed to one or more Contribution Plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">During the five-year period following December 31,
2012, the Company expects to pay future benefits to 4<B> </B>employees upon the employee&rsquo;s normal retirement age. The Company
anticipates that the benefits payable will be immaterial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 6 - COMMITMENTS</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">a.</FONT></TD><TD>Royalty commitments</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">1.</FONT></TD><TD><FONT STYLE="font-weight: normal">The Company is obligated to pay royalties to the OCS on proceeds from the sale of products
developed from research and development activities that were funded, partially, by grants from the OCS. At the time the grants
were received, successful development of the related projects was not assured.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In the case of failure of a project that was partly
financed as described above, the Company is not obligated to pay any such royalties or repay funding received from the OCS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Under the terms of the funding arrangements with the
OCS, royalties of 3% to 6% are payable on the sale of products developed from projects funded by the OCS, which payments shall
not exceed, in the aggregate, 100% of the amount of the grant received (dollar linked), plus, commencing upon January&nbsp;1, 2001,
interest at annual rate based on LIBOR. In addition, if the Company receives approval to manufacture products developed with government
grants outside the State of Israel, it will be required to pay an increased total amount of royalties (possibly up to 300% of the
grant amounts plus interest), depending on the manufacturing volume that is performed outside the State of Israel, and, possibly,
an increased royalty rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Royalty expenses to the OCS are included in the statement
of operations as a component of the cost of revenues and were approximately $769,000, $158,000 and $1.5 million during the years
ended December&nbsp;31, 2010, 2011 and 2012, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">At December 31, 2012, the maximum royalty amount payable
by the Company under these funding arrangements is approximately $21.3 million (without interest, assuming 100% of the funds are
payable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 108; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 6 &ndash; COMMITMENTS </B>(continued)<B>:</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">2.</FONT></TD><TD><FONT STYLE="font-weight: normal">The Company is a party to certain research and license agreements. Under the<FONT STYLE="color: black">
agreements, the Company is obligated </FONT>to pay royalties at varying rates from its future revenues. The aggregate royalties
payable under all of the agreements is equal to a varying range of percentages of net sales of licensed products. Royalty expenses
under the agreements are included in the statement of operations as a component of the cost of revenues and were approximately
$115,000, $19,000 and $674,000 during the years ended December&nbsp;31, 2010, 2011 and 2012, respectively.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Under each agreement, the Company is also obligated
to pay milestone, licensing and other payments to the counterparties of the agreement. The payments under the agreements are for
varying amounts and are subject to varying conditions. If all of the contingencies with respect to milestone payments under the
research and license agreements are met, the aggregate milestone payments payable would be approximately $1.0 million and would
be payable, if at all, as the Company&rsquo;s projects progress over the course of a number of years. In addition, a milestone
payment of approximately $100,000 was made in respect of the agreements during the year ended December 31, 2010. No milestone payments
were made during 2011 and 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">None of the agreements has a fixed termination date.
Subject to earlier termination for other reasons, each agreement terminates after a certain number of years following the first
commercial sale of any licensed product under the agreement or after a certain number of years without the initiation of commercial
sales of any product under the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">b.</FONT></TD><TD>Subcontracting Agreements</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Company has entered into sub-contracting agreements
with several clinical providers and consultants<B> </B>in Israel, the United States and certain other countries in connection with
its primary product development process and with expenditure of the company&rsquo;s manufacturing facilities. As of December 31,
2012, total commitments under said agreements were approximately $1.3 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">c.</FONT></TD><TD>Lease Agreements</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Company is a party to a number of lease agreements
for its facilities, the latest of which expires in 2016. The Company has the option to extend certain of such agreements on three
occasions for additional five-year periods, for a total of 15 additional years. Under the leases, the aggregate monthly rental
payments are approximately $82,000. As of December 31, 2012, the Company provided bank guarantees of approximately $298,000, in
the aggregate, to secure the fulfillment of its obligations under the lease agreements. The future minimum lease payments required
in each of the next five years under the operating leases for such premises are approximately as follows: 2013 - $976,000, 2014
- $968,000, 2015 - $985,000 and 2016 &ndash; $823,000. Lease expenses totaled $891,000, $994,000 and $971,000 for the years ended
December 31, 2010, 2011 and 2012, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">d.</FONT></TD><TD>Vehicle Lease and Maintenance Agreements</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Company entered into several three-year lease
and maintenance agreements for vehicles which are regularly amended as new vehicles are leased. The current monthly lease fees
aggregate approximately $49,000. The expected lease payments for the years ending December 31, 2013, 2014 and 2015 are approximately
$526,000, $385,000 and $175,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>


<!-- Field: Page; Sequence: 109; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>




<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 6 &ndash; COMMITMENTS </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">e.</FONT></TD><TD>Yissum Agreement</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">On August 8, 2007, the Company
signed an agreement with the Yissum Research and Development Company, the technology transfer arm of the Hebrew University of
Jerusalem, Israel (&ldquo;Yissum&rdquo;), and the Boyce Thompson Institute for Plant Research, at Cornell University, Ithaca,
New York (&ldquo;Boyce Thompson&rdquo;), to develop a proprietary plant cell-based acetylcholinesterase (AChE) and its molecular
variants for the use in several therapeutic and prophylactic indications, including a biodefense program and organophosphate-based
pesticide treatment. Pursuant to the agreement, the Company has received an exclusive worldwide right and license to certain technology,
including patents and additional patent applications relating to AChE (the &ldquo;Licensed Technology&rdquo;), for all therapeutic
and prophylactic indications. In consideration for the license, the Company is <FONT STYLE="color: black">obligated to pay Yissum
and </FONT>Boyce Thompson, collectively,<FONT STYLE="color: black"> an annual, non-refundable initial maintenance fee of $20,000,
</FONT>commencing on the fourth anniversary of the execution of the agreement, which is subject to a 12% annual increase.<FONT STYLE="color: black">
In addition, </FONT>the Company is required to make certain milestone payments equal to up to $700,000, in the aggregate, upon
its achievement of clinical milestones and royalties from sales derived from any drugs developed by the Company with the Licensed
Technology. The agreement does not terminate until either party to the agreement elect to terminate the agreement, subject to
certain terms and conditions set forth therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 7 - SHARE CAPITAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">a.</FONT></TD><TD>Rights of the Company&rsquo;s
                                                                                                        Common Stock</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Company&rsquo;s common stock is listed on the
NYSE MKT and, since September 6, 2010, on the Tel Aviv Stock Exchange. Each share of Common Stock is entitled to one vote. The
holders of shares of Common Stock are also entitled to receive dividends whenever funds are legally available, when and if declared
by the Board of Directors. Since its inception, the Company has not declared any dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">b.</FONT></TD><TD>Stock based compensation</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">On December 14, 2006, the Board of Directors adopted
the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan (the &ldquo;Plan&rdquo;). The Plan was amended on June 17, 2012 to
increase the number of shares of common stock available under the plan from 9,741,655 shares to 11,341,655 shares. The grant of
options to Israeli employees under the Plan is subject to the terms stipulated by Sections&nbsp;102 and 102A of the Israeli Income
Tax Ordinance. Each option grant is subject to the track chosen by the Company, either Section 102 or Section 102A of the Israeli
Income Tax Ordinance, and pursuant to the terms thereof, the Company is not allowed to claim, as an expense for tax purposes,
the amounts credited to employees as a benefit, including amounts recorded as salary benefits in the Company&rsquo;s accounts,
in respect of options granted to employees under the Plan, with the exception of the work-income benefit component, if any, determined
on the grant date. For Israeli non-employees, the share option plan is subject to Section 3(i) of the Israeli Income Tax Ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">As of December 31, 2012, 176,986 shares of Common
Stock remain available for grant under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">For purposes of determining the fair value of the
options and restricted stock granted to employees and non-employees, the Company&rsquo;s management uses the fair value of the
Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">From January 1, 2010 through December 31, 2012,
the Company granted options and shares of restricted stock to certain employees and non-employees as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>


<!-- Field: Page; Sequence: 110; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 7&ndash; SHARE CAPITAL </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">1.</FONT></TD><TD>Options and restricted
                                                                                                         stock granted to employees:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">a)</TD><TD>Below is a table summarizing all of the options and restricted
                                                             stock grants to employees for each of the three years in the three-year
                                                             period ended December 31, 2012:</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year&nbsp;of<BR> grant</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.&nbsp;of&nbsp;options<BR>
    or&nbsp;restricted<BR> stock&nbsp;granted</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercise<BR> price&nbsp;range</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Vesting&nbsp;period</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair&nbsp;value<BR> at&nbsp;grant<BR>
    (U.S.<BR> dollars&nbsp;in<BR> thousands)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Expiration<BR> period</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: left">2010</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,016,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 10%; text-align: center">$6.90</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 35%; text-align: center">3 years commencing <BR>
upon achievement of a <BR>
certain milestone</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">5,673</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">10
                                                       years</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">2010</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">428,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$6.32-$9.66</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4 years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,147</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">2012</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3 years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,288</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">n/a</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">2012</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,100,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">n/a</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">4 years</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; text-align: right">6,292</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">n/a</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,944,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Set forth below are grants made by the Company to
employees (including related parties) during the three-year period ended December 31, 2012 (such grants appear in the table above):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal; color: black">1.</FONT></TD><TD><FONT STYLE="font-weight: normal">In
                                                                                                                       February
                                                                                                                       2010, the
                                                                                                                       Company&rsquo;s
                                                                                                                       Board of
                                                                                                                       Directors
                                                                                                                       approved
                                                                                                                       the grant
                                                                                                                       of options
                                                                                                                       to purchase
                                                                                                                       1,016,000
                                                                                                                       shares
                                                                                                                       of Common
                                                                                                                       Stock,
                                                                                                                       in the
                                                                                                                       aggregate,
                                                                                                                       to the
                                                                                                                       Company&rsquo;s
                                                                                                                       Chief Executive
                                                                                                                       Officer
                                                                                                                       and certain
                                                                                                                       officers
                                                                                                                       and employees
                                                                                                                       of the
                                                                                                                       Company
                                                                                                                       with an
                                                                                                                       exercise
                                                                                                                       price equal
                                                                                                                       to $6.90
                                                                                                                       per share.
                                                                                                                       The options
                                                                                                                       vest quarterly
                                                                                                                       over a
                                                                                                                       three-year
                                                                                                                       period
                                                                                                                       commencing
                                                                                                                       upon the
                                                                                                                       FDA&rsquo;s
                                                                                                                       approval
                                                                                                                       of taliglucerase
                                                                                                                       alfa. The
                                                                                                                       Company
                                                                                                                       treated
                                                                                                                       the awards
                                                                                                                       as performance-based
                                                                                                                       awards
                                                                                                                       and, given
                                                                                                                       that the
                                                                                                                       performance
                                                                                                                       condition
                                                                                                                       is outside
                                                                                                                       the Company&rsquo;s
                                                                                                                       control,
                                                                                                                       concluded
                                                                                                                       that the
                                                                                                                       performance
                                                                                                                       condition
                                                                                                                       was not
                                                                                                                       probable
                                                                                                                       until the
                                                                                                                       performance
                                                                                                                       condition
                                                                                                                       actually
                                                                                                                       occurred.
                                                                                                                       <FONT STYLE="color: black">
                                                                                                                       Upon the
                                                                                                                       FDA&rsquo;s
                                                                                                                       </FONT>approval
                                                                                                                       of taliglucerase
                                                                                                                       alfa on
                                                                                                                       May 1,
                                                                                                                       2012<FONT STYLE="color: black">,
                                                                                                                       the Company
                                                                                                                       started
                                                                                                                       recognizing
                                                                                                                       share based
                                                                                                                       compensation
                                                                                                                       expenses
                                                                                                                       </FONT>related
                                                                                                                       to such
                                                                                                                       options.
                                                                                                                       Share based
                                                                                                                       compensation
                                                                                                                       related
                                                                                                                       to services
                                                                                                                       performed
                                                                                                                       from the
                                                                                                                       date of
                                                                                                                       grant of
                                                                                                                       the respective
                                                                                                                       options
                                                                                                                       through
                                                                                                                       the FDA
                                                                                                                       approval
                                                                                                                       date, <FONT STYLE="color: black">were
                                                                                                                       recognized
                                                                                                                       on that
                                                                                                                       date.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">2.</FONT></TD><TD><FONT STYLE="font-weight: normal; color: black">In
                                                                                                         February 2010, the Company&rsquo;s
                                                                                                         Board of Directors approved
                                                                                                         the grant of options
                                                                                                         to purchase 160,000&nbsp;shares
                                                                                                         of Common Stock with
                                                                                                         an exercise price equal
                                                                                                         to $6.81 per share to
                                                                                                         a new executive officer
                                                                                                         of the Company. The options
                                                                                                         expire on the tenth anniversary
                                                                                                         of the date of grant,
                                                                                                         unless terminated earlier.
                                                                                                         The first 25% of the
                                                                                                         options vest on the first
                                                                                                         anniversary of the date
                                                                                                         of grant and the remaining
                                                                                                         75% vest in 12 equal
                                                                                                         tranches on a quarterly
                                                                                                         basis for three years
                                                                                                         thereafter.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal; color: black">3.</FONT></TD><TD><FONT STYLE="font-weight: normal">In
                                                                                                                       September&nbsp;2010,
                                                                                                                       the Company&rsquo;s
                                                                                                                       Board of
                                                                                                                       Directors
                                                                                                                       approved
                                                                                                                       the grant
                                                                                                                       of options
                                                                                                                       to purchase
                                                                                                                       160,000
                                                                                                                       shares
                                                                                                                       of Common
                                                                                                                       Stock to
                                                                                                                       a new executive
                                                                                                                       officer
                                                                                                                       of the
                                                                                                                       Company
                                                                                                                       with an
                                                                                                                       exercise
                                                                                                                       price equal
                                                                                                                       to $7.55
                                                                                                                       per share
                                                                                                                       and options
                                                                                                                       to purchase
                                                                                                                       40,000
                                                                                                                       shares
                                                                                                                       of Common
                                                                                                                       Stock to
                                                                                                                       a new employee
                                                                                                                       of the
                                                                                                                       Company
                                                                                                                       with an
                                                                                                                       exercise
                                                                                                                       price equal
                                                                                                                       to $6.32
                                                                                                                       per share.
                                                                                                                       The options
                                                                                                                       vest over
                                                                                                                       a four-year
                                                                                                                       period,
                                                                                                                       with the
                                                                                                                       first 25%
                                                                                                                       vesting
                                                                                                                       on the
                                                                                                                       first anniversary
                                                                                                                       of the
                                                                                                                       applicable
                                                                                                                       date of
                                                                                                                       the grant
                                                                                                                       and the
                                                                                                                       remaining
                                                                                                                       75% vesting
                                                                                                                       in equal
                                                                                                                       tranches
                                                                                                                       on a quarterly
                                                                                                                       basis for
                                                                                                                       a three-year
                                                                                                                       period
                                                                                                                       thereafter.
                                                                                                                       <FONT STYLE="color: black">The
                                                                                                                       options
                                                                                                                       expire
                                                                                                                       on the
                                                                                                                       tenth anniversary
                                                                                                                       of the
                                                                                                                       date of
                                                                                                                       grant,
                                                                                                                       unless
                                                                                                                       terminated
                                                                                                                       earlier.
                                                                                                                       </FONT></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 111; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTE 7&ndash; SHARE CAPITAL (continued):</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal; color: black">4.</FONT></TD><TD><FONT STYLE="font-weight: normal">In
                                                                                                                       November&nbsp;2010,
                                                                                                                       the Company&rsquo;s
                                                                                                                       Board of
                                                                                                                       Directors
                                                                                                                       approved
                                                                                                                       the grant
                                                                                                                       of options
                                                                                                                       to purchase
                                                                                                                       68,000
                                                                                                                       shares
                                                                                                                       of Common
                                                                                                                       Stock to
                                                                                                                       a new officer
                                                                                                                       of the
                                                                                                                       Company
                                                                                                                       with an
                                                                                                                       exercise
                                                                                                                       price equal
                                                                                                                       to $9.66
                                                                                                                       per share.
                                                                                                                       The options
                                                                                                                       vest over
                                                                                                                       a four-year
                                                                                                                       period,
                                                                                                                       with the
                                                                                                                       first 25%
                                                                                                                       vesting
                                                                                                                       on the
                                                                                                                       first anniversary
                                                                                                                       of the
                                                                                                                       applicable
                                                                                                                       date of
                                                                                                                       the grant
                                                                                                                       and the
                                                                                                                       remaining
                                                                                                                       75% vesting
                                                                                                                       in equal
                                                                                                                       tranches
                                                                                                                       on a quarterly
                                                                                                                       basis for
                                                                                                                       a three-year
                                                                                                                       period
                                                                                                                       thereafter.
                                                                                                                       <FONT STYLE="color: black">The
                                                                                                                       options
                                                                                                                       expire
                                                                                                                       on the
                                                                                                                       tenth anniversary
                                                                                                                       of the
                                                                                                                       date of
                                                                                                                       grant,
                                                                                                                       unless
                                                                                                                       terminated
                                                                                                                       earlier.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">5.</FONT></TD><TD><FONT STYLE="font-weight: normal">In
                                                                                                         September 2010, the Company&rsquo;s
                                                                                                         Board of Directors modified
                                                                                                         the terms of the options
                                                                                                         previously granted to
                                                                                                         an executive in 2001,
                                                                                                         by extending the life
                                                                                                         of the options until
                                                                                                         2016. At the date of
                                                                                                         modification, all of
                                                                                                         the options were fully
                                                                                                         vested. The Company concluded
                                                                                                         that there was no incremental
                                                                                                         increase in the value
                                                                                                         of the awards and therefore
                                                                                                         no accounting charges
                                                                                                         need to be recorded in
                                                                                                         connection with the modifications.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">6.</FONT></TD><TD><FONT STYLE="font-weight: normal">On
                                                                                                         July 16, 2012, the Company&rsquo;s
                                                                                                         Board of Directors approved
                                                                                                         the grant of 1,500,000
                                                                                                         shares of restricted
                                                                                                         Common Stock to its officers
                                                                                                         and certain other employees.
                                                                                                         Of such restricted stock,
                                                                                                         1,100,000 of the shares
                                                                                                         were issued to the Company&rsquo;s
                                                                                                         named executive officers
                                                                                                         and vest in 16 equal,
                                                                                                         quarterly increments
                                                                                                         over a four-year period,
                                                                                                         commencing upon the date
                                                                                                         of grant, and are subject
                                                                                                         to a 24-month lock-up
                                                                                                         period, commencing upon
                                                                                                         the applicable vesting
                                                                                                         dates. Immediately and
                                                                                                         automatically in the
                                                                                                         event of a Change in
                                                                                                         Control, as such term
                                                                                                         is defined in the Plan,
                                                                                                         as amended, all of the
                                                                                                         shares of restricted
                                                                                                         Common Stock issued to
                                                                                                         the named executive officers
                                                                                                         shall vest, and the lock-up
                                                                                                         periods shall terminate,
                                                                                                         subject to certain exceptions.
                                                                                                         The remaining 400,000
                                                                                                         shares of restricted
                                                                                                         Common Stock were issued
                                                                                                         to other employees of
                                                                                                         the Company and vest
                                                                                                         in 12 equal, quarterly
                                                                                                         increments over a three-year
                                                                                                         period, commencing upon
                                                                                                         the date of grant. The
                                                                                                         Company estimated the
                                                                                                         fair value of the restricted
                                                                                                         stock on the date of
                                                                                                         grant to be approximately
                                                                                                         $8.6 million.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">b)</TD><TD>The fair value of options and restricted stock granted during
                                                             the years ended December 31, 2010 and 2012 were $7.8 million and
                                                             $8.6 million respectively. The fair value of each option granted
                                                             in 2010 is estimated on the date of grant using the Black-Scholes
                                                             option-pricing model, with the following weighted average assumptions:</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 87%; text-align: left; padding-bottom: 2.5pt; padding-left: 0">Dividend yield</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">0</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0">Expected volatility</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">75</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0">Risk-free interest rate</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.23</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0">Expected life &ndash; in years</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8.8</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">The expected volatility is based on the historical
volatility of the Common Stock and those of comparable companies. The risk-free interest rate assumption is based on observed
interest rates appropriate for the expected term of the stock options granted in dollar terms. The Company&rsquo;s management
uses the contractual term or its expectations, based on historical incidence of option exercises, as applicable (during 2010 -
using the simplified method), of each option as its expected life. The pre-vesting forfeiture rate of approximately 6.1% is estimated
based on pre-vesting forfeiture experience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">The fair value of the restricted stock is based
on the Company&rsquo;s share price on the NYSE MKT on the grant date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 112; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 7&ndash; SHARE CAPITAL </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">The total unrecognized compensation cost of
employee stock options and restricted stock at December 31, 2012 is approximately $7.0 million (net of forfeiture rate). The
unrecognized compensation cost of employee stock options is expected to be recognized over a weighted average period of 1.1
years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">The total cash received from employees as a result
of employee stock option exercises for the years ended December 31, 2010, 2011 and 2012 was approximately $501,000, $277,000 and
$1.2 million, respectively. The Company did not realize any tax benefit in connection with these exercises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">During 2012, the Company issued 861,593 shares of
Common Stock in connection with the exercise of 861,593 options by certain employees of the Company. The Company received cash
proceeds equal to approximately $1.2 million in connection with such exercises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">2.</FONT></TD><TD>Options granted to
                                                                                                         consultants, directors,
                                                                                                         and other service providers:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in"><FONT STYLE="font-weight: normal">As
of December 31, 2012, the Company has recognized and recorded all compensation costs related to outstanding options for consultants,
directors and other services providers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">No cash was received from consultants as a result of
consultant stock option exercises for the years ended December 31, 2010, and 2011 and approximately $39,000 was received during
the year ended December 31, 2012. The Company did not realize any tax benefits in connection with these exercises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">During 2012, the Company issued 326,267 shares of Common
Stock in connection with the exercise of 326,267 options by consultants of the Company. The Company received cash proceeds equal
to approximately $39,000 in connection with such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">3.</FONT></TD><TD><FONT STYLE="font-weight: normal">A
                                                                                                         summary of share option
                                                                                                         plans, and related information,
                                                                                                         under all of the Company&rsquo;s
                                                                                                         equity incentive plans
                                                                                                         for the years ended December&nbsp;31,
                                                                                                         2010, 2011 and 2012 are
                                                                                                         as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>Options granted to employees:</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="22" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year&nbsp;ended&nbsp;December&nbsp;31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">exercise</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">exercise</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">exercise</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 40%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Outstanding at beginning of year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">5,366,729</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">2.476</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">6,367,979</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">3.576</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">6,141,030</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">3.563</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Changes during the year:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.25in">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,444,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.076</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Forfeited and Expired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,441</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.551</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,856</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.207</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,858</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.372</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 0.25in">Exercised (*)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">429,309</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1.602</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">182,093</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1.652</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">861,593</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1.346</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Outstanding at end of year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,367,979</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.576</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,141,030</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.563</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,253,579</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.923</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Exercisable at end of year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,267,850</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2.183</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,647,834</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2.581</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,258,441</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.201</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.95pt; text-indent: -0.2in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.55pt"></TD><TD STYLE="width: 14.4pt">(*)</TD><TD>The total intrinsic value of options exercised during the
                                                                  years ended December 31, 2010, 2011 and 2012, was approximately
                                                                  $3.1 million, $1.3 million and $4.8 million, respectively.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.95pt; text-indent: -0.2in">&nbsp;</P>


<!-- Field: Page; Sequence: 113; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 7&ndash; SHARE CAPITAL </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>Restricted stock granted to employees:</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="5" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year&nbsp;ended&nbsp;December&nbsp;31,&nbsp;2012</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of&nbsp;<BR>
    Restricted&nbsp;Shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: center">Outstanding&nbsp;at&nbsp;beginning&nbsp;of&nbsp;year</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">Changes during the year:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 90%; text-align: center">Granted</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">1,500,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1pt; padding-left: 15.95pt">Forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,208</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">Outstanding at end of year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,496,792</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">Exercisable at end of year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">102,084</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">c.</TD><TD>Options granted to consultants, directors, and other service
                                                             providers:</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="22" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year&nbsp;ended&nbsp;December&nbsp;31,</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">average</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">options</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">price</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">options</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">price</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">options</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">price</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 40%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Outstanding at beginning of year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">1,438,692</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">4.697</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">1,438,692</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">4.697</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">1,238,692</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">5.385</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt">Changes during the year- Exercised (*)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">200,000</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">0.001</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">326,267</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">0.12</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 2.5pt">Outstanding at end of year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">1,438,692</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">4.697</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">1,238,692</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">5.385</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">912,425</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">7.259</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 2.5pt">Exercisable at end of year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">1,421,734</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">4.653</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">1,235,567</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">5.385</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">912,425</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">7.259</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 63.8pt"></TD><TD STYLE="width: 14pt">(*)</TD><TD>The total intrinsic value of options exercised during the years
                                                               ended December 31, 2010, 2011 and 2012, was approximately $0, $1.9
                                                               million and $2.3 million, respectively.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">d.</TD><TD>The following tables summarize information concerning outstanding
                                                             and exercisable options and restricted stock as of December 31, 2012:</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 114; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 7&ndash; SHARE CAPITAL </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-left: 0.75in; border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="18" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,&nbsp;2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="10" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options&nbsp;and&nbsp;restricted&nbsp;stock<BR>
    outstanding</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options&nbsp;exercisable&nbsp;and<BR>
    restricted&nbsp;stock&nbsp;vested</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercise<BR> prices</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of<BR> Options&nbsp;and<BR>
    restricted&nbsp;stock<BR> outstanding<BR> at&nbsp;end&nbsp;of<BR> year</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted&nbsp;<BR> average<BR>
    remaining<BR> contractual<BR> life</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of<BR> options<BR>
    exercisable&nbsp;and<BR> restricted&nbsp;stock<BR> vested&nbsp;at&nbsp;end&nbsp;of<BR> year</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted&nbsp;<BR> average<BR>
    remaining<BR> contractual<BR> life</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right"><FONT STYLE="font-size: 10pt">n/a
                                                       (Restricted Stock)</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">1,496,792</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">n/a</P></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">102,084</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">n/a</P></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.001</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">719,207</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.54</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">719,207</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.54</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.120</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">447,850</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.05</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">447,850</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.05</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.399</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,087</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.92</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,087</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.92</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.972</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">996,353</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">996,353</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.44</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.350</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.82</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.82</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.650</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">402,882</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">396,744</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.15</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,708,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,708,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.810</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">110,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.900</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,003,083</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">168,083</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.15</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.550</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.66</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.66</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9.660</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">68,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.83</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.83</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; text-align: right">16.700</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">387,542</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3.99</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">387,542</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3.99</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,662,796</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,272,950</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The aggregate intrinsic value of the total outstanding
and of total vested and exercisable options and restricted stock as of December 31, 2012 is approximately $19.7 million and $12.4
million, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.15pt; text-indent: -20.15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 20.15pt">e.</TD><TD>The following table illustrates the effect of share-based compensation
                                                               on the statement of operations:</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year&nbsp;ended&nbsp;December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-style: italic; padding-bottom: 1pt">(U.S.&nbsp;dollars&nbsp;in&nbsp;thousands)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -12.6pt; padding-left: 12.6pt">Cost of revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">220</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left; text-indent: -12.6pt; padding-left: 12.6pt">Research and development expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">630</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">422</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">4,756</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -12.6pt; padding-left: 12.6pt">General and administrative expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">652</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">464</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,775</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,282</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">886</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,751</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.28in"><FONT STYLE="font-weight: normal">c.</FONT></TD><TD>Public Offerings</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-indent: -21.3pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 21.3pt"><FONT STYLE="font-weight: normal">1.</FONT></TD><TD><FONT STYLE="font-weight: normal">On
                                                                                                         March 23,&nbsp;2011,
                                                                                                         the Company issued and
                                                                                                         sold 4,000,000 shares
                                                                                                         of Common Stock in an
                                                                                                         underwritten public offering
                                                                                                         at a price to the public
                                                                                                         of $5.50 per share. The
                                                                                                         net proceeds to the Company
                                                                                                         were approximately $20.6
                                                                                                         million&nbsp;(net of
                                                                                                         underwriting commissions
                                                                                                         and issuance costs of
                                                                                                         $1.4 million</FONT>)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-indent: -21.3pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 21.3pt"><FONT STYLE="font-weight: normal">2.</FONT></TD><TD><FONT STYLE="font-weight: normal">On
                                                                                                         February 22,&nbsp;2012,
                                                                                                         the Company issued and
                                                                                                         sold 5,175,000 shares
                                                                                                         of Common Stock in an
                                                                                                         underwritten public offering
                                                                                                         at a price to the public
                                                                                                         of $5.25 per share. The
                                                                                                         net proceeds to the Company
                                                                                                         were approximately $25.4
                                                                                                         million (net of underwriting
                                                                                                         commissions and issuance
                                                                                                         costs of $1.8 million).</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 115; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 8 - TAXES ON INCOME</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">a.</FONT></TD><TD>The Company</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Protalix BioTherapeutics, Inc. is taxed according
to U.S. tax laws. The Company&rsquo;s income is, or will be, taxed in the United States at the rate of up to 39%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">b.</FONT></TD><TD>Protalix Ltd.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Israeli Subsidiary is taxed according to Israeli
tax laws:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">1.</FONT></TD><TD>Measurement of results
                                                                                                         for tax purposes</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Since 2008, the Company has measured the results of
the Israeli Subsidiary for tax purposes in nominal terms in NIS. Pursuant to the Israel Income Tax Law (Adjustments for Inflation),
1985 (the &ldquo;Adjustments Law&rdquo;), the Subsidiary&rsquo;s results for tax purposes have been measured through 2007 on a
real basis, based on changes in the Israel consumer price index.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">2.</FONT></TD><TD>Tax rates</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The income of the Israeli Subsidiary, other than income
from &ldquo;Approved Enterprises,&rdquo; is taxed in Israel at the regular rate. See 3 below. According to the provisions of the
Law for Amending the Israel Income Tax Ordinance, 2005, corporate tax rates will be gradually lowered, resulting in a corporate
tax rate for 2009 and thereafter: 2009 &ndash; 26% and for 2010 and thereafter &ndash; 25%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">On July 14, 2009, the Israel Economic Efficiency Law
(Legislation Amendments for Applying the Economic Plan for 2009 and 2010), 2009, became effective, stipulating, among other things,
an additional gradual decrease in tax rates in 2011 and thereafter, as follows: 2011 &ndash; 24%, 2012 &ndash; 23%, 2013 &ndash;
22%, 2014 &ndash; 21%, 2015 &ndash; 20% and 2016 and thereafter &ndash; 18%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">On December 5, 2011, the &ldquo;Tax Burden Distribution
Law&rdquo; (hereinafter - the 2011 amendment) was officially published, discontinuing a previously approved gradual decrease in
corporate tax provided in the 2009 amendment, and setting the corporate tax rate in Israel for 2012 and thereafter to 25%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Capital gain is subject to capital gain tax according
to corporate tax rate in the year of selling the assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">3.</FONT></TD><TD>The Law for the Encouragement
                                                                                                         of Capital Investments,
                                                                                                         1959 (the &ldquo;Encouragement
                                                                                                         of Capital Investments
                                                                                                         Law&rdquo;)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Under the Encouragement of Capital Investments Law,
including Amendment No. 60 to the Encouragement of Capital Investments Law as published in April 2005, by virtue of the &ldquo;Approved
Enterprise&rdquo; or &ldquo;Benefited Enterprise&rdquo; status the Israeli Subsidiary is entitled to various tax benefits as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -37.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 37.1pt">a.</TD><TD><B>Reduced tax rates</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Income derived from the Approved Enterprise during
a 10-year period commencing upon the year in which the enterprise first realizes taxable income is tax exempt, provided that the
maximum period to which it is restricted by the Encouragement of Capital Investments Law has not elapsed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">The Israeli Subsidiary has an &ldquo;Approved Enterprise&rdquo;
plan since 2004 and &ldquo;Benefited Enterprise&rdquo; plan since 2009. The period of benefits in respect of the main enterprise
of the Company has not yet commenced. The period during which the Company is entitled to benefits in connection with the Benefited
Enterprise expires in 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 116; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 8 &ndash; TAXES ON INCOME </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">If the Israeli Subsidiary subsequently pays a dividend
out of income derived from the &ldquo;Approved Enterprise&rdquo; or &ldquo;Benefited Enterprise&rdquo; during the tax exemption
period, it will be subject to a tax on the amount distributed, including any company tax on these amounts, at the rate which would
have been applicable had such income not been exempted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">In addition to the corporate taxes in Israel, the
Company might be subject to a withholding tax on the U.S. revenue source portion of the payments made to the Company for its share
of Pfizer&rsquo;s net profits under the Pfizer Agreement. The withholding tax rate is currently 15%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">b.</TD><TD><B>Accelerated depreciation</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">The Israeli Subsidiary is entitled to claim accelerated
depreciation, as provided by Israeli law, in the first five years of operation of each asset, in respect of buildings, machinery
and equipment used by the Approved Enterprise and the Benefited Enterprise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">c.</TD><TD><B>Conditions for entitlement to the benefits</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">The Israeli Subsidiary&rsquo;s entitlement to the
benefits described above is subject to its fulfilling the conditions stipulated by the law, rules and regulations published thereunder,
and the instruments of approval for the specific investment in an approved enterprise. If there is any failure by the Israeli
Subsidiary to comply with these conditions, the benefits may be cancelled and the Subsidiary may be required to refund the amount
of the benefits, in whole or in part, with interest. The Israeli Subsidiary received a final implementation approval with respect
to its &ldquo;Approved Enterprise&rdquo; from the Investment Center.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">d.</TD><TD><B>Amendment of the Law for the Encouragement of Capital Investments,
                                                             1959</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">The Encouragement of Capital Investments Law was
amended as part of the Economic Policy Law for the years 2011-2012, which was passed by the Israeli Knesset on December 29, 2010
(the &ldquo;Capital Investments Law Amendment&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">The Capital Investments Law Amendment sets alternative
benefit tracks to those currently in effect under the provisions of the Encouragement of Capital Investments Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">The benefits granted to the Benefited Enterprises
will be unlimited in time, unlike the benefits granted to special Benefited enterprises, which will be limited for a 10-year period.
The benefits shall be granted to companies that will qualify under criteria set in the law; for the most part, those criteria
are similar to the criteria that were set in the Encouragement of Capital Investments Law prior to its amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Under the transitional provisions of the Encouragement
of Capital Investments Law, the Company is entitled to take advantage of the tax benefits available under the Encouragement of
Capital Investments Law prior to its amendment until the end of the benefits period, as defined in the Encouragement of Capital
Investments Law. The Company will be allowed to set the &ldquo;year of election&rdquo; no later than tax year 2012, provided that
the minimum qualifying investment was made not later than the end of 2010. On each year during the benefits period, the Company
will be able to elect that the Capital Investments Amendment apply to the Company, thereby making the tax rates described above
available to the Company. An election to have the Capital Investments Amendment apply is irrecoverable. The Company elected not
to have the Capital Investments Amendment apply to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 117; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 8 &ndash; TAXES ON INCOME </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">4.</FONT></TD><TD>The Law for the Encouragement
                                                                                                         of Industry (Taxation),
                                                                                                         1969:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Israeli Subsidiary is an &ldquo;industrial company,&rdquo;
as defined under the Law for the Encouragement of Industry (Taxation), 1969 (the &ldquo;Law for the Encouragement of Industry&rdquo;).
As such, the Israeli Subsidiary is entitled to claim depreciation at increased rates for equipment used in industrial activity,
as stipulated by regulations published under Law for the Encouragement of Industry, and has done so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Under the provisions of the Income Tax Regulations
&ldquo;Accelerated Depreciation in respect of Equipment acquired during the Defined Period&rdquo; (Temporary Orders), industrial
companies whose operations are mostly &ldquo;eligible operations&rdquo; are entitled to claim accelerated depreciation at a rate
of 50% on machinery and equipment acquired from June 1, 2008 to May 31, 2009.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">c.</FONT></TD><TD>Tax losses carried
                                                                                                       forward to future years</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">As of December 31, 2012, the Company had aggregate
net operating loss (NOL) carry-forwards equal to approximately $72.5 million that are available to reduce future taxable income
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">1.</FONT></TD><TD>The Company</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The NOL carry-forward of the Company equal to approximately
$13.8 million may be restricted under Section 382 of the Internal Revenue Code (&ldquo;IRC&rdquo;). IRC Section 382 applies whenever
a corporation with NOL experiences an ownership change. As a result of IRC Section 382, the taxable income for any post change
year that may be offset by a pre-change NOL may not exceed the general IRC Section 382 limitation, which is the fair market value
of the pre-change entity multiplied by the IRC long-term tax exempt rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">2.</FONT></TD><TD>Protalix Ltd.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">At December 31, 2012, the Israeli Subsidiary had approximately
$58.7 million of NOL carry-forwards that are available to reduce future taxable income with no limited period of use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">d.</FONT></TD><TD>Deferred income taxes:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The components of the Company&rsquo;s net deferred
tax assets at December 31, 2011 and 2012 were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-style: italic; padding-bottom: 1pt">(U.S.&nbsp;dollars&nbsp;in&nbsp;thousands)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>In respect of:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 9pt">Research and development expenses</TD><TD STYLE="width: 1%; color: black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: black; text-align: left">$</TD><TD STYLE="width: 10%; color: black; text-align: right">4,119</TD><TD STYLE="width: 1%; color: black; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; color: black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: black; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; color: black; text-align: right">6,003</TD><TD STYLE="width: 1%; color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Property and equipment</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">(149</TD><TD STYLE="color: black; text-align: left">)</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">(647</TD><TD STYLE="color: black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Provision for vacation</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">305</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">363</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Severance pay obligation</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">164</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">192</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Deferred revenues</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">4,746</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">10,449</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Net operating loss carry forwards</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">4,579</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">15,176</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(13,764</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(31,536</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Deferred taxes are computed using the tax rates
expected to be in effect when those differences reverse. The Company used tax rates of 39%, 25% and 0%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 118; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 8 &ndash; TAXES ON INCOME </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">e.</FONT></TD><TD>Reconciliation of the
                                                                                                       theoretical tax expense
                                                                                                       to actual tax expense</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The main reconciling item between the statutory
tax rate of the Company and the effective rate is the provision for full valuation allowance in respect of tax benefits from carry
forward tax losses due to the uncertainty of the realization of such tax benefits (see above).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">f.</FONT></TD><TD>Tax assessments</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">In accordance with the Income Tax Ordinance, as
of December 31, 2012, all of Protalix Ltd.&rsquo;s tax assessments through tax year 2008 are considered final.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">A summary of open tax years by major jurisdiction
is presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 50%; font-weight: bold; text-decoration: none; text-align: left; border-bottom: Black 1pt solid">Jurisdiction:</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 47%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt"><B>Years:</B></FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Israel</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2009-2012</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">United States (*)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2009-2012</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Netherlands</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2009-2012</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">(*) Includes federal, state and local (or similar
provincial jurisdictions) tax positions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 9 - SUPPLEMENTARY FINANCIAL STATEMENT
INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 71.3pt; text-indent: -17.3pt"><B>Balance sheets:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 71.3pt; text-indent: -17.3pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-style: italic; padding-bottom: 1pt">(U.S. dollars in thousands)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -26.45pt; padding-left: 26.45pt">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
    assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 45pt">Deferred costs*</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,558</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">89</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 45pt">Institutions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">375</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">542</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 45pt">State of Israel (see Note&nbsp;6a)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,296</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,400</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 45pt">Restricted deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">208</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">298</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 45pt">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">235</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">251</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 45pt">Sundry</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">165</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">106</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,837</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,686</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">* Manufacturing costs of inventory, paid by Pfizer,
but not delivered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>(U.S. dollars in thousands)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>b.</B></TD><TD STYLE="text-align: justify"><B>Accounts
                                                                                       payable and accruals &ndash; other:</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%; text-align: left; padding-left: 45pt">Payroll and related expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,108</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,748</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 45pt">Provision for vacation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,221</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,453</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 45pt">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,327</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,032</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 45pt">Royalties&#9;payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">89</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,560</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 52.2pt">Liability in connection with collaboration operation-
    current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,322</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,122</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 45pt">Property and equipment suppliers</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,473</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,136</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,540</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11,051</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 119; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTE 9 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION
<FONT STYLE="font-weight: normal">(continued)</FONT>:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>Statements of operations:</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year&nbsp;ended&nbsp;December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-style: italic">(U.S. dollars in thousands)</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -28.85pt; padding-left: 28.85pt">c.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenues:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left; text-indent: -0.1in; padding-left: 0.6in">Deferred revenues from the license and
    supply agreement with Pfizer</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">4,563</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">4,563</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">4,563</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.5in">Milestone payment (see note 2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Revenues from selling products</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,079</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,823</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,307</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; text-indent: -28.85pt; padding-left: 28.85pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,642</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,386</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">34,870</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 10 - RELATED PARTY TRANSACTIONS</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="color: blue; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year&nbsp;ended&nbsp;December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-style: italic; padding-bottom: 2.5pt">(U.S.&nbsp;dollars&nbsp;in&nbsp;thousands)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 2.5pt double">2010</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 2.5pt double">2011</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 2.5pt double">2012</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 61%; text-align: left; padding-bottom: 2.5pt; text-indent: -0.25in; padding-left: 0.5in"><B>a.</B>&nbsp;&nbsp;&nbsp;&nbsp;Management
    and consulting fees to the Chairman of the Board</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">6</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.25in; padding-left: 0.5in"><B>b.</B>&nbsp;&nbsp;&nbsp;&nbsp;Compensation
    to the non-executive directors (except the Chairman of the Board in 2010, and includes the interim Chairman of the Board in
    2011 and 2012)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">215</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">215</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">375</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 11 - SUBSEQUENT EVENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -20.7pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20.7pt"><FONT STYLE="font-weight: normal">a.</FONT></TD><TD><FONT STYLE="font-weight: normal">During
                                                                                                       January and February 2013,
                                                                                                       the Company issued a total
                                                                                                       of 8,000 shares of Common
                                                                                                       Stock in connection with
                                                                                                       the exercise of options
                                                                                                       to purchase 8,000 shares
                                                                                                       of Common Stock by certain
                                                                                                       employees of the Company.
                                                                                                       The Company received aggregate
                                                                                                       cash proceeds equal to
                                                                                                       approximately $19,000 in
                                                                                                       connection with the exercise
                                                                                                       of such options.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 120; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;&nbsp;</FONT></P>






</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.6
<SEQUENCE>2
<FILENAME>v334254_ex3-6.htm
<DESCRIPTION>EXHIBIT 3.6
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 3.6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDED AND RESTATED BYLAWS<BR>
OF<BR>
PROTALIX BIOTHERAPEUTICS, INC.<BR>
(Adopted February 27, 2013)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE I<BR>
OFFICES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 1.1 Registered Office.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The registered office of the corporation
in the State of Florida shall be 1201 Hays Street, Tallahassee, Florida 32301.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 1.2 Other Offices.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The corporation shall also have and maintain
an office or principal place of business at 2 Snunit Street, Science Park, PO Box 455, Carmiel Israel 20100, and may also have
offices at such other places, both within and without the State of Florida, as the Board of Directors may from time to time determine
or the business of the corporation may require.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 1.3 Registered Agent.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Board of Directors shall designate a
registered agent for service of process on the corporation for the State of Florida and for each state in which the corporation
qualifies to do business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE II<BR>
SHAREHOLDERS&rsquo; MEETINGS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 2.1 Place of Meetings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Meetings
of shareholders may be held at such place, either within or without this State, as may be designated by or in the manner provided
in these Bylaws or, if not so designated, as determined by the Board of Directors. The Board of Directors may, in its sole discretion,
determine that the meeting shall not be held at any place, but may instead be held solely by means of remote communication as authorized
by paragraph (b) of this Section 2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
authorized by the Board of Directors in its sole discretion, and subject to such guidelines and procedures as the Board of Directors
may adopt, shareholders and proxyholders not physically present at a meeting of shareholders may, by means of remote communication:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Participate
in a meeting of shareholders; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Be
deemed present in person and vote at a meeting of shareholders whether such meeting is to be held at a designated place or solely
by means of remote communication, provided that (A) the corporation shall implement reasonable measures to verify that each person
deemed present and permitted to vote at the meeting by means of remote communication is a shareholder or proxyholder, (B) the corporation
shall implement reasonable measures to provide such shareholders and proxyholders a reasonable opportunity to participate in the
meeting and to vote on matters submitted to the shareholders, including an opportunity to read or hear the proceedings of the meeting
substantially concurrently with such proceedings, and (C) if any shareholder or proxyholder votes or takes other action at the
meeting by means of remote communication, a record of such vote or other action shall be maintained by the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For purposes of this Section 2.1, &ldquo;remote communication&rdquo;
shall include (1) telephone or other voice communications and (2) electronic mail or other form of written or visual electronic
communications satisfying the requirements of Section 2.11(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 2.2 Annual Meetings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">The annual meetings of the shareholders
of the corporation, for the purpose of election of directors and for such other business as may lawfully come before it, shall
be held on such date and at such time as may be designated from time to time by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 2.3 Special Meetings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Special Meetings of the shareholders of
the corporation may be called, for any purpose or purposes, by the Chairman of the Board or the President or the Board of Directors
at any time. Upon written request of any shareholder or shareholders holding in the aggregate not less than 10% of all of the votes
entitled to be cast on any issue proposed to be considered at the Special Meeting signed, dated and delivered in person or sent
by registered mail to the Chairman of the Board, President or Secretary of the corporation, the Secretary shall call a special
meeting of shareholders to be held at the principal office of the corporation or at such place and at such time as the Secretary
may fix, such meeting to be held not less than 10 nor more than 60 days after the receipt of such request, and if the Secretary
shall neglect or refuse to call such meeting within seven days after the receipt of such request, the shareholder making such request
may do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 2.4 Notice of Meetings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise provided by law or the corporation&rsquo;s Articles of Incorporation, as amended, written notice of each meeting of
shareholders, specifying the place, if any, date and hour and purpose or purposes of the meeting, and the means of remote communication,
if any, by which shareholders and proxyholders may be deemed to be present in person and vote at such meeting shall be given not
less than 10 nor more than 60 days before the date of the meeting to each shareholder entitled to vote thereat, directed to his,
her or its address as it appears upon the books of the corporation; except that where the matter to be acted on is a merger or
consolidation of the corporation or a sale, lease or exchange of all or substantially all of its assets, such notice shall be given
not less than 20 nor more than 60 days prior to such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
at any meeting action is proposed to be taken which, if taken, would entitle shareholders fulfilling the requirements of Section
607.1302 of the Florida Business Corporation Act to an appraisal of the fair value of their shares, the notice of such meeting
shall contain a statement of that purpose and to that effect and shall be accompanied by a copy of Sections 607.1301 through 607.1333
of the Florida Business Corporation Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When
a meeting is adjourned to another time or place, notice need not be given of the adjourned meeting if the time, place, if any,
thereof, and the means of remote communication, if any, by which shareholders and proxyholders may be deemed to be present in person
and vote at such adjourned meeting, are announced at the meeting at which the adjournment is taken unless the adjournment is for
more than 30 days, or unless after the adjournment a new record date is fixed for the adjourned meeting, in which event a notice
of the adjourned meeting shall be given to each shareholder of record entitled to vote at the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notice
of the time, place and purpose of any meeting of shareholders may be waived in writing, either before or after such meeting, and,
to the extent permitted by law, will be waived by any shareholder by his attendance thereat, in person or by proxy. Any shareholder
so waiving notice of such meeting shall be bound by the proceedings of any such meeting in all respects as if due notice thereof
had been given.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without
limiting the manner by which notice otherwise may be given effectively to shareholders, any notice to shareholders given by the
corporation under any provision of the Florida Business Corporation Act, the corporation&rsquo;s Articles of Incorporation, as
amended, or these Amended and Restated Bylaws shall be effective if given by a form of electronic transmission consented to by
the shareholder to whom the notice is given. Any such consent shall be revocable by the shareholder by written notice to the corporation.
Any such consent shall be deemed revoked if (i) the corporation is unable to deliver by electronic transmission two consecutive
notices given by the corporation in accordance with such consent and (ii) such inability becomes known to the secretary or an assistant
secretary of the corporation or to the transfer agent or other person responsible for the giving of notice; <U>provided</U>, <U>however</U>,
the inadvertent failure to treat such inability as a revocation shall not invalidate any meeting or other action. Notice given
pursuant to this subparagraph (e) shall be deemed given: (1) if by facsimile telecommunication, when directed to a number at which
the shareholder has consented to receive notice; (2) if by electronic mail, when directed to an electronic mail address at which
the shareholder has consented to receive notice; (3) if by a posting on an electronic network together with separate notice to
the shareholder of such specific posting, upon the later of (A) such posting and (B) the giving of such separate notice; and (4)
if by any other form of electronic transmission, when directed to the shareholder. An affidavit of the Secretary or an assistant
secretary or of the transfer agent or other agent of the corporation that the notice has been given by a form of electronic transmission
shall, in the absence of fraud, be prima facie evidence of the facts stated therein. For purposes of these Amended and Restated
Bylaws, &ldquo;electronic transmission&rdquo; means any form of communication, not directly involving the physical transmission
of paper, that creates a record that may be retained, retrieved and reviewed by a recipient thereof, and that may be directly reproduced
in paper form by such a recipient through an automated process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 2.5 Quorum and Voting.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: black">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
all meetings of shareholders except where otherwise provided by law, the corporation&rsquo;s Articles of Incorporation or these
Amended and Restated Bylaws, the presence, in person or by proxy duly authorized, of the holders of a majority of the outstanding
shares of stock entitled to vote shall constitute a quorum for the transaction of business. Shares, the voting of which at said
meeting have been enjoined, or which for any reason cannot be lawfully voted at such meeting, shall not be counted to determine
a quorum at said meeting. In the absence of a quorum, any meeting of shareholders may be adjourned, from time to time, by vote
of the holders of a majority of the shares represented thereat, but no other business shall be transacted at such meeting. At such
adjourned meeting at which a quorum is present or represented, any business may be transacted which might have been transacted
at the original meeting. The shareholders present at a duly called or convened meeting at which a quorum is present may continue
to transact business until adjournment, notwithstanding the withdrawal of enough shareholders to leave less than a quorum. </FONT>
<FONT STYLE="font-size: 10pt">Abstentions and &quot;broker non-votes&quot; are counted as present and entitled to vote for purposes
of determining a quorum. A &quot;broker non-vote&quot; occurs when a broker holding shares for a beneficial owner does not vote
on a particular proposal because the broker does not have discretionary voting power for that particular item and has not received
instructions from the beneficial owner. Abstentions and, if applicable, broker non-votes, are not counted as votes &quot;for&quot;
or &quot;against&quot; any proposals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: black">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise provided by law, the corporation&rsquo;s Articles of Incorporation or these Amended and Restated Bylaws, action </FONT>on
a matter (other than the election<FONT STYLE="color: black"> of </FONT>directors) by <FONT STYLE="color: black">a</FONT> voting
group is approved if the votes cast within the voting group favoring the action exceed the votes cast opposing the action<FONT STYLE="color: black">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Where
a separate vote by a class or classes is required, a majority of the outstanding shares of such class or classes present in person
or represented by proxy shall constitute a quorum entitled to take action with respect to that vote on that matter, and the affirmative
vote of the majority of shares of such class or classes present in person or represented by proxy at the meeting shall be the act
of such class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 2.6 Voting Rights.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise provided by law, only persons in whose names shares entitled to vote stand on the stock records of the corporation
on the record date for determining the shareholders entitled to vote at said meeting shall be entitled to vote at such meeting.
Shares standing in the names of two or more persons shall be voted or represented in accordance with the determination of the majority
of such persons, or, if only one of such persons is present in person or represented by proxy, such person shall have the right
to vote such shares and such shares shall be deemed to be represented for the purpose of determining a quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Every
person entitled to vote or to execute consents shall have the right to do so either in person or by an agent or agents authorized
by a written proxy executed by such person or his duly authorized agent, which proxy shall be filed with the Secretary of the corporation
at or before the meeting at which it is to be used. Said proxy so appointed need not be a shareholder. No proxy shall be voted
on after eleven (11) months from its date unless the proxy provides for a longer period. Unless and until voted, every proxy shall
be revocable at the pleasure of the person who executed it or of his legal representatives or assigns, except in those cases where
an irrevocable proxy permitted by statute has been given.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without
limiting the manner in which a shareholder may authorize another person or persons to act for him as proxy pursuant to subsection
(b) of this section, the following shall constitute a valid means by which a shareholder may grant such authority:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
shareholder may execute a writing authorizing another person or persons to act for him as proxy. Execution may be accomplished
by the shareholder or his authorized officer, director, employee or agent signing such writing or causing his or her signature
to be affixed to such writing by any reasonable means including, but not limited to, by facsimile signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
shareholder may authorize another person or persons to act for him as proxy by transmitting or authorizing the transmission of
a telephone, telegram, cablegram or other means of electronic transmission to the person who will be the holder of the proxy or
to a proxy solicitation firm, proxy support service organization or like agent duly authorized by the person who will be the holder
of the proxy to receive such transmission, provided that any such telephone, telegram, cablegram or other means of electronic transmission
must either set forth or be submitted with information from which it can be determined that the telephone, telegram, cablegram
or other electronic transmission was authorized by the shareholder. Such authorization can be established by the signature of the
shareholder on the proxy, either in writing or by a signature stamp or facsimile signature, or by a number or symbol from which
the identity of the shareholder can be determined, or by any other procedure deemed appropriate by the inspectors or other persons
making the determination as to due authorization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
copy, facsimile telecommunication or other reliable reproduction of the writing or transmission created pursuant to subsection
(c) of this section may be substituted or used in lieu of the original writing or transmission for any and all purposes for which
the original writing or transmission could be used, provided that such copy, facsimile telecommunication or other reproduction
shall be a complete reproduction of the entire original writing or transmission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 2.7 Voting Procedures and Inspectors of Elections.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
corporation shall, in advance of any meeting of shareholders, appoint one or more inspectors to act at the meeting and make a written
report thereof. The corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to
act. If no inspector or alternate is able to act at a meeting of shareholders, the person presiding at the meeting shall appoint
one or more inspectors to act at the meeting. Each inspector, before entering upon the discharge of his duties, shall take and
sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of his, her or its
ability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
inspectors shall (i) ascertain the number of shares outstanding and the voting power of each, (ii) determine the shares represented
at a meeting and the validity of proxies and ballots, (iii) count all votes and ballots, (iv) determine and retain for a reasonable
period a record of the disposition of any challenges made to any determination by the inspectors and (v) certify their determination
of the number of shares represented at the meeting and their count of all votes and ballots. The inspectors may appoint or retain
other persons or entities to assist the inspectors in the performance of the duties of the inspectors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
date and time of the opening and the closing of the polls for each matter upon which the shareholders will vote at a meeting shall
be announced at the meeting. No ballot, proxies or votes, nor any revocations thereof or changes thereto, shall be accepted by
the inspectors after the closing of the polls unless a court of competent jurisdiction, upon application by shareholders entitled
to vote at said meeting shall determine otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
determining the validity and counting of proxies and ballots, the inspectors shall be limited to an examination of the proxies,
any envelopes submitted with those proxies, any information provided in accordance with the Florida Business Corporation Act, ballots
and the regular books and records of the corporation, except that the inspectors may consider other reliable information for the
limited purpose of reconciling proxies and ballots submitted by or on behalf of banks, brokers, their nominees or similar persons
which represent more votes than the holder of a proxy is authorized by the record owner to cast or more votes than the shareholder
holds of record. If the inspectors consider other reliable information for the limited purpose permitted herein, the inspectors
at the time they make their certification pursuant to subsection (b)(v) of this section shall specify the precise information considered
by them including the person or persons from whom they obtained the information, when the information was obtained, the means by
which the information was obtained and the basis for the inspectors&rsquo; belief that such information is accurate and reliable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 2.8 List of Shareholders.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The officer who has charge of the stock ledger of the corporation
shall prepare and make, or shall cause to be prepared at least 10 days before every meeting of shareholders, a complete list of
the shareholders entitled to vote at said meeting showing the address of and the number of shares registered in the name of each
shareholder. The corporation need not include electronic mail addresses or other electronic contact information on such list. Such
list shall be open to the examination of any shareholder for any purpose germane to the meeting for a period of at least 10 days
prior to the meeting: (i) on a reasonably accessible electronic network, provided that the information required to gain access
to such list is provided with the notice of the meeting, or (ii) during ordinary business hours at the principal place of business
of the corporation. In the event that the corporation determines to make the list available on an electronic network, the corporation
may take reasonable steps to ensure that such information is available only to shareholders of the corporation. If the meeting
is to be held at a place other than the principal office of the corporation, the list shall be produced and kept at the time and
place of the meeting during the whole time thereof, and may be inspected by any shareholder who is present. If the meeting is to
be held solely by means of remote communication, then the list shall also be open to the examination of any shareholder during
the whole time of the meeting on a reasonably accessible electronic network, and the information required to access such list shall
be provided with the notice of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 2.9 Shareholder Proposals at Annual Meetings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At an annual meeting of the shareholders, only such business
shall be conducted as shall have been properly brought before the meeting. To be properly brought before an annual meeting, business
must be specified in the notice of meeting (or any supplement thereto) given by or at the direction of the Board of Directors,
otherwise properly brought before the meeting by or at the direction of the Board of Directors, or otherwise properly brought before
the meeting by a shareholder. In addition to any other applicable requirements for business to be properly brought before an annual
meeting by a shareholder, whether or not the shareholder is seeking to have a proposal included in the corporation&rsquo;s proxy
statement or information statement under any applicable rule of the Securities and Exchange Commission (the &ldquo;SEC&rdquo;),
including, but not limited to, Regulation 14A or Regulation 14C under the Securities and Exchange Act of 1934, as amended (the
&ldquo;Exchange Act&rdquo;), the shareholder must have given timely notice thereof in writing to the Secretary of the corporation.
To be timely, a shareholder&rsquo;s notice must be delivered to or mailed and received at the principal executive offices of the
corporation not less than 45 days nor more than 75 days prior to the date on which the corporation first mailed its proxy materials
(or, in the absence of proxy materials, its notice of the meeting) for the previous year&rsquo;s annual meeting of shareholders
(or the date on which the corporation mails such materials for the current year if during the prior year the corporation did not
hold an annual meeting or if the date of the annual meeting was changed more than 30 days from the prior year). A shareholder&rsquo;s
notice to the Secretary shall set forth as to each matter the shareholder proposes to bring before the annual meeting (i) a brief
description of the business desired to be brought before the annual meeting and the reasons for conducting such business at the
annual meeting, (ii) the name and record address of the shareholder proposing such business, (iii) the class and number of shares
of the corporation which are beneficially owned by the shareholder, (iv) any material interest of the shareholder in such business,
(v) as to the shareholder giving the notice and any Shareholder Associated Person (as defined below), whether and the extent to
which any hedging or other transaction or series of transactions has been entered into by or on behalf of, or any other agreement,
arrangement or understanding (including, but not limited to, any short position or any borrowing or lending of shares of stock)
has been made, the effect or intent of which is to mitigate loss or increase profit to or manage the risk or benefit of stock price
changes for, or to increase or decrease the voting power of, such shareholder or any such Shareholder Associated Person with respect
to any share of stock of the corporation (each, a &ldquo;Relevant Hedge Transaction&rdquo;), and (vi) as to the shareholder giving
the notice and any Shareholder Associated Person, to the extent not set forth pursuant to the immediately preceding clause, (a)
whether and the extent to which such shareholder or Shareholder Associated Person has direct or indirect beneficial ownership of
any option, warrant, convertible security, stock appreciation right, or similar right with an exercise or conversion privilege
or a settlement payment or mechanism at a price related to any class or series of shares of the corporation, whether or not such
instrument or right shall be subject to settlement in the underlying class or series of capital stock of the corporation or otherwise,
or any other direct or indirect opportunity to profit or share in any profit derived from any increase or decrease in the value
of shares of the corporation (a &ldquo;Derivative Instrument&rdquo;), (b) any rights to dividends on the shares of the corporation
owned beneficially by such shareholder that are separated or separable from the underlying shares of the corporation, (c) any proportionate
interest in shares of the corporation or Derivative Instruments held, directly or indirectly, by a general or limited partnership
in which such shareholder is a general partner or, directly or indirectly, beneficially owns an interest in a general partner and
(d) any performance-related fees (other than an asset-based fee) that such shareholder is entitled to based on any increase or
decrease in the value of shares of the corporation or Derivative Instruments, if any, as of the date of such notice, including
without limitation any such interests held by members of such shareholder&rsquo;s immediate family sharing the same household (which
information shall be supplemented by such shareholder and beneficial owner, if any, not later than 10 days after the record date
for the meeting to disclose such ownership as of the record date).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For purposes of this Section 2.9 and Section 2.10, &ldquo;Shareholder
Associated Person&rdquo; of any shareholder shall mean (i) any person controlling or controlled by, directly or indirectly, or
acting in concert with, such shareholder, (ii) any beneficial owner of shares of stock of the corporation owned of record or beneficially
by such shareholder and (iii) any person controlling, controlled by or under common control with such Shareholder Associated Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Notwithstanding anything in these Amended and Restated Bylaws
to the contrary, no business shall be conducted at the annual meeting except in accordance with the procedures set forth in Section
2.1 and this Section 2.9; <U>provided</U>, <U>however</U>, that nothing in this Section 2.9 shall be deemed to preclude discussion
by any shareholder of any business properly brought before the annual meeting in accordance with said procedure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Chairman of an annual meeting shall, if the facts warrant,
determine and declare to the meeting that business was not properly brought before the meeting in accordance with the provisions
of Section 2.1 and this Section 2.9, and if he should so determine he shall so declare to the meeting, and any such business not
properly brought before the meeting shall not be transacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nothing in this Section 2.9 shall affect the right of a shareholder
to request inclusion of a proposal in the corporation&rsquo;s proxy statement or information statement to the extent that such
right is provided by an applicable rule of the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 2.10 Nominations of Persons for Election to the Board
of Directors.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to any other applicable requirements, only persons
who are nominated in accordance with the following procedures shall be eligible for election as directors. Nominations of persons
for election to the Board of Directors of the corporation may be made at a meeting of shareholders by or at the direction of the
Board of Directors, by any nominating committee or person appointed by the Board of Directors or by any shareholder of the corporation
entitled to vote for the election of directors at the meeting who complies with the notice procedures set forth in this Section
2.10. Such nominations, other than those made by or at the direction of the Board of Directors, shall be made pursuant to timely
notice in writing to the Secretary of the corporation, which shall be the exclusive means for a shareholder to make nominations
whether or not the shareholder is seeking to have a proposal included in the corporation&rsquo;s proxy statement or information
statement under an applicable rule of the SEC, including, but not limited to, Regulation 14A or Regulation 14C under the Exchange
Act. To be timely, a shareholder&rsquo;s notice must be delivered to or mailed and received at the principal executive offices
of the corporation, not less than 45 days nor more than 75 days prior to the date on which the corporation first mailed its proxy
materials (or, in the absence of proxy materials, its notice of the meeting) for the previous year&rsquo;s annual meeting of shareholders
(or the date on which the corporation mails such materials for the current year if during the prior year the corporation did not
hold an annual meeting or if the date of the annual meeting was changed more than 30 days from the prior year). Such shareholder&rsquo;s
notice shall set forth (a) as to each person whom the shareholder proposes to nominate for election or re-election as a director,
(i) the name, age, business address and residence address of the person, (ii) the principal occupation or employment of the person,
(iii) the class and number of shares of the corporation which are beneficially owned by the person, and (iv) any other information
relating to the person that is required to be disclosed in solicitations for proxies for election of directors pursuant to Regulation
14A under the Exchange Act; (b) as to the shareholder giving the notice, (i) the name and record address of the shareholder, and
(ii) the class and number of shares of the corporation which are beneficially owned by the shareholder; (c) as to the shareholder
giving the notice and any Shareholder Associated Person (as defined in Section 2.9), to the extent not set forth pursuant to the
immediately preceding clause, whether and the extent to which any Relevant Hedge Transaction (as defined in Section 2.9) has been
entered into, and (d) as to the shareholder giving the notice and any Shareholder Associated Person, (1) whether and the extent
to which any Derivative Instrument (as defined in Section 2.9) is directly or indirectly beneficially owned, (2) any rights to
dividends on the shares of the corporation owned beneficially by such shareholder that are separated or separable from the underlying
shares of the corporation, (3) any proportionate interest in shares of the corporation or Derivative Instruments held, directly
or indirectly, by a general or limited partnership in which such shareholder is a general partner or, directly or indirectly, beneficially
owns an interest in a general partner and (4) any performance-related fees (other than an asset-based fee) that such shareholder
is entitled to based on any increase or decrease in the value of shares of the corporation or Derivative Instruments, if any, as
of the date of such notice, including without limitation any such interests held by members of such shareholder&rsquo;s immediate
family sharing the same household (which information shall be supplemented by such shareholder and beneficial owner, if any, not
later than 10 days after the record date for the meeting to disclose such ownership as of the record date). The corporation may
require any proposed nominee to furnish such other information as may reasonably be required by the corporation to determine the
eligibility of such proposed nominee to serve as a director of the corporation. No person shall be eligible for election as a director
of the corporation unless nominated in accordance with the procedures set forth herein. These provisions shall not apply to nomination
of any persons entitled to be separately elected by holders of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Chairman of the meeting shall, if the facts warrant, determine
and declare to the meeting that a nomination was not made in accordance with the foregoing procedure, and if he should so determine,
he shall so declare to the meeting and the defective nomination shall be disregarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 2.11 Fixing Record Dates.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order that the corporation may determine the shareholders entitled to notice of or to vote at any meeting of shareholders or any
adjournment thereof, the Board of Directors may fix a record date, which record date shall not precede the date upon which the
resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than 60 nor less
than 10 days before the date of such meeting. If no record date is fixed by the Board of Directors, the record date for determining
shareholders entitled to notice of or to vote at a meeting of shareholders shall be at the close of business on the day preceding
the day on which notice is given, or, if notice is waived, at the close of business on the day preceding the date on which the
meeting is held. A determination of shareholders of record entitled notice of or to vote at a meeting of shareholders shall apply
to any adjournment of the meeting; <U>provided</U>, <U>however</U>, that the Board of Directors may fix a new record date for the
adjourned meeting, subject to the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order that the corporation may determine the shareholders entitled to receive payment of any dividend or other distribution or
allotment of any rights or the shareholders entitled to exercise any rights in respect of any change, conversion or exchange of
stock, or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not
precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than 60 days
prior to such action. If no record date is fixed, the record date for determining shareholders for any such purpose shall be at
the close of business on the day on which the Board of Directors adopts the resolution relating thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE III<BR>
DIRECTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 3.1 Number and Term of Office.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The number of directors which shall constitute the whole of
the Board of Directors shall be fixed from time to time by resolution of the Board of Directors. With the exception of the first
Board of Directors, which was elected by the incorporators, and except as provided in Section 3.3 of this Article III, the directors
shall be elected by a plurality vote of the shares represented in person or by proxy at the shareholders annual meeting in each
year and entitled to vote on the election of directors. Elected directors shall hold office until the next annual meeting and until
their successors shall be duly elected and qualified. Directors need not be shareholders. If, for any cause, the Board of Directors
shall not have been elected at an annual meeting, they may be elected as soon thereafter as convenient at a special meeting of
the shareholders called for that purpose in the manner provided in these Amended and Restated Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 3.2 Powers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The powers of the corporation shall be exercised, its business
conducted and its property controlled by or under the direction of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 3.3 Vacancies.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vacancies and newly created directorships resulting from any
increase in the authorized number of directors may be filled by a majority of the directors then in office, although less than
a quorum, or by a sole remaining director, and each director so elected shall hold office for the unexpired portion of the term
of the director whose place shall be vacant and until his successor shall have been duly elected and qualified. A vacancy in the
Board of Directors shall be deemed to exist under this section in the case of the death, removal or resignation of any director,
or if the shareholders fail at any meeting of shareholders at which directors are to be elected (including any meeting referred
to in Section 3.4 below) to elect the number of directors then constituting the whole Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 3.4 Resignations and Removals.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
director may resign at any time by delivering his resignation to the Board of Directors, the Chairman of the Board, or the Secretary
in writing or by electronic transmission, such resignation to specify whether it will be effective at a particular time, upon receipt
or at the pleasure of the Board of Directors. If no such specification is made it shall be deemed effective at the pleasure of
the Board of Directors. When one or more directors shall resign from the Board effective at a future date, a majority of the directors
then in office, including those who have so resigned (prior to the resignation being in effect), shall have power to fill such
vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective, and each director
so chosen shall hold office for the unexpired portion of the term of the director whose place shall be vacated and until his successor
shall have been duly elected and qualified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
a special meeting of shareholders called for the purpose in the manner hereinabove provided, any director may be removed from office,
with or without cause, if the number of votes cast to remove the director exceeds the number of votes cast not to remove him or
her, and a new director may be elected by of the shareholders in the manner provided by these Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 3.5 Meetings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
annual meeting of the Board of Directors shall be held immediately after the annual shareholders&rsquo; meeting and at the place
where such meeting is held or at the place announced by the Chairman at such meeting. No notice of an annual meeting of the Board
of Directors shall be necessary, and such meeting shall be held for the purpose of electing officers and transacting such other
business as may lawfully come before it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as hereinafter otherwise provided, regular meetings of the Board of Directors shall be held in the principal office of the corporation.
Regular meetings of the Board of Directors may also be held at any place, within or without the United States, as determined by
the Chairman of the Board or by the written consent of all directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Special
meetings of the Board of Directors may be held at any time and place within or without the State of Florida whenever called by
the Chairman of the Board or, if there is no Chairman of the Board, by the Chief Executive Officer, or by any of the directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Written
notice of the time and place of all regular and special meetings of the Board of Directors shall be delivered personally to each
director or sent by telegram or facsimile transmission or other form of electronic transmission at least 48 hours before the start
of the meeting, or sent by first class mail at least 120 hours before the start of the meeting. Notice of any meeting may be waived
in writing at any time before or after the meeting and will be waived by any director by attendance thereat.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 3.6 Quorum and Voting.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
quorum of the Board of Directors shall consist of a majority of the exact number of directors fixed from time to time in accordance
with Section 3.1 of Article III of these Bylaws, but not less than one; <U>provided</U>, <U>however</U>, at any meeting whether
a quorum be present or otherwise, a majority of the directors present may adjourn from time to time until the time fixed for the
next regular meeting of the Board of Directors, without notice other than by announcement at the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
each meeting of the Board at which a quorum is present, all questions and business shall be determined by a vote of a majority
of the directors present, unless a different vote be required by law, the corporation&rsquo;s Articles of Incorporation or these
Amended and Restated Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
member of the Board of Directors, or of any committee thereof, may participate in a meeting by means of conference telephone or
other communication equipment by means of which all persons participating in the meeting can hear each other, and participation
in a meeting by such means shall constitute presence in person at such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
transactions of any meeting of the Board of Directors, or any committee thereof, however called or noticed, or wherever held, shall
be as valid as though had at a meeting duly held after regular call and notice if a quorum be present and if, either before or
after the meeting, each of the directors not present shall sign a written waiver of notice, or a consent to holding such meeting,
or an approval of the minutes thereof. All such waivers, consents or approvals shall be filed with the corporate records or made
a part of the minutes of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 3.7 Action Without Meeting.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless otherwise restricted by the corporation&rsquo;s Articles
of Incorporation or these Amended and Restated Bylaws, any action required or permitted to be taken at any meeting of the Board
of Directors or of any committee thereof may be taken without a meeting, if all members of the Board or of such committee, as the
case may be, consent thereto in writing or by electronic transmission, and such writing or writings or electronic transmission
or transmissions are filed with the minutes of proceedings of the Board or committee. Such filing shall be in paper form if the
minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 3.8 Fees and Compensation.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Directors and members of committees may receive such compensation,
if any, for their services, and such reimbursement for expenses, as may be fixed or determined by resolution of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 3.9 Committees.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Other
Committees:</B> The Board of Directors may, from time to time, appoint such committees as may be permitted by law. Such other committees
appointed by the Board of Directors shall have such powers and perform such duties as may be prescribed by the resolution or resolutions
creating such committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Term:</B>
The terms of members of all committees of the Board of Directors shall expire on the date of the next annual meeting of the Board
of Directors following their appointment; <U>provided</U>, that they shall continue in office until their successors are appointed.
The Board of Directors, subject to the provisions of subsection (a) of this Section 3.9, may at anytime increase or decrease the
number of members of a committee or terminate the existence of a committee; <U>provided</U>, that no committee shall consist of
less than two members. The membership of a committee member shall terminate on the date of his death or voluntary resignation,
but the Board may at any time for any reason remove any individual committee member and the Board may fill any committee vacancy
created by death, resignation, removal or increase in the number of members of the committee. The Board of Directors may designate
one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of
the committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Meetings:</B>
Unless the Board of Directors shall otherwise provide, regular meetings of the committees appointed pursuant to this Section 3.9
shall be held at such times and places as are determined by the Board of Directors, or by any such committee, and when notice thereof
has been given to each member of such committee, no further notice of such regular meetings need be given thereafter; special meetings
of any such committee may be held at the principal office of the corporation required to be maintained pursuant to Section 1.2
of Article I hereof; or at any place which has been designated from time to time by resolution of such committee or by written
consent of all members thereof, and may be called by any director who is a member of such committee upon written notice to the
members of such committee of the time and place of such special meeting given in the manner provided for the giving of written
notice to members of the Board of Directors of the time and place of special meetings of the Board of Directors. Notice of any
special meeting of any committee may be waived in writing at any time after the meeting and will be waived by any director by attendance
thereat. A majority of the authorized number of members of any such committee shall constitute a quorum for the transaction of
business, and the act of a majority of those present at any meeting at which a quorum is present shall be the act of such committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE IV<BR>
OFFICERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 4.1 Officers Designated.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The officers of the corporation shall be a President, a Secretary
and a Treasurer. The Board of Directors may also appoint a Chairman of the Board, a chief executive officer, chief financial officer,
one or more Vice-Presidents, assistant secretaries, assistant treasurers, and such other officers and agents with such powers and
duties as the Board of Directors or the President shall deem appropriate or necessary. The order of the seniority of the Vice-
Presidents shall be in the order of their nomination unless otherwise determined by the Board of Directors. The Board of Directors
may assign such additional titles to one or more of the officers as they shall deem appropriate. Any one person may hold any number
of offices of the corporation at any one time unless specifically prohibited therefrom by law. The salaries and other compensation
of the officers of the corporation shall be fixed by or in the manner designated by the Board of Directors, or a committee thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 4.2 Tenure and Duties of Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>General:</B>
All officers shall hold office at the pleasure of the Board of Directors and until their successors shall have been duly elected
and qualified, unless sooner removed. Any officer may be removed at any time by the Board of Directors. If the office of any officer
becomes vacant for any reason, the vacancy may be filled by the Board of Directors. Nothing in these Amended and Restated Bylaws
shall be construed as creating any kind of contractual right to employment with the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Duties
of the Chairman of the Board of Directors:</B> The Chairman of the Board of Directors (if there be such an officer appointed) when
present shall preside at all meetings of the shareholders and the Board of Directors. The Chairman of the Board of Directors shall
perform such other duties and have such other powers as the Board of Directors shall designate from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Duties
of President:</B> The President shall be the chief executive officer of the corporation and, in the absence of the Chairman of
the Board, and shall preside at all meetings of the shareholders and at all meetings of the Board of Directors, unless the Chairman
of the Board of Directors has been appointed and is present. The President shall perform such other duties and have such other
powers as the Board of Directors shall designate from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Duties
of Vice-Presidents:</B> The Vice-Presidents, in the order of their seniority, may assume and perform the duties of the President
in the absence or disability of the President or whenever the office of the President is vacant. The Vice-President shall perform
such other duties and have such other powers as the Board of Directors or the President shall designate from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Duties
of Secretary:</B> The Secretary shall attend all meetings of the shareholders and, if invited, of the Board of Directors and each
committee thereof, and shall record all acts and proceedings thereof in the minute book of the corporation, which may be maintained
in either paper or electronic form. The Secretary shall give notice, in conformity with these Amended and Restated Bylaws, of all
meetings of the shareholders and of all meetings of the Board of Directors and any Committee thereof requiring notice. The Secretary
shall perform such other duties and have such other powers as the Board of Directors shall designate from time to time. The President
may direct any assistant secretary to assume and perform the duties of the Secretary in the absence or disability of the Secretary,
and each assistant secretary shall perform such other duties and have such other powers as the Board of Directors or the President
shall designate from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Duties
of Treasurer:</B> The Treasurer shall keep or cause to be kept the books of account of the corporation in a thorough and proper
manner, and shall render statements of the financial affairs of the corporation in such form and as often as required by the Board
of Directors or the President. The Treasurer, subject to the order of the Board of Directors, shall have the custody of all funds
and securities of the corporation. The Treasurer shall perform all other duties commonly incident to his office and shall perform
such other duties and have such other powers as the Board of Directors or the President shall designate from time to time. The
President may direct any assistant treasurer to assume and perform the duties of the Treasurer in the absence or disability of
the Treasurer, and each assistant treasurer shall perform such other duties and have such other powers as the Board of Directors
or the President shall designate from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE V<BR>
EXECUTION OF CORPORATE INSTRUMENTS, AND<BR>
VOTING OF SECURITIES OWNED BY THE CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 5.1 Execution of Corporate Instruments.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board of Directors may in its discretion determine the method and designate the signatory officer or officers, or other person
or persons, to execute any corporate instrument or document, or to sign the corporate name without limitation, except where otherwise
provided by law, and such execution or signature shall be binding upon the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
otherwise specifically determined by the Board of Directors or otherwise required by law, formal contracts of the corporation,
promissory notes, deeds of trust, mortgages and other evidences of indebtedness of the corporation, and other corporate instruments
or documents requiring the corporate seal, and certificates of shares of stock owned by the corporation, shall be executed, signed
or endorsed by the Chairman of the Board (if there be such an officer appointed) or by the President; such documents may also be
executed by any Vice-President and by the Secretary or Treasurer or any assistant secretary or assistant treasurer. All other instruments
and documents requiring the corporate signature but not requiring the corporate seal may be executed as aforesaid or in such other
manner as may be directed by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
checks and drafts drawn on banks or other depositaries on funds to the credit of the corporation or in special accounts of the
corporation shall be signed by such person or persons as the Board of Directors shall authorize so to do.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Execution
of any corporate instrument may be effected in such form, either manual, facsimile or electronic signature, as may be authorized
by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 5.2 Voting of Securities Owned by Corporation.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All stock and other securities of other corporations owned or
held by the corporation for itself or for other parties in any capacity shall be voted, and all proxies with respect thereto shall
be executed, by the person authorized so to do by resolution of the Board of Directors or, in the absence of such authorization,
by the Chairman of the Board (if there be such an officer appointed), or by the President, or by any Vice-President.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE VI<BR>
SHARES OF STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 6.1 Form and Execution of Certificates.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shares of stock of the corporation shall be represented by certificates,
or shall be uncertificated shares that may be evidenced by a book-entry system maintained by the registrar of such stock, or a
combination of both. To the extent that shares are represented by certificates, such certificates shall be in a form approved by
the Board of Directors. Each certificate shall be signed in the name of the corporation by (A) the Chairman or Vice Chairman of
the Board or the President or a Vice President and (B) the Secretary or an Assistant Secretary or the Treasurer or an Assistant
Treasurer, and sealed with the seal of the corporation (which seal may be a facsimile, engraved or printed); <U>provided</U>, <U>however</U>,
that where any such certificate is countersigned by a transfer agent other than the corporation or one of its employees, or is
registered by a registrar other than the corporation or one of its employees, the signature of the officers of the corporation
upon such certificates may be facsimiles, engraved or printed. In case any officer who shall have signed or whose facsimile signature
has been placed upon such certificates shall have ceased to be such officer before such certificates shall be issued, they may
nevertheless be issued by the corporation with the same effect as if such officer were still in office at the date of their issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 6.2 Lost Certificates.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors may direct a new certificate or certificates
(or uncertificated shares in lieu of a new certificate) to be issued in place of any certificate or certificates theretofore issued
by the corporation alleged to have been lost or destroyed, upon the making of an affidavit of that fact by the person claiming
the certificate of stock to be lost or destroyed. When authorizing such issue of a new certificate or certificates (or uncertificated
shares in lieu of a new certificate), the Board of Directors may, in its discretion and as a condition precedent to the issuance
thereof, require the owner of such lost or destroyed certificate or certificates, or his legal representative, to indemnify the
corporation in such manner as it shall require and/or to give the corporation a surety bond in such form and amount as it may direct
as indemnity against any claim that may be made against the corporation with respect to the certificate alleged to have been lost
or destroyed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 6.3 Transfers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to any restrictions on transfer and unless otherwise
provided by the Board of Directors, shares of stock may be transferred only on the books of the corporation by the surrender to
the corporation or its transfer agent of shares in certificated form, properly endorsed or accompanied by a written assignment
or power of attorney properly executed, with transfer stamps (if necessary) affixed, or upon proper instructions from the holder
of uncertificated shares, in each case with such proof of the authenticity of signature as the corporation or its transfer agent
may reasonably require. Except as otherwise provided by applicable law, the corporation shall be entitled to recognize the exclusive
right of a person in whose name any share or shares stand on the record of shareholders as the owner of such share or shares for
all purposes, including, without limitation, the rights to receive dividends or other distributions and to vote as such owner,
and the corporation may hold any such shareholder of record liable for calls and assessments and the corporation shall not be bound
to recognize any equitable or legal claim to or interest in any such share or shares on the part of any other person whether or
not it shall have express or other notice thereof. Whenever any transfers of shares shall be made for collateral security and not
absolutely, and both the transferor and transferee request the corporation to do so, such fact shall be stated in the entry of
the transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 6.4 Registered Shareholders.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The corporation shall be entitled to recognize the exclusive
right of a person registered on its books as the owner of shares to receive dividends and to vote as such owner, and shall not
be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any other person, whether
or not it shall have express or other notice thereof, except as otherwise provided by the laws of the State of Florida.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE VII<BR>
OTHER SECURITIES OF THE CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All bonds, debentures and other corporate securities of the
corporation, other than stock certificates, may be signed by the Chairman of the Board (if there be such an officer appointed),
or the President or any Vice-President or such other person as may be authorized by the Board of Directors and the corporate seal
impressed thereon or a facsimile of such seal imprinted thereon and attested by the signature of the Secretary or an assistant
secretary, or the Treasurer or an assistant treasurer; <U>provided</U>, <U>however</U>, that where any such bond, debenture or
other corporate security shall be authenticated by the manual signature of a trustee under an indenture pursuant to which such
bond, debenture or other corporate security shall be issued, the signature of the persons signing and attesting the corporate seal
on such bond, debenture or other corporate security may be the imprinted facsimile of the signatures of such persons. Interest
coupons appertaining to any such bond, debenture or other corporate security, authenticated by a trustee as aforesaid, shall be
signed by the Treasurer or an assistant treasurer of the corporation, or such other person as may be authorized by the Board of
Directors, or bear imprinted thereon the facsimile signature of such person. In case any officer who shall have signed or attested
any bond, debenture or other corporate security, or whose facsimile signature shall appear thereon has ceased to be an officer
of the corporation before the bond, debenture or other corporate security so signed or attested shall have been delivered, such
bond, debenture or other corporate security nevertheless may be adopted by the corporation and issued and delivered as though the
person who signed the same or whose facsimile signature shall have been used thereon had not ceased to be such officer of the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE VIII<BR>
INDEMNIFICATION OF OFFICERS, DIRECTORS, EMPLOYEES AND AGENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 8.1 Right to Indemnification.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each person who was or is a party or is threatened to be made
a party to or is involved (as a party, witness, or otherwise), in any threatened, pending, or completed action, suit, or proceeding,
whether civil, criminal, administrative, or investigative (hereinafter a &ldquo;Proceeding&rdquo;), by reason of the fact that
he, or a person of whom he is the legal representative, is or was a director, officer, employee, or agent of the corporation or
is or was serving at the request of the corporation as a director, officer, employee, or agent of another corporation or of a partnership,
joint venture, trust, or other enterprise, including service with respect to employee benefit plans, whether the basis of the Proceeding
is alleged action in an official capacity as a director, officer, employee, or agent or in any other capacity while serving as
a director, officer, employee, or agent (hereafter an &ldquo;Agent&rdquo;), shall be indemnified and held harmless by the corporation
to the fullest extent authorized by the Florida Business Corporation Act, as the same exists or may hereafter be amended or interpreted
(but, in the case of any such amendment or interpretation, only to the extent that such amendment or interpretation permits the
corporation to provide broader indemnification rights than were permitted prior thereto) against all expenses, liability, and loss
(including attorneys&rsquo; fees, judgments, fines, ERISA excise taxes or penalties, and amounts paid or to be paid in settlement,
and any interest, assessments, or other charges imposed thereon, and any federal, state, local, or foreign taxes imposed on any
Agent as a result of the actual or deemed receipt of any payments under this Article) reasonably incurred or suffered by such person
in connection with investigating, defending, being a witness in, or participating in (including on appeal), or preparing for any
of the foregoing in, any Proceeding (hereinafter &ldquo;Expenses&rdquo;); <U>provided</U>,<U> however</U>, that except as to actions
to enforce indemnification rights pursuant to Section 8.3 of this Article, the corporation shall indemnify any Agent seeking indemnification
in connection with a Proceeding (or part thereof) initiated by such person only if the Proceeding (or part thereof) was authorized
by the Board of Directors of the corporation. The right to indemnification conferred in this Article shall be a contract right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 8.2 Authority to Advance Expenses.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Expenses incurred by an officer or director (acting in his capacity
as such) in defending a Proceeding shall be paid by the corporation in advance of the final disposition of such Proceeding; <U>provided</U>,
<U>however</U>, that if required by the Florida Business Corporation Act, such Expenses shall be advanced only upon delivery to
the corporation of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined
that he is not entitled to be indemnified by the corporation as authorized in this Article or otherwise. Expenses incurred by other
Agents of the corporation (or by the directors or officers not acting in their capacity as such, including service with respect
to employee benefit plans) may be advanced upon such terms and conditions as the Board of Directors deems appropriate. Any obligation
to reimburse the corporation for Expense advances shall be unsecured and no interest shall be charged thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 8.3 Right of Claimant to Bring Suit.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If a claim under Section 8.1 or 8.2 of this Article is not paid
in full by the corporation within 30 days after a written claim has been received by the corporation, the claimant may at any time
thereafter bring suit against the corporation to recover the unpaid amount of the claim and, if successful in whole or in part,
the claimant shall be entitled to be paid also the expense (including attorneys&rsquo; fees) of prosecuting such claim. The burden
of proving such a defense shall be on the corporation. Neither the failure of the corporation (including its Board of Directors,
independent legal counsel, or its shareholders) to have made a determination prior to the commencement of such action that indemnification
of the claimant is proper under the circumstances because he has met the applicable standard of conduct set forth in the Florida
Business Corporation Act, nor an actual determination by the corporation (including its Board of Directors, independent legal counsel,
or its shareholders) that the claimant had not met such applicable standard of conduct, shall be a defense to the action or create
a presumption that claimant has not met the applicable standard of conduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 8.4 Provisions Nonexclusive.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The rights conferred on any person by this Article shall not
be exclusive of any other rights that such person may have or hereafter acquire under any statute, provision of the corporations&rsquo;
Articles of Incorporation or any agreement, vote of shareholders or disinterested directors or otherwise, both as to action in
an official capacity and as to action in another capacity while holding such office. To the extent that any provision of the corporation&rsquo;s
Articles of Incorporation or any agreement, or vote of the shareholders or disinterested directors is inconsistent with these Amended
and Restated Bylaws, the provision, agreement or vote shall take precedence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 8.5 Authority to Insure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The corporation may purchase and maintain insurance to protect
itself and any Agent against any Expense, whether or not the corporation would have the power to indemnify the Agent against such
Expense under applicable law or the provisions of this Article.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 8.6 Survival of Rights.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The rights provided by this Article shall continue as to a person
who has ceased to be an Agent and shall inure to the benefit of the heirs, executors, and administrators of such a person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 8.7 Effect of Amendment.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any amendment, repeal, or modification of this Article shall
not adversely affect any right or protection of any Agent existing at the time of such amendment, repeal, or modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 8.8 Subrogation.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event of payment under this Article, the corporation
shall be subrogated to the extent of such payment to all of the rights of recovery of the Agent, who shall execute all papers required
and shall do everything that may be necessary to secure such rights, including the execution of such documents necessary to enable
the corporation effectively to bring suit to enforce such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 8.9 No Duplication of Payments.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The corporation shall not be liable under this Article to make
any payment in connection with any claim made against the Agent to the extent the Agent has otherwise actually received payment
(under any insurance policy, agreement, vote, or otherwise) of the amounts otherwise indemnifiable hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 8.10 Indemnification and Insurance under Israeli
Securities Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to the Florida Business Corporation Act, the corporation
may indemnify and insure any office holder of the corporation from and against any payment which the office holder is obligated
to make to an injured party as set forth in Section 52(54)(a)(1)(a) of the Israeli Securities Law, 5278-1968, as amended (&ldquo;Israeli
Securities Law&rdquo;) and from and against reasonable litigation expenses, including attorneys&rsquo; fees, that an office holder
may incur in connection with a proceeding under Chapters H&rsquo;3, H&rsquo;4 or I&rsquo;1 of the Israeli Securities Law. Subject
to the Florida Business Corporation Act, the corporation is permitted to provide an office holder advanced payments to cover expenses
covered under this Section 8.10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE IX<BR>
FISCAL YEAR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fiscal year of the corporation shall begin on the first
day in January of each calendar year and end on the last day of each December following.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE X<BR>
NOTICES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Whenever, under any provisions of these Amended and Restated
Bylaws, notice is required to be given to any shareholder, the same shall be given either (1) in writing, timely and duly deposited
in the mail, postage prepaid, and addressed to his last known post office address as shown by the stock record of the corporation
or its transfer agent, or (2) by a means of electronic transmission that satisfies the requirements of Section 2.4(e) of these
Amended and Restated Bylaws, and has been consented to by the shareholder to whom the notice is given. Any notice required to be
given to any director may be given by either of the methods hereinabove stated, except that such notice other than one which is
delivered personally, shall be sent to such address or (in the case of electronic communication) such e-mail address, facsimile
telephone number or other form of electronic address as such director shall have filed in writing or by electronic communication
with the Secretary of the corporation, or, in the absence of such filing, to the last known post office address of such director.
If no address of a shareholder or director be known, such notice may be sent to the principal office of the corporation. An affidavit
of mailing, executed by a duly authorized and competent employee of the corporation or its transfer agent appointed with respect
to the class of stock affected, specifying the name and address or the names and addresses of the shareholder or shareholders,
director or directors, to whom any such notice or notices was or were given, and the time and method of giving the same, shall
be conclusive evidence of the statements therein contained. All notices given by mail, as above provided, shall be deemed to have
been given as at the time of mailing and all notices given by means of electronic transmission shall be deemed to have been given
as at the sending time recorded by the electronic transmission equipment operator transmitting the same. It shall not be necessary
that the same method of giving notice be employed in respect of all directors, but one permissible method may be employed in respect
of any one or more, and any other permissible method or methods may be employed in respect of any other or others. The period or
limitation of time within which any shareholder may exercise any option or right, or enjoy any privilege or benefit, or be required
to act, or within which any director may exercise any power or right, or enjoy any privilege, pursuant to any notice sent him in
the manner above provided, shall not be affected or extended in any manner by the failure of such a shareholder or such director
to receive such notice. Whenever any notice is required to be given under the provisions of the statutes or of the corporation&rsquo;s
Articles of Incorporation, or of these Amended and Restated Bylaws, a waiver thereof in writing signed by the person or persons
entitled to said notice, or a waiver by electronic transmission by the person entitled to notice, whether before or after the time
stated therein, shall be deemed equivalent thereto. In the event that the action taken by the corporation is such as to require
the filing of a certificate under any provision of the Florida Business Corporation Act, the certificate shall state, if such is
the fact and if notice is required, that notice was given to all persons entitled to receive notice except such persons with whom
communication is unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE XI<BR>
AMENDMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors shall have the authority to repeal, alter
or amend these Amended and Restated Bylaws or adopt new Bylaws (including, without limitation, the amendment of any Amended and
Restated Bylaws setting forth the number of directors who shall constitute the whole Board of Directors) by unanimous written consent
or at any annual, regular, or special meeting by the affirmative vote of a majority of the whole number of directors, subject to
the power of the shareholders to change or repeal such Bylaws and provided that the Board of Directors shall not make or alter
any Bylaws fixing the qualifications, classifications or term of office of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>v334254_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><img src="tlogoex23-1.jpg"></TD>
    <TD STYLE="width: 50%; font-weight: bold; text-align: right"><B>Exhibit 23.1</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hereby consent to the incorporation by reference in the Registration
Statement on Form S-3 (No. 333-171615) and the Registration Statements on Form S-8 (No. 333-148983 and No. 333-182677) of Protalix
BioTherapeutics, Inc. of our report dated February 28, 2013 relating to the financial statements and the effectiveness of internal
control over financial reporting, which appears in this Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Kesselman &amp; Kesselman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kesselman &amp; Kesselman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certified Public Accountants (lsr.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A member firm of PricewaterhouseCoopers International Limited</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tel-Aviv, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">February 28, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Kesselman &amp; Kesselman, Trade Tower, 25 Hamered Street,
Tel-Aviv 68125, Israel, P.O Box 452 Tel-Aviv 61003 Telephone:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>+972 -3- 7954555, Fax:+972 -3- 7954556, www.pwc.co.il</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>v334254_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, David Aviezer, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">1.</TD><TD>I have reviewed this Annual Report on Form 10-K of Protalix BioTherapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">4.</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)<FONT STYLE="font-weight: normal">) </FONT>for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">5.</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">Dated: February 28, 2013</TD>
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: windowtext 1pt solid; font-size: 10pt">/s/ David Aviezer</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>David Aviezer, Ph.D.</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>President and Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>v334254_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.2 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Yossi Maimon, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">1.</TD><TD>I have reviewed this Annual Report on Form 10-K of Protalix BioTherapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">4.</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)<FONT STYLE="font-weight: normal">) </FONT>for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">5.</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">Dated: February 28, 2013</TD>
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: windowtext 1pt solid; font-size: 10pt">/s/ Yossi Maimon</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Yossi Maimon</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Chief Financial Officer, Treasurer </TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>v334254_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CERTIFICATION </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Annual Report of Protalix BioTherapeutics,
Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the period ended December&nbsp;31, 2012 as filed with the Securities and Exchange
Commission (the &ldquo;Report&rdquo;), I, David Aviezer, President and Chief Executive Officer of the Company, hereby certify as
of the date hereof, solely for purposes of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that to the best
of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(1) the Report fully complies with the requirements
of Section&nbsp;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(2) the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">This Certification has not
been, and shall not be deemed, &ldquo;filed&rdquo; with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">Dated: February 28, 2013</TD>
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: windowtext 1pt solid; font-size: 10pt">/s/ David Aviezer</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>David Aviezer, Ph.D.</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>President and Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>v334254_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.2 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CERTIFICATION </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Annual Report of Protalix BioTherapeutics,
Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the period ended December&nbsp;31, 2012 as filed with the Securities and Exchange
Commission (the &ldquo;Report&rdquo;), I, Yossi Maimon, Vice President and Chief Financial Officer of the Company, hereby certify
as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that to the
best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(1) the Report fully complies with the requirements
of Section&nbsp;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(2) the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">This Certification has not
been, and shall not be deemed, &ldquo;filed&rdquo; with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">Dated: February 28, 2013</TD>
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: windowtext 1pt solid; font-size: 10pt">/s/ Yossi Maimon</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Yossi Maimon</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Vice President and Chief Financial Officer</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tlogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlogo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`1P!=`P$1``(1`0,1`?_$`:(````&`@,!````````
M``````<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+
M$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,7
M4G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R
M9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8
MF9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1
M``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B
M%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756
M-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>W
MQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:
M``P#`0`"$0,1`#\`W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4)_
MS8.PJO:'=?6U!3XNGKDJ>K35M+-4SPLC?WLS</C"Q(P(M'>_UY]\Q_ON1"3W
M&VDDT_W2#_M*GZZ)_<\V&+=>0=TGDE9"N\%:``_\1H37)^?56W^FW)?\\]0_
M^=U7_P!>O>&?TP]3UEK_`%.MO^4A_P#>5_S]'Z_E^_(_*[=WYO\`F3:=!5FL
MVMAJ<J<I5P^,?QZVL'[2;5?R_2P^GU]Y-_=?YNGY&YEW2\MH%N6N+**,AF*:
M0)JU%`U>/#K';[QOMM9[SR]ML+WDD8CO)&J$4U_2X?$/3K8Y0ZE5B+%E!(_I
M<`V_V'OK0I)4$X-.N8+"C$>AZY>]]:Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[K5L_GK9"OI/D?T_'25U73(W2.MDIZF:%&?^_>YUU%8W4%K`"_U
ML/?-#[[`'^N!M9\_W,O_`&DW'75;[AL,4GMGO!D56/[]/$`_\1+?UZI(_C69
M_P"=MD__`#OJO^OOO#/K.'Z6V_WW'_O(_P`W1C_C9N;<E'N/<;TFX,W2NV(H
M`S4V5KX&8+DT90S13J2`PN/\?9#OVZ;GM4,<NUW,]M*SD,8I'C)`%0"4()`.
M0#YYZ`//^V[=<6$"W%O#(HE:FI%:G8?4'J]O_2AV8(+CL/>X(A%K;JS?'[8^
MG^6^XOF]XO=U8GT\U<R"BG_EIWOI_P`UNL(1RERH9,[9MWQ?\H\/K_I.KE?O
M:S_0[_$?NZG^(?Z-/O?OO/)]W]Y_=;S_`'?W.KS?<^;UZ[ZM7-[^_H$_>%__
M`,#W^]?'F_>G]3/%\;6WB^+^[=?B^)77XFOOUUU:NZM<]8)>!!_7SZ70GTW[
MWTZ*#3I^HIIT\--,4I2F.'0E^YEZ"/7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW6GG_`,*+.R*+9GRJZ.Q]5F:G&O5?'U:Q88*2>=9%_P!(V[X/(7B@E`:\
M5K$@\>\"?O8<L7.]\Y;?<PP)*J;8BU+`4_7N#3)'KUU7^X9!=R^V>\-;_`-]
M-<@9^DM_7JA+;W>>WILO21UVYJZ6E;S>6-\96LK6@E*7"T@;AP#Q[Q)W#D+=
M([1WAM8Q(*4.M/4?TNLZ;;;MRFF6.E:^6H?Y^C@=#]^=68?.9V;(;@J88YL9
M1QQD83,2W=:]7(M%1L1Z1^?<;<R<@<U7=O$L%NI(<D_JQC\/S;HIYMY2W[<+
M2*.TA5G5V)[T&"M/-AU;^?F5\=_#;^^M??Q6M_=/<_UT6_YUG]?<'S^T7/QB
M>EFGPG_1X?0_T^L75]G?<+Q`?HDIJ_W_``^O^GZN.'\P[XFGIXT'^D7(?<+U
MLM"4_N1O6_W#[5>)4U?P'Q\LAYU:?\??T'_U=W;_`('G]W>&/K/ZEZ-.I?B_
M=E*5K3CY\.L(/^!M]X/Z\_6?NV+P/WMKK]5:_#]16M/%KP^5?EU99[E;K%;K
MWOW7NO>_=>Z][]U[KWOW7NBD=G?/7X7=+;WS/6O;/R>Z6Z[W_MX8]LYL_=N^
M\)AMP8E<MC:3,8TUV-JZF.HIQ78NNAJ(M0&N*56'!'L.7W-_+&V73V.X7]M#
M=I34CN`PJ`PJ#PJI!^PCJ2N7_9OW5YJVF+?N6^7]UOMFGU>'-#;N\;Z&*-I8
M"ATNK*?0@CRZ07_#I'\NC_O-/XY_^C.VW_\`5GM)_7[DO_HYV7_.1?\`/T<_
M\#U[X_\`3*;Y_P!DLO\`FZUH/YV?7&__`.8Q\@^H^V_@?M',?+7K'9?33]=[
MMWWT8M+OG;6WM]4^^-P[CGVGE<GCJHPTN<BP.>HJMH#ZA!51M]&'N"?=7;KO
MGC=X-PY20W]E%;+&[P@R*L@>5BA*@T8*Z-0^3`^?6>WW4-[V?V.Y(W+EOWAN
M8N6]_N]U^IAM]P)MY9;<V\40F1'%3&9(Y$U<-2,/+JGK#_RN?YC,.0@DE^%G
MR!CC42ZG?9,P47B<"Y^Y_)/N(;[VUYX>V94VV[+&F!$_J/Z/65UA]X?V*CNU
M=^;-D"BN3<#T/RZ&[8W\M;^8!05M;)6_#[O6F22FB5&FV=(@9EG#$`FIY(7G
MV$K[VM]PS&OA[/?.:^43>GS`Z/+C[QWL(Z@+S?L7_92/\W1L_P#9!?FSHM_L
MKG<=]/\`SR[?T_ZB?85D]IO<XHP&P[E6A_T(_P"?H+C[P?L;7_E;-D_[*!_F
MZ.DOP[^57]R):'_0!V;]Z=M04PI?X#^\:A<)40-"%^X_S@F8+;^I]]3M#?ZU
MO[JH?WE_5WP?"_'XOT6CPZ?Q:^VGKCJ&C[T^T?[[$_\`6/:?!^I+:O&%*>(#
M7APIGK;E]J^N-/7O?NO=>]^Z]U[W[KW7O?NO=4L?+7^17\3?F1W_`+Y^1G9N
M^^]\-O7?\>VH\QC=F;HV;CMN4Z[6VMA]I8_^'T>5V%FJ^(RX["1/+KJ9-4S,
M1I4A1%G,?M)R[S/O$V]7TUVEU-IU!&C"C2BH*!HV/!17)S7K*KVV^]Y[C^U_
M)EGR/L%GL\NU67BZ&GBG:4^+,\S:F2XC4T:0@44=M`:G/1<?^@8[X(_\_/\`
MD_\`^AKUY_\`:N]D?^L+RE_RD7W^]1?]:>AU_P`'W[O_`/1OY?\`^<%S_P!M
M?5JWP0^!/4/\O?K#=/5'36?W]N';V[=]5?8&1J^P\KA<MEH<Q68+![?EIZ2?
M![?V[31X]:/`0L$:%W\C.=9!`$A\H<G[;R782;?MCS/#+-XA,A4G5I5*#2JB
ME%'EQKGK'7WA]Y.9O>O?[;F+FB&R@O;:S%LHMDD1"@DDD!8222DMJD85#`4`
MQYD[_L6=1+U[W[KW7O?NO=>]^Z]U1#\JO^%)_P#*`^*,E7B\M\HL5WENVCF>
M&3:'QEQC]S51DB;1,AWAAZJCZMIY87N&CFW!%*""--Q[]U[H/^]/^%17\HGH
M?`=;Y/*]P[Q[$W'V+L;9N_Y>O.H=FT^_-V]>XO>VW\7N/'X;LNNI,_2;"VUO
M+%4F56+)89,W59&@J8I(Y(@0"WNO=6#_`!N_FQ_R_OE/\7MU_,3K/Y(;$QW1
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MWK/0;5WUD>MJVEIMERD5YKZS>.-:EI@[I"ZNDSR)"3(ONO=);^7Q_.`^$O\`
M,IZ7[3[RZ&WQF=J[5Z.KQ2]QX[NK&XOKG-=;8^;%5N<Q^Y]TSOG<QM:EVED\
M5BZR:+(QY.6G04-0LIB>%U'NO=$"WU_PJ;_E<X/?F[=A=31_)[Y65.Q,)N#<
MV[]R?&7H/)[YVE@ML[3IVJ]T;JJ<MN3/;)FGVAM^D1IJK,P02XJ.!3+]P8B'
M/NO=64?R]?YJWPF_F?;0W'N?XE]J-N?*;(./&_NNMT86NV?V7L=<L:A<559W
M:V3&J?$Y)Z25(<C035N.DEC>(3^5&0>Z]U8M[]U[KWOW7NO>_=>Z^5G_`,*Z
M_C_T3\<_YA?2&R_C]TSU;TAM#)_$39^XLEM?J78>V.O=OY#/U/;?<>/J,W6X
M?:F,Q6/J<M/08VG@>H:,RM#!&A8A%`]U[K9Y[%_DW_R^OD)_((V%N^/XO]+=
M==XX7^6YL3O/:_>/7O7^WME]C0]K[>^.V'['DSNY-T;=HL=E-VT>[]P4#IFX
M,G)5QUD59-)9:@131^Z]UJ__`/"1?<"Y[^8]V+\:]Y[7P'8_17R*^-6^:+MG
MK'>^WL3O#8&X:CK/.[8WOL;.[DVMGZ/(83)U&W<K#44]&]1!((6R<FD!G!'N
MO=-W8&Q.NNGO^%9^T-D==;1V=UAUOLO^8_T`N%VIM#"XC:&R]J8>*MZ[RE<,
M;AL33T&&PF,BDEFJ)1%'%"A9W(`N??NO=0?^%$_RH[@_F7[PSGS<VI5F#^7I
MT3\@ZWX._%.2>HJ8XNTM[4VT<SV!V]W)@*)HDAJL=GYMMT"&L.@_PR7$TP7S
MT]9I]U[JXS$]U]==:?\`",_J[K7=&;*]C?)?%=@=)=%["Q5)/F-W]D]CY;YA
M[US4>"VU@*%9<A7_`&6(Q$]14RHA2(!([F>>GBE]U[JIC^8G\/>X_P"3'_)F
M^.?QMW)E*_;?>7\S+N+*]O\`R_H<56/&N"V7T)M3;L_5GQPK:NDE-)DZ';N8
M[/\`XSFRA99<]$\*234D$3R^Z]U?3_PE_P#A)UKW1_(S^7N#PE5B]H=I_-C-
M?([H??';,6$@SNX-M;=GZVI.N]HXN6D-5C)LAA=J'<M9F(\=]U`D\V2E)D4R
M!D]U[HY/\AG_`(3M;S_E%=]=Q_(3LWY)X#M_<>^NLZGI_:FUM@;7SFVMN4>V
M<CNW;>[LGN3=,^=R,]37[@DJMI44-)20Q&GHD>H8SSM(GB]U[K:;]^Z]U[W[
MKW7O?NO=?,0_X6H_]O,>@_\`Q2S9/_OYN\/?NO=61]G_`,W#Y:]M_P`HSI3^
M7_\`!/\`E@?S#=P]M=C?#/J3XZ;B[QW?\=]UX7JZAV?5]18#8V]-V=6Y?!1[
MB7>-%O#`15:8?*U<N'HZ>EK8Z[5(T8A/NO='A_X3(?R(NU?Y<5-O_P"6_P`N
M\?B]O_);MS94'7NS.K:#)8[/5'3_`%C79/%[DW#_`'KS6*J*W#3[\WEE\+CA
M)34,\\6+HJ'QM/)-53PTWNO=:S/\T+^6K\Z?EU_/^^1VT^D^B^\,+A^Y/DE@
M<-M[OB3K;L/%]5[:V_7;+VI2[@W]7=D4^'IL"NV=MX>&LJ*F2"M+SI`T$.N9
MTC;W7NKPO^%*_P#+HK^D?Y2'\OCX=_"SH_LSLO;/0W>M)CY,9UEU[N3?>YZT
M'J?L%MR]B[PH=FXC*SPY3>N\,G/7Y"J=$@>OKF5-(*(/=>Z>/^$V?\I_Y!;L
MV[\=_F1_,3V]N?";>^(.`WEUU_+R^,?8>VJ_;,O7$VX=_P"Y=[]A?(/=>R<W
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M@[#V[N"I?)9CK3*S9=J;'Y1EC6KFI)[(H7W[KW7T`/Y'WRG7Y&?`7X[[8D^/
M?RDZ+KNBOCK\;^NJG)_(GIS,]9[8[6BHNJ<3BZ+?G1>YZ^HJ<9V?UUEJ?;WW
M4&1HRFBFK*4NBB>,M[KW5P_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
0NO>_=>Z][]U[KWOW7NO_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tlogoex23-1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlogoex23-1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`2P!D`P$1``(1`0,1`?_$`:(````&`@,!````````
M``````<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+
M$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,7
M4G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R
M9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8
MF9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1
M``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B
M%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756
M-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>W
MQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:
M``P#`0`"$0,1`#\`W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=`O\
MCLB</\?^[,JJR.V-ZJW[7*L4AAD8TNV,G.%CE`)C<E.&_!Y]QY[MEA[6\QE"
M5?\`<E[0C!!^GDR".AU[86XN_<?8;4TI)O%HN14=T\8R/,9X=:J"_(.KTC_(
M,W]!_P`Q!)_3_EC[XCB?<:#_`!F;_>W_`.@NNOQY`MZGO@_YPC_/UW_LP=7_
M`,J&;_\`0@D_Z\^]^/N/_*3-_O;_`/076OZ@V_\`'!_SA'^?J^/X#]]QYOK#
MJW8<N`KC59M=SUW\9J,NE0(%DR6<RZQ/`U+YI2B1^._D`_/TX]]-/NO<]^!R
M9LW)$\$DEQ(;E_',E1W233`%2"QH.WXOG\NN>GWBO;QK3FO=^94N8Q#!X"^$
M(R*T2*.H(:@J3JX?+Y]69^\QNL4^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[HN/S#FEI_B?\E:B"1HIH>BNU)8I4MJCDCV5FF1UN"-2L+CW
M'GNW_P!.MYC_`.E)>_\`:/)U)7LTJO[N<L(XJIWZP!'R^ICZT44W=N?2O^YR
MO_2/[<?]/^6?OB,*4X#KO0=OL:_V2?LZY?WNW/\`\[RO_P"2X_\`KW[WU[]W
M6/\`OI/V=6X?#'M'L3%T.RSC]X9BD.-VODYJ#Q20?Y)+)530R21!H&`9XJB1
M3>_#GV%-S]U_<CDVX']5=YO;'Z:33%X10:%93J"ZD;!U&M:\>L5O>+E/EJ_:
M\^MLH)/&N4#U![@!4`Y\BH/Y=6=[*[U[BK]Y[0H*WL3<531UVZ=O4=932RTA
MCJ*6JR]'!402`4@)CFA<J;$&Q]B?V[^\O[^[I[@[#MFX\U[M-M]SO5C%+&S1
M:7CDNHD=&I$#1E)4T(-#UC!OWMUR-;;%?7,&UVJ3QV<[*P#55EB8J1W<00".
MKC_??_K!7KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBN?-^L_A_PV
M^55=Y(HOL_CUW!5>2<A88_!L+.R:Y2S*HC73=KD"WL">Z,/U'MMO\`!)?9[Q
M:#B:P2"@^?IU)7LUJ_UW.6-.6_?UA3_LICZ^>6G;'H7_`'-[:_2O_*31_P!!
M_P!-GOCT>4F!H+>Z_P!Y;_H'KO07O*_`W^\GH0=N[WPN3QBU5=N#;Z5!GGC*
MIDZ"%="$!#H:J)N0?K^?9!N&QWUM<F*&WN#'I!RCGC_M>EUO!=RQZ_#D.?)6
M_P`W5L?Q)W]L2BH-MBLWMM"C*;5KT<56Y<-3E7-;<(WEK4LQ'X^ON#>==AWV
M6>8Q65VP,PX0R'R^2]8]^Z&R;U<F?Z:SNI*W*D:8I&J-)SA3CJQ7K[L[K4[^
MV.1V)L0Z=X;:D:V[MOG2D69HI)'/^Y#A(XU+,?H`"3Q[;]J>6.9I/='EI8]N
MOV;]_P"WF@MY2:+=Q,QPG!5!8G@`"3@=8]\R\L\RGES<!^[K^IL9P/\`%Y>)
MB<`?!Q)P/GU>?_IMZ8T>7_2YUAX_)XO)_?[:FCRZ=?CU_P`6T^31S;ZVY]_2
MW]/<5IH>O^E/^;KGE_4/GC5I_<V[:J5I])<5IPK_`&?"OGT)_MGH*=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$Y_F'_\`9!7S/O\`3_97>]+W_P#$:[C]
MACG;_E3MU_Z5]Q_U:;J4/9+_`*?'RK_XL.W_`/:5%U\M]&BT)S'^E?RO]![Y
M]L'U'CQZ^@\AJ\#TOMO-%_#4YC_STWY7_5#V'-R#_5'C\(Z$^U!OHQQ^)O\`
M#T</J/P&FQM_$?\`<3-_J/\`CN/8,W-B'8$_C_R=(]TUA#Q^,=&FZY$']^MK
M<0_\7:'\)_J)/<@>QCG_`%X>7*'_`):2>?\`1?H%<PF3]QW7'^Q/^3JP/13_
M`-V/T0_\?)_J4_YU-OZ>^O?^B?E_EZQ_K+^]/Q?[B_/_`'YUN>>P+UPZZ][]
MU[KWOW7NO>_=>Z][]U[JDS^=E\1/EY\N^K^C-N?$2LJJ/<>SNQMP9[>3TO:$
MG5[-@:W:LV-H0]?'DL:<JHR3#]G4VC]=OS[B_P!T.7N8^8=NMH.7#2XCE8MW
MJF"!3+$>AX9_+K*_[J/N7[9^VG,&[WWN6JM8W5C''!6T^K_468,W;I;1V_BQ
M7AUKL?\`#*W\ZG_G>9C_`-*VJ?\`[*/<)_ZV/NI_'_U73_H+K-W_`(*K[J?^
M^8O^Y./^M73SMO\`DI_SA9-S;87>E349K9O]YMNMN_#9;Y1_QO%9;:L>:H9-
MQ8W)86LW'44F7H*[#I-'-2RQO'41L8V5@UBHM?;'W*^H07M'LRU'4S1D%3@@
MC5D4XCI+?_>K^[$+"X.U*(MT^GD\%TVGPW2;0WA,KK$&1E?25<$%2*@BG6W\
MW\O3X'LQ8_#;XQ`L22%Z/ZY102;^E%V\%4?T```]Y&_U*Y/_`.C7M_\`S@B_
MZ!ZYECWK]X`*?UHW_P#[+[G_`*V=9H_Y?WP8A71%\/OC5&ER=*=+=>JMS]38
M8`"Y]M-R'R4YU/M.W%OG;Q?]`]/)[Y^\\:Z8^:^857T&X70_ZR]/5'\(/AOC
MPJT'Q8^/U$J(8T%+U)L>`)&3<HHCPBZ5)_'T]L/[=<@O\>R[6?MMH?\`H#JK
M^^/O+)A^:N8"/G?W)_ZR=.U-\/OBE15$-72?&_I"FJ:=Q)!40=8[.BFAD%P'
MCD3$!T8`_4&_M38<B\E[5>Q[CMNT[=;W\+:HY([>)'1AP96505/S!KTS)[S^
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MIQ$>1IDAEJ:!\E@ZVNHEK:>.HC9XB^M%=20`PO[KW3EN+<NW-GX:MW'NW/X3
M:^WL8D4F2SVXLK0X3#8])IXJ:%ZW*9.>FH:1):F9(U,CJ&=U4<D#W[KW7MO[
MFVWNS"TFY-K;@PFY=O5Z324.>V_EJ#,X6MCIY9*>>2DRF.J*FAJ$AGA='*2$
M*Z$&Q!'OW7NDEM/N3J#?N5EP6Q>U>M]Z9N"EFKIL/M/?.V-QY6&BIY8H)ZR7
M'X?*5E7'2P33(CR%`BLZ@D$CW[KW7<O<?44&]H^M)^U.N(>QIITI8M@2[XVQ
M'O:6IDI/XA'3Q[5?*#.O.]!^^$$!8P^NVGGW[KW2NW#N/;VT<)D=R[LSV&VQ
MMS#TYJ\OG]PY2APN$Q=(K*C561RN2GIJ&AIP[@%Y9%6Y`OS[]U[H*L-\F?C?
MN/+8[`;>^072.>SN8K*?'8C"X;M?8>4RV5R%7*L%+08['4.>GK*ZLJ9G"1Q1
M(SNQ``)/OW7NAN]^Z]U[W[KW7O?NO=>]^Z]U\I__`(4_?$[Y1_$7OGI&;O[Y
M]]N_,P]\;5['S^$H]\8FOV?ANL<!M7=6%I:/:.&P%+O?<N!K:2>/,Q/)/%2T
M#224X:1)&LX]U[I(_P`N3^1!\AOYH'\K_LCOKICY1Y#%UO4W<79%!L[XE[GQ
M&X)>O-X;NP.PME9[+[APV<Q6X*NCPV_=X4%918J`MM^8SM2P+-61Q*H3W7NJ
MW_Y2GSP[P_ER?/'I7LK8V8S5#AF[#QG7/</6]8NZ:[!;LV)O#-4.V-ZX?,;.
MVZ[9++9W$1,M=C4AIYZJ++X^F9(I2OA?W7NK!O\`A2-\*.^/@S\@NG\)V]\[
M^\OFF>]MC[V['H,CVZ-RXF38N-3L"H2/:>-PN6W]O*BCH)))8JEHZ>+&P15"
MD+3+9;>Z]U<!'_-;?^73_P`)??A3U-U)N%*#Y8?++:?>VR>KXZ17FRNQ^N_]
M.W9.-[,[3C$*,*#(4-%DQB\))(T3G*UGW4/D^PF4>Z]U3S_PD\DF_P"'K.@V
M\\RF;KWO])PLKC[A7Z>W?(RU%C>9/+&KV8VUJ&^H'OW7N@L^</5_=_<O_"B'
MY.[*^/4N\(.W)?G;V'GMN;DV:M;-N'8]/L[>E9N++;]CJJ99I,?0;`V_AILE
M-426@IJ:D)>R"WOW7N@B_F-?S2OE=_."^4V`V[OOM3,T/3=1V,.N^A>MUBI]
MM[3VOM?=F[*/#87<.\,%MR"BHMP;TRM/]K4Y:OJ(YI5=3!3"&FCA@3W7NAY_
MGM?RB:'^5IWI\<>K^B<9VUO7!93XS[$W9V#W!7XO)283<G?E/N7=.'W[-L^N
MQV+IJ/;F-C3$XZMI<.:JMK<9!6Q^6HEUI(?=>Z^BC_(!W;\I-Z_RGOBMF_F&
M=_R=TKAMXXB6H[1P]9A-^5FPL#OW<N&ZNJ]P4^3HZ++UE1/U_0X\QUM:C5==
M!HJ)9)6D,C^Z]U<I[]U[KWOW7NO>_=>Z^=3_`,+@_P#F>WP!_P#$2]W_`/O8
M[$]^Z]T>3_A+[\NNA?A7_(^^17?OR`[!V[LG9/77R=[2SE='DLK1T^8S=9)U
MMU-#@=M;>Q;RFNRNXMU96-:.@IXHW>:=_P`*KLONO=:.W074W8_\S#^8UMK8
MNPMGRG=ORC^1^7W7D]O[`H\-MVGVIMO=.\LAOC?^4P5/D))-O;>Q6QMHO7UL
M:S.]-3PT80"3TJ_NO=;.'_"VBCCQWR>^"N/A>62*@^.&]:.*29E:9XZ;L*."
M-Y61(T:5ECNQ"@$_@>_=>ZK:_DV_R]]^?S"=O_(SY(?(4;IW!\7?Y>OQ"[A/
M5N"S]0\^U*[LB;9/86^-B=?;?H\E2U%(^V<+N#(9+=.7BHEB;[Z6F,DBFI`?
MW7NJEO@%\U.Q/@%WEDOD=T\(4[>Q75W:&R>M\G44]/6Q[9W+V3LS+;*BWD*"
MMH,EC\I4[3I<S)6P4M3&8)YXD#W4%6]U[KZ)_P#)(_DCCJ'X7]Q?)?Y0P[BW
M=_,%^??3?94NZ.Q<MO&NG[#ZPV3WCM3(346`P&[*J**LVMVCN;^.+7[CS"S5
M%4M:Z4ZSB&"19?=>Z^9_3X;=?QG^1.-Q':.ULU@-W]&]O8M-[[1K(#09NAR_
M7V[J:7-X@1U@A6.J\V*DCC=K1M=6OI-_?NO=?7]VE_/D_E*;Z^,=+\J:_P"7
M_4.V]D18N&LS.QMWYBAB[KVUFI*.FJ:O:-7TU2MDNP,CN.DEJ%@TXRAK::H<
M:J>:6.SGW7NC5?`#^85\<_YE?36Y>^OB[6[ORG66V>U=V=0_QC>6UI=H56:S
MNS\=MW+5>7PV(JZNHR0VYD<;NBDEI'K(Z.L(9EFIH74K[]U[H\?OW7NO>_=>
MZ][]U[KYU7_"X0'_`$Z_`$V-CU-W@`;<$C>&PR0#]+@$?[?W[KW0-_\`"?O_
M`(3X?#3^:;\*MV_(OOW>_>6V][8'O7=/5]!CNMMR[5Q.VVPNV]I;-SL%;646
M;V?N"MJ,I5UN[9!*PJ(X_'3QA44EV;W7NMWO^7Y_)X^`W\LU<YD/B[TY!C-\
M;C-5#E.U-\9"3?/9XQ%9%0)4;8QF\,Q$:_![5FGQZ3R4%'X(9IV+RB0A-/NO
M=`=_-*_D3?%#^;5V+U;V5\B=]=V;5S'4NR\OL?;M#U;N#:>&QE7C<SG/X_4U
M653<&SMRU4U<E5Z$,<L48C^JD\^_=>Z-Q\<_Y<GQT^+/P:K?@'U#C<O@.H,S
MUUOS8.Y,ZD]!_?K<]7V5@<A@-X[[SN73'I0UN]\M3Y`NU2:80HT42)$L,:1#
MW7NJA/BA_P`)0OY:GQ1[_P"M/D#C<QW;W!E>L,M)G\3L3N;.;%W+UWELY%0U
M$.%R>X,!BM@X&7)R;=RLD61I8GF^V-931&6.1`4/NO=;.7OW7NJ)OYC_`/PG
M>_EX_P`RWL!.XNS-M[QZE[FK'B7=G9W2.3PNV<YO^G@@2FISO?'YK`;AP&>R
MU+3P0PQ9&2E%>M-"D!E:)$5/=>ZKGV'_`,(P_P"6+M?,461W9VQ\LNRL=35A
MGJL!GM\;`P5!D:4T513_`&$]7LWK;`9>",54J5`DAJ(Y=<06^AF4^Z]ULN?$
M_P"'WQN^#O4=)T9\6.J\%U%UC2YK);FDV[A)\I7-DMS9F*B@RVXLQE<W7Y/+
MY7,9"#&T\;S3SN5A@BB0)%&B+[KW1E??NO=>]^Z]U[W[KW7QK?Y\WC_X<L^6
M&K_3I?\`V9'OB_\`IG^[_NQ?^_4U_P#0_P"'T?W,U7TVX\?@MZ;>_=>ZM3_X
M2#>+_AP[`6_TZ7_T>]WZ?X5]Y_LO&K^Z^W?^+[K]/]^]%_%J]'C\/]K3[]U[
MKZ?_`+]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
'KWOW7NO_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tpg06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg06.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!!@*>`P$1``(1`0,1`?_$`:(````&`@,!````````
M``````<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+
M$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,7
M4G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R
M9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8
MF9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1
M``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B
M%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756
M-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>W
MQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:
M``P#`0`"$0,1`#\`(9_-%[H[9VC_`#%/F3M_;.^\YA<'B^]]Z4]!BJ&6F%)2
MQRU454XA2:E<J'J9)7(OP9+?CV+=K"_3'&:=1%O>Z7"<PN@K0+_DZ(9_LQW>
MW_/SMS_]3:#^@_Z8O:D0:QJ`%/LZ#4>[7%#4M\1\_F>N_P#9CN]O^?G;G_ZF
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M;]O6&I^1_>XIYV':&Z%812:6$F/X.@V/-"P^O^!]^9`BZ2!7I3;[M<_5V]*_
M&?/HZO\`,/[9[*ZY^9W>>RMC;PRVV-J8/*;,3#8+$FEBQ^/AKNLMDY2I2GBG
MIYI4,U?732O=WN\A-_P$EM%XA:@&/]GI1N^ZW`W*0=W!?/Y=$P_V8[O;_GYV
MY_\`J;0?_47M7],?0?LZ+OWM<>K?MZ]_LQW>W_/SMS_]3:#_`.HO?OICZ#]G
M7OWM<>K?MZ]_LQW>W_/SMS_]3:#_`.HO?OICZ#]G7OWM<>K?MZ]_LQW>W_/S
MMS_]3:#_`.HO?OICZ#]G7OWM<>K?MZ]_LQW>W_/SMS_]3:#_`.HO?OICZ#]G
M7OWM<>K?MZ]_LQW>W_/SMS_]3:#_`.HO?OICZ#]G7OWM<>K?MZ]_LQW>W_/S
MMS_]3:#_`.HO?OICZ#]G7OWM<>K?MZ]_LQW>W_/S]SC_`!\M!Q_ZI>]?3'T'
M[.O?O:X_I?MZ.1M;MOLJI_E[=R=A2[QS3;WPWS&Z(V7BMRN](^4QVUL_TUW/
MF,M@::3[01C'5N6PM-.ZE6<R0(=5N/:2X`^K`QQZ.;?=+DV;-FOY_/HFP^1_
M>OX[/W.1<@$R4`)`)`)'V9L3[7/;ZF+`"A^71.=VN:YU5^WKO_9CN]O^?G;G
M_P"IM!_]1>Z_3'T'[.M?O:X]6_;U[_9CN]O^?G;G_P"IM!_]1>_?3'T'[.O?
MO:X]6_;U[_9CN]O^?G;G_P"IM!_]1>_?3'T'[.O?O:X]6_;U[_9CN]O^?G;G
M_P"IM!_]1>_?3'T'[.O?O:X]6_;U[_9CN]O^?G;G_P"IM!_]1>_?3'T'[.O?
MO:X]6_;U[_9CN]O^?G;G_P"IM!_]1>_?3'T'[.O?O:X]6_;T<GX=]M=F;SI?
ME\^Z=Y9?.OL_X/=X[XVM_$#22#";OP><ZYAQ&X:$Q4J&+(T%/D*A(V;6@$IN
MAX(2W$7ALM0,_P"QT<[9NEP;>X^*@4?Y>B;?[,?WKS;L[='X^LM!?\_7_(_:
MI8PZ:0!^SHG7=KGNKJX^IZ\/D=WM?_F9^YA_B9<>+?['[+CWKZ7U`I]G6OWM
M<CAJK]O2CQO;?RGS>.GS&$SW:N;Q%*)?NLMAMN9#*8NE\$*SU(J\E0X*>AIF
MI8FO*'D4QCEK#W7Z2T'XATHBO]UN<*&_GTFT^2'>;JK+VAN9E<(R,LU`5:.0
M724%:,@Q$#]0X'Y^H]OK:6ND9'6FNKU&*OJU`YR>N_\`9CN]OQV?N8_7_=V/
M/T/_`%!_GZ^ZO:H#^E0K]G33;E<QFAU?MZZ_V8[O;_GYVY_^IM!_]1^]"'0"
M2!P].K1[M<UQJ_;T<J/MOLH_R[*KL8[RS!WTOSEI-C)N?_)!E8]GM\>ZG<+[
M>\WVWA.-?/J:K3HU"7G5;CVDT1O<JC4"$]&HW"XFMS&Q(4T'G]O^3HHN,[Y^
M1F<K8<9@]];[SF3J`YI\9A:-,MD:@11M+(8:#'XRHJI5BBC9V*H0JJ2;>S#Z
M2T&2PZ*X=QO9I?I+4,2/F>I63[J^3>#DJH,YNKLO!ST,=+-7T^9PM1B9\?3U
MLDD-#4UT60PU,U'35T\$B0O)I69XG"7*^TC6=J]4!%2&'_.1TG'\H#^5>KG<
M-VK\)_GTS#Y']Z'3;M#<QUJK+IGQ[`ZRH4:EHRH+,X'U^I']?:E;6T8:ZBC$
MM^TU_P`O53?7IR^H-]IZ[7Y'=ZO].T-S`WL1YJ`E203ZU6B9E%A]3QR/Z^[>
M##'_`&="#\NJ-N-U&:'5GY]<5^2'>A('^E#<_(N/W:`_[R**UQ[T57T'[.J_
MO6YT/\7PGSZ.4O;798_EWOV.=Y9<[X'S?_N/_><FE&67:'^@"//C;ZS"F$)Q
MRYN]3HT:_(;Z[>GV7NJ-,JFE"1_A'1R^Y3R;%`K$@-(`3]IZ*-C.^/D9G*V'
M&8/?.^\UDJC7]MC</1KE<A4^-2\@@H<?C*BJF\<:L[%4(5%)-@/9C]):>;#H
MI3<;LS_1VNHO7U/4G*]U_)O!2U5/G=T]EX*HH$I):ZGS>&GP]1109!VCQ\]9
M!DL-2RTL&0=&6G>0*LS*P345:WA:6AX,*=*3N>Y1G00U1C]G3,?D?WH/KVAN
M8'^AFH/Z$W'^1>H64\BXX]^^DM?4?LZ:>_O'.IM5?SZ]_LQW>IC\@[/W1IO8
M?NT%^?TZK49"%QR`Q#$<VL1?W@0Q_P!G0D_+IIMPNH_XL_/KW^S'][?\_/W0
M?^GM!_\`47OVE<X'`^7RZTNZW.H?%^WHY._NV>S*#X%_%OL&BWGEJ7>6Y_D3
M\KMO;AW)%]J,ME\+M/;_`$7/MK&UDIIFA>EPTVX*PP`*"OW3DD\>RZT"M<D$
M8Z-[O<[CZ53GT/[!T4;%]\?(S.5L6,P6^-^9S)U&O[?&82B&7R51XT,C_;X_
M'8NIK)_'&I9M*'2HN>/9C]):#BPIT6+>W0-+;4WYGJ3DNZODUAI:J#,[J[*P
MM10QTD]?3YK#3XBHHJ>O:2.@J:V'(X>FDI*>OEAD2!Y0BS/$ZH692/>XH+6U
M)8D$/PZU<WVZR*#I:J#Y]-'^S&][?\_/W.!<`-Y:'3=B0+G[+2@.DGD@6!]T
M%C;(2215C7JJ[S>7HU-4%.WS^W_+UT?D;WN!_P`S-W5?4%T^6@U7)L#;[/A2
M""#]"#Q[MX$$>8Z$_9UYMPNHQ4ZOV]='Y']ZC_FJ.YRH(-UEQ[!E!O93]B?U
MC@&W%[^]JJUX#]G51NUS_2_;T<C?O;/9&.^`WQAW[1;QS-/O/<WR0^5.V]P;
MD0THRF9P&U-K]$56WL362&"2$TF)GW#6-``BE34/>]Q[+(`#><!QZ.)]SN!9
M*V:U^?1-_P#9CN]AP.S]SD?U\F/%_P#&WV?'M9],?0?LZ)OWM<>K?MZ]_LQW
M>W_/SMS_`/4V@_\`J+W[Z8^@_9U[][7'JW[>O?[,=WM_S\[<_P#U-H/_`*B]
M^^F/H/V=>_>UQZM^WKW^S'=[?\_.W/\`]3:#_P"HO?OICZ#]G7OWM<>K?MZ]
M_LQW>W_/SMS_`/4V@_\`J+W[Z8^@_9U[][7'JW[>O?[,=WM_S\[<_P#U-H/_
M`*B]^^F/H/V=>_>UQZM^WKK_`&8[O6W/9^Z`.0;24!N""IL?LC8C5?\`V%OS
M[=TJ.V@_9UZ3>+KQ4&:8\ST<KY)]L]C[:Z"_E_9_`;QS.)S78'Q\[*W!O3)4
MII15[ES6-^2O;6UZ#*91I(94EJJ/!8>EIDTZ088%6U[GVF:GC$$"@IY?+HWW
M+=+E;16%:GHFW^S'=[?\_/W/_P!3:"WY_P"F/VKFB#J``,?+HI7=[DPK75Y^
M9Z]_LQW>W_/SMS_]3:#_`.HO;'TQ]!^SK7[VN/5OV]>_V8[O;_GYVY_^IM!_
M]1>_?3'T'[.O?O:X]6_;U[_9CN]O^?G;G_ZFT'_U%[]],?0?LZ]^]KCU;]O7
MO]F.[V_Y^=N?_J;0?_47OWTQ]!^SKW[VN/5OV]>_V8[O:Q/^D_=`X_$E!?\`
MV'^1_7WXQB-*$#CUMMVN:1TU?VH\S\NCD_,WMKLO95=\6HMJ;RRV"7=/P?\`
MC5OC<*8XTD:Y?=VY<#F9]P9^M$M-)JR.5J(%>5ELI(X5?H4D,?B3,H`Q7_)T
M;[[NEP+R/XO[(?X>B;?[,=WM_P`_.W/_`-3:#_ZB]J_ICZ#]G1/^]KCU;]O7
MO]F.[V_Y^=N?_J;0?_47OWTQ]!^SKW[VN/5OV]>_V8[O;_GYVY_^IM!_]1>_
M?3'T'[.O?O:X]6_;U[_9CN]O^?G;G_ZFT'_U%[]],?0?LZ]^]KCU;]O7O]F.
M[V_Y^=N?_J;0?_47OWTQ]!^SKW[VN/5OV]>_V8[O;_GYVY_^IM!_]1>_?3'T
M'[.O?O:X]6_;U/HOD;WJ8<L3V=N8E<4K+^[0<-_&<,E_^`?UTL1_L?>OICZ#
M]G5ANMQ0_%P]?F.C*_S:3_V,M^;/^/?V[_\`H>/Z>T]J53:5EA_M2U#Y^?IT
M;[TQ/,D@-*:?3Y=%PZ[^,7;_`&?M_;NY=MXO;%#C-\;GR6R^MSO+?.U=CUW:
M.\</3PRY3:W6V/W+DJ"HWAEJ"6J@IY1`%@2LJZ>G,OGE2)C.=A!)].F&"@GS
MXJ&S^WHBLH)9-3N!X6HTX#\1'YYZ!V7:FZJ92]1M;<L<?\;JMMBH.!RS4S[B
MHJB6CJMOQ5:T0IJC.4]3`\;TB$SB16`2P!-%E,ATH>ZNG\Z%A_QE6ZL8)E9R
M1V`5X#A4*?YLO6:JV9O.ACEEKME[RH8:=J%*B:MVIN"CB@?*,J8M)Y:C'11P
MOE'<"F#$&H)`CU$\V@N[=F620CPI0-&?-R8T^WO4]/+87GU"0L,K,JR8'``.
M_P!E4(S^8ZQG:.[QDJ+#-M#=J9K)T[5>,PS;8SJY?)4B>3R5>.Q38\9"NIH_
M"^J2*-T70UR+&U(KI)!JJ-,Y>.+_`)J("3]OV'I)%;7RB$34UK/,9>T9BH?"
M\L4-,C)\^H"8;,RND<6%S,DDOWWBCCQ.1>27^%R&')F)%IBT@Q<P*5-K_;N-
M,FD\>]FZ0V?C@YB0R2'^@IT-]G<#_@Z4?2SVK^!=`--(XCCP!^HRZUX<>T\.
MITVT]V4U70T%5M'=U/D,I'+-BL;)M;/)E,M#`C23R8?'/COO,H(8T)8P1RZ0
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MZ]7[/V#KU_?M;=>K]G[!UAJO^`T__+&7_H1O>G4,FH\>G8'87MN!3XO0>O5@
M/\T7_LO;Y#G_`*NNP?\`>.H^OO:&U)2*X9>*VTCC_3*R@'^9QPZ7;J=6Z2AJ
M<%\OET5G(]*=GXS9_6F^)-HY'(X#M^FW=6]?2;?4[AR6:I-C;A&U-S3S8/#K
M69?%QXW/`0@U$48F,@:.ZB_M1-="$2:C_P`LZ-U^4TF%/SJ?P\/ET@>WN_#,
ML":](+$`<57+?L%>N^M^E>S^V<]DMM;'V=ELGE,-C-S9?,FKIY</C\+3;.V_
ME=T[A@S.6RD=-C<3D:;"82H>.EJ)(ZB:10B(S$`TGN_!N;B(D:;:WM]0_P"&
M32*A/YZN'`=.V\=U<",+;,&G4M&<X515C\\`](_)[1W!BI-P"3&5E?1;6KQC
M,]G\/25F4VS05;NJ0+4YZFI?X=2BH+#Q^9XS*6]((M=;;S1&XFMIJ&0?!FGQ
M,R+]O>C=-^%)2HI3[.ECLWHSM_L"7.Q;5Z\W77OMWKK=7;.4^YP>3QD4?7FR
MZ.&NS^Y:27(4U,N4I:>&=/&*5IFJ7D1(@6-BD2Z"(LDK`ZP"!C\3",</Z;+T
M_!M5_<UDB(\):UP/)3*?+^!6Z265V9N/$5F=I'QE5E(MLK0R9[*X&FK,Q@\3
M'DJ6GK*1LCF*.E:AH4>.I"!IFC5I%8`FWO?C/./T"%9`78'S0'2>/](^76_`
MT7G@.M48*@-,"1@6'_&1PZ;<EM_<&'AHZG,[>W!AJ7(B7^'5.8P>5Q5/D/M_
M&:C["?(4=/#6^`2KK\3/HU"]KCW8W<<KE(J*5)4_-D)1O^-`XZ32V=["Y5Z5
MTA^`^!QJ7_C)&>FD@K<$$$<<\6_UQ[W]1X;"&3,C<#TRK%SVTQQP.N-_;FMN
MK5^S]@Z/AM#_`+=B]\?^+W?&[_WQ/?\`[07"+]8/S_R='5@Y?:FD:FH?+[>B
M(`JBEVN5178VN390S'@<GZ?0<_TY]F,8<RN&_LQP_8.@^LK?1RSO3Q`>TT'1
MK7^%_>BT%'-'!U[5YZNZ=C[^H>O*'M#9E7VEDNI&VPV]GW9C]@1Y'^,UBQ;.
M5\C)2Q!ZQ::)W\(5&(+KF^9+>5XJ^(LL2@Z:@!I55JFE!520*^?#/0@LMM,D
M,#S`$R0EO(9!I6G1;8]M[DE_@GBVUN2;^\R/)MDPX#,2#<T<8#/)MO11'^/1
MHIN32>8`&_T]K[N9$G$<&*/-7_2KX07]A?CY^?13%;71BDDD'"4!<>6K/VX!
MZZCVYN.63,0P[<W#--MV.2?<<,6"RTLNW((6D6:;<$24C282&%HF#M5")4*D
M$BQ]L_4!JE"*+4GYA6,;?\;5N'6_"E).A=1HU!3B?'?3_P!4=`_XUQ/62/:N
MZ9:?$UD6U=TRT>?>2/;]9%MO-2TF?DA#&:/!5,="T&9DB5"66F:4J`2>`?>O
MK$^7[>M^%??\HIZ?=N]8]@[LW'@MIX;:&?7,[DWI@NN\;_$\578;'1[TW)E*
M/#8C;V4RV4IZ7&8?(U%?71JT=5+$T:MJ<*H)#T$\<FZ):N1X+&!3_IG9V?/'
M^ST?9Q&3U8V5V5,@H%">(1082I2E?],K?/IKW?LO=6P-PY/:N\\#E=NY[$U^
M1QM5192AJ:3RS8O(U&+JIZ":>&*')X\UE*ZQU-.9*>8`%'8$$LV=[%<VZ3<=
M8U#[#P_EU>2TFLP;>Z`^I0D,:4R#Z='*^"O_``$^</\`C_+T^1'_`+T'5ONM
MXE=+'A7'\NE>V2,+>Y&/@'E\CT0_\?[`>WXU"QZAQZ)U<FM:?L'70)N/]?\`
MP_XD@>[!B31OA/'KS.54L*5`]!U:WUK\E]H]%_%;X09N+-[ZSF\NKOD1\@^P
MY^N.MNY:/85.XI,OUCE<!!VO@HL)N#+5FV]X5>+DBB/BI6J:,U2(7NQ]E<MN
M@W`1H/\`%:CS/^'H8V6XQ6^SR3I07:K(0:#BMO'(,<,,2>&>!QT+5+7_`!$W
MYNS+25VP_C[1;QJ?ASU=VML_&8'%;#K,5N?Y+]E;GQV8[MHMS+V!V5LG9F9W
M%M+;U961XS;>4S%%2XP1L\<#52)&S@A_QJ=!7Z=+ZT5!4XA>.0SBHJ35@IU4
M++P7TZ2Q30W%U!XP!EEMI6?@`9B5\(TP!BO;P/F.JQ/E'1]6X_Y!]K4?2M'1
M8[K&#<VG:^.Q>X(MUX?'!L;029N@P6X8)JJFR6`I-R/61T!CGJHXZ-8XUJ*@
M()W]MCS_`$0,YK/XDH)^0E<)Z?@"C@*\3DGHHW-HOKI%MQ^@ND#S_"NKU_%J
M^SAT`H/^^_V!]F([\-PZ+S(R$::9/H.CXP<_RN:V_P#WL/H?_@9*_P!EY2/Z
MI0_P_P#%=&\CLNU/(M-8`\NHG\O;>.U-A=Z[VW'O'<IVKB!\6_E5AH,G!N:A
MV?E)\MG.E]RX[%87;>?K]=/1;KSN0EBI\;>.9VJF41Q2.0OO>Z0K';ZH*U)S
MDD?SZ5<IR16',,:S@>"ZYKYFGJ>C:=8?,G9&Y/BUOOJ[/[6VUG,5L&3XY[7V
M]0_)O=E!VQO?L*CW?\C,GO#L')5TU1%M&/(8'KS#^C'4,,,L>!@JIZUG#SKH
M32V;*J%1IE_?R1MH)I]*(732*Y)/B."Y[C7)P.E<^^V^MB@&D;$\HJ`3]9KH
MK'[%_!\/RZ'W<'2'\OK;M%VMA,/1_'OL#;&+PO9>\MFYBG[BV%L^KR6XL!\B
M:VEVUU2O9>5WOE>RZS<&2ZSH%IW^VQM!MN';DWW<<M;5R>4%5F=P$Z1SDBW%
MS"AP:B/QIE<"@R?"6,5.<5&2>G;B2QFLA/$H-PUI,U:\9%MX2A^0\4N:`4-:
M$4`Z#.IZT^&J[RWQN%EZ5;=^<Z5RF3ZAZ53#=*"+9FX\=WP,3DJ7?U'3=]0?
M';L+>4_5`DJ<%41Y_&25N*5ZJ:@6NC@6119R7_[J5Y&_QQH8B33\9CJYI3%6
M\@*#@,=4OH]L_>S1QH/I5FE`%<:1)1!6N>WS)J>)SU5;\GZ7JVA^0?;E%TK0
MTN,ZOIMX5,>T<?C=P0;KP]%11TE(*^DPVXZ>6>#+8:'-/4"CFCFJ4^U5$6><
M+Y6-]M::2"MT:RU]*8^P=$>ZBVB=Q9"D6@\<^GK7H>5_[=<2_P#C0I?_`(&E
M/;=P@\>@XZ?\HZ?=S^X8":4\5?+J-_+QWIM?8'?>[]Q;NW.VT\0/C%\I\1%E
M*?<M#M#*SY;,])[KQ^&Q&V]P9$FEH=VYK(S)3XPZ)7:K=`D;L0/;FX04V[7;
MU%S3C6N?L..FN7)%M]Y$[_#7SS_AZ-EU;\R=C;D^+V^^KL[MG;.<Q.Q(OCOM
M/!4WR9W72=J;X[%I-W?)>?>'8%?D)ZFFVBN5Q/7F&8C'4L4!BPE///6%A)+J
M#VRVT3W6W0WH_2FNG$H!*@Q+;HU!2FG]76:C/EP`'2GF#>0MKN\]C1;R**%H
M*@'O:9ED-""&!2F""!3%#T/F<Z2_E][?QG;6%Q=%\?M_;>P^WM^;RV3FJ;M_
M8&TY\GNW#_(P0X/K&/LG+[YR79U5G*[K:A6E:&DQM!M>FV_)]VDM;5NTX#MO
M+>S6-I,2PF>UC:3&&=A5F`X`'R`P/3H2W0V1KN^\-1X*7TRQ48U$2D!%)K4D
M"M6.3C/0:UG6WPWCWMOK<!BZ1_OAE^F<AE>HNE(<-TRXV=N.C[UGPN8H=\PT
MW?5'\>.Q-WR=4H:K!5";@Q#U.-O5RX\UL4/F70&[\%C4ZA(E3YZ*L7I]N!6A
M('#H.7`M6NHU`'A^8Q\N.?3YYX]54_)VEZKHOD'VW2](T=/CNJ8-W5$>R\=0
MY^/=>-HZ,4E#_$Z7$[DCDE3)X2DSWWB43B2<&C\2K-,$\TB[;3<26LANS6?Z
MF0K04_0TG0*8KFG<<GSZ1[BEM'./I!2.AKYY`QZ]#[V5_P!NV/A\?R?E)\T/
M_>:^.!]ZM(T^J8>5/\_3E](W]7Q<X\7Q`*T\B0#C[.H/\O?>6UMA]Y;XW!O#
M<_\`='$GXN_*7$0Y:+<U!M#*39;-=-[CQ^'P^V]P9!9(J'=>8R4L<.-T1S2M
M5E`D;M8>]7\!"GP*T^TG_#TSLLIM]R"#_<6OI7'VGHVG6WS'V/N/XK[_`.L,
MYMC;&?QFPZCX\;7VY3?)_=U)VWOKL'';M^1F2WCOK(Y*:>#:<>0P?6^$=AC:
M&G@DAPD%3453.)*E&B1S0RM&J,`-,UF.VH&AQ)X]?FQ"Y_#^&E3T?WN\VL<%
MU(@&M8[_`(@'OC,0M_R4%_\`35[JTZ,#F^D_Y>^W\?VKA\73=`[^V]A\/V#O
M+9.;I^W]B;-GR.X\%\B*A=N]6CLK,[\R_:%5GJ[K3'I1::/'T.VH-O/]Y'+5
MU4GD""UEW&6&'ZESK^L"/VT(B\>92``*5\,(*G/YD])U&UF*22V2@:R,@[J@
MS?3PD&I-:>*SG3\-,<`.@NFZS^&\6\-Y;@D7I*3>N7Z<KLGU-TE'ANF(:;:&
MY*+O4X;-T^_**F[YIOCSV)NV?J:62IP52NX<9)5XU9*R>B-=%3M*KMFNCL5M
M.S']XO%;^(?5FA+2G20`*R4-`*+P7'2EX=N?>[F!E4V"27'AK7`"S!8A6M32
M.HJ<M\1SU5/\FZ7J^C[_`.W*7I>CI<?U;!O&N39U!09V/<^,H:(0TQKJ3#[@
MBDGBR>$ILR:E*%TEG04@C59IU43.;V;.ZCQ<MT&]S\"%F^E%%!QY^?0_=D_]
MNV/B'_XM;\R__>-^-WM/`B_6T^S_``]+KQBNT"04U_9T0YVT(\A_3&I=O2SD
MJG+`!/5<J/P"?\/:R%Y7.MO[*OIT1ZFKHQXA^0Z'_N;XN][]`[EV;M#M#KW)
M8C<786Q,3V7LW&86HIMW39C:.9+1P5*_W;;(M2Y/'U$3PY"AE5:O'U*F*=(W
M!45BNT:Z<,?\7K1?V9^?'I=-M>X+:I,M`Y%3@>N/Y=!#_=/=FC*RG:6ZA'@3
M,,])_=K."/`M3+&]2N;?['3B&IDE1I!4F(QJREK`B]Y[J.!$?B9;F.)1Z!P>
M[[!TU';7-TFF`:9(^YR1Q`XKG@3Y>?66/9>])9::"+9F\9IZV@J,K101;5W!
M)/6XJD(%7E*.%<<9:K&4I8"2HC#0H2-3"X]O2RI'>7=A_HML\8!\F#@DT\L4
MZ\\4T=9_#U))E4IE`,&OF:GUZ:#C<FHF=\7DU2FHJ?)U+-CJU%I\75A#2Y2=
MF@`@QE5Y4\50UH9-2Z6-Q=/%N%O,P*#]/MK]C+X@_P"J?^?JLT&X0(QE@(H&
MS3AH;PF/_.3_`#=/$6R]XS9NEVTFT-V?WBK(HJN#`MMG.)F9*"8,8LBN,>@%
M8,6Q'JJ6C$`3G6/K[<M)TFN?#<C1,5\/_FYJ*9\\1O\`ZAUJ2"YM[8R3#O4,
M3C^#3K_ZN(?^+Z<.RNO=U]3;\W9UGOK&QXC>6Q\W4[>W/C(J^DR4-!F*31]S
M215]!+/25:1D\.CLI%N?9?!=?4V,\\9K+',ZU^2L1PZ>N(9+8Q&<#6RJ>'1N
MOEAQ\:OY9W_BL?;'_P`%IW7_`,5]VJ&D#>95:_;3I;N+N;1`U/A]!T4GK+KC
M=_</8NR.J.OL=#E]]=B[GQFT=HXNIKZ/%TN1SV6E\-!1U&4R,U/08^&>6P::
M:1(T6Y+`V]F1(1#(WPJ*GHJB;4D4>-3W$2</)VHW[?7RZ$#>/QM[1VAMS#[Q
MAI]L;[VIF]Z93K>DS74V[L'VE2P]@8G&KFJS9F4BVE45N2QFXVPX>KIX):<+
M4TT<KQ-((WT(?WG"[:4';3)Z,[[9K^U+M&`Y%\\:J`"2@1B!C-014GCC/2;Z
MWZ/[=[;WGB>ONO\`KC=^X-V9K-';U'01X#+4L%-F4@J)I,?E\C54D%!@YX%I
MV,HJI$=`+%02+NB]B!!:FFN<^7GTA$5Z&"/:MJ)I^W'2%K=L;HQ=`^5RFU]R
MXW$QU+4<F8R&WLS0XA:P2/$:+^)U5%#1"I62%PJ%];6/%Q[M!<I(\.OM7ZQR
M_P`[?.@?+R[AD^O2JZLI+%O"G`,GV=26V;O)*^?%2;-W@N4I:-<C58QMJY]<
ME28YTEE3)5=`<>*NFQS1PNPG=%B8(Q#6!]M+-+'"#,P,A5LXX^+'IX?\*\04
M\ZUX@=)1;SN-2K2G$4Z3;<?[S_Q'M25UJS/P+,1_I=1T_P#&:?;TQ-(/TPE,
M29^W'1\?GO\`\7+X<G_P7I\4/_>>S_M#:@+*[#C4_P"3HWWQB;R.M/[$>0]>
MB%L2%)%N`3S]!8?4@<D#_#G^GM5*\@C)0]],=%!E2$>+**QKDCY=#15=!=JT
M?Q_Q_P`HI]K%NC\IVADNFZ7>-/D\=/+'V)B<%#N6IP=7A(ZJ3,444V'F#Q5,
MT$=/-)>.-BX*^[74IM[R"$_"X!8>OY]*[7;[S]SS;W/1K9?A``J!^7'J5V]\
M;^Z^B=[Y+K?LO8.:Q>\L+M':6^\YBL3"=SK@-K;XV[2[LV[D,_7;=&1H<,TV
M"K(Y)8YY$>G;4DPC=&4-K?07,GA6_:VID'^FC&I^/R(Z=GV[<;*(2W%N2IC2
M3`_#+A/Y],6#Z6[.W!LG>G8=!LW,IM/8='M6OS>3R%)/BS4TN]MQ4VT]MOMR
MFR$=-4[I>NS]9##HQRU3()E9@JE2="\CQ%Q<@$'Y,-0_D1TR=MW*2PFT+HW$
M3`*M`=*K17J",U(8U/#RX=)W!=?[YW'E,?A\-LW<]=6Y7=6*V/2*F#RB4Z[P
MS&1AQF/VU55DM-'14.:J:V=8Q3SRQRHQY3CW=G>$:I&!4_9CIRXA%QN)BL%T
MV^A!PKW4.O)^?EY=1=[[,W1UQO'=/7^]L1/@MW[+W#E]K[EP]1_G<;F\#6S8
M[)T>O]-1$E5"=$J7CE4!D)0@GR3^,-4?P=,74;6LX@D%'IZ=,]"?V<Q_VJ5_
M]W6%]WUMTT#@\.'H/4=6`?S:A_V,M^;2W_YK]N\'^M@\7T_H;^RW9X2U@L1/
M`ZOY\.CKF!_"YH=*5JO^3I*X[M7H3M#J#XP]>=XYKL?8S?&JO[$P]?!UUM"@
MW)/VEUAOK>E5V,*?;N6K-Q8>GV/V12;DKJG&M6UT4^/-)/35'J>ED@D7RNTE
M_)?(,.JJ%\AI4+6OG6E:4QPZ:MYK=;);9C1U=B3ZU8G^0Z.OT]_,-^/G6NZ>
ML=W:>YZ/:6T^N^C>L1T`<72;EVOL7+=4=\T/9=;W=B]S5&X:#%[FWO5;9P[K
M%)#B\=E:K-92K$U2M,+NS;QF";Q6HQ$XD'E@0S1%?/B90U?+12F:A3)>6LB%
M.`,!C_;+#)K^VD16G]*M<4+=U!_,%VUD=R=);=[`WKVCE:"#K[MSKS=;;NJC
M5[;JNP>U/E-1]F;!W3G:S+[CEIYL1M7:AA:?*U2F3#R(JPH8TU^R7]US6]K!
M&LFMX&M36GQ?3W+SMYX\0/X?G0#5G@#Y-WLKS<Y9POAI*\[TK73XEM'`J\!7
M04\2OG7304KTK>WOG%T[1X_Y3=$GNSN;=^Y^RNX?D-N#:?RYIMMS5>>ZMPV[
MNS^OLQB^O=E?8]A/N3+[!W/CMARMDJO%9"EIKUE,]+`\35?DU:07%NVUEEU?
MN_<);E_^'K(6I$>.@(&IJ[JCR&.B_<[ZR9[Q58*+JU6%2/\`0B.,@_BKDZ<4
M]>I60_F*?%_=?96&[8R/^E_;5;L79ORCV+@MKP]=X'*5>_).\,7M.FPO8>XL
MUB]VXS&[:K\GE,375N>HUBJ7^]JP8Y)P9"*2V-V]A>V7`W=E)`&_WV7N3<"0
M#ST@^'IQ6FJHX=>&Y[,VZV.XRRZDM-PBN633_:+';K`8B:]NHC7JH:5I0\>D
M;N#^8GU7OG!?)S!;@W7W1B]T]U=U_*#</5W<!QE5FMR]-]==PT>RI-N#$(-Y
M4V1Q29`[1_A.7Q6*J(/M<?,98)9/6KJ;K;KE3#<QD@+ML5LZ_P`9CO4N_$)^
M87PM)K3XZXT]%\&YPR[M<W!JEI+N'CH.(51926@4?:S^-4`4IIIG5U7E\R^W
M]K=Z=^YOL79N:WCN7!U.RNI]L_WEW_BZ?"[PW'EMC=9;5V=GL_F\9397.14T
M^9S6%GJ4_P`JE9XI%9CJ)'MS9X)(S>7$F/J;Z68+_`KA*)7SIIXXKZ#I/O$L
M,DT*POK6.W1"W"I!:IIY<>BM^SGHIZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>ZPU7_`6?_EC+_P!"M[N?[(]7A_W.M_\`3?Y>K`OY
MH?\`V7M\A_\`M:[`_P#?1]?^R^W%8Y5_WY"\?V:B#7YTT\/Y]+MT6NZR-Z!?
M\'2\VG\S=E;,^)>%ZAVYD^Q=N=J8OXQ=_=.P[CV[`,/2TVZNT/DWUKV_A#2;
MCQ^<I,G#AWV5M*OAK*E(UF2KD2$12*S2*AWFVEN$26(T9!;+3U$+@M_O0Q\N
M.>C6SWA+:&:+PP'DM9H@Q.%,B%0U*9TUK2N?4=&PW)_,>^/>Y.Q<1OK'[J[U
MV!BMO[3[\Q6ZMD8+9E+6X[O_`'-W/TIMG9<&Z]^M#OFEI*;+XG>6/GCR$U;#
MD)IJ&FIYZ=S++-'[3WEI._[S?\6YS6C+ZP"VF24J/X]871^&E:T/#I1L&]">
MXV\RL!'MEI-&PI_;EXRH8_P4)K3N^T=!!W7\Y^F>U*W-9/![Y^0'5^&7=WR=
MK,]L'9FV]NB#Y`XKO7>.+W+@,EO:NRFXLAMC`U\.&3^&Y0UN-R-124]%#)CI
MTD92AF+21=T;<"]8V^GHM!CP9YYFS_PT3!#0#3HKFM`5B:V"4K^70S[[_F0_
M'7-[%[AV9MW<G;5!6]C2_)+$;7SE+L7.TE=M;:G;O5-+M39]-N[-YGMC/9_<
MFXZ?=&)H_P".#'OC\1#$L$F/ID6!8B6_03+,C&74D8C%*<?#O(;DFOEJ6(Q>
M?QZO+23/;]XALDF1@'64R$>6G7:36P'G72THD\O@TTSJ"4S_`/,1Z$R^]:7>
M5'4]L83#;3WUVONO*]=46U\8^#^36([(^.&Q>G\#MOL>0[J&,Q4>T-P[6JH9
M1DJ7+P?P>J\M)&M3K5S)+>NY27XI].]@UN(_X9#.)A-7S(`T::#UU>722PO8
M/%2U==4JWJ7.NM*JL)B\*GS/?JK\M/GT6KY6?,C:'R"V5WOMZ#*=E9NMW9\D
M>K.TNJ*?>,,CXW:NP=K]-UG7>Z\?#%/G<G%MG(9+-Q4:_:4JM%4PP"21]2JH
M*KNSEM[:".%J2+>7,S,!\2SRM*L=/(1ZM(.:TK0<!2[W!#NL[:*QM8VL`%>!
M@B6)I*^LA75IQIK2II4UI-S<W)_-R;D_Z_\`0_X?CV):)<1K,5TNE/SQ3HAB
MB\%7S75^5.N'OW6NCX;1_P"W8W?'_B]WQN_]\3W_`.TMQ_N8/S_R='.V_P#)
M'?\`U>O1#C^@BWZO3R2%Y.DEBH+:`#<V!X!^OLR:;2"E/+C^70?B3ZJW^EKI
M!/'CY^F/\/5MT/SKZ?K<F,'5[4JMN8W(_!'8'QGI^\]M]?8*3O+K_L/;77-%
MM;==/C*^?-A]T=5[\:*?`95!)391<!53O1-3S`Q3$YV^0VLJ"1@&EC>GE1'#
M4/KPQD4^?0SGWB.T-G`(]216S(6KQ)8FM*8_GT,.\?YE75F9S>8R.RZ^LV?1
M;SW/_>+^[F=Z9W%O7#=88-.A]Q=45NP89*[OJDJ\?A\T^9BQRU77T6U&@Q]%
M!6K$]4D<"(X$>2];Q*THY_-GA:O_`%3(H<=WRRY+>62V5(2#*T@:GH-+"G'R
M)!Q3\NH6V?Y@OQLV7/GZ?9&*[*P5)CN]J7NB#+;NH=^=G9GM:FJ.C<!U]F=E
MYR6I[HV_5U>&CW?@ZY<50[WFW7C(MN99UJD:I1UJ%D5L\,<BER=<4JC"X,EY
M+=`G&=*R"*BZ:Z=6`=(+H[Q(I`Z@=KHW^\PI%3CP+*9,UXTXYZ$G:'\S?XR;
M-P>03#3=K8VKIX^L*_KZCIMC557N?8F8V=\?>Q>J\S-D-Y9/L6LP:U-/N/=L
M*X==L8S#8^'#PNTD+5A_<+C8R&O?C[/]GHT_K"U,%:U]/]7RZ*;UY\T=@8K`
M?&FMW/VAWSMJMZ?VGL#:7:74>V\+3[FVAV[GMM_)&A[?W!VAN/<.Y-R/%DZK
M*XE%J:HO1)N"7,8VF@@K5I9'=#."W:+<8[ZH*)=I-I]52%8_#KY5(+UIBM*>
M?11#,DUK.'ETO)9F#AY_433"3CZ2!*?T:US3H"OE-\G\'\@NN.OL14Y/>VX>
MP-M=\?*[?N4S^]VEK9UV!V_O#:^X^OL%0YFHR^3JG.,&,KGGH5M34,TI\+'6
MQ*+;MI>QM;>V:768($C)I3654`M2II6E:5/'CTUN^YIN=_/>(FA99G8+6ND,
M:A:T%:>M!U/^"O\`P$^</_C/3Y#_`/O0=6^S6Z?4B*>(/^4=:VT?XM<G^@/^
M?NB(*NH@7L+7)L2;#\``$EC^/;Q8K"II5:C4?X5KW-_M14T\Z<1T2K72VG,E
M#I'\34[5^6HT%<T]#T,.S_CWW5O_`&;DNP]F];[DW#LK%#<)JMP4$5'X94VA
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M@GEBD$DL<JQD`4_4D!,6:GBH:F*]5_=]Y;WUE=N#X3QQS@?\+MAHF_:S"I\N
MHM/\1/DF\F52OZ>WC@H]O97<.'W",U246-R&&?968Q^#W[D?[N5=?!N?-838
M=?DHDRU9CJ*JIJ,L/)(@U:4=M=6[4#L$UH74<:T9D8?[VK9ZK#M5[+)*$&H+
M(23_`*?]513_`$CKY]!SW%UIDNF.V^S>H<UD\?FLOU?OS=>P,IF,2E3'B\KD
M-I9JMPE9D,;'5JE5'0U4U(7C64+*JFS*#[4V4WU,)FI0!M/KT6W,;PSB)Q0@
M]&IA-OY6]:?_``8?0_\`P,E=[2RJ7GT@T)!_R='.G5M;K\AT0XV/U4'D'G\$
M<@\WY]KG[XA$WEY]%EQ*TMS'<Q=AC%/6O^#KLV-K@<7M_A<6/^W'NX8#B*XK
M_MOXOMZ:TH34CB?^,_P_97_BNABW-TGE]K=']2][567Q%5@^W=V=F[2PV"I:
M:L_C.'J.K)MN4^4K,I421C'O2Y*7<L7VXB<NJQMK`)4%+-,B[K^[PG';!=ZJ
M^9FDB"4IY&,OJK^*E,5*J.`MM/[Q5R`-R^DT4\O!275JKYAM.FGX:US0`V8X
MP"@C32>2ND:2;_6UK7X]NA4-:#M#LM/]*:#I%JED4:F[BBM7YL*GKD/I;^@X
M_P!X]W15#U44%.O$,(7U&ITGH^2_]NN)O_&A(_\`@:4]I):?5"O#_9'1Q**\
MNQ#_`(8.B&&Q%B`>;\\\CD'_`%P?:T.-56%5].BU',8[?B]>O&Q`.D%N0MS^
M6]-OR3?\_P"%S[HK>'<0T_T.*51]LI8AO]J"!3SIQ'3/8P,DBU&=0_B]/LH<
M^?1RL7\*-X9;IRC[K@WGM"#"57QKW]\F5PL]#F1F(]K=?=OT/3M=MEIDISC_
M`.\&0RN02M@D5VI12#26U\>R2XW*VV\7-DRZFV]+-!FFL7`-#2ATZ*?/57RZ
M/-LV>XO[:SN$D(%W]5JQ6C6VFIXY\35\M/SZ)IHC`*:$T\W72NF_]=-K>SY5
M6)Y*"JF-X_S=5HW^U]//U'1.DK,HKQ*U^S)'^3KF#^`+?[ZW^\>]@@LI44"V
MBQ'YLAJ9/]M2E/+U/5U8D$-DT/\`@Z/GV5_V[7^'W_BTGS0_]YKXW^T-K_N4
MWV?Y^E]^*\K`?\-'^$=$*-C]0#S?GGD?0_ZX]K5<`=PKT7QMX8Q\7KT_;6P$
M^Z]T;7VK2S04M9NC<F`VS1U=4KM34E5N++T6&@JJD1!I?MH):T/)I!;0IM[;
M11)/"G`37(B^RJLRM\].DBF*UXCIF4@6EW&PJPA:>O"O<JLG^VU5KY4X'H^>
M3_EN]AXRMSU')V-U])+MVO\`F5CZF2/';D43-\*J&BK]ZM$LM%')"-YQ5JC$
MK(%,10F?2+$A\;];^'<2&.AALOJ`-66/U$UO3AC,1>N?CTTQ4BF/ER8K:V\4
MF)+H6['3P'T\5Q7CD4E\.F/@#5S05UJL31+:--#JKZ"JVL0"+CZ7]GX1.('Z
M>E2!Z:A4#_:C'SZ#HEDC.@FLM6!/J5:A/^V.>N9^GO:(!(",#I//5D+$]'Q[
M)_[=L?$/_P`6M^9?_O&_&[VD@_W-_(?X>CV]_P"2*O1<>@,WU?M;NKK3=?<]
M#F,OUEM3=F.W3NG`8*BI\AD]T1;;,F;QFTTIZNKHJ5*/=&:H*:@K)Y'T4U'4
M2RE9-`1ERR!+5K<#N-<_;\O]GHL1`+I;D_"*8^SY]7!]`_/'8'=R]A5'<F1I
M_CKV[M?:'S7W9USVEUV^X\A2283Y"=0;D_TA;6GK-]=D5N?AW=%V#2XJJV[0
M8RHIUG6JJ8H(Z>5DU!R\LY+2WC97+,:UQ3S-/,^70YVS=;6\E=;@!$`PM:TQ
MZXXG/Y]*@_.3I>GZ4^.>]5[G[2J4Z7[@@PN]MBQ8:EFWI\MDV+\8]D[*JMS]
ML8,[WDGP6"WMF*EL3!4YO^+Q3XQ*@3ZJJ(P%2WB0W$-PR>+`UI*FGAHE9ET2
MUH:Z*'MQ6O$=6C?;KNVD2*46\\.X03%J:O%CC5]<1%1374=V:4^$]%\W#\_>
MN][=C=U9)^P^\>K<3O+</P]SG7F^=I8^KR^Y=L;4^/NW\5B]X]24F!H]XXJI
MV_M?<^7IWK:#[6J^SJJK'P25T3>34BZWB:W^@OY&$UU;1RI.IQ]09!1'/'3X
M7D.ZOJ.@ONFXK>;WN\MK_B]K?M"T`^(6PB^-!\.L3>9[-/H?)4YK^9MU#D:S
M;N_J/J7-P;ZKOD+MD]D[9DH\*=L5OPXZL[FW+WCU7U=19""J7'5VX(\]NJ+'
MY"B>DAQK4>WZ!0[1AHP7V-N]HABT`JR1@G^DEF+4OP/Q-64CU.FOXNE5_NDU
M^3JE"QEI<4![9;OZG3Q'PK^D#_MOZ/4;=WSXZBW7L;='6-#V%VGM+*9R;)YC
M#_(7:.PMV0[ZVNE?W=@^TJOKJK?>'=N\>R<IM_<./Q4E35"/-TN/H,ZR1T](
M:1YV=1;6DEO<[;.6JMBUL77%)?`2Z5LT[=9N%.=1'AY+:NW>Z7MIN$4T2?I^
M*+D`\=/CM:D"F/@%N1_2\3\.GNK:^6O9^W>Z_DOWCVYM*3.S[7[&[&SF[,!4
M[GH:?&;BJL;DWC:*IS>/I*W(TU'E:H#R31I/,BNQL[6N4NPVSVD-W;N=2S7$
MCC^B&8D+YUI6E<5XTZ0[Y>KN<L(C3PQ&H%:UK0#/`4K3H:OE?_V33_+._P#%
M8^V/_@M.ZO:R,4D(^S_!U?=<6Z#T3H&OB-VMMCHOY2?'_N;>D.3GVCU=VOM'
M?&Y8L+21Y#,287`Y*.JKX\7CYJN@IZZM:`'3$\\*R`$:Q?DPG!:`QC&H4Z)[
M631/;5%0+A'_`.<9U4_/A\NC(="?-:EVOF]\8/L1<=L[K6NV]VGD-A;=ZQV!
M#MG:=/V]OB+"XVBW=VI@>O=P[`WKN_&/M&@J,5.M+FX:JGBJRD1--/5K,E%M
M"FWR6BK6X<KWGR`-2`/G]O0LN=Z9-_AF)"6QN))3YT+1NM#ZT+<<?9T<KL3^
M:!U-D.Z_C!O'86<[DQFR.N^[\GV?VY04>`391W3%E?CYTSU169Z/:V)WE44N
MX<U3;EV+EZM:>KJC**>2-S.T\K$%W[LD"5,F:<*?Y:]>WC?GC=)+<JZEQ6@I
M3(_R=(3I[^8WU5UMN;8B;V7LGN'KKKSXU](=91;&S="9-LY_M'J[Y&4O:>5W
M6NW<QN>KQ5)]YMZ:26GKZM9:@Y'_`">945FD;>X6[W:S"W/@M+;B-:"N@@4U
M^52?3'V])KW=;:3>@9!JBJ//CGSQTE>X?G]LG/\`07<'4NQ-V;_FW9O7!8O$
M8G?6/P.[MK5.0QM?\A8^TL_M?<FYMY=P]D]BUV'?;U&\IIY\A)C5R5=44])2
MQTI:21:T+RP0HS49"NK`[M,4D?E2E6</YGMH2:U!A=7=C;M+(E&5^`]/EFM:
M?EU4"WT'^L?^*FY//U/TX`_``]F0;5"JTRD:J?F54`G\Z5Z`6D!M0;4&GK]G
M#'1\/GO_`,7+X<_^,]/BA_[SV?\`9=;_`!O]O^;H_P![_P!S(_\`FB/\/1"V
M_2W('I/)O8<'DV!.D?G@\>U9^?14&5#J==:#BM:5^5>K8/C%\S/CSUY\;-F_
M'?O+:^]]X[4H>R.[>T]VX+"8G'5F-FW6(^E]S]`UN.FJ\W1+4.V[>M<CBLUJ
M6(TV$S$S+YBWB+>Y*U]/%/'V&.F.-?4U_P!CH4\N[A;06LEC?L#9R'X?0?Y>
MC.;4_F<=!56Z]G[ZWO7=IG=+Y#HO)=M3U>S:O=U+NJ+9?0N,Z]WE3;0P^.[+
MVUM\9VHW:M=%'6;C@R]'48"LD%+!353L"43[4[OJADT#ZBYDP,CZB-(PM:\$
MT:JT[JD=O'I^3F*:]E[Y%6);>VA`(U8MI7>O$4UAM/\`1T@YX=);KW^9]U;L
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MST]3BZ>O6F`^YF73#^V1'I`>VZ-[:'P'.HDUKP_+HMWJ:'<+X7T1T@`C3QK7
MSK_L=!#0_P"9S'_:I7_W=87V8=%@X'[/\HZL!_FTLI_F7?-H@\'O[>!#?06U
M4Y!YY%]8]I]J'A6JAR`2H\QT;<U.(N9?J'KX1%`:$_X.J\+@6]2\7_VY!4G^
MER#;_6]O@?,<?4=$DB+K)8-4YX'SZ]Z?]4E_I?\`-A:P)^I''T^GO=/F/VCJ
MNF/^G^QO\W7>H6`U+P``/Z`$$`?T%P/?B2,BA/VCKPHAU)KU?8W7$>,*%&@*
MMK*`-(MJM86L"-9_VY]U#R`UHO[1ULZ6.IPQ(S2AS_+SZ[)0_5@>;V/T_P`.
M+V-K_P"P]O\`U#?PC]HZ<^JC_P"48_LZ]J'X8#Z?D_V057CZ<*2!_A[W]2[#
M2P%/M'31*RUU!E!\M)P/3A^771(/]I?I_K6']+6XM[;-*XH!]HZVJI$-*:F'
M^E/^;KW'^J7_`&_O7YC]O5M8]&_8?\W7N/\`5+_M_?OS'[>O:QZ-^P_YNO<?
MZI?]O[]^8_;U[6/1OV'_`#=>X_U2_P"W]^_,?MZ]K'HW[#_FZ]Q_JE_V_OWY
MC]O7M8]&_8?\W7N/]4O^W]^_,?MZ]K'HW[#_`)NO<?ZI?]O[]^8_;U[6/1OV
M'_-U[C_5+_M_?OS'[>O:QZ-^P_YNO<?ZI?\`;^_?F/V]>UCT;]A_S=>X_P!4
MO^W]^_,?MZ]K'HW[#_FZP517[6?U`_L2_G_:&XYMR?=B1H*U%>GH:_4PS4/A
MH<X/KZ=6`_S0V'^S[?(B]U/\5V#PP*D'_1'U_<6(^H/!_P`?:2!&5<TX^H]3
MTKW&9'OWF348V"T-#Y#HA!<$@ZQ<?0W-QS?@_4<^U*T4U-#CY=(7='720U/]
M*?\`-UT&`M9P+6M8D6M]+6^A'MJ"28N1,H$?ED=,JD<!)AUU/'M/#]G77IX]
M2<?3_8DD_P"W))_U_;E/F/VCKVF/^G^QO\W77HXY7@J1;\%22K#_`!4DV/U%
M_=J1>=*]:T)_3_8W^;KNZ@D@J"?K;B_%K&WU%N/];WHA?PTI]O5E<PG5$&+?
M8?\`-UWJ'^J7Z$?[`Z@?]OJ/^W]^$<3_`-H10=728EB\@;4?D?\`-UXL#>["
M_P#K^[DJ!I0BGV].-,I%`&_WD_YNN/'^J7_;^Z?F/V]-:QZ-^P_YNCY;04_\
M-A]\.2%!^=OQO/K.GZ=$]^W_`%6%[M;_`%P1^#[3S+JN@PI3/G]G1WMI_P!T
MSFA_8?GT0X*;"]OI]#;\\V(/^]>U3T+5!'[>@]#(5C!4-J^P^IZY\\\CD`'U
M#D<\<?@:C_MS_4^_*0,$BGV].&623$@:GV'KPN+68+;]-F`T\$>FQ]/!MQ^.
M/>FCA'<A&KJHC2,^(A<OPII;_-UT!I_2P7@CTG3P>".+?4"Q_J/>J#SI3[>K
M>(QP0U#\CUW_`(7``L!8@6"VT@<_1;"W]/=M,7R_;U70G]/]C?YNO<\BXL00
M0&XL>2#R+@G\?U]TIZ$?MZK,@#CP=>C%<,/M\NN)3D_H^BB_I^B_I`_H%_`_
M'O8'S'[>GV*(=,88K3^$_P";H^'P6]-'\X2>?^Q>OR&'I!<W;<75:*+*"1J9
M@`387_/M/<"NFA'Q`<?]7IT;[8VJWN%`;44'D?GT0ZZFUVL+$$`D$W!`!_(`
M)O\`UX]OL28#`*4D'AMG@C]KM\Z*2:#)\NB42>#)JH?'C.M10Y=.Y5KPR12I
MQZ]&YP?R2V9_H;ZTZRWYU=EMUYCI`=T#JW<.`[(K]B8HKW6V,K\E'OK#X?!2
MYW<";4SF--32)19?%QU\+"EK1+!>S,\;7=Q%/-0%C'#)GX8865T<>NHKP'=Z
MCHSVS<OW?$T(5R(RTT>#F:8%9$.,!0203@^70Z]T_P`Q-.W]G=S;1/4CX`=M
MT?;])_$/[\+D5P8[9[EZ5[:E9J)-L4$>5&%/47V00F!:AJ_S7B$)BF3WUIXL
M3&&AECOXI4%:!DBN9;D')Q5IF6ASCAT]+O,LFURVA5O$E64'!_T6UBM&S3R2
M(-^?2K[?_F68'NK#[GV7NCH[(XO8>_-J;GVQNZEVWV/04NZXVR6\>I=\8#+;
M;SN2V)D\?12XC+]7!*FEJ:*I@KX:]R3%)!$YTFW)`]U.CAI9;^WN5'E6V5U0
M?(,'->GKC?3>0V=M.C".+;Y[9R`:@7)1G(QG24`QQ\NI?6W\R[9_6&(EPVU/
MC_F<#C$VAW7LB/"XWMN*OI,[C.U),FFW<[OS=NZ=@[C[0W5NCKZBR;011'-0
M8*I4&84$,XC*Z.U0M.DIDPL)%/FTLDI`_.0Y/^#I1:<QFR:5(HR8Y&0UTG\$
M4<0\J\(U/^SU7?WEV8G='=';/<'\'&VV[1['WEOXX`9`Y7^#+NK.UV83%MDV
MI*`U[X]*H1^80QB6VK2OT]J=N1K:U,,E`=9/&N.@[?W9N;OQF5@#\C_FZ,W"
M0?Y7%<H//_#A]!_K6_V66O%[_P!`00?Z$>]%";D,*4H3Q'J.C=3_`+JW:AI3
MT/1$-)_J/]N/:F@]1^WHDU_)OV'KVD_U'^W'OU!ZC]O7M?R;]AZ'O=_=@W3\
M=NDNA5VV*$]/;W[<W@^Z6S`J1N'_`$IS;7E^P7##'P_PQ<(NVM)D^YF-0TP;
M2@4@I)HG??OK5I],-D6WK4?VPN9I"M./P.IU?#FE:BG2^*XA78#9'5]6=Z-Q
MITM_9?311AZTI76K#36N*TH>@&(N?J/]N/:H"FK(S(YX^1-1T6HU`H*MB-!P
M/$"AZZ"G^H_VX]W4@&I(_;TY4NC(H;45]#T?`$#^5U(G.H_S!]0L&9=*_&J(
M%BR@J+,X!%[\CCVDD4M<@BE*5XCU'1I)(IV6.WSXJN*BA\L]$-X_U2_[?VI_
M,?MZ*]8]&_8?\W7O3Z06%KB_)^@.JUQR+V_Q]U85F#@B@^?38)\)EHU3\C_F
MZ/CB/FV,3T71=+CKDU#TOQ/[+^,#[F&ZQ`LI[%[SQ?<S[U&$_@,H1<8E!_#C
MC_N1Y+^83K81DKO]GM[P[G<EA]1</8^&/XE@#>)G@--12O'RKT?[5ODFWP[;
M:E6\&`7QD-#VF?3X?EG5I\JT\Z=$/)4F^H?[?V<.U9'H1X>JH->/:!_DZ(ET
MJB&C:]-#@\=3'T^?70*C^TO^W]^6@-21P/G\NK>*JY8-2E/A/GCTZ/GV6ZC^
M6Q\/!?\`5\I/F>`;<$G;7QQL`3;4;*20+V4$G@>TMNI2Y9FI0CU'SZ-MQ!3E
MQ8&!\4R`TIY5!Z(=I/\`4?[<>U%/F/V]%)DSP;]AZ4>SL^=I;PVANT4HK_[I
M[KVUNC[`5`IC7?W=S=!F30K4^.<4[5?V/C$A1PA:^DVM[W%19K9V(TQWJR-G
M@@1P3\\D8&>FIB7BN556U2631K@Y<NA`^6`<\.K(\S_,E&4R.X\@G3KTYSV1
M^>E<L1WZDIHE^;>-HL<D6K^Z^FK/6\=%=B?'_%?);_)BO(:AV"-[2]%PP%R^
MWB&,5KJ87MS-3'#].16J:"IIQ!Z&+<R""XLC;!C`E^)9.T]JBRMX:T(S^I&Z
MT%3BO`@]5<*FE$34#H55OP`=(`O:_%[>Q)\)T`CPPB`&OF%H>@FS@GQ*-K+.
M3VG\35'EZ==$6!)(_P!N/=EH&J2*?;TU,_Z9PW[#T?'LHJ/Y:_Q#)8?]E6_,
MKCGZG9_QQ0#D6NS1FW^'/T(]HXD*W>LTTT'F/7H_OC39%-#3[#T1/\WN/S^1
M^>#_`+<>U%/F/V]%(F6@PW^\G_-UP**RE2(ROI]!"E/1<J-)]("DDCC@^[^'
M%*H64B@Z;+E',D>JK<<'_-UXK=]=UUF]W-B[7;6=37NUWYY_/N^I5&@`%?6H
MZI3.L%PQXX;_`#=<K&Q`:P/U4-92+`6(!L186Y]Z"Q1GQ$(+^G7NUL$-3[#_
M`)NNB+BQ*D?T)!'%R./IQJ/^W][,Q(II7]HZ\$C)IW_L;KNS?74/K]=7T/UN
M.>.?;=#IU?A^WK?A)JT]U?L/7$@```KR;``CZD^WHA;QQ$5&MNGS76M`=(^1
MZ/?\KP3\:/Y9Q'(_V6/M<\?[5\L>Z9+?ZX0W/]+'^A]E<<;AVK3CZCTZ,=PG
M2>%1%J)T^A]?F.B(:EO<,MP;@WY!^MP?J/I[,3W"@(QT5H1&@UAM8X8/^3KU
MU/U*W'T(/TYN"/\`$$^VV!0:CD?+)_8.G!X=XWASEEKYD'%/GU[4`2VH7(TL
M0>2.#8GZD7`]^74^0K4^PCI+&G@2E9&!B\LUZ]J4"P90"NFP_P!2-=A_K#R-
M;^FH_P!?=PB'\)_8>K+!%,_B%QXGV]>+`FY>Y%[$DFUR+D7X!;2+_P!;>[+`
M[UT4QY5`_D>O-I=S'*V0>NBRG^T/S_A]?;:.A5E!R#3K9MPH00Y4/4^?IT?'
MYZ$/D/ATRD6_X;U^*`Y-OIMW/$V_JOJ^HX/X)]IH$(9B:4U'S^SHUW>9);B.
M6.I01`<#QZ(=I_Q7_;CVI_,?MZ*O$]`U?L/7/GB[7M^=5SQ:W)N>`![U3YC]
MO5#''+\9=?\`:G_-UQT"Y_3S]>18WN3_`+SS_K^_4^8_:.K2QP@?I%]7^E(_
MR==VXMZ0"+$#2+@VO>QYOI'^V]V"QT[J5^WIN-!H&O7J^QO\W7K?3D<6`Y'`
M'(MSQ8^]Z8OE^WJVA/Z?[&_S=>()`%Q8?07%A_K<\>_$1CX:5^WJPTJ:C63]
MC?YNIU"I\.8Y7_BTK^1_SNL+[KCU'[>KA\'#</0^HZ^A]V=_+I^#O;O9_9W9
M/9GQIZ\WIOS=W8F]<CN3<^7.XOXCEZY=R5],*FJ%%GJ6F\I@A1/3&HLHX]@,
M7%V!I4X'4]7FP6.XN)I5%1_AZ1(_E/\`\N@C4/A_U:5L6U!=VE=(O=M0W+;2
M+'GZ<>]BXO#D&O33;#MD9TNG<!_+UX</GPZXC^5%_+F)L/B#U622``!NTFYY
M`L-S7N1[U]3=Z=>KL/GY9X9X9\O7K0V+:RVD)5O3S_93KL_RH?Y<Z_7X@=6#
MC5RN[1Z>/5_Q\WT]0Y_Q][^HO!@G-:?F.(_+SZK^Y=I/!1_+_-UU_P`-1?RY
MN#_LH'5=B2H-MV\L`"5'^_FY8!A<?B_OQN+P<3UO]Q[74C1D<1Z?;C'79_E0
M_P`N<:K_`!`ZL&DZ6NN[1I-[6/\`OYN#?WX3WK&BDDUI^?IUX[)M(XH!45\N
M'KPX?/KW_#4/\N;3J_V4#JS2#8M;=ND&Y%B?[S6!N/>A<W;&BM4_+KW[CVKC
MHQ_J^77?_#4'\NBP/^R?]6V/T.G=W/T^G^_EY_4/]O[W]1>$T!SUO]Q;6.,?
M^K]G7`_RH_Y<@)!^(750(^H/][`1_K@[FO[\9[T<2>M?N3:OX!_J_+KW_#4G
M\N3_`+Q"ZJ_]>S_[)O?OJ+SUZ]^X]J_@'^K\NO?\-2?RY/\`O$+JK_U[/_LF
M]^^HO/7KW[CVK^`?ZORZ]_PU)_+D_P"\0NJO_7L_^R;W[ZB\]>O?N/:OX!_J
M_+KW_#4G\N3_`+Q"ZJ_]>S_[)O?OJ+SUZ]^X]J_@'^K\NO?\-2?RY/\`O$+J
MK_U[/_LF]^^HO/7KW[CVK^`?ZORZ]_PU)_+D_P"\0NJO_7L_^R;W[ZB\]>O?
MN/:OX!_J_+KW_#4G\N3_`+Q"ZJ_]>S_[)O?OJ+SUZ]^X]J_@'^K\NO?\-2?R
MY/\`O$+JK_U[/_LF]^^HO/7KW[CVK^`?ZORZ]_PU)_+D_P"\0NJO_7L_^R;W
M[ZB\]>O?N/:OX!_J_+KK_AJ#^7#+Z'^(/53(_I87W98JW!'_`!\WY!]^^IO1
MY].+L&W,*JH`_P!7RZDUO\O?X2]VU^2[3[5^-77&].P=V9;+G<.Y\HFX(Z_*
M?P++5VV<0*@4.=I*?_(,#AJ6E2R`F.!2;M=C[ZB\X5ZT^P[:OQJ#_J^SJ/\`
M\-2?RY/^\0NJO_7L_P#LF]^^HO/7JG[CVK^#_5^SKM?Y47\N9CI7X@]5LUKV
M4;M8V_K8;F)M[]]1>>O6_P!Q[7_!_J_9UX_RH_Y<JD@_$'JL$&Q!_O8""/J#
M?<W!%_?OJ+P"I..JC9-I)H$!-:?GZ<./RZZ_X:D_ER'Z?$+JH_ZW][#]?I_S
M$WYM[]X]Z.)/^K'^''7ALNTD5"@C\O\`-U[_`(:C_ER\_P#.(757'U_X^SCZ
M_7_?S<?I/^V]Z^HO/7KW[EVG^$?R_P`W7O\`AJ3^7)_WB%U5]=/_`#%GU%KC
M_CYOJ+CC_'WOZB\]>M_N/:JTT9_U?+KK_AJ3^7)8'_90^J;$V!_W]EB?Z`_W
MF^O'OWU%YZ]>_<FTUIH%?R_S=>_X:D_EQ_\`>(75/_KV?_9-[]]1>>O7OW'M
M7\`_U?ETN]O_`,NCX,PXZ3I./XP]9CJW=>0D[+W#LYH]Q/CLEOK9-!#MO:VX
MY9VSYKHJO#X/>.2IXTCE2%EJF+(S!2-^-?5\ZCI1%L-A!#].%&@_SZ??^&A/
MY9ES_P`X9]2<LQ/.\#R6-_\`F*OZ^]?47IS7I-_5W;(/TF3(_P"+Z]_PT)_+
M,_[PSZD_V^\/_LJ][^HO?4];_<6U_P`'7O\`AH3^69_WAGU)_M]X?_95[]]1
M>^IZ]^XMK_@Z]_PT)_+,_P"\,^I/]OO#_P"RKW[ZB]]3U[]Q;7_!U[_AH3^6
M9_WAGU)_M]X?_95[]]1>^IZ]^XMK_@Z]_P`-"?RS/^\,^I/]OO#_`.RKW[ZB
M]]3U[]Q;7_!U[_AH3^69_P!X9]2?[?>'_P!E7OWU%[ZGKW[BVO\`@ZXU7\MK
MX(=3X/<T_7?Q=ZSVM)V'B*;J?>C4,>XYAN#KS>VX,)'NC;%8E=N"J1*/++CH
M-3QA)T,8*.IO?WCWI\ST_#LM@M5C4"O06'^5%_+D!/\`SB#U7]3R3NPGZ_DG
M<W)]^\>^/F>F&Y:VU6\9E'7'_AJ/^7)_WB%U5_Z]G_V3>_>/?>IZW^X]J_@_
MU?LZ]_PU'_+D_P"\0NJO_7L_^R;W[Q[[U/7OW'M7\'^K]G7O^&H_Y<G_`'B%
MU5_Z]G_V3>_>/?>IZ]^X]J_@_P!7[.O?\-1_RY/^\0NJO_7L_P#LF]^\>^]3
MU[]Q[5_!_J_9U[_AJ/\`ER'C_90>JO\`U[/_`+)O?O'O?4]5/+FV3X50*9_U
M8Z7>W_Y<OP7J<9'TA4?&#K27JJHR-?V[)LQH]Q_P\]D4-%A]D4^ZA.NX!D!6
M+M.NEHC'YO`8WOHU^KW[Q[WC7/2G]R6,<1B*CPST^?\`#0G\LS_O#/J3_;[P
M_P#LJ]^^HO?4])_W%M?\'7O^&A/Y9G_>&?4G^WWA_P#95[]]1>^IZ]^XMK_@
MZ]_PT)_+,_[PSZD_V^\/_LJ]^^HO?4]>_<6U_P`'7O\`AH3^69_WAGU)_M]X
M?_95[]]1>^IZ]^XMK_@Z]_PT'_++_/PSZD_V^\!_\M7OWU%[Z]678-M8T5,]
M-6Z_Y<'P4QV!PW2U%\8>M8.KJS,9OM6HV<B[C./?L&BQ^%V?3[F$[9]L@E6F
MVJR2D,:S"!HVN4+`,/?47O5SR]8!<J-/^KY=![_PU'_+D_[Q"ZJ_]>S_`.R;
MW[Q[[U/3?[CVK^#_`%?LZ]_PU'_+D_[Q"ZJ_]>S_`.R;W[Q[[U/7OW'M7\'^
MK]G7O^&H_P"7)_WB%U5_Z]G_`-DWOWCWWJ>O?N/:OX/]7[.O?\-1_P`N3_O$
M+JK_`->S_P"R;W[Q[[U/7OW'M7\'^K]G7O\`AJ+^7*?^Y0NJO_7K_P")W-[]
MX]Z/,]:/+VUS?IA,_P";/IT(6$_EP_!7<6(Q_3V;^,'6E?UKL+^*[ZVAM*:/
M<2T&#W7V#7TV-WGF*2://I6O-GZ+:&,299)70"C30JW?5[ZB]XUSTIFV"QN(
MA"R]J_Y/^*Z=?^&A/Y9G_>&?4G^WWA_]E7OWU%[ZGI-^XMK_`(.O?\-"?RS/
M^\,^I/\`;[P_^RKW[ZB]]3U[]Q;7_!U[_AH3^69_WAGU)_M]X?\`V5>_?47O
MJ>O?N+:_X.O?\-"?RS/^\,^I/]OO#_[*O?OJ+WU/7OW%M?\`!UX_R@_Y99!!
M^&?4EB""+[P%U(LPO_>KBX]^^HO?4]:/+VUS#PPF3U,K/Y;/P+RM)B^F<E\6
M>L*SK'9%/7]@[3VC,FXQC\%O'?\`D!B-Z9RCGCW#'7M/N#&;,Q<,Z23/%II%
M*JI+$^^HO>-3TJDV"QF@^D*C2.H?_#0G\LS_`+PSZD_V^\/_`+*O?O'O?4])
MOW#M8QHZ]_PT)_+,_P"\,^I/]OO#_P"RKW[ZB]]3U[]Q;7_!U[_AH3^69_WA
MGU)_M]X?_95[]]1>^IZ]^XMK_@Z]_P`-"?RS/^\,^I/]OO#_`.RKW[ZB]]3U
M[]Q;7_!U[_AH3^68/^Y,^I#_`(:MX#_>3NJP][6YNU(9CVC)^SJK['M80D)F
MG372_P`I[^5M79+)XBE^(73DV5PXHVR6.67=ZUE'%D8VFQTTU.^Z5F6.M@%T
M-M)^@-_9..;-6Z_NX.IEK\-1JIZZ:U_.E.CAN2[1-I%^T;".E=14A?\`>J4_
MGTY_\-"?RRSQ_LF74A%P?U;O(-C<?\Q3^&`/^P]G#75V*R:J1UX^7V5Z)4Y>
ML&0,`"".DOO/^71\&MUU^-V-N+XQ];Y7:73VWZ':O6>#J%W$M+M';VYZS*[X
MSF*H&@S\4\U/7[MSM97'SO*RS5#!2%LH\+B]/PG/6SR_84%0*=(\?RH_Y<7_
M`'B#U4/]CNSG_P!>8^[Q7=R*ZG_P=7'+^WI\25_+I+;K_EN?RKMA4+9+?/QO
MZ(VA0"Q6KW%F<[BDD#6LL*56[(YJC4#<>-7-^/9WM=IS#N5ZEIM,;O?/7356
M(P"3Y>@/1-NXY1VNPDO=U>-;*.FJCK7)``X_Q$=%+W/UY_(FVM-)3R]']89R
M13*BMMO;7964IG>(V(BK/XW#236(/T?V/;/VL]V-S'B0*FBOEU'5W[E^SFV/
MX=QK+>GG^SCT@:/_`(8/GJHZ:OZ!V9@3)*(Q/E]C]F?:J#_NR2>@S]9XHQ^2
M5L!^?:B^]H?=RV':$Z<M/<7V?W(4A\10?RZ./U9\%OY0'=^/ERG4?1OQZ[!I
M*=-=:NW,UN*KKZ`,+H<CB7W1%E<?=?\`CM"@/XU?7W'>\[3S-RS*R;LLGU@-
M'HK4U?+'0YVR'D/>8D>Q:L;K49!/Y]"K_P`-1?RXR/\`LD+JNQ_QW8./_0F_
M/L/F_N)SKBJ/7[>A(G*FSVJZ;;NC;-3Z_P"H="C#_+>^"/;:PU'8_P`7>L]U
MS]>4&(ZFV9-D%W)')@NNMCXBABVIM:!J/<--YZ+"19&98GF\DQ#^IV]Z^HO/
M7K;[#MX`+J".L_\`PT)_++_[PTZD_P!OO#_[*O?OJ+SUZ:_<>U?P=>_X:$_E
MF?\`>&G4G^WWA_\`95[]]1>>O7OW%M?\'7O^&A/Y9?\`WAIU'_M]X?\`V5>_
M?4WGKU[]Q[5_!U[_`(:$_EF?]X:=2?[?>'_V5>_?47GKU[]Q;7_!U[_AH3^6
M7_WAIU)_M]X?_95[]]1>>O7OW'M7\'7O^&A/Y9?_`'AIU)_M]X?_`&5>_?47
MGKU[]Q;7_!UEC_E$?RST6<)\->I5$T(BE`.\/7']Q!/H/^_I^GE@1O\`77W[
MZB\]>M_N/:_X.C7S`-F-UAN+[UWQ87^M]V9$-P`QX4DW"L5MJMQ[3,J1W;M!
MF7PA^VG1ZB02QPBZP/%_R]:T6V^QJ'/_`,R/Y(X3LGN/"(NU_G?CMJ;5P.\O
MYM797QVS>W-J4NV>K,AA]N[1^&%%KVQV;@:G.9"4PTTD\<.X:FKGH7C4(VI-
MR[),^UL910TD_P"KK?ZJ?GTNYV5(+Z=;1JHQMXS3_E'>!#*/D`2QKPZ=MU_-
M7;-9_*0[ZP6,^66VZCY4[9R7;TE?@J?Y#T>$[[VWB,/\NJ_#EZZHQVY).QMB
M8?"[(>*G:N\*+B<:5D`6)0/::^\6/:-HM88P-O>RV_6`**2'<Y\JDDU^>>DW
M*VM^:KYKVH9-]O5BJ=-85MH_"(/\)JU&^7RZC;+[TV5U9LSK#>B_('8NSMN1
M_._XTXCL[/X'^;)N[YT;0HNO,AA>PVK*+?V]]_S;=H^I=NYJM51/CI#]IEVB
M62=CX%7V;7JP#GG:[20@;.;G<V8^6L6:%,^=6Q7\O+H,7Z2Q[7/)MJZKV.:S
M<`#-!>DL<>B5/V9\^C8_-/?F_,_DNC>Y?A+\I-N9'9?RXW7BO@7NS-[5[!BW
MWUKM"NWOE\K7X7Y!=2';E7G=H47=/5M/B\Q1.(=$-=][3&JU-11CV6P17=YN
M,RW8_P`32I0DZ1BOXO(8XU%.->C[<-PCAV^]W^`D32WD,3@+J;N=5IIIW<:4
MS7TZ++\K.Q\WT#\\.H]K8?Y,]B5NR>LL?\1.O<-TK1_('>>U^^<=_>C=;[9R
M>YL9TWV%1U_7OSZVIW'C*MDWGD):JMW#M-Z66>GFI988X76V[SQ7MUX.?\>0
MYJ@)\!*!B*>`!^%^SQL&K5KTGO8K6>PM#=Z`OT,M>^B_VYJ3,#^FW_+L&`'#
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MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UR3]:_\&7_`'L>_=>Z0O7'_'GT
M'_:TW;_[V6X??NO=+C_7]^ZO&5#U;AT37Y#Y1:WN7I/KW?.X\EM?I3=>S.WL
MED(\?OO*=6T_87<.W6V9-L'K;,]B86NP>4P=-/M^MRN4I*6#)T#5]50DN*F.
M!H??N&>O&/<'E4VRED#`T]17HDF[_FQO+JWK'<5!U97&2HZLQG?^\,@O:6]-
MC=EXVMP/6.<Q4-+@<9W-E-Y;1H]S]>8Y\HV)I:C%)N/>$U1''#,NE'JIZ7LR
MM86JD]OT4^:>LSYI_JKT8[,D,>ZQM%;DL-X<J*'\%O%)$/3^W>7S]:="CV-\
M\-[[4QFVIL(G75=NO)[\^3^"S.TGAFJ<IM_:75NVJ7);,W7DL13Y@96EPF%3
M)TF0R]3)#%%D:&-FA,(;R#4UY+)NTD<QI%X@H3PH+V(]!OE];J+;]7TDAMHU
M(7M.0MM)=#^4=>GW?O9_==)O3'KM3Y!=5;PJ^O\`K;Y2;KK-Q[2VA6UVTMSQ
M;$V3U5O7;NWMU[+&\GVO'NBAK<E)#)5T.1K138RJ60+#5-+&$6Y7,-OJ:W!+
M"UD8`8K(+B-0*^78SD4]#T]$R2;IX*VS"$Z%<Z3A'7Q')^QO#_:.@A7^8)WQ
ME*+<F[<;LG;V(HXZ#=M%B-H9F+9<<&.BP/0@[3QF^I:[_2Q'VUEJ>OS:EVQW
M]UJ7&R8659:?(>9C)(IO)DCDT1L&037`!_HK/(L7_5(+_DQT[>7E]"XD6U?Q
M&`+=IKJ<:Y?+_?I;JVS8T>XUV?MN;=N;H-R[CJ\/15^2S6-P(VQ054V0IEJB
MM%A8Z_*04M)315(CB`J)F=1K.@GE1'<:H]'RZ;BF65@9+<I*?,CATJ??NE/0
M0=G=R8OI7.[1W+E<+D<W3Y*@W3A5IL=/2T\L4LC;=J1.[U1\9C`IBMAS<^\?
M??/W^VOV*@AWK>]LWB=+E@H[V-:_[?J7_:/V?O\`WAOI=HV=Q;O;*6R:4Z1O
M^S_[,N?^,>;J/)/_`!=,/]";_AQ[Q]_Y.%<C*`$V+?$2@(&JV%*Y_P!$D#^?
MXL_E3J?A]ROG.<>*V][2K$\)1=-(*8[C'&4)Q^$G%/.O7O\`9_\`9G_/O-U?
M^?3$?]'^_?\`)PODC_HR;Y_O5E_UMZW_`,!-SC_T?=D_WB\_ZU=>_P!G_P!F
M?\^\W5_Y],1_T?[]_P`G"^2/^C)OG^]67_6WKW_`3<X_]'W9/]XO/^M77O\`
M9_\`9G_/O-U?^?3$?]'^_?\`)PODC_HR;Y_O5E_UMZ]_P$W./_1]V3_>+S_K
M5U[_`&?_`&9_S[S=7_GTQ'_1_OW_`"<+Y(_Z,F^?[U9?];>O?\!-SC_T?=D_
MWB\_ZU=>_P!G_P!F?\^\W5_Y],1_T?[]_P`G"^2/^C)OG^]67_6WKW_`3<X_
M]'W9/]XO/^M77O\`9_\`9G_/O-U?^?3$?]'^_?\`)PODC_HR;Y_O5E_UMZ]_
MP$W./_1]V3_>+S_K5TF=V?.':.X\9!00[#W+3/#F,+DR\V0Q+HR8O(P5LD8T
MN6$DB1$+^+GGW[_DX9R3_P!&3?/][L_^MO7O^`FYR_Z/NR?[Q>?]:NFO_9T-
MJ?G9.XB?R?O<3]?^2_?O^3AG)/\`T9-\_P![L_\`K;U[_@)><O\`H^;)_O%Y
M_P!:^O?[.AM3_GB-Q?\`G;B?^C_?O^3AG)/_`$9-\_WNS_ZV]>_X"7G+_H^;
M'_O%Y_UKZ]_LZ&U/^>(W%_YVXG_H_P!^_P"3AG)/_1DWS_>[/_K;U[_@)><O
M^CYL?^\7G_6OKW^SH;4_YXC<7_G;B?\`H_W[_DX9R3_T9-\_WNS_`.MO7O\`
M@)><O^CYL?\`O%Y_UKZ]_LZ&U/\`GB-Q?^=N)_Z/]^_Y.&<D_P#1DWS_`'NS
M_P"MO7O^`EYR_P"CYL?^\7G_`%KZ]_LZ&U/^>(W%_P"=N)_Z/]^_Y.&<D_\`
M1DWS_>[/_K;U[_@)><O^CYL?^\7G_6OKV*^:.U,=N>+/2;(W%+%'@<AB/"E=
MBEF,E9D<761R!BV@1HE`P/YNPMQ?W[_DX9R3_P!&3?/][L_^MO7O^`FYR_Z/
MFR?[Q>?]:NEU_L_^S/\`GWFZO_/IB/\`H_W[_DX7R1_T9-\_WJR_ZV]>_P"`
MFYQ_Z/NR?[Q>?]:NO?[/_LS_`)]YNK_SZ8C_`*/]^_Y.%\D?]&3?/]ZLO^MO
M7O\`@)N<?^C[LG^\7G_6KKW^S_[,_P"?>;J_\^F(_P"C_?O^3A?)'_1DWS_>
MK+_K;U[_`(";G'_H^[)_O%Y_UJZ]_L_^S/\`GWFZO_/IB/\`H_W[_DX7R1_T
M9-\_WJR_ZV]>_P"`FYQ_Z/NR?[Q>?]:NO?[/_LS_`)]YNK_SZ8C_`*/]^_Y.
M%\D?]&3?/]ZLO^MO7O\`@)N<?^C[LG^\7G_6KI&9[YK;3S&=QF7CV/N.%*#$
M9/&M%)78EI&>OK,;4JZ,'MH5:)@;\W86_/OW_)PSDG_HR;Y_O=G_`-;>O?\`
M`2\Y?]'W9/\`>+S_`*U=8/\`9T-J?\\1N+_SMQ/_`$?[]_R<,Y)_Z,F^?[W9
M_P#6WKW_``$O.7_1\V/_`'B\_P"M?7O]G0VI_P`\1N+_`,[<3_T?[]_R<,Y)
M_P"C)OG^]V?_`%MZ]_P$O.7_`$?-C_WB\_ZU]>_V=#:G_/$;B_\`.W$_]'^_
M?\G#.2?^C)OG^]V?_6WKW_`2\Y?]'S8_]XO/^M?7O]G0VI_SQ&XO_.W$_P#1
M_OW_`"<,Y)_Z,F^?[W9_];>O?\!+SE_T?-C_`-XO/^M?7O\`9T-J?\\1N+_S
MMQ/_`$?[]_R<,Y)_Z,F^?[W9_P#6WKW_``$O.7_1\V/_`'B\_P"M?4C!_-;:
M6)SF0RS[%W#,E;AL?C$B6MQ.M)*.OR-6\C7<+H=:U0+<W4_X>_?\G#.2?^C)
MOG^]V?\`UMZ]_P`!-SE_T?=D_P!XO/\`K7TLO]G_`-F?\^\W5_Y],1_T?[]_
MR<+Y(_Z,F^?[U9?];>O?\!-SC_T?=D_WB\_ZU=>_V?\`V9_S[S=7_GTQ'_1_
MOW_)PODC_HR;Y_O5E_UMZ]_P$W./_1]V3_>+S_K5U[_9_P#9G_/O-U?^?3$?
M]'^_?\G"^2/^C)OG^]67_6WKW_`3<X_]'W9/]XO/^M77O]G_`-F?\^\W5_Y]
M,1_T?[]_R<+Y(_Z,F^?[U9?];>O?\!-SC_T?=D_WB\_ZU=>_V?\`V9_S[O=7
M_GTQ'_1_OW_)PODC_HR;Y_O5E_UMZ]_P$W./_1]V3_>+S_K5TQ)\Z-H+N6KS
MW]P=RF.HV_CL*L!R&(9P]'D<M722L6)7QNF055L;W4W_`![]_P`G#.2?^C)O
MG^]V?_6WKW_`2\X_]'S9/]XO/^M73[_L_P#LS_GW>ZO_`#Z8C_H_W[_DX7R1
M_P!&3?/]ZLO^MO7O^`FYQ_Z/NR?[Q>?]:NO?[/\`[,_Y]YNK_P`^F(_Z/]^_
MY.%\D?\`1DWS_>K+_K;U[_@)N<?^C[LG^\7G_6KKW^S_`.S/^?>;J_\`/IB/
M^C_?O^3A?)'_`$9-\_WJR_ZV]>_X";G'_H^[)_O%Y_UJZ]_L_P#LS_GWFZO_
M`#Z8C_H_W[_DX7R1_P!&3?/]ZLO^MO7O^`FYQ_Z/NR?[Q>?]:NNC\_MF,+?Z
M/-U<\?\`%TQ'_1Y]^_Y.&\A+FXV+>6MQ\08VA4KYA@LA8J1Q"BI'#/2>[^Y#
MSG/:R0IOFS,[QL`%6[#$D$44M&%#'RU$"O''14MZ?(W+Y#NO_2_L6EJ\!.N-
MQN,?%Y22&IBR-)20^*KH<HE*WBJ*2K4\6M(A]2E2/>(W./WH=RG]Z+;WVY15
MK?EU@+86W`X&G3I_+K)KE_[N]I#[3+R#S?.EQ,J$"A!(J*5%?,@Y\CPX=6K=
M/=Q;8[DVO!G<%(:?(T\<,&?PD[J:[#9$I^Y%*J^J2EG*EH)0-,L?]&!'OK1[
M3>\O)WNML:;S;E6L!&JS66"XN-(\1BG&NNN>N;?N+[6[Y[:;A+M]U&R;>LC"
M*H(!B#$(1Y4TT^S'3%E2HWUODLP4`;5+,QTHJC;H)=F-E55TFY)``%SQ[E-K
M2_M_!@V\Z[R\D*J!DK$3^FGR*C%/+J,5AL42:YW`A=NMH_$KY5(J>B:=E?(;
M#Y[ISO/LG8O9S]?;"Z7W+MK8V?[)H-CIO[+[BW/N)UAJL9UQA*G-8;'3##+4
MQ&6KE,VK6S1H=&HS'L/M]%M^^6G+NZ;>U]NMVC2".H4CPUUDEB"`*=0%S?[G
M7U[RU?<P;!=K;V-HZ1:JX;Q6*`?E2O1),;\*LM_I?W;V/\A]Z9#NGIK9OQIE
M^4E/FEFW'1Y#L7'9Z"IBV1LW+XZ:6;-[=J<GE:$FMI()GU0PE870.UI?A]U-
ML_JO%;<HVQL^8Y+SZ028'A`?VS5X'],,OYY]#"\/M#NJ<PW.X<USI=[#%M\E
MV8ZU\20QDVXIQJ)BA'S'5:O>F^>I>P.H>J*#:'Q^R^P/D'B*_=59W!G=K;2J
M-O[(SNW:^MG_`+FX?`[;I9JB1X\'!+%`*R:"&<M3L)99WD9@..5[7>]EW=DE
MW:)^39U5B2XJ'"]VHX%6:E!7'0-W>ZV_>=IY=N)-LD'-\KRK=+I-1&M?#J./
M`#JNC<..SU=D7QE'@<_593PM6G%T^#RL^36DA#.]5_#X:1ZL4WC`/DT>,`B[
M#CW(C;CM4K?7&]CH#QU#IVS@W.)/HS:/J/\`1/02[4WYVGUAO3#=@]2Y?>.V
M-XX;*!L)G]ITN5-6<E$VLXWQT<,D.4LD!\U%*LJ2JK!T`!(KN?\`5WF*-;?>
M+R+PS%V:F'[<]"_87YEV&%Y-IB<,S]X`X'T/6\A\%?D?5?+#XL=6=V96AIL;
MN;.4&1P6\Z&BA>GH8=X;3R=3@\[)002#R0T==-3+4HC%C'YBA-UL.>7//+J\
MM<SW5I&XDAED,BD<*$Z1_P`=ZS*Y<OI=PV2VGG_M_#`;[>/^7H[767^8W=_X
M>N3_`/=7@_82Z.^A-`8W_;<A0&+`7&EBRBQO:Y9;6N/]OQ[LB>(XC]>J._AH
M7]!T%W;/>'3'0NWJ#=W>/:_7?3^U<IFZ';>-W#V7O#!;+Q5?N')NZ8_"457N
M"MH(ZK)U?C=EA0EPBEV"H"P:23Q;CZ0^1Z>DC,=N+D>8Z5>2WGM##93:N#S&
MZ=MXK.;\GR5-L3"Y#.XJERV]ZC#8N3-YB':./DJQ5[D?%X:(U=0*-)C%26F:
MT?J"SZ7J@R*])K??<_3_`%;D=H8;L_M3K;KC+]AYG^[O7V*W[OO:NS\EOG/F
M2DA_@FSZ'<&5Q]5N3+^>O@3[:C6:4M,@"DL/=7\%$,:D>,/]0ZU,3;QK-3XO
M^*Z:*_Y$?'_%=GCI'*=X]08WN?["3*CJ.O[*V=2=G'%18F7<$V3&P9\NF[#C
MX<!3RUK3?9^(4L32ZO&-?M(BRQQO--@K2GV>O5J=BR>;"O3-UA\J_B]W?GZS
M:G2WR0Z%[?W7CL;)F*_;'6'<'7N_=P46*AF@II\G4X;:VX<KD(<;35%3&DM0
MT8B1I%N;,#[O$3-"9C@@TZ;>?Z9?$/V?MZ'U?[9N+!+_`%^@NC6/]&L?I[WY
M=.BY!B-QY#_/3H$JGG,;J'!+;XWP`/K?_?TY1B#_`(64W_%O=%548W:\:4)Z
MJZB4K"^2#4=%0WGW!\0-M;TW.=^3]44&]=H=C=3]=[ASV=V+AILK3=I]Q1T]
M9UEMA=UU&`J'K-V92DGIJPZ9S+CJ22*:=X4,;A[;9$N+FVVVT4+]5++IIYHD
M99A]GB5/VFGRZ9WF6Y19XY6+71LU5CYZ&ETD?[QVUXTZ5G9N7^-'36T^R^T.
MPL!U3A\)L7!5.9[0R./V'M3.[EH,%6UE*M5-G<-@\+7[FKH,C6U$3%)8)ON)
M&#Z)&]EJ`#9[6=!XFRQP1QF/RU1RLJ9X@J[U&?MZ5/\`413274$ACW#ZF0J_
MGVQ*6H#CX`1PX'IPVW!T!G(=ZX?%[$Z]Q6,VSN^FV?NNASG5F"VEMW)[NCQU
M'D\:*%<_MS&8K=]J'-J*6LI?N8/-))%"PE65?:B.:WOP)M`+AY9(SGM:I@E(
M^;&.A\OLZ1[5<Q2H7M4TCL5CQU%QXJ<2?XZC_-UEVQO[HBHWMG^E]IR;*HMQ
M]8X;8O8>1V[B]MXS%[9PM+V76[DI-B9[;N1AQM/M.JS&;K-OY%4./F^[61;,
M0TREC!I+D4VER?JC((ZT&6>)K@#\HHV_(])YY+"UA:UD5?HYG^H9<T)BFCAU
M<:U$LB'!`J!T(>178LU?B-PY@;'DR^+KY,'M_<66_NVV7Q>7E)6?"X+.UX^_
MQN5=E(DI:::.?4#J35?W2WBG`-U;U"2.CGSJTFJ-":UK3P6`KCY=+)(8I1&E
MVH98XT2AX:1)*\HH,'4'CJ>.!0CKD]#LB#<F3SDE%LJ#>E#CH(,YFY*3;D&[
MZ##SP+%3P9K+LB9ZBQ4U)9$6ID2!H@%`T@`)K?P[.19H.UY`NDUKB200KQK^
M-AU:Z\%K;P;@:E%2U:Y*1F9B?.NA3TY1[AP4\]#!#N+`2U.6>H7%PQ9O%/-F
M)(&TU:XV..J,F4>G>XD\(D,;@@V(-O&V>X=C:BEUH+DCCEUH?]Y20?83U6&(
M1*+EQV:E5/DZ#M(^P/3\^NUSF#G3*319W!S1X266+.S0YC&2Q8*:$2-/'G)(
MJEH\-)$L+%UJ3$5"&]@O#T@\1OJT_P!QY'D5?05=F3]D94#Y#IZ0R0*+2X),
MD8+_`&*[%C^UB3]IZG0305<,-323T]735$<<U-54DT53354,JZXIJ6H@:2&J
MAF3E&C9E<?0GWM5$<JQ3'XC0'[>'34<BW7;!AJ@?F30=!GN_NCJ[8LVQ8-R;
MPQ<)[([#Q_5.T9<4[YVFJ]^Y2@R>2I,'D*S"KD*3"'[3$3---7&&G@"@2/&S
MH26R3/9SDS$M%67'_/,JR2_M61:]4N6>.20)72NYV:?9#*?"9?L:1&)\ZG!Z
M1_1WRAZ-^1FU\CO;J7>O\:VA0;\SW6M/N'/X+/;&QFX]V[:J4H<O3;+GWOC\
M'_?7'15Y:&*NQ7W=%.\;JDK,C`&L%M+/X-C0_6WD=P\9\P'#&#_><:?RK7JT
MD@:;7'B'T\NC`'@@6Y)TBW(9N.%MP3S_`+S[2QUT`-\8%#]HP?Y@]/N`?U5Q
M&>'2`[`[/V1U?'LAM[9C^$KV-V+MCJC9KI09+(C)[]WF:M=N8>3^%TM3]G#6
M_P`/F+5,YCI8='[CBZADUQ>+#<)9T_4E5V!^4:ZV_P",CJ\4/C6\MRIHL;P`
MC_32@-^U<'Y=,&1[WZIP_9NZ.G\UND8??^SNHW[XS^'R>/R='1T_4T>5R>"K
M-U4N?:B_@5=#B\KAYTJX(:B2JHUT/.L:21W4R!XHE>NHNJ,!_1D!T_LTG]O2
M<(\[L4JL:SS"OR3P](_*I^?31A_DITSG.N^C>V*7=-33;#^1V5V?ANI,[EMN
M;CPT>X<GV#C*[);'I:ZBR.-HJW;1W7#0L*%LC'2QSRR0HIUR1QNJ2`Z0CFDS
MX7[3UKQD:ND=J\3\NAVL1P18_P"/YY(_WL>V64QOX#?VG6WE6!/'8:XNN/O7
M#'6P0PU#@<]<D_6O_!E_WL>_=;Z0O7'_`!Y]!_VM-V_^]EN'W[KW2Y'NZ)K;
M36G6UC64Z'?0O&OV>7Y\.B[_`"%S&P,'BMLP]DYCL&;$;]W3BNN=N;%V3MFM
MWP^\MVY.GRV>BQ:;2Q6W=P5U96U&!P-<3421^&C2(3PM#610S*AFM[Y90(I"
M(]0].'^QQZ%EAS5#MD8MTVN*Z?@)&U4'])@"*CU`()7`IQZ1VUMM]/=I8G%/
M0;N[$KJ+:N1W'MX87=.'I=O5O6.;V[14TNZL'EMNYW9]!4]=Y!:"KQ[,L"4L
M9I(4:F_R>JJS47N=L5%"+=@(`5`IP#&K`5/`DDD?,],ISM<Q2JBP[()U<."+
M:<'6I)#?[D<:FOY#TZ6R]5==P>/>L?9^4I'R0HZ!=\)N?8T*92<QF+%42[@C
MP:X_+K'E#+)#1*\\#1.V-\1QR+0+OZ=VS)<AFQ4D<:,&K_O0!_(=/CFV40BV
M%GL?A*"!3QEXQ-"<:R1V,XI4TU-D@]3*7J396(:'9V+[!W!A)**@KJBAV?CM
MS[6Q]1C=O5<^FL>GP,6)2I7$3T#U--4S-&RUC5/FG::JIJ66G3-M.MO$6Z`_
M+[?\IK]H'58^;)%F"I8;"(GD533Q>!5B1\7#]-5_TM1YUZAP=8]:B&?=X[+R
M-3C:K'TNUIMSG>6U/LJS#PU+T2[2.Z:?'1,,<]/%34*42U*+%+2^:,+63U51
M/YMNG2A683?EPQQ_U>IZ40\\ET4S;7MT]4B9O`+U!DC$CE]1.&9J8]!T.&&Q
MAP^-IL><EDLO)"K-493+5*U-?D:F5A)/5SM#'3TD2R2?YJ&GBAI:>.T<$:1@
M+[410NF7%#T']UWJ'<I%6!?IQYH*'5]IX_/%.G+VHZ*^B0?-<@8GKMS^A<EN
M340+V/VN(^O!M]/?.+^\/;;9-KY9AFDECLY59G5:D,P`()J2:_8>L\/N0=_,
MFXM"ZR7!B-2V#3\J=$(`)`(!((!!L?H??+Q76Y'CPSQO$Q-#)AR`:#52@KBG
MV4ZSXCL8H%\*Y%PLX9JB.A058GM)J:4Z]I;_`%)_Y)][\-O]^6W\^K_3V?K>
M?L'^;KVEO]2?^2??O#;_`'Y;?SZ]]/9^MY^P?YNO:6_U)_Y)]^\-O]^6W\^O
M?3V?K>?L'^;KVEO]2?\`DGW[PV_WY;?SZ]]/9^MY^P?YNO:6_P!2?^2??O#;
M_?EM_/KWT]GZWG[!_FZ]I;_4G_DGW[PV_P!^6W\^O?3V?K>?L'^;KH@CZBU_
MI<?7D#_>R/?O#;_?EM_/KWT]GZWG_&?\W7K?[ZWOWAG_`'[;?SZ]]/9^MY_Q
MG_-U[_??3W[PS_OVV_GU[Z>S];S_`(S_`)NO?[[Z>_>&?]^VW\^O?3V?K>?\
M9_S=>_WWT]^\,_[]MOY]>^GL_6\_XS_FZ]_OOI[]X9_W[;?SZ]]/9^MY_P`9
M_P`W7O\`??3W[PS_`+]MOY]>^GL_6\_XS_FZ];Z?XFPX_-F-O]>RGW[PV_WY
M;_SZ]]/9^MY_QG_-UWI;_4G_`))]^\-O]^6W\^O?3V?K>?L'^;KVEO\`4G_D
MGW[PV_WY;?SZ]]/9^MY^P?YNO:6_U)_Y)]^\-O\`?EM_/KWT]GZWG[!_FZ]I
M;_4G_DGW[PV_WY;?SZ]]/9^MY^P?YNO:6_U)_P"2??O#;_?EM_/KWT]GZWG[
M!_FZZMS;\V)(MR`!<W_V!]^\-O\`?MM_/KWT]GZWG_&?\W7O]]]/?O#/^_;;
M^?7OI[/UO/\`C/\`FZ]_OOI[]X9_W[;?SZ]]/9^MY_QG_-U[_??3W[PS_OVV
M_GU[Z>S];S_C/^;KW^^^GOWAG_?MM_/KWT]GZWG_`!G_`#=>_P!]]/?O#/\`
MOVV_GU[Z>S];S_C/^;KL*2"0+@&QL+V/'X^OY'OWAM_OVV_GU[Z>S];S_C/^
M;KVEO]2?^2??O#;_`'Y;?SZ]]/9^MY^P?YNO:6_U)_Y)]^\-O]^6W\^O?3V?
MK>?L'^;KVEO]2?\`DGW[PV_WY;?SZ]]/9^MY^P?YNO:6_P!2?^2??O#;_?EM
M_/KWT]GZWG[!_FZ]I;_4G_DGW[PV_P!^6W\^O?3V?K>?L'^;KHC3]>/]<<G@
MG@?4\#W[PV_WY;?SZ]]/9^MY^Q?\W7>AO]2?^2?^->_>&W^_+;^?7OI[/UO/
MV+_FZ]I;_4G_`))]^\-O]^6W\^O?3V?K>?L'^;KVEO\`4G_DGW[PV_WY;?SZ
M]]/9^MY^P?YNO:6_U)_Y)]^\-O\`?EM_/KWT]GZWG[!_FZ]I;_4M_P`D^[(Q
MMW$YE@`0AL9.,X!J"?2HX]66UM78(K7:L30$TH#ZG'`>?7N0`WT!-@?P2"`1
M?Z7Y]I)%MY(E:U=KB))?%6)A0!_XJ`#/\OEUJ6UFMI:01+(_^_*D_P"6G\NC
M<?#S9G8V6[&I]S[-KY<%M[",:?=N7FA\^,KZ*1O*^W%I7TK7UM=^JP/^3V$G
M'YS4^YCRK[F\Q>X1YNY:N+C:-EB;_&$4#1,P/>Q#JP[C4G33)Q3K%[[U7,/)
MD'*'[HWN*&]YG9?TW-=<?R&D@8X9!X="C_,,WYN'KOI+Y`9S;)K:?(U[=<;6
MDK:0@U.-QVY:/'T&5J_(A51HHR81)Q82'^OOO#[/V>W;M[@P07R+IB*L"U?[
M3\3<?Q')\O0=<:?>6\GVKVZN);2X>*274KHM,KCU!/5<.X.Z^M.@OY?OQ@ZO
MJME]:]X;I[:WKNSO;?\`M'.[JS:8W;55CIJ>+92;FH-DYS'UM15#&UE.O\.K
MG2!TA.I;V]Y#1;5S#O\`[J;QO.T;A+8W>T1PQ13*JU*S%EE5-2E:4%"=)KY'
M'6*XO.6;+VVVCEF>VBOK;>9KF6:-F;M:U5)(RVEE8=S&G</LZ&Q?DIW=N?X2
M9CO#.[[I]A=N_+[Y,]9_';KS/;2DCV-0=<=1]<URI*FU:E9T_@>!QM2,D9:B
M29VM.S2/S?V%+SE'8+/GV;EVR#7.S[5MES>2+(21+<F)W&IEH=3L%!I3%*="
M[:>;-\W#VYMN:+T&WO\`>MQMK&)A2MO;QS@%E!!%`J$]P/#/0T[MWG+NOY8]
M\?(+9/>>)SVV/C3M+KSICJ7J&A^0^RNLD^2/8.W<)39^MS78>Z<MN7#T];UG
MM_<&['EK)$F9LG/%+&FL+(D@*EGCL^1MMV.]L_\`'=XF>XD<K*QV^/654Q:6
M!)D5*48-04Q4]#&-K63G3=-YCN`5V2VCCC_L_P#'W=,Z^VE4)K5--3Y]`3A>
MW-S3=)X+NF'<.V=Z?*7(?)+<^X?F9F=G_)SJ'I3!;;GZXKGINK=@[[WS7?Q/
M<U;\8\-@*>D>*AV@\JY,1E7:=ZF3VNWFQVV#<Y]FM%NH]N?:;86I*2,?'DCC
M,LBKJ`$CN7%7#``F@!Z-;/<(6V<W<NAMRJQ9QI!!%*#A0*,\!]OET4'OGY==
M];!Z>^`76'Q"SVQ\G\M_D;W'V;\RNT:?J.CVWNC'8O=F_P#=554[>V)+C4CK
M4PFT:C%[A=,A2U0IY)<=C@)S'&SCV*MNY5Y?O=SY@W+G&>2RY2V8"TMZLPDG
M6-,.Q-/U#JJ2`17RZU<[K-9[98';55KZ\'B3.H%2[-3NX@84'`&#U>;\8>GL
MKT5TGM+8.YLM1Y_?+S[@WGV7GL=2TE#CLSV9V!N#);PWW68RDH$BHZ;%+N'+
MS0TD<:JJ4T48`M;WCES)NL6\[J][:$G;CB&IK2,''SXUXDGJ;=FVV;;-MB6=
MM3RKXGV5Q3^71H.LO\QN[_P]<I_[J\'[(:$D4\N/1GT5O^8CL+LSL3H6@P'3
M.Q.[]\]K)V;LW(]?S]#?(/%?&+=&P<]2??,W86Y.U<Y19S$P=?82B>9,ICIL
M1GOXD)HX1C:@L`B=?J7W&,6]3%7*UI7!X&AH?/JKJ&4JV5/'JG+^8'U)\GME
M?%?XD[K^7^?W)WK\J>M=R[YPB=S=-_''#_('X_J_86X]A18#ISO[I;^!X[<^
MYJ3>V.PM+CH]WX+$85Y:ZADI7EI$R0$RF#Z>3<3=6]##(I57&%FD`RD2',#Z
MO]$=I%Q\.:=5>65X1`S?ICR\O]7Y]&URGQQS>1^9'\G;Y2[BZ-W!L/N>;8W8
M&Q^]-M[=K-R9OJ[XXX*C^)>XHJ3K'!X6AJ:W8?6>V_\`2#D'HC)$J25];%%'
MYY?$J`[G$%A?;U+,0]M%M,LENK'X)/J+/2RD4JXC\91Q!#,:<*,0^.Z%B345
M_P`&/Y]%X_F9=G=5?(/(]7;&I_BGWQMVM^1VPMZ=4=X_*_=?P[[S[9WUT)\:
M-D=NY&'<&P.L]D["VMOV/"=N]T;MV_4UNWLL4H?X;AWARU1,VJBB4,QZKFZ:
MY`H'1''V,@(_ET8PB*6P1;I0SC5D_P"F/I3I05_6NX]H_/K?]?\`'RC^7.X]
MV=O;T[+ROR>VSW3\>\11_'?!=$8WXJ3[+ZZWITUW4VQ<AE*O>51F,%MK%XZD
MHMU'-UTE56PU^&ICK<TO+C<9]NO;;7GZ&7PCC4LP`*L/L`/$$=65XV&D@:5P
M!Y`=54?R7^E^V=L_,KX4Y.;X\]LTS=9]?=G8'LO);L_EL8;X3X/J#%[BZKJ,
M369[/_)7$YG^\'RHS#9R*CQ--0YNBBFK9,F^3"!XF4BRS_=ZW%Q'+&IMC;6V
MCNP'\-&D-.(+&I.<UJ*8Z)MUC::Q58"1)K6I`\JY_:.MX==?C<Z/7X]6D,@]
M=T:Y;25;U\VT@V]-KCV'U_W):O\`9:A0?*O^;I>8XQ9")1DKG[:?YZ=`K4#_
M`',[JX^N]M\WN=(L-TY/\_6Y'`'YOSQ?VTY,6WO$,L:];C;7?1R'X13^75!_
M?OQFW#O(?*G:&Y>NMD[YW'2?S-.D/F7UQ1]P4>4QVP^S^K*;9?5\FX=H8G>=
M/LO?E'BJW";?VEF,37*U!-%2TU.34JM*X9J[/N]MLL&U[FREMPL?JE*-\$@G
M+4+D'55*@K3S`)QT:WFSWF^[]*+-*126\:!@\8IH[CVEM0/$<,CAGHF>?^"7
M>6?[A^5O9F0S/2&!J.]NH_DWUE#6[;RNZ\7C-V5>_P#L_878/5FY=W8C_07B
M\_BDVKLW!2X_*SYW<.Y9XO/25-**"AK*>!F-INK#;^5)-A(9H'D@D,A93(I%
MW"2`*@$'4U?09]3T8;IR1S2)5N9!9PE3.RB29$\026[(X&IAJ*`AP%J<,3VJ
MQ`^_(OHS)9'?M;O+);/Z\[\V)D/EYVKV_E.E=^4?:4&TLGLO?GQQV'TY@.P=
MR4V+ZZSU=!V+T_O3%5E71X>/'5,IJ_)3P5-'DS&A0[?ND,*I9,E$@AOR#52S
M-^\KO2&%>&FF1FE*<1TWM/(7,6T<N3+;-M]W=&6S>D=Y;U/@QPVXHQD"".0:
M968D`Q-XZ$P,KD,>H_B]W#MKXR[3HL='L:D[(VGT=_+DI]L]?;NKM[8RGRF_
M?A[V]O3?V]]F9[,[<V3NN'!4.X\'EU3"92F_BXJ7AJ2(Y!25+(;[EN\']98]
MVB%0FZQR!:J%*+ML]H`36H!\3Q&])`%X8Z0O[;<S;@I$ULT4B6=S;'_&+0Z?
M&OH+HR,OBZE:)K81,M/TQ*JRA99(@<U)\5^R*[)XK?\`VAUA\4^_)=R=I_,3
M>.5Z'[1WIW=1=3]2Y7Y*]S[6[9V9WQL[>V+Z9;(YW=NR=LX">DK&I:'!Y=<1
M/'6T=?3T\HD]K8]Y6"S2T15I&D":M:5(MI)Y`3FA\0W!##A1%T_BZ.?ZF<QW
M*N&CM5,@9Q_C,)/ZL:C2`'))0PG3Y2.[1QEGCE54I5_R^>QYNR/FYN>N['Q6
M<R?>'7WRBVUM??N7W=V#1Q[^;N]\4=E]>;VV$?CY'O+;6#ZBIRN*-9G-W[B2
M*LAH$QU'235'@D)+B_@>W@M<4A:&A#K4B*Z2X75W4[F30U,A"3Z=-7G*',<#
M`B*VUEI2=5U;=FJT:W<`^+0A%D-P:&GA(TGP*Q`F_(WX:5N\/DQ\9=X]&8?I
M;9?2GQRD^*F?V,FW,-NW9>]ML9'JSM&KW)W3M.CP_P#H/W+F=PT_8PRM144!
MPFX=LQU62HZR#*1U]2K"`TVS>(K63ZH*KR%0E"ZY`63/&O"3]JJ./2V7DS?V
MM8[31;JB2>+5KFV6A8I&=1,@`C!0=WK)'7#K4O8_EQ=IQ[.^4>P]G[CZCZXV
M=V5D]C9=,-M_>&Y\QE.__P"Z??\`4=LYG&9?L;(_&^&LV7L?=/74E3%$N^*7
ML:JA354S559B(:D$O;<HK/;K;;P"ZQR!]6I=1(C$="`:9IJ^TGIZZY%YFW2\
M>[6*WC!4(P$\;E:$G"HY8NA!5T'=XH,*@R`+U=O\-NL<YTA_+[R?2]/N3&T.
M]MM;.[;-++G\KNK>>S>M<EV)6;HRNTML3[DH=A=55F4P&TJ;*T<M:F)PN(AI
M:5RU)!#3/3@.WUU9;C$M7>*=2"-.FE58')/D:4KY^71#:\LW^U;BL`B::9G1
MM*RP9P'4*2X#$Z:5!(D-?"+:'TU1?#SX,[ZZ9K,4.QGZBQ&"S'R8^,G=N]-A
M[;J]P9K;%#A^K^H^R>M.WZ>CQ6"Z"ZSV^*G/9?<N-JHJ!Z"6I6@R,5/D\A55
M#1SU&WO;:2W2-Q4QQ[@FJJU/U\$,+$U/^@B(-$!@NQ#>0Z?W#E#F:4216UD9
M#)/;RU6ZM#_N/<O<)0^+\,C2&$5J=44J#N1@`O[S_ER]A[M^.OQWZ'ZOH_C[
MA8^L]G=R56<FHL=NC:>4VGW;N3O#^_VT]W;=R<W0F]Z[,PYK:F%I]L5$6&3:
M^XXLY3+2-DRL#4C&=CS!!;[UM^[NFO\`=T5A&JZU`E"A?$9^X&I))-///'JL
M?('-83P3';!B:"MU;Y)K_P`,Q0`L2<:`903&"W6Q]V9U;D/D?MK9&6V5\F/D
M7T/18E,BTF2Z)S&S=MOO5I8:.BECW`O8W6>]#E*#$U%/*:.:DBI(W,L[`S(P
M:-,2I=V3X&ED89!PSL:5%0:5H*'AT4S6UQ8P+M]VH6XCPU"&SQ^)25/'B#3I
M#=M?''?FXMA_%79F&[`W+VA7]%_*#J#MS>?8'<F?Q,V_-T;-V36[LJ\[6U^1
MVWMG!8/*[IACS<$-)314%#%/%&`6#(Q8NF@=]S@N@H(BAG7[3/$T)K_I0VM?
MZ0%<=%]OJ2":!2=$KH3\M#!A3[:4^SHL'SI^(?R7^5^+Z0WEUY!U[TOVX3VE
M\>OD!1MOVMW!1'X>]Z5M/BNR3M3==)MS!3Y??5-B]M8[+8FG:EI%IZZNFA\K
M>`RSK-M0Q;R;B[S;+8PP`>58"Y5O],XD;5Y=HIY]*KJ](VT64:`,9WDUCXJN
M`"IKC2-(^?0N?,38^^=S]7;`Z(V9UA187;='\G?AOA^F,QMC+5^?FQ>Q>L-Y
M;8["WAN[=>)IMMT=/UE0=?[:V)64%*TU961UX:$I)#+,D+7O9IY=YMMPB'Z$
M$H;2*T:GDWR^SIF"!8MDN[<&LTT#@,>*U'$?,>5>K'9I?+)(X`"O))(B@W"Z
MVN5N.&-Q]?S[?GE,UZ;T@!B?A'#_`#],;2&^C%G.-2@?$>/6'VV34U]>E-`N
M!P'7)/UK_P`&7_>Q[UU[I"]<?\>?0?\`:TW;_P"]EN'W[KW2X]Z()%`2#UHA
M6PPJ.BV_([86_MX3_'_<G7VW:#=E;T_\A-M]J9W;U9N?'[1GR>VL=L7L/:];
M!BLQEJ6HQ@RJ5NZX)$CG,<;Q1R>O4`IT`P%"2>E$-U=0D+#(52N:`<//[.BW
M;B^*'8V_-R=B]A;OV_@VJNW*ON+(;FZUQG8U1BZG;U!F^G^LNJ>O<'CM_P"-
MVW7TK[CK8^OFK\ID$HI<=3U51'"8JBF1Y"GDLX9!D4Z+Y(Y&W,7`DET5X:V_
MS]!EG_AQ\A-P[<V/_$9=OUU-M?-=\4E#UU0#X]X+(?P/MG![/QVWMW;[K7Z2
MSO2.Y-[8:NP61BR%;AMNXO(KC<LLE'-+6I4&=2J0J@70"0.-34_;T]-"'F=\
M=Q/%5)_;2I_/IBE^#7?55O;;,VXJ3";SQ.$W-E(<UN`=L4FU/[S]:U_QLS_4
M<F!ER-%UU4=OY'L#(Y_(4Z9*OR.2?$TU'`*O'44,NJ$Z>.%SA`!]IZ?MY!;Q
MA-$34D#U*+Y!EIPX=U?M'2CG^(/?U7MG8BSQXML3U_V;N_/8OK&"H^/46YL_
M@MU=58+8-#GM]YR7IBNZ"W=N_;&=H:J>EF?;E-6G%5EFJS71$R/6SK:DE%!U
M"AKTW&TL(80-X>M$4Z54$A%"BM!G`\_,]6.=*;)RO6G3_6/7F<R39C,[)V/M
MW;.5R;9.KS0JZ_$X^*FJ6BR]=C\16Y&FBE0QQ32TE*[Q(I,,9]`W)*9,D`'I
MF&!(M3/WRDU#'B/]7#H3O;73W2.S/7>SNQMW;8P^]L+#G\918;=F4IZ2HFJH
M$CK4J-LP+,'HYZ>0D0S.MB2+-]+^P-SO[;\F^X=MMMMS591W,>V@A=0KXE<'
M57A_M>ACRESSS#R-N4VZ<L3-:S3+0A20!\P>/3W_`+*I\?S<_P"CG'CD\#(Y
MH`<G_JY>XY;[K?L.[%SR]:U))P6''Y5Z&T/WA/>*"(1+O=P5%>(6N23Z?/KW
M^RI_'_\`Y]UC_P#SXYK_`.N/NO\`P+/L-_TSUM_O3_Y^G/\`@BO>3_H]S_L7
M_-U[_94_C_\`\^ZQ_P#Y\<U_]<??O^!9]AO^F>MO]Z?_`#]>_P""*]Y/^CW/
M^Q?\W7O]E3^/_P#S[K'_`/GQS7_UQ]^_X%GV&_Z9ZV_WI_\`/U[_`((KWD_Z
M/<_[%_S=>_V5/X__`//NL?\`^?'-?_7'W[_@6?8;_IGK;_>G_P`_7O\`@BO>
M3_H]S_L7_-U[_94_C_\`\^ZQ_P#Y\<U_]<??O^!9]AO^F>MO]Z?_`#]>_P""
M*]Y/^CW/^Q?\W7O]E3^/_P#S[K'_`/GQS7_UQ]^_X%GV&_Z9ZV_WI_\`/U[_
M`((KWD_Z/<_[%_S=(O??QGZ/Q&&I:K';!Q]/4/N+;%&9?OLPY^VR&:I:.LCL
M^0(M-32LI_I>_O1^ZQ["G_G7[;_>G_S]67[Q?O(/^6U.?]JO^;I/GXZ]+7/^
M_$Q_U/\`RG9?^O\`VL/?O^!8]AO^F?M_]Z?_`#];_P"",]Y/^CS-_O*_YNNO
M]ETZ6_YX2@_\[LO_`/7#W[_@6/8;_IG[?_>F_P`_7O\`@C/>3_H\S?[RO^;K
MW^RZ=+?\\)0?^=V7_P#KA[]_P+'L-_TS]O\`[TW^?KW_``1GO)_T>9O]Y7_-
MU[_9=.EO^>$H/_.[+_\`UP]^_P"!8]AO^F?M_P#>F_S]>_X(SWD_Z/,W^\K_
M`)NO?[+ITM_SPE!_YW9?_P"N'OW_``+'L-_TS]O_`+TW^?KW_!&>\G_1YF_W
ME?\`-U[_`&73I;_GA*#_`,[LO_\`7#W[_@6/8;_IG[?_`'IO\_7O^",]Y/\`
MH\S?[RO^;K-@/CCTM5[S@QD^Q:!\>^U<KD'IOO<L`U9!E\%3P3ZQD`X,452X
M`_.KW[_@6/87_IG[;_>G_P`_7C]XSWD(I^^IO]Y7_-T)_P#LJ?Q__P"?=8__
M`,^.:_\`KC[W_P`"S[#?],];?[T_^?JG_!%>\G_1[G_8O^;KW^RI_'__`)]U
MC_\`SXYK_P"N/OW_``+/L-_TSUM_O3_Y^O?\$5[R?]'N?]B_YNO?[*G\?_\`
MGW6/_P#/CFO_`*X^_?\``L^PW_3/6W^]/_GZ]_P17O)_T>Y_V+_FZ]_LJ?Q_
M_P"?=8__`,^.:_\`KC[]_P`"S[#?],];?[T_^?KW_!%>\G_1[G_8O^;KW^RI
M_'__`)]UC_\`SXYK_P"N/OW_``+/L-_TSUM_O3_Y^O?\$5[R?]'N?]B_YN@Y
MW5\;^E,;N?"T-'L3'PTE7M_.U=3%][EV$M129#"0TLA9L@6!ACK)!Q]=7/O7
M_`L>PW_3/VW^]/\`Y^KC[QGO(/\`EM3?[RO^;J!_LNG2W_/"4'_G=E__`*X>
M_?\``L>PW_3/V_\`O3?Y^O?\$9[R?]'F;_>5_P`W7O\`9=.EO^>$H/\`SNR_
M_P!</?O^!8]AO^F?M_\`>F_S]>_X(SWD_P"CS-_O*_YNO?[+ITM_SPE!_P"=
MV7_^N'OW_`L>PW_3/V_^]-_GZ]_P1GO)_P!'F;_>5_S=>_V73I;_`)X2@_\`
M.[+_`/UP]^_X%CV&_P"F?M_]Z;_/U[_@C/>3_H\S?[RO^;KW^RZ=+?\`/"4'
M_G=E_P#ZX>_?\"Q[#?\`3/V_^]-_GZ]_P1GO)_T>9O\`>5_S=3]K?&_I3(;G
MRU!5[$H9*2FVWB*R&#[[+JJ5-1F<K!-+=<@&)>*!!R;<>_?\"S[#?],_;?[T
M_P#GZT?O%^\9_P"6U/\`[RO^;H1O]E3^/_\`S[K'_P#GQS7_`-<?>_\`@6?8
M;_IGK;_>G_S]5_X(KWD_Z/<_[%_S=>_V5/X__P#/NL?_`.?'-?\`UQ]^_P"!
M9]AO^F>MO]Z?_/U[_@BO>3_H]S_L7_-U[_94_C__`,^ZQ_\`Y\<U_P#7'W[_
M`(%GV&_Z9ZV_WI_\_7O^"*]Y/^CW/^Q?\W7O]E3^/_\`S[K'_P#GQS7_`-<?
M?O\`@6?8;_IGK;_>G_S]>_X(KWD_Z/<_[%_S=>_V5/X__P#/NL?_`.?'-?\`
MUQ]^_P"!9]AO^F>MO]Z?_/U[_@BO>3_H]S_L7_-TET^,?19WGD<6=@4'V$.T
M\+D8J?\`B&8TI756;SU+-4:OXAK)>FI$2U[6'OW_``+/L-_TS]M_O3_Y^M_\
M$5[R4I^^I_\`>5_S=*D_%/H`F_\`HZQ_/_5QS7_UR]^_X%GV&_Z9ZV_WI_\`
M/U[_`((KWD_Z/<_[%_S==?[*G\?_`/GW6/\`_/CFO_KC[]_P+/L-_P!,];?[
MT_\`GZU_P17O)_T>Y_V+_FZ]_LJ?Q_\`^?=8_P#\^.:_^N/OW_`L^PW_`$SU
MM_O3_P"?KW_!%>\G_1[G_8O^;KW^RI_'_P#Y]UC_`/SXYK_ZX^_?\"S[#?\`
M3/6W^]/_`)^O?\$5[R?]'N?]B_YNNQ\5.@`01USCR1^#D<W8_P"VR0/MR'[K
M?L,DRO\`U?MA1@:U8TH>.3TFO?O#^\KV<J+O,[L8V`6BBI*G%0*YX8ST3K=O
MQ:7=/R`K=H[*Q`VGUUAL1MVHSV6I1/41TC9&E,LM%CI*IY&J\U7+PJZBL0)=
MB`+'"CFK[JXWW[Q;\N;'`^W^W_@:Q<0J"^LK71I<&.E<>M.LM.6?O#2<O>R:
MW]_<BYYR,9/AN3IK2M"1W`#_`%9ZLDVAM#;VQ<!C=L[8QT.,P^+ITAIJ:(>M
MWL3-554OZJFLJY"7EE:[,;<@`#WTMY0Y0V7D?E>'EC885@$<2(\P`$DC(H4N
MP';J8@EJ>9/6!/,'-F]\W;^>9=ZF:2:0EO"J3&-6:"O=05H/ET7_`+6V'MGM
M%NX.O-XT/\0VUN[%;:Q.5IU?QSK')M^*2&II)A_F*VCJ8DEB?D+(@N+7'L<;
M?OLFPW]ON4"E9(BM2*]U/4_/SZ!^Z\OP<RV-Q874<;P2@_$<K7T'#'E7CUK2
M_(S^6G\D.GLEFLCUSMN7N38OEJ:K'9;:HB_OA!2LTACI\[M1C#7/7*[*K24@
MJ8'MJ#*/2,S.5_>ODG=+9(]V'T][*BAF2I+E,@-J\LXZPIYJ]DN8-EG<[0TC
MQB0Z,#L#?%2G\0H#]G2S_FBT^>ZPZF^"7Q3Q>$S-?3]0]`1;VWJV,Q.0K<:_
M8O:=2*G,T\U11T=13RY"A.-G\B.X>/[A0`+^TGM5?[1O.^<S\Q7$UO"UPZ)"
M\K4T(DBT(KGN`X'&>A3[G[!S!8[#R[M&W05LX48R1BM-90DG'GFG[>JA</TC
MW=V)41TVS>DNRMTS2J5IDQNP\]5P*O%@]5_#XJ>!5)-B[FP/^M[EM]_Y5M)(
MIKO<=L/@@ZAK^/'&GD1Q`'$XZCZPY6W^:&2(V\JO,PTFAJGR'K7^ET=+IG^2
MO\M.WJVEK.RZ3;706TBR2U%9NVHI\_NY:)K,W\*VE@7G1)`/HE;44R!P"=)Y
M]QUO_OSRQLL6K;95O+D&NN2-`Q'DO:.`ZEO9/:?FZ[7PMP8PK_1/^?K8I^'?
M\O\`^//PJQ%4W6>`FS/8&;HOM-T]J[I2FJMY9J&0K)/1T;4Z)1;<P\LES]K1
MJNM;"9YBH;WBM[@>XF[^XE^+C<V#;4I)$(J$<>1:F:_9U/'*O*-GRS:QV]S_
M`(U-&M/U`!0_+3Z='</))N23:Y-N3:UP``JBP^@`'N/Z(K$1C3#7M4<$'\(\
MZ>>?7H6L[.U2>WR'D!Z#Y=*3K+_,;N_\/7*?^ZO!^[`T!'J*=5Z$SWZ#3`K*
M0'#>O6J=<)(XY@%ECBE35$YCGABGB+0R":)C'*KQEHYD5U)!LR@BQ`(T-7CM
M<L29G&ER>++_``GY4ZKHZY(-`])87M<ZGU,.!9G+&1C8?J)U'ZDDDGWZ8F>W
MN+>0U%Q;^"3YJM2:CRKPP<8'3T;^%&8P*@]95FF0.%FE&L'5:1EN25Y.@I<:
M`18W`#&UN/=H3X"HJYT0QQ_:(T5`?M.FI\J\.JU(30.'7#4UBA>1HBVHPL]X
M=14J2(P`BDK87`!](YX]Z!`DUT\S4>H9&0C[.ZOV@=-JFDDU)KUS>::2WEGF
MF`4J!-*\FF[%R06/U9F-[W`X`L![HRU^$Z>X''RC2,#[*(#]I/ETXITFISUQ
M7Z/_`,%'_0Z^[>5//K7G7HN&1@W6V>W::+([>AICOG?#11UF)R%34+?=.3#!
MY8LM#&]S].!;VW,IDE4#^SQ7JK*UI:?4RT[B0*9/6#Q;YX'\:VO8$D#^`Y6P
M-K$@?QRP)7C_`%O:LB!G6V\)&B+%17^()K-?04.#Z]*(9;V"`*K01W!%=1C=
MFH<BK"50<?(4X9X]=>'>[7U9C:Q']&P&4M^/P<X1^!_MO:=S;E(]$$>B1`P^
MPG%?GJ7IEKG<HU=KFZ\>D9>FAETZ2*A-4CZF<'30:>TMQZY"/?((TYK:ZV-P
M5P.5%C</<?[G./7ZO]?GZ^]Q):I<)(8$)#5:G\)8N]/4EBU!Y]4:]N0CJ69+
M1(5E(2@)#9"<*5C6D)7RC1?LZXB#>XO;+[5Y`_YA_*?BX4<9O^R&-OZ7]IH/
M"FC"/`GC+`%;T\76KUK_``Z%<%OXB!3/5R;^)V0W5T[++X;5<#60C,U3I_T8
M+K<_QJO'CUR\6^>?]S6US]0?]P.5M9@%8?\`%\_*K8_U`M[>$<1`/@QT-/YU
M^7E3K0D(75X,OG_Q(^RM/T_/`7^$AB/B/77BWQ;_`(O.UN?^K#E?P;C_`)??
M]>?]?VV([=C_`&$?6G2W<!KB&5CQH+C\S_H>-2UA\]-=9U(#$>_'OB]_XUM>
MY/)_@66Y_4+_`/%]_HQ_VY_K[OX4*X\&/_5^75U:W"TDAF;_`*B*5'\.8S3-
M&J:CLI2K`IQ,.]R`#F-JD?2QP&5/XM]/XW;@<?ZWO?AP$U,*5_U?+JVN92/H
MI9+9A\18M*''`T`:,H7:L@-6*:M)U,"Y]X=[\_[F=K<DDC^`97G4""2/XY8W
M!(/]0??NSX?!CT_;_L=7NI[VZ8)+-'I\Y$C9)%/\2$RL!FE!3`U`$:JCWAWO
MR?XSM6Y))_W`92Y)()U'^-\W(!Y_(]^"0^<,=/\`5\NMP,UL/T[J[_WH?8!7
M3^%M4E?,2:`%9&D?OQ;X/_+ZVO\`@@_P'*\'_P`_GU!][F6$I2&&/52X_:VK
MP/+RQJ_A^?5/'BI3P)?^RCYU_P!]^O=_IP#_`&=8VZ,&]3;_`',;6_\`/!E.
M+``?\OO^@M_K>_("$4$!3I%0.%:9I^?6WD5U%`5^1;41_MJ"OVT'V==>#>W_
M`#N=K#D_\N#*?G_#^-V]N,[+"5CIXGE7I,BE:U\SU[[?>Q%CF=K6^EOX!E+6
MX_'\<M^/=4)>#1<?'6N.G*`\>N0BWP`P&:VN`XLX&!R@#"X:S#^.6;U*#S^1
M[]J91I6FGK8XT_!Y]</M]Z\6S&UO];^[^3X_];?OW3M8U_LZTZ[\&]?^=QM7
M_P!!_)__`%[]^Z9/'KDD&]M:?[F-J_J7Z[?R?]1_U>_?NO=(KKZ'=[;2HC!E
M=L1QG*;K.F3!9-VU?WOSRN;_`,;X4LO`_'OW7NEG]OO7_G<;5_\`0?R?_P!>
M_=68**GAU5W"+J-:=>^WWK_SN-J\_P#9OY2UC^/^+W]+'_>?;R1M)<FT%/%5
M-6>%/D?7Y=:9QI)''KOP;VL`<QM8CZ@'`92U_P#`?QRU_:>218FTM7IV-E:U
MK_HW^KSZZ^WWM]/XSM8#^G\`R@''^`S=K^[HVL`KP(7_`(U*L(_XVX)_HU/E
M3JL*M*OEJ''[>O>#>P^F9VL+@`VP&4%P/H#;.<@>_*P8:APJ1^PD?X1UM`9'
M"+Q+A/S(9OV44Y^SUZ[$&]Q_R^=K"_!M@,I].1;_`(OGTL3_`+`G^OO?5$8.
MH8<"J-^3H''YT(KZ&HZZ\&]?^=QM7_T'\G_]>_?NK@5-.O"#>O\`SN-J_P#H
M/Y/_`.O?OW7F&GKV%I=[#?>#1,OM43_W;W:4=L%EGC$'WFV"8W09Y"SZF4J;
M^E00;^]@?JM$W:RBI)P/RZJ3W:4!8_T<]#&:+L`DG^.;-^I_YAS,?U(_YZ+W
MZ$&>,2QY0\/VTZ?6UO6&I8)2I^2_Y6ZZ^R[`_P"=YLW_`-!S,?\`V1>W/`D]
M!^WJWT=__P`H\O\`QG_H+KWV78'_`#O-F_\`H.9C_P"R+W[P)/0?MZ]]'?\`
M_*/+_P`9_P"@NO?9=@?\[S9O_H.9C_[(O?O`D]!^WKWT=_\`\H\O_&?^@NO?
M9=@?\[S9O_H.9C_[(O?O`D]!^WKWT=__`,H\O_&?^@NO?9=@?\[S9O\`Z#F8
M_P#LB]^\"3T'[>O?1W__`"CR_P#&?^@NO?9=@?\`.\V;_P"@YF/_`+(O?O`D
M]!^WKWT=_P#\H\O_`!G_`*"Z0G8U+OE-OTGW&9VHZ'=.T`%@P.6B;6<_1*A9
MFSS@J&/(]^\"3T'[>M?1W_\`RCR_\9_Z"Z3)I][7-\SM2]S>VW\G]?S_`,OO
MW[P)/3^8Z]]'N'_*/+_QG_H+KWV^]?\`G<[4_P#0?R?_`->_?O`D]/YCKWT>
MX?\`*/+_`,9_Z"Z]]OO7_G<[4_\`0?R?_P!>_?O`D]/YCKWT>X?\H\O_`!G_
M`*"Z]]OO7_G<[4_]!_)__7OW[P)/3^8Z]]'N'_*/+_QG_H+KWV^]?^=SM3_T
M'\G_`/7OW[P)/3^8Z]]'N'_*/+_QG_H+KWV^]?\`G<[4_P#0?R?_`->_?O`D
M]/YCKWT>X?\`*/+_`,9_Z"ZS;;I][G?D"IF=K"8[+S&EFP64,/B&=VZ-)C&<
M5M=S];^]^!)Z?SZ]]'N'_*/+_P`9_P"@NA;^R[`_YWFS?_0<S'_V1>]>!)Z#
M]O6_H[__`)1Y?^,_]!=>^R[`_P"=YLW_`-!S,?\`V1>_>!)Z#]O7OH[_`/Y1
MY?\`C/\`T%U[[+L#_G>;-_\`0<S'_P!D7OW@2>@_;U[Z._\`^4>7_C/_`$%T
MV9:MW7@H*>JS&Z]B8VFJJZEQD%15X'+0P/7US-'14IF?<:QQRU4BE4U$!FX^
MI'LIW?>-JV"%;C?+F&TMG8*KR-I5Y#\,2G-9&_"N*^O3]IM.[WUQ])9VL\MU
MH+Z%4%M*_$U`3@>?3E]GV`21_'-FW4V8?W<S%U/X#6W%Z21_O'M:DA:%971T
M9A4*PH]/(D5.#Y$$]%L<B2>(/ADBDT.IPRL:X(_+H+]Y4^^%W;M]9,QM8S';
M&XM+)@<JL(093;^L-&V=8L[:A8W]V1A)6E13UQU:8^`5#@G4:"F>/3=X-Z_\
M[C:O_H/Y/_Z]^[=;Z]X-Z_\`.XVK_P"@_D__`*]^_=>Z]X-Z_P#.XVK_`.@_
MD_\`Z]^_=>Z]X-Z_\[C:O_H/Y/\`^O?OW7NO>#>O_.XVK_Z#^3_^O?OW7NG#
M9]/O=MW9I8LOM595VQ@G9I,#E&B\?\9SB`1QKG%*R:CR;\C_`%O?NO="E]EV
M#_SO-F_^@YF?_LA]^Z]U[[+L'_G>;-_]!S,__9#[]U[KWV78/_.\V;_Z#F9_
M^R'W[KW7OLNP?^=YLW_T',S_`/9#[]U[KWV78/\`SO-F_P#H.9G_`.R'W[KW
M20AI-]#?V4!S.TC-_<O;YD;^`9?PM#_>'<9C18SGBRRK*K%FO8J;>_=>Z5PH
MNP;#_<YLS_8;<S-O]A_OX??NO==_9=@_\[S9O_H.9G_[(??NO=>^R[!_YWFS
M?_0<S/\`]D/OW7NO?9=@_P#.\V;_`.@YF?\`[(??NO=>^R[!_P"=YLW_`-!S
M,_\`V0^[QZ-8\2OAU%?L\^M@E3J'$=>^QW\"W^YK9GJL6MMK+C6P`4%C_>*[
M$*+<_CVBMXWMMN&B.,[M]7J+_P#":\-5./R_GTQ<?4W6))&"?PUQ^SKWV78/
M_.\V;_Z#F9_^R'VNF</,[K\)8D?F>G5&E0HX`=`KD*7>@WOO/5EMJM*#MCSN
M,%EA&ZG;Z^%8T.=8HJ?VN?4>?>UO+A%^F,4;6W&I.:GCBG5&@1F\42.LIQ0<
M,=2/!O8&XS&U@;ZK_P``R@.KCU?\7SZ\?7W4S&)3]-&FL^9-*?9UM5,;`XD#
M?%J^7"G'KDL6]U%ES.UE_P#)?RG'^VS?O8)M=+VDLC*W]I$255C_`*;/`YX>
M75@L,[F:]C1Y$_LQQ&<&OICKOQ[Y'_+\VN/];`Y4?[UG![2S1P7+:I82#_S5
M)_R=6\6-<1VL(_U?9UP\&]@;C,;5!Y/&`R@-S]3<9OZGVX%0_&@;[3UXEG^)
MV'V=>\&]?^=QM7_T'\G_`/7OW:BC"BB^GIUJE,5)^9Z]X-Z_\[C:O_H/Y/\`
M^O?OW7NGWKJFWRU/NE:?,;2C5=X9$2B;;^6E+3+C<.=4;+GD*)I;Z?GW[KW0
MB_9=@_\`.\V;_P"@YF?_`+(??NO=>^R[!_YWFS?_`$',S_\`9#[]U[KWV78/
M_.\V;_Z#F9_^R'W[KW7OLNP?^=YLW_T',S_]D/OW7NO?9=@_\[S9O_H.9G_[
M(??NO=>^R[!_YWFS?_0<S/\`]D/OW7NN:T78%I+YO9IN@M_OW,SP?(AN?]_#
M]+`^_=>Z0M18YC=5QP=\;UL?]?=N2'^]'W4%A8O,P(<5IZ]:DUW!@LP":R#%
M#P)ZH%F^2/\`,1WI\Q>\=F=)U'<V]]H]5_.?:/3-)LQ/C=TH?BQCNBXL=UGF
M>RYNP_DED,_A>V<-O[";7W/E:^FBHH*EWJ4HH4$WE,1WM$BR[5!>W%%D$\[G
M4:414*:\_AJ*$GM'V]'7-MO]#OCVD&4"0@4SWO$A"X_$2>''Y=!A\/OG+\P^
MYOD7T3UQG.VNT<C4]R[W^2,VX=H]D_&OHWJ[IF+H7JK<W8.SIM]_&SN?$Y)=
MY]N=C[`SN-P2RXBJHIA(L]5-60-2Q"<VM0GT/B2$+HM(V%3^`EZMG\-2*,,9
MX]!J&0RW,9-"EM,)'`/$QX,9''4=64XXX=#-\(?YCF\>PMY_*?(?*3Y#=,83
MJ/X.4TG5FZ-S;:V_+0P_(/)U?9><VYC?EI-IVV:S;&PJB+#1[:@QFWC4XI]Q
MI7LTOB6G5%=J-%LMQ(#J,D8R,E7-`WV'R/`^72B:'5+)8IF/PYY]7D?&4:8Z
M\*H3\/$9%,=#]WE\RN[NO>_MM9?:8ZRW)\8,Y\)?E-\C^OL?A#E,IO;MK/=/
M=>[.WMM[.YW(U^-QO]T-JS2[A-/18Z@,E540ZZBKE!:&!"K;[Z*3:;FY9)!?
M):S,!3!!W&"%&I\5?#UL#2A2I%0">GKUFCWI8."/N@7\S$XI]M"<=$MK?F5\
M_4V:O4&S=\R]U][;MR'Q$[)P.\^M^NOCYLS>^*Z\^0'1&_\`N_L?K7:FTNUM
MPXOJ?<N8V53[*A3$3UFO)SXRK:2;RRA75V[=H]RE@C4_3(;L:LZ3X<%DZFH\
MJRL!3T/H>KP0Z[R)'8")A;5!\B]Q>1D?+$:DZJ`8K@]79_%'M&@[M^,_1_;>
M.W3G][P;\Z\V_F9]V;KVS@ME[HS65\#4>;GW#M+:Y;;6`S46:HZF&JIL<6H8
MYHS]NQB*DF&XQQ0%A$P.32A&>BG:+DW<]PDA[4D8"I\@32GRZ,`?^(]EL#.R
M5D!#5\^EB2`ABQ%`Q'77M[I[2VD/0Z3Y^77O?NM=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7)/UK_P9?\`>Q[]U[I"]<?\>?0?]K3=O_O9
M;A]^Z]T$GS"[`WAU5\9.X>PNOZZIQF\]L;<H:K;U=18W"YBOIZVMW)A,2[X[
M%[CCEV_6Y$TV0D%.E:IIO,5,GI!(+MQ>1&M%C!(?<;5&H*T1YE#L?154DL3@
M#)-.E5I"L\QC;AH8_L%>BP8/Y4;PZNW=V!M/N#_2_/1[(W)MK+4]#VAM_I_;
MW:S;!RO3?;F_LEFLHO45)E>N<_M6MSO5U108I:*3'Y:&M@F^\E^W$?E--V%Q
M:)M=Y$C:Y]RNXI*`]L21,8V;^%&:@5C12<`GHD7ZCZ]H)$=4!(R"!@T/$>50
M#Z$_/H4J#Y8;[EW[L3IFOZ=V[0=Q]J87:^]>OL0>SZJIV+/L7.[:WANO)5&Y
M=WT^Q6R6(W5MRCV14T<M%2XRNI*VMJ(C35;0++*K4T+?NPSL")0/3/1YM=NT
MNZ"U<'37T/R_R=%_Z7_F(Y[<6'V/MS<NQ)MR;\IO]'6V.RZJFI=W03)OOM!Y
M*K%/M]-G=;YW851L[9U#DL:<W75.8QM0())I:2DJ#`1(]+"\-C#.`="P!W/#
M2HA:X#-7@NM`*GSITU<1S0[E<6Z*QK/(J``]VBI8"G'2H):G``DX'3?TG\_=
MX4>S^ML3VM@*GL#L+,;&ZP[/[)K-LX_<\YH\?WQNW)XO:.V>K\=LWIZ+;^8.
MR\-0/5UR9VNQ,R4R*@JZ^;6_M7?6DEM-X6EJJBEL'!90]#Z'N!H<T(/26".[
M,+3)'(<,ZD*2"5*J*&GF&;AZ'H78/G!OM]L8+<%3T!*9-\=6+VWLZAV[N_/;
MXK\9M/&]EXGKC>&6W[AMI]<9'<L&,VTFX*+,@[?H,_5RX]I$,`EC:R%%:0D1
M@L1Q`S3[:<.GKM5L-1N"(X5,@U-VC3"2NJK4[1&NHG@%[N&>L&Y/YAFVL*=L
MQ8;:5'OBJFZKQO;6[O[CY/?>ZL;)BLAOG/;#7;'6V3P/5>27-;O3(;3RDTE+
MN--L"E%,L%0R5+/%'L(YX`FGRZ33L^AXX`6N0672,MJ33K6@S5-2ZQQ74*TJ
M.K&E9)(H98F+1SPPSQLR-$_CFB26,R0L7:%BC@E"S,ANI-Q[HQT?%C[>M632
M2"DX*MZ$$'^?05]B=OX'IG/[1W-N#'93*4>0H-VX6.GQ(IFJ4FD?;E6DKBIF
MA00^.E8$@DW(]P9[[^^.U^Q^R[?N',$1N9[J2FE!J9E\R`M20/48ZFGVC]HM
MS]U(95Y<E6"XA^/4::/+O!IIK_2ITG%^?/6)4$[1WP21<VCPZ\GD\-7W%O<%
M7/\`>`>T8F(CY>WF5*#NB:T6,]HKI6619`*U!#J#4'RIU,LGW(^>V<M<7^UM
M,>)8,S'TJ54@XIP)QUW_`+/QUA_SR&^?^2,+_P#7#VG_`.3@/M-_TS6__P#.
M2P_ZV]4_X"'G7_E-VC_>9/\`H'KW^S\=8?\`/(;Y_P"2,+_]</?O^3@/M-_T
MS6__`/.2P_ZV]>_X"'G7_E-VC_>9/^@>O?[/QUA_SR&^?^2,+_\`7#W[_DX#
M[3?],UO_`/SDL/\`K;U[_@(>=?\`E-VC_>9/^@>O?[/QUA_SR&^?^2,+_P#7
M#W[_`).`^TW_`$S6_P#_`#DL/^MO7O\`@(>=?^4W:/\`>9/^@>O?[/QUA_SR
M&^?^2,+_`/7#W[_DX#[3?],UO_\`SDL/^MO7O^`AYU_Y3=H_WF3_`*!Z]_L_
M'6'_`#R&^?\`DC"__7#W[_DX#[3?],UO_P#SDL/^MO7O^`AYU_Y3=H_WF3_H
M'I+[N^;?7.XL734%)M?=]/+%G,#DFDJAB@GAQ.5ILA-&OCK7]<D4#*+_`)/O
M?_)P'VF_Z9K?_P#G)8?];>O?\!#SK_RF[1_O,G_0/3&?F5L&YMMC=GU_KC/]
MOQ46Y]^_Y.`^TO\`TS6__P"]V'_6WKW_``$/.O\`RG;1_O,G_0/77^SD[!_Y
MYC=G^WQG_P!4>_?\G`?:7_IFM_\`][L/^MO7O^`AYU_Y3=H_WF3_`*!Z]_LY
M.P?^>8W9_M\9_P#5'OW_`"<!]I?^F:W_`/WNP_ZV]>_X"'G7_E-VC_>9/^@>
MO?[.3L'_`)YC=G^WQG_U1[]_R<!]I?\`IFM__P![L/\`K;U[_@(>=?\`E-VC
M_>9/^@>O?[.3L'_GF-V?[?&?_5'OW_)P'VE_Z9K?_P#>[#_K;U[_`("'G7_E
M-VC_`'F3_H'KW^SD[!_YYC=G^WQG_P!4>_?\G`?:7_IFM_\`][L/^MO7O^`A
MYU_Y3=H_WF3_`*!ZSX;YF=?X_<\.<FVUNQZ>+;V1Q#01C%F<S5>3P]='*-54
MJ&-8J!U^H-S[]_R<!]I?^F:W_P#YR6'_`%MZ]_P$/.O_`"F[1_O,G_0/2^_V
M?CK#_GD-\_\`)&%_^N'O7_)P'VF_Z9K?_P#G)8?];>O?\!#SK_RF[1_O,G_0
M/7O]GXZP_P">0WS_`,D87_ZX>_?\G`?:;_IFM_\`^<EA_P!;>O?\!#SK_P`I
MNT?[S)_T#U[_`&?CK#_GD-\_\D87_P"N'OW_`"<!]IO^F:W_`/YR6'_6WKW_
M``$/.O\`RF[1_O,G_0/0)_('Y8;*[7ZUR6S<%M_=&-KJVOQ56E7DACUA1:"I
M-1)&325<TJB5;"X6X(%B/<.>_P!][/VX]X_:^XY#V/:=RV_?)+J.>*6X:&D9
MB!/BH\#,`ZDT"L0QKV@]2C[1_=DYV]M>;(]_BN=NDET%&"U"F)J!PP<`$GRZ
M$3XK?*-<N,=UEV/D$3,!(Z+:&YJV41)EDA5DI=OY:>2_^Y)8TM35#6$ZV1K.
M!>0/NN?>POM]L;#V\]SYHCS-90F*RO'D`^LAJJE9F8YN/A$:,?$<!B`37H%_
M>,^[I9V.[3<\\DV\HL6S=Q1QL0LE"3-11B):'4WPJ6&:4Z-AO<_[_+;NK@C;
M&Y00>"K'*;<])_J>#_KV]]%IW\:&.=`5!(KCA7R/I^?6$3SHLAMS1CFAXUIY
MCY#UZ;?=>J=>]^Z]U[W[KW7O?NO=>]^Z]TY[)_X_+._^&E@O_=]FO?NO="[[
M]U[KWOW7NO>_=>Z][]U[KWOW7ND5'_S,/+?^&-M[_P!Z+='OW7NEK[]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H"\E_Q_>]_P#R4_\`W0#W[KW63W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TH^LO\`,;N_\/7*?^ZO!^_=:)`X]"9<
M7M<7%KC\^KZ<?X_CWHD`A3\1X#UZM0G(X==W'/(X#,22`%5!J=F)-E5%Y)/`
M'U][;LP^#\\=5!!0R`_ICB?(?:>`ZS1TU1*I:*&6500I:.-G6YY`NH(N1]/Z
M^_#N=8QEW)"CS8C)`'F0,FG#SZ\""@D!'AMP/D?L/`_EUQ\4H3R>-_'?3Y-+
M:-7-UU6TW%OI[VH+5TYTFAIY$\`?0GTZL010D4!!(^8'$CY#S].N7V\^M(O!
M-Y)0#''XWUR`J&!1;78%3>X_'NA=!IJ0-?PY^+-,>N<8\\=>TL&T$'7Z>?"O
M#[!7[,]<1%*8O,(W,.H+Y0I,>H@,%UVTZBIO;^GMPHZLR,"'0T84RI/`-Z$_
M/K3`JNIL+ZGAGA^WRZXK]'_X(#_L-2\_ZWNO7N@2J.,QNDZ==M\;XN#Q<?WI
MR@N2/Q^/>A+]3;,G6I&G%PMQ:_&H'\N@@P&.Z3ZFJ^XLO@:K9&R*S+9^I[K[
MVKY-P45`(L[F,#34E5V+OULEDY(]NT];MO:$=ZF84=&\%"9%`1)'"-!XU@MG
M_$6M/^<Q+_\`/_2N6XNKFY:[N:^,`MU^4`"#_CG0:87XS_$C?_5_5&-VEL#8
M&Z.K=G9K<79O2^4V;G\A78?"YS?\>Y%W'N_8.]MM;A:N>#=4&\,FM3+2UTE-
M5)4LOZ554526ID2*(?P_0?LHW^3HHM[<P3S.P[KAA<?\Y:_]`]*[8_Q;^/'6
M><ZQW-UWU)M/8V:Z6ZTK^F.L\MMV/(X=MH]3Y.MI,C6;"1*/(P4>4VZ^2I5J
MR,@E5+%5*:E9$F>:1U$VXM%$MVYPDBQ?G:FI/2IXS,OTXXR]G^]8Z6-1UYU9
MO_=>SNX)L#MO>6Y\'M+=^U=C[YBE3,11[+[(7&1[RQF):FJI\!D\/NN/#4RU
M%XJB.1([(54D&L]@VW[D\"GL,/T_VD*9A^P*>JP3G=+F.].0DBW?^\GPO^?^
MBK[<^!/\O7-]19[K#:?0/368ZDR78+[OS%#MO*9*NI*;LK9B56V9*^EWIB]R
MU&Y-NY79])]QBOM*7(TT6*HS/1"&&&26$ITO&DLP035AC_F_^G_VKGJ]J?&W
M"[_A2O[(/U/^U@=#CUIV_P#%V'8<N.Z@[9Z#EZWZDBP.PJJFZ_[&V#7;3ZVC
MB>'!;<VE7SX3.3XW;D\DRPTE-2U#1R2RZ$0-*Q]TF?Q(HG'`H#_+IM8K;:A1
MZ:FX_;T8`I+J9#'('4>I-+:@1^+6O^?]<?0\@CVLEXC_`$HZNEO'="D65.>D
M76=B]>X[*SX+)[]V7C<W2YC;NW:G#5VZL!2Y6FW%O"&>HVEM^JH*C(154&;W
M33TTDF-I63SUT<;M`D@5B&^G/'Q]%_OO/^3I9E&4V*L.2!=2I)_I8B]_\/?N
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M4X/=U+3XO-TV8I,C64DV+-;35-5X4Q67P==!E(/MUEHYUJ`L-5'&SI(@9"CO
M[>6ZMC%`Q674"#PX&O[/4>?#HPVNYVZTODFW6%Y[/(*(^@DL*+W%6Q7RIGU'
M0'83XQMAF27^)[)RM8^7BSU7E-S[4W1OC-5.47;N9VDIJ\]OK?\`N/+Y;&8[
M;>7J:2BH:V:>BBBRV25XG$E,:=%?65_>6RQ"5P5_I^0I3R^VOY4I3)C^\/;^
M243G;[^2/],C5=BN=90DBV%=2`Z\=[H'[*:"'VV_CKUOE(]R;*V5O#IK(9?9
M^7V]5[AHMNP;DK]W[%RFWL9D(-JX89^@[4E[#V/@,53Y.NPU)CJ7(4<5/MZ>
MH@B6.KDFG:T>SW]U;5$ST(_B'^;T^7'/RZ5Q[UR-;W(O!M]XK9(_QD!<`$?Z
M`2`'JQR="4-6UZ4C4/1/4_7VZ]A;!QV_.@]K[PV_C]MT.PNO(L0V*J*VDVE-
M53["J:CKN/L:GQVZLWMZ*JK:C%553C:JJH:J&`T+0Q)4Q377:K[<HAMSS-2X
M7Z8]_J/!]/4C_:U\S44FWCD."5KX6%Z#"VL'ZD?\2I%530VYR7?0^>^-C'VC
MO#O2]!]<UV,V'68O?'30P&WJO!]7[,J-OXB5<%7OM'<%1%MS85514/8C[8[!
MW!LG<&(DJ\5C<S!E/X9N$5>BG6-4IX[>'?[D#NK2-X5PH-"W^^P(`:4&#X5?
MF*9]?'>N1U7Z**POZ12:/]RU\R7*L?IAV:20:4(D$;`T6C0\+U7UCV#-!M#:
M7:G1>=SW6.V9]IT>-Z]BK(MQ[#P4FZJ#=>1Q&/K=J=I4V[=M4,&_]KT@BJ14
MI5B`2QO/]WXYEO:[:WZOTDK!].>\<`<>7&G$\*YIY=*;/=^1IE$-QMUPRR*J
M,UQ>**K**.U3;$!B"&N"`0&\2B@,%58S?$K"5./V[BJA=@3X[:]%78NBH1L_
M<M%29O&U>:3=53BMZ_8;[I:C?V(S>[)9*[(P9IJ])YX8:E`E9)65%2FL[+<8
M93()"U#6FJM>-1_@I^?&N'H=]Y>G8/'8&"=@'\3ZA&*O,"928Q`I8UC4.FL:
M`T?<W1O:=)XX((ZJK>OJDAB2HKI8:>FEK9T11-5R4U''#1T\E5(#(R0HD:LQ
M"BWLZC\,C_'./04OI8+F]/TN17\_SZ)-\U/^+;US_P!K+<W_`+BXGWSE_O#/
M]Q>5?^:;_P"`=9M?<C_Y*'-/_-1/\)Z((?J?]?WRV'G]I_PGKHD?+_2C_`.N
MO>^J]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7.-)))84A#M,\T*PI$K
M/,\QD7Q+`B`NTQDM;3ZA]1R![=MX=RGN$3:*_O`."FG^TU`X,7_#*TTT^?26
M]GMH+<M>T^C/:^KX-!!U>)Y:*?%7'#JX#K2G[+CV_P!>KVI(DNXUVGN)J02^
M1\Q'A/XEMK^&P[DD+FFES:1&YT^KQVU$M?WWM^[H?<!?;FS_`-=$,.;OIAX`
M:NDVM!F:O_$C34CYTZXX^^QY#?GF[/MOI/*@G_6(IJ%U7A#3_B/KH#\J]"O[
MF[J(.O>_=>Z][]U[KWOW7NO>_=>Z<]D_\?EG?_#2P7_N^S7OW7NA=]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW2*C_`.9AY;_PQMO?^]%NCW[KW2U]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]T!>2_X_O>__`)*?_N@'OW7NLGOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[I1]9_YC=O_`(>N4_\`=7@O=&^)/],.F9OA'V]!
M_P#+3<U5LWXV]T[KQW8F].I,I@=EU]?B.R>N^MY>X][[7S$<]*F-FVSU/#09
M.7L7(5U<\=*<0('-7%.RW7EE3WP!GB!&H5X#B?YC_"/MZ61_V;?9U1-\E>U?
MF'W?_+2WU5?-L[;^)D<?=?7N+ZZWSOG:O9G4>V_E;UY_"LO6';_R?ZNZPWIO
MS=WQ-VUV%E!#$7J-QQ8],G3TJ50AIYQ',83K%)>VIO#KHH!).O1Y4\4!%BIQ
MHT4U/G2O26`*NT7&DGCY9/'R]3T'%=UE\?\`YI_%'^6;U?C^L=U;![([Q[7W
M+\=<%O5^_P#L_?F:ZQZ+^/-?N[L?O7<W4/85-N;!4&_MG[CQ>T1C=HY:MHJC
M[;&9R/[<21TL"^U$T4T&];>8%<(\3;B:4JL4?;%;<,O+)F48)0#ATP9DM-NW
M=9@":Q?1"OF0-=/L(X`?+J7N;=VXMN?-W?M3UOO#=3?-?`?-/O[IS;W5\>_M
MT9//1_`K:7PAK-S=6NO4D^;J,#4=:4N^J+$5V/S<V/?[O<4Q+54D\DD8)H#<
MS;#=7<;4N+C:]VGN]'PK>232/:I+7(T`A(_#I^F!05Z&-S!MIW>W%P-4,%]L
MQB-0OA1,L3;A@C]569I"PQ2E#T2VMBQ79?Q;W[U3TSW%OFLV3W/TK_*IR7R(
MW1MKN/>FX\UM7YV=O]^9/;/;29#<.0W%D:C9?:F:V]]O-N'!0RTR*8X?/2Q&
MP]F^[Q6'U$0L-'[K;<!':>'4QZ5VVYFD\,GN(\>*/5J-=?#H(S73_N\7UT?$
MWE8Y))GIIUC]X6\454K5-,$KCYC(].C<_!#N'M?Y%_S./BIW_P!@9S>F+)ZA
M^1GP\J=EY/)9"DP&2W;\0>F>O,9W/NY]N"M&/JLAE.\]X9I$K)8/.8J-.0NE
M5,=J%C><O[QN#:_WDSV$JZC_`*'*HC?'#^UB?/D:T.35-??61!H9R#''=30D
MCU69I4'_`#@DCQQZVNE/$G]/&!;_``U1BW^V]DGSZ,F'Z:_9_D/0)U+?[E]U
M6N+[VWS<WM91NC*LWX-_2#Q_O7U%HXU662!0`3'4?:1Q_P!GIH2,EO%,A*J)
M,T\\YKU0)W#LWY!]IXS^8;\>NJ-GT6YNW.^?YA'5>S]]YK<SY2AV-M'XC'J3
MJK=."SW8-?AXIMPTW6V?VILZMVTHQT=3*]5DZB)4=_*&2;4K)8[8CT>>,W-Q
M)JXNUG,]R*^;,T0$->/AC3\(IT=7<GB<RRM'1+62VCA0`=H^LC%MPX=DKF8>
M0D[N.>@^INK?G'U=U9COC[O[JCO>AZ*ZB^5/:>:W/C_Y<VXL]M[<>ZNC.V>O
M:[L+IO;G1.X\SE=F=C5.Q>G>\,[7XK.42S4E134\=(LT<U%&03BQG@2PL4N^
M]89[A690!(]X-!@E<C)4*[!SFM%K4]%L4R-;[C<R`#QV@:*N?#4!T*1U^%*K
MJTB@J3CK)#U)_,OWO\RZ.DW=N?Y7;;Z*S_7&`V[C<=EY<5E=I+T_D_CG+C-Y
M8+M?M'87=&T^KL+\@JGM::9*RMQNS,GG!DY8ZJAKDH%9$+'AN;K9=XLI#`N_
MQP3O+(%7P$FD7]*2%:44"BF70`&SJX],,IAEL6<D$7$+8)%0'!(/J"*UZ0/1
M^'^0G66/^"GPJV;N'O/K//?)+H[:G7W?/7/9/9U?'V[\8L?\;>R&W?VCW/LC
M!2;DSV?VKL?NC85;7;1PN5HI(*662.A:$1%=*G-X4DW?<+ABWA)=0W**QJZP
MFV>-H37_`$3Q&5R>)C##@>FH8WM]OMPI"3D7-NU,:J/XJB@]`F!P%.K"-L?'
M#O3/?RXOEYT/A,+D.N^W.SNP/F5/L6@SE0VWY<ECM^]Q[LW!MP/D14-]AB^Q
M-LSF-*R1P%BR`E<JH?V&OJ0-ILF5`9&V>W0T&3-]7=$/_IU6J@\0.K<M*UGN
MVY37G=!<;I&\8;(6$VD:2HOHCNH+@88@$Y`Z+?VUUD_?WQ][LVATI_+-[:^*
M^\#U?\9>MI.PZ_8G6O7&]]P_W1[SVIGLUUSL';&W<SEYMU[?ZLQ=#49F/=D^
MJEJ64:5<J![-9#'+=Q&@$?[WLI"/(0+.AEC(_P!]NE5=?A*FAQTU18=C2.[`
MEO$V^Y.ILDND#D-4YJ"*@\0?GTF=[=<?-;:<&Y]D[CH_YA78GQRV;\HOE[0[
M);HSM#,5'RCS^%R.T]@Y+XL;LS/8>4W;@]W;JZ+H-US[ICF>HK7@AJOMVJX)
M*2)8CJ[N)KJR22)8UO8MD6-R`%7ZAKIB)"!C7X0T:J:J?;T86R)8Q;@'-$CN
M;.2M<K;^!,+C2?*LC0$C%2<]+7K+IKYM8_>^(W;VSLW=%=V7N/N7^5GENX=X
M8&GQ4V'W#2=9]3[IQ/?.;GR&,,6*K\;M3-UL$&;GHT2F%8[&!/&RDI(PW]88
M+@$_0Q27Z2)^$E]F2.'4#@^'=5F2OPR]XHV>@I917D.Z12W3N0XLW8$DC3^]
MS*!]DMAH63^)"5;!IT!><ZA_FI;9ZTRF1ZGW3\JJ_L[M#XQ?(1NPJ;?F],GN
MRBV?OG`_+K:?^CK#]:X3-Y[&4.R>Q:_XSY/.-@X\;6T-7DX5B/W<=0D$L:VR
M=4Y6V^WN`#?16^U*\A`UNRP3+<EVXL9)&0N6RQ4$UIT=6)D6X=YOA_>-XP!K
M3PFQ"M">"\5'`'@!T@]Y=<?S3,5TK\=<K@LO\[=[;CVSN3N67:FS*/'[@Z_S
M];'/O/9T_5D/>U5#\D-^[_VM'!2X_(FBR&^)=\848BH>FR-#%.8Y2_MPBBWB
M(S!6A*)V-P-9YP20<'`"^M`/3I5;=NS3P25-ZSU5C\0^2G!`]`,4^?2D[H^/
M_P`Y]EP?*C&=%8#Y>;,@[(^>P[=[7W!L_([N[+RF[^G-T]*XU=LOT>VV.YNJ
M]U9B/!]U0M2;FCPF8P=3#CH:(5'W%!2_;^RFV:EC;R2DF0B[U'U*%M/^\@#J
MEG*T][=2S%%M9$M1$/X:T^L-*8*G5H]%&*=&1@ZR^?N-VA\BNR-VUGRH[![<
MV7\)/CAMWJ39FW>QSUK@=[=OYS;6ZZ#OG,8S:N'SV[]FU'<>"Q<]#'4R1S5S
MTV2C+T$WWSQ5":@CE=;Y)&.N\W*:"+_A21V]DX9/X`6=_AIQ;U/2;:(9(+W;
MXG9I(8)=,FLD^(K-<LFLFI:J!/BKP'IT5^KZO_F5)\*:?`9;*?.]MU;5^8G9
M>?P&-V\=[2=L;KZ%S_56*R75V%W8U%\@F[XQ^TJ#>];5Q1SQ[KW)-A<@';*T
M-3!&M(AO>2V4EEMT]N5UBVOTEQIK)#/,@+8%2H448^0%*]'.WRQ,ER&"L9;B
MU*<#I5E4%5KP#')IQ/S/0R]<[8_FBY+YQ=-[Q[GR/=6S>IJ;9W2LF[=LQTL6
M]^BJ;JVDZ*B'R`V]VSOC%]N;)ZWI^RJSLY*\2S2;'R>X)9)J>:DJ8Z-6A%K]
M4-Q=/"H6,+<4``H"L((IZ4.1\\]%,4;O:6L>IC.7MZFIJ0TQ!KZAA@^HQU9[
M_+3ILG2_!KX^QU\513X]]O;CJMDTU46,]-U=6[ZW35]4T[:K,B1==S8T1K_9
MBT@<6]IBA2YMXG%&_<UJ[`_[\-O&78_TRQ)8\22:]*7[(KLUJ1O5S&I'DBSN
MJJ/10!0`8`'1Y?;'5NO>_=>ZY)^M?^#+_O8]^Z]TA>N/^//H/^UINW_WLMP^
M_=>Z7'OW7O(CR(I^1ZQS/.D,STL<<U6D,STD,LGABFJDB9J:*68(_ABEG"JS
MZ6TJ2;&WMIT70VD`$J?\'2B.XF\0$NQJQ)R<ZBI:O^F*@GUH/3JG;X<;-^17
M5?R9:?=O5_8.6V=W+M?=FX.W-_[TV:N"Q?Q[[1KL[NC>N2^/'3RQ;BBBS/1N
M>WKELAN"'<G@RRR9"5::>MD:II_M5=@P7;?!I^M3CYCI/>O.;_Q%=A;U^&II
M3)X?;T8S:^,S77V5[FV#NKX\;K[<WCV1\IJGM+;NY?[MT,O76[-L9_=.`R^Q
MMU[G[.EIZK"[*J>C,)BUI$HZ\)E$;$0B@@G^ZA;W43CPTBA7PYHZ'6N&U\=0
M(SJ)S7C7/3LLTDH=68F)P`17!"@JH(X$*I*CT!IPZ*?M+XY=Y=:;;^/='MGK
M7<6>VSOGY>579W;.P*JJAQO^C#=.WNUNY\S0=MR.VJ?%;)[7V1D\;39NH@\\
MU/D5H*U$8U53;UG`CP#8Y**BBJM_"I_"#Y`&IIZGK8\:0M(9&#,>[)S@"I]<
M*H_VH].A[^+FQNUMF]G]98I,9V=E.J]J=6[QP%;A_D'U3L?%;V^->1E?#'$]
M?=6?(/:N+VU4=Z[7W77P24E8):;*0IC,+1U3U@GDTRI[6%;2[EM%4:0E=8_%
MFE#_`(:=%^YQF0Q>.QD`E)[LT)R2*^9.3U9M?_7-R?KR3R>3]?K[K71.#'@_
M+'3C6\$141HJBOD`.`Q^RO7O;S`.:OG[<].(JQG5&`K?+'0:;ZZFVSW#N+:F
MV]U/E(:&@QN[<O"^)JXJ2I%2DNVZ5/)))#,'A,-2YT@`ZK&_'N(/=SV1Y-]X
M[B%.:+EXK>`4CH<1^1T?P_EU)_M][M;U[3B5^5U\6YN#634*^)3^.M-7RKTU
MK\%^G0H'W.\6L`"QSE("2."3_D!YO[A`_<2]CX3X8N=SF`_&KN5;SJ,_E^74
MMC[X?NW,/%9=NA)_`T:AE\J$?S_/KO\`V1CIW_COO#_S^4G_`-0>]?\``+^R
M'^_-V_WM_P#/U[_@OO=K^+;/]X3_`#=>_P!D8Z=_X[[P_P#/Y2?_`%![]_P"
M_LA_OS=O][?_`#]>_P""^]VOXML_WA/\W7O]D8Z=_P".^\/_`#^4G_U![]_P
M"_LA_OS=O][?_/U[_@OO=K^+;/\`>$_S=>_V1CIW_COO#_S^4G_U![]_P"_L
MA_OS=O\`>W_S]>_X+[W:_BVS_>$_S=>_V1CIW_COO#_S^4G_`-0>_?\``+^R
M'^_-V_WM_P#/U[_@OO=K^+;/]X3_`#=>_P!D8Z=_X[[P_P#/Y2?_`%![]_P"
M_LA_OS=O][?_`#]>_P""^]VOXML_WA/\W24WE\,NIL#B*>NHZC=OW$N=V]CO
MW<U3LGV^3R]+157"T`]9@E(4_AB#[\?N+^R'^_-V_P![D_S]67[W_NP.+;8?
M]HG^;IF_V4+JCZ>?=G''_%W@/^\_8\^]?\`M[(?[\W;_`'J3_/U;_@P/=?\`
MZ1?^\I_FZ]_LH75'_*QNS_S[P?\`U#[W_P``O[(?[\W;_>I/\_7O^#!]V/\`
MI%_[RG^;KW^RA=4?\K&[/_/O!_\`4/OW_`+^R'^_-V_WJ3_/U[_@P?=C_I%_
M[RG^;KW^RA=4?\K&[/\`S[P?_4/OW_`+^R'^_-V_WJ3_`#]>_P"#!]V/^D7_
M`+RG^;KW^RA=4?\`*QNS_P`^\'_U#[]_P"_LA_OS=O\`>I/\_7O^#!]V/^D7
M_O*?YNO?[*%U1_RL;L_\^\'_`-0^_?\``+^R'^_-V_WJ3_/U[_@P?=C_`*1?
M^\I_FZYX;X@=55^ZHL)+/NS[.3;F0RQ*YJG$QJJ3+8BDA"L:`A8S#7OJ'YTC
MWK_@%O9#_?F[?[U)_GZ\?O@>[!&#M@/^D3_-T(/^R,=._P#'?>'_`)_*3_Z@
M][_X!?V0_P!^;M_O;_Y^F_\`@OO=K^+;/]X3_-U[_9&.G?\`COO#_P`_E)_]
M0>_?\`O[(?[\W;_>W_S]>_X+[W:_BVS_`'A/\W7O]D8Z=_X[[P_\_E)_]0>_
M?\`O[(?[\W;_`'M_\_7O^"^]VOXML_WA/\W0*?(3XM===7=89/=VV6W)/G*7
M*86CI(LADXJRED2OK5AE1J:&CC:61P`J`'42;#W!OWB?NM>U?M;[8W'-W+<]
M]^^5G2&..4LWBF2O9&#7]4D=I%"/7J5_9;[QG.G/W/<7+?.;VL'+)@>62XA`
MC*,E-*%UH1JJ33SITN_BU\7?[K+0=C]BT*-NF2)*C;FW*F,2Q[8,BF2')U\3
MV\F;\;`QH25A0ZC9_8[^Z9]U>3DS;K+W!]U;6&7F.\A:7;[6:-7:UC)1O%F#
M`TN%.GPF/<@+@$&HZ!_WB_O$;OS%=7?(7)[-#RI#*$DN8F*O.`&4Q.P(+Q25
MJZFH;2*]&?WJ/]_AMVX(OMG<K:6(-B,KMP@W!(/))!^O/OH0[O**2$L*@YSD
M<#^7EUA;'''%3PE"T!`H*4!XC[#TW>Z]7Z][]U[KWOW7NO>_=>Z][]U[ISV3
M_P`?EG?_``TL%_[OLU[]U[H7??NO=>]^Z]U[W[KW7O?NO=>]^Z]TBH_^9AY;
M_P`,;;W_`+T6Z/?NO=+7W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0%
MY+_C^][_`/DI_P#N@'OW7NLGOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I1]9
M?YC=W_AZY3_W5X/W[K1`/'H3E8JP939@;@CZ@VM<'\&WNK*KD%P"1Z]6!(X=
M,.Y]M8#>>WLYM+=F$Q>Y=K[GQ5=@]Q;?S=+%7XK-XG)QR09#&Y*DG5HYZ6IB
MD):_.JQ4JPU"TO\`C#K)/WR+\).2/L)X=:4!%*+A#Q`X'KCCMJ;6Q%)MN@Q>
MVL!04FSL9#A=HPTV'Q\8VOB(*"#%1XW;["G,F'HQC::.!HZ=HU>)`K7`'MSQ
M9-:RZCXB5TFN5U8:A\JC!IQZH\:2!1(`P0U6N:'U'IU(7;VW4S[[L3;NWTW9
M)C5PTFZTP>*7=$F&285"8>3<2T@S+XF.H'D6F,Y@5_4%!Y]MQ@0J4B[48@D#
M`)'`G[.G)F-Q)%+.=<L%?#+9,=>.@GX:^=.H%-LG9-%3UU)1[*V;1TF3SG]Y
M\G24FU,!34N3W/YDJ1N?(TT&.C@KMR"HB609"57JPZAO)<`^]:1^GC^Q<M'_
M`$&(*EE_A)5F4D9HQ'GU2=%NII+BY`DGF4+(S99PI#*&)RP#`$`\"`?+J33;
M6VO1U5+74>V-MT==15&6JZ*NH\!B:6MHZO/R>7/U=)5P4<=1356>E&NND1E>
ML<:IBYY][7LKHP&14-,5169U4^JJ[,P'`,Q(R3UMP)-6L`ZY/$:OF^E4UGU;
M0JK7CI4#@!T_J!9^/[(_Z'3W[K?R\NBX9+-5\.>W=#!M3.5T*[XWPD=73RX8
M05`&Z<D?)"M3E::I0&Y%G0$\VX]V#D7'U./$TT^5.DQ#&V^E3X*U^?'_`%>7
M3='DZJ&KJ<A%L#,Q9"LAI:>NR$:;9CKJRFI!.*.GK*Q<P*FHIZ7[F3PQNQ2+
M6V@+J-]0'P+N.[4`R1I(H!^&DH(>H^8)''ATJ9Y)%7Q,2+IR,'L.I?V$`CY]
M9_X]E+ZCLS<=B`J@2[?"*``JZ`,X-)4+8$?CC\"U;0&S?Q(22VJ0YSF33J_X
MZ*>8Z\R1S0>!(2(Q2E..*G_+UV-P94<?W+W%<<F\FWAR3J!91F@M[\BXXL/=
M8XUC@DMZ5@E5E8'S5_B!\R#\S]G3EQX<V@GC&*#IK,D?\9_O)_HUK%W&<:N&
M_O&N/V:NX&PRU,E8,0^<&1&4DQ/WLGF^V:8P"8:P@<DG;*S-*[NQDGB1';%2
M4I23A_:%04)X:21IK0BDS>,4+4&B[DN!3^.2-XV'^DTN2%]0#4].?\?RH*VV
M9N.Z!-(\NWP-$>DJ"O\`'+?50;\&X!O?GVXI4110Q*I2$QE<<?#+L`?D3(U?
M7'#JLOZJHC8T"@I@G-:GY_Y.NOX_E>2=F[B)/Y,VWCP1^+YL@BQ_-[_GCWM7
M*R>(0-6@K3RR*5^T>1]>F[F-;H%9*A3%+'C';,I1OS`8Z?0\:]>&>RPM;9^Y
M`!^/-MZU@VH`$9L,MB!R#?CZ_6[2*$6=!E9WC9J^7AUTA?137(S7Y=/7+?5B
MX60`+<HBO3':@`TCCAJ`MQJ0*4Z\,_E1<_W.W'<A5+>?;X9E06"NPS@+K;BQ
MO<&Q]V_T.2/_`'[/XI/GJX4!_AIBGIY]-LJL4)'<D'A5]5&%)_I**!3Y`#'7
M8W!E1<G9FX23I#'R[=#,$)*#4,V&`6Y''T'`X`][D/B,2<#56@X#(84^0(Q\
MB>M&-2*9X`?L\_M/GUX[@RI#`[-W%9B"0)MO*#IU:`;9OU!=7T-^1?ZW)U+^
MM,D[8D15`IZ+(\@K_MG-?E0=..2\PFX$"E!P_9UW_>'+'3?9NXB%#!1Y=N@>
MKB[!<V`Q`)`_P-O="@:!+<_V:&6GK^M77_AQZ?/IN5%E14(TA3`13!/@4P?E
M+3];^*IIIKUT<_ECI_WYNXAH#`:9MO*#JC\>I@,W8LBGTG\7M]./;DC&0$'&
M#P\BWA@L/Z1$:BOI7IR(^$TC+QDD#FOD5#@!?0`.?V#\^CGLJQ!.S=Q<6&GS
M;>*@`@V56SC>/5I%]-KD7^I)+<J+,K*V%/BX'`>-773[2Q/V]-01+;^'HJ?#
M\.E?/PB"M?7@*^OE3KA/FLC51305&RMP3P5$,M//#.^VYHJBGF4I)!41RYET
MG@>-BI1P5*'205X]J3.[+(II2377_FXNAJ?D,?/IV(F$H4XQA*5_X6Q=?YG/
MRZQTV5JZ&FIJ*AV)FJ*BHX(:6CHJ,;9I:.CI*:-8::DHZ6GS,<%+2TT*!(XX
MU5(T4*H``]TUG6DGXH[6.`?-(T"*3ZL0H)/F:FG5&4,CQGX9+N2X/_-21S(P
M']'4QH.('GUG_C^5_P">-W%_U.V]_P#7SW3JW7OX_E?^>-W%_P!3MO?_`%\]
M^Z]UR3/Y76G^_,W$?4O`FV_<\C@?[FS]??NO=(OK_-Y*/:=$D>T=PRH,INNT
M@EP(#`[OSS$C5F4X#,1^?I[]U[I9?Q_*_P#/&[B_ZG;>_P#KY[]U[KW\?RO_
M`#QNX_\`83;>O_L/]S9Y]^Z]UR&X<H%"C9>X``%T_N[?N1=-+&V=]1)5>?J;
M`?2X.HQX3:E_V.MN=:Z3UT,[E1Q_<K<)/KN#)MZX+"WI_P!S8:.W^!%S];V%
MKNY<U(`/RZJHT@`<!UU_'LI8+_<S<06['2)MO`$M]6M_&[74WTVMI''X%FG3
M7%X52,UU#XOLKZ?EUHK4\2.O?Q_*_C9FX?P+^7;H-A]!QFP+`DV_H.!8``/Q
MR&.$0@`T\S\1^T]-M`KD%B>TUZ]_'\K_`,\;N+_J=M[_`.OGMDH"VKS'3S=Q
M!/EUX9_*W_X\W<7_`%.V]_\`7SW;KW7>$W#E1OO"2C9FY&D&VMVH($DP!D*&
MLVQ>74V96+3$4"FQ)NU[6]TCCA049%<?TJG_``$=;E)DE$R]C#^'`_G7H8CN
MC-@D#K_=K"YY$VVK'D_]7SVH6:2-0D)T1#@J@4'V5K_AZLS12-KFBCDE/%FK
M4_;1@/Y==?WISG_/O=W?]3MM?_7SWOZFX_C;^7^;K6FU_P"4>']C?]!=>_O3
MG/\`GWN[O^IVVO\`Z^>_?4W'\;?R_P`W7M-K_P`H\/[&_P"@NO?WISG_`#[W
M=W_4[;7_`-?/?OJ;C^-OY?YNO:;7_E'A_8W_`$%U[^].<_Y][N[_`*G;:_\`
MKY[]]3<?QM_+_-U[3:_\H\/[&_Z"Z]_>G.?\^]W=_P!3MM?_`%\]^^IN/XV_
ME_FZ]IM?^4>']C?]!=>_O3G/^?>[N_ZG;:_^OGOWU-Q_&W\O\W7M-K_RCP_L
M;_H+I"]B[BR\VWZ02[&W12J-T[182S3;=9"R9^B=(M$>;:35.ZA%-M(+<^_?
M4W'\9_E_FZ]IM?\`E'A_8W_0728;/96Y_P!^;N,<G@S;=-N?ZC.$'_8>_?4W
M'\;?R_S=>TVO_*/#^QO^@NN/\>RO_/';C_ZG;>_^O?OWU-Q_&W\O\W7M-K_R
MCP_L;_H+KW\>RO\`SQVX_P#J=M[_`.O?OWU-Q_&W\O\`-U[3:_\`*/#^QO\`
MH+KW\>RO_/';C_ZG;>_^O?OWU-Q_&W\O\W7M-K_RCP_L;_H+KW\>RO\`SQVX
M_P#J=M[_`.O?OWU-Q_&W\O\`-U[3:_\`*/#^QO\`H+KW\>RO_/';C_ZG;>_^
MO?OWU-Q_&W\O\W7M-K_RCP_L;_H+J1MK<&63?D$B[*W+)(NR\PBTZ3;=\LBM
MG=NEID8YSQ>.,BQ6^OGZ6][$]TQTHYU?E_FZV&VZ(^)<P1"`<::J_P#'O6G0
MN?WHSG_/O=W7_IYML_[;_B^WO[K->O+*%L92(A\;/0C\L"G6O!6-#)+;0G5E
M``U2/GW'KO\`O1G/^?>[N^@)M/MGB_(_Y?OY'M->;M+MEO&;X2FXD:G;33_@
M/3(:"Y'U%I;P_2CCJ#5^?XA_@ZZ.Z<W_`,^]W=_U.VU_]?/:^:XE$GZ;.$H"
M`:5R`?3IQ6L9%UQV\6@_)O\`H+IOK\K5Y1:9<CUAN2N6CK*?(4J57]UYXX*^
MD9FI:N..3-LGGIR[%"0;$W^H'LEW?:=IYAMUM.8+6"^MD<.BS+J5)%^&10*=
MZ_A)J/ETJBO;BUC,5@QME8@MX9*DT]22>IJ[FS:L2.OMW6/U'FVUZC^&=CG"
M[N!QJ))M]?9@SR2*GCNTLJ+I#M35I\A@`4'E0#YUZI<7,UPP+'2H&0.#'^)J
MU)8>M?/AT&.\MPY>7=NWW?9&YJ=UVQN(+#++MXO*K93`:Y59<YH583&`P8AC
MJ%@?>NF.FW^/Y7_GC=Q?]3MO?_7SW[KW7OX_E?\`GC=Q?]3MO?\`U\]^Z]U[
M^/Y7_GC=Q?\`4[;W_P!?/?NO=>_C^5_YXW<7_4[;W_U\]^Z]U[^/Y7_GC=Q?
M]3MO?_7SW[KW4_9^X<O'N[-/'LG<E0S;8P<;1QS;>5HT&9SKARSYL(0S"PY]
M^Z]T*G]Z<W_S[S=O_4[;?_U\]^Z]U[^].;_Y]YNW_J=MO_Z^>_=>Z]_>G-_\
M^\W;_P!3MM__`%\]^Z]U[^].;_Y]YNW_`*G;;_\`KY[]U[KW]Z<W_P`^\W;_
M`-3MM_\`U\]^Z]TD8=R9AM_91_[A[H#G9>WT:#S;<\T<8W#N,BH.K."-H79R
ME@=>H?2WOW7NE=_>K-_\^\W;_P!3MM__`%\]^Z]U[^].;_Y]YNW_`*G;;_\`
MKY[]U[KW]Z<W_P`^\W;_`-3MM_\`U\]^Z]U[^].;_P"?>;M_ZG;;_P#KY[]U
M[KW]Z<W_`,^\W;_U.VW_`/7SW[KW7O[TYO\`Y]YNW_J=MO\`^OGOW7NO?WIS
M?_/O-V_]3MM__7SW[KW0*Y#<.6;>^\G.R]R(\AVN&IVEP'EBT8!=&IOXR8B)
MARMFN`.??NO=9_X_E?\`GC=Q?]3MO?\`U\]^Z]U[^/Y7_GC=Q?\`4[;W_P!?
M/?NO=>_C^5_YXW<7_4[;W_U\]^Z]U[^/Y7_GC=Q?]3MO?_7SW[KW7OX_E?\`
MGC=Q?]3MO?\`U\]^Z]U[^/Y7_GC=Q?\`4[;W_P!?/?NO=/\`UUN++PTVZ3'L
M;<]3KWAD7;Q3[<&AVQN'#1E7S:O>/0+FUB3[]U[H1/[TYO\`Y]YNW_J=MO\`
M^OGOW7NO?WIS?_/O-V_]3MM__7SW[KW7O[TYO_GWF[?^IVV__KY[]U[KW]Z<
MW_S[S=O_`%.VW_\`7SW[KW7O[TYO_GWF[?\`J=MO_P"OGOW7NO?WIS?_`#[S
M=O\`U.VW_P#7SW[KW7-=TYNTG_&/=VBR`_Y[;?/[B"P_W.?6QO\`[#W[KW2&
MG`_C&ZM5R/[[[W_V.K=>24@WN+,IMR#:]QR/=@"2X'X%J?F/EU6QD1)D605#
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M=,?H&.DFOPBF3T7/%()KB%_TS;3%&)X%`J,95IG1W@4(U$UH*=&C^%WSM[+^
M4W8W<.R-W]0[,Z@Q?Q7:MZO^36XZ_?U%DZ6F^3D.XZRFBVMU5**I4R'5,NS:
M2+*MF<O]I5R5%?34*0^>*HM80-]";^H\(/HIYF3\2?:GF?A/X2>F92T&X#;V
M.J4Q&2HX"/2&1L_QU%`,C\0'2P[F^<>2Z;^2,?5>9Z:S)Z@H/C+\@OD/E.Z*
MC-X=7W@>B=L;9W77[7ZKVY25M7/D:*/'[A\==E<DM/#+5-'#2+((II/:>$&\
M2Z2'_<BW$W9YOX4RV_:?A[W<%:D8!K3J[2*M[#8GXYKB*$'R4RQM(K-YT"H:
MTJ:]%VVU_,"^6NX>O=^K+T+\;=N]H[&VOU#W9NG<FX^[-SXOX]]:?'#NGJS=
M':&`WGV+G<AM^A[`JMVXBHVN^W*NAPU'71SY.LAGC=*193[H)[7;1//-()-N
M@:>)IE5M)N8([>1K8+37XC?4*%.G156JPQTI2$OX1)`6:*-P3P`DGN(*'YJU
MNS'RTLM,U`LH^-O:V4[Y^/G2_=F:V7D>NLMVKUGM+?N2V+E6D>OVM5;DQ-)D
M9<:[ST]'524BFJ#TTD\$$ST[H9(TDU*%=W%)`]9E*NQ)*GBI\P?*HX&F.DL4
M@FGDMP"&C<J2>!H:5'RZ&GVR5*TKYBO3K#2:=>]ZZUU[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UR3]:_\&7_>Q[]U[I"]<?\`'GT'
M_:TW;_[V6X??NO=+CW[KW7O]M_L;V_V.GU6_UN?=6;2I;C0$_LZVJEF"J"6)
MH``237T`R3Z`9/ET23=?R3WE2_*/</Q]P>4ZAVU28+!]097'3[UV?W!N?<F\
MZGM"?=0KX,97;!E@V9M.FQ,>W4AB?*R*)FJ"Y/@0V9@N5GLKN^`*QV=V]NP/
M%G2UMKHE?Z+)<J@K0ZT>N*$ZNDN[98R8)=<D3R!7'@FB,R$'QM&25-/(8KGI
MLW_\]NM,!+O'`;6P.Z,UO?:Z8;*4.U\CCL8*_=VV7[7VAU9N/(8+;F%S^1WK
MC:ZAR&[(GH*7.8S#2Y(%)*=98-;HHNH[NU6)_"#QS!"")(A37(L8KJ<4-7!(
MXT!QUNZ:&RF>VN69;B-BK`1R,`PX@,JE6`_B4E3Y$]+RL^8O7M'D=RX1]B]Q
MR;FV-MW?&[.RMKP;.PDN9ZVPO7OV#Y^?=OBW<V(>HFH<M1U5##BJK*/D*:J2
M:`.@D9&'F>*ZN+.2*0S6]M#*="F16\>22..-6CU*)"8G)#$445-.JP/#<F'P
MF.F:5D!9'6@0`NY#*&TIJ6I`XL*=#GLGLS:/8M;NVEV?6S9>FV;6[=QN3S4,
M`_@=77;FVEAM\4--A\@)6&1DI]M[BH)ZDJH6)JM$N6#A5DL1B<HP<4I0M&Z`
MX!:A=0#H:J,..H'RSU91J$A%?TIC&U01D"JG/DZ4=?D17/2_]M=:Z][]U[IO
MBSN$V_OG;M9GLSBL)23;=W?31U67R-'C:=Y_O-JNL*35DT,;RLBE@H);2I-K
M#V1;QS-R]RVZKS+?65@C<&EN(0/Y.>C39MBWSF.=[?8+2:\=!_H8K7[//H2A
MV5US8?\`&0-D<\\[MP`^O/\`SL/90WN3[<$_H\Q;`\?D?WC9I7_:O,KC_;`'
MSX='']0N>T[9]BWM9AQ"V%W*!]DD4+QM]JL1Y'((Z]_I*ZY_Y^!L?_T+=O\`
M_P!</=?]<CV]_P"F@V#_`+F=A_VT=>_J)SM_T9-\_P"Y9?\`_;/U[_25US_S
M\#8__H6[?_\`KA[]_KD>WO\`TT&P?]S.P_[:.O?U$YV_Z,F^?]RR_P#^V?KW
M^DKKG_GX&Q__`$+=O_\`UP]^_P!<CV]_Z:#8/^YG8?\`;1U[^HG.W_1DWS_N
M67__`&S]>_TE=<_\_`V/_P"A;M__`.N'OW^N1[>_]-!L'_<SL/\`MHZ]_43G
M;_HR;Y_W++__`+9^O?Z2NN?^?@;'_P#0MV__`/7#W[_7(]O?^F@V#_N9V'_;
M1U[^HG.W_1DWS_N67_\`VS]>_P!)77/_`#\#8_\`Z%NW_P#ZX>_?ZY'M[_TT
M&P?]S.P_[:.O?U$YV_Z,F^?]RR__`.V?I!=C=A;!JL#1QTV^=FU$HW1M*4Q0
M;HP<T@B@W!0RS2%8ZYB$BB!9C^`/?O\`7)]O/^F@V#_N9V'_`&T=>_J)SM_T
M9-\_[EM]_P!L_2<_OQL8\_WVVASSQN7"D<\_45MC[]_KD^WG_30<O_\`<SL/
M^VCK?]0^>/\`HQ[[_P!RR_\`^V?KK^_&QO\`GMMH_P#H28;_`.K??O\`7)]O
M/^F@Y?\`^YG8?]M'7OZA\\?]&/??^Y9?_P#;/U[^_&QO^>VVC_Z$F&_^K??O
M]<GV\_Z:#E__`+F=A_VT=>_J'SQ_T8]]_P"Y9?\`_;/U[^_&QO\`GMMH_P#H
M28;_`.K??O\`7)]O/^F@Y?\`^YG8?]M'7OZA\\?]&/??^Y9?_P#;/U[^_&QO
M^>VVC_Z$F&_^K??O]<GV\_Z:#E__`+F=A_VT=>_J'SQ_T8]]_P"Y9?\`_;/U
M[^_&QO\`GMMH_P#H28;_`.K??O\`7)]O/^F@Y?\`^YG8?]M'7OZA\\?]&/??
M^Y9?_P#;/UDVYOW8L._:2HEWKM%*<;.S,!G?<N%6(3MG,"Z0F1JX()7CA=@M
M[Z5/MV#W(]OC*`G,&P:\T_W9V'H?^7CI)?<@\ZM:NK[)O@4TX[;?`<1YF``?
MGUUWYVIM_'=1[VK]F]@;;_O128^@GPIPVYL)4Y-*R+.XIB]+3P5D\TS>'4&4
M(;IJ7Z,?<,^]ONCRY:^S&X7/(F^;(W-(<Z0NY6+,36M`%G+'[*=2M[3\@[]?
M^[NW;7S7L^ZIRX4&MFLKE5`H<U,5!_J].L?QV^0N'[FPRT&1:FQ?8&*HT;,8
MHL(8<K3&ZC-8=6-Y:1I$9IX_4U*S$?HL?>ONY?>%VSWEY77;=S&CG"&@,$A3
MQ`%`&O!/:2"1YTZO[\>SF^>VF[B+;$2;978DO&&T@$U`)(&0#0_/HS`N0"0P
M-N0PL01P0?\`6/Y_/O)B:25;A4N:4?\`T0?V>,>><4H<<0?+J`V^F1C';L/"
M'#_+_.O7O=G70Y4$$#S'`_9UI6U5QPZ][KU;H(]\?\?EMS_PU]R_^[7;?OW7
MNFOW[KW7O?NO=>]^Z]U[W[KW7O?NO=.>R?\`C\L[_P"&E@O_`'?9KW[KW0N^
M_=>Z][]U[KWOW7NO>_=>Z][]U[I%1_\`,P\M_P"&-M[_`-Z+='OW7NEK[]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H"\E_Q_>]__)3_`/=`/?NO=9/?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2CZR_S&[O_#URG_NKP?NCN$`)\SU[
MH3?:B*(R+KJ`.KHA=P@XGKHD*;68D\\"]Q<`Z?ZD$BX-N#?VPC:Y_`I0^OET
MU$WC023C"QG/S^SKE:W'Y_/^'NUO_C%W](N'^D>>IX:4--/^F/EY=.1@/,82
M0M%!J>!KY?:.)ZZ/'MR-!)!%.#VRS11XJ=!D57U2$5"*@;NU$>HJ*=;9:"0J
M0PCMGFQ^((S+I'])BO;Y9%3UW[9A8S3>#2E6D`;!4F-E4Z6%0U:ZA0F@!K0]
M:D5HV"\:QQOCTD\OM45+?(8Z];WM27#$`T5BI^5.!_/RZ8>71DJ:9_X\1_,`
M,/D1UVOZ7/\`M/\`T6GO?6_$!75Y=`E.0,QNJXO_`+_;?!//`MNK)M?^SZB!
M8<BQL?Q;V\@KN)A_"T0_P=>N`(;".Y'%9./Y]!)U'TGM7IC/=T;@VC49^HR'
M?7<F9[NWA'F*NGJZ>#>.;V[M3:E71X(4=!0-1X/^';0HRM/)]Q*LPF/DL19)
MM\EM#:)8$A8H+R;6QX+KBU"OVD\>C'=9CN=_)(YK)>6")&/]^:CX,FGUHH-?
MLZ+3B/Y=G3FT\9T='LG<G:>QM\_&[,=NY#K[MG;V9V_3]C4N%[NRNZ,[V#L+
M=-57;6K\1N#864S>Z6KZ>@J:)DILA04<R.)HV9J)#<6]Y'LK@_7&UB$L0^)8
MR6J4'^_3VE,\"WKT@GD'@75];D/#->/+$W%6:-44EO\`A*T(D]#IZ1W7'\JG
MX@];R4U'B]F9/<VWLIU#+U-W5LK?U1A]\;7^3%(N[9^QL?V)\C,3F<!*-^]K
M8+>U379&ESD;TDJFMEB9&I_%%&J%["7M[9F0+-?K;_T?TS70/^'J/[8>0\^K
M;CVPQW>:I8M<5/Q!'&EY3_R[&E(3\N'1B]S_`!-Z7W9N_K7<^0P'VF(ZKZ7[
M5^/FV^O,,*+&]?'JWN#$[>V_NS;-9@*:C$\=/#A-LT]'0)234R4T+R`JPM[J
M@*3%(FTK<[;J+#B&GF20$'U[=0]:=42(O>K=4-(+ZU9C_#2TG&?]L5'VD=$V
MS7\H#I/<W6<O5L_?'RSD6OWOU1O#);K?L+9&<W?G,3T-MZ?:W2'6V>7.=9Y7
M:><ZPZQQTK2T&.GQLS55<L=16RU;QJRI3<)/.\^E,!U:'@A:0(C3M3/B!8ES
MQX9Z\7D6!:@B1+1@$]&2>21%`^?BL0/MZLSV/M;)[%VAMS9V9WAO#L+)[?Q-
M-C:S?/853B:K>^Z*F)C_`+F-RSX/#;<PTF1J5;U/2T--!I`THH^AE=UE2)4.
MM]"FOF:J"#^8SZ]5B:,37,BD50L[_P!%2:U/H.E400JN00K@E&((5P`2Q4D>
MK2!S:]OH;'VD-Q`\2S(P,65KY53XA]J^?6H7:2-Y6^%%5V/HDFKPV/\`1?0^
MD^>D]=!2>`/S;ZCZG5;_`%KA#;^H_P!<>[!E)8`U*H'/R5D$BM]AC(<?T37J
MZ2))!'<QD&WE^!AP;NT8_P!L-/V]>92I*L"K``E2"&`8*5)!%P&5P0?R.1Q?
MW907$97(E36G])1^(?+JRL':1%RT3Z''\+TKI/H:=>52S!5%V+(H`L26DX0?
MZ[_C^ONC,JF56-#!_:?T.U6[O3M96^PCJRJS^%I%?'_L_P"GW,O;Z]RL/M!Z
MR""9CI6)V:Q.A5)>RJ7?T"[DQHI+"UU'UM[?$$S7)LPI-VLF@I^(/H,FFGKH
M!:GH.J2.L-H+^4A;)HQ('/PE#P:OH:\>L1X^O'%^?\2!_P!#$#_7/M/&Z2J7
MB(95(!(\B:T'VG2W[#UNH%*^8!'V$5'\NO6-[?FU['@VN1P#];VX_K[O%^N`
M8>X,NH4\UI6OV4SU9@5TZL:S1?F?0=<BC*`2K`,+J2"`18&XO]>&'^W]U1UD
M!*&H%/Y\/\!ZV490K$=KQJX^:/JTL/DVEJ?8>N/NW5>O>_=>Z][]U[KDGZU_
MX,O^]CW[KW2%ZX_X\^@_[6F[?_>RW#[]U[I<>_=>ZR1QR2&T<<DI`)*1*S/I
M%KD*EW`NP`/]>!S[T&C+A'(`)`_;U96",'.J@->T5;'\(Q4^@J*GH`EV[O/9
M7;?:78^T>LZO<59V)C^O,/FZVL[6P>!P]51];XC<:X&7&[;?:M35XV:67/55
M)4^>JD2:I-,Z-'3>>>$K2WEBM-QMI#(J3;TD@&@FL;00P.ZFN4"Q"IQD`?/H
M]AV_EB:SBW2;<IQ?):S*(YK5Y9"6:5U!C^I6C%]"TJ:JQ?\`#I),*;X256.1
M8,?M#L[&46,H=T8_;E+A.^.H<758AMQ;^V-VI7U[YJCZ9H\MO'=K;IV9CZ>'
M+YZIR&1EI:2>GJYA3&FEGW*OC)"K6L4@18LMK!.FZ1B2-6#X8UT^T>0Z,-SM
MN4+^\FNCNE\)Y92=*V.E=;JKHH!N3I#,7`%3145N[711ZV#T_NG86]]P]BOU
MCD=Z[YWGC,[B-][AWEW/LJKI]Y_WBSF%^[R&3QN!ZOP6*HZ2DQ.WZ.FI*>EI
M((HL!2B-J?[XFFD1R_5):[K)!!)%<2V5LJ+'(P#.DLQ5TJ":Q%Z.3@+*IIY=
M)[;8>19+JSE_>-W/''<R'6]HR'P=2I(A47./$6CC.6C:.OXPN/BSUEN#I?K/
M&=8Y3:*8:EQ#9;,R[CEWO0;JJ\]FMP9NORDN/>EI\?!58^GVYBIX**F:6HG3
M^'04<2/(R/XSQ9YYI',RS*E0%#OK(T`)+B@H7F#N?D1^19>;=R]M\4QVFX>6
M[DNV:0-$T8T$'PRI:634(T$<=0!5JC&G)ER".#P?H0?J"/J"/P1^1^/;G12C
MHXJAJ!UU[]U;HD/S7"MB^NDDTF/^)[F)U6MJ^SQ2_4@V-F_WGWS;_O'8KNQY
M4VBXDN%\::8!@EL5-..2)3_L]9V?<E7Q]QNQ:PJMW&A+!P"1Z$CH@?BC7@1H
M`.`-"FP'XY%_?+^:%$?39NDMMI72Y`0M503565B,U&6/"O70,S7$I,C2D,2<
M(K:10TQ1P/V#CU[QI_J$_P"2$_XI[:\.;TB_WI?^@.M:IO\`?LG^\O\`]!]>
M\:?ZA/\`DA/^*>_>'-Z1?[TO_0'7M4W^_9/]Y?\`Z#Z]XT_U"?\`)"?\4]^\
M.;TB_P!Z7_H#KVJ;_?LG^\O_`-!]>\:?ZA/^2$_XI[]X<WI%_O2_]`=>U3?[
M]D_WE_\`H/KWC3_4)_R0G_%/?O#F](O]Z7_H#KVJ;_?LG^\O_P!!]>\:?ZA/
M^2$_XI[]X<WI%_O2_P#0'7M4W^_9/]Y?_H/KWC2X.A+CZ'0MQ?Z_CW[PYO2+
M_>E_Z`Z]JF_W[)_O+_\`0?7>A1P%4#\`*`!_K#W[PYO2+_>E_P"@.MZY_P#?
MTG^\O_T'U[0O]!_MA[]X<WI%_O2_]`=>\2?_`'[)_O+_`/0?7M"_T'^V'OWA
MS>D7^]+_`-`=>\2?_?LG^\O_`-!]>T+_`$'^V'OWAS>D7^]+_P!`=>\2?_?L
MG^\O_P!!]>T+_0?[8>_>'-Z1?[TO_0'7O$G_`-^R?[R__0?7M"_T'^V'OWAS
M>D7^]+_T!U[Q)_\`?LG^\O\`]!]=>..X/C0D7(.E;@D$$_Z]F]^$D]I_C`6,
ME?+4OGC^#Y]6022N$>>4(3D@$<,\69E'#S4CY=<5AA0G3&@O>]AS]0?K]18B
M_'LQBAAVND5S'')!/W4U+4$_8G3\D]Q>P-<FXN+?PL!V>*A'_.,]/VWMPYK:
MV<H-Q;?R4^*R^(G2NHJRE94DAF06OI)6.=)E&F2)N)E)4@D^S[E#F#FGD[G&
M'=>6KA[?F>,ZY"#03QC)1<T.,>709YAV?:.9N4GVG=(5>UG4J)V`*U)I752O
M5X'Q_P"V*SN'K^CW-E,)58;)T]0^,R,H@>+#Y:LIXT,V0PD\GKEHYBVIU-_%
M)Z+F_ON/]WKW8O/>OVZ&Y[O:R6#^&PA\0:3(T;M&Y3UJZM_JSUR&]Y/;3:_;
M_F>\Y?VZYCEDMG7"G($B+(`1\@X^WH;S[FZTU+80PR_VZ`AJ\>.*_EU$43:H
MP#\0X]=>W>G.@CWQ_P`?EMS_`,-?<O\`[M=M^_=>Z:_?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]TY[)_X_+._^&E@O_=]FO?NO="[[]U[KWOW7NO>_=>Z][]U[KWOW
M7ND5'_S,/+?^&-M[_P!Z+='OW7NEK[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[H"\E_Q_>]_P#R4_\`W0#W[KW63W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]TH^L_\`@/N[_P`/7*?^ZO!^[QJCFDG"G\^O=<^XMW[XZ_ZOWMO+K;JW
M+]W;_P`!AY:O9_4N!W!@=J9/?N<DGI8*'!Q[IW1+#@=N0R&H9YZRJ;PT\43,
M0;6*>1Y4;3%73Z]7C=8G$CD!1D]4R_)/Y??/3M;XG]EC;'Q4[G^!/;^TM[;`
MVQG8M^=O?'W&;T[APN8H]XUO8>U/A9V3FLI5;(W/V!B,=AJ2JI,A54=.U;1O
M4PXY!6+='R%$.M/[;^?58(S!M\[RT$<AJ*UH?]7GT2COC^8'\CMJ?&SI?M7K
M+O\`^6F2V?U[\8^X-STF]5^/>UZSL'L_Y?\`2/;6,VSG.B/F;A,9M/<N)V7L
MK;NPL=D::NRR/@*++UX:I%<:M8Z21[P5BNI+@]M8=M4&N##<3R([_9VT_P!,
M*9\]I`)-IA%Q1+XW]V&5L$0^#&89!G*N^I5.?/'1@ZSYP?*#']O9KY!?Z2MU
M2;2_V<+N#XA4OQ'J,)MENJ:#9^P/A;4_(+$;[#KMV#LC_2;!OK%F6NKVR9I9
M<55&F6E141V9O+8+!?-;R!KJ#][&(#B98GD2V5*4"LX4!%D$NHD$$#'2J*.T
MMMQL[(R+X8?:EE)\HY#$UWJ]!%J?6?*AK7HL>^?E7\]\5\==P[3V7\O.R<OV
MKWQ\:OY;7R?V+V[F=O\`6O\`$NF>Q?EKW-E-A;^ZIV138;:5!C'ZMKZ"A@DQ
MN/R-/65]#")M-5(&+A1>$?5V1MU/?O4D9R"QB.TW\Y<LH52!+$H)5$`8@$$Y
MZ+]QN&LH(YIB0([8,Y/$)]1%;U/R"S5Z,=\0OY@/R(^5?\Q;XX5%'V3E<5\9
MMT=#[ZZQW?T[3X[&0X3-?)GI[I+8^_\`NK<M?538I<O'E=G;_P"Q$P?AAJ?M
MDDQSH1K1]1AM=M;/M&[7;.&U6^W2VQI02QR,T4KH#4D))%)&QJ.X-4<*4GDN
M74P21,NF21'X$"6.5U2,D?B:T6&X`_WW,AXFG6R$I;PN>;_4?\%\D9O_`*UO
M9+Y]:"MX1%,]`S,"<ONI;@G^^N]Q;ZZC_>O)6X_M:2=7^P]O(1]7)./P1?X!
MUY4ECM([>Y^!Y?Y$]:__`,C.X>U9MD_S#-E[2Q?8.\N]>_\`YU]??"#JS8>R
M<Q%CMPX7J2GZIZYS^4KME5F<R^%VWLJJKNK:_=.47)55=CHY<AD%E:J0B,J6
MV]NFY[1MAA#,;R6XEE"_$8[:9EN%SQ\2V`B49[N'1]>&WVO?[B\DH(+.WA2,
MMA1+<1#Z9OLCNV65_P"@#Y=(+HGL_M3#)\6^@-Z[2[:ZJWU\3?FCWCL2+9W8
M>Y$WANR?I+/_`!F[4[5Z#F[`W9M_<.Z-H[Y6BVYF8L=-6#)9"G>HQ0+/]P&5
M6=VO+AMT?=4*_7Q\K[EXFDX-W;W%D(W'I^G)I^1#>O1-X<4-ZMFBLNVG>+0Q
MAN*VUQ%<F9"/^:D9/S!'1?L/\T?EA\H.B,/0COG&=GU&Y-O?`3LS<6[MJ]`Y
M#JRG^-/>V\?E9LG;V8ZGS+XG(8^'LO$9_9A_CM132U,9-*I+/%0U*(QK&+1T
MMGB`*I>6KH2/]&D2DQ]2<5/SR>B?<+Y?H/"?5FRW2,@$5^GB+F$5&*>G\(QY
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MG\*RVPI0W$(NKN7\/Z$4QC6OR4"F:`TKYD"MG<62Q[D'(J;10>'H:_ZN/2WK
M?G!\B=J[![,[S3<&1Z_[3[YV3_+.H:W<C;#7-=>]>;N[&Z([#W+O%TQ>^ZRH
MV9UGBLMNK"+CI:VLHLO]E4U"4PHJBLDA"-PV\"3[I'3_`!0;U=>%YTC-O`P^
M7$MTY;-#'N+3RE?W:-DL`PQ\0>\R1]A'0E=$?/SY8=D9/XI4'<_=^U_C/G-\
M]-=$9[%[3JOB?N7L>7Y==G[Y[!WILOM[;V$CQHI,OU]7]8TN`Q[O28M:9,?5
MUS5M>AQD8B1=?16\4LXM\K]!!^S]W14%>D[&`[?MS6]/IZBE"*5^L;AT$&P_
MF1\D.I/CIU?MG-_+V39U6^]OG=7=@]^=B_'5NT,W2=X=5]DRU'4OP[RNW$@4
MT.6[3H,[)FX<@&;*R44T%!BY$6.)@6W@<[?8M;9D_=_:!C&M*@'Y#S\_/CTW
M:E1=;F/A_P!V`\ZU[&[OE7TZ$JC^?7S1KOE#CNL.T$PVWMN=H='1U=;\:]M=
M1U$^[.NLGGOB;6=@[BW!O/);@3;_`&/B<+@>SHY:!,[CJ[/[?:-_X9/!1UT4
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MDIR5V$4-MM6MJ:GFCK]M+GY?LZ$<QM;B9X8J`I&E/]X7^73IVM_,X^=V+^,G
MQ(WWU[5[5H,CO_+?(K&[X[O[#Z[P^V]L]D[EZBWAC,'U=LO;F+P6+[0VKD:3
MMC%9&>2GJMNQ4];N0XMCB!02I)3F\<"PR6\<(I2QMJBA)I)+X1-.-/4GAY]$
M\"EK>LAJZW8"FO#L!_P]6]_$G=.\:[Y#_-C:N>^YBQ=+EOC9V/58)LEE,KB]
M@=I]J]$X;)=J;`P$^6CAJ:7%4F0P5'E%IO'"4?*-*T49F*A#;P&.SFE/#]XW
M$(_YLB,_]9.BZV%V+JU,I_2.S6V*^8EN`,>6.C_^Z]&W7O?NO=>]^Z]UR3]:
M_P#!E_WL>_=>Z0O7'_'GT'_:TW;_`.]EN'W[KW2X]V7_`"=>Z)!\WFV@*?XL
M0]BUN(HNN*OY;['IM]G<F33$[3J,">M>VYJ>FW75SU=)1_P=LY!2'34L*?[@
M1:KL0/9?*2)@1ZCK8^(?;T6S%=A;TV;FNPZ;I+.[1Q?37]YN_:WX\[TW?%DL
MSL3"8[:_3?55?FY-O;CJX,_48OK#']JUV=BI)H(ZC$Q:2%AFHJ4QF]U=$]--
M_N4/MZ;-Q?,#O#^Y>P/X%D\KBZ&7<'>6&W?VIN+,?':*BK=S[`P6U,ML/:NV
M.Q%H6Z+[`VSG/[R5T[5V&Q]#E\S_``>>AI(*:MCF</H:QJ:4Q_JX]*E!^JX5
M_P`<MO\`JV>FFI^:7R(KNQ-MXF+<&Q-C9'/9C+=?YS9V[<;308?:.=3XW9WL
MNFWG'LBFVIE.ZCM;&;YH(G_O'E<GC,3D:*84E'B:FI#2C<I'@R5&?!;_`(_%
MU;;?[)/]O_U<?ITK/EYWB-B;%BQ^<R:P57:F[MG]F]RU>Y?C8N`PZ8[JS";X
MVC@]A=N#$4W0&ZL1N'<6;J*1ZZ7"T.3C-')B_MXLA:8JKD`3M2E/$F]?]_/7
MC\_R].DLM3-)7^'_`"]6;]);IW;OCIOJW>6_<=0XC>VZ=B[<SVZ<=C*>OH\?
M39O)XV"IK?LZ/*0T^1HH)Y'\H@F020Z]!+:=3,=)+&FAZ>O0H>_=+>B^=Z]/
MYON>MV3MO`97$XFLQ\6[,R\V8%8::6"!<!2F&/[&GJ9/,9*I3R`ND'F]O>+O
MWE/8+F+WQM8=GY/W2VLWMF#?XP<8^VO4_?=^][.6_9^YGWC<=GOA]4I4FA\\
M=`F/@1V21?\`OML,?46(W#<6)%O^+5_A[PYG^X-[J-*3N&_;-)>8U,(KQ@:`
M`4:*W:,XH.UB,4.:CK*>'[Z'M_'&%39-U*Y/;+9JN37"RW"2#C^)0?RIU[_9
M!^R?^>WV%_MMP_\`UJ]L_P#`"^Y'_1[V?_G#?_\`;-T[_P`&GR#_`-&/=_\`
MG/8?]M77O]D'[)_Y[?87^VW#_P#6KW[_`(`7W(_Z/>S_`/.&_P#^V;KW_!I\
M@_\`1CW?_G/8?]M77O\`9!^R?^>WV%_MMP__`%J]^_X`7W(_Z/>S_P#.&_\`
M^V;KW_!I\@_]&/=_^<]A_P!M77O]D'[)_P">WV%_MMP__6KW[_@!?<C_`*/>
MS_\`.&__`.V;KW_!I\@_]&/=_P#G/8?]M77O]D'[)_Y[?87^VW#_`/6KW[_@
M!?<C_H][/_SAO_\`MFZ]_P`&GR#_`-&/=_\`G/8?]M77O]D'[)_Y[?87^VW#
M_P#6KW[_`(`7W(_Z/>S_`/.&_P#^V;KW_!I\@_\`1CW?_G/8?]M73/G?A#V!
M@*&.NJ=Y;)G27(XS&*E/_'`RS96MAH*>5S-CXP(8YI@7M<Z0??O^`%]R?^CW
ML_\`SAO_`/MFZW_P:?(/_1CWC_G/8?\`;5TVM\,]^@D?WMV;P2.5SP)L;7M_
M##]??O\`@!/<G_H][/\`\X=P_P"V;KW_``:?(/\`T8]X_P"<]A_VT]<?]DTW
M[_SUNS/]MGO_`*U^_?\``">Y/_1[V?\`YP[A_P!LW7O^#3Y!_P"C'O'_`#GL
M/^VGKW^R:;]_YZW9G^VSW_UK]^_X`3W)_P"CWL__`#AW#_MFZ]_P:?(/_1CW
MC_G/8?\`;3U[_9--^_\`/6[,_P!MGO\`ZU^_?\`)[D_]'O9_^<.X?]LW7O\`
M@T^0?^C'O'_.>P_[:>O?[)IOW_GK=F?[;/?_`%K]^_X`3W)_Z/>S_P#.'</^
MV;KW_!I\@_\`1CWC_G/8?]M/7O\`9--^_P#/6[,_VV>_^M?OW_`">Y/_`$>]
MG_YP[A_VS=>_X-/D'_HQ[Q_SGL/^VGK-0?##?F0S$6$BW=LZ.IEQ%7F#+(,T
M(13T=91T3Q6%!Y?*\M=&RG3;2;^W(ON`>XTT@C?>]GTFO^@7_I7_`)1NJ2??
M5]OE4F38]UT>>J2Q<4^:"X);[`#U"[$^'V^>M]D;BWOD]U[/R%#MRDAJZBBQ
M_P#&ONZA)ZVFH52$U..AAU+)5!CJ<>E3[`_.OW..??;CDZYY[YCWS:/W=;L1
M_87^!_V38Z$')WWH>1^<^>+?DJRV.[K<BH!AM*$D5S1Z]1?C7\;LEV]DXMP[
MBCJ<=UWBJD_<U7J2IW)64I+-BL6Q`_9U*//-R(U;2I+_`$1?=N^[!O/NWO?[
M\W=F'MY;2A[BX6NJ_8'`MCQ*CSI2@P<@CI;[_P#OQ;>W-E)8;*FOFNYCTFU/
M^@J10/I\J?+JX[%XW'X;&T6(Q-%38[$XVG2DQ^/HXEAI:6FC`6..&,>E8_2&
M%QJOR222??9_9]GY;Y<MTL]DCCBLXXU1%0`!54``4&*X[OZ5>N7V[[[?[K?2
MW6YRF;<)6+.Y))).:$_T1V_EU//M<%8.SG@QKT31BA)]>NO=NG>@CWQ_Q^6W
M/_#7W+_[M=M^_=>Z:_?NO=>]^Z]U[W[KW7O?NO=>]^Z]TY[)_P"/RSO_`(:6
M"_\`=]FO?NO="[[]U[KWOW7NO>_=>Z][]U[KWOW7ND5'_P`S#RW_`(8VWO\`
MWHMT>_=>Z6OOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@+R7_'][W_\
ME/\`]T`]^Z]UD]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=*/K+_,;N_\/7)_
M^ZO!^_=>Z$WW[JDB>(A3UZ!KO[X_=0_)_JW<G3?>&S,=OG8.YX8S4XVN#Q5>
M*RU)KDQ&Z-N92G:.OV_NK;]6XGH*^EDCJ*:9;JUBP;7E3IZ23Q+<6OIT"TO\
MO#X65>V^D]J9'X];$R.&^/=$N/ZMIJB/*P#&4\N1H,YDX]PB@R5&F_J?/[FQ
ML.8R%/N`92DK,P@K)8FJ!K]OO)]3(JDT3Q)$)\_#B0-!GY2,].F5M[NX0S>2
M_P"3_BNA`C^(7QGC^0=7\JTZ9V</D%6XBKPE9V0T.2DKIZ.OPU+MO(5C8*7(
MOM)-Q9#;5#%BZC++CQE)\8@I'J#``@;ME9;>,R?VS(&?_3L-3_\`&B>G0$>'
MQ7_W)\_RP.D-LG^7O\+>N=O;IVKL?X\[(VW@-Z=@[&[1W)CZ";<CK6[SZRSD
M>Y.NJNFJ:W/U59B,)L7-1B?$X:CD@PM"S.(J0+(REQRW8J?VJN6C^3F-XV/_
M`#B>0?9TB,(G\0WA_2,>AO\`FGK5P/\`G*D?\NEQL7XA?&GK'<VV=Y=?]/;6
MVGNC9NY.Y=X[7R^(;+Q3X?<_R%K*6O[IS4,,F3EI)JSL"LH8GJ_-')'"L:I3
M+"BV]VCNEBLAM\9[1&B+_P`T4=W3\O%>3I>98V1HR3XC3&1O^:I14;\_"5.C
M)+:S\<:`+?[%!_3VGZ;Z+;E-W8"@W!O"EJ*NH2HAWSO<.(\5EZA03NG)<I-3
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MF:DP&`PU*M#C,;23Y"EKJV6"EHXDC5I)6D(7DF_NP```'`&H^1]1Z'Y\>J>'
M'PTK2A'`<#Q'V'S'`^?2N7?6W`?36U@//TP6>O<@J?\`EU_5E-C_`%'O>HU4
MFITTI\@.`'I3RIP\NMMIT,&^!AW?/'GZFG#I*;HFV-N^*DARF;WG0I1&I:`[
M:KM^[7;RU*(JU%2<%'0FKGH)(UEI3)J\,PORC.K,SVC7TAFUE)#Q/F?S-3T<
M;+S#?[9"(-GMH9H14`2`TSQX$?['ETCQLWJE=.C.=GQ*@TQPP[W[@6*",.'C
MAID->5B@IXFEIXPVHK3U<ZWU,CJC.T;<"1)-*9-)4_,9JO\`I2225.#7(Z.F
MYUWMG=Y#ML4C5UJ(AVG!9>.=`&M/68"/X6(/$;)ZE!7_`',=E2*I7]J3>?<#
M4\T8<ZH)H_X@&>.HIO'326(U4U+`!9T9G]^Z]MH1XTU"23GS(`)/S(%*]:'.
M^\*=7B[:IH`=,0-`"2*58AB&;"FHTO)BBBG9V7U2RE7W#VC(S,9'FEWCVHU0
M]3)&5FKIG$H1JRIK5CR,C*J@Y&&.0#QAHCK]T[9G]:;(I^6!3YX`'V8X=;'.
MV]!%B63:]*GM7P^T$5&FNK$8)*AA0F/3)\7=UR&SNJP69<_V?"QL0\.\>UE>
M)D4"GDIR\[I')0,9F@+AV1ZZJN2KH(]_NG;!2DTW:*#Y#T'H/EPZ]_7G>CJ)
MFVXAADF(!C44#$!A^H0O>/PE4`IK-?#9O4_Z?XUV08^?\G.[^VS2^$OZJ,I]
MWYFI'Q]L:5U\XY1'_G!Y#7]S[51OU9>[XOZ6*9QG&,^5/3K8YYWL%3XNVU4U
M'Z0H#76:=W`$B1?(RO+'\*TZX?W*ZHYU9[M.77<2M+OCM]I)BY)G>H9:U0QJ
MYA#/+I"EIJ2G86TNKN?NW;]1?QYO$)J37)-*5KYFF*\:8ZI_73>`FA9-M\("
M@'A"E`2`*:N`8^'3@8&:3BJD<FV=U:QU_P!X^UDF`>U1'OGM]:A'D1?\HIV:
MM98JF.K#UJE@RBMJ)6(,;!$T-KVT`#QYM(->/G_JK^WTZM_7;>M1*R[9J(H?
MTZ`]ND*3J^$J#J;BI6.A!<D]C9O5"E3'F^S(D1E,4,>]>X?MX$5P8J9(VR#,
M:>FIC)11+J]-%431F[%77:[*C.)K2>3M`&3G&0!\A7'H<CJT7/._^(J_3V-U
M9_$7":2#4$:@#360`S#\+544&.G[8V,ZGZW&ZGVE2Y.CK-[[F;>&\<OD*?>.
M<S6YMQ_P;$[;I\IE\QF(*_(54E#MS`T./@0LD<5)1Q`+KUDKE62)/"8DIJ+?
M[8TJ?2IH*GB:"O09W2\@W#</J@@2?1IHN%"C@`.%`3CTJ:<>ES_?C;7_`"N5
MG_GCS_\`]:_>^D?7O[\;:_Y7*S_SQY__`.M?OW7NO?WXVU_RN5G_`)X\_P#_
M`%K]^Z]UR3?&VM2_Y96?J'_+CSW]1_U;/?NO=(OK[>.WJ?:5#'+5U8<93=EP
MN&SCBQWAGW!!3&L+%6'OW7NEE_?C;7_*Y6?^>//_`/UK]^Z]UQ?>NUY%*25-
M3(C`!DDP&<D0@'4`5?%,I`;G_7]ZH.O=<O[[[9"A!5U00``(,#G0@"@*JA!B
M](4``6M:WOVE3Q`Z]YU\^NO[Z[7$8A^YJ?"H4+#_``#.>%0A9D"Q?PKQC0SD
MBPX)-OK[WUZI&1QK7\QP/VCKE_?C;6LR_>5?E90C2_P+.^1D4DJID_A>LJI/
M`O8>_>5/+KP)'#'7#^^FUO'XON*CQ<'Q?W?S?BN',H/C_A6BXE8L#;AC?Z^]
MDDY/'KW7,[YVVQ):MK6))))PF?))/)))QER2?>NM``<.NO[\;:_Y7*S_`,\>
M?_\`K7[]UOK)A=\;:3?F$G-76^--M[KB.G!YQI!)+5;8=?VEQQD"LL1]5K?U
MY/NNE:ZJ#5ZTSU=I9770[,5]"21^P]##_I#V@+WK:^]S>^W-PW^I_P"K5[=6
M1T72C$*/($@?L'311&-64$_,#KW^D39__*[7_P#H.;A_^M7O?C3?QM^T]:\.
M/^%?V#KW^D39_P#RNU__`*#FX?\`ZU>_>--_&W[3U[PX_P"%?V#KW^D39_\`
MRNU__H.;A_\`K5[]XTW\;?M/7O#C_A7]@Z]_I$V?_P`KM?\`^@YN'_ZU>_>-
M-_&W[3U[PX_X5_8.O?Z1-G_\KM?_`.@YN'_ZU>_>--_&W[3U[PX_X5_8.O?Z
M1-G_`/*[7_\`H.;A_P#K5[]XTW\;?M/7O#C_`(5_8.D%V-OO:U3@*-(:NM8C
M=.T';5@,]&`L>X*)WNTF,122HX%[L>`/?O&E_C;]IZ]X<?\`"O[!TF&WQMK4
M;UE8>3]<'G[_`.QOB[^]>++_`!-^T_Y^O>''_"O[!UU_?C;7_*Y6?^>//?\`
MUK]^\67^)OVG_/U[PX_X5_8.O?WXVU_RN5G_`)X\]_\`6OW[Q9?XF_:?\_7O
M#C_A7]@Z]_?C;7_*Y6?^>//?_6OW[Q9?XF_:?\_7O#C_`(5_8.O?WXVU_P`K
ME9_YX\]_]:_?O%E_B;]I_P`_7O#C_A7]@Z]_?C;7_*Y6?^>//?\`UK]^\67^
M)OVG_/U[PX_X5_8.I.VM\;93?M/4/5UOB39>8C9A@<\S:FSFW=("#&&4J`MB
MUM(_K[LOB7!\$R,`WGJ/V^O6PJ1G6%6H^0Z5V^\CUUV#M/+[.S>1RZ8C.)2P
M9$T>`W##4O3TM?25YBCG;$DPBI^V,3LH+>-V_)'L'<X\HP>Y_*%QRMNKE;(&
MF2:$#U!-#T(>6M_F]M]Q'-.WEI+ZM1DDKQX'B!GAT_XG=W7N"QM!AL,)<7B<
M72PT5!CJ/;&X8J:GIZ=`D2)&N)M86U7-V+$DW/LZY:Y>L.4]H7;-N5(K>-:*
MB`(@H*=JK117SH///2+=MWN-VG:]N9));M\EW9F?.::F):GEQZ</](NT3_RG
MY#_T'=Q__6KVLA0",`@5SY?/HHC6B#5ENO?Z1=H_\K^0_P#0=W%_]:O;W3O7
MO](NT?\`E?R'_H.[B_\`K5[]U[H+-Y[YVS/NW`315=<8X]L[B5F;!9Y#JDRF
MWRNE&QHD91XS<@$#BY]^Z]TV?WXVU_RN5G_GCS__`-:_?NO=>_OQMK_E<K/_
M`#QY_P#^M?OW7NO?WXVU_P`KE9_YX\__`/6OW[KW7O[\;:_Y7*S_`,\>?_\`
MK7[]U[KW]^-M?\KE9_YX\_\`_6OW[KW3EL[?.V8=W9F62LK=$NU\)"FC!9YV
M+KF\W(UT7&%U4*/J1;W[KW0J?Z1=H_\`*_D/_0=W%_\`6KW[KW7O](NT?^5_
M(?\`H.[B_P#K5[]U[KW^D7:/_*_D/_0=W%_]:O?NO=>_TB[1_P"5_(?^@[N+
M_P"M7OW7NO?Z1=H_\K^0_P#0=W%_]:O?NO=(^+?VU3O[*3"MKS&VR\!"MMO[
M@+F1,_N61@8_X9K5=#CU$!;\7O[]U[I8#L7:!`/W^0YY_P"/=W%_]:O?NO=>
M_P!(NT?^5_(?^@[N+_ZU>_=>Z]_I%VC_`,K^0_\`0=W%_P#6KW[KW7O](NT?
M^5_(?^@[N+_ZU>_=>Z]_I%VC_P`K^0_]!W<7_P!:O?NO=>_TB[1_Y7\A_P"@
M[N+_`.M7OW7NO?Z1=H_\K^0_]!W<7_UJ]^Z]T"N0WQME][;SE6LK-$W]V#&3
MA,Z&(@P*B4F,XWR+I+"UQS^/?NO=9/[\;:_Y7*S_`,\>?_\`K7[]U[KW]^-M
M?\KE9_YX\_\`_6OW[KW7O[\;:_Y7*S_SQY__`.M?OW7NO?WXVU_RN5G_`)X\
M_P#_`%K]^Z]U[^_&VO\`E<K/_/'G_P#ZU^_=>Z]_?C;7_*Y6?^>//_\`UK]^
MZ]TH>NM][7IH-U>:MKE\N\,C-'IP.?D!1\9A0"3'C&4-=3<7N/?NO="+_I%V
MC_ROY#_T'=Q?_6KW[KW7O](NT?\`E?R'_H.[B_\`K5[]U[KW^D7:/_*_D/\`
MT'=Q?_6KW[JP9@*`FG7O](NT?^5_(?\`H.[B_P#K5[W4]5Z]_I%VC_ROY#_T
M'=Q?_6KWJIK7S'6J`\?]7G_ASU[_`$B[1_Y7\A_Z#NXO_K5[U0<?.E/R]/L^
M77J"M?.M?SX?X,=<E[$VB0_^7Y#A+G_?N[B^GD0?\ZO^I][ZWTB9F89;="W?
M2N^=\<!B+:]U9,&POI%S:UA]?Z_FH)-\8?\`0!&#^=/7_)TX(9)K9#":7#/3
M^=!CJL'=G\T/9^RNVM][!SO0'<:===:?)/9_Q6WCW_2[KZ5GV?C^T]]56SZ#
M;T5'UO)V/3=V9O"5&3W[BZ=JBBV_.8FF=RI2*33K;)%NHY+F8UMQ#<,M,=T2
M,5_8PR/,8Z4[Y8R[0\EJW^Y4>@_D\:O_`(37K'U7_,_P?9N[.M<))\:N[-G;
M2[K[+W]TYT]V;F]X]'9;`;X[-V&V]E?;,VU-J=E9KL?:-)N"38->M+E,OB*/
M'TX16J9$$B'VY#'*VR'=G_T'9TNF`I^I*6/8OIK&0!D:3C/26[:!9+FSMC6Z
M_>4MO&U&I"BK$0S@C]3PRQU!=3OJ&D-I-!:^,/SZZX^66^<]U]UIL/M7'9OK
MO:]57]YMN_"TF%I^A>R:3<^2VPW0N_7%?.<GVK*V(J<@(<3]W01XJ..I:IT5
M5.&=@A^JM9KZW<&W6T@=,'NFGP$`-#^D<D&A/F.DMX+FVGBL@P^LD1Q3!H8A
MJ,O\.F4?#'7Q$KWHO2ZS/S'ZHPGREQ'Q(F7=D_855UEOSM/<6YA@:^CZWV3A
MM@4V!K\EB,QNRM2"BRFZ:G$9]*PT6-:L>A@56J_")(A*S8J]S!=$T,\2SNO#
M"I(J1U'F.ZA/F>/5-UNTVMA'(*N9XE]1I>UFE8?G(BD?($<#T".+_F4['WQU
MON;L3IGH;Y'=T5.([^W3\?,)L;;.TL9M7<FY<QLS9<78&=W]7U?8^8VI@>M.
MMX=K,\T-=NBJQ<U5*D44</DJ8$=%=,6VO;KE"%GO;61JUJ-<<NEB`M?*@H.!
MX^?2U5-UN&XVT!*PV\EH(PM5($T.MP3BO=P/D.&.CC=&]S;1^0?3/6'>.P)<
MJVS.V-EX/?&VUS%*V.S%/C,[2"KCI,K1+-40T]?1N6AE\<LD+NNJ)WC96)WN
M,<%LX6U4>%4TKDT\JD\?MZ31)$S.C(C2HQ!)4$U!J"3ZAQX@/E(`_$="GK<'
M];_\E'_BOM,Y`I15R!Y#K4,:`'5'&&#&E%`I\QC!H6%?1F'XCU[R/_JW_P"2
MF_XK[IJ'\*_L'3G@V_#PH=-*4T"FGAII3X0O8%X:`%X#KVM_]6_]?U'_`(K[
MWJ'\*_L'6_#A.3''JXUTBM3DFO\`$Q`+'B2JD\!U[R.?[;_\E-_Q7W[4/X5_
M8.O>'!_OJ*G^E'K4?L8LX]'9FXL>O>1_]6__`"4?^*^]:A_"O[!UKPH/]]1?
M[R/2G_'"8_\`FF2GPDCKWDD_U;_\E'_BOOVH?PK^P=>\&WX&*(KZ%12GF.'`
MT6HX'2M?A'7O(_\`JW_Y*;_BONIRP88(],=5:%&-15?4*=(8GBS`<6)R2<DY
M/7C)(?[;_P#)1_XK[N9&*Z3PZ?#43PZ"E>-,_MZZUO\`ZIO^2C_Q7W3JO7M;
M_P"J;_DH_P#%??NO=>UO_JF_Y*/_`!7W[KW7..1UD0AV!#J0;GZ@CW[KW2%Z
MYD<[/H/41_N4W;]"1S_?+<`)_P!<VY]^Z]TM];_ZIO\`DH_\5]^Z]T$G8O;H
MV1G]H;$V_M#<'9'9F_:/<>5VQLG`9##X4G`[0.(3=&Y-P;FW%6T6"VY@\7-G
MZ&")YV::LK:J."&-_6\7@"30<3U5]6@Z/CH:?;Y?SZ9)?D;U]MW`8K+=L560
MZ1RU?6[EQ]3M+LB":DS5!+M/)?PK.Y<U&%3+XZJV)33E)8MQJZ8:6EGBD-0A
M?2NM:Z=?X-)?_:(2K_\`&@>E"H);N_@B^&.2U2#_`$SQ*T]?XJL217X1@=*[
M(]T=38>&GFR_9>T<;!55^]\1#55N<IZ>EDR?6N-GR_8%,*MW^S2;9V,HYIZX
M,X6")"?7<>VBYU^%^,::_:;B.(_\88C[37I+#,EZG^*`ZAJK^5O)(/\`C:@_
MRZ"7*?,[X\8NNVLLW9&)DV]NBE[!E.[8FK/X5MZOZXCVS5Y_";@QKTPW+BLG
M#CMU4U4WGHHXZ>CO53M'3E)&9,LR,`]*4+'_`$H8K_E7IN5I8[CZ8$%]*GAZ
MJ#_AZ7]7\BNC:'+YC`UG;FQZ7*;>P-7N7-QR9HG'X["4.WH=W5M;49J-)<&D
ME#M.H3*34ZU4E7#CG6J>!8'5_:W2RBC?%4C\U)5O^-`]/ZXXU`E^/H0]J[NV
M_OC`X_=&T\NF;V]F(FJ,3EX(:^EIJ^FC>:,U$,60I:2I:&5H6\;E0K+I9=:.
MK'76Z@Y7ATH-;_ZIO^2C_P`5]^Z]UEP18=@X%59S_OU]XA>26!>NVHS@$^HA
MF-R/>A-'$_B7B^%;OA-1IG[>K0ZFOI4$;RVZ+4!:U_:.ALU2<W:3ZG\D?D_X
M>[B*%.V::X\7ST0AE]11O,4I^?5+=KBYA$ZQ6Z*U:+)*5<4)'<OD<?LZ]J?_
M`%3_`.W/_%/?M%I_OZ[_`.<`Z>\.Z_ALO^<YZ]J?_5/_`+<_\4]^T6G^_KO_
M`)P#KWAW7\-E_P`YSU[4_P#JG_VY_P"*>_:+3_?UW_S@'7O#NOX;+_G.>O:G
M_P!4_P#MS_Q3W[1:?[^N_P#G`.O>'=?PV7_.<]>U/_JG_P!N?^*>_:+3_?UW
M_P`X!U[P[K^&R_YSGKVI_P#5/_MS_P`4]^T6G^_KO_G`.O>'=?PV7_.<]!WV
M:\@VY1@DV_O9LTG5<@6W'07(X`%A^?Q[WHM/]_7?_.`=>\.Z_ALO^<YZ29:2
MY]3_`%/]IS_O-^??M-I_OZ[_`.<`Z]X5S_#9_P#.<]=:I/\`5/\`[=_^*^_:
M;3_?UW_S@'7O"N?X;/\`YSGKVJ3_`%3_`.W?_BOOVFT_W]=_\X!U[PKG^&S_
M`.<YZ]JD_P!4_P#MW_XK[]IM/]_7?_.`=>\*Y_AL_P#G.>D)V=NVOV-L7/;K
MH84JJG"PTM4*:I,JT]1&U?2P2T[R(=<;30RL%8`Z2+^XX]U^;WY$Y#W#FBP=
MO$L8Q*S2H!VUH1H."*"H/0X]N>6+;FWFA.7MP"F6X4+$(I"0')P2P_P''4CK
M_L'`=D[;IMQ;<JG>.0K#74,DH-=BJY4+34%="MM$BVNC\I-'9EMR/:?VK]UN
M6O=GE"SYGY883S2P`30`T=)0>Z0CB%)P!PJ>M^YG(&]^U7,$_+O,D#AS$)(9
MQ\!!-`N,$@<>EYMAG'8=)RW_`!X^:-]3:O5G-N$"]R=-OH/I[E%"EW%KMP89
MX,RHQJ2.&*\,GR].@,\'@6D%PTZ/+*W``>E>AGUN/[;_`.W]I9(4DM6LSJ$+
M&IH2#^T9Z;4Z6U<?MR/V'KVM_P#5O_M_?EA1<BO[>F1$BFHKUUJ?_CH_^W_X
MU[>)J:].@4QU[4__`!T?_;_\:]ZZ]U[4_P#QT?\`V_\`QKW[KW02;X=O[X[<
M!9C;:^Y1?40?^+KML\$$6]^Z]TUZW_U3?\E'_BOOW7NO:W_U3?\`)1_XK[]U
M[KVM_P#5-_R4?^*^_=>Z]K?_`%3?\E'_`(K[]U[KVM_]4W_)1_XK[]U[IRV2
MS?WRSWJ;G:>!8C4PU$9S.*+V-[`,??NO="[J?_CH_P#M_P#C7OW7NO:G_P".
MC_[?_C7OW7NO:G_XZ/\`[?\`XU[]U[KVI_\`CH_^W_XU[]U[KVI_^.C_`.W_
M`.->_=>Z1<+N.P\MZV_X\;;O]HB]MR;F8`E;$@,M['CW[KW2TU/_`,='_P!O
M_P`:]^Z]U[4__'1_]O\`\:]^Z]U[4_\`QT?_`&__`!KW[KW7M3_\='_V_P#Q
MKW[KW7M3_P#'1_\`;_\`&O?NO=>U/_QT?_;_`/&O?NO=>U/_`,='_P!O_P`:
M]^Z]T!>29O[][W];?JVDQYM=EV\%4DBQNJ_3W[KW676_^J;_`)*/_%??NO=>
MUO\`ZIO^2C_Q7W[KW7M;_P"J;_DH_P#%??NO=>UO_JF_Y*/_`!7W[KW7M;_Z
MIO\`DH_\5]^Z]U[6_P#JF_VY]^Z]TH^LW?[;=JZW`&]<I]&-C_N,PAN1?3?U
M'\>_=>Z$S4__`!T?_;_\:]^Z]UT787)E8`<DE@+?7Z_T^GOW7NNR["]Y6%B`
M;L!R38#G\D_CW[KW789S8"1KG@>KZGG_`(H?]M[K.ZK&/#_M?/KW76LBUY&%
M[6NUKWN!:_U)/NX>*15@C_W)8<?(4]1PZV:>$:?VGEU[6VF_D8`DK?5_:'U'
M]+BWO3*;9OIKCNN#D$<*=5BKX1\7^UK]F/LZY*SV<:WO8"U^;ZTX^GU]^ZWT
M"51<9C=?`_X_?>Q_VVZ\D?\`'^GNNG]1V_C6E?3KVN8F-E_3\-]6<ZJ&ORI7
M\^B&=2_R_.AMB]^=Y?)7?'7'479_<7:'R$RG=NRNR,YUAA)^P.K\75;2VAMK
M%[.Q6[,J<KD)),)5;=J:N&KIS3(C5QT0K(GD+.W6XV[9_P!U^())REPI<"G]
MN'`Q4_!J]<T\NEN]W\N];G+?,A2*18P!6OP1+&36@K6E?EPZ+1T__*=PGQVW
M=TKW;T=N[K;:?R2Z^R7>5!VEV)D.ISD-N]]]?]R[DW;NNBP>],%!N*FS5-O+
MK[+YC''';AAKQ6/34,U*X^WJ?''4)/%MRV>JD-OMJ14_CF1U42<?ATNQ*&M?
MXNDTD9N?KG:6LEW=._#^S@=4!AKQKJC!$JE6'`<>G?HS^5YGNG,EOZ2J^5?;
M>=QOR5V=/DOF+6;;SNZ>N=]]D?)1=V'=%#\@NF][;:W'_$>D9'Q]3-MZMPT`
MK8:K;T%'`)4D@>20PFFBM=%K;@IMT=[;@BM23$%DEDKBBR:M*K^`J35O)!++
M(;E+F4:KY8_!UC%8J!46F>Y0!5ZZG_$>CEU?QKOW]\:NYJ+>^5J,9\=NG>V^
MI(L-NILGNS=>\HNS(]A1TNY<WO7*9-JBLS&*79%ZV6J@J)\G+4^1Y$93=G;)
M#MN[S12+K6:P,!'#03.LYD/&OPB/3C+:JXH;;I8Q;I="1W`A21)=7$'PX)(0
M.(^,.7!\@*9K7HI7=/P#[XWEU=\@.L^HODYM?K2D^27RVW)\A.T)LYUMNO-P
M;BZNW#MW;&*K.@J^?:?9&RMQP8K.9+;$;9?)T.0HZBLQTCTD8A#NY2[;M,4&
MW;38W,I+;.+SNX"<74OB:J&I40CMI4ZF(:H`H52W(EO;N\MAI-VUN0O'28(_
M#5:^9DRP-!2A%#U8MU+M;-[%ZPV!LK<DFQ9,YM#:F(VU6MUAM&KV!UQ&,/3)
M14=+LG8]=F]RUFT]MT./IX8:6ADR%684CMY&O?VKED>6*-'4AT4`U.:TH?+I
M+9(\5U(SMJ5G8UX<3T(7U/OQ;4!44(%.E4Y"2Z5&*5Z];W1F(5V45*Q2/3U*
M*6"_[:E`?+Y]45M1H104ZZ]O%`'9*_"T0^WQ%=B?]IIH?6OE3JYIY'KWMJ0^
M&<_/_H7_`'KRZV`#Q-.O>[T7UZT!BIX]=V]U]>M&H%1QZZ]^.(]9P=5"/1?X
MOLKCKQ^'&9/(>I].O>_-57"^6DDGT.*#\\_LZL/#-26HOE\_7]G^7KUO?ES\
M?:.KHL3N%+TJ?3_9Z[]^-?P=W3+$JKM3*\!_%]G7K>VX':569UTE:_G3K0)-
M"PI4==I^M?\`@P_WOWN-]:ZJ4SU=M->PZAZ](7KC_CSZ#_M:;M_][+</N_6N
MEQ[LHU&G6Q]C'[!4_L]/4^714>^]LU7^D#8/9&TJ;.OO[;.TMZ[&J::7JG<G
M9>P-X=:]AU^`&XMI[H?:F6PF<P==1Y[!T%;2U%)4-/$K2&6GDI'GJ*1/]2T4
MH*JK:6&"X6M,T%1YTI]I'KT<[?MEG<E6GW/:;=SD)+<:7)U*H4KI-"2U0#^$
M,>(H2(;T^(62W5M+.;3I<YOF&CWC@^UL)DMK5GQ[[<BZWV5E^T\E04N/RW7^
MU<9VMBESF-V8V#D@H\7NNMK\0*@G*&*E$L$U0F-WN!0*]I<8LIX"0%#$RR/*
M'&*#0'"`4J=)ST>6'*4]K=)<27^U,1>^,1]10$']((3H.%T:RV>QD(&:!1;P
M^-^5WL</@,GN+L>@Z]VMN/M_L#;L6+^,F_I=W5>Z>W]L4M2XW%6U^ZTQE;MW
M:^6Q;54=&E!#59"BE:@J/#7O'!+7ZB07SW30R"KUTD<*7"24KY_#2M.'=Y4Z
M+]JY-GVVR\`W^SM*5J3]9I;NM9%II\(T8$Z2*XD(2M#J`Y9C;^ZMZYC)[N[#
M&\8]U97KGOG858NQ?C'O##X?'1=M;,V3M&GKTJJK<63W/N"HP=-A8Y:F:JJ:
MBJK$J_LZ9EAHYTIV[R5KM65(I$+6[QUI6A>9)`W'\(C*D?TP:^73,/)-Y#>O
M>7&Z;)("#11=^2K'_P`+XG5VX%2CC&D:BSX[X:8;&8?(;/CJNXZS!U4><R=)
M/D>I>[,A74_8FX^LI.G*W(Q[8J.UQU#38&#*2S5<-7%B8LG]H1!)5G&@9&1;
M+?O<2%Q'HK),X#L%Q+*\RJ*\616$9I2K`G%>M;AR7)-.K-O&PQ+KTYN^/ZGA
MU'Z61_HA_P"%=_'MZN#VG6PY';."J(*?-TD$6)H\?!%N'!U^W,L5QE/#CE:H
MPN3TU^/69:?R11RA9?"0VD"UU*BJEB1CT-0?SZ++K:KW;%1:P7%NW&2*0.%^
M9%/\OGT_>]=(^BA_++=VY]H4W7]=M7/93;M?45FYZ::MQ%9+1U$M*8,-*::2
M2(AVA,L:MIO:ZCW@E]^3G_G?DW9-BL^7;[Z>>[)<N%^$+3!%<U]:CK,#[HO)
MO+O-EWO$7,,`N$L2%-<>)J."/X:?GT3O_3OW'^>S-ZL?R?X]5B_^P!X]\\IO
MO%>]TTID7F"ZC4T&E:!104P#4YI7CY]9OGV)]HJU;8[5F.:MJJ:YS1@/EPZ[
M_P!._<7_`#\O>O\`Y_ZS_BOMK_@A??#_`*:.]_E_FZU_K$>T'_1AL_\`C?\`
MT%U[_3OW%_S\O>O_`)_ZS_BOOW_!"^^'_31WO\O\W7O]8CV@_P"C#9_\;_Z"
MZ]_IW[B_Y^7O7_S_`-9_Q7W[_@A??#_IH[W^7^;KW^L1[0?]&&S_`.-_]!=>
M_P!._<7_`#\O>O\`Y_ZS_BOOW_!"^^'_`$T=[_+_`#=>_P!8CV@_Z,-G_P`;
M_P"@NO?Z=^XO^?E[U_\`/_6?\5]^_P""%]\/^FCO?Y?YNO?ZQ'M!_P!&&S_X
MW_T%U[_3OW%_S\O>O_G_`*S_`(K[]_P0OOA_TT=[_+_-U[_6(]H/^C#9_P#&
M_P#H+J+6=U]LU\(IZOL/=U1"L]/4B.HS55*@GI9HZBFE`8C2\,T8(]Z/WA/>
M\\>8[W]H_P`W5T]C/:),KL5G7[&/^%NL/^F3M?\`'8>Z_P#8Y6>_^QLP%_=?
M^""][O\`IH[[]H_S=.?ZR'M+_P!&*R_8W_0777^F7M?_`)^%NK_SZU'_`$=[
M]_P07O=_TT=]^T?YNM?ZR'M+_P!&*R_WEO\`H+KW^F7M?_GX6ZO_`#ZU'_1W
MOW_!!>]W_31WW[1_FZ]_K(>TO_1BLO\`>6_Z"Z]_IE[7_P"?A;J_\^M1_P!'
M>_?\$%[W?]-'??M'^;KW^LA[2_\`1BLO]Y;_`*"Z;LKV=V-G*&?%YC>FX,GB
MZM52MQ]=D)YJ6JC1Q(BR)K'Z9%!]E7,7O/[L<T\NW7+&];S+<;=>*%DUBK%1
M^&H(%/R]>C#9O:/VTV#=!O>T[5%!N:+2-D-%4@DAJ&M37Y^74SK/LK</6&X8
M<Y@I0].Y$>8P\CF.BS5([@M2S*&`BG"C]F91Y(G`(XN/9I[/^[?-'LUS-;;]
MR8TGT,%ND<UFTG;<]X9B'(I&216I1Z"H\^DWN5[:;9[H<M/M/,2Q3;VI8P3A
M*%>T@+2I)&:GNZMKZ>W_`+>[%W-C-P[=JA-!-LC-QUM+*Z??XRM7/;;$E#D(
M-7EBJ%:Y#L`DR^I">0.X/MA[F<M^ZG+R\W;;*$WNXB47%D"&-L?,M*`!)D`8
M1<FO7'_G3D2_]NM^EY=WJ)S*CGPI#VC_`'DU\OZ71FO<A=!3KWOW7NO>_=>Z
M][]U[KWOW7N@CWQ_Q^6W/_#7W+_[M=M^_=>Z:_?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]TY[)_P"/RSO_`(:6"_\`=]FO?NO="[[]U[KWOW7NO>_=>Z][]U[KWOW7
MND5'_P`S#RW_`(8VWO\`WHMT>_=>Z6OOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7N@+R7_'][W_\E/\`]T`]^Z]UD]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=*/K+_,;N_\/7*?^ZO!^[*NJOR'7ND?\C^Z]P]`==_Z2,'T?V=W[0XO
M<.(H]X;4Z>.VJK?>W=FUZ5`R>_:#!;HS.WZ7=%)MV=8?N,=2U0R$T$CR0H_B
M=?:..Y,EVEKI/>U*\?V#S/Y]5=@BECY=5/?+O^:[EZGX[=`_(WX-[JV0G0/9
MV_MT;6[(^4';W3?;N]>O^F\ULO.;>P_]P.S=C;4&WMR]=IN&OK\@M;NK(R-B
M<0F(=(?/-54\BKEC9GT'`I75Q1AZ1M^-_P"C0?;UYFTQA^-?+HSNZ_F9WIC/
MF/\`!/I#%=2["EZ!^3.W=XUVX_D+C-Z1;IPF\]WX/HG,]O4^WNAL=2/CLJ^S
M,6<=3R5&X,S2QK7P5J0T]'&RO(JKZ%UMMQFEJDNWVDD^DC^T6.6VBTUKV,?J
M-60U-!'G4)1=DV0O=!H212OI7SI_DZ@?S*/E%\IOB;MVB[1ZHI?CU3=5[=PV
M*1<'VI#NO=/;'R;[QW5O#'8/9WQ5Z.VEM'.X"JVKNK=.$6:I3<LL&=BBFD4-
MCE@IYY@56<?U&Y+`&-)=PAMJTPJR1)(9B:Y":J%<<*ZLTZ,3$19I=UPXX?.M
M*5Z"8_/OY"1?-[L;J3?&&INF.C,3E=R;$Z3C[!^+W:=5%\@>P]I_'Y>T-Q[>
MVI\HT[%PW76/W#B]VPY"&'$C;-5'7X_#5)IZXR,!'N=!:V&X21,LES!#=RJ0
M0&TVCK'0+QI+JU:J]E`*-7K:P&GU`J0E,4XZG5>/^VK^5.B/?RN/YSOR6^8G
MR=Z4Z<[1W;\-.P=N]P=<;\W1N3;W277'R3ZK[(Z/S.T=NT>X**DW)F>[:6DZ
M\[*DR56[X^2DVK6Y>42"2KC?[:$LQOM]E'/KLBY>X%O',)"/)E5BE!_IJ5P,
M5\\)-RF-K;B]`U-J`*<#EV2M<B@TUX>=.MHA=?C?@^33IT<:M>M!HX-@U_3S
M_K_3V5+)6%I"*.'T@>N0*U_GT\PTP+/ZK6GY5X]`I4W&7W6!?_C]]\+]";@[
MJR8M?^R3^#_7WM6+;;)*?C%>M^*;O<([9\)@=4I=S?+'NZ:K[[QFWNU?]#6V
M,G_,CZ=^!.+[*J,-MNJA^/'7LG6VW<SOGM7&ON6BK,"^\NQ=X;C&-QM;FA-C
M\=45M"PIY&CT.QM2*^QQ[C*WZKM(/V.P'^#HQWP1V&XOMT=/!54-?],H8_S/
M3-4_++Y$_&[M3MKXY[+[#P_SDJ\3W#\/NO>M]_\`>>X,#M/,;)W!\HAV%3;A
MZ^[6WWTGL6GP>Y*K8L6RZ3.TPI<)#DXL7E1!/&2*9W4)%>3W%M',I19Y)`O`
MZ@D$LQX'&(ZYID4&2.B)BD59(&U+2K<<#4%''YL!CI&]X_S6.W,;VC\@_CYM
MW8FR,+1;<Z4^75-L_OOK[<F\<YD-J][?%_IN#>N[Z2IBW7L6CV%D(Z#<=3+#
M'04E7D*W'0I3M7`2.\"[OK5[CE/ZU!5KG;UE3(!8O<O`#2NI2V@BI`P*UX=+
M)S!:J?J,-KT<":/I#!<#T(->'1KN_P#N'M.LIOY?'4-!W?FOCU0?*7"UF0[.
M^06WZ+93[[.8VETYA-]X7K+K^OW_`('/;#P&^^X,S/5NE1/05<K4^.JX:6G+
M/JB6W_T?[ZW6]B8&T>R*VW'OD^LMV`\BM(%E:K`#&FM2`2/:)IFY*MY;E6.X
M.VW`C)Q);3^*25K6C::C\\CHJ_5/S:["CJ^G\-M_O#NON*+KKN7YL[)[9H_D
M'U%M'IKLS/MU%\:7[EV!USV91[3IZK%Y?);4J*^D>3.XN#%M6^;2]*6B*N2<
MS>+8[!%N:@9Y?W*Y!#`_!=V4*F@)J>Z0`<<$TI0]+;]9-NWJWALU=K8[UM2,
M=)`$3I>>,>'!2$KYFH^?2ZJ?YLV[<M7[3VGL+J[J+.;S[(ZO^`F9V+79GM3*
M8[KC"=E_-I>Q:BJP_9VX<7ALU7839G7M%UZ[0S4M/-D\E/6PP^)"P/L;;[;0
MVV\WD":?#CN9E'#@BM*?V1@MCCP&<=;V]I'VJWDD5_J#"FKM/Q:17R]>IW9W
M\T;M[K>/-RU'3GQQS(Z)Z=Z_[?\`E+'AODJ^4I\M3;][2W%U?2[?^)6=Q6TZ
MK$=J9;%UNU:JHK(<L<9)3U<T.*=17?4@N$*RZ<5`'F//_8Z6RH_[M\5E?Q/$
M(^$\,4\NL&\/YK?8FS>NOD'\@*OI+J/)=(]>[B[EZYZKVQ0=WO!\G-U=A=/=
MJX#J.:;?'4%7MN.#&[*SVX<I)6338>JR%=A<5%%)50EZF.S]G"LDJ1O0^)<0
M1C(SXD@4C\Q7K1AE>PB>-6UG63@C"+J8DD4P.G7I;^9)\D.XMP=%[#7XP[*V
M#OG>6YOD5CNWX-_;QWQAJ';&V/CE1=?9W-9WKK"?W9J=UY?-[EPF^FI:3$YF
M''3196E`GD6"\C%K(T<+7KL/`%I>2$U!_L@$7AFJE@*?/I$':+<TVV8.+IF"
MA=+&I9&=<@:<JC'C3%.)'154_F]_(+O?I[.;IVCTFWQ]J1V7\3MT=2[MS^Y:
MC"[>WOU-VO\`(;'];5^T^QLYN[;-5%M^7<&,C=*S,86CKL:():B.E8U-,P*Z
MYM575)(P\/7M@X_BD@+-^1(\^F-P>XA8$JX6O\)\OL'GT=+I3^8!\C.YNZ>M
M>@J7I#H;&;U?L?Y,[([SW7C.W-YYWK7`8WXU[SZ_Q&5S_3&4@V=+D]\C=.%W
M]%'#3Y*GQYH<K320U3JL;DE#Q31IXC8CH/,5[IUMABM<S,$_/5\.>E4THEW1
M8(0YR!\+<?`>YXD?[X1G_+3\1`Z">O\`YMG:M%A\WO6C^//56?VKOW:OR;SW
MQGVSCN]QCNU:S*?&/=HVKEL7\D=M9_`T&$ZSI]Y5,SRT3XZOK3#4B'&RDU55
M3`/7%8XH22*G!^T$@_X#T9Q&"._GBG8*5I@D#BH(^>0:YZ5/2/\`,5WYV]NS
MI2IWQM5-B9S"UWS-P7=G6>P\SN6+'1YCH;IW9?9F!QV;VOV;UWM_?E-N.;%;
MD!2C>6CAHZO6_EK8&5EUNUS$E_?Q1&L4'+2W)XX8WIBQZFGIY9..F]EMY+_F
MC:+9!JBN-U:'&0:VSO0G@!V\3Y_/HMV#_FG?).'>F8[1WCA^C:/;&_\`X<?'
M?L7H#HK;/:6YM[;1J-\?(#Y`Y79FRJK?F5V[UG4=CIVP^VI8Z&OP6&I,E35D
M]*HI#&QE:,0W5D(;7=6D`%Q!N&WQ\00%EMYY,$&A^$5^>/3I'8VTD]KM\H#^
M!)^\!J(R3!-"AJO$"K'2?,<,]+/<'\Y#NFA^/'QM[YQ7Q@V1'2=B4G?F6[WB
MW!OO?'V'4^,Z`[07K3.2T.&VQLS<'8%)1;@F2:>/,9?#_P`&Q-0L='7.LLA;
MV@OHXPT"N0$<BOYG_5\^E<EDUS:RI8:VNPAH-+#NIC)`''SK3I88W^9_VAW]
MW'\B.@.M.H<YUML;#[;^2^SNG_DU15TU=7X_MCH38";JEW)F*'-X==F979^3
MKWC\$5!-65='2RQ25JE*J,JDW-9-LB,\0!B'`U'#[./5IE%UNVWV]O72I03B
MA%#3NXC(!\Q_EZMG^-O960[G^._1'<&6HTQV6[0Z?Z[WWEZ")&BAI<KNG:F(
MS.2A@CD)D2"*OJ)@@-R$*B_'M;O,(LQ$%P9$4_F0#T5;'=-NC7,4PHJ32*/L
M#D#^70U+^M?^##_H;VB"&,!3@T_P]*HHA"GA@U`)_P`/2$ZX_P"//H/^UINW
M_P![+</OW3O2X]^J1PZ:F+A/TP2U1P-/Y_Y//HK7R?S.ZJ6O^,NU=L;PW;LN
M#L_Y.;4Z_P!V9#8^0@Q.XZ_:E5U[V?N6LP]'E:C&Y+^'1UV5VU0M)+"JSA8=
M(:QL:-!#("7X_GGY5%2*^HST8+-=K&J6TEFM2*A[2*1^.:2,I*FE:,#4'(R.
M@!IN_.V-A;W[5ZKQ>-W!WK7=;;O[=P77F2S>X<?B]P;RIMM]-]5]DP[-W#54
M=!AL5NC<6U<MO>JQ1F<TU<Z4RQ/(:MFD]H=-J?\`B/;_`/.:?_H#HJFDN5W<
M0"2?17_?K_Y^L>8^<^[(*+:6!V]L:#<?9&5F[H_OKCZ'K+Y!)%LA.G,7M++5
MVW]S]:KLQ^T]E[NW!%OG'DM7QR8G%TOEK/NJN$Q)[,/$C50L3WRJ*4"R#0!Z
M+5P:#RJ`?4=+I4<3N&6`J*Y+2%B?Z7;3CQ-3TUQ?/O?6:W-MJ+9W2<>X-N;N
MR>5V1A*.:NR^*K:3M/']&9GN&FV=DNQ\E]GUK6YE:W$2XFOQ.-6OJ<7$R5E;
M64^M:4W$J?[]W*G^G7_K9TY%9^+#XTBV@-2#W2TQ_M.G:L^<.]8L?L;:V/Z^
MBR'<.[=];PVCF]M1]4_(AI.NZ?9W66"['J:/>_5T&V:OM*DW'GL?GZ:GH6I9
MJW$24TAKUK7A0PK0B*<4=[IJ?[]8$?:M&;/Y#'GTEN/ITJMLMG(U,@PB8C[!
M.JJGIJ4ZO(XZ/%U#V`>UNJ^N^S6P=5MF3?VT,)NN7;U=+%45>(FS-$E5-0S5
M$*1)4K#*Y\<FE"T14E4)*CU-/:OP]4MEL&C9Y[:5+X?`P*(@/S1&((I7%./0
MA^]].]$Z^7>W-P;CINO:/;^$RN=JX:S<]1-2XB@J<C414XIL0IGDAI8Y9$A#
M,!J(M<@?4CW@#]^KEKF'FVUV#^KEE=77T*,)]$3]E1CB!J_VM>LSON>\Q;%R
M]?;\=ZO+>W%ZZ&'4Z]]":^?;_MJ=$I'5/:#<CKK>Y%S_`,PQF/ZV_P"53WS:
MB]JO<V:,2P\O[R\3$D,MG<,"*G@1&0>L])O<KV\@D\&??=H250`5:[@!&!Q!
M<$=>_P!%':/_`#[G>_\`Z"^8_P#J3VY_K2^Z7_3.;W_V17'_`%KZ:_UT/;?_
M`*/^S?\`99;_`/6SKW^BCM'_`)]SO?\`]!?,?_4GOW^M+[I?],YO?_9%<?\`
M6OKW^NA[;_\`1_V;_LLM_P#K9U[_`$4=H_\`/N=[_P#H+YC_`.I/?O\`6E]T
MO^F<WO\`[(KC_K7U[_70]M_^C_LW_99;_P#6SKW^BCM'_GW.]_\`T%\Q_P#4
MGOW^M+[I?],YO?\`V17'_6OKW^NA[;_]'_9O^RRW_P"MG7O]%':/_/N=[_\`
MH+YC_P"I/?O]:7W2_P"F<WO_`+(KC_K7U[_70]M_^C_LW_99;_\`6SKW^BCM
M'_GW.]__`$%\Q_\`4GOW^M+[I?\`3.;W_P!D5Q_UKZ]_KH>V_P#T?]F_[++?
M_K9U@J.LNQZ-!+5["WA2QM)'$LE1MW*PH99I%BBC#24JJ7ED<*H^I)][_P!:
M3W2_Z9S>_P#LBN/^M?7O]=#VV_Z/^S?]EEO_`-;.L?\`HX["_P">&W;_`.@_
ME/\`ZFX]^_UI/=+_`*9W>_\`LBN/^M?7O]=#VV_Z/^S?]EEO_P!;.O?Z..PO
M^>&W;_Z#^4_^IO?O]:3W2_Z9W>_^R*X_ZU]>_P!=#VW_`.C_`+-_V66__6SK
MW^CCL+_GAMV_^@_E/_J;W[_6D]TO^F=WO_LBN/\`K7U[_70]M_\`H_[-_P!E
MEO\`];.O?Z..PO\`GAMV_P#H/Y3_`.IO?O\`6D]TO^F=WO\`[(KC_K7U[_70
M]M_^C_LW_99;_P#6SJ'7[(WIBZ2:OR6TMR4%#3+KJ*RLPN0IZ:!;JH:6:2G5
M$!9@!<\GV@W3VYY]V3;IMUWC9]QM=OMU#2/+;RQZ5/XB&4-I_I`4XYQTNV[G
MODS=[D6FU;I97,[</"F212?X=2$KJ_HUU4(-,CJ7L/8>X.Q=PTFW=NTIGJ)R
M'JJE]0HL;1WM-75\H5ECIX0#8</(XT(;D^U_MS[5<S>[6]0;%R\*6<P5YKA7
M3]"`L%\0KJU'NHNA07S\-.D7/O/FR^WNVKNV[3K#<@MX2$,6=@I-**"0*>9H
MOE6O5MO1W6FWNK]Q4.!P:&6>79>7JLKEYTM69FN_C>W(WJJ@!M,$<<?$,(NL
M2&PYO[[D^T/M#R[[,\I0<M;2WU%YH'B7609C2I%&[AG.0.N0_N;[H[S[L<V7
M6Z[M;B"W@)\$@J=0K08&1CU`Z-5[E7J.>O>_=>Z][]U[KWOW7NO>_=>Z"/?'
M_'Y;<_\`#7W+_P"[7;?OW7NFOW[KW7O?NO=>]^Z]U[W[KW7O?NO=.>R?^/RS
MO_AI8+_W?9KW[KW0N^_=>Z][]U[KWOW7NO>_=>Z][]U[I%1_\S#RW_AC;>_]
MZ+='OW7NEK[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H"\E_P`?WO?_
M`,E/_P!T`]^Z]UD]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=*/K+_,;N_P##
MURG_`+J\'[]4CAU[I,?('XV]*_*;9-#UIWYL>'L7KVDW3A-XU.S,CF,[C=N;
MAS&WS5MC:7=U!@<GBCNC;D3U&N3%UKS8ZJ=4^X@F50GNT<4/B"1J%@>!J!^T
M`D?ETW*&,9"?%3'1>OE-_+\ZW^177O7.Q-F;SWY\88NKI6QNUF^/.1QFQ=NG
M8F7R.#GWAL#-;#3"UFQ<QA,W28.&:DFDQ@K,3E(4JJ9U)D22Z2:;AIF).H$%
MB`&<4II=0=**/XHR7/F./6Y!J@T`=U.'0GP?#OI[&9GX<5^W8-Q[=Q'P8H=Q
M8GH[;&/S$53AWQ&XNIZGILXK>,N5H,EF,W38S:=8ST\D=32S_>())'E5BOM3
M>[M=W5[N:*H6SN=K,*'%&=F1F6G$9C3)`'#JJPK^YQ;'_<C433[3Z\.BQ]C_
M`,KK!]D=@]&]JU7S'^9V"[!^.M'V1%UAN.EWAU!NFLQ&0[1W=F-T;@SY'9W3
M&_Z;^\])B\G%M_'Y&)8*G'8"@IZ2%E`EDE+[:")5C9S1A'"[#_AJ1(C#T.5X
M\.E,[_XM'%$22HX=#!GO@?LW>'<E)VYOONKY&]@XO!5VZ-R[%Z8WIV#ALYT[
MUMV)N[8&1ZUS/9&R</4;4CW5C\Z=L9>N2BQ\^7J=OXN?(SS4N/C:P]LFTC,D
MP%-,MO<)7_FLM2I^UP,T],BE>F8[BXCI'IK$Q0MP_#(A_DH)QZ>O1<OC%_)S
MZ6^,O9/3?8H^27S3[[I_CO3Y<]#]<_(#NZCW=U7U-D\QM>MV.^9V?LK";3VM
M1464H-FYBNQU)Y'DIH(:@_M%@&]J]ON9[&TBN%_Y*!C9'&,+X2*!7_3`C\NG
M+F&VF<``".CUX\?&D9?VJ0WVGJW)0VA_TZK?T;1?R)SIU!PO%_U$_P"-_:<J
M38AZ?XV&KI_V>'\^J\1H/PCH!*K)XV/.;M@J,EC87CWMO;6DU=3Q2W.Z\F1>
M,S!@I`_/MS32)K8?BZL\D<SK-`*.M/VCH`XOC_T7)E?D!49RCV[N_;/R:R.W
M\SVYUQO/^[^Y>N\]F\%M6AV7-EUVUE*6HIEJ]P[>P^/CR`<R1RRT$,R+'+K=
MZQ1&&T7;U^%"3_O1U?Y>M7)DNYC<3&LI`%?L%!_@ZF[+^/OQ<ZXVE@-@]>=1
M=(;'V/M3>M#V5MO:6U=J;4PN`PG8>-FEGQV^L=CZ*GBAAW?12SN8<B0:J(&R
MN%``4_4@B*,XFC8^&?,.5(/[8]8_/JB05*Q-PF;1^05I/\,8Z;ZSXR_$;(;N
MW=V#7]'=`5>_-_IF(]\[TJ-C[-;=6[HMP[<J]HYZ+<F>%*N3R\>;VM7SX^K6
M>1Q4TLI24/868&LQI$A/T80!!Z1ZR5'_`#EU'Y=/PSPO&T]R*QFU:?\`VQ9H
MA_QRO4CN+I[KGN+9-+U?N2'J3,=8QT&-Q]1UUOOKG9?8^RZE,"D*;;BAP&X*
MJGI,11XJ&$17I!#4K`---44CAFD3[GM-]<*BVI^,T&?,X\NCWE>[V/E_:GAW
ME6<,[QH!3N\*18%4DAM-?%IJ'`9\N@]VG\8-@;`Q.S=O[$R'2.S<%UU)GY-A
M8O;/0?4>#I=HS;KQ,^V]TUN$I\2M'04&2W-MVJDAR$L4"1U4@C!C%`LN.G+I
M[>]W>*."8`VT,(4@DY@GFD$BG/`RV]:#I9-N?)D4#7%QM3%DCDGK]94AK0*@
M_P!#XUF)'SZ0F%^!_P`==O;5WIL3![+^+.%V3V30T&,[#VEA_C!TGC]O;TH,
M7E:W.8JFS^'2*3'9-,'FJV:MQWW,4_V=965<EG66E2B4B7<[F07+@>-(RN<M
MQFE%L>)]'KT[+N7)<,AB7:C1"5%+S&*`'^S\J8^T]/U3\..F:R?JNJJL+\:9
MZCHRDAH>FFG^-/4,Z=74<%7'E(L?L82SM5;;Q<>2B51#2S1R"B`3R_Q`MDVT
MD=[*GB:1J:M>/ECU^5>KC=N398O`_=;::UI]9CC7_??F,$>G4E_B)U/+O7L;
ML:HA^/U;OKM_`S[6[5WA7_'7INJW-V5MRLABI<AAM^9H1PU>Y*+-P1JV064@
M5<U-2FR0QU,%;86]Z#&P4#PIHY>+?Z$X?U^77OWAR@PCA3:VIXB1_P"YG`2G
MPS_H?`ZLU]!T];"^,^Q^JZ/9N.ZQRW3'7=#UU1;GQG7\.R>C.J]NOLC&[W:C
M_OG3[7>BD$6);=+8RFJ:XK&T597HTE3'/2?;T%*T^W[A-;&R(&AHYHSDY\<J
MWK_0I@](_P!Z<E74B7(VI_JF\1E/UF5,.F+'Z?I(2.DE3_"OH^DQN^\/1[?^
M,M)B>TMSX[>O9F'IOC-TZN&[`W9B<H^?Q6<W?C999ES]7B<TS-2/5O--!!//
M>1ZZ2+(0./:[C-$(,4'@>9X6RE/7YG/'Y].R[MR4?]R-J;!_Y3/G7_??Y?8>
MEGL+XX[/ZJ@V=3=8YCI78%-UUA\_@.OZ/:?1G6F!I-FX/=>9I]Q;HPVWX\/7
M4$N*Q.Z<S")<G#2O`U8(*9@\=5'4U=8U^[]P(*&AC-*BI\ITN1Y\`4KUI=RY
M*$XO/W4VL>?UGGX3VU?[/CHD*?Z7YBO3%0?$;J7&;E[.W?0TWQ^I=T=UXZKP
M_<.Y(/CKTO%GNT,5D5D@R5'OO(QTRKN1,I'*:JJ2HC:EJ,JJ5+P&E3^'LVVW
MWUPXC"J`C$\6\S7U^?2V7?\`DY$6X.UW!,@'!U<873ARE3PK7U'4[8'Q:ZXZ
MHH]IT'5LW176U#L2?=E3LRCV+T)U?MRGVG4[^IZ2DWM4[:CI:M_X5/N>DQ=+
M#5M>1JF%94J34`T?V"F:U>"1K^YC5D^F\&7CF(N6`.>'B&M.JMNW*$%Q!<P;
M9,MP&)A)G$162E"5`0UHE0&/\1'0?4_P$^-U'BMY82CV+\4Z7$=BBW8&(I_B
M]TW!B=[H-QC>B4VZJ2&:*;-4(W8!4:)9O*D,<?CECKQ+DIK30[W%$]G/EGD2
M5\GBJLL7GFBLW[>D\>^\E@).NUN8:.L=;S@"RF4?V?`D*#\AT\YWX1]%;HVW
MM+9FX\!\;,_L_8&X,GNG8NV<Q\;.EZ_#;/W#FJEJK-YO;F->),=ALIGJR=JR
MODI88(JC(Q03"..&.>EJD[_6LRS%5TQY.6X?MZHF\<H0@K'MD@=Q3_<P<:$?
M[[]37[0.IVX?B'UGG\YV;N^;,=2X'L+N38>:ZQ[&[8V;TOU3M7MO/[)W%A!M
MS-XT]ATHFR\%7)AJ>#[>:03I'4K-))'-`:6CI+0[=N>OZV^SMIS2IQ7CY_X:
M]5N-TY.EA5+7:"U\M<?6$5)`&2$!/"O'B>C<[6H=F[.VOMK9VVJG"XK;>T=O
MX;;.WL9#7THBQV$P.-I,1B:*(&8'128ZBCB%[$@7/))]G=W=#<BK>2@`?8.'
M\N@?#%%:JT=JN@N2:5K2IX5\Z5I7SI7I_CRN'+I?,8H^M>!D*2Y]7T'[WU/M
MMFUFO6XX9(%\.0U>M?VYZ0W7>4PZ[2H5.5QL=LGNP@/7TER#O+<)O_GOZ>Z]
M7Z6W\5PW_.YQ7_G?2_\`7[W[KW2(W]LGJ3M/$46![(PFR-[X?&YFCW%C<?N,
M4-?!CL_CHJJ#'YO'EITEH<K1P5T\:3Q,D@CF=;Z3;WXBHIUL'2:^G37#U=T5
M3;>H-HP[*ZP3:V+H=Q8V@P'\+PAQ=+0;N"#=5-'3&ZVW(L2_?N;R5CJ'E9I/
M5[8^EKGJAC#W`NO/IIGZ/^.-5M;&['JNNNJ:G:&(R]9G\9MZHQ>(FH*+-Y*"
M2ERN6A+R&J_B.5I96BJIFD9ZB$^.0M&`@>`TC3Z=79M;%_4UZXUW1?QIR>XI
M-W9'J[INMW-+,:B7-S[=VV:UJ@X63;3U(TQK"M5-MN5\?+*$$LU$QA=FC)4[
M_P`/5A*57P_(]>DZ.^.$FTFV$W7?5?\`<TYE=QG;W\.Q/V']X%I4H%S6KR_>
M#)+0(*82B4.*4>"_B]'OU.F5A",9/,CH6,?+M;$T%%BL35;<Q6*QE)!08S%X
MR3&T&-QN/I(U@HZ#'T-*T5+1T5)3HL<44:JB(H`%A[]U?J7_`!7#?\[G%?\`
MG?2_]?O?NO=<<%FL1_?[!.^6QL8&V=W+J.2HT5C]UM0A=33@$FU[7]N22[BW
M]C>VMU\GC4_ETW+$RC];;9[9?5'8?GT-)SF#)).9Q/U/TRU'_4_TJK>V?%OQ
MB50)//PY5C3_`&J:#I'RKQJ?/JBGM'AHI3R,D)D?_;.6&H_.G"@\NNOXW@_^
M=UB?_/M1_P#U5[]XUW_"_P#V4#_H#JU6_P!]P_\`9/\`]#]>_C>#_P"=UB?_
M`#[4?_U5[]XUW_"__90/^@.O5;_?</\`V3_]#]>_C>#_`.=UB?\`S[4?_P!5
M>_>-=_PO_P!E`_Z`Z]5O]]P_]D__`$/U[^-X/_G=8G_S[4?_`-5>_>-=_P`+
M_P#90/\`H#KU6_WW#_V3_P#0_7OXW@_^=UB?_/M1_P#U5[]XUW_"_P#V4#_H
M#KU6_P!]P_\`9/\`]#]>_C>#_P"=UB?_`#[4?_U5[]XUW_"__90/^@.O5;_?
M</\`V3_]#](#LG-8AMNT:19G%D_WJVDS`9.D<%4SU$WJ`J&L%(!'^(]^\:Z_
MA?\`[*!_T!UX,X_T.'_LF_Z'Z3IS>+))&;QH!)('\3IOR;VYG]Z\:Z\@_P#S
MG'_0'7M4G^^X?^R;_H?KK^-8O_G=XW_SY4OY^G^[_P`^]B6[/!7_`.<X_P"@
M.MZI?]]P_P#9-_T/U[^,XS_G=X[_`,^5-_U_]^\6[/!7Q_P\?]`=:UR#C'#G
M_EV_Z'Z]_&L7_P`[O&_^?*E_Z_\`O7C71X!_^<X_Z`ZW64<8X?\`LF_Z'Z#7
MMVB7>O7NX-J8G-88UV;CHJ6%JO*TB4D2_P`0I)*B6<F8W$,"%R/RH(X]QA[T
M\L<R\X^V&Z[#RL8'W>[B$<T4FF5Q;D_&KZ016K"E,4KY]2)[5<Q[+ROS@F]\
MUW+VVT6L8DB2-3$KS@GBM36H"@^H^SKKJ[9>QNK]N183"Y3#SULY2HS6:EKZ
M,UF7KT]+23?Y0SQ445M,$!],:?U))]E/L_[)<B>R_+&W[)M6WLN\/8K+<7;$
MDR.6!,0KP"GNI\NC'W.]TN<_=??9.9;]C#MM/!@A'PZ`21)3U8<3T)>V<SB!
MV%32'+XH(-EYR,D5](JA_P".[<)%S.%7Z^YIE=;DJ\>$3R_EU%L2M:AHY,N_
M0R?QW"?\[G$?^?3'_P#U3[UUOKW\=PG_`#N<1_Y],?\`_5/OW7NO?QW"?\[G
M$?\`GTQ__P!4^_=>Z]_'<)_SN<1_Y],?_P#5/OW7NO?QW"?\[G$?^?3'_P#U
M3[]U[H)=ZYG#OO+;S#+XHHNV-Q*Q&0HVL[Y3;]AJ6<K_`&1[]U[J#_%<-_SN
M<5_YWTO_`%^]^Z]U[^*X;_G<XK_SOI?^OWOW7NO?Q7#?\[G%?^=]+_U^]^Z]
MU[^*X;_G<XK_`,[Z7_K][]U[KW\5PW_.YQ7_`)WTO_7[W[KW3AL[+XB+=^<D
M;,8E8SM7"()'R5$JEES6;?2`U2IO[]U[H6/X[A/^=SB/_/IC_P#ZI]^Z]U[^
M.X3_`)W.(_\`/IC_`/ZI]^Z]U[^.X3_G<XC_`,^F/_\`JGW[KW7OX[A/^=SB
M/_/IC_\`ZI]^Z]U[^.X3_G<XC_SZ8_\`^J??NO=(R/-8;_2!E)#F,0L1V1@8
M_(<IC](D7/[G<*3]R!R#[]U[I9_QW"?\[G$?^?3'_P#U3[]U[KW\=PG_`#N<
M1_Y],?\`_5/OW7NO?QW"?\[G$?\`GTQ__P!4^_=>Z]_'<)_SN<1_Y],?_P#5
M/OW7NO?QW"?\[G$?^?3'_P#U3[]U[KW\=PG_`#N<1_Y],?\`_5/OW7NO?QW"
M?\[G$?\`GTQ__P!4^_=>Z`W(YG$?WZWN_P#%,8T9_NJ%=<A1LI88!;^I9R#I
M/UM[]U[J5_%<-_SN<5_YWTO_`%^]^Z]U[^*X;_G<XK_SOI?^OWOW7NO?Q7#?
M\[G%?^=]+_U^]^Z]U[^*X;_G<XK_`,[Z7_K][]U[KW\5PW_.YQ7_`)WTO_7[
MW[KW7OXKAO\`G<XK_P`[Z7_K][]U[I]ZTS6'6GW86S&)&O>>48`Y&C3Z8_#+
MP7J`"++[]U[H2_X[A/\`G<XC_P`^F/\`_JGW[KW7OX[A/^=SB/\`SZ8__P"J
M??NO=>_CN$_YW.(_\^F/_P#JGW[KW7OX[A/^=SB/_/IC_P#ZI]^Z]U[^.X3_
M`)W.(_\`/IC_`/ZI]^Z]U[^.X3_G<XC_`,^F/_\`JGW[KW7)<[A+/_N9Q'Z;
M_P#%TQ_^K0?\K/\`4^_=>Z!"NP>#J<UNZ>KPF&J)YM];YEDGJ<923S,_]Z,G
M?R3O`[LH5?J?I;WK56)KD?AZLZ1PNL$!J[?X3T56N^7/P7QG<C_'?(]]?'B@
M[UCW11[(?JBOS>`H-YQ[TR20RX[:,F-KH*=%W'D$JHC!2>0RRF5%4%F52U9W
M@D3Z\<'J,?T3I_R=;O+95;Z2YQ,M"?+B*C^1Z@[)^9OP&[)WY6=7;`^0WQSW
M=V/CSN85>R,%F\%6;DB?9L5;-NN"/&K3B:KJ]O0XZH:K@@\L\2P2$IZ&LI2W
M\1)+STI_EZ;5D)2VCX</\%.A4V;VU\:NQ<GM##=?[YZAWMENP.O).V]D8[:]
M3@LS5[IZOBRL>!??V(BH8Y?-M@9V9:+[EBB?=:HO\XCJMX;8W$)N/)>KRJ8)
MA!YGI59'<'3>(WM@NM<KE.M\=V%NC;FX=X;;V77'`T^Y<YM+:34J[IW-08F0
M"K?`;>?(4XJJQU2GB,Z@O];,6\OU$A7^#/[.MS_[K9(RWXW4?M(Z`RE^7GP0
MK>K=S=X4OR"^-L_3^S=SP[+W7V1#N;:LNU<!NRI=5I=N9'(H"(\Q6!P\$`#/
M41AGCU(K,-0R5G6U(PH2E?,0,\A_+_&.M68/C7@/S_R]&.V_#U]NS`83=6UJ
M?96X]L[EQ&.SVW=P86CP^2P^=PN7I(:_&97$9"ECDILACZVBJ4ECFC9D97!!
MY]N20_3N;<\4)7]F.F8?[%?]*/\`!T[?W:VY_P`\YM[_`,\N/_UO^.']/=>G
M.O?W:VW_`,\YM[_SRX__`*\>_=>Z]_=K;?\`SSFW_P#SRX__`*\>_=>Z]_=K
M;?\`SSFWO_/+C_\`6_XX?T]^Z]U[^[6V_P#GG-O?^>7'_P#7CW[KW7O[M;<_
MYYS;_P#YY<?_`*__`!P_K[]U[KW]VMM_\\YM[_SRX_\`Z\>_=>Z]_=K;?_/.
M;>_\\N/_`.O'OW7NO?W:VY_SSFWO_/+C_P#KQ[]U[KW]VMN?\\YM_P#\\N/_
M`.O'OW7NN_[M[<_YYW;_`/YY<?\`]>/?NO=<X]N;<$D9_N[M_AU/_%EQY_M#
M\&"Q]^Z]TB.O<!@)MI4#O@,&Y.2W6"9<1CW;T;QS\:@,:<'2(T`M^/?NO=+3
M^[>W/^>=V_\`^>7'_P#7CW[KW7O[M[<_YYW;_P#YY<?_`->/?NO=>_NWMS_G
MG=O_`/GEQ_\`UX]^Z]U[^[>W/^>=V_\`^>7'_P#7CW[KW7O[M[<_YYW;_P#Y
MY<?_`->/?NO=>_NWMS_GG=O_`/GEQ_\`UX]^Z]U[^[>W/^>=V_\`^>7'_P#7
MCW[KW7O[M[<_YYW;_P#YY<?_`->/?NO=9L+MO;TF_L#&-N8-P=K[N=T.&QS(
MQ%;M?QL\0I2C/$DA56T@V)'MQ$T?#MUI:'U=D'Y]*?"DM\M"UU\EST,O]T]M
MDDC:V!(N>1@,9;ZG_IB]MR>(7)\-G^<4*R1G_2O7N'E7UJ/+I,TEJ6)8PVK?
M[Z>%BZ?(D(1GCQX$=>_NEMS_`)Y7!?\`G@Q?_P!1>Z:9/]\W'_9,O^?JNNT_
MY2;7_G"__6OKW]TMN?\`/*X+_P`\&+_^HO?M,G^^;C_LF7_/U[7:?\I-K_SA
M?_K7U[^Z6W/^>5P7_G@Q?_U%[]ID_P!\W'_9,O\`GZ]KM/\`E)M?^<+_`/6O
MKW]TMN?\\K@O_/!B_P#ZB]^TR?[YN/\`LF7_`#]>UVG_`"DVO_.%_P#K7U[^
MZ6W/^>5P7_G@Q?\`]1>_:9/]\W'_`&3+_GZ]KM/^4FU_YPO_`-:^O?W2VY_S
MRN"_\\&+_P#J+W[3)_OFX_[)E_S]>UVG_*3:_P#.%_\`K7T@>R=K[?AV[1RQ
M[<P=.XW5M&/6,)C8CHESU&C@LM*I(=3:W-R?Z>_4?_?-Q_V3K_GZ]KM/^4FV
M_P"<+_\`6OI+';&WKW_NW@CR?^7'0@'G\#[?@>_>"\JLI@N2`I)_36+`%3WZ
MA3]N>'6BMA-V27"%:@_I0N)*C(IV#\\\.@H[HRE#UOL.HW9B]K;:GEQ^9P45
M13U>$H/MYZ"KR"05\#O]J/$\L#C0]SXV&H#W"_OSS[NWM5[=Q\]<NVMS)&DR
M^)29#V*07KW_`,(/^#J4?9?DS9/</G"7:-[GO8T>-DC+1O36P*H?]Z(KTH-A
M9KKSLC;M-N3;V&V\\,NE*VBGQ&+CR&)JW"VQ]?$E.H5[_P":?],T9#*;>Q)[
M6>Y_+ON1R=%SKRI=1Z;L5NK0'O"GC5>/`TZ)>?\`V\W;D'F67DKFFV?_`!/%
MK=T/AEA\-&^T=+/^[>W/^><P`_J#A<>""/J"/!^/<C#Z*@_=J%-O_P!#4\53
MR'Y=`H"[`I?N)+[\;#(9O,_GU[^[>W/^>=V__P">7'_]>/>^M]>_NWMS_GG=
MO_\`GEQ__7CW[KW4C;.VMO-OZFB.`P)B;9>;D:(X7'&,R#.[<",$-.1K%^6^
MOOW7NAA_NIMG_GFMN?\`GCQ?_P!1^_=>Z]_=3;/_`#S6W/\`SQXO_P"H_?NO
M=>_NIMG_`)YK;G_GCQ?_`-1^_=>Z]_=3;/\`SS6W/_/'B_\`ZC]^Z]U[^ZFV
M?^>:VY_YX\7_`/4?OW7N@HWIMK;T6[]OI'M_`*DNV-Q-+&,+CA&SQ93;XC8H
MM.H9@)3S]1[]U[IM_NWMS_GG=O\`_GEQ_P#UX]^Z]U[^[>W/^>=V_P#^>7'_
M`/7CW[KW7O[M[<_YYW;_`/YY<?\`]>/?NO=>_NWMS_GG=O\`_GEQ_P#UX]^Z
M]U[^[>W/^>=V_P#^>7'_`/7CW[KW3GLO;>VWWAFTDVY@)$3:F%=(WPV/:.-Y
M,UG(G=4>!H]3(;$Z;^_=>Z%;^ZFV?^>:VY_YX\7_`/4?OW7NO?W4VS_SS6W/
M_/'B_P#ZC]^Z]U[^ZFV?^>:VY_YX\7_]1^_=>Z]_=3;/_/-;<_\`/'B__J/W
M[KW7O[J;9_YYK;G_`)X\7_\`4?OW7NDA3[9VTO8631]N8!HDV5M^58OX+BS&
M)6W%N-6D5&I"@D>./26L3;CW[KW2O_NIMG_GFMN?^>/%_P#U&/?NO=>_NIMG
M_GFMN?\`GCQ?_P!1^_=>Z]_=3;/_`#S6W/\`SQXO_P"H_?NO=>_NIMG_`)YK
M;G_GCQ?_`-1^_=>Z]_=3;/\`SS6W/_/'B_\`ZC]^Z]U[^ZFV?^>:VY_YX\7_
M`/4?OW7NO?W4VS_SS6W/_/'B_P#ZC]^Z]T">0V[M\;VWK"=OX'QH=K%$&'QV
ME!)M]?(B+]KHC$C`%B!<D>_=>ZY_W;VY_P`\[M__`,\N/_Z\>_=>Z]_=O;G_
M`#SNW_\`SRX__KQ[]U[KW]V]N?\`/.[?_P#/+C_^O'OW7NO?W;VY_P`\[M__
M`,\N/_Z\>_=>Z]_=O;G_`#SNW_\`SRX__KQ[]U[KW]V]N?\`/.[?_P#/+C_^
MO'OW7NE#UKMK;LE)NM9-N[>D:/>F40,^%QTA6)<;A6C1&>F.A`9&NH%OI[]U
M[H2/[J;9_P">:VY_YX\7_P#4?OW7NO?W4VS_`,\UMS_SQXO_`.H_?NO=>_NI
MMG_GFMN?^>/%_P#U'[]U[KW]U-L_\\UMS_SQXO\`^H_?NO=>_NIMG_GFMN?^
M>/%__4?OW7NO?W4VS_SS6W/_`#QXO_ZC]^Z]UR7:FVK/_OV]N<H!_P`6/%\^
MM#8_Y)]+CW[KW085`<Y;=7J*D[WWP"5M?G=.3Y4$JNL']))L#R?=`M-NDB\S
M7KT"^%X5\WQ^)0GY5_S=4\[%_EV[A[([U^56\N_^Q>ZMO]-[I^>.-^0FQ^@M
MLYSK&BZF[1Q^Q=L]2979'86X:VDV?E.UZ,G?FSP9<='G,6DXQB++2K$[^1'8
MVZ6^P11./UM<A_:YI_(]'',C6EWS%-<0J-)AA\S_`+Z6OGZ]%G^/'PI^7G2.
M<^('9?8]+VAWMUUUUW3\A^P=Q?%)\_U)@JWX\=D9_=/;F2Z@[TZNS6'BV['O
M7`5^W]QRT&1P&<S64>EGST58I(@>"`XM)7%A+$U/A!C'^_'%:1'S[ZDX->W'
M1!:Q1PW37=`(8V7Q.-50UK(,T&F@'"F<^72F^"_Q,^;?QGWU\B-STG671_6^
MZ?F_BJOOC$;JGP<V^=C_``S['@W_`)G-R_%;?6U\!V)MG/[VV-D-K[FDR-#6
M;8JZ?&INO[YY@(G@+U$LEO8I;V[@5NXBS`88%J30&OX8QZ4:GGTL=H]QO_WM
M%VVZAE\,\`H`$4WK^J1ZT].C'?(#X2[X[%^1>V>S]N[;VE1[^[%^$/RUZ,[R
M[ZV]"V#QO^DSL3KW8>S.KM&'RN>S6[:#:$=;19">@H*9ZN''()&F<32-+*PA
M@MKFZ=*+&;"=E&3^H+Z%0P^8MV9!7%"30FA">]UWEY`)JM`LBFGV,OIZ"O5=
MN<^#?RZW[B-H]N9;X]=L=;#J[*_%[9>3^/W4W=74VS>\.PL;T=\6.T.A=S]K
M]>[]Q6XXMCX)WWEV#238HUN9H<G5;=IJAFCIZ@I%[]*!-?27>W!5#&\*UJ0@
M,%B$&3D:E<X]3Z=*+5X8[Q5=:QR+;Z_Z1:>Z$OV$Q")3Y#2#05)-_GQ.VAVA
ML#XP]!['[KK,17=M;1ZIV?M[L&HP:X^+&/N+'XJGBJXHEQ%%C<5455(%2"JG
MI:>&FJ*F&2:-%1U`,MP>$EGH#.2=1]6\SZ9/19M7C":=;DZH0[!`?):F@Q\O
M7H?S[*(2Q4EN->E::LZOXC3[.NO;O5^O>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NN2?K7_`(,O^]CW[KW2%ZX_X\Z@_P"UKNW_`%_^
M/RW![:<E9%:OZ?GU[H.OD!\C-F?'/'[(R.\,+NO.Q[WW;%MY8-I4-%7U6U\!
M2T_WF[^R-RQ5U?C_``;$V!03Q5.4J(F:5(I8U1'=@"XDL37:?\HY[:?TC@?S
MZ;E65HR8C1E&H_8N3_+I8;U[GZJZ^P^X\UNG?.`H:/:F5_NWF$6N2HJUW5)M
MJIWC0[4IJ>,&6HW+EMLTKUE+2`"26'U`:>?=YF0FL7`R2Q?[>VIXO[=0KZ=4
MAF$@9/QK%'*3_0N`?"_XZ:>O27V_\END=SX_KFII.P<%B,IVKM7;6[]F[9SE
M6N.SE3C-WT$F0V[2UL-1&U+C,OF?%)#1TU5+!+630R)`LA0^ZZE,G@?Z+XBQ
M_P"WD4.O_&6'3_B1Q6)OY1^DL;2'_2QDHW_&E/4>I^4WQ[Q8PL.X>W=@X#)Y
MW$X+,T6*J-Q4M?*:3<]#/D=M^.KQ:U=!4/N2EI93C`DFK*/&T=(LT@T^VQKO
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M`)HF93^2T_R]-=%\D_CYD*C/TE'W-UY/-M7%[CS6X3_>&EBIL9B]G9=MO[NJ
MY:Z?Q4$_]ULZOV61C@EEEHJHK%,J.R@OHZ20"91VNJLI^3UT_LTGI3?1?2W+
MV_FKQ)^81S)_O1*'Y4Q3H0MF[WVAV%@XMR[(W#CMS8*6JJZ`9#&O+IBKZ"7P
MUV/K*:IBIZ['Y"CD($D%1%%,EP2MF4FO3/18/EYN#.[?I>O*S`YC)X6KEK=S
MP2U.+K:BAGD@-+B"89):9XW>(E0=)-K@'ZCW@)]^SFCF+E2TY?'+MY/:"]1O
M'T,?U*`4K6M/]K3K,C[GO*^P<PW^_C>K6.Y%FZ"'66_3J36E"*_[:O1)CV;V
M/<_[_P"WC]3_`,Q%E1^?^HKWS6C]TO<>)/#BWO<UC!-`+B0`9/`!J#K/Q_;G
MD1CJ?:;$L0*DQ*2<#S.>NO\`2;V/_P`]]O'_`-"/*_\`U5[O_KK>Y7_1]W7_
M`+*9?^@NJ_ZW'(7_`$:+#_G$O^;KW^DWL?\`Y[[>/_H1Y7_ZJ]^_UUO<K_H^
M[K_V4R_]!=>_UN.0O^C18?\`.)?\W7O])O8__/?;Q_\`0CRO_P!5>_?ZZWN5
M_P!'W=?^RF7_`*"Z]_K<<A?]&BP_YQ+_`)NO?Z3>Q_\`GOMX_P#H1Y7_`.JO
M?O\`76]RO^C[NO\`V4R_]!=>_P!;CD+_`*-%A_SB7_-U[_2;V/\`\]]O'_T(
M\K_]5>_?ZZWN5_T?=U_[*9?^@NO?ZW'(7_1HL/\`G$O^;KW^DWL?_GOMX_\`
MH1Y7_P"JO?O]=;W*_P"C[NO_`&4R_P#077O];CD+_HT6'_.)?\W6&?L3?]4@
MBJ=[[LJ(UDCF$<V?R<B"6%Q)%(%>I(UQN`5/X(O[T?=7W*/'?=U_[*9?^@NM
MK[<\AJ:C:+"O_-%/\W7#_2!OS_GM=U?^?[)_C_JI][7W6]RDK3?=T[E*FMQ(
M00PH10L1P/Y>75F]N^17&D[38TKY1*#CY@`]0Z_=^[,M3&ARNYL]DJ)G21Z.
MORM;5TSNC*R,\$\SQ.49`1<<$>RC=>>><-XV3^K^[;G>W&R*VOP7E<KJ!K4Y
MJ<^1-#Z=&.V\H<L;5<_4[;8VT-R<:E0`YQ_EZ4/6G96>ZLW##F\)*&I92D&9
MQ,KZ*'+4"MJ-+.I],+!K"*5?7"Q!`(N/8N]E?=K=O9KFJ'F2PGDBVJX8>-""
M"CJ>(TL&`_VM.@A[K>V^R^[/+DW*U[;(^X0+^C*:AT(X'4I!/#\5>K:-B[XV
M_P!B;>I=R;=J?+33*J5E([HU;BZ^VJ?&Y")21%/$"&5@;2(=0X/ON5[9>Y7+
M_NGRP-_Y3/U-U*BR21?\HQ89C&G/:?6IZY$<]^W_`#+[6<R?N+?(/%LD<HLF
M>Y0:!JCUZ5Y]R`&B9%,;5>G>/X6\Q^6.@>8_#=J2:T9JCAV@_A_+YYSUU[]U
M[J3M?_F85+_X9&:_]WVW/?NO=#/[]U[KWOW7NO>_=>Z][]U[KWOW7N@CWQ_Q
M^6W/_#7W+_[M=M^_=>Z:_?NO=>]^Z]U[W[KW7O?NO=>]^Z]TY[)_X_+._P#A
MI8+_`-WV:]^Z]T+OOW7NO>_=>Z][]U[KWOW7NO>_=>Z14?\`S,/+?^&-M[_W
MHMT>_=>Z6OOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@+R7_'][W_\`
M)3_]T`]^Z]UD]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=*/K+_,;N_\`#UR?
M_NKP?OW7NA,9E16=V5$16=W=@J(B`L[NS6541022>`![TWB!28@IDI@-@?F>
MMCCT6SLOY=?'SK3HSL?Y$S=F;1WSUMU?M_<.?SU;U=N;;._ZZN?;3T]/DL'A
MZ?!9J:GK,U3U]9!!+"TT:TK3!JAX8E9Q=O#>T2>W+^!(:0L1^H\G\,HI18JU
M`90#2F?/J]%IT56E_F.[JF^,=1\FY_@K\I*/"X*OWU)O[:=9N+X[X.IV+L?9
M-!4YB;L_^_F[>W]O==[UV)D<=220+4X.OKZFFR$4U/+3JT8DD8N9?H;=8)BK
M750S-YA)3HA`IBK25`%.`]>DD=R"C#3J<&HIYL?CC^R(`-ZDMG'0O;A^<VT-
MI?##9?S1W3U3W%M[!]A8+KBOVQTMDL3M6B[EJ=P=O9_%8#KG9F0H\AN6#9F"
MSF=K<]1EZBLR]/0T,,RO4RBS`6OK>ZM;Q=KK2^++$>%1*R@G]A)Q\NGH/U;7
MQP3H7Q#J.-2Q#46/^F2A-/7'0`YW^;=U-A^N]L[PH.A?D;NK>=5_I^K.Q>EM
ML8;KC(=B]-;8^+&:I-N_('>N]JJ?L>EV1N#;6P<QD*>&)]MY;+S9II@*".5E
MD55,$1EGA5:,DMN+BH-1X<CB-,^FHX/3L<3R6TH']O',(_GJ"&0X^:J>@_[V
M_G7]1]'[][!V]2?%?Y?=S]9]4[4ZOW]V3\A^G=D;+W!T[LW8W:VQ\'V/@MQY
MBOR>^\7N2EIZ39^;6KJ(S0&;0MHU=K`I81(]\\;?V,4S0D>KK2I^T`C'Y]6E
M>&01R6X&E[8RT'H:JI^P,IZN%7/XS^[#;M^XD_@8VY_>DU8IG,XP?\-3-_=M
M0_YT3?PL^3P?YSD+^KV\+:X&]FT/]@1A>B5;B4[0UP6_6#`5_,=!74_\7?=9
MM?\`W^^]N`1>QW9DQQ?ZW!]V01"X,<[:4":OMQT932RR[4D,"`DR'/GQZKS[
M.^<YV-LCYM[VQ.S</F*/XN;_`-H=$]>T];G*JCF[<^0.[<)LYJ?9U2(8)&Q&
M$@WGV7@\29:<35;`5DPC*I$&+I)I[NWM6M47Q+N=$A6M`RM<?3LY)X:&#%OD
M.ESV3P[BZW!/@Q6SO,WFABM_'50!QUH`!7.HT'3#M#^9#LNAZ&ZS[&[GV%O6
MB[7W=VEV3\?=U=.=";5W!W;F<-WYU$-SU.\MDX&CQT-#FLGCJO#[6DR.,JYX
MXO/155.\@17U^UUS+;PW%H(W_P!U[V4EVLAP4,+")WIPK%(Z(`:`B6IH0!TB
MM;=_K+BUO.RY2\2VEBJ-,D<T32QJ237]71^$$BAIT&F4_FS;#S=5V'4]6==[
MNS.P]K_$OJWY4[7[<W;M?=6-Z_W!B>S]Y?W;I=O9>7$T=3E<-/C($EC.B.>>
M7*4U53E$6CD=Z7@GV^YAMYD`CDW*RMW%?[-[](F>X%/QD2`A#VG!K0]%FX[D
M+>(W-JHQ873E*TJUF&*V^<:(PM=?Q5.1T=GY5]G=R=6=%;[[.Z"VUU!OK=W6
M^W,QOW=&V>VMW[JVO@O[E;5VKF-S[CCHJ_8^#W/E8]W2ICDBQ]+5004LQ9S)
M,FFP1W=R+;;GET%XE,A9A\6E&T$4X4:H<YXKCH06EE+>;C;[9!0W-R(@O^GE
M34%_WJ@!^?5>6+_F>=S]:[N^$F*^5O3'3^T-E_,#96;[`RG873N^M^[HP?1V
MU\M3];474^2[";>VU=MO2TVXMY=@1XC+SQK+28Z:>D=)F1I2IH)+6TWR?EV2
M31';;1;WLL@%2IG,X5".%#X2"O'/RRBF8QPJU.][^:W6OXEMEC:X<?.(R`@&
M@-6J:TJ$.*_G#]J[LSO0VW<;M_X4]1UW<'4#]E--\C^ZNU]F4N6S;?('LGI.
MFV1UG)M7K_<[;AR\E)L6#(.M:*33)6^,,5`/M/!:32;U)MLS@1I:6<Q?S+7-
MDEVZTX=C.8P1Q`!.3U6:41*@=2KZ;DL?(&W=EH3ZR:<?.HZL0^57RV[&Z*[Z
M^(?0O7O3%3O_`"/R,W/NL[VWIE:7=J;,ZXZ_Z]P:9[>F0H\CMG%9)JW=Z46J
M6DIJT4U&D&F2>15:XU:U7=Y;/<!X6U1QE_%&6*JK%R5.`%.@5X=V?+IR5HAM
M$6X1,#<R3+'H-`-3@L@!.22%8T`KC'GTE-X_S6/B#L78=!V/N#,=C0;;S'17
M6GR(PRT_7M94Y3);`[=[-_T1[$I(J49%*>GW9D]Z`Q2451-##3P6EDJ%5E!5
M/;R^($B&H-H7_FY);)<QKZ95QBNH_A!..K6*K>D,M1`8Y')_HQ.8Y?\`>75@
M/6G3JW\Q?IJF>AWIF9\GM/IR7XR;C^0^1J]Y;-WOM[MC&S8'M/'=5IM&;8M5
MB6A;+Y'<62BH:2@CDFK\AD98A2+-!*LOLOGN/`N;B`@$0_2D$&NH72R%#C`/
MZ;40D2&A.F@)#%LTD]Q;VQ`#S0W;MGX6M&B$JBO$!90U3\NH>2_FA_&W$[:Q
M66J]I?)3^^&2WMNWKFJZ-A^/^[Y>_P#;.]=G=>R]K9#!;OZM21\G@GK^O(CE
MJ"I,LM#5TAU"9"'"*?BG$<=3#HE8L<4%N(S-C^@)8^/FV:=;=C#<&";M(\/S
M'^C#5%]NH>0SZ`]&6F^3O3X^+\GS"H\WDLKT8O3Q[UBSF+PU159JIZ^7;QW*
M]53;?\D=3)DH\>C*U/KU"960:BO+>]F78I+>WO%I=SW\%OI]!-.D)8>I`?4!
MP)%">M[>6O+7ZAQI?_&,<?['53_>J9].BRQ?S1_C;-CC)'M'Y*?WL?M39O4%
M!U3-\?=[47;N9W+V1L3+=D=;Y7"]?Y!*3,9#9N_=IX*KJ,;E0%@8PLLRPZ6/
MO<DT$,IMY6`G!N<5'"T:-9R<X*B:$T-/C/RZHLA?2$%6.BOVN&*T]:Z'_8*=
M<M[_`,SWX\;4JNV,+C<!W-N?.=;87M/^!5U#U;N"'KKMGLCIW:M5NK?_`$MU
MGV85EVWN/LS9]+0U"92B4JL#4=6(FF>ED3W2XD:!)2VGQ$A\0`GB.)+>BJIU
M,?(5Z4-X1AMYX"SI,0?+"&/Q1ISEV6@1?-B!TE-H_P`V[XIU%?\`%W9':.1W
M9U3VW\F=A]9[PIME;EVO58^CZZJNU6?'[(QV_<GD:NGGPE)O?.T\T6"J/!/]
MW2"*JG%-%/&287UI/:O=Q(I\6V![6[3J6-I'1Q^%T"]P\@PZ1VEPLNWP7MR5
M4R2LCZ#J`TLJAD/%D8N`#3R;TZCR?S7.A]C[`V1NGM[%=A)E-U[+W_V?E7ZB
MZKWUOO:6SNK^O^Y\ETWG=][MRE53T%?M?`;=RM/!-E*BMB1(HY3)#YDL/:+;
MI%O[BTB7$=U8VMP#BH-VS"-0#Q!TFAXGAT]!+&SHEP=#$W2L!0D26LKQNHSD
M:%#D^5<XZ./TKWD_:>]OD/L#)8:BPN>Z([1QVU(I,;72U]#NK8.]-D[?[!ZU
MWS"U0D<U--G\%FY(:B&QCCJJ.302I`#JQR#;/KY11Q<R1%?(:)TBK7S)#:O2
MM!Z];#I)>26\1K&NW6URK8JQG5BRT'`*5H#Q/$CHPGOSC2Y4<`2.MJ:J">)'
M7)/UK_P9?]['NO6^D+UO_P`>=0?]K3=O_O9;A]Z<:XS'PKY]>Z!#M3XF;.[W
M[(S>\NW<ON+,;6;J2MZBV7M'9N\-^=>U&$P^\*F>M[;K-P939>Z<"VZYM[O3
M8FGCI:F*6EI:7%K=':9@68X?#55K4B17J0/PL#3Y5X5XCB.G8I?"UXKKB=/L
MUJ5K\Z5K3@>@`@^$7;,U!L_:^X>[-FYS;>,WWL3LW=6<.RLZF_=Q[@V#U-E>
ME,104=6^Y7P%!09;:\V/KJNIJ*>HJFR<$Z*!!,K)5+<HY<N3_CE_/_V7Z"4^
MR'1V'BU3JITAAMD@EDF4DF2PL+4CR'T/BTD%/Q3>+WKP72-)->E-B_B#V+!B
M8ML5W9FQ9]M[PH_CE7]L24.T-Q29R;=7QJQ&W<)MV7K2HR>X9:?%;>WIC]FX
MV2M3)15=5C914R4DI,PCC?10MRMQY+>07``Q4PPI$$)XE7T:F/')`Q3JMU:_
M4[$VQZRJM8W%MX@RP%Q+)*9*<-2>)I45H0H)R>GS;?P[R."PFV\7)OG$54V#
MW=\.MS5-3'MRHA&0A^+E0]7-16_B,LL)W8[?Y$[73'R`LPD;EF-IMSM2(B.9
M"CW#5.*_46DUI0T_WV)O%7U90#@D]:%H!%?1:C2]BM4K_OOZ731E]3)I[@:4
MKBO32/A57G"=C8F3?N&FEW]G=C9=ISM>=FIZ/9?ROW+\EIZ*N$F1$M0*R'<:
MXL$>-8YHC.01*B!5MK';MP7<%[V5[9M)P#].)@`3QH_B]WIH%./1CN<G[RW:
M;="!'XT,T>@95?&6!=0)R2G@5%>.LUX#IN[/^%_8&[6[MCVAVCLS$Q=_T_:^
MW]YU.Z=F9[.U.$VWV!V%2]@8R7:J8O<>-BJ]R8R6.:DJFKV>"2*:*5%BDA];
M<J>+);R$YMYS(/Z5;EKG2?05;PZC\(KQZVTNK<;S<2HK=V7TY7R0?2"TU@^;
M$#Q*'&HTK3/4'L;X"/V'L+KW8]9V3#BH.OZCO[+QU./Q67QYR^?[>[8VIVWM
M2223$9[&96AQFW\QM*&GR?V]5'65L,K/2STTJA@Q;6WTT20JQ*I!;Q_;X`E&
MK[7\7N]-(IQZ<W"Y.X7DEXX"-).\M!P!=473]BZ,'YGHS_Q]Z=R/3V`WA'N#
M,46<W9V!OJNW[NBLQV7[!W#11U\^%PFW:2BAW#VENS>F^\^U+C,!#KJ\A6^6
M1F*"-$C6ZKI+T&?RYVYN+<])U[1;9PF3SV0BK-S5#T>+HZBNFCIQ!AHVGDCI
MHY)$B5Y%741;4P'Y]X!??MY<W[FW8=CO>6=OO[JYLV*:!%@AJ`DD&HIUF;]S
MCFCEK8-]WVVWRZ%O#=@/K-,%3P'K7HF7^B'M/\]=;T!_(_N]DN#^1S3CWSI?
MV7]VXVTKRUO$BX.I8AI-17%6!H*TX>76=,?NO[>3H)$W6T53@!G`;&,CRK2O
M77^B'M+_`)]WO3_T'LE_UX]T_P!9KW=_Z9?>_P#G"O\`T%U?_71]OO\`H[V/
M_.0=>_T0]I?\^[WI_P"@]DO^O'OW^LU[N_\`3+[W_P`X5_Z"Z]_KH^WW_1WL
M?^<@Z]_HA[2_Y]WO3_T'LE_UX]^_UFO=W_IE][_YPK_T%U[_`%T?;[_H[V/_
M`#D'7O\`1#VE_P`^[WI_Z#V2_P"O'OW^LU[N_P#3+[W_`,X5_P"@NO?ZZ/M]
M_P!'>Q_YR#KW^B'M+_GW>]/_`$'LE_UX]^_UFO=W_IE][_YPK_T%U[_71]OO
M^CO8_P#.0=>_T0]I?\^[WI_Z#V2_Z\>_?ZS7N[_TR^]_\X5_Z"Z]_KH^WW_1
MWL?^<@ZCU/5?9=(B2U.P=WT\+RQ0"6;`9)4\\\BQ4\5_M_USR-I7^K$#W[_6
M:]W?^F7WO_G"O_0?7O\`71]OO^CO8_\`.0=8_P#1CV+]/[B;NX^O^X#)?\13
MGW5O9SW:1=4O+6[QI_$\0TC[:,3G[.JO[I<@`#3N]@:D?Z(.%<_RZ;<ILC>>
M$HVR.7VKG\70(\<4M;D<36T=+%),Q2%9)YXHHAY&'`O?V5[U[<\\<L;>-TYG
MVJ^MMN)IK\,T_G3HXVSGGD_?=P^AY=W.RNIU74RB0:L9H`*U/H/7IZZTZWW#
MVAN"#!X2`QP1/'/E\M+&TE'B:"3T>>4!;2U;AOV8!=Y&M^`3[/\`V=]GN8/>
MSG&#9-DC_P"0W;$-/=,*11Q@Y4DX\:G"/A7SIGH,>Z/NGL_M9L$N];B8QNMV
MI%O&":LQ&`_FH^8'5M&Q-B;>ZYV[3[:V[2B"EA;RU50X1JO)5S(J5%=7S*+S
MU$I3TW)$2^E+#WW(]L/;KEGVMY<BVKD02VZM$HDG=0LLY`R\D8)5&;B54D#R
M/7)+GWG_`)IY\W^7=.890096(A7N1`3\*N<D#R)%3TL/<BZ8E`\)`IIW$?B;
MS8^A/IT`E14+%!0,U>O>_=6ZD[7_`.9A4O\`X9&:_P#=]MSW[KW0S^_=>Z][
M]U[KWOW7NO>_=>Z][]U[H(]\?\?EMS_PU]R_^[7;?OW7NFOW[KW7O?NO=>]^
MZ]U[W[KW7O?NO=.>R?\`C\L[_P"&E@O_`'?9KW[KW0N^_=>Z][]U[KWOW7NO
M>_=>Z][]U[I%1_\`,P\M_P"&-M[_`-Z+='OW7NEK[]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[H"\E_Q_>]__)3_`/=`/?NO=9/?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW2CZR_S&[O_#UR?_NKP?OW7NE]E<909O%Y/"Y6G6KQ>9Q]
M;B<G2.65*O&Y*FEHZ^E=E(94J:69T)!O9O;4\*7$+025T.*&F#UL&AKU6\_\
MJSXA=6TG<6\OAW\>/CU\=?D'V5TUG^H<7O=>M(=R];PX3,"B>IP6Y^G*W(-L
M;,[<W4N,CH\WXJ*"NKZ9R7GD=0"J@GEBBTL=4K8=J:=2^@480_TES7/6PU.`
MZ)1T#_+!^1F!^#V_/C?O+,=5=;4G>/RCZH["WMT9L;<G869Z=ZJZ#V5V3M[,
M]M=>=6Y//1U69I9NYL/M/SG$018S#X^.L2F54]996&A:%4F&MU<G43G0,P1U
M]('JZMQ8D@T'21;@(I0(*YH?Z38=O3O4!2/(#H_/SJ^.GR*^4G77:'3NRLQT
M9BNJ<IA>FMQ;.VCORBW>T79>\=@=E?WH[#Z<[L;!QU='1?'_`+$V=BZ'$^7$
M02Y6DF:9G6:((@*8Y73>H+V<^+-!<Q3$G'B2(B@EN--;`N1P!-!7I7;3&*R:
MWB`16CN(U(XHL\/@BG_--0"OJ>/5>U#_`"L/EEL?J?:T74^\/B_A.RLILGYI
M])[KZRKX^R:?H'I'H3YF[NPFZ)]M_'RIQ>!_O?FJCI.NP3?PNDR]+C:3+"NF
M61Z)8U#&L,LU@MH9'-Q-#M-O9,S_`!2?3S"7QV.>^2FA@,`"H)/2JTF2W>:1
M5`\:]-P1Y`FW>`KPH1WEZT'<*4H>BJ?+?^0CWUVMWKN;<O5.(^#.Y^OJGJKX
M^]4=>]H_('*_)^'O[J*GZ:Z@VSU6-X[*PG4>XMN]85>;HZW;_P#&\?!EQDX7
MK(HDF*PLZ%!'^E/<SCXKC<)+K_2&0*/"'JJZ:AC0FIZ2PI]-:Q6VO6(K7P<@
M"OZCR%\<#WZ:5(HH/$GK9^79>XO]#[]<_P"D/-'>'^BW^XO^EG[6E&XANO\`
MNDFW?])/V6K[,YG^-_[EO#J\?F/CU:1?V8MN!:_6_P##4,H(I4T-01Q_/I$+
M1!9FSJ=!:M?/C7I+SJ3EMU6^AWKOFS6)4VW5E`5#6M<_2X^E_:$+#+<,]Q41
ME-(IGRZ?!FAMDC@H9`]37[>JV]R?RZ-A=I;R[FQ?<TT&\OC_`-B_*K9OR_I>
MIU\<N+W7V%1=9X_96Z]G]MXG)8F>EW'U[_>;`4F>H:6GJHF>L<++9(`LB6*-
MTVFWLC3ZBQ^K6W/HMTK48D<&BD8NH-<_/HUNK\ON!NH?[*Z%J;@'R-M(ITK6
MM1+&OAL<8/RZ4O7W\MGXY]1[ZH]U]44^>ZUVOB>YF[XV]T]LU<!B.IMK;^KN
MG*_I7<4NV-NPX`5>'Q6Z=OU<==7P15"^3+0+.I16D1Z7\'UN[2PM_P`D%[*>
MV4_B5+HP2RC3_1FM8J9R&8^71)#',X@OKJG[S%W#+)3(;Z9;@1-J\R?'H13`
M7H/L7_*FZ7P6R*+KG#=J=W4&SA\9-M_%C<&'BR>QI8-X[-V5OS(=B;+W/GGJ
M=BRU%/O+;>=S%:L<M"])12PU)$U+*51E,;VX?<=PCN[@`*=SVR>2G\%A#!#4
M#S-(<+45Z8O+%)+&2&`*;@V%Z`37_<F[U@K_`*2C`EO(]'!J/B[T9%M_OS"[
M3Z]VUUWD/DSMO<6W>Y]X;'P>,PV[]\/N3;N;VS5;BSN4^RJ$S&Y:6@W#5-!4
M5:3(LS!BA`T^T*1:H9;2?-O*9%/J$>0&OVZ*_GCH]MKV6PY@L=YM,BS>W<5_
MBA3A3T+`?EGH,<S\%.DMTTO7&*W@-Q;KV[UO\7-X_$>GVUF:G'28;=/66]Z#
M9U!ELCN:.#%15;;MIALFDEI*JDEI8J:I:29(0XB*,W%G]7>7^X3$B[OK:SMB
M1Y16CS,OYD.M1YY'2"X,TL2*M`T&ZW<R#UAOXXA<$GR96B`5?Q5KCID^*'\O
MWI_X?2[0EZZW'O[<IV7T'B?CMB_[^UF!RKU&SL/V=O'MBES%?)CMOXMYMU/G
M]ZU,$M0&$+4L40$:R!W=?-<7)^OGB"_5316:1?\`-BQ6W>I_#^H"!Y%<CK9A
MBDDC:4G0(+X-Q/?<2,T?^FP14G(-:UZ,)OOI#:W8/9_3?:N;KLY%FNE(^S(-
MO8JAJ*>'"9>F[5V@-D[C@ST;T4U=(M-A[O2?;34S1U%F<N@T>[:A=Q_3WW;"
M]D8'*Y/ZBGQ#\Z,L=/4$GRZ8GM(G2UCC)*P7,,^?XX4D0#[")6_9T0C9W\I'
MJ?9.'W+AZ#Y!_)[)_P`2ZBVYT;LVNSVY.N<O)U=UELKLN?M39>U-L8JKZT?;
M^X<+A,Y,:2>CW)29RDRM`QCKDJ/>X+J>)8RRKXJ-'(2">Z6*S2V2M:BAT`$@
M5"Y4AL]+@R6\B0VF++P9HSQ!I<2-)(>-?B=O/[*=*7;?\J+XW[?ZV'6$^X.T
ML[AGZCW9U34Y"LS6W\7D_N=W]QT7?<_8V'BVYM7#8;:N\-O]G8NFKL13XNDH
ML%CUA6-,>1K+%LML[S3M4%62QC0^JV:R@8_YNG+ZI33^TH2#2T=DFM[FX`\9
M+:_5Z?[\O6MU8"E*J(X>/K]O2\V9_+TZXVQNG;W8NX>TNZ.T.VZ'?6_>PMZ=
ML=@YO:M5NOM#<.^^G:GHE?[U4NW]GX#;./Q&T.O9U@Q-#B,=C::*>/S3+.SR
M^16Z?K@`UMFCND;%#_C8@$I%/,?3H1ZU(Z2W4`O;KQY\#7;,*>1M%TQ?M''T
MZ?\`=WP_IL9_+SW1\%>H\]+]K2_&/,_'KKO<_8-234*C[5J-M8/+[LR&W<3&
MR3(LP:HEH:)2`/0G%CKFAYN9+FTW"4`7=ON5M.16@\.*YCE:A]="&@\S0=++
M4I;V@A_&/J?^JNK1_A%?3I(=6?R[M@[!W'L+LC<?:?<?9?;>TNQ^N.S:S?>^
M=PX#*Y+)2]7]5;CZGV1UN[8_:>"I1USM#`;QR+4P2GBRM;62?=5E5),\KLS=
M65M>3M=2J%F;]X`TKD;@]N92<Y(%I#3[2!PZ06\4T4<98@R+X1(\@8A(``1Y
M'Q&_9\^NXOY;72QW]N;=&1WSW)E]A93<7<&_-I=!UNY\+%U!UCV?W[MW-;:[
M;[(V51T.V:;=S[CW)1;ER,L$.5RN2QN-K*^IEI*:%I=:OW*1W-O=!U'CRVA@
M`]590CJ3Y!T&FOX2:^72N***W:RB@)$%OH!:E2OAQ".-P*Y*$!ROXJ4\^D7M
M7^51TMMO?W3G953VCW)N7=/4^SNL=BY:JW$G5<\G;>W>D<CEZWIZAWWDJ+K"
MFS6!CV1198X]QM6IV^N8QT$$.2%9XR[K;J^N+F_W"ZDHWU9DD!X:YIX6BF=A
M^$,"M!P&FH&>D,-FHL[:R8".&-R6H:E$#H\:`_BTE3GCW_+I1Y7^6-T9E^O=
MT]:U6\^U5P6[?CIVE\9\E4P9/;<62BV3VWV[4=T;AS%'*=LRTD>Z*'<\Y@I)
MG@>G6D_7`TG[GMC;(K:PFL`"?I[3;=O@..[Q+!W9/M4ZSGIRWM5DGBNKW$P?
M<9&TY'B7TLA('R\,H2?)JCRZ'WH+HK-=6[Y^2._]S9+&9'+]T]F;<R&"CQ4E
M3/'B.K^M>N=M====8G)23X_'D[@:#%UU;7*BR11RUOC2614!]Z$\TFT-9S_[
MD->2RFG#2]PD@SZZ%J1ZXZ>CA2WOI)H<V_[IM+9?7Q(5<25^6INUO,=&;TG_
M`'P;_HWWIR&=F'`D_P"'JR@A0#QH.N:(2Z`?EU'T(_(_)%O=>K=(7KF-EV?0
M!N",KNX$<DBV\MP_6P-O?NO=+?2>!?@``"S<`?0#CZ#W[KW7M)^GXYXLWY^O
MX_/OW7NN[-8BYL3<CU6)_J1;D^_=>ZZT<6_`O86:PO\`7^S^??NO=>TFUK\<
M<6:W!N/Q^#[]U[KVDC\_2_X;\C2?Q^1Q_K>_=>Z[LQ_)^@']KZ`W`^GT!]^Z
M]UUI/]?]X;\\G\?D^_=>ZYX(_P#&0<"R^G_?K[O%_P!+#37;4'Z1ZARG!]["
MW<KE+N]\2W7*`P@YZL:VZ!]OD=+EL/3&/\O0VZF-^7/)Y&H@\G\^]ZG?NN'D
M,OF5*JORHNDTQ3'KTPZ1!B#%)*?XS,RECYG3Y=>U-_M?^V;W[L_BG_WI?^@>
MJ:8?^49_^<[=>U-_M?\`MF]^[/XI_P#>E_Z!Z]IA_P"49_\`G.W7M3?[7_MF
M]^[/XI_]Z7_H'KVF'_E&?_G.W7M3?[7_`+9O?NS^*?\`WI?^@>O:8?\`E&?_
M`)SMU[4W^U_[9O?NS^*?_>E_Z!Z]IA_Y1G_YSMU[4W^U_P"V;W[L_BG_`-Z7
M_H'KVF'_`)1G_P"<[=!YV<7&W*-O6%_O;LL&^H7/]Y*&UK\$CZ_U]^[/XI_]
MZ7_H'K>F&G^XS_\`.=NDJ?)<W9AZCP3("#?FX(%C[<C$1U*TDBDQM0MID75I
M.FJT'$TS7''IZ".)I`!;-P/&=O3H)^Z]DY7L78-1M/%5$4%3D,Y@&EGJ'(AI
MJ*EKTGKJMXP==1X:53I2P#,;?GW"/O?[><S>['MG'R;975O%NAN4ULR*BK"6
M`D(:F6$=2!YG%>I2]E.;]F]M^:I=ZGMI7<HV@>(S_J4.@'.!JI4^G2@Z_P"O
MMO=;[;I=N;>@,<,;&:MK9@&K<G6D`/6ULP75+._-APL:6118$D2>UWM-RM[7
M\LGE7EJ*+]UVF6TL/$OG'^CR-2J$\=%:>715S_[A<R<^<Q3[ANNN=Y:^)'_H
M=O7B8CP:E210#I:Z3_L/QPWT_']GW(2327"B>84E<5(I2A/E3R^SH`I''$@B
MB=I(U%`S"C,/4CR/7M)_WP;_`(I[MU;KVD_[X-_Q3W[KW4C;`/\`I#I5L;_W
M&S3?I;Z#/;<YM:]C_7Z>_=>Z&;G^C?\`)+?\4]^Z]U[G^C?\DM_Q3W[KW7N?
MZ-_R2W_%/?NO=>Y_HW_)+?\`%/?NO=>Y_HW_`"2W_%/?NO=!)O@?[_+;8L;G
M:NYF_2U[#*[<!-K7(X/T]^Z]TV:3_O@W_%/?NO=>TG_?!O\`BGOW7NO:3_O@
MW_%/?NO=>TG_`'P;_BGOW7NO:3_O@W_%/?NO=.6R@1O+.\$WVI@5O8@7.=S9
MM<@`V`N??NO="YS_`$;_`));_BGOW7NO<_T;_DEO^*>_=>Z]S_1O^26_XI[]
MU[KW/]&_Y);_`(I[]U[KW/\`1O\`DEO^*>_=>Z140)[#RW!XV+MX\BPM_>/<
MRFY-@+%A];#W[KW2U%SS9N?]I;_BGOW7NO<_T;_DEO\`BGOW7NO<_P!&_P"2
M6_XI[]U[KW/]&_Y);_BGOW7NO<_T;_DEO^*>_=>Z]S_1O^26_P"*>_=>Z]S_
M`$;_`));_BGOW7N@,R0)WYO=;6)_NG;4"M_]^^&O=K?0>_=>ZRZ3_O@W_%/?
MNO=>TG_?!O\`BGOW7NO:3_O@W_%/?NO=>TG_`'P;_BGOW7NO:3_O@W_%/?NO
M=>TG_?!O^*>_=>Z4?6:D4V[6_P!5O7*$``DV&+P?-P"MK_X^_=>Z$OG^C?\`
M)+?\4]^Z]U[G_4M^?[+?G@_C\CW[KW7?^P;CZ>@_TM_3^G'^M[9I/_1ZUH3Y
M==?3Z!O^26'^]#VXJC35O[3K=`,#AUZQ)OI-[AKE6OJ`L#>WU`]VU,WQ=48/
M^"G7K$6.GZ&]PK7!/)(X_)`]^ZTOB5[J4Z[5?2XT&VD<:#;]:?BW]??NG.BY
M93:V(K<_O&JG_BHEGWUOB244^>S=)$S?WHR0%J>FKXH$``^BJ/?OEY];((76
M<)Z^7[>H/]S,%_U>O_0FW%_]<_?C@T/'K0SPZ]_<S!?]7K_T)MQ?_7/WXXP>
M/6Z'KW]R\%_U>O\`T)MQ?_7/W[@0#Q/6N(J.'7O[EX+_`*O7_H3;B_\`KG[]
M^'5^&@SY9!(S\P"1Z@$C'6P">&>O?W+P7_5Z_P#0FW%_]<_?AW"HR.M)^I4Q
M]P`J:9H/G3AU[^Y>"_ZO7_H3;B_^N?O2D/\`!G[,]>^77O[EX+_J]?\`H3;B
M_P#KG[WUL@CCCKW]S,%_U>O_`$)MQ?\`US]^ZUU[^YF"_P"KU_Z$VXO_`*Y^
M_=>Z]_<S!?\`5Z_]";<7_P!<_?NO=>_N9@O^KU_Z$VXO_KG[]U[KW]S,%_U>
MO_0FW%_]<_?NO=>_N9@O^KU_Z$VXO_KG[]U[KW]S,%_U>O\`T)MQ?_7/W[KW
M7O[F8+_J]?\`H3;B_P#KG[]U[KW]S,%_U>O_`$)MQ?\`US]^Z]U[^YF"_P"K
MU_Z$VXO_`*Y^_=>ZY)LS!:U_XO7ZE_YB;<7]1_U<_?NO=(KKW:.%FVC0R2?Q
MC4<INNY7<>X$'HW?GHQP,G_J4'^N>?S[]UHD#B>EG_<O!?\`5Z_]";<7_P!<
M_?N/#K9!`U'"CS\NO?W+P7_5Z_\`0FW%_P#7/WXXX]>.*@\16OY4!_82`?2H
MKQZ]_<O!?]7K_P!";<7_`-<_?N.?+K="/RK_`"`)_8""?0$$X(Z]_<O!?]7K
M_P!";<7_`-<_?J&H7\1X?/[.M$$&AP>O?W+P7_5Z_P#0FW%_]<_?O.GF.O#/
M#R%>O?W+P7_5Z_\`0FW%_P#7/WL@CCUX9&H?#Z]>_N9@O^KU_P"A-N+_`.N?
MO77NO?W,P7_5Z_\`0FW%_P#7/W[KW7/"[)P#[\P<!_C8B;;6[)-*;GW)&WD2
MLVPHM)'E%DM:0W%[$_ZWO<8,K:8NYO09/\NM$@$J2-0X]#%_H_VW_7<`Y/TW
M?NJWU/\`U>/>W5HV*2`JXX@BA'V@YZ\K*PU*05/F,CKW^C_;?^JW#_Z%^ZO_
M`*\>Z5'6^O?Z/]M_ZK</_H7[J_\`KQ[]4=>Z]_H_VW_JMP_^A?NK_P"O'OU1
MU[KW^C_;?^JW#_Z%^ZO_`*\>_5'7NO?Z/]M_ZK</_H7[J_\`KQ[]4=>Z]_H_
MVW_JMP_^A?NK_P"O'OU1U[I!]B[(P-+@*.2(YW4=T[1B)EW3N6==,VX***0!
M9LJZ`LK<&UP;$>_5'7NDN=F8$$V_C('X']YMQ6M?BU\H3[;D?2M5XU'7M?A=
MW35G=OX+"X/,YHP9RH7#XVMR+0)NG<4;5"T5+/4O3ASE-*>18_J>`1[)^;MU
M3E_:9=S:IBA@>5P,DK&A=J`>H4T'1ORW8/NNX16B8DGE2-3PS(P0?S/33LIM
M@]@;<H=R[;J\S4456H\T4FYMPK64%4B!JB@KX!D[TU73L#<&ZNMG4Z3[#OM]
MS[RI[D\I6/.G(C%RX4SQ@ZFB!R?%4$F,#^F!Y]'O-_)O-7MES+=<M[FC`942
ML"$\Q761II\Z]*L[+P0_YW0^G_,3;B_IQ_R\_P"GN0Y)XKJX:2W=)`S$C0P8
M$>JE201\QCH%".2"(>.0:"A8'M)]0W`CY@]=?W+P7_5Z_P#0FW%_]<_;0()(
M!%0:'Y'TZWY`^1X=>_N9@O\`J]?^A-N+_P"N?O?7NI&VMEX%]]T].W\:\3;-
MS$QT[GW&C^1,[MT*RRKE!*HL>0#I/]/?NO="[_H_VW_7</\`Z%^ZO_KQ[]U[
MKW^C_;?]=P_^A?NK_P"O'OW7NO?Z/]M_UW#_`.A?NK_Z\>_=>Z]_H_VW_7</
M_H7[J_\`KQ[]U[KW^C_;?]=P_P#H7[J_^O'OW7N@MWELK`P;LP$$?\;\<NVM
MPN^O<^Y)'+Q93;^@B1\H9%`$AX!L>+CCW[KW39_<S!?]7K_T)MQ?_7/W[KW7
MO[F8+_J]?^A-N+_ZY^_=>Z]_<S!?]7K_`-";<7_US]^Z]U[^YF"_ZO7_`*$V
MXO\`ZY^_=>Z]_<S!?]7K_P!";<7_`-<_?NO=.&S]DX"?=V:BD_C1C3:V$E73
MN;<<;ZVS6;B-Y8\HDA72>`38'GW[KW0J_P"C_;?^JW#_`.A?NK_Z\>_=>Z]_
MH_VW_7</_H7[J_\`KQ[]U[KW^C_;?]=P_P#H7[J_^O'OW7NO?Z/]M_UW#_Z%
M^ZO_`*\>_=>Z]_H_VW_7</\`Z%^ZO_KQ[]U[I(1;%V]_?W)P'^.M&FS=OU":
MMU[GUB5L_N5"?*,L)2NE!Z=6B_-K^_=>Z5_^C[;?^JW#_P"A?NK_`.O'OW7N
MO?Z/]M_UW#_Z%^ZO_KQ[]U[KW^C_`&W_`%W#_P"A?NK_`.O'OW7NO?Z/]M_U
MW#_Z%^ZO_KQ[]U[KW^C_`&W_`%W#_P"A?NK_`.O'OW7NO?Z/]M_UW#_Z%^ZO
M_KQ[]U[KW^C_`&W_`%W#_P"A?NK_`.O'OW7N@4R.RL"-[;SAOFS'$=KE+[GW
M&9`9<$K.6F.4\S<C@%K#^GOW7NLW]S,%_P!7K_T)MQ?_`%S]^Z]U[^YF"_ZO
M7_H3;B_^N?OW7NO?W,P7_5Z_]";<7_US]^Z]U[^YF"_ZO7_H3;B_^N?OW7NO
M?W,P7_5Z_P#0FW%_]<_?NO=>_N9@O^KU_P"A-N+_`.N?OW7NG_KG8^`J(-U^
M0YW]K>.1B3Q[IW+%Z$QN'9;^/*J&:\AN?SQ_3W[KW0C?Z/MM_P!=P_\`H7[J
M_P#KO[]U[KW^C[;G]=P_^A?NK_Z[^_=>&5+CX!Q/E^WKW^C[;G]=P_\`H7[J
M_P#KO[]^/P_Q^GG^SCU[\'B?@]?+]O7O]'^V_P"NX?\`T+]U?_7?WL`EUB']
MHX)4>;4XZ1Q-/.E:>?7J@<>O?Z/MN?UW#_Z%^ZO_`*\>ZJ0Y`0@D@D4S4#B1
M3T\_3SZU4?ZOV?X<=>_T?;<_KN'_`-"_=7_UX][_`-7\J_X"#]A!Z]J7U'^H
MT_P@C[01US7K_;@$@ON'E`#_`+^_=7_'2,_\[?@W'OW6^D'4$'+[I_QWQO8?
M4`$G=63L+L0+D_2Y`O[U6MNUR/PU_EU?7X^WQVG\4O\`EZK.W7_,[Z]V7VMO
MK8F=Z$[_`(^N^M?DCLWXK;U^15,G4<_5.$[7WY/LZBV]3-@V[2B[AKL-/DM_
M8J!ZFFVS-X_N"[*$C<K2UD^LLA??Q%A_O)*_Y.E>]VQVK<#8GBL<9_WI%;_+
MUCZO_F=[0[-W3UMAQ\:_D9LS9_=/9>_>F^G.U]U-TK-LCL3M'83;TCDVEC\?
MMGMS/[]P9S\NP,FE)693#4='&T2?<20K(K>W8@)XI)>)CIP^=>/[.BE9P\\=
MM4!+B012&O\`9Q/EYO\`:$*/]MT*'QC^?O47RUWQFNONJMJ=H0Y_8.U*C*=W
M#=6W<?@Z3H7?\&[,GM'_`$%]DRG,5,A[=>IP5=7?:8I<C0#%4ZU1JM%1`)+1
MQ>);&]_WU1OV=;FN/`E6,_VS2O#I_P"%0_V4_P!DU?S^?2^R_P`Q>FL1\I<=
M\1)*K<-1V?)UCOCM?<>63!U%-L#9.W]B4>!R-?C=P;OR!I*"IW+68O<$=6M%
MC_O7I*1?+6?;B6$2;VM5F+029A@HK?9;@PG^4A'6KVZ7:S&[_"SJ/R)ST7^G
M_F@]([BZ]K=^]:===W]JU=5\B-R?&KKWK_;&TL/@M_\`:^\]H[(/9.>W%L_"
M]A;CV9#C=E4FPH*C*I4YN;%U,U+3^BG+S0)(BMY%6$[N2%VI;.6X8UP/"E:+
M)%1@+0_/'1A'`8-ZNMKM:`&[C@'V2Q"4?M+='BZC[1VEW=U=U]W!L.HK*G9G
M9NT,'O7;,N2HWQV27%YZBAK8*;)X^1GDH,G1-*T-3"Q)BFC9;FWLZN+:&QU3
MV_\`N/*=2_Z5LC^1Z*MLN5OXBB?[D1X;_3#!Z$0^RQ4T#[37I3$\S@^-\88C
M\AUU[MTYU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
MR3]:_P#!E_WL>_=>Z0W7`OLV@_PRN[?_`'LMP^]>?6C#XO=Z=*#)[CP&$K</
MC,MFL=CLCN$Y3^`T%94+#59C^!8]\MF?X?$W-4<5BXFJ)]-_'""Q]TDD\%/$
M_P!6>K%_&7Z(<9.W]N.@HP7R6^/>Z-P8K:VW^YM@9?/9T+_!\?19VGD^^DDV
MO1[WIJ5:PZ<;3U]=LS(0Y:GIYIXIZC'OYXT:,%@_#']0NKSH3UL'QY`#AIB3
M_P!E!#_]8>DMMGY==%[RWEF=G[5WMA,Q#@*#!9');L_C.)QNUQ#G,5V!G8XZ
M2HRU70U];+0X7KFMK966`0-02Q54<CT_DE1BYE^FN6MF_#XU/^;,$$_[/U^E
M5T!%]CU_ZK`6_P#U@ITJI/DIT#'L>J[*?MG:D>QJ'-Q;9J\]+)D85BW#/3Q5
MM/A1C)*!<U+D)\=*M4L:TQ9J0_<`&`&4+Y8PNYJ@_P!"2G[.DT-;MZG&K/[>
MF^7Y.]*40W;79?>^(PVV=JU.QJ:#>-56TU;MW=K=B;13?&W9=FS823*UN>A;
M`,TDQBA)C\;O8Q*T@+=NN/J+&XW(GX+MX_\`>0I_;GIN$-'OC[4*DL+=#\A/
MX_'_`)P]*O'=X=/YK=6.V1A>RMH9C=.8PD.X\/BL7EDKQE,)48I,]35U'DJ6
M.7#3-/M^5,@L`J34&A=:C1X#Y/:A9A/")?4];@--OC'DTL__`%1F>#_GSIAH
M_DQ\>\AMS-;NH^XMCU.V=O9C&8#,9BGR,U1!2Y?-2R18:E@IZ>EEK\LN9,$A
MHIJ*&I@K%AE>!Y$C=EUU[I5=1]H[9[IZZVUVALTU+;7W6N6FPTM6U$\M32XG
M.Y/`-6+)CJNOH9::MJ,4\L#1S.&A=2;$D#W7N&>@?^3?8N\.M?[AYG9>6;#9
M2KFW3CZBK6FI*LO1/%A9VA,=9#,BWG@1M0`;T_6WO"3[[7NKS3[7;'8[OR9,
MUE-<R!00:9)ZRV^Z[R3RQ[E[A.V_VHT:3Q'16Q\M._P`!O\`F```L,+@;?3F
MU\??D^\"Y?O8?>%M'^G?F*=74"H%K'(!4`_VC*2W'B2?3RZR_?[LOLDCE9-A
M@G<$UD-U+&6^>A7"K3A0`<*^?7?^S:_(#_GX$_\`YY,!_P#6[VW_`,%Q]X+_
M`*:2X_[(H?\`H#JO_`S^Q_\`TS=O_P!ELW_6SKW^S:_(#_GX$_\`YY,!_P#6
M[W[_`(+C[P7_`$TEQ_V10_\`0'7O^!G]C_\`IF[?_LMF_P"MG7O]FU^0'_/P
M)_\`SR8#_P"MWOW_``7'W@O^FDN/^R*'_H#KW_`S^Q__`$S=O_V6S?\`6SKW
M^S:_(#_GX$__`)Y,!_\`6[W[_@N/O!?]-)<?]D4/_0'7O^!G]C_^F;M_^RV;
M_K9U[_9M?D!_S\"?_P`\F`_^MWOW_!<?>"_Z:2X_[(H?^@.O?\#/['_],W;_
M`/9;-_ULZ]_LVOR`_P"?@3_^>3`?_6[W[_@N/O!?]-)<?]D4/_0'7O\`@9_8
M_P#Z9NW_`.RV;_K9TWY/Y0=XYBGCI,EOB>IIHJNDKEB.)PT0%30U$=52R7BH
M5),51$K"_P#3W[_@N?O!?]-)<?\`9%#_`-`=5/W9O9`\.7(!_P!1TW_0?40_
M)+N@_7>M0?\`R&8G^O\`A1^WH/O<_>`$M7YDN-.?^(4/_0'6S]V3V0E&C^K=
MO7_GNF\O]OU#K_D)W!DZ*JQU9O&>>AKJ6>CJJ=\=BU6:"ICDAG0E*0.!)');
M@^TFZ?>P]\MZMI;*XYBGDMFC=77Z*(:E92&6NC%5)%?+HRL?NY>S6VW$5W:<
MO01W$,BR(1>RFC(P930OFC`&GGTT=4]IY_JK<,.4Q3-58NH:.'.81Y3'3Y>E
M+V`0`VILA3CU03J-2LMC<$CV1>R?O3S5[%<RVW,>QSF;E6_9?KK,'BAX@CSQ
MC/1W[P>TNR^Y?+DAG`;=F4T^T]6Q;.WE@-_8&EW)MRM6KH:H$2*Q05-'5!BL
MM#7P:S)35D3J=2L`&_4FI3?WV\Y"]QN3_<SEE>;^18A!:!`3$,>$&_`0*4T\
M.N0_.O(>^>WW,S<H<PH4LW<^`#_`#VT_+I3&_%_Z>QZT4:1QRQ\9D#M_IB2#
M_@Z"JZU=X'X1.4'V"E/\/77MOJ_4G:__`#,*E_\`#(S7_N^VY[]U[H9_?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]T$>^/^/RVY_P"&ON7_`-VNV_?NO=-?OW7NO>_=
M>Z][]U[KWOW7NO>_=>Z<]D_\?EG?_#2P7_N^S7OW7NA=]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW2*C_YF'EO_#&V]_[T6Z/?NO=+7W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW0%Y+_`(_O>_\`Y*?_`+H![]U[K)[]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z4?67^8W=_X>N3_P#=7@_?NO=3NS^T^ONE=@;L[6[6W5B]
MB];[%QIS.\-YYV26+"[=Q*U%/22Y+*300SRP45--5)Y9-!6*,EVLH)'NK)\0
M/1;_`)$_.SI'H#X[X+Y(8VM;O7:>_=P[=V9U'CNE<]M#<9[4WKNV/)5.W<'M
M_=U=GL=L/%TE51X>LFGKLADJ>"F2ED5@9M$3Z^?7K<5V>X4X[CQZ!CLG^9YL
MOK*B^+6,S7QV[[?MOY7;;W+N/:?1&5K^D>M^QMIT^SZ_:^(SL6XZKN#MKKW9
M68>?+;NHH\2F$RF3J<W#*L])"\9N-FIW]G&0$'^#JB#_`'0*E1\1^SCT,G87
MSVZ$ZQ^4G7?P_P!SUN>3MO?'4W8/=F=-%14E1MGJC8/7>U<GO"NJNRLO]\CX
M_*YS$8'(MCZ2CBK99DH9)FT0-%([=L9P]]S&P/TVQP+W9H/J9M!S\]8Z?$:L
M5J<LO^`#HI>=_G3]`;7Z,[0[UW'T9\GL'C.O-O\`2?8F"V+D-H;%._\`M[I3
MY#[CK=K]4=U=8XZA[!K<36;1SN4QU0LU'D:S'YJB,6F:C5W4'UP]MM444\+"
ML>X36IIY%D,SJ?GX2/\`ETGEDCAD$;YU`'..+JBG_G(R=&#VS_,CZ'WK\P>M
MOACM'$[ZW!OCL[H.@^0N)W_CZ'!R=78S:^6VLF]\1MO+9C^.#-+O/([2J*>O
M2FAH985@J$9IE!]KK"TDN(-VN$0_36%S!&6.`&FC21``<FL3H,<-.>JR_3F$
M-'_:-J(^Q)7AD_ZKI+^=>K!%/#G_`&B__)Z'VDZ=7^R;[!T"-2`<MNOTBW]]
MM\7!O8`[HR@(LO+7!^EQQ^0?=54BPD@/Q-7JQC^DNHYE.J($&GD#T0'J?^7?
MT!L[Y#=Z?)WL;K3J/M3N/LOY%9/N[K_L/,[!HZG>76.)FVCLS;6'VI29K+-6
M,]=@Z_;U56P5M/'"D358,2I(K,4UM$UOR[#9QXN%>0DCCEV(_ETIW.];=-\E
MOI:F%HXP`<CM0+C]G18NF/Y3%)\:MU])]X]#[LZOVW\EMB9SOF/N#>>9Z^RF
M0V5WUL;N?<V[MVXVAW-@UR[9K$=@=>9?)8I<=N"DJ8ZN6DHZFDF+4M2J*Y&T
MD=N(*D2.,_.G1-%"?&G$@K%(A2AX%&^-?]*:+4>=!TI^@?Y8F\>D<OOVJE^5
MG9V8HODUM"ISWS+RNT\YN3KOL'?'RC&ZVW31=_\`1.\,/DI:CIV"KQU?4;;R
M&%TU4,^`@HU4I/$[NI(FCLA:J2%:9-0!XIJ&H'Y$8/2U?`6Y-Y.BO-X*Q5(J
M?#C%(UK_``Q_@'EY=')KOC742?(GXU]ST6]JZLPGQ^Z9[@ZHJ</NR;(;CWCO
M6;LU.O*>CW/E]X5%0G\0RN.@V0[5TM5#)45TM0I#IH-U8>%.9))HE"[5+&P9
M!\!9P2]1P)=J$^I%>DFXV(W6FLX'`>GI3HK6]?Y?G9=14[MWUUGW-LG;?<*?
M-GLWY==69S>&PL]NC8VWJ'MKIS_0=N;8&]=MXK=.!S>=J(-K5U75TU;0UU+'
M'6)3ZHWB61&#FU[>L'+PV2Y!_=QV>X@,8X5DNY)*`'%:$<>C476F^.Y*`)S<
MQ3Z_Q?I1+$&)]1IT_9T>/XW]+XSXY]!]0=$8C*U>?H.J-A8+9PW%6P4])6[C
MK<=2J<MGJRBI6:EH9LUF)*BJ:&(E(_*%!LOL17DI>9HE/^+(Q"+Y*HPJ@>0`
MP!T76MO%9DM`JI,QJQ`H6)XD^I)X]#5[2=*"234\>O>_=:Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZY)^M?^#+_O8]^Z]TA>N/\`
MCSJ#_M:;M_\`>RW#[]U8,R\#3I`=U=9;UWS7]>;DZ]W%M3!;JZ_R.]%@BWQB
M<WF-LU^&W_LW([,S#2P[<K\;E5RN)BJXJRB'D,$K1-!,4#B5*LJNNE@"/GU:
MW,<5RD[@41@Q_+/10L'_`"],A1]%8WI#*]GT$].O:?7N^MP;FQ&W9\97UV&V
M=\<Z+H+(X_&4[Y&H%-G,E]N^0I9II)(*:%_MY%DY;W8,\::8R5%/+I1XB11U
M``D1(^'$&%)5)_(RCI<47Q)[*SV^,?O3LS>O3^:7#[3VAL6GVYA>NMP#;V:V
MULSK+N3KJ(;KHLMN*5\M_>!.UDEK*"-XJ6&EHWI8)-,@F!5?17$NYRW$;,0W
MU?\`U5L;*$4_.(T^=>D=[)(8+0LQ))7\Z,6%?L9F8>A)/GUPV9\4NXMD1[1W
M-B>SMHS;RZRWQ5[AZRV%GJSM?>G36UMLY;JJ7JG/;8I,SO/<N;[?6.NQ]0V1
MIE?)RTF-J1]M3Q"GDD(/:FYFG;41(S&C>=/D>MK$]G<M*C?IUPHX`>G2AI_B
M_P!C[;WGB.UMG;_ZYD['V[D]OU^-H<SL*OP/6]=&G4,G5&[::?;^S\A15>VT
MJ=8KL4<=?[6*,TTXF6HEE4OM+%]NV*?;F<M+-+,U>)U2B+0?M'AM0_,])=9F
MYCCW0`J%N;$U&,0_55KZC]7/Y=(K;?P8S>UZ[#8;#]B8S;FRIMH3[8[+RNRD
MWKMK>/:RU_7VY]CU-!NC9<NYLKTS+1T;[F,V.S(QB[@QE'1TM$D[PP:CJU3P
MXB,T.B@KPTHJ/3[7#$_,GI2<1Q1BFE6NSP_W[>32C/V,,<//J!U]\(]_==9K
M8?8>'W_LBJ[,Z=I]CX'K7^.3]V;KV=EMI[,VQOK9TM!O,[V[)W5N';SY?!;^
MFGI:';Y@QV&R-,&A$J3RA%/7NCA]"];Y?J+J;:G7FX,[B=S9O`MN&?*Y[`86
M;;F$R-;N#=.;W+,^*P516Y&;%4,+9CQ1Q-/(0$O?GW[KW03?*W9>[M[Q;"Q>
MSL!D=Q9*EJ-S5L])C(/N)H:-8<+$]1(@9=,0>55O_5@/>!WWY?;?FKW(Y?V_
M:^4XGO9;:4-0YIUF#]T7GWE[E#<[ZXYPF6VL9(R$!PH/R'11#\>>\;\]6[NO
M^?\`<=_V%]X!-]WKW]>C#EMY.U>X2*H:@`KI)QPI3K-&#WQ]HH8A&-T9P">X
MO4FI)_RTZZ_V7GO#_GUV[O\`SW?]A?=?^!X]_O\`IF)/^<J_Y^G?]?7VB_Z.
M1_WKKW^R\]X?\^NW=_Y[O^POOW_`\>_W_3,2?\Y5_P`_7O\`7U]HO^CD?]ZZ
M]_LO/>'_`#Z[=W_GN_["^_?\#Q[_`'_3,2?\Y5_S]>_U]?:+_HY'_>NO?[+S
MWA_SZ[=W_GN_["^_?\#Q[_?],Q)_SE7_`#]>_P!?7VB_Z.1_WKKW^R\]X?\`
M/KMW?^>[_L+[]_P/'O\`?],Q)_SE7_/U[_7U]HO^CD?]ZZ]_LO/>'_/KMW?^
M>[_L+[]_P/'O]_TS$G_.5?\`/U[_`%]?:+_HY'_>NHU7T-W+01)/6];;II87
MGIZ5))J$(K5%5*L-/$"9?U2RL%'^)]^_X'CW^_Z9B3_G*O\`GZV/?3VC;`W(
MU_TW4<](=NC_`)IYN8'Z$&B`(YY!'EO[H_W>??[3_P`JQ(?^;J_Y^G$]\?:8
MGMW$U_TW6"JZ:[5H:6IK*O8.XX*2D@FJJF=Z/T0P0(TLLK6<G3&B$FU_I[1W
M'W?/??9X7O9^5W6)49B3*M`J@DDBN0!GIZW]Y_:O<YA;P;DPE9@HHWF<#\\]
M-?7FP-P=E[CI-O;<AUL^F:OR+AC0XF@!O)D*N15-XT4$HBD/,XTJ?U>P_P"S
MOMGS+[F<XKL/+=L296`NVT]L"GB4/!:#A3HS]Q^>-A]M>5'YBWJY"2QJ3:@-
M1YV'`..+5-*U\J]6T==]=;>ZPVW#MS`QLUG6IR.1J!JK<QD'B1)J^K8:55P$
MTQH!IC3TCWW8]H?:C:?:;EB/ES:]!C6%4E<"AN744,LI_$[<23D]<A?<_P!S
M]U]T]]_K#NP?ZHN6C5C7Z=2:B./^%5\@.EP?<B(S$%3\*F@'H/(#H$RT)#5J
MQ4$GU/S^?7O=^FNI.U_^9A4O_AD9K_W?;<]^Z]T,_OW7NO>_=>Z][]U[KWOW
M7NO>_=>Z"/?'_'Y;<_\`#7W+_P"[7;?OW7NFOW[KW7O?NO=>]^Z]U[W[KW7O
M?NO=.>R?^/RSO_AI8+_W?9KW[KW0N^_=>Z][]U[KWOW7NO>_=>Z][]U[I%1_
M\S#RW_AC;>_]Z+='OW7NEK[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MH"\E_P`?WO?_`,E/_P!T`]^Z]UD]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M*/K+_,;N_P##UR?_`+J\'[]U[KAW-M#?&_\`JO?NQ^N][XSK7>FZMO5F$V]V
M!E]E83L?'[4J,CXZ:JRL^P]QNFW]T/!C6F$--6_Y.\[(9`R@J?=>ZJ<WK_*9
MQW5/PQ[WZ7^-=3LGMWLSO#>-!VGW;%\KMG[>S_7OR$S&)QN0I*K;5#LG86`V
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M+74F9SDWV5!1Q)C6IY)9VD=>[:-+W94_W#NI2)5_#*B2F2$./Q",T9`:T(%.
M'3-G,SQP2R#A!'7_`$WAJ&_,D$D^9Z0>`_E1?)/.[)HL1VUO;H.3<.PME?`W
MXX;!38M3V*V`W'\=OASV]+V5N#=F]Y-PX!:K'=J]F4M8\$>)H:>?&8Z2+2:Z
M59"ZIWMT@,2W*B9)+^2Y<,*UD:SN82YK^(^)2OG7JF^@3B1H%`;Z4*"O$,+J
MVD!^1&@GY4Z7GPM_E3]J_&#OCI3MO=/9VS]\Q=9[G^6%'EJQ*C/ON*HZHWYL
MKK_JWXP;,Q7W6(IJ64]:==[!CI\H)I$19YV:G><LSDULMWD;8FLF+"6YM[=Y
MJG,L\4TJ^(_\3B%8HPQSX:(O`#IYHK94D$4:J1>RZ:"GZ3HDI0>BFXDFF(X>
M+([\6/5Z*CA_\4''^Q3T_P"W'LLZKY4\N@%J\C0QYW=T,V0H()(][[W#I-64
M\4@)W5D[?MM)J`('OWXJ]51=`()+5]>N/\3Q7_.VQ?\`YWTW_7SWNO>9/7R\
MNKGA3AUU_$\5_P`[;%_^=]-_U\]T9`TJRYJM<>77B:@#KW\2Q7_.VQ?_`)WT
MW_7SV\\AD;4:#!&/GY_;UX&AK2O7?\3Q7_.VQ?\`YWTW_7SVVO;#X(X!JU\_
M7[.M`D,&'D0?V=>_B>*_YVV,_P#.^G_Z^^WFF+-72HS7_8^SS^WJAC!B\*II
MX#1?.C.7+?Z8$T'E3RKUU_$L5_SML7_YWTW_`%\]L].NQ=RYH"37KW\2Q7_.
MVQ?_`)WTW_7SW[JO7OXEBO\`G;8O_P`[Z;_KY[]U[KW\2Q7_`#ML7_YWTW_7
MSW[KW7OXEBO^=MB__.^F_P"OGOW7NO?Q+%?\[;%_^=]-_P!?/?NO=>_B6*_Y
MVV+_`/.^F_Z^>_=>Z]_$L5_SML7_`.=]-_U\]^Z]U[^)8K_G;8O_`,[Z;_KY
M[]U[KW\2Q7_.VQ?_`)WTW_7SW[KW7OXEBO\`G;8O_P`[Z;_KY[]U[KW\2Q7_
M`#ML7_YWTW_7SW[KW7-,EBBZ#^+8P^M>!7TUSR.!^Y]??NO=(;KO(8Q-HT*G
M)XY+93=EO)74P)OO+</(_<^EO?NO=+;^)XK_`)VV+_\`.^F_Z^>_=5==:-&2
M0&4C''(IUV<GBC;_`'+8OC_INIO^OGO75I/U"Q/XS*?L\5D8T_TI0!?D36N.
MO?Q/%?\`.VQ?_G=3?]?/=PU!2@\L^>"3_.M#\@.M2@2I&C<(N'S^W_8ZZ_B6
M*_YV^+_\[Z;_`*^>VV74``2M/3JS$LY<_B-:>77?\3Q7_.VQ?_G?3?\`7SWN
M,&-@Q):DJ/GUCUT'V'6:_8.K,]5TT`P<^>:9_+R^WKK^)XK_`)VV+_\`.^F_
MZ^>]G(4?PZ_^-R-(?V%J#Y4\^J`4_P!7RI_/B?GU[^)8K_G;8O\`\[Z;_KY[
M]U[KW\2Q7_.VQ?\`YWTW_7SW[KW76"RV+._L&S9/'QVVQNY;_?T:@_Y7M0@:
MFF`N;?3WM?#2X:Y")J8<*5`^RO6@&%LMJ68HIXUR?MIT-)RV(!/^Y?%GD_7(
MT%_K_P!1'NABMV.J2,,YXFK"OY!@/V#KS*":BJCT!-/\/77\6Q'_`#ML7_Y\
M:#_ZH]^\&T_WT/\`>G_Z"ZKH^;?M/7OXMB/^=MB__/C0?_5'OW@VG^^A_O3_
M`/077M'S;]IZ]_%L1_SML7_Y\:#_`.J/?O!M/]]#_>G_`.@NO:/FW[3U[^+8
MC_G;8O\`\^-!_P#5'OW@VG^^A_O3_P#077M'S;]IZ]_%L1_SML7_`.?&@_\`
MJCW[P;3_`'T/]Z?_`*"Z]H^;?M/7OXMB/^=MB_\`SXT'_P!4>_>#:?[Z'^]/
M_P!!=>T?-OVGI`=E9;&';M&L>5Q18[KVBQ_RZD>RIGZ)G("3FUQQ<_CZ>_>#
M:?[Z7_>G_P"@NO:/FW[3TFSEL62;9;%<G\UT%_K^2:CD^VWBLP*F(4J/Q/\`
M]!=.11R%J15+T/F?3[>F7<8H<YM_.X6/,XB%\OBLACHJAZZF,=,]72R4XD=!
M.&<7EO:_-O93SCLS;_LD^W0Q!$GMI(]2L^H>)&R5%6(J-514$5\O+HYY2OTV
M/=XK^8:C%,DA#$T.APU#FM#2AZ2W66S=E=9;:I<#@\ABY9SXY\OF)ZVC-;F<
MB%"2U%81-J$2L-,,5@L45@!>Y]@CV?\`:/8/9?DRVVG;(R=^D4+)<.%,TO#X
MV55'[`.A+[D^Y&\^[/.=QN]](3L,9)BMU+>#%\T!)/[2>A!.3Q7_`#M<6/S8
M5U,`/\`/(;#W*4D+K(0[%6!X#@/LZ`GC1N"R*"I\_/KC_$L5_P`[;%_^=]-_
MU\]V)K^SIH"G7OXEBO\`G;8O_P`[Z;_KY[UUOK+MG*XL=@TSG*XO0-EYN._W
MU,/4,[MPVU&8*+_X^_=>Z&7^,XC_`)VV+_\`/E0__5'OW7NO?QG$?\[;%_\`
MGRH?_JCW[KW7OXSB/^=MB_\`SY4/_P!4>_=>Z]_&<1_SML7_`.?*A_\`JCW[
MKW7OXSB/^=MB_P#SY4/_`-4>_=>Z"7>N5Q;[RV\1E<9H7;&XE)%?2MZGRFWR
M/4LQ7^P/?NO=-_\`$L5_SML7_P"=]-_U\]^Z]U[^)8K_`)VV+_\`.^F_Z^>_
M=>Z]_$L5_P`[;%_^=]-_U\]^Z]U[^)8K_G;8O_SOIO\`KY[]U[KW\2Q7_.VQ
M?_G?3?\`7SW[KW3ALW*8R/=^<D;*XM4.U,(HD;(480E<UG'*C5.IU7'^M[]U
M[H6OXSB/^=MB_P#SY4/_`-4>_=>Z]_&<1_SML7_Y\J'_`.J/?NO=>_C.(_YV
MV+_\^5#_`/5'OW7NO?QG$?\`.VQ?_GRH?_JCW[KW7OXSB/\`G;8O_P`^5#_]
M4>_=>Z1D>6Q?^D'*R?Q3%B,[(P$?D.2H0HD7/[G<(3]Q]2#[]U[I9C,XC_G;
M8O\`V&2H?_JCW[KW7OXSB/\`G;8O_P`^5#_]4>_=>Z]_&<1_SML7_P"?*A_^
MJ/?NO=>_C.(_YVV+_P#/E0__`%1[]U[KW\9Q'_.VQ?\`Y\J'_P"J/?NO=>_C
M.(_YVV+_`//E0_\`U1[]U[KW\9Q'_.VQ?_GRH?\`ZH]^Z]T!N2RV,_OUO=OX
MECO&?[J`.*ZD8%AM];BZS$&Q^O\`3W[KW4C^)8K_`)VV+_\`.^F_Z^>_=>Z]
M_$L5_P`[;%_^=]-_U\]^Z]U[^)8K_G;8O_SOIO\`KY[]U[KW\2Q7_.VQ?_G?
M3?\`7SW[KW7OXEBO^=MB_P#SOIO^OGOW7NO?Q+%?\[;%_P#G?3?]?/?NO=/W
M6>6Q2T^["V5Q@U;SRC6-?2+_`,N_#*""\XN"%]^Z]T)G\9Q'_.VQ?_GRH?\`
MZH]^Z]U[^,XC_G;8O_SY4/\`]4>_=>Z[_C.(_P"=KB__`#Y4/_U1[V37@`,G
MA\_+\N(ZT54^0X#^7^?SZZ_C.(_YVV+_`//E0_\`U1[HJ`4KEJ<3Q/6S3R%!
MU[^,XC_G;8O_`,^5#_\`5'MWQ#^(`_;Y9\O\'V=;4Z?G]OV'_B_MZ]_&<1_S
MML7_`.?*A_\`JCW5R';50#/E]@Q]G6N)!^5/YG/V^77)<SB+/_N5Q?Z;_P#%
MRH?]6@_Y6/ZGWKKW0&5^!P=7G-WSU6#P]5//OG?$LL]3C*.>=W.ZLF/7++"[
MN`!QSQ[]^*G6I&$=H+QLQDTH./\`F_GU'_NSMG_GF\!_YY\?_P!>/;C1E1J)
M!'RZV,@$XJ*YZ]_=G;7_`#S>`_\`//C_`/ZG]L+(&8J`<=;H*5J*`]W]%?-S
M_17`-,Y&.O?W9VU^=N;?_P#//C__`*G]NHNN585XL0*^0KZ]:&5KP:O#ST_@
MD_TDGX#Q]0.N_P"[&VO^>;P'_GGH/_J?WL(2BN*481FGF/$C:05^P*0WS(I4
M9ZW&/%;2N#\^NO[L;:_YYO`<G_G3T'_U/[IUZ(&9I47!BX_/[/\`9Z]_=G;/
M_/-X#_SSX_\`^I_?ND\<Z24H#GKW]V=L_P#/-X#_`,\^/_\`J?W[I013KW]V
M=L_\\W@/_//C_P#ZG]^ZUU[^[.V?^>;P'_GGQ_\`]3^_=>Z]_=G;/_/-X#_S
MSX__`.I_?NO=>_NSMG_GF\!_YY\?_P#4_OW7NO?W9VS_`,\W@/\`SSX__P"I
M_?NO=>_NSMG_`)YO`?\`GGQ__P!3^_=>Z]_=G;/_`#S>`_\`//C_`/ZG]^Z]
MU[^[.V?^>;P'_GGQ_P#]3^_=>Z]_=G;/_/-X#_SSX_\`^I_?NO=>_NSMG_GF
M\!_YY\?_`/4_OW7NN<>V=LB1#_=O`<.O_+GQY_(_'@Y]^Z]TB>OMO;=FVE0/
M)M_!R'^);K4F3$X]V]&\<_&@#?;CT+&B@#\>_=>Z6?\`=G;/_/-X#_SSX_\`
M^I_>P*]>Z]_=G;/_`#S>`_\`//C_`/ZG]Z)IUHF@)]!UX;8VT?\`F&\!_P">
M?'_]>/?O]C^9(_E2I^1'6BVD,2#1=?\`U3CCD/[1(`/Z0-<4/7?]V-M?\\W@
M/_//0?\`U/[]GZE+;\;J"#Y`'U_V.KL-!(/$==?W8VU_SS>`_P#//C__`*G]
MZ8Z93%Q*FA/EUZ)3-JTXT+4U].O?W8VU_P`\W@/_`#SX_P#^I_>S@TZK$1+`
M)U/:6(IYX\_LZ]_=G;/_`#S>`_\`//C_`/ZG]^ZWU[^[.V?^>;P'_GGQ_P#]
M3^_=>ZRX;;6VFW[@(SMS",IVQNYG0X;&M&66LVN(G>,4WC9XD?2'M>Q/O8BO
M4N&M[JWD@*BM9&C`/V=Y/\NF3=[>UNMQ;7"3AC33&LA8?;V`?SZ&4[1VQ<VV
MO@+7/TP&-M]?\*/W36OD'/S5'8?DRJ5/Y$_MZN6/D%I\Y(T/YJ[JP_,#]G77
M]T=L?\\O@/\`SP8[_P"H_?M8])?^<4O_`$!U[6?2/_G-#_ULZ]_=';'_`#R^
M`_\`/!CO_J/W[6/27_G%+_T!U[6?2/\`YS0_];.O?W1VQ_SR^`_\\&._^H_?
MM8])?^<4O_0'7M9](_\`G-#_`-;.O?W1VQ_SR^`_\\&._P#J/W[6/27_`)Q2
M_P#0'7M9](_^<T/_`%LZ]_=';'_/+X#_`,\&._\`J/W[6/27_G%+_P!`=>UG
MTC_YS0_];.O?W1VQ_P`\O@/_`#P8[_ZC]^UCTE_YQ2_]`=>UGTC_`.<T/_6S
MI`]D;5V[#MZCEAVWA(I!NG:::X\'CT(27/44<@9A2J=+JUK<W)_'OVL?PR_\
MXI?^@.O:S_PO_G-#_P!;.DPVT]OZC_OU\(;,>1@Z%0;&W`,/`]U<J10K+2H_
MT*7_`*`Z<BDD5ZH8PU#_`*)&WEZ*Y/\`+[>F3<^'PN$VQN#,TNU\"U5BL+E<
ME$DV"Q[1,U!2O4QJ]X+!9'C*\7(O]/9-SKNM[R_L5QN42RLL%K+)18I:GPXV
M>@J@%3IQ4@5XD#HZY/LH-\WJ&PG95$MQ'&23@:W523\LYZ0_5.[NO>V-N0Y?
M&;>V[39>F2./.8-L7C/N\;6:+N3:G4S4DI]4<MRH7@V/N,/9'WDV7WCY.MMU
MM9"V^QJ#)`Q7Q8^&74,1^PGJ0?=GVLW/VIYLN+"2*FP2$B*=0?#D^2$@$_F!
MT)_]V-M6'^_;P%_\</0?T_ZA_<Y)JNV:9B$!-:MP;YC_`&:=1'$B_P!DO;IQ
M0\1\L5Z]_=C;0_YAO`?^>?'_`/U/[8%:D$$4/^H]692AH>O?W9VS_P`\W@/_
M`#SX_P#^I_>^J]9]L[8VXV_J:([?P)A.R\W*T1PV.,?D&<VXJ-H-.1J%^3[]
MU[H8?[I;8_YYG;G_`)X\9_\`4GOW7NO?W2VQ_P`\SMS_`,\>,_\`J3W[KW7O
M[I;8_P">9VY_YX\9_P#4GOW7NO?W2VQ_SS.W/_/'C/\`ZD]^Z]U[^Z6V/^>9
MVY_YX\9_]2>_=>Z"C>FV-N1;OV^B;>P*I+MC<3RQC#8X1N\64V^(V913@%E$
MIY_'OW7NF[^[.V?^>;P'_GGQ_P#]3^_=>Z]_=G;/_/-X#_SSX_\`^I_?NO=>
M_NSMG_GF\!_YY\?_`/4_OW7NO?W9VS_SS>`_\\^/_P#J?W[KW7O[L[9_YYO`
M?^>?'_\`U/[]U[ISV9MC;,F[\W')MS`2(FU,*\<;X;'LB/)FLY$[JK0,FID/
MUM^/?NO="K_=+;'_`#S.W/\`SQXS_P"I/?NO=>_NEMC_`)YG;G_GCQG_`-2>
M_=>Z]_=+;'_/,[<_\\>,_P#J3W[KW7O[I;8_YYG;G_GCQG_U)[]U[KW]TML?
M\\SMS_SQXS_ZD]^Z]TD(-K;8'8.3C?;>WVB396WYEB_@F+,:RMN'<BO(J-2%
M!(\::2UB;6]^Z]TK_P"Z6U_^>9VY_P">3&?_`%(/?NO=>_NEMC_GF=N?^>/&
M?_4GOW7NO?W2VQ_SS.W/_/'C/_J3W[KW7O[I;8_YYG;G_GCQG_U)[]U[KW]T
MML?\\SMS_P`\>,_^I/?NO=>_NEMC_GF=N?\`GCQG_P!2>_=>Z]_=+;'_`#S.
MW/\`SQXS_P"I/?NO=`ID-M[=&]MZPG;V"\:':Q15Q&.LJR;?7R(BFFT1B1@"
MQ`N2/?NO=<_[L[9_YYO`?^>?'_\`U/[]U[KW]V=L_P#/-X#_`,\^/_\`J?W[
MKW7O[L[9_P">;P'_`)Y\?_\`4_OW7NO?W9VS_P`\W@/_`#SX_P#^I_?NO=>_
MNSMG_GF\!_YY\?\`_4_OW7NO?W9VS_SS>`_\\^/_`/J?W[KW2@ZUVQMN2DW4
MLNW-O2-'O3*(K/AL=(RQ+C<,\:(7ICH2\K77Z?3W1W$8!/F>O="1_=+:_P#S
MS.W/_/'C/_J3VZ%)B,WD!6GGUM1J('KUW_=':_\`SS.W/_/'C/\`ZD]L&50*
MT/5Q'5M-1U[^Z.U_^>9V[_YX\7_]2>W*XK\@?V^7VCSZHHU2",<3)(GYQ*')
M^Q@:+YU!K3KW]T=K_P#/-;<_\\F+_P#J3WIFTD"A);QJ4_X3'XK#_;*>WY\:
M=5C;Q?#(!'B>#3Y>.^A:_P"DXOZ#A7KW]T=K_P#/-;<_\\>+_P#J3W=P5D,=
M"3XN@$<#^F\@<?T"$(KQJ1BF>O(?$9`O!T#5\A4A0#\R2`.O?W1VO_SS6W/_
M`#QXS_ZD]UJ*H!^.!91]C.R:3_2!4D^5",]>C)D#&A&DD9\Z,4)'R#*1^77:
M[2VQ:3_?M;<Y0#_BR8S_`%:&Q_R3Z<>]];Z#64%LMNH?TWKO9O\`'_CZ\B!_
M6X!:Y%B2`0.3[J&K823GXEKTGB;Q8XK9O@,M/Y]4*;@_F2_*B/YE]G=);!Q/
M3V_\#UY\S-H_':DZ$POQ\^2N1[GW5UCE:;857O+M*/Y#XG.5OQZVC-L?%[KK
M<G44^5@B;[3%E75/.DGM+MUPTNSQW<_:C.XJ>&'(X]'O,UJ;3>GM(`3IBB-!
M\XE;IB^)/\SWY+?(7OWKSJHYGXW[QK=_;][DV]NKJ+8G17R-VCV=T7UEL#.]
M@;5Q'?\`N#LG>^[ZSJ7M#9.-W%MK%4V3H\&L4E5-ETABF@ECD"F-I$LEK)*.
M+2(B?TG<,55?F0IH/.G1!!*INTBD_LSB4?QQ8UQ`?Q,=)`X]IZ,?\)_Y@W9O
MR([$^0NW.Y:3H3J+:'PHDJNF_DENZ'>E#_"MU_(U=WY"AIMR=:Y3*;O%!LWH
ME]I8M'!SWGR<V;K_`+%9U^RFDD<AT1;6;J0A9&E,4=<%YA_H:^K?+I9<47<%
MMDS-3)'#P`*Q1_Z:+\6:C->A*[M^<F_^H_D;1[.'56"R/QTB^)WR/^2%)VG3
M[LQ^9W#VQ7]&;/VGNU,9UOC<%75=%AMGFGSQ@?(9/R292KDO3)'3P&29#9LY
MEN%FJOA+(X!_WU'*L*2?Z4EM(/6MU;P9[>*T[I&D0$+DY8`X_/HIE7\\OF]!
MT=W9NC-Y7X@[,[-Z5V!\?>_I9DZP[OWSM'?'6GRCV/DLMUATSMW:]#V7MO<$
M'=E%V'!2X%LF^1DQN26K2845,&L'2&$_TM/\9\98M/XO$=0ZQT_C9"&`\U->
MO6I5&NYF($1A>6IX>%&Q1Y`?X5<%2>`((\NKDNEZCMNKZCZWK>_J'9N*[MK=
MFX2L[3Q'7D>239&&WQ64<%5F\/MD9BMR.3;&8FHE-*'FJ)FDDA9PVEE]Z4AE
MU"A!Z00(RD8-.A+][Z,&\OLZ][]U7KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KDGZU_X,O^]CW[KW2%ZX_P"//H/^UINW_P![+</N
MRH[`E02!U[J/N[L;#;,W+L;;&2HLI4UN_P`[T_@T]%'3-2TYV)M2IWCEX\B\
MM3%)&U7BZ5XZ;1%(/+8LR@$^TL\E%T1FLM1CS^?5XXY)I%BB4M*Q``&22>`'
MSZ*7MS^83UAF\/B]Y5_7O9NV>K:O/8+:V2[.S<>S_P""X7<>Y.E\?WKAL75X
MC'[HK-SU\$VSZXQ3UE%134U-DXFIV(5HW*RW"M`3(0)-)I\S3%.K1QDNNL4C
M)C)/EID#,A^QECD*^H1CY=8Z7YG9J#LG(X/>O5&^.O\`;$6S-F[TV_BZO`X?
M=N]-RT.=V/W?OZNEIAM+>F3H$$^$ZMIXZ:@BBGRL.2:>BFA+NDJ)-QGCL6EB
ME8+.IO!I)H?TK&RE&/\`32D_GTLW"**&%+DD""31W>1UR.C_`+(TC8_(CUZ6
MFV?F1@-Z[(V9NK9G6VX]V;C[$W)D-M=?]?;9WYT]N2LW6,-LY-_9S,P[RPV_
M*K8F'I,+M<L]939.MH\A3U:_:^!I60E<B$[EK([50T/Y=%NWS0W,@4L"QZXT
M7RLR$F\MR;3CZIWGG=RUM?L&EZYZNIJ3%[/[(E3,]51=E[XCWVV^,]BMM[9J
MMH4KF)Q)41F6=H8H1,\EP7[7<PS;%>;A*RAH[FX:I/"*$0B1SZ*AE0,?(NH\
M^F9+R2VYP.T1J3`]O`H(&#+.9O#C_P!/((G*KQ(1O3KALWYQ]3[WW768''8K
M/XW#8?83]@;@W-N3([/V]5X3&T^SZO>F15^N\GN2+LG-XO$4N*JZ.LRV+QE=
MBZ?)TT]$93)"S%3$-5L'_$"M?]O&LJ5_T\;JZ^JL#Y].1);0VRO%*K"664*`
M>)BD:*2G^DE5HV]&4CRZ8=B?/GK7LB;#X39NS-U;AW[O&?:U1U[UYAMT=5YK
M-;QV[N[%;DSM!G9<]B-]5>S]CRXO`[3KJO+X[/5M!DL4J1I)`SS1ZO=7)HP0
M_$>`]>A]^.O9F<[CZ9V=V3N3!_W9SFY)-T??[>-)-128<X?>6X<!34%53SU=
M>T60@HL7$M4!-*GW(D*,49;>ZMH?T/00?+_/YW;U'U]68+,Y3#54U;N:GEJ,
M36U-#420&FPY,,DM+)&[PE@"5)(N`;7'OG_]_CF7?>3.6MNW38-SW&)KF4*6
M4D`_*O\`+K-C[FVQ;/S%OM_8;YM>WO#;Q%EJH/1)CV1V(>3V!O2YY-MT9D"_
MYX%8!]??.!O<WW1MR(EW_>$``[?JITI4`_`LBA>-:`#U\^LWX.0.2[Z,72[+
MLY5R>-K`_!B/B9"3P\R?3KW^D?L3_GX&]/\`T*,U_P#5ONO^NG[I?]-#N_\`
MV6W/_6WI[_6UY-_Z,NS?]D=M_P!:^O?Z1^Q/^?@;T_\`0HS7_P!6^_?ZZ?NE
M_P!-#N__`&6W/_6WKW^MKR;_`-&79O\`LCMO^M?7O](_8G_/P-Z?^A1FO_JW
MW[_73]TO^FAW?_LMN?\`K;U[_6UY-_Z,NS?]D=M_UKZ]_I'[$_Y^!O3_`-"C
M-?\`U;[]_KI^Z7_30[O_`-EMS_UMZ]_K:\F_]&79O^R.V_ZU]>_TC]B?\_`W
MI_Z%&:_^K??O]=/W2_Z:'=_^RVY_ZV]>_P!;7DW_`*,NS?\`9';?]:^O?Z1^
MQ/\`GX&]/_0HS7_U;[]_KI^Z7_30[O\`]EMS_P!;>O?ZVO)O_1EV;_LCMO\`
MK7U@GW]ONJ01U6^-VU,:O'(L=1N/+3()(G62*0+)5LH>.10RGZ@CW[_73]TO
M^FAW?_LMN?\`K;U[_6UY-K7]R[-7_GCMO^M?7#^_>^!S_?3=)/\`CG\F;_ZY
M-2;^ZM[H>Z;B@Y@W@G_GMN?^MO3L?MQRD'_3V3:BWHEK:HWY,8B!\\9X=<)]
M\;UJ(I*>?=NY9X)D:*:"7-Y)XI8W5D>.2-J@JZ.KD$$6/MB?W']T]RC:WN.8
M-V,6DUUWMR5I3.H&6A6G&N"*UZ41\@<L6!\:/8K0$9-$LZCSJ*0`U%,4S7AU
MSV7O+<&P=PTFY-N5/V]92,!/#(6-)D*6_P"[0UL2W$M-*H((^JFQ%O=O;#W!
MYG]K.:(>:N6[AEMM0^HS^G<CS6+R:O`4Z+.=.5N7O<'EQN4][@6?Q%I:D"KV
MY(HI<_AIBM?*O5M'5W96&[5VO#N3$)/2RPR"CR^.F!U8[(+$DDE/Y+`3I('U
M1LO`3@\^^YGL][L;=[U\NQ;S9E(%AA7Q4KF%Z9CD_A8'B#UR%]W?;>Y]K=_E
MVG<)*2QSLBNV!*`<.OJ#T(GN8))3-0TH@%`?)@/Q#U!]?ET`B[2*K,*'2.O>
MV^J]2=K_`/,PJ7_PR,U_[OMN>_=>Z&?W[KW7O?NO=>]^Z]U[W[KW7O?NO=!'
MOC_C\MN?^&ON7_W:[;]^Z]TU^_=>Z][]U[KWOW7NO>_=>Z][]U[ISV3_`,?E
MG?\`PTL%_P"[[->_=>Z%WW[KW7O?NO=>]^Z]U[W[KW7O?NO=(J/_`)F'EO\`
MPQMO?^]%NCW[KW2U]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T!>2_X
M_O>__DI_^Z`>_=>ZR>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NE)UE_P'W=_
MX>V4_P#=7@_;L4:RL5;@!7KW0:_*[N_?/QVZDJ.V=D]11]UP;;S^(7?&TE[5
MZ\Z?RM!L6NDGILQNC;FYNU,GA-BY'.X*H-.T>+R%?CDK4=PE3&RIK:633=+"
MW]F6S]G5)-6@Z/CIC[>JC/EG_,^[/[)^+GQV^4?P9W%NWK3XZ;]WENK&=V=]
M9SXTY/N/=O3E7L[<>V<%08K=G4HR]/5P]797*UV3BR^Z\/'EHPE!#!1N&KEF
M2D**;YE?%OZGAT],Q%D&3,_H./0C=B_-GY/83Y5])5]9G\_M+X!;GP'Q4Q$G
MR.Z[^-VT=_\`27<G:_?;UK38^#L#?'8V%[0Z\V1NK*9+!8;#U^$P^Y$Q59DP
M,F]/(C*7Y=-E<B*_`AG:\O%59&"DJD,;(0,UJ2:4.2,'I3;B.[M?J[)EE18(
MI&*YTF5RCDGRX`'HL,W\UCY?;)ZIJ^Z=T5O56\:+Y)?&SM_O#XY[%H^MY-OP
M_'?<6P?E)LWXZX';>\]Q46YZNN[EP%3A>S\;EZZ:I7'3MD<?-!#H@F32U`'A
MVQKU@ID@M[.49RQO%^GET^1"*FIZ<`P/2NQ@BDO/#C*^'%>7J?;]-:+)%3[9
M:*O]*OKC)WY_,B^='QUK*;KJKW;UIVENOX^_.;<_5'?_`&#3=046T:?N+XX;
M9^/>R/DEF*O!;/ILQGZ'K[?N%VANJLI)*FAGD@D?')+I0.X9MKJ/:]UL(+TB
M&Q_<=[J9N`FM[JUM85+'\<OU%%K75D`4/0:CDN'VAFLXVDNW^E6)%R[LL4]T
M(U'$LQMS@<?ET<_X$?.3NOY3_-KYG[)S^4V=6_&':NU\'O7XJ18/`4--GZO9
M5-V[V-TOD=VYO=M*[2;JH]ZYSK&MR-""`E-1SQJI:VHFUCM,L?)4&ZW?;N$6
MXS6DD9%'33''.%?/'3*K`$"@8&I!PU+N#27]G%""8)X&9C0TJP$[BO\`0GEE
MA-*4>-EX@]7(+]'_`."C_H=?9=T9]`C/QEMU#GG>N]P?Z$?WKR9M8@@D$7%[
M@$`_CWK2!`UL/Q5_GTR5^GL([STD_P`O09]9=3[0ZARG;>8V4N:I:ON[M?*=
MT;^7(9B;)4U3OG,8+;.W*RIQ--+&D>)QIQ6T:%4IE#HDB,X-W-F4@"[:FTC_
M`$-F/^],6_R]&>XW1O=T;=#^.*-?]Y0+_DZ+Q3_`?X]X[;?1^`P,/8>ULC\<
M=U]G;NZ?W[MK?=7B^Q]L5/<DVZ*KLK!ONS[&>7([1W14[MJ))<9+":=)8*61
M`LM.C^U<#K;VLEFV8YHS%+ZK`:&1T_X:"J!>!H6Z+8+>&"Z-W+YD$?ETV=<_
MRX_B)U37;,K-E=9BGIMJ]/U'1N:P&=K:7=>U^W]C5&Z#OE*CO?;^Y,9DZ#MC
M>6/WS+/F:3-9$&OI\A65#J^B7QJX)&G:.)POBBX@8J``H@MVU0,OI(_^BC[*
MD]*WFMGF%Q%Q"E?6H.#T..Y_CAT_N_>NP]\YO:L+UG6W6'973>U]M4318W8D
M77';5!@L5O3;5;M&BIX<?4T-3C=N4M/3(AB2DA#)&H4@!`/&=3>J:0S;>MLP
M]3,XNE_ZM-TTJJUY%=-QCD5OV,#_`).@%V-_+D^,FP=E5VQ,=2=G[AQF4[&Z
M<[*R>4W[VGN/>VY\A6?'N6@DZ3V=59[.&>HDZSZUCQD$6-P>GP1Q(`S,WJ]F
M2SD7`W04`6[2?ADA(1$23YG!H?(4'ETB"->1W=LM%'T,ML*8`\28RX'D"#GU
M/1[68NS,W+,26/\`5B;D_P"Q/M!"NF)5]%'^#I3$VN-6]5'^#KC[<ZOU[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7)/UK_P9
M?]['OW7ND-UN?]^=0?\`:TW;_P"]EN'V]'-X2E?XNO4Z9.T.H=N=L1;;.8S&
M\]L9/:5?F:[!;CZ_W%_=C<=)'N;!5^V=TXLY!Z')Q2XK<N`R<M+5*8O,JZ)*
M>6">..54G@?J^-]O\^E5E-]-=QW'^^W#?[SGH)L/\+/C_AMB8KK./;V>R&R\
M1O?:W8$>'S&YJ[)KD,]L[K*#J+#TV8JZA#69+"3[(IA#64SR!JJH9IC(K&PN
M0=%%\ACI-/<LD83\2QP+_P`X(YT_ZS]2MN?$/J[;NXZ;=HW#VYGMRT%%@\5B
MLWN7LK)5^0P>&VMM3?&RML8?!ST5)C&Q5+M[;_8>32FECM6/.T51///4H9G1
M-8F_N6NKW.LS'_G-!!;_`/6"GY=;W*7Q]LM+,U-:#_5^WJ/1_#WK*@6KR5-N
MKMF'L6LW=3;W?NNGW=A*3MV#.TNTWV$KT^<I-HP[:>DJ=CS2XNIBJ,1/]W32
M:IB\Z1S(9+XB;RH;_<:1:K_I3PZH((K5BD6)%-#]H_V>G2I^)_5I>DK\+D^R
MMI;EQU=M[(8C?&VM^UR;TPU3@-ER]>2_8YG/4F?CJH=Q;/J9:;*)7P5PJY9/
MN/3.D4D:6.&WBM;C;5`,;O."/+PYO"\;^<47[.K64(.ZON-QF=5A9?\`FK#X
MO@?REE_;UB3XC=-BOV2U7!NW,;5Z[H%I-H]9;@W.^=ZZQ%8^U\KLZNSD%!DJ
M&HW2<OEL#GJZ.L5LN:"JFK)JF6F>ID:8N1QM%JU?&_AZO^;<:Q1?]450=-6L
M%M<68E@';'+*P_YN2-)+^V=GKU"QOP^ZNP]%0QX_<G;5/G-O5>VZG8N]UWZ@
MWCUI3[2H\UB<%BMBU@P0PM)CJ;`[ER./F;(4&2K,A15C1UM14B*G\-^G`GBC
MZC_?6?VXZ&SK+KK;?4FQ-O\`76T'S#[<VU'D$Q\FX<S5[@S<[Y3+5^;KZG*9
MJN+5F3K*G(Y*61YI29&+<DV%O=:^I^?02?(GJG=?;<NQ]O[/3'RY*@.Z<K,F
M1KEQ\)I(DP-*3'*R2!YO-4)Z;?0D_CWAO][GV3YK]Z.7+'9]A'?;2AO]7Y=9
M0_=K]WN7O:JYGW??_@N5T_/HN@^$W>1`)@VHI(!*G<41()'//V_/O#$_<6][
MI:2+%M;*0,RSA9#0`=ZD5!Q^RAZRGE^]E[.+(P:VO&:M:H.W.<4/#KO_`&27
MO'_CEM3_`-"&+_ZG]Z_X!'WO_P!\[+_V4K_FZ;_X+3V:_P"42_\`V?[/7O\`
M9)>\?^.6U/\`T(8O_J?W[_@$?>__`'SLO_92O^;KW_!:>S7_`"B7_P"S_9Z]
M_LDO>/\`QRVI_P"A#%_]3^_?\`C[W_[YV7_LI7_-U[_@M/9K_E$O_P!G^SU[
M_9)>\?\`CEM3_P!"&+_ZG]^_X!'WO_WSLO\`V4K_`)NO?\%I[-?\HE_^S_9Z
M]_LDO>/_`!RVI_Z$,7_U/[]_P"/O?_OG9?\`LI7_`#=>_P""T]FO^42__9_L
M]>_V27O'_CEM3_T(8O\`ZG]^_P"`1][_`/?.R_\`92O^;KW_``6GLU_RB7_[
M/]GIJS'P][EP5&E?71;8^W>NQV.'BS\3O]QE*R*AI?3]O^CSS#4?PMS[T?N)
M>]X_T#9O^RE?\W6Q][/V9/\`Q%OA^7^SU$'Q)[@_,&VB+?\`.]3_`.IO?O\`
M@%?>].[P-FX_\I"]:?[VOLW&NN.VOM7Y]0LK\6NU\-C*_+5D6W5H\91U%=5F
M/.1O*L%-%+/*8X_M@7(CBO;B]_:3F'[D_O1RWMTFZW$&SFVBB>1P+A22B*7<
M`>9*@T'F>C7;?O/^U&\3Q65K;WPN)Y$C2M::I&"*3GAJ(Z1_4'4.<[9SPAIS
M)0[7H'B?.YJ1"JTT=PZTU";A9\E4KQ&%-E!NUO8$^[][`\Q^_/-B27"&TY1L
MV#-Z!1T,_>/W@Y?]L.6)-M9@.;`A"XSJ]:_/JV';&V<)L_!4&W=O4,>.Q>/B
M6."!``SL;M+4U+VO-65#L3(Y/)X_'OMSR5RML?(7*PY&Y2L56+0%:<#,ND`>
M(3YZN/7);FCG#>N?N9UW#FYBZRDNE<X/#I]/L4,D,4:6\+:C&@5ODPK4?S'1
M#,*3NH^`-1?L\NNO=.F^I.U_^9A4O_AD9K_W?;<]^Z]T,_OW7NO>_=>Z][]U
M[KWOW7NO>_=>Z"/?'_'Y;<_\-?<O_NUVW[]U[IK]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW3GLG_C\L[_`.&E@O\`W?9KW[KW0N^_=>Z][]U[KWOW7NO>_=>Z][]U
M[I%1_P#,P\M_X8VWO_>BW1[]U[I:^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z`O)?\?WO?_P`E/_W0#W[KW63W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]TH^LO\QN[_P`/7*?^ZO!^]&;P.[UQU[IO[GZ#Z6^16W<)L[OCK+:';>S]
MO;LQ.^<9M/?6)CSVVTW9@%JEP>9K,+5,<=EI<7]]*8H:R.HI@SZC$2J%;"'Q
M!X_IG[>O=`3\LO@CTM\O-N]?XC=U3O/KG-=6UA386]>F-TY;K/<^WMJ9.IP_
M]\.OJ>IVM58V"39&\,;A*>GJ*!T,4$E-35$(26FC)UU[INF_EU_&1]]=9;OI
M:#M#%;;ZCCZO.SNB\;W#OQ/CB<KTGCCC.H=S9[I:KRE9M7+[FZZIXZ>3'5.F
M)35T<%34QU%1'Y#N25)0;C>J&\15D6O&D_Z0IZ87K4"7,+^'MQ/T3LT3_/P:
M2MG[6X=)C!_RM_AW@X^XZ%MI;YW#@.Z-E[HZYK=G[M[.W;N':'5^PMY[TJ^R
M=S[2Z&PE76K'T_ALOV+4KG73&/KCR5-3O$T:0)'[]''X<,UO<D".V)1Q_P`+
M50D7_54'I4FXV\+-?6W]D5%P/MN/TS_,=3L)_+0^+V(VWMW;M?3]H[VJ,+N_
MN#?F8WAV-VAN'>^_NQ]V]Z=:UW4&_P#.=G[MS(DK]W5;]=5BXW'*P@AQT=-`
M8T)CY1WMK;[W96O[PHSPP>'*.`#^)'(__5:.+\Z=-6>K;+R*5*!+7<!(WV00
M3VXIZ4-QT(?QP^#OQ[^*&2PV4Z7P>X\)/@?C[UG\9<?#EMSU>;HQU;U+GMT[
MFVE'-3U$,?GW,V9WE7R5V19O)6!T#*"@).&OYS9M8-B)I_%8?\/\-(S_`-4D
MC^?1;;V#0+#XAK)%XU3_`,UI7E_Y_P"'1O%^C_\`!1_T.OM%TNZ`ZNE5<SNU
M5IZE].]][#5%]D8GONK)DE#-50RW!XY4?X7'/OWG_2ZTU/"&K^Q^?P_YNH_F
M?_E5K/\`;8W_`.K_`'[\7]/^?^?K>*?T?Y?EU[S-_P`JM;_ML;_]7^_>?SZT
M:4[J:?GP_GUUYF_Y5:S_`&(QO_$U_O8KJQ753RXT_P`-.M+HIVZ:?*G7?F;_
M`)5:S_;8W_ZO]Z']F*?V55I_#72=%/*NC5I_HUIBO5NNO,W_`"JUO^VQW_U?
M[]G1C^RI^5/\%/Y=:33J;PZ:JYIQK3SIYT]?+KEYG_Y5:S_;8W_ZO]^Z\*4&
MFFGY<.O>9_\`E5K/]MC/_J_W[K?7O,__`"JUG^VQG_U?[]U[KWF?_E5K/]MC
M/_J_W[KW7O,__*K6?[;&?_5_OW7NO>9_^56L_P!MC/\`ZO\`?NO=>\S_`/*K
M6?[;&?\`U?[]U[KWF?\`Y5:S_;8S_P"K_?NO=>\S_P#*K6?[;&?_`%?[]U[K
MWF?_`)5:S_;8S_ZO]^Z]U[S/_P`JM9_ML9_]7^_=>Z]YG_Y5:S_;8S_ZO]^Z
M]UR29]:_Y+6?J7\8W^H_Z;_?NO=(GKR4KM&A"05$@_BN[R&C%`%]6]-Q-;]R
ML1KI?2>+7'%Q8G1IY]>Z6GF?_E5K/]MC?_J_WO/7NN/F;_E5K/\`;8WZ_P#G
M?[WGK3:?Q4KGC_/C_/\`GUWYF_Y5:W_;8W_>?\O][[J>=/\`9-/YUI\Z^?7C
M3MU?[7_H7_8Z]YF_Y5:S_;8W_8_\I_OQU:EK753'K3RIYT^S'6S\1K\=<^M?
MGYUZ]YF_Y5:S_;8W_P"K_;8TZC2FJAKZTQJK\N%:_*OEU8:JXK7'V^>G_+I_
M.GGU[S-_RJUG^VQO_P!7^[G54UK7%?V"G_&:4^5*8Z;BT^'^A_99^'X>)U<,
M?%6OSK7/77F-O^`M9;_6QO\`]7^_9ZN*Z3I^'SIP_/R_;U[S'_E5K/\`;8W_
M`.K_`'[/5>WY?RZYX>ID3?N`=*"MF8;;WBHBB_A@E.JMVD2ZF7)Q1:4TV/J#
M786!YL[']17]'77^C7_)TU+]/X8\?1X/EJII_*N.AA&0G_YT>8^I_MX#^I_Z
MOWM-/X7C-]5I^HKW:Z:OSU9X>OETXFC0/#IX?E3A^5,=>_B$_P#SH\Q_R7@/
M_K][9_Q/_A7_`!GJV>O?Q"?_`)T>8_Y+P'_U^]^_Q/\`X5_QGKV>O?Q"?_G1
MYC_DO`?_`%^]^_Q/_A7_`!GKV>O?Q"?_`)T>8_Y+P'_U^]^_Q/\`X5_QGKV>
MO?Q"?_G1YC_DO`?_`%^]^_Q/_A7_`!GKV>O?Q"?_`)T>8_Y+P'_U^]^_Q/\`
MX5_QGKV>@_[*K9I-O4:G$Y2`?WJV>?)*V(*`KN"B.G339>:0LXX'`']2!S[]
M_B?_``K_`(SU[S^?2;\Q_P"56L_/T7'6_P!L<@3;VU-]'H_T+B/X?7IN:OAX
M]1TS[I;'S[7W#!EER-%C9L+DDR%=!%0324M`U)4+6S1PPULLTKI3DD!58D_0
M$\>P][@1[--R].F[2)%MQMI1(P%2L9C8.0$#,2$U$``L3P!-.A5RS)N4=_:M
MM\;278N(C&*@:I!(IC6K$`5:@J2!ZD#I-]8R;$CV/@X^MH5GVE'%XZ&>D2A6
M2HF0::BHR"S5D-6F1F<%G69%=;V`M;V%_:BW]LK3VTVRT]G[A+K:55=<Z*R2
MLM,F9&5)Q7S\5!\^CCW6F]Q;[W"N;GW$ADLM[UFD,K"1*YP&5I(N/HU.EZ9F
MOS2UE_\`6QO^'_3?_OC[F#]</2WU%*=NBNG3_1TXT_9CH!RF<NIO0HNJ<,4'
M^DIC3Z:<>G7A,_XI:S_;8W_B:_VD&BITTU5S3U^?S^W/6C7SX]=^9_\`E5K/
M]MC/_J_W;K77>W:J:/L*C9<?D:@_W*S:F.$XU'`.<V\=9\N3CA*`BQ]0-R+"
MU[>Z]T,7\0J/^='F?^2\#_\`7[W[KW7OXA4?\Z/,_P#)>!_^OWOW7NO?Q"H_
MYT>9_P"2\#_]?O?NO=>_B%1_SH\S_P`EX'_Z_>_=>Z]_$*C_`)T>9_Y+P/\`
M]?O?NO=!1O.KFEWEMTMC<G3:=L;C`68XQS)?*[=)9!!E98E5;6.IKW(X(O;W
M7NH?F?\`Y5:S_;8S_P"K_?NO=>\S_P#*K6?[;&?_`%?[]U[KWF?_`)5:S_;8
MS_ZO]^Z]U[S/_P`JM9_ML9_]7^_=>Z]YG_Y5:S_;8S_ZO]^Z]U-V=5RQ[RSA
M7&Y*>^T\&"(CB05MG<R=1\N5A72?IP2;_BW/OW7NA6_B%1_SH\S_`,EX'_Z_
M>_=>Z]_$*C_G1YG_`)+P/_U^]^Z]U[^(5'_.CS/_`"7@?_K][]U[KW\0J/\`
MG1YG_DO`_P#U^]^Z]U[^(5'_`#H\S_R7@?\`Z_>_=>Z1D==/_I!RK?P;+7.R
M-OKX]6$\@`W#N8AS_N:\>AB;"S%K@W`%B?=>Z6?\0J/^='F?^2\#_P#7[W[K
MW7OXA4?\Z/,_\EX'_P"OWOW7NO?Q"H_YT>9_Y+P/_P!?O?NO=>_B%1_SH\S_
M`,EX'_Z_>_=>Z]_$*C_G1YG_`)+P/_U^]^Z]U[^(5'_.CS/_`"7@?_K][]U[
MKW\0J/\`G1YG_DO`_P#U^]^Z]T"];4,^^-[.U#6Q,S;8!AE_AAECT[;0*6*9
M*2$ZSRNEV_QL>/?NO=9?,_\`RJUG^VQG_P!7^_=>Z]YG_P"56L_VV,_^K_?N
MO=>\S_\`*K6?[;&?_5_OW7NO>9_^56L_VV,_^K_?NO=>\S_\JM9_ML9_]7^_
M=>Z]YG_Y5:S_`&V,_P#J_P!^Z]T]=:UDT5/NQ4Q>2J0=Z91C)!_"452<9A!X
MV6IS,3ZQ:YM=>>#_`$TVFG=2GSZ]T)/\0J/^='F?^2\!_P#7[W8:M/;71_+K
MW7OXA4?\Z/,_\EX'_P"OWO77NO?Q"H_YT>9_Y+P/_P!?O=9=&K]>FK2OQ<:5
M[./E6NGRK6F>KQ^)I_2U:-3<*TU4&OAYTIJ\Z4KCKW\0J+_\6/,W_P`7P'_$
MY[W9O]$U\:=]?2OXZ^6K^+\7SZ87P?"[='@:%X4TZ*]ORTZOA\J\,]=_Q"I_
MYT>9_P"2\!_]?O=>VC<--3J]*U%=7SU4K7.JGG3IQJ]VOU.JOK4:M5?.M*U\
MZ5S3KK^(5'_.CS/_`"7@?_K][L:U->.K/^FH./SI3YTIY4ZL=>:U^?[,5_+K
9DN0J+/\`[@\S^D?V\#SZT^G^YWW[JO7_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tpg17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg17.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!$P*>`P$1``(1`0,1`?_$`:(````&`@,!````````
M``````<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+
M$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,7
M4G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R
M9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8
MF9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1
M``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B
M%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756
M-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>W
MQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:
M``P#`0`"$0,1`#\`L,_DP?R4OY7WRI_E?_#_`.0GR#^)NV.T.Y^T^O,ON/L'
M?^>WUVW%F=TYP;\W=CCD\DF+[`Q]!]T]'0Q(QCA0-HN1<DGW7NK/O^@='^2U
M_P!X(;!_]#[NO_[9OOW7NO?]`Z/\EK_O!#8/_H?=U_\`VS??NO=>_P"@='^2
MU_W@AL'_`-#[NO\`^V;[]U[KA)_PG5_DKQ(\DOP4Z^CCC5GDDD[`[J1$11=F
M=V[."JJ@7)/`]^Z]UYO^$ZW\E97CC;X*=?+)+J\2-V!W2'DT#4_C4]G:GT+R
M;?0>_=>ZY_\`0.C_`"6O^\$-@_\`H?=U_P#VS??NO=>_Z!T?Y+7_`'@AL'_T
M/NZ__MF^_=>Z]_T#H_R6O^\$-@_^A]W7_P#;-]^Z]U[_`*!T?Y+7_>"&P?\`
MT/NZ_P#[9OOW7NO?]`Z/\EK_`+P0V#_Z'W=?_P!LWW[KW7O^@='^2U_W@AL'
M_P!#[NO_`.V;[]U[KW_0.C_):_[P0V#_`.A]W7_]LWW[KW7O^@='^2U_W@AL
M'_T/NZ__`+9OOW7NO?\`0.C_`"6O^\$-@_\`H?=U_P#VS??NO=>_Z!T?Y+7_
M`'@AL'_T/NZ__MF^_=>Z]_T#H_R6O^\$-@_^A]W7_P#;-]^Z]U[_`*!T?Y+7
M_>"&P?\`T/NZ_P#[9OOW7NO?]`Z/\EK_`+P0V#_Z'W=?_P!LWW[KW7O^@='^
M2U_W@AL'_P!#[NO_`.V;[]U[KW_0.C_):_[P0V#_`.A]W7_]LWW[KW7O^@='
M^2U_W@AL'_T/NZ__`+9OOW7NO?\`0.C_`"6O^\$-@_\`H?=U_P#VS??NO=>_
MZ!T?Y+7_`'@AL'_T/NZ__MF^_=>Z]_T#H_R6O^\$-@_^A]W7_P#;-]^Z]U[_
M`*!T?Y+7_>"&P?\`T/NZ_P#[9OOW7NO?]`Z/\EK_`+P0V#_Z'W=?_P!LWW[K
MW7O^@='^2U_W@AL'_P!#[NO_`.V;[]U[KW_0.C_):_[P0V#_`.A]W7_]LWW[
MKW7O^@='^2U_W@AL'_T/NZ__`+9OOW7NO?\`0.C_`"6O^\$-@_\`H?=U_P#V
MS??NO=>_Z!T?Y+7_`'@AL'_T/NZ__MF^_=>Z]_T#H_R6O^\$-@_^A]W7_P#;
M-]^Z]U[_`*!T?Y+7_>"&P?\`T/NZ_P#[9OOW7NO?]`Z/\EK_`+P0V#_Z'W=?
M_P!LWW[KW7O^@='^2U_W@AL'_P!#[NO_`.V;[]U[KW_0.C_):_[P0V#_`.A]
MW7_]LWW[KW7O^@='^2U_W@AL'_T/NZ__`+9OOW7NO?\`0.C_`"6O^\$-@_\`
MH?=U_P#VS??NO=>_Z!T?Y+7_`'@AL'_T/NZ__MF^_=>Z)%_,N_D3?RFNC/Y>
M'SB[GZH^&NS=F]G=5?%'OKL'KW=V/WSV_/7[7WGM+K3<><VUN"AAR'8E902U
M>'R]%#41K/#+$SQ@.C+=3[KW6Q1\=:B>K^/O155532U%34].=8U%143R/+//
M/-LG"22S32N6>2661BS,222;GW[KW58O\^W;V(WE_+VJ-C;DI9,CM/?ORP^!
M^Q=XX9:VOQ\6?VAN[YE=(X'<N`K*G%U5%7+0YG#UTU/,(Y4<HYLP-B/=>Z;O
M^@=+^2U_W@AL'_T/NZ__`+9OOW7NO?\`0.C_`"6O^\$-@_\`H?=U_P#VS??N
MO=>_Z!T?Y+7_`'@AL'_T/NZ__MF^_=>Z]_T#H_R6O^\$-@_^A]W7_P#;-]^Z
M]UP_Z!UOY*WD\/\`LBG7WET>3Q?Z0.ZO)XRQ42:/])VK06%KVM?W[KW7D_X3
MJ_R5Y`6C^"G7TBAWC)3L#NI@'C=HY$)7LX@/'(I5A]000>??NO=<_P#H'1_D
MM?\`>"&P?_0^[K_^V;[]U[KW_0.C_):_[P0V#_Z'W=?_`-LWW[KW7O\`H'1_
MDM?]X(;!_P#0^[K_`/MF^_=>Z]_T#H_R6O\`O!#8/_H?=U__`&S??NO=>_Z!
MT?Y+7_>"&P?_`$/NZ_\`[9OOW7NO?]`Z/\EK_O!#8/\`Z'W=?_VS??NO=>_Z
M!T?Y+7_>"&P?_0^[K_\`MF^_=>Z]_P!`Z/\`):_[P0V#_P"A]W7_`/;-]^Z]
MU[_H'1_DM?\`>"&P?_0^[K_^V;[]U[KW_0.C_):_[P0V#_Z'W=?_`-LWW[KW
M7O\`H'1_DM?]X(;!_P#0^[K_`/MF^_=>Z]_T#H_R6O\`O!#8/_H?=U__`&S?
M?NO=>_Z!T?Y+7_>"&P?_`$/NZ_\`[9OOW7NO?]`Z/\EK_O!#8/\`Z'W=?_VS
M??NO=>_Z!T?Y+7_>"&P?_0^[K_\`MF^_=>Z]_P!`Z/\`):_[P0V#_P"A]W7_
M`/;-]^Z]U[_H'1_DM?\`>"&P?_0^[K_^V;[]U[KW_0.C_):_[P0V#_Z'W=?_
M`-LWW[KW7O\`H'1_DM?]X(;!_P#0^[K_`/MF^_=>Z]_T#H_R6O\`O!#8/_H?
M=U__`&S??NO=>_Z!T?Y+7_>"&P?_`$/NZ_\`[9OOW7NO?]`Z/\EK_O!#8/\`
MZ'W=?_VS??NO=>_Z!T?Y+7_>"&P?_0^[K_\`MF^_=>Z]_P!`Z/\`):_[P0V#
M_P"A]W7_`/;-]^Z]U[_H'1_DM?\`>"&P?_0^[K_^V;[]U[KW_0.C_):_[P0V
M#_Z'W=?_`-LWW[KW7O\`H'1_DM?]X(;!_P#0^[K_`/MF^_=>Z]_T#H_R6O\`
MO!#8/_H?=U__`&S??NO=>_Z!T?Y+7_>"&P?_`$/NZ_\`[9OOW7NO?]`Z/\EK
M_O!#8/\`Z'W=?_VS??NO=>_Z!T?Y+7_>"&P?_0^[K_\`MF^_=>Z]_P!`Z/\`
M):_[P0V#_P"A]W7_`/;-]^Z]U[_H'1_DM?\`>"&P?_0^[K_^V;[]U[KW_0.C
M_):_[P0V#_Z'W=?_`-LWW[KW5=_RN_D@_P`J_K?YH?RM>K-C_$/:>W=@?(CO
M'Y)[,[IVU1;Y[=>CW_M;8WPN[T[:VIA,O+4]A3U<5'ANQ]D8G+1_;20.U30Q
MAF:/4C>Z]U8[_P`)W_\`MRU\`/\`Q$68_P#?E;Y]^Z]U=#[]U[KWOW7NO>_=
M>ZJJ_G%'XPR_#^3&_+G&[DJ.I<MV5M.AIL['M+M??G3^RNQ6H-PR]:;Q^4NS
MNGMR;6W%N;XU8?>,5*=Q4%95)BJR5Z6&=HW>&:/W7NM1;:E)V?7[;^(,&]-E
M?(;$?+6A^.7\IS;/\K.M[!I^V,UO";*[)^=78&.^8F]-L9B'"8O$;8QV]^E:
M*BSF;HMQ0T==1=;5^,HZX/!`CM[KW6^M\A,7W_FNI-TXWXO[PZOV'W?4-A#L
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M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5P?SA_\`MU#_`#(__%(/
MDY_[Y_=OOW7NC;?&W_LG;H3_`,0MU;_[PV"]^Z]U7+_/&_[(AVS_`.+M_P`N
MW_X.'H;W[KW5P?OW7NO>_=>Z][]U[KWOW7NM.[^8E%MZ7^9_7Y_X3;;[RD_F
M`+L_Y8[(['V[2X/N_$]AY!-Q_`/?%!T/W5MC?V?J\YT[DOAGLC=E'C*2#;6+
M3$35G9%7!6PRFMIG@J?=>Z,3_P`)T,?MZDW'\H)>A\1O3"_%YN@?Y>%%7T^Y
M,5OG#X>?YO8[I/=T/S*GH:7?4%-5S=BIFFP$>^:B!2L^?4&9WJ!*WOW7NK,N
MW_D?\M.E_P"9W\1NCLKE.C-S?$?YE1]U;3VMMZCV9O+$]Z=;[OZ3Z%J>VLGN
M3+[[DWC6[-W1A=P9G"3T<-#'A:.2GI:M6:9Y(?W/=>ZM6]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5,_.7_MXC
M_),_\68^7_\`\+J^3OOW7ND)_P`)W_\`MRU\`/\`Q$68_P#?E;Y]^Z]U=#[]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZIZ_D$?]NB?AI_X;'9?_O\>S_?NO=7
M"^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[JN#^</_`-NH?YD?_BD'R<_]\_NWW[KW1MOC;_V3MT)_XA;JW_WAL%[]U[JN
M7^>-_P!D0[9_\7;_`)=O_P`'#T-[]U[JX/W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U3S\X_^WI'\D;_`,21\]/_`(#+=?OW7NKAO?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW53/SE_[>(_R3/_
M`!9CY?\`_P`+J^3OOW7ND)_PG?\`^W+7P`_\1%F/_?E;Y]^Z]T'GS)^<?\RG
MKOY==D])_&O9/\N;;G4&P]A]5;BQ787S9[\W5U)G=^Y_?E'N.HW!B]F8[:V2
MR$F3I=FS8.-*QYZ&D$7WM/IDF\A\?NO=!]U5\V?YT>=[3Z:I-P=,_P`K_NWI
MW</>G4_7?>-?\,^^^T^W^RNI.N-_Y^7'Y[M/)X?)'&83&;=VMBJ&IJ):BJDD
M]48"PR@/I]U[K8E]^Z]U[W[KW7O?NO=>]^Z]U2[_`,)]-T;9SG\IKXIX;";C
MP.8R^T\/V)BMU8K%9C'Y'([9RE3W+V3D*?&[@H:.HFJ<+D)J&=)E@J5BE:)P
MP720??NO=71>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[JN#^</_VZA_F1_P#BD'R<_P#?/[M]^Z]T;;XV_P#9.W0G_B%N
MK?\`WAL%[]U[JN7^>-_V1#MG_P`7;_EV_P#P</0WOW7NK=<G43TF-R%52QI-
M4TU#5U%/#(=,<L\,$DD4;L60*CR*`3<6!^H]^Z]UJK==?S-?YTW8&R-M;TR-
M7_(.ZGK=R8V/)S];]L?+CM/#]D;.:9Y`N%WGB]N[BW+A:#.TZ*#-%3UU2B:@
M"P:ZCW7NK4?Y=_R!_F4=M]B]H;?^;G5?Q&H>KJ/K;KO?/2'>_P`,=X;^W_U+
MV1D=S;@WKA]V;73=N^<D[9#,;4I]MTD\R4E''#&E=&?/*6*Q^Z]U;-[]U[KW
MOW7NO>_=>ZI7_F'[PVEL+^95_)3W5OK=.W-E[7QO97SJ3([DW;G,7MO`4#UW
MP\W-0T25N9S-518ZEDK:VHCAA5Y%,LKJBW8@>_=>ZN*VQNK;&]L%C]T[,W'@
M=W;9R\<LV*W%MC,8_/X+)Q0U$U)-+C\OBJBKQ];'%54\D3-'(P61&4\@@>Z]
MT_>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[JIGYR_]O$?Y)G_`(LQ\O\`_P"%U?)WW[KW2$_X3O\`_;EKX`?^(BS'_ORM
M\^_=>Z!'^=QT/\5=M;?Z\^0F:_EU?%3Y:?)'N[NCJSXTT'8GR9KZ'8O6G7]!
MG<1NJIP&ZNX>RYJ6KEPNT**?`1X2@6T1J,OEZ*F20R2QQ2^Z]TKOY,O0^;Z9
MS?R!J,O\-?Y;GQ37<&*ZWA@K?@/VQ6]EY'>QQM7O1Y*7LZ*KQE`,/18'[P/B
MF4MYY*NJ!`T7/NO=7P^_=>Z][]U[KWOW7NO>_=>ZIJ_X3^XG%8_^4E\1:V@Q
MF.H:W,8#L>LR]71T5-3565JXNZ^S*>.JR4\$22UU2E/&J"24NX0`7L/?NO=7
M*^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[JN#^</_`-NH?YD?_BD'R<_]\_NWW[KW1MOC;_V3MT)_XA;JW_WAL%[]U[JN
M7^>-_P!D0[9_\7;_`)=O_P`'#T-[]U[JWZ>&*IAFIZB-)H*B*2&:*10T<L4J
M%)(W4\,CHQ!'Y!]^Z]UIL?,SXL_'G8WS0WW\5?BG_*,_DX8C%=9=1]5]G93?
MOS>W+0=+S=HIVG7;UHQ/TQM_!X)Y=Q;9V-6;+EQ^9K-<HILE(L3B+7#Y?=>Z
MV<?@5M:KV5\0>BMK5W7?Q_ZGJ\/M&>GGZ[^+&;EW'\?MK.^=S%1]CUAFYJ:D
MER."E683.YC'^5RS"YMJ/NO=&[]^Z]U[W[KW7O?NO=:YG\]'%XS,=V?`6@S&
M-Q^6H6ZL_FT5#464HJ7(T;5%%_+D[2JZ.=J6LBF@::DJHDEB8KJCD4,I!`/O
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M`_\`$19C_P!^5OGW[KW12/Y^/:'Q^[QVWU1\/<=NKXR]I_(;JGY-=*]W;Q^'
M/R6^2^$^+6RNWNLSLO?\,F)SN>WI7;9H>PL=5+N2DGHZ#$UT\U-ETI:J:.9*
M2:CF]U[HPG\FGXU[@Z*J^\-P9/\`E<_&3^7AB=^8;KDX/<WQU^26-^0</=$&
M*JMY2R4^;EQF,H:?!T6SUR224<JO(M6V2E`MXN?=>ZO4]^Z]T6GY5_(VH^,?
M6V+WMBNC^[OD5NC<^^]J=;;-ZJZ#VI0[DWEG=T;PJ*B&@J<ID,_F-M[,V+LW
M%PT<L^3S^>R>.Q&/B0"6?R211R>Z]U6OL7^>KT)VYN_XI;$Z5^.WRC[:W7\I
M^M?]*L>%VQ@.J<?6]-;2HN[MT?'W<=7VG!NSMG;SRG;/8FQ<XD_]W1GA44&+
MEJZ3[B`HS>Z]T]UG\XVJRV].[MN]0_RY/GUWQM'H?O'L[X^;K[=ZZP7QPHNM
MLCV'U%N:;:.\Z;"9'?\`\B]EYF3'TN;A\<,M314QF#K906TCW7NJWOY-7\Q#
MN+JS^6C\6MA8#^5I_,,[EQ&W]O;ZCH>S.KMO?'&KV%NJ.O[:W_E&JMNU.ZOD
M5M7/RT]'+7-2RFHQ].?N()-`:/3(WNO=6<_\.H=\_P#>F;^:7_Z"OQ0_^ZJ]
M^Z]U[_AU#OG_`+TS?S2__05^*'_W57OW7NNC_-1[Y`)/\F;^:98`DVVI\46/
M'/"K\JB2?\!S[]U[H_?Q`^4&P_FE\:.G?E+UCBMU8+8G=.THMV[>PN]Z#'XS
M=F*IS75N,J<?GJ+$Y3-XR"OI*_'3(W@JYXF"AE<@^_=>Z,C[]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[JJ3^;G_`#2<%_*@Z(Z][NSW3.:[LA[![8HN
MJZ;;V'WE1;'_`(945>T=U[M.7JLQ6[=W.LJ+!M5X5@6F#.TNK6H0ALF/NN?=
MOO?O-<Z7W)]CNT.T/8[8UX97@:XUA9X8-`198:9F#%B^*4H:U!-O6[KLUNMP
MT9DU/IH#3R)K6A].J</B;_PK!V'\I?DWT)\;J?X3;PV74]Z]L;'ZJI=VR=Y8
M3<,.VZO>^?HMOTN9J<(O66$?)4N/J*Y9)8EJH7:-6TDM93E?[G?W96]^VWMW
MO?/\G-]K=Q[-MEQ>-!^[I(C*MO$TIC$GUDFAF"D*2C`$BHIGHCLN<H[R[CM1
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MMM8;=M9NF'`Y3/8>N!BJZ2"H>>F<6D5??NO=,N\OE'48+Y'_`!8Z4VGLK;&_
M-B_)7:?:N[6[AH>\NJL*=JT'7^U<;N?;\VV>KLKEUW]W/C-[QY$(:[;,-72X
M>$+4UC+!(K'W7NE[LGY5?&#LKLG<73777R-Z)W[V]M`UJ[KZLV9VWL'<_8FV
MFQLGAR2YW9>$S];N/%-C9O14">F0P/Z7TGCW[KW0$?R\OG/B/Y@'3W8?;F&Z
MYRG6--U_\B.Z/C]-@\KN*CW-/DZWIS<:;>J=SPUU%B\3'34N==_(E*T;O3V*
MF23AC[KW1\O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5P?SA_^W4/\
MR/\`\4@^3G_OG]V^_=>Z-M\;?^R=NA/_`!"W5O\`[PV"]^Z]U7+_`#QO^R(=
ML_\`B[?\NW_X.'H;W[KW5O-=6TV-HJS(UCM%24%+45M5(L4T[1TU+"\\[K!3
MQRSS,D49(5%9V^@!-A[]U[K24^4?^@_Y^_S%.RN_?C'\?OY;7\U79O8_2G26
MQ<)M+Y'?-G;_`%?VUU+N[K>HWTFY*#9W1NXZ2DWSL?"[B@W)2'(TM=AGEJLC
M1_<1SQ%YX/?NO=;9/P>Z^S'57Q0Z4Z]S_0/7?Q;S.U]K3T&0Z`ZFW2N]>N^L
MIY,YEJO^![7W4M%CUS5%.E2*MY?"G[]2Z^K3J/NO=&L]^Z]U65V)_-`Z[ZI^
M5^%^-._NA/DGM;:.XM^2=/X+Y29W8^!PW0&>[DAZ<S??$^Q-MU>4W91]A;FQ
M]'UWMRM:IW'08&HVY2Y.GDHY:Q7CD=?=>Z5'\NS^8=MO^8YUIF.X=A?'_OSI
MOK>.+:U9LC=7=5%UG1T':.+W30Y')1Y'9B=>=E=@U4"XBAI::6MI\M'C*N%,
ME2D1,';1[KW5;/\`.ZRF,J/D-\#\5!D:"?*8_J'^;5/7XR&LIY,A1057\MOM
M=J::KHDD:IIX:@#T,ZA6_!]^Z]UL)[3_`./5VS_X;^&_]UU-[]U[I0>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NJS?YKO\R/"?RM/C'B?DCG>ILOW-39CM?:O5<&T</NR
MBV7-#5[GP6[L^N9J<W78/<2+2T=/M&2/Q)2N\DDZ<JH9AD-]V;V`O/O(^XDO
MM_9;G%M,D6V37AG>%K@%8I8(O#$:R1=S&<&I<`!3Q-!T4[SNJ[/:"Z9#("X6
M@-.()K6A]/3JA[H+_A7/L'O3O7I?I*+X,[SVW-W#VOUYU;3[A'>^%S7\#J.P
M-W8C:=/EVQ`ZLQ;9-,=-EEF:`5,!E5"H=2;^\T^=_P"ZYWSDSDS=^<&YRM+A
M-JVRZO#%^[GC\06T#S%-?UCZ-00KJT-2M:'AT';;G6*XN([?Z=AK=5KK!IJ(
M%::?GUMH]M=J[`Z+ZO["[G[5W)0[/ZUZLV;N+?V^]T9'RFCP6U=JXNIS.:R,
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M%[7ZMW)NK=6Q=N]E;`S^]]BPT]3O?9V%WCMW*[JV=3U<:2TD^ZMO4.1GR^WH
M:J*16C:KAA5U8$$@^_=>Z2]#\C_CQDZY,9C>^>F,ADI-I5^_H\=0]H['JZY]
MB8HU2Y/>J4D&<DJ&VEC6H9Q/D@OV<)A?7(-#6]U[I487M?JW<>PCVIM[LK8&
M>ZO%!6Y4]D87>.W<IL(8O&/-'DLD=X4.1GV\*#'R4\BSS?<>.(HP8@J;>Z]T
MVXGO'I7/[`/:^"[@ZNS75JSI3-V5B>P-IY+8`J)*ZGQD=.=Y4>6FVZ)WR55%
M3A/N=1GD2,#4P!]U[IHR7R1^.^&VCDNP,OWWTOBMAX;=%7L?+[VR7:6QZ':.
M*WK0,%KMGY+<E5G8L-0[HHF-I<?+,M7&?U1CW[KW2"[+^2LVR^S_`(M;'VCU
MW4=I[3^2V:W;02]H[9[$ZSQFV^O,1M[:]%N7%;DFQ6?W+0;B[$QVZDK/%3+M
MJGR4D`0S3!(FC9O=>Z%+%]Z=)9SL3)]0X7N+JS,=LX1)Y<SU?B^PMI9#L3$1
MTT?EJ9,GLJDR\VY:!*>+U.9:9`B\FP]^Z]T6CX._.G:?SB_V:[^ZFPMS;$_V
M5'YA]R_#S</]Y<AB,A_>[<O338),IO/!?PF23[/;^:.=7[>"ITU2>-M8Y'OW
M7NCU>_=>Z][]U[KWOW7NJF?G+_V\1_DF?^+,?+__`.%U?)WW[KW2$_X3O_\`
M;EKX`?\`B(LQ_P"_*WS[]U[I@_GV]J5747Q&ZYRC/\4]K[2W_P#)#K/J'M+N
M3Y=]18'OCK;I3KG>V-W;)5[X@ZASD-0-^Y.7=&(Q>->ECAJ!245?45LT:T]+
M-4T_NO=%0_X3]=<=`;1W]\L,[TG\SOA+\G)<U@NJ8\_LWX2=*Y7X_P"S.N&_
MBF_IXLUGNO*+>N<V!%4;NE#1TTV,QF/E48^59&D5E5/=>ZV;_?NO=$#_`)E7
MQ\^4WRF^+>X^B?B;WKM3X[[QW_F\1BM^=@[FQ6[<C55/4OBKY-Y[,VS7;(S>
MW=R;8S.]2M-CY\I1U<%92XF:L%++!5R05,'NO=5,=D?R0^\.WC\;<=N7,_R^
M=@T/7.UOC9LW<N]>F?BKNW:7<?0&W_BMWWG.V]G8OX1]EY;L//;HV5C^QML5
M5'A,[%N6LR;4-3]_6TSS"ODI5]U[HQ?\MOI'I_Y(]"?S+>H.^>MMG]M]6;N_
MG`_S!I=R]?[]PE'N/:N;?!_(J'<>%;)8C(1RTM4V+SV*IJN`LI,=1`CBS*#[
M]U[H3OY`,,--_*!^%E+3QI#34FT.PZ2E@C&F."EI>Z^RZ>F@B7^S%!!&J*/P
MH`]^Z]U<5[]U[KWOW7NH>1_XM]=_U!U/_6E_?NO=5&?R"O\`MSU\#_\`Q$5=
M_P"][O#W[KW5O_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM/O^?I_(
M[K.TNG-H[P_E_=!=H=E]\[H^1=7NSM6CK/D-V!NB@CVGN':^_,CFLMC]J]W=
MNU.Q\)&V\JRB1/X33P5%/'+XHU6F+J.JGW(_OCQ<M<UW6U>^.][=M_)5ML"P
MV;+M=M"QGBFMEC1IMOL1<2'P%D)\9V5BNIB9`IZ!',G+YF@5]MC=[DRU;O8X
M(-31VH,TX?X.M?GX4?\`"?C^933?+WXT5/R'^&V_]O\`1%/W9UU4=PYR#M+8
MNWY\3UO3[FQ\V\*^GS>Q.SZ;>F+J*?!QS-'-BI(\@C@>!A+I/O./W?\`OR_=
M]D]K.88^0^;+&?G1MGNA8QFSN)0]T87$"F.YM#`X,A4%9@8B*ZQIKT&K#EK=
M1>Q&Z@86WB+J.H"BUSD-7AZ9].MQ?Y__`,FC86Z?Y6'S7^'WPDP^ZMO;^[SP
M^R-Y83%[_P"[^U^Q:;=&]NH=Z;;W]M_:T>;[BWWO"/:\.ZH]M/C0T4U'1?<5
M44U4VB+6G!/W)]W.>?=J[M;[GB>TGN;.-TB,%C8V0"N0S!A96]N)#4"AD#%<
MA2`364+.PMK!66V#`,:FK,W#_3$T_+I&]'?S4/G+WGNWXB?&_IK^5I\G>HNP
M:+=FQ\'\Y=_?+GJW.=9_'_ICJS;>'>@[&JNGNR,=G8Z;LW>67JZ;S[6$4)@J
M842.:E_RAI:2-.EG5%O>WQ`[8D^._P`[O@ONS^7)\@.VOYI?R%_F!;G[@Z#^
M=.*Z6DRO7U?M#<7<.U-V["[S7YGQ7I>H\!L;K[&U^/J<&]?228MZH0FG0U-5
MX?=>Z&[Y;?RYNT^R]T?\*3M[;Z^)>ZNZ^V]U]#_`';GQ=[4K.CLMN7,]G;UV
MGT%M''=MYGX[9*?;U55Y7+'?.UJ>3*M@6>IAF@BAG(*:![KW1B]E?!?>72WS
MHQU;TQ\3MT]:]69[_A-3G^H]XY+874.3VYM#<OR8J-U1G^X>[\CA\+38W<'>
MU?04D3S4U<\V>JE17DUVO[]U[HL?Q8_E8PT.<_X3+0;X^`,M/C=J[*^8^8^;
MK[H^/$BQ8;=U7L!=Q=:2?)^?*[9#I6R[^19<%#N<D+5*L5,H4"/W[KW07Y_X
M)_,/$?RRNN=MX7X_=SX3K?X]?SP>\.\^PN@<5\=SV=N:?XQKG<O#L/L#9/Q9
MWM'B,+WKUWM&NR(KJ;;0BEQ^4AG:9$>*&21/=>ZR]A?`SM_L'^5A\Z1UKT9\
MP=R8?Y3?/[XH;SQ/3^[_`(A[5^,U5F\3LO>>$PW:O=/57Q9ZER.<W#UELO>V
M!>GER<N4Q^*FD.*%88PK2,ONO=60?,?XG=/?#;^97TYW/O+^7#N'Y%_RUL=\
M!.Q/C[U9TM\8OBSC^\MK="_)7<G<-5OO>.>J^A-K8F>EV_6]Q[+K#C?[T"B5
MJBKG,,\ZJCRK[KW6+:_1/<E'\K?Y#79'4W\N_LWXS]>=*_&3^9NE9\>LGN#<
M?8.#Z`KM_=75+=0]>]I]S5='+3;)R_:F2D3[>ERDT-3C):]J'2)*5XT]U[JL
MOX#=%?)+(?/[^4CW/D?A/W)\>Z+ISM[Y2;;^16Q]A?R[7^,W0GQJK^SNO=Z8
M;:VT:#MYDW-W)\@\3G\B//D-T;DS>0V_C?NZ>.!Z:6KGB/NO=;'?\@KJ/M3I
MGXE]^[;[=ZWWQUAN',_/SYA;TQ&#W]M?,[2RV4VANCL*&NVWNC'X_.4=%55>
M`SU&#+1U:*T%3&-4;,.??NO=7A^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>ZK@_G#_]NH?YD?\`XI!\G/\`WS^[??NO=&V^-O\`V3MT)_XA;JW_`-X;
M!>_=>ZKE_GC?]D0[9_\`%V_Y=O\`\'#T-[]U[JX/W[KW6F7_`#K.Q>OM[_/G
M?7QM^1OR6_EG_#WK':_1'4'8/6.5^4OPGV5\LNQ>Z*O?N3W]C]^94[QR#1Y;
MI^MV'E=JTU+2T2U5!6U]+5QUE/YHS*\7NO=;&G\K+;>Q]H_R_OC)MWK;N'97
M?VQ\;LC(KM[N#KG#9[;FQ=[TM1N_<E7-D-K[?W-G]T9K"8FCK*B2DCI9JZ<0
M?;E(]$82-/=>ZL`]^Z]U1GW%_+M^;7='\P/>/R8W?WO\8-Q]!U75V\>C.F.N
M-]].[_WMO?XU=?=B;`RFU.Q]U]44E3OS&=357;O9N5R"'<&8SN%RKUF!IUPL
M304#S1R>Z]TN?Y5G\M#??P3W;\A>QNPLQ\<</F>Z]O=%;$I.J_A]U)E^DNAL
M3B>A-N[EP-)VAD-F9;.9DS]P]I/N=YL]/3K#2P14=/!&]1I,OOW7NB-?SH.C
M^G]I_,[XB][;:ZVV?@^Y>U^BOYI6V>RNS<9A:2DWEOC;VR_Y:_:E/M/#;ES<
M2+5Y7'[>A15I(Y2PA50%L/?NO=;+&T_^/5VS_P"&_AO_`'74WOW7NE![]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>ZU(?YXW\BW`;[^+<>7^`/1':O8?R,R_P`@-N;BW/B<
ME\E.U=W4;['R6&W_`#[LR5)MKN_N*NV%2R1;DKL:%:E@2LIXI&6#3"91[ZA?
M<X^^;?;+[D&U][]ZVRPY"BV.6*%TVFR@;ZA)+80HTNWV*W)K$LM0[%&(!>KZ
M3T"^8.7EDL]6VQNUT9`3^HQQ1JX=J<:?/K6?^-?_``GU_FE1?(SH*7MWX7;]
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MM\?R^OD;M3X];K[%I\CU#N&LVC3_`!LDZT^26,Q=5MKI'#]"T6/J?[PX^7,8
ME:>D'VTWF0,D/NO="-WU_+X[#[)[8_G#Y[Y.?&W*?('N_9?\D;XU[7ZT[1S?
M5N9[!H]T_+#;'QI;'[YW%TGG:G`U='N#M9>P]L0-3U>'\F9@=C$A05$L<GNO
M=#G\+?A95?'[YI?RB]X]:_&3<O5B[N_DI]@T'REWA@^K=P[>DW'W;GMG;7W#
M78[OC<28>G:O[1R6[YYI6I\[*<JU1&D86T$21^Z]T0/XB_RN-L3_`!F_X3I5
M/8'P3R2[\W-\O?D/-\SJC=/0VX*?=E?L)=V;\;;&)^1?\2VY%DHNM)\9@L5#
M28[<(3#34'[21-#4S";W7NEYV)\-/E!0?RY_Y@_474'0G9^V^FNN/^%$&[^V
M<WT7@ND-R[DQNZO@EMJHVO)6?Z+^@#/M%.YNH<7G4QF53;V'J(,;EJ3%2K%4
M1)"\B>Z]TG>P_BMO?<W\J_\`GB;K^/O77?VZ-F?(3/?#2FZ[ZJV[_+QR7PNZ
MNWOOWK?M+KQM[=E?&;XOX[L#L3L.EBDPD<4.YZN?`X6&MK<?]U&9_#(M+[KW
M5B_R[^%/QI^%WR[_`)=F\M\?!2M[%_E:[$^/'=NW-V=5]5?'',_(#9O77R^W
MUCMIQ0=R=N]*[9V_NK+;BSN_]E[<H\-%GJW&5\J9"B5I9(Y41_?NO=8-K]0S
MY#M7_A.ON/H/X&?(?XG=$]=_)#YT[GI.GNRDWQOC</4&P]X=<25>UMQ=AY#,
MU6Y*WI_$=DYN:6KQF'S%52"A$ZPQQJ`%'NO=57_'GKSMK=7SA_EP=U)\)-X_
M&7L+9'\RG>E1\ENM.K_Y?_<6T*3H;&=A;HW9@Z7(=U_._?V1WCOGY)U?9U+_
M`)=430U<6U,102RB2*CA^U$WNO=;-?\`(NZY[#Z[/\V<=@["WIL0[S_G)?-+
M?.SO[Y;6SFV/[V[(ST^Q3@]Y;8_C=#0_Q_:>:%/)]ID:3RT=3XV\<C:3;W7N
MKX/?NO=>]^Z]U[W[KW53/SE_[>(_R3/_`!9CY?\`_P`+J^3OOW7ND)_PG?\`
M^W+7P`_\1%F/_?E;Y]^Z]UP_GG==8W=OQ;ZB[`J^^?B5\;<E\?/E-UAW7M[M
M+YH8B7<G3M-E\/MO?^U$VR=K^4T6YL_NJFW?)21TE13U=J-JF:!8:R&FJZ?W
M7N@N_DL_(#)=S;G^1.+R7RI_EG?)*7;>"ZPKT@_EY].[FZVEVBF8K]]P>;M'
M+Y>2HQV<BS)QFG%4\4GFIFIJIW4+*A/NO=7Z^_=>Z][]U[KWOW7NJ2?Y6&_-
MJ]6=&_S/>R]\Y:GP.S.O_P":G_,XWENK-51M3XO;^V^W,EE\M72`>IQ3T-([
M!5NSD!0"2![3W5U!8VLEY=-IMHD9V/HJBI/[!T;[!L6Z\T;Y9\M[%$9]ZO[J
M*W@C'%YIG$<:_*K,`3P`R<=)G_A.IW9U]V+_`"V>NNJMI5\TFY/CAN+>W7>]
M<?7-"F0ON'>FY>P]L;A%+%S#B]P83=`2(G4!54=5$&?PEB%N2N;8.;]L>]11
M'<1RLCH#6@J3&?\`;)2IX:@P&!U//WG/N\[I]W/GBVY9N)WO=GO=OAN+>Z*A
M1(^E4NXZ#`,5P'TK\7@/`S]SGJ]SV,>L;^O>_=>ZAY'_`(M]=_U!U/\`UI?W
M[KW51G\@K_MSU\#_`/Q$5=_[WN\/?NO=6_\`OW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NJX/YP__`&ZA_F1_^*0?)S_WS^[??NO=&V^-O_9.W0G_`(A;
MJW_WAL%[]U[JN7^>-_V1#MG_`,7;_EV__!P]#>_=>ZN#]^Z]UJ6_S2<U1_&+
M^8KV+W-MS^8-_*R^+FXN_NBND\3NKJCYC]-9;M[LC,4W5M7OW&;<[`)IJ^>K
MVQ09"/.56/@^V^QHZ^#')Y89YZ83#W7NM@S^7YOR?L[X;=";\J.S.H>XYMQ[
M1JJQ^SN@]BYCK7IW>/BW#FJ-<KL#9&>1,K@L'HIA$%D`$TL;S)^W(GOW7NCC
M>_=>Z][]U[KWOW7NM5__`(4O]H[FZ2KO@?V?MC#4&9J:3_9X.NJM,I)(E%0T
M/>7QDJ>F*W)F.$B2IJL?0[XFFIX[JIFC4L=*D$%<^\U?U3V%KV#2=RD8)"K9
M!8FK,1YA%J3\](\^LG?NE^P?_!!>[,'+.Z"=.2;."2YW*6(Z'6)5*Q0I)0Z)
M+B<HBFA(02N!V=7M?`3Y5;-^:'Q-Z@[^V515F(I-R;>3#9_`UR:)]O;UVFYV
MYO+"1L997JL=0[@QTXHJEM+5=$89]*B0*#GEO>X.8MDM]W@H/%0:E_A<8=?R
M8&GJ*'SZC3WJ]K]U]FO<_>/;K==3';[IA#*13Q[5Z26TX\OU(60L!A9-:5JI
MZ.-[/.HMZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[JIGYR_\`;Q'^29_XLQ\O_P#X75\G??NO=(3_`(3O_P#;EKX`?^(BS'_O
MRM\^_=>Z:_YW<'1T&P_@7N3Y`9[%[5V%MC^9%\?JBLW%OO9NR][=&4%-N#:?
M:NSMRTO?M%OO<^V</M_K[-;'W'E:*ESJ-6383<4^-J_MI(HY2ONO=`Y_)'^)
M=!\<=]?(*KP/S.^'GR5V9C>JOC[T!UOMCXCIL^#(TW571^0[6CZU[4^3IVIG
M,K2Y[Y!;GVSNY,+5Y=$"5M'@DU3U+(/#[KW6PQ[]U[KWOW7NO>_=>ZU9.KOB
M=WA\VOA5_,=^.?2_:VT^HH-[_P`Z#^8!+V7G=SXO.91\WL7"=XU^6_NKC!@Y
MH9J1LIN2EH)*IWU+)24\D!!69O82YSV+<N9-F.T;=.EN)77Q&8$U09TBG"K:
M2?4`CSZR$^[/[K<D^RGN7'[B\Y;5=;L]C;2?1Q0O&@CN9`$\=_$!#:(3*J`9
M5W5P:H.DK_PG:^`_>_3>*V5\UL1W5LFMZ/\`DKUEGL9O7IW^#;A&XTGV]N;-
MX_:>5CR1E3"'.;=W%A9U$I4J,?D*J)1K<,`)[:\E[KR]=MN@NHGL)A)')&%8
M$F.1D5A7%0RFE?PLPXGK+#[[?WF_;_W@V"'D1MAW"UYLVY[.]M+MY861$O;2
M"XEA<+5BCP3J&"TK-#$]=*T.V+[FCKF7U[W[KW4/(_\`%OKO^H.I_P"M+^_=
M>ZJ,_D%?]N>O@?\`^(BKO_>]WA[]U[JW_P!^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U7!_.'_[=0_S(_P#Q2#Y.?^^?W;[]U[HVWQM_[)VZ$_\`$+=6
M_P#O#8+W[KW5<O\`/&_[(AVS_P"+M_R[?_@X>AO?NO=7!^_=>ZU#?YAG5GQV
MWW_,V^7.,K?D_P#&[XO?)K%=6?`+Y#]0U_SDVYU8>H=X;_ZAS_;>WDI]G;CS
MN_L=N?<W4>Y>J<WFML;[VR<?32T^3KJ#*4\E2J^,>Z]UL#_RR^H:+H3X'?&?
MJ''=V[.^15%LCK\XZG[AZZJ\;6==;I6JSV:RAI.O)</D<KC8]@;3>O.%PD,5
M0XI\9CH(CI9"B^Z]T>OW[KW7O?NO=>]^Z]UIX?\`"B[XT=O]R?*3XQ39#M7;
MU%UKNGJ+Y.2=;[/EQ66']S*_XW]&;J^2':>;S<L<\L&4R78^,VG3XJDE@6+[
M<4U,)5*QNSQ#[A\A[QS5=?O"*ZB2SMK=M$15B20"S&HQ5B`*^@`IBIZ+_<X^
M]C[;^P6P'D_<-@O[CF3>MWB^IOXYH5C6-F2&!2C@/X<"O(^D$G7)(VJC!5L3
M_P"$_7Q%[>^,?QB3>.=[HVIV+TM\FMI=9]Z=?[)PV&SE%E.N]T[GVO#)NF&M
MKLC/]E--68TX^BK$@C*-58L.C`%M:OVKV"_V79?J);A)=OO(XYD0`@QLR]U2
M<<-*FGFO[0[]_GW;Y1]S/<T[18;/=;?SARU=WFVW-R\D;)=P0S$0%50:@`_B
MRQEB#HG(()IIO\]RGU@5U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW53/SE_[>(_R3/_%F/E__`/"ZOD[[]U[I"?\`"=__`+<M
M?`#_`,1%F/\`WY6^??NO=(G^?YFH4^,_QLZ^^S^))K^ZOFWT_P!48S/_`#BZ
M?V]V[\;]F5&X=E]JU=1NK>,6Z*JGQ&R\E0X[&318S*%)Y9ZR=<8JQC(-40>Z
M]U1W\.?D'W7_`"]_G)DNG]E9S^43N_86XODY\#_C7VUB_@]\:L+U%N7MW&_+
MO)=E8G:59MO?'7F<FQ[=D_'J?;F6SV9VSE(ZZ*+;T_W<<RFJ(@]U[K>;]^Z]
MU[W[KW7O?NO=4\?R</\`CQ_YAG_C7O\`F-_^_NJ?>QQZH_P'[#TI/Y&<JS?R
MI_B$R@@)M??\!U6!UTW<?8M/(18GTEXC;_#V'N6#7:!_ST7/_:3-U,'OFA3W
M$<'SV?9#^W9-N(_P]6Q^Q!U$77O?NO=0\C_Q;Z[_`*@ZG_K2_OW7NJC/Y!7_
M`&YZ^!__`(B*N_\`>]WA[]U[JW_W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW5<'\X?\`[=0_S(__`!2#Y.?^^?W;[]U[HVWQM_[)VZ$_\0MU;_[PV"]^
MZ]U7+_/&_P"R(=L_^+M_R[?_`(.'H;W[KW5P?OW7NM//^:%LA/D7_,Q^1_7<
M?8G\H'IA>B?C'T/OB?/?S(?B5TWOG?>_Z_></8TRQ;,[%[`DDS.X.K]FTFV8
M4RV2B#I@JS(I2QT=0VM_?NO=&F_X3[?-7NGM_&M\:>QS\<,MLG;7P^^.GR@Z
MTB^-?2T?0.%Z2Q_=^Y^SL)7="[UZXQ.0K-ITM='_`'.AW'@*_&PT29;!96.N
M:(K51B/W7NMF;W[KW7O?NO=>]^Z]UKO_`,[J&&H[\^`%/4"]/4=4_P`W"GG'
M]8)_Y;O:T4H_V,;GWL`,=+?"<'JK/)$IEB-)5[E/H1D?S'1U/Y,M94TO\O[J
M[KK)3/-F.BMY]V="Y4R.7EC?JON3?&V\3%+?U*Z[<@HC8VL"/Q;V#.0F8<MI
M:.:R6L]Q`?\`FU/(H_XS3K);[VD,4GO3=<PVRZ;/?-JVC<XZ<"+W:[29R/6L
MQDSU:9[&76-?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=5,_.7_MXC_),_P#%F/E__P#"ZOD[[]U[I"?\)W_^W+7P`_\`$19C
M_P!^5OGW[KW2M_G-=H2[6^-?6?2.*Z8^.7=F\/F9\CNN/BOL3#_+_''*?&/:
M6ZMX8G=^]:;?G;E!'&:_)4.!H.OZA,51T,D&1J\[/11TS^4A']U[HI_\IOKW
M$]8]W=U_`OOOXJ?R\]O]O?#=>IOE%U[VG\(.N&PG6\DOR!Q79>P*;,;AVYO"
M')[HZZ^0>"Q6R<A0RU+U9J*[;F0A:`1TY)G]U[K8D]^Z]U7-_-.W]#U=\1]P
M;^RORVWK\-]H[:WGLFLWSV'U1LC;>^^[]^;8ER;T9Z+Z(QVZ(LAC\3V_V]G:
MFAQ>'R*X[+2TKN]J4H[SP>Z]UK>5'S;_`)H/75#MK+]Y?)G<&%[C^('4_P#+
M`W'D^C]MT/3N1P'RER?S@^<&^>FNPL#W?48G:F1?=V]]E=)T.)P53-LVMQU!
M0;OHZZM@9B]_?NO=6X_R]^R=\]/?'+^9OO\`ZUZ-WW\D-XX#^<#_`#`H\1TY
MUMF=D8#>>ZTR?R0I</7R8G+=C;CVIM"F7`8VNER51]U7PM)34DB0B29HXWV.
M/56%5(/IT-_\A:MER'\I;X?U4]))03R8#L[S4,SH\]%*.\.S1)25#Q,T+5-*
MX,<A1FC+J=)*V)#G*QKM'V75V/V74W4S^_::/<7SJVP[`WV:MAVPTQZ5IU;Y
M[$74-=>]^Z]U#R/_`!;Z[_J#J?\`K2_OW7NJC/Y!7_;GKX'_`/B(J[_WO=X>
M_=>ZM_\`?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5N[S_FV_`KK[*;
MKP^[NW=UX>MV3D,WB]S/-T%\B),;C*S;E34TF8UYR'JF3!RT=)/1R#[I*EJ5
ME76LA0AO80N>?.5[1WCN+B16C)#?H3T!7![O"TT%.-:?/K(W9ONG>^_,%K:W
MFT;1:S07L<;PTW3:0[K*`T?Z1OA*&8,.PH'!-"M<=56_R\_^%!757<&[ODMA
M?E1G\GL2F7M/);L^.<6(ZXWGO*O;IG)@T%#LK*T'6&T]S9%\WLW^%PU=57U4
M0%4^7=1)I@50!^4_=6QW">\CWMVB7QRUO2-W/A'`0B-6-4H"6(SJ.<=91_>!
M^X%S5RCM/+=Y[76\5]+^ZT@W8R7EO;K^\$[FN4:]GA3P[C6T:11MV"!25K(3
MT9;^9M_,7P.>_E+?/+Y!_"'N#>>WNQ>D-D;7DQ>_(.O=^]>YW:F=S.^-J4\,
MV*I^T]D;?&1-7B)ZF)Y((*B.-7(8HY7W*.T[YMF^(\FVNSI&0&K')'0G(_M%
M4GAY5ZP2]P?:OGCVMNK:SYVM8;6XNXV>(1W=G=!E0A6)-I/.J$$C#E2>(!`-
M*9_@_P#S`^Y:WYU_RVNLOB[_`#4NW_YG>(^1>&S9^<O1?8/6&W<CA/COMZGZ
M]Q>X*K?E+V9MWK[:?]TY=L[GFJZ>*G:IE:HDHA!,[_=11N;=1YU6QU]_-4[S
MW)T'VIN&;^<7\]*3^8VG;?<.U/C;\-MD_&VF[9Z\[5SVV]ZR8OK'9M+DATCD
M<!FUW-%)'3UT29F27'JX8TLC*E/-[KW5XO\`-%^=7\Q?^5]UU\&/YFV[=QTF
MX]N]C=%[6Z,^9GP)W3N+"8+9.$^3N[^H:W=V![&ZMD6AK]PT-7M[L'&55-N"
MCHJBI08_&I'$%6KJ:R'W7NK;?Y=.[=\_'#X,=+=@?S(/FSLO>_=_R$IT[AS^
M^^S>RNN=J=?X>I["P]!NC"]5=0UOW&`VU7[5V3M6:G&NBDJDJZMZFJAD-))`
MD?NO=$:^=WS"_F&;3_F;_P`M?8&U3L;IWX$]N_+K;'6N$W)M'?&,WMV-\O<;
ME>HJ??.<W!GJ.BQ55B-@].X&LKYL704*U9RF7K8&R#-]J:0+[KW1/?YA?S?^
M?>[/DA_.$W5\;?E;N'XY]?\`\F/J'XU;TV7U5@MB;!W+M3Y"[Y[+VY-V5V$W
M<\VZL)D\WD-O_P!WL758BBHZ*II8XOV:A=$HF:;W7NC!?S&>Z?F;D_BU0_S(
MS_,9QWP%^+,?P=ZT[8Z"ZDZDVGM7<W:G;OS![/V31;ZVWL;L%>R=E9R/=NU\
MW79&##8W!X:J:62%9*RJ2&.&IE/NO=7X_"?>O>79'Q`^,G8'R9VS!LSY![TZ
M,ZRW/W)M>#'MAUPO8>;VCBLAN>CEPC,[8&L7)3NT^/N?L)V>GN?'?W[KW1G_
M`'[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5<'\
MX?\`[=0_S(__`!2#Y.?^^?W;[]U[HVWQM_[)VZ$_\0MU;_[PV"]^Z]U7+_/&
M_P"R(=L_^+M_R[?_`(.'H;W[KW5P?OW7NM7?^9CM7LCYX?.[L'XV=3=$_P`J
MJLK_`(/]%]6=J[K[._F2]45G9^Z=\/W+4[TSF&VEUC28MJ*LP/2NVZ?9C_WD
MRLLT\*9:L6-8T9&,GNO=6\?RO>T.N/DK\0.G_F!M'HCKCHS>/R-V%MBJ[*QG
M7N"P=%1Y3+]3PUO46)AHMQXO'4-7NK8&#Q^T##M&6H:1(-N/3+#I1C?W7NK$
M/?NO=:NOSQ^3?RCZ:^>G;M;\8OF9O'MG=/1'2G;?R"[O^*M?A.K\)\9NA^B-
ML_%'?^:ZJZHRU`]-5]D]H_+'N_O?"46X\+)09*.MH]MQU!K*&'%BG>I]U[H>
M/Y)7R&[\["[!^0/3W;'R/WI\K-K8+XP?RZ?D_@^S-^G959GML]C?+_IG>6]>
MW.O*'+;%VYMK%_W(AS&UJ3*[?Q<L,D^&H,@8/++$T3GW7N@&_G+]F;ZSGSC^
M*G6.6Z-WWM+8>Q.A/YH&:VEWSE\SLFJV#VOE-Q_RU>U)LUMC:6%Q.X:[?.,R
MNRY"4K9,MCJ&GF9&-.\RD-[]U[JSW^6[XMI=D_S%.G%(3^Z7S%_TH8^FL5^W
MP7R'Z.ZD[/I2BG_=-1G*O)2!APS,WYO[!O*U+?<MZV__`'WN;2`>BSQ1R#^9
M8]9*^_1?=^2?;/G`Y%WR-%9,W\4NTWU[9-^8C6%2/(`=6G>QEUC5U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=$0RO\T+^79A*S)8_*?-+XY4E?AZFMH\C1-VCMB2KIJO'RRP5
ME*U/#722R5$,T+)H0,Q86`)]AA^=.4XF*ON-H&4D$>(M:CCY]3E:_=F^\'>Q
M1SVO)O,+PS*K(WT4P4JP!4U*@`$$&IH`./587P"_G\]#?(;>_P`FL)\DM^=;
M?'_;VV>Q9<M\>,OO7*T^SX-T].5[RXO&XG-5F6KFI:G?N'GQB5U:$:+R1Y8)
M%&5I'<@OE;W2VO=KF\BW>6&UB2:L!<Z-41P`2336*:CZZJ`=O637OW]POGOV
M]V3EJ]]NK#<=^O[G;A'NT=NAN##N"@.\D:HM1:R!S%'4'28-3-64#HY7S"_F
M+=82_P`OOYX=\?"/Y%=3]B=J?&[XW]@]CXO*[)S6U.Q(]E[FHMJ;@R>SLGGL
M#*<GCIJ6JK\%,8HZR!Z>H-/(I#!6'N1]MWS9]X+C:KF&X,=-7AN&TZJTK3A6
MAI]AZPPYU]K?<;VX6V?GW9-SVA+LN(#=020B4QZ?$"%P`Q36FH#(U+7B.J`O
MCA_-C^<^V.V/Y3M9G/YFOQ3_`)AT?S_[`Z=V-WA\.>N.D.JME]S_`!HQ/:^U
M*#-;HW=D=P=/[IS.3A_T+UE?+'DSG*3$K(U"X-)H-1)1FG0"Z+[5?SEOFAD\
M;\]]^;E_G5_&[XY=A?&WY-?*'K7I+X3[S^&?6>_]Z]Q;7ZDS$J]:XW&[KPT^
M-W@#V%72G;]-+%C:^JCJ:-IY)'U-I]U[JT3Y6_S0_P"8;\0OBO\`RY?YK'9V
MQ1)\9]\]9;'PO\PCX<4>S-M;>WOL?>O:&WIGV)VOUMN7=L<&^=O)5[IKZ:GJ
MMOY/(2I1AJ*GE0R3U533^Z]U:7_*.[#^:G;GQ!V]\F/GQO;:J[\^2^6G[DZQ
MZKVUMW:FVMN=$]&[R@CRW5?7PS.)HJ7*;QSM7MFHCR=5792HJ:R..JAII+34
M\[R^Z]T3'^:'_,<^<7QY^7?P8Z8Z0Z7_`-'/QI[/^=WQ/Z"[5^4>]IME[@@[
MGA[N^]S65ZDZ7V15G(Y:CP^,VMBZ\9W=<L=/-29.""EHBI\DDONO=`S_`#'O
MYA'\P=?EO\W^F/A!VKU/TCL_^6/\&,=\Q^V8^P.H*'MG)_(K=V3QM5OR'J-Z
MS)YO$?Z/MH-UUCVTY'&_[DAD6968QR1M3>Z]T(/>_P`M_P"9'\@OB]T;\W_C
MKW[\;/Y?_P`,9OY?^%^7/;/<O9VR</W9O#*]YYO"4F;7X_KLW==;B\=MKKND
MBF2"//TKU67KJR4P4]/),U/$_NO=6O?RSOD7VQ\M_@/\5/DIWELBCZ\[6[DZ
MCP&]-X;8QM)6X_%"LKWJHJ'<.&QV2GJJ[&X3>F(IZ?-45-+-,]/2Y".,R2:=
M;>Z]T>?W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U4S\Y?^WB/\DS_P`68^7_
M`/\`"ZOD[[]U[I"?\)W_`/MRU\`/_$19C_WY6^??NO=2OYXFR.W^Q/BGUKM+
MK+XIS_-S:.3^3'5X^0OQ@I-M[/R==V?T%2XG>5=NZDQ6[]UY/&5O4V=Q.:I<
M75XW<V$+9JCR,4$,1BAJ*B>+W7NF#^3-LKKWJ?:O<'6?5O\`*;[A_EE;7AKM
MJ;LK\CV]NG;V^LSW=N'+)G:"H=]Y1;WWWO3,S[*I<<EDR=9X*:/)`4R)KF!]
MU[J[;W[KW0%_('XQ?'CY7;,Q_7?R6Z7ZX[TV)BMQ4F[<;M#L_:N*W?MZBW/0
M8_)XJASU/BLQ3U-)'E:3&YJK@CF"ZTCJ9%!`8^_=>Z!_"_RX?@1MS+]%Y[`_
M#[X\X?,_&3^(_P"R_P"1QW5NU*2IZC_BNY<GO2K&R7AQR_P<+O+,UF7@""U+
ME*J6KA\=1(TA]U[HIG\G`WV1_,,)Y)_F]_S'"2?S_P`9NJO>QQZH_P`!^P]!
ME_PGC[=VYO?^7!U7UQB*+>'\8Z>R?96"W1E<ILO<6'V=-DL]W#V/N2EQ6UMY
M5^/@V]O"MQN)R5.]>E!43O0O41I/H9@"&>4Z_N@@_P#*9=_]I4W4X_>#,9]Q
M4:/@>7>7J_:-AVT']A%/RZO4]B7J$>O>_=>ZAY'_`(M]=_U!U/\`UI?W[KW5
M1G\@K_MSU\#_`/Q$5=_[WN\/?NO=6_\`OW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NBR_,#XRXGYA_'[?/QWW'V%O[K7:_8D>-H=T9[K:JPM%N>MP-%D
MJ7)5NW5J\]ALY1Q8G.FD2"N40:YZ4O"6T2.&)M_V:/F#:I=IFEEA@EH&:,@,
M5!J5JP(HU*'&1C@3U)7M'[E7?M#S]8^X.W;?8;EN>WEVABO%D:%960HLNF*2
M-C)%J+1G517HX&I5(JM^)O\`PG]^/7PW[_Z\^174_P`AODF-X=?9*HJ8L7EL
MIULV`W)B,E0U.*SFV-QT^.Z]H*NKP>;QE9)%,B31R*2LD;I*B.H(V+VKVGE[
M=8MVL;N\^HB-:$QZ6!%"K4C!(()!S\QD#K*3W7^_S[@^\/(6X>WO-?+_`"Y^
MZ+^,*71+OQ89$8/'-"7NF59(W564E2#0JP*LP-A?\R7XB9/YZ?!WY#_$/#[Y
MH>M<EWCM#';8I-\Y+!3[FH=NO0[KV_N-JNHP5+E,+49%)8\(80BU4)4R!KG3
MI,H=8(]#UT%TU@>B^I.L^N,90[=.2V/UOL78V8W#@MO4.W_[RU>T-LXS`SY>
M:FI@\R+D)Z!IUCDEE:/R6+,1<^Z]U1KMW^0!M:I_E>;Z^`'9'<U-F.R!\@.S
M_DST+\E=G[/K]K;DZ)[<W3NI]U[*W)MRA_O159<RX*1GH<F*?)4CY#'U,RQ/
M3R^*:+W7NE]N;^3AV)\N>_\`X\=H_P`S_OG87RSZM^-7QJR_4FU.A,#UCE]F
M;)WSW9O/;\.T^Q/DKV,F4WCN""NW;N;!AI*>@I(((<3D(*.II)8FIF$WNO=+
M/XI_R6>L-B_%C!?#+YQS]:_/OI'HCLW>6<^($O:W7-1!O#J+JG<KRC%=>;DK
MJG<>7HMS9';%-(T%-D*9*&,4D@IDIXJ>GIT3W7NC'_*[^7E3=^]I_P`MC>6P
MMX8#JG9G\OGO2D[3Q^PX=J3Y.EW/M3%[$.QL+L3;]139G&0[6BQ5"D8BF>*K
M18HP@CXO[]U[H@WSH_D@]L_([O[Y:=@_'OY=XGX]]3_S'-@]-=:_.S8&9Z?@
M[!W)N#$]*_;8O"[CZ:W.=T8.DVGN+<&S(I,36QUU)50`3S5&J1I$CA]U[IB^
M8G\E[Y<]V?*[XX]X="?,_IWK'I_X9=5[-ZV^)WQ^[B^,Y[ZVCU;D]N;7QV!K
M>T*G&9O?V)VMG^T9I:"+[#,38W[C&4]'1B`K-3K-[]U[J_?I3`]J;7ZEZ]V[
MWCO_``O:G;V&VMBZ#L7L;;FTH=AX+>>ZJ>`)E<_BMFTU;D8-MT5?/ZTI$GE6
M(<!O?NO="A[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[JN#^</_`-NH?YD?_BD'R<_]\_NWW[KW1MOC;_V3MT)_XA;JW_WAL%[]
MU[JN7^>-_P!D0[9_\7;_`)=O_P`'#T-[]U[JX/W[KW6J-_--^/N]NX?Y@VYL
MMWO_`";]Z_S1OC;B.F^GXNB-Y;&W!USTSN+I_>]#7;TJNSMG56]*'>6T]\=O
M;)W5/D<?6MCMPU/\-PU;'.M)22+5S2M[KW6QC\2\E-E?C9TU/-\=\E\2TI=D
MXW#T/QNRIVM]YT[B-OM-@<)LW3LJ:?:L5+0X?&P/3QT3>**GD1+*RLH]U[HQ
M'OW7NBBU'P#^$57WG)\G*OXG?'ZJ^1,V<;<TW=M3U7M"?L^7<#XO^"-F)-YR
MXI\Z^0;#C[7R&8M]N/'^GCW[KW0@]`_%OXW_`!5V_N#:OQKZ+ZKZ)VWNO<=5
MN[<N$ZJV1M_9&-SNY:N**GES&4I<#0T4595K2PI#$7!$,"+'&%10H]U[JDW^
M>/44]+WE\!9ZJHIZ6%>J/YMR&:IGBIX0\O\`+?[5CB0RS.B!Y)&"J+W9B`.3
M[]U[HPNSNU]L?&KYY?+W=NX*7=>?VAV7\(OB)\@JN#KG:.?[)SU4.L]S=C=&
M;HRF'VQLN@S.=S*8B@K,5)D'IH)?MJ.+S26CC9@#+'_%N>MP@_Y2K"VF_.-I
M(3_+37\NLE^:R=\^ZERCNG$['S7O6VD^86\@LMQC!]`6$Y7YZNK3ND.Y=I?(
M'K':O;NPZ#>=#L[>M`F7VV=^;&W3UWG\CAJD"7&YH;8WEB\/GH,5F:-TJ:*>
M2G1*JFD25"48'V,^L:.A8]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5<'\Q;X2;B^6'Q?WUT=T/
M7]2]/;R[&R>&I-S[[W!L.GK)Y=E15YR>Y<1CJW!T2Y2@RFX9Z:"&6I&O52/4
M1FS2AU"/-O+<N^[++MNV&"WN)F`9V2O96K`$"H+&@)]*CSKUD5]WKWIV_P!J
MO<RQYVYY3=MWV?;HI&AMHKDJ!<%=$,CK(^ATB4NRIBD@C;(32:,/AU_PG:^4
M'Q1^3'4'?5-\D.AMPX_86[:.JW5MBLV/NW*TVZMCY%9,1O;;1H<K3#'O4YG:
M]=50TTDI`IJIHIP0T:GW&?+_`+2[SL>\V^Z+=VKK%("RE&(9#AUH12I4D"O`
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MS:;Z^/\`N;=M7MG-]1U%5O"JV]MO>%%5XG,X.>'.4..FFI30ULII9ON?'/'[
MKW0A=G_RKOF]_,&W'\%=A?S1NR>@MZ?%7XO;"JMQ=^=8=+[H[-DRGRZ^3]%C
M\KM/:^_=X_Q'8VP:3;6QZ#;-3#724M+4_<)EJG)Q11BFJX'I/=>Z?_C7_)"I
MZSXCY?\`EW?S&,EM?Y9?$KHCOC(;^^#.8PG8O;NR>V-L]7U%-NS'[<V/W!-M
M9MC)+D]AXW<U3!0_993(X]X*UH%BABHJ-1[KW1EOFW_+,RO<O77\KWJ+XUY'
M9?777'\OGYK_`!7[U."WWF]XY&>;I+XZ[;W)M=-F;8RPH=TYC-;R;%Y*ECI9
M,M41QS^)WJ*L.;M[KW11_P"8A_*B^:_:?R>^4O>OP=[4^.6V<#_,)^(&/^&?
MRNP?R"I.Q(\QL?`T$%1MV+MWIZKV%CLI2Y[<R]?U4F+7%Y44E-%.?/Y9=86G
M]U[H%?FQ_)M_F"]CTGP(^/GQMW_\--[?!#X'=/\`5>W\=\=OEK5]X0[:[_[G
MZ]P%1MZ/L?O;:?4F!-/N_`8F&DH:O%827,/0)6-6&IAFAJGB/NO=;''QMHN_
M,=T?UW0?*`=-KWQ18>>E[!3X^4NZZ'IJ*M@RF0CQ$&PJ/>_^_IIL3!MQ:-'2
MKLRU*RA/V]'OW7NAP]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5,_.7_`+>(
M_P`DS_Q9CY?_`/PNKY.^_=>Z0G_"=_\`[<M?`#_Q$68_]^5OGW[KW2O_`)PF
MT^]-V=*=%YOHS:^^.W<;TK\N.DNZ_D!\>^INS,;UAVEW=TKL:+=62EV9M3.9
M'+X2ER-=B^P/X#N-L)-54PSU-@I:5)/(R*WNO=!%_*UI.].Q/EE\\/EEG_C]
MW?\`$+H+Y$T/1M7MSH+Y#=@XK<O8>XN]-ITN^,9VCWG2]>8;<^[,=TSM[<NT
MI=M81,?%4JN5EPIJ@BJB!?=>ZO/]^Z]U[W[KW7O?NO=4\?R</^/'_F&?^->_
MYC?_`+^ZI][''JC_``'[#T6S_A-"W7Y_E[92/;?]T?[\)WMV>W9(PJX@;H^Z
MDRD9VF=ZM1`91J@[:$?V'WI+"BTB+]NWL,<I&NTO3A];=_\`:3+U.GWA4*>X
M%OJ%'/+/+Y^=#LMC0G\N%?+K8:]B;J#NO>_=>ZAY'_BWUW_4'4_]:7]^Z]U4
M9_(*_P"W/7P/_P#$15W_`+WN\/?NO=6_^_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>ZK@_G#_`/;J'^9'_P"*0?)S_P!\_NWW[KW1MOC;_P!D[="?^(6Z
MM_\`>&P7OW7NJY?YXW_9$.V?_%V_Y=O_`,'#T-[]U[JX(D`$D@``DDFP`'))
M)X``]^Z]UK4?-K)=R]2_.3Y,]J;C^(O=_P#,,^.?RX^%VR/B]UAM_P"/W?FT
M-L8WI_;>0J=Z)WML3>FR<UO[:,NWX.WLM78O)0[\H!+4T4%,]+%,IC=5]U[J
MV#^5QUAW;TO_`"_/BOU;\B]PKN7N/9?6-+B-VU2[QA[#?$1#+Y:IVSLNHW[3
M35-+O.MZ]VA44&!GRD4LT5=-C6F2217#M[KW1^/?NO=>]^Z]U[W[KW5"?\V6
M?X^4OSM_DWS_`"G?J!.BH^R_FV=Z-WRFT9.JED_V4O/#;YW.N^U?:FH;A^V^
MT-6+"L\92SZ??NO=9^_FZ6V;\@_A_P!@?&I>LEZ-[L^&WS_^-^W*KIR/;<'6
M3Q87:>,[YV_1[9&S43:QIILYL#<1*TUA]V)OK(S^P9N?^*\Z[7=#A<V]S;D_
M,!)T'_&'IUDQR,1OOW8>?-C<U?9=XV/>(U_HR/<[9<,//`NH-1],GAU:C\,O
M^R/OBC_XK7T7_P"^OVM[&?6,_1E/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=5,_.7_`+>(_P`DS_Q9CY?_`/PNKY.^_=>Z0G_"
M=_\`[<M?`#_Q$68_]^5OGW[KW0-_SK.A?B5B=B8K?V[_`.7=B/G/WG\P>_\`
MX[=`T&R\SW=N+H?:F<WGLK:_<53U'F^Q.SWW!3;<V'@-GX7,;AH:1UIXSD\C
MF*>D?R2R0%/=>Z=OY*_Q%R?Q@S7R&JLC_*<ZJ_EGC>6+ZTIXLIUM\RY_E=-W
M`<'5[WD>@S%)-//_`'(CV3_%!)!("/OSE'7_`'1[]U[J^_W[KW7O?NO=>]^Z
M]U3Q_)P_X\?^89_XU[_F-_\`O[JGWL<>J/\``?L/01?\)PA$/Y96U3&T;.>Y
M^[/-H*%T<[N=U2;22P<1.K`-SH8'Z$>PGR<X;:Y@*56_NP?^RB0Y],$'K(3[
MR5O)!SUMKN&"R\H\O.I((!'[HM%JI_$-2E:C%01Q!ZOD]BOK'[KWOW7NH>1_
MXM]=_P!0=3_UI?W[KW51G\@K_MSU\#__`!$5=_[WN\/?NO=6_P#OW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NJX/YP_\`VZA_F1_^*0?)S_WS^[??NO=&
MV^-O_9.W0G_B%NK?_>&P7OW7NJY?YXW_`&1#MG_Q=O\`EV__``</0WOW7NK?
M:BGAJZ>>EJ(Q+3U,,M//$UPLD,R-'+&2I!`=&(X(/OW7NM.7YL_"WXS9KY=5
MWQ&^,G\BSH;Y3S_%SX[]+?Q#>_<WS0SGQFQ^.V'O_*=@UNQ-K]8[?S&1R>2W
M[MS;U9ALM'D,PDDHILE(]),498C+[KW6S)\">O)^J/A_T1UW4]`;/^+,^U=H
M2X^3X_;!['?MW9_6!?.Y>K&`P?9+JK[MII14BJ:I/TEJ&2YT7/NO=&\]^Z]U
M[W[KW7O?NO=:['\\-$D[U^`B2(DB'J;^;C=)$5T-OY;O:Q!*N"I((N/Z'W[K
MW1@OYOGEV+\,^F?D3CZ9U'QE[?ZHW]G)*.GD>6'8>_=MY_HG?<*PTR-(U-)A
M>V3+(JJ;^$<<>P3SQ(+&RL]\;$=AN,$KG)I$S&*3`R1IDK3Y=9/_`'6+*3FG
MF;F/VLB`>[YLY.W6PMD)50U[#$NX68U,0H8S684,2`-9J1U8;\+:BCJOAY\4
MIJ"MI,C1M\;NCU@K:"IAK*.I2+K/;,1DIZFG>2&:,LALRL1[&%O<P7ENEW:N
M'MI$#(PX,K"H(^T'K'+>=FW;ES=[K8-^@DM=[LIY(+B%Z!XIHF*21M0D55P0
M:$@TJ"1GHS'M[HMZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>ZJ9^<O_`&\1_DF?^+,?+_\`^%U?)WW[KW2$_P"$[_\`VY:^`'_B(LQ_
M[\K?/OW7N@Q_GD=:U?S(Z2VI\=.FNHJSYN;UZ/\`DY\>NW/DO\)=B_(#;/1^
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ME3U7NWL7LGY#?S3_`.;]4]9U^*JL'2[/VCG.MNX\#2P5^_&R-=!DY\3)F-Y4
MCM%0PS2/#!*MU=D!&J\E,_LIS?[S7.Y65EM_*SV,"6\HD:>^O-R:9+6"W"*5
MJ#"\DK.P"Q([T(4]2Q["^V-Y[T^\^Q>UUJDAM=PF:6[E6@%O86U)+N8DD4(C
M[(_XI7C7BPZ+!_PFU^>61ZI^1N;^'>\7>IV)\F<M6[BV;/\`=T5%CMF]MX#;
MF5R55)%1S201"C["P.(CQS1TX:4U])0*B:&E88>>SO,I3=KO:=TGTB[!ECU!
MCKN=2AD!`HK/&7<EJ`F((.Y@#U@_O%O8*QW#VRVSW)Y0M8X[GE:&.SGCB`'^
MZIB$BH*U*V<I4J!\,4TSFH7K>X]Y'=<1^O>_=>ZAY'_BWUW_`%!U/_6E_?NO
M=5&?R"O^W/7P/_\`$15W_O>[P]^Z]U;_`._=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>ZK@_G#_P#;J'^9'_XI!\G/_?/[M]^Z]T;;XV_]D[="?^(6ZM_]
MX;!>_=>ZKE_GC?\`9$.V?_%V_P"7;_\`!P]#>_=>ZM^FFBIH9:B>1(8((I)I
MI9"%2**)"\DCL>%1$4DG\`>_=>ZT[_GS\2ZKYJ?.#._,7:?\JX?SD_BEVY\;
M^B\7T-VGC/Y@6T?C]LWKJMVM7]@R;SH>K,71;XPT^=VGO-\W1U5=)6TY:/*T
MTLE-*\=3(B>Z]UL.?R_,IUEL'HKJKXMX;J+;OQ,[/ZGZAV[NK<OPH@[BQ_=>
M[>@MF;RW5O*BVL,MOBDR64EW-B-PY/`9%Z7(F:1)9$EB#7A('NO='Y]^Z]T"
M&7^2?1&"[RPOQHRO:.U:7OG/]<;D[>QW5_WKS[G7K/:61Q6)SN],G3TT,U/@
ML)!DLU!#!)724YK6$OVPE%/4&+W7N@R^)_SV^'_SFI-\5_Q+[WVAWC0];5>#
MH=[UFT8LZE-@:G<J9A\%'//F<1BXZI<FF`K#&].94_8:Y'%_=>ZU7/\`A0W_
M`#1>K.HOG)TAT=E>MM_YC._&WJ7Y2?WGS&/JMNT^)S[_`#1^'^[^G-G+@%J:
MYJS3M#)[KIZW)M41PZX(Y$@$CA=6=_L)]P?G[[P'MU![D;#ONS;?MMQ<3Q+%
M<)<O+6&0QEB8D*`:@32I)6F030!C=.:+7:KLV<L4CN`#4$4R*^9Z*?\`S#?^
M%`N`_F'_`!+HOCAT#U!VAU-@*O<6VF[8S6]<IMRNEW1MW:5)%D<5M7&0[7KJ
MQUH)]S04E=62U`B!^RAC4,LDH7"_[_7LCO7W8-UVGVQWC>+'<]^W:R-].MI'
M.JPVRRM%`':55!,\L<K!5)*K""]`ZUZO_P!UO[96?./,&Y^^6[PA-NV9S8V`
MD9"6O)HM5S*!6H^GMG2,$C2QNFTG5&:6^?\`"8WYAU78G1?8GQ"WGD\U7;IZ
M4K_[^]<39:IJZVFEZDW1/1XVNP&'>97CHJ/9>\E+^$.$T9N,1+:-].._LWS$
MU[M<FP7))GM>^,GSB8Y'^T<_L<`<.O?WE/LU#RQSY9^[NRJB[9OP$%XJT&B_
M@C[)*"G^Y%NHX`]\$CL:R"MW_P`?^\_D!V3W[\E.KNR.N.G-J[+Z"W)@]IT>
MY]D=F[VW9NG=.4WALK979>UZBJVUGNK-H8G#8]-F[P$5>R9.JEBR<!CB26!A
M,)IZYC]'4]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5,
M_.7_`+>(_P`DS_Q9CY?_`/PNKY.^_=>Z0G_"=_\`[<M?`#_Q$68_]^5OGW[K
MW4[Y\_RH/Y47?>_MR?,+YR8.GVIGWV]M/9^Z>V,_\H.U.@-GQX7;WW&/VI09
MFHV]VEL39T,L+Y!XH7F432O):[,??NO=%U^(G\HG^0SF>W-H]Q?$+([/[F[*
M^.N]MD]H8>MZ_P#G1VKWU2;!W=B,I-E-D9[<.V(>\=YX*(/DL-,U*N1I6AJ3
M3RJ%<*X'NO=;#OOW7NB-?S(_BWMOY?\`PM^0?3V5ZPV[VYNZJZH[/S'2VT]T
M+CFQL?>T/66\\/U3FX/XU4TN`@R^(W1FXI*&IKV^VH:OQU5XY(4EC]U[JB#M
MOX$_/7$=M_!KL'H?JCN_:7R'V)\.?Y?/QUA^0.TODYU70_'7J7#],;]IMS_*
M7KGY0="YB&CW+V'@*_;=36KBGV_4;HI<[D)H=*4,E%'+/[KW5&G\RCX7?++Y
M<X+<=7\7>@>S>[J?8'\V;^='2[SEZYV_/GCMB7<OR#ZJJ-OQ9=*9_-2_Q>'"
MU30DKI?[=Q>XM[ZJ_P!VG[K^TWMM8\XVWNAN^U;8M[<;8]NMZR*LHA2]$C()
M`5)C,B@^8UCUZ!O-<&ZO+;S;4)O$59`6C)!`)7!*D&AIP^726_X3@?'ON_<O
M\TWX^]U8OK#=V8ZBZIV'O*F[(W^F,,NUMDY+<O2G9VT]L0YS(3.(J:MRVZ<7
M-1TRJ&E:IA:P`1F!#S)[H>SUU]T?W1Y'V[==E?G:Y]VM_N+2VC,9N);2;F*"
M[AFA`0.('MBTB$$+X:FG$`Y*_>/?>I>=^2;PR71L)?;#EDN2[Z2R[6(7#]Q#
M'Q(V#5J2PSG/7TN/?,CJ'.O>_=>ZAY'_`(M]=_U!U/\`UI?W[KW51G\@K_MS
MU\#_`/Q$5=_[WN\/?NO=6_\`OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNJX/YP__`&ZA_F1_^*0?)S_WS^[??NO=&V^-O_9.W0G_`(A;JW_WAL%[]U[J
MN7^>-_V1#MG_`,7;_EV__!P]#>_=>ZM\JJ:&MIJBCJ4\E/5P34T\>IE\D,\;
M12IJ0JZZD8BX((_'OW7NM97N3^3'_P`)L?C7E\7MGOR'J#H'-9J@DS&"VSVG
M\_.WNJJ_(8AJN>!LCAL!N;Y#X&67$_>Q21B2GA\`D1E!N"![KW5G/\NG^7M_
M+A^).+W)W7_+ZVO@QM[O[;NWJ7)=E;8[OW]WCMK?FVMIY+.28%L#N7=G8&_<
M/+C\?DLI6@28Z55:1F5B=(`]U[JSCW[KW5)OR+_E_P"Y,M_,4I_E!T3TUL[&
M)V)\$_FSU=W/VA1[DPVQ=P[Q[S[*H?CSMCI"@W=N6.DSV]OMHMK];5-+29.G
MQ64I<!3TS.L'DD$4_NO=(G^2-\7OEI\7<=W1LSM;8O<O1?Q@QNS_`(_;-^._
MQX[^^1&Q?DWOC8^]]B[3S^'[RW/LW?77\U7A]N],;KKY,/%@,0TM.Q-!/5KC
M<2DXIF]U[K5+_P"%.?Q0^1FY_P":?N;L/;73>_\`.;*[2ZGV_5["W+C\3-78
MC=:=&]*'=O;IP4T3R!EZ\VGMVKR.4CLC4]-!),058,W>?^[[]\_9_E3V&VCD
M/F3F/:K'G.7=KI$LYI@D[O<71\%51N)DUKIS0ZJ5K4",.:MLW"?=)+J&%VMQ
M&I+`5`HN?V='3_X33?#[Y*=$[*^>';O=O0V]]@=<=L_$/;6>ZDWGO3;JT>`W
MS1UN)W?N>@R.U:JKUC)4U5@<A358DB!3PS1DD:EO"W]Y][G>V_.^U\O\N\J[
MKM^X\Q[1N]]'>0Q.KRVS(B1,DP`JA6560J3\0;&#T:\E0;G9^.S>-#;S1K0A
MF4-7S%"*FGGUL"?R+*G&];_'+/?$BNJ+[GZ#;8&]-KI6V?)93HOY+]=[<[QZ
MYSD5;*JSY*A@W!N?/XB1@TBPU6*>-B&](XF<H".PFW#E\T$MI>R.@]8+@F:,
MCU`+.GR*TZS7^\4]WS9MO)_N^FI['F#EFUM[AJDA=UV>-=MO485.EV2"VN,T
M+K.'%1DGA^-G_95G\Q;_`,3-T/\`_`E=*>QKUC%T>3W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U4S\Y?^WB/\DS_`,68^7__`,+J^3OO
MW7ND)_PG?_[<M?`#_P`1%F/_`'Y6^??NO=9_YX/QGW[\C_C+T_5]?=7_`!X[
MBKN@?E%UU\@-R["^66_Z?87QRS&QMH;1[%P.ZHNUC7T%9B=R8*2BW8L4='5O
M30054D5:[R+2-2U/NO=)O^3=L[<>/QW<&^W^$G\L;XM;%W?3;,H=K;]_EP;[
MV/V#A^V*[`U6Z3FL7OS.;$V?MS%R1[+&1@:@4U%2RR9&I&F/DM[KW5WWOW7N
MO>_=>Z][]U[JG?\`DX,%V/\`S#&8A57^;U_,<9B38`#NZJ))/X`'NK`E2!QI
MU[]I^SJCG_A*IV]M;:_8/RN^/FY\D:'L7>N)V1O/9^-F>G^TR6$ZVW#V13[I
MHJ*<.'GRU&_8])4F%=9>G$TB^F%S[!.W<[<O[_[@[_:;$S';)[TW,#,-)>L4
M4<]!4X\5"T?F4:I`I0=`?O4^P'-O*/LM[<^Y6\Q.FXV_+5EM&YP_%]-+$)9K
M-F-*@O'(\,U<)-&B`DOUNG>QQUS^Z][]U[J'D?\`BWUW_4'4_P#6E_?NO=5&
M?R"O^W/7P/\`_$15W_O>[P]^Z]U;_P"_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>ZK@_G#_\`;J'^9'_XI!\G/_?/[M]^Z]T;;XV_]D[="?\`B%NK?_>&
MP7OW7NJY?YXW_9$.V?\`Q=O^7;_\'#T-[]U[JX/W[KW6J/\`S.OCMOSK[^87
MOWY.3?&K^4#W;U_\A>I>E.M=MU?\SSNG;>V]TTN^^J6W?#DJ/I3#;WVQD,=M
M_'9O'[MHH<K0T)K'R-30TM3J@<R1R^Z]UL1_#O:V[]E?&7I[:V_>HND>AMW8
M?:QI\SU%\<)4FZ/V/-)E,C44^,ZXEBP^`B;!3T4T=3Z:2%1//(`&'K;W7NC*
M^_=>Z][]U[KWOW7NM=;^>/32UO=_P-HJ>WW%9TY_-[I*>][>>I_EJ]M0PWL"
M;>1Q[7[5N4NR[K:[S`2)[.ZAG4^C0R+(#^14=5=!(C1G@RD?M%.C!_RO=[UG
M8/\`(RZ#R%>)/XKMOX@[TZKR5/(==139/IG&;SZBJZ*8`LPGI9]DF,CZW'N?
M?O;[6NU?>.YL"4\*\W(7RD<"NXPQ7X8?(_4U'15L+Z]H@KQ5-/\`O!*_Y.FS
M+=([^V[\7OAI\[_C=E-M[>^0OQY^&_55!O;;^\<HFWM@?(/X[4O66V]U;RZ>
M[!ST@\6VZO#ST<N7VUG)0T.'RH<SJ:>>1HL0^9=NNH95YGV=D3=;2-@ZN=*3
MP#N>)V_#2A:-SA6XX)IE)[)<Z;%N-C/[&>XT5S<<@<P7L36\MNAENMJW9J06
M]_:Q<9A(&6"\MEHT\%/#(D0!R5_R:OYM%!\N/G+\P]B[NVBVTJ_Y&[DH^X^F
MT2;'O+C=O=7;&P?7<VQ]R5`J:?\`B&?CV'MK%Y".2C@E$D\.2=],2Q:0AR#[
MB2\S[[>;=>T1'/B6RXJ$7#1D@#4U*/7UU^5`,C?O;?<UL/8WVJY<YQY8+W-S
M;(+3>YAK*27,IUPW:JS'PHC(7M0HH-/TP(UEV;:-]R_USEZ][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJF?G+_P!O$?Y)G_BS'R__`/A=7R=]
M^Z]TA/\`A.__`-N6O@!_XB+,?^_*WS[]U[IN_G>]8Y'O+X\=78+;^V-A?('!
M]*?*/I?NGO\`^'>Y^XMI]2GY*]083&;ZA/5]3G-T9O#X,5_]X:JAW/C,7EI8
MZ#.S[:-.1*VE#[KW0&?R4^HVPW?GS2[WZZ^*FU/Y??QT[7VST#MS9/P\V]VE
MUMO;)U>_MA_Z2&WM\A-R;#ZHW!G]E=-U&\L9G\9@:;'TK0RY2+`M5SI?QO)[
MKW6Q+[]U[KWOW7NO>_=>ZH(^`?5V\.[?B?\`S8.H=A]E5'3VZ.R/YI?\R[9U
M#V518+^\E?M.DSO=D]!FJ_'8G^+X%I,E-@YJF"GF6K@DI)IEG0EHPI*]ZL[C
M<-IN+&UF^GFEB*B0#45!P2!49TU`-0034<.AM[;\S[1R7SWM7-N^[:N[[9MU
MXEPUFTO@K.T7=&KOX<H""4(SJ8V#JIC(HQ(U\OY!OP&WKWEW9@?DIMOO2LZ)
MWET15=>]L;3PD>RJ7>M-VCUQN;?G</6&[*&HKHMXX!\-BLP>J\KAZN-X9IA%
M7EM*Z4+@CF'V%F]K?=B3EFVW<SSV&V[-N"R_3Z/%3==M@OGB*>,VD1>.UN6U
M'6!KHA.D=2/>#[[VU>Y7W:+/<-WY027:.;I=YVV:+]X&MA<[9+`+>97^C_5<
MF6*[C!6/2\>FKCNZ^@)[DOKD#U[W[KW4/(_\6^N_Z@ZG_K2_OW7NJC/Y!7_;
MGKX'_P#B(J[_`-[W>'OW7NK?_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=5P?SA_^W4/\R/_`,4@^3G_`+Y_=OOW7NC*=.;LV[L+XE=5[ZW?E:?!;2V7
M\=-C[LW1FZM9GI</MW;G6F+S&;RM2M/%-4-3X_&4<LSA$=RJ'2I-A[]U[JK?
M^;%W9U#\A_Y;O6_;?1?96R^VNL]V?-'^776;>WOL'<.-W+M[(Q_[._T(984R
M&,GGB@KZ-V\=32R^.II9@8YHTD5E'NO=7HLRHK.[*B(I9F8A555%V9F-@JJ!
M<D_3W[KW6I1_,AV1L>+Y[]E_(CLSX*=`_P`W'I[OCXT].[$Z'Q><^2GQTVMD
M_C%E]F5_8L6[L31;9[EW11XR@V1W%D]P4^7&]<*KU6/JJ*:!G4!-7NO=7H_R
MI.HM]]"_RZ_B5U#V5O/`;ZWIL;JFAQ65S&U=W)O_`&SBX)LMELCAMB;?WO'6
M9"/=F&ZPP5;3;:IL@D\J54.)616(8'W[KW5A'OW7NO>_=>Z][]U[K7L_G0X#
ML#=WRE_EA[)ZKV9_?_L'?]#_`#*NO=K[8;<F$VC!/D=]_!'?>U$R=;G]PRQ8
MRBQ^!7+&MJ`=4TL,#)"CRLB&DBZT9/4$?MZ\,'I:?RB>L-J=G_#3Y4?%/O?K
M/&U6W.J?GW\M.MMT]2;CKJ+/T&*H\AVC1]ZX3;^0K<'4_P`,RL-"O9%/()::
M0TU1IU+=&L<IOO6UW#F?E7FTUU[Y[?<O73'C62*R%A+GS(DLF'RI0]$FQ]D,
M\'^^[N5?R+:A_)NCP_(?X#[1[)^%>\/A)\?MSTOQ1Z]W?34V%FJ=B[1CW#28
MS:4^;I\ON?:V-P-5G\&E)CMU4\+450(ZI%2CFDB5-#%?>'_,NSR[_LTVT13F
MV\8`,X74=-066E5PP%#G@2//J<O9/W(V_P!HO<K;O<2_VF/>CMC/)%;/,8%\
M<HRQ3:Q'+W0LWB("A[U5J@J#UKI_%O\`X3[YK:7R@[@J^LOG5O;K/?7Q*[-Z
MZQ>U.P-M=/8HYO)U&\^G-F=DU>02FJ^Q9*'&K%3[XFQ4E-*M?35E,C>9&25X
M?<5V'LR^V7D=_9;M+'=1M566$`@_+]4C(J"""""001CK/CFS^\MM>=^7+OE3
MF?V_L;W8;V$QS0R[F[1R*2"-0%BK`JP#*RLK*RJR,K`,+Q*/YD_(7X<UL6T?
MYBVQ(\[UG"ZTV#^=W0FT<YDNIJNFUB*GE^0/5^,3-[IZ'S1C*&IR,/\`$-KR
M3R'QS4T:&PW7F'=N7V\#FV+59\%O8$8Q'_FO&*M"?5AJCJ<$`=8N3>S_`+?^
M[\1W;[O5\8.9""TG+.Z7$27RFE2-KO7\.'<XZUT0MX5X%4:DD9A6SK8^_=D=
MF[6P^^>N=W[9WYLS<%*E=@MU[/SF-W'M[+TD@NM1CLQB*FKH*N/\$I(;'@V(
MM[&=M=6U[`MS:2)+;N*JR,&4CY$5!ZQHWO8M[Y:W2;9.8K2YL-YMVTRP7$;P
MRQL/)XY`K*?M'SZ5GM_HJZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJ9^<O
M_;Q'^29_XLQ\O_\`X75\G??NO=(3_A.__P!N6O@!_P"(BS'_`+\K?/OW7NB<
M_P`ZCXE_)/LSN+J[)_';^6%\3_F9L#MSL'I>L^2F[^V=[Q[?W7F(.H=N=V8C
M;.U-ZTF9I8Z'9NQ=O8?>QFH=Y8NIJ,A0SU4U#+1M%4J[>Z]T*_\`)D^'/<GQ
MK[H^4F\]\?#+X:_!+8/86P>E-O[1Z8^,O8U-VWNC.9_:&7[+K=Q[\WKO5,;0
M5T>$JX-R4M)044Q:..:&9HD0F1YO=>ZV$/?NO=>]^Z]U[W[KW5/'\F[_`(\C
M^87_`.->_P"8W_[^^I]TD_LV_P!*?\'7AQZU*_Y?_<^]^J]T_`S&T_<?8W1'
M7W;G6&TNF=R=C;#S>%P<*#,?S+?D[7YG;^XZ[/;8W114=++U\^8>BJC'`U+5
M/Y!*JHWL=?>IO[/EW[P&W[C>$I9[AR9RY;%@,"9-DVIHRWH")&!8\!GK*KV9
MY.W_`-X?NL\R\E\KQI<<R<I\T_OU(2P5WL+FTNK>^$0R7D$EG`ZQKW.U%&2`
M=VK`]B?(I?G-E>@Y.Q>E<ITKM?I#:_;U5AVZOW=)W8:+<6;W1L#%X?,[\3NA
MMK1U51N#:<N4_B)VK&E73^6D2G1XS5@"B1"YC#`R*`2*BH!K0D<0#0T/G0TX
M'K%U[2ZCMH[R2*1;.5G5)"K!':/29%1R-+,@="Z@DJ'0L!J6H`YK^7!\J,IF
M<OE*/^<?\_\`!4F2RF0R%)A,;MGX=/CL-35M9-4P8K'O7_&:KK6HL=%*(8C-
M+)*8T&IF-S[OTGZ9:K^6K\KXJ:HE/\Z3^8;:."9SIVO\,=5DC9C;3\88VOQ^
M&4_XCZ^_=>ZK1_DU_`OY']E_RQ/AYOK:G\U;YM]-;=W'UE55N*ZPZ_V]\5ZK
M9NSJ=-X;GI3B]OS[S^/NZ=T2T1E@:6]9D*J77(WJ"Z57W7NK-?\`AM+Y8?\`
M>Z3^89_Z"_PP_P#N7O?NO=>_X;2^6'_>Z3^89_Z"_P`,/_N7O?NO=>_X;2^6
M'_>Z3^89_P"@O\,/_N7O?NO=>_X;2^6'_>Z3^89_Z"_PP_\`N7O?NO=>_P"&
MTOEA_P![I/YAG_H+_##_`.Y>]^Z]U[_AM+Y8?][I/YAG_H+_``P_^Y>]^Z]U
M[_AM+Y8?][I/YAG_`*"_PP_^Y>]^Z]U[_AM+Y8?][I/YAG_H+_##_P"Y>]^Z
M]U[_`(;2^6'_`'ND_F&?^@O\,/\`[E[W[KW7O^&TOEA_WND_F&?^@O\`##_[
ME[W[KW7O^&TOEA_WND_F&?\`H+_##_[E[W[KW7O^&TOEA_WND_F&?^@O\,/_
M`+E[W[KW7O\`AM+Y8?\`>Z3^89_Z"_PP_P#N7O?NO=>_X;2^6'_>Z3^89_Z"
M_P`,/_N7O?NO=>_X;2^6'_>Z3^89_P"@O\,/_N7O?NO=>_X;2^6'_>Z3^89_
MZ"_PP_\`N7O?NO=>_P"&TOEA_P![I/YAG_H+_##_`.Y>]^Z]U[_AM+Y8?][I
M/YAG_H+_``P_^Y>]^Z]U[_AM+Y8?][I/YAG_`*"_PP_^Y>]^Z]U[_AM+Y8?]
M[I/YAG_H+_##_P"Y>]^Z]U[_`(;2^6'_`'ND_F&?^@O\,/\`[E[W[KW7O^&T
MOEA_WND_F&?^@O\`##_[E[W[KW7O^&TOEA_WND_F&?\`H+_##_[E[W[KW7O^
M&TOEA_WND_F&?^@O\,/_`+E[W[KW7O\`AM+Y8?\`>Z3^89_Z"_PP_P#N7O?N
MO=>_X;2^6'_>Z3^89_Z"_P`,/_N7O?NO=>_X;2^6'_>Z3^89_P"@O\,/_N7O
M?NO=>_X;2^6'_>Z3^89_Z"_PP_\`N7O?NO=$9_F=?R_ODQL/^7)\[=Z[A_FU
M_.GL[`[4^)'R"S^9ZXWCMSXFP;2W[B\5U=N>LKMG[GGVO\=MO;DAV_N2FB:C
MK&H*ZDJUIYG,4J/9A[KW0Y=<_`'Y6XOXS[#W]B_YMW\R')QX[HK:^[\=UQU_
MM#X65^<R*4FP*',TFR=DTNX_CQ2Q5N5JUC6@QL=?D8UDF:,3U*@M*/=>ZUT=
MY?RF?FCT'@=U?/KN_NWLWI#8/</S4^`E3)\+<ED^J,IN?M.IS7S)Z+H,9V)\
MJX>@=E]5?'[`]C8V>=<I#1[=PN3R$%:BI5Y5W%2L_NO=?0?G@AJH)J:HC2:G
MJ(I()XG&I)894,<L;C\HZ,01_0^_=>ZTFNP_Y>WS"R'R6[;VYN;^1O\`RLNR
MNB^M=F]:];_&FNWKW#3[`VM1[$V]E^S:B>HV3N*7`OO+/39],G25F4PV5I8%
MVW*T*4\LWW<S^_=>ZV<_Y7W3G8?Q^^!'QKZ=[7'3T?8FQ]F9+'[JH^@J+&4'
M46)R-9N_<F77!;-I\-18[%-3;?I<C'154L$$<=174\\H'KN?=>Z/O[]U[KWO
MW7NO>_=>ZIY^<?\`V](_DC?^)(^>G_P&6Z_?NO=.OP._WY_S_P#YQ?4J!(:3
M_3U\:OD#C85.GRQ=Z?&+9^)RU8([_P"[=R]3UJ,P'J:,WY]Y1>]0_>OL?[4<
MT&IE_<F[;8Y]#MV[SNBU^45[&0/GT2[=V;E?0^7B1O\`[W&*_P`U/5N/O%WH
MZZ(W\;/^RK/YBW_B9NA__@2NE/?NO='?FAAJ89:>HBBGIYXI(9X)HUEAFAE4
MI+%+$X9)(I$8AE(((-C[T0"*'(/5D=XW$D9*R*000:$$9!!&00>!ZK3WI_+2
MV3MO=68[5^%79V\O@WVWF:R3*YQ>IJ:@S/0N_LFY#/+V;\;\^QZXSAGM9JO%
MIA,H-1856KZ@^YY.MH9VON79I-MOV-3X5#`Y_P"&6[?IM]JZ&_I=9([-]Y'>
M=QVN'E;WFVRSYWY3A0)']<6CW.U3TL]WB_QN*G$),;B$\#%3J+!\G/FU\>].
M/^6'Q/J.Y=HT:E9?D!\'6K=_4[TZ`!:[=OQMW74T7;FWI5A4R51P-1NJ!6U"
M,!0H-1O/,>T]N^6)N+<?Z/9U?\VMVI*OJ=!D'ITZ_MI[+>X'Z_M7S4NS[NYQ
MM?,FFU-?X8-W@#6$HKVI]4MDQ%-1K6ABNE?G1\1_D)6/ANJ^^M@YC=\#B&OZ
MYS>3?9':>(J;>NDS/5V^(-N]@8JHB>ZLL^.2S"WLVV[F;8=U;P[&ZB:X'&,G
M1*/D8WTN/S7J/><_8_W9Y`A%YS1L-_#M+"JW<:"YLI!Y-'>VQFM7!X@K,<=$
M<^<WR2V3U]\^?@5T/D?E%VMTS6=N9/==;V#M/:>Z-I838%9LO";9WJ>NUW:<
MYM7,Y+%YCL;N!L?C:>HAJJ>*JH<74TSF,LKNQN7-.U[7O=GL%T3]9>5TG%%I
MA=6:_J,"J4KW#-.C7DKV$Y\Y\]KN8_=O8XT/+7+1C$RD/XD^JC3^!12I^CA9
M)[C65I$X*ZC4"Y3V).H4Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZK[^07
M=7?NT/F%\5.BNL^QN@\1M7O>G[`R.X]J[XZNWCNSLV@P74N!DW3NG/[?SN$[
MLV5AHJ#<$=718BF%1AICCZN5JDFM17IXTLE]9Q7<=A+*BWLRLR(3W,$IJ(']
M&HK_`+!H?V?*O,FX<O7G-EC97$O+6W2PQ7-RJUA@DN"P@21O(R%&"\16@)!9
M=5@GM5T0=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U4S\Y?^WB/\DS_P`68^7_
M`/\`"ZOD[[]U[I"?\)W_`/MRU\`/_$19C_WY6^??NO=,_P#/&Z=VM\A.KOA+
MT=O[<N'7KOM;^89T1L7?_4.5[)W?U-/\@=K;CVIVAC*_K_`;RV;23UB[DVG)
M4Q[UH\;5RTE%EY-K?:&=9Y:=7]U[HIG_``G_`/Y<7?/P*W]\FX^SOBOM?XX[
M;R'5GQVZ<GW=2=S0]S97Y0]M=*Y/MVGWK\E=L7RN4R_577G9VW=U8:L.UJ\Q
M&DS)JI((85>6%/=>ZV;/?NO=$G_F&_);M?XC_$GM_OCI7HVN[^[`V)L_=.?Q
MNT_X]@]L[5V[1;<VAN+=F7["[(S.9S&'J8^OMFXS;TM17TV+,^8R+F*CHXQ+
M4":+W7NJ@^Q_YTOR(VKE>O=V;=ZKZ/R'3G5_Q\_EA=S?,HYJ;L&D[$RE?_,H
M[*I>L\1B_CI#0Y*HV]AZ/JEI#F*K^\1R4F4@D%%&U/(AJ7]U[H:?Y>G>FS/C
M/\<OYFO<G8&*["SFT]G_`,X'^8##D\;U9UMO7MO?-2<]\D*7;5$V'V!U[AMP
M;MS20U^6BDJ6I:25:2E62HE*0Q2.M7%4(^1Z]UHS1]3_`"?WS\0^GN]:7KSN
M)OC%MS&9W:N)[!SV/QF*ZQI\T_R`[GKJ*+#5%%0XF6&>#<7857CVDS$E7DX\
ME)44_F2`04\15]^6+FC?/=Q&@L;Q-@V_E7EVCLFE'(Y>VPR3@US'0`(QI55K
M3NZ[$_W;N[^QGMQ[>#][\P[.?=OFS=7C-IXH:YCC2XEALK$(`6\61F>=T'$S
M(#\`/5FO\J_^:UVSUI_,5VUVQ\FNT<OO7:O?F#VCT#V]NG=%11PQXC`8V#'8
M3K'=E3]M34M!20[#R]-`U94"-7>@K,C/*9*B>21L8N2.>;^SYM2]WF=I(+I5
MAE9B,*`%C<\`-!`J?X2Y-22>LC/O1_=6Y2YE^[U<\L^VFUPV>Z[#-/N=A%"K
M$R2NSRWENI)9V-TC,(TK02I;(H6.-5'T3@00""""+@CD$'Z$'\@^\M.OGJX8
M/'J)D?\`BWUW_4'4_P#6E_?NO=5&?R"O^W/7P/\`_$15W_O>[P]^Z]U;_P"_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZK@_G#_\`;J'^9'_XI!\G/_?/
M[M]^Z]T;;XV_]D[="?\`B%NK?_>&P7OW7NJY?YXW_9$.V?\`Q=O^7;_\'#T-
M[]U[JX/W[KW6G)_-+_ET_P"ST_S%/E-N_%=4[+^<F_/C7UW\"NQL#\:,OWWO
M?IC/8WKFIS?;6$[A^-(FJ)=O;%P$7R"VKE)-Z87=<.0F>@S>V5HYEC\[+-[K
MW6PE_*DZ#[.^+O\`+O\`BIT%W)M/;.P^Q^L^MS@]Q;)VEDZ'.8G:0GW'G<MA
MMN3[AQ@_ANYMQ8;`9&EI\QE*<M#D\O'4U2,RS!C[KW5A/OW7NJ4/DK_,\[M^
M.?S7[$Z>W1\<*?#?&CJ_X(?+GY:4796:W-C*K??>N>^,.W.IMV9JAZ\P>"S5
M<FR-A8Z#L&7$/59VC.0RV6AF:G@IZ2D2:O\`=>Z??Y67SZ^1GRKW;W%U)\J=
MF=-;=[,V+TG\0/DWMC+=%)O.FV?6=7?,CKW<^]-O;,S=#OG,[@RO]^.L<KL^
MMQU=D(:F.BR\4D-1#34IUQ^_=>Z"3Y=][;,W=_.U_E+=!8S%=A4V]NH]S?,3
M=&Y\MFNM]Z8/KK(XW>_PJW348F'9G9F5PU+LG?&6I$D45]'BJVJJ,>UUJ%C9
M2/?NO=#]LT_W$_GA=X8-`D-'\A?Y;O2O8U_T&MS_`$#\@.R>OLF/PLLE'@NV
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M^Z?N1[<S^-R+OFY[5J:K+;W$D<3_`/-2$-X4@]1(C#Y=?.U^5'P4^<V\/D;D
M\K@OA?W_`+"VSV%V#N?;7QXZYW,FZ-Z9'';4VQ0;BW=@MC8;,;MS^Y<CDY,%
ML?;]9D)HONI*95AJ&A`A"H,5-TY3YPN=VDO;';;V*W64F(=[&-`:H`S,QQCS
MI7ACKOUR']X+[N.R>W]IROS5SKRQ?[M-8A=PD'T\"7MQ)&%NI&@ABBCI(200
M8PQ0`25:I.X3\5N@_P":/V%T#U?V#O;^87W#TKV)N/;44N]^I.YOB9\<][9?
M:6Y,=55>)R5-]_1TNV,M+A\E44!K:`SS"K:@J(?-IEU@3OLFU\[7FUPW=SNU
MQ;7CIWQ36L#E6!(.>TT--2U-=)%<]<H/<_GO[K_+O/>Y<O;)[?;1O/+MM<4M
MK[;M]W:VCGA=5=#I)FC$D8;PY=*^'XJ/HJE"3$P?&K^9JLFFH_F=[)D@4$*Z
M_!'KD53V(TM*1VNE/J*_JTHHO]`/9L-GYSKG>HZ?\\4=?^KO4?/[D?=I*UC]
ML[T2?^+/=Z?R_P`1K]E2>G6/XL_/RJ31F/YH^YX58$.=I_$#XXX.2W/^;DW!
M0;S:,\_7GZ#_`!O<;)S2V)-[?_:VMNO_`!X/TE;W1]A(CJL_;"U)\O'W_=Y1
M^8B:WKU#JO@O\E,Q_P`7_P#FE_,5[_K&V-I?%_9X]1.L1_PKHMVC]'"\L5//
M/O1Y9WB3^UWO</\`:K;)_@AZ<C]\/;BT/^(>V'*`]/&GWFX_;XFY9^?KUP7^
M7KVJ%&O^9U_,)9K#4PW;\?T!/Y(7_9?#I!/XN?>OZIWW_1ZW;_>H/^M'5S]X
M'E7R]L_;^G_-#=?^]KUT/@3\@*!0<%_-(^;M/*H8*VX*'XU;IBN2Q!>&NZ&I
M_):_Y;Z?T%O?OZK[JG]EO6Y`_P!(6[?X8>M'WVY!G/\`CWMCR4R'_?3;O"?R
M*[F:?LZ;ZOXK_P`P;;%)55N`_FM9JHH:"">KD';'Q!^/NYJ**"GC::67(9+:
M;]:UT=-%$A+N)5LH)N/K[HVR<UPJ6BWQBH%?U;6!A^97PS3\^E,/NC[`;G*D
M%_[5PK.[!1]#O^ZPL230!4G%XI8G@-)SUHE_)K^9'\D^Q?G3B?E53]TP;KWM
MT3G$VEU!V'M#:8Z]P.2V1M++9FEILGCMBUN5W9!@J'L6BR=94Y"DGJ*SRQY*
M2*0E`J+C1NO.6[S\U)OWCK-<6CA8F"F-&1"?P:B0)`26&HGN(KUW`Y`^[5[=
M;5[!77M*-LFV[:-_M6EOH7G6ZN(+JXCC)_QHQ1K))9ND:P2>$J@PHP6M2=V_
MI#YV?/;M#J+KGNK&_`/8'<W7?96T<+O'![I^/?RWV6:Y\?E::.6:BGV5W+M#
MKBHILWB:DR4U92?Q21Z>K@DA9B4)]Y&;;S-S1>V$.XIM45Q:31APT%TE:'RT
M2K'0@U!&K!!'7%_G7V-]B.6>;-QY-N.?;_9^8-NNY+>2'==BN-&I"0&%SM\]
MV&CD72\<G@`/&RN``:="J?YF%!M<^/NCX4_/SII8;BOS-;\<ZWM;:-)I!+2'
M<O0FX.TX7IP!^MH8_P#6]KOZXK#C<=NW2W]2;<RH/]M`TG^#H+_\#9/N8U\F
M\Z<A;P3\,:[LMC<-\O!W.*R-?D&/V]*O:/\`-;_EW;PKUQ$7RNZPV?FBT<;X
M+MNIS'2>;AFD.E8)\3V_B=D5T4VOTZ2GZN/;]OSSRE<-H%]#')_#+6$_LE"'
MHJW?[J_WA-G@^J?E7<[RSH2);`1[C&0/,/827*D4S6O#H[>T.P-A]@X],OL'
M>VT=\8J1%DCR>T-R8;<N/DC?],B5N%K:VF9&_!#6/L1V]W:W:>):R1RIZHP8
M?M!/4*[OL&^\OW!M-^LKNRN@:%+B&2%P?0K(JG^72N]J.BGKWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JIGYR
M_P#;Q'^29_XLQ\O_`/X75\G??NO=(3_A._\`]N6O@!_XB+,?^_*WS[]U[HI?
M_"@[?6X=V8WXO?%?-_R__FA\H^J-]_(+K+?F5[*^*6Z'VU6X?,;=PW:B0[5P
M.4V[F8,]C.T,+5T]'EZ%<U3TNW):75,*Y*NF14]U[I2?R0>L^TMB]O\`RKR%
M5\7_`)^_'KHG*;&Z1H-DUW\POOS</:O:&Z>P<=E.S)]ZTVT]KU^\]U8/;NT\
M5B:_&$UE)'!-532!)GE"(D'NO=;&/OW7N@W[DZLVSWGU#VKTGO23*P[.[AZW
MWSU9NR7!5D>/S<6V>P=L93:6>DP]?-35D-#E4Q>7E-/,\,JQ3!6*,!I/NO=5
MQ[S_`)-?Q0WMO3I+=E=N/O/%XKJ+KCXR=5[FZXP?8=#0=<?(G:/PXW1'OCXV
MP?(;;[;7GJ=XUO6>\XSD8)L=4X8UDC&&K$]*$@7W7ND]_)P8MLK^88Q_4W\W
MW^8XQ/TY/=]43]/\?=)#1&(XT/7AQZ(I_)K^*V#^5_\`)N^).U]U=G]G["V_
ML[N[OKL#^$]>Q=65./W1NC9_RZ["W3L^KW;1=H=7]ETF4HMMYW"1S14<:04M
M4))$JXZA"BID)]YV-)/<>V20!HVY2Y9!!`((_J_MN"#@_8>D'+MU<V4:W=E+
M)#=Q7,K))&S(Z,)7HR.I#*P\BI!'D>E5_,;^)_875O;.U_GCMKH'X[S=/?#B
MGZWW#F(<%F4D[(WQU=@]RYG_`$_Y'</4E%T)A.NZB3-]?;RJG:)<Z30G"1UL
M+%M-(N'_`#GM5E:;=%OEK;0^+MUPD[!8T[X?@G4BF1X;%A7@5!&>LR?NS\^\
MS\P<Z7_M7OV];B;#G+9KC:X9);NX/T^XXN-KG1C(2K?61)`VFA=)V1B5ZV-,
M-E\7N##XK/8.NILGA,WC:'+X?)44BRT>0Q>2I8JS'UU)*GIEIJNDF22-APR,
M#['D<B2QK+$0T;`$$<""*@CY$=8G7EI=6%Y+8WR-%>PR-'(C"C(Z,5=6'DRL
M""/4=9LC_P`6^N_Z@ZG_`*TO[OTFZJ,_D%?]N>O@?_XB*N_][W>'OW7NK?\`
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5<'\X?_`+=0_P`R/_Q2#Y.?
M^^?W;[]U[HVWQM_[)VZ$_P#$+=6_^\-@O?NO=5R_SQO^R(=L_P#B[?\`+M_^
M#AZ&]^Z]U<'[]U[K1\^7]-N7Y8?S'/D?OGM_^3W_`#::C=/6&P>J>JMI[X^+
M'?\`D.MGS.W:#+]FC(5E9EL/O[$;`S>Q-RU=##78)\)/)4LK5,N2ACDDIQ[]
MU[K:$_E9;0[?V'_+]^,6T^^NO,[U/VSB=BUJ[MZZW1O_`#_:.Y=J/6;LW%D,
M-CMP[YW1G-RY_-YP[=JZ26K%375#TE1(],&"PJJ^Z]T?_P!^Z]T5/M[X9=']
MZ]PX#NGLW%9G<.=P7Q_[S^,TFW'RW@V7G^I_D3-LR3LW$;@Q$5*M;65F1AV-
M2003Q5<'AADF&EF=63W7N@S^#?\`+GZ,^`E)V`>J]R]O]@;C[(Q_6.V<[OGO
M'?B]@[RI.N>D=JS[)Z6ZKPN2@P^!I,?L'J[;%944V+I_MWJW-5-+5U-3,YD]
M^Z]T7+YQD_\`#I'\D87-O])/SS-OQ<?#'=@!M_4`G_;^_=>Z>/E/?8/\U_\`
ME<=DQC[>B[5V)\U_B]N&M*VCDGR6P-C]\[(H)91P#-D.F\D(U/ZI'XY]Y0>V
MU-[^[+[D<OMW3;9>[!N\2^8"7-QMMPP'R6^BJ?(#HEO/T]YLY?)UEC/^\AQ_
MQT]6V^\7^CKKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z*]W-\88>Y>U.F>UY^[.Z
M.O\`(=&9JLW'L[:VP)^K(MI5F?RNW]T[.SN5W#!O'JS>6?R$V<V5O*NQ,T<6
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M]JDC2)!'&H6,<`!0#[`.B"ZN[J^N'N[V62:Z<U9W8N['U9F))/S)Z</=^D_2
M1W?U_L/L''OB=^[)VCO?%2(T;XS=^V\-N7'NC?J1Z/,T5;3,C?D%;'VGN+2U
MNT\.ZCCE3T=0P_80>C;:-_WWE^X%WL-[=V5T#4/;S20N#_IHV4_SZ)#O#^5%
M_+PWED'S+_%;KC96>+221[AZ>7.='9ZGGD(=JBGRO3V8V/61S^0!M6K]7)O[
M#=QR-RG<-XAL88Y?XHM4+?MB*'J;-G^]3]X/9X/HUYIW&]L<`Q;AX6Y1$#%"
MFX1W*D4Q2G#I(G^6UE]GWFZ&^>?SOZ=>&YQ^#RW<F.[YV-1>D".,;7[]VKV%
M5-3QLH_;2OB!%Q^;^V/ZGR6^=KW3<[?T4RB=!_M9U<_\:'1L/O'6F[CP^>N1
M.1=W!^.5-O?;+EO7]?:Y[45/J8F/7'_19_-EZY`_N=\L/BG\C*2,G31=_?'?
M='46<EB"&T3[KZ-WSD,0*C5;][^[V@_7Q?CWKZ'GJT_W'OK&['I/`T1_WJ%R
M*_/1^76_ZT?=3YB/^[CE3FGEV0CXMKW:&_C!KQ\#<K99-/\`1^JK_3ZZ_P!F
M@_F+=>D)VQ_+AH^P\=36^]W5\6/DSU_O%I45;O-1;`[@Q/3^Y7O8Z8TJ9W)L
M#:_OW[ZYMM,7VT"5!Q:VN$?]D<HB;^9Z]_K9?=YY@&KE7W%?;[EOA@WO9[JW
MIZ!KJP>_A'S)11UT/YL?QXVN%7OSK#Y:_%B0$)-4]\_%_M7&[>BD"DL3O;8.
M%[`V0U,&4@3_`,1$-K$L`??OZ];3!_R5(;^Q_P":]M*%_P![0.E/GJIUL_=3
M]P=S/_("W/E/FD4J!M>]63RD?\\UU):W.K^AX6KY=&7ZJ^<?PW[P,$74WRBZ
M(WU7U.GQ87"=G[1DW&"X!59MLSY6#<%.YU#TR4RM?BWLYL>9>7MRH+&]M96/
MD)%U?[S75_+J-N:?9+W@Y*#/S5RQOMC`O&22RG$..-)@AB/VAST:565U5T97
M1U#(ZD,K*PNK*PN&5@;@CZ^SOCU%Y!4T.".N7OW6NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NJF?G+_P!O$?Y)G_BS'R__`/A=7R=]^Z]TA/\`A.__`-N6
MO@!_XB+,?^_*WS[]U[IL_GO]<]I]F_%?IS!=>=7_`"E[WVK3?*[JW)][]#?$
MG<E=LOL7MWI"FVUV"NZ-LY?>.)S.$RVW]JT&:EQF39H9'%5DJ&CI7\"S_>TO
MNO=!Y_)1ZBZ?ZOSGR(FZM_E\_/WX/RYK%=9QYJN^:_9>YM_T'8T=#6;X:@H^
MNXMP]L]EC%U>V&JY7R;1)2&5*ZF#-)H`3W7NK]_?NO=>]^Z]U[W[KW5"7\MG
MY&=`_&[JSYZ[G^07=/5O2>W<]_.1_F-X+!YOM/?6V]BXS,9H=R9"O.*QE9N3
M(XZ"NKUHJ:28Q1%G6-"Q%A?V*^5.0>>/<&YFVWD7:-RWC<(83))'9V\MRZ1U
M"ZW6)'*KJ(6IH"2!QZ8GNK:T4/<R)&A-`6(%3^?13O\`A-9\XNA%^%O7?Q:W
M3V9T]LWL?&]J=QX_K[;>9[RZT?L3M7([R[@[$WJ8-O=2IEX]]XJ"BQF4IA3/
M4TY&5UM)2ZD4^\H?O1>T/NQ!S1%S3<<L[['RS9\I<OK/=M93BWA:#9K&"=99
M=&A&AF1HY`Q!1E(:A'1+LM_8F$P":(S-/+1=0J:R,105J:@U'KUM!;FVW@]Y
M;;W!M#<^-ILSMK=6#RVV]PX>MC$M'E<'G*"HQF6QM7$>)*:NH*J2*1?RCD>\
M+IH8KB%[>8!H74JP/`JPH0?D0:="_;-ROMGW*WW?;)&AW*UGCFBD4T9)8F#Q
MNI\F5E#`^HZU^.G?F-WA\/9.J_Y<O\(Z2WEVSU=WU2_%K:-9WEW!NWK+/;QZ
M4W7M[<6^?BWVMMNCVWU3V%!NC`2=>;>;:>6*2P34FYJ"&ETN]0+`/EO>K795
M7E+>)@NY6UP+>'5QFB8%[=Q]L8\,G@'4*35@.LL_>KVRW[W-GE^\+[<[>T_)
M.\[.V[[EX5-&WW\,D=OO%N]36JW4@O(U^-[6=IE7PXG8;"M=K_AE7Y`HD^QJ
M-80ED#_;OJ",RJS*&^A(!(_'N0>L/NJCOY!7_;GKX'_^(BKO_>]WA[]U[JW_
M`-^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U7!_.'_P"W4/\`,C_\4@^3
MG_OG]V^_=>Z-M\;?^R=NA/\`Q"W5O_O#8+W[KW5<O\\;_LB';/\`XNW_`"[?
M_@X>AO?NO=7!^_=>ZU%OYI_QGRG9O\R+LK>7?'\NK^8G_,)Z%J^A^D,7TI/\
M<^[,_P!3=<=+[PQ55OL]I8+#87;/:^P5W1+O(5N)KJRNJGAJ*2LAEA$,\3Q2
MQ^Z]UL3_``!VKMO9'PYZ%VIM#HSM+XT[:PFSYJ/#]%]U;FK=X]I=;TO\>S$H
MPF\MS9'<F[Z[+9*621JE9)<E5.L$\:EETZ%]U[HX7OW7NO>_=>Z][]U[JGGY
MQ_\`;TC^2-_XDCYZ?_`9;K]^Z]T7[^>S\N>AOC7@?B?V!F.T.N_]//Q>^7G0
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MI?2K,%K4A6(%`>CBWO[&[<QVLT<C@5(5@33UQT?3W'?2OKWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z\0"""+@\$'D$'\'W[KW1:
M>U?AG\2>\1,W;WQHZ,[$JIM1;*;IZPV=D\XC,K*ST^?EQ'\;I)"&/JBJ$;_'
MV3WW+VP[EF_L[:5O5HT+?[U2H_(]21RO[Q>[')-%Y2YDWS;X1^"&]N$B-/6(
M2>&P^3(1T5IOY2_QCVTS3]#[R^3_`,5ZHN9$_P!EX^3?;>U,-&_-@NR]R;AW
MCL+[8:C^Q_"_`0;:+>R3^HFS0YVN2]L3_P`(N)5'^\,SI3Y::?+J4!]Z[W+W
M+MYZL^6>:8Z4_P!VVS6$\A'_`#T0Q6]SJ_I^-J_I=>'Q5_F"]>G5U#_,FKM[
MXVEM]GM7Y4_'#K7L85"JA58:W?W5=9TSNV[$+JD9*ACR;7/OW[CYJM/]P-X,
MB#@MS;QR?M>,Q-_AZ\?=+V!Y@%.;?;A+*Z?XI]DW>\M*9XK:WJ[A!ZT`*#AG
MKO\`TF_S9>MP3O'XN?$[Y)T,9L:SH3OW=O3.XYHE4WF7:?=^S,W@15-:_A_O
M&$)X\H^OOWUO/5G_`+D65C>+ZP3M"W^\S(5K\O$_/KW]6ONI<QG_`'3\S\U\
MMS'\.Z;7!N,0/IX^VW$<NG^E])7^CU[_`(<JJ-F6A^0/P<^=72+06&2S]-TI
M#WIL"ALI:27^]_Q]W%V4[4R%2-<E%#<`$#GW[^N)M\;KMFYVU.+>#XR#_;P-
M)_,#K7_`WQ[P-?(/._(^]!O@B.XG;;ILX'T^ZQ6>3Z+(U//AT(&P_P":3_+V
M[$KDQ.'^6746!SK2+"=M]F9R?I[<Z5+`$4LFW.V*/9>:2JYMX_!JO]![56O.
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MTI\`K7AU)L7LES[/[.2^^<=NAY%AW06+-5O%U$`?4!-.DVPF9;8R:Z^.P0*:
M,18Q[/\`J).JF?G+_P!O$?Y)G_BS'R__`/A=7R=]^Z]TA/\`A.__`-N6O@!_
MXB+,?^_*WS[]U[I1?SJ]A]_=@?%?8^-Z<VEW]V5UYBN_M@Y[Y9]1_%/>1V'\
MDNU_C)0X7=\6Z=E]2YZ+)X7(5&3FWS5;>K,EC:*MHZW+86DK*6*9/*P;W7NB
M<?\`"?[:_P`QJ+$[VW'W9U?\K>B^E*;XP_"KJ/#]9_+K)U<>YLQ\END.N,WU
MWWCVAU+L'+9#(;@ZXZHW1MK#[8A9:[Q2Y[*TTV1*B5YD3W7NMD;W[KW7O?NO
M=>]^Z]U\V3^<C;_9%>S_`*:O^@@?^9[;Z7M_>3<5[?FU[7]]6O[J#_IZ'-'I
M^X8O^TI.@/SS_N%!_P`U3_QWJIG^2SI_X=>^`VJUO]F2V!^JWZOO9-/U_.JU
MO\??4G[WE?\`@9^=OXOW!<_\<Z!.P?\`)9MO^:J]?8!]_*YU-W6A/_/1KOF+
MWI_,(P6[=D?';NS:&UNG<U@.EOCKOJ'K7<6(R/8>^-LY++[XJ=S;0SCXN.7<
M$U5N:DKJC"K32S1G&XY*J)5:::^,WN-!S3O?-7U.W6%Y]/9T2*187JQ1BQD#
M!<C63H()&D`C)/7<;[F&Z^PGM?["#9.<^;>6SO/,7B75_:S[C;!8DN(EA2T>
M%I1I86ZK]0K*K>(\D;$JB4V\O@3\LJ;YC?%/:?9V5IEV_P!KXC&5^Q.^NOJJ
M!L9G^N^Y]GK-A=\;?SNW:A8LEMQJO)TC5]'354<<PQ]7"2+W]SMRKOHY@V:*
M\D&B^4:)T.&CF3#JR\5J1J`.=)'7*+W^]JI/:'W+ON6K1OJ.59F%UM=TIUQ7
M>WW`\2VEBF%4FTHPBD="5,L;T-*=%F_D%?\`;GKX'_\`B(J[_P![W>'L1]0M
MT>3HKY8]:_(;=79.S]B;<[FQ.7ZES7]VM\R]D=']I=7XC&;F_A^$S/\`=RES
M6^]KX+%Y;-_P#<N/R/V])+,_V%;#/^AP??NO=&;]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=5P?SA_P#MU#_,C_\`%(/DY_[Y_=OOW7NC;?&W_LG;H3_Q"W5O
M_O#8+W[KW5<O\\;_`+(AVS_XNW_+M_\`@X>AO?NO=7!^_=>ZU(/YOO6_S%QG
M\Q;K?O23XT?.7Y7=%[<R/QUFZ$HOAWN/(UNV.K=O8RD[=P_RUVWOWKK%[LVV
MF-[5[&FW)MVIP6[LC#-1TE!2+%'4T\E*P/NO=7W_`,L/8WR.ZT^`?Q9V)\M\
MAF\C\A-L]84./[`.Z-S0;TW9C;9+)S[4VYO'>5,\M/NW>>U-D38W&9?)I)**
M_)4D\_DD\FMO=>Z/A[]U[KWOW7NO>_=>ZIY^<?\`V](_DC?^)(^>G_P&6Z_?
MNO=::G_"N;3_`,.B;*M;5_LHO55[6O\`\S#[CM?\^_H0_NN#_P"`XWG_`(M-
MY_VBV'44\Z_\E=?^:"_\>;H2O^$>!7_AP+Y$"XU?[*!N$@<:M([DZ>U$#ZV!
M(O\`[#V'?[UC_IR&Q?\`BTQ?]H-_T]R/_P`E*7_F@?\`CR]?1G]\$>I0Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7N@]W]U'U3VM0-BNT.LNONR,6Z&-L=OW9FW-WT
M+(004-)N#&Y"`J0?II]I+JPL;Y-%[#%,GHZ*X_8P/0@V'FSFKE6X%URQN>X;
M==`UUVMQ-;M7_31.A_GU7IVK_*J_E_87`[P[+VC\8\EL?=NV=MYW<M%%\5]U
M=C=+[WS53@\76Y.#![6Q/4N[-IXW(9W+20?;T=.U,XDJ)$4#GV%+[DCE6.*2
M]@LFCN$1F'TS21.=()TJ(F4$G@!3B>L@>5OO2>_=[?6G+.[<S1WNT75S%"QW
MN"TW"VC$KJAEGDOH)W2-`=<CAP0JDD]:,F)ZY_F8;&^9NQ^^J/X^_*V?Y#T^
M\I>V=B8K?VU>T=Z=CY[`==5>!I:J@RE?N&AFW?O+;N#VWE,;A<G4S!@]#5QQ
MR%1*J^\;HMKYY@WM-]CL=Q-ZDP<,\<SMVTHK,PU,-(TFO%<==K+_`)\^ZKNW
MM=<>U-YS3R;'RS=;?):R16UWM]M$#*&,DL,$4@B@?QF,ZA!1)2&&17KZ6'66
M[Z[L#KC86^\GM+<6PLEO+9VVMT9'8^[Z*3&[JV=7YW#T>3K-K[CQ\JI+1YO`
MU%2U+51L`4FB86'O+ZRN&N[.*Z>-XGDC5BCBC(6`)5AY%:T/S'7SF\S;1!L'
M,5_L5M=V]_;6=Y-"ES;L'@N%BD9%FA<8:.4`.A'%6'5:/SE_[>(_R3/_`!9C
MY?\`_P`+J^3OM3T2=(3_`(3O_P#;EKX`?^(BS'_ORM\^_=>Z7W\W[K_Y$[SZ
M/Z(W'T)L+LGN?#],?+?ICNWOSH#I[?L'7'9W>/2?7Z;FKJW9VT,_59+#TN4K
M<'V#/M[<4N$DJZ89NGPKTBR"1T5O=>Z![^5[A?D-OKY7?.OY;[M^-W?WPU^/
MWR-H^D)MK="?)/>M+F^P=S=[[-I-Z8WM;O"AZ\H-P[FQW3>`W!M&IVQA!CH:
MA1E)</\`=:%5$5?=>ZO$]^Z]U[W[KW6&6HIX619IX8FD-HUEE2-I#<"R!F!8
MW8#C^OOW7NJ(_P"6;T#T9\@^L/GMMSOCIOJ_N;`8/^<?_,;S6&PO:>P]L;]Q
M>(S![EKZ%LIC:'=&,R=-0Y!J.HDB,L2K(8W*DV-O8HY6YWYSY&NI;_DK=MRV
MB^FB\.22SN9K9W2H;0[0NA9=0!TDD5`/'IF>VM[E0MS&DB@U`8`T/Y]$._X2
M[_'/J;=OQ$K^Z]W]!_&?,[GV)\B^U<5UCVN>L,37]]X#-8C-//D5R>]\MC*B
M6@QV*QV6HXL+_#9H9*>$RA['23E5]Y_W5]S;T<M;9+S%O;\O[O[?['-<V[7M
MP8;B22W99WFBUB.5I9(RTC.K%VJ7)/1'LMC9+XSB*/Q8[J4`Z14`'`!I44!Q
MZ=;:?O"WH1=`]V?\>.@.[:S!Y'N?HWI[MS(;92HCVW7]G]9[*W]6;>2KDBEJ
MTP=5NO"9:?$I52P(T@@:,.R*3<@>_=:(!XCHI'R1^&&YY^P\G\K_`(=;TPW1
MWRK&%BQN\H<W0U=?TA\E=M8FGD&/V9W_`+1Q<D%14UE%#>'%[IQ^C.X=&*AJ
MB$)"@4W7EZ=KX[[R_(MMOE`'U`F&X4<$G4<3Y+(O>OS%`,@N0/>+:XN5U]JO
M=ZRFWKVK#LUOX3*FX[/*_P`5QM<[@A5)HTUE+6VG(!(1BS-6W_PG_P#F[T?1
M_P`OKX3_`!@[&K\QTOW%'UA60[#P_:N.?:FW>\,4^]=TR)N+HW>==)_=OL.A
M,\Q@>B@J$S%/-&ZR4FE1(RQ>9-M&ZOLMV6MK\-1!*-*S"@.J%SVR#-*`Z@0>
MWSZ#<WLGSM)R!;^YO+R0[SRB\1:Z>Q?QYMLD#,IAW.W4>-:/1=8D9#`R,I$M
M25%F'P5[$V-O[L?^8B=F;JPVY&PWSHS^-R\6,JEGFQM;A/CU\>=DY"*JBL'6
M./<^R\I2)*-44LE%*$9M#65[=O.W[L]Q'8R!WM9S%)\G4`FGJ,TKP)##RZ#G
M.GMMSC[?6NSWG-=HUM;[[M<>X69)KXEM*S*A;'9)10YC/<J/&QH''5AGLTZ`
MO7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U7!_.'_[=0_S(_\`Q2#Y.?\`OG]V^_=>
MZ-M\;?\`LG;H3_Q"W5O_`+PV"]^Z]U7+_/&_[(AVS_XNW_+M_P#@X>AO?NO=
M7!^_=>ZUROF[@ODIU#\Y?D[VGN3X,?)K^89\=?EG\-=F_%7K3;_QY[9Q>W,=
MTWAJF?>`[ZZZWULO*;QVG+MD=MY3)XG)Q[YH1)64%/`U+'(I1U'NO=6C?RQ.
MH^^NA_@+\7.H?DWE:G*]W[$ZRI,-O1:W=!WO78!#E<I6;7V/7[R+2+NS(=>;
M.JL?@9\DKR1UTV-:9))%<.WNO='O]^Z]U[W[KW46FK:*L\@I*NEJC$0)135$
M4_C+7TB3Q.V@G2;7M]/?NO=5!_./_MZ1_)&_\21\]/\`X#+=?OW7NC:_+WX>
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MUL81MNZ)%"[F*.5;B$RR%%!_QJM?U#T3[#!!;>/:JB+<0S,M0`&*,=:5/$BA
MH/\`2_+K8(]X:]"'KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@_7J;
MJM.QY.XDZSZ_3MR7!':\O::[,VXO8\FV6:!VV[)O<8T;F?!,]+$32&J-.3&I
MT>D6]UJ@K7SZ$#W[K?53/SE_[>(_R3/_`!9CY?\`_P`+J^3OOW7ND)_PG?\`
M^W+7P`_\1%F/_?E;Y]^Z]TU?SX=F]J[W^*_36*Z[V)\O.W-J0?+'JNN[YZ:^
M$]7E\+W)VET?3[:["_O/MT[JP-?CLIMG;E!FVQF3EE6015E90TU$[T_W(JZ;
MW7N@^_DH]?=0[(SGR(DZO^%G\T#XE2Y'%=9IF:O^8CNK=6X\9OB.FJ][M0TW
M5$>Y.TNQ4I:[;[3RMF&B2D+QUE&&:2P">Z]U?O[]U[KWOW7NM0[^=7M>6;^9
M_P#'/M>7:F&[WWUUUUM\:]J?'+X=]A_'3Y!;IPO>NZ]Y_+"KJNU]Z].?(#K/
M>V`ZYZ[[1ZEV?2T>4R$VX*6L@Q6.H89*FFEI:SR+[KW33V!\[.X_Y=W\M3^9
MK\@N@Z3:-5VA)_/)^:FPL#D-\8FHW!M[#T^Y?D/DJK,92IP%+7XILQ/-A\-/
M211FI@6*2J$]V\0C?(_[J_L5MWWB?=9/;G==RN-JLVV^XN3/#$DTE8=%$"2,
MJT8ODUK04'&H*-[W-]IL3=H@=M8%"2!G[.J-/Y+'\^;M7X+[4V%\+\9T-L;L
MW;_;GRD@W#E=]9?=F>VWF\3)W%FMD;6S%+C<108[)8SQ8LT#5-.7:S/*586%
MSU3][/[O'E7>.3K/>OZR[BL_*?)JV,5;:$_4KMRW,\<LH#C0S^($94)`"@@Y
MP"-MYLGCN&C\%*3W&H]QQKT@@8\J5Z^FE[X.]2=U[W[KW4/(_P#%OKO^H.I_
MZTO[]U[K6!^*NUJ[=W_"9_X[87;?QKI_E1V%DNAJW#=9];3;4H-UR8[>V>[#
MW;A\7OV"&L:&?%ML%:M\K]S2RPU0:E6.-T,FH!3G:!KCERXCALQ>W;+2./2&
MH[8#YX:*ZJBAQ0'/60'W8-T@VCWIV:]W'F-N5^7XI_$O+L3M`'MXAXCVI*U#
M_5%1!H<,E'+,I"T-2O\`*0V9_-P^&_R)WV_3WQ0W-O+#;GW%C.J>^]H]HG)[
M;V=C]TX_&XC?6&GW!N^@EK9MG;MQ6"WK!-!DIJ6OI8J/.,9X7635'!G)&W>X
M?*^Z%[;;I&@N*+(LM50T-0VL5TD5(#$$`$U'F.JOWHN<ON<>^W(<=KO?.-E%
MNFSEY;2:P*3W,990DD(MV"B>-PJ,\"/&[-''H<$:6VU.NOYFO2U1N?&=6?)W
M;.]?A#WAD'2DI>O_`))4M#MS:NZ*X%(I?]&'=M!4U?4?9&/:ID6.!J3*0ULS
MD#[56N!-]ISEMQF6RWE)-MW(XT7`"JQ_X7,*Q2"N!1@3_#URTYA^[7SE'MLO
M,_MG<V7.O),8U&ZV@M+/"N2/K-N8+?VCZ068/"T:C/BD9ZL;@GAJH8:FFFBJ
M*>HBCGIZB"1)89X94$D4T,L9:.6*6-@RLI(8&X]BX$,*C(/6.[H\3F.0%9%)
M!!%"",$$'((."#UE][ZKU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U7!_.'_[=0_S(_\`Q2#Y.?\`
MOG]V^_=>Z-M\;?\`LG;H3_Q"W5O_`+PV"]^Z]U7+_/&_[(AVS_XNW_+M_P#@
MX>AO?NO=7!^_=>ZU$_YIW1V7WQ_,F[-W1WS\'_YK/S?Z#J.A.C<?TBWPXW]N
MOKSK#J+>&/J]_-VGA(J#;/9VQ*7=E?NO[O$UU3D)IHZFDJ%DIF@FB\$R>Z]U
ML5?`';^VMJ_#GH7;^S^H>[.A-LXO9\T&'Z?^1N9R&X>[=ATK9[,2G#]A9G+;
MCW;D:W,-+(TZ&7(U3+2S1+J4*$7W7NCA>_=>Z#CN*LW#CNH^T\AM&++3[KH>
MN-[UFV(,#AGW%G9MPTVV<G/A8L+M]*_%OG<M)DDB%-1BJIC53%8Q+'JUCW7N
MM:/_`(31]>8?IZB^2O6/7VQ]O;LZXPFQ_C+493Y<TOQL[G^+^^^UNXZG`;]G
M[*Z<[8VIW'N?<4V^=_\`2=;5QRUV;Q2TD"5&>DIITUK$D7NO=&Z^7NWN\:/^
M=C_*3W%NOLK9&<Z(S.YOF+2=4=88KKFKPF^MC[HQ_P`+-U+O3-[I[*EW=DZ/
M>N+W%-J:CHXL/C&QX(#2U%M7OW7NKZ??NO=:]G\Z+L+>/\M6LP'\W/X_T^WL
MAOK&8W;WQC^0_4.Z?XG3;,[]ZSW/E,ED.LLQD:O#2QU.(["Z;WK))+C<D(WE
MGQ&2JZ*1_$(XVSH^Z1L6U?>"BG^Z[SPTZ;-)))NVUWT.@S[;=Q*B7:*)`0]K
M?6]!+%4*L\4<RC668!G?I7VHC>K:AD`$;J>#J?A..#*>!]"1U2%T]_PKT^1_
M8_;?5O7F2^('25#CM^=C;(V77UU#OK??WM%1;IW-C,'55=']Q!-!]U305S/'
MK1DUJ+@CCWF)S7_=9\A<O\K[EOUOS3N[SV5A<3JK6]OI9H8GD`:E#0E:&A!I
MP/0?@YVNI9TB,$8#,!Q/F:=;Z'OBGU(W7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U4S\Y?\`MXC_`"3/_%F/E_\`_"ZOD[[]U[I"?\)W_P#M
MRU\`/_$19C_WY6^??NO=2/YX]?VM0?%#KIMJ9/Y$X+H>I^2?6%'\WL_\2J?+
MU'R*POQ'FQF[O[[UW7_]W*>KW338[^^J[>CW%/B8I,C#MIZYHT:/R@^Z]T6/
M^1ADZ*L[-^7=)\6]V?,/?'\L^DP?23]!Y_YFQ]B-GH>_*@;_`/\`3IA^C*[M
MK'8OL>LZ@I=O1;8EJUR,0@AW!-4BEN&F9O=>ZV-??NO=>]^Z]U[W[KW6FOVQ
M\)N^OG[_`"T/YC?0'QPQ&WLYV3+_`#VOFEO*+';FW+0[4Q\N$VWWEN-<JZ9;
M)#[(54(R,;+&[)K4-8E@%;+;[E/N_P`E>R'O;'SQS]+/#L`VNZ@+11-,PDE\
M,I5$[J'014`T-*XR"'F.PN=RVTVUJ`9=:G)I@5ZUE/Y6?\IKYD?+?N_9'8O3
MFV-E5NU^B^R_CWV+V%4[BWYA=OU5#M#<N[:_.XC+X_'U)DK,O'446P<J"D"/
M():8II+$#WV*]T_OL^PO^LVF_P`=YN#;9S7MF[0;<?HI@TDMJ&M)DD4C]$K-
M(@&L@%&#UTGJ/[+ES=/WAX15-<#QE^X8#=PIZX'EU]9/W\W_`%+W7O?NO=0\
MC_Q;Z[_J#J?^M+^_=>ZJ,_D%?]N>O@?_`.(BKO\`WO=X>_=>Z&GX/[]7<?:?
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M3/)JV)+\MWEUMY_WV#XUO_SAEU`?[1D^7EUD&GWE)^:46U][.6]CYPCI0W<D
M9V[=Z`4`&YV`B>2@R/J8KBI%6K5JY%[%_FK]+CP[Z^/WQV^9.W:;TKN?X_\`
M9-?\?^S9:.)FU5F2ZQ[FCSNQJW*/$`?#0[KIXW8V4+^GWOZOGC;L7-I:;A"/
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M[8W32K6[8W'@=QT3#4M7@<QC\O2LIM9EJ,?45$1!N.;_`)]R)%/#.NJ%U=?5
M2"/Y=8:W^U[GM<O@;G;3VTP_#+&\;?L<`]/WMWI!U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5P?SA_^W4/\R/_`,4@^3G_`+Y_
M=OOW7NC;?&W_`+)VZ$_\0MU;_P"\-@O?NO=5R_SQO^R(=L_^+M_R[?\`X.'H
M;W[KW5P?OW7NM2S^;8O64GSUWE_PX_DOYCV,^+T71W5!^`C?!M.XO[AS]OO5
M[X_TY?WLEZ:I*JJ_V8R/.)@?[NC-6QO\%*EN/?NO=7P_RP)?DI/\`/BO-\O?
M[UGY#2]6X]]_'?Z1Q]BM`V1R1V6W9<:`%.S6V!_"CN,.!*,W]UY/W-7OW7NC
MY>_=>Z][]U[KWOW7NJ>?G'_V](_DC?\`B2/GI_\``9;K]^Z]U<-[]U[JG7^>
MI\*^\?GW_+_W5\>/CQ0[:R7963[*ZSW51T>Z]Q0[7Q4N*VOFI:O+'^+5-/44
MZ5,<$H9$<*'`(!O8'*S[F?N[R=[(^^%MSWST]Q'R_'M]W"S0Q&9P\R`)V`@T
M)%"16F,4J01\PV%QN6VM:VU#*74Y-.!ZTN^O/^$R_P#-PZC[`V+VO_HIZ@W?
M_HQWEM?L+^Z>'[UVK29?<_\`<O.4.X_[O8NKR-)%CZ7(YG^&_;0R3NL*22`N
M0H/OK?OW]X?]U_FG8[SEG]Y;I:_O&UEMO&?;IF2'QXVB\5U4EBL>K4P4%B`0
M,]`.+E/>H)5FT(VA@U`XJ:&M/SZ^@;\0/FWTU\R]JYZNV&VX-E]F]=Y%-M=W
M_'WLW%MM+N[HO>H1C/M?L;9-7(U71"1HW-#DJ<U&*R<*F2EJ)`KA.''NG[0<
MV>T^Y0P[UX%WR[?QF7;]SM'\;;]QM_*:UN`-+4QXD3:9HB0)$6JDR58W\%\A
M,=5E4T=&PZ'T8?X#P/D>C@^XKZ7=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U4S\Y?^WB/\DS_`,68^7__`,+J^3OOW7ND)_PG?_[<M?`#_P`1%F/_
M`'Y6^??NO=)P?*?=C_SNNU>D>ZOE!C?C_P!)=$_$SJO=_0_Q^SN4VGL_!?*S
M.=TU^\J7L[MG)Y[<C4V1W,_2V4VE18>EQM#-:EFG:HTJ&JO-[KW6'^6KW]V5
MNOY\_P`SKX[4_P`HZKYG?&_J[.]0=M=9]IU4NW<ZW2^_.^9NQ<WV!\6Z3?NT
MHDV_NS`]?4^#H*C%TD3/-M^BF6BGM)=5]U[J\KW[KW7O?NO=>]^Z]U3S_)M_
MX\G^85_XU\_F-?\`O[ZGW[KW54O_``G(F@VCOK;FWHP(_P#39_++Z2[3(!LM
M37=1?-#YF]4Y*30#9I::AW%C@[6N%D0?T]Y.;^'W;[G_`"Q?'/[FYZWNR^Q;
MZRVZ^3\BT<M!ZJ>B:+]/?YE_WY;1M_O+.O\`E'6W![QCZ.>O>_=>ZAY'_BWU
MW_4'4_\`6E_?NO=5&?R"O^W/7P/_`/$15W_O>[P]^Z]U;_[]U[KWOW7NO>_=
M>Z][]U[H.^W-O;ZW;U=V%M;K'>=+UUV'N/9^X,'LS?U;AY-P0;+W%E<944.,
MW1_!8LABGR<V#J9UJ8HON(E:6-=1*W!27\5S/92P64@ANWC94<C5H8B@:E17
M3Q`KQZ$/*>X;'M/,^W[IS+9MN/+]M>12W%JL@B-Q$CAGA\0H^@2`:&;22%)I
MG/6IYU[_`,)>.P=B=D;/['J?F#UKO6HVMN_#;LK-O;Z^.-1NO;.[3C,K!DJW
M#[KPN;[-K:#.8G/)&\-9%.CB6.5K\F_N#+3V5NK:\CO&W"&0I(&*O;ZE:AJ0
MP,A#`\"#Q'75;F#^\YV'?.7+OER+E'<K*.YM)(%FMMW$$T&M"BR021V:M%)'
M4-&RD:6`\L=7P;B_E`?RV]Q5;9%/BCL+9^3(]&2ZLR6\NH*V!KZ@U/-U=N;:
M)A*MR+"UQ]/<G3<@\GS-K^ABC?UC+Q'\O#9.L%MN^]S]XW;8OI_ZU7UW;>:7
MJ6]^I_TPO89Z_GTQ_P##4W5&$*_Z+_DW\_>F(XTT04>P/F+VI7XR`<:;8CLB
ML[`QDH4`"TD3BW'MK^H]C'_N%>[K;#TCNY"/V2%Q_+I</O3\U7E?ZS\L\A;R
MQ-2UWL%DKG_FY:+:N/R8=9A\'OEWM@(O6?\`-4^2]'%%?QT_;W5'QP[HB<`$
M(M34U77&T,M.H'U(JD=CSJO[W_5K?H?]PM\O`/\`AL5O-^VL:'^?5/\`7L]I
M=R)/,OM;RV['SL+[=]N(_P!*%NYT'YH0/3KF.I_YM&TU(V_\Q/B-VT(V&A>U
M?B=O/8U1.BD<5%9UAW@]/%*XX+)2:1]0OX][^AY[@'Z6X6$__-6U=/YQS?Y.
MM?UJ^ZCNS5W#E#FS::C/T.^6]R`?D+W;02/D7K\^L@WG_-]VO=LQT5\">V88
MU+6V'WKW;U?75!!X5*3>_4F\Z*F=A_JJN10?[7OWU'/T/]I;;7./Z$TT9_8\
M3@?MZJ=G^Z/N>++?.>]J8G_B5MFW7JC_`&UM?6[-_P`XP?EUY?EG\_\``Z?[
MZ?RL]W5\"$+/6]1?++X_[[5K#UR4^-WA4=6Y1T_U(,8)]^_?O-47^Y.R2$>L
M5U`_\G\,]>/M1[!WP/[E]T+1)#P6_P!BW6V_(O;B]0?/-.N1_F0Y_"ZDW[_+
MQ_F,[1:(GSU.*Z'VQVCC(E47:0574_9F\ZJ6,6^JTYO[W_6^6/%UM.[Q_,0+
M(/VQ2.?Y=:'W<["]`;8O<'V[NP>"R;I-9.?EIOK.W4'[7Z[/\V[X?8K2.P!\
MB^HI"NJ5.TOB)\G-KQTW]155PZJKL;#8_4F?2/ZVY]^_KYR_'_N7]7;G_AEK
M<+3[3X1'\^O#[IWN]=U_<']7MV6N#9;]LTQ;_2K]<KG\EKTJ-O\`\V+^6YN-
M_%2?,WHO%S`@-3[PW=%L*IC)MZ9J;?$.WIX6%^0ZJ1^?;\7/7*$V%W&V4_TV
MT?\`']/17N'W5/O&;:-4W)V^2KY&W@-T#]AMC*#^1/1B]J_++XL;Z\7]RODK
MT#N\S:?$NV.XNO,Z\A87"JF+W%5.6/\`2U_9M!ONR77^XUY:R5_AEC;_``,>
MH\W3VI]T=CK^^N6]_M-/'QMONXJ?[W"O0Y8_*8W+0"IQ>1H<E3&UJC'U=/60
M&_(M+3R21FX_Q]F:.D@JA!'R->@1<6MS:OX=U&\<GHZE3^P@'J=[MTQU[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5<'\X?\`
M[=0_S(__`!2#Y.?^^?W;[]U[HVWQM_[)VZ$_\0MU;_[PV"]^Z]U7+_/&_P"R
M(=L_^+M_R[?_`(.'H;W[KW5N68J:ZCQ&4K,91?Q+)4F.KJG'X[R"+[^N@II9
M:2B\IXC^ZG58]1_3JO[]U[K60^$7RIPGR$_E#]O[T^4/\VI^F?DKW-FNU.P^
MW.Q/]('7'6787P3WKC-P4M')T7L;K[+M19_:.U>O(=BI3G%5D39'*KDJV6EF
M0UL$B>Z]U;?_`"E^]^Z?DW_+>^'W?/R'IV3N+LOI[$9[>&1?$QX%MTF.OR>-
MP._FPT%/24N-/8NV*"BSWB@AAIT_B-HHTCTJ/=>ZL1]^Z]U[W[KW7O?NO=4\
M_./_`+>D?R1O_$D?/3_X#+=?OW7NKAO?NO=>]^Z]U[W[KW5?'RY^`6VOD#NS
M`?(+IW?V<^+WS5Z[Q<F-ZW^3G7>/HJK)UN'#"H'6_=>SJLQ8+NWIS(54:-48
M/+W:G8>2BJ*60N7G/VN][MPY'VR;D;FNRAYC]HK^4/=;1=,P17X?56$ZUDV^
M^520MQ#A@=,J2"FDLO=M2Y<7,#&&_4=LB^G\+C@Z_(_D1T$?3G\Q7<W6V^]M
M?&?^9;L/"_%KY`9RL3;_`%WV_CLA4U7P^^461C_;AJ.F>T\OXTV;O7**OE?9
M.Z'HLY3F1%IWK@P8"CFOV&V_F#9;CW"^[Y>S<R<CPH9;JQ90-\V=.)%_9I7Q
MX$X"_LQ);M0EQ#0],P;H\4@M-U40W)PK?Z%)_I6/`_T&H?2O5L?O&3HYZ][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJ9^<O_`&\1_DF?^+,?+_\`^%U?)WW[
MKW2$_P"$[_\`VY:^`'_B(LQ_[\K?/OW7NCW_`"G^"7P[^;F(P.%^6'QSZM[U
MI=K2U,NUZO?.W(*S.[:-=X_OXMO;GI&H]R82ER!AC-1#35<4508T,BL46WNO
M="%\>_C1\?\`XG]<T74GQLZ?V!TGUO05M5DX]I=>;<H-NXRHRU=XQ79G*?9Q
M+4YG-UJ0QK-6UDD]5*D:*TA5%`]U[H</?NO=>]^Z]U[W[KW5//\`)N_X\G^8
M5_XU\_F-?^_OJ?>B0H+'@!U[K3L^!O\`/#^-_P`)=]_#'*[GZK[MS]?\<OB?
M\G?BAW=_=:EV-)#NJ7?_`,D</W?UKEMD#*;QQAKL7@JN@KX:_P#B'V,T3U2F
M%)1J/OL#[=?</]S^;?NN-RNV[;$DN^[KM/,%@6:Z*PHUC<PSQW!%L2LC0W,%
M/"$B%HV!8#22`;OF>R@WOQO#E(B22)OASW`@C/"H/&G'K>7_`);/\Q7J3^9W
M\?<G\B>F=G]A[(VMB.R-Q]85F%[+HMOT6?\`X[MO#[:SE55TXVSN#<F,FQD]
M!NJF\;_<"02!U9!I!;GA]X'V%YH^[KSS'R'S;=V%YN4NWQ7:R6C2M'X<LDL8
M4^-%$X<-"]1II32034@"S:MTAW:V-U`K*@<K1J5J`#Y$^O5@7N#NC+J'D?\`
MBWUW_4'4_P#6E_?NO=5&?R"O^W/7P/\`_$15W_O>[P]^Z]U;_P"_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[I+9_8^RMV1/!NG9^UMRP2`B2'/[?Q.9BD!^H>/(TE2C`_P"(]L2V
MUM.*3QHX_I*#_A'1I8;WO6U,'VN\NK9QP,4LD9'YHPZ+INKX#_!W?!=]V_#W
MXQYZ:0LSU5?T9UH]<6869_OUVTE8'M^1)<>RF?E?EJYS/M]DQ]3#'7]NFO4A
M[7[\>]NR@+M7-_,T$8_"NYWFG[-/C%:?*G0&9#^4!_+<K9WJZ+XK[.VG5L6(
MJ^N]Q=@]9U$;-_;BEZ^W?MIHF7\6L!8?T]EC\@<H,=2V,:-ZQM)&?^J;KT.+
M?[W/WC8(Q#+S1>74(_#=PVEXOV$75O-7IN/\J'X^8I57KWMSYK]2B+_@..O/
MFK\BJ6*F(%E\5+N7?>YJ,A0.%>-E_P`/=/ZC;4@I:7&XP?\`-.[G'_'G8=/_
M`/!4\_W3%N8-IY+W8GC]7R[M+$_:8;:%OS!!Z]_PWAVC@F,FP?YF/\P/`N%"
MQ0[QWSU!VS0QD7L7CW[TUD:^?D\ZZDD_U_/OW]4[V+-KO.ZK_IWBE'_&XB?Y
M];/W@^6;\:=^]M>0)A7)M[:_L6/YVVX*H_).L9^*_P#,<P8_WZO\TJ7-Q1L#
M!2=K?#+I'<A=`?\`-U62V)F.LJV6XX+`!OS[U^X^;HO[#>]0]);2%OYH8SU;
M_72^[K??\E3VO$+$9:QYAW*'/J$N8[Q1]G7CM#^<-MME&)[N_E_=GPH+'^^O
M2'>O6]9,!_:-3L[M?=U+`[?FU,ZC^GO9M^?X?[.YVJ8?TX9HS_QB5A_+K2[O
M]T/<03>;+S]MCG_E&W+;+M1^5Q8P,?\`>Q]O7'_25_-YVPK'-_%?X3]I>,D_
M\8Z^3W9NPY:E0?I%!V!TEDH:>1Q]`T[*#_:/O7UG/L(_5L=NG_YIW$B5_P"<
MD)_P]6_JW]TK<V`LN:.=-K!_Y2]FL[D+]IM=Q0D?8H/RZXCYB?/;`LIWO_*E
M[)FIU6\U9U1\I/CIV*MQ]?MZ#-YGKO*RWMP#"I]^_K!S1$?\9V.:GK%<P2?R
M)C/\NMGVA]A[X']R>ZFW"2N%OMEW:T/YO''=1C_>CUQ/\S+)80..P/Y>?\R/
M9AA;34U5!\=<5V7B8@/URK7=5=@;SFEA7_5"#D?CWK^N3Q_[E;3O$=/,6XD'
M[8G?_!UL?=KMKVAV#W!]N;P,,*V[/9R'Y:;ZUMP#\M77/_AW[X68QTBW]D._
M.I)F!UIVE\4/DKM2*`@785-<_5U7C:<+;DM,%_Q][_K]R['BZ-U`?^&6UPO[
M3X9'\^JC[H_O-=@ML$>P[L@_Y0M\V>8G_2K]:KG\EKT%/R:_G>_!WJKXX=I=
MJ=,]]]5=P]I;<V\R]>]3TV8KJ7<&YMYY6I@Q6"I\CMRJAQ&Y(L!C:VL6LRKJ
MD,D6/IYM+K(4NAWGW(Y:L=HGOMONH+B]1.R($ZF<F@JIHVD$U;AV@^=.A3[;
M?<H][N:?<7;.5N<-AW3:.6;BX_QJ^,:F*&W12\A293)#XKJIC@!+`RNE05U=
M'^^'OR>V+\R/C?U7\B^O9'&#[$V[%5U^-EBJHIMN;LQLLN(WGM2<U<$#5,VU
M]TT-70F=`T%1X/+$[QNK$5[#N]OOVSV^[VW]G/&&I_"W!E/S5@5_*O6/_NQ[
M<[Q[2^XV[^WF^`_6[9>-$'(H)HC1X)U_HS0LD@]-6DY!'1E_9OU'G5<'\X?_
M`+=0_P`R/_Q2#Y.?^^?W;[]U[HVWQM_[)VZ$_P#$+=6_^\-@O?NO=5R_SQO^
MR(=L_P#B[?\`+M_^#AZ&]^Z]U<'[]U[JOCLW^4]_+4[G[@J>_.U/A!\;]]=O
M9#+19[,[VW!UEM^KKMRYR%HW7,[MHOMDQ&[LJ[1+KJ,G3U<LFD:V:P]^Z]T?
M^DI*6@I::AH::GHJ*BIX:2CHZ2&.GI:2EIXUAIZ:FIX52*"G@B0*B*`JJ```
M![]U[J1[]U[KWOW7NO>_=>ZIY^<?_;TC^2-_XDCYZ?\`P&6Z_?NO=7#>_=>Z
M][]U[KWOW7NO>_=>Z#GMGJ'JWO?8&X^JNY^O]I=G]<[MHGQ^XMF;VPE#N#`9
M2G;F-I:'(0S1Q5=)+:6GJ(]%133*LL3I(JL#[ECFGF/DO>X.9>4[ZZV[?K5]
M44]O(T<B'SHRD55AAE-5=258%21TU-!#<1F&=5>)N((J.JJH/B?\Y?@;>J^`
MG9]/\G?CKCKR1_!GY:[YRB[GV;BXB"N#^-'RLR$6:W#M^DBC"PT."WQ%E\12
M0H1'707%LE7]S?9OWJ_3][=N;EWGR3!YAV6W3P9W/^B;MLRF.*5CEI+C;S!.
M[&K0O3).++<-NSMK^-:C_0I#D?*.3)'R#U`]>A7ZJ_FV_%W<VZ8>I>_H][_"
M/Y$_;RN_17RZPD'4V8ST]."DK]9=A9*MDZD[:QE54*5HY\#G:J6I1D9H8BX7
MV&N9?NO^X^W[:>9^2#9\X<AZA_NQV20WJ1@Y`N[5%^MLG49D6XMT5""`[4KT
M]#O5F[^#<ZK>Z_@D&DG_`$K?"WRH>J6*G_A8G\&X*BH@7XQ_*V189YHED^VZ
MB3R+'(R+)H/91*:PM[7-KV]Y=1_W4OO*\:N>8N602`:5O<?]FG1">>-O!_L9
MO^,_]!=;&WP7^8.Q/GM\6.K/EAUKMO=FT=F=K4^Z)L3MW>\6)AW/C'VEO7<>
MQLE%DEP>3S&+(ERFV9I(6BJ'#0.A;2Q*K@/[S>U6]>R?N3N7MES#<6MUNVV&
M$/+;ES"_CV\5PA3Q$1\),H8%11@0*BA(HVZ^CW*S2]B#+&]:`TK@D>5?3HVO
MN+^EO7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U4S\Y?^WB/\DS_P`68^7_`/\`"ZOD[[]U[I"?\)W_`/MR
MU\`/_$19C_WY6^??NO=70^_=>Z][]U[KWOW7NO>_=>ZJW^57\UOISXG_`"%Q
MG0^Z>L.WMZ8[`X?I#<OR![AV51;.DZV^-&VODKV[/T5T7F>R3GMW87=.73>G
M9%++#-#@<=E*C&8]/O)T\9`/NO=!'_*8W3M?8W5_\QG<>]=R[?VCMW&?S??Y
MBBY'<&Y\SCL!@Z`U/?$E#3?>9;+5-)04OW-9/'%'KD77(ZJ+LP!JX)0@<2#U
MX=?+5W;TSV@^!W!W)'LW*R]75N<R]72;WA^UEP5335.Z*O#P3PU$=0SR12Y/
M]E2%L7_PY]_4?]W'WG]I=]]N>3^1]EYDV6ZYQ'+MC$;**[A>Z$D%DAFC,`?Q
M0\01S(I6JA6)P.H5W?;K^*[N+F2&1;?QF.HJ=-"QH:\,UQTC-E=@[QVA78J+
M";SW;MW%0YJBR-32X#<.;Q4.M*BF-15+3XNMI@:HPP*-:CR'2`#P/>0^\[%M
M.Z02O>VEK/<&%E#2QQOBAH"74]H))H<9/13'+(A`5F`KY$]6([A_G1_S3*C<
M&=GQGSY^3$>-GS&3FQ\:=@Y6C1**6MG>D1*1%B2E58&4",*H0>D`6M[@;;_N
MC_=M%A`)^2N7FF$*:C]-&U3I%3JSJJ?Q5->-3T:/OV\:C2YEI7^(];['\B#Y
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M_P#LB]^Z]UV/E5\7S]/DAT*?SQW!UZ?I]?\`F(O?NO==?[-7\7O^\D>A/_1P
M]>?_`&1>_=>Z]_LU?Q>_[R1Z$_\`1P]>?_9%[]U[KO\`V:KXOV!_V9#H6QO8
M_P"F#KVQM];?[^+FWOW7NNO]FK^+W_>2/0G_`*.'KS_[(O?NO=>'RJ^+YX'R
M0Z$)/``[@Z]Y_P#7B]^Z]U[_`&:KXO?]Y(="?^CAZ\_^R+W[KW7O]FK^+W_>
M2/0G_HX>O/\`[(O?NO==_P"S5?%^U_\`9D.A;7M?_3!U[:_]+_WB^OOW7NNO
M]FK^+W_>2/0G_HX>O/\`[(O?NO=>_P!FK^+W_>2/0G_HX>O/_LB]^Z]UV?E5
M\7P;'Y(="@C\'N#KT'_WHO?NO==?[-7\7O\`O)'H3_T</7G_`-D7OW7NN_\`
M9JOB^;V^2'0IMR?^,P=>\?Z_^_BX]^Z]UU_LU?Q>_P"\D>A/_1P]>?\`V1>_
M=>Z]_LU?Q>_[R1Z$_P#1P]>?_9%[]U[KL_*KXOCZ_)#H47%Q?N#KT7!^A_X^
M+Z'W[KW77^S5_%[_`+R1Z$_]'#UY_P#9%[]U[KL?*KXOGZ?)#H4_GCN#KT_3
MZ_\`,1>_=>ZZ_P!FK^+W_>2/0G_HX>O/_LB]^Z]U[_9J_B]_WDCT)_Z.'KS_
M`.R+W[KW7?\`LU7Q?X/^S(="V/T/^F#KWFW]/]_%[]U[KK_9J_B]_P!Y(]"?
M^CAZ\_\`LB]^Z]U1E_-Q^)?7W\RS</5%/M3^81\1^H^NNM,9F*R3;>2SNSL]
MF]P[ZSU2(*O<&1S6,WYC//0T&`HJ:FHJ=D)@>2J?4WF`2-.?.1K_`)QE@$%U
M%;VD*DZ3&6+.QRQ((P%``'EW>O6;WW3?O4\I?=OL-TDW38K[=N8MREC43)=)
M''%;1+58DC>-Z,TK.\C@]X$0H-%2+/\`*2Z=V5_+AZZ[+ZAW[_,)^+O<G76Y
MMS8_>FQL5AMZ;6VY6;)W%4T4N.WC:?*;^RT51BMQ4]%CI%IXTC$-33RR7)G?
MVNY$Y3W'E"TFL+JZ2XM'<.@"E2C4H_$G#`+C%""?/H*?>P^\%R9]XKF';>;M
MCV*YV?F*VMGM[EY)XY5N(0P>WPD:$/$S3`L2=2.JX$8ZO7V_N+;^[,-C]Q[5
MSN'W-M[+P"JQ6>V_DZ+,X;)TI=D%3C\ICIZFAK8"Z,-<;LMP1?CV/>L3.J^/
MYP__`&ZA_F1_^*0?)S_WS^[??NO=&V^-O_9.W0G_`(A;JW_WAL%[]U[JN7^>
M-_V1#MG_`,7;_EV__!P]#>_=>ZN#]^Z]U[W[KW7O?NO=>]^Z]TC>Q=_;7ZIZ
M^WWVCOC(C#[*ZVV;N??V\,L8I)QB]K[.PE=N'<&1,,0:6846)QTTNE06;38<
M^_=>Z(7_`"_OYE&R_GM-V!A*3I?MKX_[XV/LGI+N&EV/V\=DU&6W7T1\E-L9
M?=_1?:V%K=A[JW9B8:3=^'P%:E9BZF:+)X6MIFIZN)7*D^Z]T6#Y_P#;'5FV
M/YIW\FJGW-V9U[MRHV=O_P";M9NVGSV]=M8>?:]'N#X<;HI\#5[AAR.3II<-
M39NHE2.DDJ1&M3(ZK&6+`'W7NK2O]FK^+W_>2/0G_HX>O/\`[(O?NO=>_P!F
MK^+W_>2/0G_HX>O/_LB]^Z]U[_9J_B]_WDCT)_Z.'KS_`.R+W[KW7?\`LU7Q
M?Y/^S(="V'U/^F#KWB_]?]_%[]U[KK_9J_B]_P!Y(]"?^CAZ\_\`LB]^Z]U[
M_9J_B]_WDCT)_P"CAZ\_^R+W[KW02=V]@_`SOOKO<'7G;G8'Q'[=VOE,=7(-
MI=B;VZ>W=@IZZ2CFBI9DH-Q9>KHZ:L25QXZA?'+"UF5U(!`HY/YNYDY)WZ#?
M>5]RO=KW&.1?U[6:6"0*&!8:HF5BI'%34,,$$8Z9N+>&YB,4Z*Z$<&`(_GU\
ME.L^"/RW6KJU3HC=ZHE3,H$<F#EC51*X54E@R\L$B`#AD9E8<@D<^_J$A^]9
M]VPQ*3SURN3I''<;8'AZ&0$?80#ZCJ%CL>\5_P!QI_\`>#_FZW?_`.4CN_\`
MF&_&;^7M\>=B[5^07\L'"8O"478LX^.ORPSN\>JNX]@#)=M;[R_V.8[%Z][`
MW=CLB^Y#6G*TC5>UX9:>BR$,3ZO'J/''[T7.GW0_<'WVWW>-TDYJFN9GM!^]
M-EN]MO;"YTV-LFJ.VN8X67PM/@R".\8-)$["FJ@D#9;;?[3;(HT$`4:NR175
MAW$Y()X\15>!ZLA/\SOYL[6)I]R_%?X&]EF)5#Y/IO\`FM]0XF&I<?K>FQ';
MG5NS9HT/]E9*L&YY;WC^/;_[K.Y#Q+#W%WK;JGX+_EJ1R!Y5DLMQG!/J0GY=
M&OU6]IAK2-_]+,!_)D'^'J9'_-^[XIM(RO\`+SIWN&+2;9_F/?RZ,_"-*@C1
M]YWQM^H;4Y(&J)387M<V]MGVA]A)?]Q?=O91\IMDW^(_RLY!^QC_`)>M_7[H
M/BL)/RDB/_/PZR+_`#B^VF-E_EY;L'(&I_G9_+DC0$_37(_R8"(/\2;>]'V9
M]DP*GW:Y:I_TK-^/\AM]>O?O'<?^4";_`'N+_H/K,/YPO;0(,G\O?<8C!&LQ
M?/?^6U-*$OZC'"/D^IE<#Z+<7/%_=/\`6=]D3A?=KEO5Y5VKF`#\S^[<?;UO
M]X;E_P`H$W^]Q?\`0?4K_AXCL#_O`#L#_P!+4_EN_P#W6'MO_6;]GO\`PK'*
MO_9!O_\`WJ^O?O#</^4&?_>XO^@^D;V#_.(WG5;$WYCJKX(=KXB2JV;N2G@R
MF.^6_P#+URHHGJ<)7Q"LUXGY6/5AZ-F#@4R35!(]"%]()UR_[+>T_P"_;"2W
M]T^4)B+R']-K3>T+TD6B`/ME#JX=VE<Y-*D-R[C?>$P-C<#M.=4?I_I^OESG
ML;L(DEM^;S)))).Z,X22>22377))]_38.7MB`I]%:8_X4G_0/4->++_$W[3U
M]#+^4M_-HGZ=_EU_%7K3._$WY'=IUNT^OLACYNPMO=I?$7^&[E+[RW-4Q5-)
M1]D?)W9V^*."GAG$`CR6.I)T$("Q^(QL>`/WJO97D?>/O!\T;C-[@\D;)<2W
MZ%K&[;<8I[<_3P@K(L&W2Q:F^/L=@0U2=51U*>Q[C<Q[5"@M+F0!?B700<GA
M5P?ED=6))_/`VVKR1U7P3^7T10@*U-N_X15\;_75:6G^7_B(''(+`_[#WC\?
MN_<ED`Q^ZOMN:^MUNBG]AVJO^#HU_>MQYV-Y_O*?]!]8D_GK=9)3R35GPI^;
M%,T9;5%%!\3*YM"V`9!2?*Z1I";_`$4$^[G[N?+Q<)%[H>V+`^9W*^7_`(]M
M@I^?7OWO+3-E>_[PO_0?7G_GS=%P0QS5/Q$^=,6LHCK%L?X\UIB=E)*L*#Y,
M5+%5L?4!8_ZY`]^7[MFWNQ6/W*]K33UWF=:_[UMX_9U[]\..-G>_\XQ_T'UQ
MD_GZ?&N":.*I^,GSF@$@)\R]0];5D2*+B\AQO==;(MR+6TEO\+<^_+]V974M
M'[A^UQ(\OW^JG_C=LH_GU[]\^MI>_P#.+_9ZQ_\`00)\2HYVIZOHCYM4+HH8
MM/T/AYD]5BJWH.Q:PZF4W^EOZD'W?_@7[UD\2+GOVQ<$^7,=L/\`CR+UK]]+
M6AM;W_G"?\_6%/\`A0K\*/++#4]6_,FB>(Z6\_QUR$H+WY130[CK+D?6_"_T
M/NQ^ZQO>D/'SG[:.#Z<S6`_X\R_Y^O?ON/SM[S_G"W7"/_A1#\"C-+!4[0^7
M%"T/#M4_&?>CIKN!XU>CFJ@6L;_ZFP^M_>V^ZES3H#Q\U^W#@^G-&U_M[IE_
MS]>_?D'`P7G_`#A?_-UU-_PHK_EYTTL<55C/E13&2Q#/\8.S)$5"VDR.::AG
M(52#<`%K#@>]I]T[G.12T7,OMVU/_#IV<?EFY'7OW[;CC#=_\X)/\W4G_H(G
M_EQ?\K7R5_\`26^XO_L<]M_\"?SU_P!'_D#_`,>G9/\`MLZ]^_;;_?5U_P`X
M)/\`H'KW_01/_+B_Y6?DK_Z2WW%_]CGOW_`G\]?]'_V__P#'IV3_`+;.O?OV
MV_WU=?\`."3_`*!Z[_Z")OY<=K_<_):PXO\`[*WW';_;_P!W/?O^!/YZ_P"C
M_P"W_P#X].R?]MG7OW[;?[ZNO^<$G_0/77_015_+;C]55E/D;0P"WDJJKXN]
MS+3P@FRF1HML2R`,Q"BRGDCW[_@3N?CB/?>07?R"\T['4_96\`_GU[]^VOG%
M=4_YH2_]`]8YO^%''\KRGC>:???>$,,8U222?&3O)407`NS'9=@+GWM?ND>Y
M;L$3=.2"QX`<T;%_VW=>_?UF.*7/_."7_H'HO/RA_P"%'G\O3,_&GY"XCI;N
M+NK;_<65Z1[4QO5&=@^/_<6!FPW9-?L;.4NQLG%G,GM"''866BW/-2R+5SLL
M-,RB1SI4^Y`]L?N?\]#W)Y?/,EQR;><O?ONQ^J@7F+99VFM_J8O'B6"*]:28
MR1:E$4:EY"="@DCI+>[_`&WT<O@BX67PVTGP9!0T-#4K04/F>'6B%_P\1_-/
M_P"]@'RL_P#1Q[O_`/KA[[G?\"C]VSSY'Y:K_P`\$'_0'49_OS>/^4F;_>CU
M]4#^6KOO>7:/\O;X2]C]B;DRN\=^;Y^+71VZMX;LSM2U;FMR;DSG7>W\AF,W
MEJQ@'J\EDJZ=YII6]4DCEC<D^_FR^\)LNT\M^^O.'+^PV\5ILMES)N,,$,8T
MQQ11W4JI&B_A1%`50,```8ZF#:I))MLMY926D:%"2>))45)Z+I\Y?^WB/\DS
M_P`68^7_`/\`"ZOD[[A[HPZ0G_"=_P#[<M?`#_Q$68_]^5OGW[KW5T/OW7NO
M>_=>Z][]U[KWOW7NJ/OG%_*=[$^57R6W9V+LWN[96Q.CODEM/XD[%^7^P]Q;
M`S>XNP<Y@/AG\A*SY!]>5/2V[\=NS#X7:N5WK5U\F!S1RN/R$-/0@5-.K3^@
M>Z]TS?RW^K^E>Z?CY_,XV%\B=A=<=D]-Y7^;I_,3RV]MH=M8';^YNO*NAVS\
M@!NFER&Y<3NJFJL!)2;?R6(AKTFJ4T4TM,DUU*!A[KW3?T?_`"8?Y%/>GQ0P
M>TNC/CS\<.X^I:LY+$8OY`]?3;;S?;F0K<1N^IRN3B/R*V:*7?[93'91&H)U
M&1208Y11R*:<Z".?;?W&YL]IN<[/G[D>X2UYGL#)X,C11S*OBQ/"]8Y5=&K'
M(ZY7%:BA`/2:\M(+ZW:UN1JA:E14C@01D9XCIFI_^$P_\G&FJ(*D_'G>4XIY
MHIS#5=[]RS4TPB=9#%4PMO/3+!)ILZGAE)'O*>;^\4^];/"\#[[::'4J:;;8
M5HPH:?XOZ'HD'*6Q@U\)L?TV_P`_5-NX_P#A-Y_)^;-;1JC_`#.\WM^#NCL[
M>W774V)BWKT$M)NS?6T=Y/LW=/7^QW;&HN?R>S-XSQ8*JBI]9I\G)#2/IJ)H
MHWFRR_O5O=>SLH;0\M[`YBB1-1>[!.E0M:>+BM.'ET6MR/8LQ;QI<FOX?\W5
MQ7P'_E!?R8,5\>*[8FPNN/B3\^Z_J_>.^]J[X[WW_P!==$]O=A?WQ7)U.9J-
MG[LW-A]OU?VDVUJ#)4]/1TS.&2A6%T)1E8X*>^WO)O7OU[DW?N7S!:VMEN5W
M#!&8K<N8U6WA2%2#(S,20@)J:>0%!T)MLV^/:[-;.)F9%)-32N37RZ)]_*K^
M)G\FG"_RNOY>V_?F%\=OY?V.[/[\VG/@<+NWO?K+I*+>?:V]FWMN&@2EI\QO
M+$?Q?<^5BA>D@=S))X?+`CLODB#0]T8='@A_EV_\)[OC14=IT^^^D/Y?E!49
MGY#IC-V0]VX+I+.-U[VWVSMK#;NV[TMMY=W8YO\`1WA9-H)#E\-M6'P4]#C:
MB2KCB2"1Y/?NO='._P"&>?Y4/_>MSX/_`/I,73O_`-B/OW7NB'=P_"7_`(3@
M;SZ_WZNY^M/Y;G7>V>G>X=D;6[,W?L"BZ$ZWRVR>R=M;NCSM#UKN[<^!HZ.L
MQT.XJW:-;C\QB)W$>0QU+DZ6=?'!5^+W7NC);%_E]?R+NS]]]B=8=<_#K^6Q
MOKL7J27$0]G;)VGTET!GMS;#EST$E3AUW3A\;MZIK</_`!".%Q&9D4%XV0V=
M64>Z]TMM\?RLOY-W66SMS]A]B_`;^7]L;8>RL'DMS;OWENSX\]'X#;.V=O8>
MEDK<KFL[FLGMBFQ^+QF/I(FDEFFD2-$4DGW[KW1/C\$O^$Y_5_9OR3WSN+J7
M^7C29G!8'K6M[AV5OC"])UNQ.EL7@HXMNX'(;;V#E\:<)UM5;NR&^<?%F6H(
M8YLKDJO&K5`SR4JO[KW1T]O_`,IG^4'NW`X3=6UOY>WP*W)MC<N(QV?V[N+`
M_'+I/+X//8+,4<.0Q.9PV5H-K3T.3Q>3H*B.>GJ(7>*:)U=&*D'W[KW16.\O
M@3_PGL;$=]](]B]#_P`N7J?<6S^J<CF.W3M_:'1'6O;'3VQMU4M#A*;?D.;Q
MV+HMS=?Y6FGW3CFQV1C\=13UF0Q[1^NJI1+[KW2NZV^"'\@;<^Y-D]*]?_&3
M^6IV#V#ENHMN=H;3VQ1=9=`;QW[N[J:MH:./"=F1K'AJS+[DP^<I)(JG^*?N
M"J683EBKZS[KW0H]H_RSOY*_26Q,]V?V_P#!7^7OUKUUM:.BEW'O;>GQ[Z0V
M_MK"1Y+)4>&Q[Y/+Y':T%'1K697(P4\9=AKFF11RP'OW7NB@8KX8_P#";+=?
M;^S^S\'U_P#RV<AF<O\`'O>N9VUL/'0="IU5N+J7&[BJMQ[E[F?K=*5-JY3+
M[8;K?+01[FDA-11XBARL:2"GBJC'[KW1P.K_`.6;_)7[LV)M_L_J#X+_`,O3
MLOKO==/45.W-Z[)^/O1VXMMYF*CK:G&5OV.6QFV*BDFEH,G134U1'J\D%3#)
M%(JR(RCW7NDWF_Y?/\B[`]M;>Z`SWPX_EO8?NK>.(?,[9ZLKND.AJ'?N<Q1@
MS%0E9B]O/MZ/+3"II-NY*:GT)Y)X<;5R1!DI*AH_=>Z!3J'^7E_PGLZQP/1_
M0N$Z1_E\=A9_>%=OSK_J:L[,P'1_:';';NX^KMSYG;G8F.CW=N#'5^XNPMS[
M.W7CJO%9`F2:>GK*1J1K21>,>Z]T;_)_RC/Y1^$QN0S.9_EV?!'$8?$4-7D\
MMELG\;>EJ#&XS&T%/)5UV0R%=5[5BI:*AHJ6)Y)99'6..-2S$`$^_=>Z)#DO
M@I_PG,[8S'Q=[(P_57\NN&AW)V3NK$](4.P<9T9M_9G?F]1B*G8N9V)F]NX>
M@AQO;4.`R&Y*9X,55).M'G)<?(BBHDIUD]U[HR?4'\O'^1M\@L%F=T=&?#/^
M6[V]MS;VYLILS.YSKGH_H/>&*Q&Z\,M/)D\!D*[![=K:>ER=+3UD$WB=@S03
MQ2KJCD1F]U[IJWY\#OY#O5U5OZ@['^(_\M#8]=U7L?#=E]DT6Y^E_C]AJO8N
MP=QY>MP&W-V;JIJW;\,V$PNX\[CIZ+'S3J@KJN)H8/))Z??NO=`%UU\#O^$Y
MW6-5O3$4G5?\NW==7ON@W;\NZC_21C^C=]_W>ZMW?BH][3YC8];N&BJH-I]'
MX/:M*<EB,91O'C,;A]=1`BTQ:3W[KW1HMI_RW?Y(^^^KJ#N[9OPG_ER[DZ>R
M>WJO=E%VAB.BNA*O8<NVL<M2V3SC[ICVZ<-!C<5]E.*N629%I'@D6;0T;A?=
M>Z+-V;\"/^$ZW9XV/USDNI/Y=VQLWG]I;+^56THNO,7T7UIN[=/3VUA_I/H-
MY-D<-08_(9;IK=.U]N5=3DU=CCLOMV"M:352Q3O'[KW0C[4^)?\`PGGWUE>H
M<%LWXY?RL-SYOO[';ARW2F'PG5GQRR&4[0Q^TZG(4.YJC95!3X1ZO._P*OQ%
M93U2PHSQ5%%4Q,!)3S*GNO="?O+^7#_)#Z[W#B=I[^^%7\N+9>YL[M?>F]\3
M@MT]&]!X')UVR^N:&FR>_P#=\-)D]O4TO]U]EX^MAFRE>P%)0QRJTTB!A?W7
MNBL=?_!G_A.*G8>.[$VUUC_+JW=7?,VHPM%U)M+,4/1FYM@YRLZEIZC9&4I>
M@=B5]#+A=L5=9F*L0;@CQ,4;Y/.>):@-5Z$/NO=&<Z>_EW_R./D)M*HW[T5\
M,?Y;_;VRJ3-Y3;55NKKGHWH/=^!IL_A3%_%,/49/";=K*2'(4<=1%*T;,&,$
MT4JWBEC=O=>Z#G>W\M#^0SW#TX:*G^,_P$P6Q^\]T9[X];*[/ZKV+TEL[<&6
M[1GR^Y-D5NT>HNQ]MXB&L3M+%;DVQDZ:G3%325U/68V?2MX)-/NO=<LI\)O^
M$^O6*8;:F[/CA_+%P]?2]G8[XXTR[NZX^/,F>K.ZH-O;?S"=9Y2LR6(-;5]F
M/@]Q8VLJZ.<_?`9&"290:B/5[KW5P/6W6?773>Q=M]8=2[&VGUIUQLW'_P`*
MVEL38N`QFUMI;:QGGFJOX?@MOX:FH\7BZ/[FHDD\<,2)K=C:Y/OW7NB,?SA_
M^W4/\R/_`,4@^3G_`+Y_=OOW7NC;?&W_`+)VZ$_\0MU;_P"\-@O?NO=5R_SQ
MO^R(=L_^+M_R[?\`X.'H;W[KW5P?OW7NO>_=>Z][]U[KWOW7N@Q[MZKP/>O3
M/;G2.Z:BLI-L=Q]8[^ZKW'5XXQKD*7`]A;5RVT<O44+2J\0K(<?EY&B+`KK`
MN"/?NO=5M?RR_P"7-VI\,<_V/V)WUWALSN[LO<W2GQ<^+VTJ_KSKC*]9[:P7
M17Q"V?N3:?7-5E\7FMY;UKLIV3O:7=M9D=PU$=1#CDJ!'%101Q*0?=>ZY?-/
MX1_RANS_`)/_`!X[8^:W6GQBJ?D)O#<F;VGUC2=JT&PJ>O\`D+FJ_:-#U[1;
M6WG@<_0R/W#3;0H\MCXL%39`5$6)R\]#]MIJ9:=']U[H4_\`AGG^5#_WK<^#
M_P#Z3%T[_P#8C[]U[KW_``SS_*A_[UN?!_\`])BZ=_\`L1]^Z]U[_AGG^5#_
M`-ZW/@__`.DQ=.__`&(^_=>Z)YW%_+<_D`[5["FWYV5\>_@GUODOB%@J;=G:
M6T*?9O46T]D8/`?(%*OK_8>1^0.PZ+"Q8G.TV9R^'G&TDS4)>'*(9J)?*P)]
MU[HSNS/Y5?\`)W[$VEMK?NQOY?7P,W5LS>.#QFY=K;EPWQKZ;K,3GL!F:2*O
MQ66QM7'M'14T-?1SI)$XX9&!]^Z]TIO^&>?Y4/\`WK<^#_\`Z3%T[_\`8C[]
MU[KW_#//\J'_`+UN?!__`-)BZ=_^Q'W[KW1"NS?@O_PG*H.T<SO7>?4_\OG9
M&>^%*Y:F[@V'C,#TUMG96#F[BIL)M'$4_?'7=!B8L3N_)462FI(MOQ9*">?$
MYBM`@5*JH"M[KW1WMO\`\IG^4)NS`X3=.UOY>OP*W'MG<N(QN?V[N'!?''I/
M*X3.X+,4<.1Q.9P^4H=K3T62Q>3H*B.>GJ(7>*:)U=&*D'W[KW3O_P`,\_RH
M?^];GP?_`/28NG?_`+$??NO=>_X9Y_E0_P#>MSX/_P#I,73O_P!B/OW7NB<]
MV_RV?Y`'7O9$'9/;7Q\^"W5F2^+VTH<OO[94NS^I-H;"H]N_([+T^P.OL]W?
MUO3X:'$;CES.Y]I3TFS)\M3M)!D6J_L;R2O[]U[HU.U_Y3_\H'>NVMO;RVE_
M+S^".X-J[LP>)W+MK/8OXT]-U6,S>`SM!!E,/E\=4IM'144.2Q]5'-$XX>-P
M1]??NO=/O_#//\J'_O6Y\'__`$F+IW_[$??NO=8:C^3E_*?J:>>F?^6_\)XT
MJ(98'DI/C7U-154:RHT;/35M'M:"KI*A0UTEB=)(VLRL&`/M^UN9K.YCO+8Z
M;B*174T!HRD,IH00:$`T((/F.M,`RE3P(ZI;WK_)J_X33;#R?:+;SWEM':3?
M'^NPF#[HPN2^7^]::/8^9WM7-BMKT6\8ZK>TV6QV3GRE%/300Q31E:F.>*="
M\3+'FZ?[QC[UY.H[[:%O^E=8_P`_T*'\^@W_`%1V/_?3?[VW^?JV_K'^2U_*
M&VQU_M+"[:^!7Q)W]M^EPM)+A=Z[WZEV#VSNC=&-KU.0H\UE>R-W8K<.X=WM
M70U8>*LJ*VHU0%!&WB5`,2N?>>>9?<OG"_Y[YPG6YYEW*;Q;B142(.X54!"1
MJJ+VJHHJCA4Y)/1[:VT-G;K:VXI"@H!4G^9Z7?\`PSS_`"H?^];GP?\`_28N
MG?\`[$?80Z4=>_X9Y_E0_P#>MSX/_P#I,73O_P!B/OW7NJYMT?%3_A-#)V9F
M^QLOUY_+JP&4^+E-G]@]H;(HML=08/K_``>5[+W=B]DT'^EOKJ'!18;.;MHM
MX[.FQ>WJBM@DJ**JDKXJ;U22V]U[JP;"?RD_Y1FY,-B-Q8'^77\%<M@\]C*#
M-8;*T/QFZ<GHLGB<I2Q5V.R%),NT=,U+64<Z21L.&1@??NO=.?\`PSS_`"H?
M^];GP?\`_28NG?\`[$??NO=>_P"&>?Y4/_>MSX/_`/I,73O_`-B/OW7NB`[N
M^&W_``FVQV]LQW5N+K3^7)MRE^/.4S70G86WX\+TAB.JL-OKL'*TC4^.[)V+
M%BTV]EM_XBKZ^R%/BZVJB>?%QTV:C1T$-=X?=>Z/S!_*`_E-54$-33?RXO@U
M44U1%'/3U$'QFZ;F@G@F02130RQ[2:.6*6-@RLI(8&XX]^Z]UE_X9Y_E0_\`
M>MSX/_\`I,73O_V(^_=>Z;\O_*0_E&8#%9+.Y[^7?\#L)A,-0U>4R^8R_P`;
M^E<;BL5C*"!ZJNR.2R%9M:&DH:&CIHFDEFE=8XT4LQ`!/OW7NB6R?`W_`(3L
MYON3J'>\'3/\OF/<N[_CGNOL7K3KN@VQTS0]==D](9V*CWU4]VGKA,1'M_=O
M\)V_L6MJ<3N&2)Y*?#Q95J=S3I5-'[KW1C^F?Y=/\D3Y#;$Q_:'1OPA_EZ=I
M]>Y6JKZ+&;RV5\>.ELU@*ZJQDYI<A#2Y&EVFT,STLX*OI)%_?NO="K_PSY_*
MD'T_EO?"$?\`EL?3_P#]B7O6E?0=>Z#?N7^3C_*3R74/:6-S7PI^'/36)R77
MF\\=D>WL!T5TMLS/=6T=?MW(TE1V'@]WUNU8Z/:^9V9',<C2Y"9A%23TZ2MZ
M5/L1\F\QW/)7-^U<Y;?%%+?[3N-M>1)("8WDM9DG17TE6T,R`-I8-0FA!H>F
M;B%;FW>W<D+(A4TXT8$8_;UK>O\`\)ROY,46=VOMBH_FC;RI=P;TZ@A[^VMB
MZSL+X_T55F^EZG;61WG2]FT:5>U80=H5>S\-6Y:&K8JDN,H:JJ0M!33R1]+O
M^3KWN^34\M\N?MO?^VCH'?U&L/\`?TW_`!G_`#=;>OP5QO1NW?A_\=ME?&SM
M3']U])=;=5[3ZMV#V=C\UA\__>K$]9XV'8TE9D<C@8*3%_QV&MP,L-?#'#!]
MM61R1-%&R%!S>]P.<K_W$YYWCGS=(H8-RWG<KB\ECBU>$CW,K2LD>MF;0I8A
M=3$T&23T+[6W6TMH[5"2D:!03Q(`IGHI7SE_[>(_R3/_`!9CY?\`_P`+J^3O
ML(=*.D)_PG?_`.W+7P`_\1%F/_?E;Y]^Z]U=#[]U[KWOW7NO>_=>Z][]U[KW
MOW7NJ%?Y?'4%-\@_B/\`S?NA*S.5.V*3NW^8W_-FZCJMR45*E=5[?I^Q]][C
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M:WJ8D^_=>ZUVOD/_`":_DQWQOWM?MD?(GI_8N_,QOC!5G6=/USM;NGK?;L6W
M\)L#Y.]7XO>F\)]J=LQ;IP6_\!M?Y(I5_P``VY74>Q\]F=OU57DZ"5MSYC3[
MKW1U?A3_`"\.Q/C!\A]]=K[V[>VGV-MB#:7;^SNL#A]D5>UM_P";B^0OR&KO
MDYVCN3N:O7+U6V<EG<3OVK_AV"CPU'1TD6*,C2(LD@C3W7NA5_F=_!G+_P`P
M[XJ;M^.&*[HSG3/\<.2R<E31[<VWNW:>\\A#M'<^*VOMKLS;FXL;7G+;'Q>\
M,OC\\T=%)2UT>1PU)-#,KQ`'W7NJT:G^2Y\AL;W#N3O#"_)'JW<V_<!O[9'<
M'75?OWKS=0PN_>P-M]@]%[]GQ_;&R-M[EH=D]>;?IO\`0[44DM7L"AQ.0W/5
MY.FRF=%968FE#^Z]U=?\1.A!\6OB]T%\<_[R-O"3I;JG9?7=3NDT/\*CS];M
MK"4N/K\I28G[FL.(QU76Q2/2TGFF-+3E(O(^C4?=>ZJ2[*_E$]YY?Y*]_P#>
MG6_R+VMBMO;^[>V=\F-C==[ZQO96Z=N9GNG97:WQ9[9V]MOM';G]]EVAANNM
MOY?XTSTD.1VC08K<>1I-TE<C+5)A<?')[KW3_P##/^49V-\6>\NF]\Y7NK8&
M\.O>M\AE^YLU08S8&<PV_<I\A=W_`!UD^-NZ]OX3+U.YJ_"XGX]46W:VHR^'
MQLD$V6I:Y8*=YGAB\C>Z]U;W\@=F]@=B=%]P[`ZHWI2=;]F[WZTWKM+8/8=;
M15.1@V'N[<6WLAB<#O+[&CGIJFJFVQDJN.MB1)$9I8%Y'OW7NJ>/E'_*0['[
MTR^VNJ]E[RZ$V#\2.OOBY6]*=8;-J=A;NJ^R-H=KIU=NOK?;_>F;R6&SV$PO
M9>8V_M_.G`4-#FGEIJ#;^7SK0`9')BJ@]U[JRKX4_'S>GQSZCW'M_LK<VU=T
M=E=E=U]W]^]A5.P<3E<'U[BMV]X=D[@["R>V]B8S/5V2SD6V=O#,I2Q35DS5
M-9+')4R+&TQC3W7NB/\`RP_E?=F_(WYH4'R2VM\B3TW@9.O]N;7?-[.PM>.W
M-AY7:W6GR=ZV@R.Q*:LK:KJ7-YS*1?).3(46YMPX7(;DVC)B'IL-/%!E*H1^
MZ]T67H#^1[VAT!N#I?%XWY);#W;U?LKM?![NW7C\ETW1;7W7@=B]/?-K>_S6
MZ3VITZVRLCA-L;?K=P[JWE-C=XS9"DJ8S!+(V."1I!`GNO=7Y=N]?8[MKJ?L
M_JO+TV&K<3V9UYO7K[*4>X\?6Y?;U7CMY[;R>W*VFSV*QN6P&1R>&GILDR55
M/3U]%--`61)X682+[KW6NQL;^1'WGM7<?5O87^S:?P_L.;>&3K>[<KC\[WEG
MJ>@V9)NGH/(TF*ZQFW=V/DI]^9'*[+Z'7;]9%V#'G,92QYP5U%3Q5F&Q[/[K
MW5G7\M;X-;\^%6T>P,=V5V#LC?FY-TT'16P\/)USM7,[0VS1];_&GHK9/0/7
M.0R6,SN:SM9-V!NK;^S1DL]+%,M%%4SI2TRM#3++)[KW2%^3/\MO+=H=Y=O_
M`"!Z>SW5/7V]=_;-^'63I*//[$KZK&;P[M^'GROC^2NW-P=Q5>V\AA\KNO:F
M[\/A,3M:<I(<ECZ*E$D+N(88??NO=5V3?R!.TI(Z:A7Y(=?K%3]04E$,LVP=
MX&#_`$KTNRZ[%G;O^CT;T&PGZJGWU6_Q'^\#0_Z1(]N*=K+D_P"#L5]^Z]U<
M9TI\-_[N?$+?7QU[S/6_:.8[AWC\B.T.T*"GVA/-T_\`WU^17<N_>\,OM_;F
MS=UU6;K)]A[,W-O<4U!'7R2U%5%0K/,%ED9%]U[JM;LK^3]\@>T]D=)=%;D[
M>Z`/1W4?P+P/QAI9H.N=Z0=@P_(#%_'//=%O\F&DQVXL9BMZ5>-QF7EPV%Q&
M<FGIL+M?+YI*?37Y!:J#W7NGOK#^4+W?MWOG:G=F]>[.GZIM]]_[0^3OR2P.
MT^O=W4K8SL3J?O7OSO;KG:7QTR66W54';FP<YE.]'QNYFS4536UD.-:HA"25
MTD<'NO=6!_(WX72]N?)#J3Y,;$K>K]H]A]<])?)7J')YW>/6L6^*O=5/W!L[
M%8;KNBW+!%D\%/N?K[8&Y8*W(5F`J*R*"O2OFCCDIWE>7W[KW5<`_E)_*+-X
M/K38.\>V/C35]5U_=?=7>7?^SL1L/LV/+Y+<O:W8+[VVIC=C]B97=.1[#W5M
M_I'<=76;OP-%NO)U=-5;TGHYJQ'H,-CJ5/=>Z/G_`"]_@[N[XK]5=J[/[MW=
MU[V=N#MBNZYQ.=H]A;2RVV>O!L7J#XV=0_%O:=$^W]R9C/UU1F]V[*Z@@R>>
M+3?;"MR,E+`IIZ>.23W7NB3;D_DH[OK,9\2:?K[Y/IT_#\1_E-VSWEU_LC9O
M4NP*_K#;^V^SOEAV)W]"=E[:W'@LE+M?LK;77^[*#:%)5QR/B(Z"CGB6C6GJ
MYXY/=>Z!"@_D$=M;0Q78>U]M_+_"[YP':^_.WJ'>&2[8ZBQ3;OINK_D5L_XM
MT'=/85!EM@5.U(,Q\H<SN_XT05R9O(QRXRK;)25,\*U;U#U'NO=;.'OW7NJX
M/YP__;J'^9'_`.*0?)S_`-\_NWW[KW1MOC;_`-D[="?^(6ZM_P#>&P7OW7NJ
MY?YXW_9$.V?_`!=O^7;_`/!P]#>_=>ZN#]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=5<_.3^7WN[Y8=S=0=C;7[1VWL?;V'VWA^M.XL-N#:>4W%G,KUQ@?DI
M\?OE#0UG5>6Q^X<-2;3WY/N[X^TN)FJ:^GR%)_#\HU0L7W%%`LONO=6C>_=>
MZ][]U[KWOW7NJ@_E'_*^H^Z-X_*S>NQX^D<6/DEM;X?G+;)WGLK?%#MC=/8W
MQ=[J[1[8K=W]F9WJ#?G6F^LMD=VTV]<324>1I<@E=BZC!4\L@K($2E'NO=6#
M_&'J?=71/QWZ6Z:WQV9G.Y=W]9=;[5V7N/M+<HJAF]\9;`XJGH*S/5OW^1S&
M2)JI(B(S5UM;6&)5-14U$VN9_=>Z'7W[KW7O?NO=4A=^?RS?DCVW\F]S?)O!
M]Y=#X+<&R=Q=;[E^/FVZWIW>LN`S#[![AH^W,9A_D#2P=G/!5#"25>9QZ9/9
MT6WZW/R9&EK\RM3-B,?%'[KW5GOQ1Z)I_B_\9>@OCG2[BGW=#TAU%L'J_P#O
M3442XR3<4NS-M8[!5&97%)45B8FGR-11M+%2+-,M+$RQ!W":C[KW1@/?NO=>
M]^Z]UKZ]K_R4=Z;H[=^6G;N*^1F)[73Y-Y?I;>]9UO\`(S8U:,"-\=0=S]B]
MD;:BS?8?QYS_`$EVZ=O]9;9W?08?8[09AJG#18R)*O[^&"B2E]U[JZSX_=;[
MCZ=Z*Z<ZGWAV+GNWMU]:=9;'V+N3M3=*LFX^Q,YM7;F.PN4WGFTDJ\A.N2W'
M643U4HEJ*F;7*?)-,^J1O=>Z%[W[KW7O?NO=:[^7_DS=^87LKMWL;K#Y0;.@
MBJ^^]X]^],;"[-VOVEO[84FZ^U=W_(7/;ZK.U=OUW:IQ^'KMM;<^268PV$&Q
MX=NT60_A]+D,Q3U=:\DB^Z]U>%\?>I*+H'H7I'HC&YFKW'CNE>HNMNI:#<-?
M3QTE=G:+KC9N%V=2YFMI(99HJ6KRD&&6>2-'=4=RH)`O[]U[H7O?NO=>]^Z]
MU3=\I/Y8V\/D/MOY$9&KWGU1N'M+MWY-[%[BV=E^Q<!V[2X'8W6G5/3\G5?4
MO7E#D.H^VNL]\8O.=8Y[/YW>>-KZ/("B?<F6J6EHR:EYX_=>ZM3ZHV?F>O.K
M>MM@;CWMG.R]P[&V!L[9^>['W.L:;E[`S.V=NX["Y3>VX4BDFB3.;KKJ)Z^K
M"NRBHG>Q(Y]^Z]TOO?NO=>]^Z]UK9[H_D8=HR;][>[6Z_P"^>K=J;ISNY>R,
M%U%LG*;+[@W;TWM#ISN'`?,;;6_*3([+W+W1EZC`;UBA^9^9RE!2[;J<7MI,
MUBFG-$L67JH:3W7NMA#JS85#U5UCUSU?C*^MRN-ZWV'M#86/RF2*'(Y*AV?M
M_'[>I*_(&/T&MK(,<LDI7CR,;>_=>Z7GOW7NDEOS8^U.R]G;CV%OG;>WMX;2
MW5BJG$9W;.Z\-0;AVWF:&H4:J/,X/*05..RE`TBJ7AFC>-[6(/OW7NJ!JG^2
M)V%5[?Z?V#/WYUU4;$VC\8^ANJNP8,EUENZKS&X^T?CC\8/DM\8]EY'!5&'[
M)VR^,Z>WE@ODQ75VX<-YXLN_\,%/29&`5\TT'NO=6E_R_P#XO[W^(GQ]AZBW
MUO[';UKAOK>NZ\)A]LR;YFZ^ZIVMN3))4X+J/K&7LW=V^^P9-A[0IHBU+_%<
MK53">JG$0@IA!3Q>Z]T=OW[KW0=]M]:;7[CZSWOU?O3`;<W/MK>VW<A@\CA-
MVX.AW)MRK:HB+T,F5P63AGH<G3T.1CAJ!'(A!>)2+$`^_=>ZHW[,_D_=[]K;
M(Z5Z)W-WATB_0_4?P3P_QAH:=.K-X)ORE[WH?C[G.D9_D]%54&^,7A=V9JAQ
M>5?$8;%9Y:VEPFV,GF(*4QUV2:LB]U[JU#X5_'C>?QSZNWAA^RMV;7WCV=VM
MWAW+\@.QLAL/!Y;;77^/W=W)O;([MK]O[%PF>S&?SM)MK!4]1#3QO6U<U353
M)+42:#+XT]U[HJOSE_[>(_R3/_%F/E__`/"ZOD[[]U[I"?\`"=__`+<M?`#_
M`,1%F/\`WY6^??NO=70^_=>Z][]U[KWOW7NO>_=>Z][]U[K7F^/E+_-2^$>Y
M_F!L78/\MS8_R,V!V[\[?E;\F-A]GQ?.7K#J:7);,[S[(J]U[<H:_8^?ZYW'
ME<3DZ#&%!.)*D_N,0%&FY]U[HR/^SA?S??\`O3/LW_TY=TO_`/:;]^Z]U[_9
MPOYOO_>F?9O_`*<NZ7_^TW[]U[KW^SA?S??^],^S?_3EW2__`-IOW[KW6&H^
M7O\`-]GIYX/^&:=FKYH98M1_F6],$+Y(V0,0.G`2!?\`J/?NO=&!_E/?'7M'
MXE_RZOBC\=>ZL=B<1VIU9ULV#WMBL%FJ;<6*QV9J]R9[-/14F;HE6CR8IJ?*
M1H\L5XS(&TEELQ]U[JPWW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5<'
M\X?_`+=0_P`R/_Q2#Y.?^^?W;[]U[HVWQM_[)VZ$_P#$+=6_^\-@O?NO=5R_
MSQO^R(=L_P#B[?\`+M_^#AZ&]^Z]U<'[]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[JIGYR_\`;Q'^29_XLQ\O_P#X75\G??NO=(3_`(3O_P#;
MEKX`?^(BS'_ORM\^_=>ZNA]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5:'
M\X#;FZ*_^73\L-\[![$[OZR[*Z3Z*[@[FZRW!T+V=OKK#=C]A;%ZOWA6[3H\
MG4["R./R&[=NG+2QS386I$]'6S11%XRR(1[KW59VY^]/DO\`$3MK"]-=%;B[
M`[`FS_2?\J_#XG>ORGWK\@_D=1X[=/S3^=?9_47;>YMPT67[)Q,.3K=D;4K8
M:N)Z>HHJ^FHZ>"FJ)S004L,/NO=!M@OYO/\`,=V]TYW#OG=O473_`&7N?#?$
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MSTZ?Z\[9R'56W]D9:GZFVQ_-9^2>XH.X]F]Y]L9[?.,^*?\`,>QG2'7_`%+M
M'/3=I8NMV?3[ZZTW;+)2$#(TN+AIH_X9CUHHD@C]U[JV?^75E]YKWO\`S4^O
MMQ]B]G;^VUUA\Z\9B>N:3M#?>Y-_5FQ]L;W^*/QN[9R>T-KU^YJVMJ\/LVEW
MEO\`R=1C\;"RTE#!4"*%510/?NO=6H>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJX/YP_
M_;J'^9'_`.*0?)S_`-\_NWW[KW1MOC;_`-D[="?^(6ZM_P#>&P7OW7NJY?YX
MW_9$.V?_`!=O^7;_`/!P]#>_=>ZN#]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=,&Z]NTF\-K[DVED*W.8V@W1@,QMVMR.V,]EMK;DH*3-8^HQM36
M[>W-@:N@SFW<Y2PU)DI*ZBGAJZ2=5EB=)$5A[KW6KYT+3]O]'8C;.Z*+L/Y<
M]EY?<G\]7?7Q-F@[J^1/RC[)H,%\9NL]^=[T.Q9:##9CL),?+B5Q&$H(:W(5
M\-9C<]&(GR"U;+`T?NO=9^@/YG?\S[==3\<]S]F8?H:JVGV1!_*NWEO_`&K@
M/C;V_M7/46WOYA'>?8'0^_MF8O<F6[FSM/ALET/0;'3=-3DZK&S>26N6EJ*6
MFI5$S^Z]T8'X*?S&?F5\J]Q?-/:W=G7FT.M,5U?U#V]N&CPNW]O;HVCV5\?^
MQ=L]E]E;!VSU;O.NKMR[FHMUY'.;#VQ2;BAR<L6VLB*A)9H,;+BZS'U7OW7N
MB)_$+YN?S(,+UO\`#[J+K7>NWMP[2WGMS^5UL[.=I_(KK;O#Y%]HYW=_\P;X
MJ]F=]]P=QYCLZO[IVU%EL)U-V'MV(8O#>-*""EK8L;+54=/#`#[KW0S;?_F1
M?.7<^V]B=UX38V$V_P!L]J?"K^5SD<CB-P;2[SS?4&V^R?DE_,1[$^.'<N8@
MZD_TA8?&4$F`V`%S5H7I\]30>!*^OJ**"G5/=>Z&_P"+_?OR0[0^?GPKRO<>
M]=TX_<FXMF?S@>@^V=H;2K^Q-B=#]I_[)!\H^G.MNF.YL;T'N3=^ZMO[3W;G
MMM;PKZR:MAJ*R:>.N2-:J2FAIU3W7NMC'W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U4S\
MY?\`MXC_`"3/_%F/E_\`_"ZOD[[]U[I"?\)W_P#MRU\`/_$19C_WY6^??NO=
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MNO>_=>Z][]U[KWOW7NO>_=>ZK@_G#_\`;J'^9'_XI!\G/_?/[M]^Z]T;;XV_
M]D[="?\`B%NK?_>&P7OW7NJY?YXW_9$.V?\`Q=O^7;_\'#T-[]U[JX/W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U`RF+Q^;
MQF1PN6I(:_%9>@K,7DZ&H773UN/KZ>2DK:2=+C5#4TTK(P_*L??NO=!KT;T5
MU'\:NK]L=*]$[%PW6G56RX\C#M38^WONUPF`@RV6KLY7T^-BK:JKFIZ:;*Y*
M>41A_'&9"J!5`4>Z]T+/OW7N@7K/CMTGD.^<1\GZWKK`57?V`Z^K>J<)VA.E
M7)N3$]>9+*-F\CM7'LU4:*EQM?E6\TVB$22LJZF(10/=>Z&CW[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U4S\Y?^WB/\DS_P`68^7_`/\`"ZOD[[]U[K5^_EC_`.D'_9#O
MC;_=?_H)+_N__<O(_P`*_P!D<_V6/_93OMO[V[C_`.9(?Z8O^,G?W1\FK_B\
M_P"5_=^;_=>CW[KW1[_^,O\`_A7Q_P"R,^_=>Z]_QE__`,*^/_9&??NO=>_X
MR_\`^%?'_LC/OW7NO?\`&7__``KX_P#9&??NO=>_XR__`.%?'_LC/OW7NO?\
M9?\`_"OC_P!D9]^Z]U[_`(R__P"%?'_LC/OW7NO?\9?_`/"OC_V1GW[KW7O^
M,O\`_A7Q_P"R,^_=>Z]_QE__`,*^/_9&??NO=>_XR_\`^%?'_LC/OW7NO?\`
M&7__``KX_P#9&??NO=>_XR__`.%?'_LC/OW7NO?\9?\`_"OC_P!D9]^Z]U[_
M`(R__P"%?'_LC/OW7NO?\9?_`/"OC_V1GW[KW7O^,O\`_A7Q_P"R,^_=>Z]_
MQE__`,*^/_9&??NO=>_XR_\`^%?'_LC/OW7NO?\`&7__``KX_P#9&??NO=>_
MXR__`.%?'_LC/OW7NO?\9?\`_"OC_P!D9]^Z]U[_`(R__P"%?'_LC/OW7NO?
M\9?_`/"OC_V1GW[KW7O^,O\`_A7Q_P"R,^_=>Z]_QE__`,*^/_9&??NO=>_X
MR_\`^%?'_LC/OW7NO?\`&7__``KX_P#9&??NO=>_XR__`.%?'_LC/OW7NO?\
M9?\`_"OC_P!D9]^Z]U[_`(R__P"%?'_LC/OW7NO?\9?_`/"OC_V1GW[KW7O^
M,O\`_A7Q_P"R,^_=>Z]_QE__`,*^/_9&??NO=>_XR_\`^%?'_LC/OW7NO?\`
M&7__``KX_P#9&??NO=>_XR__`.%?'_LC/OW7NO?\9?\`_"OC_P!D9]^Z]U[_
M`(R__P"%?'_LC/OW7NBN?.#_`$F?[)G\KOXU_P!!1'\'_P!EU[D_BG^S-?[*
M/_LN?V'^C_/_`'7^GC^X'^_Y_P!#WAO_`'D_@_\`N2_@_P!Q]O\`NZ??NO=;
MG?QY\7^@'H[P?;>#_0_UGX?L_O?M/%_<O">/[7^)?[D?MM%M'G_>TVU^J_OW
M7NJL_P#A0)H_X;;W+?\`OEYO]F2^%/V7^C7[C_2E]_\`[-QTU]E_HIT?Y#_I
M2^XT_P!W?O\`_<;_`!?[?[K]C7[]U[JK0_Z8+F__`$%[WN?I_LC%O]A;BW^M
M[]U[KK_C+_\`X5\?^R,^_=>Z]_QE_P#\*^/_`&1GW[KW7O\`C+__`(5\?^R,
M^_=>Z]_QE_\`\*^/_9&??NO=>_XR_P#^%?'_`+(S[]U[KW_&7_\`PKX_]D9]
M^Z]U[_C+_P#X5\?^R,^_=>Z]_P`9?_\`"OC_`-D9]^Z]U[_C+_\`X5\?^R,^
M_=>Z]_QE_P#\*^/_`&1GW[KW7O\`C+__`(5\?^R,^_=>Z]_QE_\`\*^/_9&?
M?NO=>_XR_P#^%?'_`+(S[]U[KW_&7_\`PKX_]D9]^Z]U[_C+_P#X5\?^R,^_
M=>Z]_P`9?_\`"OC_`-D9]^Z]U[_C+_\`X5\?^R,^_=>Z]_QE_P#\*^/_`&1G
MW[KW7O\`C+__`(5\?^R,^_=>Z]_QE_\`\*^/_9&??NO=>_XR_P#^%?'_`+(S
M[]U[KW_&7_\`PKX_]D9]^Z]U[_C+_P#X5\?^R,^_=>Z]_P`9?_\`"OC_`-D9
M]^Z]U[_C+_\`X5\?^R,^_=>Z]_QE_P#\*^/_`&1GW[KW7O\`C+__`(5\?^R,
M^_=>Z]_QE_\`\*^/_9&??NO=>_XR_P#^%?'_`+(S[]U[KW_&7_\`PKX_]D9]
M^Z]U[_C+_P#X5\?^R,^_=>Z]_P`9?_\`"OC_`-D9]^Z]U[_C+_\`X5\?^R,^
M_=>Z]_QE_P#\*^/_`&1GW[KW7O\`C+__`(5\?^R,^_=>Z]_QE_\`\*^/_9&?
M?NO=>_XR_P#^%?'_`+(S[]U[KW_&7_\`PKX_]D9]^Z]U[_C+_P#X5\?^R,^_
M=>Z)K\@O](O^S,_`?^)?]!,G\3_TL]V_W>_TP?[*Q_IN^]_V6#MK[[_92O[J
@?[]'_2/_``GS?WE_O1_N/_N%_&OL_P#<E]K[]U[K_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tpg17a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg17a.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!$@*>`P$1``(1`0,1`?_$`:(````&`@,!````````
M``````<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+
M$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,7
M4G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R
M9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8
MF9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1
M``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B
M%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756
M-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>W
MQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:
M``P#`0`"$0,1`#\`LX_D?_RA?Y97R"_E2?"WN3NKX4=$=D]H[[ZSR^5WCOG=
M&U/OMP;CR4/8&\<?'796L^Z0U-2M%111!B/T1J/H![]U[JU?_AB'^3Q_WKP^
M-7_H%?\`X[[]U[KW_#$/\GC_`+UX?&K_`-`K_P#'??NO=>_X8A_D\?\`>O#X
MU?\`H%?_`([[]U[KW_#$/\GC_O7A\:O_`$"O_P`=]^Z]U[_AB'^3Q_WKP^-7
M_H%?_COOW7NO?\,0_P`GC_O7A\:O_0*__'??NO=>_P"&(?Y/'_>O#XU?^@5_
M^.^_=>Z]_P`,0_R>/^]>'QJ_]`K_`/'??NO=>_X8A_D\?]Z\/C5_Z!7_`..^
M_=>Z]_PQ#_)X_P"]>'QJ_P#0*_\`QWW[KW7O^&(?Y/'_`'KP^-7_`*!7_P".
M^_=>Z]_PQ#_)X_[UX?&K_P!`K_\`'??NO=>_X8A_D\?]Z\/C5_Z!7_X[[]U[
MKW_#$/\`)X_[UX?&K_T"O_QWW[KW7O\`AB'^3Q_WKP^-7_H%?_COOW7NO?\`
M#$/\GC_O7A\:O_0*_P#QWW[KW7O^&(?Y/'_>O#XU?^@5_P#COOW7NO?\,0_R
M>/\`O7A\:O\`T"O_`,=]^Z]U[_AB'^3Q_P!Z\/C5_P"@5_\`COOW7NO?\,0_
MR>/^]>'QJ_\`0*__`!WW[KW7O^&(?Y/'_>O#XU?^@5_^.^_=>Z]_PQ#_`">/
M^]>'QJ_]`K_\=]^Z]U[_`(8A_D\?]Z\/C5_Z!7_X[[]U[KW_``Q#_)X_[UX?
M&K_T"O\`\=]^Z]U[_AB'^3Q_WKP^-7_H%?\`X[[]U[KW_#$/\GC_`+UX?&K_
M`-`K_P#'??NO=>_X8A_D\?\`>O#XU?\`H%?_`([[]U[KW_#$/\GC_O7A\:O_
M`$"O_P`=]^Z]U[_AB'^3Q_WKP^-7_H%?_COOW7NO?\,0_P`GC_O7A\:O_0*_
M_'??NO=>_P"&(?Y/'_>O#XU?^@5_^.^_=>Z]_P`,0_R>/^]>'QJ_]`K_`/'?
M?NO=>_X8A_D\?]Z\/C5_Z!7_`..^_=>Z]_PQ#_)X_P"]>'QJ_P#0*_\`QWW[
MKW7O^&(?Y/'_`'KP^-7_`*!7_P".^_=>Z]_PQ#_)X_[UX?&K_P!`K_\`'??N
MO=>_X8A_D\?]Z\/C5_Z!7_X[[]U[KW_#$/\`)X_[UX?&K_T"O_QWW[KW7O\`
MAB'^3Q_WKP^-7_H%?_COOW7NJU?YQ?\`)\_EA=#_`,K[YM]P]/?"/H7KSL_K
MWHO<>Y-D;WVWM/[+/[8SU#4X]J/+8BL^[<TM;3ECI<#\D?0D>_=>ZV=]LF^V
M]OD\DX/$DD_G_(*?W[KW50O_``H`QM!F_P"5)\A\'EJ6.NQ&=WS\4<'F,?/J
M-/D<1F/F#T)C<ICZE5*EZ:NH*F2*1;C4CD>_=>Z5Q_D1?R>6)8_R\/C3<DDV
MV0%%R;\*M8%4?X`6'OW7NNO^&(?Y/'_>O#XU?^@5_P#COOW7NO?\,0_R>/\`
MO7A\:O\`T"O_`,=]^Z]U[_AB'^3Q_P!Z\/C5_P"@5_\`COOW7NO?\,0_R>/^
M]>'QJ_\`0*__`!WW[KW7O^&(?Y/'_>O#XU?^@5_^.^_=>Z]_PQ#_`">/^]>'
MQJ_]`K_\=]^Z]U[_`(8A_D\?]Z\/C5_Z!7_X[[]U[KW_``Q#_)X_[UX?&K_T
M"O\`\=]^Z]U[_AB'^3Q_WKP^-7_H%?\`X[[]U[KW_#$/\GC_`+UX?&K_`-`K
M_P#'??NO=>_X8A_D\?\`>O#XU?\`H%?_`([[]U[KW_#$/\GC_O7A\:O_`$"O
M_P`=]^Z]U[_AB'^3Q_WKP^-7_H%?_COOW7NO?\,0_P`GC_O7A\:O_0*__'??
MNO=>_P"&(?Y/'_>O#XU?^@5_^.^_=>Z]_P`,0_R>/^]>'QJ_]`K_`/'??NO=
M>_X8A_D\?]Z\/C5_Z!7_`..^_=>Z]_PQ#_)X_P"]>'QJ_P#0*_\`QWW[KW7O
M^&(?Y/'_`'KP^-7_`*!7_P".^_=>Z]_PQ#_)X_[UX?&K_P!`K_\`'??NO=>_
MX8A_D\?]Z\/C5_Z!7_X[[]U[KW_#$/\`)X_[UX?&K_T"O_QWW[KW7O\`AB'^
M3Q_WKP^-7_H%?_COOW7NO?\`#$/\GC_O7A\:O_0*_P#QWW[KW7O^&(?Y/'_>
MO#XU?^@5_P#COOW7NO?\,0_R>/\`O7A\:O\`T"O_`,=]^Z]U[_AB'^3Q_P!Z
M\/C5_P"@5_\`COOW7NO?\,0_R>/^]>'QJ_\`0*__`!WW[KW7O^&(?Y/'_>O#
MXU?^@5_^.^_=>Z]_PQ#_`">/^]>'QJ_]`K_\=]^Z]U[_`(8A_D\?]Z\/C5_Z
M!7_X[[]U[KW_``Q#_)X_[UX?&K_T"O\`\=]^Z]U[_AB'^3Q_WKP^-7_H%?\`
MX[[]U[KW_#$/\GC_`+UX?&K_`-`K_P#'??NO=>_X8A_D\?\`>O#XU?\`H%?_
M`([[]U[KW_#$/\GC_O7A\:O_`$"O_P`=]^Z]U[_AB'^3Q_WKP^-7_H%?_COO
MW7NO?\,0_P`GC_O7A\:O_0*__'??NO=>_P"&(?Y/'_>O#XU?^@5_^.^_=>ZK
M2^7/\G_^6+L7YX_RFNM-G_"7H;;VP^[^X?EEMWMO:V,VF(,3V!@]F_#/MGL/
M:N+W)"*HM74>!WOMJ@R=,A($=72HX_-_=>Z/G_PG<_[<L_`#_P`1)F__`'YF
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M2?*7JW?_`'7T'\G>H>QNK>J*>MK>TMXX[=5)B\?UIC\?C:S,U63[`@W",1D-
MF8I,1CJFJ6JR4--3R4U/+(CLD;E?=>Z1OQH_FD?R]/F-V)ENI/C)\M^G.XNR
M\+CJ[,5.R]K;AD&>K,1BY(HLGE<#1Y2DQQW/C,<TZ&>HQIJX84=7=@I!]^Z]
MTA*O^<;_`"SVQ&Y\AM[YD]&;KK=K]4]A=R5V(PN\Z>:HCV3UGG:K:FY<AD*G
MP-2X1X]UTIQ\$58T5152G7!'+'Z_?NO=,?\`*H_FS_';^:WT;2]F]55>*V=V
M9BZ>KJ^S_C[5[PQNZ]_]44DF[=S[:VO6;JDQU#C(UH]XTFV7KZ&001AH)0I%
MP2?=>ZM/]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U4A_/E_[<Z_S#?_`!7#=O\`
M[D8WW[KW5J>V/^/:V]_VH\3_`.X%/[]U[JI/^?9_VZY[Q_\`$G?#[_X,[X^^
M_=>ZN(]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U47\Y?^WE
M/\D;_P`3U\U__@`.]??NO=)#_A.Y_P!N6?@!_P"(DS?_`+\S??OW7NKH_?NO
M=>]^Z]T'_:W:.QNDNM-^=O\`9N?I=K]?=:[4SF]-X9^LU&'&X#;V/GR.0F2&
M,-/5U30P%(*>)7FJ9V2*)6D=5/NO=%$VO_,H^,>YO@;_`,.-29#?6VOCJ,)N
M'*O'N;8^4H^RDR&W^R,IU"=G_P"CVA;)9>3>V9[*QG\&H,:A>:HKJB&/TESI
M]U[H5?B;\O.L/F)LK>>[.O,/V%LS,]8]F;BZ<[7ZQ[<VC+L7M#J_LS;%!A<S
MD=I[RVT]9DZ:FJYMO[EQN1IIZ2KJZ.JHJZ*2.9B65?=>Z--[]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZTA/A!_
M*%^.'S[^?O\`/(WE\I=N=\8RKV9_,'WK0]>U>Q^SNR.H,9EL+N++[^S%94^'
M;M5C*+=`DTTLD501,4AE700DOJ]U[JJW9/0OR$Q_\B?X;[IVSMOM?"=8_&[^
M<?OGM3OE<'T^_;VYMA]=8*IBPN%[DR_2NYZ%L=V=@.NLFLYJ*#(P28^IGJ52
MI`B,C)[KW5N?Q>S6Q),7_-U_F%_&OO\`[!_FY=Y;C^%F+VGV%USOG^7EF/C1
MT)VKDL3'/3[?Q.:V=2;4VGB^YMS87:F"J8LMAL?C16UN*>6!IVEJD*>Z]T4_
MX0]N[Z^3/\XO^2_W:>X*;O:"AZG^0^!['DZK^!6>^(?4/QIW=F/CONO+9/XS
MTV\Y<73P=M5>Q:RM:"9Y9F@QX:-X3_E[(ONO=62_\)POAUUA4?RL/D%NO<7Q
MTV;+WIV?W%\NMH97<F]>N<5)O[<6'*1;:PFUWRVZ,6V5BVPS4JQ+0H\=`TXD
M=D,K2,?=>Z$C_A*+V5TY%\!J/XNTVP\]L;Y:?'#+;XQWR@QNX^FMQ;$SM#-N
MKNGM/+]?XO.[YRVV\91;OR%)@V=5HEK:JJQ:HT<L4(*AO=>ZVG??NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=5(?SY?\`MSK_`##?_%<-V_\`N1C??NO=6I[8_P"/
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M&?P+_D^X?Y/X7Y._(#O#YJ?$G#9W:.3ZUVI/W1V%V)V-LOK_`&'4R[>RT-9N
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MC?\`B>OFO_\```=Z^_=>Z2'_``G<_P"W+/P`_P#$29O_`-^9OOW[KW5T?OW7
MNO>_=>Z*C\R/BM1?,/J3%]3Y#M?L7I^GQ/:/5W:T.Y.MZ78.4R%?F.I=X8[?
MFV,)N#;W9^R^P-B[GVH^ZL+15E3C\CBJJFJ):.+6K*K*WNO=5!XC^4=\P\;_
M`"[(_P"7K7_)[J;=>V7K.U^WG[*W;L?-3[PQ?R$I/F1M7Y5?'RCPT&TZ;9F!
MEZ9FGP^1&]H*ZCJLX^4R\C8NHCH8:>DC]U[JR?X!?%CM;X[8_P"2W8/?VZ.O
MMR=[?+?Y(9_Y$]DT74E-N*'J[9,LVP>O>K=J;%V55[NBI=SYZAPNT>M:.6IR
M5=34<]97U4Y$$<:H#[KW1(OYGG4.*ZH^4/\`+Q^7'7>^^[=I]N=G_P`Q[XG?
M'G?5'BN].V8>J=P]2;LP'8N(W/M:MZ2.[VZD89ZAQ4"U-4,,*QW4R>42,S'W
M7NKX/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO==`!190%`^@```_/T''OW7NNP`/H+<D\?U)N3_KDGW[K
MW7O?NO==``7L`+FYM^3]+G^IL/?NO==^_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZJ0_GR_]N=?YAO\`XKANW_W(QOOW7NK4]L?\>UM[_M1XG_W`I_?NO=5)_P`^
MS_MUSWC_`.).^'W_`,&=\???NO=7$>_=>Z][]U[K#4/-'3SR4\(J:A(97@IV
ME$`GF5&:*$S,KK")7`7400M[V/OW7NJF_P"7)_,<WE\TNVOE]U+O'9?15(_Q
M:R?5M'+V1\;N\,WWAU?F<KV1BMUY+,=<5N=W+UGU9E8NPNK7VRD.9>DH:G&2
MR5B+%*CQO'[]U[H//@1_->WQ\O\`NKK79F].@]L]8=7_`"EZ`[?^3GQ'WG@>
MS<EO/=F>ZRZ6[HPO4&>Q7<^U*[8FU\9LG>^X:3=6*W%00XC)9NCBH*IZ:><5
M,)U>Z]U9UW1\GOC;\;VVDGR$[_Z8Z,;?U=78O8R]O=F[,ZX;>62QG\/_`(EC
M]K#=^9Q!S];0?Q:E\T5+Y7B^YBU`>1;^Z]T.$<D<L:2Q.DD4B+)')&P>.2-P
M&1T=25='4W!'!'OW7NN?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>ZTZ?D!_(K[N^8GS5_G:]@;ZV7'U;!W8GQ,[2_EX?
M):'<VUY,QA.^^C.O#3C)8I=O9^JWQLW%R9JF.'R\E724C&DJ_N:42ST\#I[K
MW0U[X^/?\T7YAY3^01W%\D?C!4;*[M^'?RHW5E_F=)%V)U!7XV@V_@:/9.(Q
M?=E`,%ONMI\C0=E4FV9*^3&8P5-915\DL(IU@\#O[KW16=^_!_\`FQ?'^G_G
M6?"3X_\`PMVMW[T[_,Y[.[Q[NZR^5V6[ZV'L?;W7>&[OV[FUWOL[=NS<L[[V
MS^^*.BFBQ&#@5**C3,N*N::3'O)(GNO=&1V)_+@^9N)[)_X3%;AR734]+B?@
M-T?V/M/Y;5#[SZ^D;J'<&=Z.V/MO%X^LAAW7++NMZG<&'J*028(92)9$U,PC
M(<^Z]TB^S/Y/7R\^0&WO^%(_6];M7'=;Q_/3N#X]]A?$O=N?W=MN3`=F-TWD
M\QO^6FR2;<RF;S.U,7E\K34F*E?*TE))%+6&7QO'$Y]^Z]TH/Y6_P)S^V/E+
M\9.P>Y?Y-?=WQX[(^/FQMTTN9^5?<'\R_<OR!V5LW?51US5;)R7^A7IBN[7[
M$DSN+[.GJ949'AHJ'"TDH8-,]/!?W7NB';!^"VZY?^%)NY/@O@\SBLU\'.HO
MD++_`#GLKUQ04\5;1['[:W3U[A,7MW$9B$2O28:6/MC-X[[/'2)Z\"8IE4J]
MA[KW6^+[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJ+^<O_;RG^2-_XGKYK_\`P`'>OOW7
MNDA_PG<_[<L_`#_Q$F;_`/?F;[]^Z]U='[]U[KWOW7NO>_=>Z][]U[KWOW7N
MJ=_YO_\`G?Y6G_C8CX7?^X7:WOW7NKB/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW52'\^7_`+<Z_P`PW_Q7#=O_
M`+D8WW[KW5J>V/\`CVMO?]J/$_\`N!3^_=>ZJ3_GV?\`;KGO'_Q)WP^_^#.^
M/OOW7NKB/?NO=>]^Z]U#R-&<ACZZ@%764!KJ.IHQ78Z9:?(41J87A%70SM'*
ML%93Z]<3E6"N`;&UO?NO=5@=;?RN,/L#L;?_`'?DOF!\N]_=_=D5_P`?<7N;
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MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z`O9'QEZ`ZW[C[8^0FQ>IMF;9[
MN[TBV_3]N]HXW%(F\M^TNU*"GQFW:3/9B1I*B:BQ-#211Q0H4BM$A*DJI'NO
M=#I[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>ZJ+^<O_;RG^2-_XGKYK_\`P`'>OOW7NDA_
MPG<_[<L_`#_Q$F;_`/?F;[]^Z]U='[]U[KWOW7N@M[E[CV1T-U_ENR^PFW4=
MMXBIQ-`])L?8&^^TMX93)Y[*T>$PN)VYL#K/;F[-\;FRF2RE?%%'!08^HD&H
MNX6-7=?=>Z`?&?S`/B9F?A_D_GCC>TS5?%["8/<&>S>_DV9OU<KAXMJ;GK-E
M;FQ.4Z[DVPG9-#NG`[OQ\^,JL3)B%R459$T9@O:_NO=#)T/WUU_\C]@0]E]:
M0[_I]LSYC+X)8>S.I>T^E-U)D,'4"EKQ/L7N/9VQ=ZTU'Y3^S4R4"TU2OJA=
MUY]^Z]U6Y_.`94D_E:LS!57^</\`"XLS$!5'V7:W))L`/?NO=7#1RQS1I+#(
MDL4BAXY(W5XW1A=61U)5E(^A!M[]U[KG[]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJD/Y\O\`VYU_F&_^*X;M_P#<C&^_
M=>ZM3VQ_Q[6WO^U'B?\`W`I_?NO=5)_S[/\`MUSWC_XD[X??_!G?'WW[KW5Q
M'OW7NO>_=>Z][]U[KWOW7NO>_=>ZKC_G"*S_`,J/^9"BB[-\(?DXJ@?EFZ>W
M:`/]B3[]U[I9?RZ_D3TGW]\6>FDZ:[%P/87^COI_J#:6]),!]])!@-RTNPL7
M0UF$JZBJHZ:!\A0UV*J8*B.-G:GG@>.32ZE??NO='J]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5%_.7_MY3_)&
M_P#$]?-?_P"``[U]^Z]TD/\`A.Y_VY9^`'_B),W_`._,WW[]U[JZ/W[KW7O?
MNO=%J^7>WNT]V=`[XVST]LP=@;PS<>*H#M6G^178?Q/S>2P<F7HGSO\`=;O[
MJS;^Y-[=?;FI\<CR4D]+!$*AE-/)/#'*T@]U[JH[X_?!3Y==1?RY\?\`!'MG
MHGXX?([K;.[&^0F7WCUG5_(SL/K&HQ]=O#OK&;]ZFZ%@[HVCU!2;JWC-2;(S
MN8J,[V/5T5)FJ_<E)"TL,HGEK7]U[H^'\LKH/Y*_'KHO?>VODWO&MS.>WAWW
MVAV1UEUY7]V]B?)2?X^=,;KGQ)V+T0>_>UZ#&;_[4.SC0U=2V1KX5$;Y`TT)
M>""-V]U[JD7_`(4Y_%_JRAZU^/GROS69[;R>>K?G3\2]L[TV;E.W.R<WT3'U
M[MZFWIDMR9)>@:K/U/5L.83`;?D:HKXL3]],C3+K8SR!T&Z;G9;-M\NY[@^B
MSA6K'B>-``!DDD@`#B3T+N0^1N9O<KF^PY&Y/MS=<Q;C-X<*5"K4*79W=B%2
M.-%9W=C154G)H#M0=?8[8>*V+M"@ZNQFU\/UO#MS#G8N,V3CL;B=GTFU)Z&&
MHP4>V<;AH*;$T6#..EC:FCIHTA6(KH`%O:R.1)HUEB(:)E!!'`@BH(^1'0:O
M+.ZVZ\EV^^C>*]@D:.1&%&1T8JZ,#D,K`@@\"*=+#W?I-U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW52'\^7_`+<Z_P`PW_Q7
M#=O_`+D8WW[KW5J>V/\`CVMO?]J/$_\`N!3^_=>ZJ3_GV?\`;KGO'_Q)WP^_
M^#.^/OOW7NKB/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U7'_.#_[=2?S(?_%(?DY_
M[Y_=OOW7NDE_)B)/\NOI4DDG^\W>_)-S_P`S_P"S_?NO=6D^_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJB_G+_V
M\I_DC?\`B>OFO_\```=Z^_=>Z2'_``G<_P"W+/P`_P#$29O_`-^9OOW[KW5T
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M_P`B7EK=;!S?MR[F!`P9?$9C').A%5:.Z*^*&!),_P!0"%TBM['N3>L'.O>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJ0_GR_]
MN=?YAO\`XKANW_W(QOOW7NK4]L?\>UM[_M1XG_W`I_?NO=5)_P`^S_MUSWC_
M`.).^'W_`,&=\???NO=7$>_=>Z][]U[K!4R314U1+3TYJZB*"62"E$D<)J9D
MC9HJ<32D11&9P%U-Z5O<\>_=>ZK%^#?SK[K^1OR(^7WQC[[^.NS>E^P_BC#T
MGD\QE^JN[)^^.OZN/O';.<W9B=AYS=51UMUFV$[5V=AL5!-EL;%354'AKX9H
MI3"\4DWNO=(_^6[_`#+-P_/#?'<VW,YM7XY]<KUGDMX4%+UYM'Y)97L3Y)8F
M':O:^[.MJ?+]O=*9?IWK_P#T=X'<E+ME,A05U)ELU32BLBA+!C?W[KW63^=S
MWETGUE_+<^8?6O9O;_6?7._._OBE\D^ONE-I;XWMMS:^XNUMZU76&2Q,6UNO
M<-FLC15^\,__`!#<E!$:2@2></60@K^XMVIYX;:%[FX8)!&A9F/`*H))/V`$
M]+MKVS<=[W.VV7:(7N-VO+B."&)15I)976.-%'JSL%'V]([^0=V_M'MG^6_U
MH-O5L(SVRM\=N8#?NWON(ZBLVIN7-]D[FW_38FJD18_N8Y=M[QH9X:@(B3)+
MP`RLJA_E3F>RYLVO]YV8*`2,C(34J5.*\/B0JXQC53B.I@]_O8SF7[OO/IY'
MYCD6X9[*"YAN$0I',DJ#Q`H);^QN%F@;N.HQ:Q17`ZN>]B7J$>O>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JHOYR_P#;
MRG^2-_XGKYK_`/P`'>OOW7NDA_PG<_[<L_`#_P`1)F__`'YF^_?NO=71^_=>
MZ][]U[H+^Y>ZNJ/CUUUGNVN[-^;=ZUZYVQ_#US>[-SUGV>,I)\MD:7#XFBCT
MI+4UN2RV6KH:6EI8(Y:BIJ)4CC1G8`^Z]TC-N?+#XT[M^/+?+/;O>76>4^-,
M>U\QO2?NZ'=>+CZZI-L[>J*VCS^4K]QU$\-'CTPE?CJBFJXYS'-3U4+P2(LJ
ME![KW3ST%\C.C/E+UY3=K_'GM#:7;?7M3ELM@/[S;/R2U])29_!3BFS6`RM/
M(D-?AL[BIG45%%5PP5,2NC,@5U)]U[JG_P#X4!]8Y/NGI+X#]2X3<-!M+,=@
M?S6_AO@,5N?*82HW+C,%D2.R:^BR.0V]29O;=5FJ*&IH5$M-'D**25"0LT9L
MP]U[H8OD5A]_?"'M79G\PQY,5G]L;CV_L_JG^9%@NM]M9?!;9SFUZ21,7L?Y
M2[7V=D,]N_,T%?TEDJXTV5BER&2JY=H5+JTK?9>3V!=^1^7=T7FRV!-@X6.]
M0"M4X1W``_%"31^),1/\->LJ_:>YM_>7D.7[OF^2(O-=J\U[RO<2,%"W1&N[
MV=G;`AW)5UVX)54OD7)\73U;WC<EC\SCJ#+XBNH\IBLK14N2QF3Q]3#64&1Q
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M??NO=6I[8_X]K;W_`&H\3_[@4_OW7NJD_P"?9_VZY[Q_\2=\/O\`X,[X^^_=
M>ZN(]^Z]U[W[KW4/(4TM;05U'!756,GJZ.IIH<E1"G:LQ\L\+Q1UU(*R"JI#
M54CN)(Q+%)'K4:E9;@^Z]U5+\6/Y6.1^)NQ\QUYL7YU_+;-;=W!V_MKN[/U>
MX*7X[1;SW5OFE[)I^P^R<EOOL3;_`$3A=]]B5/=T$`P>Y*C.Y'(5)PH2GHI*
M3Q1%/=>Z&;HGX#T/57R?W7\O>R/D/W9\E>ZLGU+5_'_8V:[8H^HL'C^KND*[
M?\?9E9L;;V+ZAZPZV@SU77[KI*62HS&;_B63DAHH8UE0>7R^Z]T3_P#X4$]:
M=B[\_ES]O;@Z_P!O]6U=%U+MO=';7:6ZM]4T$^\MN=0=<;>K-][RQ?4,LFV<
MW+3;TW;4[7H:=R*O%I+20O$\X$@*`WGK:=\WW8FVG8VB1YF`D:1F7],9*C2K
M?$0`>';4>?62OW4_<#VK]JO=>#W#]TX=PN;7;(7>RCM88IC]8_Z:RR"6:$`0
MQM(R$%B)2C"FC-/?_";[97R'Z/\`DKO39>7RVSX.G^[^AJ[M.3;U;G<RN3W$
M>O.U-U=44>].OZ081L7DZ_:&\<-7XG/4\L]))%19BAJ+RVC01W[<;#S!RCS1
M/LFX/!X$MHLI"LQ#48JKQU4`E#5)`:4#J<XZS(^^C[L^T7WA_8C:?=#E"WW0
M;MM_,,NWQR2P0HT)>!)I;>\T3NT:7$82XM'7Q`S6\J$(2_6Z)[G;KE%U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO==%E4@%E!8V4$@$G^@!^
MIY]^Z]UT652`S*"?H"0"?]8'Z^_=>ZX^:+R^#RQ^?Q^;PZU\OBU:/+X[Z_'K
MXU6M?CW[KW7HYHI@S0RQRJCO$YC=7"R1G3)&Q4D*Z,+$'D'Z^_=>Z\)8C(T(
MDC,J(KO$'4R*CE@CLE]2HY0@$BQL??NO=<$JJ:6>>ECJ8)*FF$35-.DT;STZ
MS*6A,\*L9(A*H)74!J`X]^Z]UZ*JI9Y:B&"I@FFI'6.JBBFCDEII'02)'41H
MQ:%WC(8!@"1S[]U[K/[]U[KWOW7NO>_=>Z][]U[KWOW7NH_W5**D41J:<5AA
M-2*3S1_<FG#^,SB#5Y3")#IU6TWXO?W[KW4CW[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]TWOE\3'E(,')D\='FJJBJ,C2X=ZVF3*5./I)88*JO@Q[2BKFHJ:>
MHC2254*(\B@D%A?W7NH.YMT[8V5@ZW<V\MQX':6V\9]M_$=P;FR^/P.#Q_WM
M93X^C^]RV5J*2@I?NZ^KB@B\DB^2:5$6[,`?=>Z?O?NO=>]^Z]U[W[KW51?S
ME_[>4_R1O_$]?-?_`.``[U]^Z]TD/^$[G_;EGX`?^(DS?_OS-]^_=>ZNC]^Z
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M[^Q&/I]E4^_EWE(V/=B\V>FHKU<W^3_YOQ^Z]UL!YO"8C<N%R^W-P8RBS6`S
M^+K\)F\/DZ:*LQN6Q&5I):')8S(4DZO#545?13O%+&X*O&Y4@@^Z21QS1M#*
MH:)U((.0010@CS!&#TJLKV[VV\AW';Y'AO[>59(Y$)5XY$8,CHPRK*P#*1D$
M`CJK/X:9K+_#_NO-?RV^Q\E6U>QX\1F^R_@/O3,U,]74;JZ(H:E)=V]$9++U
M3,U?OGX[Y"N6*FC9VJ*O:<])/H1*9_8)Y>DDV#<6Y0NV)MM)DLG.=4(^*$D\
M7@)H/,Q%30`=9/\`O#96GNYR9#]XSEV)%WHRQV?-%O&`H@W-@1!N:1K33;;J
MBEG-`J7RRIJ9I!U;!['/6*W7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T1WN+YKY'
MJ+L3.=?0?#/YP=L1X5,6Z;]Z>Z<VSNSKO-?Q/&4N2*X//U_8^"J:M\<U4::J
M$E+%XJF)T&H`,0UN',;V%VUH-NW*<+3OBB5HS4`]K&1:TK0X%"#U-W)_LM;<
MV\O0<P/SER3M33%P;7<-PF@NX]#LGZL2VDH77IUI1VU(RG!-!1%U/_PH7?>/
M\QGL/84G5?=&YOCONO:NW^L.F.IMJ[3VCDNYX>Z-M9&67+Y.JP#[GHL?/6[P
MKLID<=-2QYJ=8XL9CFB4R-4!HQL?=?ZCFZ:U,%R^TNBQQ1*J&;Q5.3IU`5<E
ME(UG"I3->LYN:O[OP;1]WC;]]7==EMO<&UNI;S<+Z>>=-O.WS)1$$O@LX6W5
M(9E<VR$M-<ASI$=+V>MOF!ENZ_[][;7XL?,3H:;#==;GW/2[V[UZLP.P]J2U
M6/@BIX,3B\SB]^;EJY=R225GW$$(IU4PT\KEP4`:4]JWYMTN#;FQW"V`0MJG
MB5$-"!I!#MW&M0*<`<]8$\^^TL'(NSQ[O'S5RCO;/<+%X&UWTMS<+J5V\5D>
MUA`B73I9M=0S(-)K4:?/\H[L;YI]E[7^$_='4/8?\SC=6/J^@_F5N+^9)V?\
MEMY=S;@^'FY<7C-K=DT?1=7T#GNV<E78C+=JXW=]#0)%4[(D"4<M.XJVT)6*
M!!U$/3S_`"1.Y.^^V_E#_+EV)2]Q_/;!4_:/PS[\[2^;%'\TOD%O;=G4GRUV
MS/%7;)Z[W+\*<-N'L#=V;&Y-G;QJ1593*8V7`UF.H*1V,!7RM/[KW0T?RV_D
M#\@.X/YF?7?\M;LWY:=C[J^-G\NSM_YF=A].=TG?'8T6[OYA%1UCNO`;>V3U
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MOELKMO`[TS,DU3-E]Y;6V978[&9:IDEFFFR%),TDLTA:5_=>ZL)]^Z]T6GY-
M_(^K^->V=N;EI/CO\E?D6VX<^^!?;OQFZ]PW8NYMOJF.JLB,YN/&9G=^SXZ#
M`.:7[=9XY9F^YD1"@#:A(7MWR!%[@[C<;?+OW+VP""#Q/%W>ZDM89>]5\.)X
MX)RTO=JTD*-`8UQ3I)=W1M$#B*66II2-0Q'S-2,=?.3_`)BO\\'^9MMWYP?)
M?"=5_(?Y)_'GKO&]F9.EVETGOS!;.VQO#K;#QT=`(-M[@V_'1[DCQ60IFU.T
M0KJKB0-Y"2???#V%^YS]WB_]G>7[SF78N7]]WV3;T,VX6TDTT%TY+5EBE)B+
MJ>`)C3A2@IU%^Z<P;LFX2K#++%$'PA`!4>A&:?MZV$_Y'_\`.$^26\_ACF<U
M\BOC_P#S#/F_O^+NW?-'3=P],]+;)[`VI2[=AV[LB;'[(DSLN^]ALN:PM945
M-1+3FB81QUT1\K!M*8+_`'Q/NJ>W^T>[4-IR'OO(G)VR'9[=C8W]_<6LS2F6
MX#7`C%M<?IR*$4-XF3&W:*5(EY?WRZDL"UU%=7$GB'N5`PI08K49'V>?1E.Q
M\/OC^97_`#AOD%\0NU.__DY\??CC\1/B;T1V?LOIOH#N#<OQ\W=V9V5WM'+E
MLSV-V%N;8>0@W)GJ;K*":+$18Y*I\?29)(I.2\ZU/+RYA%M<R6X=)!&[+K0D
MHVDD:D)`)5J54D`D$8'0U!J`:$5'4'NO^8Y\V/CGE?F;TE\2]G=3]^=7_P`F
M;X\=+[E^5_;GS1[*WVWR`^153N/J6N[6GH-AY/KS;^-VY3;THNLMO2U&1S^;
MIIJ?)YJ32E,-3-[8ZWT%G?7\^'YF8[_9N^U_C9\;_CAN'XX?#?X__!#Y7;^J
M>XM\]D8#MO='5WS&ZFVUV,>OMIXG:N-R&VU[!Q#9FJ=,M62P8VDIJ$1M1UDT
MZE/=>Z4G:_\`.Y^;GQKV%_,$?Y!?'+XT0=L_&7XV_%OY>=-8'J_?O9&YME9?
MK#Y(]OXOK1^N>T,[N'&;9R=5V)LY*]A)EL33TF+JJE"Z4OA5?+[KW2:[>_G"
M?S;NG,K\XMI;C^+GP'GW-\$.F^M/EYVED<9V_P!Z5N!RGQ][,PU9F<;U3L^D
MFVA09'.]VXV+$Y!:G<%3)C-O`X\^/'2?<0W]U[I]^3O\_?O[:W?';&P?B[\;
M-O\`9.!^-_6_Q8W[V!UUE^N_E#V5W'WIEODIL';O;M1L+IO<O1'7.Z.K>I\G
ML+KC<<3??[WE\&:R2/%2PB&.25?=>Z-Y2?S-_EAF_G%\Z^M,/TMTCCOAA_+I
MV3U_VO\`(+L7=&X-^4/R'S&SNR?B76=\X39G7?7M#3UNUZCL+%[KQE1%D)LI
M4T./AQBBG17K`9#[KW1%_DS\W_FSW#_)I[6^:ORFZ1^.F)Z![CVA\3.W/CSL
MKX^]^_([9';^$Q?9OR7ZKQV*VIW'O;;;;.K)<A3[-W#1Y1J[;>1H:>6KCEQ]
M50M"S,?=>Z,/WO\`SF>Y>C_Y@?7WQXH?]E([4Z2W9\W.G/A9N';'62_)O=/>
MW661[A%/BL5NWLGN:HV#C?BOMS?&`S<WFR&P1DZS<"43):=I/.:?W7NC%_R$
M<GE<I\2>_I<OD\AE:FG_`)BOSXHHJC(UM37314M-\AMTI!312U4DLB4T()T(
M"%6_`Y]^Z]U=U[]U[JI#^?+_`-N=?YAO_BN&[?\`W(QOOW7NK4]L?\>UM[_M
M1XG_`-P*?W[KW52?\^S_`+=<]X_^).^'W_P9WQ]]^Z]U<1[]U[KWOW7NO>_=
M>Z][]U[KWOW7NJX_YP?_`&ZD_F0_^*0_)S_WS^[??NO=5'](XW*=5?RU_A'\
M^-HT-76;C^$_<G?>X.Q:+&Q--7[D^+/9/?O8FT/D/@%IX[?>/@<%)2;GIA)K
M6"?`EU76U_8+YQ1[%+;FB`$S;=+JD`XM;242=:>>E:2#T*5X]9-?=MN;7FFY
MWOV)W9T3;N<[#PK1G("P[U9ZI]JEU'X1+*'LWI0LMR%)TCK9[Q&7QF?Q.+SN
M$KZ7*8;-8ZBR^(R=%*L]%D<9DJ:*LH*^DG0E)J6KI9DDC<&S(P(]C&.1)8UE
MC(:-@"".!!R"/D1UC;=VES87<MC>QM%>0R-'(C"C(Z$JRL#D,K`@CR(Z<?=^
MD_7O?NO=>]^Z]U[W[KW7O?NO=`WWKOSM+KG8C[CZ?Z-R_P`A=XC,8RA7KS"[
M\V1US6MBZMI1D,Y_>/L"OQV`$.)5%+0>0SS:QH4V-B_<[J^M+7QMOMFN[C4!
MX8=(S0\6U2$+CTXGRZ&/(VQ<K\Q;Z-NYOWR'E_9_!=OJY+6YNUUK31%X-JKR
MUDJ:-32M.XY'6J=_/"_FK_)O;/5VW_BKD_C_`+I^(G9V_P#);4[+RF9'=_6G
M8FXI.O-J;AJ:W$4]`_5>4R$NVI<QOK;U.YDJY8C44N/FB6.2.5R(.]R>>-Y@
MLDV22T>PO9660GQHY&\-6)%/")TU=1Q.0I%"">NIOW)ONL>VNY\SW'NC:\P6
MO-O+5A%/9I'^[;RTB%W/$JR%A?(@F$=M*PI&ITO*CEE9`#9[\,OYJ'RP^6GQ
M[V5VQUG_`"]=R=N4Z4R;1WGO#;GR4^/^S\;6=D;9H*"GWB(-I[OS6*W)MVFJ
MZ^=:RFIZJ!6%'50LK2(5D8:<O<[[[ONU1WUGM+W`II=UN($!D4#7VN0RU.0"
M.!'$9ZQF]X_NN^U/M1S_`'O*O,ON#;;3(6,]O;S;/NMPZVDSN;>L]O')#*54
M&-W1O[1'!"L"HK&_F][2E^0?\SOX$;6[8^!78ORNR^Z?Y=WR.W!-\1MH]K[#
MVUG=G]E5.Z=J_89RM[+K.R-@[,IDV#EIA3U&7QV2J)4UK44L%08U7W(UM)--
M;I+<1F*=D!9"0Q0D94LM5-#BHP?+K"_?+/;MNWFZL-HO%W#:X9W2*Y6.2%;B
M-6(298I0LL8D4!@D@#K6C"HZJ\^4/QG^1/3N_?ACT?\`,CXT9#^9/W;\?_Y'
MOR$W]V1UU)\@ZS:63V%58/Y&[JS&W]_XKL!*ILOV%NCH;9.5Q^!6FQ#5.2RO
M@+T#3^*(L_T5=&,^3>ZNV_CI\%_Y&_RF^&/?66^4G\SW_9<^V=A['RF'Q>?W
M=/\`(/XG9#I?>?9G<J;XPNY,OB-QU.%^+LT.*?&39-%KX\Q26EI_NCXX?=>Z
MO2_EQ][=*?$SX&?RYNN_C7T3\POEQUY\B^O\3OK._(?IKK+$;_P>/[/[(W1C
MZWN#?OR-W#GNP,'F-GYRH[+W7EJG)0^/*38VFQE5`6<T:J_NO=`!\/NKJ;XV
M?SI_YN&'Z[W3V5V1N.H^$'QY[5_C/;'8.=[-WAN3?^X,OVGGO"^1SE1+%08>
MEJ?MJ''8G'P4F,QM!'%!3T\:#U>Z]U4W_+BVYM+;6\/^$\?RFZTW%F<A\L?G
MUO'Y\4'SH[!IMZY[(;W^06V*7!;[RF\*OM:)LO*E1#U)G<;2G&RB&G&'GIX6
MCTR*A'NO='X_E7_%_H3*_P`WWMOY._RWL)N3K7X"])]&[A^,_8_9%7V;O[>F
M#^=_RO;=51EMY[NVU4;\W3N+)]@8#JVEE@BR.ZO(]+79ND4T;31RRS#W7NMN
M'W[KW7O?NO=49?S=/DM\R]F_'OYM]9]?_P`OG?F_^CV^+_:%+4?+'$?)7H#9
M^(P6-SO4F7DW7NB/JW.[EI>U9TZZFJYQ+!!2_=Y`T;&D5A)&3,7W>(TE]_.2
MHI5#1/S5M8((J"#>PU!!P0>%#T7[L2-KN2./@/\`\=/7RO/](&_-.G^^^[M-
MM-O[R9G3I^EK?>VM;W]7/[BV.O\`N):_;X2?M^'J#O%D_B;]O7UL?C!\K_GI
MO@['VGV5_*^W[TEL0]7U=>G<^=^4OQL[(Q*93!["DR>U*2HV'U]NO(;\K/[[
MYFEIZ)/#"STCU0>?0J.5^/OF#_DOWXI0"]G%/D)7`_EU/L7]DO\`I1_@ZI3_
M`).G07PP[;^$^Q_YN_R3FS'<7\QW&]M=V]O=F=I9CN7?.W^UL1W/L#?F_P"G
MP'QOQ.WH]WTN+QFW:S9>)HJ"CV=+CI:.NI:]"M*\34ZQE'3G2OZ(_FD?S$Q#
M_+G^07:W<7QS[0ZK_FG;1^3&1V[\>^ONG9-K[@^*^1ZMZEWIV7LW);;[$_O[
MG\SV[BMNU&VH:'>/\9H:04,[RQQ6;2Z^Z]T'OQS^?'\Z+OS/?RU=ICY1_$K;
M-5_-+^*W=':6`S#?$W+Y9_C17?'C%[=S=?N+&T@[<QT':N[NSL7DHQ4P9`8_
M!XFIJYA34<D=-%]Q[KW3_P!*?S1?YGOS/VO_`"[MG]1=L?'WH3L/Y,?"GYI]
MN]R;]SW1E5VABZ3?GQ,[[K^IZ#/["VG-O+;4%!4;Y_NRJ3T]945&.H(,M4U"
M4L\M-2P'W7NLWQ7_`)O?\Q>23^7O\@OD?GNANRNF?GW\1OG/VU2="=3]1YO8
MVY>LMS_!SJ2K[$ILK1=BY7>>Z\EO'-=S2X:1:VC:CI<?B7JQ#20R"(3-[KW2
MO^"/\RW^;!W/M6/O_LOK_*;H^._;_P`)N^/D/'OFO^-6V^GNM?COVSM/9=3O
MCJ7:_5F^:/NG?^?[_P"N-Q4D,^/K)<YC:#*BNIXYKQ1/)`ONO==[9_F&_P`T
M*F^#'\O+M#??>WQKH^Y_YM/R`^-_5/4^^Z?HBJHNO_B+L3L#KO<>X-QYW*X:
MNWS##W'V;N\;<IJFAH*R;%XRGRM=4TL7DIHH"/=>Z$+O#OG?OQG^</5F>^0_
M;7Q=W=VOU%_*+^>78.[?G-3?'W,BDP66ZS[XPN`VO7R];[/[!S.X!@L1!601
M;EVCA\FU3D,\E7!134YF2*/W7NJG_F;\_OE?\@?@G_-<^,7R/W/N'LG;.R^A
M?Y?WR-ZG[![%^+N(^(W9U1A>V?F%U?BZO&Y+JS;_`&;VACYME9&EH:2NPM75
MU-+ETC:2.KC9K%?=>ZWWJ+_@'2?]0T'_`%J3W[KW4GW[KW7O?NO=5%_.7_MY
M3_)&_P#$]?-?_P"``[U]^Z]TD/\`A.Y_VY9^`'_B),W_`._,WW[]U[JZ/W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=4[_S?_\`._RM/_&Q'PN_]PNUO?NO=7$>_=>Z
M)S\W/C'7?)?J6DAV)GH]B?('J/<N.[=^-O9RQCS[([=VHLLV'BR$BJTE1LO>
M=*\N%W!1L)(:K%5LNJ-WCBL'^9-F;>+`"U;PMU@<2V\G\$J\*_T''8XX%2<$
M@=2_[+>Y<'MOS6[[Y`;[D+=K9[#=[,\+BQGH)"@P!<6YI<6L@(9)HUHRAFJ]
M_#;Y.4/RJZ6Q^^:S`R;%[.VOF<OUMWQU372:\QU+W7LN9,;OS8N25F>1X*2O
MM58ZH)(K,554U0#^X0'.7]Y7>]N%RR^%>HQCFB/&*9,.A^PY4^:D'SZ1>\'M
MI-[7<Y2;)#.+[EFZA2\VR^44COMNN`7MKE/*K+5)5_T.9)$_#4FK]GG46]>]
M^Z]U[W[KW7O?NO=>]^Z]TDM^[33?NQ]X['DSVXMJQ;QVOGMKR[EVA64N.W7@
M(<_BZK%RYC;61KJ'*4F/SN.CJC+23R4\ZPSJKZ&M;VQ=0?56TEL7=!(C+J0@
M,NH$54D$!A6H-#0]&VP[J=AWNSWM8+>Z:SNHIQ#.K/!*8G5Q',BLC/$Y72ZA
MU+*2*BO5".V?^$T?P-V;N3;V[]K]G_+7";GVKG,3N7;V;H.S>O(<AB<[@Z^G
MRF)RE'.O3^J*KH<A2QRQN.5=0?<70^SO+%O,EQ#-?+.C!E821U#`U!'Z7$$5
MZSNW+^\C]]-XVVXV?<]LY4FVRZ@>&6-K.[*212*4=&'[PRK*Q4CS!ZV"Z[&T
M^3Q=9B*\R5-+D,?48VM)80S3T]73O2U)+TZPB*26.1N4"Z2?2!Q[E@<.N?C$
M%B0``3P%:#Y9J?VDGHM_QX^'_2'Q>^+.U?AQU'A<SB^C-F[0W/L?!X7+;BR>
M<S46W]X9+/Y7.P5&XZZ5LG45%16[EJV24MJC#@+8*+>ZUT7G!?RH?B!M7;?P
MOV_M/!;^VK5_`/"=@;;^-&\=O]B[AQF^]IX#M':]=M+?.'RFZ8)A7[AQV=QM
M:)'BJ=2QU$,4B!=)!]U[KAM#^4M\*.O]I?"S:6Q]@[@VFGP$W_G^ROCMN3![
MTSU%O+%[FWM-6U/9;;PW,M0<AOC&=JU.0E?<E+D#)#E;A9`$4*/=>Z'CYD_#
M'I[YU]1R=']Z9'M6FZZK<E-79W$=5]N[_P"HIMVT-7@LUMS([6WG6[`SF$J-
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M^O38#.[VX_O#??+VOY&VSV_Y=L^7'V3:;58(6GM;IYF122#(R7T:%LTJJ**`
M8K4D,7?*>V7MR]U,TPDD:IHRT_+M/^'JS?\`E[_R^ND?Y:O1%=\>.@<QV+G-
MCY#L'<79,];V?G<'N'<@S^YL;M_$U\$==M[;&TL>N+BI-MT_AC^T,BL7+2-J
M%L=O?3WRYP^\'SHG/?.\5A#O,=C%:!;2.2*+PXGE=25EFG;66E?4==*4`44R
M;[9MEOM5N;6V+&,L6[B":F@\@/3TZ17RX_E6_$KYF=J[1[Z[%Q_:O7W?&S-I
MU/7N/[J^/7<_8O0O9F3ZXK:Z7)5?7NY-S]<9W"U&XMIRUU1+(L%4LDD!FD$,
MD:R.&AKHPZ!CLG^1;_+U[-RF)K:W:'<6T<7_`**.M^C>Q]H]<_(SNS9&T_D%
MU/U'2Q4/7NS/D9BL+O6&3N2EP%'"(ON\O++DJI+"HJ)@J:?=>Z&S?O\`*M^&
MG8N/^8&(S>PLU08CYQ=<=(]3][8G;>[<QM[%U&Q?CQMQMI]4X796.QLL5'L:
M';V"80G[!(Q,J+K!`M[]U[J)WI_*A^&WR+J>[ZKM#:&[LE)\A>A>H/C9V6,9
MO[<>'2OZLZ-WY%V/U_CL8**J0XC*T.Z*>.2HK8B)JJ)!&YTEM7NO=*_LO^6W
M\6.VL[\LMQ[RVUN>IRGS5Z'V9\<.]Y:+>>;H(\QUAL'&[AQ.VZ'`PPS>/;F6
MIZ/<U2)*RG`EE(0MRIO[KW06;\_E"?$S>/9-'VSM_._)?I+>U3UWUAU1V!D?
MCG\H^[.B8NZ-@]-8:/;O6N#[CINN=W8--[R[6V_']C!6R>+(&C8PM.T=E'NO
M=&FV5\.^AMA]L?*WN;$;5J:W>'S4CZ[I_D)#N#+5N>VYN^BZOZ]J>K]L8^#;
MN1>;&XN@;9M9+35D4*!*TR%Y02??NO=$6VS_`"+/@+M;IOM;X_4F*[XRO3O:
MN.V3MX[!W5\D>X]V[<ZSV9U_VM@^ZMN;&Z:Q6X]U9*AZUVM'V-MRDKJB*AC%
M15>,QRS-&Q4^Z]TL,_\`R9?A'N+ONK^0=7B^YZ3/U7RBV?\`-4=>8KOSM/'=
M&T_RIV?DL7DD[PBZ:I]QKL27?6XOX1%3Y.IFI)1/2F2.-81(Y;W7NCI?&CXN
M=1?$G9&Z.O>E\5EL1MK>':_9_=&;I\SG*_/U,V^NWMV5V\]YU<%7D'DFIZ"H
MS60D,%,O[=/%95^A)]U[HP_OW7NJD/Y\O_;G7^8;_P"*X;M_]R,;[]U[JU/;
M'_'M;>_[4>)_]P*?W[KW52?\^S_MUSWC_P").^'W_P`&=\???NO=7$>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[JN/^<(VG^5)_,A;2&T_"'Y.-I:^EK=/;M.EM)5K
M'\V(/OW7NH_\N?XLX#J;X0=>];9;L?LCN38/;74N!W/E=J=L1=:U.-P/^E_;
ME1NWLG`8)]A=<[!K:G;NZ,]O6NEDARLN3FAC98HI4C!5FYHH[B)H)E#0NI5@
M>!!%"#\B#3I9MVX7NT;A!NNVR-#N-K,DL4BFC))&P='4^3*P#`^1'31_+)W)
MFMC;,[:^#F_<C55_8'P6W^.K<)7Y*0ODMV?'7<U))NOXU;XD9@JR)4=>3C"2
MF,%4K,#,A)8'V$.39I+:WGY:NB3=;9+X8)XM`PU6[_\`./L^U#UD7]Y7;;/>
M]XVGWMV*-4V'GBP^MD5!V0;M"P@WBV'$U%T/J17)2Y0TH1U9W[&?6-'7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]T2WNK^77\(_D7OZO[2[P^-_7?9?8.3H<9C*[=
M6YJ3)5.3J,?AJ5:+%TA:')00I#1TJA$"HO\`4W))]AW<>4N7-WNC>[E:1373
M``LU:T`H!Q\AU,G)GWA/>GV\V*/ECDGF+<-MV&)W=882@0-(VIVRA)+,:FI/
MRZ%/X_?%?X]?%7!Y_;7QXZIVQU-@-TY>'/;@Q.U8JR"BR>9IZ*/'19&>&JK*
MM5J5H84B+)IU*HO>P]K=JV3:MDB:':8$@B=M3!:T)I2N2?+H,<_>Z'/_`+HW
ML&Y>X.Z7.ZW]K$8HI)M)9(RQ<H"JKC42<UH2:=*#+]!=.Y[N[9WR/S&P<+7]
MX=?['W/UMLWL:8UO\=P&QMY9#'Y3<VW*-4JTH#19:OQ4$CM)"\JE"$=0SAC7
MH!=8<G\>NE<UW=C?D?ENNMO9'N_#]6YGI/'=B5<-1/FJ;JG<.?IMT9K8XB>H
M.-EPN2S])'4R*\#2%P0&"LRGW7N@9Z0_EZ_"[XW[DV/N[I'X];%Z^W#UEL#=
M_5G760Q2YBK_`+B]>[^WSD^RMY;4VE29?*Y&AV_B]Q;VS-575(I8HG<S-$&$
M%HA[KW0O?'_XX='_`!7V`_5GQZZYP75773;GW/O&/9NV37I@:/<.\LK-G-RU
MF-HJZMK$Q4&3RU1).:6F\5)$[GQ1("1[]U[HK?5W\IG^7'TIWECODMU5\1^J
MMD=[XG<6YMV8[L[#4F:3<M+N+>5-F:/<^5CFJ,Q/3&HR]+N"M20-$4"U#:57
MBWNO=*7J;^6-\`.B>W.P^]^H?B=T]L'MKM3'[EQ6]=YX#;GAK:W&;SD:;=^/
MP]#-43XC:-'NF1V.1CP]/0)6W/F#@^_=>Z1W0?\`*(_EJ?%SM;;7>/Q]^'G4
M?57;.SHLS#MC?.UZ#,0YK"Q[APN0V[FEHFJLQ54R?Q'"96III"8R?',UK$W]
M^Z]U8[[]U[KWOW7NDKOK8^TNS=E;MZYW]@<?NK8^_-MYO9^\-LY6-IL9N#;.
MX\=48C.8;(1*R-)1Y+&U<D,@#*2CFQ!Y]F>S;QNG+V[VN_;).]MO-E<1SP2H
M:/%-$P>.13GN1U##'$=4DC26-HI`#&P((]0<$=5F_P##&O\`*1M;_9#NB[?3
M_BU9J_\`M_XW?WD+_P`&/]Y__IM-Y_WN/_K7T4_U?V7_`)1X_P"?^?JU*AH:
M3&4-'C:"GCI:''TM/0T5+"-,5-24D*04U/$MS:.&&-54?T'O&R::6XF>XG8M
M-(Q9B>)9C4D_,DUZ.``!0<!T0K'?RK?Y=>(^2R_,+%?$#I;&_)%-R3;S3L^A
MVT:6OCWK422S5&]XL'#5)M2+>L]5.\[Y=:`9)JEVF,WE)<M=;Z]U!_*N_EW=
M!=E;S[@Z<^(G3G7_`&-OW$;HP&?W+@<!-'+3X3>T=1#O#$[5QU165&'V%CMS
MP5<L==#@J?&I512,D@921[]U[H6MC?";XJ]:5WQXR>Q>D]H[<R'Q.V/O#K;X
MZUE'_%9)^JMC[_H<=C=Y;=V[)59*H,E'N&AQ5/'4-5?<2D1\."S$^Z]TT]9_
M`KX?=-UO660ZPZ$V5LVKZ:V+VAUGUA+B5RP_N=L3NG=\F_>TMM8N.IR=1$:'
M>6[YGKJHRK)*LLCB-D1F4^Z]U,V1\&?B3UO#\<Z?9'16RMOP?$?"=C;;^.$5
M+%DIDZGP7;F+_@G96,VZ*S(U/EIMXXHF"L%7]R70FQ4DGW[KW03=0?RI?Y=O
M06\=\;]Z;^)W5_7FY^Q-I;TV%NBIV]3YN#&OLOL5HGWSM?`;=FS,^W-F83=)
MIT^\I\-24$<P1018`>_=>Z%#?/P-^'O9GQDVQ\-M_P#Q^Z_W;\9=DXC;&#V=
MU)FZ&LK,#M2BV93&BVK+MRN>M_O!A<K@:1FBIZ^FK(ZY(Y)%\UI'U>Z]TF-O
M_P`MGX([6VYMC9V!^+O55#M+9W1O8OQJV_MDX:>KP%+T;V[N`;K[.Z[J\16U
ME309?$[ZW/JR&3EK(ZBLJJR669YC)+(S^Z]T'&S_`.3]_+1V%LCL3KG:?Q"Z
MPQ.S>W-L[/V=V=B=>Z*Z3?>VNO\`>=)V#LG%[GRN2W#69G+1[7W9CJ:IHGEJ
M&E@CI8*=6^V@BA3W7NK)554544!550JJ!8*JBP`'X``]^Z]UW[]U[KWOW7NJ
MB_G+_P!O*?Y(W_B>OFO_`/``=Z^_=>Z2'_"=S_MRS\`/_$29O_WYF^_?NO=7
M1^_=>Z][]U[I*;XWYL?K':N9WWV3O/:G7NR-N4RUNX=Y;XW%B-I[5P5&TT=.
MM7F=PYZLH,1BZ9JB9$$D\R*7<+>Y`]^Z]TR1]P]22]:#N>+M+KF7IXX1MRCM
MB/>^V7ZT.W%8HVX!OM<F=KG"*RD&K^Z\`(_5[]U[J3UOVIUAW)MF+>O4/8^P
MNU-FSUM;C8-V];[PV]OC;,V1QLO@R-!%GML9'*8J2MH)CHFB$I>)N&`/OW7N
MJM/YO_\`G?Y6G_C8CX7?^X7:WOW7NKB/?NO=>]^Z]U4M\H:.J^#/R-H/GWM.
MFG3H3M4[4ZM^>VU\93RR4^(HXJB+!]5?+&*CID<FOZRGK$PVZ)%5WGVU4I-H
M+41D`%WI6Y:W<<T0`_NN?3'>J!P'PQ7-/6.NB3UC(-.VO65OME-%[W>WDGL/
MNS*>>MK\>]Y8G=@"[$&6]V,L?P7@4W%F"0%NT9-5)0O5L-)5TF0I*6OH*JGK
M:&MIX:NCK*2:.II*NDJ8UFIZJEJ(6>&>GGA<.CH2KJ002#['*LKJ&4@J14$<
M"/4=8K30RV\K03JR3HQ5E8$,K`T*L#0@@BA!R#@]2/>^F^O>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>ZJ0_GR_]N=?YAO\`XKANW_W(QOOW7NK4]L?\
M>UM[_M1XG_W`I_?NO=5)_P`^S_MUSWC_`.).^'W_`,&=\???NO=7$>_=>Z][
M]U[K#4R2Q4]1+3T[54\4$LD-*LD<+5,J1LT=.LLI6*)IG`4,Q"K>YX]^Z]U6
M)\'_`)X=R?(SY"?+[XS=^?'':O1W8OQ/I^E<OF\IUIW;_I[V#5TO>&V<[NW#
M[*SFZSUSUM_`>T]HX7$0S9;&1TU9`(:Z&:*=H7BDF]U[H)/@C_-AS_S#[GZ_
MV-N7X^4/5/6WR5Z([;^2OQ&W]1=I/O?<&_.J^F>YL1T[N6#M?9C[#VO2]9[V
MS*[FQ.X,=18_*;BI#BJXQ3U4=5`\;>Z]T[_SU/D9T+TK_+-^9NQ.W.X>NNMM
MY]Z_$?Y/;(Z9VMO3=>'V]G>T=X#JG*8\[9V+C,E5056Y<V*W<5!%]M2K)+KK
M(A;UK?W7NK!/B8"/BM\9P18CX_=,@@_@CKG;=Q[]U[HE?R[?_98/F)\7_FQ1
MK]GU_P!BU-%\*OE#-&`E)3;9['SARGQ]['RY`6G@@V)V_(<54ULMWCH=R%-2
MQJ?8(WX_N7F"RYC7%K,1:7/H%D:L$A\NR7M)/X9/3K*/VE7_`%S/:'F;V8F.
MO?\`;E;F+90?B::TCT;K:1_B)N;#]=(U(!EM*T+$=6J^QOUBYU[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW51?SE_[>4_R1O\`
MQ/7S7_\`@`.]??NO=)#_`(3N?]N6?@!_XB3-_P#OS-]^_=>Z"_\`F)?S*/D3
M\`^[-V9RH[G_`)5NZ.AQAMMY+`?'/N[Y![X^._S.IJK^[](<U'@ZC&8+M_;N
M]Z+/Y:.:IQH;;6/DCAF2(R2VUGW7NK`_Y<7SA3^85\8\'\CTZ*[3^/0RVY=P
M[9.Q.V*$T^4JSM\T7^_HVQD31XQMR;'S8K?]Q^1-)2&H,4@,2Z.?=>ZF?S'-
MQ[GVI\0>T\[L3XBTWSC[!HDV^W7OQWR>V<#NW`;BWRVX<:NU]S[HP^X(YZ>3
M;77V6,><K&IHI,@(J`BET3E)$]U[JGKJ'X][8VC_`"@*?^71GOB]_,+J-E;W
MZ;[RW)VKO;:W1/5.U.P*3?LO>>W=W;SQFS>G\]O_`'!A,%-OK<_85=E-E;=2
MGR-*^U,+412EZJ,1U'NO=6/_`,HS%?(_#?&C>E%\BNNY.N(Q\A.V9NB:#/\`
M3_4O07:.XOCW/58B38&[N[.H>CJ+&=:;+[2S-><E]W!0TE%)+114DU13Q5$D
MB^_=>Z)M_-MZ]^1E/\G_`.6AV3DOD=@\E\9:W^:9\*,%@OC%'T?A*'/X/?B8
M[L=9M^S]^IO&?/9:BE>"H889L)%$OW`'W!$8U>Z]UL)^_=>Z][]U[IDW-MK`
M;SVYG]H;KQ%!N#:^Z<-D]N[CP.5IXZS&9K!9JBGQV6Q61I90T=319"@J9(I4
M86='(/U]MS0Q7$+V\ZAX74JRG(*D4((]",'I;MNY7^S[C!N^U326^YVLR2PR
MH2KQRQL'1T89#(P#*1P('58_PHW)N#XN]L;C_EM=JYC(Y3';/P-;V'\)=_9^
MI>HJNQ_C1!614M3U?792H-\EV'\<Z^JCQ52FK[BKV[)058B6-)&]@SER:79;
MY^4+YBR1J9+-V_T2WK3PR?.2`G2?,QZ6I0'K)7WGVZP]SN5;?[QG*\4<5S=S
MK:<QVL0`%IO!4L+U4'P6F[*IF0TTI=B>(L691U:G[&_6+O7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=5(?SY?^W.O\PW_Q7#=O_N1C??NO=6I[8_X]
MK;W_`&H\3_[@4_OW7NJD_P"?9_VZY[Q_\2=\/O\`X,[X^^_=>ZN(]^Z]U[W[
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MAO=5M[KW1O?B7_V2K\9O_%?>F?\`WW.V_?NO=.GR3Z+VK\F>A.V>@]Z`KM[M
M39&:VI45J('J,+7UE.9,%N2@!("Y3:^>@ILC2-_8J:5&_'LMWC;(-YVN?:[C
M^RGC*U]"?A8?-6HP^8'0U]N.>-T]MN>]JY[V;_<_:[V.<+6@D1326%OZ$T1>
M)_5'8=`/_+M[VW7WG\9MO1]H@4_?72N?W'\>/D1C7<O/2]R=/5HVON3*2$V+
M0;UH8:/<%,X`5Z7*QE1;V6<I[G/N>S(+W&Z6SM!./26(Z6/^W%''R8=#K[PG
M(VU\D>Y-PW+'=R+O5O#NVTO2@;;]P7QH4'H;=C):N*DAX&!ST>;V)>H0Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJ+^<O_;RG^2-_
MXGKYK_\`P`'>OOW7NDA_PG<_[<L_`#_Q$F;_`/?F;[]^Z]U7;_,J^*F6[Y^=
M_8N^/C+\`<-MSY)['INJ=LY3^9K5_P`R]_B)_=_<>[]F;<H]A[>JNLNL9-_=
M@;BK(J:JHL530Y/;E,V4-,B0"HB:$O[KW5XO\N+IGYE=#?&/!]>_.WY'8?Y1
M=]4FY=PY"I[(P>,^SHZ+:=<:+^[FT'RDVW=J9'=M3M]89M>6K,?35=7YAY%]
M`)]U[H^'OW7NO>_=>Z][]U[JG?\`F_\`^=_E:?\`C8CX7?\`N%VM[]U[JXCW
M[KW7O?NO=>]^Z]T2[YP?&C.?(7K+"YKJW+TFSODOT3N:#M[XS]@U`T0X#LW!
M4TR?W:W!(I62IZ^[+Q$DV"W!2,6AGH*PR,CO!&`'>9-GDW6R62R81[Q;/XMN
M_P##(OX6_H2"J..!4UH:#J9/93W(LN0.99K+F>)KSVWWRV-AO%J,F6SE(_6B
M'`75G(%N;604994TAE#MTM?B)\EL'\K.D\'V;18BJVANZ@R.6V)V]UIE25W!
MU/W)LNI_@_8G7&?A<+,E9M[.1MX)'5?O*"6GJE`2=?:G8=XBWS;EO%4QS@E)
M8S\44J8DC;YJ>'JI#>?1-[M>V]][6\YS\MSRK=[3)''=6%XG]E?;?<#Q+2[B
M(P5EC(U`$^'*LD9-4/1G/9SU&G7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5
M2'\^7_MSK_,-_P#%<-V_^Y&-]^Z]U:GMC_CVMO?]J/$_^X%/[]U[JI/^?9_V
MZY[Q_P#$G?#[_P"#.^/OOW7NK%OD?V)VWU3T_N??G1W0>5^3G8^"FP3XGI;`
M]@;.ZQS>[,?69_&T.X9L1N[?TM/M.FR.`V_4U.1BIJN:`5[4OVR2QR2HP]U[
MH@'37\Y#X_;Y[[ZZ^)W>/3ORC^&/R@[7J:W'=<]2_)?IRMQ5-O[)8S'U>3R$
M6R.S>N<GV'U=G*.*BH)9(YY<M2"4*%"B1U0^Z]U;C[]U[KWOW7NO>_=>ZKA_
MG#?]NH?YD?\`XH_\G?\`WSN[O?NO=&<^)?\`V2K\9O\`Q7WIG_WW.V_?NO=&
M"]^Z]U57D&/Q1_F:X[)V^QZ;_F.[0CP&1<#QXS`_+OHG`2U&!J)&LM+0S=P=
M+)/3``"2MR6VTU%G91[!#_[H^<@_#;]WCTGT6ZA7M^0\6&H_I-'UE';@>Z?W
M:Y+;X^</;N[,J#B\NP[G*!*!^)Q8;AI?S$<-V:``'JU3V-^L7.O>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJB_G+_V\I_DC?^)Z^:__
M`,`!WK[]U[I(?\)W/^W+/P`_\1)F_P#WYF^_?NO=5H?S4?A;V/B?FID<OC_Y
MC^POB5L#^93WI\<]]8'"]C?%C#;_`-E87OG^7SU]L_>_7,&ZN\=P=O;*QFU&
MW+5=<156,Q;4H.=J(Y*'2X5W?W7NM@WX,KW0O1P'?/RTZG^:._/[X[D)[FZ8
MV#M?KC9G\&_R#^';1&W=H;KWCB/XKMYO)YY_O/-()T#H"NIO=>Z-]555-0TT
M]96U,%'24T3SU-5531T]-3PQJ6DFGGE9(HHHU%RS$`#Z^_=>ZZAK*2HI8ZZ"
MJIYZ&6`5,59#/%)2R4S)Y%J(ZA&:%X&C]0<$J1S>WOW7NN%#7T.4I(,AC*VD
MR-!5)Y*:MH:F&KI*B/45UP5-.\D,J:E(NK$7'OW7NJ@OYO\`_G?Y6G_C8CX7
M?^X7:WOW7NKB/?NO=>]^Z]U[W[KW7O?NO=5,?(F&7X'?)FE^;>WXGIOC3WY7
M;3ZT^<F$I@ZXK8&Y!+#M[J7Y:1T<0,=/'B*BJAVWO*9`ODQ$])6NLDE(S@"[
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MO>_=>Z][]U[KWOW7NO>_=>Z][]U[JI#^?+_VYU_F&_\`BN&[?_<C&^_=>ZM3
MVQ_Q[6WO^U'B?_<"G]^Z]U4G_/L_[=<]X_\`B3OA]_\`!G?'WW[KW0X_S7Z7
MJ.O^!O=V-[R[G^270/7&439&,RO9OQ'AWA5]^XS(UW8&UZ;;F'V30;%VQN_<
M62CW7N&2FQF1IDH7@GQM7.D\D,)>5/=>ZUJOY/'QM^0G2OR]ZGGZ+_EY5'8?
MQ:J\SFZKL;YY?/7X3;.^+WS6VMCI\)E_L-P;(WUN'Y&;N[*[,FSE9+#335`V
M;B))Z>=BT2H6D3W7NMVSW[KW7O?NO=>]^Z]U7#_.&_[=0_S(_P#Q1_Y._P#O
MG=W>_=>Z,Y\2_P#LE7XS?^*^],_^^YVW[]U[HP7OW7NB5_S`N@=Q_(;XQ;RV
M_P!=3#']V=>9';_=_P`>\XMA483O+J+)1[PV!+!*01"F<KJ&3#U+6/\`D62G
M%N?8=YJVN;=MFDBM,;E$5F@/I-$=:?[T1H/R8]3-[!\^;=[?^Y=G?\PCQ.2]
MPCEVW=8_*3;;]#;W0(\_"5A<(/\`?D*="I\5N_\`;WRE^._47?VVH&H*+LO9
MN-SE?A9&)JML;GB$F-WCM"O#$LF2VANRAK<;4*>1-2M[6[)NL6][3!ND(HLT
M8)'FK<'0_-&!4_,=!?W1Y"W#VP]P=VY#W)M<VVWCQI(.$T)H]O<+_0G@:.9/
MZ+CHP'LUZ`/7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U47\Y
M?^WE/\D;_P`3U\U__@`.]??NO=)#_A.Y_P!N6?@!_P"(DS?_`+\S??OW7NBH
M?\**-X5VQ,+\1=S97HWXP]T]<8[)_(RISN/^5WQ.W5\J>OLCV)1=:8+*=0=3
MX&DZ_P`76[WZX[![LSN/J\1A\O#/3X[[J(?>I5".&FD]U[H*/Y&?S@HNV/E5
MW+\?NBMH]#]8_$[+[6[H[=V9\:>EOCP_35;\87V'V-U)U]L;<6\=Y4>/PF,[
M4G^4F(W7E\G'524%/-!+M9TI[0!XH_=>ZNC_`)I&Y>O-H_"+N+/]E_%+<_S<
MP=#'M>3$_&';&PL[V2W:.]/[UX<['Q^Y=K8'%9V:;8V)W4*7(9NHGH:ZGI,9
M233-35+(E/+[KW5#TNQMQ]=_R&\=\$NC=L?*?M_L7+=?[B[+WQ_`/C'\C.J<
M#4=?;:^7W6F]/E=T)UW@NS]H[1WW@L//UIV'G<%L;;\],F0W9MN@G-&DCLT?
MOW7NK4/Y,VPH]G;,^:N:Z^ZPW/TM\5>R/G'V)OKX>]8[FZTW1TLF%Z:JNL^H
M\+F\WM#I[>.W]I;AZQV!O#MS";DR.*Q51B<6=$SU2TR)4JS>Z]T`7\VV/Y;_
M`.S0?RSY,M5_',_#8_S3?A0NW*/'8_LQ?DTO9W\.['\\N;R53DVZK?8GE^ZT
M1P4JY#28KO</?W7NMA3W[KW7O?NO=>]^Z]U[W[KW2;WEL_:_86TMS;#WO@L=
MN?9V\L#EML;IVYEZ=:K%YS;^<H9\;EL5D*=^)J2NH:EXW'!TMP0>?;-Q;PW<
M#VMRH>WD4JRG(96%"#\B.C'9]WW/E_=K;?=EGDMMXLYTF@FC.EXI8F#QNI\F
M5@"/F.JWOA#O'='QZ[&W7_+@[DSN1S>6ZKV^=\_$KL7<$[25G</Q6DKQCL1M
MVJR$P5<GV-\?:MXMO9E`5FJ,8,?7"/1)))["/+=Q-M5V_*.X,6D@37:R-QEM
MJT"U\Y(#V/YE=+4H2>LBO>K:-LY_Y>M?O$<GP1P6FZ7'TV^VD0[;#>PNN28*
M/@M-U6MU;G*K-X\);4JKU:+[&G6,G7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U4A_
M/E_[<Z_S#?\`Q7#=O_N1C??NO=6I[8_X]K;W_:CQ/_N!3^_=>ZJ3_GV?]NN>
M\?\`Q)WP^_\`@SOC[[]U[H?OYHO7'RB[1^'NZL!\-ZU:7O["]F?'_L+:]++V
M76]04FX,)UAWMUYV#OK:>2[`H#Y<)B=U;(VWD,?5AP\-335#PR(Z2%&]U[JN
M'^69W1_-HWIV1NGL;L7H3X^]C?$3Y9_(/<?=V$[KV3\\Z/N_'])=69/8.V=G
MT&P^GL12;,6@WIM#%[IV!)41K138NG^[R]6XIT*N[^Z]UL3.VA&?2SZ59M"`
M%VT@G2H)`+-:PY'/OW7NB%?!7YJ[@^8TORHQV[.A<]\>MS?&#Y-;@^.F7V?N
M;?>U=^YS*OBNO.N>QL?N7)UFR4J=K82NR.'[&IDFQM%DLS#2R1,!6RDD+[KW
M0)_RX_YF5?\`/S=O<6';8/1/76,ZQRV\,13[=VM\LL)VYW[22[2[4W;UHM7V
MYT)3=6[)S73V-W#'M1LCCZB?)9.*IBJ$C5B?7[]U[IR_G6]C]>;)_E;_`#XP
M.\]^;+VCG-^?#/Y/8/8V&W/NG!X#+;SS0ZBW%"</M/'96NI*S<65\V0IT^WH
MTFFUSQC3=U!]U[HY_P`2_P#LE7XS?^*^],_^^YVW[]U[HP7OW7NO>_=>ZJK^
M,);XN_.3Y*?$&L'V/6G?RY#YL?&E6&BAI,AN/)TF`^3O6^-8Z88FP784M#N2
MEH80!%1[@F<*%1C[!&R_[I>9;S8&Q9W5;RW]`6(6XC'^E>D@4<`YZRC]S*>Y
MOLERY[MP]_,FPE>7=X_B9(4:79KQQQ/BVHDM))6KJDM4!-2!U:I[&_6+G7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U47\Y?^WE/\D;_Q/7S7
M_P#@`.]??NO=)#_A.Y_VY9^`'_B),W_[\S??OW7NFCN_X5[SZ-[>GWQ\0_YJ
M/9WQ%[,[\WOO3>>)^./R5W-MSY,?&+L[=4U<VZ=\8W8'4G;N:Q78VPHZJNS:
MS5J[*W+1Q8Z*>/PTB(%C;W7NAT^#?R5^6._NZNZ_CK\M=@_#ANS.DML[6K=S
M]M_$#Y&8K?6,RE?GJRH;![3[!^.^[X*7OSHK-5&$E;*48S+Y'%U<4DJTU6S*
M#)[KW5HWOW7NO>_=>Z][]U[JG?\`F_\`^=_E:?\`C8CX7?\`N%VM[]U[JXCW
M[KW7O?NO=>]^Z]U[W[KW7O?NO=$D^<OQOW3WGU[MG?'3.0HML_*?XZ[D;MKX
MT[PK7\%"F]:*ADH\WUWNF96C:?KOM_;;38'.4[,(O%415+*STL8]ASF7:)]S
MM$N=N(3>[1_%MW/#6!0QM_PN5:HXX4(/X1U-/LC[B[7R1O\`<[)SC&]S[7\P
MVWT.\6ZBK&V9@T=W`,TN[";3<VS@:JJT8($K'H3?BA\D=K?*WI':_;NW,?7;
M<R55-D]L=A;!S0\6YNK^T]HULF#["ZUW32,L<U+G-H[CI9J=M:1_<0>*H1?%
M,A*S8]W@WS;4OX04<U61#\4<BG3)&P\BK`CYBAX$=!KW4]N=T]K.=+GE/<9$
MN+=0DUK=1YAO;*=1):7D+"H:.>%E;!.EM49.I&Z,=[-^H[Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[JI#^?+_VYU_F&_\`BN&[?_<C&^_=>ZM3VQ_Q[6WO^U'B?_<"G]^Z
M]U4G_/L_[=<]X_\`B3OA]_\`!G?'WW[KW5P-5,*>FJ)V#$0033$(&+$1QLY"
MA%=RQ"\6!-_H/?NO=?/R^(OR1Z^^/^$Z>[+Z)Z?^7F!^1%;N';O=/4?Q4WQ_
M-IDR?PVW_P!8]N;%^4?;N\=_9_`[=Q^4P>R\LJ=`[H+[*W'@Z/+)F<AC:BHO
MY)57W7NM\7I7M'#=Z=+]2]U;:I,AB]O]Q=8;#[1P%#DTB7*8[#=@[4Q6[,52
M9"-#)`,A2467C28`LOD4VN/?NO=5Z?'[^6IV)\?\_P!][DQ/SW^1&X<K\C_D
M9U]\F.RJBKV%\=,"];O3:M7L['[QQ%$VV.I<4*/:_:G7.P\9MG*TB`)3T4#5
M%'X*R6:>3W7NA,Z%^`L_5WRKWA\R.V/D=V?\D>Z,IU!6?'G8F0WKM#I[8&(Z
MXZ1KNPX^SZO:=/B^H-@;(CWAG:S=-'2-+F<NU35>"D5(UB\D[2^Z]T#W\\3H
M[I;M7^6'\W]W]H=1=8]C[LZ@^'_R>W;U-N??>P]K[MW#UANH]39NK.YNO<UG
M\77Y'9FX#586CD^\QLE-4%Z6$Z[QI;W7NCW?$LD_%;XSDDDGX^],DD\DD]<[
M;N2?Z^_=>Z,#[]U[KWOW7NJS_P"9SM'<V`ZOZ\^8O6F*J<KVM\%=_P`/>U'C
M,<I_B6[NFI*&3;OR.ZZC=06^WW/U-65E8J#EJW$TMK$>P=SG!-%91<P6:EK[
M;)?&`'%XJ:;B/_;1$G[5'627W:=VVV_YFW#VAYEE6+E;GBP.V,[_``0;@&$N
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M^Z]U[W[KW7O?NO=>]^Z]U47\Y?\`MY3_`"1O_$]?-?\`^``[U]^Z]TD/^$[G
M_;EGX`?^(DS?_OS-]^_=>Z*U_P`**NH^I.Q]C_&7+=E;KP.#R6+J_D'L';..
MWS\,.^OFALH4?<'7.&VGN7L#';6Z`1=Q;$[HZHCIZ3+['S-;,E%'E%ENI91)
M%[KW0/\`\@WXU;TW-VKO#Y]#N;H?M_KS<>%^27659V3L#HSOWI#O/MOMSL+N
M3K#<N_*+O*G[YQ=!G]U;7Z,FZC7%;8JFEJ*B.JR^4@D$3T[^7W7NMJCW[KW7
MO?NO=>]^Z]U3O_-__P`[_*T_\;$?"[_W"[6]^Z]U<1[]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>ZJ7[O1O@)\IHOEMB5:B^*GRASFUM@?,;&Q`IANI^VY33;9
MZE^4:4Z#[?'8;<,TU/M?>LX\::'Q^0E\CQ2M[`NY?\A?>_WZF-CO65+L>44O
MPQ7/R#8CF./P.:D'K*SDHCWX]L#[477?[I<LP376P.<R7UB*S7VRD\7DB`:\
MVY>XU$]NNE64=6S*RNJNC*Z.H964AE96%U96%P5(/!]CKK%0@@T.".N7OW6N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NJD/Y\O\`VYU_F&_^*X;M_P#<C&^_=>ZM3VQ_Q[6WO^U'
MB?\`W`I_?NO=5)_S[/\`MUSWC_XD[X??_!G?'WW[KW1TOEWU9\K>S-I;2E^(
M/RAPGQF[)V=NEMQ5DF].FMO=U];]IX3^$UU$_7N_L#D<KMS<^#PM375$-4N3
MP&4H<G32P"WE1FC/NO=:^&]_C_LOJ6;<,?\`,G_X3S_''M[;VX<IGLOO'Y8?
MRR^J]I]X8?,Y;=%?0Y3<V\=V=$9'![%^4^Q_N)L3%5Y"MQYW.\1\NB5@TQE]
MU[K:AV;'MV':&U8=H8V'"[2BVW@X]KX>FQ,F!I\3MU,92KA,;3X.6FHY<-#0
MXT11)2-#$U,J",HI72/=>Z4GOW7NO>_=>ZKA_G#?]NH?YD?_`(H_\G?_`'SN
M[O?NO=&<^)?_`&2K\9O_`!7WIG_WW.V_?NO=&"]^Z]U[W[KW46NH:/)T59C<
MC2T]=C\A2U%#7457$D]+64=7$\%52U,$BM'-3U$$C(Z,"K*2"+>ZLJNI1P"A
M%"#P(/$=.P3S6TR7-NS)<1L&5E)#*RFJL",@@@$$9!ZJ_P#Y;E=7]+Y'Y!_R
M^MT54\E?\1]])DNE:BOF>6JW#\3NX9LEO#IBHAJ)R9<E)L&I_BFU*MU++`V'
MA4E=:K[!G*#/MSW?*LY.NPEK"3Q:UEJ\63QT=T1]-(ZR:^\7!;\XV_+_`+^[
M6JB#FRQT;BJ@!8M\V\);[@"JX070\&]C!H6$[D5H3U:5[&O6,'7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5%_.7_MY3_)&_\`$]?-?_X`#O7W[KW2
M0_X3N?\`;EGX`?\`B),W_P"_,WW[]U[H\7R[^.7=/R(P^R<=TS\SNY_AQ6[7
MRN7K\[F>G-J]4;IK-\TF0HZ2GHL7G8>U-F[OI*2EPTU.\T+4B0N[3,)"P":?
M=>Z@_!?X983X0=3;MZ]H^U^S>\MV=F=Q=B]^=K=M=LU.!?=N^>T^T*RBJMTY
MML9M7#;?VSM[&R+C*=(:&AI(H8RC.=4DCL?=>ZA?S(,GL3#_``;^2U?V3V5O
M+J7:,7669CJ][;`W?N?8>[*7*5#04VV<+B]U[*:/=N*&[-S2T>*G&/EAJ*BG
MK'@$B+(S#W7NJ8-F_)'IWO3^0]T;\=MP?+&JZ;[L[&_ES;5_O/VYNC;_`'5D
M#L',]*+TWUOWMF=_[LVMBZ/,8C);5[#W72XO*(^5H\G(*R6IA9H(9ZB/W7NC
MY_R0=^4^^?A_NR/#]583KO9VROD?W-L;8>[ME;L[SWAU?\@MIX3(8B:D[\ZH
MR/R.SFY.V*;86\:^OJ:."GK*^LI%J<9.]'/)3NA'NO=%R_FVM\N/]FA_EGKE
MH_CE_LFG_#IGPH.W)<=/V:?DY_I._AW8_G7-P5,`ZK&P_-]UH,$AR&GQ7%]?
MOW7NMA7W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TD=_["V?VEL?=O6_8&`Q^
MZMC[ZV[EMJ;LVYE81/C\U@,Y138_)X^JCN&\=12SLH92KH;,I#`$,75K;WMM
M)9W2A[:5"K*>!4BA'[.C;8=]W?EC>[3F+8)Y+7>K&XCG@E0T:.6-@Z,/L8#!
MJ",$$$CJFG8WRQ[-^`?7W=_Q?[8V1NSY`[O^(6Q:_MOJ+,P[LVSMO=G=OP8P
ME%E:J'?$.6WC58[%;@[$Z%CQJ;8W)0I(E76.*&L0.*IY`$>7;V7:I9>5]VDK
M-:1ZX97-/%M?)B3C5#_9R_8K>=>LAO>7EFQY]V_;_??V\L].W<PW8M=SL;="
MW[OW\@&2".-:MX&Y5^KL0`:EY8``8PO5QG6VY=Q[QV)M?=&[=F3=>;BSN+BR
M&3V74;AP>[)L!).\AAI'W'MJ>IP.6\E,$E$M+(\9$@%[@^QH"&%1D'K&5T>)
MS'("LBD@@BA!&""#D$'B.EQ[WU7KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJ0_GR_]N=?YAO_`(KANW_W
M(QOOW7NK4]L?\>UM[_M1XG_W`I_?NO=5)_S[/^W7/>/_`(D[X??_``9WQ]]^
MZ]U<#5(\E-41QR+#(\$J1S.NM8G:-E61E#QEEC8W(U"X'U'OW7NOG9[=Q7S:
MDV7MCX9X/L3=OR9ZWASFV:O,]?\`4G\Z'XO;W[7["[BZFV1\A,'#G_C5!BNX
M]I]O];=4;QWWO78NZ,=U_IEDH8]AU\E9%%.46J]U[K?R^/.*[.P70/1N$[LR
M:YKN;#=/=9XKMS,)50UJ9;L['[+PE)OW)K64X6"K6OW5#5RB5`$D#ZAP1[]U
M[H8??NO=>]^Z]U7#_.&_[=0_S(__`!1_Y._^^=W=[]U[HSGQ+_[)5^,W_BOO
M3/\`[[G;?OW7NC!>_=>Z][]U[KWOW7NJK/G>)/C?WQ\8/Y@>,U4FV=D9V+XQ
M?*::,:()?CIWGN#&T6W-X9F4?2BZ>[I_A.2O_8I,E6GZ$^P1S/7:-SLN:DQ#
M&WT]S_S0F8!7/RBFTM]C-UE'[&:?<7D7F;V"N>_<[V`[SL@.2-VVV)VFMXQ_
M%?[=X\/S>&'JU,$$7'(/((^A'L;]8N=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U47\Y?^WE/\D;_Q/7S7_P#@`.]??NO=)#_A.Y_VY9^`'_B),W_[
M\S??OW7NKH_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U3O_-__`,[_`"M/_&Q'PN_]
MPNUO?NO=7$>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU5O^%0?>/6N
MT.I>ANJ*&)Q\B-SYO=N:P6X\+EZW$9[9W2N4V_6[.[(Q.2EQLD,U?MKMFHKJ
M?&RXZH8T=<F-G=U9J91[A#WIW*SM]OMK%1_NU=G(8$@I"5*2`TXK+4*5.&TG
MTZZD_P!V/R1S)N_-V^<T3,/Z@6T-O')#)&LD=QN*2K<6CH'!"S6(5I5E0>)$
M9HP"!(>C@?R!/GYB/E7\1-N],[UW9CZGOWXXT$&QLQB*_)P?WDW5UEBXJ>FV
M%ONGHIYVK\E246*DBPV0J%#E*VB628J:J+6(/:WFF/?-@3;[EP=TM!H()[FC
M%-#@<2`*(Q]14_$.HA^_I[#W7M;[MW/.&RVKKR)S#(;E)$0^#!>.6-S;,P&E
M&=PUQ$AI6.0J@(B>E]/N3^L%.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JI#^?+_VYU_F&_P#BN&[?_<C&
M^_=>ZM3VQ_Q[6WO^U'B?_<"G]^Z]U4G_`#[/^W7/>/\`XD[X??\`P9WQ]]^Z
M]U<,X)5@`I)4@!^5)(-@P_*G\_X>_=>ZUK.H?Y4/S$D^8/Q=[W[+ZC_DU?&7
M9OQP[EW)V[4[G^`?QS[&V7W[V11Y38>^=B_Z--S9S>.-QNVCM#<U/O,565E/
MEJHJRCAFI=,B7/NO=;*;MH1GTLVE6;2@U.VD$Z57^TQMP/R??NO=$/\`@W\V
M<A\QS\HZ3/\`16[?CYG_`(P_)3<'QXSNT=\[NVANO<62FQ/7W7G8]#N;)R;&
MJ<KM?`U&2P?8M*),=39/++2/&RM5.^I$]U[HMOP>_FRT_P`R.YMG]=UOQYSG
M4FQ.^ND^T_D7\2^S<AV/A=XS=R]2=/\`<.+Z>W77;QV9CMNXBHZEW75U>X\5
MF<=C/O\`/15&&KM4E5!4Q/3>_=>Z5'\[7M;J[K[^5W\[MM;^[)V!L?<79/PX
M^3VW>NL!N_>.W=M9K?VX!U'N"G."V5BLUD:*NW5F1/E*9/M:&.>?741+IO(@
M/NO=':^)8M\5OC.#P1\?>F00?Q_QCG;?OW7NC!>_=>Z][]U[KWOW7N@T[FZG
MVAWOU+V1TQOZA&0V9VCLK<6QMQTUE,O\+W'BZG&3U-([`^#(4/W`GII19H9X
MT=2&4'VCW&QM]SL9MNNA6WFC9&^QA2H^8X@^1ST).3N:MVY&YKV[G'87\/>-
MLO8KF(^6N%PX5O5&II=>#*2IP>B@_P`M3M?>.]?CU+U)VY7?>=^?$K>>=^,'
M=$TA<5&<S?60IJ3:'8"K-^_/0=G=<5.(SD52;I/+62A6;0Q]D')]]<7&T_07
MYKNEA(UM-_2,>$?[)(]+U\R3U+?WD.5MGV;W`'-G*2:.1.:[.+>=O`I2*.\J
MT]J:8#6=V)[8I@JJ)4"H'5A/L5]0!U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U47\Y?^WE/\D;_`,3U\U__`(`#O7W[KW20_P"$[G_;EGX`?^(DS?\`[\S?
M?OW7NKH_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U3O_-__P`[_*T_\;$?"[_W"[6]
M^Z]U<1[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HJORN^(G6WRXZYW%
MU]O*HGVC4;IP59M+*]@;4V?U1FNQ8MG9.CR='E=LX7<'9_7G8<.WJ6M&5DE6
MIHJ>"OI:@"2GGB<L623V%C=.)+F&*1P*`NBL:>E2#CH_VKFSFG8K=K38]SW"
MRM7?6R07,T*EZ`:BL;J"U`!4BM`!P'0-]C?RWNG=[]>;(Q^$S63ZV[_ZIDDR
M_5ORSZXVGUMUYW'MG=A1X_XIEJ3K/9^Q-B[IVWEZ4K29C;T^+CP^6H08Y(DE
M*SH2[IRKM=_&KVRBTW&(ZHIX55'C;\@`ZG@Z-56&,&A$G\B>_G/7*-W-;[W/
M)S%R;?QB*_VO<I9;FUNX:UI^HS-;SQGO@NH2LT$@#`LNI&:N@_F)OS:W9>&^
M)/SFP6$ZR^1N02>#JKL_`K44O1'RTQ>.5!)FNJ\M7FVV>RH861\QLJOD&0II
M&\U$:FD=3$EVOF"Z@O%V+F55AW<_V4BXAN@/.,GX9/XH6[AQ6JG![SW[0['N
M?+4WNO[(SS;E[>1D&^LI:-N>Q.]?T[V-?[:S)!\#<(P8G`T3>'*IU61^Q?UC
MIU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW52'\^7_MSK_,-_\5PW;_[D8WW[KW5J>V/^/:V]_P!J/$_^X%/[]U[J
MI/\`GV?]NN>\?_$G?#[_`.#.^/OOW7NKB/?NO=>]^Z]UQ8$JP5BK%2`P`)4D
M6#`&X)!_KQ[]U[JISX\?RVNX?C[G_D%N3'?/OM_<63^2GR/Z^^2W9$T_3O0>
M$^[W5MJIV9B=^;>I%Q6S!'3;7[7ZQV#C-LY"%%5Z&GB:KHVBK)99']U[KE\)
MOY3VQ/A?VSBNQL=W?V9VMM_JGJKL/H3XL]<;SP^R,7A/CMTIVGVK1]P;SV?0
MYC;.#QN>[#RU5N7#XVCILOF97J:7#8V&E52QEFD]U[KC_.\Z=ZB[*_E?_.?=
M/8W5G7&_]S]6?#OY/;GZPW'O;8^V-U9[KC<IZDSU2=P[#R^=Q=?D-H9PU&)I
M9/N\?)3U&NFB;7>-"/=>Z/'\2S?XK?&<GDGX^],DD_G_`(QSMOW[KW1@O?NO
M=>]^Z]U[W[KW7O?NO=55]FA_BI_,CZL[DA)H>H?GUM_&_&[M<C]O'XOY*];8
M_)Y_X[[MK6/!KM^[)7,[3%A=YJ6@4_07!%Y_NCYO@W`8L-T06\OH+B,%H&/S
M=-<7VA>LI.6B/=+[N>Z<GOW\W<AW#[O8^;OL]XZ1;M`H_AM;GZ>^^2O/U:I[
M&_6+?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW51?SE_[>4_R1O_`!/7S7_^
M``[U]^Z]TD/^$[G_`&Y9^`'_`(B3-_\`OS-]^_=>ZNC]^Z]U[W[KW1/_`)^Y
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M794&5Q./B>>H`S)STT;?;K_DW[OH]U[K83]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=`SWW\?NI?DUUKFNINZ-HT6[]GYAH*N.*5YJ+
M,;?SE"6DQ&ZMI9^A>#+[6W;@JAO+19&AFAJJ=[Z7TLRL7[IM5CO-FUCN,8DM
MVSZ%2.#*PRK#R8$$=##D3GWFOVVYCAYJY.NWM-WA!4D4:.6-O[2">)JQS02#
M$D4BLC"E14`BO;;7?/<?\OC/8;JCYL[MRG:OQAS.4H]N]-?.O(4J?Q;9LM=/
M%18#KCYCQT$,='@\N9)$I*#?\<<6)R[F/^)+2U3RR>PI#N>X<J2K8\QR-/LS
M,%BO2,I7"QW=,`^0GPK8UT))ZR`W+D7E#W^L9N:O9>TBVOW+AB:;<.6D;].X
M"@M+=[!J):2.@+R;62T\`U?3F2-44VTTU33UE/3UE'40U=)5PQ5-+54TL<]/
M4T\\:RP5%//$S130S1,&1U)5E((-O8Z!#`,I!4C!ZQ2DCDAD:&9625&(92""
M"#0@@Y!!P0<@]9O>^J=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW52'\^7_MSK_,-_\`%<-V_P#N1C??NO=6I[8_X]K;W_:CQ/\`
M[@4_OW7NJD_Y]G_;KGO'_P`2=\/O_@SOC[[]U[JXCW[KW7O?NO=>]^Z]U[W[
MKW7O?NO=5P_SAO\`MU#_`#(__%'_`)._^^=W=[]U[HSGQ+_[)5^,W_BOO3/_
M`+[G;?OW7NC!>_=>Z][]U[KWOW7NO>_=>Z*=\X/CK-\I?C%V?U)A\A_`M^56
M-H]V]1[K1Q!4[.[DV#DJ3>75NZ*6KNKT?\,WGA:3SNI!:D>9#Z78$BYDVD[W
MLTUA&=-T0&B;S25"'C8'RHX%?E4=2K[*>X2>V'N7MG-EY'X^Q+(T%_`15;C;
M[I&M[V%EX-KMY'T@\)`C<0.IOPM^1$?RG^,W57<]10?P3=.>P4F&[*VLZ-#4
M[-[8V?756T^T-H55+)IGI9,!OC#5T$:R*KO`L<EK./=^7=V_?>S0;BPTSLM)
M%_@E0E9%IY:7!`KY4/3'O)[?'VP]R=UY.BD\?:X)_$LYZU%Q8W"K/93AAAO%
MMI(V8J2`^I:U!Z-)[.NHQZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJB_G+_V\I_D
MC?\`B>OFO_\```=Z^_=>Z2'_``G<_P"W+/P`_P#$29O_`-^9OOW[KW5T?OW7
MNO>_=>Z9-Q[9VYO##UFW=V[?PFZ=OY`0BOP6X\509O#UPIJB*KIQ68S)P55%
M4B"J@25-:-ID16%B`??NO=)K&=3=5X6D3'X?K3K_`!-!'C-P82.BQFS=N4%)
M'AMV34]1NG$)34N-BA7&;EJ*.*3(4X7Q5CQ(TRN54CW7NE#M;:>UMC8#&[4V
M5MK;^S]KX:`TV'VWM;#8[;^`Q5.TCS-3XW#XFFI,=0P--*SE(HT4LQ-KD^_=
M>ZJ6_F__`.=_E:?^-B/A=_[A=K>_=>ZN(]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TR;DVUMW>6W\UM/=V"Q&Y]K[CQE9A=P;
M=W!CJ3+X3-XC(P/2U^+RV+KX9Z+(4%93R,DL4J,CH2""/;<T,-Q$T$ZJ\#J0
MRL`00<$$'!!\P>ENV[EN&SW\.Z[3/-;;G;RK)%-$[1R1R(=2NCJ0RLI`(92"
M#D'JI>IVCW1_*^JILSU1A]Y?(#^7BLTM9N/I>B>OW9W?\.\>\CS5FX.F&JI:
MG,=H]"XM&,E9M:627,;?IT,^.>>!9H`!6@W'DMO$L5DNN4^+0BK36H\VBKF2
M$><9[D&5)%1UE9'NW)OWF8A9\U36>P_>!H%AW!@L&W;^P%%BW#2!'9;FYQ'>
M*!!=,?#G5',;=6C=8=H]=]T["VQVCU1O'`[^Z^WEC(<OMK=>VJ^+(8G*4,MU
M)CEC(>"JIID:&HIYECJ*6HC>*9$E1T`TLKVTW&U2]L9%EM9!564U!'^<<"#D
M'!`(ZQCYFY8Y@Y-WVYY9YILY[#?K.0I-!,I5T8?+@5849'4E'0AT9E()7OM5
MT1=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U4A_/E_P"W
M.O\`,-_\5PW;_P"Y&-]^Z]U:GMC_`(]K;W_:CQ/_`+@4_OW7NJD_Y]G_`&ZY
M[Q_\2=\/O_@SOC[[]U[JXCW[KW7O?NO=>]^Z]U[W[KW7O?NO=5P_SAO^W4/\
MR/\`\4?^3O\`[YW=WOW7NC.?$O\`[)5^,W_BOO3/_ON=M^_=>Z,%[]U[KWOW
M7NO>_=>Z][]U[KWOW7NJJNG%;XJ_S%^Z.A)V^QZD^<6%R?RMZ5B(\6/Q??6S
MJ?$[;^3>R,>"+25V[,0<-O$1K90S5[\F]@1M_P#NCYMN-K.+#<E-S#Z"=*+<
M(/FPT2_[UUE)S@1[I?=YV;GM._FSDF9-CW$\7?:[@O-LUR_HL$GU&WU.32`=
M6J^QOUBWU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5%_.7_MY3_)&_P#$]?-?_P"`
M`[U]^Z]TD/\`A.Y_VY9^`'_B),W_`._,WW[]U[JZ/W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=4[_S?_\`._RM/_&Q'PN_]PNUO?NO=7$>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJLNSOBKVM\7]^[
MH^37\OK'8V:7=.3FW+\@/A5DLG#MWJCOFJ<:\KO7JRLE5L9TWW_/`G_`R*-,
M+N&547)1+(#4.";S8[[9;I]YY5`JYU3VA.F*8^;QGA%/\QV/C6*Y.3_+7NER
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MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JI#^?+_`-N=?YAO
M_BN&[?\`W(QOOW7NK4]L?\>UM[_M1XG_`-P*?W[KW52?\^S_`+=<]X_^).^'
MW_P9WQ]]^Z]U<1[]U[KWOW7NF/<^X\/L[;6X=W;AJQ08#:N#RVX\Y7,CR+18
M?!T%1D\G5LD8:1Q345*[D*"3;CW[KW57OP%_FAI\UNP$Z^W+\>-U]`9+?/QD
MZU^:G04^>W[M7?J]K?%SM?=.?VCM;>69AVU2T9ZZWS3Y+#P/D-NS/D/M8,C3
MLM;*2ZK[KW3A_+O_`)E4OS^W)V_2XKJC877VT^L<WNS;]+5XWY/]7]K=G5&3
MVGV;NWKB:'L7I':F/HM[],_Q<[1ER-"<U_P*I94\>H$.?=>Z(C_PID^?%5\0
M/@SD^F*'8&%WQ-\Y-F=Y_':LK<CNN7`U^Q<+F^MI<5D=[8O#PXC)/NDXF3=$
M(>F:2DBUO&K3*9%]Y??=!^[#8?>>YDWC8;_>)MG3:[**</';K<%_$E,>DJTT
M6D"E0:FIQCH@W_>FV6&.58Q)K8C)I2@KZ'JL7_A/7_.V[([L[ZZ?^`&\.O-W
M;D7=.VM\-_I>WYWOF=[56V\%U5L;=.X]F;;VIL*HV+BL9A,=2;=P])B:ADKV
MDJV@%7(3*60SU]Y3^[XV?V"]H]P]SK/FFZW2>RFM4%N]C'`K?47$4!/B+<2$
M:?$U#M-:4Q6H*]GYKDW2_2R:!4#!LAB>`)X4'IUN[>^8_0SZ][]U[KWOW7NO
M>_=>Z][]U[JNO^9EUAN_<70F+[WZEH'K>]OAOOC#?)[JJEIM256XX]@PU:]F
M]<.\2M//0=E]4UN8Q3TRAO/4RT_I+(M@ESC97$VUKN=B*[GM\HN(OZ6BOB1_
M9)$76GF:=9"_=LYFVG;^>Y>1N:W"<C\X64FS7I.1";HK]'=BM`'L[Y;>8.2-
M*"3-">CJ=4=F[2[HZQZ^[=V%D4RNR^S-F[<WSM>O0H6J,)N?$TN7Q_G5&<0U
M<5/5A)HB=44RLC`,I'L1V-Y!N-E%?VIU6\T:NI^3`$?GG(\CCJ&>:N6MUY-Y
MEW#E/?8S%O.VWDUM,OI)"[1M0^:DK56X,I##!'0@>U71!U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW51?SE_P"WE/\`)&_\3U\U_P#X`#O7W[KW20_X3N?]N6?@!_XB3-_^
M_,WW[]U[JZ/W[KW7O?NO=5E_S8>]>T^B?C/LB;J/>]5U3N'N7Y7?$SXVYON/
M'8[;^3RW3^Q.^N]MF]>;Y["P<&[L5G=HT^X,7MO+ST^/J<I15=%25E5%,\3F
M-1[]U[HB_4GR*^7W;/\`+J^;?6'67R'QF\/F9U-\COF-\>/BAW#O'/\`2NR^
MP>X=A="=[8K8>W.R:QLEAL-U5E<_AZ'.)M[(9J'"PX:7,11-+"LTX5_=>Z/1
M_*J[\D[TZ$[)H<SNSY';N["Z+^1_;70/;-1\H,IT'N7L'"]C[$DP5?F-MXS>
MOQEVML_IS>VS<10;BI!09#&T:S$O)#4GS1,![KW5#/\`PH(_G![2^/'RK^,'
MQAR_1&[\]D/BW\GOBW\XZW><&[\-C<9OS;VTL=OIJG9&#Q<F*K:O&UM3-FO"
MN0J)3&LU-*#`5T.V?7W</N&[_P#>*]N?]</;N8[/:[?ZZ>V\&6UDF8F$(2P=
M)D'=KP"N*9)K@+;OS/%M-W](\+.=(-0P'&OR^75O'\H3^<GLS^;=3]]5&T>C
M-T=+CHJ?KJ&N7<F\\3N\;B_TAQ[SDIFI&QF$PQQYQAV;('#B3R"=2"-)!CS[
MTWW3MW^Z_)LD>Z[S;[M^^A=%?"@>#POI3;UU:Y)-6OQQ2E*:36M1TKV3?8]Z
M$A2,Q^'IXFM=5?D/3JZ+WB1T?=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1!?DY\,,COW>]'\E_C)O>F^/_P`QMK8N
M/&X_L*/'R5VP>X]M46F2+JKY&[/HVA&_-B5GB6*GKEMF\`^BHH)@8A`X7WGE
MY[JY&\;-(+7F!%H)*5251_H5P@^-#P#?&F"IQ3J>/;3WCMMBV5_;?W*LFW_V
MANI2[VI8+=;?,W&]VFX:OTURM2S1'_%KD:HYT[RX>/BW\S\=W/N+/=%=P[.J
M>@/E]UWCXZWL3H;<E?'5KEL/Y#31=F]-;G"0T/:74F:G4F#)40,U#(?MZZ*"
M4*9'-EYA3<9FVS<(S:[]$*R0L:U'^_(FX21'R894X8`\4?N=[.7')VW0<\<H
MWB[][2[A(5M-SA4KX<E*FSW"'+65]&/BADHLJ_J0LZU"GB]B3J$^O>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[JI#^?+_VYU_F&_\`BN&[?_<C&^_=>ZM3
MVQ_Q[6WO^U'B?_<"G]^Z]U4G_/L_[=<]X_\`B3OA]_\`!G?'WW[KW5Q'OW7N
MO>_=>Z8MT[:P^\]L;CV?N&E^^P&Z\#E]M9RBUO%]YA\[CZC%Y.E\D962/[BB
MJG34I!%[CGW[KW5/'Q?_`)1FZOB[D,!N+;7S:[2S^\NO>M/CC\8.I=U9+JCJ
M*FJ]C?";X\=G5_8H^.=501X>IQFY\QV?!DGQ.>WG-%#EQ24]*]%%2R0N9?=>
MZ'+XW?R[\GU!\NM^_-+MCY`Y+O/MW<'3U;\?-EIC^GNK^D-N[1ZAR/9$7:-9
M0;AQG6E!3GLC>\^XJ&D3^-5[Q+!30.E/20FHG9_=>ZK%_P"%1?P7[,^6GPJP
MG;W7N6Z^Q>.^%F/[H^0'8R;PK,U1;@S&P,-UO)D\SA-@'$;:SL-=N&N?;<9%
M+6U&-I)72,O."@MF_P#<@^\IR-]VOFK?-\YXM=TNK3<]OA@C%E'#(X>.8R'Q
M!-<0`+I."I<ZL%0#4!OF39[G>((HK9D5D<DZB1Q%,4!ZU^/Y(7\F#Y9[Y[(V
M1\R_CQ\[N@NGIMBT_8%#_>/K"<]O]L=>;BR&+W7M;:M)O?J#>>P:78V<V-V/
M%3--/33YFBJ*W;E7]Q2315!C9,D?O7??U]HO?3V0W3VUY2V[F"WWV]N+-XY+
MJ"U2$"WNHIWU-%>3."5C(4",U:E2!4]$^Q\KW^V;DEY.\1B4,"%+$Y4@<5'K
MZ];7R?S'OD]\*I(\!_->^-@VUUU22I21?/\`^(&-W;VS\5ZBGU%(LOW3UJ:7
M)=X_&9V5HEJ*FNI,_MQ:F1M.42);CD?T/.K=NK^U^L.[MC8'LWISL/97:G76
MZ:1:[;F^>O=S8;=^U,W2G@RXW/8&LKL;5^-O2X20M&X*L`P(]^Z]TO\`W[KW
M7O?NO=>]^Z]UQ=$D1HY%5T=61T=0R.C`JRLK`AE8&Q!X(]^XX/#K8)4AE)#`
MX/55_P``"_QT[>^3G\O7*R-!A.I-S-W_`/&*&<LJU?QA[WS>5S(VUB5>[34?
M3G;(S.!=N!'3342*--C[!'*W^ZB_O>5'Q'`_CV_SMIB3I'RBEUI]A7K*+WZI
M[A\I<M?>`M1JO=VMOW7O)'X=YVR-(_&D/`-N%C]/<@9)99B37JU+V-^L7.O>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>ZJ+^<O_;RG^2-_P")Z^:__P``!WK[]U[I(?\`"=S_
M`+<L_`#_`,1)F_\`WYF^_?NO=71^_=>Z][]U[I#]D]9]==R;%W+UAVWL3:/9
MG7&\L><3NS8F_-O8K=>T=R8TS0U(HLUM_-TM;B\C!'54\<J"6)M$L:.MG52/
M=>Z!&I^#OPRK=F8+KJK^*7QWJ=A;8ZXW#T_MS9T_3NP9=MX'JO=N>P^ZMT]?
M8C#O@30X_:.XMT;>H<G6T,2+!59&DBJ9%:=%<>Z]T+W4O3G4W0NQ,-U?TCUI
ML3J+KC;WW/\``]B];[4PFS-IXMZVHDK*Z:BP.WZ*@QL-17UDSS3R"/R3S.SN
M68DGW7NM&/\`X4Q_RS_ECWG\^NI>^NO-I[9R/6_?-9\>OB%UQDZ[>VWL77Y'
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MCNI],/RZ_E;_`"ZZWIXV*U6_/C3/LCYJ]:001A?+E:M^JLEB.U\9C--V_?VD
M)8P+.H^I\?N_<@\SU?VM]R.5MP<CMMMV%QL%V2>"*+Q'LW?R[;W2?(^77OWK
M=0_[FV<Z#UCI*OV]M&_XST,W3W\V;^7/WAEUVQL[Y9]68/?!F%))USVSD,AT
M9V5#7^D-CFZ_[FQVQ-V2UT;-8QQ4DE_J"1S["7-7W8O?ODZU_>.Z\L;E-L^G
M4+JR5=QM"O\`']38-<PA3ZLX^=#T_!O6UW#:$F02?PMV-^QJ'^75A=-4TU93
MPU='405=+4Q)-3U--+'/3SPR*&CEAFB9HY8G4W#*2"/I[@J2.2)S%*I6130@
M@@@CB"#D$>G1H""*CAUG]TZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=%8^4GQ&ZS^5&WL"FY)\WL?M#KW(2;CZ7[VZ_JUP7;'3F[_`!A4
MSFSMQ(C.]!6A%CR6)JA-C,K3?M5$+6C>,DWK8;/>XE\;5'>Q'5#,ATRQ-ZHW
MH?Q*:JPP1P(E#VQ]V.9/:^_G.W"&]Y9W",1;AMETOB6.X05_L[B(XU+4F&=-
M,T+]T;@%E8GVV?GONKXHU5;T[_,QBI=F;MPN)R.0ZU^3.PMH;CR?3_RCV]@H
M?/5RX+;FVL=G<UL7O*AQJ&HR^S/%,9M$E3BGGI62-":QYANMLN!M'-ICBNJ'
MPKD=L%PJBI/I%,`*M$3DY0D$#J2N:O9W8N>-H?W$^[PMUN&PZT%]LKGQMUV>
M65@BJ0.Z^V]I&"P7T:U52%NE1T=^CE_$/Y==-_-WI?%][]&5NXJW8^2S.:VZ
MPW1MK*;7RU%F]OSQP92AEI,A$*>N2`SQD5-%-54;%B@E,L<J(?;)O5CS!ML>
MZ[<Q:UDK2HHP*DJ0PS0U'#T(/GU$ONC[9\U>T'.UYR#SG$D6^V?AEBC%XI$E
MC65)(G(76A5J:J"C*R\5/1G?9MU'_7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW52'\^7
M_MSK_,-_\5PW;_[D8WW[KW5J>V/^/:V]_P!J/$_^X%/[]U[JI/\`GV?]NN>\
M?_$G?#[_`.#.^/OOW7NKB/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U7#_`#AO^W4/
M\R/_`,4?^3O_`+YW=WOW7NC.?$O_`+)5^,W_`(K[TS_[[G;?OW7NA_EBCFCD
MAFC2:&9'BEBE19(Y8Y%*/'(C@JZ.I(((((/OW7NJB.T?Y1G7V`WUGN^OY>W;
M.[_Y</R*SU6^6W-D>C\3BLS\;^WLI^K_`(SQ\3<X\/4V]6J"SZ\IBHMO[B5Y
M6E&1+V]^Z]TA*?\`F6?(KX93Q;8_FT_&YNN-F4\L5'2?/CXHX[>';_PZRT;,
M(HLEVQMA:&O[J^+M5/))$CG.T66V\LS.5S`B6_OW7NK?>M^S>N>X]D[?[)ZE
MWYL[LWKW=="F2VSOC8.Y,/N[:>?H)"56KQ&X,#65V+R$(=2I,4K:6!4V((]^
MZ]TN/?NO=>]^Z]U5A_,8I*CHO=?QR_F&;?AF1OC#O1MC]^I11NTN<^)W=]=B
MMJ=DS5L$"M-D1UCN@8;=5*A&F!<?5/=59R03S:IVR>TYKBK_`(E)HGI^*VF(
M62OKX;:)!Z:6/KUE!]WF:/G?:N8ON_[@5(YFLOJ=K+$4BWS;5>>T"DD!/K(?
MJ+)SQ;Q8EH2%ZM(IJJFK:>"KHZB"KI:F**HIJFFECGIZB":-989H)HF>.6*6
M)PRLI(92".#[&JL&`92"I\QUC%+%)#(T4RLDJD@JP(((-""#D$'!!X'K/[WU
M3KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[JHOYR_]O*?Y(W_B>OFO_P#``=Z^_=>Z2'_"=S_MRS\`
M/_$29O\`]^9OOW[KW5T?OW7NO>_=>Z][]U[KWOW7NO>_=>ZIW_F__P"=_E:?
M^-B/A=_[A=K>_=>ZN(]^Z]U[W[KW7O?NO=`SW#\<OC]\A,.<!WQTAU+W+AC&
MT:8[M#KS:>^J:!6!&JD7<N)R1HY5O=7B*.AY!!Y]BWE7G[GCD6Z^MY+WC=-I
MNZUU6=U-;D_Z;PG34/4-4'S'3$]K;7*Z;F-)%_I*#_A'5>E5_)>^*FT9Y\E\
M6=^?*7X,YF:>2L9_B?\`(WL/9NSY:MBS*:SJ3>5?OWI^IHO(07IA@8X7`^@/
M/N=8OO;^Y>Z(MO[DV7+?.5HJA?\`=UM5K/.%_HWL"VU\&IP?ZDL.BP[#9IFS
M::W;_A;L!_O)JO\`+K`>B?YP_2NI^I/F[\<OEQ@H6/VNT?F3\?JOJW=R44>H
MK2+W'\9\K04%9D'4!5JJS9LO/,BO]1?^NGW4^;Z#FCD_?^5[PCNGV+<UO("W
M\7T.[(S*O$E$OE_HD=:^GWRW_L+B*=?25-)_WJ/_`"KUX_/[YL]/ZX_E3_*J
M[Z.*I3XINP_A5V'UY\N=M5@35Y,DNP14]7=TXVB"KJ:(8"MG4'T^0^_#V0]H
M.:J'VU]R]D^J85%KO]K=;)*OHGU-+RP=O1OJ8U/GIZ]^\K^#_<RSDT_Q1,L@
M_P!Y[6_D>J;?YBO_``J?I?C)W!M/87QGZ"@[4V]7==T&?WO_`*==N]T="=A[
M(WY/N+<6.K-F9/8V\]E8#)>.CPV-HJH5<23TTS5;*DK>-@,L/8;^[8F]Q>5+
MG>_<+>SMM\E^T=O^[I;#<K6XMA%$RSI<03RK5I'D30Q5U"`LHU#HCW3G`6DZ
MQVD>M=-3K#(P-3BA`\J9^?1T?Y'W\\7?G\US?G?NS>Q^F.O.F!U%M78NX<)-
MMC>.9S=5N.;=67W#C:ZFGIL[2T>B/'IB8F5H=1O+9OJON(_OB_<XV;[LVR[)
MNNP[M?;M^]+FXBD$L$<:Q"%(W4@QDY;61W>F//I?R_S!)O,DB2QK'H`(H2:U
M)]?LZV.?>`W0HZ][]U[KWOW7NO>_=>Z][]U[KWOW7NJ9/YYG7?R;[R^&LGQ]
M^+_0E3W7N3M?>>$AW?7I+LF.+K[:.TJB'<DF6HFWEEL8L&X\YEZ:EHJ6>EU2
MP4K5;!XW\9://<NTWG<^7OW5LMJ;F:>0:CV=BJ=51K([B:`$9`U9!IUF-]R'
MF'VUY(]XAS][F[\NR[;M5G(8%I<UNIYP8=#?3HY,,<9>1U?M:00C2PU4IG_E
M`?RX?YAG6V]-Z]0_(J?YK?$_I?-86LWEM+<W1O?NP]M;9QW95++C:+(0;GVA
M#5[^Q^4EW5@(XUCJEQX>*3&QQN2DEXX\Y`Y0YLL[B2PW8[C8[<REU:&=%42"
M@.I:N#J7ST_A`X'&8WWNOO%_=^YCV>RYM]O%Y+YKYQAF6WGAW+:[F:9[-@[*
M89RMJZ"&4DE/%H1,S`!EHVP#_LB/R,PR%=E_S2?F=0:>8O[[8#XS]D*MAZ1(
M<QT90SSJ/SJDN?R?S[E3^K&[QBEOO>XC_3K;R?X81U@/_KY^W=XVK>?;#DV0
M>?TTN\6?[/#W)@/R'7`_&'^9%BQ?!?S0L?F0EO'#V'\)>G,J'`_%15;'W9UY
M*Y/Y*JI/^'O7[EYP3^RWH-_S4LXC_-&CZL/<W[N5U_N=[8R0UXFTYCW!*?8M
MS!=C]I/7;=?_`,W3!!?X3\EO@SOX1_C>GQE[>V>]0!_QTEVAWWDTA9OSIB8#
M^GO9M>?8O[.\VR7_`$]O*G_')SU5=_\`NF7Q_P`<Y;YWL*_\HV\V$]/L%QMB
M5_,CKC_&/YQF'*M4[$_EP[[A7EUQ'8GR1Z]JY0/J(X\ML'?=+$[_`.U3$#^I
M]Z\3W!C^*+:)1\I+B,_S1Q_/J_T?W/[P4BOO<6Q<_P"_+3:+M1]ICNK9C^2]
M>;OO^:5@VTY?^7KT=O1%_5/U_P#-VAQKO;ZF&DWYT=@U-_P'G3_$^_'=.=HO
MCVFVD']"\`_D\(_P]:7D/[L%\*VON!O=DQ\KKEMG`^UK7<I/Y*>NE^9GS9Q#
M'^]_\J;O2*)/US]?_(7XN[_0@?4PPS=A[4K9?\+Q(3[\.8>8X_\`<C8[D#^A
M/;/_`-9%/\NMM[.>RUT*[1[I[&S'RNMJWJU/YD6DZC_>CUQ_X<@W9C"4W=_+
M?_F08&1+^23#]);![!I%T_4I-L'M[<%1,HYY6&Y_`/OW];YTQ/L^\*?E"D@_
MXQ*W^#K?_`Y[5=#5M/N-[<S@\!)N5U:M^8NK"(#_`'KKR_S6^AZ!2V].DOG+
MUN$_SQWK\)?D1`D']3)-@=D9^`JO]59A_0GWX<\[6O\`N1;;G#_I[.<?X$;K
M3?=7YZF(&S;UR1N)/#Z;F/:FK]@DN8C^T#KR?SCOY=,1"YSOS(;,EO9X>P.E
M^^MA/"WY$[[MZPP\$-C]2S@>_?ZX/*(_M;HQG_AD,Z?\>C'6S]S[[P[YL=AC
MO5\C:[CM=U7[/`O9"?V=+[!_S4?Y<&XA&<?\VOC=!Y+:5S?:6V=LOS]`Z;DK
M<2\9_P`&`/M5%SORA+E=RLQ_II%7_CQ'1!??==^\5MY*S\E\Q,1_ONRFF_ZL
MK)7\NAOV]\P?B5NWQ_W5^47QVW(90#&N"[KZVRSN&_3I2AW+.YO_`*WLRBY@
MV&?^PO;1_P#2S1G_``-T"MP]H?=C::_O3ECF&VIQ\7;KQ!^UH1T-.(WAM+<"
M"3`[IVYFXV`*OB,WC,DA!^A#455,"#[,8[B"7,3HP^1!_P`!Z!EWM&[6!TW]
MK<0-Z21NG_'E'2C]O=%W7O?NO=>]^Z]TAL1V9U_G]^;RZOPN[\%D^P^O,7M7
M-;XV=25T4V>VOBM[QY67:5=F*%3Y:2GS\6#JFIR?U+"3P"MTT=Y:RW4EE'(K
M7<2J70'N4/722/+50T^SH\N^6M_L-BL^9[RTGBY?W"6>.VN&4B*9[8H)UC;@
MQB,B!_0M3R-*R?Y\O_;G7^8;_P"*X;M_]R,;[4]$?5J>V/\`CVMO?]J/$_\`
MN!3^_=>ZJ3_GV?\`;KGO'_Q)WP^_^#.^/OOW7NKB/?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U7#_.&_[=0_S(_P#Q1_Y._P#OG=W>_=>Z,Y\2_P#LE7XS?^*^],_^
M^YVW[]U[HP7OW7NO>_=>ZQ3P054$U-4PQ5%-41205%//&DL$\$J&.6&:*0-'
M+%+&Q5E8$,#8^_=>ZJ#['_E&[-V;O7<'>/\`+E[DWC_+D[WW!7R9S<]!U'BL
M=N?XI]NYEM/DD[J^)&?F@ZQS-36HK1OE]O#;>?C,SS"L>3Z^Z]TDJ/\`F:][
M?$"II-I_S:?C9-TKMU*BFQE)\Z_C3%N?N/X2;AEFEAI:?(]A1QX^?N#XO3Y"
MKJ8XEBW5CJS"H^MOXR8E#>_=>ZM_V%V#L/M3:&![!ZQWKM/L38>Z:"+*;9WI
ML?<.)W7M3<&-GOX:_"[@P5778G)T<EC:2&5T)!%_?NO=%;_F)]U=6=`?"?Y'
M]B]R8S'[BV/'U=N?:U3LW(R(D._,MOC&S[1P6QU!=)&_O-ELQ%32M'=X*=I)
MK:8B0'>;=QL=JY<O+O<%#VW@,I0_C+C2J?[8D`^@J?+J9?N]\F<T<^^]'+O+
MW)TLEOOAW.&=;A!4VJ6SB>2Y]/T4C9U!H'<*G%AUJ9?R&/YHO>O6<F[/B"G3
M6]_E0-Q9#+=H]?87;O8&R,!V%@/L<:)>Q<?B9.T]Q[?Q>\:2IHZ*GR-/BX*^
M&LA>*MF194D<107[7\[;E9^)L`MI;TNQD0+(BNH`_4`\0J'X!@H8'XB`?+JS
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M;^70.YC^[K[[<IJTN^\I;]';+QE2TEGA`XU\>W66*E.!UT/ET<G'Y''Y:DAK
M\774>2H:A`]/6X^J@K*2=#R'AJ:=Y(94(_*L1[$*.CJ'0@J?,&HZAZ>WN+64
MP72/'.IH592K`_,$`C\^IGNW3/7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW51?SE_[>4_R1O\`Q/7S7_\`@`.]??NO=)#_
M`(3N?]N6?@!_XB3-_P#OS-]^_=>ZNC]^Z]U[W[KW5=7\SOY&]J_'#X][(K.D
M\KA-K=G=X?*#XO\`Q;VQV#N3;T.[<+U<WR'[FVKUOENR*G:M55T-!N*LVI@L
MO53T%'53)239$TXG#Q:XG]U[JO"J_F0?*/KS^5_\SNV-Q9_8>]ODM\7?FKV1
M\%-K=P5NQX,%L[>E3COE5L/XZ[5[YW-USALM#B*2?;F*[*@K\OC:&IBQLN4Q
M<L*^&&4HGNO='M_EJ]\=[]H?[.;TY\AM\X7MW>_P]^7^YOCSCNZ<'LO$]??Z
M3MIGJGJ7MG!9+<6T-NSS;9P^\MOCLZ7%9!<<(:63[.*3Q1R/(#[KW5=?\[WY
ML]9=<]J_`3J;,]=?)?+9_J;^9;\.NY<_G-F_&?N;>FP\[MRAQ'8M7+M[8.^]
MM[1R.V=_=CRQY.-8=MXJHJLQ/(DJ1T[-%(%]U[HY/_#UWQG_`.\>?YDW_IMG
MYB__`&I_?NO=>_X>N^,__>//\R;_`--L_,7_`.U/[]U[KW_#UWQG_P"\>?YD
MW_IMGYB__:G]^Z]U[_AZ[XS_`/>//\R;_P!-L_,7_P"U/[]U[KW_``]=\9_^
M\>?YDW_IMGYB_P#VI_?NO=>_X>N^,_\`WCS_`#)O_3;/S%_^U/[]U[KW_#UW
MQG_[QY_F3?\`IMGYB_\`VI_?NO=:EW_"@8[$_F`][[,^5F`J/D;T#U-U3T)@
M>M]Y9KY!_`+YV[-H,37TO8V\LS'F:S/T7Q^R^VL?A*U]\4E)%)55<#FK_;TG
M6A;I?]S#[ZGMW]V[VXW'DWF_;-ZO=PN]ZDO$>S2U:,1O;6T(5C-<P,'#0,2`
MI6A'=6H`.YBY<N]XO$N+=XU18PM&U5K4GR4^O2>_E6?#?XB?&K/]UU7\P?XP
M?([Y4;>WIM_9E#UE0[:_EK_S!JO)[(S&(R6=J]Q96+)9OH79-9AVRU'64<:R
M450\DGA.K0%74?\`WE_[Q2\]P;'9T]B)^8^6[^TGG:[:86J)<1R)&(DTQSW*
MR:&5R1(H`U8J2:-;-RDMHTAW,0S*P&FFK!%:\0M/+AU<0(?Y.&&)DZU^+G\Z
MWI*HL?'/TSU#_-VV)'3M_9>FQM%63X:G9#^D)3!1_3WB@?O@>]EX-/,,VQ;Q
M'YB_V+9;@G[7:Q$A_-Z]'G[@VU?[(2QG^C+(/^?J==#M;X_8'2_6WRN_X4Y[
M%>$_Y+29+XZ?*;MO#PJ"2L;X_NOXL=A5$\:G_55%R/J3[V?O,6M]V\P>W?MM
M>@\63:)+*0_/587EL`?]IU[]S,O]E=WB_P#-P,/^-JW61?FM\AMO2:=B?S!?
MYME31(1X:+NK^0ANCLX:5_2E3D=G=)=0YFHN/U,*A&/]1[K_`*[_`+`WRUWK
MVHL%F/%K#?=WM/V).]]&/D-)'7OH-U7^SOFI_2BC;_!I/3J/YKW\PC:2+_`]
MY9;N)(E-T[+_`)%'\S_JNOJR.`&K>N=S[NH*5V^I(I'4?@?CVT.8ONA;H?\`
M'N6>?MI8_P#*)O&V7JK^5UM\#-_O8ZWX._I\,UK)_IHW7_CKGJ'_`,/]?S#-
MH/;._P`LK=O<T,9LTG6'0G\R+JZLJ@/J]/0=F_"[/T<!;\+)7$`_VOS[?_JY
M]S[=!_B?-//6TL?*\V2PO%'VM:;I&Q^T1_EUKQM_3XH+:3_2R,O_`!Y#_AZ$
M[9?_``I#[>R!C7L#^23_`#/-KG4%F?:72_8>]4`!L7A_C?5G7WD!^H#%/\2/
M:8^TGL-?-IV7W5VM&/#]X;+N]F/S:&*]4?;4];^OW1?[2Q<_Z22-O\)7JN'^
M<W_PH%^2YV#\=ZWX=;%^=?P*W#4;D[!7L27Y)_&K"=;4F_,?'B]JG`8[:N2W
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M"K7K;R_X>'^.O_/A?YA?_IO/Y:?_`&K_`'RT_P"!4Y\_Z/?(O_CS[+_VU]#;
M]^6O^^[G_G#)_P!`]>_X>'^.O_/A?YA?_IO/Y:?_`&K_`'[_`(%3GS_H]\B_
M^//LO_;7U[]^6O\`ONY_YPR?]`]>_P"'A_CK_P`^%_F%_P#IO/Y:?_:O]^_X
M%3GS_H]\B_\`CS[+_P!M?7OWY:_[[N?^<,G_`$#U[_AX?XZ_\^%_F%_^F\_E
MI_\`:O\`?O\`@5.?/^CWR+_X\^R_]M?7OWY:_P"^[G_G#)_T#U[_`(>'^.O_
M`#X7^87_`.F\_EI_]J_W[_@5.?/^CWR+_P"//LO_`&U]>_?EK_ONY_YPR?\`
M0/7O^'A_CK_SX7^87_Z;S^6G_P!J_P!^_P"!4Y\_Z/?(O_CS[+_VU]>_?EK_
M`+[N?^<,G_0/7:_SAOCL[*J]!_S#69B%55_EY?+0LS$V"J!U>222>![U_P`"
MISY_T>^1?_'GV7_MKZ]^_+7_`'W<_P#.&3_H'I+;/_G@?#_L/#-N/K_K;YQ;
MZVZF7SFWWSVS?@G\GMS85,]MC*U6"W+A'RF%ZZK:%<OMW.4,U'74Q?S4E7"\
M,JI(C*/#[JO/AX;WR(?_`!I]E_[;.O?ORU_WW=?\X9/^@>E,_P#.$^.4BE).
M@OYA+HPLR/\`R\OEDRL/Z%6ZN((]^/W4^?#QWKD7_P`>?9?^VOK8WVW4U6.Z
M!_YHR?\`0/2!SO\`,O\`A#NA73<WPZ^9FXDDOY$SO\L'Y(Y=7O\`76N0Z=J`
MU_S?VEE^Z+S?/_;;I[?O_IN9-C/^&ZZ/K'W'W_:R#ME]O-N1P\)KJ.G^\$=`
M;N+Y)_RD]VA_[R_RP.Z\T\A)::O_`)/7<<U22?JPJCT.*E6/]0X/LLE^Y9N\
M_P#;7?MPQ^?,&PU_;]3T-]O^\G[R;33]V\U\XP@>2WNXA?\`>?%I_+H%\UD_
MY)&=?R5/\KGY0X^6^I9=L_RU?E[LZ6-O]5%+M+K_``DD)'X*$6]E\OW%[R4U
M:Z]O`?Z/,NS)_P`=O!T,K'[Y_P!X?;UT0\V<Q.GI,K7`/VB>*0'\^DW?^4+0
MN)=I_$O^;)UY,.4DZ^Z4_FG;56,_AHJ:@JQ11E?P%B`']/;/_`*;JAK!NW)D
M1_H<W[:O\AN%/Y=&1^^S[U7"Z-VNK/<$/E=<O[7,3]K-M^H_[UUT=\?#/'MJ
MV?O[_A1%L%0"(X-M[%_F#U]+"/P(Z3>G6V[:8@?[4C`_F_O7_`.\Y*?\7YJY
M;B_TO.6U$?L>\8=>'WOMVG6F[\G<BWY\S-RO;*Q^UK=(&_81T7[Y6?+C+])?
M&SN_LGX\_,7^>)CNQ-D]?YC<&R$^1/Q$W;5]80YVB,'V?]^=Z]@_%'%8W!;?
M)<K/5UE=3PQ@@M)>P,L^Q'W)-_;WEY:BYUYCY?W;DQMVA%Y8KS+M%S)=05)>
M%([6=;MV?^&`^*?P^H#7.GWCN6N8N4]PVR/V]Y1V[>)[5TBO;*RW&UEMW-*3
M1JUY);ZE\A)&R9R.M1KJ'^;-_,0V9\H-R?(O;?R>W?C^Y>ZZ[![>[1WB^`V%
M7'=V$.2P44.-K-OY':57M>CIJ"GQ%/%2"EHH#10Q^.`QHSJW9*Y_N]?N=;6]
M]S%8<EVZ;S+`^N3Z[=&U47':U\4&G2M***4^9Z@+=_?SW:YBY'VSVRWG=C-R
M/M$NNTMOIK1!`YUZF65+=9R7\1S)KE;Q&;4^I@"/I)?SXB6_DY?S"F/U/QMW
M63_KF?&D^_FP(H2/GT(>K5ML?\>UM[_M1XG_`-P*?WKKW52?\^S_`+=<]X_^
M).^'W_P9WQ]]^Z]U<1[]U[KWOW7NF/<VX\/L_;>X=W;AJUQ^`VM@\MN/.5[J
M[I18?"4%1D\G5LD:M(ZTU%2NY"@DA>!?W[KW57_P)_FBTOS5W]_<#<7Q[WA\
M?LCO3XS=;_-/H6HW-OG:&]T[7^+/:NZ,_M':N^<K%M98_P#1WO.#)X6%\AMV
MI>M:D@R-,XJY2SJGNO=,GPD_FRX#YE=S[<ZV'06\^I]F=U=.=F_(3XG=H;@W
MEM7<E+WQT_U%VYCNGMXYS*[6P4:Y3JS<+Y;/XS*X_&5DU?\`=X6O69IX9TDI
ME]U[H2/YR>8Q&-_E4?S%:7(Y3&X^IRGPF^3M-C*>MKJ6DGR-3_H@W2GV]##/
M+')5SZYT71&&:[J+7(]^Z]T/OQ1[#V!3?%OXU4]1OG9T$\7Q_P"FDEAFW-A8
MY8W'7.V[J\;UH96']"/?NO=#[_I*ZZ_Y[[97_H58+_ZO]^Z]U[_25UU_SWVR
MO_0JP7_U?[]U[KW^DKKK_GOME?\`H58+_P"K_?NO=>_TE==?\]]LK_T*L%_]
M7^_=>ZCU>_\`J^OI:FAKMZ["K:*MIYJ2LHZO<>WJFEJZ6IC:&HIJFGFK'AGI
MYX7*.C@JRD@@@^_=>ZJ!W[_+:Z6ZWWAG.ZOY:'RDQ_\`+K[GS>0DSFY]H==Y
M#;&\?AUV]E&$?G7MOXEYC-T6P(:VOAA\'\;VF^VLW2B5YEFEEX/NO=5G_P`R
MO^;+W!\;?CQAMA_S'?Y8O2GR/SG^D[;]/MKL'K;MC%;]^$G:$V/P.XY*K=>*
MJLOA<]VMTYV30I-IHML;DPLYJ*.6KFI\K,L)5\C?NP?=IV7[U7N'<>V^_7W[
MOLK?:Y;X2?3+=5:&6"()X;2Q`5$['5J)%*4[J@QVOW.YQ]I[G^L_(]_=[=O+
MJ8#+;RM#)X3T=DUKG26C0D>9`/ET1'^5]_.2^(G=_P`]_C7U3M+^4I\7?C?N
M/>V\\IB<5W=M7>U&^X.OIQL[<M6^4QL<G5FWDDEJX*9Z-E-;!>.I87)])RG]
MZO[K7D/V-]KMX]V-KW_ZJ_V6V69(OW9%!K+2QQ$>*MW(4Q(34(W"E,]&]]]Z
M[WPY]M'Y0YHYAWF\V&^`2:&:\EEC=5(<!D848!E4BOF`>MZ3_25UU_SWVRO_
M`$*L%_\`5_OF7T%^@:[*Z^^'/<L,M/V[LSXV=H13*RR#L#`]9;P8AA8E9,_3
M5\B/_1E(8'D&_LNO-HVK<12_MK><?\,C1_\`CP/0QY;]Q.?^3G$G*6^;OMC#
MA]+>7%O_`"BD4$?(XZ)OD/Y:O\L^&MGR_7-!3=`;@F9I%SWQQ^1O871U33RL
M/\Y#B^ONQ<-MG6IY&N@<`CZ6]A]^0N60QDM(9+68_BMY983^Q'"_\9ZF"W^]
MG[XO`MGS#N5IOVWK0>%N^WV&Y*0/(O=6TDU#YTE%>H7^RK=B['%^B_YNWR`V
MTB$&+%=ZY+H+Y/81%46%.\V^-K8/>DM/_KYOS6_W9^?=?ZK[O;?\DS>;]/E,
M(KD?\;17I_MZ_/I__7U]O-[/_(X]M.4[DD9?;)+_`&60_.EM<RVX;_J&T_T>
MN_[X?S-^O2%Q_>W\MSY*XJF"ECNJ'L?XX[TR*KPP2MVQNGN79\51(/P:**,'
M\VX]^\/GZT^"7;+R,?Q)+;N?S4RI_(=>^L^Z/S`";BRYYY;NVX>!<;?N]LGV
MK-'M]P0/E(Q^74JF_F#?)K:`=NWOY?FY:^@I>*G/?&CY._'7O6"<*?7/1[7W
M)NGJ#>Y0KZ@GV#O;@$GCWL<P<R6W_)0V6X*C\5O-#/\`L5C$_P#QGJC>T/LI
MO-!RA[G;1'.W"+>=NW#:R/0-/$E_;?*HE`]0!T`WR<_GX_&'H3H3M/L"/9G;
M>"[HV;MJ3)[*Z/[VZN[&ZEDW[GEKJ*D7;U/OVDVKO#9=+,8:F242)63*XA(6
M]P?<M^PNT[-[T>\?+WM)=S7^T76_7XMEDELY2R-X<DE0#HB8TC(S,H^?D0SS
MQ]WWGSD_E&_YXV^[Y:WWEG;H/&FGVS>MONM$>I4U&`3K=TJR@@6Y85R`*THG
MVE_PLCWQG]V;<P>4^"NQ<+BLWN#!XFMR\WR'S"QX>AR&1IZ.OR=2]1U/!3M%
M103-,=31(JH=36Y'7/>?[J/9-JVB[W0<[73_`$UM+*%_=D8KX:,Y!/UQH.W)
MH:#/6*$/.TUQ+'!':UE=PN')J6(``&CCY>=3Z=;=H_F*_P`OQI3"/G-\/Q(-
M1*M\E>FE_1^KEMYA3:_]??%2/=-MF`,5Q"P(\G7_`#]33<\C\YV2ZKO:=RB`
M-.ZVF4@_,%*C_)UQ?^8S_+WC_P`Y\[OAK']/U_)_I%?K]/U;X'U]JEGA;X74
M_81T22[7N<']O;SI_IHW''AQ'3)D?YGG\MK$HTF0_F`_"NF14\C$_*+I.0A`
MP0MIBWM(QLQM]+^W>/2$]O''2"R/\XK^5'BBZUO\QKX7QLAD#+%\B^KJMKQ#
M4ZJM)N2=G:QX`N6/`N??NM5!X=(FN_GE_P`H+'$BH_F)_%J2Q0?Y!V9BLIRZ
MZA;^&?>`@#ZD<*>#8^_=>K]O2,K?^%`O\FFA!,OS_P"E9[*'_P!QJ;URY(9_
M&-(Q6TJTLVH?07-N;6Y]U+(OQ,H^TCIZ."XE_LHI7_TJ,?\``#TE*W_A1M_)
M;H=0?YQ[5JBOEXQ?57?^7U&']81L7U/5HU[^DWLWX)]M-=6J?'+$/M=1_EZ7
MP[%OUQ_N/87\G^EMIF_P(>DC6_\`"F'^3'2-IA^5>X,H=:1K_"/C?\GJX,9$
MU@KHZ=6ZCZ'_`!]L-NFUI\=U;#[98Q_S]T:P\B<]7/\`N/L>]2?Z6PNV_P`$
M)Z@_]!*_\JFI77A-]_(3<H,:2K_`OB%\EJC6K3>'TFKZTH@=+?4WM_0D\>Z?
MOC:/^4JV_P"<J?\`072G_6Y]P_\`HP;W_P!D-U_UJZYK_P`*-?@962B'`]:_
M.;<TSM4)%%AOAGW"KS/3KK*1C+XS%<R)RNK2+?6WO8W;:FP+JVK_`,U8_P#H
M+IN3V^Y_B&J38=["^OT%W3]O@TZ<8_\`A0#\=*TC^"_#S^95G0S0A7H_B<U`
MC"="T4A?<._L(L:,18E].D\FPY]W_>6V_P#*3;_\Y4_Z"Z3_`-2>=O\`HR;S
M_P!D-U_UIZEP?SU=GY0'^[O\N3^9SFG$8E\9Z;Z(P[:!+XI69<U\E:%X_&2+
M:@-=_3?WL;CMS86XMR?^:B?]!=4?D[G*(:I=GW=5/F;*Z`_G%U.7^<YOBMU#
M$_RIOYA,CZG2/^-UOPRVU&[`:XR\F1^6A,43I]6*V5O3R?=OK[#_`'_!_P`Y
M$_Z"Z:_JIS9_T:=T_P"R.Y_ZU=2(_P";/\F,HK2;<_E$_*NNC!72V8^17P)V
M[82)>,3"H^3=9X9=?ZD-RB^H_P!/>Q>V1X30G_;I_GZ;?EKF:,TDVS<E/SM;
M@?X8^HS?S0?GI5,%Q7\G'L7U#AMP_/\`_E_X%;J;2*WB[AR[*?\`CGQZ_P#:
M?>S>68%?&B_WM?\`/U4<N\Q'_EG;A_V33_\`6OKY_7SO_F)?S`9_FE\J)Y_D
M/\H>A9IN^NSI)>E-L_*S>>XMO=4NV[,G?8&%SO7N\$V)E\;M8#[.&HPX&.E2
M(-!^V5]_3O\`=L]F_9[>?N_<E[ON?*W+=WN-SRSM\LLTNVV4LDKO;1LSO(\+
M-(SDEF=F)).23U`N^W>ZVF\W5K))<1/'.ZE"SJ5(8C25)!4CA0@4ZWW/^$UG
M:'9?<'\JKK+>W;78>^>T=YUG:'=%%5[N[$W9GMZ[GJJ/'[XK8*"DJ,]N2OR6
M5GIJ&`:(8VE*1(-*@#CWQH_O!.7.7N5?O*[CL_+%A9[;M*;=8,L%K#';PAFM
MU+,(XE1`6.6(6I.3GH?\JS2S[.DDS,\FMLL23Q]3T/?SE_[>4_R1O_$]?-?_
M`.``[U]X3]"/I(?\)W/^W+/P`_\`$29O_P!^9OOW[KW5T?OW7NO>_=>Z"7O+
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M"%M[KW0Z^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z`KY*](])_)/I3
M>_0_R(P]%N+J#LRDH,-N_;U=N/*;3BS-/C\OC]Q4-(F<P>5PF8HY(\GA89O\
MGJ8G81$&Z%@?=>Z&FAK:#(4T=3C:RDKZ-M21U-%4Q5=.QB8QNJSPO)&Q1E(/
M-P1S[]U[J9[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJE_FE_P`J;XX_S2MO
M]*;9^0_97:'7%+U1NC=-7LV7K+/[(P55G\QOG&XBCK,57_WTVANV*OE%/MJ.
M2FBI4AFN)"=:\+DE]W/[S_._W9[_`'7<.2[+:[V7=H8(Y1>I.X00-(R&/P)X
M""?%8-J+`BE`*9)]WV6VWE42X9U$9)&FGG3C4'TZ+)_+X_X3X?#S^6W\E<-\
MD.H.X/D%NS?U)L[>&T,=MWLS<O6M;MZJQNYJ:CILM6"@VUUMM;,U%700Q+H*
M50B0R7=6]-I&]]?OU^Z/O_R#)[><U[9L-KM$EU#.9+2.Z6;5"2R@&:[F322>
M[LKC!'23;.6;+:KH7<#RM(%(HQ6F?L4'^?5^OO"?H1]>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW39ELWAL#3)6YS+8S"T<M33T4=7EJ^EQU-)65<@BI*1)ZR6&)Z
MFJE(6.,'6[<`$^_=>Z!WH[HWI7XL;*AZIZBPU+L;:F>W_P!D;[H\!6[DR^8J
M<IOGM+=^X^T=_P!7056Z,MD\K4RY7<F=R%?]K%(8:2)BD,<4$:HONO=#K[]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z+I\N>BMB?)SXS=W?'[L_<^4V7U]VYU
M]G=D[NW9A:_#XS*[?PN7@$55E*#(;@HLCA:2HI0`RO502PC^TI]C?VVY[W/V
MQY\VGW`V:*"?=-HO8[F*.8,8G>,U"R!&1])\]+J?0])KRU2]M9+60D)(I!(X
MY]*]:SE'_P`)(?Y=FVZ[:VX)OE=\G($JLQAY]O25^[.CX*//5QFBKL=18Z9N
MK8AD9*]8@8T@9GD0W6_U]]![K^]3]ZKNVDM7V#E<)(C*2$OJ@,"*C_'?GT%%
MY(VY6#"6?!]5_P"@>K?OY\@"_P`G3^86H^B_&_=@'^L*C&@>^81-37H:=6J;
M8_X]K;W_`&H\3_[@4_O77NJD_P"?9_VZY[Q_\2=\/O\`X,[X^^_=>ZN(]^Z]
MU[W[KW3#NK;6'WIM?<FSMPTWWN`W9@<QMK.48D>(U>'SN/J,7DZ82QD/'YZ*
MJ==2D$7N/?NO=4Z?%[^49O+XO9#;^X]N?-OL7<6\NO.K_CA\6NIMSY/IWJ:G
MFV5\(OCUV=7]B2_'7(8P4=9C=TY[M6DR3XC/;TD2FRJ4E/324,%)+"QE]U[I
M;?!W^4WMSX7]MX#L/_3WOGM[:W3/4/9'Q\^)_7.Y-I[4VY1=!]*]K]M4/<&\
M-N9#<6!!RO:6YI,U@L5C:3,5RT;4V&QL<'V[RR35#^Z]T8KY]?R[OC+_`#&N
MF<]U-\ANOML;@R9V7V)MGK'LO([9PVX-Z=)9SL7!4^%R&_.MI\U3U%/B=T4$
MF.HJJ&2VEIZ&'5<+[]U[HOFT?Y%7\I7;6T]K[;R'P&^,&ZJ_;VW,%@JW=&;Z
MBVH^;W)5X?%TN.J,_F9(:-8Y<MF9:8U-2X'KFD8_GW[KW2A_X9$_E$_]ZZ/B
M9_Z*#;'_`-2>_=>Z]_PR)_*)_P"]='Q,_P#10;8_^I/?NO=>_P"&1/Y1/_>N
MCXF?^B@VQ_\`4GOW7NO?\,B?RB?^]='Q,_\`10;8_P#J3W[KW7O^&1/Y1/\`
MWKH^)G_HH-L?_4GOW7NO?\,B?RB?^]='Q,_]%!MC_P"I/?NO=5D_S7?^$ZW0
M7??QMP&S/Y<WQD^(_P`=.]:/MC;6?S.^)=OMUN*[KBDV]NZASVW!G]H[3W-D
MIC6YK(XVH^V>G6&3[7475D4-E[]RKWWY-^[S[LW7._/$5_+M$VR3VBBTCCEE
M$DL]M(I*R2PKHTPN"0Q()7M(J00<Q[9<;M8K;6Q42"0-W$@4`8>0/KU47\%?
M^$JGRPZL^6O278'RY@^(7;GQOVQN:MK^U^N/[U[RWB=UX%]NYJEH\>-L9_JK
M$8;,Z,[44DWBJ*F&,>/5<E0ISC^\=_>"^R/NS[(\Q>W/+-KS%'OFZV:11-/;
M6\<(83Q2'Q'2\D=1I0T*HQK3'F`UM'*NY6.Y17<S1&)&J:$D\",54>O6U5_P
MR)_*)_[UT?$S_P!%!MC_`.I/?%_J1.O?\,B?RB?^]='Q,_\`10;8_P#J3W[K
MW7O^&1/Y1/\`WKH^)G_HH-L?_4GOW7NO?\,B?RB?^]='Q,_]%!MC_P"I/?NO
M=>_X9$_E$_\`>NCXF?\`HH-L?_4GOW7NO?\`#(G\HG_O71\3/_10;8_^I/?N
MO=%:^;7\@OX(=F?%'O'8/Q.^%?Q)ZG^1>Z-F28[J;L238..VFNU-TC)XZICR
M7]Y,%@<SF,*314\T7GIZ::0>33ITLWN9ON\^X&R^U7O5RY[B<Q+<OLNT[@)Y
M1;JKS%?#D3L1WC5F!<&C.HQQK3HNW:TDOMNFM(M/BR)05X<0<X/6K5L__A)!
M_,BQV[MJY#<V\OB#D]M4.Y,%5[BQQ[*[&JOO\#392EFS%%]K+TW%%4_=8Y)$
M\;,JR:M)(!O[[);[_>>?=ZW+8[W;K:RYH%Q<6DT2DVEJ!JDC9!4B^-`2:$T.
M/(]1]%R9NR2JY:"@8'XF\C_I>MSP_P`D;^4423_PW1\2N3?CI[:P'^P`HP`/
M];WP'&!3J4NNO^&1?Y1/_>NCXE_^B?VO_P#4GOW7NLD?\DK^4=$;Q_RZ_B<A
MN#=.H-L*;CZ'BD_'NK(KX8`CIZ&XGMSJ@=D:HX$CAPX=3$_DN?RGHO\`-_R^
MOBS'^/V^J=O)Q];>FG'%_;#65F_QQ1G[5!_R=&L7,W,5OB"_O(Q_1FD7_`PZ
MGQ_R</Y6,(TP_`OXTQ+>]HNML/&+G\V1!S[3ML^TN:O:VY/SC0_\^]'$'N/[
MAVJZ+7?MYC2O!+VY4?RE'4A?Y/?\KU?T_!;XYK_P7K_&K_T+;VT=AV(\;*T/
M_-F/_H'I<GNU[K1_V?,_,2_9N5X/\$W4D?RA_P"6.H`7X/\`QY``L+;#Q_T_
MV_MH\M<N$U.WV5?^:$7_`$#TO7WO]Z$4*G-W,X4?])2^_P"M_0+4_P#(S_EW
MP?(S)]Y'H3KZ;:&0Z5PW5$7Q_EV=A6ZGQVXL7OC+[OG[@HJ#1]Y'V'E<;DHL
M-43ZM#8VDB2U[^Z_U8Y:_P"C?8_\X(O^@>G1[Z^]H%!SCS32M?\`DJWW'_G/
MT.!_E(?RSC]?A'\>S_Y(6.]U_JKRQ_T;K'_G!'_T#T\??WWS/'G+FC_N:7O_
M`%NZZ'\H_P#EF@@CX1?'JX^A_N#C??CRKRR10[?94_YHQ_\`0/7E]_??)&#K
MSCS/J'_23O/\LW7/_AI/^6>?^Y(_CS_Z`&,_XI[K_5/E?_HW67_.&/\`Z!Z>
M/WA/?8\><>9O^YE=_P#6WKDO\I7^6BA)7X2?'D$BQ_XQ_B_I_L5]Z/*/*S8.
MW67_`#AC_P"@>KQ_>(]^8B3'SES,"?\`I(W7_6WKG_PTS_+4_P"\)?CS_P"B
M_P`5_P!&^]?U/Y4_Z-UE_P`X4_Z!Z=_X(_W^_P"FSYF_[F-U_P!;>N:_RG?Y
M:R`A?A-\>.3?GKS#M_O+1D^ZGDWE-N.W6?\`SB3_`#=.Q_>5^\%$*)SGS+0^
MM_<'_#(>N7_#4'\MC_O";X[?^BZPO_7KW7^I?*7_`$;K/_G$O^;IS_@FOO"_
M]-GS)_V73_\`0?6K!\S/^$N'=?</RA[I[*^/6U_C%U+TQNW>=9E-@;%C[3[0
MHFQ6'>&G22JJ,6NP,O18*IS->DU8^.HYWH<>9_MZ?]F-/>2NQ_?<^_+R'L=E
MR1[<\Q[-M_(>T6D-G86[;;82-%:VZ".)6>2QD=F"@5+.Q^9XF8^4MP^X+NFP
M0[O[V;+SGOONQ>F2XW2^6XE19[N>1Y)"H3<H@574$#E%>33K<!F(ZV@OY3'P
MXW%\#/@YU=\:MXX39F'W?L[);UR&YI]@[NW3O+;FX,GN+=>4RZ;CAR.[L;B<
ME15V3QU1!]U1QP)203HWA`1@HCOG+W0]T/>#>CSM[PWEO?\`/4L4<4TT$,4$
M;I"-$5(X8H8U.@#51!5JGSH,9/<FW]JK?G2]_P!9:'<;;VYD9'M8;[-Q"6C7
MQ8V;QIRZ"768W:0L4(#9%2%_SE_[>4_R1O\`Q/7S7_\`@`.]?85Z`O20_P"$
M[G_;EGX`?^(DS?\`[\S??OW7NKH_?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJS_\`
M"A4=/KW+\6I?E_38BH^)(^)G\RJ#!C>5)/5["3YA5'3>RTZ%!012T2]P2X@9
MQ=AE@,@,MYOX816:??NO=7I_R\8^V(?@1\*H>]QG!W3%\4^@(^U!N?S?WG&_
MDZLVLNZ1N7[G_*O[QC,"45_E_=^[\FOU7]^Z]T<7W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U4?_`#P-M_'VK_EU=U]@=_\`Q^V;\E?]$<&,W1TKUGOJ#*5.
M!K?D/N^K7IWIVIJZ;#Y#&UE12'=W9D,%6@DLU!//^DV=?=>Z-)_+Y^&FP?@!
M\/\`I'XI]=Q1OCNL]J1)N3,H&5MV=B9^>;</8^\9(F)%*NY]Z9.MJXJ9+0T=
M/)'3Q!8HD4>Z]T<SW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UK^_S:^E9IOF
MO_)W^0,_8_:V2-'_`#%>E^JL/U#_`'@BCZ4VU2UO5WR-W3N3L9=FT.+@FR79
M6>FQ^.Q[9?(U=2*#&4?V]''3_<UC5'NO=$`VWVG\N=T_\*,?C)V)\C/CE\F-
MC8K<&#^=/2'1FTJNFZRJ.G=L_'395%UC1;3[>V]D*'L:?.9/-[PS4]=GM]5E
M;14533T^8P.-QU-D$Q[RCW7NMP'W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
MK,?\*2^POA1M?JWH39GR-VQU[O7OGM>3N3K+XQKWKN'=%+\<.DIM_;0Q6TNS
MOE1W1MO"QY6@R<?2>!RM+/MV=,779],[50PX@T[S555![KW21W9T+MK:OR__
M`.$Y/;NT/DUW-\E-IST-=U+U_F]S[GGEZLR6Q]G_`,N_LPGN+`[-.,I:N/L#
MNVLIJ?*YK,9:JKJ]XEIZ2%H((W27W7NMI7W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U3A_/0[6^'?3'P9GW]\TNO)NZMC83M[K>OZTZ'FW%D=O[5[J[SQT^5
MR77&R>S5IZB+`YGJ>GJ:.HRVXZ7.PUV%7&8R2>6CJYX:>GD]U[K3N^6>TNI,
M+\-_A5M/#]V=!=N;7VW_`"_/YA6X-G]I[FQN[=Q?'3=G=>Y?D]M?/57Q4_ER
M4>Y,719[KKY;=5Y-JG`;!W-61UT])M^FIBF&J(Y-%-[KW6W7_.$JZFO_`)#7
MRZKJS$[KP%76_"JEJZK!;\JSD-\X6IJ<#MJ:?$[SKS'$:W=>.E<PY&8JODK$
MD:PO;W[KW5S.V/\`CVMO?]J/$_\`N!3^_=>ZJ3_GV?\`;KGO'_Q)WP^_^#.^
M/OOW7NKB/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U6-_-Z^0G;?QM^$VX]W]&;G&P
MNS=]=O\`QRZ)P'9/\'Q.?EZSI^^>]^O^J<[OZAP^X*2OP-=F=N;?W352X\5T
M$](F0,#RQ2(IC;W7NDQ_*:[L[F[*VA\R^H^[>R,_W3G?AO\`//O/XJ;4[FW=
MBMKXK>O9'7>S<'U]O39^3WTFR<#M?:-?O7!T78#8C(5E!C:&*K>@65H$E:2_
MNO=6P>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7ND;V+M[<.[M@;VVKM'>^4ZT
MW5N7:>X<#MOL7"8S#YK,[$SN6Q-708G>&*P^X:6NP.5R.VZZ>.LAIZV&6DFD
MA"2HR%@?=>ZIP_DZUWRP[`S'RW[6[A^;/9'RW^.F+[HW!\?/C-D.Q>M>FMA9
M/<%1T-F,CLSN[N&!^I]F[9@EVWN3MNDR6"P4$LLY;'X!JR3U5D:Q^Z]U>#[]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z(?_,MW?\`*;8/PO[SWI\0<UUCM/M7
M:G7^^=TUN^NT:?-9.AV'LG:VP]U[EW)NK9VV\/25$.ZNR:3^$008.BR,E/B!
M65`J*QY((&II_=>ZUV?YA7\[;MOX]?RZ/@AL[K+O?9&S?FCW-\*?B7\NNZ.T
M^R,ML7';A@ZOW1-U;M[<<77NU=QXF?![[[A[EWAFLFZT-%CI8L3MG#9W(RI2
M>*BE]^Z]UM^;;W'M_>.W<#N[:>;Q6Y=J[JPN+W'MG<>"KZ;*X3<&W\Y0P9/#
M9O#9.BDFH\EBLKCJJ.>GGA=XIH9%=25(/OW7NGKW[KW7O?NO=>]^Z]U[W[KW
M7O?NO=`I\D*?L"JZ$[?AZL[=VET#V`>O]S/MGN_?>W<?NW:'4U;#C)YI>PL_
MMW+Y?!8;)T&U*..6M9*VJBH5:$/4:X5=&]U[K6>QWR:_F@Q?RK?YB_R%Z!^0
ML_9?6'7&8[3WK\3/F'\L^O\`";9[LWS\5>L?CEE-V]D=N]<;&Z[V)M':.ZI-
MW=TX.:CZSK\_C*"F_@-6V3JEKH:>CIJGW7NMEOXQ;GSN]_C7\>MY[IR4^9W-
MN[H[J;<^X\O4K`E1E<[G]A8#*Y?)5"4T4%,D]=D*N25Q&B(&8Z5`L/?NO=#C
M[]U[KWOW7NO>_=>Z][]U[KWOW7NL-2*@T\XHWACJS#**62IC>:G2H*,('GAB
ME@EEA66Q=5=&9;@,#S[]U[K3FW]\P_YBG276/\SS>VP?GU6_)+K_`*'Z#VKL
MFI^3^\.D.N-K]5X/^9)N?Y%8G:F9Z)^%>$VELO*'=>+P/4V?BVZ]'F)]VT.&
M[!GQRUU;H:M1/=>ZN-_DP]\][=Q]6_*?:GR&WUV1NG>O0?S#[)ZCV]MGO[$]
M>8[Y0=;=:T>U=A[EV5M;Y%UW3N%PG3NY]]UD.X:C)4N4VO\`>XNIP]92*:N6
MHCG2+W7NG[YR_P#;RG^2-_XGKYK_`/P`'>OOW7NDA_PG<_[<L_`#_P`1)F__
M`'YF^_?NO=71^_=>Z][]U[KWOW7NO>_=>Z][]U[J+64-#D(TAKZ.EKH8YX:F
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MK&U330SLBL06"&5'*AB!>WUM[]U[K**6F`IP*>`"DXI0(HP*8:#%:G]/[/[9
MT^FWIX^GOW7NL_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J/4T=)6HL=92TU
M7&C:U2I@BG17L5UJLJL`VEB+_6Q]^Z]U%DP^(ECI89<5C9(:&J2NHHI*&F>.
MCK8RS1UE*C1%:>J1G)$B`."38\^_=>ZJB_GR_P#;G7^8;_XKANW_`-R,;[]U
M[JU/;'_'M;>_[4>)_P#<"G]^Z]U4G_/L_P"W7/>/_B3OA]_\&=\???NO=7$>
M_=>Z][]U[KWOW7NO>_=>Z][]U[H'^_.A.I/D_P!1;VZ([TV;0[^ZK[#QU/C=
MT[8KJO)XX5:4.1HLSBJZ@R^$K<;G,'F\'F\;35U!7T-33UM#6TT4\$L<L:L/
M=>Z3_P`:?B_TG\1.L8^H^AMI5.U=H/N7<V]LQ+EMR[IWQNS=N^-Z927,[NWO
MOG?>^<SN+>F]MX;DR<IDJ\CE*^JJI0J)K$<<:+[KW1@/?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=`YT!T#U-\7>H]H]%=&[439'5NQ5S:[8VRF5S><
M_AYW)N3,;NSDLF7W'DLOG,A49/<F?K*N62HJ97,D[<VL![KW0Q^_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NDKOO9.V>R]D;RZYWKC1F=F[_VKN'9.[<.:FLH
MAE=L[JQ%9@L]C368^HI:^D%=BJ^6+RP2QS1Z]2.K`$>Z]T67?WP"^(':'QTV
M]\4M^]'[6W+T=M/K[KCJO;FV,A+ESF,1L#J6IP%7L#;5'ON+)1[]CHL%/MFC
M-_XGY*D(XG:5990_NO=&\I*2EH*6FH:&FIZ*BHJ>&DHZ.DACIZ6DI:>-8:>F
MIJ>%4B@IX(D"HB@*J@```>_=>ZD>_=>Z][]U[KWOW7NO>_=>Z][]U[H(._>B
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M=7XNK-0M+DJ*JQ]2U)5U5!5BGK()*>8TM=12T];15`CD.B6&1)8VLR,&`(]U
M[JI_K#^1C_+!Z@V7VCUQLGXZY*/K_N7K^LZR[`V3N3N_O_>VU,EM>NW9A-^2
M28K`;Q[1SN,VGNB#>FW:/*4^=Q,5#FZ:NA$T54CLQ/NO='9^+WQ&Z&^'6R=P
M[$Z&VIE<#C]Y;UR_9&_-P;JWMO?LWL#L+?\`GJ:@HLKO'?\`V1V5N'=>^]X[
M@J,?BJ6E6?(9"=H:6FBACT1HJCW7NB/_`#E_[>4_R1O_`!/7S7_^``[U]^Z]
MTD/^$[G_`&Y9^`'_`(B3-_\`OS-]^_=>ZNC]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW01;$[ZZ?[.[$[DZFV%OS#;F[%^/F:VIMW
MN;:F/%:,CL#-;XVS!O+:F/S+5%)!2O-F]LU*5<1IY)E$9LQ5P5'NO="[[]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJ0_GR_]N=?YAO\`XKANW_W(
MQOOW7NK4]L?\>UM[_M1XG_W`I_?NO=5)_P`^S_MUSWC_`.).^'W_`,&=\???
MNO=7$>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7N@<V)\@>G.S>SNZNFMA[\Q6Y.SOCKD]E8?NK:-%!DH\AU_D^QMKKO/95)E
MIJNAIZ"HDW!MAA5Q&EFJ%5/3(4<%??NO=#'[]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>ZJ+^<O_;RG^2-_P")Z^:__P``!WK[]U[I(?\`"=S_`+<L
M_`#_`,1)F_\`WYF^_?NO=71^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>ZI0_GS?(CMOXY?#KK/+=8=N9[XZX#M/YA_&CHWOCY);73&IN#X_
M?'SLK=]3C^R>S\3ELQ09+&;;K,?%24M"N2FB/VOW]T9)3&X]U[K6QZY^377_
M`$;N+^:?)L3YQ_);O+;G<O\`,>^"/Q\ZV^7'5??7QZZGW5VQ)4_&C?T=#1]O
M?+S='7>0ZGV%U?@X=I24&1WQA<0N2SCX2!J1G^^J)C[KW0N='?S1?EYT9\2?
MCS_,5[9[Z[*[M^-?Q7_F&?,CX8?)C`TN],#VTO8_0.[,-21_'7LC<^_MJ[=V
MSB.U=P]7=AK1T-%NZCH*,YNER\#>`1S%1[KW6T/_`"EZ;Y%S?R^?C?O+Y8[\
MW/V#\@.WMH5/>/8&0W5.LE;MR3N;,Y'L;;G7U#3(BC%8KKW:.XJ##PTEV^W-
M&R@@65?=>ZL:]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U4A_/E_[<Z_S#?_`!7#
M=O\`[D8WW[KW5J>V/^/:V]_VH\3_`.X%/[]U[JI/^?9_VZY[Q_\`$G?#[_X,
M[X^^_=>ZN(]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW5*?\^KY`=O?'?X2[0S_5?:FY^@,)V#\KOC9TYWO\B=F"EAW3T#\>>Q]\C$
M]F]H83+5U!DZ7;M?CJ>.FH4R#0EZ4Y#5$R2^-U]U[K6@Z]^2_6?16\/YL%9U
M_P#-GY/]];)[=^?/\M_X^];?+KK_`.1W3G4.Z^RCD?CQVE!2IW3\S<]UOE=B
M;%Z<V[_=.?%Y'?>)Q0R>73#TS4T\OW<]0_NO="ST5_,X^7'0_P`4.E_YBW9G
MR`[1[U^-/Q$_F0_,OX7?(7;-+V31=STG9/QRWMMW##X]=A[B[)P^W]J4'<F<
MZK[+EHZ/&;R7'44V9H\U"1!'#((E]U[K:7_E+8WY$0_R^?C?NKY8;^W;V'\@
MNVMH5/>/8N2WC7/69#;M7W/F<CV1@NO:*!RQQ&(ZZVMN.APT%"&9:7[)D6R@
M*ONO=6-^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJ+^<O\`V\I_DC?^)Z^:_P#\
M`!WK[]U[I(?\)W?^W+/P`_\`$29O_P!^9OKW[KW5T?OW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NF3<FV=M[RP.4VMN_;^$W7MC.4DE!F]N;
MDQ-!G,#F*"6WEHLIB,I3U6/R%)+I&J.:-T:W(]^Z]T@ZOH;HVOVWE-FUW3'5
M%;L_.4V`H\WM2KZZVA4;;S%)M2EBH=K4N4P4V'?%Y"FVU10)#CTFB=:.)%2$
M(H`]^Z]T7;Y@?`'HOYE_''/?%3>29GK;IO>O8.PM^]B8#IRFVGLY^P4V-O+`
M[W;:NY6GVQEJ:3`;MRNV:*/+/!##D*BF@")4Q_7W[KW1VJ>GIZ.G@I*2"&EI
M:6&*GIJ:GB2"GIZ>!%BA@@AB58X888U"JJ@*J@`"WOW7NLWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NJD/Y\HO_`"=?YAMN?^<<-W'_`&U1CB?]L/?NO=6I[8_X
M]K;W_:CQ/_N!3^_=>ZJ3_GV?]NN>\?\`Q)WP^_\`@SOC[[]U[JXCW[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=-6<P6#W/A\CM[<N&
MQ6X<!F*66@RV#SF.H\MA\I0SKIGH\CC*^&HHJZEF7AXY49&'U'OW7ND94=-=
M05>W\GM.JZJZWJ=K9JBPN-S.VJC8VV)MOY;';:@6EVY09/#28ML=7T6`ID6.
MBBEC>.E0!8@H%O?NO=%R^8'P+Z,^:'QZS7Q>[!3/;%Z?W?V!U_OWL#;_`%(-
MK;0;L(=?[NP&\XMI[K>JVOFJ>JVQNC);8H8<L(8H*^HI8%CCJH;!A[KW1T((
M(*6"&FIH8J>FIXHX*>G@C2&"""%!'%##%&%CBBBC4*JJ`%`L./?NO=9??NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=5%_.7_MY3_)&_\`$]?-?_X`#O7W[KW7SK_B
MO_V3YU?_`-Q#_P#Q9\E_V1U_V3!_Q\N;_P"9+_\`9I?U_P"FWS^_=>Z,!_ZE
M:>_=>Z]_ZE:>_=>Z]_ZE:>_=>Z]_ZE:>_=>Z]_ZE:>_=>Z]_ZE:>_=>Z]_ZE
M:>_=>Z]_ZE:>_=>Z]_ZE:>_=>Z]_ZE:>_=>Z]_ZE:>_=>Z]_ZE:>_=>Z]_ZE
M:>_=>Z]_ZE:>_=>Z]_ZE:>_=>Z]_ZE:>_=>Z]_ZE:>_=>Z]_ZE:>_=>Z]_ZE
M:>_=>Z]_ZE:>_=>Z]_ZE:>_=>Z]_ZE:>_=>Z]_ZE:>_=>Z]_ZE:>_=>Z]_ZE
M:>_=>Z]_ZE:>_=>Z]_ZE:>_=>Z]_ZE:>_=>Z]_ZE:>_=>Z]_ZE:>_=>Z]_ZE
M:>_=>Z]_ZE:>_=>Z]_ZE:>_=>Z]_ZE:>_=>Z]_ZE:>_=>Z]_ZE:>_=>Z]_ZE
M:>_=>Z]_ZE:>_=>Z]_ZE:>_=>Z!;Y&?\R*[0_P"XC#_CVO\`N;+_`+)G_P"+
MGCO^9W_]^_\`^5O_`&K1[]U[KZRNWO\`BP8/_-?\6?&?YC_,?\`H/\S_`,VO
M]3_A[]U[JF'_`(48_P#;FOYC_P#`_P#X#]%?\6;_`(^/_LI?IK_CTO\`L\?^
M=3_U<?#[]U[K1VG_`,_-_P!Q7/\`G9/\_P#Y_P#6?\]_S=_U7^/OW7NL7_J5
MI[]U[KW_`*E:>_=>Z]_ZE:>_=>Z]_P"I6GOW7NO?^I6GOW7NO?\`J5I[]U[K
MW_J5I[]U[KW_`*E:>_=>Z]_ZE:>_=>Z]_P"I6GOW7NO?^I6GOW7NO?\`J5I[
M]U[KW_J5I[]U[KW_`*E:>_=>Z]_ZE:>_=>Z]_P"I6GOW7NO?^I6GOW7NO?\`
MJ5I[]U[KW_J5I[]U[KW_`*E:>_=>Z]_ZE:>_=>Z]_P"I6GOW7NO?^I6GOW7N
MO?\`J5I[]U[KW_J5I[]U[KW_`*E:>_=>Z]_ZE:>_=>Z]_P"I6GOW7NO?^I6G
MOW7NO?\`J5I[]U[KW_J5I[]U[KW_`*E:>_=>Z]_ZE:>_=>Z]_P"I6GOW7NO?
M^I6GOW7NO?\`J5I[]U[KW_J5I[]U[KW_`*E:>_=>Z]_ZE:>_=>Z!S?O_`#-+
HH3_N(L_XO'97_,V_^9S_`/'B2?\`9*'_`&?W_/5?]F1_$/?NO=?_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tpg19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg19.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!80)Q`P$1``(1`0,1`?_$`:(````&`@,!````````
M``````<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+
M$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,7
M4G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R
M9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8
MF9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1
M``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B
M%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756
M-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>W
MQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:
M``P#`0`"$0,1`#\`VKOBC\0/C-VGT)LCL#L3IK9V[]Z[GJ=YUVX-RYJEJJK*
MY>LBWYNBC2IK:C[M3+,*:FC2]OHH]^Z]T8G_`&0#X9?]X[==?^>ZJ_\`JWW[
MKW7O]D`^&7_>.W77_GNJO_JWW[KW7O\`9`/AE_WCMUU_Y[JK_P"K??NO=>_V
M0#X9?]X[==?^>ZJ_^K??NO=>_P!D`^&7_>.W77_GNJO_`*M]^Z]U[_9`/AE_
MWCMUU_Y[JK_ZM]^Z]U[_`&0#X9?]X[==?^>ZJ_\`JWW[KW7O]D`^&7_>.W77
M_GNJO_JWW[KW7O\`9`/AE_WCMUU_Y[JK_P"K??NO=>_V0#X9?]X[==?^>ZJ_
M^K??NO=>_P!D`^&7_>.W77_GNJO_`*M]^Z]U[_9`/AE_WCMUU_Y[JK_ZM]^Z
M]U[_`&0#X9?]X[==?^>ZJ_\`JWW[KW7O]D`^&7_>.W77_GNJO_JWW[KW7O\`
M9`/AE_WCMUU_Y[JK_P"K??NO=>_V0#X9?]X[==?^>ZJ_^K??NO=>_P!D`^&7
M_>.W77_GNJO_`*M]^Z]U[_9`/AE_WCMUU_Y[JK_ZM]^Z]U[_`&0#X9?]X[==
M?^>ZJ_\`JWW[KW7O]D`^&7_>.W77_GNJO_JWW[KW7O\`9`/AE_WCMUU_Y[JK
M_P"K??NO=>_V0#X9?]X[==?^>ZJ_^K??NO=>_P!D`^&7_>.W77_GNJO_`*M]
M^Z]U[_9`/AE_WCMUU_Y[JK_ZM]^Z]U[_`&0#X9?]X[==?^>ZJ_\`JWW[KW7O
M]D`^&7_>.W77_GNJO_JWW[KW7O\`9`/AE_WCMUU_Y[JK_P"K??NO=>_V0#X9
M?]X[==?^>ZJ_^K??NO=>_P!D`^&7_>.W77_GNJO_`*M]^Z]U[_9`/AE_WCMU
MU_Y[JK_ZM]^Z]U[_`&0#X9?]X[==?^>ZJ_\`JWW[KW7O]D`^&7_>.W77_GNJ
MO_JWW[KW7O\`9`/AE_WCMUU_Y[JK_P"K??NO=>_V0#X9?]X[==?^>ZJ_^K??
MNO=>_P!D`^&7_>.W77_GNJO_`*M]^Z]U[_9`/AE_WCMUU_Y[JK_ZM]^Z]U[_
M`&0#X9?]X[==?^>ZJ_\`JWW[KW7O]D`^&7_>.W77_GNJO_JWW[KW7O\`9`/A
ME_WCMUU_Y[JK_P"K??NO=>_V0#X9?]X[==?^>ZJ_^K??NO=>_P!D`^&7_>.W
M77_GNJO_`*M]^Z]U[_9`/AE_WCMUU_Y[JK_ZM]^Z]U[_`&0#X9?]X[==?^>Z
MJ_\`JWW[KW7O]D`^&7_>.W77_GNJO_JWW[KW7O\`9`/AE_WCMUU_Y[JK_P"K
M??NO=>_V0#X9?]X[==?^>ZJ_^K??NO=>_P!D`^&7_>.W77_GNJO_`*M]^Z]U
M[_9`/AE_WCMUU_Y[JK_ZM]^Z]U[_`&0#X9?]X[==?^>ZJ_\`JWW[KW7O]D`^
M&7_>.W77_GNJO_JWW[KW7O\`9`/AE_WCMUU_Y[JK_P"K??NO=>_V0#X9?]X[
M==?^>ZJ_^K??NO=>_P!D`^&7_>.W77_GNJO_`*M]^Z]U[_9`/AE_WCMUU_Y[
MJK_ZM]^Z]U[_`&0#X9?]X[==?^>ZJ_\`JWW[KW7O]D`^&7_>.W77_GNJO_JW
MW[KW7O\`9`/AE_WCMUU_Y[JK_P"K??NO=>_V0#X9?]X[==?^>ZJ_^K??NO=>
M_P!D`^&7_>.W77_GNJO_`*M]^Z]U[_9`/AE_WCMUU_Y[JK_ZM]^Z]U[_`&0#
MX9?]X[==?^>ZJ_\`JWW[KW7O]D`^&7_>.W77_GNJO_JWW[KW7O\`9`/AE_WC
MMUU_Y[JK_P"K??NO=>_V0#X9?]X[==?^>ZJ_^K??NO=>_P!D`^&7_>.W77_G
MNJO_`*M]^Z]U[_9`/AE_WCMUU_Y[JK_ZM]^Z]U[_`&0#X9?]X[==?^>ZJ_\`
MJWW[KW7O]D`^&7_>.W77_GNJO_JWW[KW7O\`9`/AE_WCMUU_Y[JK_P"K??NO
M=>_V0#X9?]X[==?^>ZJ_^K??NO=>_P!D`^&7_>.W77_GNJO_`*M]^Z]U[_9`
M/AE_WCMUU_Y[JK_ZM]^Z]U[_`&0#X9?]X[==?^>ZJ_\`JWW[KW7O]D`^&7_>
M.W77_GNJO_JWW[KW7O\`9`/AE_WCMUU_Y[JK_P"K??NO=>_V0#X9?]X[==?^
M>ZJ_^K??NO=1ZOX"?#2.DJI%^.W76J.GF=?]QU7]5C9A]*X'ZC\$'W[KW6L'
MX8OZ/_U.G_Z^^_=>ZVC/@E_V2IU7_K;W_P#?C;O]^Z]T;GW[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=`7W[\G?CK\5]H
MP;\^27=_5W1FSZJLCQU%N'M'>N`V9CLA7R34T`HL;)G*ZD;)52R5<>N.`2-&
MKAF`7GW[KW3OL_O_`*-[!ZD3OS8W<'6N[>D6VY6;N;MK;^]=O97KR#;..H&R
MF3S=7NZDR$N$H\?B\>C2U4DLR"F16\NC2;>Z]T'_`,<OFI\1_E\FZ'^+GR0Z
M;[]_N2^-3=\?5>_MO[QGVW_&!4G%/F:?#UM348^+(_93"%Y%5)#$X4DJ0/=>
MZ,[[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NHE?_P``
M:W_J$J?^M+^_=>ZTRO?NO=;0_P`$O^R5.J_];>__`+\;=_OW7NC<^_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K0#_G';
M_'9W_"A=NO.R?@+V3_-`V]\>_AWM)>E/B-UQF<]A<"=Q;PEH=W[J[&[13'X;
M>D=7A<10[DK@WCQL*5M;#A8*EG2G77[KW11>[.R_B@W\FC?G5'PBVA\C/B_@
MOD/_`#:.E>B?FK\/.Y^P7W%FOC[N3+[;W9NO/;6ZIJ(,;@LQB=F[DJ=@T6+$
MV<IIZNMCV[)3U=)'/3N??NO=7)=G?%WH;^6)_P`*%_Y1VV_A/UMA.C]H_*#I
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MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW42O_`.`-;_U"5/\`UI?W[KW6
MF5[]U[K:'^"7_9*G5?\`K;W_`/?C;O\`?NO=&Y]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5$O\`,;_E8_)_N7Y2;,_F
M`?RXOE[B_AS\R,!T[4?'K>U;NSKS;V^.L^V>I*K<R[FIZ/=%)6;=W%+!N#"5
M["2.IJL;EUJ%HJ")!1FD28^Z]T4#:7_":C!9[^7M\F/CO\BODKFNTOF+\IN^
MJ/Y?;O\`EAC<#-BEVC\EL#C\K_=;*[?P-1D'ER&`H,ANG/1Y&M08O)Y6ESU7
MH%$5I8Z?W7NA:^`/\GOYI;/^:VU?GI_-&^9^U_EWW%T7U!+TO\:,#L'9M%MW
M:&RL'FES$6XMT;CCJMF;66KW8*/+2P4]72TBU]09FEK*V<0T\2>Z]UL?^_=>
MZ07:AMUAV.1P1L+>!!'X_P!^]D??NO=*#:__`![.W?\`M18C_P!U]/[]U[I]
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW42O_P"`-;_U"5/_`%I?W[KW6F5[
M]U[K:'^"7_9*G5?^MO?_`-^-N_W[KW1N??NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2"[5
M_P"97]D?^&%O#_WGLC[]U[I0;7_X]G;O_:BQ'_NOI_?NO=/OOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>ZB5__`&M_P"H2I_ZTO[]U[K3*]^Z]UM#_!+_`+)4
MZK_UM[_^_&W?[]U[HW/OW7NO>_=>Z][]U[KWOW7NDME]\[)V_N';>T<]O#:V
M$W7O*++S[0VQE]P8G&[AW5#M\8\YZ;;>%K*N')9R+"#+4GWC4L4HIONHO)I\
MB7]U[I4^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z07:O_`#*_LC_PPMX?^\]D??NO=*#:_P#Q[.W?^U%B/_=?3^_=>Z???NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U$K_`/@#6_\`4)4_]:7]^Z]UIE>_=>ZV
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M:2CW)LZLW5MW'9VIVMN&DECBEI<YMZ:O:DJXV162HA=2`1;W[KW2_P#?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T@NU?^97]D?^&%O#_WGLC[
M]U[I0;7_`./9V[_VHL1_[KZ?W[KW3[[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NHE?\`\`:W_J$J?^M+^_=>ZTRO?NO=;0_P2_[)4ZK_`-;>_P#[\;=_OW7N
MC<^_=>Z][]U[KWOW7NO>_=>ZTO?YOF'HLW_,%^,/RGP?\]GKCXH]>]$=O_*#
MJ^#$]E;(V=NW=_Q;[DQG477N#[@VOT7A:+KW[7MF?<.*W]@(-PXK>%?"-N4F
M4BJ:.MJVF2E@]U[H?_Y7=-\;NY_YDFU?D%F_YZ.-_F?_`"5V/\=.R>L>N.MZ
M#HG8G2\^`Z^SV>P6?W=F*A]G*U-G*;&U$098VCAG5ZC496C3QGW7NML/W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=:!_\`PI/^5/6E7_-S^-7QR[K[^^6>P?CAUK\7
M,IN#LG#?!/(4U+WMC>T^PLMNW,8:DKZ#.9+'[:S=%4X#;6W*MDJ%D>BQU5-)
M$VN9@ONO=.^[_E_U#\7/Y#N2G_E6?-/Y6]OY7YA_.?9_QQR7<WR9S%-6]Z_&
MW>/9W7^&FWULRNC&%Q4FW$H=A[&`HJG"&K\5=F)*V@KG($L?NO=&I^.G47;W
M\DW^<U\)?AY@?EQ\AOD]\>?YB/3._:+?>TN]MUT^\LCM;N3JS&[AS%-O7;=;
M4T%!3X+;XB2&&"*D45TT4E1'6/4**4P^Z]UN8>_=>Z07:@OUAV.!R3L+>``'
MY_W[V1]^Z]TH-K_\>SMW_M18C_W7T_OW7NGWW[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=1*__@#6_P#4)4_]:7]^Z]UIE>_=>ZVA_@E_V2IU7_K;W_\`?C;O
M]^Z]T;GW[KW7O?NO=>]^Z]U[W[KW56'\PWI3Y>96EZWWS\(^L/@;V/\`W2S7
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M\6W:>@K(I*JCK$6EH_MXHX'J9*F8P>Z]UMJ^_=>Z`#N7J?K?*[*[,W)DMFX.
MMSLVS-U5LN3GI2U5)5T^WJWP3M('%Y(_"MC_`(>_=>Z&/;!)VUMXDW)P>))/
M]2:"G)/OW7NGSW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1*_P#X`UO_`%"5
M/_6E_?NO=:97OW7NMH?X)?\`9*G5?^MO?_WXV[_?NO=&Y]^Z]U[W[KW7O?NO
M=>]^Z]UK>?S<-^=&=[4.P<1\@?B7_.G[:ZLZM[M[VZJS_3OPGZRW?3=>]Q5^
MV,'U!D(>QNW8=F[OV]GMV]-9*EW/-0[*R"5])!D*M<]&T5Z=3[]U[H:_Y5_R
MH^+%9ND?&'XJ_P`I'YQ?`'9\NVZ_=&0WEW!\(:3X\=29:LVM2XZ@IZ/='85+
MN7+UNY-_Y6EJA]L^1^YK:TI,[S%]3-[KW5['OW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[I!=J_\`,K^R/_#"WA_[SV1]^Z]TH-K_`/'L
M[=_[46(_]U]/[]U[I]]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=`;\ALS\B\#UQ4Y'XN;%ZA[$[5CRV,2GVWW?V
M1NOJK8LF!=IOXU63;MV;USVEFHLI2QJAIX!BFBF).N6,`$^Z]T5W^6%\K?D#
M\V?BYM#Y-=X]0]3=.8KMBBH]S=4[?ZQ[2W5V=6U.S9A44E14;YFW+UOU[#M[
M<,67HY42EHFR<#4^ES.KDQCW7NK%/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U2#_/%ZLS9^-:?(79/R&^6?2>_=C=B?
M&7K+&4O0'R4[/Z:VAE-O=O\`RNZ@ZYWI5;HVCLK,X_"[CW!+L_>V0I:2OJ8W
MJ:,O&\;#Q*/?NO=6Q]&=/8SH7K';O5F'WOVSV+CMMME6@W?WAV9NKN#LS*G+
MYBNS,HW#V#O6NR6Y,XM%+7M!2BHF?[:CCB@2T<:@>Z]T+?OW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZB5_\`P!K?^H2I
M_P"M+^_=>ZTRO?NO=;0_P2_[)4ZK_P!;>_\`[\;=_OW7NC<^_=>Z][]U[KWO
MW7NO>_=>ZU8_YM/Q]_F5Q_S#_@GWWU+_`#%NA>B.CJ3LWL;8G4D/=6VMCX23
MJWM/N7KK'[*Q^P6V6N<P];\M'[+KJ1XL)2M22U^U6\];.PIX9*OW[KW0_P#P
MY^-GRM7^:++V7\S/YHG2'R7[J^/_`,8LUM!_B]TYU?#T]F,)M#MK<F,R>%[%
MWMM"CWA54M;CXJBDEBIJ]L?+()*B&(S1J45_=>ZV'??NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2"[5_YE?V1_X86\/_`'GLC[]U[I0;
M7_X]G;O_`&HL1_[KZ?W[KW3[[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZP57_`:H_Y82_\`6MO?NO=55?R-O^W2
MOP5_\0K2?^]'N'W[KW5KGOW7ND_NS:V"WQM7<NRMT439+;.\-OYG:VXL<E97
M8]J_!;@QU3B<O1+7XRIHLE0M58^KDC$U/-%/$6U1NK@,/=>ZH7_DL_#+XZ=7
M[U^;_;6R]E9VB[`ZU^>OS"^-VQ\[E^TNV]W)M[I/:VZ=HC;VQ*/#;PWWG\"]
M%BA3((JF2E>O`!'G(9K^Z]UL$>_=>Z][]U[JL3`?SEOY:NY^W\9T'@ODYBZ_
MN#,;OQ^Q,?L5>MNYH,K-N;*[C.T<=222U77,&.I:"KW(#2)7RS)CS(K'SZ59
MA[KW5G?OW7NO>_=>Z][]U[KWOW7NO>_=>ZJ<_G:?]N^-X?\`BP_P6_\`@Y?C
MI[]U[JV/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U$K_\`@#6_]0E3_P!:7]^Z]UIE>_=>ZVA_@E_V2IU7_K;W
M_P#?C;O]^Z]T;GW[KW7O?NO=>]^Z]U[W[KW5'W\WKXJ=^=D]K_R]OF?T!TA@
M?ECFO@-W%VAOS=7Q.W%NW;NRD[6VOV7UR-N)NC:.:W?19#:[=G]4;AP5#D]O
M05<:>2KD9HYHY$4-[KW0-_$+J+Y4_)S^:?1?S*OD3\-8/Y>N(V/\6=Q_&W"]
M=[E[/Z[["[>^1>[,[NJBW+-NO=DG7M-2TL>U>OMM4@IL>:Z2>L\B@1KX%)B]
MU[K8E]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=(+M7_
M`)E?V1_X86\/_>>R/OW7NE!M?_CV=N_]J+$?^Z^G]^Z]T^^_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NL%5_P&J/
M^6$O_6MO?NO=55?R-O\`MTK\%?\`Q"M)_P"]'N'W[KW5KGOW7NO>_=>ZJ9_E
M-?\`%N_F,?\`C6;YP_\`O5;9]^Z]U;-[]U[KWOW7NJG]LNY_GC=S(78H/Y5_
MQULI8E1;Y8?)<BRWL+&1C_L3_7W[KW5L'OW7NO>_=>ZUX?YAGP5^+7>/\UW^
M7@W9_6U?N-/D1M'YA1=S4U/V5VOMO'[[3I+J'J^7JW^)8S:F^<'C:5MH25\S
M0-2Q0&5I&,QD//OW7NMA/'T-+BZ"BQE#%X*''4E-0T<&N27PTM)"E/3Q>29Y
M)I/'#&!J=F8VN23S[]U[J7[]U[JIS^=I_P!N^-X?^+#_``6_^#E^.GOW7NK8
M_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW42O\`^`-;_P!0E3_UI?W[KW6F5[]U[K:'^"7_`&2IU7_K;W_]^-N_
MW[KW1N??NO=>]^Z]U[W[KW7O?NO=4#?SK/C3N+Y5]I_R^^G]]5'R8@^'V_>P
M>Z>N^Z*[XVU^X:;^Z7>O86R]M[<^)'8W<D.U9:/,+U)LW>,^;-15/4P8ZFRM
M70K6ZH)FM[KW53'\COHK9'7O\P3I_%=>?%SY4;#[EZ&^+7?73_\`,2W1W_E>
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M,WDO)3&@DEBIJ6IEB2J#>_=>ZKWS'\Z7Y`=+?\)\?C3\_-W4^TNV/FA\F/X?
MU1UI05^(I-J;8W)W/OCL3?\`MW;^1EV[MR@I<,:;:NT]JS9%Z`28ZGKS0&-J
MB(RW/NO=9_A=\[/YK'Q=_F/=)_R^OYNNZ.A.UXOF?T]FNP_CUVSTWA8]J_W.
MW[L:GS==N/JO,4&(V-M6#/9&HQV/!JS-1I!2324STV0J$>>%/=>ZVEO?NO=(
M+M7_`)E?V1_X86\/_>>R/OW7NE!M?_CV=N_]J+$?^Z^G]^Z]T^^_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NL%5_
MP&J/^6$O_6MO?NO=55?R-O\`MTK\%?\`Q"M)_P"]'N'W[KW5KGOW7NO>_=>Z
MJ9_E-?\`%N_F,?\`C6;YP_\`O5;9]^Z]U;-[]U[KWOW7NJG=L?\`;\CN?_QE
M?\=?_@K_`)*^_=>ZMB]^Z]U[W[KW53/RS_[>M_RA_P#PU?YB_P#[YWJ/W[KW
M5LWOW7NO>_=>ZUO?^%$?\QWXG?&GXXX_X^=K;HKLEV'OWL_H7?,>T=G5%'/G
M\)B.H>[.ONY(:W,121U7VL6:FV)'2B+QF84T[SV`$0E]U[JZCXC_`"XZ3^;'
M2>U.]^B-UT.YMH[FH:::HIX:FGERFW<G)`DU1A,W3PR.::MIB_I;_-S1V="5
M/OW7NC->_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[J)7_`/`&M_ZA*G_K2_OW7NM,KW[KW6T/\$O^R5.J_P#6WO\`^_&W
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M'2GR!W)M+YO_`!Y_X2X]X;^ZP[`K&W_U6F5^>&SMC=/;LVZV4JJK`[@_V6K=
M&4BV=B<#ELI%_&X<6U!/AVK9154XGB:.9_=>ZWS]E9C-[BV;M+<&YMKU6R-Q
MYW;.!S&X-EUN0HLO6[0S>3Q5)6Y7:]7EL;_N.R=5@*^>2DDJ(/V9GB+IZ6'O
MW7NE-[]U[KWOW7NM+_\`G`?&O^:;5?)#^8)\U,E\<?CKW=\:=B?!#O/H?XY[
MKW;WC4;+W#\=^E-V=-;DJ>_NT=O=<4DT]+NCM[<*YC*0B:M59YJ2BI:6$K'H
M'OW7NJT:CJCYV=^_\)EOB5NF'X];6RO6GPJ[ZZG^2G5D?6^\Z[=O9'<G1&S,
MWW[0]M[ASVTZ?$U)V?FMD[BW-3RM`AJ`V'@JJHK>$1O[KW5CO5?RZZ__`)Y7
M\]#^7E\B/AUM7LT]$?`#I3L_>7>W9V[]F5F(P>)WSVABMR8/"=7G[R6B2+)3
M3"!J6K26H:N5YVCI1%23RCW7NMU'W[KW0#=Q[2W)5['[+R5-VAO+%T#[+W5.
MNWZ/%==2XN*&/;U;Y*-*C([&KLV8)]!U%JQI1J.EUXM[KW0N[8(.VMO$"P.#
MQ)`%[`?84_`N2>/?NO=/GOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[JES^?'L2HR/P&WUVYM_M#OGJO?O36>ZVJ-FYWH[O?M;I2:4]C=T
M]4[`W+#NF+K3=6VZ?>-*VVLM41TD632JCH99FF@$<K%O?NO=6?="=';5^.O6
MF)ZKV9N+M'=6`PU9EZZFS/<?;'87=F_)Y<UD:C*54>2[![1W#NC>.3I:>>I9
M*:&>LDCI8`L402-54>Z]T,OOW7NL%5_P&J/^6$O_`%K;W[KW557\C;_MTK\%
M?_$*TG_O1[A]^Z]U:Y[]U[KWOW7NJF?Y37_%N_F,?^-9OG#_`.]5MGW[KW5L
MWOW7NO>_=>ZJ=VQ_V_([G_\`&5_QU_\`@K_DK[]U[JV+W[KW3;F<SB=NXC*9
M_/9&BP^$PF/K,MF,MD:B*DQ^,QF.IY*NNKZVJF9(:>DI*:)I)'8A5523Q[]U
M[K1.^?\`_P`*9?CQM'^:3\:\SUWUY2]D];?$ZO[2VCD^R)JFNHZR4=Q8K";5
M[!J\+3JRQI3'&8"F%.98GD@\?DD4F1H(_=>ZV&D_G4=:=G4F-@^(_P`=OD#\
MGL]F,=15M,NV=IRX;;-(^0I(JJ&.MW`(\V[>%)U9FCIC"ZW*RZ;-[]U[KB*S
M^<_\C=/VV/Z.^$NS:]#>2MD3L'L>&DDX-T4;AI8,@$LR`1X]E:X9E]^Z]UKL
M_P`[[_A.KN3/]98'Y3Q?)P;Y[<CWYM/:_:N[NR:>#;5!E:CMC?N"V;M^>B$N
M8K8IYZ[>VZJ:EC5Y8YA+51*"8;B'W7NK5/Y#G0G3_P#+FW3V1\%M_;0R^P/E
M/2**Z@W+N+<=3D\/V[LF:.GR\K[-]<6%%0E?#)7,M/&QJ("0A7[>6,>Z]UL^
M^_=>Z+I\I*3Y)5'5&0J/BQV#T_UKV7B:Y,S4Y_N[K#=G;6S*C:N-QF5GR^(B
MVQLWLOJK+P9JMJA2F"L.2DB@CCD5J>4NI3W7NBT_RH^Z_E%\F?A5TW\E_E/N
MCI;.[H^06R=G=M[0P_2?6V[^N<-L?9^\=J8?)P[0W`F\.RNR:K=.X<;E9:DO
MDJ>3'4\L+(@I5*%W]U[JR'W[KW3-N'<>WMHX7(;DW7GL-MC;N)A%3E<]N'*4
M.%PN,IS(D0J,AE,E/34-%"99%77)(JZF`O<CW[KW2*V9W;TQV-E)L'U[VYUC
MOS-T]"^4GP^S-_;5W1E(,9'+!!)D9L?A,M75<=#'/51(TS((P\B@F["_NO="
M=[]U[KWOW7NO>_=>Z][]U[KWOW7NHE?_`,`:W_J$J?\`K2_OW7NM,KW[KW6T
M/\$O^R5.J_\`6WO_`._&W?[]U[HW/OW7NO>_=>Z][]U[KWOW7NM.WX]?/SHO
M^7W_`#+/YQN[/DWTG\L-Q]C=S?*[;]-U[V5U]\:>TNVX<GTQL'8&.PNW]N4&
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MEFJG$$'E,5/%IBB5(T1%]U[K?.Z9KZ'*]/\`5&4Q>^<AV?C,EUKL6OQW9>6I
M!097L.AK-KXNHI-\Y.A6DH%HLANVGD6OFB$$`CDJ"OC2VD>Z]T)7OW7NO>_=
M>ZPU--3UE//25<$-5254,E/4TU3$D]/403(8Y8)X95:.6&6-BK*P*L#8CW[K
MW6&BQV/QM%%C<=045!CH(VB@H**E@I:*&)V9GCBI8$C@CC9G)("@$D_U]^Z]
MU$Q&WL!MZ*:'`8/#X.&HD66HBQ&-HL;%/*JZ%DFCHH85ED5>`6!('OW7NG?W
M[KW2"[5_YE?V1_X86\/_`'GLC[]U[I0;7_X]G;O_`&HL1_[KZ?W[KW3[[]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJ9_GD?]NO?DC_VM
MOCW_`/!.],>_=>ZMF]^Z]U[W[KW6MY_/]_G=8C^6;U+6]8=88S)YCY(=B8AZ
M+!5\V*R-/@-E4>7HI6@RR96:E2@KLQ)3:GB,3R)2A2QO-IC'NO=$N_X3[_SY
M/B]N?X>[;Z`[UCH^@<K\>L52[5P^3I\1N;+[/S>)JJJKKZ:CAEQ=!FJZ#*QR
M54CK=2CP_KT.H\ONO=7Y?\.\?RY/^\H-K_\`H)]E?_85[]U[H(._/YY?\NWI
M/I[?O:5%W?CM^UFSL#4Y2CVGA-O[TQ]=FJT:8J.B6OSFV,=CJ.*:JD0.[2%P
MI.A)'THWNO=4#_R)O^%#O0/9O=WR"Z,[EVO@^C)._P#Y!=G?(3:NZONZE<)6
M[N[+R%/7;DCW#-63U"XZ&ODHHBC:M%&W#EHV,D7NO=;O`((!!N"`01]"#R"/
M]?W[KW7?OW7NJG=L?]OR.Y__`!E?\=?_`(*_Y*^_=>ZMB]^Z]T5?Y@_*GJOX
MC].9KL7L]XLF:U)\'M'8<'@GS78FY:N!EI=M8N@E63SP3:P:R9D>*FIR6<$E
M4?W7NM,3=?\`(GZT^2'SL^%W8WR=P6*Z*W+\T]P=^]GU'1'7FVIJ+$T.S>G,
M-MO?1PVY%FD>DP^9K,5NB".GA9=4<=EJA(RF%?=>ZWH.JNJ.O.DMA[<ZRZLV
MIA]F;)VIC:;%87!86DBI::"FIHQ&))FC425=9.07FGD+2RR,69B3[]U[H0_?
MNO=5.?SM/^W?&\/_`!8?X*__``<OQT]^Z]T+WS\^%$'RIV7A=V=?Y7^X?R6Z
M@J?[S=)]ET$QQU?1Y>AE%>FV,ID8=,O\"RU5"NEFU"DJ2)0-)E23W7NFW^7]
M\UY_DMMG<'6?;6*_N%\J>EIVVWW'U]70C'55758^44']\\)0.06Q&5G0>=(]
M24M0]@?#)`S^Z]T>[?/_`!Y.\/\`PUMP?^ZFK]^Z]U7;_)8_[=*_RZ__`!4;
MI7_WC<;[]U[JSOW[KW21WYL#8?:>T,[U]V=LG:/8VPMT48Q^YMD;\VWAMW[0
MW%CQ-%4BASNVMP460PV7HQ40))XJB&1-:*UK@'W[KW5,'\D[XV_'7K?:GRX[
M"ZZZ"Z5V!OVC_F%_S!NK:/>^RNK-C;6W?2=8[=^3>YJ3;_7--N7!X*AS4&P\
M%28.BBH\0LXQ]+'1P+'$HBC"^Z]U>;[]U[KWOW7NO>_=>Z][]U[KWOW7NHE?
M_P``:W_J$J?^M+^_=>ZTRO?NO=;0_P`$O^R5.J_];>__`+\;=_OW7NC<^_=>
MZ][]U[KWOW7NO>_=>ZI#^$WR/^5_RM_F@_S%CF.T-O;7^'?PLW5C?BGLGX\T
M.UL?7[@W7V?7X#:6\MQ=T[BW\M/09"!D:BFIZ"A+5<45-720B.%XI*FL]U[K
MATO\B/EET1_-SWK\#OD7W!MSY"=2?)KIKL;Y;_&#-XSKZBV'O#H#%;4[&;`Y
MWI/=512Y6KAWIM>+&92-\9DG::N$M/H9((&")[KW1W_G+MCY[[FV5LJ+^7_N
M3XE[8[#H]TUDF]:WY;[4[$W5M6;9E5@:^B--M2#KB2/)T>X)LC/&LSS_`+#T
M32)]38^Z]U0?0=W_`,VO*;N[3V'C?G/_`,)Q<AO#H['T.5[DP%'@NYZFNZNQ
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MW7NO>_=>Z][]U[KWOW7NJF?YY'_;KWY(_P#:V^/?_P`$[TQ[]U[JV;W[KW4#
M*93&X3&U^9S.0HL3B,51U.1R>3R-3#18_'T%'"]15UM;5U#QP4M+301L\DCL
M%1022`/?NO=:R'RVZJ7^?CNW</4>S]J;<P?P^Z7CW+C*CO\`W/MQJG/;]W]-
MCW2CH=BU>F+(TF%IJY89T\+!H8@*N8>1J>F/NO=#Y_(B^"OPTVQ_+1^.F^=N
M?'_8N4K^X]I+O_<E9V+MS;N_<P<G-DLGC5BBKLWBJE*>%(:(,WB56ED=FD9K
M*%]U[JXC_95OC!_WCAT+_P"B?Z]_^QWW[KW03=Y_R\OAQW_U3O3J+>/Q[ZFQ
MV`WKAJG$UF1VKUYL_;F?QS3(1#78W*XK#4M3%/32V;0S-%*!ID5E)'OW7NM4
MC^7'_(4VMUBWRC[Q^(G;,51\B/CA\Q>T^F=A'L79^-GV[55?1^6HXLGMXSY=
M,DE'C\K65\7VU0T4L<FBU0S#2\/NO=;(_P`/?YC.,[;W7-\=/DGM67X^?+;;
M3+C<ML'<8;'8/?53$G&5Z_KZR1HZDUZ+Y4H?+*[H==-+41W9?=>ZM#]^Z]U4
M[MC_`+?D=S_^,K_CK_\`!7_)7W[KW1Z_DA\C>L?BQU/N+M_M;,IC-OX.$QT-
M!"T;YC<V<F1SC=M[?HW=6KLMDI4LJCTQH&DD*QHS#W7NJO?B1\<NS_F)VYCO
MY@'S2PST=-"%J?BY\?\`(B27"]>;6:;[K$[OSF+J41)<Q5@)44PFC$T\UJN4
M*!31I[KW0I_+/_MZW_*'_P##5_F+_P#OG>H_?NO=6S>_=>Z][]U[JIS^=I_V
M[XWA_P"+#_!;_P"#E^.GOW7NK8_?NO=5,?S`?B)O^JW/@/F[\1C_``'Y5=.P
M"KR>(H(@M+W3L>ABMDMIYNBC*1Y?+IC%>&!']593$T^KR+3%/=>Z,5\:_ESL
M+YD_&C/]C[2'\(W'C]MY[`]D;"JY#_&]A[SIL+5C(8:O@D"5!HYY$:2BJ&11
M40?TD21$]U[H(?Y+'_;I7^77_P"*C=*_^\;C??NO=6=^_=>Z][]U[JIO^4%_
MS*7Y@_\`C4;^8_\`_!1[Z]^Z]U;)[]U[KWOW7NO>_=>Z][]U[KWOW7NHE?\`
M\`:W_J$J?^M+^_=>ZTRO?NO=;0_P2_[)4ZK_`-;>_P#[\;=_OW7NC<^_=>Z]
M[]U[KWOW7NO>_=>ZUBOG1TGTCTM\T/E)\C_B/_-KI?Y</RVROQ]Q'?/S/ZMH
M.JMD_)G8VX^HNG:!<..ZM^]`UM%-FL=NVBV]NB!H)J1S75JL];%23&6KF?W7
MNL7\CB;X7_(/Y&?(/Y7XC^99E/YI/SQI>N]M["WYVEN#I//?'C!]2],9O=FX
M<S@=J]0=0[AVO@H<)M_)Y>C*Y*JH*BN2*6-(_P#)4J]%1[KW6QQVYM?<^^.J
M>SME[)W;4[`WGN_KW>FU]H[[HH#4UFRMS[@VWDL3@=VTE,)J<U%3MO*U<59&
MGD36T(&I;W'NO=?/TV[\(_G+MWKW>7P0VI_)Z[6VEVCV+_+MP/P1[`[GH4ZJ
MI?CANSO2B^2$W<>4^86Z>^UR'\,W312;.>++4[3F;<4&;A3$PI')%$Z^Z]U]
M`SJ79V5Z\ZJZSV!G=R5>\\YL;K[9FSLSO"O^Y^^W7E=L[<QN%R.Y*W[VLR%9
M]WG:NB>JD\M1/+KE.J1VNQ]U[H0??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M2"[5_P"97]D?^&%O#_WGLC[]U[I0;7_X]G;O_:BQ'_NOI_?NO=/OOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[K"]1!&VF2:%&M?2\B*UC]#9F!L??NO=9@00"#
M<'D$<@@_0@^_=>Z][]U[JIG^>1_VZ]^2/_:V^/?_`,$[TQ[]U[JUNOKZ'%4-
M9D\G64N.QN.I:BNR&0KJB*DHJ&BI(GGJJRKJIWC@IJ6F@C9Y)'8*BJ22`/?N
MO=4)]E=A=D_S;NULQ\?^B<SF-C_!?KK-4]/W;W501ST=;W'E:&=)CLS9\TJ(
MLV(=XPT:$%&2U74@I]M`_NO=78]<=7;#Z8ZYP?6?6>V\?M39>T\/_#<+AL;$
M(XHHHXF,E142<RUF0K9BTM142EI9YG9W8L2??NO=5T_R-O\`MTK\%?\`Q"M)
M_P"]'N'W[KW5KGOW7NO>_=>ZJ9_E-?\`%N_F,?\`C6;YP_\`O5;9]^Z]T9OY
M@_!SICYE;5IL?OJAGV[O[;RM/L#MK;"QT>^-EY%'\],]-7QF&3)8E*M5DDHI
MG\9:[1M%+:0>Z]U7YU?\S._?@AOC!_'/^8M'4;AZ]R=4N'ZD^8.(I:RMP.;I
M498J3'=BR)&]1%700E?-42**ZG_5.M1%_E0]U[H.L-\Y?BC0_P`V[Y8]UGN[
M8=9L3JW^7GTUU5G*O'9_'5V0R^]]J]W]N]CY+#[4QL%0:C<,DN$[`H(J<P`K
M450E5"4C,GOW7NEK\>^G>QOYE?<F%^:7RGV_5[>^.FS*Z6?XL_'K+:GH<O3Q
M5"M3]B[SH)%$&22M>!)09$TU\JJJ@442+/[KW5[JJJ*JJH55`554`*J@6"J!
M8``#@>_=>ZU[/YA'SJ^&_1W\V?\`EM8[N'Y+].];5_2&T/FG/V[2;OWIBL-/
MUS%VUT[U7_HS?=RU4RC"+OD4LO\`##.4^[\;>.]O?NO=;!5#74>3HJ/)8^IA
MK*#(4M/74-73N)(*JCJXDGIJF"1;K)#/#(K*PX*D'W[KW4KW[KW5+?\`/8[;
MZHV;\',[LW>/:'7.T=WYSO#X5[@PFUMU;YVOMW<>9P."^;GQ^K<YFL5A,SE:
M+)9'$X6AH)YZRHAB>&F@@EDD94C=E]U[JWG9.^]C]E;;Q^\NN=Y;4W_L_+&J
M7%;KV3N'$;JVWDC0U<]!6C'YW!5E?BZPT=?3202^.5O'-&R-9E('NO=*OW[K
MW6DK_/R^;&SOY4O?.Z=]?%#-;MVCWA\@^O,YMGMG85%MFII.LLID]Q4:28_=
MT>4K*>''+FGHZB6JG>B$CPU::X94GEJ53W7NC-?\)WOYW/Q[[O\`BEUY\:^U
M*?!=!;JZ&V[B.MML5E>U3B^N,U@<#C#_``O&P;BR+-CL9E:+'0`(*B=$J(]*
M^F>RR>Z]UM+[9[/ZUWJ%.SNPMC[L#BZ_W:W9@<YJ%K\#&5]4?I[]U[IQWIO7
M:?7.T\_OK?.X,9M;:&UL94YG<&X,Q5)28W%XVD37-4U,[FP'T5%4%Y'8(@9F
M`/NO=4C_`,CKY6_&CNG9_P`L]E=.]O8+?6Y:KYP_+KN^;"Q1_P`-RE/M'NKN
MC<._MOO%13U$TE;_``NAS<=/6/&2(IQR`CHS>Z]U?![]U[KWOW7NJ9.@_E!_
M,RW1_,'WI\1>Z=D?!+'[`ZFZKZY[Q[%W9U=N?Y!5N\Z[K_N3.=S[0V!BMET>
M[-MT6"EWCC-R=1M)F5KC#1+0U:FFEEEU(GNO=7-^_=>Z][]U[J)7_P#`&M_Z
MA*G_`*TO[]U[K3*]^Z]UM#_!+_LE3JO_`%M[_P#OQMW^_=>Z-S[]U[KWOW7N
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M:CXQ_P`H'^69BJ'$PUT'?>'[:F_FL]DUE++C6R5)541R><W5U]V7F8XYO((4
MH\)CHW!_A\>J?W7NOH?='MV,W2O4#=PJ%[;;J[K]NTE48U57L8[3Q)WNH&&)
MPX`W-]UQ2?Y-_P`<O1I]^Z]T*/OW7NO>_=>ZH4_F/_SOJGX<?)S;7PG^,GPN
M[E^?ORNKNN!W%O/K/J/*'"T?7O6['(+'D,YD\9M3L#.R9V1*:GJ/M1B8Z9:2
MNIF:J$T\,$GNO=<]F_\`"A'X?;L_E?=G_P`SFHVEVEMO;'4&\*[J'>W2&9P@
M7LB@[\0X.+"]615T"R8&5,]+NG&2KERZTM)1U3/4I%/#+3+[KW37_+K_`)XN
M=^6WRA7X9_*CX.]P_`7Y#;OZIC[NZ2VKV/G*S>6-[;ZVIVRJ9G+T>3DV#L*I
MV_/2+B)Y:7S4T]+714]0JSQS1+#-[KW5_GOW7ND%VK_S*_LC_P`,+>'_`+SV
M1]^Z]TH-K_\`'L[=_P"U%B/_`'7T_OW7NGWW[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]UKW_SB/@Q\0^VN]?Y=O9O97Q^Z\WEO_N+^8)TGTAV?NO,XVIDR^]^I
M/]"7R$RHZ_W!/!60+7[:_B>WJ"H^W9=)EI(B?T\^Z]U?[A,+BMMX;$;=P5#3
MXO"8'%T&%PV,I$\=+CL5BZ2*AQ]#3)<Z*>DI($C07-E4>_=>Z<_?NO=4!?\`
M"AKYG_%_H/X0[OZ7[J[#?`[M[FS76!V]@,#%397<D5!LSMC96_ZK+U.,9]<.
M.J4V@],C%2[M(S*I2*1D]U[I-9?Y$[\_G09O"=1?%O(;AZ\^$L.*VYN#OSN=
MTAI<UO=,O2192'KG;C05$\$L,B?MF)'9)W5JBH_R=(XIO=>ZO8ZAZBZ]Z)Z[
MVQU7U=MRCVMLK:6/CH,5C*-;LY'JJ<AD*EAYLAE<C.6FJ:B4M)-*Q8GW[KW0
MAU7_``&J/^6$O_6MO?NO=55?R-O^W2OP5_\`$*TG_O1[A]^Z]U:Y[]U[KWOW
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MPM=,U16X?%U=0P4-/58^DJ)F"`*H:66%W(518<\#W[KW3F`%`50`````+``<
M``#@`#W[KW7?OW7N@0[3^,OQN[SRN*SG=OQ\Z0[BS>"H)\5@\QVGU1L/L'*X
M;%U,SU%3C<5D-VX#+U>.H*BHD9WAA=(W=BQ!)O[]U[I>=?\`7'7G4VT\9L+J
MO8>S.L]C84UC8;9G7^U\'LS:>);(UM1DL@<9MW;E#C</0&NR-7+43>*%/+/*
M[M=F)/NO=+/W[KW5:_\`-$_ET=!?S%_C5O+K;N';U"V>PFW\UE]@[XC@5<UM
M;,T=%-6P(E;'&U4<35U$"^:-;M&;2QVD7GW7NB(?RAOY:/P#W/\`RR?B1NN?
MXV;3RC=M].[0[5RE3NAJC);CI\IOG#TN7J:5<[134%4D=,)E2Z$%V!=RS,3[
M]U[HV&YOY)_P'S<DDV!V/OKKJ>1B_EV%V7NF@,<A.K7%%G*K<$$5C]`J!1_3
MW[KW1$OG'_(8W+VK\8NU>L?C_P#,#Y&T65S6"D?`[!WWON7+[0RM90M]U!C6
MDC%!'15-6$\*2O&4]6DM'J\J>Z]UJV_R?/Y4?S_^)78^Y_F)D>O^ZIML]*]F
MY3K[=.R^D]V4NW-WYU-I5\M/O"H2*6FRF0KCCQ!)2RPPT%2:422QU`!8JGNO
M=?0&^+?\POXR_+)$Q6P]Y?W<[&@#1Y;J7?T<>U^P<;60V6JIX,55S&#.)3RZ
M@7H):C2%NZH>![KW1X/?NO=5-]3_`/;Z_P":?_C/7X*?^_N^:/OW7NK9/?NO
M=>]^Z]U$K_\`@#6_]0E3_P!:7]^Z]UIE>_=>ZVA_@E_V2IU7_K;W_P#?C;O]
M^Z]T;GW[KW7O?NO=>]^Z]U[W[KW1+\OW=\(?DA6U_3^^JWJGM"?'_(O=_P`9
MUZ_[6V-39>BRGR(ZPZ_/:VZMD;=PF_MNOCMQYS;77IERYJZ%*BF^UAF:.9C%
M*%]U[HU^U-H[4V'M[%;1V/MC;VS-J8*E2APFV-J87&[=V]AZ*._CH\5A<134
M>-Q]*E^(X8D0?@>_=>Z0/R$W[N?JKH/O#M#9.W!O#>?6_4'9>_=H[2-+D:X;
MIW/L_9>:W#@-N&BQ!&6K!F\KCHJ;Q4O^42>73'ZROOW7NM'O<_S5_FM8[KC-
M]M[V_GM]'=;X;L7X#TWSTZ`CQ/Q.^-E/UCW!EJ.MW%BNZ/B[LKL?/4:Y.E[5
MZ<W/!B,'20)'G,Y62Y$/54E(]*PE]U[K=]^..XO[X?'GH;=O\0W7EO[T=,=7
M;B_BN_'Q\F^,G_&]D8/)_P`0WF^)5,4^ZZW[GR9$TP%.:QI/&`EO?NO=#-[]
MU[KWOW7NJ&/GE\HOA'V)\H=[?R\]X?)'L+^7E\P\STIMK>>'^:&!QO7G3^8R
MO4=+N;#;IK.K.N_D5ON59,G2YNK69JW$1A*;R4-84?[FG8>_=>ZTX.XNU\37
M_P`HO=?3&QMH;*W#T'_+<_G;=48+(?+7J;;V83"_)3KRNQ'<N/E^0?:$HK]T
M1[BW_F:M<(U?D*;(UB5:9[%PPTU/$M,)?=>ZV%/EEW)U)\O/^%&?\EEOB]V7
ML/NJ#J3IOOWM#LO(]<[JP6>Q>U=C[CVQN>DP\V6S&/KI,?\`Q1YZ*3R8D2MD
MJ97C:6G19HR_NO=;>7OW7N@#[DJ^TDV3V7%B]O[`J-NC9FZEBK<AO'<='F6H
MSMZM^XEDQ=-L6NHDJ4N^B,5;*UA=UN;>Z]T,&V+?W:V]:Y'\#Q-B18V^PI[7
M`)`-O?NO=/GOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JIW^:+_P`?W_*C_P#&
MK'2G_O@_DY[]U[JV+W[KW3%N;<^W=E[?S&Z]VYO&;;VSM^@J,KF\[F:R#'XO
M%XZD0R5%96UE2\<,$,:#DD\FP%R0/?NO=?.X_G8_!M_YGV]^XOFQ\3L9OW'=
M7=89K;NWMP=F=L[NGINN]YY[<VYZ#:]7)LRCW)4+68F@;)Y2B2DIJ<RFG5T2
M2.GCFAAA]U[K:<_D=_RC:/\`E<_'J@Q6Z-Y;EW3W%O3$QS;WHWW)E)MF;:-=
M+2Y*;"XK;R5AP<V1IJN`"2L\3M%ZHH'T-+)/[KW5Y'OW7NL%5_P&J/\`EA+_
M`-:V]^Z]U55_(V_[=*_!7_Q"M)_[T>X??NO=6N>_=>Z][]U[JIG^4U_Q;OYC
M'_C6;YP_^]5MGW[KW5LWOW7NO>_=>ZJ;VHB0_P`\;NU842):G^5Q\=JVI6)5
MC6IK/]FF^1E%]Y4!`HGJ_LJ.&'RO=_##&E]**![KW5LGOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z2V^?^/)WA_X:VX/_`'4U?OW7NJ[?Y+'_
M`&Z5_EU_^*C=*_\`O&XWW[KW5G?OW7NO>_=>ZJ=_E".[]2_,`N[N1_-%_F/`
M%V9B%'RCWU906)LH_`^@]^Z]T.7RD_ER_&;Y5O)N#=&U9=C]I0%:C$]P=;RI
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MNHE?_P``:W_J$J?^M+^_=>ZTRO?NO=;0_P`$O^R5.J_];>__`+\;=_OW7NC<
M^_=>Z][]U[KWOW7NO>_=>ZU%/YYWP7_E[]/]N]+?++>6\OFQM?N;O?Y#U\>`
M^+?PHWKN*+>?RA[LS74>Z-F/F.M]O0[AQF/ZAW_725F%&X]XT<-5]Y00KC9:
M4SY0U'OW7NE9_)9I?B1C_FKV!UTM+_-<^/7S/ZRZKK=P5/QH_F&=_9[?>W=U
M]4;QDP<![!V5B7KZO;VZ*K&5,L,;.NF:A,CE!)HG,'NO=;0':^]Y.L^K>RNQ
MXMKYS>\O7^P-X[WCV7MBF-9N3=\FU-NY'/)M?;U($E-5G,^U`*2DC"MKJ)46
MQO;W[KW6F'O/(?-7?OP%ZM_FA]@?$?\`DY[T^$76>)J?EEU-\#JWI#=-9V%L
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M]3F=S[DR-/2Q--F*^JJ,M)/#',:GRQHZ^Z]T%/PH_E4_`'^7;E-YY_X>_'+;
M74>X^P**@Q>Z]SC<&]][[GK\/CIFJ:;"4NX>Q-S[MS&'PCU;"::CHIJ>GJ9X
MXY)DD>*(I[KW5A7OW7ND%VK_`,RO[(_\,+>'_O/9'W[KW2@VO_Q[.W?^U%B/
M_=?3^_=>Z???NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]UTS*BL[LJHJEF9B%55479F8V`4`<GW[KW3729W"5\PIZ',8JMJ&5G$%)D*
M2IF*IRS"*&9W*J/J;6'OW7NG7W[KW7O?NO=>]^Z]U[W[KW7O?NO=5._S1?\`
MC^_Y4?\`XU8Z4_\`?!_)SW[KW5BO</<?6_0G7VX.T>V-U8[:&R]MTQGK\ID)
M+/-,P;[7&8RD354Y3+Y"1=%/2P*\TS\*+`D>Z]U23A]K=]?SA-V46[NQ8-S]
M%_R]=NYE:W:>PHYI,7O;Y`3X^H80YC-31']O".R$"4:Z6E!*4HFGUU2>Z]T.
M/\Y'8FS>MOY1_>FP]A;:Q&T]G;:F^.N+P6W<+1QT>,QU%3_)SI@)%#`@]3LU
MWDD<M)+(2[LSL2?=>ZN2]^Z]U[W[KW6"J_X#5'_+"7_K6WOW7NJJOY&W_;I7
MX*_^(5I/_>CW#[]U[JUSW[KW3!NO<N,V9M;<F\,TN3?#;4P&8W+EDPN&R^X\
MPV,P6.J<I7KB=O;?HLEGL]DVI:5Q!145-45=5+IBAC>1E4^Z]U1=_)M^3VP=
MW;T^:?5L6S?D/M/=?:_SF^6_R>V(_9_Q9^1W4VV<WTWO;=&TY-K[@_OMV3U?
MM;9]!E\O%,'CPM370YH*KEJ4!'(]U[J_#W[KW7O?NO=5.[8_[?D=S_\`C*_X
MZ_\`P5_R5]^Z]U;%[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MDMOG_CR=X?\`AK;@_P#=35^_=>ZKM_DL?]NE?Y=?_BHW2O\`[QN-]^Z]U9W[
M]U[KWOW7NJF_Y07_`#*7Y@_^-1OYC_\`\%'OKW[KW5LGOW7N@:[^^/\`U-\G
M.K-T]-]U;/Q>]-B;MQ]115^-R5-#-+22S02P193$U$L<CX[+48F8Q3)R`2K!
MD9T;W7NM-;^7[_PG.^*O2_\`-S^0FRNR\I6]E[=Z#V'U;W_UAL?(8^$;>K=I
M]Q;D[!P.TURLWGDD$^,S'6N4AJZ9EU!846)O#+K;W7NMX/'X^@Q-!18O%45)
MC,9C:2FH,=CL?30T=!CZ"CA2GI**BHZ9(Z>EI*6GC5(XXU5$10J@``>_=>ZE
M^_=>ZB5__`&M_P"H2I_ZTO[]U[K3*]^Z]UM#_!+_`+)4ZK_UM[_^_&W?[]U[
MHW/OW7NO>_=>Z][]U[KWOW7NJ?\`^:E\$OD5\E]S?#_Y2?"_LCKOKWY@_!'L
MC?V_>IZ7N/'97)]3]A[8[0V2-G]E=:[N&%IZW)88[OQV-HJ:+)PP2344#5'B
M,,LD=3#[KW00_#/X1?S`-Y_/S(?S(/YEV[OCIB.P=D=$9+XY_'SH7XL?WOR.
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M^R/_``PMX?\`O/9'W[KW2@VO_P`>SMW_`+46(_\`=?3^_=>Z???NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TW9?$XS/XG*8+-T%+E,
M-FL=6XG+XRNA2HHLCC,E32T=?05<$@*3TM72S/'(C`AD8@_7W[KW5`7\M_X/
M_$#HW^:/_-(R?3OQNZ?ZUR/3&7^)>W.J*[9VRL3A*CKW`]G?%[$Y[L+$;3>D
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M```>_=>ZJC_GD?\`;KWY(_\`:V^/?_P3O3'OW7NK9O?NO=>]^Z]T!WR%ZM[!
M[AZYJ-F=9?(3L?XR;HFR^,R$?:/5>W^K]R[LIZ&A:8UF#BQG;VQ>Q-GFARZR
M*LTC8XU*!!XI(S>_NO=`1_+\^%-9\!^BL;\>Z/Y$]M=_["VG]I0]:Q]M8;JS
M&9#KG;%+#)?:N%J^L]A;'DR^-GKYY*II\L:^M$CE5F$85![KW1Z/?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U4[MC_`+?D=S_^,K_CK_\`!7_)7W[KW5L7OW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z+[\E^G-_]Z=:2["ZY^179GQB
MS=3F*2LK>QNJ-O=5[EW15X2.AR5%D=JO0=P;#[%VK%B\P:^.26:.@2NC>F3Q
M31J9`_NO=!3\!OAS7?!/X_[<^.4/R#[5^0&R-@TN(V_U?5=LX?J_%Y?KO8.W
M\!B\#A=@XB?K+8NQHLQA\>N.:=:K*K7Y-Y9W#U+($5?=>Z.Q[]U[H.>W,MVE
M@NM]VY?I39>TNQ.U*'&K-LO96^][U_6^T=PY7[JG1J+.;YQFT=^U^W*04;RR
M">+#U[%T5/'9BR^Z]U5[_*XZF^??0==W?L7Y0=&_'79777:7?'R7^3V/WMU-
M\D-W=H[EQ^\^_>X*CL6FZSJ-EY[H;KND?!;=QVX:R%LZ,L):B2CB_P`@3SMX
M?=>ZN(]^Z]U[W[KW53?4_P#V^O\`FG_XSU^"G_O[OFC[]U[JV3W[KW7O?NO=
M1*__`(`UO_4)4_\`6E_?NO=:97OW7NMH?X)?]DJ=5_ZV]_\`WXV[_?NO=&Y]
M^Z]U[W[KW7O?NO=>]^Z]U6'_`#&_YFVU_P"7Y7_'/8./Z%[D^4/?GRMWON;9
MG2/1?26/H)MT;G_N-B,?G-\YRHRF8EAQ6-QNV<?F*-Y0Y:0I.TI"4\%1-%[K
MW3)\/_Y@WR:^27<,76O:W\K;Y9_$C:DFVLYG'[=[CR_7=9LR'(XK[/[/;DD&
MW,K4Y0Y/-_<MX"J%!XFU6'/OW7NCY?(S8.4[6^/?>_5V#H\5D<UV3TUV?L'$
M8_.Y3)8/"5^4WCLC.;=Q]'F<UAX:C+X?%557D42HJJ6.2IIX6:2)6=5!]U[K
M5U^'6Z?YZ?Q`Z,V9\)-F;N_D5[\JOB#UWM_9F>I-U_)+N5>T=G[,I*BGQ^TJ
MOM';^V8<,FW'-+E:&BCJZG'T2UCO$QU2S7?W7NMLG94F[YMF[2F[!IL!1[]E
MVS@9-[T>U)ZZJVO2[ODQ5(VY:;;=3DU3)5&`@S)F6C>H43O3A#(`Q/OW7NE-
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z07:O_,K^R/_``PMX?\`O/9'W[KW
M2@VO_P`>SMW_`+46(_\`=?3^_=>Z???NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]T#G?.<[VVYUIF,K\;^O.NNT^V8*O$)@MF=J]E9KJ39>1HI\G30YR?([X
MV_U]VAE,;48_$/-/3QIAJ@5,Z+$S1*QD7W7NB2?RQOF-\IOG#U0G>_<_QQZ<
MZ*ZLW0FY:/K:HV!\@MR]P;OS.=V-V/N_K;=])NK`9?I/K+&[:QT&4V?--0U%
M/D,B]5#(NN*$W`]U[JS[W[KW7O?NO=5,?#3_`+><_P`Y7_P\?@A_\"1AO?NO
M=6S^_=>Z][]U[KWOW7NO>_=>ZC5E3245'55E?/!2T-)33U-;4U4B14M/201-
M+4SU,LI6.."*%&9V8A0H)/'OW7NM!3Y.?`#XG?/7^8=U/\H*/IS^Y7QH[4^<
MVROB909/9\\6(C[2W=E-D[XWSE-URX.JHI<?)@Y4Z^JZAC"8UIFKJ>/QRAY(
MX_=>ZWNNL^L]B=.[%VUUIUIMG%[0V1M'&4^(P&`Q%.E-1T5'3H%!(4:IZF=K
MO-,Y:2:1F=V+$GW[KW2Z]^Z]U4S_`#R/^W7OR1_[6WQ[_P#@G>F/?NO=6S>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJG=L?]OR.Y__
M`!E?\=?_`(*_Y*^_=>ZMB]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4T="_%G^9;M7^8)
MO/Y>=S]C_!?*[$[8ZMZ[Z/[&V=UAL+O[%[OI.O>G,WW+N[K_`"6RLENO?N5P
MM+O.OW+VW(F9DKHZFAEH:5%IH89=4C^Z]U<O[]U[KWOW7NHE?_P!K?\`J$J?
M^M+^_=>ZTRO?NO=;0_P2_P"R5.J_];>__OQMW^_=>Z-S[]U[KWOW7NO>_=>Z
M][]U[K7_`/Y]77?7D.T/BI\J.Q/YE%?_`"US\4.TM[;FZ[W]MWI?#=S;SW[V
M=OC8D^`QNV-H8"7(4FYLKD?[E4.>IIL'1T^0H<U29&45],Z4T3)[KW01_P`F
M'O3/_)CNG>.Y\-_/+W[\_<'UOM3(T6^/BWV1\+]B_%O>&#J-PR8U-M]C5E/+
M083L"3"XZ35%#+!324$TM4JRR*QC5O=>ZV&NW,%O;='5'9VVNM-S0[*[&W%U
M[O3!;`WE44J5U/M+>V6VWDL?M7<T]%)'-'60X'.U$%4T3(PD6(J00;>_=>Z^
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MI9]7_P`S?X(=Q_%'<_S;V!\E.O,K\:=C8FKRF_.Q*NMJL,-B34&/I<E5[>WA
MMS+TE%NC`;P6&N@2+$3T:Y&JGGBCIXI7EC#^Z]T''P/_`)PO\O?^9/N#>>S_
M`(C]\4V^]Y[#QU)FL_LS<&TMX]=[K;`U<QIOX]A<%OS![?K]Q8:BJRD-744*
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MJ=72]B-UDO=KYD?(,UXZL_O$C/\`=?9G(_:C7]EJ]'OW7NK:??NO=4]_S/>[
M=Z[NKNOOY??Q^K2>ZODS,E'O3)T3NQZ\Z=\DG]XLQE)*>\E"F9HZ6<.25;^'
MP3BUYHR?=>Z0/S(Z2V5\<]M_R:.F>OJ):3;.Q?YGG1>*IY3&D=5E:[_0%\G9
M\MG<D4XER>;R4LM3.US^Y(0/2`![KW5X7OW7NO>_=>ZJ9_GD?]NO?DC_`-K;
MX^?_``3O3'OW7NK9O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW53NV/^WY'<_P#XRO\`CK_\%?\`)7W[KW5L7OW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[J)7_P#`&M_ZA*G_`*TO[]U[K3*]^Z]UM#_!+_LE
M3JO_`%M[_P#OQMW^_=>Z-S[]U[KWOW7NO>_=>Z][]U[JAW^=!\6ODMV+V+_+
MU^9GQHZ1VY\L,W\!N[]^]C;R^)VZLWB,%2]J[2W[LNCPLVZ-J56XJA,%-VGU
MA7[?AK-LK-%+)#DJI:B-9#`:>?W7N@A^%?4/S*^5/\VC<'\S?OWX8G^7_P!:
M["^+M;\;MJ['W1NC:&Y.[OD)N+.9S"YRJW5VD^R:[[(8#8M/3R4N(DK(VD6*
M*".(R#R?:^Z]U?[VYA-F[FZH[.VYV-FWVSU[N#KS>F$WWN2/<C[-DV_LW*[;
MR5!N?-IN^*JHI-JOBL)//.,DLT+4)C\P="FH>Z]UI@[0^9WR9^/_`'?MSIO^
M27\P?DA_.9ZUI=R46&WGTIWSU/E.X^I^I((:EZ"BVPO\QG[KKNBV'ACM+[RI
MQJUAS=%&V"IO5.M5(DONO=;K>RJ_<^5V;M+*;WV_2[3WGDMLX&OW=M:@RT6?
MH=M;GK,525&?V_1YV"*"'-4N&RLDM-'5I&BU*1B0*`UO?NO=*;W[KW7O?NO=
M4A_/OI_^6'\->W]Z_P`W;Y;[0J-^=U577.,Z#V)M#<DI[-;?.8K(Z.FVCUOT
M5TMG8J_$OVANF7'/3Q34449B@K*^>=XH):N;W[KW6IM\Y/@[V9\//Y769W[W
M'L'"_'JL_FK?SB>D>S=^_$C!5&+&WNCOCW58SN'?'7?1.<JZ/$8;^%[DP-?4
M"JR:X]J5*&.EI*4+!)#5QO[KW5T_S-ZXZZ^.W_"CG^2?)\==D;/ZOE[$Z7[Z
MZ[[&I^O<!B,=#N#K7`[9W94;>HLUC:&F>ECIH*G(5`3)"*.LG'H>H=8D5/=>
MZVWO?NO=%_[D[$@Q^S.R\$=F]BUKQ[-W32?Q3&[.R-;A9#/MZL`GBR49$,E-
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M`'[KW7O?NO=5+_R-O^W87Q[_`/#J^37_`,%CWE[]U[JVCW[KW2?W7NO;6Q=M
M9S>.\<YC=M;6VUC:K,9[/9BJCHL;BL911--4U=74RE4CCC1?\2QLJ@D@'W7N
MM?+^5%\]_BO\I_YA?\T/<?5?:N"R&6[@WYT*-E[0K)&I,[D\3T3T['U;GLK3
M"94IZHY*KQHK8J>)GECIW8-=HI='NO=;%OOW7NO>_=>ZJ83_`+?JU/\`XR8H
MO_@PJ_W[KW1__D+WILGXV=.;[[H[`JUIMN[(PL^1:G$B)5YG)O:##X#&J_\`
MG<CFLG)%3Q``V9]1]*DCW7NJZ/Y7_1F]MP2=@_/KY!4C2=Z?*"=LGMN@K8WO
MU_U`TD3[:P6+BJ!Y:!,O1TU.ZK966@@I@>7D!]U[I]_FB_\`']_RH_\`QJQT
MI_[X/Y.>_=>ZMB]^Z]U[W[KW1*_FW\$>I/GUL'"]7]U[U[ZVYL3%Y&3)Y';G
M2_=6].HL;O.9:W"Y7&0[]IMI5E+#O"DV]F=OTM=C8JQ9%H:V/S1:7-_?NO=#
M=T'TKC?C[UGB.L,3V%W+VA0X>MR];'O'OOM/=7<O9=>V8R51DY*?+;]WG65V
M?R5%0/4&&CBED*4U,B1)95`]^Z]T,WOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>ZU_-E?.#X793^>1V7_#/EU\9,B=S?R_?C_TGMP4/>_5]6<_
MW+1?*_Y`FLZEPO@W0_\`%.RZ09VA,N"@\F43[V"\`\J:O=>ZV`_?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW42O\`^`-;_P!0E3_UI?W[KW6F5[]U
M[K:'^"7_`&2IU7_K;W_]^-N_W[KW1N??NO=>]^Z]U[W[KW7O?NO=:4W\WSY`
M?RP.K?FOT]\1_D?L+YS/CM\]X?)3O;O;?VTNROEAL.HZ^S'9?5_5\N!W#TOM
M_9F(R.*[YZ^WGE.LZ'')C<+4BAV@T5?,B1RU-9'[]U[H0_Y1^Z_Y=]1_,_VG
MM'^7EUI\VM\[57XT=H[F[%[[^0_9GRIAVQL',IG]O8F@V*W5_<&WX=KY>3<E
M+-%-399ZQ)8)M444;,&/OW7NMK?Y";HV/LCH/O#>G9VW(MX];;0Z@[+W1V%M
M&?'4&8@W3L?`;,S66W9MR;$95XL7E(LY@:2HI6IJEEIYQ+HD(1B??NO=:C.Q
M_F#_`#F^GOY=6"_FT[`@_EW;$^&.-P.-[<HOY>6P>KUVG!A/C?-+2[6I9<5V
MYA<G0-!V7#C8X*U<:'NM4!`83(G\&]^Z]UN&=8;_`,/VOUIUYVEMZ"NI<!V5
ML;:6_P#!TV3C@AR5/A]XX#'[BQD&0BIJBKIHJZ*BR*+*L<LB+("%=A8GW7NE
MS[]U[KWOW7NM>C^9[_(P['_F0?+'K+Y24G\QCN?XV5/1VV\7B.D-E]:]?4M6
MG5V>AGJZ[<&_-N;GI^Q=KU\&]=S9&J5ILBD$57'3TM+`LI2FBM[KW3MM#^1*
M^\/A[\F?AY\Z_GA\EOGUMKOK)[-W#LK?G<N0RPWK\?=U;'I<U_!MR=95F=WQ
MOWQ5KY;)Q5-3"[1T=9%3FGJ(989I`?=>Z=OY<W\BW`_"CY(5/R[[S^8??OSL
M^0^#ZPI^E^H=]=WUF3I(^H.LF;)-EMN;?Q]1O+>$^22N7)R0TZSU2T>.@FG$
M%,LL[RCW7NKZ_?NO=(+M7_F5_9'_`(86\/\`WGLC[]U[I0;7_P"/9V[_`-J+
M$?\`NOI_?NO=/OOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJ*_GO[8VSN'^4S\WZS/[<P&=J]O=
M(;BR>`J<UAL;E9\'DVJL;3')8>6OIJA\9D/MY6030%)0I(#>_=>ZM)V5M#:6
MR-OTF$V5M7;>SL+_`,#?X-M3!8K;F)6LJHXVJ:I<9AZ2BHDGG*C6P0%K"_T'
MOW7NE9[]U[KWOW7NJE_Y&W_;L+X]_P#AU?)K_P""Q[R]^Z]U;1[]U[K7\_GI
M9WK/Y`=.4_P6VMNSMK._)#M#(T<.V.NNBL[+!74<>0"Q?Q#LNGIRU(,='1EY
MZ&":T\<@%3^W`'D/NO=:A7\L+^1#\Y.N/D?\A]_X.L6F[)^&NZ,/AY^OMO=B
M3;'WCN*NS4+9S%`UF)JHZBGK\EMZF>KH$2KAC<A9H:EV,`?W7NM\WXB?S*NG
M_D#DTZAWYCLQT#\CL"8\-GNG.T)9Z'*UN5I(Q#4#;&:RL-$=P/*Z:A!,L.0(
M:_BD7]P^Z]U97[]U[JIA/^WZM3_XR8HO_@PJ_P!^Z]T`W=-34?S+_G+B?C9@
MYYJSXF_$7,TV[>^,I22,<3V#VA!)+#C=D+41$15=-13Q2494,UD6OD'TB/OW
M7NKVJ:FIZ.G@I*2"&EI:6&*FIJ:GC2&GIZ>!%BA@@AC"QQ0Q1J%55`"J`!Q[
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M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NHE?_P``
M:W_J$J?^M+^_=>ZTRO?NO=;0_P`$O^R5.J_];>__`+\;=_OW7NC<^_=>Z][]
MU[KWOW7NO>_=>ZUF_G9VYD:ON/'KB?YR/\I'H/O_`./7?G?>6V4_R&ZR^/F\
MNW^A>L^Q]G=:[;VSU?A9MZ]A4NZ=@[ZP\.(W$FX\M3K15&X<?F:2FGC6.C`D
M]U[H7_Y;G?/R0[%^2,&W^S_YU_\`+P^>>U6V-NJN;H?XS[)ZCP?9<U?2MC12
M;PBR.RNP-PYE<%MPRL*M?MFA;[A`S*;'W[KW5_5?04.5H*W%Y.DILAC<E25-
M!D*"LACJ:.MH:R%Z>KI*JGE5XIZ:I@D9'1@596((L??NO=:\<'_"9CX'09:#
M;1[;^:\_Q1I.P4[-I?@14?)//2?#^#=22&N6=-@_PD;H-,,XS5^DYLR&9BID
M,1\?OW7NMA^DI*6@I::AH::GHZ*CIX:2CHZ2&.GI:2EIXUAIZ:FIX52*"G@B
M0*B*`JJ```![]U[J1[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z07:O\`S*_L
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M!;@_]V&)]^Z]U:?0_P#`*C_ZA:?_`*U)[]U[J5[]U[KWOW7NJE_Y&W_;L+X]
M_P#AU?)K_P""Q[R]^Z]TP_*?Y\[_`-\=CU/P[_E^XJF[*[^KO-0[[[2B\=5U
MWT;C=8ILCD*[+F.?%U>?QY<AF;R4])+:,)455H%]U[HQGPI^`W7_`,2L=D]V
MY7*57:OR'WSY:[L[NW=!EKL_F<C7O]SD,=@9*YZBIQ&`^Y/Z=9J*L@/.[61(
M_=>Z!+X:?]O.?YRO_AX_!#_X$C#>_=>Z,S\M/@?\?OF)A4C['VX^'WWBX;;4
M[8VD8L/O_;-5$-5&T66BC_W+8^FG57%)5B6$6)C\;G6/=>ZKCH.]OF]_++K:
M7;'RDP^:^5WQ.@J*?'X/Y![.I)JOL786+U".FAWM03RO/614T+!2M?*=12T-
M?)81>_=>ZK?^5/\`-M^/57_,CWEF_BIV5_?'O+?'P$P/Q<V#0O1C;]#AMV;K
M[O\`](T^Z?O<Y-058R.`PN5\,=*\,<B5J"4@T\;2'W7NMC[X(?%##?$#X^;9
MZXCE@RN^<N6W?VKNM6$]1N??^;CCGR]2U:Q:6JH,;Z:2D+,=4,(D(#R/?W7N
MCF>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NHE?_`,`:W_J$J?\`K2_OW7NM,KW[KW6T/\$O^R5.J_\`6WO_`._&
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M=(+M7_F5_9'_`(86\/\`WGLC[]U[I0;7_P"/9V[_`-J+$?\`NOI_?NO=/OOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZI
MO_F^[&V3FJ3^7WE\SLW:F7RM=_-/^">WJS)Y7;F'R.1JL#4=AY?SX6HK:RCF
MJ9<5-Y&UT[,8FU&Z\GW[KW5P.+Q6+P>/I,1A<;08?$X^%::@QF+HZ?'X^BIT
MOH@I**DCAIJ:%+\*BJH_I[]U[J?[]U[JJ;^>1_VZ0^>W_B`MP?\`NQQ/OW7N
MK3Z'_@%1_P#4+3_]:D]^Z]U*]^Z]U3M_.-_FV=:_RL.@,CN[)4-5N?N#=&*G
M7K;:<>.K)\>M3/-)C:;/9RL6):):*GR*Z(Z<RJ\TH]>B(,_OW7NM5;^4E_.$
M[J^;756ROY9VTL]L[XOUV8[!W+!D=_;8P&?FRD>P^R]V9?<E?@-LO@*:1*6M
MS6Z]QU:RS$4LQEK-+U$%)KE3W7NMYKXL?$WISX@];TG774F`6E$OBJ]U;LR(
MBJ=V;XS:QZ9LUN7*A%DJ9"S-X8%TTU*C%8D6[%O=>Z,Q[]U[JICX:?\`;SG^
M<K_X>/P0_P#@2,-[]U[JV?W[KW0:]Q=8XGNCJ[?75.=RVX,'A]^[<R&V\CEM
MK9.7#YZBI<A'XY9*"OANT98>F1&#1SQ%HY`R.P/NO=?-UF_X3"_)EOYLQZ33
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M]U[W[KW7O?NO=>]^Z]U[W[KW42O_`.`-;_U"5/\`UI?W[KW6F5[]U[K:'^"7
M_9*G5?\`K;W_`/?C;O\`?NO=&Y]^Z]U[W[KW7O?NO=>]^Z]UIY_SF_C;C^C/
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MI9B`"??NO=8:'-8?)X>EW#C<MC,A@*['Q9>BSE#7TM7AZS%3TXJX,G2Y*GED
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M+91ZW^)/9W=7R9I*:7`;UP>RXHL?LRGR6*IZ>([AR.0AI,A48ZFJVE5YU6".
MC6Y*3I<Q1^Z]T><;,_G(?)L%]V]@]2_"'8U=XW;"[(I5WMV6E)(3>,Y4395:
M>N2-BK,F0H`#8A+CW[KW6'-?R+/C3V=LK>N$^1O9?=OR)WAOC;^4PM?O3L/>
M-340XZHR,!1,ICMMAZB":6FFTN(JRIJXSI%M+`,/=>Z+U_PG3_EV?$[XW_%#
M#?(_J+;&1R&_>X-Q]J8^7=N]*6AEW-@L+L3M/>O638G'2P3URTZ9"39[S/,L
MID:GE2'T@2>3W7NMCOW[KW7O?NO=5,?#3_MYS_.5_P##Q^"'_P`"1AO?NO=6
MS^_=>Z][]U[JI=`/^'UJEK#5_P`-+T0U6%[?[.'7FU_K:_OW7NK:/?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=1*__`(`UO_4)4_\`6E_?NO=:97OW7NMH?X)?]DJ=5_ZV]_\`WXV[_?NO
M=&Y]^Z]U[W[KW7O?NO=>]^Z]U27_`#@>_P#Y08;)?'?X7_$;I/XK=S]J_+?;
MWR/W378CYC4-1NCI^OV/\<-D;8W-N+8,/75+4XY]\;W[*J=[4E#C(9:D4E,L
M4TE5']OY:BF]U[JOG^3C\COEE_IL^).Q^PZ#^6'U5\9?FE\7>W?DWU9L3^7?
MT)N'KO([AWOUS7=>;>W?M;N*GSF0I(-E9KK^7>CQRU5)0U4&2R>/J:)*MA3N
M#[KW6UU[]U[KWOW7NO>_=>Z][]U[KWOW7NM5#_A3SU!\[^ROB?\`(G=>T/D)
MM[ISX`]/?'#"[T[%ZYVMCI9>W_D-W=4=ESX6'9.XLVL,"X;I3#;=K\76U<2U
MJ&NKE,4E'5IIEI/=>Z*]_,J[J[#ZL_X31?RN>K>M=R9C8J_+#9WP%^,&\]U[
M7RE5A\YA.N-Y](KG]UTF-%$816T^X*#:(Q=72/)##/05DR.2I*-[KW7+9GQ`
MZE_DF_SY?Y;O2?PGJ=^;;Z;^=W1_:O7_`'YUGN#?NZ-P;=W'N7K7%;BSV%[*
MJ!G,EF):G.+5M":>DM'38\Q2?;,BU=0C>Z]UNG>_=>Z!?M_?FQJ'8/96&KMZ
M;3HLNFR=V4KXNKW'AZ;(QU,VWJ[Q4\E%/61U*32>1=*E03J%OK[]U[H3-K@C
M;6W0001@L2"#P0104]P1_7W[KW3Y[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NJ%.XNGN[-V?S@=E=.XOY^_-_KOJ#LCXH=I?*G(=8[`WUU%CM
MI8+>75?=/0O6V'V;MJ+-=)9_*4?6V;P6^LA+DZ*HJJJOFJV5XJV!`8S[KW5]
M?OW7NO>_=>ZJ8_FU?\6/^7C_`.-9_@;_`._#RGOW7NK9_?NO=,^X=P8/:>"S
M&Y]S96AP6WMOXVLS&;S.3J(Z3'XO%X^G>JK:ZMJ92L<-/34\3.S$\`>_=>ZT
MO?YK77FU?YJ_2GRI^9^_=BOMCXA_$7KO+Q]6;JQVW**G[4[AW%@<U0_>Y/%9
M>NFQ\M+CXTJ9`IDE:&CAD6GT/+)4Z/=>ZVBO@A\&^A_@#T#M7H[HG;5)BL7C
M\=02[BW$:2&'-[QS24P$N6R\R:WTAY'\$&MD@1CRTC22/[KW1T/?NO=>]^Z]
MU4O_`"-O^W87Q[_\.KY-?_!8]Y>_=>ZMH]^Z]TV9JDR%?A\M0XG*O@<K6XRO
MI,9G(J.ER,F&R%12RPT65CQ]<KT5<^.J7680S`Q2E-+@J3[]U[JK7XB?R]?D
M1\;OD[W#\E.Q/Y@6]_D-/\@J?:DO<NQ<[\=NBNN,1N_.]=[&@Z]ZXSE+F=AX
MJER^VFVIMVF1&IJ`PP5[C74!V))]U[JUWW[KW7O?NO=5,)_V_5J?_&3%%_\`
M!A5_OW7NK9_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=1*_P#X`UO_`%"5/_6E_?NO=:97OW7NMH?X)?\`
M9*G5?^MO?_WXV[_?NO=&Y]^Z]U[W[KW7O?NO=>]^Z]T"'</QPZ5[\RW46?[9
MV'C=VY_H7M#;W<W4&<J*C(T&6V)V/MF0MCMPX:OQ=915`\U.[TU732F2DK:6
M5X9XI$:WOW7NBS?'#^5A\$_B;\ANV_E1T1T1B=G]Y=TS9V3=V\I\_NK<?\-A
MW5N*KW;NR@V'AMR9O*X3KG&;JW)6-5Y&GPE/0PU4BH'70BJ/=>ZL(]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW5<?\W/XS=I_,C^6_\K_C)TG28.N[3[?Z^H-M[-I=
MR9F/;V#FR,.\=LYF89#,S05$5#$N/Q<Q#,A#.`O%[CW7NB!_*/\`D_=A_+C^
M2G\4_@YFMW8CJWY5?%GJ;XX;DZYW71Y2KS&S=O\`R)Z*ZQI]IO05V2QRT[9'
M:V7:KR..&0%-.:45$=:E-*\*Q-[KW0(_"/\`EV_S3.]/YAW4/\P/^;_G/CSC
MLE\0NH,MUG\;NK.B7KLYCLSNO><.:I-R]I[DJZS+9*/![@@Q^1T3R1S2?Q"5
M:<)3TL=,YJ/=>ZVAO?NO=!7VUM_`S]<]DUL^$P\]8VQMW2M5S8RBEJ6E3;U?
MHD:>2!I6==(L2;BWOW7NEOM?_CV=N_\`:BQ'_NOI_?NO=/OOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJ<W=_V_'Z&_\`&6GR@_\`@JOBK[]U
M[JV/W[KW7O?NO=5,?S:O^+'_`"\?_&L_P-_]^'E/?NO=6S$A068A54$LQ(``
M`N22>``/?NO=4*][[]WE_-,[\K_B)T9F\AA/B)U)FZ.I^3O<6%D9(=_9:@JB
M\/76UL@MZ>MI#4TS)'IUQSS(]4X:"GA$ONO=#%_.(V#M#JW^2Y\T.O-@X*AV
MSL[:'QKRN$V]@\=$(J2@Q]'6XE(T4<O+-*UY)97+232NSN69B3[KW5O]#_P"
MH_\`J%I_^M2>_=>ZE>_=>Z][]U[JI?\`D;?]NPOCW_X=7R:_^"Q[R]^Z]U;1
M[]U[KWOW7NO>_=>Z][]U[KWOW7NM>&+Y5;C/\XV3N'_9)/YB:]63?$JE^&Z]
MA-\.>S5V>.SH_E)5;H;<KYTP_:+U2-NS+7?WBO\`9?:WD_3[]U[K8>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U$K_P#@#6_]0E3_`-:7]^Z]UIE>_=>ZVA_@E_V2IU7_`*V]_P#WXV[_
M`'[KW1N??NO=>]^Z]U[W[KW7O?NO=5Q;M_F>=`].=Q;VZ<^4F#[*^(S8?=R[
M6ZS[A^06U&VO\<>^8JBAQ-70Y3K'OS&5>9ZUCJ99LQ%!)B,Y7X?-1SW04K,L
M@3W7NB%_"3YK?S7NY/DIU?MON_XY)A^J-YMN6K[JHZ7XV;DZ]ZX^/^W(MG9_
M-;+W#U/\QJWY&]@=??,&EW)NNFP^+3^[VW*)9Z/+29&,I!2.#[KW6PC[]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z07:O_,K^R/_``PM
MX?\`O/9'W[KW2@VO_P`>SMW_`+46(_\`=?3^_=>Z???NO=>]^Z]U[W[KW7O?
MNO=>]^Z]UP$L9(`D0D_0!U)/^L`??NO=<_?NO=>]^Z]U4YN[_M^/T-_XRT^4
M'_P57Q5]^Z]U;'[]U[KWOW7NJE_YLS"7'?R[:&(B2MF_FO?!NMBHT(:JEH\9
MOW)3Y*KCIP3*]-CX'#SN`5B4@L0"/?NO=(GYU?(_LKO?M.#^71\/LD5[&W73
M6^0_:M!)(^+Z:Z[G$2YG&29"D<&GS]=15`2J",LT:RI21_Y1.?#[KW5D/QF^
M-_6WQ3Z@VSTYU?C1287!0";)Y6>.(9?=6X:B./\`BVY\]/&H^XRF4GCN>2L,
M2I$EHXU`]U[HD?\`/'_[=(?/;_Q`6X/_`'88GW[KW5I]#_P"H_\`J%I_^M2>
M_=>ZE>_=>Z][]U[JI?\`D;?]NPOCW_X=7R:_^"Q[R]^Z]U;1[]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J)7_P#`&M_ZA*G_`*TO[]U[K3*]
M^Z]UM#_!+_LE3JO_`%M[_P#OQMW^_=>Z-S[]U[KWOW7NO>_=>Z][]U[K7=[]
M^)G\W_L#Y;;URVVNYJ:OZ5W1VGCZ[8N6RG?FSZ+XX[)^-;9'&'<W2G;WP9S'
MQ(W=4]W;_P`WM:GSN/7<;;UIT%7G,;4DJ,2RR>Z]U9%U1_+CZ1^.O<.([5^,
M>Y>V/CYMPY'.U6^OCOL/L'-5?Q=W]29O'Y-%IH^B=UR[@V1U;68C<63DS%-5
M;(@VU)+72S_=BJCF*+[KW5@'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[I!=J_\`,K^R/_#"WA_[SV1]^Z]TH-K_`/'L[=_[46(_]U]/
M[]U[I]]^Z]U[W[KW7O?NO=>]^Z]U&K:*ER-'5X^N@2IHJ^EGHJRFE!,=12U4
M3P5$$@!!*2Q.5/\`@??NO=:Y7P7_`)<?P;ZS_FS_`#_FV%\:.M]KR?&C;_P5
MW1T,<91Y-4ZMW#V/UMW14[ZR^TX9\G-!CZS=$V,IVJVTD2F%21<>_=>ZV/O?
MNO=8*JJIJ*FJ*VMJ(*2CI():FKJZJ6.GIJ:F@C:6>HJ)Y62*&"&)2SNQ"JH)
M)M[]U[K49[2_GN?R_=M_SO.M/)NG+9/%[/\`CSV)\3\MV;CZFGEV+2Y/LKM#
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MW7NJ5/\`A05W=U#U-_*M^5NV>S.QMI;&W!W%U?N'875>'W)EH,=D-_[T`H\O
M_=?:U+*?-E\T<;1RS""(,_C0M]`3[]U[JSKX\_(OHCY1=;47:/QT[:V+W5UR
MV1K=N1[VZ[SU)N/;DF<PB4R9;%ID:)FB^]H#41^6,V9-8N!?W[KW0X^_=>Z]
M[]U[JI?^1M_V["^/?_AU?)K_`."Q[R]^Z]U;1[]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[J)7_\``&M_ZA*G_K2_OW7NM,KW[KW6T/\`!+_L
ME3JO_6WO_P"_&W?[]U[HW/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I!=J_\`,K^R/_#"
MWA_[SV1]^Z]TH-K_`/'L[=_[46(_]U]/[]U[I]]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW53/Q1_[>Q?S<O\`PP?Y;_\`[Z_O7W[KW5L%34T]'3SUE9404E)2PRU-
M555,L<%/34\"-+-///*RQ0PPQJ69F(55!)-O?NO=4K?++^83M#NW^^/P]^(G
M4LOS&[$WIBJ_:V[I\<U5'T[M*@J_\EJZS/;LHZBBCR4=!+ZC)#54M#&Z#_*V
M8>,^Z]UJC'_A+;6YG^9AU)U7V%VEL3;^VNQ.KLY\F>P]D[4RV0R62H,+M/>.
MVMN;VBP/\2BHZZLIH=U;QQU,X6\+5%:K)*(`X3W7NMUWKK^53\!.M*+&T^(^
M.&R<Y5XVFIH!F-[#);RR57+3P)"U94_Q^NK:%:BH*:W$4$409B%15LH]U[HY
M&TNHNJ=@HD>QNL^O]G(B!%&U]G;>P)T@!?4^+QU*[D@<DDD_GW[KW53_`/-U
MZOZ[R.Y?Y=':.4V3M?+[WIOYD'Q,ZD_C>7P>-R<U1UYV9O6KQ^[]LU8K*:85
M-!7T]*NA6_S+,Y2PD<-[KW5T2J%`50%50%55``4`6``'``'OW7NN_?NO=1*N
M@H:]42NHJ2M2-M:)5T\-2J.1I+(LR.%8J;7'-O?NO=<Z6DI**+P45+3TD`8L
M(:6&.GB#-^IO'$J)J:W)MS[]U[J1[]U[H&^^^O>R.T>L\SLWJ?O?=OQMWOD*
MO#SXWMO8^T.N-\[BP5/C\I2UN1HJ3;?;&UMY;)K(LY0PR4<KU./EDACF+PLD
MJJX]U[HHW\O+X&;[^`^R*KJJI^87;/R)ZGHJ?*G8>PNR.O.D-JTO7V6W+O7<
MF_MWYK&;@ZTV#M;=.=J-R[AW35220Y2LK*>F5@E.D2@*/=>ZL=]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U$K_^`-;_`-0E3_UI?W[KW6F5
M[]U[K:'^"7_9*G5?^MO?_P!^-N_W[KW1N??NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5(W\_P`^>/;GP)^!C[G^
M/5?0X3Y!=^]O;`^,_3FZ<KBERF+V=NGLM,S4U^[)_+,M)05^#VOM^OEQ]140
M5E/%D1`9*>5+K[]U[JL_XI]@?S$_Y7'\V'XL?`_YF_.+='SSZ>_F!=-[LS6V
M-R;]V[5Q[QZH[KZTH<[E:_#[=FJMV9ZLH]I2T5-%#45<E3)!DA4!Q14LM+Y)
M?=>ZVZ??NO=5;?S8?YDOQ^_ET_&?>&[NW-P4,F[-Y;=S.WMA;#BJ-69S];EJ
M.?%G(RTD&NLAPM`]02\BH7FD7Q1`MJ*>Z]T/WP0^9W17SG^.VQ^Z.A]U4>>P
M57A,31YO$?<T[YO:F:CH(EGQ&;IH78Q/JB8PR@>.>,76S*Z)[KW1RB0HNQ`'
M]20!_O/OW7NL35%.A`>>%"1<!I44D?U`+#CW[KW6!LECD)#Y"B4K^H-50*1;
M^H,@M[]U[IBGWULBFBDGJ=X[5IX8A>6:?<.(BBC`-B9))*Q407XY/OW7N@%^
M0/S/^-7QHZGW?W)VCVWLG';3V=B:K)U4=#N;!Y#+9*2GB+QXW$8^#(--5UU2
MUE'TCC!+R,D:LP]U[K4`_EY_\*1?C#NOYP?/OM;?.P-W8K._(3'=6Q==X["U
M>-EBS^%^/6#W?M_9F&I8\I-CTAK<GB]VU,U=5N^I3$)5@,998_=>ZO`QW1OS
MA_F8M0;I^3FY:[XK?$[*?:Y3!=!=?9`CL#L#!SA:BBJ-Z9LJ3!2U]-I?_+%*
MV?5%01W$OOW7NK?.C?CWTW\;=E4FP.EMAX38VW*=8C4IC:?7DLS5QQZ#DMP9
MFH:;*9S)2<DS5,LC"Y"Z5LH]U[H@>[O^WX_0W_C+3Y0?_!5?%7W[KW5L?OW7
MNO>_=>ZJ8_FU?\6/^7C_`.-9_@;_`._#RGOW7NK9_?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U$K_P#@#6_]0E3_`-:7]^Z]UIE>_=>ZVA_@E_V2IU7_`*V]_P#WXV[_
M`'[KW1N??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW5!/_"C?X6]]?,KX$;??XTX!-\]N?&/O[KSY38+J]83+7]G
MT76^)W9B\UM'"Z*RCFDS9Q>Z)*VFIH2U3D)*/[2`>:>,^_=>ZK=^-N[?DU_.
M5_G$_#/YI[K^$W?_`,-.@/Y>/36^FSV6[ZVW7[&W#OWNKM+'[AQ";=VKC=PX
MZ-]Q[32FF@F4TD23T<<,[U=0C34D,GNO=;C'OW7NM1#_`(4D?R+\[\V=GY+Y
M7]![AW-4]O;"H)LGNCK[*YG/9["YS"TE-''59#;&(DER$E#-0T,%Y**CB]*A
MI*>.[31R>Z]T)_\`**_X3P[5^+OQ9QF/[X[5[LQ_:W8?V>Z=UX3JCM//]?XC
M!+64<;Q8*O7"2NF1GCUAY(K^&"2_ZY3(Y]U[JT"H_DZ?&.L01UG9/ROJXU;6
ML=5\B]Y5**X!`=4F5U#6/U`O[]U[IGJ?Y*/Q!K&5ZS=/R2JW1="/5=Y[AJ71
M+WTJTU([*MS>PXO[]U[IGE_D7_""HD>:HJ>]:B60ZI)9^V\A++(?ZR2/BVD<
MV%N3]/?NO=/$'\C_`.!,4D;R;5[(JE0@M#4]G[B:&86L5F$31.0?J;,IO[]U
M[KAN+^1M_+QW+MK<FV:_K#<4U+N/!Y'"2RUF_-S9(4:9&G>G:JAH:^MGQU3+
M$'N$J(IH6^C(??NO=4M?RR_^$O'1OQP^7'>W9W>-:W9NU.NMYQXOI+;4LLM)
M!48S,X7'[@HMP5=30U0K:2.BI<JM/XO*M29XI(V;P*6J?=>ZVQXNFML011P0
M9[M"""&-(H8(.W^SX8(8HU"1Q0PQ[L6.**-``JJ`J@6`M[]U[K)_H?V[_P`]
M)VK_`.CD[2_^RWW[KW2'G^*?355V1C.XJG';RG[7PNRLUUOB.Q).TNS6W;C>
MO]QYO![ES^S:/+G=OGAV]F-P[9QU;44X]$E310N>4'OW7NEQ_H?V[_STG:O_
M`*.3M+_[+??NO=>_T/[=_P">D[5_]')VE_\`9;[]U[H!>\_C7U?O>KZ.H]XT
MF]=X4F`[ZV9O3"0[A[+[)S$>WMW;0PF[,[M7=^(^YW1*<5N#;F:I(IZ.LC*2
MP2#AK,0?=>Z'K_0_MW_GI.U?_1R=I?\`V6^_=>Z]_H?V[_STG:O_`*.3M+_[
M+??NO=>_T/[=_P">D[5_]')VE_\`9;[]U[KW^A_;O_/2=J_^CD[2_P#LM]^Z
M]U[_`$/[=_YZ3M7_`-')VE_]EOOW7NO?Z']N_P#/2=J_^CD[2_\`LM]^Z]T@
M^M^MJ'.;9FK\QNKMB>M7=W8F.623MWLZ!AC\+V#NC#8B+QP[HA0K!B:"!%?3
MJD50S%F)8^Z]TO/]#^W?^>D[5_\`1R=I?_9;[]U[KW^A_;O_`#TG:O\`Z.3M
M+_[+??NO=>_T/[=_YZ3M7_T<G:7_`-EOOW7NO?Z']N_\])VK_P"CD[2_^RWW
M[KW7O]#^W?\`GI.U?_1R=I?_`&6^_=>Z0-5UO11]HX+`)NKM@82KV#NO,55/
M_I=[.,;Y7'[BV;14$QJ#N@S(\5)DZE0@<*P<DJ2H(]U[I??Z']N_\])VK_Z.
M3M+_`.RWW[KW7O\`0_MW_GI.U?\`T<G:7_V6^_=>Z]_H?V[_`,])VK_Z.3M+
M_P"RWW[KW7O]#^W?^>D[5_\`1R=I?_9;[]U[KW^A_;O_`#TG:O\`Z.3M+_[+
M??NO=(#M3K>BV_UQO7-X/=7;%-F,7MW)5N-GC[=[-J9(:R"!GAD2";=$\4S*
MX_2R,#_3W[KW2_\`]#^W?^>D[5_]')VE_P#9;[]U[KW^A_;O_/2=J_\`HY.T
MO_LM]^Z]U[_0_MW_`)Z3M7_T<G:7_P!EOOW7NO?Z']N_\])VK_Z.3M+_`.RW
MW[KW7O\`0_MW_GI.U?\`T<G:7_V6^_=>Z]_H?V[_`,])VK_Z.3M+_P"RWW[K
MW0?['ZXH\MD>QH,GNKMB:'"=@5.'PZOV[V="(,3'M;:F02&-H]T1&H05V1G;
MR.78EB-5E`'NO="!_H?V[_STG:O_`*.3M+_[+??NO=>_T/[=_P">D[5_]')V
ME_\`9;[]U[KW^A_;O_/2=J_^CD[2_P#LM]^Z]U[_`$/[=_YZ3M7_`-')VE_]
MEOOW7NO?Z']N_P#/2=J_^CD[2_\`LM]^Z]T'^Z>N*+'[OZQQM#NKMB/'Y[/;
MAI,W$O;O9LJU%+1;+W!E*1))7W0\E,$R5'"X9&0L5"DD$@^Z]T('^A_;O_/2
M=J_^CD[2_P#LM]^Z]U[_`$/[=_YZ3M7_`-')VE_]EOOW7NO?Z']N_P#/2=J_
M^CD[2_\`LM]^Z]U[_0_MW_GI.U?_`$<G:7_V6^_=>Z]_H?V[_P`])VK_`.CD
M[2_^RWW[KW3;F>IL'2X?*U--N;M9*BGQM=/`P[B[1<K-#2RR1,$;=C*Q#J."
M"#_3W[KW3'U_UCC<SL/9.7RVZ.UY\KE=H[;R63F?M_L^!YLA78:BJJR5X(MT
MQ1PM)4RL2BJJJ38`#CW[KW2N_P!#^W?^>D[5_P#1R=I?_9;[]U[KW^A_;O\`
MSTG:O_HY.TO_`++??NO=>_T/[=_YZ3M7_P!')VE_]EOOW7NO?Z']N_\`/2=J
M_P#HY.TO_LM]^Z]U[_0_MW_GI.U?_1R=I?\`V6^_=>Z;>OL=/@-_]D[<BR^Z
M<GA*+%[!R&-CW/N7/[I>DK,G%NA,G]ED-Q5^1K(XIQ00%XEE\:LH(4%B3[KW
M0S^_=>Z][]U[J)7_`/`&M_ZA*G_K2_OW7NM,KW[KW6T/\$O^R5.J_P#6WO\`
M^_&W?[]U[HW/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NHE?_P``:W_J$J?^M+^_=>ZTRO?NO=;0_P`$O^R5
M.J_];>__`+\;=_OW7NC<^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
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MO=:AW\LSLO\`F/YO_A1CVUM'^8GV+B1V17_RZ*WL+_0!U9N;,U/1O1&.W/V%
MU'D-N==[=P_\6R6`R^X-KT-=-_$,RD^2EJZVLJ"M=4(0Y]U[K<Z]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW6J?\[OY4GRL^7OR:^7WR<^=W\R;?GP\^#/4VT(*OXH
MX+XX]R9C:N"V#MW%80)O'?W>6*W-AL1M[&U,LF#@KJ]*.KJJO)SUC0Q5U'!2
MT\#^Z]T='_A.#V[\O.\OY7/6O8_S&W=NOL/=F8[`['INJ.Q-^0E=[[]Z)Q63
MI,=L?=6Y*NHMELS+D<K3Y44.0K@:JOQ*4D^N>.2.HE]U[J]_W[KW7O?NO=>]
M^Z]U[W[KW50_\Y3XW?-WY5_'C8O47P]^1./^,FU\IVKB*WY7]BXW,[NV]VD/
MC?38O)0[XQO5N2VG0UTU9F3253U$V*=J`Y<T\--]]3P/4)-[KW5(?_"<??G8
MF0^<'S'ZP^.?S.[L^4W\L?KWKG;4FS$^7672A[_I^[\Y-M/+2Y;9_7^YOL>Q
ML1UY2T>3S,&1RLN(P>+R-5-0H()9X3(/=>ZW-/?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]UH3_`"-_F']\_,O^>_\`RT=[=6;VW5M_^7QA?FCNCXR]'C"9S*[<QW?&
M]NII.N*CY&]@9;'8HTM-N_9$VZ-T8S$8=ZRHK*9Z7'-+%%`:JH5_=>ZWV/?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]UH!_\*0/E=UI6?S@>A_CKW?\AOEQUU\;^K_B
MM)F.P,3\$,E!3=WXSMK?^7W5N#%4.8QV;RN.VUF**HVSB-O5C"9))*/'U;O$
MVJ9@ONO=;%__``GVF^(5;\&LKF/AE\J?D=\KNNMP]R;DSFY]Q?*S+/D.YNN-
M^U&T-B4.6ZMS=*<1B(,70X3'8ZCK(4I?O*&>6OEGIZJ>.0-[]U[J\WW[KW7O
M?NO=>]^Z]U[W[KW5%_\`PHK^;/:_P3_EB=D=E]&;FK]A=M=B[]Z\Z.V;V3CE
MH'J.N'W_`%];5;CW?%]]'*T%92[-V]DJ:CJ:=354-?5054=C#?W[KW5$O\EP
M]4/\]NI4^$_\]_L7Y7[@EPF??YJ?&OY0X;NF@PWR$RE)B,Y-GMZ?&N'>E-A:
M/(KM>IJ:[+T;O)D,CCXJ9)YZFHHZJI@3W7NMZKW[KW7O?NO=>]^Z]U[W[KW7
MO?NO=:`/\VS^47M'XHYSHWJ?X]?S!OYD79OSA^<G>5)L;X^=.YWOVDDV+BL?
M7;EQ]5V)V#OB'`[;Q6>Q?7NPL%EF99!5P:F4LTO@IJIX_=>ZW8OAC\=:SXE?
M%CH[XX9+LS=O<F4ZDV)CMK9?M'?-3-5;HWOF$FJ:_+9W(R5-57U,<=1D:Z44
MT,M14204BQ1-+*R&1O=>Z,Y[]U[KWOW7NO>_=>Z][]U[K4Y_X4/]@;YV#\F?
M@3!\E>_^[>D_Y2>_JG=FT/D)#\6]X56VN[-Q]YTU'N#<FQ:?.8G:BR=G[HZY
M#XG"W&#I\A]B5K9)(4J9*%G]U[IX_P"$YN_NR^P.W?GX_27??<'=W\J;9._\
M-LGXE/\`)K>-3NGO?;W8D-'09WLB@@Q^Y+=C[6Z]CJLQ4BE@ST-!+4JU-,E.
M*K^(D>Z]UM7>_=>Z][]U[KWOW7NO>_=>Z+'\U-^]K]6?$#Y0=E=$8#^]/=.P
MNA.U]W]5[>%(<@<QO[;^R,UE-K4*T`E@^]>;,4T5HM0$A])X-O?NO=?-=V#\
M\=K?%OXT_'7^9=U[_.1^4_<W\R/=?;NVI/DO\-]Y;ASVX]B;CZ^JMW9C_2#L
M[.;5W#C6Q5-CH-KX"CDI<K55U30S32PFAAI96A>G]U[KZD^W\O'N#`X3/0PR
M4T6;Q&-R\5/*RM+!'DJ.&L2&1DNC21+,%)'!(X]^Z]T[^_=>ZB5__`&M_P"H
M2I_ZTO[]U[K3*]^Z]UM#_!+_`+)4ZK_UM[_^_&W?[]U[HW/OW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[K6^_G7_#OYAS?*#X$?S4/@KUO3?(?N;X-9[<^W=X?&BKS..P60
M[+ZO[)5\-EI]EY&OQ\T%/G*.ASN3IJUWDEFIZ>JAK*6"22CDCE]U[K#_`";_
M`(K?,S=WS2^<G\VKYZ]*T'QG[:^5N$V+TYU9\>H=S+GMP]?=5];PX7'9*LWA
M+CZ2EQ5?-GY-DX*/'5,BQ5[I054\D$457%J]U[K9']^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW6NQU]\5/D5B_^%,/>GR^R'4NZ:3XS[D_E\X/JS!=QRC&_P!T\GV#
M2[@ZGJY]K4[+D&R?\22GPU6Q#4ZI_D[^K].KW7NMB?W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=:7?\Y_/?S7/D[\VL'U-A/Y7G=7R@_EF?'S<^(STG4.*W[B>JMK_
M`#![)P^.HLG0[H[6W)03[HR>>Z@VENF0C&;;%)30Y+[3[FM.N5(:?W7NMDW^
M7#WI\D_D!\<X]W?*3X:5'P2W_@MY9?9&"Z)FW10[L@I]@[=PVW/[L[DQM9C<
M+@*3'XNN>MJ:."C2F1:=:#T^DJ![KW1]_?NO=>]^Z]U[W[KW7O?NO=53_P`V
MC:W\R67I?8?;/\LOL7'4/;/1'8./['WW\>LQA-KU./\`E=UMC)**JSO4<6YM
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MJG<&0@DJY*:G_8@:8HGI4>_=>Z5'OW7NO>_=>Z][]U[KWOW7NM;?^8?5_P`S
M[XG_`,PO$_,OX?\`\O#X\?/;JK>/2>.ZJR%3A=K[!ZX^6W6VX8YJJHK,+4=V
M/#DM_9OK.J&'CK(D-)54"OD):*2.G>*EJ)?=>Z$[^0;\"/D/\2.M_E3W]\I\
M'M'K/NGY^_(#+?)?<'QYV33H^&^/]!G*O<.2Q6PY\K#75=+59>,;FE,U)!JA
MQD4<,!EEF$VCW7NK^O?NO=>]^Z]U[W[KW7O?NO=5!_SR_P"7UO#^97_+Q[,^
M//6,F"7N#$;EV5VWU%3;JRM1B-K9?>_7V3DJ'VUGJJ%'A%-NS:>1RF+@:IT4
ME/75D%1,Z1PLP]U[JB'XY?#K^8=\S?YGOP(^07;_`/+!ZB_E7]3?R\XMPC?&
M[>L\YLXUG>==-C):/#;0VW0[5;$5N8V/)D<']O2PZ:VEQ6,RM;)+7U;5$%/)
M[KW6ZU[]U[KWOW7NO>_=>Z][]U[KWOW7NM>K(_%?O;N__A1KC?DYVSTYO:A^
M+?Q&^%#;9^-79E?6X7+]<;E[SWQDL<V\\CC,;6F;)[<W-#M[L7*X]VI(HGE.
MW8Y'G*/X3[KW6PK[]U[KWOW7NO>_=>Z][]U[KWOW7NM;[^:W\8OEKM7^97\`
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M#^[/Y>O\T_\`F.Y79WQ7[[_E!?$#X@YC(]R8S/?,_P#F'[(VAUEL'+=R]>;$
MWI!*M%L@[023-4E9GJ*"-W;$R9"3/SPP5##'4HJ;^Z]U]!/$8NDPF)QF%H`Z
MT.(QU%BZ-99#+*M)04T5)3B25O5(XAB%V/)//OW7NG'W[KW42O\`^`-;_P!0
ME3_UI?W[KW6F5[]U[K:'^"7_`&2IU7_K;W_]^-N_W[KW1N??NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1*__
M`(`UO_4)4_\`6E_?NO=:97OW7NMH?X)?]DJ=5_ZV]_\`WXV[_?NO=&Y]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U$K_`/@#6_\`4)4_]:7]^Z]UIE>_=>ZVA_@E_P!DJ=5_ZV]__?C;O]^Z
M]T;GW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW42O_P"`-;_U"5/_`%I?W[KW6F5[]U[K:'^"7_9*G5?^MO?_
M`-^-N_W[KW1N??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW22W\-Y-L3>HZZ;%)
MV"=I;C&Q7SH8X1-Y'#U@VPV9"`N<4N;\!J+"_AU6]^Z]UHQ_.7^9=_PIE_EZ
M[U^+FP._\S\`9,_\NNP:SK+JC^Y.S\EN&C3<U#EMCX6<[JJ*BJPYPV.^][!H
M+3(DX*^4Z?19O=>ZMLR7;7\_'X^_";Y;]G?+[M?^6IUKW/@\ETA#\:M]9W=6
M/Z_Z-PU)D]ZU.,[83M;<V]ZG`82BJLGA:NA@P2R3KY*]R@N64>_=>ZN*ZO\`
MESU7M[KGXN;=^2/R,^-V"^0W>'2^UM[4F'Q':>RZ'"]HY:FV;0YO?NZ>G8*K
M-1ON[8-/5"IJJ>MH?/3"@TR%]'/OW7NG'9G\PGX(]B[.[+[#V)\QOC-NS8?3
M*I)VQO'`]V=>9';774$L[TM-5;QS5/N!Z#`4=951M%3S5$B15$HT1LS<>_=>
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M[QVMDS`WCJ(Z/.8"LKL?--32>F6,2:XVX8`\>_=>Z+Y!_,3^!-5W%_LOE/\`
M,SXQS]W?Q)<(.K8N[>O'WHV=:4PC`)@USYJY-P&8:?L%!J]7'CN1[]U[H8N]
M/D=T!\8MGCL#Y%]T]7=&[)>L7'0;H[5WQMW8N%J\C(I>/&T-;N+(8^*OR,B"
MZT\)DF8?13[]U[H.=@_.OX9=K=2[[[VZQ^4O0>_^G^L,769GL?L3:G:NS,QM
M/86-H:2:OJ:O>N8I,Q)2;4@BI('D+5[4X"(Q^@-O=>ZK7_DT_P`['KG^;''W
MP#2=:]1;RV/VAG<1UCT?'V1C=R]O9_IO`X?;3MVIN+$:Z*HGH*[<&<>F,^/H
M_P"'4Q5(O-*]W;W7NC]_S$OFIL/X`?$/N?Y,;US6RJ+);'V3N>JZVVSO?<]%
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MC1X`X*E[\>_=>Z&YNP]@)L8]GMOC9Z]:KM_^]A[".Y<,-CC:WVGW_P#>4[K^
M]_@/\`^Q_>^\^X^W\7KUZ>??NO=:W/\`.0_GH83H3XL]4]Q_RTODC\7N\]S9
M3Y:["Z0[.DV_N+:G<U#M_;6Y=J[ZR]3#58S;6YEGPU;65VVX?MZN3]IXPWCU
M:@??NO='TSWR3^6$'\V3I#H#&]Q_#F@^*V[OCPV]MW],YKL':='\Q\QOML%O
M6L3<&SNN9\RF[Z[8$=9C*%VJH:.2G6&GJRSCQFWNO=&XSW\Q7X#[7VMO3>^X
M?F;\8\/M'KG?+]8[[W#7=V]>0XO:79$0JFDV#GJHY_1CMY1I0S,V,DM6!87)
MCLK$>Z]T8G97;75G9'7F.[<Z^[(V+O?JO+8>?<.,[(VINS!9_8M=@J2.66LR
M]/NO&5U3@Y,=1)3R&>83Z(?&VLJ5:WNO=%9QG\SS^7)F=M[VWCB_G7\2ZW:?
M6V5Q>$W]N2'O[K(X3:.4S=6^/PM)GLD=R"DQS9>OB:"E:1@E1,I2-F8$#W7N
MCMXW)8_,X['YC$5U)D\5E:*ER6,R5!/%54.0Q]=!'545=1U4+/#4TE732K)'
M(A*NC`@D'W[KW5,'\VWY_=M?'/>GPK^'/Q+R6VZ3YA?.COW;>Q]HY/<VWXMU
MXGK?IO;V4H:OMWLW(X"I9**NDQV)G6GI(YSXR&J)?^4>X]U[HOV\/YJ_;?5_
M\^?<GP/[/WYU#L;X7[+^&I[ZW3O#>M%BMJY7![BI\%2UM1F,YV-ELU0XC%X+
M[R?F*2)$&H*&O;W[KW5W'0GR@^./RGVS7[S^-G>G5'>^U<3D/X3EL]U1OS;>
M^L=B<H8S*N/RL^WLA7C&UDD(UI'/XW=/4H(Y]^Z]T%_87\PSX']2]J4_1_9_
MS'^-'7_;]14PT0ZWWAW3U]M_=]/6U+I'345?A<GGJ:LQE;5/(!%#4K%)*3Z`
M??NO="YW%\C_`(_?'G;NW]W=\]V=5]-[5W7FZ+;>V-R=F[\VSLG![AW#DJ::
MMQ^$PN4W%DL?19/*UU'3R2Q00N\DD:,R@@$^_=>Z[[/^1W0'2>:ZZVWW%W7U
M9U;N#M[/Q;5ZJPF_]][:VEE>Q]S3U..HX=O[(H<YD:*IW/F9:O+TL:TU&LTI
M>HC4+=UO[KW0<=C_`#O^%/3^?[#VGVI\L?COUYNKJ7#XO<'9VU]X=O;%P&Y-
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MU!/`S7+7]^Z]T?\`]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW42O_X`UO\`U"5/_6E_?NO=:97O
MW7NMH?X)?]DJ=5_ZV]__`'XV[_?NO=&Y]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]UIB_P#"K+_LJ7^1'_XN%N7_`-^)\6_?NO=6-_\`"J$`_P`DSY2W
M%_\`?P]%GG^H[LV+8_ZX]^Z]UKX_.OI?8GR'^6?_``E7Z1[/Q1SW7'97Q5Z9
MVQOK;PK*S'P[BVE58[KJ7.[<K*G'S4]8,;GL;#)1U*(Z^6GF="0&/OW7NA5/
M\MCX2U__``JJJ_B[#\>NO<7\9J3XGX?NK(_'[$XG^&=0Y_>^&V-10XR?-[%H
M9(,%DL539>:+)M031/12Y"`321,68-[KW17>H:K<?Q#@_P"%;O7_`,3(<CUC
MMGJA&Q'7&S]CU==0XW8&VZCMG?VS,[D=KTT<DSXF;;?7F4K4@FB*R4U/"NEU
M$2%?=>Z*WA_AAV5OC^4E\0]]]>_$G^73\5ZV?<VP=Z]7_P`S;>7SPV'UEW%N
MCM2#-UV6R.(W1)N:AP\=+N7)3XRHIO[N5.5D_@4V/5HHUDIC?W7NOIJ],UF[
M\AU!U37]@U6+KM^UO6^QJO>];@\A0Y;"UF[JC;&+FW)5X?*8Q5QN2Q53F7F>
MGJ*<"":%E=`%(]^Z]UH\?#+XQ_##Y4_\*8/YO6P_E]L_87:<F%KLINCJ/J;L
MV2GKMH[CW'#/M7%;HW(FTZ^>/&;GW'M/;6484JRQSO24]?4SH@*&1/=>Z*%T
M+OC>WQ1V3_PJDZM_E^[HS]'\<>G<?05G3LFS,Q79K`]>U69[/S6Q=^Y#8><@
M^Z:*KPW5[9>%*Z&H,J4>$IZ@R.8$E]^Z]T+61^`7\I:F_P"$O,'RIHMM]5?[
M,TO1]#OV#OY=RQKW&WRB?=U.E3UY]\N7_B'[><9L,<#X?%'CE^Y\0D'W7OW7
MNI_?/17R0^<7Q>_D)]VGO;XC;[^=VR^A,A-MGX-?.W<VV?%\I\%E<SD:?9&^
M:#K_`'K-28O?^9S^TMI0)71Y'[5<C(E/)%6&I71)[KW1E_Y2>;Z'RW\P'Y;?
MR_?F-_*.ZT^&OS#^07QLS_\`I=V[TOO3.UOQK[4ZOCQN!RM?MJLZ0H-YY_87
M7=!N:@\61HZC#54\<LK3(?MI9V\GNO=*G_A'!T3T/!TE\H.\QL#9<7?^!^1N
M_.IL3OP!#O?']6R;:V'FI=G4Y-6TD>W3F(!/I\7JE%RQL`/=>ZOG_GR]3]:=
MJ?RF_FR_9&Q]M[V;KGHGL/LS8C;BQL.1.T^P=M;5RR;?WC@S*+T&?PPKIOMZ
MA+,GD8?0D>_=>ZTQOD%L?#]"?\)/OBIO[H;KS`]?;A^7G;6Q-J_+[LC9],-O
M;A[1VEM7?O>U5M'$]C;@I$-16X9LMC*.G+3,(A'&L3!ED9']U[HRE1\/^^>N
M?EI_*3[1ZD^*'\M;^6KN_978>Q:W:6X>M_GYUQ6[U^8O2V0KMEX_=F$I-LYF
MCV^W;>9RNV<G4A*Z#^)9#(OF3"7DU1:?=>Z"CJ/8O=7RZ_FS?SHL_OGX#?%O
MY^[\V7VUN/8]?MKY??(RBZ@EZ'Z7PFY=[[;PE3UOA,UA<L[X:FVM@J""3/4B
MTTF&2&!TG1ZYGD]U[H'N_,1\F?CW_P`)J]Q=,YWN'J;?_2>7_F5[5VO0;@^-
M?R%VM\B=J;+^/&XMGY7>U7U5FMZ['J,A!2QXCMG%P5$E'6R1RL]3`&B"3A#[
MKW1E/^%#OPC_`):'QI^%W\L7?WQ"V%U'L'L;>'9W6^*P.<ZXJJ#^-]S=03[,
M;-9S>F[JJAJ9IM\RT&Z%QDG\8JO+-'49&2(2@2>,>Z]U9OV8!_T%S_"<V%_^
M&\ZOFW/&R^\K<_['W[KW1'?Y$O\`+Y^(?S+^1/\`.[W1\HNEMJ]VS['^4?8^
MT-D8O?=-+F,%L^+>>[>XJK<FXMN8B684.,WE7##TD:95$%=310!898]3ZO=>
MZKEZ;W[VYL;_`(2I_/3;/6V=W53[<HOYB--UON!,=6ULIP74.XH^L7W-BC-&
M))*+`;ASJTE/7H#'%/\`?2B0GS2!_=>Z,-_.T^*_\I7J#^1Y\'^S_BMANF,%
MW[O&'HZ';.\>O<SCINR>W\+F-@3YKN"?LTXVNGR.Y5QNXH8:JL;)(?X/EDBI
MHO!J\)]U[KZ$?QW_`.R?^C/_`!#O67_O%83W[KW6LE\DJNHS'_"N#X&8G=ZR
M28';'P<["R76B5+,]-'N3(8+O,9J:BC8:$G^U$NIAR=(_H/?NO=%8^1GQ9Z.
M^7?_``KGQW6/R'V%ANT.M,/\+=O;_K=@;FB>LVIN7,[7V;5+@*?<^)$B4V<Q
M&/R>12M^SJ!)32U%-%Y$=1I/NO=!S\*MK2?#;^<)_P`*+>L_AGM:GZ\Q/7'P
MFW9V!T[U=M"F>+;6)['Q6S=F[OVF<#MR%9*97QFYMT5IQ]+''HC6J-/&%C:P
M]U[H'?Y3WP9_E4_)+^1+\GOE%\K,;UMOWY)Y2#Y,;J[H[W[#W;Y.W.K]]X:C
MS61V%)ALO79A,C@Z^MB2ARE,BH7S]=7R)**KR"(>Z]T0COCLGN3L#_A,A_+:
MW)W77YW,4VQOYBU=LSK_`'#N7SO43=1[6P^_(-K1/DJN-7FQ>&J8LCC:*1VD
M"T=`B*VB,`>Z]U?'_P`*-=^[+W#\U/\`A/K@\3N;`9+/57R[V-OA,)096BK\
MBNTLYV-T/#B-Q&"FED?^"Y.IA=*:IL(JAHG\9;0UO=>Z+]-\)?CW\ZO^%8WS
M3ZV^3G7N.[5ZMV3\9\%V9/L'-UV5H\!FMPT6P^D=EX6IR\6'K\;55Z8@;UFJ
M(8S*%6H1'(.@#W[KW6;^9#_+\WUC/YJ])O[^73C?Y;WS4W=UC\3]A=/5G\KK
MY/5^P]Y;IZ:ZOZQVQMW`8U]D=4[WW!B:.EP\N!:BJZ"N7)4.3I*G)5,ACEBG
M,S>Z]T?O_A-/WG\==RO\[?BYL[X)2_`[O_J#LO%Y;Y0]487LO=G9?5.4W3G:
MO=NVF?:<&ZLSEX=ARX6HP%5CYL-2/-2)1Q4XBJ9HHU6'W7NFO_A([5Y5/B7\
MV]O0/._7NW/Y@';M-U_J=WI(J2HV[M!LE#1$CQK&$AI78(;:GU$7;GW7NML;
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=1*_P#X`UO_`%"5/_6E_?NO=:97OW7NMH7X).G^RJ=5
M^I?IO?\`M#_GXV[_`/'W[KW1N=:?ZI?^2A_Q7W[KW7M:?ZI?^2A_Q7W[KW7M
M:?ZI?^2A_P`5]^Z]U[6G^J7_`)*'_%??NO=>UI_JE_Y*'_%??NO=>UI_JE_Y
M*'_%??NO=>UI_JE_Y*'_`!7W[KW7M:?ZI?\`DH?\5]^Z]U[6G^J7_DH?\5]^
MZ]U[6G^J7_DH?\5]^Z]U[6G^J7_DH?\`%??NO=>UI_JE_P"2A_Q7W[KW7M:?
MZI?^2A_Q7W[KW7M:?ZI?^2A_Q7W[KW7M:?ZI?^2A_P`5]^Z]U[6G^J7_`)*'
M_%??NO=>UI_JE_Y*'_%??NO=>UI_JE_Y*'_%??NO=>UI_JE_Y*'_`!7W[KW7
MM:?ZI?\`DH?\5]^Z]U[6G^J7_DH?\5]^Z]U[6G^J7_DH?\5]^Z]U[6G^J7_D
MH?\`%??NO=>UI_JE_P"2A_Q7W[KW7M:?ZI?^2A_Q7W[KW7M:?ZI?^2A_Q7W[
MKW7M:?ZI?^2A_P`5]^Z]U[6G^J7_`)*'_%??NO=$(^9W\MGXI?/?>/QQWW\C
MMM[FW!N+XJ;YK.Q.G:C;V]L[M.GQ.YZ_*;-S-14Y>DP]1##GJ=J[8>.815`9
M56-U'$C7]U[H5?F3\/NC/GE\?=X_&/Y%XC,9_J;?=5MRMW#B]O;DR6U,K/4;
M4W#C=T89J?-X>:&OI5AR^*A=U5K2("C74D>_=>Z+YN3^5#\,MU]H?"3N#,[3
MW=-O?^7OM/`;*^,];%V#N*"CVY@-M4V.I<5!N/'QU0I]WSQPXJ$/+6AWD*G4
M3<^_=>Z$2+^7I\88?G=4_P`QY-O;C'RDJNL%Z@FW*=Y9H[9;9*T4&/%&-FF?
M^"+6?;4R#[@)Y+B_U-_?NO=,?2W\LWX@=#=S_+WO?9.Q,A6[V^=%;7UGR2H]
MY;FR>\=H;V3*UVX*_*8V/:&=DJL)C,/D9-SUL<]+%%XI8)?&P*`#W[KW1!-K
M?\)F/Y/VT>V</VG0=!;GR%%M[=DN^,#T_N+MSL#<71N*W-+5M6_>P];Y?-U5
M!4T:3%0*"IEGQQBC2)H&C71[]U[J_2%*>GBB@@6&"""-(88852.*&*-0D<44
M:!4CCC10%4```6'OW7NM+3J7^2?@_F%_.$_G"[I^=?Q?[0H.@NQ-R;3W5\;.
M\HZC<W7-34Y^&OCI,KE>J>PL'5T<T[5F&9XJR#]^EJ*<!9HFLMO=>ZV:OAK_
M`"XOAK\"NB,[\<?C=T]@]M=9;RFRE5V)2;AJ*G>F9[-K,SCVQ&3J.PLWN67(
M5NYTJ,.YHUIIC]G#2$PQ0I&64^Z]U6W2_P#"8+^372=LKVFGQSSDU#'N)=UP
M]/U7:N_:GI"+.+-YO-_H^ES+038YA^V<?+428XP?M>#Q>CW[KW1]?G!_*K^#
MG\PK:O7>V?D;U%3UE7T^HBZCWKU_F\GUKO[K*C44`&*V=N?:-1CJG'X)3BZ9
MEQ\BS4,;P1ND*NH8>Z]TF?@A_*$^"W\NC<V\NP?COUYGI^V.P,>,-NWN'M+?
M6XNS^S<G@Q-2U,F#BW)N>LJ/X3BJJKH89:B&BAIA4R11F;7XTT^Z]TD_B?\`
MR4_@)\)?E1OWY?\`QSV/O78_:'85)N^BRF%_TE;FR76^+@WUE*7,;D7`[(K:
MJ2@HEJ:VC3P)(\\=%&-%.L26`]U[JP?O_H_KOY,])]H_'WMBBKLIUIW#LO.;
M`WQCL5EZO!Y*MVWN*C>ARE/19C'215V-J):>0A9HF5T/(-_?NO=%VVC_`"X?
MAYM3X18W^7;/U;2;S^)V,VSD=IP]=;_R^2W5-)B\CN/(;M,TFXJVI7.Q9C';
MBR+U=#70SQ5=#.D;P21M&A'NO=$U^*'_``GR_E?_``Y[NVS\@^KNI-V[A['Z
M_#?Z+:KMGM+>/9V%ZJ>Q6"HV'@=S9&HQV-KJ`.YI:FH2JJ:1W+PR1O9A[KW2
MG^:?\B+^6[\\.W:WOON?JS<^W^XLYBJ7!;PW]T_V/NGJW+[^PU)##2)0[YIM
MN5L>(W*\F.IHJ62JGIC6O2Q1Q&;1'&%]U[HSNU_Y9_P7V=\-:_X`X/X^;)A^
M*.7Q-5C,YUA4?Q"L3.U=;509&JW1F-QU-=)NBNWO)EJ6*L7,O6?Q&&IAB>*5
M/%&%]U[JMC!_\)>OY/&"VG-M:/I'?F4D.Y]O[DQFZ\YW3V#E=X[;@VU69"OQ
MNUMK9JIRY7;VTY*O(EZNEIHHWKVAA:IDE:)"/=>ZLKR_\NCXMYOYO=?_`,PO
M(;=W+)\F>LNKWZ?VGN./>N<BVW2[(?'[CQAHZK9ZU(PE;6_:;JK!]Q)&9-3J
M;W1;>Z]UA^(?\N'XK?!W._)#<?Q]VYN7!93Y6[^J>RNY),]O7.;HBR^ZZNKW
M'6S56(ARU3,F`IFJ-U5A$--I0!U'T1;>Z]T27L;^6EM#X-?RV_E5\?\`^7!\
M9=B=_P!9VMG<IV+N;XU_)7>>XMV[/[HDW$NW\/V!M>+-Y3<&(J,+EZ[:.%$F
M''WM-#%DZ>)A)'(XD7W7NM/'?W\M3?GR<Z2VG\2OBI_PG[^0_P`)ODEVSVIL
M>N[R^3W=>?W_`+CZ6ZSVCMBNR<V=H.K=[]LUM=58?9F4K\A'75-)2U4=5/!2
M""/^(R>)A[KW7TJ>OMKP[$V%LC9$=9]]'LW:&VMJQUKA4>L3;V&HL0M4R#A6
MJ%H]9'X)]^Z]U0I_.,^+/;]#\M?Y:?\`-`^-_6V^NW.P/A]W53]>]V]<]8XC
M);FWUNGXT=MSR8/=F5P&VL125F1S4^R!F,@\T$*,WVN4EE8:(&(]U[JS>'^7
MO\8#\ZC_`#(4V[N5?E'4=6IU&VY)-WYM-N#9!H8Z$43;)>88:.O%*@!F,8E#
M<GGW[KW7NJ?Y>'Q?Z8^8O?WSMV)MW<5'\A_DOM_';8[8SN0WEFLIMW*XC%1[
M:BI(<9M.LJ),-A9%3:=$&>!%+:&_U;7]U[JN[MG_`(3._P`G_N'N+-]RY_X_
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MYYNLVU6[1IALP14E#LZ>H;!XVJ`V#C?WXHQ)^V_/[CW]U[H!_G%_)<^`7\P+
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M?^2A_P`5]^Z]U[6G^J7_`)*'_%??NO=>UI_JE_Y*'_%??NO=>UI_JE_Y*'_%
M??NO=>UI_JE_Y*'_`!7W[KW7M:?ZI?\`DH?\5]^Z]U[6G^J7_DH?\5]^Z]U[
M6G^J7_DH?\5]^Z]U[6G^J7_DH?\`%??NO=>UI_JE_P"2A_Q7W[KW7M:?ZI?^
M2A_Q7W[KW7M:?ZI?^2A_Q7W[KW42O=/L:WU+_P`!*G^T/^.+_P"/OW7NM,GR
M1_\`'1/^2E_XK[]U[HU]%]*W_M=;@_\`=[D??NO=3/?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UF
M?_-Q^_=>ZP^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z['U'^N/\`>_?NO=2G_P`W_L/^B3[]U[J)[]U[
MK+#^O_8'W[KW6,_4_P"N?][]^Z]UU[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>ZR1?YQ?]C_T*??NO=<#]3_KG_>_?NO==>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KB_Z&_P""
..M_O1]^Z]T!/OW7NO_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tpg19a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg19a.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`N@'T`P$1``(1`0,1`?_$`:(````&`@,!````````
M``````<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+
M$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,7
M4G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R
M9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8
MF9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1
M``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B
M%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756
M-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>W
MQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:
M``P#`0`"$0,1`#\`VN_BM\5NB.V>B-E=B]B;*J=T;UW34[RK<_GZW>6^X:K)
MU4.^]S4,4TT5#N>DI$9*2DC2R1H+*.+^_=>Z,)_LB7Q4_P"?5C_T-^QO_LO]
M^Z]U[_9$OBI_SZL?^AOV-_\`9?[]U[KW^R)?%3_GU8_]#?L;_P"R_P!^Z]U[
M_9$OBI_SZL?^AOV-_P#9?[]U[KW^R)?%3_GU8_\`0W[&_P#LO]^Z]U[_`&1+
MXJ?\^K'_`*&_8W_V7^_=>Z]_LB7Q4_Y]6/\`T-^QO_LO]^Z]U[_9$OBI_P`^
MK'_H;]C?_9?[]U[KW^R)?%3_`)]6/_0W[&_^R_W[KW7O]D2^*G_/JQ_Z&_8W
M_P!E_OW7NO?[(E\5/^?5C_T-^QO_`++_`'[KW7O]D2^*G_/JQ_Z&_8W_`-E_
MOW7NO?[(E\5/^?5C_P!#?L;_`.R_W[KW7O\`9$OBI_SZL?\`H;]C?_9?[]U[
MKW^R)?%3_GU8_P#0W[&_^R_W[KW7O]D2^*G_`#ZL?^AOV-_]E_OW7NO?[(E\
M5/\`GU8_]#?L;_[+_?NO=>_V1+XJ?\^K'_H;]C?_`&7^_=>Z]_LB7Q4_Y]6/
M_0W[&_\`LO\`?NO=>_V1+XJ?\^K'_H;]C?\`V7^_=>Z]_LB7Q4_Y]6/_`$-^
MQO\`[+_?NO=>_P!D2^*G_/JQ_P"AOV-_]E_OW7NO?[(E\5/^?5C_`-#?L;_[
M+_?NO=>_V1+XJ?\`/JQ_Z&_8W_V7^_=>Z]_LB7Q4_P"?5C_T-^QO_LO]^Z]U
M[_9$OBI_SZL?^AOV-_\`9?[]U[KW^R)?%3_GU8_]#?L;_P"R_P!^Z]U[_9$O
MBI_SZL?^AOV-_P#9?[]U[KW^R)?%3_GU8_\`0W[&_P#LO]^Z]U[_`&1+XJ?\
M^K'_`*&_8W_V7^_=>Z]_LB7Q4_Y]6/\`T-^QO_LO]^Z]U[_9$OBI_P`^K'_H
M;]C?_9?[]U[KW^R)?%3_`)]6/_0W[&_^R_W[KW7O]D2^*G_/JQ_Z&_8W_P!E
M_OW7NO?[(E\5/^?5C_T-^QO_`++_`'[KW7O]D2^*G_/JQ_Z&_8W_`-E_OW7N
MO?[(E\5/^?5C_P!#?L;_`.R_W[KW7O\`9$OBI_SZL?\`H;]C?_9?[]U[KW^R
M)?%3_GU8_P#0W[&_^R_W[KW7O]D2^*G_`#ZL?^AOV-_]E_OW7NO?[(E\5/\`
MGU8_]#?L;_[+_?NO=>_V1+XJ?\^K'_H;]C?_`&7^_=>Z]_LB7Q4_Y]6/_0W[
M&_\`LO\`?NO=>_V1+XJ?\^K'_H;]C?\`V7^_=>Z]_LB7Q4_Y]6/_`$-^QO\`
M[+_?NO=>_P!D2^*G_/JQ_P"AOV-_]E_OW7NO?[(E\5/^?5C_`-#?L;_[+_?N
MO=>_V1+XJ?\`/JQ_Z&_8W_V7^_=>Z]_LB7Q4_P"?5C_T-^QO_LO]^Z]U[_9$
MOBI_SZL?^AOV-_\`9?[]U[KW^R)?%3_GU8_]#?L;_P"R_P!^Z]U[_9$OBI_S
MZL?^AOV-_P#9?[]U[KW^R)?%3_GU8_\`0W[&_P#LO]^Z]U[_`&1+XJ?\^K'_
M`*&_8W_V7^_=>Z]_LB7Q4_Y]6/\`T-^QO_LO]^Z]U[_9$OBI_P`^K'_H;]C?
M_9?[]U[KW^R)?%3_`)]6/_0W[&_^R_W[KW7O]D2^*G_/JQ_Z&_8W_P!E_OW7
MNO?[(E\5/^?5C_T-^QO_`++_`'[KW7O]D2^*G_/JQ_Z&_8W_`-E_OW7NO?[(
ME\5/^?5C_P!#?L;_`.R_W[KW11_]E=Z,_P!GC_T1?W,JO]''^RT?W^_NK_?/
M?GV/]\?](O\``OX]Y?[S_>_=?P?_`"?3Y?%HYT:N??NO=&X^"7_9*G5?^MO?
M_P!^-N_W[KW1N??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U7U\Q?G#N;XZ]F=&?'SI7XX[L^4_R1[_Q/9V\=G=7X/L#8
MG4>$H.M^FZ+;\O8>\MP=C]C54.`HY:#)[RPU%18V&*>KKIJ\N!'%!)(/=>Z`
MQOYLV'WQT+\3>P?CC\:.U^].]_F,-ZOUK\7_`..;/ZZW7MC']/9FIVWWQNOL
M[?FYJV?96T>ONK-RT?\`#/X\KU5!G,A78Z+'M,N0@D]^Z]T<+X;?+'%?+CK/
M.[HJ.O=V=+=H];;\S_4G>W1._P"HQ57O;IWM?:T5!697:V6K\)45.(SV(R>%
MS%#E\)F*-C19K!Y&DK8+),%7W7NC;>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HAO_=2
MO_RSG_YK7OW7NES\$O\`LE3JO_6WO_[\;=_OW7NC<^_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K7<_G`;!H>T?DO\?MN
M_)_I/Y8[P^%6U^K=V[RV3VA\%>IM[]@=\[=^5-;6Y_96X-G;VW;TYB-Q=V==
M=59KI?<:U%/%B8*+$;AR,<]/E9ZB.G@I3[KW0']'8[Y/_%V;X(_+_M_XQ?(/
M=/2_QYVW\SOA9@-@]?=-;<RORCV3\4>U.P.F,U\2NZNU?CST?1QTCYR#`]&P
M8?=.&VMAZ:IQ8RU+724$(@JXO?NO=6D_RQ-H]B5Z_,GY2[^ZTWQTM2?-GY5U
M?>O774W:>*3`]K;3ZQVWTQU#T5M'(]C;>6HGEVKN3?=)U(VX!A:@)6X>DR<-
M)5#[B*3W[KW5E6Y,`=QXX8\9O<&`M415'WVV\@N,R)\0<>`U+4]2/MY-?K73
MR0.>/?NO=!_U@N3Q^>[1VU6[BSVXZ+;FZ<)3XBIW'60Y#)4U+D]C;8S%32_>
M14M*TL`R%=*Z!PQ760#:P'NO=#![]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z(;_`-U*_P#RSG_YK7OW
M7NES\$O^R5.J_P#6WO\`^_&W?[]U[HW/OW7NO>_=>Z][]U[KWOW7NO>_=>ZU
MS_YR?\]7>/\`+<WO7=4="?%>L^2N_>MNG<%\C_D3F-P;L_N%L#I_H_>'85+U
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M]^Z]U[W[KW1#?^ZE?_EG/_S6O?NO=+GX)?\`9*G5?^MO?_WXV[_?NO=&Y]^Z
M]U[W[KW1?^Q?E;\:>H.S=E],]L=Z]6]9=H=C87([AV!LS?\`O+";/RV]<3B)
MY*;*3[6&X*O'TV=FQTL9\\%-))41+9F0*03[KW0ZT%?0Y2AH\GC*RDR.-R-)
M3U^/R%!40UE#7T-9"E125E'5T[R4]5255/(KQR(S(Z,&4D$'W[KW4OW[KW6F
MA_PIKVM_)[W-VMU7COF#\NNZ?BO\I<]U+4;=KI?CQLBN[+J]\?'X;Q3-8K`=
MZ;*QE-3QUVW3O7'5-1MPU61I_P#*Z6ID$,ZP(8O=>Z,[_P`)K<__`"W<S0?+
M*7X>?(WY#?+[Y&9;*=:[F^5/R+^2>U=Y;8WQNW%5YWOBNGMOT<.YZ[)0/B-K
MT&%RL:A*BJJS+*[RRB%J:"#W7NMI+W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=!/L7_F8'=O_`(=VU/\`WV>S??NO="Q[]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB@4G_`&7UN#_Q4#9_
M_OY]\^_=>Z-_[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z(;_W4K_\`+.?_`)K7OW7NES\$O^R5.J_];>__`+\;
M=_OW7NC<^_=>Z][]U[K6B_G];;V3V[G>D.C*3^3CN_\`FC=V[HV'V)5[-WCB
ML]G>LMI]"8#(9+!XW)KN7N#;8I:K;=9N3[.>?'Q5=?04\=90QR1R/*Y3W[KW
M59GPN_D3?ST/CQA\EV;T7\\NL?@16R4]#E-E?"_;NZ^Y/D=TA25./IL68\'V
M!5=HYW?>W<-5Y>7;E%3U]9B:7<.FD9XX&2%13'W7NMQ;N^J^0V&^-O9%7T)C
M=C;N^4.-ZGSDO5^+WK)-0]=[A[@IMNRG`4VXI(:[!3TNU\CN9$$Q6HI&6G8^
MN/ZCW7NM.'<O1'_"D#>WSSQ7S!SOQ+_E0YKY*X'XX5?2>3V?EMUX3<='DNJJ
M_>AW)B=TY#:V?[<RVZL-EL/GVFHZ3+8ZJH(I:6IGI)A.LFD>Z]U?Q_*AW'_,
MOK]U?(7;?\Q3IGX,]-Y3;M!UC+L+#_$/(XZ7<=1/EO[X5&X1VCB:7?6\:[&T
MJT,>-EP[3I2B835)3R`77W7NKH/?NO=>]^Z]U[W[KW7O?NO=:[_\SKNWM7=?
MSKZ[^'6)V;\[>P^H,'\1J_Y*;OZQ_E\;PP75O:79FZ-P=OUW7.#;LGN3+=@=
M1YC8'7O6M+LYZVAH,)N6AK]S9;*^&:*II**2%_=>ZB?Z5,'\^<O_`"R?BSU)
M\B/EAM+XN]O_`!R^1?R![&WW1;]W-U1\M>P\C\2]Y]1=*4G27;/96"AP&_-H
M9/!=D]BUS[PJ\54P5V5RFVQ3-424]1+._NO='?\`Y8>ZM_8L?,OXK[W[(WUW
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MO?NO=-V7R"XG$Y3*O$TR8S'5N0>%&"-*M%32U+1*S`A6D$=@3P"?;L$1FF2$
M&A=@M?2IITW+)X432D5"J3^P5ZH57^?%M%@&'QIW98\B_9&#!M^+C^[)L;>\
MC#]W6]!I^]H?^<#_`/6SJ$O]>NU_Z-TO_.5?^@.N_P#A^':7_>-.Z_\`T9&#
M_P#L9]^_X'6]_P"CM#_S@?\`ZV=>_P!>NU_Z-TO_`#E7_H#KW_#\.TO^\:=U
M_P#HR,'_`/8S[]_P.M[_`-':'_G`_P#ULZ]_KUVO_1NE_P"<J_\`0'7O^'X=
MI?\`>-.Z_P#T9&#_`/L9]^_X'6]_Z.T/_.!_^MG7O]>NU_Z-TO\`SE7_`*`Z
M+M3_`,Z_:J?+C+[]_P!EXW08ZCXU;;VN,9_I!PHE22D[5W9DC6&I_N[H,<BU
MH73IN"O^/M&/8"\.XG;_`-Z0U%N)=7@MYN4I37\JUZ5'WBMA8B]^@DH9C'3Q
M5\E#5KH^=.C$_P##\.TO^\:=U_\`HR,'_P#8S[6?\#K>_P#1VA_YP/\`];.D
MO^O7:_\`1NE_YRK_`-`=>_X?AVE_WC3NO_T9&#_^QGW[_@=;W_H[0_\`.!_^
MMG7O]>NU_P"C=+_SE7_H#KW_``_#M+_O&G=?_HR,'_\`8S[]_P`#K>_]':'_
M`)P/_P!;.O?Z]=K_`-&Z7_G*O_0'2FV5_.^VIO'>>S]GI\==TXY]V[KVYM9,
M@_86%J4H'W#F:+#I6R4Z[=B:HCI7K!(R!U+!;`@GVDO_`+O]Y8V$]\=TA800
MO)I\%Q70I:E=>*TI7I39^\=M=W<5I]!(IEE1*^*IIJ8+6F@5I6O5ZGO'GJ:.
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z(;_W4K_\LY_^:U[]U[I<
M_!+_`+)4ZK_UM[_^_&W?[]U[HW/OW7NH.3R>/PN-R&8R];2XW%8FAJ\GD\C7
M3QTU%C\?00255;6UE3*RQ4]+2TT322.Q"HBDDV'OW7NM#S^85WA\]]P?S/NC
M_EO\=/YK_P#+<Z[^,>ZMC=_8WX@]W[][=ZN@ZBV1L6C_`+O;9[#V-V!CZO;N
M5D[)WQD=Y4\U/25M'0;CBQDJZ):ND:R>_=>ZLU_DPXCM?MCYZ]S_`"J^4/\`
M-B^#WSP[\;XJXSHW:_5/PIWEM_,83;O56/[2Q6],GV%O7;^$P&QZ>@R6,W35
MT^.IZF/%3M+'E&6:K73!#[]U[K:<]^Z]UIP=E_R3?YU>Z_YG?>WRAZZ_FE#J
M?;&_^K<UMS9/>]+L#$YO=V`Z]R/<^6WKM7XG-U\V=I:G^[6P,;5PUR;B\ZI5
MS1+%X@S-I]U[JX3^55_*[[>^#&_/E+\@?D_\OMQ?,WY0?+"KZJQ^_P#L[);,
MH-AXN+9_2FW<GMSK[&PX2"OS%54YJEH<W40U%4U2D+4L%+&D*M'))+[KW5S?
MOW7NO>_=>Z][]U[KWOW7NJ]OE%\%]Q=R]W;)^4/0OR6[`^)?R/VGUEF>C,MV
M#L_9O7_9N`WYTKG=T46]I-F;OZ][*Q.3P%;D]N;LHWK<#E8VCGQ3U]<NB=:F
MT?NO=!=N7^57M#!=/_&#9OQD[X[3^-G<GQ$JMYR]4_(_&XS9?8>]]P4?;F6J
M=P=]8;N+:VY<+2;'[,P?=NYZU\[F:*6CHZ6+<45-D*2.!Z6*/W[KW1I_AQ\3
ML+\1>LLUM0[^W?W+V9V+OK<';/>?>O8:8R/??<?:^ZDHJ?,;LSE-A::DQ&%Q
MM!B<718G"XBBC6APN$Q])0TX\<`)]U[HV?OW7N@GV+_S,#NW_P`.[:G_`+[/
M9WOW7NA8]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=)O>7_'G[K_\`#;SO_NKJ
MO:JQ_P!SH?\`FJG_`!X=)[S_`'$E_P":;?X#U\^Z+_-I_P`%'^]>^E;?$>L%
MQPZR>Z];Z][]U[KWOW7N@OB_YGC7?^(:Q'_O?YSV3+_RLC?]*]?^K[]&A_Y(
M:_\`/:W_`%:7H4/9ST5]>]^Z]U[W[KW0G=)?\SJZ;_\`$M=:?^]M@_93O_\`
MR0+[_GBG_P"K3]&.S_\`)8M/^>J+_JXO6_'[YQ=9O=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]T0W_NI7_P"6<_\`S6O?NO=+GX)?]DJ=5_ZV]_\`
MWXV[_?NO=&Y]^Z]TV9O#8O<>&R^WLY10Y+"Y[&5^&S&.J0QI\AB\I2RT.0HI
MPK*QAJJ2=XV`(.ECS[]U[K5U_F>_&[X$_#3!_&3KV?\`D/[^^:WQ9V!MGN++
MR;J^.^.SFZV^-%)DLW3[QW=22[%2K^ZR,>\LM.<E)45^7QM,BQ3>*21XVB/N
MO=#+_)B[!_D>[V[?WLO\O+XY-\6_EM2=122]J]3;YZI[)ZT[@P/5-=ENO,ID
MERR;FGRVTZW;K;NRN&B$E#7RO45$`DC#0`2-[KW6QQ[]U[K6M_F-_-[^8]\*
M_P"95M'<_P`;?AE\ROG=\8]Q_&/'X'L?J/K[K_)T_3>T.P)][9G(8???7?9^
MV-O;VKZOM-L?B_LLYC,IC8J2EQ<U/)#)+)4?Y/[KW1^OY:O\P7Y(?.*N[?I.
M_?Y;?R)^`</6])LFHVO6][5&6F@[0EW3-NF/+TNV1E>N=@LLNT4P%.]7H^Y!
M&1AOHXU>Z]U:Q[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@GV
M+_S,#NW_`,.[:G_OL]F^_=>Z%CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TF]
MY?\`'G[K_P##;SO_`+JZKVJL?]SH?^:J?\>'2>\_W$E_YIM_@/7S[HO\VG_!
M1_O7OI6WQ'K!<<.LGNO6^O>_=>Z][WU[H%J''=J'M`[MK]K[$IL#4;5H]G3_
M`&F_LW696"DI=R9'-G,144O7U%2U$SP5@3[4U$8#@_O6]AV*+>_WS]=+#;+:
MF`1&D[E@!(7U`>``30TTZAG\71U))M7[K^DCEG,XE,@K$H4DH%TU\4D9'Q4/
MV=#3[$/1+U[W[KW7O?NO="=TE_S.KIO_`,2UUI_[VV#]E.__`/)`OO\`GBG_
M`.K3]&.S_P#)8M/^>J+_`*N+UOQ^^<76;W7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=$-_P"ZE?\`Y9S_`/-:]^Z]TN?@E_V2IU7_`*V]_P#WXV[_
M`'[KW1N??NO=)[=VX8MH[4W/NR>@R.5@VQM[-;AFQF(@%5ELC%A<;4Y*2@QE
M,7C%1D:Q*8QPQEE#R,HN+^_=>ZTB_P";%_-#[>^4G6?PB[.ZDS?\VSX=_'[N
MC`=\_P"D_J7XU?'';TWR"R%=U]V%B]J8FOW-OF'M7;57U_))68I:G%P05-1'
M68VHF=]#/I]^Z]T9+_A.A4_R\*7Y'=OXOXR_#3^9#UG\@,CT9793L'Y0?/R%
MJS)[[V;1=@[/CGV-C,EC=RU&UZ',5F:RM!5""FQ---44>(#2SRM`S/[KW6X'
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MX?Q_F3?]\XOS_P#_`#][L_\`N;_?NO=6F?RUOGQ\D_F^.X#\A/Y<7R!_E_\`
M^C<[&&U/].==DZP=J?WK&ZSF?[LC)]==?R1G9O\`=ZE^\TK4J?XG#RA%F]U[
MJTOW[KW0+_(CY`=7_%GI;L/O[N;.3[?ZXZSP$V?W%6T6-K<UEJD"6&CQN%V_
M@L9#49+/;DW!E:J"AQU#3HTU765$<2B[7]^Z]T57>'\T#XP;1^-_QL^2\2=L
M;VP/R^I-JU/QPZMZTZJW1V!WWVM)NK;9WDE'MGJ7;4%=N"HGV]M&*7)9=VTT
M^-I(6:64$QJ_NO=&.^+_`,H.HOE_U!ANZ^ELMEJ_:V2R>>VWEL/N?;^6V?OC
M8V]MI92HP6\NONPMEY^GH\[L[?.S\Y22TF1QU7$DL,J7&J-D=O=>Z,)[]U[H
M)]B_\S`[M_\`#NVI_P"^SV;[]U[H6/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW2;WE_QY^Z__``V\[_[JZKVJL?\`<Z'_`)JI_P`>'2>\_P!Q)?\`FFW^`]?/
MNB_S:?\`!1_O7OI6WQ'K!<<.LGNO6^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NA.Z2_P"9U=-_^):ZT_\`>VP?LIW_`/Y(%]_SQ3_]6GZ,=G_Y+%I_SU1?
M]7%ZWX_?.+K-[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB&_]U*_
M_+.?_FM>_=>Z7/P2_P"R5.J_];>__OQMW^_=>Z-S[]U[KWOW7NM0OY[?.O\`
MGQ]9?S;]E=>?&+X.9+LKHS!;-[;H^J=C1=@8S%=7_)C;J8;;]55=G]B[AJ<]
M1XS8^Z.N\E4RPXW'UE9C:BKN?'#,&!/NO='^_EI;G_G0][_,KM+Y`_S"^E<-
M\//CKB?CIB.IMA?&7`=I;<[#P^Z^XI>PX-UU'=5'!@,QNJ7&UM%L]*C#5;U5
M=3*ZR4X@@E(GDC]U[J_;W[KW6MY_.LRG?-7O[;F-WA_).ZU_FE?"O9O74>]:
MW>D.^=N8CNGKKL:?,5M#G<9A,374.9W92[;AQU-C*NL.*Q\\=52F62ID2*D8
MK[KW0X?R0OFS_+W^0?7_`&S\>/@M\:-T_$&K^.>8QF8[EZ%W%L?`;9.V-S=E
M9;==-09%]P[9W%NC%;RR>8BV3,\DYJY)Z>E6GA<(J)&GNO=7I^_=>ZU1?YGF
M4[0^8G\U>'^7ONO^8WO_`/EK?'/K3X<X#Y$X?/\`66]\=U7NGOOLW<G8]5MF
MMQW]]\OGMHO64.RL-1AVH::KJHP%=VA5FDD3W7NC#?R)>W>X*7M_^8_\'=W_
M`"PW!\[NGOA5V1T5B>BOE5NK*4VZ-Q;CQ':76==FMU]8Y;>N.JLOC]TUO569
MVZE)43-D:RJ6LJ)]?BB:&)?=>ZV-/?NO=4P?S)MD_-?=W>W16Z>J/BQUE\FO
MCAT-M#=/;]+@-R_)"DZ(S=!\J?#G]L[/WMFZ3+;'WOCMT[<ZHV!75E9AJ811
M!\YES42NKT%,??NO=5,_`_N+_9;^G/Y$/S"^8&+PW0'QQVW\`NY/BJ.U*_=)
MWEL#;NY.T*+XQ;NZ$WUV;N6DP>,QG4='VUM/J;.TRG(%HL5E9(<;-5NU4''N
MO=7(?RH\O2=I9?\`F!_*?9*U]7T+\KOFM7]F?'C=5=BLE@8>Q.NMG]`]&=*Y
M3L3`8?*TM'5?W0W;V#UCF:C$9#QJF9Q_BKU]-0I/NO=6K;DH=PY#'"GVUGZ;
M;>1%1%(<C5X1,_$:90XEI_L9*_&J&E+*1)Y+KI^AO[]U[H+.I:/-T&[.Z*;<
M.;I]P91=Y;::7)TN(3!PR1/UMLTP1+CXZW(*C0IP7\IUG\#W[KW0Y>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NDWO+_CS]U_^&WG?_=75>U5C_N=#_P`U4_X\
M.D]Y_N)+_P`TV_P'KY]T7^;3_@H_WKWTK;XCU@N.'63W7K?7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW0G=)?\`,ZNF_P#Q+76G_O;8/V4[_P#\D"^_YXI_
M^K3]&.S_`/)8M/\`GJB_ZN+UOQ^^<76;W7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=$-_[J5_^6<__-:]^Z]TN?@E_P!DJ=5_ZV]__?C;O]^Z]T;G
MW[KW7O?NO=:\_P#.#V!\R>L_EK\#_P"8E\:/C7NSYQ[-^*F+[KVQV'\5]H;W
MK-J;DI<MV?A<?B=L]Q;0QJ29>+<F>PJM444L<&$RE5!`RL8_$S34WNO=)'^6
M%C_GM\HOYEG?O\RKY(_$'<WP$Z9W=\1]F_&3:W0N_M^3YGL+LG?>T.RXMV?Z
M7=T[6BPFUVIYL#BA7X:FKLGBZ*I_ATU)'1F>$U$OOW7NMD;W[KW6F'_PH<VU
MUYVO\VNH.FZG!?S(?G+OS(=$T&]\I_+C^'?8D77O3^*V#M_>F;HI.X^V\UC-
MM;_W!1Y3=>1R$F/@$>!EDFAH`BU]$3%Y?=>ZLF_D!;Q^!]3U[WWU-\8?@EN3
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MU[KH@,"K`,K`AE(!!!%B"#P01[]U[INFPV(J,:,-/BL;-AQ'#",5-0TLF-$-
M.Z201"A>)J41P21JR+HLI4$6('OW7NIL$$%+!#2TL,5-34T4<%/3P1I#!!!"
M@CAAAAC"QQ111J%55`"@6''OW7NLOOW7N@GV+_S,#NW_`,.[:G_OL]F^_=>Z
M%CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TF]Y?\`'G[K_P##;SO_`+JZKVJL
M?]SH?^:J?\>'2>\_W$E_YIM_@/7S[HO\VG_!1_O7OI6WQ'K!<<.LGNO6^O>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NA.Z2_YG5TW_XEKK3_`-[;!^RG?_\`
MD@7W_/%/_P!6GZ,=G_Y+%I_SU1?]7%ZWX_?.+K-[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NB&_]U*__`"SG_P":U[]U[I<_!+_LE3JO_6WO_P"_
M&W?[]U[HW/OW7NO>_=>ZU%/^%)'Q9[F^7/?'QBZGQ\'?V2ZEJ_BA\[=U];8/
MJ3(9>FVGE_FMUUU7)O#HG%;_`'Q>-RF,Q,.<^T>BBJ<O]A35$$T])35L,\SA
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M=&5S6:Q>Q]C[QW5@MT[GJJ"LQ]7F8-,3O44U&!%`SR>Z]U=M[]U[KWOW7NO>
M_=>Z][]U[KWOW7N@GV+_`,S`[M_\.[:G_OL]F^_=>Z%CW[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]TF]Y?\>?NO_PV\[_[JZKVJL?]SH?^:J?\>'2>\_W$E_YI
MM_@/7S[HO\VG_!1_O7OI6WQ'K!<<.LGNO6^O>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NA.Z2_YG5TW_`.):ZT_][;!^RG?_`/D@7W_/%/\`]6GZ,=G_`.2Q
M:?\`/5%_U<7K?C]\XNLWNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ(;_`-U*_P#RSG_YK7OW7NES\$O^R5.J_P#6WO\`^_&W?[]U[HW/OW7NO>_=
M>Z*5\C?GI\+?B'DL#A?D]\H^C^BLWN>EFKL!@^RNP]N[9S65H(',4F0I<17U
MJ9%L?Y5*+.8A"SJRJQ96`]U[H3NANZN@_D#L&D[0^.'8_6G:W7.<JYTAWCU9
MG\#N/;U7DJ=(FJJ:IK\!-/#'E:>.:,R0S:9T5U+*`RW]U[H9_?NO=:\_\QC^
M:I\]^HOG5M7X`?RX?@MMSY8]NTOQXA^2?9^5W[ORDV9M_![&S>\*_9."3$U%
M5N3:6.I6H\OAY$JYJVNU5$U=314\)*2N?=>Z-U_+0^07\T_O&N[AB_F1?"3K
M?XA4.VZ39$G455L'LW!]A2;]J\K-NE=ZP92+#;[WK_"DVY#08MH6D^W\QK7`
MUZ#I]U[JU[W[KW6GA_.:[V^3Y_FB;+^/$_\`-AVG_*3^,$?Q4B[)V?VB:;"5
M5=VOV<-Y-B-V;0W++1;GV_DZ>MQ6,FHZG&QYJNQU(M,)VQ\-3+-4,ONO=6,?
MR.WR;+\D_P"(_P`Z7$_S>?5U1X?X7!CH5Z$%NPM?F^RWWO>1F[*-K:VIU_W!
M>D.=17W7NK]_?NO=5O\`S_VK\EXMH[M[>ZY_F%8/X+].]1]2[BW=N7)U'1G4
M^_A5;NP:9K)/N+L/>_<%1F,/0]84V*%)%+B<7CL9E)*B.21<J!(D*>Z]T37_
M`&:WYK?*;:?\L'H79F]<?\+>_P#YB_%?/_+SY%=G4'6>"WYF^N]I]68/IV#<
MW6W5.Q.SES^W*#=>]]_=U8L&IS]+7PXS`TM9H$E88+^Z]T=#^73WAW3V!AOD
MGT3\B]W8;M#NKX8?(G)_'K=G=&WMJT.Q<7W-AZSK?KKN3K_?M7LO&S/C-K[O
MJ-@]IXZCW!24218Q<U1U+T2BE>(#W7NK`\WN#`[:HQD=QYO$8#'F:.G%=F\E
M18JC-1*&,4`JJZ:"`S2!&*KJU$`V''OW7N@KZMS>&W#O'NK*8#+XO.8R7>6V
M8HLCA\A29.ADE@ZUV:DT:5=%-/3M)"_#*&NI^OOW7NAK]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=)O>7_'G[K_\`#;SO_NKJO:JQ_P!SH?\`FJG_`!X=)[S_
M`'$E_P":;?X#U\^Z+_-I_P`%'^]>^E;?$>L%QPZR>Z];Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z$[I+_`)G5TW_XEKK3_P![;!^RG?\`_D@7W_/%/_U:
M?HQV?_DL6G_/5%_U<7K?C]\XNLWNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z(;_W4K_\LY_^:U[]U[I<_!+_`+)4ZK_UM[_^_&W?[]U[HW/OW7NO
M>_=>Z^>STQWY_(OK_F__`#3>W?YT.]=N=G_*&H^>G?G3O6NU>V.LNX.R=H[*
M^.G4FX:/:?7AVQC-@;4S^RZ6NE;%3X]S.HKZ6'%C1H6JG,WNO='W_D;]J_`N
MF_G-_,WJ[^5)O&/*_!_N#X6[)[\W'LJGPW9F`V]L+Y$;*[@H]BYG$[#PW9D.
M*S&/P%3M;>Z5M0!2/3K)70TM-)%34<<"^Z]UN7^_=>ZT]O\`A1MM'X);-^0G
M1O?'RN_F.?-7XR]H3]99+9/3W3/PZP]!7[VDVK_'*F??N]H<I0T6-R^'PN>J
MI*2GKDK\S!2U38Y!30RR1SV]U[HX'_"=3:?Q<R/6O>G>'Q<_F'_+[YP8+>^1
MV-LK>>TOEUFLQ-NWH?=&S(MS988J';>8+G#Y#=-#NY6J:FDEJJ&M2AB$4[M#
M($]U[K9)]^Z]UJ:_SF:GK[MSYT8'XV?&S^3OT#_,N^<M+T%@>VNV=\=Y9#$[
M5VYU=TC%N?*[:V7A:K+9W+;1I<YD\KF)JAJ=5S$"TJ2`"*H9W%/[KW1KOY"V
M\.CG;Y?]*T?\NSK7^6S\SN@MW=5;2^7'3W6+T>4V[N>DS^ULWNKI[?.)W)C?
MNJ&MV]F,?DLP]!2BNR+4\3F45,T=3&Y]U[K8<]^Z]U3C_,W^''S*^7G9'QXB
MZGG^(^[?C;T[E'[,WET-\F\EWE0;=[;[KQ=;*>OLGV%C>J:6IQ>]NNNLA##E
ML=@LA>DJL^5GK8IXJ6GC/NO=*;N'XM_.3?C?%3Y4;)WC\5MC?S`/CYA^T>O]
MW82HQ?:>=^)G9O37<69P4^\>NDGF6#M7:M3!_<#:^;H<Q34[5<.7Q4M(Z/05
M4@]^Z]T8/X)?%S?WQQV7VIN?O+?.V.R?DO\`)CM_,]]_(?=^P\)7[9ZZ;>^1
MVUM?8FW]I=<[?R=149&BV1UYUQL;"X*AJ*P_Q')K0-6UG^4U$EO=>Z.]44M-
M5Q^*JIX*F+4'\=1%'-'J6^EM$BLNH7X-K^_=>Z"CKZGIZ7??=D--!#3PKN_:
MI$4$20Q@MUILTL0D:JH+'ZFW/OW7NA>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=0<G!6U6-R%-C:\8O(U%#5P4&3-+'7#'5LT$D=+7
MFAF>.&L%).RR>)V59-.DD`^_=>Z()T<_RFRWR$[BV7OGY*87=>S.D\YUQ32X
M6CZ)VMMFOWA1;VZ_@W55P5V=I-SUTN+DHZ^K"Q/30*?'&`P8DM[]U[JPGW[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW2;WE_QY^Z__#;SO_NKJO:JQ_W.A_YJI_QX
M=)[S_<27_FFW^`]?/NB_S:?\%'^]>^E;?$>L%QPZR>Z];Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z$[I+_F=73?\`XEKK3_WML'[*=_\`^2!??\\4_P#U
M:?HQV?\`Y+%I_P`]47_5Q>M^/WSBZS>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[HAO\`W4K_`/+.?_FM>_=>Z7/P2_[)4ZK_`-;>_P#[\;=_OW7N
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MW7NM9+^8C\=^Q^T?YIF"SO\`+._F%X'XF?S+ZWXCTF)[DZNW?T]G^T^OM\_&
M7%;]J*K;.Z]S;AJMF[XV)L#<&*W16-#0TE52_=91`KPF$QNU1[KW0^_R8.B\
M%TIVY_,+B[D^82_,'^97N3LWIRK^>.X5Z[S_`%91[#:CZVE7HC9^UMLY3%X/
M$YG82;.JJZ;#YS&T=-25],WB2*)*9$'NO=7X>_=>Z][]U[KWOW7NO>_=>Z][
M]U[H)]B_\S`[M_\`#NVI_P"^SV;[]U[H6/?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$^Z1_[*F^;?_:_Z!_\`?,XSW[KW1P??
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=)O>7_'G[K_\`#;SO_NKJO:JQ_P!SH?\`
MFJG_`!X=)[S_`'$E_P":;?X#U\^Z+_-I_P`%'^]>^E;?$>L%QPZR>Z];Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z$[I+_`)G5TW_XEKK3_P![;!^RG?\`
M_D@7W_/%/_U:?HQV?_DL6G_/5%_U<7K?C]\XNLWNO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z(;_W4K_\LY_^:U[]U[I<_!+_`+)4ZK_UM[_^_&W?
M[]U[HW/OW7NO>_=>ZTG/YFG5G\OKY)YK^9G_`#'MB/\`.GXZ;B^!V^MH="_(
MGY'?#GMK;.PD^5&^\+_<W9^]NMMO[=S62J,;+D.GLEG,%#F,E*<7]Q/3:3'5
M2!)![KW0U?\`":'LKX+;:[/^1OQWZ7^.OS8ZB^4V[.O-L?(CM#M3YY0TLW<G
M?FP9-TU.V8<[03XREHJ#'[7P6Z=P"5/V4;(U65FE\]6\,I@]U[K:7^0O1VR?
MDST7VY\>>R7SD>P.ZNOMT]:;R?;63_@NX$VWO#$56%R[8;+&GJQCLD*.K?Q3
M&*0(]CI/T]^Z]UI$_(SIC_A-1V)\N]K_``T[S^2?;&S*3X;?$K;O46([O;Y.
M;:P76B5?77<.^\/6]$Y^=]L568KN\-M9;<^1KLBW@BI10(B#2\=C[KW5J7\@
M/:'\J_JWY(?S!^H_Y8^=[A[,P&Q\!\8)NP.\=X=L83M'JKL>/<^&[&SVWJ+J
MZ?&XS$Y#'5VS<C5Y7'YHU4(\M5&@CNB!F]U[K:&]^Z]U1#_,1_E?_,3M;Y38
M/YU_RUOFABOAY\FJSIZB^/W;4&^-A478?7O:/66*W'5[IV]-4TN8QF[:3![@
MVWDZMQ'HPTXJ$T$34[(YG]U[H8OY5_\`+:[7^%&4^2O??RD^3>3^5_S(^96X
M>O-Q=^=E0[<H-F['I(.K-O9+;>Q-J[(VU0TU)X\?M_&9JII_NS!0I-3)311T
M5,L%I/=>ZM\]^Z]U[W[KW1<ODG\O/C%\/-K83>ORA[SZXZ,VON;-G;>W<MV'
MN.CP4>>SB4%5E)<;AZ>9FK,E44V.HY9YO#&XAB74Y4$7]U[H9ME;UVAV1M#;
M._\`8&YL%O38^\\'C-S;2W;MC)T>:V]N3;^9I(J_%9G"Y:@EGHLCC<A1S))%
M+$[(Z,"#[]U[I3^_=>Z"?8O_`#,#NW_P[MJ?^^SV;[]U[H6/?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$^Z1_[*F^;?\`VO\`
MH'_WS.,]^Z]T<'W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2;WE_QY^Z_P#PV\[_
M`.ZNJ]JK'_<Z'_FJG_'ATGO/]Q)?^:;?X#U\^Z+_`#:?\%'^]>^E;?$>L%QP
MZR>Z];Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z$[I+_F=73?_`(EKK3_W
MML'[*=__`.2!??\`/%/_`-6GZ,=G_P"2Q:?\]47_`%<7K?C]\XNLWNO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z(;_P!U*_\`RSG_`.:U[]U[I<_!
M+_LE3JO_`%M[_P#OQMW^_=>Z-S[]U[KWOW7NM*[Y(;>[E_EF[P_F'?%WY(_R
M[>[OYC?\L#^8S\A=X?*C:^X?C-2;EK^R=L=J=J9_`[OWOU7V@NS)</F,-B<9
ME=B4]1BYX)*33#11%:BK:KJ8J3W7NK"?Y3'7/RW^3/SK[[_FM?)_X[[C^'VP
ML_\`&/8/PZ^'70&\7B_TAS?'[";[J>S'WMVI1UL\VX,;NV;+T\!B2IAH"8Z^
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M=>Z>?Y+1Q+_%[N.;8'\._P!E_J?G5\W:GXLG;`I%ZY;XYS?(+>#[`?J:/'VQ
MD764E2:YL4*4+2E"YA'C*D^Z]U:QN.3<\6/#;2HL#797[B(&#<>3R&)QXI2'
M\SBJQF)S52:A6TZ4\(4@F["PO[KW1=]EU?<XWQW$:?;W5S5+;JVR:Y)=X[M2
M**4==;1$*TTB[$D::)J8(Q++&0Y9;$`,?=>Z$[[WO/\`YYOJ?_T-MX?_`&O_
M`'[KW7OO>\_^>;ZG_P#0VWA_]K_W[KW7OO>\_P#GF^I__0VWA_\`:_\`?NO=
M>^][S_YYOJ?_`-#;>'_VO_?NO=>^][S_`.>;ZG_]#;>'_P!K_P!^Z]U[[WO/
M_GF^I_\`T-MX?_:_]^Z]U[[WO/\`YYOJ?_T-MX?_`&O_`'[KW7OO>\_^>;ZG
M_P#0VWA_]K_W[KW7OO>\_P#GF^I__0VWA_\`:_\`?NO=>^][S_YYOJ?_`-#;
M>'_VO_?NO=%1Z;JNVA\EOF.U#@NNI,J^=Z+_`(U#5[LW-#04\B]0XT40QE3#
MLN>HK$EI+-*98H#')=5#K9O?NO=&N^][S_YYOJ?_`-#;>'_VO_?NO=>^][S_
M`.>;ZG_]#;>'_P!K_P!^Z]U[[WO/_GF^I_\`T-MX?_:_]^Z]U[[WO/\`YYOJ
M?_T-MX?_`&O_`'[KW7OO>\_^>;ZG_P#0VWA_]K_W[KW7OO>\_P#GF^I__0VW
MA_\`:_\`?NO=>^][S_YYOJ?_`-#;>'_VO_?NO=>^][S_`.>;ZG_]#;>'_P!K
M_P!^Z]U[[WO/_GF^I_\`T-MX?_:_]^Z]U[[WO/\`YYOJ?_T-MX?_`&O_`'[K
MW2:QN].Z<EN;<VUXMI=71U6UZ;`5-54OOC=A@J5W!#7S4RP*.O\`R*T"X]@^
MK@ZA;\^_=>Z4OWO>?_/-]3_^AMO#_P"U_P"_=>Z]][WG_P`\WU/_`.AMO#_[
M7_OW7NO?>]Y_\\WU/_Z&V\/_`+7_`+]U[KWWO>?_`#S?4_\`Z&V\/_M?^_=>
MZ]][WG_SS?4__H;;P_\`M?\`OW7NF[,)WEEL1E<4=O\`4\(R>-KL>9O[Z;PD
M\/WM++3>7Q_W!37X_)?3J%[6N/K[=@E\&=)J5T.&IZT(-.FYH_%B:*M-2D5^
MT4ZU_D_D5=T*JK_IUZP.D`7_`+O;K%[?['WDH?O%N37]T+_V4G_K3U!H]DT_
MZ.1_YP#_`*V]<O\`ABSNC_G^O6'_`*#VZ_\`BOO7_!%/_P!&E?\`LH/_`%IZ
M]_K*)_T<C_S@'_6WKW_#%G='_/\`7K#_`-![=?\`Q7W[_@BG_P"C2O\`V4'_
M`*T]>_UE$_Z.1_YP#_K;U[_ABSNC_G^O6'_H/;K_`.*^_?\`!%/_`-&E?^R@
M_P#6GKW^LHG_`$<C_P`X!_UMZ]_PQ9W1_P`_UZP_]![=?_%??O\`@BG_`.C2
MO_90?^M/7O\`643_`*.1_P"<`_ZV]>_X8L[H_P"?Z]8?^@]NO_BOOW_!%/\`
M]&E?^R@_]:>O?ZRB?]'(_P#.`?\`6WKW_#%G='_/]>L/_0>W7_Q7W[_@BG_Z
M-*_]E!_ZT]>_UE$_Z.1_YP#_`*V]>_X8L[H_Y_KUA_Z#VZ_^*^_?\$4__1I7
M_LH/_6GKW^LHG_1R/_.`?];>E/LG^2?W1L[>NS=X#NGJ_(':6[=M;I&/.%W7
M3"O.W<W0Y@41J1',:<59HO'Y-#Z-5])M8I+_`.\`]]83V/[J5?&ADCK]0336
MA6M/!%:5K2HKZ]*;/V;6TNXKO]X%O"E1Z>"!72P:E?$-*TI6G5]/WO>?_/-]
M3_\`H;;O_P#M?^\<NIMZ]][WG_SS?4__`*&V\/\`[7_OW7NO?>]Y_P#/-]3_
M`/H;;P_^U_[]U[KWWO>?_/-]3_\`H;;P_P#M?^_=>Z]][WG_`,\WU/\`^AMO
M#_[7_OW7NO?>]Y_\\WU/_P"AMO#_`.U_[]U[KEMK=V]9-[S;+WG@MK4$TFU7
MW105VV-P9;,1O'!EX,344E9#E=N8-H7+5*.C(T@(#`@<$^Z]T*WOW7NB&_\`
M=2O_`,LY_P#FM>_=>Z7/P2_[)4ZK_P!;>_\`[\;=_OW7NC<^_=>Z][]U[HH6
MXOGE\3\!\5-Y?-6C[DVQO3XX;'Q^9JLIV!UY-)O:"MR6%W$-FR[4PF-P,=7D
M<KO.NWK)%AJ7%I']W-DYXH`H9Q[]U[H$OA7_`#2^A_F[V#NWJ/;/5_RBZ![9
MVKL^/L2'K3Y8]#;EZ*W=O#KQ,S2;;RN^-BT>:J,A2;FV[MW<F3HJ#(R13K)2
M5-?3JT>F56]^Z]T<3Y%=-P?(?H;N#HJJWKO/K>G[=Z[W7U[/O_KK)IAM^;-B
MW5AZK$/N/:&6DBG3';AQ*U7FI9BC".9%)!]^Z]UH)?)_^7M\;?AS_,EVK\0_
MD]_./_F-?'KH;-?$ZL[NHN\NT.X\K3T._>U)^Q6VOC^L]E[KH,9_=;%0X+:]
M#59+)&NI)YY)F@IXFC,JEO=>ZN6_X3>U74.)[X_F>]8]$_);Y"_-CJ3K7>O0
M%!UU\K^U]][QW7LK>VWL]L;/YK)[$VWC\\1M^EWCUSO*;)P9/*8I(8<UCZC'
MSF&-%BU>Z]UM>^_=>Z][]U[KWOW7NO>_=>Z][]U[HOOR*^)_QH^7.U<1LCY/
M=%]8=[[3V_FUW)@L%V?M#$;LH<+GEHJK&_Q;%)E*:=\?7/CZV6%WB9"\4A5K
MCCW[KW0P[1VCM;8.UMN['V/MW";0V;M'"XW;FUMK;;QE'A=O[=P&'I(J#%8;
M"XG'PT]#C<9CJ*!(H88D2..-0%``]^Z]TH??NO=!/L7_`)F!W;_X=VU/_?9[
M-]^Z]T+'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NB?=(_]E3?-O\`[7_0/_OF<9[]U[HX/OW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7ND7A]KU&,WIO7=$E5#+3[HH]J4U/2HCK-
M2MMZFRL$[3.QT.M0<@I33]`IO[]U[I:>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7ND6VUZANPX-Z?=0_:Q;+JMKFBT/]P:BH
MSE'EEJA)?Q^%8Z8H5_5J(/T]^Z]TM/?NO=$-_P"ZE?\`Y9S_`/-:]^Z]TN?@
ME_V2IU7_`*V]_P#WXV[_`'[KW1N??NO=>]^Z]UH#?)K>VS.VNSL]N_\`EX?#
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M;(83939G<P@HJ:*6JIJK)M%^W'+'$Y3W7NK>OY#_`')\B,C+\N/B;WU\/OAC
M\#ZWXE[UV'BH_C?\68LABLWBL[VK@<CO^NWYN_#PY[=.S\EM/?>!J\9/@LUB
M\C4M720UL,^@TT:^_=>ZV%_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]T$^Q?^9@=V_P#AW;4_]]GLWW[KW0L>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z)]TC_`-E3?-O_`+7_`$#_`.^9QGOW
M7NC@^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z(;_W4K_\LY_^:U[]U[I<_!+_`+)4ZK_UM[_^_&W?[]U[
MHW/OW7NO>_=>ZK+V/_)L_EC];?*&3YF;(^'_`%GM_P"1IW7F-]4^^Z6HW9+C
ML9O3/+-_$]TX3K^KW)4=;8'/235,L\5318>"6FJY&J(3'.3)[]U[H^9ZFZP;
MM.+O$]?[0_TQP[$JNKX^T1M_&+OP=<UN=H=T5.QFW0M.,O)M:7<>-@KOL6E-
M.*J,2!0UR?=>Z$'W[KW6EM_PHU[.^!W0OR_ZI[7J/F;\XOAG\^WZ'3;VX-]?
M"G:C;]$_QSFWC7-MJ@[<P66[-ZCQ^/ILENN3)IB)<?FEDDEB=JZGD$="P]U[
MHRG_``F.W9\1^PX/FGO_`*:[*^:WR4^26Y=V];5'RE^5/S#Z_38=?OR>*EWC
M!UIL':U%1]I=JTB5&P,+#5R5\-1D),@HR,#LRTKTM/3^Z]UM:^_=>Z][]U[K
MWOW7NO>_=>Z(7\P]S_S$=ORSU_PWV]\.8]F[7Z]RV\=T;E^3VX>VY<CN#=&,
M;+S?W!P.W.MJ;"T6U,6V*HJ:H?<M=EJ](Y)WB.+*Q>9_=>Z)=C/YD7RB^6./
M^'FRO@CU1TGM3N+Y"_#S:WSF[9K_`)697?>3Z]Z/ZAWL[;9V-M*CQ769VWNC
ML+>^^>Q8:ZDAJ*:HI:7%8W#3U-7`7JJ2%O=>Z/\`?!7Y09GY8=$?WVWOLNBZ
MU[BZ^[%[,Z%[_P"NL1F7W-M_9?>G2>[\EL/L?$;5W4::FAW/M*HR^+^]Q=;&
M&UT%7$DI\Z2JONO='']^Z]T$^Q?^9@=V_P#AW;4_]]GL[W[KW0L>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NN!EC61(FD02R*S)&742.J6ULB$ZF5-0N0.+^
M_=>Z[=TB1I)'2.-%+.[L$1%')9F8A54#\GW[KW78(8!E(96`*L""""+@@C@@
MCW[KW4')UKX_'UE;#15.3J*>EJ)J7%T4M#%796IB@DE@QM`^3K,=CA75SH(X
MO/40PZV&N1%NP]U[JCWO;^8KM7^6YG>]_E=\S_CO\BNH.B>[^SNC]B[4WE!#
MT9V#48W<=!U;78DTVY-L]<=X[JW-14]34;6K&BEIJ2L0HBZM+.J^_=>ZNVVU
MN#&;LVY@-U865Y\-N;"XK<&)GEB>GEFQF9H8,C02R02@20R24M2A*,`RDV//
MOW7NGA98V>2-9$:2+3Y45U+QZQJ3R*#J36O(O]1[]U[KH2Q-(\2R1F6,*SQA
MU,B*]]#.@.I0UC8D<V]^Z]U1=\OOYJ'<?QV_G&_`#^7'M?KOK/-]5?+;9&4W
M-O;?&?7=)[!V[6T<_94,5/M9\=GJ+;D5*%V33EONZ&J=S-(`5LI'NO=7J^_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7N@^[:[(P73G579G;NZ%F;;75G7^\>Q=P)3&,5+X39.W<CN7*1TQF9(ON'
MH<8X340NLBY]^Z]U0=_)0_F;?S(?YH.5S/R([.^,_P`?>J_@)N=.R,)U?NG:
M>],WD.Y*3>^Q]S8K%4&)W#B\IGZN#-8NMHZBNBJJZ+&X^/[RBU1HD;!6]U[K
M8O\`)&9#$'0RJBR-'J7R!&+*KE+Z@C,I`-K$@^_=>ZY,P4%F(55!9F8@!0!<
MDD\``>_=>ZZ1UD571E='4.CH0RNK`%65@2&5@;@C@CW[KW1>_EGW%F/C]\8/
MD3WAMG&XC.[GZ<Z1[-[1P>"SCU0Q.4R>R-H9C<./H\LN/GI\@,555F.6.<PR
M1R>,MI96L1[KW5!W4/\`.6_F'=\?RB/CA\]_CY\`\!\GOD)V_P!X;UZZWMTQ
MU/E-UXC:VS-B[0WCV)ML[WIXLA6;FW-**N7:5!2/JJ)8J>JR/F?]I/'[]U[K
M9?V[79+*;?P62S.)?`Y?(X?&5V5P4M1'5R87)5=%!45V)DJH0(JE\=52-"9%
M`5REQP??NO=.RNC@E&5P&="58,`\;%)%)!(#(ZD$?4$6]^Z]UT98ED6(R1B5
MU9TC+J)&1+!V5"=3*MQ<@6%_?NO=<_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]T0W_NI7_P"6<_\`S6O?NO=+GX)?]DJ=5_ZV]_\`WXV[_?NO
M=&Y]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6O3_-`_DM[Y^=/;WR@[2V+V]M;:-'\
ME/Y>4'Q#SFW-T8W*25N-W_UGWI@?D1TMNK#9G&4M538_:==O3;L./W/'/35M
M6V,D<T0CFLP]U[I6?R9?Y?\`\[_BYV#\OODE_,*[>ZAW[WO\J/\`0-@J_;?1
M='74^Q*2@Z#V)7;)H.PLO--M_9F.J.P=^T-?$N6--B(@\F/6=IW,_B@]U[J^
MKW[KW7O?NO=>]^Z]T$7>O3])WQUCN#J^N["[=ZLIMPR8B23>_178N;ZH[.Q!
MQ&8H,RB;?WUMUDR^'CR#T`IJM8C:HHY986],A]^Z]U2E_,$^-OS*K=C?';X7
M=+=.?)OY??"RAH]Q[E^6>[<G\S.J=K?('Y`TLN>RU=MGXX;V[-[MW'@M[R=9
M96LJA4;IK:"5:G);?CIL%!+%"]6Z>Z]T(&Y-D_-?K7NOHCYZ=&?!*@S>X<Y\
M4JGX==V_!RI^0?2^S]Y=.[1Z_P"RMT]@='[OZT[-CKFZ3S^+6?(U-%G<<,CY
M8,=7XXT2>:CK8I/=>Z.M_+F^.W9?QWZ!SR]W';=+WEWUWEW?\J.Y]M[)R-1F
M-B;#[%^0>_\`*[_S'7FR<Q6TU-D<QM_8]+7T^-%;/K>MJ:>:=&$4D:+[KW1U
M=R;6V]N_'#$[EQ5-F,<*B*K%)5AS$*F`.L4P\;HVI!(UN?S[]U[J/M;9>U-D
MTM71;3P..P--D*S^(5T=!#XS65OVU/1BJJI"6DGF6DI8HPS$D)&JC@#W[KW2
MG]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1>/EQW+6_'7XL_(SOK&4$>4RG3G279W9
M6*QTT,M13UV5V;L[,9[&4M5!`R32TDU?0QK*$(8QEK$'W[KW6FI_)\_E3;J_
MFI_%';G\T#Y$_/SYBX7Y?]H]V;QW7LC>W7_:$U-M[K?']:=BS[>&!.S*E#35
M-'G*G;,^NC@J:&EIL=+!##&H1B_NO="?VQM3?G\ZK^?G\I/@?W?\@>[NKOAG
M\$>HZ3(X_J'IS?-;UW6]E;MF@V!C,KN#/Y"DII5KJG(9W?DLKSRP3F+'T-/#
M3^(23/)[KW0=?!K=O>7P,_F)_P`X+^431=_=N=U_&CK[X6=J]W=+U?9NZJ_<
M^Z^J\N>I-H[NQD.-W&7CGPU2<1V4:&J6F%-!55&.IZI(HI=1;W7NJP_B1\#.
MX_F5_(;[L^?7:_SU^5/]YOB5A^ZY?C!U/@-_Y#&]?;*@ZOR!W_NBHW5+*]5G
M=SYS>V;SU8L-9'4TT^,@$*(\J1I%'[KW2D_FHX?<GS`_X3F?RQ?YBG=?:G:>
MYN]ML;A@^.65HZS=;U&RM\X:'??=>WX]][SPE132S9;LB*@ZNHU&5\ZRRB>;
MRB1F!7W7NK#/YMWQ%HOY7_\`PGQP>/Z`[Y^1N>RG9/RD^-?<.0W9V'V?7Y3<
MN#RFX.N9H)ML[:KL+!@QB]F4K8""6.@M(AGN[LS6(]U[IZ^2O4/?'\E#^4UW
MS_,.VG\R._\`N_YO?/+:7Q]V?V!V+OK-P5NU.N=V]IY.NWIG=Z]6X9Z&6NP>
M7PVV\A58K&U-743+3NL,L$=/9($]U[HM_P`\OY8&Z?Y;?\JWIC^:UT/\Y_EV
M?FIM6#X[]C=D[USW<>7S6T>P:KNBMVW39'%4.`JM4B8[`Y7=T1@2LJ:^'(4$
M,J54<AFNONO=&/\`D'VYF?D!_/I_X3<][;CH4QFXNY?A5L;L_<&/BIVI(:/-
M[VVKW)N#*T]/2O=Z>GCKJZ3QH22B6%S;W[KW6\W[]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJC_G;_`!IVO\HO
MY9/RNVANS>/86RJ/8'4^_.[\;D.N-P+M_)93/=2;&W1NO#[;S\CTU5%E-FYZ
MJIA!DZ)E'G@;TLKJK#W7NM/[^4[@ZO\`EX_\)]/E-_-KZ:[*[8?Y$;SV/V/T
MEMG9V8W"N5Z9Z\R4_>F)V5A>Q-L[#6@6&#=V+$Z5IJZJ6>(SQE3&(Y)`WNO=
M$D@K]^1?#_H?Y0?#_8?\^#='\UJ;,;'[7W9\BLIU=W!NKXS=K19[*5>:W;B<
M/6XS,;@I\]L*+'Y)#BIUH7BRRQ.*A/#5%8O=>ZMF_G'_`#D[1[R_F&_!+X0]
M_P"$^:N&^-?^RJ=>_(SY-_';X/;7W)7_`""[-[5WUM#<6<R&T*O!X#*X;-S;
M:V-4XN"DJXQ4,F-B:NE*&=8GB]U[I5_RG>\_DA\3?E7_`#",7TGTM_,9P/\`
M+,VY\.^R/D+TYM_^8%UKV-M[(];=P]5[.P>9&W,1F=U5.2HA0;CKUR-"E+25
MTE174<4$TR"2!I#[KW1(/B3_`"\^X?Y@G\IWY<_S@>U?GU\I,5\L,_COD_N/
M'4F%WU4R]95.P^NL+FZ/=O6V\]HR,\U;M_?E)3Y"D%)33TE#C:&2E\=-(B.D
MGNO=`#VUOO?/7_\`PDE^`.6V%O3=VQ\I4?._M&EJ,EL[<F9VQD*BE7?'R/JE
MI:BLPE;0U$],E73QRB-F*"6-'`U*I'NO=6K_`,T7!]^]^_S_`'^7W\2>L_E3
MW+\:\%\CO@SA=D[^WEUEN3)0YREV94XONC=O8$>WZ.:K.,Q^Z]W8+:#8Z/*>
M/[BFDF24EQ'H/NO=*3^6OL;M'^65_P`*%_D5_+9ZI^0/;G</QXWG\5<AVSB=
MN=Y;OJ=Q/1[X39VW=^8#)UU4S4^+I\IC\I75]'-D:6FI9*J@J[3JS(&'NO=:
M[6\NX^GODG\2_D?O?NKY%_.'?G\\'<GR>S&W>L-D]?Y_M#<W6NY=L2;YP.#F
MVOLVGV;2U>P%VI2XN++QI%15RU$573T<5)"U.R"3W7NOI=_RQ?C/6?$7X(?&
MKHW,U^_J_=F`ZVPN?W]_I+W;7;VW7C>QM\Q?WT[`P4^=R!:=L=@-WYVLHZ*G
M!*4M)!'$I8+J/NO='S]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T0W_
M`+J5_P#EG/\`\UKW[KW2Y^"7_9*G5?\`K;W_`/?C;O\`?NO=&Y]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=)'?^QML=G[%W
MGUMO;&19K9O8&U=P;*W7AYF9(LIMS=&)J\)FJ!W0AXUJ\=6R)J4AEU7!!'OW
M7NM3[I'_`(3P?S"OBM+FOCU\7?YQ'8'4/P!W'V/-O?(]88KK:C/<./QE?64=
M7F,'@=\1UL?\$KLQ%0105=9C:O&4]79II:-C)+&_NO=&O^;W\COO+>_SHJ?Y
MDG\N+YJU7PN^46\-FT.QNW8\]L&@[!V%V-04.)QV".7J\=,7AAR.2Q6$QZ5M
M/4T-=335%##51?;U"L[^Z]TMO@9_(ZR/QAQ_S1[D^0'R9S7RE^=7SCZWWEUQ
MV7\AMP;7AP.#VSA-SX2MQD>-VIM6GK)YTI'K#1359,L$;08ZFI::"EAAM)[K
MW4SX;?R7=W_%[^3CWQ_*ZS'>^W-V;G[EQ7?%!!VYC-EY+&8'`R]OXN''4$DN
MUZO-U60K8\)]NKS`52&;40NFP]^Z]T&^[/Y`2]B?R.>KOY2&\N_:./>W4.=J
M]^;2[RPNS*D;?&^U[*[`WSCVKMF5F:_B$V`EP_8-7BJA5KEG`;[A"641GW7N
M@R[>_D9_.KY/_P`JG(_`'Y3?S#MN=O\`9M)WUUOV#U_VUD^IW@P&Q>I^L]FP
M[2PO6$>+Q%9@,QN"LDE:HK6R=9(U09)M$C2VUGW7NK@_EM_+FZJ^:W\OZJ^!
M'=.8R:[<J.N.OMJT._=N4\,&<VUO/K6@PPVQO[!T-:\U*U119?#+*]),S1ST
MLLM.[`.7'NO=4$1_\)R/GOW1L/I_XC_-3^;/GNXOY??2N;VY58/I/9O5-+M3
M?6Y]N[*1Z;:&V<[O6KKJNL2GP^-(I::2LJ<T*&(ZH(Q)%"R>Z]U:!W__`">I
M^T_YGW\O'YW;#[.VQUWUC\$>K$ZNH>DEVED*^OSN'QM+OF@V_38'<,67IZ+"
MT&.Q^[8H=$U/.VFEX-VX]U[J\?W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T"/R8ZCJ._\`XY=^=$TF;BVU5=S]
M,]G=54VXIZ-\C!@:CL'9>:VI#F9L?'/3/718R3+"9H5DC,@32&%[^_=>ZJ@^
M%W\EG:71_P#*&W-_*B^0_85-W#M3?=/VM2[JWULS"U.SY:<]A;LJ=VX7*;<H
M<K6YN6CS6S,K]K54TLS2Q/54JEXS&2A]U[HDO2W\G/\`G4?&_KG;OQ<Z0_G2
M83:'Q5V5.<'L:6?XS[<S7=.T.O%R+5,&W,)GLU49."GEI:1FCI[U[1TH?1!X
MXTC1?=>Z-S_,D_DR[[^5G?GQV^<7Q0^5^:^*/SM^..TJ?86*[>J-H4>\ML]B
M[3C&15Z+?&W#44Q^YTY[)QL;55+4TN1E@GIW"Q/'[KW0U?"_X7_S$]M;B[@R
MG\R+Y][?^7VQ^R>J<GU1B^C]B],X+JWKG"4FX*F%=P;JKJN@2ERN6S^0PJ38
M\(\7C2"KD(:X4>_=>ZIKZ_\`^$R/RPZMVSW+\1.N_P":[V1L7^6GVWN/<VY\
MIT!MO8-%'V)D3FJ)8J?;65WK5UD\%#AZUZ&A@S;XXT\.;I*<B:C5W)'NO="=
MV1_PFU["WY_)J^.7\K:+Y3[.QNZNC/D+N?NRO[=;K;-3[?W#1;ESW9V5?`TF
MUQN9,C0U5'3]A*JS/5R(\E,;J`XM[KW1_NUOY0>Y^Q?YO'PN_F9TO=N"QFVO
MBKTB_5&5ZHGV?7U&;WA6IM/M/;,&8Q^Y8\S'0XJE<]CK,\4E-*X^T*AO7=?=
M>Z#+Y$?RO]T;)_F8?)/^<?\`WO3LS:5+\&^R.M#\5MN;;S%%V!O+(XOI^7;[
MXW#;XH\K)%3ON&+$%(!!0M5QS5`":F47]U[K2Q^%7R$K?C+_`"WM[=R=(_SL
MJGXG?(#8N?[7S'6_\N`=+8SL+,TF5EW?5_P;9=#NW>U!E,J*W?2QB::K@QTE
M##YQ]V0_W`'NO=?1;_E1=V_)'Y'?R\_BWW=\M]J#9O?_`&)UTF=WQB_X')MB
M2NC;,Y6FVQNBHVU)'"<!5;RVE3T.5EI!'&D+UA5$1-*CW7NK#/?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$-_[J5_^6<__`#6O?NO=+GX)?]DJ=5_Z
MV]__`'XV[_?NO=&Y]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]T!,_P`6_C+5;N;?]3\=NBZC?;5;U[[TGZEV#+NMZ]Y4G>N?<,F`
M;+-6M-&K&8R^34+W]^Z]T.WOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z(=8_\.5_0_P#9'-_]A_I;M?\`V_OW7NJZ>EO^9<8;_MYC_P`7+=O_
M`#(C_F4?_'X[@_X\C_JV?\=/^FKR^_=>Z%/_`-/&>_=>Z]_Z>,]^Z]U[_P!/
M&>_=>Z]_Z>,]^Z]U[_T\9[]U[KW_`*>,]^Z]U[_T\9[]U[KW_IXSW[KW7O\`
MT\9[]U[KW_IXSW[KW7O_`$\9[]U[KW_IXSW[KW7O_3QGOW7NO?\`IXSW[KW7
MO_3QGOW7NO?^GC/?NO=>_P#3QGOW7NO?^GC/?NO=>_\`3QGOW7NO?^GC/?NO
M=>_]/&>_=>Z]_P"GC/?NO=>_]/&>_=>Z]_Z>,]^Z]U[_`-/&>_=>Z]_Z>,]^
MZ]U[_P!/&>_=>Z]_Z>,]^Z]U[_T\9[]U[KW_`*>,]^Z]U[_T\9[]U[KW_IXS
MW[KW7O\`T\9[]U[KW_IXSW[KW7O_`$\9[]U[KW_IXSW[KW7O_3QGOW7NO?\`
MIXSW[KW7O_3QGOW7NO?^GC/?NO=>_P#3QGOW7NO?^GC/?NO=>_\`3QGOW7NO
M?^GC/?NO=>_]/&>_=>Z]_P"GC/?NO=>_]/&>_=>Z]_Z>,]^Z]U[_`-/&>_=>
MZ]_Z>,]^Z]U[_P!/&>_=>Z]_Z>,]^Z]U[_T\9[]U[KW_`*>,]^Z]U[_T\9[]
MU[KW_IXSW[KW7O\`T\9[]U[KW_IXSW[KW7O_`$\9[]U[KW_IXSW[KW7O_3QG
?OW7NB^?]S2?]U*?^9)?^5]_X_#_WU7_R3]^Z]U__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tpg57.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg57.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!;0)G`P$1``(1`0,1`?_$`:(````&`@,!````````
M``````<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+
M$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,7
M4G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R
M9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8
MF9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1
M``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B
M%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756
M-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>W
MQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:
M``P#`0`"$0,1`#\`W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW6H;\/OY?VR_YZ>`[T^?'SJ[T^3^X*/=GR1^0?5_QEZ4Z^[@RG5VQ
M?CETCUCORMV)M[#T&+VC14]%G-]Y.?`-497(NTM'7/'#))`TYG=_=>Z5GR2V
M#\T/CWT?_+L_E(5?\P?LO?&YOF;\U^U^J<]\Q]K1T^)[PVW\.^J,#F-\9GJ&
M?<M=7[IR*]P5&,DI<8,["8X:)*=Z&>&2FU>7W7N@\^:G\OW'?R+,'T;\^_Y?
M'??R#P%)M/OWI'JKY)]"=N=J[D[1Z^^2W6':6_,-L9Z#+MGA4P[3W%@I\W/-
M35D-+)%`U4TU.D%1!%Y/=>Z+KL'M'<_QD_X4&?*[Y9[@[6S.)Z3S?SPVI\!N
MWML;BW+DCLG%;?[[^)D_;'6>XZ3#IA,PM'447:/3$-.TJS4BF>KI81Z9IC[]
MU[H/OY7&[.U^Q/YF?RN^3W8.^]S96H^=7\ICY9?,G!;5;<^1R.V-B[-S_P`N
M\SU;T_@]LTDF(VZM)'A^K>K\6(YFIFFD$IF$Q$Q`]U[JJSX]2?RP,_\`R\>O
M\UL#?W\RBO\`YP60Z]EEZGBZ;JODY6X:K^57]ZJZ'J2';N2_A9ZS;"RY=,6M
M9)!6WCI?.:=OO%C'OW7NK@_YEE9\HOG3O'8'QFS&^SLGY(_RMOY6N'^7G?T]
M-N3%X+&[Q_F![SVMUMN/`]+XVHQ^X<;0;HJ<AC]EY*H"^:JPKRU#1LRNAU^Z
M]T.G\Z?Y9=>?-;^5G_)X^2JX;NS<G57R+^<GQHJNU>M.B)<M2]X;IP^4ZW[=
MQ/:_4^P:+;E9BJS+[ZESE!7XW&0P/&E56QPR0D!HV]^Z]T#G\J+;6R<W_-*Z
MTA_E7]9_S"OCYU+TAA]X47\SS8OSY[!?&4]3@=U[5KAT/MS&]/;BWGO#?8W^
M^XIJFOHJJ:*FI(Z17D724D:3W7NA5Z?POSQ[8_EC_P`\K:GP9W!N/)?(.H_G
M+?-?`8^BH]UP8K?62ZBI]S==Q]A['ZJW+N2/(T&UMW9+:$M33XEU\)IWD?[8
MI4-%?W7NDK_*`[$^%_5_S6Z<ZGZB[,_F.?RW.^-PTFX<-W1\`/G=C]U=C]?_
M`"LR!VZ9MOG8&^=XRTM%M?>FT"5R=)E8*3%UF4H7^W@I/`\OD]U[H;/A?_+W
MV3_/5V!VU_,*^=7>_P`H]Q2=G=]_(#8OQLZ@Z_[CR76.Q?C9T?UMV/GNOMJ[
M?P^&VC04V-S6]:N3;IJLID)#/15\D<,CP-4-4R2^Z]U7Y\L.R/EQ%_+,^=W\
MOWLWY,[Q[-[$^#W\T;XE_'?J/Y89:OR^&[+R_7W:FX,'G]DG><V,J!F*S*[#
M>L.JK-=4SU$;B%7\5-"S>Z]T;3MWYG]Q]Y["_E#]-?("JS>T/FE\.OYZ7Q(^
M*?S(P\>5CI)-Z[BQ.Q]^UVW.U*=L+D9:?.;$[RVO%#F(I#IIIZU:M4B$*1%O
M=>ZV+?YO'RJWE\)?Y:OS`^3G7):'L3K3JBH7K_("#&5:X/?.]<[A.O-H;EGH
M<Q!58S(TFU]Q;LILC-2S1NM5%2M%8EQ[]U[JE+?'\@#$;0^)N6^5VT?G)\S,
M?_,KVMU5/W[/\N,OW7NS-T>6[9QFSY-T[EHJCKJ^.QB[$SE*M3A:>`JU?38V
M2,S253I+'/[KW53_`,Q?DAMKYU[^_DG=T?,OJ#Y@]V[>[O\`Y=W;>\NS>I/@
M'3[JR':FY.R\%O"BPB[XQNUME97:<D6W9,MBILA70QLL./BJA$NN.,:O=>ZV
M@?Y'_3WQAZ[^/?9V[/C!T/\`.KX[[>WSVJ^/W+L+Y^T^\\5VQ4Y?9VVL.M+N
M/;F`WGN#<=50[)R%)N+PPU$,RI55=-.I6\(/OW7NJ@OYR_P[^=?R_P#YG-?G
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M-UX[<.>I*>J>>HRU7-5MI:H!_0%0>Z]U8M_)KV/\`^D,_P#*;Y&=)_%W^:=\
M4EZLZ42/L?-?S#\/V5@=L[AZ^JJ^NWOF)NM,+N[=VYZ7.Y_;;=:I)7201I44
MT%3%&I(JF'OW7NJR_P"73\@=\]4_.OXD_P`SOM+=^0_T=?SK>[/E?TCGNO9L
M]1Y67I>@W/V#A,I\*XLQMV#+UE'@I-VT'7[I/645'2_L2O+5M&`5?W7N@M_F
M15?P_J/YT?\`-%R?SCZ3_F.]Z]9]9];_``[W%M>L^#<N]:G;/3&-F^/U!6]@
M;@[EFP6\]I8G:F#S<%%1S4-552B$FAKG-K,WOW7NM@C_`(3M;;[PQ'Q([)W)
MN>N[/7XE=C]SYG?G\O7;7>W86&[-[LVK\6,UBL>-N4.]-PX"NRV+H<965D!G
MQ>-%7-/1QM*9?5+Y)/=>Z#?YW[%W/_,K_FO[9_E@[O[J[EZA^)/3/PXH/ESW
MILOIS=XV%E_D+N?<O<-)LG9&T<_NS%44V>IMH;;.+^YJ*431>29A)$4F6.:/
MW7NGW:/\KK,_RW\;\X<G\>OEQV?DOA[OSX-]VUH^(?;FZ]Q]E;BV3W;C]GU,
M([AZ[WWF-R1Y#`XBOQ&/:"NC:CGEEJYU4S%$I13>Z]T"FS=P[@;_`(205FY6
MSF9;<8_E>;[R(S[9.N;-BO3:6X72N&5,YKQ5H5!$GDUBWU]^Z]U49_,CJNYZ
M?L#^4KW5U1O[=>(WW\1OY*6POG1C,1!NG(8_%;^R7QVRG5.\=UX#=,9QFX5R
MQW-L9\M`I>F>22L:$R2",27]U[H7/EWW9N'Y<_SK/A3\J.O.V*[(_'3I[^8#
M\"?A;U=B-G[HRT6T]YU_8O3F<^4W<VYLQBI-O89ZR6DRNY<)A(==5.FB@G\D
M0$L>GW7NKP?Y.V8S&3^6_P#/,ILGE<GD:;$?S)LG08FGKZ^KK(,71#K/;<GV
M6.BJ99(Z*D#L3XX@J`GZ>_=>ZH2R.\=WC^6;V-7_`-Z]S"OC_P"%1M=MY*W^
M/945B8`=_8>`8)*G[OS)AQ"2OVH806_L^_=>ZWT:NJIJ&EJ:ZLGBI:.CIYJJ
MJJ9Y$B@IZ:GC::>>:60JD<4,2%F8D``7/OW7NM"CI3Y6;CI/GEU;_/9R>^\@
MWQR^6O\`,-[3^$=;UY/DHA6X;XK9K8VWND?C[VG)LELJR;?-!VOUE)/DZE,:
MF2J(Q*DI7R&1_=>Z,-_,!_D[?$#"_P`W#^69U+C<Q\CJ;9/S\WW\\MX_(G'T
M_P`C.QHCELML/JRB[4VF-HS)D"^SJ"@WCG*B1X:0A)J4I!Z54'W[KW1PNR_B
MMU_MO^;O\2?@!M[.;^I>@:[^2O\`)WI=*'+;QR^Y,\F!R?8\6VX,[6Y7-S5?
M\8W9BJ:N\M/754<LJ31H?HH'OW7NB\[5_F4]Z]*?R/\`N?XXYG+]@;@_F/?'
MWOO)_P`I#:-4E%.F^=V]Q[LS]1MGI'L'%R5LDU0O_&$\A!D(LA-4R2SUV++^
M<33QD>Z]T2O^8K\8^A_C5\W_`.7)\->_>N_GC\K>G^HOY5=1C,EM+X.0[TS7
M=&[.VL5W9G?XKVYG\#M+/;<KJC`9+*5^4FR53++K6IR%-Y2Y]^Z]U=U_(JZ1
M^&&UMV_('L?XO_%K^9Y\9L]2[=V5LC<\'\P_'=A[=H]X8C.Y+,9ZEFZPQ&\]
MV;EI<E4X2LVR%R=3"(I*9*J!+D3'W[KW4/\`X4<_`CHON#X9?([YO[GR7;>+
M[V^-'QES]-U;7;*[9W?L[:=(<7N"KS]%49S9^%K8,/GJI,CN"HUR3H9)(=$9
M-D33[KW10>T.A\/_`"L/Y5'5F3^"78/<O67R&_FE=C?R^OCGE^Y-Y=G;C[/J
M.K=S=U0SSYW?VT,;NN:N?;M13[>SV>@B.)6&LBJZNEJ(W5J.,K[KW7'YX_R?
M,%_*T^*._?YB/P0^6GRRV3\K?BIAX>V=Z;Q[6[=SG:N`^2&VZ#*8ZL[$V5V=
MLVOCH]M)%ONKTUDK4U(M'YHS'+3LCB6'W7N@R_G6?`WX[]H;)^$O\P19>[=H
M]Q?/;YI?R^>N^YL3MSOG?U+LREZ[[OVE18?=FW-I[?@JJ7%8*L3!X*EABKZ>
MGCD$R//H#R.#[KW0^?S)/C5TS\=.G/@S_(X^,>\.Q-GXCYQ_*J?L_L7=&_.S
M]P;FW#M3X]=+5F([.[IKY.Q]P9:DSFWSE,EC,1!CQ3U<<GCBJTC24-*I]U[H
M(=M_(_=6[?\`A,I_,`Z$W;N7(M\@_P"7?L_MOX9]H[AH:PTE5DLAU+NK&P[`
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MQSF?[AWMG-IBCB_TJXZ"LP>S:_(R8C!YBEI^NL9X:N`+/$R2%6!D8GW7NCI]
MT;AW!'_PD>P^Y8\YFH]R-_+!Z%R+;@CRE<F<-?-MGKIYJXY59Q7FKF+L7D\F
MMM1N3<^_=>ZJY_F<KTGNK^8E\#MM_*3J7YV_(GJ$_P`F#K#=C=;?!+^^N:[4
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M9:<8&BR4T3U-+C*F`4./>&"-4E`:3W[KW2TW/_(,ZME^`'6OQ%Z[^1O<'7_>
MG4/?<_R\V3\T*!:)NTW^5N5J<K5;J[-S.,I:JB#X3="9RHII,33U\7A@CI6:
MHGFIO)+[KW2)I_Y17SQ^5?;W06YOYK'S^V=\C>B_C;OK`]L;5^.?1_2-)U#L
MKM3LS;DBU6`S'=LDE?4TVZ,3@:^D@ECH_M)8YHY:J%/MDGD9_=>ZD?(C^2#O
MWN_:W\V+'X[Y`879^Z_GOW_\=_D'T=NK$XS=.,KNB]W]!X["T>.J=QU.+RL%
M7N">IDQ\KPFC:!8F=6-RH`]U[HPFU?Y4&2V+\O,;W[LWL#9^`ZQVY_*)PO\`
M+'VGUA3;?STU?@:W;V[ESN&WM#FJO+U"3;4H,1%'2+0R!ZTE-33GW[KW1P/Y
M:7Q*S_P2^"WQQ^)&Z=XXCL#/]'[*J]JY+>.!QM;A\1G9JG<^?SR5-#C<C/4U
MM+%%!F%B(D<DM&6X!`'NO=5I]>?\)X_AUV1O7Y(=Z?S%>M^OOE[\B/D-\DNR
M^Y%WK'4]E[)QW7O6^XOX-C.NNF<13[=WM@(,[CNO]NX..,9*HHX:JIEG</J"
M*[>Z]TA=H_R*.P.NMA="]&;%[VV'C.B?BU_.*V[_`#'N@ML2[/W*<ELGH:F?
M<&9R/Q@BE?.U<E3D<'N?<53+B\]4U=6\\50YJ4!"(/=>Z/OW+_+SW97_`,R?
MX]?S%_CGV'M[JC=.(VMG>H_F)LW)8_,S8SY-].5--CH-F4U<,-404J[ZZUGA
MEFQ5?71SJ%AI83ICB%O=>Z)U%_(^WO5_&CY:]/0?+3<W4_;';O\`,X[<_F1?
M'OO;IBBW!@<WTMNK?%?A*C;.V-R89MR8^+?,5%CZ*LI,BCSQ4DHJDFBC$L"D
M^Z]U/VK_`"L?GU\@.]?B_P!H?S.?G=UIWQL7X;]Q[;^1/3O6O0?QXPG3U5N#
MNC:E+/#MO.]@;YGJ:S,_W=P%6(ZAL7CXHJ?*,[I4:%2+3[KW2>R/\IG^85\9
MNWOD7N7^5_\`S$=K=#](?)_L?=7=&Z^AN^^DZ3N'`]5]K;WK*O)[OS72U<E?
M34NVL3N++Y.>I>C%%#%"L5+"ZU(@63W[KW3?D_Y`U/A?@-D/BQL_Y$9+>W??
M9GS$ZG^8OR-^4_<V#JLQNGN7?>PM]8O=&3IZNAQF3ER..H!B<8*3%T\M=5K3
M2RSSN[/4R$>Z]T*'SW_DEX+Y7_S&O@__`#$.L-][<ZFWS\>NVNM=\=_XBMP6
M2R*=]8#J'=&WLWUXO^XNLHJ:DWKMK#4V3Q,&1K!-IH*N&*VB`*WNO=7!?([H
M/K[Y3="=O_''M:DK:SKCNWKW='6V\8L7/!29:+";JQ51BZJMPU;44M;#C\WC
MA.*BBJ3%(:>JBCD`)4>_=>ZUY*G^3;_-DS71%/\``[<?\X.*K^#L>.7K^KS%
M#T+#3?+;)]*TWEEI>O*SM:7<\RO'+2>/#2RO/(&PJ>!Q+!JI']U[JPO:'\JW
M;W4?S-^!/>G2NX<!LOHCX/?$'LSXK8+J:?$UE5N?.TN\QBEQ6Y#N*EDI,8U7
M&^.:IR<LU.9ZZMFDF)U2,1[KW5O7OW7NJ6_EI_+Z^<.<^6.Y?E7_`"^OG-B/
MBYEN[NL=K=7_`"*V/VEU=_IQV7E9-@3R4VQ>TNL,%E\O!1;.[!Q6W,C44%3&
MBQ8^N6"GDD4RF9W]U[H\?P*^&FP?@%\4NJ?BMUSF,MN?#=<8_+39;>.=BBI<
MSO?>F[,]D]V[YWGD:"FEFH\7/N;=>;JZL4D#-#2QR+$C,$U'W7N@E[*^$.Z-
M]?S//C-\^*7?V#Q^T^A_CAW-T?E>NY\1D)MP;AR?:.8Q^3H\]09F.J3&T=#B
MUH@LL4D32.;:3SZ?=>Z+#_,$_EX?-/O+YL_'CYM_"CY0]/\`QY["Z/Z,[&Z4
MGB[7ZDR':U+F,=V-N*FS&3JZ7'Q9.AQ\&BFI$C4NID1P2"02/?NO=`]V=\`/
MYS7R2^-_R8^,WR6_F'_&/<VT/D)U?1=74N9Z_P#C#6;)S>RJ',;ZVG5]AY<-
M3YMTW"-P=64&:P$=#(T">7+K4">)J==7NO=,'R%_X3*?RY-Q=$;EP/Q)Z7V3
M\8?E+CH-H9SISY(T]?V?O&IV!V%LG=.W=U4&X9]I9WL2OP=?3YA\#)1U*203
MB"&L>1(W>-%/NO='N^.?P`W=UM\VOGS\M.VMY;$W]A/G-U-\3>O\]UEC=NY(
MT.&K^B.H\KUUV`N7J<S+)1;AV[OBOS51+2PFFA:.C?QS*6)O[KW4C^61\#>Q
M/Y>&"^0/1\7:N*WW\6<SW9N;LKXG;!>GSQW1\?\`8N]:NJR6;Z>J,GE:JJH<
MAL_!Y(QRXA*;Q^$RU+2!Y)6<^Z]T'GSY_EF=H=[?('J_YQ_"KY+#XA?-OJO9
M=1U7-O?)]?8?LKK7N+J"OW#39^HZY[9VE7/2U=71XRL-3-05D$CRP-.\>@$Q
MS0>Z]TE_A_\`RINQ]K=U=T?+?^8?\E5^:/R>[KZ4RWQHF.#V)1]4=.=8_'W,
MYK)Y3.==[`VGAZMLF[[H:K1ZW(3S15,=WCCOJ:9_=>Z('_PPY_,!H^ALE_+J
MPW\UBHH?Y9&2R-;BALN7HS&5'R9Q_3>1D;+UG25'VBV=_AS;2DRK-1EBJQ-C
MI'0TPIR:`^Z]U9=V#_*LV_N_YD]`=TXK<F&P/QWZ8_E]=K_`F?IFGILT-T5N
MSNPJ>DP>-JL-NX5TD=!1X7:E**2\J256M0X<DW'NO=$LZ%_D1[]Z:^//\MCJ
M6K[[VCN+?'PP_F"-\VNX>P:C;^[ZJ7NZ*C&X-NX';V/CRV?K:S"Y[$=:C`8.
M.HFD:D$.&1A%<G5[KW0E=U_RJ/G)U]\I_DG\E/Y8_P`]=M?%W&?,F>EW'W_T
M_P!K]-P]N;.HNT<=@,9@$[:ZQJJC+^7!;MSD,$\]:):?QB>0>J6`004ONO=(
M_LK^1)N;'?RS.NOA!\?_`))P0]U;4^7^V/FMO7Y,=T[0KMSU7:7=V-WCE-[9
M[=>Y=I8[-3JM1DLC-04\<)J9T:DQZBH>::269_=>Z$*O^'/\\'L3K'O_`*I[
MQ_F&_%+>.VNXNA>R.I\$VS_B_7;#RNS]U;^H*;`4V]SE:3*5\V0@V_@JO($4
M#)HJII8PS(`77W7N@HW]_P`)</Y7F9^*><ZAV'T7L[9WR)EZ6CV1MSY.S5O:
M&1R>.[6H]JP8NG[=J]C2=G-M^6HK-RT_\2GQZWIU\K1I=0/?NO='5W9_+Y[M
M[-^2?\HKY,=D]S;*R>\/Y>FR.\\+W2E%MO,&3N[=W<G1VWNJJC<^TZHU%#3[
M7C7.8:7*U,-33RAEJ/%'ITAC[KW0L[V^#^YMU_S3.D/Y@T&_<%1[3ZG^)797
MQPK^N)L/D)-Q9?,;ZWW2[NIMS4F;2J7&T^-H8*?PO`\)E9^0UCQ[KW19M[_R
M<MK;Q_G';`_FAMORDIMG;;V'C<CNGH=L'`]%N[Y'[0VIN?K3KONBOJ!3_P`.
MJ:[:77&Z7@IYYD?*T];1T[0U*4ZM"?=>Z;?G=_+L^<?;?SWZI^>'P@^573/Q
MYWOU_P#%S._&?)T';'3M?VQ%EL/N/LFM[`RM?24J92BQU*)9%HHT8IYHV@?U
M%9"![KW1H?A%U+_-`Z[WGO.O^=_RYZ"^1>Q\AMBFH]D;?ZCZ"?J/+[?W6F5@
MFJLQE<N<I6KE,;+B%D@%-HN)7#W&FS>Z]T+7\P[XOYOYJ?"3Y+?%/;>Z\5L;
M.][=7YG8&+W=G,?5Y7$X"JRDE*Z9"OQU!-3UE73QBG(*QNK<W_%O?NO=!9\D
M?Y<^R?EE_+MPWP)[6WIGL"N'ZQZ?VWA^V.OE7&[EV?V7TM1[8J]F]E;22M:2
M>EEQVZ]KPU)I_/%+/1/+3&>/RM(/=>ZJSWC_`"<OYFGRQVIL'XU?S`_YIV-[
M;^%^S\QMFNWKLGJ+I&+K3N/Y!X;8U90#;^V.XNQVS=7]]09RCI/N,O+HK#-D
M0LYCFG6.HB]U[JSO^8?\!*[YC=4_$_JSK?=6U>I<1\9_F-\9/DE!1U>WJNMP
M]7LOX]UF6D'7NW\?B*BA3#U%=0UT,%'*0U/3I#I*6(M[KW1=_D%_)7Z0^<?S
MM[,^4OSTP^ROD+U)3]+]<],_&_H^HCWOM^?K"'`9?-[IWUO'.;JVQNC;$^4R
MNY]Q9V98*0)/!#3,29-5E'NO=%DWC_PGVV[L/`?S"^F_A5O/K[X[_&'YY?%/
M9'4U5TY4X+>FY$Z^[TV!N7(56-[43.Y;<V<RV?P>9VOFZZFJ*(U%*\%1*&19
M%_3[KW1BOB=\4/YU?3&\.C<!V_\`S`?BIV+\<>LXMK;:W7USM7XK3;6WCN3K
M[:^%BPE+A,5O*3-RR8O+O2T<'^5LK>I2Q4WTGW7NC6_S7/@_N;^8G\*M]_%?
M:._<%UIG=W;UZ>W53;NW'A\AGL30Q=8]K;0[%JZ6?&8RKHJR:3*4NVGIHRLB
MA))0S<`^_=>Z0OSS_EY;L^1'?OP\^8OQR[%V_P!)?*SXI=BT:U6^,WC\U68?
MMCXXYA<H_8O0&]H=O5-)D*[`[AK*T3T+2F:''SSU,JQ-)*"ONO=$OWI_+-_F
MC==?.#YN_*GX/?.7XY]*[3^:6[.H]U;HV1V?\=\AVCF\;/U'UC0=>X6-<Q49
MJGI8=;FNG;P(JNDZ!AJ2_OW7NK//BCU1\X=O=*=F[+^<OR'ZF[_[.W3E,]3;
M.WGU1U,_5&W]N[,RNT\?BJ7#97`"OK&RN2IMP"MJFJ0R%H)TC_L7]^Z]T&?P
M%_EY4OQ<_E@=<_RY.Z-RX3M_#83JOMCJ7L//;?Q^3VYAMX;7[7W3V!E,S24=
M%5UE1E,>K;>WRU&[>;69$:1=((`]U[JHU?Y#W\P+,=$[:_EW;U_FJR9W^63M
MG)X7%ML:DZ+QN.^2>X^G-NS1Y;#])9GL^+._81[1I\A''1J4$D<6/IH46G,"
M+1+[KW5MU!_+ZK<!_-!ZT^=FV-X;>PO5W6G\OJI^$>'Z>BQ66ESL$B]NT786
M(W%3[BGR$M&V"QV$H(J`4TL;U)E3R&1@>/=>Z+/@/Y2&_>K<_P#S4=A=(=O;
M0V9\2?YC'3F_Z?;'1E=@L_54_0'R1[&Z[R^Q]X=B[3IJ2MAPL6QMZUF<FR.5
MQE*M/4//%`L;B.*-$]U[HOWS?_X3]8WY@_RM_AM\+SV=M/:?R8^&G5_5O6>Q
M?DBFW<U_"Z[`X#9V&V3VIM:MPM'7QYJ78_8U!BH:PT3S%HZ^@HW9BB2I)[KW
M6PIU1LZIZ[ZMZUZ_K*Z#)U>Q=@;.V=59*FADIZ;(5.V-NX["3UU/3RO)+!!5
MRT)D1&9F56`))%_?NO=+_P!^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0&_)GOK9OQ=^/O<7R&[`K::AVGU!U
M]N3?&2^YDE0Y";#X^67$X"B2GAJ:NKR^Y<RU/CJ&G@BEJ*JLJHH88Y)71&]U
M[JFGXK_S7=^]2?%7Y4;Q_F1M1YGO+XC573N_^P-O]#X/;>;S6<Z;^36.V+/U
MO7;4VY@\W!@=P5.Q^R-R9_95::.NDJ*F7:K5$J)5U:T@]U[H7<O_`#Q>C-KR
M[MI][_%;YT[&JNJ]];!VGWU2[FZ4VI!+\>MN]MU>T:+J+LSMQJ#L_(T^,VCV
M9-N]#C*/&OE-RJE#5O58NF6.,R^Z]T+$'\W;X[S_`"`BZ7'6?R2CV%4?)2?X
M<4GRRDZIB7XM5?RDI\A)MN3IJ'>W]Y#O+^,'?\,FUERC;>7;[[E0T*UY;U>_
M=>Z##JG^>A\3NR7PN9W%UE\H.D>J=T]6?(;MS9_>O<W5&,P/5&\=N?%2BJLK
MWS!MK);:WGNW<V1JMC8>@J*KS_PI,?7QP,E'4SS:8V]U[H;_`(K?S0^MOE/W
M?A?C[#\=_EMT'V'NCH/+_)K:4'R-ZHP?7^+W5TUCMV[)V=1;EPE?B]\[J:6M
MS.3WU3,N-ECAR-!%$_\`$(:-WITG]U[JF/Y*_P`T#Y,=9[\_F,[RP_\`,@^+
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M4/\`/7ZZQ&R/ESU;TYL'O/JGY,=>_#?Y3?(OH7<'>'6>U,-M7>$OQ\V;F<K6
MY>78-5OC(]J;:H8<KBYVI8MX;9V]%E$H*A(2[!4?W7NA\V/_`#7^F^L#V]6_
M)S?V_*'9NV^].SNL?]*^7ZDP.V^K^O=\=8?&KJCOO-=$4E?LK=>[-W[PR>7V
M;GLOGMO9FOP]`V;E@K,4B)54U%%6^Z]T(?\`,<^8W:72W\K+LSYA]4097H#L
M.GV]TKN#!_Z8=F[?W3G.L,1V1W-UGM#-9#>VQ,5GLYA*W,8796[*JIEQR5TS
MPS@1L1,C(/=>ZK5Z)_FJ]H9'KKYWOF/E[B_DMU3\;<C\,ZK9/S:ZH^)%%L/<
MG]Z/D;VUBM@;FZ2KOC]O;>6W=K;NAPJP4[+N6EKZ:*GI=P5%A4UN+^W]^Z]U
M9CC_`.;O\=\AW]1],CK/Y)4FP<M\CLC\/\%\LZWJF*#XLYWY/XNNJMO573N.
MWM_>-MY'+MOO'56V8LG+MZ/`3[BII*..O9@&/NO=%NZ4K/YEE7_,M[,^,>_/
MY@VT-Y=4]$=2_'#Y';@QE+\,.MMKY;LG;7<_97>&V,MU0V<H=_U=9M!,5BNF
MT6+.0"JJ9'R3-]NA@4R^Z]TA?@/_`#Q-H[V^/73V7^:6TNY^MMWY_P"/GR"[
MTSGR,SO3E)M3X[]EX?XRY"HK^Z).L&P.X<SNVM_N)M>MI':23!4M#DWCD^PG
MJF:,2>Z]T.>+_GJ?%S_17W+VAOGISY4]43]-[`Z;[=EZSW[UQLL=K=D=1]X]
MFX/J/:'875NT]I=F[J3<M!C]Z[CHZ;+XV:IHLYBWJJ>.:B$U5312^Z]T\]M_
MSKNANA-R=5[=[J^.OS#ZL'96X^K=GY',;\ZOV/M?&]>;K[CR5%0[)VYGJ?+]
MITN=WSEC3URU>2CV-1[M&(ABG2L:*IIJF"'W7NE'L'^<?\?]\]O8'K2HZ5^5
MVQ]F[G^3&_\`X<8'Y';VZDQ=#\>,I\E]A[[W;UVO5U)O7$;SS>;>KWAN39\]
M/A\G_"1A9ZN>*BFJX*Y9Z:#W7ND]UO\`SP/B7VANVMP^#V3W_C=BY7;7?FY>
MF>[-Q['VMB.J_D<OQOP^8W%V-ANFJE]^R[SJ<W4;>VWD\AA8L]A<"F:H,=45
M%*[QQEO?NO=!I\X?YU.`Z(^/G7W8'0'378_9_:';WQT^-7RYV!MG+[3Q-3A*
M3H[O+Y`](]15M-NU*+L;`5U'V#'2=NPTU%24L]11KF:BF\L[TXE/OW7NE%A/
MYO.P=E8W?E/G]C_++O[N#<7RM[JZEZW^+W6_QWV5#WQM3'=-]0=3]I=H[63$
MX/M&MVCN?;'2^+[!I%R6X\AFJ&NR&5RL>/IJ.=UIVF]U[H8=X_S=.C=L]U==
M=%8+H[Y;]C[PWMTAL7Y%[CBV3TF1ENI>H]_9S+X"@W'V%UKNW<NU>Z:FNV_6
M8"M.;Q>W=LY_*XE(0)J<22Q1O[KW1Z?DCOO/=<?&[OOLW9T]/3;GV'TAVEOO
M:U57T0JZ6#/;7V'G=P8.>LQU1XQ4T\60H8FD@DTZU!5K7/OW7NJ@<9_/`Z\Z
MDZ8ZDJ.[>F?DYVOV'A?@7\5/F;\H.PNB>H]L9GJ[K/8?>.P\CD]P=B;CK:_?
MVW?X)BL3GMJ9.:7$TM/4Y)Z4@X^FK$IZLT_NO='6VU_,PZ>WK\H<I\:-E=3?
M)O>>/V[V!_H;W9\D=J]*YG/?&?9O>`VA2[YGZBW7O_&UM1G<'N/'X#(4@K,A
M-AQMVAK:R"DJ,E%42"/W[KW5B_OW7NM:3Y,?SD?D?UG\E.]^G\)T!V%B]E?'
MO^8G\)/C_%N7;G5E!O;-]O\`4_=VP=M;DW_UWM_'?W_R%?DNX]]Y+/??;2:A
MQU!3KMV6GEJI8:GRJ/=>Z./4?SM?CM%LC9^0I^C/E=7]V[S[N[CZ!H_B;!UW
ML:F^0&)WW\?\)M[<W;]1N!,IV?C^H\7MC96WMY8.IFR#;L:*9\U24\`EJGDA
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MG+[%ZPCS&=QL.1^*_P`GLC)DU^5&Z-EPTM#/355'3R83=,"Y"2*:DCA26/W7
MN@#^)?\`,5[F^1W=%%L_>'\WSK7JOLW)_+GNCJ2B^'5+\"L?NC*-MWK?Y';[
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ME\E0U-?1M4>;#+324P:<'SGQB_NO=+3)]J_-3Y7_`"P^2G5'QC[QZK^,/3_P
MKWUUEUQO+,;LZ-;O+L#O#MC=76FT^Y]R8"JHLCOW96#V-U'BMC]@X.D@K,?(
M^?K,E)6G7310P^7W7NE+V]_,GK?BV.N.I>Z_CWV_WK\L\AT[N#NOMCJGX*[-
MJ>X<)L+J[:.X*G:=;V_4Y+L++=8U%!LO=F;HW3$8DO7;@DJ5GHXH:QJ9JB7W
M7N@PWO\`ST/B3M7(559M[KOY,=J=6X'J3X_?(#?G?O6O5N+R?376?17R0I:^
MLV+VAOS.Y[>6W-P8C%T=-C9I*[&Q8NHSH2*5J:AJ1!/X_=>ZS9/^=OT-@(-R
MX_='QI^;>V>Q\!W7T=TA0])9?I+`KW#NW,?)7:O9N[.C-T;9VE2=B5<4NU]^
MTO4N8@"UE51Y;%SQJ<C14D6N5/=>Z5/_``\AT#+UWB\U0=(_+#)]\93O[/?&
M-?A;0]1XP_*JB[BVML^#LW<>$K]K5.\Z;KR#!8?J.LI]VR9P;F;"O@:J&6.J
M>5Q#[]U[I-Y7^=S\<$PW0";-Z0^5_9?:7R`W)WCLK'?'W:G6FS\3W7U[OKXV
M9/"83O#878NW.P^RMCX6EWSL3+;AIHFQ.(R68KJ^,M444=13(TOOW7N@(^3'
M\W?>G2OR3V?L;J'KSN3O_$]A=X_!K8.X.J&Z$Q>T,_U?L'Y(]0?(#L*23:>5
MW-V;L3>>:[=WQ/UO3N<5NK%8NFVXN(K8'6224%/=>Z-9U%_.+^+_`'1\B-O=
M#[6VEW9CMN[][+['Z8ZI^2&Y]I;7PGQY[9[:ZKI<Q4;KV#LG<,N^)=]'+//M
MC,4N,GR.WL?09BLQ-1#13SN81+[KW2![._F:S?&'Y'_S"J?O7'[NWCT5\<C_
M`"X]M=7[/Z@Z^IMU=HOO/YAY3?VS,E#!CHLGCLEO3^([PI</X:6(M501)(E-
M%/)((V]U[I_C_G,=)2;2E;_9<?F,._?]F%R'QDHOAU'U1M.L^2V4[,Q'5FW.
M\LT]%A<?V35]:IM/"=-;JHMQUN5J-SP4M+0RZ)"M1:$^Z]T63HG^=K14G7>=
MRW<?5O?G:7;O97S&^;>P>A_CWU;U'MK;G=.W^@_C9O>GQL]7V=@-][VV)M3;
M&3ZUH,QC<5F9*_,)D*W,5L45-#4LQ*^Z]T<"7^<;\18MH]>;S$/:51CN\.HM
MI=J_'.AHMG4=?F?D'DMS[ZPG55?TSUW046?G%%WGL/M3=.)V_N+`9Y\,<569
M))GG:B@KJJD]U[JT^@J)ZNAHJJIH:C%U-324]148VKDHYJO'3S0I)+0U4N/J
M:V@EJ*21C&[0330LRDH[+9C[KW4OW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%,^8'Q
M1PGS'V1L'J;?FYY:+IS'=O[$[%[FZV;`TF;PW?NR^OZFJW'C>F]X-65M,E'L
M?-;\I,/D,O'XJM,G18Q\?-"8*N5E]U[JOKO_`/D9?&+?$&7QOQ>AV7\'MN=@
M=??Z..[-I=&=,[.H-J=OXG#=K=9=Q]>YK<&`Q5;M3&4^[^NMV]=2IC\H8ZBJ
M&/S=?2ADCF<-[KW0R=]?RO<'WHW\P!ZGN;.;:/SRRWQ'RN4^UV;C<F.LI/BB
MVTVQ\6*$^<I?[S+O?^ZJ_<&?[7[+S'0)=(O[KW0<4_\`*/S</=E/DW^8/8TW
MP_H?FM/_`#!*'XBGKG8R5<'R/GWW/W)9^_EF_OM/U-%WK5R[I7;AH`_F84C5
MII1I]^Z]T'V]_P"3GMS$_%7HCJ`[OWOWK2?%GXW_`#\Z?INN\*NU.JMQ?(BA
M^:>S,S@,OMVFWWF\OD<#U+F\3%7FFQ^1F2NI%FD66H"1HP]^Z]T`_P#*XZ1^
M>&9^=M-\@/D]3_).;K3H[X.9GXH[1W!\J.LOC[TGO#+[AW-VSUGO&EHMD[&Z
M`WUV?1;QH\5M_K%WW%O'*Y2@_C%;4T,=#C*6.&H+^Z]U;KT%\%.J>D^R_DKV
MQE*#:G96]?D)\H,U\EZ#<>Y>N=K)N;K*MR?7W5^Q:+9VW-SRID\S4T&%FZU&
M1IJL24KI49"0+$A76_NO=%^[`_E883>_77RDVI0=\[VV7O;O;YS[<_F!]8=F
M[>VQ@9,GT'WGL'!].4771I-O9:JR&#['V]M[.].4U;5TN06E7)0ULM.1"4CG
M'NO=!11_RA^P)<SBN[-T?-O=FZ?F-'\P.N?EGN3OZIZ.V!0;-S;]9=(;V^->
MW.J\?T31YD;?V[M2FZ6["RE&E9'E9LE_%IER$DLOC2F'NO=%6Q'_``G(P.%V
MYO':5+\N:P83,=?_`#*ZIVY+!\9^I\1N@;.^:FQ\YL_L+<_;N_MOY7#[\[X[
MLP[2XAZ3<^:R4=,U'BFICBT>J-3#[KW1LMV_R6M@]GT7:.P^U>^^P,[T=VG\
MAM]_*;,=;[/P=!L+.Q=SY[HOK+HKKK/R=@4^8S=358_I:CV'4;EP-,,?"R[N
MJ:+(R2G^%4\4GNO=&X^3?PUWM\J/@EF?B%O_`+_J*;L//87JN')_(C'=:8MZ
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M9E#ARU"(HLA%4227D"JNEO=>Z`KJK_A/SL?K_I[M;K7)=U]<+N3L+!=&[.QG
M873OPI^/_P`=LC0[3Z9[VZO[WJ9=^4O6@I\IVEO??6;ZIQ]+6Y2KR='20(SS
M18_S<GW7NA+^6O\`)'Q?RC^4'=GR,3Y)2[$A[QI>A:[<&VZGX^=5]A;RP6Y/
MCA5[0R_7N)V;W3NJ4;\V5TQF-S;#QF5W)M/"'&39FO2HD&4ION7`]U[H,_@_
M_+0^2.7K,-NCY/\`>F],#TKUW_,9^6GS`VK\,LEU9U_2T=7V))\G>[MV](=B
MT_<>+R=1OB+K>H7<]!OFAV[*LLC9F5#45;TH^R7W7NG+XW_\)[>C/COV)G<O
MC^P]HYOK>GP_>6&ZVH*#XJ]`[7^1>V*3O#;F\MFUU-OKY<T^#RG9_:='M#:G
M8&3I<;YZ?&U4K+2-65%5'3R0U'NO=-L'\B#?>=V/5[4[5_F`[V["KMN?#WK#
MX<])9:D^/76>S:#J/9W1G?'2W?W4.XFP.,SU:F^\OC]R](XVESZ9*H'\=I)"
M(Y*#0`?=>Z%^L_D\]B8S(MVYUC\YMY=8?+.'Y$]_]]T'?6+Z/V%G]NQP_*3J
M+I[JWNW8N0Z8W%GJW;>1H,O6=+8K.XBN%=#48;((J*LT*NDWNO=*CYL?RE]Z
M?,/:?3NU*CYJ;YVQ4=;[3VWM_,]D[JZ3ZC["[O?=&VZPU8[FZ7[BQE'UUO+X
MZ]RYY*VLAR>0P,TV(JZ=J>'^%K##-'5>Z]T>2EZF[D[)ZE^6?3O=.^(9<'VI
MF>UNO^FMPT>`PT>X=I=(;SZPP6S\/_>*EQN4J:/<NX<3NJISE9%55%1#55]%
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MBIJ8*7W7NB6]F?RJ)>P/EINKY'TGR/SV`V7O7Y1?$3Y>[@Z8?K/;>70]P?$K
M;6#V%AY,7V)_&\;FZ+:^]-A;=IJ.IH)*2H^TK#+5QR/K$*>Z]T`'R*_D-==]
M]5^8WC+W'@O](A^8GR1^5>UI>V_CAUE\A.HL=C/E#M#K/:N_^K-V](]C9!]N
M;VBQDG4^(K\1G_NL?DL?5Q-H3QR2(_NO='*R7\M78\W\LW?W\MK`[WBVEMKL
M/J7L#KG*]B;7ZQV'M.CQF9[.KLOG-V;GVYU-L:DVCL?`XS^\&=J9:+$4QC2G
MIRD4E1/(KU$GNO=9>T?Y9_6O8?SA^)OSLQ6^MT['[#^-B9^FW;M#!T=$^Q^_
M(:SJ3?G4^T<QOW&^>E-/OOKO%]@UR8O.K]S5KBY9,:RFG,30>Z]T,/7WPXVQ
ML_L[YU[^SFZ\KN[#_.K<^RLYN[9[4LVW4V=B]J?'S9?Q]KL#A]QX;+IF:P9[
M#;0^^-8AHJFDFJBD1_;20^Z]T3+KG^59VQC\Y\>]N=]_S`.X/D=\=?B3VGLK
MN'X]]1;EZJZKV?O>CWCU;#DZ/JG_`$P]Y[;HVW-VQB=A4.6=888J#!S9"6"!
MZZ:I"2)+[KW7?0_\NOYM_&JI_NEU%_,LQN'Z"7O'M'MZ/J+,?"KK7/Y=<7W%
MW9NSNS?6R6[.J^S4SDBUN7WMD*2GR1I?-312(R1?MJ@]U[H?OF;_`"[MG?,_
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M$6]^Z]T7/N7X`]H9;N[LOO'XH_,KL+X@9GY!TFT:#Y';:P'6/7':NUM_56SL
M&VTL9V1LN@WM3T\G6/>7]S$I<2^Y(WRE+/1XO'BIQM0:.(^_=>Z![?G\I?=&
M"J>J-Q?#SYI]L_&+L+8GQBR/Q$WSO_=NR-H_);-]O=49#=V2[$.Y-S'L6KQ+
MX_NJ+L7<&5S+;G@E?[BIRDZST<L8C5/=>Z99/Y*76.)Z%^4_QTV+W1O/;6P/
MD9\4/B+\3<')E=N8O<^=ZUVK\1\1O'#X#<TF0?*8F+>N=WA!N]GK$DBQ\-/)
M#^U=7TK[KW07?S#_`.7%W1OKY![$^07QV[$WMC=_=P_-3X#;AW1GMN;,V;FQ
M\;MG_%/JKY6[?/;4M%N[(RXO?F"R>7[=HX,KC*FF0FG?PQ$F8S0^Z]T*C?RB
M]\P8#;79.*^:V\\9\\<%\G=Z?*FO^7XZ9V%4X+<N\M_=54/Q\SVT,Q\=)<J-
MF?Z/*?X_8>@VS0TD63CKJ0T,=;]X\S2*_NO=,F^_Y,F0W5\48?CU2?*RHR>]
M=V=L=N=X]]=G]O\`QPZA[DVWW#VSWAG(]U[T["QG5F5?`'IK>6VMST5-/L_)
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M+>?W7NBJ[^_X3X;<[`VAU]4;H^2V([+[PV)WI\I^Y:KLOY!?$[I3OGKS?,/R
M[W#A-X=G8+>'Q^W944FQSG:#=NU\=6X?.8RHQL^/\,D*P&&9D'NO=&.R'\FC
M:%;MOH7!TG?V[MK5/Q`V1C5^(51L+KW8NP,#TWWM5=@4W9N_^^,CL79\>'V;
MNRKWUF\;3X9L!2TF$QU%LZJRN(5Y6RM36CW7NK,.@L?WSCL)OZ+O_<F`W1FI
MNW>P:KK^NP.WL=M<4O4<V3C_`+BXS)XG%Y;/4R9"AIEF"2O6U-5/1F!ZHI5-
M-#'[KW0[>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJ[_`)FOS_WA\&,#T[!UYU_U
MEV)OSNK<&[-O;2P'8?8^\MM5V8S&U,5B\Q%M;8G7/4G5/=G=/:^\=UQ5[TU#
M2X+;TU+258A6NJ*<55/Y/=>ZK+/\^/Y+;QZ=R7>74'PFZTS.QNL?Y>/6W\PC
MOI^P/D7F-F9;:VV,]O;Y`[+WCUCL7%8_J#<M;N[>!?H:LJ\)-6)BJ1HS)%D6
MHY_"DONO=9?YA7\QSY?]A=+_`"NJ?C/T]!US\>OCW\BOC'\=NP/DO3]_56R^
M_<1VEE^U?C9N_?,NP^LL%M.KH\MU=#M[M/';;R$\VXZ#)5\>3J7BI)*=)$'N
MO=&8_FJ_(WYC]2?*3XE]9_'[*;8Q75':'QL_F#;F[67(;RK]KYZ:?JCJS9&8
MI=V8=\=L/<>1CW)U719O^)[>AILA01Y3(U4L-7+31PQ3GW7NB<](_P`Z+Y$?
M&'X>['SGS'^.F-SL^`_E7]&?+_JC>FV^_P"I["['[KAKMT=%_'NEJN^)MP;%
MP6-V)NGLC?\`W#B-P5E70Y'<?V&-EK&G\U9&(']U[JR;^5M_,^K/G]D^^=C;
MLVCUG@M]=(2]?Y8[DZ+WEV1V3TUO+:/8V+R<F/;#;Q[+Z@Z9SU/O#:^X=N9&
M@S&,EQ?[06GJ(998*A']^Z]U6IA?F7\G^F.VOYI.0[/[<W7N7XQ]E_*'Y>_&
M;I#/Y?*344GPW[\ZI^+VT^SNL:'&[QJ)YZG&=?\`?D>X*G'8B!I:"AP.[L+1
MPTVNJSX5O=>Z8!V-_,4ZOZB^$N/Z/[;SF_9?YOWPT^+O6&U=]]R=@;AWEF_C
M!\UH.AMO[][5[LPB;HW2E;3[)WU\;,#N[<+8_&+((^P\#1S>#3DYDE]U[HS/
MROZ`[HKNXL%LC;/>'ST[I^+OQ[Z!V3U)G]F?!'YC4&T/EQU!WQF)Z3*Y#MSY
M+XW<.^,!V/WUE^QMB9W!Y3"05&7J%Q='1Y.K;$U,=;3,WNO=$O[=[EW=W#WI
M\$MM8GO'^9[\W>HMS?RRMP]I'<_\O#>E1\9.QNSM]XGOO:6RZ/NKMW8M-VQU
M!A\<8<%55.(KZ<54LT>7E%J55U&+W7NMBSXWUVU.@?A?A=Z[JD^36VMG[*V%
MO+M+==/\P]\9'M+Y';3PM-)G-XY_&]C[FJ=U;ZJ<IE,'1I*E+30Y6NC@I$AI
MXG*JJCW7NM=O^6K_`#:\S7]K?(G.[Z[]R7?U=\C/C/W9\U]A],Y:MWVE%\9=
M_P#3F<[$WB_QFGJMPX%<7MNFR?QVSFT8RF#5L=_&]K9VI6)YJFWOW7NCY[$_
MFG_/7MG$_'':W6'P%ZFW#\@.^_C3+\Y6ZUR/RNCP.UL%\4J@]>X3:-'3]A5O
M5OVM?W[O[>&]9(J;#R4D&W\70Q0RUN75Y94I_=>Z;/F?_.RW_P#%3Y,XSI7'
M_'/86\<#M[<GQIPO<&(B[CW'G^\-BXSY%Y786#BW/F]K=6=3=B]3=:X+9VX-
M\QXLR[SWG@CFZY:<XY9X,A02S^Z]TO?YV6\]]X/+_P`NW9>U:OYCUNV^T_EA
MO;:_8W7_`,%.R*_K#Y!=D[:PWQ:[VWIC\'MW/4F]NO:>?'8/=&VZ',5\%1EJ
M:-J''S%2T@13[KW1+OBY\W>R>F]A]"87Y,9#Y+9W)]??/SYI[.I]@]N=RY"C
M^5/27QYZV^%W=_R0ZMVC\P,-MV#^[OR&WMG]@;4FR6!BR>2J<;58_*X7)IE*
MJKH"X]U[K+\J/YO'SVQ7PQ[.W95_&_K[XU[U^1?P#[@^97P:[.V7WO3]HY3;
MNS.JZ3KK=&]J;N/`Y?JS&XS;':^!ZG[9Q&:P]+CTS^"R.6#T$]5"NN:+W7NE
M)WQ_/^["^,7=-=T3VIT7TJ-V="[8^.T_RCQ>-[E[/RV]-R;E[FV[MS?6YJ+X
MC[<P'0&;I.UZ/KCKK=5%D:A]SUFS:G*5S345#3RO&LDONO=62=7?.CY+=\_)
MSMO9O4_Q-PV8^(/2W>>[_B]V/WUD.[<%M_M["=H;+V1B=U;FWSC.E,EA8,?E
M^H\1E-QT.*UP[@_O)/+(U5%C&BC9![KW5-_Q1_G#?,7XZ?`/HG>/R+Z*V[VC
M1[@_EV_)/Y0=/]J9WY'9[=O;G<>4^)K;!EW1)W=CZSKJ2EV53]DTW9%+-B*B
MDS&?KJ>*/370PRAXT]U[H]68_FZ_*3KS*=L=.=L?#'KK&?*6'>'PHVA\?NNM
MC?(R7=/7FZ<I\[LWV]A.M,?V[V5E>LMLOL6JZ\_T+9>HW)-A\=GZ656A3'O4
M>36/=>Z"7L;^97WD.^_C9A.^MFY3X];Y^)7S!^2&S?F%UETGVC6]D]7=N;"V
M_P#RN^\OEWU_6;4SU9B>OZW>V%R.U3B,E%C<[B\;+0;@I$U*#&LB^Z]T)>)_
MG0]U=5['C[9^9'PZPG6?6_:?PA[<^=_QK;IGO"D[9W7N3K[IS&;#W)N+K;MO
M&9S9NP<;L3L>LVOVYMBHIYL;4YK#^6IJ8S4:H+>_=>ZY9W^;/\SNB^S<EL#Y
M;?"SJ+KRAV!TSTQ\F^WMQ]3_`"+SO;,>U_COV7WD.E]\[QQ6.J.I-H5&0SG1
MSU*93/T<K14TV-HZVHHJFH6*)9O=>Z??F7\Y^Q.W_P"5[_-2[TZ8FR?56W^C
MMP]I=3?'/N[8&]LA'N7L.#J>MVEMC>?;.V,WA:6FQV+PK]F_QS%8>KQ.2R,=
M90X\32203O+2P^Z]TZ=L_P`U;Y)=;_(3OC9V$^*W6NY?C9\9?E]\1OB7V5V]
ME^^\G@^S=P9CY:XWX^08#,;#ZKINL,UCJZIV)GN]J:3++DLWCJ>HH%1J266<
M5$</NO=%Z[8_F&_+_O;?/PG['V;U%3])?"K>W\U3$]);8[3V]WW5OW-VGMSI
MW(=^=<[\V]VYTUC-J4&#QG6_96\NN<I)04D.XLI*HQ5*]=31B6-Q[KW6/X:_
MS]]Z_-CM7#=9]8]&=.QY#O/K?N7>GQHPZ=M]GYG>&#W#UK0U&Z=H;-^6E+3=
M$T>RNHF[2V)CJNKI<CM[/;MHL?7PBBF+SRQ(_NO=6A?R^?G_`%/\PJB[`[(V
M+U/7]=]([$;;?7[Y/>V=HJCL/)=]PX#%[A[>V4FWL"N0P5-M/J:ISM-@GRIR
M#R9?-4]8U/`M#%3U-5[KW5DGOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HF_P`K
M_@OTC\QLGU-N'M#(=L[7W=TID-XS[#WMTMV_O[IC>=%A>QL/08#L?9E=N3K_
M`#.&R=?LW?V(Q-)!E*)W'G2ECTNEFU>Z]T".T_Y1GPNV1UEW+T[MK:N^*#KK
MO#XUQ?$3=&W7[$W'6IAOC[1;K[@WAA=A;1KJVHJ,EAH=OY+O+/Q4=8\U17+2
MR01R32>%6]^Z]TF^W?Y,OPG[GWYN??6YJ+NO!Q[ZS?6>\NP.OMA=^=G[(ZB[
M`[,ZBGV\^QNV=[]6X#/TFS-R]EXZCVICZ6;*5-([U<%*GF5Y0)/?NO=&=^4'
MPAZ.^7.<ZFW3VHN_\?NCI:;?\>RMP]==B;IZ\RAV]VMMNFVIV9L?<,NVZ^DA
MW+L;?F%H*2/)XVL26&H^SB^@#!_=>Z"S<?\`*S^&F\]I;8V)O+K[,;JVCM+X
M88WX%8C!YK=^?GIH_C_A<_U_NK!4\DL-7!5C?V`W+U?A,A0;BCDCRM'64:S0
MRI)9A[KW0Q?%[X>=;_%&BW0NT=Z=Z]G[CW@V&@SO8'R)[P[$[X[`EPFW(*F'
M;FU:+<_8>;R]5B=JX%\A5S4U%2K#$*BLGD?6SW'NO=)K/?R^_BUN[J+Y8=$[
MRV#/O#J[YJ]E[P[<[[VQN3.93(09S?.],)LK"9'+8&I,\=7M1L8O7F(J\;]B
M\38[(4BU,#)+9A[KW2FA^&'1L&#^&^WEQ>X6QWP1J\#7?'L2;FR4E1B*G;?2
MNY>@,9)N:H9C)NO3UQNVMAD^ZOY*IUG/K4>_=>Z"/Y$?RROC7\D.WV[XSV4[
MYZM[3RVTZ+K_`'_N?X\_(7MKHB3MW8&-J%GQVS.UZ#KK=&%QV\\-0(98(GFB
M6M6FF:'S^-8EC]U[I$]A_P`HWXG[PR/362V'E.__`(RS="]*R?'CK=/B=\@.
MR/C\,=T]+N&BW6^R\G4;%R]%7Y_'R;BQT%;(U9--)/51+-*SRC7[]U[H=:_X
M.=3[C^)N6^&F_P#>/>G:O4NXP:;=F8[5[HWMO_M+>6$FWO3[XR&U=W=F;AR%
M9NC<.T\Q)3G$5N.J97IJK;TLF-D4TSLA]U[I7?);XB=*_*_:NR=H]L8C-"AZ
MZW3)N[9F1V=N"OV=N#`9"LV7NGKG-46/SF%:&OI\'N78.]<IALG1HP@KL;6R
MT\H:-BI]U[HN'</\ISX@=U;,^/VR]PXSM?:L?QMZCQGQ^V)NOJKNCL;JG?\`
MF^A*'!X+`5O3'8F]=B9W!Y[??7&XJ3;5%+D,?72NLM7#YT:.1Y&?W7ND_P!N
M_P`G;X6=T=B;N[%W/C>X\-)OBCZJEW'L38_?':.S>I\EO7HK`X';'2G:U;UC
MA=Q0;0RG9O5F!VIBZ;#Y"MI:F*),?`9()64L?=>Z,1\MOA%U+\S,7U/1]F;G
M[EV=FND=]U/8_6F^^D.V=V=-]B;:W97;-W%L#(U]%O/9-5C\S#'D=J;KKZ2>
M..1%EBJ74^DD'W7N@=ZY_E0_#SKB'9<L6WM_[]W%M3N'?G>V=WUVYV;N[M/?
MO;?8W8W36\OCYN+)=U;KWI7Y;*=EXU.G-\UN!HZ"O=J.CHEB6.,%6+^Z]T'>
MQOY)_P`#MDX/LC:]1MOMWL+:^_\`H_>?QIPVW.V>^>U>R,/TOT'V!-)+NSJC
MX_TVYMRUAZ?VGE52DB:/$M%,*?&TD0D\<6EO=>Z?9_Y07Q5J-WX/?#;N^4L&
M=&S^NMC]KMCOE+W+AZ/Y/X+JJ"3'[(;Y3T6'W/00]Z9;%X*3^%/6YCR553B4
MCHYI'IXXXU]U[H2H?Y97Q3H_E/6?+K&X;L7#]@9/=;=DY;8N%[:[`Q/0V8[A
M?;/]S'[LS'1U!G8.NLIVS)M<)2/F)Z)Y9/&D[JU2BS#W7ND7G_Y1OPQW+TKU
M/T!E=L[ZDZXZ6^-O=OQ0V)0Q=B[BAR=+T]\@H-ET_9.-R676;[O*YNNBV#CO
MM<A,34491_&1Y&]^Z]TO.[?Y:7Q2^065[?S_`&1MG=E5N+N7;'Q_VYF=RX'?
MFY=K[DV=7?%W-;[W#T=OGJ[<&!K:'+]==B[(S/8^5FAS.-FBJI?,(Y"\6I&]
MU[I*==_RH/AUUU!LADVUOS?N=VEVSV;W=G=Z=M]E[M[2WOV]V+VWTWN[X_;Q
MRW=VY]YU^5R79M'-T[O2KP-+15[-24E"D2QQ@H2WNO=`U1_R9?C'U9USW-C.
MFMNUG8N]MY?'S>GQRZIP/S*[.[F^0G273_4V\I)*G*=/[(V9D-[T>9V%U)F)
MHZ2*NHL#6T5<U+CJ2.*H00*#[KW1&?C7_*W^<?1$ORL[K&V_C[NCM[LKXK[6
M^'74W2'=_P`N/DW\I>NLUL([NGRVZ=T]P=Y=K];TV]Z7;>$V[E9,?A=D83;J
M4,U+3-%4UZR5354?NO=6K]3?RU^D=E_RTMC?RR]X15FX.GL3T?A^HM]56VJE
M]FY'=E5(T68WKN6DK<)%1U&*K]U;QEJLC+*@$[R5+-(SR,[-[KW0@;O_`)?G
MQOWN_=SY["[J=_D)\A.A_D]V0U)O#+T;5G;/QO'48ZNR>(,,@.&Q.._T(X`U
M5%#:&L,,OD_SS^_=>Z`RB_D[?"[&=W8'O#%4'<F,J]H=\S_)G9'5%%WKV9'\
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MUC8ZZ%JBEJFBGA$R%U`=;^Z]UQK.P-AX[%X[-Y#>VT:'"YCR?PG+UFY,-38O
M*>(VE_AV0FK4I*WQG]7B=K?GW[KW3K_>/;W\4HL)_'L-_&LE0G*8[$?Q2A_B
ME?C!KOD:+'^?[NJH1XV_>1&C])YX/OW7NGGW[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3!NN*2?:^Y((6SB338#,11/MB2&'<J228
MZI1&V]+4R14\6<5B#2-(RHM1H+$"Y]^Z]UH>?!IOCQM+XV_.WI[Y0_'CM/>_
M0&*[ZZZQ>Y/F7DNF.S,F^U.U:Z;-Q;5K?YEGQ3H]XXO978G:7QSWW'05O855
M2?WJQ>=?*4ARPDI6CF3W7N@\W1U)A-O_``[^$^\>Y*O;?6?3.U\O_,[WGTF.
MT?Y;V=^0WQ/^0':6^>W\=N7HO,XKX[UM30Y+XR87O_J['5C[`VH,54PX_'F0
M8TI5M"Q]U[HR.!^[WW\FMJ9OM[XT=G=.?S9>P?Y@?\M;MGHW:6.V;V=/NGI_
MX(X_J/H*3O[8?7G9M'2Q;0VS\;.OZ#&]KXC<V%DJZ:D-5*\%=2RU<E&5]U[K
M=[SYW`,74':Z8:3-7B^U3/RUL.+*^5?/]Q)CH9ZM2(=6C2I]5K\>_=>Z8.NM
MS9+=VTZ7,YBCH*#*KE=T8;(4^+J*FJQWW6V-TYG;,T]%/64]+5-35CXCS()(
MU=1)I-R+GW7NEQ[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ9L/MS`;>;+O@L-C,.VX,U5[CSC8VBIZ(Y?/U\5/#79G)&GCC-9DZN&DB62>
M35(ZQJ"2`/?NO=//OW7NO>_=>Z][]U[H*NF/^/&?_P`/GM?_`-^KO3W[KW0J
M^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NL<<T,QD$,L4IA
ME:&81R*YBF4*S12:2=$JJX)4V(!'OW7NLGOW7NO>_=>Z][]U[H*NF/\`CQG_
M`/#Y[7_]^KO3W[KW0J^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I
M/[L:H3:VY7I:_(8NJ3;^9:FR>)QIS.5QU0N.J3#7XS#K%,V6R%'(!)#3!',\
MBA-)U6]^Z]UHC_!CMOX\UOQU^</17RI[S[:IL=NCOOKS+YGYDP]I?(_!_%'N
MSM3LE]PIUCE/FI@</N;%=F_$7>FX]\[7I:;MG;E9FMJ4\\;4E(]511K2$^Z]
MUUUYNKI_+?'[XI[-^;G?.].M/AU#UI_-ZWQUSN_#_(3O/8'Q[WE\ENNN^]N8
M_P"/.7^//;.4SM%V3N_KK%]09K<^1ZGPNX,OE<A6P0/.JY"H"*_NO=9OCOW/
MOK=.[.BNSOD%WWWU3?S:X/FA_*NZVZUZQW1OOL/;78N=^&_8G2'QYROR&$'Q
MOCBQ^TMS=7;EI]U]IY+=V?FP<_VF1Q[RU%;2STL"O[KW6]WGJK-4>,GJ-O8B
MDSF50Q"GQM=EC@Z:=6D592^2&.RI@,41+`>!M1%N+W'NO=!QT5)63==4\N0I
M(J"OEWCVC)64,%9_$8:.J?M'>33TT5?]M1_>QP2DJLOBB\@&K2M[>_=>Z%_W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]TTYC/8/;U+]]G\SB<'1`E369C(T>,I00-1'W%;-
M!#<*+_7Z>_=>ZKJ_F`_S&^H_B9\1_DCW3U]VW\>]W=P]4=3;RWCL#K3<7:.V
M)6W7NW!T#/B\)4X##;FI-SY**:O9%EIZ,I4R#T*RL01[KW1,][]__P`W';'2
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MC_CQG_\`#Y[7_P#?J[T]^Z]T*OOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H)>Z>^NE/CCL?(]E]]=J["Z@V'BD8
MU>Z>P=SXG;&*,H%THZ2;*5-.V2R502%AI:99:F=V"1HS$`^Z]U7!'_,5^0OR
M3'VW\N_X3[][.VI6EH\=\H/E56Y#XN?&^H@:7QQY_:.'SV%RW??:N%*@O')C
M=L45+5#28JLQMY5]U[J4OP>^=O>"BI^6?\ROL3:N(K2TM=U'\#-B8#XU;6HT
ME;]S$CN#<C]E=[Y:A$8`6HILIA*J]^0#;W[KW2AP7\EO^7%257\4W[T'-\@<
M_*I6MS_R>[*[2^1E7DB2Q\E=C>W=Y;KVV\IUF[)0H2";W]^Z]T@?FG_)X^)O
M:_PJ^2?1'QD^)7Q`ZF[<[*ZBW7M'K#=R=,;&VA0[8WED,4:3`9:?<.U]F5FX
M,'#1SH@-31Q2SPKRJL18^Z]U6/W)_*=^1G;76F]-DT/\H#^2_P!9;IW/L#<.
MS,5V?UG\CNY]B;MVS7Y?;U;AL=N&.MV+\-MI93-+A:NK%4*&IKC3U.@Q2DJ[
M$^Z]U8/U-_+8^9GQ4ZBZIQGQ(_F"=AXS=>R>MMAX'=/17RJAF^3WQCW!N3;^
MVL3C<]0;2S>57;/?/56V*S)TDOVBXG.2TM%3:$AQ\:W3W[KW0H;4_F>U73>Z
M,+U+_,OZ9KOA1O\`S61I\%M;NG^,2[]^%/:V5J'CAI(]F_(6''XVEV#E\D[Z
MDPF]Z/`5R`A4DJ""1[KW5LU+54U;34]91U$%71U<$5525=++'/355-/&LL%1
M3SQ,\4T$T3AD=2592"#;W[KW6?W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW05=,?\`'C/_`.'SVO\`^_5W
MI[]U[H5??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=([L#L3874^S=P=B=G[TVMUYL+:F/FRVYMY;TSN,VUMG`XVG&J:MRV;S%32
M8^AIU^FJ21;L0!<D#W[KW55)^;/RC^;<CX3^6IU;0;5Z<J7DIJ[Y^_*/:VXL
M)U764NN6&2N^-W1DCX#L3OJ=E0FES&1;;^U?(H85%:ED?W7NA7Z4_E;=$;*W
MS0]Z_(?.[P^;_P`H:9ON(N]_D]+C-WOM&J:[/3=,=5P4=/U5TCA('8_;PX'%
MPUJ+_G:R=RSM[KW5F'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I-;QV9M#L3
M:V=V/O[:^WM[;,W1CJC$;DVGNO#X_<&W,]BJM=%3CLQA<K3U6.R-%.O#1S1N
MA_I[]U[JH*O^*WR?_ES2U.]?Y>E7E^^/BY0O-D=X?RYNRMUS563VEB?.]5D:
MKX3=L[GJYZS8]?20.[T^Q-P5%3MNL(,5#/C9'C'OW7NK"/BO\O.C/F/L"JW]
MTIN6JK7P&6FVOV'L'=&*K-I=J=1;YHE_W*[`[7Z]S*0;AV/N_%R*RO354029
M1Y:>2:!DE;W7NC->_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z3^[:NHH
M-J[FKZ3)TN$JZ+;^9JZ7,UU'+D*+$5%-CJF:')UE!"1-74M!(@EDA3U2HA4<
MGW[KW6E'\*ODQ4[J^/?S(VE\H/YDORBZNS6V.W^LN_NZ.U^E=YTW8FTOE1U?
MV'75^+VE1?!'L1,+ANU^B-S_`";WEB:7&_W(QD,&4P\%-'08O'TTM375$7NO
M=+/OGL7YS/T]\)=N;R[TRVUL-0=3_._Y05_5F^_YDN<^'/R7W-TML3=FU'Z-
MZ>[(^1/7&.WU'V_V]T]TIF5J-PM6O1:\WJFRV1A6GJS4>Z]TX[1^<V_.YNP\
M9\Q-C?,'Y!;#W)0?S%?Y;/Q@Z+^'>[^Q\51[9S?Q"^375?QUS^\J7M3X^U#Y
M&7L3LW<6*[FW;EJC>4SU62IJK:Z3T=5%3T%2A]U[K<?S^97`8N?*/C<SEUIV
MB!H<!CILKE)?+*L5X*&`B658]6I[?I4$_CW[KW0<]%58KNNJ>M%-6T0J]X]H
MU(I,E2O19&E$W:.\I!!74;EGI:N+5IDC))1@0?I[]U[H7_?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5:_P`BOYC6V]D]DY#XP_%7KK,_
M,CYDP0Q?Q+IWKG*4N.V1TW#6E4I-S?)SN.IAJ]H]+;<C,GD%'4&JW%7J--'C
MIM8<>Z]T'W7_`/+@W-W1O/;O?'\SCLK$_*SM#;V3BW'U_P#'W`XRNP7PHZ`R
M\<JST4NQ^I<K/4S]L;RQ&A57=>]3D*XNNNDI*"RJ/=>ZMEAAAIX8J>GBC@@@
MC2&""%%BAAAB4)'%%&@5(XXT4!5```%A[]U[K)[]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>ZK<^6/P-KNP-_TORP^(^]\=\:_G/M7%PX
MVA[/BQ4M;USWKM:@;S1=/_*79.->F'9/7M;I\=)D1;<&VY66HQM2FAH)?=>Z
M4/PZ^==!\@MP;LZ![JV%6_'#YL=0X^DJNX/CGN?(PY`5>(GD-)1]L]);L5(*
M'MWHW<]2A-#FZ%1+1R-]ID(::J70_NO=6!>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z)`_\MCX'5FUNR=CY_P")_1.[]E]M]XY+Y([\VGO'K/9^YMNY
MONG*XN;"S[\EQ&6P]10IFX<95U,4$H37`M94A"OGEU>Z]T^U/\O;X)5G5&U>
MB:SX=?&FLZ6V-N^KW_LWJFKZ6Z^JNO\`:N]Z]ZF2OW9M_:<^!DPN)S]<]9*9
MJJ"%)9?(VMC<^_=>Z$VO^+_QNRO=&VOD;DNA>H*_O[9NWQM3:7=%7UWM2?L_
M;6V13UU&N"P>]Y,4VX<7BHZ/*5,*PPU"(L4\B`!78'W7NAU]^Z]T%73'_'C/
M_P"'SVO_`._5WI[]U[H5??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
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MCYG;[RW8U;\,/FQM[;_4_P`VMG86IS6(FP)JJ?J#Y9=<XMEIW[Q^..3R9\M5
M3`%3N/:D\CYK:M8Q299:0Q53>Z]U97[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[H*NF/^/&?_P^>U__`'ZN]/?NO="K[]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>ZK,^0W\Q?'X#LC-?%SX;=;U?S(^8^.AC3/]=[
M1S,6&ZEZ%6M731[D^47=+4U?MOJW%PEO*F%B%=NK)*NBEQY#B5?=>Z9>B_Y<
M^1RO9>`^4W\P'LFD^7?RGP<SY'8>-DPTN%^,/QFEJ%'^XSXX],9":MHJ/-42
M_MR;QSIR&ZJ[2'$](I\`]U[JTWW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T5;Y<?$'JOY
MC=<4>RNP3F]M;IVCFZ;>_3G<FQ*_^`=L]%]GXI&.!['ZPW7"C56%SN.DLL\+
M:Z+)TC24E9#-32O&?=>Z*W\7/E]VIL3M?&?!?Y_#![>^3K4-?4='=XX3'_P#
MI_YO;'P,0>IW5L&)V:CV;W;@Z`+)NO8SRF>E<M78TU&-D!@]U[JTWW[KW7O?
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M7">KK<G7.HIJ4>Z]TLMN_/7^8S\C-E_&KK;ISM#JGIW>F^/CW\W?EC3_`"2W
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M[KW7O?NO=>]^Z]U[W[KW7O?NO=$Q^<WRYK?AQU7L?>V`Z?S_`'OOCM'O3J/X
M\];=8;>W9MG8M1N/L+N7<8VWMB*MW?O"2/;VW\7'5W,U14>A>`;`EA[KW5;?
MR1_G&_(_X6[2P?9GR^_EG[AZ:ZRRN\MI[/;+47S/^,?8>^\E5;HW'B=OF+KW
MJ3:N2EWSVEG<8N5%7)BL-!/6-2PR/8*I8>Z]T*U1COGM_,>EDBRDG8/\MGX2
MY"21/X913T>-^?GR#VZTNG3DZZ%LEB?B)LO-TJG5#`:_?$D+D-)BF;CW7NK*
M/CO\:.B_B?UIBNHOCWUMMWK/8F+DFJVQN#IW:OS>9K&,N3W-NS/ULE5GMX;L
MS-03+6Y3)U-57U<AU2RL??NO=#I[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NBZ?*/XL=._,#JC(]1=S8.KKL1)7T&XMJ[HV_D9]O=@=9;\P<IJMK=E=8;R
MH-.7V5O_`&GD+5%!D:1U=&!CD$D,DL3^Z]T2#X]?*?M[XV=L[6^#G\PG/4F2
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M:FHF9(H(((D+.[$*J@DD`>_=>ZUA?YHGR[[B^;>S^O=J?RMN@>SOE%!\8/F)
MT)W+O'Y2[*VYMO/=)8+=?3>]7R,NVNJ<7NS>?7J?)[/8&O;R9:+;^4I\+1I%
MXY<GY'*I[KW13.VN@MY=P=69VCJOY=W\T?O;YW=I=D_&^6O^:7S$V-\=:3&[
M"V]LGY*=1]F;WQW7N$VC\AMS8+X]=:P;5V?7Q08O:F%66962.LGJ2SS>_=>Z
MW-/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T"_P`@
MOCUT]\I>I]T])=Z[*QF_.N]W4\4>1Q&0\U/5T&0HY5JL/N/;F8HY*?+;9W9M
MW(1I5XW*4,T%=054:2PR(Z@^_=>ZK(V)\B.X/Y;>[]L_'SYY;SR_9?Q<W1FZ
M':/QK_F#Y](S-@ZS(S)1[8Z0^:M730PT6U=]EV6DPF_F2'";F`1*]J/(E_-[
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M@?F%\8NG/DGMW`Y#:E'VGM7^*Y#:66FAJLCM'=&(R>0VSO3:=76TP%/D)-L;
MPPE=0?<QA8ZD4XE4`.`/=>Z,Q[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[H*NF/^/&?_P^>U__`'ZN]/?NO="K[]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HN/R@^6/1
MGP\ZX;LWO7>`V]BZS)4^W=H;:Q./K=R]@]F;TR/HPFP.K]AX6&KW+OS>^>J"
M(Z7'T$$LA)UR&.%7D7W7NJ[\?\<ODO\`S)ZJEWE\\<7G?CI\07E@R&ROY?&V
MMS/#OCM2A$GW%!G/F_V!M>N05M-4($D'6^!J?X/3DA,O5Y"1&@'NO=6_;5VG
MM?8NV\)LW9.W,%M#:.VL;2X;;NU]L8F@P6W\#B:&,0T>,P^'QD%+C\;04L2A
M8X88TC0"P`]^Z]TH/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=)/?>P]E=H;-W-UWV-M7`;XV)O3"UVW=V;0W3BZ/-
M[>W%@\G`U-7XK+XJOBGHZVCJH7(9'4C\CD`^_=>ZIJCV]\C?Y1>I]C8WL;Y<
M_P`LJB=YZG8%,<EOKY3?!K`J[23R[`\KU6>^0OQMV[2DL<-(TN[MLT45J1\C
M2Q>%?=>ZMRZ<[IZF^0O7.V>W>D.PMJ=H]:;PH4R&W-Y;-R]-F<-D8&`\D7GI
MW+T>0HY#XZFDG6*JI)E:*:..164>Z]T)_OW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NDEOG?VQ>L=K9;?'9.\]J=?;+P-/]UG-W
M;VW#B-J[9PU-J"?<93/9RKH<700EV`#2RH"2!]??NO=%9_V?7HK,=F]0=6=9
MTO9_>&0[LVM1[YVAOSI;J[>'8/2-#LC)',1XS=VZ^],1CFZIV]A,A58.:&(R
M99ZAW*D1%3J'NO=!NF\?YE?>?5F\AM;J7IGX*]B?Z0,-C=E9+NG<]/\`*:NK
M.K11Y1=R[HK-I]29O96V=O[WDKUHFQ5%/G,I2+"\HJU#JJGW7NA$;X>YO=79
M]'V=V_\`)_Y"]A4)ZPBZ\SG1>(W/C.MOC;FZW*;)GV;OO==9UOLW$TFXLED-
MWFMJ*V.'*;@R<6(J9%:B,1C1A[KW5</3/\J[Y??"K9G87QC_`)?_`,H/CYT;
M\2NQM[;FW=19?=_QPR^\?E1U##O21(\QC=H=AXSL;;VRNR,CMW&Q)1X#+[OQ
M%?D:&C@IH)7J%IHR?=>ZN&^-GQ_Z_P#BMT1U;\>>KH,C%L7J?:=!M7"39FM?
M)9S*M`TM5E=PY_(NJ&OW!N7-5=3D*^<*BRUE5(P500H]U[H;_?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]TV9JNJL9ALMDJ'&5.;K<?C*^NH\-1R0Q5>7JJ2EEGI\92
MRU#)3Q5-?-&(D9R$5G!8@7]^Z]UKS?"+^:I\ROD9\=OFEV=D>E>G]Y=W]/\`
M9F8VOL_XQXO<>X>J>T_CIFI8`D_7/R[V_O\`QT-?CML]8K33UM9O7#^4[EBI
MJV#&XH30Q"3W7ND+WS_.1^36T_CE_+0[&V3MCKG9VYOEG\0ZKY9_(SLC.?%_
MY3?)'I_I_;&-V%UGF:U<7M/X[;CD[`V]B_[S[\D,U?G*DX['8BF:6>J,P2.;
MW7NA&E_FS_);*=N2]@]?;2^,787P7V+\P?B7\%]Y[CP.X=[3]Q=H;\^4VT.H
M,Q0_(+I[/T60R'6N.ZBV_F?D!MC[;"5\-?DLIC8J^7^(4TJP1O[KW6P5F\]A
M-M8V?,;ARV.PF*IC&M1DLK604-%`TTBQ1"6IJ7CA0R2N%6YY8@>_=>Z#;HJN
MHLIUS3Y+&U=/7X^OWCVC64-=23)44M925':.\I:>IIIXRT<T$\3!E920RD$>
M_=>Z%_W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U79\OOGU0='[PPGQK^/NP:GY/?.7L3$C);`^/&V,I'CL?M#`5$GVR]M_(
M;>XAJ\=TWTSAYFURU]:IKLJR_;8RGJ9V]'NO=,WQ9^`>0V9V,GRR^8_8=-\I
M/F]E,;44-+V#58F3&=3_`![V_D[R5O67Q5ZXK9:JGZZVI&'\-9FIO+N?<&DR
MUU5ID^W3W7NK+/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U5=V[_+TW-L#L3<7R6_ER
M=A8+XM=^;FR29SL_J_,8BNRWQ&^3=8G%2>Y.J\)/1R;3WU6Q>B/>VU_LL[$Q
M)JTR"$Q^_=>Z0,W\X/8'Q]P>[,+_`#(NI=X_!SMO8^S-V;NCIMPU--O?HWO*
MFV1M^LS^5C^-G?>.BQFSM[[@S%-0,*#;68_@.YFGFB@-&[MK/NO=9L3_`#;]
MTYW:6,WYA_Y5?\TG([/S.W*+=^*S]-U5\<#15VVLCBXLU0Y>!'^4J51IJG%S
M+,H,8DTM8J&X]^Z]U9#\<^]]D?*'H3IWY&]:QYN'K_O#KC:/:.S8=RT$6+W#
M#MS>F%I,[BH<WC:>KKX*'*0TE:JSQ1SS(D@(5V%F/NO=#1[]U[KWOW7NO>_=
M>ZZ)"@LQ``!))-@`.223P`![]U[HJ_=GS>^)_P`=L?M/(]O=Y[(VS'OO==1L
M;9E'0U-;N_,[HW=1S45/7[?PF`V51;BSF0R.-FR,`JDCIR*7S*9B@-_?NO=!
M[E?E'WUN[=O?G6W1WPV[7?<?5&!R4>QNTOD)6X/ICX]]N[^H\SC<=!MW:6YL
M?6;Y[+K=MSX^KGK1FX]K&BD2E,<99I$/OW7NF^#I[YV=H'H3='9_RFVK\?JW
M9];+GN[^H/C'USA=W;2[0KJ7="Y7`;=INV.[,9D]XX3:R[<A7'9B.DP]+4Y%
MY)98)J/]L)[KW2DV1_+V^+.T,EVYF,WLG-=R9/O+<^+W5V/+\A]\;Q[\QV5K
M-N;BJ]U;1Q^-VUVGFMS[3VWAMEYFL:3%4V.H*5:0+&H)$<>GW7NC835VS-@8
M6CI:BLVQLK;N,I8Z3'T\U1BMMX7'T5,@2*FHX9'HZ&DI:>,`*B!40"P`'OW7
MNBC=C_S+_P"7IU+--1]@?-;XQ8'*TX<RX!>Y]B9?<XT&SZ=KX+-9/<,A5N"%
MIB=7'U]^Z]T53L;^=?\``.LZ]W^_4_<N_>RMQT^SMW-B*KJ#X]_(7?\`_#\Q
M28/(O1UO\0P/5U7BX8Z*JB64S--X8U0NS!03[]U[JKS^5CU?U=\[>CN@ZG=?
MR3_GIT/<^X/C;UWV?VYV)NGOOYP]-]#9_?N2V]M9MYQ];;YS\F`Z^W%C\KN'
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MK$-.E152K"`?=>ZX[X_E*=;;AZ&^+W1^PODK\M.AI?BST./C'MWLSI?LW#;9
MWKV!T;7;-P.R]S;)[*QF2VCF^O<S+N*FVQ05J96FPE'F,1D:99\954;%@?=>
MZ26V_P"2)\3MC=G;"W)U_O+OO8_1^QMY]&=K3?$#!]D!_CIN_NGXU[1P6RNE
M>VMTXW*8?(=AU&Y-GX;9^`DDI*;<%-A\G6[>Q]374=1+!J;W7NKC??NO=!5T
MQ_QXS_\`A\]L?^_5WI[]U[H5??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
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MF1=:/V]_+_\`FGU]1;$@[)W%N'XL=_4>R=G/MVFW379;?LG5&[4V5%@,-44E
M:U3N<;C>G_AQAC-0E9XS$0^D^_=>ZU'=C?,[^75TO\6,'N'XM?-+^9S\/)MN
M]<X+KCM#;>+^-OR&[^^(D/<]#M*AVGO/:N5V1WEUMO3:&T\_5;U2HIJB';^?
MP+?=L%!"!4]^Z]U;Q_+@K/YQ_P`<_@!\,MMR?&?XI]Y[)VW\;NHZ&@Z^G[,[
M*^+?R1V5B*396*^SV9O;#]C[/WUUSEM[X*D44U=4&OP,+3Q,WVZW('NO="EN
MK^?1L+I?$UV8^2GPQ^4?7F,P>\L)USN?<G466^/WRJVAMG?^XJ.MK\+M++U_
M1W<N>W/3Y?,4>,J9J2-L,#/#`S`#@'W7NEEN#^>CTWA\KA:*E^%7\SJIPF=V
M_7YR#?\`E/@KW7@=@4$PPU5D=N8O*Y.IP=3N&.IW3710TD+TV*JXZ=J@23%$
M5B/=>Z*)+_./[X[PZBCB@P'9GP>[;K>P9W2AV_\`R^/FI\V=P+U1_!8?LJ6B
MICT[U!L^F[5GW%)()80,SBEHXE*2O(Y">Z]T(<GR=Z=[&[/WSV+N/K#^>'\D
M<7V#UUD.L<CT+4_%KO;JKXXT^$W!M*@VMO!L/U9G]O\`3=",MN&>FEJ!7Y:O
MKJS'U%=*:.HAA`*>Z]T-G2??VY.EMDX?K+X5?R,?DYUWLW`5N4K\%@-U1?%/
MXSX"++9P1C,YLU&3[CW%E?XGGUC1JZMJX!6U3"\Y9A[]U[H;!VY_..W\X_NG
M\-?AMT!03`6J^]?E7O7M+/T!;Z>;:_2744&#K]`/JT;BAY%AJ!N/=>ZX#H'^
M;MO]C)OW^8-\=.DJ:0D3XGXW_#9MQS^![JT-)N;OGMK>,E)4*C7%0<=)ZQ<1
M@<#W7NO?\-<;@W@K'O;^8]_,<[>\S:JO%87O;!?'S:TX8WEI/X)\<=B=7U4F
M.>]O%45E0Q7AW?Z^_=>Z>,+_`"7/Y9M!4??;D^+NWNW,I(PDK,GW[O#LCOV?
M(S@@F>MINX-X[SQ<DC$7(6G1+\Z;W]^Z]T<GKSXH_%[J2"EI^K/CET5US%1!
M12+LCJ;8>V&IPEM'BDPV!HY5*V%C>XM[]U[H8=R[>H=T;9S^U*\S08S<6"RN
MWJUJ-EAJ(:'+X^?&U!I'*.D4T=/4'QDJ0K`<'Z>_=>ZI^ZR_E)]K],]=;#ZD
MZO\`YM?\Q;:'6W6&T-N[!V!M.D3X;U]'MG9FT<52X+;.WZ6LS'Q-R.5JZ7#X
M>AAIXWJ9YIF2,:W8W/OW7NK!_AY\7MG_``P^-_6?QHV'N7>&\ML=94FXH:+=
M6_ZK#UF\=P5FZMX;AWQG,KGZC;^&V]A7K:S/;FJ7M345-$J%5""W/NO=&7]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T%73'_'
MC/\`^'SVO_[]7>GOW7NA5]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=-V/R^)RWW'\+R>.R7V<S4U7_``^MIJS[
M6H7]5/4?;RR>"9?RC68?T]^Z]TX^_=>Z][]U[KWOW7NO>_=>Z][]U[I/;MW=
MM;8.V,_O;?&X\)M#9^U<379[<VZ-RY2BPN`P&%QD#U60RN8RV1FIZ''8^BIX
MV>665U1%%R??NO=4PU>]._?YN<T^$Z9SG8'QA_EESS3T.Y>^\>N2V/\`(KYN
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MNO=>]^Z]U[W[KW7O?NO=>]^Z]UQ9T5E5G56<D(K,`SD"Y"@F[$#^GOW7N@C[
MG[SZTZ%ZB[5[N[%W%28_8?3.R=R;]WU64DU/6UE!A=KXNKRE=##1),KS92J2
MC,-+3DJ\]2RQKZF'OW7NJ:\W_,+_`)CFP.GL5\TNROCC\3\7\:<CMM>V,E\:
ML1W3N6H^;.W>@VIVS%9O:GR571P].[U[$VYM*^3R&TZ!(R6AEHH,A)5J%;W7
MNK>,!\I/C=N;88[/Q7>_44FPH\+MO<%?NBI[$VC18C"8O=\,$VVYMPUE7EX8
M=OOF/N42".L,+O*=`!<$>_=>ZS3_`"A^-%-G>OMKU'R&Z.AW+VS34E;U7M^3
MMC8:9KLJCKZV;&T%7L'%MGA6[PI:W(T\E/#)CTJ$EF1D4EE('NO=!]-\^/@]
M#M_LO=0^7_QIJ=N=,Y''X?MS,X_NWKK)T/666RV9GV[B\7OR;';BJAM3)9'/
M4LM%!!6^&66JB>)5+JP'NO==CYY_"]\_TYM6'Y0=)56X_D)08[*](86A[`P%
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MNK;/PH^>FX:[J7/83`KLM^A\3L_=G9K9G.5>%DRW5$78>_\`:&$W5A,+'1FM
MKIY*ZD\5%)&ZJ[.$]^Z]THZ3Y2=[YW>G1.%VY\#N_H=E]K[<P^Y-_P"_-\[O
MZ1V5_H"3)U>0IZO;_8&U%[%S^=R^[,'%2135-)A17Q-'4H(IY&5U'NO=)>G[
M:_F0;GV3VK5X?X==#=:]@X7<N`QW4&&[3^5-9G=L[XVS/E,C2[HW+NO+]7]0
M[BKMHU.-Q4%/5T%!'3U;UKSF&66E*&3W[KW28[FZU_F:=K[3I-OX+M_XK=0X
M7<G0&Y]N=H8#:VPNS]W;UD[EW)M'=.(:;K3M/+[SVO0;:V;B\KD,=-15=5MZ
M?)1/3RNX8,B+[KW6K1U%\N-B;:^)V^_Y-7R(WW\W\C\E*7X_;3V3C/BKU!\:
MNO>K,TG:N'I=P;;W#\2-CY3;&Q]XQ[\P/:--DZ/=N8WSDJP4E9MBI3*_?TTQ
MK$]^Z]UL]?$?^6_UWLKK?X5]@_)+!Y?L?Y?_`!T^,W4/4N4W[E^TNS,YA*'<
M.T=@1[;W!44NT6W>O7N7R$LM=5T\N2GQ4U551V9I#P??NO='NZAZ!Z,^/^`G
MVMT7TYUAT[MNKK?XE68/K'8NV=CXRLR.F5!D*VCVWC,=#65P29U$T@:0*Q`-
MC;W[KW0N>_=>ZA5N2QV-5'R-?14"2L4C>MJH*59'`U%4:>2,.P7FPYM[]U[I
MGIMY[/K*Z/%TFZ]M562EE:&+'4V=Q<]=),H9FBCI(JIJAY5522H6X`/OW7ND
M=OOO?H[JZK_A_9O<O5/75?X(*G[+??8FT-HU?VU4SI2U'VVX,QCYO!4O$PC?
M3I<J0";'W[KW3-U[\FOC?VWNBNV1U3\@>DNS=YXS%MG,CM+K[M78N\]RT&%2
M:GIGR]9@]N9W)9.FQB5%9#&T[Q"(/*BEKLH/NO=`/V/_`#./Y>?4.[MT[`[,
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M1/U_G"=&U=SA?B__`#*LXD?_``(>F_EU_*C%"G9O\VC+NGKW;\D[2`$@PK*J
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MMD3X/I2DQ&2P6?ZTV96=W;1QF;R#[DI<BTU?4ST=%4PTDGOW7NGS^?+_`#2_
MDU_+-VA\9ZGXO]>=*[[W1W7NCMJGW-/W>N[9-N[=VKU5L2BWE7UE&FTMT[3J
M5K*I:MD!>:=I'2."&"2:9`/=>ZJC^!7\[7^9Q2_)CX^?'SYA]=?"?:G6&]?D
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MOE/LE))<$Q`N/=>Z<)OYB_QC7(_('#TE=VYE\M\9:>LJ.U,;AOCQWQDZN,4&
MYHMH54.RUINO'3L>ICSLP01X%L@SP!JA0:=&E'NO=-\G\QGHTT'0^4Q_7ORR
MS>.^1%55TNR:O!_#OY)Y./;KT6Z8-H33=KBGZV+]14AR<XE2;<0Q\<E`KU:,
M:=6D'NO=.#_//9[9#O\`Q5#\>/FADZ_X]0U4N9CIOB[V/34W934FYXMJR0=(
M93+T>,Q':D\E5)]W&,=4%9,:C5:DPC5[]U[J,_SIE>AZ*R.-^&WSIRU)WC45
M,$GAZ(H<=5].)3;GBVR:KN_'9W>V)K]DTT_D.0B,4=<SXQ#.!]$/NO=97^9N
M_9:GY`T6.^!_S1GJND(YVVY-7[7Z;Q.)^0<D.Z$VV(^C\E4=U2'*+-3,<JC9
MN+!WQBE[>:T!]U[K`?EOWQ44_059C/Y?7R6EI^WII4W]#E=R]#8;)_'V&/="
M8#S=CT$O:E2,F9<:6RR)AI*\FA4`D3GQ#W7NJIOYO7RY^8M+TW)UI-\2.Y.D
M.E-V_+CISH[?'<^)^3/1G7E;V[TKO'=6?PM=@]M]A4.YJNM^/6/[9RN/Q&)J
M=P9QJ`8W&YJ2)IH:F10/=>Z`?L3KR;X,=]?RI=\?$?X(-\1.XOD;WY@^H>]>
MJMC?*/8FZ<'N_J?,5.<IM];1[+Z_Q6<ST/=%;M[86-&]Z7?V/A<[:J:%8J^L
M)J?&_NO=7K2]W_.J>7OVFH?@MM>D;8ID3H7(9CY5[)&/[Y*[K7%1S9*'%;)K
M\AU7%+M75EK5\=4ZN!26+DR+[KW7'_2S_,"G7H+[?X>].44F[F:3Y#_Q3Y2W
MCZ<@BW.M`U/LTXSJ6M;M"NJ=J$Y"*PQD*U`^U=U_SQ]U[KINP_YC-1)W]!2?
M&/XQT)VXSI\;:W+_`">WHU'VA_O[%HXY>T(\7T)6UO6,1V6&KF%%'G7%?II0
M#&34CW7NN9W;_,FG_P!`(3I#X=XXYC5+\G'J/D#VUDUV((]TFG6CZ86#H;'M
MV')5;-M5?<9<X!8<C_DYBDB_?]^Z]T6OY1_-#Y;_`!"Z_P"]M^]W8WX7[5@J
MLS#M?X4;:PN]>]>P.R>]]Y5VZ&AP^Q<OU=@NNL?N7,;VS.T-#PX_;#Y'QY)_
MWI8J)'JE]U[HF$'Q7_FW?S!-W?&3N'YUX+XB=>?'C`Y#!;QWI_+TR63[;RV&
M.1HLQ05M'NWMR7;E5+B>U=^TF+#U&+VSEZ^;:N`KTC-739"H$C1^Z]U:[%B/
MYE<5)WI04.X?@GA(0(:;XKR4^Q>]\C38"@@W0%BC[OQ$>^,)'F?%L-!$D6WJ
MC'(N4LX/VX\9]U[J1_`_YEQ?H'_C)/PA2.A3_G**W3_><DFY)!NAY;]#W[GC
M79Z-LS3!;/\`\:(R=YN8?V??NO=8#L3^8_51=_4\_P`A_BQB_P"/SJ/C77XO
MX\;^K*OKJD&ZVJ6/:--D^YVH]_U3;+TTEZ+^%H,B34:?%^Q[]U[K*.M/YA;3
M=`,_RHZ!C@VQ$J_(Y(OC1FG?M69=R&L,G7S2=P?\8X67:UJ$B;^)Z:J]2."(
M1[KW6,=*_/>HA[_IJCYQ]?4!WQ/&?C_D<9\2=OSUG1%,N[&RDB9VER/:<U%V
MS-)M&V*U58QZB8FLMJ'A/NO=$#_F=_$SYW]A?$3KFDC[XC^4V*Z8W+U3V'\G
M/CKMSXX;*VOG/FOM[K;N_;G8NX\/MQ8=Z5L.T:Z+8^),,.UH!64FXZBB6%Y4
M:IT>_=>Z('W9W!F_Y@U#1?'/XS_+GLOY-=R[]^17179O3-'_`+))_H*C_E;8
MGJ[MK%;^W/V=V1OK,;3P3KGMG]?4=1M6EP^0F&1S=;.:=89(YYR/=>ZV`C\:
M_E0U;T'5/_,`[+\'6$42]LT472?1<<'R'ECW+)F'FW*QVN\FQ_-A6&**X0P`
M0*)A:<ES[KW4)?B=\B?L^^Z:3^8?\BVJ.V:FFGZ\KDV%\=8IOCTD&ZGS[TW7
MD8ZE:'.056'9</)_'UR;?9@R*5J2)A[KW4L?$;N>:MZ`KZW^8%\K6DZ<IZ>/
M?5#CL5\=,=A_D9/#N:3/R5';5&_1M;64/W%`XQ3)MJIP0%`@(/W%YS[KW45/
MA7OY:#OBB?YZ?-263NFJIJG`UYW9U"E9T0*?=;[E--TPT73:18BFGHV&)D7*
MIEM6,73<3?O^_=>ZGI\+,^V1Z#RE=\TOFI6U/1M+1T^2@7M+:>,Q?>4M)N&7
M<!K.\,1B.NZ&@W74522_82BD3'1MCD6(*&O(?=>ZAI\#L<N-[TQK?+3YURKW
MM6TE=5UK_)?<(R/5CT>Z)=T+3]'U<>*C;K.CG:7^'S14H=),6JTYX&KW[KW4
MH?`_:[Y7H',U?R2^;E;6?'RDH:3$QR?*WL^DQO:'V.XYMRK4]\8;%9#'XCMV
MKJ9YOM)GRL$@EQRK3$>(6]^Z]TWI_+NZB7%]\XENVOEY+3_(:OHLCNZ>7Y;=
MZO7[6J*#=,V[8%ZIKO[Y"HZOIVKIS3218=J:.7'!:1P8`$]^Z]U/7^7OT.,O
M\?L_7;H^1.4S'QMH\?C^OJ[*_)WO2I?,#'[@FW+33]DP?WZCI.SZY\E.RR2Y
MJ.L>6F"T[7@58Q[KW03;\^&/\M_J[$=X83N#<$&T,+\FZJASG:E!VK\O.W-N
MP;B;%;NDW;1S[>FW+W)C:G9U'!N>HU$8*2@C=`M.^J`>+W[KW0>=7=<?R9.W
MNU>@-A=/]B_'3N#N3XR[=,G1FT]C_*C)]G[ZV/M[;&=?>$E9/B<5VSN#*[AA
MQF:RIJGJ,VE?)I<*S&)0J^Z]T5?Y33?R(.MJ/YF?%'L7!8;;&]>]\-5XKY-X
M/KCJ'O7L#=B9/(+4;YPV[*RMVYLS=N"Q^<VQE\RN>HIXI!%354:R,MD*CW7N
MM6KXV=7=Y_)CL[K_`"N_MN].8SX6]OKU5_+:Z%^67:GPUWQLG.=(=2Q_WYAZ
M;[T^->`WYMC'[`VAVC\J8Z/+T=9G,'N'+4-'N7=='45]+3O%2(ONO=;56T]V
M?$SI?:6Z>E.F_P"0G\N,YL?)Q8+:&[8,9\,?C?MS;'9M/US4&CVEF=WUO8/:
MNU)-Y009"F-535M=33U"R.:K0K/J/NO=6']3XO9N]>CL;W-2_P`MM>I^T>F\
M7G<3TKT1V/LWX];9[-QD.TQ)D=MXG8&Y]NYO<^S>O,/G\K52?8,N3I$IYF>6
M2./5J;W7NBKX_LCYY34FX*3;/\C[IG9$>[)X:K<\6\OEU\::2DW)4TE2]?%4
M[BI>O=@;M_B\Z5<[20O4&5TG+.=-]1]U[H\&[Z7O^@^/^QM[]5?%;X\3?*3&
MX;:U''U/O?LM-M=?=>BLG67<F(PW<&UNJ-SY27';<ED:6`46#A2K8$JJ,1?W
M7NBLX7*?SC/NY!_LJ/\`+`V7C<ID*5MQ14?R/[[W+592(U(DJLG))2?%[:,%
M35PQ2.8XIXY"TG)E4-8>Z]T<SY)4?S3?$[-@^&^0^+6$R<<]>F^6^1V#[4S6
M*2A%+2IATV=2=89K;\Z30U7F-0*R30T814TG4??NO=`+U-MW^;M3=C[1J.\^
MV?Y=N9ZCBRR/OO%=5=%?([;W8E=@Q#-Y*?:>;W9W]N3;F,RCU'CM+5T%5$J:
MOVR;>_=>Z7OR/ZX_F";MWW1Y+XO_`"<Z"Z<Z\BP%)2U>U^R?CGG.UMQ5>XTJ
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M=5_=]?#7Y"]7=9=K]SYW^:;_`#/=[4>R]M;JWL_5_3&S_BQ6;DW*N-IZO(8W
M96P=N[7^*64WI597(.D-'3)353SR2-J9U4M;W7NM?=MQ1T'\MO"6V7_-0W#_
M`#4<;W/_`+.KE^YX_@O\O]N]@9?O;<6-I=G[\Z<H.X\9T?C\9B=O9'H7R;"I
M\BFC&12005Z11Q1QQQ^Z]UL(=5?RU>ONZ>K^N^T9OF-_.#P%'O[9FWMXT&TN
MP?FUWYUEOK:46Y,52Y1L!O#:E"^ULOA]R8LU`@K*2OC>:FGC91IYO[KW5@/8
MGQ&ZS[6^/^V?C?OO<W=.8V5M>FVK!!N>F[P[/P/;69FVA3BGH,ANGMG;NY<3
MOK<F1R`N^0EJZV3[^5B\P9K$>Z]T4K&_R5OY>=#DL=E:KK3M;/5>)KZ/*X[^
M\?RL^5F8IZ?*T%1'54^0^TJ>Z/M9Z@31W82(\;@D,I!(]^Z]T;;Y(?"WXM_+
MV/:D7R4Z9VMV['L>3*2[33<TF85,))FDI$RDE(N+R>.!>L2@A#%]9`06MS?W
M7N@KZI_E<?R\>CM^;7[1ZF^'W1NQ^Q]E53U^U=\X?9M)_>K"9"2DJ*&3(T><
MJVJ<@,B])52(:AG:8ASZKGW[KW0R=F?#?XD]T;U3LGN#XR=!]I]@QXFGP*;U
M[#ZDV)O+=`PE(TS4F)_CFX<%D,B<=2M42&.'R:$UMI`N??NO=*?K/XV_'?I:
MNDR?3W0W375>4EH9\9-D^NNLME[+R4V-J:B*KJ,?-D-N87'5DM#/54\<CQ,Y
MC9XU8BZBWNO=*FKZEZJK\M/GJ[K/KZMSM55/6U6:J]F;<J<M4UDG^<JY\C-C
M7K)JI[\R,Y<_D^_=>Z56(V_@=OPRT^`PF(P=//)YIX,1C:/&PS3!0@EEBHH8
M4DDT*!J()L+>_=>Z=_?NO=>]^Z]TG-XX*LW3M+=&V<=N7.;-K]Q;>S6#HMW[
M9:@3<FUJO+8ZIH*?<6WWRM#D\8F;PLLXJ:4U%-40">-2\;K=3[KW5)6V?Y(V
M:V?T+/\`%_;W\T'^8!1=`U>TMU;&K^LIZ7X<Y/"9/:V^GS$N\\9E:K+?%"NS
M64;=%1N&NEK:FHJI:J>:JDD:4NVKW[KW5L?QDZ.B^-'0'4W0%-V-V%VS0=1;
M-QFQL3V!VMD,-E>PL_@\&'I<$-S9/`83;N+R%9B<.(*&.9*.)Y(*:-I3)*7D
M?W7NAU]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4+)429/'5^-DJ*VD3(4551/58ZK
MFH,A3)5P20-44%=3LL]'6PB35%*A#QN`P-P/?NO=4X?!+^4P/B9N_P":G8F]
M.[-T=L=C?*7[KKRCWWEZ:AAST_3F#QM=2[$SG;DE!3X\=K]_I-GJQ<WNW(LU
M9E(8(!^T6FU^Z]TW;M_E!;B@Z<^'&R^A_F3O_H+MWXE_$G)_"*?N?%=6;'WU
M!VAT#NS:>Q\!OK&Y+KC=]?/B-K;OR.<ZWPV9Q66I:V=\364A1XJR%RH]U[I'
M[&_D7[&ZKWIL#;G6ORA[@V]\-]J]I_&KY`;F^*&0P&S]P5.]N^/B=LO9.R^I
MMXR]YU<$&]\#M>>+JG:5?G,#3TKQ9.OP2M'44L-1-"?=>Z3O\[G^7A\OOG/O
MWX!;Y^+&&^,&>?X@]TY[NO<NW/D_N;>^-V=O6N+;-_@>SZW`[,V/NB7,;?K_
M`.`3-7F6HIK#QJ$D!;W[KW5-F_O^$\??'\P#YL=1?(SY#?'?X/?''H"3?7;<
MORHV_P#%3OGNB3LGNC-5V\M^23;L$U?TWL_;E)G,)NIHXJ22#[6:HH-;5,TC
M%(X_=>ZMGP?\G#Y*?%':V*V_\,_DGTAWEM/KV/-U/2?5?\R7XW;0[HJ.F<EE
MV&0G?JOOOKNGV=V!M"FGSE/!6-!-C<C$]7$)YO*Y8M[KW1'<C\R_YOGPCR.\
M5^</\HCXF]K[-W7)4_Z2?D%\9]KYU=J]@T,U5%75V;['K]F[0[AR*RY;)T_W
M,IW'@,/10>,3U$Z,H!]U[JZCIO\`F%?"GL/XF;/^3F/VMLG+ILVAQ?\`>GIW
MXXX7"?*SL?HG);AS45+6XZ?:?0F!W)N?'4>/G:*MR-33XNE2EI[SU*1B-RON
MO="_TK_,^_ER]XYK^"=8_*WHY=\9"?P2;(W7N"EZL[)JJXRE9:1MB]D4^T-X
MUE9#4N5D5*20K(;'DB_NO=6"@@@$$$$7!'((/T(/Y!]^Z]UW[]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z1O877FP^VMD;GZU[/V=MOL#K[>N(JL!NW9>[\/0
M[@VUN+#5JZ*G'9?#Y*"HHJVEDL#I=#I90PLP!'NO=%-^./\`+7^#WQ*WM5]E
M=!?'W;.RNP*G#3[;I]YY#.;TWYN7!;:JI$DJ]M;0S'8NYMVUNR=N5;1)YJ##
MO0TDJHJM&550/=>Z/)[]U[KWOW7NO>_=>ZK#^1W\P^HQ79F3^*'P@ZZI_EQ\
MRJ:.)-S[8QV9?$]&_&VDK%`@W;\J.VZ&"NQ^Q::%6\M-MFB%5NS,A=%-21HW
MW"^Z]T\?%?\`E^KUQV)+\J?E=V,_RN^;V<Q<^-F[?S^%3$;"Z6V_D#Y:SK+X
MN=:RSU^.ZDV'&S>.HK$>;<&=TF7(UDFOPI[KW5DGOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[K!4U-/14]165E1!24E)!+4U554RQP4]-3P1M+/45$\K+%#!#
M$I9W8A54$DV]^Z]U4_\`RX_YG5/\Y=^?(78^Y.O9NJ*K:FYAV#\96RWW-%4?
M(?X9[ER>7VEUS\A<%35]3-)4TV?WGLG.15"P!(Z>E>@=D7[@%_=>Z.=W'\TO
MA]\>,K-@>^/E-\>NG-PP4U/5R;<[+[CZ^V7N3[:LA\]'*FW]P;@H,S*M;"=4
M.B!C,INFKW[KW2?^/7SS^'ORPW9NC8_QN^0&PNY=R[,PM-N+<U'L:KKLM2XO
M#5=<N-IJY\RM`F$J8Y:YQ&%AJ)'N;E;<^_=>Z`/>7\TGK/;^\]W;`V=\7?Y@
M?<FY-E[@R^V,HW67PP[?.UZS+82MFQU:,#O_`'[B]B;"W!C_`+NG81UE'DIJ
M250'20H0Q]U[HQW1'R'[![RZSWMORL^*7?/0^X-OU&6I-I=9?(,];[1WAOV6
MCPT>1QE32/LO?G8N&V]C<ODI!0^6NJ$>"16D:,QBY]U[HGX[B_G.[S*G;7PF
M^%735++SYNY/F#OO?F7H@WZ1)@NHNB9<57/'?UA<S"+CTDWN/=>Z.)5[;^7^
MZ_C1%M^L[0Z6ZC^6&0QU*N1[&V+UUN+LGI_;N3CSZ5%4V`V+OK<^`S^9IJC;
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M6*HI\SAFGH997HY76GJ9#&4DTNONO=51[Y_DDY[LCI"#XW;S_FB_S`\MT?18
M/9FW,9U[%3_#O$8O#8CKFKP>0V#!@Z_"?%'&YS"5&SZ_;6/GQ]3254-332TD
M;+(&%S[KW5W6U\/5;>VUMW`5N>R^ZJW!X+$X>KW/N!J%L]N.JQE!3T51GLVV
M,HL;C6R^8E@-14FGIZ>`S2-XXT6RCW7NGSW[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T%73
M'_'C/_X?/:__`+]7>GOW7NA5]^Z]U[W[KW1#/D%_+,^%/R2SR;[WOTKB-J=O
MTA>7#]]=+Y+,]']\82L9_*M;0]L=65^UMWU,D<WK$5;4U=,7`+1,0/?NO=$/
M[4_EW?-#:"0R;/[.^.?\RCKC#24]3C.E/YG?4&U,MVGCH<;415E#3;/^6W7V
MT)LO+EJ>:)135&Y-K95T*`RU#NS2CW7N@W^2/RVV+O@[%QG\P/9W\R'^4KO;
MKZIRM-@.Z^FM_P"X<K\;*RKS,-%3-'EN[NBZ??\`U+N+$>2CB--3[ZP&-2$L
M=*`&0CW7NCF_$+9WR0KMQ[(["ZU_FJ;'^<WQ-J/NQF:'=W4_3NZ=_P!?CY\9
M5C%38+OSH+.[+V]/E8LH87F%=MV1?#%(FC6UT]U[H6_D)\E?F=TMV9D:787\
MOS<7R7Z(AQ>(K*7L+J'OSJW$]GPU\E+KSV/JNFNS#LO[XT5;^W2M0YN?[B,:
MW$9.E?=>Z7/QB^9N'^2^=W/M";X\?+/X^;TV=AL?F\YM_P"271.>ZZH7ILE5
MR44,&W=_4-7N7K#>-=%-&6EI\3FZR:*(B1D"$-[]U[IVVE\]?A)OK=^<Z^VI
M\M/COENP-M9S)[:SVPU[>V-1[UQ><P]?)B\ECJO:>0S5)GTFILA"\)/VY1G4
MA2;>_=>Z-/09+'Y6ECK<77T62HY?\U5T%5!64LG`/[=13O)$_!'T/OW7NIOO
MW7NNB0H+,0``2238`#DDD\``>_=>Z*K\1?FC\?\`YQ;%WOV-\=]W?WNVOU]V
M_P!C=);DJY(H*>6#>?6><?#9>6"&&KJ_-@LU`8,ABJNZBMQM7#,%7657W7NC
M5^_=>Z*]\H/F;\:OAQM>BW/\@NT<+LV;.U`QVRMETL=;N7L_LG.RDQT>V^L^
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M7?6X!CZ3<K[:ZHWOUCG.C>V][U^WF:*&AP^T.[8]AU6,ASTX`HJO)&CIID]8
M;3]?=>Z)V_R>_FP;Z0KUO_+&ZTZOBE_X"9?Y-?-79M`AB<`I/5[=Z*Z^[?RU
M*\8/JA:4.2+74>KW[KW1P^U-M?+W?'1>T\5U;VAT_P!"?(6J3:U3OW=59U[F
MN[^O<5(,>QWEBME87*[@ZZR->ARC@8^LR&D^"/\`=IPS^GW7NBK[>^$7S>R>
M=P6;[A_FS=][@@P^8Q>5J]L=+]`?&KI#;.?I\=70UDN"RZ9'9/:NXCA\G%$8
M*CP9*"I:%VTS(WJ]^Z]T#G\[OX?]Z?*[XZX;!_&_:O=>_P#LV?<F%V=E-K=;
M?+&J^->VJ'JG/9O'Y#M/<6<QF0W-@=D]@[GJMIX>?"X>#)QU24E1EON&1H8I
M$?W7NJMNN/@!WSTA\G?A)WS\3OY)\OQMS?QY[`GVUV#N#=GS]ZA[;HMR_'7?
MNU,CL7>V`@H<SOK<>9H-Q;,%=3YO`?8&*GAGIJBG$6BJ]'NO=;2V?^._0&Z]
MY5?8FZ.C>G]R]@9""@IJ[?.X.M-F9G=]938N!:;&T]3N3)86IS,\./ID$<*M
M,5B10JV``]^Z]T)N'P6#V]2+08##8K!T*VTT>'QU)C*1;7MIIZ*&&$6O_3W[
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MZ^J*#9.]7E95\O\`',1D?*B^-KQEE/NO=(!.E/YNGQYC9>G/E?T3\W=FT42B
MBV3\S.NJKI_MK[:%CIH8>_?CU02;9RF1F4W-7D]C/<V!`MJ/NO=2$_F4=Z=5
MEZ/Y;?RS/F)UA]FJFOWW\?,5M7YE=6")0H>OCJ^F\L>U(:>9KND+[2,\:<2!
M6%O?NO=!?N3YF_R'OE?/5;?[OW)\-\KG<A)XLKMWY9]58#K#<\5=4W5Z+)0_
M('9>TZZ+)N\FDIY#(7-A<^_=>Z.C\?>N/@'L+I_>/37Q/SG2VR>K>PI=Q5>8
MQ?0?:F)HHTR>Z</!@LGF-MY?:FZ:BMVWE5QU+"*:;'34YI7B1X0C"_OW7NBV
M2_RX,1M6E(ZN_FD?S%>JJ*G4F.&N^56U.XL;1*!HA$4?R'V'VLT5/!<!8VD:
M.P`M8`>_=>ZK6_GN_+#??Q5^'?PP^.G4O\RFCZ][`[H^2FV>D>[_`)/[]K.L
MMP=B'H*JV/V!_I2[%WGC=@[,I,9C4P-358K[F?!X;&U+U!@A@,4DS-[]U[K7
M+C[T[4_E\_)#XN[>_E6?S8=]_-/`?([?72?4W9.Q^M_AKMK!4$U'L*3;76G5
M.%?$;L@VSUQOC<>>VOD*G%TQAW#ALQD*FFA-?6D$5$?NO=;FVY*+^='\M,53
MQ[1SO2/\K78<M%5TSUVXL1@_EU\H=Q)68P4T&3JL+CJO!]&=521U+-4)3PY'
M<M7$[*KNAC*O[KW03?#/^35\A/BSWMC/D!N_Y_8GO[?^2W+39CM/?G9OQ"V+
MNGO;L/`K4,]?L:A^0.]^R=Y;QZ[VGD*=C$*3`4M!3TZV\<0T*??NO=62_);X
MO=Z][;QPN8Z]^>'R"^+>S<=M],7D]D]([0Z'K9LYEUR%55ON.?=7:W5W8V4H
MZF6EEBIC!%&(%CAU*`[L??NO=0/CY\),MT9V!'V/N+YF_-CY"9:/#9+##;G>
M?;^#S'73+E!3B3)/U[LW8VRMM-F*3[<?;5!AO3ZFT`:C?W7NDIVQ_*D^"G?'
M:6Z.XNZNHL[VAO3=U?#D,FF[^Y>[Z_:$$D%#2X]:?%==Q=BTVP<50M!1H3!#
MC5BUZFL"S7]U[HQ/Q]^(?Q;^*%%G\?\`&GX_=2=&T^[):"?=;=9;&P&TZS=-
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MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=`S\B.LMR]S=(=F]6;.["J^J
M]S;YVID,#AM^4NVMM;S3!5=2$8?Q3:.[\?E-N;HV[E(XVHLICZF("LQM1/$D
MD,CI-'[KW6MMU!_(;^2?6_Q3Z[V;M?M_XP8CM3+X+O\`VKVATWW9\<,=\@/C
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M\,[`V)LW?6-T,G\/WCMC";GHM#WU)]IFZ&N@T-?D:;'W[KW1--S_`,JC^6GO
M'(KF,]\$?BI-F4;4F9Q_2.PL%F%]08JN5P.%QN06-F4%E$FEB!<&P]^Z]T'X
M_DO?RL_N6JI/A-TQ4L\DDDE/78_-U^.E,NHNDN*K<W/C)8;M<1M"8U(%@+"W
MNO=`M\B?Y(?Q8WC3=+Y[X?[$^._P>[<Z3[CI^W<1V3LOXE]2=B0;J9>O-]]>
M5FU-\[2R[;9I=T8:KI-\M7JU55R-%DJ"FJ`#+&KK[KW7#-?RU?FEVAFNB:'Y
M`?S*,)V1U'TE\A.DOD/%U=M#X.]6=1MN+<'1>_<9V#MC!KNW;O9.3J\!BZW+
MXM4J#!22$QL;+];^Z]U=3[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z"KIC_CQG_\`#Y[7_P#?J[T]^Z]T*OOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB(?.O^8!U9\#MN=956\=H]
MA]J]A]S[[H=B]4],]28>CS?8^_*F&OPZ[OR.!H<G7XG&30;-PF72KEA:I2HK
M9I(*2F22>H0#W7N@6J_YPWQ;IN^\'TE'M#Y$5.WZ_L/J;I3<OR%;I?/8OH3K
M/O\`[SV[C]T=5]#=EY_/5.)WMM;LS=&.S^(BD@;`24.+K\YCZ3(55)4U`C7W
M7NK6/?NO=!5TQ_QXS_\`A\]K_P#OU=Z>_=>Z%7W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TWX_*X[*BK;'5D%8
M*#(5>*K3`X<4V1H7$=91RV_3/3R&S#\'W[KW3A[]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z@TF2H*^?)4U'5PU
M,^'K4QV4BB<,]#7/04632EJ!_8F;'Y&"8#_42J?S[]U[J=[]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z@+E,>^3
MGPJ5D#96FH*7*3T`?_*8L?6U%924E8\?U$%14X^=%/Y:)OZ>_=>ZG^_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MH!RF.7*1X4UD`RTM!-E(Z`N/N7QU/404DU8L?U,$=34QH3_JG`]^Z]U/]^Z]
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M/B:7)Y&-J"LF%/*ONO=;&6?Q#9W%SXQ,OF<&T[1$9+`54-%E(/%*LEH*B>FJ
MXD673I>\9NI(X^OOW7N@KQ72-/A*0T.*[,[:HZ1JW)Y!H4W3CY`:W,Y*KS&3
MJ"TV!DDU5>2KII6%](9R%`4`#W7NG'_114_\_5[<_P#0FQ7_`-COOW7NO?Z*
M*G_GZO;G_H38K_['??NO=>_T45/_`#]7MS_T)L5_]COOW7NO?Z**G_GZO;G_
M`*$V*_\`L=]^Z]U[_114_P#/U>W/_0FQ7_V.^_=>Z]_HHJ?^?J]N?^A-BO\`
M['??NO=>_P!%%3_S]7MS_P!";%?_`&.^_=>Z]_HHJ?\`GZO;G_H38K_['??N
MO=>_T45/_/U>W/\`T)L5_P#8[[]U[KW^BBI_Y^KVY_Z$V*_^QWW[KW7O]%%3
M_P`_5[<_]";%?_8[[]U[KW^BBI_Y^KVY_P"A-BO_`+'??NO=-F,Z/I<,M<N,
M[+[9I%R63K<S7!-TX]_N,GD9!+6U;>7`R:&GD%RJZ4'X`]^Z]TY_Z**G_GZO
M;G_H38K_`.QWW[KW7O\`114_\_5[<_\`0FQ7_P!COOW7NO?Z**G_`)^KVY_Z
M$V*_^QWW[KW7O]%%3_S]7MS_`-";%?\`V.^_=>Z]_HHJ?^?J]N?^A-BO_L=]
M^Z]U[_114_\`/U>W/_0FQ7_V.^_=>Z]_HHJ?^?J]N?\`H38K_P"QWW[KW7O]
M%%3_`,_5[<_]";%?_8[[]U[KW^BBI_Y^KVY_Z$V*_P#L=]^Z]U[_`$45/_/U
M>W/_`$)L5_\`8[[]U[KW^BBI_P"?J]N?^A-BO_L=]^Z]U[_114_\_5[<_P#0
MFQ7_`-COOW7NF^BZ2I\=49:KHNS.VH*C.Y"/*Y:4;IQ[FMR$6,QV&CJ7$F!=
M8V7%XBFA`0*NF(&UR2?=>Z</]%%3_P`_5[<_]";%?_8[[]U[KW^BBI_Y^KVY
M_P"A-BO_`+'??NO=>_T45/\`S]7MS_T)L5_]COOW7NO?Z**G_GZO;G_H38K_
M`.QWW[KW7O\`114_\_5[<_\`0FQ7_P!COOW7NO?Z**G_`)^KVY_Z$V*_^QWW
M[KW7O]%%3_S]7MS_`-";%?\`V.^_=>Z]_HHJ?^?J]N?^A-BO_L=]^Z]U[_11
M4_\`/U>W/_0FQ7_V.^_=>Z]_HHJ?^?J]N?\`H38K_P"QWW[KW7O]%%3_`,_5
M[<_]";%?_8[[]U[KW^BBI_Y^KVY_Z$V*_P#L=]^Z]TVITA31YBISZ=E]M+EZ
MO&T6'J:T;IQ^N;&XZJR%;14K1G`^`+3U64J'#!0Y,I!)``'NO=.7^BBI_P"?
MJ]N?^A-BO_L=]^Z]U[_114_\_5[<_P#0FQ7_`-COOW7NO?Z**G_GZO;G_H38
MK_['??NO=>_T45/_`#]7MS_T)L5_]COOW7NO?Z**G_GZO;G_`*$V*_\`L=]^
MZ]U[_114_P#/U>W/_0FQ7_V.^_=>Z]_HHJ?^?J]N?^A-BO\`['??NO=>_P!%
M%3_S]7MS_P!";%?_`&.^_=>Z]_HHJ?\`GZO;G_H38K_['??NO=>_T45/_/U>
MW/\`T)L5_P#8[[]U[KW^BBI_Y^KVY_Z$V*_^QWW[KW7O]%%3_P`_5[<_]";%
M?_8[[]U[IM;I"E;,19]NR^V3F(,9/AHJ[^]./UIC*JJIJV>E$?\``?`5DJJ2
M-RQ37Z``;7'OW7NG+_114_\`/U>W/_0FQ7_V.^_=>Z]_HHJ?^?J]N?\`H38K
M_P"QWW[KW7O]%%3_`,_5[<_]";%?_8[[]U[KW^BBI_Y^KVY_Z$V*_P#L=]^Z
M]U[_`$45/_/U>W/_`$)L5_\`8[[]U[KW^BBI_P"?J]N?^A-BO_L=]^Z]U[_1
M14_\_5[<_P#0FQ7_`-COOW7NO?Z**G_GZO;G_H38K_['??NO=>_T45/_`#]7
MMS_T)L5_]COOW7NO?Z**G_GZO;G_`*$V*_\`L=]^Z]U[_114_P#/U>W/_0FQ
M7_V.^_=>Z]_HHJ?^?J]N?^A-BO\`['??NO=.&`ZPHL+N.CW35[KWON?)XW&9
M7$XT;GS5/74E#39J;&3Y)Z>FI,;0*:BH;#P#6Y?2JD`"Y]^Z]T)GOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JJW^;_\EOE7\4/B-N7N
M+XM8;KR#(;3K]N9/L'L/L25LK3[+VG-OS8^V?X5M38<,);=^\][3;H>FI9:J
M:GQN*IJ>HJ9S)+]M!+[KW0*_)#Y)_./IOY[=*['Q_:O0.7V9WCW/L3KKI7X.
M[3V+E]U=M=A?'^EHJ6J^1_RR[9[BJ9\95]/1]/TU?6U./HJ?'5F`KY,70X^2
MKDKLH5B]U[JM_N#^:)_,:WQ\K_YL'^RZ=H=']??&7^63U!D^^-I;=W5TQ4=C
M9#Y++TH^Y]N]S]9UF^H]P;9R&P\/6[_ZHW?@JK(TU+55^,RM'%]LTM*LCGW7
MNC\]/]N?._?_`/,HZZZLHOF+LO<O0]=\>(OFGW7TO/\`&K8F%RG6?6O<&>K]
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M'?<9BHB6J@I#[KW1:OD)_,#_`)AO;?\`,X^8/Q*^'W<73'272/Q(^*>Y^YX]
MZ[SZ3;N>M[+[?Z6P^Q<OV5U=,\NX=IR[7QTV6[VVYCLQ-&:N>AI<>DU`QGJY
M8Q[KW2#Z-_G,_+#N[Y`?';<,DVW]I;#[9[?^)G4%;\>\;TEN'<G1O]T_D9TA
MU+VON'L+/_S!7J:?9>QOD%MBI[0JX,9U=611Y7(38O'8XP-6Y9)??NO=;8GO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HHOSJ[&^0'5'
MQ:[>WY\9=O;&S7;.W-F;GS&*RW962J:38^P\;@]LYK/9;?V=Q..BDS&\5V[2
MXK_)L)2&&7)5LL,4D]/3^:>/W7NJ=>^OF_\`/[:/Q>^$?RHVWW/\>]I4G;?Q
M?^+^X=A]#/U?D^P^[_G_`/-CNW:^V]QY#H/#X.DJ\)2=*=8?9R^63/8&3*UF
M*I\A65U9'3T6,4R>Z]U@^47S@^?_`&E_-SV=_+:^(7;'4OQUV=%\:<IO/M'M
MK=G4,'?.1V_WSB=MT79\O7%!AJ[,[0HHJF'8VZ]K35#O-44[8C.M41`5BQQK
M[KW1*L3_`#V?EYDD^/O=W8=3M?IK;66Q?PXRD/QHQ?Q[WMOO`_,C87>N\\5U
M9WSVOL/Y+254>)Z1_P!#'8&9EIZ?&9'7%3RT5+%6RU+92F#>Z]UN0>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@@[YS7<>`ZHW;D.@-
MJ;0WCV\::CH-EXSL#/U.V]BX^ORF2H\;4;KWA7X^GJLO5;;V7CZJ;+5=!0)_
M$,G#1FDIGCFG25/=>ZUY-S?/CY]5O\L_X<?.6;Y&_'?I'";F^.6.WWORKR/3
M.3[5[;^57RRW5DGQ?4?Q:ZBZ7Q51AJ'!8'LRK@,4U?B*ROW`DTR^"DAIZ:HJ
MO?NO=#Y\N/G5\_\`!;MWKLGX][&ZGVQO?H#^695?*/Y/8?>&0BW1M'J'NWLJ
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M\H^^JSIC*=C;FW=O#K'O[L7I[H_I7X[_`![GR-!C<P_:-=@XJ9Y)<M-N)YJ6
MF@HZ:HJ:R:1/=>Z'SL?YM?S!L]NKXF]6=5=6=6;&^0NX?@5N_P"6_P`KNL=[
M5M36;0ZFW/N3^Y?7'6^(W-E98EW12;0V[O?+;LSGVV*:HS69EV4^&<TRU35T
M?NO=!YN/^8#\Z/\`ANG^5I\H=I4?5;5?R*RWP)D^4W:6X:&$5,Z?(SM[I7K?
M/;(ZLZRQ\7V-!F=V+V+6ULF6JIUHL+C\>\4$4U74P24WNO=;$/OW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J#E*BLI,;D:O'8]\MD*6A
MJZBAQ4=33T3Y.LAIY)*;'I65;)2TCULZK&)92(XRVIC8'W[KW5`?77RG_F1]
ML=._/&'=/:OQ&^,G8GQR^<=/UYOOM?=F,R.Y.L/BM\4J/XZ].]Y;TK\/%DEP
M]!W;VCLYM[OC#6YVHP&$K)ZBHK=4--3TU(_NO=1-M?S#OF1N_P",/P*FV/A-
MM[Z^0'RO^4N_ML]>9:KVJG5];\B/AYT+0]D]A2]_GKG>(J:/I:3Y`;!V-@(*
MR"HJ)FVQ#O),G0QU2PPTS>Z]TP[;^8'\P'?GPG["[@["^3?Q)^)IZ)^9'S(Z
MZ^6'R=S/7N6WIMGJOJ;X]=E;FV;M/;G174V;DQM)V-F=S;@Q]-B(ZO/9*FR4
ME+I:&FK,E4QQ+[KW5PGP8[5[D[Q^(G0';WR`V1!UYVWV'U[B]T;KVM!15^(\
M"9*6IEV[F:G;N6OEMH9'=>UOL<M58.K9ZK!U-=)CYG>2F9S[KW1K_?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=`?\D/CSUI\K.E=[]`=P4.5R77'84&
M%I]RT6#S-;M[*3QX#<F&W9C129C'.E91E,Q@:=F*$:T5D/#'W[KW13<K_*[Z
M'R/S`SGS?I.T/E?MKNK=&=V#EMSTVTODQV9MWKO<6(ZW>@DVUU_F=@8[*18.
MNZP\E"6J]ONO\,K&J9VEB9I6/OW7N@QWE_)&^`V^Z7;-/G=H]GQSXYNP*3L+
M*8+NCL7;.9^16UNTNV*SNW?FP/DWE-OYO&U7>>Q=Q=CY">NEH,XU0JB>6-&5
M))%;W7NCU]9_%SIGJ'N3NGO?8>VFPW8/?>&ZCV]OZJ6K>3%#!=(;5J]F]>X?
M;F)*BEVWC,7@JUTD@I@D4T@5V74`??NO=&%]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=!1WMTOL7Y&]+=K]`]GTF0K^N>Z.O=W=8;ZH
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M,.1[]U[JLKL#^3A\7-^;DZ'W=2]B_+?K3/\`QK^/VSOC-T[D.GOE)VEUG-M+
MJO9=!38RDI*-]M96E>+<&=HJ"ECS&3C,=9E4I(%J'=8E4>Z]TI^X?Y1WP_[N
MR.\-U[KI>W\+VKO/MK+=Q5?>NP.Z=_;![TP^;SW5V!Z6S6U-N=J;7RN.W5B>
MLLEUCMRFQ,FW!.V+^W!*Q*^EU]U[J+B_Y/WPKV_V#UGO+:^$[:VMM#JB7J/(
M;;^/.`[S[2H?C!6[AZ)Q<>*ZHW9N;H8[EEV'N+<^T5I*2J2JJ:=C59"BBK*I
M9ZDRRR>Z]U:'[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>ZQ3PI4034\H)CGBDAD`)4E)4*.`1R#I;Z^_=>ZJ6W=_)<^(^Y]M?%O:N,WC
M\INN,=\-NO:OK;H&HZH^2_9?7V4V?AJ^J^YK\Q_$L#D8*FJWC7(L<$N7)6N>
MF@BB,FF-0/=>Z-;B?@YT7C:/Y&PUB;ZW/E?E7U9L[ICN3=N\-^9[<^\\WUWL
M7JJJZBP&`Q^Z,K//E</#'A,MD\G,89!YMPYK(Y-KU5;.[>Z]T7[M'^3U\'.X
M,WU;F=Y[*WRT/6O6O5?3N:VU@>U-];:V9WIU?TA6XO*=3;'^2>TL)F*+!=X[
M?V-E<4M310YR&H&N:9)-<,AC]^Z]U:"JJBJB*%55"JJ@!5518*`.``![]U[K
MOW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U5#V#_`";?
MB1V!L3X^==#<GR4V%M[XP;N[?W]U`>K?D3V)L#)8/>W=N]LYOW>>[*W(8'(0
M2Y3<5-FMS9"+$ULH-3B**MF@IGC21K^Z]T:[K/X:=0=9;IW1ORGKNQ]]=@;P
MZ)ZS^..<W]VKV)N/L;>L_5O5E-N9</C(MS;EJ:S*T^1W#E-W5N4SU6L@ES67
M=:RI+S(K>_=>Z9O]D.^//^RO]'?$#^#;E_T*?'C)?'_+=9XO^]>4_CM#6?&?
M>&T]\]5-E-Q:_P"(9B/'[@V50/5K,2*V-&23TN??NO=')]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U6]WG_*N^+/R`V9W3L3>
M$_<6!P7R!^2>VOE;VD>O>W]W;'K]P=M;1V%M+KS;\DE9A:F)EVEC\3L3$5:X
M=@]#_%J"&MT>>-&'NO="3U'\"NF^I-S=);U;=7>/;.\/CSMSMS;/56Y^^NYM
MZ=Q9S;U+W77;<GWGD1D=Y5M?43YV'$;8APV-K"1-C<'45-!"5IZB1#[KW0(]
MN_RAOB;W)L3']<YO*=][4VUC?DSVU\NX(^M^]-\;&K)>\^YMSY3=^Z=T5=5A
MJR-JN'&9S-U<F&IY`T>(%1(*?1J/OW7NC]]/=84'3/6NT^L<9N[LG?E#M&AJ
M*&GW=V_OW<'9_9.<6HR%9D6JMU[]W355NX-R5R25IC2:IE=T@2.,'2B@>Z]T
M)?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJK]Q_SL_Y7&TMP9O:VX/E
MMM3'Y[;F6R&#S5!_<GMFJ^RRF+JI:*OI#4T6P*FCG-/4PLA>*1XVM=6(Y]^Z
M]T#/=/\`/R_EM;5Z@[0W-UA\JM@[@['P&P-VYC8>"S6P>YSB,QO#'X.MJMN8
MW)K#LC%2O0UN6BBCE5:JF+(Q'FB_6ONO=`#DOYYOQQV-G^MZ_)?S#?C)VKM;
M,=D[5VOOG;N!^(?R,ZWS=#L_.R55+E]S8K=&2[+WQ1T]5M]A'/X7QE2*A`T=
ME+!Q[KW1R_\`A]/^5#_WF%M3_P!`'N+_`.UU[]U[HQOQH_F._"GYB;QS/7_Q
MM[XP7:&\=O[>EW7E\%CMN[YPE31[>AR%#BY<F9=U;6P-+/#'7Y*",K%(\@,@
M.FUR/=>ZTA?D'_-E_F$X/O\`^=V+ZA_F(_(VM^1O3/\`,>[,Z9^+_P`#=K_"
M[;?;'5/:/6>W>W,-A]K[;W!W+BMLTDF$^XI*VNQTF-EFDRLM/0PE93)6++%[
MKW6PGN_^=YW_`-=[Q_F`5N[OB1U^G0_\LZBZPJ?D=V)_ILR^.W_N'*]F=-8O
M>.(V5UCU;3]=;B@J-V3]E92/#M)DLW2XBCH7^XDK'=&3W[KW1,_GW_/@^>W2
M?46Y>H)/C?TY\;_EYN[8/QE[_P"MLQ0]QUO=>T1\9?D+VIB^I*JIBJ_]%^%H
M,1W?M#?N2IL1D::LAJ<1#2U<V1Q\M?\`;1)-[KW1[OYC/\Z_M'^7+7[-H.Q>
MC>A=TYC;O5/6_9W?77FV/D'NW.=MU-'N+,X[#]BUW0VR=L]+;A6IV%UU4/4H
MFX>QZKKVFR\J`4T16.5Q[KW1!_BK_-(^4O97R8ZPVMGNUNQMX;<[8_G6?S"_
MCSU]A)\AUULO!4'1767Q\Z\[&Z=ZQ[!H*;JC=.9S>W-OY'<I*O09'&Y2GFED
M>:MKD5(??NO=6J?`3^:_W-\VODYNGXP5GQ3BZLW7\7\1OO"?/C,YC?-;68'J
M#N6AWON3:G5W7O2]>NVHX^Z<;O\`Q&VWSDN5<8BGHL5*C#RRND3^Z]U2G_-'
M^<_\P7;G\UCY;_'?HOY#_P`P[:G6W572W0FZ^O.O/@O\*.LOEM'0[LWSU^N1
MRC]F2[DGP6=V'@,YFH@]/6^;)&61IU2%1"%;W7NC5],?SB.S:?\`X;#[7[^[
M*;=>"WI_+?\`FU\E/E9#TKDL%2=<5N\_BSM63,;JQ6Z.O\CUEDM\+VOM'^#3
M4>2Q^-S>%H\9N!:J(4E53B`>_=>Z,?US_,E^4/S6R?67Q/W7LM?Y>&^_YA?Q
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M&@IJW:+8S)P9?;6-CHYM4JRRQL@/NO=")\B_YZO</PY[NZWZE^1WQ_\`CS+6
M1[PZ=V%W[M#HWY&[U[;[=V%/W#F6PN)[.P&W:+HO&[$Q'5L-=DJ"GI8M[[CV
MCN;)U(D$6,2&IQ\U3[KW43XT_P`]OOSM&K^'_8W<OPYZ_P"K_BY\O?F1OCX(
M[3[0VOWYD-]=@8WO/$Y[?.W]C9.KZP/6>(\6P-XYO9TF,>I?)"JHJJ"HJ)HH
MZ0TDE3[KW0`YK_A4KMR;<W:-5U]\=\'O[K7%[/\`F'4]8S8??^^O])M%NWXJ
M[4W1NC#Y?Y`;:R/3^)V5UEUAW=3[-K!A:O%[AW#F*(/&*R@C<2(GNO=&(^7O
M\[?O;J_I;HG,].]$=;CL3Y%_RE>X_P"8SC\IO;?&=J-O=9YOK#J?;79V0V@N
M)H-L13[ZI*+%9JJ:F,D^+-?4TD,,AITG>6+W7NBN]-_SH>_.B<K1]I?.%,WG
M<;L+^1#TO\Z=R;*ZOWWM[.=?]D[S[#[PVYUYU_N5,'4]&[4W5M'M_M.+<N.7
M-,N:J-K8!ZV6GAI)HJ<9!_=>Z/#WU_-\^9'Q&^,X[A^57P'VKUCN'>/:?0FR
M>MM[8/ONN[!^+F!VEWA@,CN/*[Y[[[,VMUE6]E=88WI2+`U5%N::FV?E:":O
MJJ%<;4UD=09%]U[JT3^7_P#*G-_,GXU[9[PW#@NJ<+D<OF=PXC[CH_NW;/?_
M`%1N6BQ%=X\9NO96_L!38C*Q8W.XZ6*63%;@Q.#W'B:GR4U?002("_NO=51_
M+3^8EWW\6OYF_P`WL539FHWUT-\9?Y'V?^:^!Z!KY,3@]NYWN3:/=V9QDV8G
MW72[=R.Z<=/F-LXT8YR)*BFBB8R+3-(+^_=>Z"NM_P"%#O8'0NW<)OCYM_#3
M&=5;/[?^`T7SL^.DW3_>$/;F4W9B84VS3'K+L>FJ]B;4786X]PY+>6+-#6TP
MRM!305B?=.KI4BG]U[JZ#X5=Y?+_`+BQF\$^7/Q2VW\<<QCZ'86Z-AYSKSN;
M%]S]>;\VQO[;G\9EP\67?`[-W/B=_=>9&&2@SU/+BCBGDDAEQ]=60N67W7NC
MR^_=>Z@93)T&%QF1S.5J4HL9B:"KR>1K)0QCI*"@IY*JLJ9`BNY2"GB9C8$V
M'`/OW7NJIF_GI?RHE9E/S"VG=25-MA=PL+@V-F7KHJ1<?4<>_=>Z.%1?-?XM
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MT^1G6&V=Y9SJ#LWLC-IE*O/TYPM-28P*QCIZ2".&%O=>Z0?RZ_F'_P`PK</\
MQ[Y.]4['^3WSZV]UCU_T_P##+>NU]J_RQ/AEU;\[^O\`%YKN3XY;0WQO?)5N
MZMW2;"SF,V/N/<]1/6[8R,S5#9JFEG814JP+&?=>ZMZ_F:]T_,3X[_RE/AWE
M.J?D_P!O;;^1O:G>'PYZJW-W_O?J;8.T^Y*NA[RRDM+G6WUU#6TV>V=M3>=%
M'EH(LCB87(IJRC:$3CU.?=>ZJ)^0W\W3^8;N_:7P2/6O=NY>I=P='0_'7KGY
M^+A^LMNPOOWY"=H_+[=7Q;S&PMV5V\*+,T6,8TOQUWCD8WVY$:9ZO[T>986H
MUC]U[I0_R[?YL'S-^?&>_E^_#+='RB[*Z%R.[=[_`"6W#\@/EOF>G<?0;C^2
MVZ^K.V=\9G:GP]^.>\ZS8-1TY29C&='RXNNW#E33+64T2I#`9*R,Q5GNO=&U
M[SZQ_FGTO\W3KWX/[1_G+]W;0Z\^0'1'=_RFPF2I?C=T)DZCJ_%[3[*&&P'5
M&-H\C1R2[EQM!B,DD(RM5515#BG!>%BY(]U[JRO^:3\C?D]@.]?Y=W\OCXL=
MO4'Q^[,^>N\>\Z#<_P`FZW8&%[+S/6_7GQZZD&_-WILW8V:K*/"R[YWA/E*9
M**MJ1)28\PN67UJR^Z]T$F0^1WSA_E+?&?O'._-?NK9_\QG/5/R&Z=Z1^%%5
MMS&X+IGMS?VZ.\ZREHL1L_Y!#%[=_N#UW'BLOE7J(,@DN0UXBB)+!YJ>+W[K
MW0.;^_GR_(GK7MW!?#C</PLZZK/G31?,7ISXJ[ZZSPOR*R,W33XSY$=5[D[4
MZ@[6V9W!7=3T57/B*W%X98<IC<AAJ?(T31S$1LQAC;W7NEET1_/;[([%WW\<
M<5V1\2<'L;KSN'Y>]C_R[-V[RVUW1_?#,X;YB==+N"HKZO9.U:C8N`.XOCQ-
M3XBF1LYDJO#YY)ZXZ,1)'3%Y_=>Z#;X]?\*$.U]R[%^'WR-^4GQ"V5TC\1/F
M)5_(39^S.T=B]XY3M;L#`]@]"4&_\O)_'NK8>LL%50[1WI!UY7T5#-%6S5D%
M7"\M5%#3M`T_NO=#;\>/YX'96]]T_'UN_?AO/UMU]\X/C9WQ\HOA/)U/VJO=
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MZVOM;=?QOW7L/%56^>I]R[XWQT+VGMSLO;N1SN`S/6>\>R>M.G][5^0V_6X+
M(8S.4M9M^E2EJX$:&6>.8%?=>ZM[]^Z]T5[Y&?-'XP_$JMZ^Q_R)[:P_6-9V
MIE:O"[!@RF)W/E&W%DJ&7&P5E/"=N8/,I1+3RYBF#25)@B'E'JX-O=>Z1%9_
M,8^%>/W]WEU=6=\[>@WY\:]K;BWKW=MY\%O3S["VQM*7&P;BRM;5KMHX[*)B
MI\Q3))'CYJN8M*`J,0;>Z]T2[>?\X+H;/P[:WCU)\BNA=G=/[JWE7=<=>]@=
ML;&[JW!_II[(P-)MNLW7M;;&%VICL!D]BX':S[NQ]'59G+13>6LF?P4SPQ>6
M3W7NC(=<_P`TSX=[P?MK:^YNUL-LCMCXX[<WQG_DAUQ68W=V1J>J(NL-Q#:7
M8$\N<I=L#$;HQ>(S[(L$N-DJ)JF">)Q""S(ONO=.%7_-8_E]T&PNJ>SZSY*;
M8@V)W?N7<6S^K=P/MKL'P[LW'M+)8W$;CQD%&NT#DL8^*R.7IHY)*V&FA)F4
MJ[+<CW7NJD_YXOSH^;WQ%^;?\N+&_%+/9#+]>U.R_E+WU\D>B*/'X2I;NWJ/
MXWX[KO?6_P#"8RKJL'D<Y3[JQ?639ZHQ,='54BRU@02>0`(WNO=!C\>/E[\[
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M<I2UV262>F,.J)YE,?NO=6M_R5>R_F!V[\@.RLEWE\C_`.:AOG8^SNK62/K_
M`.?'\N[J_P"'VQ<QN#<FX\3'C=P[*WMM#=>XLQN/=&VJ3#U44N-T1P_:Y`RN
MQ*(/?NO=$T_F-_SD^Y^D?YKN4I^O_DWM78_Q-^$W9?PTZ<^2?QTJMQ=;TNY^
M])^_L]NBK[;WOMC;>>Q51VSN*3IC;>Y<&:V+:\=92VI0)Y*9O,??NO=6O=Z_
MS7^\.N_F]\G_`(T]?_''K'=73?PZ^.77'RV[W[XW?W9F]L5N+Z3S&)RFY-_1
M;0Z_V]UEO3(;PWY2;>Q%3+@J2*H@HJV6F9*JJIC+#K]U[I5?&/\`F4?+#N#H
M+=/RJ[4^$.T^KOC[NKXP)\K/CGORC^4?7U3BLSM+(3S56"V%W_F-[8G86,Z>
MWKD-FU=!N&:LI#G,)1XMZE):D5T`HY/=>Z;/Y5_\WJH_F!]P?(3H#=_7.Q=N
M;YZ2VIUUV9@^Q>D]W]A[ZZ,[2ZU[)BGI<?E=H;@[9ZFZ0WS45V*SN/J*>29<
M%)BZM033U3F)P?=>ZU2>O?YM'\TVAJ<GWF_RH^;>9Q>Q_F3EMC;C_P!(_P`'
M>O:S^6CM_IK%][Q;%W!6=M_+?:*4^]=MXC;&S:R1\B:7#BJHJJ)$6H#VE'NO
M=;`>YOYQ>[.A._?YDVW8]O[P[^SN#^9_P8^(GPYZPS/9.S<3UQG^SOEAU%D=
MR;5IL-NK"]5T-7UUUY5S8^7)Y2NRV0W.TZ1`TLT/DC@;W7N@4[7_`)U7S\W-
M\NOC#\+.O.B.B>IN_MN_.6N^/?RPV?E.X-P;LV1O&D@ZC@[=Z\7KGL^+J-JK
M%];=@[,R-57U=3+A$W+2Y'$04,E-2PU4LK>Z]T/&]_\`A1IU_MCYQ9CXW8?J
M"AW1U7L7Y<R?##L?.XC<F_:WO[$;WI**6+/]U8SJFFZE;8$OQ\V?NYDPN1K:
MG>,&=::*6II\=-3M`TONO=!%\C_YP7SK[<_E>_);YK])?&Q/CUT#NKHC?O8?
MQ3^4NV^X-H[][&VKD>NNXMI=>P/W%U)NC9F,Q^V)NUH:C)S;?3&2;B>G@IG3
M(Q4DA5U]U[I?[T_GG?([XP=?]T[:^2_Q/V1!W=UA_+GZZ_F#=84>TN]9]XX+
ML#K/+]H;6Z8SVW^W\]3]9[;AV%VI'N#<4.0-/@J7/X:2)I%CK`$0O[KW4OL'
M_A09V1\7\SV1LSYD?"RAV)V)4?%SICY6?'':O4/>N/[-QW9NVN[>U,#TUM[K
MO?NZZ_9.UJ3KG?N-WON6GBJITILCAS#354B5+1BF>I]U[H)OGE_-[^8NUOCU
M\J^FLSLG#_#SYS_%3M_X%5>Z,AU'V#C.\>N]U]/?*/MG!8J*KVGN;=W7.WVI
MZAL1)-B<K25^+BJHZAVEI6:'1,?=>Z-7V7_//W7L;L;NO?.*^+F+S_P/^,WS
M=VW_`"_.]._)NWGQG<.+[MRN>PFV-S;OV?T8VPJA-Q=8;!W#NO&4=8YS,64R
M#3M+0T\T*.\?NO=!?\G?Y\'R-ZRIOEYV=T-\,>M.U?C;\5_F9MKX#UG9.]_D
M/E.N]Y9KO^JS.T-N[PR53UW#U7N&6FZUVON?=4>+%;#6S5M3--!4PT\M**EZ
M?W7NIU5_/R[,W/T9\<(.F_B=@]]?.7M[N7Y9=.]D?%>M[*S=)3]2Y3X:[?WG
MG.UJO(9+`[%W'V*YR#XK"P8>*MVQ0-4RY?3/]N5B$WNO=;,GOW7N@X[AZTQ?
M<W4_9/4>;R>5PN'[,V-NG8F3S&":C3-8JAW5A:S"U.1Q39&DR&/_`(A115AD
MA$\$T)=0'C=;J?=>Z+S-\6NR-R;BZ]RG9ORP[2[%V_U[V#MOLFCV?5]?]$[8
MQV8W!M)ZFHP<>4RNTNL\1N!,?!6SB62.GJ8&ET!6;06!]U[HYOOW7NO>_=>Z
M)M\/_A+UK\+ZCY/5'7&Y-[[B;Y5_*KM/Y<[Z3>E;A:Q,%V!VU%@8=P8+:@PV
M$PII=I42[>A^TBJC5U:ZF\E1)Q;W7N@>_P"&K?C-E*_^8T=\MO+L+;7\SFLV
MM5=_;-W+D<0F$PB[1V$^P<2G7,^(PF-S&`J:>E*9"&KJ*FLJZ7)PQ3P21F-0
M/=>Z)[N3_A/?\7^P^O.R=K]O_(#Y:=S=B;UV9TYUCL_O[LK?VQ<YVYTOU5T%
MO;$=A]6]=]8UL/6M%MBEP>+W;ATK,C+DL9D:[.U#F;(3U$X64>Z]TN_DM_(R
M^/GRJK=]9?L?OWY48S.]W_'OKSH'Y/YC9&^-D;6J/D]'U!3)_HL['[8IZ3KJ
M2B@WEM++K]\]-@(\)M_*R*D5=CJBF3PM[KW4#I3^1'\=.D-S=1[VP?=7R`SF
M\.G_`)9][_,O"9S-5W64?\4[:^0/4>U^H-TP9/'8KK;'XV/;&%Q.TJ6OQE+3
MQ0R15Y?S230$0CW7NA6^('\GKH/X4=S[:[^Z@[/[RE[/J]G]D;;^0^XMS;EV
MUE*CYBY_L3>^5["7LSY(^/:=+_>3L;9FYLW5R8;(XK^$&FIYVIW66G)B]^Z]
MT''R<_DH;2^0GRT[0^9&ROG9\_\`XD]H=P[3Z[V9OVB^)_<VV^K-OY["]8X5
M,)MB'(C^X67S61%/&'FT5%9+&D\LC1J@8CW[KW4_K#^1/\+^K!\<:#&5O:6Y
M-L?'KHKY/]$5&U-[;CPVY\7W-B/F%!.G>VZ^W9\AMQLGE]T[KJJZIG`H)\=C
MX6J"BTOB5$7W7NA&^(/\HCHKXB=O;/[GI.V_D1WON3ISJ/*?'WXTXWO[?."W
MA@/C/T=E<G2U\_7W5-%AMH[9J`124%/C?XQEYLGG&P\$="U6:91&/=>Z:,K_
M`";?CMEOB=\\OB!-V%W)%U__`#!?D7V7\F.V=P19;9W][]J;U[0W3LK=N;P_
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MY#.5N`PE97355#105#"0>Z]T!6T/^$]WQTQ%1MU>P/E%\S^[\+L_XE=V?"#9
MVV^T^R-A9#$[/^./=>T*C8]9LW;`V_UAM^JQM;L_`UDL>,R#22U;JL$=6]3#
M24L47NO=+#8G\A7XM8>FSF-[;[5[\^2&(W#\!*#^7!D<9VWENN(8D^/&W>R8
M>RMA_P`/FZ_ZWV348_>_7-?0T5)A<K&WEIX*""9Q+6(:EO=>Z%/;G\I/%8#J
M3??7D_SK_F`;BWIO'*]7RXWNK<7>&%K]X[1VET[C)<)LKK6BV,NQH>C-V[!J
M,/75L.>HMR;3S3;H>M>;+25<Z02Q>Z]TE^GOY5=5\2MR_$/$_%;N+M7;^P=@
M?(_Y#?([Y>UVX.RX<`OR>W/W?L;^#Y*J[&ZPV#L'!;%W;DH]S46*DPU)0C;.
M!VS28Z1XJ*JFE15]U[H8?D7_`"K.B_DMW=\DN]]Z;W[4P^Z?D]\!MP_R\=[8
MS;62VK3X'"]1[DW;D=X5F[-L09/:F3KJ?L.'(Y)XXIZJ>JQPA4`T9:['W7N@
MS[0_DE_$3NJ#X_X?M;(=D[UVC\?O@]N#X%8;:.1RVVX<9NOJO/[>VQM\;NW'
M5TFUX,M2]FX-MITE?CLEC)Z"*CR,:SI!J2/3[KW2GZK_`)5J]6U&QLLOSU_F
M![TW/L_N?I_LW)[BW=WKCG._M@]'[8RNU=E_'/>VVMO;.P&R\ETQ6TN9FJLX
MD6-@SVX:\K49')5$BJ1[KW5KWOW7NO>_=>Z][]U[H+>[.KJ;NOJK>W55=N?<
MFSJ'?&(.$K]P[1EQD6?HZ"6JIIJVGI#F<=E\7)3Y2EA>DJHYZ:5):6>1"!JN
M/=>Z"+:/QHW-A>T]C=I[L^17:G859U_AMWX#"[=RN`ZCVS@:G$[TH\939/&Y
M?^XG76V<KD<935.$H:RGIFJ1!'64<,FDE`/?NO=&O]^Z]UQ=0Z,AN`ZLI(^M
MF!!M_CS[]U[JBNO_`.$^OPOROQ7^)OQ6RFZNY*[#_#'Y#[B^1O3/9LN8V2.S
M:;<F\.S,GVAN[:6:R2;%7!U>QMQYC(10U5)!04T[QX^C?S>>`2GW7NK#.]OA
M)UI\@/E!\,?E=NS<>]L5OOX09KN?.=9X/;]9A(-J;DJN\-@TO7FYH][TN0P>
M0RM9!C<12+-0BAJZ%DJ"3(94]'OW7NJ^OE3_`"#_`(V?)WNCNSN#&_(?YD?'
M&@^4:XB/Y6]/_'#N6CV#TW\CTQ>+I,!,W9FRJO:F<AKI\Y@8)J>ODAEA-4]7
M/.W[\KR-[KW3%V;_`"">J-Q=][[[[Z(^<'\P3X5Y+L'8/1W6.<V3\2^\,)UG
ML^797QWZRP?4_5F&J#5;'SNYLS#MW:V#'B;(9&K=)ZF=U*^5A[]U[HY7;_\`
M+5V%WS\4/C[\4NV^\_D)OVA^/O:'2_;N/[DW5N[`[@[J[#WATCN.3<N`K.R-
MU9?:]90YQLY62:,C)#1TT\D8'BDB8:O?NO=%NW5_(?\`B'N8_(%X-S=I[:F^
M1?S/ZI^;.[9]MS[!H)L)O;J+<6;WAM[KO;+OL6?[7JVKW=NK,92IH9_N*O\`
MB&7JYXZF.2=V/NO=+##?R6_C;MWX,]1_![`=A=T8:A^/O<U9\@>A/D+C\SL^
M#Y!=/=M5G;NX.W6W?LC<8V8=IT=8M5NK(X<QSX:H@FPU6\4J/+:8>Z]T;?<?
MPEZYW/\`-_J3YYY+=.^3VMT]T#O;X\X/;L55@4V/EMK;[W#2;DRV<S=$<"<T
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MMK)D,OLHIE.Y^RZ>NCR>S,V8=E4^OK6C:L_R>"$P9)=(\E:_-_=>Z(G_`"J_
MY#M1UG\??A_6?/G=?;6[=\_'>F^1=5C?AKN+L3KWLCXH["WEW3NCL+;];OK!
M8K$[5JZ_*Y;*]7[@AFBII<W4X[%Y.OJIZ>G@J)9]?NO=']^,G\EGXX_&?L38
MF_:?MOY,]O4W1?6._NF/BGLWMWL^DRV!^*'679Z34V]L%TID]L[:VKO+&YC)
M8IHL=!G,CE,AG*#&4T-)35<4$2(ONO=%U[#_`.$YWQ:[EH.TI.[OD1\LNY-\
M=A;)V5UA@>V-_;KZMJNS.NNM]F]RX/N]]MX[<F%ZGPC=AY7=6Z=M4,&6W!O6
M/<NXZBBA*)71O(\C>Z]T96N_DP?&+/-\]=N;OWKW-N_IC^89O=NUNW^B\SGM
MH_W)VAW%+D-M9:?MCJS.4>R:;L+;&\8\IM.BFI6GS%;24+PH8($*(5]U[HXO
MQ+^+&2^+NV]UXO</R9^3?RFW-O#+XS(Y'?GR9[%H]XYG&8_!86EP.$V]M3;^
MV<!L_8>T<534=,9JM\?B8*W+U\TM7D)ZJH8.ONO=&T]^Z]U[W[KW7O?NO=%N
MWM\?,AF=X9K>W6_<G8O265WF,:O8M-L>BV)F,7O5\501XBAR\M!O[:.[8=O;
MJAPT$-'_`!/&_;3R4U/"LHD,,;+[KW0P=?[#VUUEL[!;%VC22T6`V_32P4B5
M-545]=4SU5549#)Y3)Y"K>6KR67S.5K)ZNLJ96:6HJIY)')9C[]U[I8^_=>Z
M)EV[\'^KNY_E_P#%CYF[ISN\8.P/B;M+OC9NQ]J8ZIP8V)N;%?(/:E#L_>!W
MICZ[!UN8KI<?C*!6HA2UM)&LCMYEF6RCW7N@I^!7\KGXZ?RY^M?D/U#\>J[?
M$'7WR([@WKW!D]O;CR&"K*?8-;O3;6&VK+M'8)Q6W\/]EM'!8K!PI00UHK:F
M+Z/-(``/=>Z"T_R7?BA6_P`M?K/^6%N'-]KYWI_IS()N7K#L\[FQ&$[RV/O^
M@WUNCL';W8NV=X;>V[B\9AMV[;S6[JN&FF@QZ1O0NU/*DB22Z_=>Z+77_P#"
M=GXV[JZ7^2_6G:ORH^<'=O8WRHEZ5H^P?DWW!W%@M\]]XO:/0.\\1O\`ZZV-
MM3/938[;<QN`Q^Z,2)Y'FQE16L'T).BQQA?=>Z-]\,?Y9NY?B#VSD.T\Q_,9
M_F-?+"FK]EY?9Z=:_+'O^A[0ZTH)<KD\'DEW90;>I]GX*2#=F-7"FGIJKS$1
MT]94*5/DN/=>Z!&J_P"$_/\`+AW3UQ\EMK]N=38WO#M/Y2;Y[F['WU\H.S]L
M[`RWR*V]O#N*MK,C+E.O=]X[9^+AV8NQ:ZI2;"T]'21TR2PZJF.I,L_E]U[H
MP/3/\JWHKJ?LCM/LS-[R[*[CRO=?P[Z>^%/:.)[2FV5D,!O'K'J#:E3LZ#,Y
M;&[>V;MV.3=.]<-62+F2NG'2L[>"E@4E??NO=!'UM_)(^-^S>H^V/CYOGN?Y
M7=[]"=@]"R_&#9?4/;7<DE;LSHGHO^\!W1C]H]6T&U,%M4S9;`YFGH#CL]N`
MYS.45)BZ2CBJEHT>GD]U[H3?AM_*OZ\^&G?>\?DA@_D!\C.YNS>R>D]B]']B
MY+N_<6QMQTVY,%U?6C_1WE*"DVWL+:4.SZG:VWE3%1T.(6CQ4].GGFI9*UYJ
MJ7W7NJ_8O^$TO18PN[^MJCY^?S+#\<.Q>PMP[_[$^*N-^0.V]O=`;T.[MY#>
MVZ]MYG96!ZYQY_@FX<H`M0\4\=:0!(LXF`D'NO=&\WK_`"1?B7OFJ^4]?7[D
M[@PV4^2_:_QN[QPV;VON?!83<'QR[6^)VQAL+I/>G06<BVQ+DMO9?;6+&IWR
M<F6-3J>)[P221-[KW2&;^0_\?4KMB=CTGR(^5$'RBVC\FZ[Y89OY=5.ZNM,O
MW9V'V7DMD4_6]1C=WPYCJRNZX78U'LFDCQ^.P^.P-#2XF$R_9B$SS:_=>Z,'
MB/Y5/4FTODUOCY!=>=W_`":ZRV9VWVO+WUW9\5^ONRJ':_QO[C[IJ<!/MS)[
MZWWMO&[:BWC6P;FH33R9["09R#`;BJ:*"7)T=64L?=>Z+-6_R!/C=4]/=J_'
M.'Y'_,FE^.F]>N=]=8]9]#CMG`2=7_';;W9^^=N=B;];J[;W]QHUS4^3W)MJ
M(T";LDW'3X*GFFCQT=-K#+[KW0I?)S^2K\;?E1N3>6Y]\=B]U8.OWM\`\+_+
MOR,6U<QLNGI:7J/!=K;;[=I-VT4>5V3E9%[$DW#M>""2>1GQQHW=12"0K(ON
MO=3?D-_)2^(WRD[*E['[DRG:6=E?X7[.^$]/@<=N+!X:AQ&S]@=K8/N/:':&
MWLI2;9_O%@>XL!O';].]-DZ>K6EBAUJ*6[D^_=>Z#W/_`,B7X\[[ZN[MVAVO
MW[\HNW^T_D5OKX];T[>^2W8F[M@93N?<=)\8-S4FY.I-D4,N.ZWQ6Q]N[)Q!
MHD@J*2BPT,E62U1)(:IO-[]U[I8[\_DD?%SL#O+=W9^2[`[\QG4_9?R%VO\`
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M*"6L4+6T6160U0#*8E>*;W7NJF_Y?V%P%?\`+[Y5>+-9O*=N[TPM51R?(G8V
MZ]QTV=R^,BZG^/"5-;\A>B-Z4E1A-C=O8O<549L0<A1U<&.R"9K$4,-/1TDD
M,ONO="YUOB-DUNT_C9UMW5N*MROQ^3>7\QJ/<=9VGOO,2XC+[ZZ\^4M91=4R
M[QW]G<Q3UF4W5AMM-N&JQL=77:M=)-5Q1^2@BDI_=>Z#;KK<^Z\_L?"]A]E[
M@W#/\K-O[H^`V'Z?J-QY&NH.S&Z\[#P?QV_TR)MC:TTE)49W![NDS6]?[QU`
MHJG[C[:K^Z>V.C^V]U[HX?R[[K[1Z[[6RVW^LLWM/:N;K.HNCQA]TYK9M'NJ
MMP^0[(^8_6W3^7J9J:?)8M\IC(=L;JJ6AHFGBC^\T2ZKBWOW7N@XS_R3^2/3
M>]>W.N\GNO\`TSQX;<=7T#U5N+([)VYA=QY+Y$;^ZFZ:[6Z8@WDFR,5CMO4N
M"S4W8.=Q\E0,?08^BI,'3O52R35+/[]U[I*8'Y<_*_);L[`P<"8.ARM-3?)7
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M6G8>]YNRJ[I7M7`;-Q.^<C@=N;;W!G<1N?I;JKM6V?QFS\;A=L)5XO)=@5%)
M`])14VNC@A,H>;7*_NO=%4P5!U9L3'_/?'_(GM;=>3ZQP?R1Z[R&\<SOG>U7
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M]M!6I3TN2PM12(\!A$2>Z]U8;W>:;I;HKKS`[(H,;!AMM]J_$3K##4&;IOXW
M3TFULO\`(?ISKEXA]_(TDF4I-O9-_M*IV::"L6.<7=!?W7NBP=%=U=_93>_0
MNX=]=JX_>.V/D!W%\JNLWZ^@V#M?;F%V1@NF\MW35[+RF`S>-63=F4W0N-ZR
MHZ/)2UU;/058J*B6.DIG\0C]U[HMWS1[N[@&`^7?7F?[OK=D4F0V;VM1=:MU
M[2]%[CV?@,3L7$X_=L<]7EX=PU?=FP>R*+;F+JSG9=TXE=M&5YJ?'R)-+CY/
M?NO=#A/\I^Z=M9JNS&.W52=JY3#]@;^Z;H_CY3X';D.YMV[9V%UANC>VW?D/
M%7;7Q*[N6N[+K=N452#2TIVM_"L[!%1TPF$57-[KW2%[$[T["BP/Q]S]!V;#
M\I=RUO??26]J+KOJS'[7VGNK'9[?_77<7BZGK,S09?%["@V-_$J&%J9\_5_Q
M7%4M/4564J*N)(I5]U[HYB=][VQWPUW?\@,3+C.SM_XG:V\]RG`46WLIAL5@
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M-'M_K&ER&;_T\YN>1Z."CR$^`VN?`(IS4U\?NO=%L^.'RS[_`)-K_&O9>.J,
MA0[9QW6WPYZ[CR==DNCDV[OK;';'1/46YMY=\M/OWL"7OO)9K9LV[LM-C%Q.
M"RFW*A]MU$5?//KK*C'>Z]U8K\.N_M[]XT^^LKV+F]LXRJVSF\7LK;>U<5B:
MW"'=V%BQ[Y'#]\41W'!29N?;O=$4TT^%IZ99\;!1XYUCJ:JH%28O=>Z17S@[
MN[%Z>RM=5];U^UL-N.B^)/R*WU@,[N#;%/N-\3NS;?:?Q;VS@JJ6G>NQL];M
M^*'?E5)6X]9X%K9(X"98VB1A[KW0=YSNGO/9G;>XOC9N3OZGHL<V[MBBI^2^
MX-D]:X?.;`Q>[>L.Q=^Q[=?$MAZ+JP'-9SK^'&XRIR=#+/XJNI0_<U'V\D/N
MO=)KKWY$9_"_+VG.<[)V?6;([-QG5%#O3=BK58+8V5@Q?1W=>X\!F=IQ[JK_
M`/?H4NZ<[AJ>J5?))]XEDCEJ(?',_NO=%W['^6?9'=WQKWKGLIW_`+2ZTP^-
MVOLW-[9?$X_;$%/\BZ+?GR$W=LN&+;V:JJZCR]/!@L'M/'X['3[:JDD.5K_N
M*QJJ-XZ(^Z]T*M)\@?D9F]L=D9O9_:NW^M<'TK\7^U/D))MG;G6&S<A'O3=V
MV._?DQMZBP^9R.X8\H,/L_(8#JREAR,=!3T^2GJI7J(:ZG;6DONO="GCOE%V
MQF.Y.DY*KMS:&U8.POE+G^ALU\::K;6V9\W4;!P'5?:>\L5V'A<O6U--V%2Y
M3=S[4QV=6I=:C$G`U<4,$.IOXA-[KW0P]Y=F]ZX?OCLK&=>;LF3:727Q0Q/R
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M:LL?3&V=O[^VGWYV%N&GPFT-SOV#O'`=PU&3ZVZ^AQT,$NR\)75O\;E=<I%/
M(&Q\?NO=)/MSNON'<YJMC;V^1M?L3/#Y)?'S<6,R^RZ#X[;@ZUPNSL#\T.JM
MAU1V;O#`9W<VY,-C(:'>6,ARF,[%QU-E,A6B1*0M34N1AD]U[ITH_D9\NJCK
MQ]_R?(/"LU9\:_EY\G?X53]/[%CHJ/\`V5[LO`[7V;U_BJN22IJ!MS>V%W2H
MW3751JZ^:>DCDQ,N'622,^Z]U,WK\Y_DS09CNK,8G"KM^FVSC/DG@<5MS<;=
M*R;4VSC>H.GNP=^[)[BQ>%IM_O\`(O.Y+=&;VQBIIJ;+8*DVS-ALS'X)D*T]
M=7>Z]T[;[W7WK1?(SXI]6;Z^4F0DI(>RNB.WJK=HV1U7L]LM4]J].?-["9;J
MQ\=_"#B&V565'5%,N,28U>;2IR$A^]GGAI'B]U[JR7Y.]B[FZRZPBS6U:JCP
MM=G-]]<;$K]Z9*DBK\9UK@-_;UPNT\]V7D*2KT8J6GV-B\K)D!]^\>.62%35
M$P!U;W7NJ_L9N/L3N;Y)_%'`;D[6KL_M'JCN+Y+4=+G<9MW9C;8^1`ZRZ\ZI
MRNU>P\C30X>7"4.9VME-Z9C#&LV\T%-'D*2K>%:9G:G@]U[IN^5O=.^\EO=Z
M.M[BP?7%%U]\RNANL]N="5>-P,>7[7V\9-B;[3?XR595XW?50<OD,O5TZQ4?
MEP,V*PU5!+3SS/+40>Z]TC-W?+#Y`8SX[S[4I:':R[GS_P`7MO\`R:V]F7V)
M25>QZ/X[X;XK3;I[$Q=3A@!MV81=VX2GVT*::KCK8<;NB"H2$QP0B;W7NEK\
MBNZ]^97?^WJ>K[>P^Q:;8'S2^./6VV?CVN/PE)G.XL'Y-@;_`(=ZT65DJ*7?
MS5&X\EEJJD@CH%J,&^,Q-1`]+4SM)40^Z]T@=D?,OY8]@X#:]/'DQU_D^U\[
M\:JJJS^Z<3T'NVKZ?R7<W<&U]E[IZSVQM'K#L/=]3)C:+;.2R,>-GWP:+<-%
ME<<[5,-<AGI*/W7NEUN_Y"=S"F[?Z6W;\B<%UQ1]61_(B.;Y%[HVAL"AK-]5
M/6VT>I,Y@]A[AQ=5'@=A8^JJZ+MBNJZ_^#1XW*S8S#PM2O2/]S5-[KW3Q\2.
M]NR:?=/QZV7OOLJ>;9FZ>JNK]N[(V[@UZ<W;MJO6+XQ[>[$D??M9%NYOD?LO
ML]JC#9:OJ<ADL?-M%Z`4M.'-97T\@]U[JWV">"J@AJ:::*HIJB*.>GJ()$F@
MG@F02130RQEHY8I8V#*RDA@;CCW[KW50N3Z#R'='S?\`DQF:_JKXZ=E;8VIN
M_H#%Y#*=P5&^:O?>V<4W4NTLSE:#8E%BL;D-MTU(8ZR2KITED@\F1ED:;T%6
M]^Z]U%WG\D^V=I;9P^[*;?.,V'U[@NS_`)ES;T_N%A^D*W>E53]4?*+?&U,-
M79;KSM7=6V\KO#8<.S,-,V:79;S;QR6;D1*91+4)[]U[H7H_DSN_$3=K]D;D
M[CV9BH]K5_R2P_\`LMF4V3+E,_M7;G1#;[;;O8L)VP$[-J:G=^#VG09VMCR2
M)BZG&9RG@Q_AG:EEKO=>Z+1U%\B>X.P_E/U)U?V)O2GW'2[3[AZ_WGCI5W-T
M_D-UTT79_P`8OG=!E-H[QQW0-?E>O<3AJ*LZLI,AB,=-EMQ9$02K55.0D9HH
M:;W7NC<]S?(7M?8'>IZ$Q.NKW/W/O/HF7H"MH=H+E*'"[$EJ,S+\CI]SLTR1
MUD&P-O==UN0J*Z:2$1?WKQ5/`KRHU_=>Z*ELOYY?(&HI-\;LW=@:K;./RFP=
M\;A?;^ZH^E<G_H:W=@^Q]I];;*VUMW;FP^R7[*K*;/U>Z)$RDG8\6V(Z;(T8
MG>IQM$*NGIO=>Z[Z.^1GR@[E[HI>@F[SH=LTN`W_`-ETV<WK18?HGLSLK*[>
MV]T_\>>S<#MC.U^Q,8_2NUMUT.4[7J8,C%C*+,QPT&F%*N>=H\@GNO=#?\O_
M`)2=Z=5=SR[-ZXV_7KB-H=7[-[(PX:MZ3QFW>WMU;JW=O;;-=USN2N[6WUM7
M>T6)P4&V,<2^PZ#,9J*JSU.TT;?Y-15WNO=(',_)/Y,]?[97NV3>]+VG3;J[
MD^<'6.VNAJ;KS!8?"T&,^/N/^5&?Z\&/S^#IZOL/.[SF;H7'4-?(]2:2KIZR
MI,=!#.(Y5]U[H,(NZMY[0^5VZHL;\BME?(YI=E=85*[GI-O[+2':<E/\=/YD
M':%#C*"BV;DZK;N.KY\MLZ@E2J6&/(3X)UI:N2K%JEO=>Z7F-^1_R5V5C.JL
M3O'N7$[OJ^_.BNCNR<UV%6]=;.VMB>A:GLC?&SME[MW7MO%8V/\`AU3L_!TV
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MP>.3O#&];X_LKY-]@=`P[4Q'5NR]PR=9;?V7\<,EW=5Y'#YW<4#UNX^PXMV;
M9FQB5F3IWQ"X>K<28=JR..J'NO=`Q\=?D_VEG=S;W[=E[HVO7[IW5O3X31YK
MXQ4N)P4U5O$=U]-]!;:W=NO#M4Y'([ZPM+A*'+5V>H(,/%!00OB:V2M6KBDD
M:F]U[J7COF]\L=R;>RU?2K#U_F-\0[-F"[WQW2&Y:7HC/9CY+],]-Q[8P.RM
M@=CY+LG,461V]O[++6KOZFP62CRV,5H!#JFH*;W7NKM-EX7/;=VOA\+N?>.3
M[`SU!3O%DMXYC%;>PF3SLS5$TJU57BMJXO"[>HY(X9%B"TM+"A6,$@L6)]U[
MI4>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z`#O7Y!8;H?&)F<SL;L+
M=V(H<97;FWAE=FX?&3XS8NR<3+!#EMTYS(9_,X"CR,M-)4H*?"8I\CN/)'5]
MECZCQOI]U[I+8'>?06P_E%N;J;9^SI<=W1WC@\MV]V;NS`;8:/!96MZSPG6F
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MK1&1\A24<*113$F2.)%52%`'OW7NH";0VE%F,YN&/:^W8\_N:@I,5N3.)A,:
MF8W!C*"*2"AQV<R:TPK<M044,SI%#.\D<:N0H`)]^Z]TR8KJKJ_!0;:I<'UO
ML'#4VS*[(Y/9]/BMG[>QT&U,EETDCRV0VU%28Z&/!5V4CF=:B6E$4DZL0Y8$
M^_=>ZSIUIUS'M2MV&FP-DIL?)2U,^1V8FU<$NU*^:MKOXG635NW10#$54M7D
MO\HE:2%C)/\`N-=N??NO=*G'8S'8>CAQV)Q]%B\?3^0T]#CJ2"BHX/-+)43>
M&EIHXH(O+/*SMI4:G8D\DGW[KW3-3;*V;15>=KZ/:6V*2NW1DL=F=RUE-@<5
M!5[BS&':!\3E<[414B39;)8MJ6(T\]09)8#&NAETBWNO=/L%%1TTU944U)34
M]1D9XZG(3P01135U3%2T]%%45DL:*]3/'14L4*NY9A%&B`Z5`'NO=)W<6P]C
M;OQV0Q&[-F;4W1B<O6TF2RN+W%MW$9O'9/(X^&FIZ#(9"BR5'4TU;6T5/1PI
M#+(K21I$BJ0%4#W7NN]I[%V1L.A;&;&V=M79F-:VK'[3V]B-NT+:9JFH7528
M>CHZ<VJ*R9QZ?URNWU9B?=>ZSX79^T=M8.3;.W-K;<P&VY6R#R[?PN$QF*P<
MC9:::HRK28FAI8*!VR<]1(]03&3,\C%[EB3[KW3A'A,-#3UU)%B,9%291`F3
MIHZ"E2GR*+CZ?$JE="L0CJT7%4<-,!(&`IXDC_0J@>Z]U!Q6T=IX+$8;;^$V
MQM[#X';CQ2[>PF*PN-Q^(P4D/F\,F&QM)30T>+>+[F328$0KY&M^HW]U[IXJ
MJ.CKHE@KJ6FK(4J*2K2&J@BJ(EJJ"JAKJ&I6.971:BBK:>.:)P-4<L:NI#*"
M/=>ZB0X3"T_V7V^(Q<'\-J:VLQWAQ])%_#ZO)?<_Q&JHM$2_:U-?][-YWCTM
M+Y7U$ZFO[KW2>K.M>N<CE=PYW(;`V579S=V$.V=V9FLVK@JK*[GVXT4,#;?W
M#D9Z!ZO-80PTT:&DJ7E@TQJ--E%O=>ZFXS8^RL+E*;.8;:&U\3FJ+;=%LVCS
M&,V_B:#*4FT,;*L^.VK39"EI(JN#;=!.BO#0JXI8G`*H"/?NO==XO9.S,&E1
M'A=H[8P\=7N*LW?5)B\#BL>E3NS(*5K]T5"TE)"LVXJY6(FK6O4R@^IS[]U[
MI]I*&BH!.M#1TM&M555%=4K24\-.*BMJY#+55DXA1!+55,IU22-=W;DDGW[K
MW3%@MD[,VO18W&;9VCMC;N.PU3D*S$8_!8'%8BBQ59EFJ'RM7C:3'TE/!0U.
M3>LE-1)$JM,97+DZFO[KW3K4X7#UM0:NLQ.,JZHK0(:FIH*6>H*8K(+EL8AF
MEB>0KCLHHJ8!>T-0!(EGY]^Z]TU9O9.S-RTTU%N/:.V,_1U.7H-P5%)F\#BL
MK33Y[%QTL.,S<T%=23Q2Y?'144*P5+`S0K"@1@$6WNO=8I]A;&JJZ@R=3LO:
M=1DL5@:O:V+R$^W</-78W;&0C6&OVY05<E&T]'@:V%%6:CC9:>10`R$#W[KW
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MKU>_=>Z=TVUMV..JACP&%2&NH9L76Q)BJ%8ZO&5$]955&.JD6`+44,]5D:B1
MX7!C:2>1B"78GW7N@(I?BSUE%W5_ITR$VY]Q;IHG-3MC$;CR]/E]L[)R#4=7
M0-7[4@GQPSE%XJ7)URTM)/7U..QPR%1]E3TWD&GW7NC#BAHEK9,DM)2KD9:6
M&AEKQ3Q"MDHJ>6>>"DDJ@GG>E@GJ9'2,L45Y&(`+&_NO=,6*V1LS`PR4^#VC
MMC#039ZNW3+!BL!BL=#+N?*1S19/<<D5'20H^>R,51(L]80:B978.Y!-_=>Z
MG';NWVIX:,X+#&DI\-/MVGI3C*(T\&WZI*:*JP4,!@\46&J8J*%9*50('6)`
M5(5;>Z]UBK=J[7R66V_GLCMO`U^<VG]^-K9FMP^/JLMMK^*TJ4.4_N_D9Z>2
MLPW\2HHUAJ/MGC\T2A'NH`]^Z]TG:CJ?JRJ7=B576G7]2N_:FAK=]+4;-V[,
MN]*S&5)K,;5[L63&L-QU./JV,L$E9YGBD.I2&Y]^Z]TI%VQMI*9:--O8-*1,
M;D,,E*N)H%IEP^6DCFRF*6`4XB7&Y*:%'J(`/%,R`NI('OW7NHC[)V;)ELCG
MI-I;8?.Y?`IM;+9I\#BFRV4VQ&TCQ[<R.1:D-96X%'E8BCE=J<%B0G)]^Z]U
M[-;)V9N,TIW#M';&>-%58:NHCFL!BLH:2MV[4557M^KI374DYIZK!5==-+1R
M)9Z629VC*EV)]U[I]KZ"ARE#68S)T=)D<;D:2HH,ACZ^GAJZ&OH:N%Z>KHZR
MDJ$D@JJ2J@D9)(W5D=&((()'OW7NFW%[7VUA*3"4&%V[@L10[:HFQNW*+%XF
M@H*3;^.:**G:@PE-24\4.*HF@A1#%`L:%$46L`/?NO=0\ALC9>7SU)NK*[0V
MOD]ST%`,70[CR&`Q-;GJ+&"L7(#'4F8J:27(4U`,@HG\*2+'Y@'MJY]^Z]U/
M?;FWY($I9,%AGI8\/-MU*9\71-`FWZA(8Y\$D)@,:X>>.FC5Z4#P,(U!4Z1;
MW7NH-9LG9F1W!0;LR&T=L5VZ<70QXS&;EK,!BJG<&.QL5:F2BQ]!F9Z1\C24
M,>1C6H6*.18Q.H<#4+^_=>Z]0;)V9BI,I-C-H[8QTN;W`-VYJ6@P.*HY,ONI
M6A==S91Z>DC;(;@5Z>,BME+U(**=?I%O=>ZX9G8NR=QTZTFX=G;5SU*N=IMT
M+39G;V(RE.NYJ*-8:/<2PUU)/&,[20H$BJ[?<1J`%<`>_=>ZPP=>[`I<\^ZJ
M78^SZ;<\F"CVN^Y(-LX6'//MF)8DBVZ^8CHER#8*)8$"TAD^W4(MDX'OW7NE
M32TM-0TU-145-!1T='!#2TE)2PQT]-2TU/&L4%-301*D4$$$2!410%50```/
M?NO=<(:&BIZBLJZ>CI8*O(/#)7U4-/%%45TE/`E-3R5DR(LE2\%-&L:%RQ5%
M"BP`'OW7NDUE^O=@[@;#OGMC[0S;;=S<NYMOME]M87)-@MR3U;9"?<&'-913
M'&9N:O<SO5P:)VF)<OJ-_?NO=3X]I[6ASN3W3#MK;\6YLWCJ;#YG<<>&QR9W
M+XBB+M1XO)Y=:89"OQU(96,4$LCQ1ECI47/OW7NFK;/6O76RX*>EV=L'96TZ
M6CJ&JZ2FVSM7!8&"EJVCR$355/#BZ"EC@J&BRU4I=0&*U,HO:1[^Z]TU1]5;
M:;M&;MW(5&;S6ZH=OMMC;<&8R;5>!V-BJTTK[C&S,.L,4&(K=XRXVB;*U#&:
M>I%#`BLD:LC>Z]THEV/LI)MV5";0VNL^_(HX-\SKM_$K-O."*@DQ44.[)!2!
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MT2R$:Y!5S!B?*^KW7NF'LCJ3:_9>S\ALZMFR^UH*[%0X.+-[)JZ?`Y['X>&6
M*0X:FJ#15F/JL!4I%XJC&5E-58RJA)CFIY%X'NO=<.INF]A]+;%I^OMDXH08
M02U=;E9ZY:6HR.Y<QD4CCRN;W!+!2TE)5Y#))$B.L<,--#!''!!%%3Q11)[K
MW3ILWJCJWKJHKJSK[K78&Q*O*0PT^3JMF[.V[MBHR-/3N\L$%=/A,=0RU<,$
MLC,BR%E5F)`!)]^Z]TZTVQ=DT=!N?%TFSMJTN,WK697([RQU-M[$04&[<AG:
M<4F<K]ST<5(M/GJS,TJB.KEJEE>HC&F0L./?NO=<9]A;&JL5MO!5.S-IU&$V
M;68C([0P\^W</-BMJ9#`1&#`UVV\?)1M28.LPD+%*26E2)Z93:,J/?NO=/"8
M3"Q3I4QXC%QU,>1J<O'4)04B3QY:LI)*"KRB2K$)%R-50S/#).#Y'B8HS%21
M[]U[ID@Z^V%2YK&;DI=D;0IMQ82EGH<-GX-M8:'-8BAJJ2#'U-'C,I'1+74%
M+44%+%!)'%(B/#&J$%5`'NO=2*?9.S*2LSV0I=H[8IJ_=5?C<IN>NI\#BH:S
M<>3PWA_@^1SU3'2+-F*_$_;Q_;35#220:%T%;"WNO=*?W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5V_S")C3[%QAWECNBLMUQ534]%LV/L?-
M;PV]V9@_DM+5/_H;W+TQ-M_`[GHMU;^Q]3Y_X'A/'ALA69W[3[;+4QO[]U[I
M85*9>/Y+_"5-Q5&:JMPI\:_DBF;J=Q46(H,_59=7^+0RE1GJ+`5^2P5#F9:T
M.U3#0U%321SEUAE>,*S>Z]T=;'OD):&DDRM+1T62>"-JZDQ]=/DZ&GJ2H\L5
M)D*G'8BHK($;A9'I8&8<E%^GOW7NIGOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
"_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>16
<FILENAME>plx-20121231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings-->
<!--produced on 2013-02-28 @ 11:25 AM-->
<xbrl xmlns:country="http://xbrl.sec.gov/country/2012-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:plx="http://www.protalix.com/20121231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xhtml="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:href="plx-20121231.xsd" />
  <dei:AmendmentFlag id="AmendmentFlag.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate id="CurrentFiscalYearEndDate.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus id="DocumentFiscalPeriodFocus.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus id="DocumentFiscalYearFocus.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">2012</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate id="DocumentPeriodEndDate.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">2012-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType id="DocumentType.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">10-K</dei:DocumentType>
  <dei:EntityCentralIndexKey id="EntityCentralIndexKey.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">0001006281</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding id="EntityCommonStockSharesOutstanding.9180.0.0.0.0.0.0" contextRef="as-of-2013-02-15.9180.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">93497809</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus id="EntityCurrentReportingStatus.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory id="EntityFilerCategory.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityPublicFloat id="EntityPublicFloat.9179.0.0.0.0.0.0" contextRef="as-of-2012-06-29.9179.0.0.0.0.0.0.0" unitRef="USD" decimals="-6">359000000</dei:EntityPublicFloat>
  <dei:EntityRegistrantName id="EntityRegistrantName.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">Protalix BioTherapeutics, Inc.</dei:EntityRegistrantName>
  <dei:EntityVoluntaryFilers id="EntityVoluntaryFilers.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer id="EntityWellKnownSeasonedIssuer.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:TradingSymbol id="TradingSymbol.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">PLX</dei:TradingSymbol>
  <plx:AgreementMaintenanceFee id="AgreementMaintenanceFee.7858.73722.70469.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.73722.70469.0.0.0.0" unitRef="USD" decimals="-3">20000</plx:AgreementMaintenanceFee>
  <plx:CashlessExerciseOfStockOptions id="CashlessExerciseOfStockOptions.7858.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <plx:CashlessExerciseOfStockOptions id="CashlessExerciseOfStockOptions.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">31000</plx:CashlessExerciseOfStockOptions>
  <plx:CashlessExerciseOfStockOptions id="CashlessExerciseOfStockOptions.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">9000</plx:CashlessExerciseOfStockOptions>
  <plx:CollaborativeAndLicenseArrangementDisclosureTextBlock id="CollaborativeAndLicenseArrangementDisclosureTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;NOTE 2 - LICENSE AND SUPPLY AGREEMENT&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; On November 30, 2009, Protalix Ltd. and Pfizer entered into the Pfizer Agreement pursuant to which Pfizer was granted an exclusive, worldwide license to develop and commercialize taliglucerase alfa, except in Israel. Under the terms and conditions of the Pfizer Agreement, Protalix Ltd. retained the right to commercialize taliglucerase alfa in Israel. Under the Pfizer Agreement, Pfizer made an upfront payment to Protalix Ltd. of $60.0 million in connection with the execution of the agreement and shortly thereafter paid Protalix Ltd. an additional $5.0 million upon the Company&amp;#39;s filing of a proposed pediatric investigation plan to the Pediatric Committee of the EMA. Protalix Ltd. received a $25.0 million milestone payment in connection with the approval of taliglucerase alfa by the FDA in May 2012. Protalix Ltd. is entitled to 40% of the results (profits or losses) earned on Pfizer&amp;#39;s sales of taliglucerase alfa. Such result (profit or loss) will be calculated while, in addition to other adjustments, taking into account Protalix Ltd.&amp;#39;s cost of goods sold and Pfizer&amp;#39;s commercial expenses, with certain expenses capped or borne solely by one party ("Collaboration Operation"). Of the losses incurred by the Collaboration Operation through December 31, 2011, 40% will be deducted from the cash payments to be paid to the Company as its share in the profits from future years, if any. This deduction will be limited to a certain percentage of any quarterly profit. As of December 31, 2012, the Company accrued a liability in respect of these losses equal to $8.5 million, out of which $5.4 million is classified as a long term liability, and the remainder is included in accounts payable and accruals-other.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company has determined that the initial, non-refundable upfront license fee payment of $60.0 million together with the first $5.0 million payment will be recognized on a straight line basis as revenue over the estimated relationship period (approximately $4.6 million per year). The Company has estimated that the relationship period for its arrangement with Pfizer will be approximately 14 years (commencing upon the Company&amp;#39;s receipt of the up-front license payment) based on the Company&amp;#39;s last material patent relating to taliglucerase alfa to expire. The $25.0 million milestone payment received in connection with the FDA&amp;#39;s approval of taliglucerase alfa in the United States was considered to be a substantive milestone for purposes of revenue recognition and, accordingly, was recorded as revenue during the period in which the milestone was achieved.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company&amp;#39;s deliverables under this collaboration include an exclusive license to taliglucerase alfa as an enzyme replacement therapy for the treatment of Gaucher disease, certain research and development services as required under the Pfizer Agreement for taliglucerase alfa and manufacturing of taliglucerase alfa.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; According to the terms and conditions of the Pfizer Agreement, the Company retained manufacturing rights and sells its products to Pfizer. In addition, Pfizer is required to reimburse the Company for certain costs it incurs in connection with certain development expenses for taliglucerase alfa. In connection with the payments received under the Pfizer Agreement, Protalix Ltd. is obligated to pay certain royalties. See Note 6a.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</plx:CollaborativeAndLicenseArrangementDisclosureTextBlock>
  <plx:CollaborativeArrangementProfitSharePercentage id="CollaborativeArrangementProfitSharePercentage.7856.68651.999.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.68651.999.0.0.0.0" unitRef="UPure" decimals="1">0.4</plx:CollaborativeArrangementProfitSharePercentage>
  <plx:CollaborativeArrangementProfitSharePercentage id="CollaborativeArrangementProfitSharePercentage.7856.68649.999.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.68649.999.0.0.0.0" unitRef="UPure" decimals="1">0.6</plx:CollaborativeArrangementProfitSharePercentage>
  <plx:CommitmentAmount id="CommitmentAmount.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1300000</plx:CommitmentAmount>
  <plx:ConsiderationForLicense id="ConsiderationForLicense.7858.70480.70469.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70480.70469.0.0.0.0" unitRef="USD" decimals="-3">700000</plx:ConsiderationForLicense>
  <plx:DepreciationAmortizationAndAssetImpairment id="DepreciationAmortizationAndAssetImpairment.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3692000</plx:DepreciationAmortizationAndAssetImpairment>
  <plx:DepreciationAmortizationAndAssetImpairment id="DepreciationAmortizationAndAssetImpairment.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3631000</plx:DepreciationAmortizationAndAssetImpairment>
  <plx:DepreciationAmortizationAndAssetImpairment id="DepreciationAmortizationAndAssetImpairment.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3133000</plx:DepreciationAmortizationAndAssetImpairment>
  <plx:EffectiveAdjustedIncomeTaxRateThereafter id="EffectiveAdjustedIncomeTaxRateThereafter.7856.5011.136.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.5011.136.0.0.0.0" unitRef="UPure" decimals="2">0.18</plx:EffectiveAdjustedIncomeTaxRateThereafter>
  <plx:EffectiveAdjustedIncomeTaxRateYearFive id="EffectiveAdjustedIncomeTaxRateYearFive.7856.5011.136.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.5011.136.0.0.0.0" unitRef="UPure" decimals="2">0.18</plx:EffectiveAdjustedIncomeTaxRateYearFive>
  <plx:EffectiveAdjustedIncomeTaxRateYearFour id="EffectiveAdjustedIncomeTaxRateYearFour.7856.5011.136.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.5011.136.0.0.0.0" unitRef="UPure" decimals="1">0.2</plx:EffectiveAdjustedIncomeTaxRateYearFour>
  <plx:EffectiveAdjustedIncomeTaxRateYearOne id="EffectiveAdjustedIncomeTaxRateYearOne.7856.5011.136.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.5011.136.0.0.0.0" unitRef="UPure" decimals="2">0.23</plx:EffectiveAdjustedIncomeTaxRateYearOne>
  <plx:EffectiveAdjustedIncomeTaxRateYearThree id="EffectiveAdjustedIncomeTaxRateYearThree.7856.5011.136.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.5011.136.0.0.0.0" unitRef="UPure" decimals="2">0.21</plx:EffectiveAdjustedIncomeTaxRateYearThree>
  <plx:EffectiveAdjustedIncomeTaxRateYearTwo id="EffectiveAdjustedIncomeTaxRateYearTwo.7856.5011.136.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.5011.136.0.0.0.0" unitRef="UPure" decimals="2">0.22</plx:EffectiveAdjustedIncomeTaxRateYearTwo>
  <plx:EmployeeSeveranceObligationPayment id="EmployeeSeveranceObligationPayment.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">177000</plx:EmployeeSeveranceObligationPayment>
  <plx:EmployeeSeveranceObligationPayment id="EmployeeSeveranceObligationPayment.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">181000</plx:EmployeeSeveranceObligationPayment>
  <plx:EmployeeSeveranceObligationPayment id="EmployeeSeveranceObligationPayment.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">174000</plx:EmployeeSeveranceObligationPayment>
  <plx:ExpectedDefintedBenefitContributionDuringPeriod id="ExpectedDefintedBenefitContributionDuringPeriod.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">773000</plx:ExpectedDefintedBenefitContributionDuringPeriod>
  <plx:ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod id="ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">963000</plx:ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod>
  <plx:ForfeitureRate id="ForfeitureRate.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="UPure" decimals="3">0.061</plx:ForfeitureRate>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="GrantsAndReimbursementsReceivedOrReceivable.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">7976000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="GrantsAndReimbursementsReceivedOrReceivable.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6775000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="GrantsAndReimbursementsReceivedOrReceivable.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">7740000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment id="IncreaseInLiabilitiesForPropertyPlantAndEquipment.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1136000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment id="IncreaseInLiabilitiesForPropertyPlantAndEquipment.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1473000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment id="IncreaseInLiabilitiesForPropertyPlantAndEquipment.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2720000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <plx:LiabilitiesAccruedFromLicensingAgreement id="LiabilitiesAccruedFromLicensingAgreement.7856.70846.999.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.70846.999.0.0.0.0" unitRef="USD" decimals="-3">5400000</plx:LiabilitiesAccruedFromLicensingAgreement>
  <plx:MaximumAggregatePaymentsOfRoyaltiesToGrantReceived id="MaximumAggregatePaymentsOfRoyaltiesToGrantReceived.7856.70473.70469.3241.4187.0.0" contextRef="as-of-2012-12-31.7856.0.70473.70469.3241.4187.0.0" unitRef="UPure" decimals="0">1</plx:MaximumAggregatePaymentsOfRoyaltiesToGrantReceived>
  <plx:MaximumAggregatePaymentsOfRoyaltiesToGrantReceived id="MaximumAggregatePaymentsOfRoyaltiesToGrantReceived.7856.73722.70469.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.73722.70469.0.0.0.0" unitRef="UPure" decimals="2">0.12</plx:MaximumAggregatePaymentsOfRoyaltiesToGrantReceived>
  <plx:MilestonePayment id="MilestonePayment.7858.70109.4951.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70109.4951.0.0.0.0" unitRef="USD" decimals="-3">25000000</plx:MilestonePayment>
  <plx:MilestonePayment id="MilestonePayment.7858.68653.4951.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.68653.4951.0.0.0.0" unitRef="USD" decimals="-3">25000000</plx:MilestonePayment>
  <plx:MilestonePayment id="MilestonePayment.7858.70110.4951.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70110.4951.0.0.0.0" unitRef="USD" decimals="-3">8300000</plx:MilestonePayment>
  <plx:MonthlyRentLeaseExpense id="MonthlyRentLeaseExpense.7858.70487.70469.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70487.70469.0.0.0.0" unitRef="USD" decimals="-3">49000</plx:MonthlyRentLeaseExpense>
  <plx:MonthlyRentLeaseExpense id="MonthlyRentLeaseExpense.7858.2904.70469.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.2904.70469.0.0.0.0" unitRef="USD" decimals="-3">82000</plx:MonthlyRentLeaseExpense>
  <plx:NumberOfSubsidiaries id="NumberOfSubsidiaries.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="UPure" decimals="0">2</plx:NumberOfSubsidiaries>
  <plx:OtherGainsLosses id="OtherGainsLosses.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-446000</plx:OtherGainsLosses>
  <plx:OtherGainsLosses id="OtherGainsLosses.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-5418000</plx:OtherGainsLosses>
  <plx:OtherGainsLosses id="OtherGainsLosses.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4602000</plx:OtherGainsLosses>
  <plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses id="ProceedsFromIssuanceOfCommonStockNetOfExpenses.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">25328000</plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses>
  <plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses id="ProceedsFromIssuanceOfCommonStockNetOfExpenses.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">20650000</plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses>
  <plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses id="ProceedsFromIssuanceOfCommonStockNetOfExpenses.7861.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="ResearchDevelopmentAndEngineeringExpenseNet.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">28689000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="ResearchDevelopmentAndEngineeringExpenseNet.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">31043000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="ResearchDevelopmentAndEngineeringExpenseNet.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">29951000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:RevenueRecognizedOverDesignatedPeriod id="RevenueRecognizedOverDesignatedPeriod.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4600000</plx:RevenueRecognizedOverDesignatedPeriod>
  <plx:RevenueRecognizedPeriod id="RevenueRecognizedPeriod.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">P14Y</plx:RevenueRecognizedPeriod>
  <plx:RoyaltiesOnSaleOfProducts id="RoyaltiesOnSaleOfProducts.7858.70473.70469.3248.4187.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70473.70469.3248.4187.0.0" unitRef="UPure" decimals="2">0.03</plx:RoyaltiesOnSaleOfProducts>
  <plx:RoyaltiesOnSaleOfProducts id="RoyaltiesOnSaleOfProducts.7858.70473.70469.3241.4187.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70473.70469.3241.4187.0.0" unitRef="UPure" decimals="2">0.06</plx:RoyaltiesOnSaleOfProducts>
  <plx:RoyaltiesOnSaleOfProducts id="RoyaltiesOnSaleOfProducts.7858.70475.70469.3241.4187.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70475.70469.3241.4187.0.0" unitRef="UPure" decimals="0">3</plx:RoyaltiesOnSaleOfProducts>
  <plx:ScheduleOfOpenTaxYearsTableTextBlock id="ScheduleOfOpenTaxYearsTableTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; WIDTH: 50%; FONT-WEIGHT: bold; TEXT-DECORATION: none"&gt; Jurisdiction:&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; WIDTH: 1%; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: right; WIDTH: 47%"&gt; &lt;strong&gt;Years:&lt;/strong&gt;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;Israel&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;2009-2012&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;United States (*)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;2009-2012&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;Netherlands&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;2009-2012&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; (*) Includes federal, state and local (or similar provincial jurisdictions) tax positions.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</plx:ScheduleOfOpenTaxYearsTableTextBlock>
  <plx:ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock id="ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt; &lt;table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1.25in" cellspacing="0" cellpadding="0"&gt;&lt;!--StartFragment--&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Year of&lt;br /&gt; grant&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;No. of options&lt;br /&gt; or restricted&lt;br /&gt; stock granted&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Exercise&lt;br /&gt; price range&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"&gt;Vesting period&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Fair value&lt;br /&gt; at grant&lt;br /&gt; (U.S.&lt;br /&gt; dollars in&lt;br /&gt; thousands)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Expiration&lt;br /&gt; period&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 10%"&gt;2010&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;1,016,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; WIDTH: 10%"&gt;$6.90&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; WIDTH: 35%"&gt;3 years commencing&lt;br /&gt; upon achievement of a&lt;br /&gt; certain milestone&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;5,673&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt;10 years&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;2010&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;428,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: center"&gt;$6.32-$9.66&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt;4 years&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;2,147&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;10 years&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;2012&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;400,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: center"&gt;n/a&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt;3 years&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;2,288&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;n/a&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;2012&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 1,100,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; n/a&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt"&gt;4 years&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt"&gt;6,292&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: right"&gt; n/a&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;2,944,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;!--EndFragment--&gt;&lt;/table&gt; &lt;/div&gt; &lt;/div&gt;</plx:ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock>
  <plx:ScheduleOfUsefulLifeTableTextBlock id="ScheduleOfUsefulLifeTableTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="WIDTH: 65%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.9in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;Years&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 85%"&gt;Laboratory equipment&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 12%"&gt;5&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td&gt;Furniture&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;10-15&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;Computer equipment&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;3&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 98.65pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</plx:ScheduleOfUsefulLifeTableTextBlock>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable id="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable.7856.4416.344.68641.1319.0.0" contextRef="as-of-2012-12-31.7856.0.4416.344.68641.1319.0.0" unitRef="UShares" decimals="0">102084</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue id="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.7856.68641.1319.70805.3871.0.0" contextRef="as-of-2012-12-31.7856.0.68641.1319.70805.3871.0.0" unitRef="USD" decimals="-3">5673000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue id="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.7856.68641.1319.70806.3871.0.0" contextRef="as-of-2012-12-31.7856.0.68641.1319.70806.3871.0.0" unitRef="USD" decimals="-3">2147000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue id="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.7856.68641.1319.70807.3871.0.0" contextRef="as-of-2012-12-31.7856.0.68641.1319.70807.3871.0.0" unitRef="USD" decimals="-3">2288000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue id="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.7856.68641.1319.70808.3871.0.0" contextRef="as-of-2012-12-31.7856.0.68641.1319.70808.3871.0.0" unitRef="USD" decimals="-3">6292000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue id="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">8600000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue id="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.7859.0.0.0.0.0.0" contextRef="as-of-2010-12-31.7859.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">7800000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue id="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.8554.4416.344.68641.1319.0.0" contextRef="as-of-2012-07-16.8554.0.4416.344.68641.1319.0.0" unitRef="USD" decimals="-3">8600000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm id="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.7858.68641.1319.70805.3871.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.68641.1319.70805.3871.0.0">P10Y</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm id="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.7858.68641.1319.70806.3871.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.68641.1319.70806.3871.0.0">P10Y</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm id="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.8555.4416.344.70821.1319.0.0" contextRef="from-2012-07-15-to-2012-07-16.8555.0.4416.344.70821.1319.0.0">P24M</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod id="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.8555.4416.344.70821.1319.0.0" contextRef="from-2012-07-15-to-2012-07-16.8555.0.4416.344.70821.1319.0.0" unitRef="UPure" decimals="0">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod id="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.8555.4416.344.68641.1319.0.0" contextRef="from-2012-07-15-to-2012-07-16.8555.0.4416.344.68641.1319.0.0" unitRef="UPure" decimals="0">12</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.7858.1033.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">1000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.7858.461.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">3138000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3139000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares id="ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.7858.1033.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.1033.4957.0.0.0.0" unitRef="UShares" decimals="0">1496792</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
  <plx:SupplementalOfferingAndStockIssuanceCosts id="SupplementalOfferingAndStockIssuanceCosts.7858.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <plx:SupplementalOfferingAndStockIssuanceCosts id="SupplementalOfferingAndStockIssuanceCosts.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">60000</plx:SupplementalOfferingAndStockIssuanceCosts>
  <plx:SupplementalOfferingAndStockIssuanceCosts id="SupplementalOfferingAndStockIssuanceCosts.7861.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <plx:SupplementaryBalanceSheetsInformationTableTextBlock id="SupplementaryBalanceSheetsInformationTableTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-INDENT: -17.3pt; MARGIN: 0pt 0px 0pt 71.3pt; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt;December 31,&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-STYLE: italic"&gt;(U.S. dollars in thousands)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2011&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2012&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -26.45pt; PADDING-LEFT: 26.45pt; FONT-WEIGHT: bold"&gt; a. Other assets:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt; WIDTH: 74%"&gt; Deferred costs*&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;1,558&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;89&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-LEFT: 45pt"&gt;Institutions&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;375&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;542&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt"&gt;State of Israel (see Note 6a)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1,296&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;2,400&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt"&gt;Restricted deposit&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;208&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;298&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt"&gt;Prepaid expenses&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;235&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;251&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt"&gt;Sundry&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 165&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 106&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 3,837&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 3,686&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; * Manufacturing costs of inventory, paid by Pfizer, but not delivered.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;em&gt;(U.S. dollars in thousands)&lt;/em&gt;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.5in"&gt;&lt;strong&gt;b.&lt;/strong&gt;&lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt;&lt;strong&gt;Accounts payable and accruals - other:&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt; WIDTH: 74%"&gt; Payroll and related expenses&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;1,108&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;1,748&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt"&gt;Provision for vacation&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1,221&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1,453&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt"&gt;Accrued expenses&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;2,327&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;2,032&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt"&gt;Royalties payable&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;89&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1,560&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 52.2pt"&gt; Liability in connection with collaboration operation- current portion&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1,322&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;3,122&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; PADDING-LEFT: 45pt"&gt; Property and equipment suppliers&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 1,473&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 1,136&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 7,540&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 11,051&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</plx:SupplementaryBalanceSheetsInformationTableTextBlock>
  <plx:SupplementaryIncomeStatementInformationTableTextBlock id="SupplementaryIncomeStatementInformationTableTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="10"&gt;Year ended December 31,&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2010&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2011&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2012&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-STYLE: italic"&gt;(U.S. dollars in thousands)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center" colspan="2"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right" colspan="2"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right" colspan="2"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -28.85pt; PADDING-LEFT: 28.85pt; FONT-WEIGHT: bold"&gt; c. Revenues:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in; WIDTH: 61%"&gt; Deferred revenues from the license and supply agreement with Pfizer&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;4,563&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;4,563&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;4,563&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 0.5in"&gt;Milestone payment (see note 2)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;25,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.5in"&gt; Revenues from selling products&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 2,079&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 3,823&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 5,307&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -28.85pt; PADDING-LEFT: 28.85pt; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 6,642&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 8,386&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 34,870&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</plx:SupplementaryIncomeStatementInformationTableTextBlock>
  <plx:TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal id="TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">39%, 25% and 0%</plx:TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal>
  <plx:WithholdingTaxRateOnForeignIncome id="WithholdingTaxRateOnForeignIncome.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="UPure" decimals="2">0.15</plx:WithholdingTaxRateOnForeignIncome>
  <us-gaap:AccountsPayableOtherCurrent id="AccountsPayableOtherCurrent.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">11051000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:AccountsPayableOtherCurrent id="AccountsPayableOtherCurrent.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">7540000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:AccountsPayableOtherCurrent id="AccountsPayableOtherCurrent.7856.70518.70516.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.70518.70516.0.0.0.0" unitRef="USD" decimals="-3">3122000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:AccountsPayableOtherCurrent id="AccountsPayableOtherCurrent.7857.70518.70516.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.70518.70516.0.0.0.0" unitRef="USD" decimals="-3">1322000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:AccountsPayableOtherCurrent id="AccountsPayableOtherCurrent.7856.70519.70516.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.70519.70516.0.0.0.0" unitRef="USD" decimals="-3">1136000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:AccountsPayableOtherCurrent id="AccountsPayableOtherCurrent.7857.70519.70516.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.70519.70516.0.0.0.0" unitRef="USD" decimals="-3">1473000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:AccountsPayableTradeCurrent id="AccountsPayableTradeCurrent.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5267000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccountsPayableTradeCurrent id="AccountsPayableTradeCurrent.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5032000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="AccountsReceivableNetCurrent.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1410000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="AccountsReceivableNetCurrent.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1374000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="AccruedLiabilitiesCurrent.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2032000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="AccruedLiabilitiesCurrent.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2327000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent id="AccruedLiabilitiesCurrentAndNoncurrent.7856.70846.999.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.70846.999.0.0.0.0" unitRef="USD" decimals="-3">8500000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
  <us-gaap:AccruedRoyaltiesCurrent id="AccruedRoyaltiesCurrent.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1560000</us-gaap:AccruedRoyaltiesCurrent>
  <us-gaap:AccruedRoyaltiesCurrent id="AccruedRoyaltiesCurrent.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">89000</us-gaap:AccruedRoyaltiesCurrent>
  <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent id="AccruedRoyaltiesCurrentAndNoncurrent.7856.70473.70469.3241.4187.0.0" contextRef="as-of-2012-12-31.7856.0.70473.70469.3241.4187.0.0" unitRef="USD" decimals="-3">21300000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
  <us-gaap:AccruedVacationCurrent id="AccruedVacationCurrent.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1453000</us-gaap:AccruedVacationCurrent>
  <us-gaap:AccruedVacationCurrent id="AccruedVacationCurrent.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1221000</us-gaap:AccruedVacationCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">14786000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">11148000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AdditionalFinancialInformationDisclosureTextBlock id="AdditionalFinancialInformationDisclosureTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;NOTE 9 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-INDENT: -17.3pt; MARGIN: 0pt 0px 0pt 71.3pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;Balance sheets:&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-INDENT: -17.3pt; MARGIN: 0pt 0px 0pt 71.3pt; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt;December 31,&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-STYLE: italic"&gt;(U.S. dollars in thousands)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2011&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2012&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -26.45pt; PADDING-LEFT: 26.45pt; FONT-WEIGHT: bold"&gt; a. Other assets:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt; WIDTH: 74%"&gt; Deferred costs*&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;1,558&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;89&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-LEFT: 45pt"&gt;Institutions&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;375&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;542&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt"&gt;State of Israel (see Note 6a)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1,296&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;2,400&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt"&gt;Restricted deposit&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;208&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;298&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt"&gt;Prepaid expenses&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;235&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;251&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt"&gt;Sundry&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 165&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 106&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 3,837&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 3,686&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; * Manufacturing costs of inventory, paid by Pfizer, but not delivered.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;em&gt;(U.S. dollars in thousands)&lt;/em&gt;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.5in"&gt;&lt;strong&gt;b.&lt;/strong&gt;&lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt;&lt;strong&gt;Accounts payable and accruals - other:&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt; WIDTH: 74%"&gt; Payroll and related expenses&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;1,108&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;1,748&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt"&gt;Provision for vacation&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1,221&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1,453&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt"&gt;Accrued expenses&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;2,327&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;2,032&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt"&gt;Royalties payable&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;89&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1,560&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 52.2pt"&gt; Liability in connection with collaboration operation- current portion&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1,322&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;3,122&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; PADDING-LEFT: 45pt"&gt; Property and equipment suppliers&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 1,473&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 1,136&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 7,540&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 11,051&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;Statements of operations:&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="10"&gt;Year ended December 31,&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2010&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2011&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2012&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-STYLE: italic"&gt;(U.S. dollars in thousands)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center" colspan="2"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right" colspan="2"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right" colspan="2"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -28.85pt; PADDING-LEFT: 28.85pt; FONT-WEIGHT: bold"&gt; c. Revenues:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in; WIDTH: 61%"&gt; Deferred revenues from the license and supply agreement with Pfizer&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;4,563&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;4,563&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;4,563&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 0.5in"&gt;Milestone payment (see note 2)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;25,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.5in"&gt; Revenues from selling products&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 2,079&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 3,823&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 5,307&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -28.85pt; PADDING-LEFT: 28.85pt; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 6,642&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 8,386&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 34,870&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="AdditionalPaidInCapitalCommonStock.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">180145000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="AdditionalPaidInCapitalCommonStock.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">145814000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.7858.461.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">4612000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.7860.461.4957.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">886000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.7861.461.4957.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">1282000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4612000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">886000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1282000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1780000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1410000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.7858.4381.4617.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.4381.4617.0.0.0.0" unitRef="USD" decimals="-3">4756000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.7860.4381.4617.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.4381.4617.0.0.0.0" unitRef="USD" decimals="-3">422000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.7861.4381.4617.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.4381.4617.0.0.0.0" unitRef="USD" decimals="-3">630000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.7858.2354.4617.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.2354.4617.0.0.0.0" unitRef="USD" decimals="-3">2775000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.7860.2354.4617.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.2354.4617.0.0.0.0" unitRef="USD" decimals="-3">464000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.7861.2354.4617.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.2354.4617.0.0.0.0" unitRef="USD" decimals="-3">652000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">7751000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">886000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1282000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.7858.1183.4617.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.1183.4617.0.0.0.0" unitRef="USD" decimals="-3">220000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">7761168</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">7469088</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">7280469</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AssetImpairmentCharges id="AssetImpairmentCharges.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">0</us-gaap:AssetImpairmentCharges>
  <us-gaap:AssetImpairmentCharges id="AssetImpairmentCharges.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">10000</us-gaap:AssetImpairmentCharges>
  <us-gaap:AssetImpairmentCharges id="AssetImpairmentCharges.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">43000</us-gaap:AssetImpairmentCharges>
  <us-gaap:Assets id="Assets.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">78727000</us-gaap:Assets>
  <us-gaap:Assets id="Assets.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">51805000</us-gaap:Assets>
  <us-gaap:AssetsCurrent id="AssetsCurrent.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">61170000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="AssetsCurrent.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">32491000</us-gaap:AssetsCurrent>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="BasisOfAccountingPolicyPolicyTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;Basis of presentation&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company&amp;#39;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP").&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock id="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;a.&lt;/td&gt; &lt;td&gt;General&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;1.&lt;/td&gt; &lt;td&gt;Operation&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: 0in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: 0in"&gt; Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the "Company"), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&amp;#39;s proprietary ProCellEx&lt;sup&gt;&amp;reg;&lt;/sup&gt; protein expression system ("ProCellEx"). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency ("EMA") application process in the European Union. The Company&amp;#39;s two subsidiaries are referred to collectively herein as the "Subsidiaries."&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: 0in"&gt; On May 1, 2012, the U.S. Food and Drug Administration (&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;FDA&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;) approved taliglucerase alfa for injection, the Company&amp;#39;s first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the "Israeli MOH") in September 2012 and recently in Uruguay. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by each of the FDA and the Israeli MOH.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO&amp;trade; by Pfizer Inc. (&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;Pfizer&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;), the Company&amp;#39;s commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the &lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;Pfizer Agreement&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;). The Company, through Protalix Ltd., markets ELELYSO in Israel.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel. The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company received an additional $25.0 million milestone payment in connection with the FDA&amp;#39;s approval of taliglucerase alfa in the United States, which was considered to be a substantive milestone for purposes of revenue recognition, and, accordingly, was recorded as revenue during the period in which the milestone was achieved. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel, where the Company retained exclusive marketing rights. &lt;font style="COLOR: black"&gt;In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold&lt;/font&gt;.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; In December 2012, Protalix Ltd. entered into a Clinical Development Agreement with Pfizer under which Protalix Ltd. will continue to manage, administer and sponsor current, ongoing clinical trials relating to taliglucerase alfa. According to the terms of the agreement, Protalix Ltd. was eligible to receive a payment of $8.3 million upon the achievement of certain near-term clinical development goals. The goals were achieved, and the payment made, in December 2012. The Company evaluated the terms of the agreement and the nature of the payment made by Pfizer and concluded that the amount received represents an upfront funding of the anticipated costs of the Company&amp;#39;s ongoing clinical trials relating to taliglucerase alfa. Accordingly, the amount was deferred upon receipt and will be recognized as a reduction of research and development expenses over the ongoing clinical trial period.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company is cooperating with Pfizer to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed for Brazil and other countries. The European Commission (EC) issued a Commission Decision refusing the marketing authorization for taliglucerase alfa in the European Union. This decision is an endorsement of the EMA&amp;#39;s Committee for Medicinal Products for Human Use (CHMP) June 2012 opinion recommending against the marketing authorization of taliglucerase alfa. While the CHMP gave a positive risk-benefit assessment for taliglucerase alfa, its recommendation was based solely on the orphan market exclusivity granted to VPRIV&lt;sup&gt;&amp;reg;&lt;/sup&gt;, Shire plc&amp;#39;s Gaucher disease treatment. It was not based on the safety and efficacy profile of taliglucerase alfa.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States and Israel. In addition, patients are being treated globally through the Company&amp;#39;s clinical trials and related studies, compassionate use programs, special access agreements, named patient provisions and other programs designed to ensure that treatments are available to Gaucher patients in light of recent shortages of approved treatments. On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d&amp;#39;Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease. An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations to hospitals. Notwithstanding the EC&amp;#39;s decision not to approve the market authorization of taliglucerase alfa in the EU, the Company, together with Pfizer, will continue to supply taliglucerase alfa as required by physicians under the ATU process for as long as it is authorized by the French regulatory authorities. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in Brazil and in other countries.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; On August 10, 2010, Pfizer entered into a short-term supply agreement with the Ministry of Health of Brazil pursuant to which the Company and Pfizer have provided taliglucerase alfa to the Brazilian Ministry of Health for the treatment of Gaucher patients. During the remainder of 2010 and the first quarter of 2011, the Company and Pfizer completed the supply of products deliverable under the short-term supply agreement. During 2011, Pfizer recorded an allowance for sales returns in connection with the supply agreement because the Brazilian Ministry of Health requested that Pfizer consider the replacement of certain vials that might expire during 2012. During the third quarter of 2012 resupply for certain vials was completed. Revenue, net of allowance for sales returns, generated from the Brazilian Ministry of Health was recorded by Pfizer, and the Company recorded its share of such revenues in accordance with the terms and conditions of the Pfizer Agreement.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;2.&lt;/td&gt; &lt;td&gt;Liquidity and Financial Resources&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; In addition to the approval of taliglucerase alfa by the FDA and the Israeli MOH, successful completion of the Company&amp;#39;s development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. In accordance with the terms and conditions of the Pfizer Agreement, the Company received a $25.0 million milestone payment in connection with the FDA&amp;#39;s approval of taliglucerase alfa in the United States. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all and the Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Obtaining marketing approval with respect to any product candidate is directly dependent on the Company&amp;#39;s ability to implement the necessary regulatory steps required to obtain such approval in the United States and in other countries. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;b.&lt;/td&gt; &lt;td&gt;Basis of presentation&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company&amp;#39;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP").&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;c.&lt;/td&gt; &lt;td&gt;Use of estimates in the preparation of financial statements&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;d.&lt;/td&gt; &lt;td&gt;Functional currency&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; The dollar is the currency of the primary economic environment in which the operations of the Company and its Subsidiaries are conducted. Most of the Company&amp;#39;s revenues are derived in dollars. Most of the Company&amp;#39;s expenses and capital expenditures are incurred in dollars, and the major source of the Company&amp;#39;s financing has been provided in dollars.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below) reflected in the statements of operations, the following exchange rates are used: (i) for transactions - exchange rates at the transaction dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.) - historical exchange rates. Currency transaction gains and losses are carried to financial income or expenses, as appropriate.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;e.&lt;/td&gt; &lt;td&gt;Cash equivalents&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company considers all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;f.&lt;/td&gt; &lt;td&gt;Inventories&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Inventories are valued at the lower of cost or market. Cost of raw and packaging materials and purchased products is determined using the "moving average" basis.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Cost of finished products that are capitalized is determined as follows: the value of the raw and packaging materials component is determined primarily on a using the "moving average" basis; the value of the labor and overhead component is determined on an average basis over the production period.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Prior to the FDA&amp;#39;s approval of taliglucerase alfa, manufacturing costs related to taliglucerase alfa were not capitalized; rather, such costs were expensed as research and development expenses. Effective as of the FDA approval of taliglucerase alfa on May 1, 2012, the Company capitalizes manufacturing costs associated with taliglucerase alfa.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;g.&lt;/td&gt; &lt;td&gt;Property and equipment&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;1.&lt;/td&gt; &lt;td&gt;&lt;font style="FONT-WEIGHT: normal"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization.&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;2.&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal"&gt;The Company&amp;#39;s assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="WIDTH: 65%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1.5in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;Years&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 85%"&gt;Laboratory equipment&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 12%"&gt;5&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td&gt;Furniture&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;10-15&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;Computer equipment&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;3&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 98.65pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Leasehold improvements are amortized by the straight-line method over the expected lease term, which is shorter than the estimated useful life of the improvements.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;h.&lt;/td&gt; &lt;td&gt;Impairment in value of long-lived assets:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company tests long-lived assets for impairment if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted and without interest charges) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their estimated fair values.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;i.&lt;/td&gt; &lt;td&gt;Income taxes&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1.25in; TEXT-INDENT: -0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;1.&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal"&gt;Deferred income taxes&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; The guidance prohibits the recognition of deferred tax liabilities or assets that arise from differences between the financial reporting and tax bases of assets and liabilities that are measured from the local currency into dollars using historical exchange rates, and that result from changes in exchange rates or indexing for tax purposes. Consequently, the above mentioned differences with respect to Protalix Ltd. were not reflected in the computation of deferred tax assets and liabilities.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;2.&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal"&gt;Uncertainty in income taxes&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Tax benefits recognized in the financial statements are those that the Company&amp;#39;s management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit the Company&amp;#39;s management deems more likely than not to be sustained.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;j.&lt;/td&gt; &lt;td&gt;Revenue Recognition&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company recognizes revenue when the earnings process is complete, which is when revenue is realized or realizable and earned, there is persuasive evidence a revenue arrangement exists, delivery of goods or services has occurred, the sales price is fixed or determinable and collectability is reasonably assured.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;1.&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal"&gt;Revenues from the license and supply agreement with Pfizer&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company recognizes revenue from milestone payments received pursuant to the Pfizer Agreement in accordance with guidance regarding revenue recognition and accounting for revenue arrangements with multiple deliverables. As the arrangement with Pfizer requires the Company&amp;#39;s continued involvement with respect to the proposed commercialization of taliglucerase alfa, the non-refundable, up-front license payment the Company received from Pfizer was deferred and recognized over the related performance period. The Company estimated the performance period of 14 years (commencing upon the date of the Company&amp;#39;s receipt of the up-front license payment payable by Pfizer under the Pfizer Agreement) based on the date the last relevant patent expires. See Note 2. The Company adjusts the performance periods, if appropriate, based on the applicable facts and circumstances. Each milestone payment that is considered to be substantive for purposes of revenue recognition is recorded as revenue during the period during which the milestone is achieved.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;2.&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal"&gt;Revenues from selling products to Pfizer&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company recognizes revenues from products sold to Pfizer upon delivery, when the sales price is fixed or determinable and collectability is reasonably assured.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;3.&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal"&gt;Company&amp;#39;s share in the collaboration agreement&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: 0in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: 0in"&gt; Under the terms and conditions of the Pfizer Agreement, the Company is entitled to 40% of the profits or loss from sales of taliglucerase alfa, and related expenses incurred, except with respect to sales in Israel, where the Company retained exclusive marketing rights. Since Pfizer bears most of the risks and rewards relating to the agreement, the Company&amp;#39;s share in the profits and loss in the agreement is recognized on a net basis. The Company recognizes its share of net profit or loss from the Pfizer Agreement based on reports it receives from Pfizer summarizing the results of the collaborative activities under the agreement for the applicable period. Under the terms of the Pfizer Agreement, for its subsidiaries operating outside the United States, financial information is included based on the fiscal year ending November 30, while financial information for the U.S. entity is included based on the fiscal year ending December 31.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;k.&lt;/td&gt; &lt;td&gt;Research and development costs&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment and supplies for research and development activities. Grants received by the Israeli Subsidiary from the Office of the Chief Scientist of Israel&amp;#39;s Ministry of Industry, Trade and Labor (the "OCS") are recognized when the grant becomes receivable, provided there is reasonable assurance that the Company or the Subsidiary will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Reimbursements received from Pfizer are recognized when the reimbursements become receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the reimbursements and there is reasonable assurance the reimbursements will be received. The reimbursements are deducted from the research and development expenses as the applicable costs are incurred.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; In connection with purchases of assets, amounts assigned to intangible assets to be used in a particular research and development project that have no alternative future use are charged to research and development costs at the purchase date.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are consumed or the related services are performed.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;l.&lt;/td&gt; &lt;td&gt;Concentration of credit risks and trade receivable&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits. The Company deposits these instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;font style="COLOR: black"&gt;The Company&amp;#39;s trade&lt;/font&gt; receivable &lt;font style="COLOR: black"&gt;represents mainly amounts to be received from Pfizer, as the Company currently receives most of its revenues from Pfizer. The Company does not require Pfizer to post collateral with respect to the receivables. The Company performs periodic credit evaluations of Pfizer&amp;#39;s financial condition and believes there is no significant risk with respect to Pfizer&amp;#39;s payment of the receivables.&lt;/font&gt;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;m.&lt;/td&gt; &lt;td&gt;Share-based compensation&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company accounts for employee&amp;#39;s share-based payment awards classified as equity awards using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period, net of estimated forfeitures. The Company estimates forfeitures based on historical experience and anticipated future conditions.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company elected to recognize compensation cost for an award with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; When stock options are granted as consideration for services provided by consultants and other non-employees, the grant is accounted for based on the fair value of the stock options issued. Options granted is measured on a final basis at the end of the related service period and is recognized over the related service period using the straight-line method.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;n.&lt;/td&gt; &lt;td&gt;Net Loss per share&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Basic and diluted loss per share ("LPS") are computed by dividing net loss by the weighted average number of shares of the Company&amp;#39;s Common Stock, par value $0.001 per share (the "Common Stock") outstanding for each period.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Diluted LPS does not include 7,761,168, 7,469,088 and 7,280,469 &lt;font style="COLOR: black"&gt;shares of Common Stock underlying outstanding options and restricted shares of Common Stock&lt;/font&gt; for the fiscal years ended December 31, 2010, 2011 and 2012, respectively, because the effect would be anti-dilutive.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">52035000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">27001000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.7859.0.0.0.0.0.0" contextRef="as-of-2010-12-31.7859.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">35900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.7862.0.0.0.0.0.0" contextRef="as-of-2009-12-31.7862.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">81266000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="CashAndCashEquivalentsPeriodIncreaseDecrease.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">25034000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="CashAndCashEquivalentsPeriodIncreaseDecrease.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-8899000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="CashAndCashEquivalentsPeriodIncreaseDecrease.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-45366000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock id="CashAndCashEquivalentsPolicyTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;Cash equivalents&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company considers all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:CommitmentsAndContingencies id="CommitmentsAndContingencies.7856.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="CommitmentsAndContingencies.7857.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsDisclosureTextBlock id="CommitmentsDisclosureTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;NOTE 6 - COMMITMENTS&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;a.&lt;/td&gt; &lt;td&gt;Royalty commitments&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;1.&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal"&gt;The Company is obligated to pay royalties to the OCS on proceeds from the sale of products developed from research and development activities that were funded, partially, by grants from the OCS. At the time the grants were received, successful development of the related projects was not assured.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; In the case of failure of a project that was partly financed as described above, the Company is not obligated to pay any such royalties or repay funding received from the OCS.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Under the terms of the funding arrangements with the OCS, royalties of 3% to 6% are payable on the sale of products developed from projects funded by the OCS, which payments shall not exceed, in the aggregate, 100% of the amount of the grant received (dollar linked), plus, commencing upon January&amp;nbsp;1, 2001, interest at annual rate based on LIBOR. In addition, if the Company receives approval to manufacture products developed with government grants outside the State of Israel, it will be required to pay an increased total amount of royalties (possibly up to 300% of the grant amounts plus interest), depending on the manufacturing volume that is performed outside the State of Israel, and, possibly, an increased royalty rate.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Royalty expenses to the OCS are included in the statement of operations as a component of the cost of revenues and were approximately $769,000, $158,000 and $1.5 million during the years ended December&amp;nbsp;31, 2010, 2011 and 2012, respectively.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; At December 31, 2012, the maximum royalty amount payable by the Company under these funding arrangements is approximately $21.3 million (without interest, assuming 100% of the funds are payable).&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;2.&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal"&gt;The Company is a party to certain research and license agreements. Under the &lt;font style="COLOR: black"&gt;agreements, the Company is obligated&lt;/font&gt; to pay royalties at varying rates from its future revenues. The aggregate royalties payable under all of the agreements is equal to a varying range of percentages of net sales of licensed products. Royalty expenses under the agreements are included in the statement of operations as a component of the cost of revenues and were approximately $115,000, $19,000 and $674,000 during the years ended December&amp;nbsp;31, 2010, 2011 and 2012, respectively.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Under each agreement, the Company is also obligated to pay milestone, licensing and other payments to the counterparties of the agreement. The payments under the agreements are for varying amounts and are subject to varying conditions. If all of the contingencies with respect to milestone payments under the research and license agreements are met, the aggregate milestone payments payable would be approximately $1.0 million and would be payable, if at all, as the Company&amp;#39;s projects progress over the course of a number of years. In addition, a milestone payment of approximately $100,000 was made in respect of the agreements during the year ended December 31, 2010. No milestone payments were made during 2011 and 2012.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; None of the agreements has a fixed termination date. Subject to earlier termination for other reasons, each agreement terminates after a certain number of years following the first commercial sale of any licensed product under the agreement or after a certain number of years without the initiation of commercial sales of any product under the agreement.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;b.&lt;/td&gt; &lt;td&gt;Subcontracting Agreements&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company has entered into sub-contracting agreements with several clinical providers and consultants in Israel, the United States and certain other countries in connection with its primary product development process and with expenditure of the company&amp;#39;s manufacturing facilities. As of December 31, 2012, total commitments under said agreements were approximately $1.3 million.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;c.&lt;/td&gt; &lt;td&gt;Lease Agreements&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company is a party to a number of lease agreements for its facilities, the latest of which expires in 2016. The Company has the option to extend certain of such agreements on three occasions for additional five-year periods, for a total of 15 additional years. Under the leases, the aggregate monthly rental payments are approximately $82,000. As of December 31, 2012, the Company provided bank guarantees of approximately $298,000, in the aggregate, to secure the fulfillment of its obligations under the lease agreements. The future minimum lease payments required in each of the next five years under the operating leases for such premises are approximately as follows: 2013 - $976,000, 2014 - $968,000, 2015 - $985,000 and 2016 - $823,000. Lease expenses totaled $891,000, $994,000 and $971,000 for the years ended December 31, 2010, 2011 and 2012, respectively.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;d.&lt;/td&gt; &lt;td&gt;Vehicle Lease and Maintenance Agreements&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company entered into several three-year lease and maintenance agreements for vehicles which are regularly amended as new vehicles are leased. The current monthly lease fees aggregate approximately $49,000. The expected lease payments for the years ending December 31, 2013, 2014 and 2015 are approximately $526,000, $385,000 and $175,000, respectively.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;e.&lt;/td&gt; &lt;td&gt;Yissum Agreement&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; On August 8, 2007, the Company signed an agreement with the Yissum Research and Development Company, the technology transfer arm of the Hebrew University of Jerusalem, Israel ("Yissum"), and the Boyce Thompson Institute for Plant Research, at Cornell University, Ithaca, New York ("Boyce Thompson"), to develop a proprietary plant cell-based acetylcholinesterase (AChE) and its molecular variants for the use in several therapeutic and prophylactic indications, including a biodefense program and organophosphate-based pesticide treatment. Pursuant to the agreement, the Company has received an exclusive worldwide right and license to certain technology, including patents and additional patent applications relating to AChE (the "Licensed Technology"), for all therapeutic and prophylactic indications. In consideration for the license, the Company is &lt;font style="COLOR: black"&gt;obligated to pay Yissum and&lt;/font&gt; Boyce Thompson, collectively, &lt;font style="COLOR: black"&gt;an annual, non-refundable initial maintenance fee of $20,000,&lt;/font&gt; commencing on the fourth anniversary of the execution of the agreement, which is subject to a 12% annual increase. &lt;font style="COLOR: black"&gt;In addition,&lt;/font&gt; the Company is required to make certain milestone payments equal to up to $700,000, in the aggregate, upon its achievement of clinical milestones and royalties from sales derived from any drugs developed by the Company with the Licensed Technology. The agreement does not terminate until either party to the agreement elect to terminate the agreement, subject to certain terms and conditions set forth therein.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CommitmentsDisclosureTextBlock>
  <us-gaap:CommonStockParOrStatedValuePerShare id="CommonStockParOrStatedValuePerShare.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="UPerShare" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="CommonStockParOrStatedValuePerShare.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="UPerShare" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="CommonStockSharesAuthorized.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="CommonStockSharesAuthorized.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="CommonStockSharesIssued.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">93489809</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="CommonStockSharesIssued.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">85630157</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="CommonStockSharesIssued.8542.0.0.0.0.0.0" contextRef="as-of-2012-02-22.8542.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">5175000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="CommonStockSharesIssued.9212.0.0.0.0.0.0" contextRef="as-of-2011-03-23.9212.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">4000000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="CommonStockSharesIssued.8554.4416.344.68641.1319.0.0" contextRef="as-of-2012-07-16.8554.0.4416.344.68641.1319.0.0" unitRef="UShares" decimals="-3">400000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="CommonStockSharesOutstanding.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">93489809</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="CommonStockSharesOutstanding.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">85630157</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue id="CommonStockValue.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">93000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="CommonStockValue.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">86000</us-gaap:CommonStockValue>
  <us-gaap:ConcentrationRiskCreditRisk id="ConcentrationRiskCreditRisk.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt;Concentration of credit risks and trade receivable&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits. The Company deposits these instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;font style="COLOR: black"&gt;The Company&amp;#39;s trade&lt;/font&gt; receivable &lt;font style="COLOR: black"&gt;represents mainly amounts to be received from Pfizer, as the Company currently receives most of its revenues from Pfizer. The Company does not require Pfizer to post collateral with respect to the receivables. The Company performs periodic credit evaluations of Pfizer&amp;#39;s financial condition and believes there is no significant risk with respect to Pfizer&amp;#39;s payment of the receivables.&lt;/font&gt;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:CostOfRevenue id="CostOfRevenue.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">8144000</us-gaap:CostOfRevenue>
  <us-gaap:CostOfRevenue id="CostOfRevenue.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1525000</us-gaap:CostOfRevenue>
  <us-gaap:CostOfRevenue id="CostOfRevenue.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4383000</us-gaap:CostOfRevenue>
  <us-gaap:DeferredRevenueCurrent id="DeferredRevenueCurrent.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">9437000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent id="DeferredRevenueCurrent.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6121000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent id="DeferredRevenueNoncurrent.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">48888000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent id="DeferredRevenueNoncurrent.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">50923000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredTaxAssetsDeferredIncome id="DeferredTaxAssetsDeferredIncome.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">10449000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsDeferredIncome id="DeferredTaxAssetsDeferredIncome.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4746000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment id="DeferredTaxAssetsInProcessResearchAndDevelopment.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6003000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment id="DeferredTaxAssetsInProcessResearchAndDevelopment.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4119000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
  <us-gaap:DeferredTaxAssetsNet id="DeferredTaxAssetsNet.7856.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:DeferredTaxAssetsNet id="DeferredTaxAssetsNet.7857.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="DeferredTaxAssetsOperatingLossCarryforwards.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">15176000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="DeferredTaxAssetsOperatingLossCarryforwards.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4579000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment id="DeferredTaxAssetsPropertyPlantAndEquipment.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-647000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment id="DeferredTaxAssetsPropertyPlantAndEquipment.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-149000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits id="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">363000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits id="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">305000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments id="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">192000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments id="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">164000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="DeferredTaxAssetsValuationAllowance.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">31536000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="DeferredTaxAssetsValuationAllowance.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">13764000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax id="DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">36000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
  <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax id="DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">14000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
  <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax id="DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">26000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
  <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent id="DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1247000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
  <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent id="DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1043000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount id="DefinedContributionPlanEmployerDiscretionaryContributionAmount.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">670000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount id="DefinedContributionPlanEmployerDiscretionaryContributionAmount.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">641000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount id="DefinedContributionPlanEmployerDiscretionaryContributionAmount.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">531000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="UPerShare" decimals="2">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="UPerShare" decimals="2">-0.43</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="UPerShare" decimals="2">-0.36</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock id="EarningsPerSharePolicyTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;Net Loss per share&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Basic and diluted loss per share ("LPS") are computed by dividing net loss by the weighted average number of shares of the Company&amp;#39;s Common Stock, par value $0.001 per share (the "Common Stock") outstanding for each period.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Diluted LPS does not include 7,761,168, 7,469,088 and 7,280,469 &lt;font style="COLOR: black"&gt;shares of Common Stock underlying outstanding options and restricted shares of Common Stock&lt;/font&gt; for the fiscal years ended December 31, 2010, 2011 and 2012, respectively, because the effect would be anti-dilutive.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate.7858.3241.4187.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.3241.4187.0.0.0.0" unitRef="UPure" decimals="2">0.39</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate.7858.5011.136.3248.4187.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.5011.136.3248.4187.0.0" unitRef="UPure" decimals="2">0.26</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate.7858.5011.136.3241.4187.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.5011.136.3241.4187.0.0" unitRef="UPure" decimals="2">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate.7858.5011.136.70497.2525.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.5011.136.70497.2525.0.0" unitRef="UPure" decimals="2">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate.7858.70497.2525.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70497.2525.0.0.0.0" unitRef="UPure" decimals="2">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate.7858.70496.2525.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70496.2525.0.0.0.0" unitRef="UPure" decimals="2">0.26</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="EffectOfExchangeRateOnCashAndCashEquivalents.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">127000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="EffectOfExchangeRateOnCashAndCashEquivalents.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-388000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="EffectOfExchangeRateOnCashAndCashEquivalents.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">589000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="EmployeeRelatedLiabilitiesCurrent.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1748000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="EmployeeRelatedLiabilitiesCurrent.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1108000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">7000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">P1Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="ForeignCurrencyTransactionGainLossBeforeTax.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">554000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="ForeignCurrencyTransactionGainLossBeforeTax.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="ForeignCurrencyTransactionGainLossBeforeTax.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">968000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized id="ForeignCurrencyTransactionGainLossUnrealized.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">171000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized id="ForeignCurrencyTransactionGainLossUnrealized.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-350000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized id="ForeignCurrencyTransactionGainLossUnrealized.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">591000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock id="ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;Functional currency&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; The dollar is the currency of the primary economic environment in which the operations of the Company and its Subsidiaries are conducted. Most of the Company&amp;#39;s revenues are derived in dollars. Most of the Company&amp;#39;s expenses and capital expenditures are incurred in dollars, and the major source of the Company&amp;#39;s financing has been provided in dollars.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below) reflected in the statements of operations, the following exchange rates are used: (i) for transactions - exchange rates at the transaction dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.) - historical exchange rates. Currency transaction gains and losses are carried to financial income or expenses, as appropriate.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="GainLossOnSaleOfPropertyPlantEquipment.7858.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="GainLossOnSaleOfPropertyPlantEquipment.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-8000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="GainLossOnSaleOfPropertyPlantEquipment.7861.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:GeneralAndAdministrativeExpense id="GeneralAndAdministrativeExpense.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">9763000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="GeneralAndAdministrativeExpense.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6931000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="GeneralAndAdministrativeExpense.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6876000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GrossProfit id="GrossProfit.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">26280000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit id="GrossProfit.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1443000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit id="GrossProfit.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6861000</us-gaap:GrossProfit>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock id="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;Impairment in value of long-lived assets:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company tests long-lived assets for impairment if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted and without interest charges) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their estimated fair values.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="IncomeTaxDisclosureTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;NOTE 8 - TAXES ON INCOME&lt;/strong&gt;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 0.75in; TEXT-INDENT: -0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;a.&lt;/td&gt; &lt;td&gt;The Company&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Protalix BioTherapeutics, Inc. is taxed according to U.S. tax laws. The Company&amp;#39;s income is, or will be, taxed in the United States at the rate of up to 39%.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;b.&lt;/td&gt; &lt;td&gt;Protalix Ltd.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Israeli Subsidiary is taxed according to Israeli tax laws:&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;1.&lt;/td&gt; &lt;td&gt;Measurement of results for tax purposes&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Since 2008, the Company has measured the results of the Israeli Subsidiary for tax purposes in nominal terms in NIS. Pursuant to the Israel Income Tax Law (Adjustments for Inflation), 1985 (the "Adjustments Law"), the Subsidiary&amp;#39;s results for tax purposes have been measured through 2007 on a real basis, based on changes in the Israel consumer price index.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;2.&lt;/td&gt; &lt;td&gt;Tax rates&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; The income of the Israeli Subsidiary, other than income from "Approved Enterprises," is taxed in Israel at the regular rate. See 3 below. According to the provisions of the Law for Amending the Israel Income Tax Ordinance, 2005, corporate tax rates will be gradually lowered, resulting in a corporate tax rate for 2009 and thereafter: 2009 - 26% and for 2010 and thereafter - 25%.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; On July 14, 2009, the Israel Economic Efficiency Law (Legislation Amendments for Applying the Economic Plan for 2009 and 2010), 2009, became effective, stipulating, among other things, an additional gradual decrease in tax rates in 2011 and thereafter, as follows: 2011 - 24%, 2012 - 23%, 2013 - 22%, 2014 - 21%, 2015 - 20% and 2016 and thereafter - 18%.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; On December 5, 2011, the "Tax Burden Distribution Law" (hereinafter - the 2011 amendment) was officially published, discontinuing a previously approved gradual decrease in corporate tax provided in the 2009 amendment, and setting the corporate tax rate in Israel for 2012 and thereafter to 25%.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Capital gain is subject to capital gain tax according to corporate tax rate in the year of selling the assets.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;3.&lt;/td&gt; &lt;td&gt;The Law for the Encouragement of Capital Investments, 1959 (the "Encouragement of Capital Investments Law")&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Under the Encouragement of Capital Investments Law, including Amendment No. 60 to the Encouragement of Capital Investments Law as published in April 2005, by virtue of the "Approved Enterprise" or "Benefited Enterprise" status the Israeli Subsidiary is entitled to various tax benefits as follows:&lt;/p&gt; &lt;p style="TEXT-INDENT: -37.1pt; MARGIN: 0pt 0px 0pt 1.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 70.9pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 37.1pt"&gt;a.&lt;/td&gt; &lt;td&gt;&lt;strong&gt;Reduced tax rates&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; Income derived from the Approved Enterprise during a 10-year period commencing upon the year in which the enterprise first realizes taxable income is tax exempt, provided that the maximum period to which it is restricted by the Encouragement of Capital Investments Law has not elapsed.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Israeli Subsidiary has an "Approved Enterprise" plan since 2004 and "Benefited Enterprise" plan since 2009. The period of benefits in respect of the main enterprise of the Company has not yet commenced. The period during which the Company is entitled to benefits in connection with the Benefited Enterprise expires in 2021.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; If the Israeli Subsidiary subsequently pays a dividend out of income derived from the "Approved Enterprise" or "Benefited Enterprise" during the tax exemption period, it will be subject to a tax on the amount distributed, including any company tax on these amounts, at the rate which would have been applicable had such income not been exempted.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; In addition to the corporate taxes in Israel, the Company might be subject to a withholding tax on the U.S. revenue source portion of the payments made to the Company for its share of Pfizer&amp;#39;s net profits under the Pfizer Agreement. The withholding tax rate is currently 15%.&lt;/p&gt; &lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 1in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;b.&lt;/td&gt; &lt;td&gt;&lt;strong&gt;Accelerated depreciation&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Israeli Subsidiary is entitled to claim accelerated depreciation, as provided by Israeli law, in the first five years of operation of each asset, in respect of buildings, machinery and equipment used by the Approved Enterprise and the Benefited Enterprise.&lt;/p&gt; &lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 1in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;c.&lt;/td&gt; &lt;td&gt;&lt;strong&gt;Conditions for entitlement to the benefits&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Israeli Subsidiary&amp;#39;s entitlement to the benefits described above is subject to its fulfilling the conditions stipulated by the law, rules and regulations published thereunder, and the instruments of approval for the specific investment in an approved enterprise. If there is any failure by the Israeli Subsidiary to comply with these conditions, the benefits may be cancelled and the Subsidiary may be required to refund the amount of the benefits, in whole or in part, with interest. The Israeli Subsidiary received a final implementation approval with respect to its "Approved Enterprise" from the Investment Center.&lt;/p&gt; &lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 1in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;d.&lt;/td&gt; &lt;td&gt;&lt;strong&gt;Amendment of the Law for the Encouragement of Capital Investments, 1959&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Encouragement of Capital Investments Law was amended as part of the Economic Policy Law for the years 2011-2012, which was passed by the Israeli Knesset on December 29, 2010 (the "Capital Investments Law Amendment").&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Capital Investments Law Amendment sets alternative benefit tracks to those currently in effect under the provisions of the Encouragement of Capital Investments Law.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; The benefits granted to the Benefited Enterprises will be unlimited in time, unlike the benefits granted to special Benefited enterprises, which will be limited for a 10-year period. The benefits shall be granted to companies that will qualify under criteria set in the law; for the most part, those criteria are similar to the criteria that were set in the Encouragement of Capital Investments Law prior to its amendment.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; Under the transitional provisions of the Encouragement of Capital Investments Law, the Company is entitled to take advantage of the tax benefits available under the Encouragement of Capital Investments Law prior to its amendment until the end of the benefits period, as defined in the Encouragement of Capital Investments Law. The Company will be allowed to set the "year of election" no later than tax year 2012, provided that the minimum qualifying investment was made not later than the end of 2010. On each year during the benefits period, the Company will be able to elect that the Capital Investments Amendment apply to the Company, thereby making the tax rates described above available to the Company. An election to have the Capital Investments Amendment apply is irrecoverable. The Company elected not to have the Capital Investments Amendment apply to the Company.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;4.&lt;/td&gt; &lt;td&gt;The Law for the Encouragement of Industry (Taxation), 1969:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Israeli Subsidiary is an "industrial company," as defined under the Law for the Encouragement of Industry (Taxation), 1969 (the "Law for the Encouragement of Industry"). As such, the Israeli Subsidiary is entitled to claim depreciation at increased rates for equipment used in industrial activity, as stipulated by regulations published under Law for the Encouragement of Industry, and has done so.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Under the provisions of the Income Tax Regulations "Accelerated Depreciation in respect of Equipment acquired during the Defined Period" (Temporary Orders), industrial companies whose operations are mostly "eligible operations" are entitled to claim accelerated depreciation at a rate of 50% on machinery and equipment acquired from June 1, 2008 to May 31, 2009.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;c.&lt;/td&gt; &lt;td&gt;Tax losses carried forward to future years&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; As of December 31, 2012, the Company had aggregate net operating loss (NOL) carry-forwards equal to approximately $72.5 million that are available to reduce future taxable income as follows:&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;1.&lt;/td&gt; &lt;td&gt;The Company&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; The NOL carry-forward of the Company equal to approximately $13.8 million may be restricted under Section 382 of the Internal Revenue Code ("IRC"). IRC Section 382 applies whenever a corporation with NOL experiences an ownership change. As a result of IRC Section 382, the taxable income for any post change year that may be offset by a pre-change NOL may not exceed the general IRC Section 382 limitation, which is the fair market value of the pre-change entity multiplied by the IRC long-term tax exempt rate.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;2.&lt;/td&gt; &lt;td&gt;Protalix Ltd.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; At December 31, 2012, the Israeli Subsidiary had approximately $58.7 million of NOL carry-forwards that are available to reduce future taxable income with no limited period of use.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 0.75in; TEXT-INDENT: -0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;d.&lt;/td&gt; &lt;td&gt;Deferred income taxes:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; The components of the Company&amp;#39;s net deferred tax assets at December 31, 2011 and 2012 were as follows:&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt;December 31,&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-STYLE: italic"&gt;(U.S. dollars in thousands)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2011&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2012&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td&gt;In respect of:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt; WIDTH: 74%"&gt; Research and development expenses&lt;/td&gt; &lt;td style="WIDTH: 1%; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%; COLOR: black"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%; COLOR: black"&gt;4,119&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%; COLOR: black"&gt;6,003&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt"&gt;Property and equipment&lt;/td&gt; &lt;td style="COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; COLOR: black"&gt;(149&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;)&lt;/td&gt; &lt;td style="COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; COLOR: black"&gt;(647&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt"&gt;Provision for vacation&lt;/td&gt; &lt;td style="COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; COLOR: black"&gt;305&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; COLOR: black"&gt;363&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt"&gt;Severance pay obligation&lt;/td&gt; &lt;td style="COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; COLOR: black"&gt;164&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; COLOR: black"&gt;192&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt"&gt;Deferred revenues&lt;/td&gt; &lt;td style="COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; COLOR: black"&gt;4,746&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; COLOR: black"&gt;10,449&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt"&gt;Net operating loss carry forwards&lt;/td&gt; &lt;td style="COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; COLOR: black"&gt;4,579&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; COLOR: black"&gt;15,176&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;Valuation allowance&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; (13,764&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; (31,536&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse. The Company used tax rates of 39%, 25% and 0%.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;e.&lt;/td&gt; &lt;td&gt;Reconciliation of the theoretical tax expense to actual tax expense&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; The main reconciling item between the statutory tax rate of the Company and the effective rate is the provision for full valuation allowance in respect of tax benefits from carry forward tax losses due to the uncertainty of the realization of such tax benefits (see above).&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;f.&lt;/td&gt; &lt;td&gt;Tax assessments&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; In accordance with the Income Tax Ordinance, as of December 31, 2012, all of Protalix Ltd.&amp;#39;s tax assessments through tax year 2008 are considered final.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; A summary of open tax years by major jurisdiction is presented below:&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; WIDTH: 50%; FONT-WEIGHT: bold; TEXT-DECORATION: none"&gt; Jurisdiction:&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; WIDTH: 1%; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: right; WIDTH: 47%"&gt; &lt;strong&gt;Years:&lt;/strong&gt;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;Israel&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;2009-2012&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;United States (*)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;2009-2012&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;Netherlands&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;2009-2012&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; (*) Includes federal, state and local (or similar provincial jurisdictions) tax positions.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock id="IncomeTaxPolicyTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt;Income taxes&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1.25in; TEXT-INDENT: -0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;1.&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal"&gt;Deferred income taxes&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; The guidance prohibits the recognition of deferred tax liabilities or assets that arise from differences between the financial reporting and tax bases of assets and liabilities that are measured from the local currency into dollars using historical exchange rates, and that result from changes in exchange rates or indexing for tax purposes. Consequently, the above mentioned differences with respect to Protalix Ltd. were not reflected in the computation of deferred tax assets and liabilities.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;2.&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal"&gt;Uncertainty in income taxes&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Tax benefits recognized in the financial statements are those that the Company&amp;#39;s management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit the Company&amp;#39;s management deems more likely than not to be sustained.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2977000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6147000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-1029000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="IncreaseDecreaseInAccountsReceivable.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-243000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="IncreaseDecreaseInAccountsReceivable.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-3891000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="IncreaseDecreaseInAccountsReceivable.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6860000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="IncreaseDecreaseInDeferredRevenue.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1281000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="IncreaseDecreaseInDeferredRevenue.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-3005000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="IncreaseDecreaseInDeferredRevenue.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-4563000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInInventories id="IncreaseDecreaseInInventories.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3760000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories id="IncreaseDecreaseInInventories.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-910000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories id="IncreaseDecreaseInInventories.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1189000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInRestrictedCash id="IncreaseDecreaseInRestrictedCash.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">80000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:InventoryDisclosureTextBlock id="InventoryDisclosureTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;NOTE 4 - INVENTORIES&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;a.&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal"&gt;Inventories at December&amp;nbsp;31, 2011 and 2012 consisted of the following:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap"&gt;December 31,&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt; (&lt;em&gt;U.S. dollars in thousands)&lt;/em&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;2011&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;2012&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 70%"&gt;Raw materials&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 12%"&gt;279&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 12%"&gt;2,118&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;Work in progress&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;192&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;Finished goods&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 1,729&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;Total inventory&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 279&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 4,039&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;b.&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal"&gt;During the year ended December 31, 2011 and 2012, &lt;font style="COLOR: black"&gt;the Company recorded&lt;/font&gt; approximately $363,000 and $684,000 respectively, for write-down of inventory under cost of revenues.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:InventoryFinishedGoodsNetOfReserves id="InventoryFinishedGoodsNetOfReserves.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1729000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves id="InventoryFinishedGoodsNetOfReserves.7857.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:InventoryNet id="InventoryNet.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4039000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet id="InventoryNet.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">279000</us-gaap:InventoryNet>
  <us-gaap:InventoryPolicyTextBlock id="InventoryPolicyTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;Inventories&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Inventories are valued at the lower of cost or market. Cost of raw and packaging materials and purchased products is determined using the "moving average" basis.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Cost of finished products that are capitalized is determined as follows: the value of the raw and packaging materials component is determined primarily on a using the "moving average" basis; the value of the labor and overhead component is determined on an average basis over the production period.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Prior to the FDA&amp;#39;s approval of taliglucerase alfa, manufacturing costs related to taliglucerase alfa were not capitalized; rather, such costs were expensed as research and development expenses. Effective as of the FDA approval of taliglucerase alfa on May 1, 2012, the Company capitalizes manufacturing costs associated with taliglucerase alfa.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
  <us-gaap:InventoryRawMaterialsNetOfReserves id="InventoryRawMaterialsNetOfReserves.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2118000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryRawMaterialsNetOfReserves id="InventoryRawMaterialsNetOfReserves.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">279000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves id="InventoryWorkInProcessNetOfReserves.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">192000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves id="InventoryWorkInProcessNetOfReserves.7857.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:InventoryWriteDown id="InventoryWriteDown.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">684000</us-gaap:InventoryWriteDown>
  <us-gaap:InventoryWriteDown id="InventoryWriteDown.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">363000</us-gaap:InventoryWriteDown>
  <us-gaap:Liabilities id="Liabilities.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">82084000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="Liabilities.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">77882000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity id="LiabilitiesAndStockholdersEquity.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">78727000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="LiabilitiesAndStockholdersEquity.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">51805000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent id="LiabilitiesCurrent.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">25755000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="LiabilitiesCurrent.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">18693000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesNoncurrent id="LiabilitiesNoncurrent.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">56329000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LiabilitiesNoncurrent id="LiabilitiesNoncurrent.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">59189000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LongTermDebtNoncurrent id="LongTermDebtNoncurrent.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5425000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:LongTermDebtNoncurrent id="LongTermDebtNoncurrent.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6566000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="NetCashProvidedByUsedInFinancingActivities.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">26558000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="NetCashProvidedByUsedInFinancingActivities.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">20927000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="NetCashProvidedByUsedInFinancingActivities.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">501000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="NetCashProvidedByUsedInInvestingActivities.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-2286000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="NetCashProvidedByUsedInInvestingActivities.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-5868000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="NetCashProvidedByUsedInInvestingActivities.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-7992000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="NetCashProvidedByUsedInOperatingActivities.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">635000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="NetCashProvidedByUsedInOperatingActivities.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-23570000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="NetCashProvidedByUsedInOperatingActivities.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-38464000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-11618000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-36529000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-28998000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.7858.4458.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.4458.4957.0.0.0.0" unitRef="USD" decimals="-3">-11618000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.7860.4458.4957.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.4458.4957.0.0.0.0" unitRef="USD" decimals="-3">-36529000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.7861.4458.4957.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.4458.4957.0.0.0.0" unitRef="USD" decimals="-3">-28998000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.7858.1033.4957.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-12-31.7858.0.1033.4957.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.7860.1033.4957.0.0.0.0" xsi:nil="true" contextRef="from-2011-01-01-to-2011-12-31.7860.0.1033.4957.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.7861.1033.4957.0.0.0.0" xsi:nil="true" contextRef="from-2010-01-01-to-2010-12-31.7861.0.1033.4957.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.7858.461.4957.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-12-31.7858.0.461.4957.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.7860.461.4957.0.0.0.0" xsi:nil="true" contextRef="from-2011-01-01-to-2011-12-31.7860.0.461.4957.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.7861.461.4957.0.0.0.0" xsi:nil="true" contextRef="from-2010-01-01-to-2010-12-31.7861.0.461.4957.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:OpenTaxYear id="OpenTaxYear.7858.17552.2525.3248.4187.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.17552.2525.3248.4187.0.0">2009</us-gaap:OpenTaxYear>
  <us-gaap:OpenTaxYear id="OpenTaxYear.7858.17552.2525.3241.4187.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.17552.2525.3241.4187.0.0">2012</us-gaap:OpenTaxYear>
  <us-gaap:OpenTaxYear id="OpenTaxYear.7858.17690.2525.3248.4187.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.17690.2525.3248.4187.0.0">2009</us-gaap:OpenTaxYear>
  <us-gaap:OpenTaxYear id="OpenTaxYear.7858.17690.2525.3241.4187.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.17690.2525.3241.4187.0.0">2012</us-gaap:OpenTaxYear>
  <us-gaap:OpenTaxYear id="OpenTaxYear.7858.17619.2525.3248.4187.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.17619.2525.3248.4187.0.0">2009</us-gaap:OpenTaxYear>
  <us-gaap:OpenTaxYear id="OpenTaxYear.7858.17619.2525.3241.4187.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.17619.2525.3241.4187.0.0">2012</us-gaap:OpenTaxYear>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-12172000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-36531000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-29966000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent id="OperatingLeasesFutureMinimumPaymentsDueCurrent.7856.70487.70469.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.70487.70469.0.0.0.0" unitRef="USD" decimals="-3">526000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent id="OperatingLeasesFutureMinimumPaymentsDueCurrent.7856.2904.70469.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.2904.70469.0.0.0.0" unitRef="USD" decimals="-3">976000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears id="OperatingLeasesFutureMinimumPaymentsDueInFourYears.7856.2904.70469.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.2904.70469.0.0.0.0" unitRef="USD" decimals="-3">823000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears id="OperatingLeasesFutureMinimumPaymentsDueInThreeYears.7856.70487.70469.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.70487.70469.0.0.0.0" unitRef="USD" decimals="-3">175000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears id="OperatingLeasesFutureMinimumPaymentsDueInThreeYears.7856.2904.70469.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.2904.70469.0.0.0.0" unitRef="USD" decimals="-3">985000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears id="OperatingLeasesFutureMinimumPaymentsDueInTwoYears.7856.70487.70469.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.70487.70469.0.0.0.0" unitRef="USD" decimals="-3">385000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears id="OperatingLeasesFutureMinimumPaymentsDueInTwoYears.7856.2904.70469.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.2904.70469.0.0.0.0" unitRef="USD" decimals="-3">968000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesRentExpenseNet id="OperatingLeasesRentExpenseNet.7858.2904.70469.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.2904.70469.0.0.0.0" unitRef="USD" decimals="-3">971000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet id="OperatingLeasesRentExpenseNet.7860.2904.70469.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.2904.70469.0.0.0.0" unitRef="USD" decimals="-3">994000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet id="OperatingLeasesRentExpenseNet.7861.2904.70469.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.2904.70469.0.0.0.0" unitRef="USD" decimals="-3">891000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLossCarryforwards id="OperatingLossCarryforwards.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">72500000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards id="OperatingLossCarryforwards.7856.5011.136.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.5011.136.0.0.0.0" unitRef="USD" decimals="-3">58700000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards id="OperatingLossCarryforwards.7856.70506.2525.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.70506.2525.0.0.0.0" unitRef="USD" decimals="-3">13800000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OtherReceivablesNetCurrent id="OtherReceivablesNetCurrent.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3686000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:OtherReceivablesNetCurrent id="OtherReceivablesNetCurrent.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3837000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:OtherReceivablesNetCurrent id="OtherReceivablesNetCurrent.7856.70510.392.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.70510.392.0.0.0.0" unitRef="USD" decimals="-3">89000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:OtherReceivablesNetCurrent id="OtherReceivablesNetCurrent.7857.70510.392.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.70510.392.0.0.0.0" unitRef="USD" decimals="-3">1558000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:OtherReceivablesNetCurrent id="OtherReceivablesNetCurrent.7856.70511.392.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.70511.392.0.0.0.0" unitRef="USD" decimals="-3">542000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:OtherReceivablesNetCurrent id="OtherReceivablesNetCurrent.7857.70511.392.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.70511.392.0.0.0.0" unitRef="USD" decimals="-3">375000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:OtherReceivablesNetCurrent id="OtherReceivablesNetCurrent.7856.70512.392.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.70512.392.0.0.0.0" unitRef="USD" decimals="-3">2400000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:OtherReceivablesNetCurrent id="OtherReceivablesNetCurrent.7857.70512.392.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.70512.392.0.0.0.0" unitRef="USD" decimals="-3">1296000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:OtherReceivablesNetCurrent id="OtherReceivablesNetCurrent.7856.70513.392.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.70513.392.0.0.0.0" unitRef="USD" decimals="-3">298000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:OtherReceivablesNetCurrent id="OtherReceivablesNetCurrent.7857.70513.392.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.70513.392.0.0.0.0" unitRef="USD" decimals="-3">208000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:OtherReceivablesNetCurrent id="OtherReceivablesNetCurrent.7856.70514.392.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.70514.392.0.0.0.0" unitRef="USD" decimals="-3">106000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:OtherReceivablesNetCurrent id="OtherReceivablesNetCurrent.7857.70514.392.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.70514.392.0.0.0.0" unitRef="USD" decimals="-3">165000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities id="PaymentsForProceedsFromOtherInvestingActivities.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">138000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities id="PaymentsForProceedsFromOtherInvestingActivities.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">165000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities id="PaymentsForProceedsFromOtherInvestingActivities.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">137000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsOfStockIssuanceCosts id="PaymentsOfStockIssuanceCosts.8544.0.0.0.0.0.0" contextRef="from-2012-02-01-to-2012-02-29.8544.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1800000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts id="PaymentsOfStockIssuanceCosts.9211.0.0.0.0.0.0" contextRef="from-2011-03-01-to-2011-03-23.9211.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1400000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="PaymentsToAcquirePropertyPlantAndEquipment.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2068000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="PaymentsToAcquirePropertyPlantAndEquipment.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5705000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="PaymentsToAcquirePropertyPlantAndEquipment.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">7855000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent id="PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2016000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
  <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent id="PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1700000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
  <us-gaap:PensionAndOtherPostretirementBenefitContributions id="PensionAndOtherPostretirementBenefitContributions.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">36000</us-gaap:PensionAndOtherPostretirementBenefitContributions>
  <us-gaap:PensionAndOtherPostretirementBenefitContributions id="PensionAndOtherPostretirementBenefitContributions.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">14000</us-gaap:PensionAndOtherPostretirementBenefitContributions>
  <us-gaap:PensionAndOtherPostretirementBenefitContributions id="PensionAndOtherPostretirementBenefitContributions.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">26000</us-gaap:PensionAndOtherPostretirementBenefitContributions>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense id="PensionAndOtherPostretirementBenefitExpense.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">276000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense id="PensionAndOtherPostretirementBenefitExpense.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">155000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense id="PensionAndOtherPostretirementBenefitExpense.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">377000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock id="PensionAndOtherPostretirementBenefitsDisclosureTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;NOTE 5 - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Israeli Subsidiary is required to make a severance payment upon dismissal of an employee or upon termination of employment in certain circumstances. The severance pay liability to the employees (based upon length of service and the latest monthly salary - one month&amp;#39;s salary for each year employed) is recorded on the Company&amp;#39;s balance sheets under "Liability for employee rights upon retirement." The liability is recorded as if it were payable at each balance sheet date on an undiscounted basis.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; The liability is funded in part from the purchase of insurance policies or by the establishment of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities are included in the Company&amp;#39;s balance sheets under "Funds in respect of employee rights upon retirement." These policies are the Company&amp;#39;s assets. However, under labor agreements and subject to certain limitations, any policy may be transferred to the ownership of the individual employee for whose benefit the funds were deposited. In the years ended December 31, 2010, 2011 and 2012, the Company deposited approximately $174,000, $181,000 and $177,000, respectively, with insurance companies in connection with its severance payment obligations.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; In accordance with the current employment agreements with certain employees, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee&amp;#39;s rights upon retirement. The Company is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in the Company&amp;#39;s balance sheets, as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies (the "Contribution Plans").&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; The amounts of severance pay expenses were approximately $1.1 million, $816,000 and $1.0 million for the years ended December 31, 2010, 2011 and 2012, respectively, of which approximately $531,000 $641,000 and $670,000 in the years ended December 31, 2010, 2011 and 2012, respectively, were in respect of a Contribution Plan. Gain on amounts funded in respect of employee rights upon retirement totaled approximately $26,000, $14,000 and $36,000 for the years ended December 31, 2010, 2011 and 2012, respectively.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company expects to contribute approximately $963,000 in the year ending December 31, 2013 to insurance companies in connection with its severance liabilities for its operations for that year, approximately $773,000 of which will be contributed to one or more Contribution Plans.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; During the five-year period following December 31, 2012, the Company expects to pay future benefits to 4 employees upon the employee&amp;#39;s normal retirement age. The Company anticipates that the benefits payable will be immaterial.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:PrepaidExpenseCurrent id="PrepaidExpenseCurrent.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">251000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseCurrent id="PrepaidExpenseCurrent.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">235000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:ProceedsFromCollaborators id="ProceedsFromCollaborators.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">60000000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:ProceedsFromCollaborators id="ProceedsFromCollaborators.7858.68654.4951.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.68654.4951.0.0.0.0" unitRef="USD" decimals="-3">5000000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="ProceedsFromIssuanceOfCommonStock.8544.0.0.0.0.0.0" contextRef="from-2012-02-01-to-2012-02-29.8544.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">25400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="ProceedsFromIssuanceOfCommonStock.9211.0.0.0.0.0.0" contextRef="from-2011-03-01-to-2011-03-23.9211.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">20600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="ProceedsFromSaleOfPropertyPlantAndEquipment.7858.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="ProceedsFromSaleOfPropertyPlantAndEquipment.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="ProceedsFromSaleOfPropertyPlantAndEquipment.7861.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ProceedsFromStockOptionsExercised id="ProceedsFromStockOptionsExercised.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1230000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="ProceedsFromStockOptionsExercised.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">277000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="ProceedsFromStockOptionsExercised.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">501000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="ProceedsFromStockOptionsExercised.8519.68640.3555.68647.5007.0.0" contextRef="from-2013-01-01-to-2013-02-28.8519.0.68640.3555.68647.5007.0.0" unitRef="USD" decimals="-3">19000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="ProceedsFromStockOptionsExercised.7858.70543.1319.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70543.1319.0.0.0.0" unitRef="USD" decimals="-3">39000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="ProceedsFromStockOptionsExercised.7858.70546.1319.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70546.1319.0.0.0.0" unitRef="USD" decimals="-3">1200000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock id="PropertyPlantAndEquipmentDisclosureTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;NOTE 3 - PROPERTY AND EQUIPMENT&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.5in"&gt;a.&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal"&gt;Composition of property and equipment grouped by major classifications is as follows:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt;December 31,&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt; (&lt;em&gt;U.S. dollars in thousands)&lt;/em&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;2011&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;2012&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 70%"&gt;Laboratory equipment&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 12%"&gt;13,079&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 12%"&gt;14,502&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;Furniture and computer equipment&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1,522&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1,818&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;Leasehold improvements&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;13,705&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;14,447&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;Equipment under construction&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 1,113&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 329&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 7.35pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 29,419&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 31,096&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-SIZE: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-SIZE: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-SIZE: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-SIZE: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-SIZE: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-SIZE: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt"&gt; Less - accumulated depreciation and amortization&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; (11,148&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; (14,786&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 18,271&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 16,310&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 4.3pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;b.&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal"&gt;Depreciation and amortization in respect of property and equipment totaled approximately $3.1 million, $3.6 million and $3.7 million for the years ended December 31, 2010, 2011 and 2012, respectively, out of which the Company recorded a total write down of approximately $43,000, $10,000 and $0, respectively.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentGross id="PropertyPlantAndEquipmentGross.7856.70112.4117.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.70112.4117.0.0.0.0" unitRef="USD" decimals="-3">14502000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="PropertyPlantAndEquipmentGross.7857.70112.4117.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.70112.4117.0.0.0.0" unitRef="USD" decimals="-3">13079000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="PropertyPlantAndEquipmentGross.7856.70134.4117.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.70134.4117.0.0.0.0" unitRef="USD" decimals="-3">1818000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="PropertyPlantAndEquipmentGross.7857.70134.4117.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.70134.4117.0.0.0.0" unitRef="USD" decimals="-3">1522000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="PropertyPlantAndEquipmentGross.7856.2905.4117.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.2905.4117.0.0.0.0" unitRef="USD" decimals="-3">14447000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="PropertyPlantAndEquipmentGross.7857.2905.4117.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.2905.4117.0.0.0.0" unitRef="USD" decimals="-3">13705000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="PropertyPlantAndEquipmentGross.7856.70136.4117.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.70136.4117.0.0.0.0" unitRef="USD" decimals="-3">329000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="PropertyPlantAndEquipmentGross.7857.70136.4117.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.70136.4117.0.0.0.0" unitRef="USD" decimals="-3">1113000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="PropertyPlantAndEquipmentGross.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">31096000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="PropertyPlantAndEquipmentGross.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">29419000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentNet id="PropertyPlantAndEquipmentNet.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">16310000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="PropertyPlantAndEquipmentNet.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">18271000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="PropertyPlantAndEquipmentPolicyTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;Property and equipment&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;1.&lt;/td&gt; &lt;td&gt;&lt;font style="FONT-WEIGHT: normal"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization.&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;2.&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal"&gt;The Company&amp;#39;s assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="WIDTH: 65%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1.5in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;Years&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 85%"&gt;Laboratory equipment&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 12%"&gt;5&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td&gt;Furniture&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;10-15&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;Computer equipment&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;3&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 98.65pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Leasehold improvements are amortized by the straight-line method over the expected lease term, which is shorter than the estimated useful life of the improvements.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="PropertyPlantAndEquipmentTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt;December 31,&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt; (&lt;em&gt;U.S. dollars in thousands)&lt;/em&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;2011&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;2012&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 70%"&gt;Laboratory equipment&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 12%"&gt;13,079&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 12%"&gt;14,502&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;Furniture and computer equipment&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1,522&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1,818&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;Leasehold improvements&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;13,705&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;14,447&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;Equipment under construction&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 1,113&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 329&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 7.35pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 29,419&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 31,096&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-SIZE: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-SIZE: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-SIZE: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-SIZE: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-SIZE: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-SIZE: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt"&gt; Less - accumulated depreciation and amortization&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; (11,148&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; (14,786&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 18,271&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 16,310&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 4.3pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="PropertyPlantAndEquipmentUsefulLife.7858.70112.4117.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70112.4117.0.0.0.0">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="PropertyPlantAndEquipmentUsefulLife.7858.1086.4117.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.1086.4117.0.0.0.0">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="PropertyPlantAndEquipmentUsefulLife.7858.2275.4117.3248.4187.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.2275.4117.3248.4187.0.0">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="PropertyPlantAndEquipmentUsefulLife.7858.2275.4117.3241.4187.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.2275.4117.3241.4187.0.0">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction id="RelatedPartyTransactionAmountsOfTransaction.7858.70521.4351.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70521.4351.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction id="RelatedPartyTransactionAmountsOfTransaction.7860.70521.4351.0.0.0.0" xsi:nil="true" contextRef="from-2011-01-01-to-2011-12-31.7860.0.70521.4351.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction id="RelatedPartyTransactionAmountsOfTransaction.7861.70521.4351.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.70521.4351.0.0.0.0" unitRef="USD" decimals="-3">6000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction id="RelatedPartyTransactionAmountsOfTransaction.7858.70522.4351.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70522.4351.0.0.0.0" unitRef="USD" decimals="-3">375000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction id="RelatedPartyTransactionAmountsOfTransaction.7860.70522.4351.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.70522.4351.0.0.0.0" unitRef="USD" decimals="-3">215000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction id="RelatedPartyTransactionAmountsOfTransaction.7861.70522.4351.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.70522.4351.0.0.0.0" unitRef="USD" decimals="-3">215000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock id="RelatedPartyTransactionsDisclosureTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;NOTE 10 - RELATED PARTY TRANSACTIONS&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="COLOR: blue; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="10"&gt;Year&amp;nbsp;ended&amp;nbsp;December&amp;nbsp;31,&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; FONT-STYLE: italic"&gt; (U.S.&amp;nbsp;dollars&amp;nbsp;in&amp;nbsp;thousands)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2010&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2011&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2012&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -0.25in; PADDING-LEFT: 0.5in; WIDTH: 61%"&gt; &lt;strong&gt;a.&lt;/strong&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Management and consulting fees to the Chairman of the Board&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"&gt; 6&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"&gt; -&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"&gt; -&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -0.25in; PADDING-LEFT: 0.5in"&gt; &lt;strong&gt;b.&lt;/strong&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Compensation to the non-executive directors (except the Chairman of the Board in 2010, and includes the interim Chairman of the Board in 2011 and 2012)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 215&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 215&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 375&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:ResearchAndDevelopmentExpense id="ResearchAndDevelopmentExpense.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">36665000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="ResearchAndDevelopmentExpense.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">37818000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="ResearchAndDevelopmentExpense.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">37691000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpensePolicy id="ResearchAndDevelopmentExpensePolicy.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt;Research and development costs&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment and supplies for research and development activities. Grants received by the Israeli Subsidiary from the Office of the Chief Scientist of Israel&amp;#39;s Ministry of Industry, Trade and Labor (the "OCS") are recognized when the grant becomes receivable, provided there is reasonable assurance that the Company or the Subsidiary will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Reimbursements received from Pfizer are recognized when the reimbursements become receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the reimbursements and there is reasonable assurance the reimbursements will be received. The reimbursements are deducted from the research and development expenses as the applicable costs are incurred.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; In connection with purchases of assets, amounts assigned to intangible assets to be used in a particular research and development project that have no alternative future use are charged to research and development costs at the purchase date.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are consumed or the related services are performed.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="RetainedEarningsAccumulatedDeficit.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-183595000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="RetainedEarningsAccumulatedDeficit.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-171977000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RevenueRecognitionPolicyTextBlock id="RevenueRecognitionPolicyTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;j.&lt;/td&gt; &lt;td&gt;Revenue Recognition&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company recognizes revenue when the earnings process is complete, which is when revenue is realized or realizable and earned, there is persuasive evidence a revenue arrangement exists, delivery of goods or services has occurred, the sales price is fixed or determinable and collectability is reasonably assured.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;1.&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal"&gt;Revenues from the license and supply agreement with Pfizer&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company recognizes revenue from milestone payments received pursuant to the Pfizer Agreement in accordance with guidance regarding revenue recognition and accounting for revenue arrangements with multiple deliverables. As the arrangement with Pfizer requires the Company&amp;#39;s continued involvement with respect to the proposed commercialization of taliglucerase alfa, the non-refundable, up-front license payment the Company received from Pfizer was deferred and recognized over the related performance period. The Company estimated the performance period of 14 years (commencing upon the date of the Company&amp;#39;s receipt of the up-front license payment payable by Pfizer under the Pfizer Agreement) based on the date the last relevant patent expires. See Note 2. The Company adjusts the performance periods, if appropriate, based on the applicable facts and circumstances. Each milestone payment that is considered to be substantive for purposes of revenue recognition is recorded as revenue during the period during which the milestone is achieved.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;2.&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal"&gt;Revenues from selling products to Pfizer&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company recognizes revenues from products sold to Pfizer upon delivery, when the sales price is fixed or determinable and collectability is reasonably assured.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;3.&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal"&gt;Company&amp;#39;s share in the collaboration agreement&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: 0in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: 0in"&gt; Under the terms and conditions of the Pfizer Agreement, the Company is entitled to 40% of the profits or loss from sales of taliglucerase alfa, and related expenses incurred, except with respect to sales in Israel, where the Company retained exclusive marketing rights. Since Pfizer bears most of the risks and rewards relating to the agreement, the Company&amp;#39;s share in the profits and loss in the agreement is recognized on a net basis. The Company recognizes its share of net profit or loss from the Pfizer Agreement based on reports it receives from Pfizer summarizing the results of the collaborative activities under the agreement for the applicable period. Under the terms of the Pfizer Agreement, for its subsidiaries operating outside the United States, financial information is included based on the fiscal year ending November 30, while financial information for the U.S. entity is included based on the fiscal year ending December 31.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:Revenues id="Revenues.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">34870000</us-gaap:Revenues>
  <us-gaap:Revenues id="Revenues.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">8386000</us-gaap:Revenues>
  <us-gaap:Revenues id="Revenues.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6642000</us-gaap:Revenues>
  <us-gaap:Revenues id="Revenues.7858.73899.73897.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.73899.73897.0.0.0.0" unitRef="USD" decimals="-3">4563000</us-gaap:Revenues>
  <us-gaap:Revenues id="Revenues.7860.73899.73897.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.73899.73897.0.0.0.0" unitRef="USD" decimals="-3">4563000</us-gaap:Revenues>
  <us-gaap:Revenues id="Revenues.7861.73899.73897.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.73899.73897.0.0.0.0" unitRef="USD" decimals="-3">4563000</us-gaap:Revenues>
  <us-gaap:Revenues id="Revenues.7858.70480.73897.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70480.73897.0.0.0.0" unitRef="USD" decimals="-3">25000000</us-gaap:Revenues>
  <us-gaap:Revenues id="Revenues.7860.70480.73897.0.0.0.0" xsi:nil="true" contextRef="from-2011-01-01-to-2011-12-31.7860.0.70480.73897.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:Revenues id="Revenues.7861.70480.73897.0.0.0.0" xsi:nil="true" contextRef="from-2010-01-01-to-2010-12-31.7861.0.70480.73897.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:Revenues id="Revenues.7858.4541.73897.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.4541.73897.0.0.0.0" unitRef="USD" decimals="-3">5307000</us-gaap:Revenues>
  <us-gaap:Revenues id="Revenues.7860.4541.73897.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.4541.73897.0.0.0.0" unitRef="USD" decimals="-3">3823000</us-gaap:Revenues>
  <us-gaap:Revenues id="Revenues.7861.4541.73897.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.4541.73897.0.0.0.0" unitRef="USD" decimals="-3">2079000</us-gaap:Revenues>
  <us-gaap:RoyaltyExpense id="RoyaltyExpense.7858.70473.70469.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70473.70469.0.0.0.0" unitRef="USD" decimals="-3">1500000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense id="RoyaltyExpense.7860.70473.70469.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.70473.70469.0.0.0.0" unitRef="USD" decimals="-3">158000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense id="RoyaltyExpense.7861.70473.70469.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.70473.70469.0.0.0.0" unitRef="USD" decimals="-3">769000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense id="RoyaltyExpense.7858.70477.70469.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70477.70469.0.0.0.0" unitRef="USD" decimals="-3">674000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense id="RoyaltyExpense.7860.70477.70469.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.70477.70469.0.0.0.0" unitRef="USD" decimals="-3">19000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense id="RoyaltyExpense.7861.70477.70469.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.70477.70469.0.0.0.0" unitRef="USD" decimals="-3">115000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense id="RoyaltyExpense.7858.70479.70469.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70479.70469.0.0.0.0" unitRef="USD" decimals="-3">1000000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense id="RoyaltyExpense.7861.70480.70469.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.70480.70469.0.0.0.0" unitRef="USD" decimals="-3">100000</us-gaap:RoyaltyExpense>
  <us-gaap:SaleOfStockPricePerShare id="SaleOfStockPricePerShare.8542.0.0.0.0.0.0" contextRef="as-of-2012-02-22.8542.0.0.0.0.0.0.0" unitRef="UPerShare" decimals="2">5.25</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:SaleOfStockPricePerShare id="SaleOfStockPricePerShare.9212.0.0.0.0.0.0" contextRef="as-of-2011-03-23.9212.0.0.0.0.0.0.0" unitRef="UPerShare" decimals="1">5.5</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock id="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt;December 31,&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-STYLE: italic"&gt;(U.S. dollars in thousands)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2011&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2012&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td&gt;In respect of:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt; WIDTH: 74%"&gt; Research and development expenses&lt;/td&gt; &lt;td style="WIDTH: 1%; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%; COLOR: black"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%; COLOR: black"&gt;4,119&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%; COLOR: black"&gt;6,003&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt"&gt;Property and equipment&lt;/td&gt; &lt;td style="COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; COLOR: black"&gt;(149&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;)&lt;/td&gt; &lt;td style="COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; COLOR: black"&gt;(647&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt"&gt;Provision for vacation&lt;/td&gt; &lt;td style="COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; COLOR: black"&gt;305&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; COLOR: black"&gt;363&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt"&gt;Severance pay obligation&lt;/td&gt; &lt;td style="COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; COLOR: black"&gt;164&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; COLOR: black"&gt;192&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt"&gt;Deferred revenues&lt;/td&gt; &lt;td style="COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; COLOR: black"&gt;4,746&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; COLOR: black"&gt;10,449&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt"&gt;Net operating loss carry forwards&lt;/td&gt; &lt;td style="COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; COLOR: black"&gt;4,579&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; COLOR: black"&gt;15,176&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; COLOR: black"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;Valuation allowance&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; (13,764&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; (31,536&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="10"&gt;Year ended December 31,&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-STYLE: italic"&gt;(U.S. dollars in thousands)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2010&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2011&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2012&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -12.6pt; PADDING-LEFT: 12.6pt"&gt; Cost of revenues&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;220&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -12.6pt; PADDING-LEFT: 12.6pt; WIDTH: 61%"&gt; Research and development expenses&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;630&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;422&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;4,756&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -12.6pt; PADDING-LEFT: 12.6pt"&gt; General and administrative expenses&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 652&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 464&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 2,775&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 1,282&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 886&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 7,751&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock id="ScheduleOfInventoryCurrentTableTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap"&gt;December 31,&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt; (&lt;em&gt;U.S. dollars in thousands)&lt;/em&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;2011&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;2012&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 70%"&gt;Raw materials&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 12%"&gt;279&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 12%"&gt;2,118&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;Work in progress&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;192&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;Finished goods&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 1,729&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;Total inventory&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 279&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 4,039&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock id="ScheduleOfRelatedPartyTransactionsTableTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="COLOR: blue; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="10"&gt;Year ended December 31,&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; FONT-STYLE: italic"&gt;(U.S. dollars in thousands)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2010&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2011&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2012&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -0.25in; PADDING-LEFT: 0.5in; WIDTH: 61%"&gt; &lt;strong&gt;a.&lt;/strong&gt; Management and consulting fees to the Chairman of the Board&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"&gt; 6&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"&gt; -&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"&gt; -&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -0.25in; PADDING-LEFT: 0.5in"&gt; &lt;strong&gt;b.&lt;/strong&gt; Compensation to the non-executive directors (except the Chairman of the Board in 2010, and includes the interim Chairman of the Board in 2011 and 2012)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 215&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 215&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 375&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
  <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock id="ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="5"&gt;Year ended December 31, 2012&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Number of&lt;br /&gt; Restricted Shares&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center"&gt;Outstanding at beginning of year&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center" colspan="2"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center"&gt;Changes during the year:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center; WIDTH: 90%"&gt;Granted&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 7%"&gt;1,500,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt; PADDING-LEFT: 15.95pt"&gt; Forfeited&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 3,208&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2.5pt"&gt;Outstanding at end of year&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 1,496,792&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2.5pt"&gt;Exercisable at end of year&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 102,084&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock id="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="18" nowrap="nowrap"&gt;December 31, 2012&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="10" nowrap="nowrap"&gt;Options and restricted stock&lt;br /&gt; outstanding&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap"&gt;Options exercisable and&lt;br /&gt; restricted stock vested&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Exercise&lt;br /&gt; prices&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Number of&lt;br /&gt; Options and&lt;br /&gt; restricted stock&lt;br /&gt; outstanding&lt;br /&gt; at end of&lt;br /&gt; year&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Weighted&lt;br /&gt; average&lt;br /&gt; remaining&lt;br /&gt; contractual&lt;br /&gt; life&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Number of&lt;br /&gt; options&lt;br /&gt; exercisable and&lt;br /&gt; restricted stock&lt;br /&gt; vested at end of&lt;br /&gt; year&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Weighted&lt;br /&gt; average&lt;br /&gt; remaining&lt;br /&gt; contractual&lt;br /&gt; life&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 18%"&gt;n/a (Restricted Stock)&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 17%"&gt;1,496,792&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 17%"&gt; &lt;p style="TEXT-ALIGN: right; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; n/a&lt;/p&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 17%"&gt;102,084&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 17%"&gt; &lt;p style="TEXT-ALIGN: right; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; n/a&lt;/p&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;0.001&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;719,207&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;2.54&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;719,207&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;2.54&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;0.120&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;447,850&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1.05&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;447,850&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1.05&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;0.399&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;23,087&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1.92&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;23,087&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1.92&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;0.972&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;996,353&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;3.44&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;996,353&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;3.44&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;2.350&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;40,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;5.82&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;40,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;5.82&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;2.650&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;402,882&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;6.15&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;396,744&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;6.15&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;3.020&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;50,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;5.10&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;50,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;5.10&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;5.000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1,708,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;5.10&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1,708,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;5.10&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;6.810&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;160,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;7.10&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;110,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;7.10&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;6.900&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1,003,083&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;7.15&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;168,083&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;7.15&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;7.550&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;160,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;7.66&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;90,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;7.66&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;9.660&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;68,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;7.83&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;34,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;7.83&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt"&gt;16.700&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 387,542&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 3.99&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 387,542&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 3.99&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 7,662,796&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 5,272,950&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="22" nowrap="nowrap"&gt;Year ended December 31,&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap"&gt;2010&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap"&gt;2011&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap"&gt;2012&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt; Weighted&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Weighted&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Weighted&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Number&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;average&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Number&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;average&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Number&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;average&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;of&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;exercise&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;of&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;exercise&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;of&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;exercise&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;options&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;price&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;options&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;price&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;options&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;price&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in; WIDTH: 40%"&gt; Outstanding at beginning of year&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 7%"&gt;5,366,729&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 7%"&gt;2.476&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 7%"&gt;6,367,979&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 7%"&gt;3.576&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 7%"&gt;6,141,030&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 7%"&gt;3.563&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;Changes during the year:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-LEFT: 0.25in"&gt;Granted&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1,444,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;7.076&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 0.25in"&gt;Forfeited and Expired&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;13,441&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;3.551&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;44,856&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;6.207&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;25,858&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;4.372&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.25in"&gt;Exercised (*)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 429,309&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 1.602&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 182,093&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 1.652&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 861,593&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 1.346&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;Outstanding at end of year&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 6,367,979&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 3.576&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 6,141,030&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 3.563&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 5,253,579&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 3.923&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;Exercisable at end of year&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 4,267,850&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 2.183&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 4,647,834&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 2.581&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 4,258,441&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 3.201&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: -0.2in; MARGIN: 0pt 0px 0pt 84.95pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock id="ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="22"&gt;Year ended December 31,&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt;2010&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt;2011&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt;2012&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; Weighted&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; Weighted&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; Weighted&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; Number&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; average&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; Number&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; average&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; Number&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; average&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; of&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; exercise&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; of&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; exercise&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; of&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; exercise&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;options&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;price&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;options&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;price&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;options&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;price&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in; WIDTH: 40%"&gt; Outstanding at beginning of year&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 7%"&gt;1,438,692&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 7%"&gt;4.697&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 7%"&gt;1,438,692&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 7%"&gt;4.697&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 7%"&gt;1,238,692&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 7%"&gt;5.385&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in"&gt; Changes during the year- Exercised (*)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;200,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;0.001&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;326,267&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;0.12&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in"&gt; Outstanding at end of year&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 1,438,692&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 4.697&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 1,238,692&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 5.385&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 912,425&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 7.259&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in"&gt; Exercisable at end of year&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 1,421,734&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 4.653&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 1,235,567&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 5.385&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 912,425&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 7.259&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1.25in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-LEFT: 0px"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;2010&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px; WIDTH: 87%"&gt; Dividend yield&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"&gt; 0&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt; %&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px"&gt; Expected volatility&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 75&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px"&gt; Risk-free interest rate&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 3.23&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px"&gt; Expected life - in years&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 8.8&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:SecurityDeposit id="SecurityDeposit.7856.2904.70469.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.2904.70469.0.0.0.0" unitRef="USD" decimals="-3">298000</us-gaap:SecurityDeposit>
  <us-gaap:SeveranceCosts id="SeveranceCosts.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1000000</us-gaap:SeveranceCosts>
  <us-gaap:SeveranceCosts id="SeveranceCosts.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">816000</us-gaap:SeveranceCosts>
  <us-gaap:SeveranceCosts id="SeveranceCosts.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1100000</us-gaap:SeveranceCosts>
  <us-gaap:ShareBasedCompensation id="ShareBasedCompensation.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">7751000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="ShareBasedCompensation.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">886000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="ShareBasedCompensation.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1282000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.7858.68641.1319.70805.3871.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.68641.1319.70805.3871.0.0">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.7858.68641.1319.70806.3871.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.68641.1319.70806.3871.0.0">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.7858.68641.1319.70807.3871.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.68641.1319.70807.3871.0.0">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.7858.68641.1319.70808.3871.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.68641.1319.70808.3871.0.0">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.8547.1817.1319.0.0.0.0" contextRef="from-2010-02-01-to-2010-02-28.8547.0.1817.1319.0.0.0.0">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.8551.1817.1319.0.0.0.0" contextRef="from-2010-09-01-to-2010-09-30.8551.0.1817.1319.0.0.0.0">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.8552.1817.1319.0.0.0.0" contextRef="from-2010-11-01-to-2010-11-30.8552.0.1817.1319.0.0.0.0">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.8551.68641.1319.0.0.0.0" contextRef="from-2010-09-01-to-2010-09-30.8551.0.68641.1319.0.0.0.0">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod id="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">3208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod id="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.7858.4416.344.68641.1319.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.4416.344.68641.1319.0.0" unitRef="UShares" decimals="0">3208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.7858.4416.344.68641.1319.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.4416.344.68641.1319.0.0" unitRef="UShares" decimals="0">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.7856.4416.344.68641.1319.0.0" contextRef="as-of-2012-12-31.7856.0.4416.344.68641.1319.0.0" unitRef="UShares" decimals="0">1496792</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.7857.4416.344.68641.1319.0.0" xsi:nil="true" contextRef="as-of-2011-12-31.7857.0.4416.344.68641.1319.0.0" unitRef="UShares" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="UPure" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0">P8Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="UPure" decimals="2">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="UPure" decimals="4">0.0323</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.8545.0.0.0.0.0.0" contextRef="as-of-2012-06-16.8545.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">9741655</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.8546.0.0.0.0.0.0" contextRef="as-of-2012-06-17.8546.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">11341655</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.8548.70821.1319.0.0.0.0" contextRef="as-of-2010-02-28.8548.0.70821.1319.0.0.0.0" unitRef="UShares" decimals="0">1016000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.8548.1817.1319.0.0.0.0" contextRef="as-of-2010-02-28.8548.0.1817.1319.0.0.0.0" unitRef="UShares" decimals="0">160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.8550.1817.1319.0.0.0.0" contextRef="as-of-2010-09-30.8550.0.1817.1319.0.0.0.0" unitRef="UShares" decimals="0">160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.8553.1817.1319.0.0.0.0" contextRef="as-of-2010-11-30.8553.0.1817.1319.0.0.0.0" unitRef="UShares" decimals="0">68000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.8550.68641.1319.0.0.0.0" contextRef="as-of-2010-09-30.8550.0.68641.1319.0.0.0.0" unitRef="UShares" decimals="0">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.8554.4416.344.70821.1319.0.0" contextRef="as-of-2012-07-16.8554.0.4416.344.70821.1319.0.0" unitRef="UShares" decimals="0">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">176986</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.7856.4416.344.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.4416.344.0.0.0.0" unitRef="USD" decimals="-3">12400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">19700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.7856.70543.1319.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.70543.1319.0.0.0.0" unitRef="UShares" decimals="0">912425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.7857.70543.1319.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.70543.1319.0.0.0.0" unitRef="UShares" decimals="0">1235567</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.7859.70543.1319.0.0.0.0" contextRef="as-of-2010-12-31.7859.0.70543.1319.0.0.0.0" unitRef="UShares" decimals="0">1421734</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.7856.70546.1319.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.70546.1319.0.0.0.0" unitRef="UShares" decimals="0">4258441</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.7857.70546.1319.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.70546.1319.0.0.0.0" unitRef="UShares" decimals="0">4647834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.7859.70546.1319.0.0.0.0" contextRef="as-of-2010-12-31.7859.0.70546.1319.0.0.0.0" unitRef="UShares" decimals="0">4267850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.7856.70543.1319.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.70543.1319.0.0.0.0" unitRef="UPerShare" decimals="3">7.259</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.7857.70543.1319.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.70543.1319.0.0.0.0" unitRef="UPerShare" decimals="3">5.385</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.7859.70543.1319.0.0.0.0" contextRef="as-of-2010-12-31.7859.0.70543.1319.0.0.0.0" unitRef="UPerShare" decimals="3">4.653</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.7856.70546.1319.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.70546.1319.0.0.0.0" unitRef="UPerShare" decimals="3">3.201</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.7857.70546.1319.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.70546.1319.0.0.0.0" unitRef="UPerShare" decimals="3">2.581</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.7859.70546.1319.0.0.0.0" contextRef="as-of-2010-12-31.7859.0.70546.1319.0.0.0.0" unitRef="UPerShare" decimals="3">2.183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.7858.70543.1319.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70543.1319.0.0.0.0" unitRef="USD" decimals="-3">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.7860.70543.1319.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.70543.1319.0.0.0.0" unitRef="USD" decimals="-3">1900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.7861.70543.1319.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.70543.1319.0.0.0.0" unitRef="USD" decimals="-3">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.7858.70546.1319.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70546.1319.0.0.0.0" unitRef="USD" decimals="-3">4800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.7860.70546.1319.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.70546.1319.0.0.0.0" unitRef="USD" decimals="-3">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.7861.70546.1319.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.70546.1319.0.0.0.0" unitRef="USD" decimals="-3">3100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod.7858.70546.1319.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70546.1319.0.0.0.0" unitRef="UShares" decimals="0">25858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod.7860.70546.1319.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.70546.1319.0.0.0.0" unitRef="UShares" decimals="0">44856</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod.7861.70546.1319.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.70546.1319.0.0.0.0" unitRef="UShares" decimals="0">13441</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice.7858.70546.1319.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70546.1319.0.0.0.0" unitRef="UPerShare" decimals="3">4.372</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice.7860.70546.1319.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.70546.1319.0.0.0.0" unitRef="UPerShare" decimals="3">6.207</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice.7861.70546.1319.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.70546.1319.0.0.0.0" unitRef="UPerShare" decimals="3">3.551</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.7861.70546.1319.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.70546.1319.0.0.0.0" unitRef="UShares" decimals="0">1444000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.7858.68641.1319.70805.3871.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.68641.1319.70805.3871.0.0" unitRef="UShares" decimals="-3">1016000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.7858.68641.1319.70806.3871.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.68641.1319.70806.3871.0.0" unitRef="UShares" decimals="-3">428000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.7858.68641.1319.70807.3871.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.68641.1319.70807.3871.0.0" unitRef="UShares" decimals="-3">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.7858.68641.1319.70808.3871.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.68641.1319.70808.3871.0.0" unitRef="UShares" decimals="-3">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.7858.68641.1319.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.68641.1319.0.0.0.0" unitRef="UShares" decimals="-3">2944000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.8555.4416.344.72242.1319.0.0" contextRef="from-2012-07-15-to-2012-07-16.8555.0.4416.344.72242.1319.0.0" unitRef="UShares" decimals="0">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.7856.70543.1319.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.70543.1319.0.0.0.0" unitRef="UShares" decimals="0">912425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.7857.70543.1319.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.70543.1319.0.0.0.0" unitRef="UShares" decimals="0">1238692</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.7859.70543.1319.0.0.0.0" contextRef="as-of-2010-12-31.7859.0.70543.1319.0.0.0.0" unitRef="UShares" decimals="0">1438692</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.7862.70543.1319.0.0.0.0" contextRef="as-of-2009-12-31.7862.0.70543.1319.0.0.0.0" unitRef="UShares" decimals="0">1438692</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.7856.70546.1319.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.70546.1319.0.0.0.0" unitRef="UShares" decimals="0">5253579</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.7857.70546.1319.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.70546.1319.0.0.0.0" unitRef="UShares" decimals="0">6141030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.7859.70546.1319.0.0.0.0" contextRef="as-of-2010-12-31.7859.0.70546.1319.0.0.0.0" unitRef="UShares" decimals="0">6367979</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.7862.70546.1319.0.0.0.0" contextRef="as-of-2009-12-31.7862.0.70546.1319.0.0.0.0" unitRef="UShares" decimals="0">5366729</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.7856.70543.1319.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.70543.1319.0.0.0.0" unitRef="UPerShare" decimals="3">7.259</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.7857.70543.1319.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.70543.1319.0.0.0.0" unitRef="UPerShare" decimals="3">5.385</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.7859.70543.1319.0.0.0.0" contextRef="as-of-2010-12-31.7859.0.70543.1319.0.0.0.0" unitRef="UPerShare" decimals="3">4.697</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.7862.70543.1319.0.0.0.0" contextRef="as-of-2009-12-31.7862.0.70543.1319.0.0.0.0" unitRef="UPerShare" decimals="3">4.697</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.7856.70546.1319.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.70546.1319.0.0.0.0" unitRef="UPerShare" decimals="3">3.923</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.7857.70546.1319.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.70546.1319.0.0.0.0" unitRef="UPerShare" decimals="3">3.563</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.7859.70546.1319.0.0.0.0" contextRef="as-of-2010-12-31.7859.0.70546.1319.0.0.0.0" unitRef="UPerShare" decimals="3">3.576</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.7862.70546.1319.0.0.0.0" contextRef="as-of-2009-12-31.7862.0.70546.1319.0.0.0.0" unitRef="UPerShare" decimals="3">2.476</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.7858.70543.1319.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70543.1319.0.0.0.0" unitRef="UPerShare" decimals="2">0.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.7860.70543.1319.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.70543.1319.0.0.0.0" unitRef="UPerShare" decimals="3">0.001</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.7858.70546.1319.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70546.1319.0.0.0.0" unitRef="UPerShare" decimals="3">1.346</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.7860.70546.1319.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.70546.1319.0.0.0.0" unitRef="UPerShare" decimals="3">1.652</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.7861.70546.1319.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.70546.1319.0.0.0.0" unitRef="UPerShare" decimals="3">1.602</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.7860.70546.1319.0.0.0.0" xsi:nil="true" contextRef="from-2011-01-01-to-2011-12-31.7860.0.70546.1319.0.0.0.0" unitRef="UPerShare" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.7861.70546.1319.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.70546.1319.0.0.0.0" unitRef="UPerShare" decimals="3">7.076</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy id="ShareBasedCompensationOptionAndIncentivePlansPolicy.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;Share-based compensation&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company accounts for employee&amp;#39;s share-based payment awards classified as equity awards using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period, net of estimated forfeitures. The Company estimates forfeitures based on historical experience and anticipated future conditions.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company elected to recognize compensation cost for an award with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; When stock options are granted as consideration for services provided by consultants and other non-employees, the grant is accounted for based on the fair value of the stock options issued. Options granted is measured on a final basis at the end of the related service period and is recognized over the related service period using the straight-line method.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2.7858.70541.344.70524.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70524.4870.0.0">P2Y6M15D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2.7858.70541.344.70525.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70525.4870.0.0">P1Y18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2.7858.70541.344.70527.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70527.4870.0.0">P1Y11M1D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2.7858.70541.344.70530.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70530.4870.0.0">P3Y5M9D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2.7858.70541.344.70532.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70532.4870.0.0">P5Y9M26D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2.7858.70541.344.70533.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70533.4870.0.0">P6Y1M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2.7858.70541.344.70535.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70535.4870.0.0">P5Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2.7858.70541.344.70534.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70534.4870.0.0">P5Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2.7858.70541.344.70536.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70536.4870.0.0">P7Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2.7858.70541.344.70537.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70537.4870.0.0">P7Y1M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2.7858.70541.344.70538.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70538.4870.0.0">P7Y7M28D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2.7858.70541.344.70539.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70539.4870.0.0">P7Y9M29D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2.7858.70541.344.70540.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70540.4870.0.0">P3Y11M27D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2.7858.4416.344.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.4416.344.0.0.0.0">P0Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit.7858.68641.1319.70806.3871.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.68641.1319.70806.3871.0.0" unitRef="UPerShare" decimals="2">6.32</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit.8551.68641.1319.0.0.0.0" contextRef="from-2010-09-01-to-2010-09-30.8551.0.68641.1319.0.0.0.0" unitRef="UPerShare" decimals="2">6.32</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.7856.70541.344.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.70541.344.0.0.0.0" unitRef="UShares" decimals="0">5272950</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.7856.4416.344.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.4416.344.0.0.0.0" unitRef="UShares" decimals="0">102084</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.7856.70541.344.70524.4870.0.0" contextRef="as-of-2012-12-31.7856.0.70541.344.70524.4870.0.0" unitRef="UShares" decimals="0">719207</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.7856.70541.344.70525.4870.0.0" contextRef="as-of-2012-12-31.7856.0.70541.344.70525.4870.0.0" unitRef="UShares" decimals="0">447850</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.7856.70541.344.70527.4870.0.0" contextRef="as-of-2012-12-31.7856.0.70541.344.70527.4870.0.0" unitRef="UShares" decimals="0">23087</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.7856.70541.344.70530.4870.0.0" contextRef="as-of-2012-12-31.7856.0.70541.344.70530.4870.0.0" unitRef="UShares" decimals="0">996353</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.7856.70541.344.70532.4870.0.0" contextRef="as-of-2012-12-31.7856.0.70541.344.70532.4870.0.0" unitRef="UShares" decimals="0">40000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.7856.70541.344.70533.4870.0.0" contextRef="as-of-2012-12-31.7856.0.70541.344.70533.4870.0.0" unitRef="UShares" decimals="0">396744</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.7856.70541.344.70534.4870.0.0" contextRef="as-of-2012-12-31.7856.0.70541.344.70534.4870.0.0" unitRef="UShares" decimals="0">50000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.7856.70541.344.70535.4870.0.0" contextRef="as-of-2012-12-31.7856.0.70541.344.70535.4870.0.0" unitRef="UShares" decimals="0">1708000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.7856.70541.344.70536.4870.0.0" contextRef="as-of-2012-12-31.7856.0.70541.344.70536.4870.0.0" unitRef="UShares" decimals="0">110000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.7856.70541.344.70537.4870.0.0" contextRef="as-of-2012-12-31.7856.0.70541.344.70537.4870.0.0" unitRef="UShares" decimals="0">168083</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.7856.70541.344.70538.4870.0.0" contextRef="as-of-2012-12-31.7856.0.70541.344.70538.4870.0.0" unitRef="UShares" decimals="0">90000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.7856.70541.344.70539.4870.0.0" contextRef="as-of-2012-12-31.7856.0.70541.344.70539.4870.0.0" unitRef="UShares" decimals="0">34000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.7856.70541.344.70540.4870.0.0" contextRef="as-of-2012-12-31.7856.0.70541.344.70540.4870.0.0" unitRef="UShares" decimals="0">387542</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.7856.70541.344.70524.4870.0.0" contextRef="as-of-2012-12-31.7856.0.70541.344.70524.4870.0.0" unitRef="UShares" decimals="0">719207</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.7856.70541.344.70525.4870.0.0" contextRef="as-of-2012-12-31.7856.0.70541.344.70525.4870.0.0" unitRef="UShares" decimals="0">447850</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.7856.70541.344.70527.4870.0.0" contextRef="as-of-2012-12-31.7856.0.70541.344.70527.4870.0.0" unitRef="UShares" decimals="0">23087</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.7856.70541.344.70530.4870.0.0" contextRef="as-of-2012-12-31.7856.0.70541.344.70530.4870.0.0" unitRef="UShares" decimals="0">996353</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.7856.70541.344.70532.4870.0.0" contextRef="as-of-2012-12-31.7856.0.70541.344.70532.4870.0.0" unitRef="UShares" decimals="0">40000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.7856.70541.344.70533.4870.0.0" contextRef="as-of-2012-12-31.7856.0.70541.344.70533.4870.0.0" unitRef="UShares" decimals="0">402882</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.7856.70541.344.70534.4870.0.0" contextRef="as-of-2012-12-31.7856.0.70541.344.70534.4870.0.0" unitRef="UShares" decimals="0">50000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.7856.70541.344.70535.4870.0.0" contextRef="as-of-2012-12-31.7856.0.70541.344.70535.4870.0.0" unitRef="UShares" decimals="0">1708000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.7856.70541.344.70536.4870.0.0" contextRef="as-of-2012-12-31.7856.0.70541.344.70536.4870.0.0" unitRef="UShares" decimals="0">160000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.7856.70541.344.70537.4870.0.0" contextRef="as-of-2012-12-31.7856.0.70541.344.70537.4870.0.0" unitRef="UShares" decimals="0">1003083</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.7856.70541.344.70538.4870.0.0" contextRef="as-of-2012-12-31.7856.0.70541.344.70538.4870.0.0" unitRef="UShares" decimals="0">160000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.7856.70541.344.70539.4870.0.0" contextRef="as-of-2012-12-31.7856.0.70541.344.70539.4870.0.0" unitRef="UShares" decimals="0">68000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.7856.70541.344.70540.4870.0.0" contextRef="as-of-2012-12-31.7856.0.70541.344.70540.4870.0.0" unitRef="UShares" decimals="0">387542</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.7856.70541.344.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.70541.344.0.0.0.0" unitRef="UShares" decimals="0">7662796</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.7856.4416.344.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.4416.344.0.0.0.0" unitRef="UShares" decimals="0">1496792</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2.7858.70541.344.70524.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70524.4870.0.0">P2Y6M15D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2.7858.70541.344.70525.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70525.4870.0.0">P1Y18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2.7858.70541.344.70527.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70527.4870.0.0">P1Y11M1D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2.7858.70541.344.70530.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70530.4870.0.0">P3Y5M9D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2.7858.70541.344.70532.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70532.4870.0.0">P5Y9M26D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2.7858.70541.344.70533.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70533.4870.0.0">P6Y1M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2.7858.70541.344.70534.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70534.4870.0.0">P5Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2.7858.70541.344.70535.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70535.4870.0.0">P5Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2.7858.70541.344.70536.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70536.4870.0.0">P7Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2.7858.70541.344.70537.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70537.4870.0.0">P7Y1M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2.7858.70541.344.70538.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70538.4870.0.0">P7Y7M28D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2.7858.70541.344.70539.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70539.4870.0.0">P7Y9M29D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2.7858.70541.344.70540.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70540.4870.0.0">P3Y11M27D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2.7858.4416.344.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.4416.344.0.0.0.0">P0Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.7858.70541.344.70524.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70524.4870.0.0" unitRef="UPerShare" decimals="3">0.001</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.7858.70541.344.70525.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70525.4870.0.0" unitRef="UPerShare" decimals="2">0.12</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.7858.70541.344.70527.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70527.4870.0.0" unitRef="UPerShare" decimals="3">0.399</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.7858.70541.344.70530.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70530.4870.0.0" unitRef="UPerShare" decimals="3">0.972</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.7858.70541.344.70532.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70532.4870.0.0" unitRef="UPerShare" decimals="2">2.35</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.7858.70541.344.70533.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70533.4870.0.0" unitRef="UPerShare" decimals="2">2.65</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.7858.70541.344.70534.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70534.4870.0.0" unitRef="UPerShare" decimals="2">3.02</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.7858.70541.344.70535.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70535.4870.0.0" unitRef="UPerShare" decimals="1">5.0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.7858.70541.344.70536.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70536.4870.0.0" unitRef="UPerShare" decimals="2">6.81</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.7858.70541.344.70537.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70537.4870.0.0" unitRef="UPerShare" decimals="1">6.9</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.7858.70541.344.70538.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70538.4870.0.0" unitRef="UPerShare" decimals="2">7.55</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.7858.70541.344.70539.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70539.4870.0.0" unitRef="UPerShare" decimals="2">9.66</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.7858.70541.344.70540.4870.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70540.4870.0.0" unitRef="UPerShare" decimals="1">16.7</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.7858.68641.1319.70805.3871.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.68641.1319.70805.3871.0.0" unitRef="UPerShare" decimals="1">6.9</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.7858.68641.1319.70806.3871.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.68641.1319.70806.3871.0.0" unitRef="UPerShare" decimals="2">9.66</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.8547.70821.1319.0.0.0.0" contextRef="from-2010-02-01-to-2010-02-28.8547.0.70821.1319.0.0.0.0" unitRef="UPerShare" decimals="1">6.9</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.8547.1817.1319.0.0.0.0" contextRef="from-2010-02-01-to-2010-02-28.8547.0.1817.1319.0.0.0.0" unitRef="UPerShare" decimals="2">6.81</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.8551.1817.1319.0.0.0.0" contextRef="from-2010-09-01-to-2010-09-30.8551.0.1817.1319.0.0.0.0" unitRef="UPerShare" decimals="2">7.55</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.8552.1817.1319.0.0.0.0" contextRef="from-2010-11-01-to-2010-11-30.8552.0.1817.1319.0.0.0.0" unitRef="UPerShare" decimals="2">9.66</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:SharesOutstanding id="SharesOutstanding.7856.1033.4957.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.1033.4957.0.0.0.0" unitRef="UShares" decimals="0">93489809</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="SharesOutstanding.7857.1033.4957.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.1033.4957.0.0.0.0" unitRef="UShares" decimals="0">85630157</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="SharesOutstanding.7859.1033.4957.0.0.0.0" contextRef="as-of-2010-12-31.7859.0.1033.4957.0.0.0.0" unitRef="UShares" decimals="0">81248472</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="SharesOutstanding.7862.1033.4957.0.0.0.0" contextRef="as-of-2009-12-31.7862.0.1033.4957.0.0.0.0" unitRef="UShares" decimals="0">80841237</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7856.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-3357000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7857.0.0.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-26077000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7859.0.0.0.0.0.0" contextRef="as-of-2010-12-31.7859.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-11323000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7862.0.0.0.0.0.0" contextRef="as-of-2009-12-31.7862.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">15883000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7856.1033.4957.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">93000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7857.1033.4957.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">86000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7859.1033.4957.0.0.0.0" contextRef="as-of-2010-12-31.7859.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">81000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7862.1033.4957.0.0.0.0" contextRef="as-of-2009-12-31.7862.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">81000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7856.461.4957.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">180145000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7857.461.4957.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">145814000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7859.461.4957.0.0.0.0" contextRef="as-of-2010-12-31.7859.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">124044000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7862.461.4957.0.0.0.0" contextRef="as-of-2009-12-31.7862.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">122252000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7856.4458.4957.0.0.0.0" contextRef="as-of-2012-12-31.7856.0.4458.4957.0.0.0.0" unitRef="USD" decimals="-3">-183595000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7857.4458.4957.0.0.0.0" contextRef="as-of-2011-12-31.7857.0.4458.4957.0.0.0.0" unitRef="USD" decimals="-3">-171977000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7859.4458.4957.0.0.0.0" contextRef="as-of-2010-12-31.7859.0.4458.4957.0.0.0.0" unitRef="USD" decimals="-3">-135448000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7862.4458.4957.0.0.0.0" contextRef="as-of-2009-12-31.7862.0.4458.4957.0.0.0.0" unitRef="USD" decimals="-3">-106450000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="StockholdersEquityNoteDisclosureTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;NOTE 7 - SHARE CAPITAL&lt;/strong&gt;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;a.&lt;/td&gt; &lt;td&gt;Rights of the Company&amp;#39;s Common Stock&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company&amp;#39;s common stock is listed on the NYSE MKT and, since September 6, 2010, on the Tel Aviv Stock Exchange. Each share of Common Stock is entitled to one vote. The holders of shares of Common Stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. Since its inception, the Company has not declared any dividends.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;b.&lt;/td&gt; &lt;td&gt;Stock based compensation&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; On December 14, 2006, the Board of Directors adopted the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan (the "Plan"). The Plan was amended on June 17, 2012 to increase the number of shares of common stock available under the plan from 9,741,655 shares to 11,341,655 shares. The grant of options to Israeli employees under the Plan is subject to the terms stipulated by Sections 102 and 102A of the Israeli Income Tax Ordinance. Each option grant is subject to the track chosen by the Company, either Section 102 or Section 102A of the Israeli Income Tax Ordinance, and pursuant to the terms thereof, the Company is not allowed to claim, as an expense for tax purposes, the amounts credited to employees as a benefit, including amounts recorded as salary benefits in the Company&amp;#39;s accounts, in respect of options granted to employees under the Plan, with the exception of the work-income benefit component, if any, determined on the grant date. For Israeli non-employees, the share option plan is subject to Section 3(i) of the Israeli Income Tax Ordinance.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; As of December 31, 2012, 176,986 shares of Common Stock remain available for grant under the Plan.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; For purposes of determining the fair value of the options and restricted stock granted to employees and non-employees, the Company&amp;#39;s management uses the fair value of the Common Stock.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; From January 1, 2010 through December 31, 2012, the Company granted options and shares of restricted stock to certain employees and non-employees as follows:&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;1.&lt;/td&gt; &lt;td&gt;Options and restricted stock granted to employees:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 1in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;a)&lt;/td&gt; &lt;td&gt;Below is a table summarizing all of the options and restricted stock grants to employees for each of the three years in the three-year period ended December 31, 2012:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1.25in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Year of&lt;br /&gt; grant&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;No. of options&lt;br /&gt; or restricted&lt;br /&gt; stock granted&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Exercise&lt;br /&gt; price range&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"&gt;Vesting period&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Fair value&lt;br /&gt; at grant&lt;br /&gt; (U.S.&lt;br /&gt; dollars in&lt;br /&gt; thousands)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Expiration&lt;br /&gt; period&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 10%"&gt;2010&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;1,016,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; WIDTH: 10%"&gt;$6.90&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; WIDTH: 35%"&gt;3 years commencing&lt;br /&gt; upon achievement of a&lt;br /&gt; certain milestone&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;5,673&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt;10 years&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;2010&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;428,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: center"&gt;$6.32-$9.66&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt;4 years&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;2,147&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;10 years&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;2012&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;400,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: center"&gt;n/a&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt;3 years&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;2,288&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;n/a&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;2012&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 1,100,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; n/a&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt"&gt;4 years&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt"&gt;6,292&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: right"&gt; n/a&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;2,944,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; Set forth below are grants made by the Company to employees (including related parties) during the three-year period ended December 31, 2012 (such grants appear in the table above):&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1.5in; TEXT-INDENT: -0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 1.25in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="COLOR: black; FONT-WEIGHT: normal; WIDTH: 0.25in"&gt; 1.&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal"&gt;In February 2010, the Company&amp;#39;s Board of Directors approved the grant of options to purchase 1,016,000 shares of Common Stock, in the aggregate, to the Company&amp;#39;s Chief Executive Officer and certain officers and employees of the Company with an exercise price equal to $6.90 per share. The options vest quarterly over a three-year period commencing upon the FDA&amp;#39;s approval of taliglucerase alfa. The Company treated the awards as performance-based awards and, given that the performance condition is outside the Company&amp;#39;s control, concluded that the performance condition was not probable until the performance condition actually occurred. &lt;font style="COLOR: black"&gt;Upon the FDA&amp;#39;s&lt;/font&gt; approval of taliglucerase alfa on May 1, 2012&lt;font style="COLOR: black"&gt;, the Company started recognizing share based compensation expenses&lt;/font&gt; related to such options. Share based compensation related to services performed from the date of grant of the respective options through the FDA approval date, &lt;font style="COLOR: black"&gt;were recognized on that date.&lt;/font&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1.5in; TEXT-INDENT: -0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 1.25in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;2.&lt;/td&gt; &lt;td style="COLOR: black; FONT-WEIGHT: normal"&gt;In February 2010, the Company&amp;#39;s Board of Directors approved the grant of options to purchase 160,000 shares of Common Stock with an exercise price equal to $6.81 per share to a new executive officer of the Company. The options expire on the tenth anniversary of the date of grant, unless terminated earlier. The first 25% of the options vest on the first anniversary of the date of grant and the remaining 75% vest in 12 equal tranches on a quarterly basis for three years thereafter.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1.5in; TEXT-INDENT: -0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 1.25in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="COLOR: black; FONT-WEIGHT: normal; WIDTH: 0.25in"&gt; 3.&lt;/td&gt; &lt;td&gt;&lt;font style="FONT-WEIGHT: normal"&gt;In September 2010, the Company&amp;#39;s Board of Directors approved the grant of options to purchase 160,000 shares of Common Stock to a new executive officer of the Company with an exercise price equal to $7.55 per share and options to purchase 40,000 shares of Common Stock to a new employee of the Company with an exercise price equal to $6.32 per share. The options vest over a four-year period, with the first 25% vesting on the first anniversary of the applicable date of the grant and the remaining 75% vesting in equal tranches on a quarterly basis for a three-year period thereafter. &lt;font style="COLOR: black"&gt;The options expire on the tenth anniversary of the date of grant, unless terminated earlier.&lt;/font&gt;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1.5in; TEXT-INDENT: -0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 1.25in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="COLOR: black; FONT-WEIGHT: normal; WIDTH: 0.25in"&gt; 4.&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal"&gt;In November 2010, the Company&amp;#39;s Board of Directors approved the grant of options to purchase 68,000 shares of Common Stock to a new officer of the Company with an exercise price equal to $9.66 per share. The options vest over a four-year period, with the first 25% vesting on the first anniversary of the applicable date of the grant and the remaining 75% vesting in equal tranches on a quarterly basis for a three-year period thereafter. &lt;font style="COLOR: black"&gt;The options expire on the tenth anniversary of the date of grant, unless terminated earlier.&lt;/font&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1.5in; TEXT-INDENT: -0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 1.25in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;5.&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal"&gt;In September 2010, the Company&amp;#39;s Board of Directors modified the terms of the options previously granted to an executive in 2001, by extending the life of the options until 2016. At the date of modification, all of the options were fully vested. The Company concluded that there was no incremental increase in the value of the awards and therefore no accounting charges need to be recorded in connection with the modifications.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1.5in; TEXT-INDENT: -0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 1.25in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;6.&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal"&gt;On July 16, 2012, the Company&amp;#39;s Board of Directors approved the grant of 1,500,000 shares of restricted Common Stock to its officers and certain other employees. Of such restricted stock, 1,100,000 of the shares were issued to the Company&amp;#39;s named executive officers and vest in 16 equal, quarterly increments over a four-year period, commencing upon the date of grant, and are subject to a 24-month lock-up period, commencing upon the applicable vesting dates. Immediately and automatically in the event of a Change in Control, as such term is defined in the Plan, as amended, all of the shares of restricted Common Stock issued to the named executive officers shall vest, and the lock-up periods shall terminate, subject to certain exceptions. The remaining 400,000 shares of restricted Common Stock were issued to other employees of the Company and vest in 12 equal, quarterly increments over a three-year period, commencing upon the date of grant. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $8.6 million.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 1in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;b)&lt;/td&gt; &lt;td&gt;The fair value of options and restricted stock granted during the years ended December 31, 2010 and 2012 were $7.8 million and $8.6 million respectively. The fair value of each option granted in 2010 is estimated on the date of grant using the Black-Scholes option-pricing model, with the following weighted average assumptions:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1.25in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-LEFT: 0px"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;2010&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px; WIDTH: 87%"&gt; Dividend yield&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"&gt; 0&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt; %&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px"&gt; Expected volatility&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 75&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px"&gt; Risk-free interest rate&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 3.23&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px"&gt; Expected life - in years&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 8.8&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; The expected volatility is based on the historical volatility of the Common Stock and those of comparable companies. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term of the stock options granted in dollar terms. The Company&amp;#39;s management uses the contractual term or its expectations, based on historical incidence of option exercises, as applicable (during 2010 - using the simplified method), of each option as its expected life. The pre-vesting forfeiture rate of approximately 6.1% is estimated based on pre-vesting forfeiture experience.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; The fair value of the restricted stock is based on the Company&amp;#39;s share price on the NYSE MKT on the grant date.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; The total unrecognized compensation cost of employee stock options and restricted stock at December 31, 2012 is approximately $7.0 million (net of forfeiture rate). The unrecognized compensation cost of employee stock options is expected to be recognized over a weighted average period of 1.1 years.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; The total cash received from employees as a result of employee stock option exercises for the years ended December 31, 2010, 2011 and 2012 was approximately $501,000, $277,000 and $1.2 million, respectively. The Company did not realize any tax benefit in connection with these exercises.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; During 2012, the Company issued 861,593 shares of Common Stock in connection with the exercise of 861,593 options by certain employees of the Company. The Company received cash proceeds equal to approximately $1.2 million in connection with such exercises.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;2.&lt;/td&gt; &lt;td&gt;Options granted to consultants, directors, and other service providers:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: 0in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: 0in"&gt; As of December 31, 2012, the Company has recognized and recorded all compensation costs related to outstanding options for consultants, directors and other services providers.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; No cash was received from consultants as a result of consultant stock option exercises for the years ended December 31, 2010, and 2011 and approximately $39,000 was received during the year ended December 31, 2012. The Company did not realize any tax benefits in connection with these exercises.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; During 2012, the Company issued 326,267 shares of Common Stock in connection with the exercise of 326,267 options by consultants of the Company. The Company received cash proceeds equal to approximately $39,000 in connection with such exercise.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.25in"&gt;3.&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal"&gt;A summary of share option plans, and related information, under all of the Company&amp;#39;s equity incentive plans for the years ended December 31, 2010, 2011 and 2012 are as follows:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 1in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;a.&lt;/td&gt; &lt;td&gt;Options granted to employees:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="22" nowrap="nowrap"&gt;Year ended December 31,&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap"&gt;2010&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap"&gt;2011&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap"&gt;2012&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt; Weighted&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Weighted&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Weighted&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Number&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;average&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Number&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;average&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Number&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;average&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;of&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;exercise&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;of&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;exercise&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;of&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;exercise&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;options&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;price&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;options&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;price&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;options&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;price&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in; WIDTH: 40%"&gt; Outstanding at beginning of year&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 7%"&gt;5,366,729&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 7%"&gt;2.476&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 7%"&gt;6,367,979&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 7%"&gt;3.576&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 7%"&gt;6,141,030&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 7%"&gt;3.563&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;Changes during the year:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-LEFT: 0.25in"&gt;Granted&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1,444,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;7.076&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 0.25in"&gt;Forfeited and Expired&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;13,441&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;3.551&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;44,856&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;6.207&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;25,858&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;4.372&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.25in"&gt;Exercised (*)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 429,309&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 1.602&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 182,093&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 1.652&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 861,593&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 1.346&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;Outstanding at end of year&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 6,367,979&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 3.576&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 6,141,030&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 3.563&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 5,253,579&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 3.923&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;Exercisable at end of year&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 4,267,850&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 2.183&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 4,647,834&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 2.581&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 4,258,441&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 3.201&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: -0.2in; MARGIN: 0pt 0px 0pt 84.95pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 70.55pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 14.4pt"&gt;(*)&lt;/td&gt; &lt;td&gt;The total intrinsic value of options exercised during the years ended December 31, 2010, 2011 and 2012, was approximately $3.1 million, $1.3 million and $4.8 million, respectively.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: -0.2in; MARGIN: 0pt 0px 0pt 84.95pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 1in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;b.&lt;/td&gt; &lt;td&gt;Restricted stock granted to employees:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="5"&gt;Year ended December 31, 2012&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Number of&lt;br /&gt; Restricted Shares&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center"&gt;Outstanding at beginning of year&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center" colspan="2"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center"&gt;Changes during the year:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center; WIDTH: 90%"&gt;Granted&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 7%"&gt;1,500,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt; PADDING-LEFT: 15.95pt"&gt; Forfeited&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 3,208&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2.5pt"&gt;Outstanding at end of year&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 1,496,792&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2.5pt"&gt;Exercisable at end of year&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 102,084&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 1in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;c.&lt;/td&gt; &lt;td&gt;Options granted to consultants, directors, and other service providers:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="22"&gt;Year ended December 31,&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt;2010&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt;2011&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt;2012&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; Weighted&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; Weighted&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; Weighted&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; Number&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; average&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; Number&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; average&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; Number&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; average&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; of&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; exercise&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; of&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; exercise&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; of&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; exercise&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;options&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;price&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;options&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;price&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;options&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;price&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in; WIDTH: 40%"&gt; Outstanding at beginning of year&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 7%"&gt;1,438,692&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 7%"&gt;4.697&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 7%"&gt;1,438,692&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 7%"&gt;4.697&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 7%"&gt;1,238,692&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 7%"&gt;5.385&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in"&gt; Changes during the year- Exercised (*)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 200,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 0.001&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 326,267&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 0.12&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in"&gt; Outstanding at end of year&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 1,438,692&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 4.697&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 1,238,692&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 5.385&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 912,425&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 7.259&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in"&gt; Exercisable at end of year&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 1,421,734&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 4.653&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 1,235,567&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 5.385&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 912,425&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 7.259&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 63.8pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 14pt"&gt;(*)&lt;/td&gt; &lt;td&gt;The total intrinsic value of options exercised during the years ended December 31, 2010, 2011 and 2012, was approximately $0, $1.9 million and $2.3 million, respectively.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 1in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;d.&lt;/td&gt; &lt;td&gt;The following tables summarize information concerning outstanding and exercisable options and restricted stock as of December 31, 2012:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="18" nowrap="nowrap"&gt;December 31, 2012&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="10" nowrap="nowrap"&gt;Options and restricted stock&lt;br /&gt; outstanding&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap"&gt;Options exercisable and&lt;br /&gt; restricted stock vested&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Exercise&lt;br /&gt; prices&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Number of&lt;br /&gt; Options and&lt;br /&gt; restricted stock&lt;br /&gt; outstanding&lt;br /&gt; at end of&lt;br /&gt; year&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Weighted&lt;br /&gt; average&lt;br /&gt; remaining&lt;br /&gt; contractual&lt;br /&gt; life&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Number of&lt;br /&gt; options&lt;br /&gt; exercisable and&lt;br /&gt; restricted stock&lt;br /&gt; vested at end of&lt;br /&gt; year&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Weighted&lt;br /&gt; average&lt;br /&gt; remaining&lt;br /&gt; contractual&lt;br /&gt; life&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 18%"&gt;n/a (Restricted Stock)&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 17%"&gt;1,496,792&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 17%"&gt; &lt;p style="TEXT-ALIGN: right; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; n/a&lt;/p&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 17%"&gt;102,084&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 17%"&gt; &lt;p style="TEXT-ALIGN: right; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; n/a&lt;/p&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;0.001&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;719,207&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;2.54&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;719,207&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;2.54&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;0.120&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;447,850&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1.05&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;447,850&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1.05&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;0.399&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;23,087&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1.92&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;23,087&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1.92&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;0.972&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;996,353&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;3.44&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;996,353&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;3.44&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;2.350&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;40,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;5.82&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;40,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;5.82&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;2.650&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;402,882&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;6.15&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;396,744&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;6.15&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;3.020&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;50,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;5.10&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;50,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;5.10&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;5.000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1,708,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;5.10&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1,708,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;5.10&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;6.810&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;160,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;7.10&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;110,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;7.10&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;6.900&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;1,003,083&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;7.15&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;168,083&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;7.15&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;7.550&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;160,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;7.66&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;90,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;7.66&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;9.660&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;68,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;7.83&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;34,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;7.83&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt"&gt;16.700&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 387,542&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 3.99&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 387,542&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 3.99&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 7,662,796&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 5,272,950&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; The aggregate intrinsic value of the total outstanding and of total vested and exercisable options and restricted stock as of December 31, 2012 is approximately $19.7 million and $12.4 million, respectively.&lt;/p&gt; &lt;p style="TEXT-INDENT: -20.15pt; MARGIN: 0pt 0px 0pt 92.15pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 72pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 20.15pt"&gt;e.&lt;/td&gt; &lt;td&gt;The following table illustrates the effect of share-based compensation on the statement of operations:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="10"&gt;Year ended December 31,&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-STYLE: italic"&gt;(U.S. dollars in thousands)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2010&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2011&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2012&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -12.6pt; PADDING-LEFT: 12.6pt"&gt; Cost of revenues&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;220&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -12.6pt; PADDING-LEFT: 12.6pt; WIDTH: 61%"&gt; Research and development expenses&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;630&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;422&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;4,756&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -12.6pt; PADDING-LEFT: 12.6pt"&gt; General and administrative expenses&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 652&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 464&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 2,775&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 1,282&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 886&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 7,751&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 0.28in"&gt;c.&lt;/td&gt; &lt;td&gt;Public Offerings&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 78pt; TEXT-INDENT: -21.3pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 56.7pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 21.3pt"&gt;1.&lt;/td&gt; &lt;td&gt;&lt;font style="FONT-WEIGHT: normal"&gt;On March 23, 2011, the Company issued and sold 4,000,000 shares of Common Stock in an underwritten public offering at a price to the public of $5.50 per share. The net proceeds to the Company were approximately $20.6 million (net of underwriting commissions and issuance costs of $1.4 million&lt;/font&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 78pt; TEXT-INDENT: -21.3pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 56.7pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 21.3pt"&gt;2.&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal"&gt;On February 22, 2012, the Company issued and sold 5,175,000 shares of Common Stock in an underwritten public offering at a price to the public of $5.25 per share. The net proceeds to the Company were approximately $25.4 million (net of underwriting commissions and issuance costs of $1.8 million).&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="StockIssuedDuringPeriodSharesNewIssues.7858.1033.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.1033.4957.0.0.0.0" unitRef="UShares" decimals="0">5175000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="StockIssuedDuringPeriodSharesNewIssues.7860.1033.4957.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.1033.4957.0.0.0.0" unitRef="UShares" decimals="0">4000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.7858.1033.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.1033.4957.0.0.0.0" unitRef="UShares" decimals="0">1187860</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.7860.1033.4957.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.1033.4957.0.0.0.0" unitRef="UShares" decimals="0">381685</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.7861.1033.4957.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.1033.4957.0.0.0.0" unitRef="UShares" decimals="0">407235</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.8519.68640.3555.68647.5007.0.0" contextRef="from-2013-01-01-to-2013-02-28.8519.0.68640.3555.68647.5007.0.0" unitRef="UShares" decimals="0">8000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.7858.70543.1319.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70543.1319.0.0.0.0" unitRef="UShares" decimals="0">326267</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.7860.70543.1319.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.70543.1319.0.0.0.0" unitRef="UShares" decimals="0">200000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.7858.70546.1319.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.70546.1319.0.0.0.0" unitRef="UShares" decimals="0">861593</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.7860.70546.1319.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.70546.1319.0.0.0.0" unitRef="UShares" decimals="0">182093</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.7861.70546.1319.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.70546.1319.0.0.0.0" unitRef="UShares" decimals="0">429309</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.7858.1033.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.7860.1033.4957.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.7858.461.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">25383000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.7860.461.4957.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">20586000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">25388000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">20590000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.7858.4458.4957.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-12-31.7858.0.4458.4957.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.7860.4458.4957.0.0.0.0" xsi:nil="true" contextRef="from-2011-01-01-to-2011-12-31.7860.0.4458.4957.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.7858.1033.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.7860.1033.4957.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.7861.1033.4957.0.0.0.0" xsi:nil="true" contextRef="from-2010-01-01-to-2010-12-31.7861.0.1033.4957.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.7858.461.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">1198000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.7860.461.4957.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">298000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.7861.461.4957.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">510000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1199000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">299000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">510000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.7858.4458.4957.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-12-31.7858.0.4458.4957.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.7860.4458.4957.0.0.0.0" xsi:nil="true" contextRef="from-2011-01-01-to-2011-12-31.7860.0.4458.4957.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.7861.4458.4957.0.0.0.0" xsi:nil="true" contextRef="from-2010-01-01-to-2010-12-31.7861.0.4458.4957.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:SubsequentEventsTextBlock id="SubsequentEventsTextBlock.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;NOTE 11 - SUBSEQUENT EVENTS&lt;/strong&gt;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 56.7pt; TEXT-INDENT: -20.7pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 36pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal; WIDTH: 20.7pt"&gt;a.&lt;/td&gt; &lt;td style="FONT-WEIGHT: normal"&gt;During January and February 2013, the Company issued a total of 8,000 shares of Common Stock in connection with the exercise of options to purchase 8,000 shares of Common Stock by certain employees of the Company. The Company received aggregate cash proceeds equal to approximately $19,000 in connection with the exercise of such options.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:UseOfEstimates id="UseOfEstimates.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt;Use of estimates in the preparation of financial statements&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="WeightedAverageNumberOfShareOutstandingBasicAndDiluted.7858.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">90845901</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="WeightedAverageNumberOfShareOutstandingBasicAndDiluted.7860.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">84645364</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="WeightedAverageNumberOfShareOutstandingBasicAndDiluted.7861.0.0.0.0.0.0" contextRef="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">80960300</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <xbrli:unit id="UShares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="UPure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="UPerShare">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:context id="from-2013-01-01-to-2013-02-28.8519.0.68640.3555.68647.5007.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:EmployeeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionExerciseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-07-15-to-2012-07-16.8555.0.4416.344.72242.1319.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OfficersAndDirectorsInPrivateTransactionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-15</xbrli:startDate>
      <xbrli:endDate>2012-07-16</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-07-15-to-2012-07-16.8555.0.4416.344.70821.1319.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OfficersAndCertainEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-15</xbrli:startDate>
      <xbrli:endDate>2012-07-16</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-07-15-to-2012-07-16.8555.0.4416.344.68641.1319.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-15</xbrli:startDate>
      <xbrli:endDate>2012-07-16</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-02-01-to-2012-02-29.8544.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-02-01</xbrli:startDate>
      <xbrli:endDate>2012-02-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.73899.73897.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:SupplementalInformationRevenueAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.73722.70469.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:YissumAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70546.1319.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockGrantedToEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70543.1319.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70540.4870.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OneSixPointSevenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70539.4870.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:NinePointSixSixMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70538.4870.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:SevenPointFiveFiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70537.4870.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:SixPointNineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70536.4870.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:SixPointEightOneZeroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70535.4870.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:FivePointZeroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70534.4870.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ThreePointZeroTwoZeroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70533.4870.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:TwoPointSixFiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70532.4870.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:TwoPointThreeFiveZeroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70530.4870.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ZeroPointNineSevenTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70527.4870.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ZeroPointThreeNineNineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70525.4870.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ZeroPointOneTwoZeroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70541.344.70524.4870.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ZeroPointZeroZeroOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70522.4351.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:CompensationToTheNon-executiveDirectorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70521.4351.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ManagementAndConsultingFeesToChairmanOfBoardMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70497.2525.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:TaxYearThereafterMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70496.2525.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:TaxYearTwoThousandNineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70487.70469.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:VehicleLeaseAndMaintenanceAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70480.73897.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:SupplementalInformationRevenueAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:MilestonePaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70480.70469.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:MilestonePaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70479.70469.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ProbableAggregateMilestonePaymentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70477.70469.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ResearchAndLicenseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70475.70469.3241.4187.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ProductsManufacturedOutsideOfIsraelMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70473.70469.3248.4187.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OCSMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70473.70469.3241.4187.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OCSMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70473.70469.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OCSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70112.4117.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70110.4951.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:UponNearTermClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.70109.4951.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:UponFDAApprovalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.68654.4951.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ScenarioTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.68653.4951.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ScenarioOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.68641.1319.70808.3871.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:EmployeesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:GrantYearTwoThousandTwelveSecondMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.68641.1319.70807.3871.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:EmployeesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:GrantYearTwoThousandTwelveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.68641.1319.70806.3871.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:EmployeesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:GrantYearTwoThousandTenSecondMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.68641.1319.70805.3871.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:EmployeesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:GrantYearTwoThousandTenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.68641.1319.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.5011.136.70497.2525.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:TaxYearThereafterMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.5011.136.3248.4187.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.5011.136.3241.4187.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.461.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.4541.73897.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:SupplementalInformationRevenueAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.4458.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.4416.344.68641.1319.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.4416.344.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.4381.4617.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.3241.4187.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.2904.70469.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.2354.4617.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.2275.4117.3248.4187.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.2275.4117.3241.4187.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.17690.2525.3248.4187.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.17690.2525.3241.4187.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.17619.2525.3248.4187.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">country:NL</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.17619.2525.3241.4187.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">country:NL</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.17552.2525.3248.4187.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">country:IL</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.17552.2525.3241.4187.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">country:IL</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.1183.4617.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.1086.4117.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.1033.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.7858.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-03-01-to-2011-03-23.9211.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-03-01</xbrli:startDate>
      <xbrli:endDate>2011-03-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-12-31.7860.0.73899.73897.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:SupplementalInformationRevenueAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-12-31.7860.0.70546.1319.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockGrantedToEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-12-31.7860.0.70543.1319.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-12-31.7860.0.70522.4351.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:CompensationToTheNon-executiveDirectorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-12-31.7860.0.70521.4351.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ManagementAndConsultingFeesToChairmanOfBoardMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-12-31.7860.0.70480.73897.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:SupplementalInformationRevenueAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:MilestonePaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-12-31.7860.0.70477.70469.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ResearchAndLicenseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-12-31.7860.0.70473.70469.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OCSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-12-31.7860.0.461.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-12-31.7860.0.4541.73897.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:SupplementalInformationRevenueAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-12-31.7860.0.4458.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-12-31.7860.0.4381.4617.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-12-31.7860.0.2904.70469.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-12-31.7860.0.2354.4617.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-12-31.7860.0.1033.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-12-31.7860.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-11-01-to-2010-11-30.8552.0.1817.1319.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-11-01</xbrli:startDate>
      <xbrli:endDate>2010-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-09-01-to-2010-09-30.8551.0.68641.1319.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-09-01</xbrli:startDate>
      <xbrli:endDate>2010-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-09-01-to-2010-09-30.8551.0.1817.1319.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-09-01</xbrli:startDate>
      <xbrli:endDate>2010-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-02-01-to-2010-02-28.8547.0.70821.1319.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OfficersAndCertainEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-02-01</xbrli:startDate>
      <xbrli:endDate>2010-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-02-01-to-2010-02-28.8547.0.1817.1319.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-02-01</xbrli:startDate>
      <xbrli:endDate>2010-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-01-01-to-2010-12-31.7861.0.73899.73897.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:SupplementalInformationRevenueAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-01-01-to-2010-12-31.7861.0.70546.1319.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockGrantedToEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-01-01-to-2010-12-31.7861.0.70543.1319.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-01-01-to-2010-12-31.7861.0.70522.4351.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:CompensationToTheNon-executiveDirectorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-01-01-to-2010-12-31.7861.0.70521.4351.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ManagementAndConsultingFeesToChairmanOfBoardMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-01-01-to-2010-12-31.7861.0.70480.73897.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:SupplementalInformationRevenueAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:MilestonePaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-01-01-to-2010-12-31.7861.0.70480.70469.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:MilestonePaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-01-01-to-2010-12-31.7861.0.70477.70469.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ResearchAndLicenseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-01-01-to-2010-12-31.7861.0.70473.70469.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OCSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-01-01-to-2010-12-31.7861.0.461.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-01-01-to-2010-12-31.7861.0.4541.73897.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:SupplementalInformationRevenueAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-01-01-to-2010-12-31.7861.0.4458.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-01-01-to-2010-12-31.7861.0.4381.4617.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-01-01-to-2010-12-31.7861.0.2904.70469.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-01-01-to-2010-12-31.7861.0.2354.4617.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-01-01-to-2010-12-31.7861.0.1033.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-01-01-to-2010-12-31.7861.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-02-15.9180.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-02-15</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.73722.70469.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:YissumAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70846.999.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:CollaborationOperationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70546.1319.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockGrantedToEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70543.1319.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70541.344.70540.4870.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OneSixPointSevenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70541.344.70539.4870.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:NinePointSixSixMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70541.344.70538.4870.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:SevenPointFiveFiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70541.344.70537.4870.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:SixPointNineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70541.344.70536.4870.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:SixPointEightOneZeroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70541.344.70535.4870.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:FivePointZeroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70541.344.70534.4870.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ThreePointZeroTwoZeroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70541.344.70533.4870.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:TwoPointSixFiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70541.344.70532.4870.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:TwoPointThreeFiveZeroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70541.344.70530.4870.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ZeroPointNineSevenTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70541.344.70527.4870.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ZeroPointThreeNineNineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70541.344.70525.4870.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ZeroPointOneTwoZeroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70541.344.70524.4870.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ZeroPointZeroZeroOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70541.344.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70519.70516.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:AccountsPayableAndAccrualsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:PropertyAndEquipmentSuppliersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70518.70516.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:AccountsPayableAndAccrualsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:CollaborationOperationCurrentPortionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70514.392.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:SundryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70513.392.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:RestrictedDepositMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70512.392.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:StateOfIsraelMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70511.392.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:InstitutionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70510.392.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:DeferredCostMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70506.2525.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:RestrictedAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70487.70469.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:VehicleLeaseAndMaintenanceAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70473.70469.3241.4187.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OCSMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70136.4117.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:EquipmentUnderConstructionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70134.4117.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.70112.4117.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.68651.999.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.68649.999.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:PfizerIncorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.68641.1319.70808.3871.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:EmployeesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:GrantYearTwoThousandTwelveSecondMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.68641.1319.70807.3871.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:EmployeesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:GrantYearTwoThousandTwelveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.68641.1319.70806.3871.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:EmployeesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:GrantYearTwoThousandTenSecondMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.68641.1319.70805.3871.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:EmployeesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:GrantYearTwoThousandTenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.5011.136.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.461.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.4458.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.4416.344.68641.1319.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.4416.344.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.2905.4117.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.2904.70469.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.1033.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7856.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-07-16.8554.0.4416.344.70821.1319.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OfficersAndCertainEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-07-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-07-16.8554.0.4416.344.68641.1319.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-07-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-06-29.9179.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-06-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-06-17.8546.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-06-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-06-16.8545.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-06-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-02-22.8542.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-02-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.7857.0.70546.1319.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockGrantedToEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.7857.0.70543.1319.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.7857.0.70519.70516.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:AccountsPayableAndAccrualsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:PropertyAndEquipmentSuppliersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.7857.0.70518.70516.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="plx:AccountsPayableAndAccrualsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:CollaborationOperationCurrentPortionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.7857.0.70514.392.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:SundryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.7857.0.70513.392.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:RestrictedDepositMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.7857.0.70512.392.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:StateOfIsraelMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.7857.0.70511.392.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:InstitutionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.7857.0.70510.392.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:DeferredCostMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.7857.0.70136.4117.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:EquipmentUnderConstructionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.7857.0.70134.4117.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.7857.0.70112.4117.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.7857.0.461.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.7857.0.4458.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.7857.0.4416.344.68641.1319.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.7857.0.2905.4117.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.7857.0.1033.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.7857.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-03-23.9212.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-23</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2010-12-31.7859.0.70546.1319.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockGrantedToEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2010-12-31.7859.0.70543.1319.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2010-12-31.7859.0.461.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2010-12-31.7859.0.4458.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2010-12-31.7859.0.1033.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2010-12-31.7859.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2010-11-30.8553.0.1817.1319.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2010-09-30.8550.0.68641.1319.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2010-09-30.8550.0.1817.1319.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2010-02-28.8548.0.70821.1319.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OfficersAndCertainEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2010-02-28.8548.0.1817.1319.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2009-12-31.7862.0.70546.1319.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsAndRestrictedStockGrantedToEmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2009-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2009-12-31.7862.0.70543.1319.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2009-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2009-12-31.7862.0.461.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2009-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2009-12-31.7862.0.4458.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2009-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2009-12-31.7862.0.1033.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2009-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2009-12-31.7862.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2009-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>17
<FILENAME>plx-20121231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings-->
<!--produced on 2013-02-28 @ 11:25 AM-->
<xsd:schema targetNamespace="http://www.protalix.com/20121231" elementFormDefault="qualified" xmlns:plx="http://www.protalix.com/20121231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="plx-20121231_cal.xml" xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" />
      <link:linkbaseRef xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="plx-20121231_def.xml" xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" />
      <link:linkbaseRef xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="plx-20121231_lab.xml" xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" />
      <link:linkbaseRef xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="plx-20121231_pre.xml" xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" />
      <link:roleType roleURI="http://www.protalix.com/role/Commitments" id="plx-c" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>106 - Disclosure - COMMITMENTS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/ConsolidatedBalanceSheets" id="plx-cbs" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/ConsolidatedBalanceSheetsParenthetical" id="plx-cbsp" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/CommitmentsDetails" id="plx-cd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40601 - Disclosure - COMMITMENTS (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/ConsolidatedStatementsOfCashFlows" id="plx-csocf" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/ConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiency" id="plx-csocisecd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>006 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/ConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiencyParenthetical" id="plx-csocisecdp" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>007 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/ConsolidatedStatementsOfOperations" id="plx-csoo" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DocumentAndEntityInformation" id="plx-daei" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/Inventories" id="plx-i" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>104 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/InventoriesDetails" id="plx-id" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40401 - Disclosure - INVENTORIES (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/InventoriesTables" id="plx-it" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>304 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/LicenseAndSupplyAgreement" id="plx-lasa" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>102 - Disclosure - LICENSE AND SUPPLY AGREEMENT</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/LicenseAndSupplyAgreementDetails" id="plx-lasad" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40201 - Disclosure - LICENSE AND SUPPLY AGREEMENT (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/LiabilityForEmployeeRightsUponRetirement" id="plx-lferur" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>105 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/LiabilityForEmployeeRightsUponRetirementDetails" id="plx-lferurd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/PropertyAndEquipment" id="plx-pae" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>103 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/PropertyAndEquipmentDetails" id="plx-paed" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40301 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/PropertyAndEquipmentTables" id="plx-paet" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>303 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/RelatedPartyTransactions" id="plx-rpt" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>110 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/RelatedPartyTransactionsDetails" id="plx-rptd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>41001 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/RelatedPartyTransactionsTables" id="plx-rptt" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>310 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPolicies" id="plx-sap" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" id="plx-sapd1" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesPolicy" id="plx-sapp1" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesTables" id="plx-sapt" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" id="plx-sapulopaed" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Useful Lives of Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/ShareCapital" id="plx-sc" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>107 - Disclosure - SHARE CAPITAL</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/ShareCapitalFairValueAssumptionsOfOptionsGrantedDetails" id="plx-scfvaoogd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40703 - Disclosure - SHARE CAPITAL (Fair Value Assumptions of Options Granted) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/ShareCapitalNarrativeDetails" id="plx-scnd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40701 - Disclosure - SHARE CAPITAL (Narrative) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/ShareCapitalOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails" id="plx-scogtcdaospd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40706 - Disclosure - SHARE CAPITAL (Options Granted to Consultants, Directors and Other Service Providers) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/ShareCapitalOptionsGrantedToEmployeesDetails" id="plx-scogted" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40704 - Disclosure - SHARE CAPITAL (Options Granted to Employees) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/ShareCapitalRestrictedStockGrantedToEmployeesDetails" id="plx-scrsgted" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40705 - Disclosure - SHARE CAPITAL (Restricted Stock Granted to Employees) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/ShareCapitalShareBasedCompensationExpenseAllocationDetails" id="plx-scsbcead" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40708 - Disclosure - SHARE CAPITAL (Share Based Compensation Expense Allocation) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/ShareCapitalSummaryOfOutstandingAndRestrictedStocksDetails" id="plx-scsooarsd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40707 - Disclosure - SHARE CAPITAL (Summary of Outstanding and Restricted Stocks) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/ShareCapitalSummaryOfOptionAndRestrictedStockGrantedToEmployeesDetails" id="plx-scsooarsgted" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40702 - Disclosure - SHARE CAPITAL (Summary of Option and Restricted Stock Granted to Employees) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/ShareCapitalTables" id="plx-sct" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>307 - Disclosure - SHARE CAPITAL (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/SubsequentEvents" id="plx-se" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>111 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/SubsequentEventsDetails" id="plx-sed" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>41101 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformation" id="plx-sfsi" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>109 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" id="plx-sfsiapaaod" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40902 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals, Other) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationAccountsReceivableOtherDetails" id="plx-sfsiarod" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40901 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Receivable, Other) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationRevenuesDetails" id="plx-sfsird" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40903 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Revenues) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationTables" id="plx-sfsit" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>309 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/TaxesOnIncome" id="plx-toi" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>108 - Disclosure - TAXES ON INCOME</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/TaxesOnIncomeDeferredIncomeTaxesDetails" id="plx-toiditd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40802 - Disclosure - TAXES ON INCOME (Deferred Income Taxes) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/TaxesOnIncomeNarrativeDetails" id="plx-toind" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40801 - Disclosure - TAXES ON INCOME (Narrative) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/TaxesOnIncomeOpenTaxYearsDetails" id="plx-toiotyd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40803 - Disclosure - TAXES ON INCOME (Open Tax Years) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/TaxesOnIncomeTables" id="plx-toit" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>308 - Disclosure - TAXES ON INCOME (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2012-01-31" schemaLocation="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2012-01-31" schemaLocation="http://xbrl.sec.gov/invest/2012/invest-2012-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2012-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2012-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2012/elts/us-types-2012-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2012-01-31" schemaLocation="http://xbrl.sec.gov/country/2012/country-2012-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2012-01-31" schemaLocation="http://xbrl.sec.gov/exch/2012/exch-2012-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2012-01-31" schemaLocation="http://xbrl.sec.gov/currency/2012/currency-2012-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:element name="AccountsPayableAndAccrualsAxis" id="plx_AccountsPayableAndAccrualsAxis" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" />
  <xsd:element name="AccountsPayableAndAccrualsDomain" id="plx_AccountsPayableAndAccrualsDomain" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="AccountsPayableAndAccrualsLineItems" id="plx_AccountsPayableAndAccrualsLineItems" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element name="AccountsPayableAndAccrualsTable" id="plx_AccountsPayableAndAccrualsTable" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" />
  <xsd:element name="AgreementMaintenanceFee" id="plx_AgreementMaintenanceFee" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="AnnualIncreaseToMaintenanceFee" id="plx_AnnualIncreaseToMaintenanceFee" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType" />
  <xsd:element name="CashlessExerciseOfStockOptions" id="plx_CashlessExerciseOfStockOptions" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="CollaborationOperationCurrentPortionMember" id="plx_CollaborationOperationCurrentPortionMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="CollaborationOperationMember" id="plx_CollaborationOperationMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="CollaborativeAndLicenseArrangementDisclosure" id="plx_CollaborativeAndLicenseArrangementDisclosure" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element name="CollaborativeAndLicenseArrangementDisclosureTextBlock" id="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" />
  <xsd:element name="CollaborativeAndLicenseArrangementTable" id="plx_CollaborativeAndLicenseArrangementTable" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" />
  <xsd:element name="CollaborativeArrangementProfitSharePercentage" id="plx_CollaborativeArrangementProfitSharePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType" />
  <xsd:element name="CommitmentAmount" id="plx_CommitmentAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="CommitmentsAndContingenciesAxis" id="plx_CommitmentsAndContingenciesAxis" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" />
  <xsd:element name="CommitmentsAndContingenciesDomain" id="plx_CommitmentsAndContingenciesDomain" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="CommitmentsAndContingenciesLineItems" id="plx_CommitmentsAndContingenciesLineItems" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element name="CommitmentsAndContingenciesTable" id="plx_CommitmentsAndContingenciesTable" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" />
  <xsd:element name="CompensationToTheNon-executiveDirectorsMember" id="plx_CompensationToTheNon-executiveDirectorsMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ConsiderationForLicense" id="plx_ConsiderationForLicense" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="DeferredCostMember" id="plx_DeferredCostMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember" id="plx_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="DepreciationAmortizationAndAssetImpairment" id="plx_DepreciationAmortizationAndAssetImpairment" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="plx_DocumentAndEntityInformationAbstract" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element name="EffectiveAdjustedIncomeTaxRateThereafter" id="plx_EffectiveAdjustedIncomeTaxRateThereafter" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType" />
  <xsd:element name="EffectiveAdjustedIncomeTaxRateYearFive" id="plx_EffectiveAdjustedIncomeTaxRateYearFive" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType" />
  <xsd:element name="EffectiveAdjustedIncomeTaxRateYearFour" id="plx_EffectiveAdjustedIncomeTaxRateYearFour" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType" />
  <xsd:element name="EffectiveAdjustedIncomeTaxRateYearOne" id="plx_EffectiveAdjustedIncomeTaxRateYearOne" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType" />
  <xsd:element name="EffectiveAdjustedIncomeTaxRateYearThree" id="plx_EffectiveAdjustedIncomeTaxRateYearThree" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType" />
  <xsd:element name="EffectiveAdjustedIncomeTaxRateYearTwo" id="plx_EffectiveAdjustedIncomeTaxRateYearTwo" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType" />
  <xsd:element name="EmployeeMember" id="plx_EmployeeMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="EmployeeSeveranceObligationPayment" id="plx_EmployeeSeveranceObligationPayment" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="EmployeesMember" id="plx_EmployeesMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="EquipmentUnderConstructionMember" id="plx_EquipmentUnderConstructionMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ExpectedDefintedBenefitContributionDuringPeriod" id="plx_ExpectedDefintedBenefitContributionDuringPeriod" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" id="plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="FivePointZeroMember" id="plx_FivePointZeroMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ForfeitureRate" id="plx_ForfeitureRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType" />
  <xsd:element name="FundingArrangementsMember" id="plx_FundingArrangementsMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="FurnitureAndComputerEquipmentMember" id="plx_FurnitureAndComputerEquipmentMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="GrantsAndReimbursementsReceivedOrReceivable" id="plx_GrantsAndReimbursementsReceivedOrReceivable" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="GrantYearTwoThousandTenMember" id="plx_GrantYearTwoThousandTenMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="GrantYearTwoThousandTenSecondMember" id="plx_GrantYearTwoThousandTenSecondMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="GrantYearTwoThousandTwelveMember" id="plx_GrantYearTwoThousandTwelveMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="GrantYearTwoThousandTwelveSecondMember" id="plx_GrantYearTwoThousandTwelveSecondMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="IncomeTaxDisclosureLineItems" id="plx_IncomeTaxDisclosureLineItems" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element name="IncomeTaxDisclosureTable" id="plx_IncomeTaxDisclosureTable" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" />
  <xsd:element name="IncreaseInLiabilitiesForPropertyPlantAndEquipment" id="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="InstitutionsMember" id="plx_InstitutionsMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="LaboratoryEquipmentMember" id="plx_LaboratoryEquipmentMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="LiabilitiesAccruedFromLicensingAgreement" id="plx_LiabilitiesAccruedFromLicensingAgreement" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="ManagementAndConsultingFeesToChairmanOfBoardMember" id="plx_ManagementAndConsultingFeesToChairmanOfBoardMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" id="plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType" />
  <xsd:element name="MilestonePayment" id="plx_MilestonePayment" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="MilestonePaymentsMember" id="plx_MilestonePaymentsMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="MonthlyRentLeaseExpense" id="plx_MonthlyRentLeaseExpense" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="NatureOfOperationsPolicyTextBlock" id="plx_NatureOfOperationsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" />
  <xsd:element name="NinePointSixSixMember" id="plx_NinePointSixSixMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="NumberOfSubsidiaries" id="plx_NumberOfSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element name="OCSMember" id="plx_OCSMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="OfficersAndCertainEmployeesMember" id="plx_OfficersAndCertainEmployeesMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="OfficersAndDirectorsInPrivateTransactionMember" id="plx_OfficersAndDirectorsInPrivateTransactionMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="OneSixPointSevenMember" id="plx_OneSixPointSevenMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="OptionExerciseMember" id="plx_OptionExerciseMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="OptionsAndRestrictedStockGrantedToEmployeesMember" id="plx_OptionsAndRestrictedStockGrantedToEmployeesMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="OptionsAndRestrictedStockMember" id="plx_OptionsAndRestrictedStockMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" id="plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="OtherGainsLosses" id="plx_OtherGainsLosses" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="PfizerIncorporationMember" id="plx_PfizerIncorporationMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ProbableAggregateMilestonePaymentMember" id="plx_ProbableAggregateMilestonePaymentMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ProceedsFromIssuanceOfCommonStockNetOfExpenses" id="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="ProductsManufacturedOutsideOfIsraelMember" id="plx_ProductsManufacturedOutsideOfIsraelMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="PropertyAndEquipmentSuppliersMember" id="plx_PropertyAndEquipmentSuppliersMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ProtalixBioTherapeuticsIncorporationMember" id="plx_ProtalixBioTherapeuticsIncorporationMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ResearchAndLicenseAgreementsMember" id="plx_ResearchAndLicenseAgreementsMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ResearchDevelopmentAndEngineeringExpenseNet" id="plx_ResearchDevelopmentAndEngineeringExpenseNet" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="RestrictedAmountMember" id="plx_RestrictedAmountMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="RestrictedDepositMember" id="plx_RestrictedDepositMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="RevenueRecognizedOverDesignatedPeriod" id="plx_RevenueRecognizedOverDesignatedPeriod" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="RevenueRecognizedPeriod" id="plx_RevenueRecognizedPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType" />
  <xsd:element name="RoyaltiesOnSaleOfProducts" id="plx_RoyaltiesOnSaleOfProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType" />
  <xsd:element name="ScenarioOneMember" id="plx_ScenarioOneMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ScenarioTwoMember" id="plx_ScenarioTwoMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ScheduleOfOpenTaxYearsTableTextBlock" id="plx_ScheduleOfOpenTaxYearsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" />
  <xsd:element name="ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" id="plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" />
  <xsd:element name="ScheduleOfUsefulLifeTableTextBlock" id="plx_ScheduleOfUsefulLifeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" />
  <xsd:element name="SevenPointFiveFiveMember" id="plx_SevenPointFiveFiveMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" />
  <xsd:element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element name="SignificantAccountingPoliciesLineItems" id="plx_SignificantAccountingPoliciesLineItems" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element name="SignificantAccountingPoliciesTable" id="plx_SignificantAccountingPoliciesTable" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" />
  <xsd:element name="SixPointEightOneZeroMember" id="plx_SixPointEightOneZeroMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="SixPointNineMember" id="plx_SixPointNineMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="StateOfIsraelMember" id="plx_StateOfIsraelMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="StockOptionsAndRestrictedSharesMember" id="plx_StockOptionsAndRestrictedSharesMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="SundryMember" id="plx_SundryMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="SupplementalInformationAbstract" id="plx_SupplementalInformationAbstract" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element name="SupplementalInformationRevenueAxis" id="plx_SupplementalInformationRevenueAxis" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" />
  <xsd:element name="SupplementalInformationRevenueDomain" id="plx_SupplementalInformationRevenueDomain" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="SupplementalInformationRevenueLineItems" id="plx_SupplementalInformationRevenueLineItems" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element name="SupplementalInformationTable" id="plx_SupplementalInformationTable" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" />
  <xsd:element name="SupplementalOfferingAndStockIssuanceCosts" id="plx_SupplementalOfferingAndStockIssuanceCosts" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="SupplementaryBalanceSheetsInformationTableTextBlock" id="plx_SupplementaryBalanceSheetsInformationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" />
  <xsd:element name="SupplementaryIncomeStatementInformationTableTextBlock" id="plx_SupplementaryIncomeStatementInformationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" />
  <xsd:element name="TaxBurdenDistributionLawMember" id="plx_TaxBurdenDistributionLawMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" id="plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element name="TaxYearThereafterMember" id="plx_TaxYearThereafterMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="TaxYearTwoThousandNineMember" id="plx_TaxYearTwoThousandNineMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ThreePointZeroTwoZeroMember" id="plx_ThreePointZeroTwoZeroMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="TwoPointSixFiveMember" id="plx_TwoPointSixFiveMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="TwoPointThreeFiveZeroMember" id="plx_TwoPointThreeFiveZeroMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="UponFDAApprovalMember" id="plx_UponFDAApprovalMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="UponNearTermClinicalDevelopmentMilestonesMember" id="plx_UponNearTermClinicalDevelopmentMilestonesMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="VehicleLeaseAndMaintenanceAgreementsMember" id="plx_VehicleLeaseAndMaintenanceAgreementsMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="WithholdingTaxRateOnForeignIncome" id="plx_WithholdingTaxRateOnForeignIncome" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType" />
  <xsd:element name="YissumAgreementMember" id="plx_YissumAgreementMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ZeroPointNineSevenTwoMember" id="plx_ZeroPointNineSevenTwoMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ZeroPointOneTwoZeroMember" id="plx_ZeroPointOneTwoZeroMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ZeroPointThreeNineNineMember" id="plx_ZeroPointThreeNineNineMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ZeroPointZeroZeroOneMember" id="plx_ZeroPointZeroZeroOneMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>18
<FILENAME>plx-20121231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings-->
<!--produced on 2013-02-28 @ 11:25 AM-->
<link:linkbase xmlns:plx="http://www.protalix.com/20121231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef roleURI="http://www.protalix.com/role/ConsolidatedBalanceSheets" xlink:href="plx-20121231.xsd#plx-cbs" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="plx-20121231.xsd#plx-csocf" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiency" xlink:href="plx-20121231.xsd#plx-csocisecd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiencyParenthetical" xlink:href="plx-20121231.xsd#plx-csocisecdp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ConsolidatedStatementsOfOperations" xlink:href="plx-20121231.xsd#plx-csoo" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/DocumentAndEntityInformation" xlink:href="plx-20121231.xsd#plx-daei" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/Inventories" xlink:href="plx-20121231.xsd#plx-i" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesTables" xlink:href="plx-20121231.xsd#plx-it" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" xlink:href="plx-20121231.xsd#plx-sapd1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPolicies" xlink:href="plx-20121231.xsd#plx-sap" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesPolicy" xlink:href="plx-20121231.xsd#plx-sapp1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesTables" xlink:href="plx-20121231.xsd#plx-sapt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapitalNarrativeDetails" xlink:href="plx-20121231.xsd#plx-scnd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SubsequentEvents" xlink:href="plx-20121231.xsd#plx-se" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SubsequentEventsDetails" xlink:href="plx-20121231.xsd#plx-sed" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="plx-20121231.xsd#plx-cbsp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/LicenseAndSupplyAgreement" xlink:href="plx-20121231.xsd#plx-lasa" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/PropertyAndEquipment" xlink:href="plx-20121231.xsd#plx-pae" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/LiabilityForEmployeeRightsUponRetirement" xlink:href="plx-20121231.xsd#plx-lferur" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/Commitments" xlink:href="plx-20121231.xsd#plx-c" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapital" xlink:href="plx-20121231.xsd#plx-sc" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/TaxesOnIncome" xlink:href="plx-20121231.xsd#plx-toi" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformation" xlink:href="plx-20121231.xsd#plx-sfsi" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/RelatedPartyTransactions" xlink:href="plx-20121231.xsd#plx-rpt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/PropertyAndEquipmentTables" xlink:href="plx-20121231.xsd#plx-paet" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapitalTables" xlink:href="plx-20121231.xsd#plx-sct" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationTables" xlink:href="plx-20121231.xsd#plx-sfsit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/RelatedPartyTransactionsTables" xlink:href="plx-20121231.xsd#plx-rptt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/PropertyAndEquipmentDetails" xlink:href="plx-20121231.xsd#plx-paed" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesDetails" xlink:href="plx-20121231.xsd#plx-id" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/LiabilityForEmployeeRightsUponRetirementDetails" xlink:href="plx-20121231.xsd#plx-lferurd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CommitmentsDetails" xlink:href="plx-20121231.xsd#plx-cd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapitalSummaryOfOptionAndRestrictedStockGrantedToEmployeesDetails" xlink:href="plx-20121231.xsd#plx-scsooarsgted" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapitalFairValueAssumptionsOfOptionsGrantedDetails" xlink:href="plx-20121231.xsd#plx-scfvaoogd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapitalOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails" xlink:href="plx-20121231.xsd#plx-scogtcdaospd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapitalSummaryOfOutstandingAndRestrictedStocksDetails" xlink:href="plx-20121231.xsd#plx-scsooarsd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapitalShareBasedCompensationExpenseAllocationDetails" xlink:href="plx-20121231.xsd#plx-scsbcead" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/TaxesOnIncomeTables" xlink:href="plx-20121231.xsd#plx-toit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/TaxesOnIncomeNarrativeDetails" xlink:href="plx-20121231.xsd#plx-toind" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/TaxesOnIncomeDeferredIncomeTaxesDetails" xlink:href="plx-20121231.xsd#plx-toiditd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/TaxesOnIncomeOpenTaxYearsDetails" xlink:href="plx-20121231.xsd#plx-toiotyd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationAccountsReceivableOtherDetails" xlink:href="plx-20121231.xsd#plx-sfsiarod" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/RelatedPartyTransactionsDetails" xlink:href="plx-20121231.xsd#plx-rptd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" xlink:href="plx-20121231.xsd#plx-sapulopaed" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/LicenseAndSupplyAgreementDetails" xlink:href="plx-20121231.xsd#plx-lasad" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" xlink:href="plx-20121231.xsd#plx-sfsiapaaod" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapitalOptionsGrantedToEmployeesDetails" xlink:href="plx-20121231.xsd#plx-scogted" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapitalRestrictedStockGrantedToEmployeesDetails" xlink:href="plx-20121231.xsd#plx-scrsgted" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationRevenuesDetails" xlink:href="plx-20121231.xsd#plx-sfsird" xlink:type="simple" />
  <link:calculationLink xlink:title="002 - Statement - CONSOLIDATED BALANCE SHEETS" xlink:role="http://www.protalix.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:label="loc_AssetsCurrent.5874.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6556.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.5874.14.6" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue.6556.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_AccountsReceivableNetCurrent.5451.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.5874.14.6" xlink:to="loc_AccountsReceivableNetCurrent.5451.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherReceivablesNetCurrent.13172.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.5874.14.6" xlink:to="loc_OtherReceivablesNetCurrent.13172.14.6" order="4.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_InventoryNet.11417.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.5874.14.6" xlink:to="loc_InventoryNet.11417.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_Assets.5880.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Assets.5880.14.6" xlink:to="loc_AssetsCurrent.5874.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.7957.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Assets.5880.14.6" xlink:to="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.7957.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.14697.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Assets.5880.14.6" xlink:to="loc_PropertyPlantAndEquipmentNet.14697.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LiabilitiesCurrent.11668.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" />
    <link:loc xlink:label="loc_AccountsPayableTradeCurrent.5457.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesCurrent.11668.14.6" xlink:to="loc_AccountsPayableTradeCurrent.5457.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_AccountsPayableOtherCurrent.5442.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesCurrent.11668.14.6" xlink:to="loc_AccountsPayableOtherCurrent.5442.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredRevenueCurrent.7671.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesCurrent.11668.14.6" xlink:to="loc_DeferredRevenueCurrent.7671.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LiabilitiesNoncurrent.11699.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" />
    <link:loc xlink:label="loc_DeferredRevenueNoncurrent.7662.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesNoncurrent.11699.14.6" xlink:to="loc_DeferredRevenueNoncurrent.7662.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LongTermDebtNoncurrent.12289.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesNoncurrent.11699.14.6" xlink:to="loc_LongTermDebtNoncurrent.12289.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13885.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesNoncurrent.11699.14.6" xlink:to="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13885.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_Liabilities.11702.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Liabilities.11702.14.6" xlink:to="loc_LiabilitiesNoncurrent.11699.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:calculationArc xlink:from="loc_Liabilities.11702.14.6" xlink:to="loc_LiabilitiesCurrent.11668.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquity.11731.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquity.16667.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesAndStockholdersEquity.11731.14.6" xlink:to="loc_StockholdersEquity.16667.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:calculationArc xlink:from="loc_LiabilitiesAndStockholdersEquity.11731.14.6" xlink:to="loc_Liabilities.11702.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_CommitmentsAndContingencies.6842.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesAndStockholdersEquity.11731.14.6" xlink:to="loc_CommitmentsAndContingencies.6842.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_RetainedEarningsAccumulatedDeficit.15457.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_StockholdersEquity.16667.14.6" xlink:to="loc_RetainedEarningsAccumulatedDeficit.15457.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_AdditionalPaidInCapitalCommonStock.5617.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_StockholdersEquity.16667.14.6" xlink:to="loc_AdditionalPaidInCapitalCommonStock.5617.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_CommonStockValue.6874.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_StockholdersEquity.16667.14.6" xlink:to="loc_CommonStockValue.6874.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:title="008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xlink:role="http://www.protalix.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" />
    <link:loc xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents.8714.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.14.6" xlink:to="loc_EffectOfExchangeRateOnCashAndCashEquivalents.8714.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivities.12731.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.14.6" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities.12731.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.14.6" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivities.12740.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.14.6" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities.12740.14.6" order="4.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment.13779.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.12731.14.6" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment.13779.14.6" order="1.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PaymentsForProceedsFromOtherInvestingActivities.13667.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.12731.14.6" xlink:to="loc_PaymentsForProceedsFromOtherInvestingActivities.13667.14.6" order="4.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.14507.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.12731.14.6" xlink:to="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.14507.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInRestrictedCash.11007.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.12731.14.6" xlink:to="loc_IncreaseDecreaseInRestrictedCash.11007.14.6" order="2.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.68650.14.6" xlink:href="plx-20121231.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.12740.14.6" xlink:to="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.68650.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.14555.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.12740.14.6" xlink:to="loc_ProceedsFromStockOptionsExercised.14555.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensation.16244.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_ShareBasedCompensation.16244.14.6" order="6.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DepreciationAmortizationAndAssetImpairment.68637.14.6" xlink:href="plx-20121231.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_DepreciationAmortizationAndAssetImpairment.68637.14.6" order="7.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitExpense.13882.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_PensionAndOtherPostretirementBenefitExpense.13882.14.6" order="8.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsReceivable.10853.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_IncreaseDecreaseInAccountsReceivable.10853.14.6" order="9.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInInventories.10936.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_IncreaseDecreaseInInventories.10936.14.6" order="10.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.10871.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.10871.14.6" order="11.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossUnrealized.9966.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_ForeignCurrencyTransactionGainLossUnrealized.9966.14.6" order="3.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitContributions.13875.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_PensionAndOtherPostretirementBenefitContributions.13875.14.6" order="4.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInDeferredRevenue.10850.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_IncreaseDecreaseInDeferredRevenue.10850.14.6" order="5.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetIncomeLoss.12771.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_NetIncomeLoss.12771.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_GainLossOnSaleOfPropertyPlantEquipment.10196.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_GainLossOnSaleOfPropertyPlantEquipment.10196.14.6" order="2.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:title="004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" xlink:role="http://www.protalix.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:label="loc_GrossProfit.10358.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" />
    <link:loc xlink:label="loc_Revenues.15575.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_GrossProfit.10358.14.6" xlink:to="loc_Revenues.15575.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherGainsLosses.68648.14.6" xlink:href="plx-20121231.xsd#plx_OtherGainsLosses" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_GrossProfit.10358.14.6" xlink:to="loc_OtherGainsLosses.68648.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_CostOfRevenue.7176.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_GrossProfit.10358.14.6" xlink:to="loc_CostOfRevenue.7176.14.6" order="3.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetIncomeLoss.12771.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:loc xlink:label="loc_OperatingIncomeLoss.13080.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetIncomeLoss.12771.14.6" xlink:to="loc_OperatingIncomeLoss.13080.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossBeforeTax.10004.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetIncomeLoss.12771.14.6" xlink:to="loc_ForeignCurrencyTransactionGainLossBeforeTax.10004.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:calculationArc xlink:from="loc_OperatingIncomeLoss.13080.14.6" xlink:to="loc_GrossProfit.10358.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ResearchDevelopmentAndEngineeringExpenseNet.68652.14.6" xlink:href="plx-20121231.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_OperatingIncomeLoss.13080.14.6" xlink:to="loc_ResearchDevelopmentAndEngineeringExpenseNet.68652.14.6" order="2.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpense.10284.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_OperatingIncomeLoss.13080.14.6" xlink:to="loc_GeneralAndAdministrativeExpense.10284.14.6" order="3.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpense.15293.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_ResearchDevelopmentAndEngineeringExpenseNet.68652.14.6" xlink:to="loc_ResearchAndDevelopmentExpense.15293.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_GrantsAndReimbursementsReceivedOrReceivable.68642.14.6" xlink:href="plx-20121231.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_ResearchDevelopmentAndEngineeringExpenseNet.68652.14.6" xlink:to="loc_GrantsAndReimbursementsReceivedOrReceivable.68642.14.6" order="2.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:title="40301 - Disclosure - PROPERTY AND EQUIPMENT (Details)" xlink:role="http://www.protalix.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.14697.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:loc xlink:label="loc_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment.5600.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_PropertyPlantAndEquipmentNet.14697.14.6" xlink:to="loc_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment.5600.14.6" order="1.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentGross.14698.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_PropertyPlantAndEquipmentNet.14697.14.6" xlink:to="loc_PropertyPlantAndEquipmentGross.14698.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:title="40401 - Disclosure - INVENTORIES (Details)" xlink:role="http://www.protalix.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:label="loc_InventoryNet.11417.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:loc xlink:label="loc_InventoryRawMaterialsNetOfReserves.11392.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_InventoryNet.11417.14.6" xlink:to="loc_InventoryRawMaterialsNetOfReserves.11392.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_InventoryWorkInProcessNetOfReserves.11424.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_InventoryNet.11417.14.6" xlink:to="loc_InventoryWorkInProcessNetOfReserves.11424.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_InventoryFinishedGoodsNetOfReserves.11388.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_InventoryNet.11417.14.6" xlink:to="loc_InventoryFinishedGoodsNetOfReserves.11388.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:title="40802 - Disclosure - TAXES ON INCOME (Deferred Income Taxes) (Details)" xlink:role="http://www.protalix.com/role/TaxesOnIncomeDeferredIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:label="loc_DeferredTaxAssetsNet.7623.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" />
    <link:loc xlink:label="loc_DeferredTaxAssetsValuationAllowance.7732.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_DeferredTaxAssetsNet.7623.14.6" xlink:to="loc_DeferredTaxAssetsValuationAllowance.7732.14.6" order="1.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredTaxAssetsOperatingLossCarryforwards.7678.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_DeferredTaxAssetsNet.7623.14.6" xlink:to="loc_DeferredTaxAssetsOperatingLossCarryforwards.7678.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredTaxAssetsDeferredIncome.7661.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_DeferredTaxAssetsNet.7623.14.6" xlink:to="loc_DeferredTaxAssetsDeferredIncome.7661.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments.7710.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_DeferredTaxAssetsNet.7623.14.6" xlink:to="loc_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments.7710.14.6" order="4.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits.7709.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_DeferredTaxAssetsNet.7623.14.6" xlink:to="loc_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits.7709.14.6" order="5.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredTaxAssetsPropertyPlantAndEquipment.7500.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_DeferredTaxAssetsNet.7623.14.6" xlink:to="loc_DeferredTaxAssetsPropertyPlantAndEquipment.7500.14.6" order="6.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredTaxAssetsInProcessResearchAndDevelopment.7627.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_DeferredTaxAssetsNet.7623.14.6" xlink:to="loc_DeferredTaxAssetsInProcessResearchAndDevelopment.7627.14.6" order="7.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>19
<FILENAME>plx-20121231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings-->
<!--produced on 2013-02-28 @ 11:25 AM-->
<link:linkbase xmlns:plx="http://www.protalix.com/20121231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef roleURI="http://www.protalix.com/role/ConsolidatedBalanceSheets" xlink:href="plx-20121231.xsd#plx-cbs" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="plx-20121231.xsd#plx-csocf" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiency" xlink:href="plx-20121231.xsd#plx-csocisecd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiencyParenthetical" xlink:href="plx-20121231.xsd#plx-csocisecdp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ConsolidatedStatementsOfOperations" xlink:href="plx-20121231.xsd#plx-csoo" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/DocumentAndEntityInformation" xlink:href="plx-20121231.xsd#plx-daei" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/Inventories" xlink:href="plx-20121231.xsd#plx-i" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesTables" xlink:href="plx-20121231.xsd#plx-it" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" xlink:href="plx-20121231.xsd#plx-sapd1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPolicies" xlink:href="plx-20121231.xsd#plx-sap" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesPolicy" xlink:href="plx-20121231.xsd#plx-sapp1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesTables" xlink:href="plx-20121231.xsd#plx-sapt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapitalNarrativeDetails" xlink:href="plx-20121231.xsd#plx-scnd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SubsequentEvents" xlink:href="plx-20121231.xsd#plx-se" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SubsequentEventsDetails" xlink:href="plx-20121231.xsd#plx-sed" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="plx-20121231.xsd#plx-cbsp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/LicenseAndSupplyAgreement" xlink:href="plx-20121231.xsd#plx-lasa" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/PropertyAndEquipment" xlink:href="plx-20121231.xsd#plx-pae" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/LiabilityForEmployeeRightsUponRetirement" xlink:href="plx-20121231.xsd#plx-lferur" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/Commitments" xlink:href="plx-20121231.xsd#plx-c" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapital" xlink:href="plx-20121231.xsd#plx-sc" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/TaxesOnIncome" xlink:href="plx-20121231.xsd#plx-toi" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformation" xlink:href="plx-20121231.xsd#plx-sfsi" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/RelatedPartyTransactions" xlink:href="plx-20121231.xsd#plx-rpt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/PropertyAndEquipmentTables" xlink:href="plx-20121231.xsd#plx-paet" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapitalTables" xlink:href="plx-20121231.xsd#plx-sct" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationTables" xlink:href="plx-20121231.xsd#plx-sfsit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/RelatedPartyTransactionsTables" xlink:href="plx-20121231.xsd#plx-rptt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/PropertyAndEquipmentDetails" xlink:href="plx-20121231.xsd#plx-paed" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesDetails" xlink:href="plx-20121231.xsd#plx-id" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/LiabilityForEmployeeRightsUponRetirementDetails" xlink:href="plx-20121231.xsd#plx-lferurd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CommitmentsDetails" xlink:href="plx-20121231.xsd#plx-cd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapitalSummaryOfOptionAndRestrictedStockGrantedToEmployeesDetails" xlink:href="plx-20121231.xsd#plx-scsooarsgted" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapitalFairValueAssumptionsOfOptionsGrantedDetails" xlink:href="plx-20121231.xsd#plx-scfvaoogd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapitalOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails" xlink:href="plx-20121231.xsd#plx-scogtcdaospd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapitalSummaryOfOutstandingAndRestrictedStocksDetails" xlink:href="plx-20121231.xsd#plx-scsooarsd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapitalShareBasedCompensationExpenseAllocationDetails" xlink:href="plx-20121231.xsd#plx-scsbcead" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/TaxesOnIncomeTables" xlink:href="plx-20121231.xsd#plx-toit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/TaxesOnIncomeNarrativeDetails" xlink:href="plx-20121231.xsd#plx-toind" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/TaxesOnIncomeDeferredIncomeTaxesDetails" xlink:href="plx-20121231.xsd#plx-toiditd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/TaxesOnIncomeOpenTaxYearsDetails" xlink:href="plx-20121231.xsd#plx-toiotyd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationAccountsReceivableOtherDetails" xlink:href="plx-20121231.xsd#plx-sfsiarod" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/RelatedPartyTransactionsDetails" xlink:href="plx-20121231.xsd#plx-rptd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" xlink:href="plx-20121231.xsd#plx-sapulopaed" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/LicenseAndSupplyAgreementDetails" xlink:href="plx-20121231.xsd#plx-lasad" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" xlink:href="plx-20121231.xsd#plx-sfsiapaaod" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapitalOptionsGrantedToEmployeesDetails" xlink:href="plx-20121231.xsd#plx-scogted" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapitalRestrictedStockGrantedToEmployeesDetails" xlink:href="plx-20121231.xsd#plx-scrsgted" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationRevenuesDetails" xlink:href="plx-20121231.xsd#plx-sfsird" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:definitionLink xlink:title="006 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY)" xlink:role="http://www.protalix.com/role/ConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiency" xlink:type="extended">
    <link:loc xlink:label="loc_EquityComponentDomain.1773.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_CommonStockMember.1033.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EquityComponentDomain.1773.7.6" xlink:to="loc_CommonStockMember.1033.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AdditionalPaidInCapitalMember.461.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EquityComponentDomain.1773.7.6" xlink:to="loc_AdditionalPaidInCapitalMember.461.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_RetainedEarningsMember.4458.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EquityComponentDomain.1773.7.6" xlink:to="loc_RetainedEarningsMember.4458.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementTable.4950.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" />
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.4957.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementTable.4950.5.6" xlink:to="loc_StatementEquityComponentsAxis.4957.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementLineItems.4952.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StatementTable.4950.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.9.6" xlink:to="loc_StatementTable.4950.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementLineItems.4952.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueNewIssues.16603.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_StockIssuedDuringPeriodValueNewIssues.16603.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.16628.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesNewIssues.16628.7.6" order="4.50000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueStockOptionsExercised.16599.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_StockIssuedDuringPeriodValueStockOptionsExercised.16599.7.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.7.6" order="7.50000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_NetIncomeLoss.12771.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_NetIncomeLoss.12771.7.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.73695.7.6" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.73695.7.6" order="8.94000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.73697.7.6" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.73697.7.6" order="9.94463" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SharesOutstanding.16423.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_SharesOutstanding.16423.7.6" order="9.94286" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockholdersEquity.16667.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_StockholdersEquity.16667.7.6" order="9.94287" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.5667.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.5667.7.6" order="9.94311" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.4957.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_EquityComponentDomain.1773.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementEquityComponentsAxis.4957.6.6" xlink:to="loc_EquityComponentDomain.1773.6.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.4957.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_EquityComponentDomain.1773.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementEquityComponentsAxis.4957.8.6" xlink:to="loc_EquityComponentDomain.1773.8.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.559.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_StockOptionsAndRestrictedSharesMember.68661.7.6" xlink:href="plx-20121231.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AntidilutiveSecuritiesNameDomain.559.7.6" xlink:to="loc_StockOptionsAndRestrictedSharesMember.68661.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.559.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.6.6" xlink:to="loc_AntidilutiveSecuritiesNameDomain.559.6.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.559.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.8.6" xlink:to="loc_AntidilutiveSecuritiesNameDomain.559.8.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:type="locator" />
    <link:loc xlink:label="loc_ProtalixBioTherapeuticsIncorporationMember.68651.7.6" xlink:href="plx-20121231.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.7.6" xlink:to="loc_ProtalixBioTherapeuticsIncorporationMember.68651.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_PfizerIncorporationMember.68649.7.6" xlink:href="plx-20121231.xsd#plx_PfizerIncorporationMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.7.6" xlink:to="loc_PfizerIncorporationMember.68649.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.6.6" xlink:to="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.6.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.8.6" xlink:to="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.8.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4553.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioTwoMember.68654.7.6" xlink:href="plx-20121231.xsd#plx_ScenarioTwoMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.7.6" xlink:to="loc_ScenarioTwoMember.68654.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScenarioOneMember.68653.7.6" xlink:href="plx-20121231.xsd#plx_ScenarioOneMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.7.6" xlink:to="loc_ScenarioOneMember.68653.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_UponFDAApprovalMember.70109.7.6" xlink:href="plx-20121231.xsd#plx_UponFDAApprovalMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.7.6" xlink:to="loc_UponFDAApprovalMember.70109.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_UponNearTermClinicalDevelopmentMilestonesMember.70110.7.6" xlink:href="plx-20121231.xsd#plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.7.6" xlink:to="loc_UponNearTermClinicalDevelopmentMilestonesMember.70110.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementScenarioAxis.4951.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4553.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementScenarioAxis.4951.6.6" xlink:to="loc_ScenarioUnspecifiedDomain.4553.6.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementScenarioAxis.4951.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4553.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementScenarioAxis.4951.8.6" xlink:to="loc_ScenarioUnspecifiedDomain.4553.8.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.68658.9.6" xlink:href="plx-20121231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesTable.68659.9.6" xlink:href="plx-20121231.xsd#plx_SignificantAccountingPoliciesTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.9.6" xlink:to="loc_SignificantAccountingPoliciesTable.68659.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.68658.7.6" xlink:href="plx-20121231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_NumberOfSubsidiaries.68646.7.6" xlink:href="plx-20121231.xsd#plx_NumberOfSubsidiaries" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.7.6" xlink:to="loc_NumberOfSubsidiaries.68646.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromCollaborators.14370.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.7.6" xlink:to="loc_ProceedsFromCollaborators.14370.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_MilestonePayment.68644.7.6" xlink:href="plx-20121231.xsd#plx_MilestonePayment" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.7.6" xlink:to="loc_MilestonePayment.68644.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborativeArrangementProfitSharePercentage.68635.7.6" xlink:href="plx-20121231.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.7.6" xlink:to="loc_CollaborativeArrangementProfitSharePercentage.68635.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.6878.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.7.6" xlink:to="loc_CommonStockParOrStatedValuePerShare.6878.7.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.5816.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.7.6" xlink:to="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.5816.7.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesTable.68659.5.6" xlink:href="plx-20121231.xsd#plx_SignificantAccountingPoliciesTable" xlink:type="locator" />
    <link:loc xlink:label="loc_StatementScenarioAxis.4951.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesTable.68659.5.6" xlink:to="loc_StatementScenarioAxis.4951.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesTable.68659.5.6" xlink:to="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.5.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesTable.68659.5.6" xlink:to="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.5.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40701 - Disclosure - SHARE CAPITAL (Narrative) (Details)" xlink:role="http://www.protalix.com/role/ShareCapitalNarrativeDetails" xlink:type="extended">
    <link:loc xlink:label="loc_AwardTypeAxis.344.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AwardTypeAxis.344.6.6" xlink:to="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.6.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_AwardTypeAxis.344.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AwardTypeAxis.344.8.6" xlink:to="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.8.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.6.6" xlink:to="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.6.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.8.6" xlink:to="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.8.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" />
    <link:loc xlink:label="loc_AwardTypeAxis.344.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.5.6" xlink:to="loc_AwardTypeAxis.344.5.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.5.6" xlink:to="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.5.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_CommonStockSharesIssued.6875.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_CommonStockSharesIssued.6875.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SaleOfStockPricePerShare.15652.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_SaleOfStockPricePerShare.15652.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.16337.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.16337.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.16333.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.16333.7.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.16378.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.16378.7.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.68656.7.6" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.68656.7.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.68657.7.6" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.68657.7.6" order="9.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.16272.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.16272.7.6" order="10.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.9.6" xlink:to="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.9.6" order="11.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStock.14449.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ProceedsFromIssuanceOfCommonStock.14449.7.6" order="13.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_PaymentsOfStockIssuanceCosts.13770.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_PaymentsOfStockIssuanceCosts.13770.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.68655.7.6" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.68655.7.6" order="12.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.16275.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.16275.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_RestrictedStockMember.4416.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.7.6" xlink:to="loc_RestrictedStockMember.4416.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ExecutiveOfficerMember.1817.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.7.6" xlink:to="loc_ExecutiveOfficerMember.1817.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_EmployeesMember.68641.7.6" xlink:href="plx-20121231.xsd#plx_EmployeesMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.7.6" xlink:to="loc_EmployeesMember.68641.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_OfficersAndCertainEmployeesMember.70821.7.6" xlink:href="plx-20121231.xsd#plx_OfficersAndCertainEmployeesMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.7.6" xlink:to="loc_OfficersAndCertainEmployeesMember.70821.7.6" order="1.25000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_OfficersAndDirectorsInPrivateTransactionMember.72242.7.6" xlink:href="plx-20121231.xsd#plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.7.6" xlink:to="loc_OfficersAndDirectorsInPrivateTransactionMember.72242.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="41101 - Disclosure - SUBSEQUENT EVENTS (Details)" xlink:role="http://www.protalix.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3555.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3556.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_OptionIndexedToIssuersEquityEquityAxis.3555.6.6" xlink:to="loc_OptionIndexedToIssuersEquityTypeDomain.3556.6.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3555.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3556.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_OptionIndexedToIssuersEquityEquityAxis.3555.8.6" xlink:to="loc_OptionIndexedToIssuersEquityTypeDomain.3556.8.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3556.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_EmployeeMember.68640.7.6" xlink:href="plx-20121231.xsd#plx_EmployeeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_OptionIndexedToIssuersEquityTypeDomain.3556.7.6" xlink:to="loc_EmployeeMember.68640.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SubsequentEventTypeDomain.5005.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionExerciseMember.68647.7.6" xlink:href="plx-20121231.xsd#plx_OptionExerciseMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsequentEventTypeDomain.5005.7.6" xlink:to="loc_OptionExerciseMember.68647.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SubsequentEventLineItems.5006.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_SubsequentEventTable.5008.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsequentEventLineItems.5006.9.6" xlink:to="loc_SubsequentEventTable.5008.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_SubsequentEventLineItems.5006.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsequentEventLineItems.5006.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.7.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.14555.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsequentEventLineItems.5006.7.6" xlink:to="loc_ProceedsFromStockOptionsExercised.14555.7.6" order="9.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SubsequentEventTypeAxis.5007.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_SubsequentEventTypeDomain.5005.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsequentEventTypeAxis.5007.6.6" xlink:to="loc_SubsequentEventTypeDomain.5005.6.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_SubsequentEventTypeAxis.5007.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_SubsequentEventTypeDomain.5005.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsequentEventTypeAxis.5007.8.6" xlink:to="loc_SubsequentEventTypeDomain.5005.8.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_SubsequentEventTable.5008.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" />
    <link:loc xlink:label="loc_SubsequentEventTypeAxis.5007.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsequentEventTable.5008.5.6" xlink:to="loc_SubsequentEventTypeAxis.5007.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3555.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsequentEventTable.5008.5.6" xlink:to="loc_OptionIndexedToIssuersEquityEquityAxis.3555.5.6" order="4.25000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xlink:role="http://www.protalix.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:label="loc_StatementLineItems.4952.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.6878.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_CommonStockParOrStatedValuePerShare.6878.7.6" order="1.02000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CommonStockSharesAuthorized.6879.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_CommonStockSharesAuthorized.6879.7.6" order="1.03000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CommonStockSharesIssued.6875.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_CommonStockSharesIssued.6875.7.6" order="1.04000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CommonStockSharesOutstanding.6864.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_CommonStockSharesOutstanding.6864.7.6" order="1.05000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40301 - Disclosure - PROPERTY AND EQUIPMENT (Details)" xlink:role="http://www.protalix.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentTypeDomain.4099.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_LaboratoryEquipmentMember.70112.7.6" xlink:href="plx-20121231.xsd#plx_LaboratoryEquipmentMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PropertyPlantAndEquipmentTypeDomain.4099.7.6" xlink:to="loc_LaboratoryEquipmentMember.70112.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_FurnitureAndComputerEquipmentMember.70134.7.6" xlink:href="plx-20121231.xsd#plx_FurnitureAndComputerEquipmentMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PropertyPlantAndEquipmentTypeDomain.4099.7.6" xlink:to="loc_FurnitureAndComputerEquipmentMember.70134.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_LeaseholdImprovementsMember.2905.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PropertyPlantAndEquipmentTypeDomain.4099.7.6" xlink:to="loc_LeaseholdImprovementsMember.2905.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_EquipmentUnderConstructionMember.70136.7.6" xlink:href="plx-20121231.xsd#plx_EquipmentUnderConstructionMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PropertyPlantAndEquipmentTypeDomain.4099.7.6" xlink:to="loc_EquipmentUnderConstructionMember.70136.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentLineItems.4115.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfPropertyPlantAndEquipmentTable.4693.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PropertyPlantAndEquipmentLineItems.4115.9.6" xlink:to="loc_ScheduleOfPropertyPlantAndEquipmentTable.4693.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentLineItems.4115.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentGross.14698.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PropertyPlantAndEquipmentLineItems.4115.7.6" xlink:to="loc_PropertyPlantAndEquipmentGross.14698.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment.5600.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PropertyPlantAndEquipmentLineItems.4115.7.6" xlink:to="loc_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment.5600.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.14697.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PropertyPlantAndEquipmentLineItems.4115.7.6" xlink:to="loc_PropertyPlantAndEquipmentNet.14697.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_DepreciationAmortizationAndAssetImpairment.68637.7.6" xlink:href="plx-20121231.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PropertyPlantAndEquipmentLineItems.4115.7.6" xlink:to="loc_DepreciationAmortizationAndAssetImpairment.68637.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AssetImpairmentCharges.5835.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PropertyPlantAndEquipmentLineItems.4115.7.6" xlink:to="loc_AssetImpairmentCharges.5835.7.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentByTypeAxis.4117.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentTypeDomain.4099.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PropertyPlantAndEquipmentByTypeAxis.4117.8.6" xlink:to="loc_PropertyPlantAndEquipmentTypeDomain.4099.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentByTypeAxis.4117.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentTypeDomain.4099.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PropertyPlantAndEquipmentByTypeAxis.4117.6.6" xlink:to="loc_PropertyPlantAndEquipmentTypeDomain.4099.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfPropertyPlantAndEquipmentTable.4693.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentByTypeAxis.4117.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfPropertyPlantAndEquipmentTable.4693.5.6" xlink:to="loc_PropertyPlantAndEquipmentByTypeAxis.4117.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40601 - Disclosure - COMMITMENTS (Details)" xlink:role="http://www.protalix.com/role/CommitmentsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_RangeAxis.4187.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4188.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeAxis.4187.8.6" xlink:to="loc_RangeMember.4188.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeAxis.4187.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4188.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeAxis.4187.6.6" xlink:to="loc_RangeMember.4188.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeMember.4188.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:loc xlink:label="loc_MinimumMember.3248.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeMember.4188.7.6" xlink:to="loc_MinimumMember.3248.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_MaximumMember.3241.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeMember.4188.7.6" xlink:to="loc_MaximumMember.3241.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CommitmentsAndContingenciesTable.70468.5.6" xlink:href="plx-20121231.xsd#plx_CommitmentsAndContingenciesTable" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeAxis.4187.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesTable.70468.5.6" xlink:to="loc_RangeAxis.4187.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_CommitmentsAndContingenciesAxis.70469.5.6" xlink:href="plx-20121231.xsd#plx_CommitmentsAndContingenciesAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesTable.70468.5.6" xlink:to="loc_CommitmentsAndContingenciesAxis.70469.5.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_CommitmentsAndContingenciesAxis.70469.8.6" xlink:href="plx-20121231.xsd#plx_CommitmentsAndContingenciesAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_CommitmentsAndContingenciesDomain.70470.8.6" xlink:href="plx-20121231.xsd#plx_CommitmentsAndContingenciesDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesAxis.70469.8.6" xlink:to="loc_CommitmentsAndContingenciesDomain.70470.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_CommitmentsAndContingenciesAxis.70469.6.6" xlink:href="plx-20121231.xsd#plx_CommitmentsAndContingenciesAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_CommitmentsAndContingenciesDomain.70470.6.6" xlink:href="plx-20121231.xsd#plx_CommitmentsAndContingenciesDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesAxis.70469.6.6" xlink:to="loc_CommitmentsAndContingenciesDomain.70470.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_CommitmentsAndContingenciesDomain.70470.7.6" xlink:href="plx-20121231.xsd#plx_CommitmentsAndContingenciesDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_OCSMember.70473.7.6" xlink:href="plx-20121231.xsd#plx_OCSMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesDomain.70470.7.6" xlink:to="loc_OCSMember.70473.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ProductsManufacturedOutsideOfIsraelMember.70475.7.6" xlink:href="plx-20121231.xsd#plx_ProductsManufacturedOutsideOfIsraelMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesDomain.70470.7.6" xlink:to="loc_ProductsManufacturedOutsideOfIsraelMember.70475.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_FundingArrangementsMember.70476.7.6" xlink:href="plx-20121231.xsd#plx_FundingArrangementsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesDomain.70470.7.6" xlink:to="loc_FundingArrangementsMember.70476.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ResearchAndLicenseAgreementsMember.70477.7.6" xlink:href="plx-20121231.xsd#plx_ResearchAndLicenseAgreementsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesDomain.70470.7.6" xlink:to="loc_ResearchAndLicenseAgreementsMember.70477.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ProbableAggregateMilestonePaymentMember.70479.7.6" xlink:href="plx-20121231.xsd#plx_ProbableAggregateMilestonePaymentMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesDomain.70470.7.6" xlink:to="loc_ProbableAggregateMilestonePaymentMember.70479.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_MilestonePaymentsMember.70480.7.6" xlink:href="plx-20121231.xsd#plx_MilestonePaymentsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesDomain.70470.7.6" xlink:to="loc_MilestonePaymentsMember.70480.7.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_VehicleLeaseAndMaintenanceAgreementsMember.70487.7.6" xlink:href="plx-20121231.xsd#plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesDomain.70470.7.6" xlink:to="loc_VehicleLeaseAndMaintenanceAgreementsMember.70487.7.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_LeaseAgreementsMember.2904.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesDomain.70470.7.6" xlink:to="loc_LeaseAgreementsMember.2904.7.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_YissumAgreementMember.73722.7.6" xlink:href="plx-20121231.xsd#plx_YissumAgreementMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesDomain.70470.7.6" xlink:to="loc_YissumAgreementMember.73722.7.6" order="10.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CommitmentsAndContingenciesLineItems.70471.9.6" xlink:href="plx-20121231.xsd#plx_CommitmentsAndContingenciesLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_CommitmentsAndContingenciesTable.70468.9.6" xlink:href="plx-20121231.xsd#plx_CommitmentsAndContingenciesTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.9.6" xlink:to="loc_CommitmentsAndContingenciesTable.70468.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_CommitmentsAndContingenciesLineItems.70471.7.6" xlink:href="plx-20121231.xsd#plx_CommitmentsAndContingenciesLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_RoyaltiesOnSaleOfProducts.70472.7.6" xlink:href="plx-20121231.xsd#plx_RoyaltiesOnSaleOfProducts" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.7.6" xlink:to="loc_RoyaltiesOnSaleOfProducts.70472.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived.70474.7.6" xlink:href="plx-20121231.xsd#plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.7.6" xlink:to="loc_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived.70474.7.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_RoyaltyExpense.15586.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RoyaltyExpense" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.7.6" xlink:to="loc_RoyaltyExpense.15586.7.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AccruedRoyaltiesCurrentAndNoncurrent.5534.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.7.6" xlink:to="loc_AccruedRoyaltiesCurrentAndNoncurrent.5534.7.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CommitmentAmount.70485.7.6" xlink:href="plx-20121231.xsd#plx_CommitmentAmount" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.7.6" xlink:to="loc_CommitmentAmount.70485.7.6" order="9.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_MonthlyRentLeaseExpense.70486.7.6" xlink:href="plx-20121231.xsd#plx_MonthlyRentLeaseExpense" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.7.6" xlink:to="loc_MonthlyRentLeaseExpense.70486.7.6" order="10.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SecurityDeposit.16065.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.7.6" xlink:to="loc_SecurityDeposit.16065.7.6" order="11.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_OperatingLeasesRentExpenseNet.13072.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.7.6" xlink:to="loc_OperatingLeasesRentExpenseNet.13072.7.6" order="12.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_OperatingLeasesFutureMinimumPaymentsDueCurrent.13089.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.7.6" xlink:to="loc_OperatingLeasesFutureMinimumPaymentsDueCurrent.13089.7.6" order="13.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_OperatingLeasesFutureMinimumPaymentsDueInTwoYears.13087.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.7.6" xlink:to="loc_OperatingLeasesFutureMinimumPaymentsDueInTwoYears.13087.7.6" order="14.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_OperatingLeasesFutureMinimumPaymentsDueInThreeYears.13081.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.7.6" xlink:to="loc_OperatingLeasesFutureMinimumPaymentsDueInThreeYears.13081.7.6" order="15.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_OperatingLeasesFutureMinimumPaymentsDueInFourYears.13094.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.7.6" xlink:to="loc_OperatingLeasesFutureMinimumPaymentsDueInFourYears.13094.7.6" order="16.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ConsiderationForLicense.70492.7.6" xlink:href="plx-20121231.xsd#plx_ConsiderationForLicense" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.7.6" xlink:to="loc_ConsiderationForLicense.70492.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AnnualIncreaseToMaintenanceFee.73723.7.6" xlink:href="plx-20121231.xsd#plx_AnnualIncreaseToMaintenanceFee" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.7.6" xlink:to="loc_AnnualIncreaseToMaintenanceFee.73723.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AgreementMaintenanceFee.73724.7.6" xlink:href="plx-20121231.xsd#plx_AgreementMaintenanceFee" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.7.6" xlink:to="loc_AgreementMaintenanceFee.73724.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40702 - Disclosure - SHARE CAPITAL (Summary of Option and Restricted Stock Granted to Employees) (Details)" xlink:role="http://www.protalix.com/role/ShareCapitalSummaryOfOptionAndRestrictedStockGrantedToEmployeesDetails" xlink:type="extended">
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.8.6" xlink:to="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.6.6" xlink:to="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_PlanNameDomain.3870.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_GrantYearTwoThousandTenMember.70805.7.6" xlink:href="plx-20121231.xsd#plx_GrantYearTwoThousandTenMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PlanNameDomain.3870.7.6" xlink:to="loc_GrantYearTwoThousandTenMember.70805.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_GrantYearTwoThousandTenSecondMember.70806.7.6" xlink:href="plx-20121231.xsd#plx_GrantYearTwoThousandTenSecondMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PlanNameDomain.3870.7.6" xlink:to="loc_GrantYearTwoThousandTenSecondMember.70806.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_GrantYearTwoThousandTwelveMember.70807.7.6" xlink:href="plx-20121231.xsd#plx_GrantYearTwoThousandTwelveMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PlanNameDomain.3870.7.6" xlink:to="loc_GrantYearTwoThousandTwelveMember.70807.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_GrantYearTwoThousandTwelveSecondMember.70808.7.6" xlink:href="plx-20121231.xsd#plx_GrantYearTwoThousandTwelveSecondMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PlanNameDomain.3870.7.6" xlink:to="loc_GrantYearTwoThousandTwelveSecondMember.70808.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_PlanNameAxis.3871.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_PlanNameDomain.3870.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PlanNameAxis.3871.8.6" xlink:to="loc_PlanNameDomain.3870.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_PlanNameAxis.3871.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_PlanNameDomain.3870.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PlanNameAxis.3871.6.6" xlink:to="loc_PlanNameDomain.3870.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" />
    <link:loc xlink:label="loc_PlanNameAxis.3871.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.5.6" xlink:to="loc_PlanNameAxis.3871.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.5.6" xlink:to="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.5.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.9.6" xlink:to="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.16275.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.16275.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit.16365.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit.16365.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.16378.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.16378.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.16272.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.16272.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.68655.7.6" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.68655.7.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.68656.7.6" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.68656.7.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_EmployeesMember.68641.7.6" xlink:href="plx-20121231.xsd#plx_EmployeesMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.7.6" xlink:to="loc_EmployeesMember.68641.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40706 - Disclosure - SHARE CAPITAL (Options Granted to Consultants, Directors and Other Service Providers) (Details)" xlink:role="http://www.protalix.com/role/ShareCapitalOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails" xlink:type="extended">
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.8.6" xlink:to="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.6.6" xlink:to="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" />
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.5.6" xlink:to="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.9.6" xlink:to="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16369.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16369.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.16332.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.16332.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16356.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16356.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.16305.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.16305.7.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.16322.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.16322.7.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.16330.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.16330.7.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.14555.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ProceedsFromStockOptionsExercised.14555.7.6" order="9.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember.70543.7.6" xlink:href="plx-20121231.xsd#plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.7.6" xlink:to="loc_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember.70543.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40707 - Disclosure - SHARE CAPITAL (Summary of Outstanding and Restricted Stocks) (Details)" xlink:role="http://www.protalix.com/role/ShareCapitalSummaryOfOutstandingAndRestrictedStocksDetails" xlink:type="extended">
    <link:loc xlink:label="loc_AwardTypeAxis.344.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AwardTypeAxis.344.8.6" xlink:to="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_AwardTypeAxis.344.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AwardTypeAxis.344.6.6" xlink:to="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable.4676.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis.4870.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable.4676.5.6" xlink:to="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis.4870.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_AwardTypeAxis.344.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable.4676.5.6" xlink:to="loc_AwardTypeAxis.344.5.6" order="1.50000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis.4870.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis.4870.8.6" xlink:to="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis.4870.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis.4870.6.6" xlink:to="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems.4871.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable.4676.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems.4871.9.6" xlink:to="loc_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable.4676.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems.4871.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.16364.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems.4871.7.6" xlink:to="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.16364.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.16378.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems.4871.7.6" xlink:to="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.16378.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2.15612.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems.4871.7.6" xlink:to="loc_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2.15612.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.16348.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems.4871.7.6" xlink:to="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.16348.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2.15607.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems.4871.7.6" xlink:to="loc_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2.15607.7.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.15602.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems.4871.7.6" xlink:to="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.15602.7.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ZeroPointZeroZeroOneMember.70524.7.6" xlink:href="plx-20121231.xsd#plx_ZeroPointZeroZeroOneMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.7.6" xlink:to="loc_ZeroPointZeroZeroOneMember.70524.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ZeroPointOneTwoZeroMember.70525.7.6" xlink:href="plx-20121231.xsd#plx_ZeroPointOneTwoZeroMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.7.6" xlink:to="loc_ZeroPointOneTwoZeroMember.70525.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ZeroPointThreeNineNineMember.70527.7.6" xlink:href="plx-20121231.xsd#plx_ZeroPointThreeNineNineMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.7.6" xlink:to="loc_ZeroPointThreeNineNineMember.70527.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ZeroPointNineSevenTwoMember.70530.7.6" xlink:href="plx-20121231.xsd#plx_ZeroPointNineSevenTwoMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.7.6" xlink:to="loc_ZeroPointNineSevenTwoMember.70530.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_TwoPointThreeFiveZeroMember.70532.7.6" xlink:href="plx-20121231.xsd#plx_TwoPointThreeFiveZeroMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.7.6" xlink:to="loc_TwoPointThreeFiveZeroMember.70532.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_TwoPointSixFiveMember.70533.7.6" xlink:href="plx-20121231.xsd#plx_TwoPointSixFiveMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.7.6" xlink:to="loc_TwoPointSixFiveMember.70533.7.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ThreePointZeroTwoZeroMember.70534.7.6" xlink:href="plx-20121231.xsd#plx_ThreePointZeroTwoZeroMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.7.6" xlink:to="loc_ThreePointZeroTwoZeroMember.70534.7.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_FivePointZeroMember.70535.7.6" xlink:href="plx-20121231.xsd#plx_FivePointZeroMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.7.6" xlink:to="loc_FivePointZeroMember.70535.7.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SixPointEightOneZeroMember.70536.7.6" xlink:href="plx-20121231.xsd#plx_SixPointEightOneZeroMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.7.6" xlink:to="loc_SixPointEightOneZeroMember.70536.7.6" order="9.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SixPointNineMember.70537.7.6" xlink:href="plx-20121231.xsd#plx_SixPointNineMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.7.6" xlink:to="loc_SixPointNineMember.70537.7.6" order="10.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SevenPointFiveFiveMember.70538.7.6" xlink:href="plx-20121231.xsd#plx_SevenPointFiveFiveMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.7.6" xlink:to="loc_SevenPointFiveFiveMember.70538.7.6" order="11.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_NinePointSixSixMember.70539.7.6" xlink:href="plx-20121231.xsd#plx_NinePointSixSixMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.7.6" xlink:to="loc_NinePointSixSixMember.70539.7.6" order="12.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_OneSixPointSevenMember.70540.7.6" xlink:href="plx-20121231.xsd#plx_OneSixPointSevenMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.7.6" xlink:to="loc_OneSixPointSevenMember.70540.7.6" order="13.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionsAndRestrictedStockMember.70541.7.6" xlink:href="plx-20121231.xsd#plx_OptionsAndRestrictedStockMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.7.6" xlink:to="loc_OptionsAndRestrictedStockMember.70541.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_RestrictedStockMember.4416.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.7.6" xlink:to="loc_RestrictedStockMember.4416.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40708 - Disclosure - SHARE CAPITAL (Share Based Compensation Expense Allocation) (Details)" xlink:role="http://www.protalix.com/role/ShareCapitalShareBasedCompensationExpenseAllocationDetails" xlink:type="extended">
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1710.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4618.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1710.9.6" xlink:to="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4618.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1710.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_AllocatedShareBasedCompensationExpense.5724.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1710.7.6" xlink:to="loc_AllocatedShareBasedCompensationExpense.5724.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpenseMember.4381.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.7.6" xlink:to="loc_ResearchAndDevelopmentExpenseMember.4381.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpenseMember.2354.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.7.6" xlink:to="loc_GeneralAndAdministrativeExpenseMember.2354.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CostOfSalesMember.1183.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfSalesMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.7.6" xlink:to="loc_CostOfSalesMember.1183.7.6" order="1.50000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis.4617.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis.4617.8.6" xlink:to="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis.4617.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis.4617.6.6" xlink:to="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4618.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis.4617.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4618.5.6" xlink:to="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis.4617.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40801 - Disclosure - TAXES ON INCOME (Narrative) (Details)" xlink:role="http://www.protalix.com/role/TaxesOnIncomeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:label="loc_EntityDomain.99.7.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_SubsidiariesMember.5011.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsidiariesMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EntityDomain.99.7.6" xlink:to="loc_SubsidiariesMember.5011.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_LegalEntityAxis.136.8.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_EntityDomain.99.8.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_LegalEntityAxis.136.8.6" xlink:to="loc_EntityDomain.99.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_LegalEntityAxis.136.6.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_EntityDomain.99.6.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_LegalEntityAxis.136.6.6" xlink:to="loc_EntityDomain.99.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeTaxAuthorityAxis.2525.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_IncomeTaxAuthorityDomain.2535.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxAuthorityAxis.2525.8.6" xlink:to="loc_IncomeTaxAuthorityDomain.2535.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeTaxAuthorityAxis.2525.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_IncomeTaxAuthorityDomain.2535.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxAuthorityAxis.2525.6.6" xlink:to="loc_IncomeTaxAuthorityDomain.2535.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeTaxAuthorityDomain.2535.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_TaxYearThereafterMember.70497.7.6" xlink:href="plx-20121231.xsd#plx_TaxYearThereafterMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxAuthorityDomain.2535.7.6" xlink:to="loc_TaxYearThereafterMember.70497.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_TaxYearTwoThousandNineMember.70496.7.6" xlink:href="plx-20121231.xsd#plx_TaxYearTwoThousandNineMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxAuthorityDomain.2535.7.6" xlink:to="loc_TaxYearTwoThousandNineMember.70496.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_TaxBurdenDistributionLawMember.70504.7.6" xlink:href="plx-20121231.xsd#plx_TaxBurdenDistributionLawMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxAuthorityDomain.2535.7.6" xlink:to="loc_TaxBurdenDistributionLawMember.70504.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_RestrictedAmountMember.70506.7.6" xlink:href="plx-20121231.xsd#plx_RestrictedAmountMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxAuthorityDomain.2535.7.6" xlink:to="loc_RestrictedAmountMember.70506.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeAxis.4187.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4188.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeAxis.4187.8.6" xlink:to="loc_RangeMember.4188.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeAxis.4187.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4188.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeAxis.4187.6.6" xlink:to="loc_RangeMember.4188.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeMember.4188.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:loc xlink:label="loc_MinimumMember.3248.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeMember.4188.7.6" xlink:to="loc_MinimumMember.3248.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_MaximumMember.3241.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeMember.4188.7.6" xlink:to="loc_MaximumMember.3241.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeTaxDisclosureTable.70493.5.6" xlink:href="plx-20121231.xsd#plx_IncomeTaxDisclosureTable" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeAxis.4187.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxDisclosureTable.70493.5.6" xlink:to="loc_RangeAxis.4187.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_LegalEntityAxis.136.5.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxDisclosureTable.70493.5.6" xlink:to="loc_LegalEntityAxis.136.5.6" order="1.50000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeTaxAuthorityAxis.2525.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxDisclosureTable.70493.5.6" xlink:to="loc_IncomeTaxAuthorityAxis.2525.5.6" order="2.75000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeTaxDisclosureLineItems.70495.9.6" xlink:href="plx-20121231.xsd#plx_IncomeTaxDisclosureLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_IncomeTaxDisclosureTable.70493.9.6" xlink:href="plx-20121231.xsd#plx_IncomeTaxDisclosureTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxDisclosureLineItems.70495.9.6" xlink:to="loc_IncomeTaxDisclosureTable.70493.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeTaxDisclosureLineItems.70495.7.6" xlink:href="plx-20121231.xsd#plx_IncomeTaxDisclosureLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate.8745.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxDisclosureLineItems.70495.7.6" xlink:to="loc_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate.8745.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateYearOne.70498.7.6" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxDisclosureLineItems.70495.7.6" xlink:to="loc_EffectiveAdjustedIncomeTaxRateYearOne.70498.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateYearFour.70501.7.6" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxDisclosureLineItems.70495.7.6" xlink:to="loc_EffectiveAdjustedIncomeTaxRateYearFour.70501.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateYearTwo.70499.7.6" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxDisclosureLineItems.70495.7.6" xlink:to="loc_EffectiveAdjustedIncomeTaxRateYearTwo.70499.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateYearThree.70500.7.6" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxDisclosureLineItems.70495.7.6" xlink:to="loc_EffectiveAdjustedIncomeTaxRateYearThree.70500.7.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateYearFive.70502.7.6" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxDisclosureLineItems.70495.7.6" xlink:to="loc_EffectiveAdjustedIncomeTaxRateYearFive.70502.7.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateThereafter.70503.7.6" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxDisclosureLineItems.70495.7.6" xlink:to="loc_EffectiveAdjustedIncomeTaxRateThereafter.70503.7.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_WithholdingTaxRateOnForeignIncome.70505.7.6" xlink:href="plx-20121231.xsd#plx_WithholdingTaxRateOnForeignIncome" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxDisclosureLineItems.70495.7.6" xlink:to="loc_WithholdingTaxRateOnForeignIncome.70505.7.6" order="9.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_OperatingLossCarryforwards.13067.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxDisclosureLineItems.70495.7.6" xlink:to="loc_OperatingLossCarryforwards.13067.7.6" order="10.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal.70507.7.6" xlink:href="plx-20121231.xsd#plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxDisclosureLineItems.70495.7.6" xlink:to="loc_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal.70507.7.6" order="11.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40803 - Disclosure - TAXES ON INCOME (Open Tax Years) (Details)" xlink:role="http://www.protalix.com/role/TaxesOnIncomeOpenTaxYearsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_IncomeTaxContingencyTable.2508.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:type="locator" />
    <link:loc xlink:label="loc_IncomeTaxAuthorityAxis.2525.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxContingencyTable.2508.5.6" xlink:to="loc_IncomeTaxAuthorityAxis.2525.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeAxis.4187.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxContingencyTable.2508.5.6" xlink:to="loc_RangeAxis.4187.5.6" order="1.50000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeTaxAuthorityAxis.2525.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_IncomeTaxAuthorityDomain.2535.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxAuthorityAxis.2525.8.6" xlink:to="loc_IncomeTaxAuthorityDomain.2535.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeTaxAuthorityAxis.2525.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_IncomeTaxAuthorityDomain.2535.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxAuthorityAxis.2525.6.6" xlink:to="loc_IncomeTaxAuthorityDomain.2535.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeTaxContingencyLineItems.2528.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_IncomeTaxContingencyTable.2508.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxContingencyLineItems.2528.9.6" xlink:to="loc_IncomeTaxContingencyTable.2508.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeTaxContingencyLineItems.2528.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_OpenTaxYear.13045.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxContingencyLineItems.2528.7.6" xlink:to="loc_OpenTaxYear.13045.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeTaxAuthorityDomain.2535.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_IL.17552.7.6" xlink:href="http://xbrl.sec.gov/country/2012/country-2012-01-31.xsd#country_IL" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxAuthorityDomain.2535.7.6" xlink:to="loc_IL.17552.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_US.17690.7.6" xlink:href="http://xbrl.sec.gov/country/2012/country-2012-01-31.xsd#country_US" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxAuthorityDomain.2535.7.6" xlink:to="loc_US.17690.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_NL.17619.7.6" xlink:href="http://xbrl.sec.gov/country/2012/country-2012-01-31.xsd#country_NL" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeTaxAuthorityDomain.2535.7.6" xlink:to="loc_NL.17619.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeAxis.4187.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4188.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeAxis.4187.8.6" xlink:to="loc_RangeMember.4188.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeAxis.4187.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4188.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeAxis.4187.6.6" xlink:to="loc_RangeMember.4188.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeMember.4188.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:loc xlink:label="loc_MinimumMember.3248.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeMember.4188.7.6" xlink:to="loc_MinimumMember.3248.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_MaximumMember.3241.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeMember.4188.7.6" xlink:to="loc_MaximumMember.3241.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40901 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Receivable, Other) (Details)" xlink:role="http://www.protalix.com/role/SupplementaryFinancialStatementInformationAccountsReceivableOtherDetails" xlink:type="extended">
    <link:loc xlink:label="loc_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis.392.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ReceivableTypeDomain.4239.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis.392.8.6" xlink:to="loc_ReceivableTypeDomain.4239.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis.392.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ReceivableTypeDomain.4239.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis.392.6.6" xlink:to="loc_ReceivableTypeDomain.4239.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_AccountsNotesAndLoansReceivableLineItems.410.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable.4698.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AccountsNotesAndLoansReceivableLineItems.410.9.6" xlink:to="loc_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable.4698.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_AccountsNotesAndLoansReceivableLineItems.410.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_PrepaidExpenseCurrent.14246.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AccountsNotesAndLoansReceivableLineItems.410.7.6" xlink:to="loc_PrepaidExpenseCurrent.14246.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherReceivablesNetCurrent.13172.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AccountsNotesAndLoansReceivableLineItems.410.7.6" xlink:to="loc_OtherReceivablesNetCurrent.13172.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ReceivableTypeDomain.4239.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_DeferredCostMember.70510.7.6" xlink:href="plx-20121231.xsd#plx_DeferredCostMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ReceivableTypeDomain.4239.7.6" xlink:to="loc_DeferredCostMember.70510.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_InstitutionsMember.70511.7.6" xlink:href="plx-20121231.xsd#plx_InstitutionsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ReceivableTypeDomain.4239.7.6" xlink:to="loc_InstitutionsMember.70511.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StateOfIsraelMember.70512.7.6" xlink:href="plx-20121231.xsd#plx_StateOfIsraelMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ReceivableTypeDomain.4239.7.6" xlink:to="loc_StateOfIsraelMember.70512.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_RestrictedDepositMember.70513.7.6" xlink:href="plx-20121231.xsd#plx_RestrictedDepositMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ReceivableTypeDomain.4239.7.6" xlink:to="loc_RestrictedDepositMember.70513.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SundryMember.70514.7.6" xlink:href="plx-20121231.xsd#plx_SundryMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ReceivableTypeDomain.4239.7.6" xlink:to="loc_SundryMember.70514.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable.4698.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="locator" />
    <link:loc xlink:label="loc_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis.392.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable.4698.5.6" xlink:to="loc_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis.392.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="41001 - Disclosure - RELATED PARTY TRANSACTIONS (Details)" xlink:role="http://www.protalix.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_RelatedPartyTransactionLineItems.4347.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable.4689.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RelatedPartyTransactionLineItems.4347.9.6" xlink:to="loc_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable.4689.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_RelatedPartyTransactionLineItems.4347.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_RelatedPartyTransactionAmountsOfTransaction.15187.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RelatedPartyTransactionLineItems.4347.7.6" xlink:to="loc_RelatedPartyTransactionAmountsOfTransaction.15187.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_RelatedPartyDomain.4349.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ManagementAndConsultingFeesToChairmanOfBoardMember.70521.7.6" xlink:href="plx-20121231.xsd#plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RelatedPartyDomain.4349.7.6" xlink:to="loc_ManagementAndConsultingFeesToChairmanOfBoardMember.70521.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CompensationToTheNon-executiveDirectorsMember.70522.7.6" xlink:href="plx-20121231.xsd#plx_CompensationToTheNon-executiveDirectorsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RelatedPartyDomain.4349.7.6" xlink:to="loc_CompensationToTheNon-executiveDirectorsMember.70522.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_RelatedPartyTransactionsByRelatedPartyAxis.4351.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RelatedPartyDomain.4349.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RelatedPartyTransactionsByRelatedPartyAxis.4351.8.6" xlink:to="loc_RelatedPartyDomain.4349.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_RelatedPartyTransactionsByRelatedPartyAxis.4351.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RelatedPartyDomain.4349.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RelatedPartyTransactionsByRelatedPartyAxis.4351.6.6" xlink:to="loc_RelatedPartyDomain.4349.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable.4689.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" />
    <link:loc xlink:label="loc_RelatedPartyTransactionsByRelatedPartyAxis.4351.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable.4689.5.6" xlink:to="loc_RelatedPartyTransactionsByRelatedPartyAxis.4351.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Useful Lives of Property and Equipment) (Details)" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentTypeDomain.4099.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_LaboratoryEquipmentMember.70112.7.6" xlink:href="plx-20121231.xsd#plx_LaboratoryEquipmentMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PropertyPlantAndEquipmentTypeDomain.4099.7.6" xlink:to="loc_LaboratoryEquipmentMember.70112.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_FurnitureAndFixturesMember.2275.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PropertyPlantAndEquipmentTypeDomain.4099.7.6" xlink:to="loc_FurnitureAndFixturesMember.2275.7.6" order="1.50000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ComputerEquipmentMember.1086.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PropertyPlantAndEquipmentTypeDomain.4099.7.6" xlink:to="loc_ComputerEquipmentMember.1086.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentLineItems.4115.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfPropertyPlantAndEquipmentTable.4693.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PropertyPlantAndEquipmentLineItems.4115.9.6" xlink:to="loc_ScheduleOfPropertyPlantAndEquipmentTable.4693.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentLineItems.4115.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentUsefulLife.14662.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PropertyPlantAndEquipmentLineItems.4115.7.6" xlink:to="loc_PropertyPlantAndEquipmentUsefulLife.14662.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentByTypeAxis.4117.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentTypeDomain.4099.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PropertyPlantAndEquipmentByTypeAxis.4117.8.6" xlink:to="loc_PropertyPlantAndEquipmentTypeDomain.4099.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentByTypeAxis.4117.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentTypeDomain.4099.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PropertyPlantAndEquipmentByTypeAxis.4117.6.6" xlink:to="loc_PropertyPlantAndEquipmentTypeDomain.4099.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeAxis.4187.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4188.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeAxis.4187.8.6" xlink:to="loc_RangeMember.4188.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeAxis.4187.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4188.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeAxis.4187.6.6" xlink:to="loc_RangeMember.4188.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeMember.4188.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:loc xlink:label="loc_MinimumMember.3248.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeMember.4188.7.6" xlink:to="loc_MinimumMember.3248.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_MaximumMember.3241.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeMember.4188.7.6" xlink:to="loc_MaximumMember.3241.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfPropertyPlantAndEquipmentTable.4693.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentByTypeAxis.4117.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfPropertyPlantAndEquipmentTable.4693.5.6" xlink:to="loc_PropertyPlantAndEquipmentByTypeAxis.4117.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeAxis.4187.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfPropertyPlantAndEquipmentTable.4693.5.6" xlink:to="loc_RangeAxis.4187.5.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40201 - Disclosure - LICENSE AND SUPPLY AGREEMENT (Details)" xlink:role="http://www.protalix.com/role/LicenseAndSupplyAgreementDetails" xlink:type="extended">
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:type="locator" />
    <link:loc xlink:label="loc_ProtalixBioTherapeuticsIncorporationMember.68651.7.6" xlink:href="plx-20121231.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.7.6" xlink:to="loc_ProtalixBioTherapeuticsIncorporationMember.68651.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_PfizerIncorporationMember.68649.7.6" xlink:href="plx-20121231.xsd#plx_PfizerIncorporationMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.7.6" xlink:to="loc_PfizerIncorporationMember.68649.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborationOperationMember.70846.7.6" xlink:href="plx-20121231.xsd#plx_CollaborationOperationMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.7.6" xlink:to="loc_CollaborationOperationMember.70846.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.6.6" xlink:to="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.6.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.8.6" xlink:to="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.8.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4553.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioTwoMember.68654.7.6" xlink:href="plx-20121231.xsd#plx_ScenarioTwoMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.7.6" xlink:to="loc_ScenarioTwoMember.68654.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScenarioOneMember.68653.7.6" xlink:href="plx-20121231.xsd#plx_ScenarioOneMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.7.6" xlink:to="loc_ScenarioOneMember.68653.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_UponFDAApprovalMember.70109.7.6" xlink:href="plx-20121231.xsd#plx_UponFDAApprovalMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.7.6" xlink:to="loc_UponFDAApprovalMember.70109.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_UponNearTermClinicalDevelopmentMilestonesMember.70110.7.6" xlink:href="plx-20121231.xsd#plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.7.6" xlink:to="loc_UponNearTermClinicalDevelopmentMilestonesMember.70110.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementScenarioAxis.4951.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4553.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementScenarioAxis.4951.6.6" xlink:to="loc_ScenarioUnspecifiedDomain.4553.6.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementScenarioAxis.4951.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4553.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementScenarioAxis.4951.8.6" xlink:to="loc_ScenarioUnspecifiedDomain.4553.8.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.68658.7.6" xlink:href="plx-20121231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ProceedsFromCollaborators.14370.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.7.6" xlink:to="loc_ProceedsFromCollaborators.14370.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_MilestonePayment.68644.7.6" xlink:href="plx-20121231.xsd#plx_MilestonePayment" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.7.6" xlink:to="loc_MilestonePayment.68644.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborativeArrangementProfitSharePercentage.68635.7.6" xlink:href="plx-20121231.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.7.6" xlink:to="loc_CollaborativeArrangementProfitSharePercentage.68635.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.68658.9.6" xlink:href="plx-20121231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_CollaborativeAndLicenseArrangementTable.70133.9.6" xlink:href="plx-20121231.xsd#plx_CollaborativeAndLicenseArrangementTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.9.6" xlink:to="loc_CollaborativeAndLicenseArrangementTable.70133.9.6" order="5.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_AccruedLiabilitiesCurrentAndNoncurrent.5515.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.7.6" xlink:to="loc_AccruedLiabilitiesCurrentAndNoncurrent.5515.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_RevenueRecognizedOverDesignatedPeriod.73718.7.6" xlink:href="plx-20121231.xsd#plx_RevenueRecognizedOverDesignatedPeriod" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.7.6" xlink:to="loc_RevenueRecognizedOverDesignatedPeriod.73718.7.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_RevenueRecognizedPeriod.73719.7.6" xlink:href="plx-20121231.xsd#plx_RevenueRecognizedPeriod" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.7.6" xlink:to="loc_RevenueRecognizedPeriod.73719.7.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_LiabilitiesAccruedFromLicensingAgreement.74712.7.6" xlink:href="plx-20121231.xsd#plx_LiabilitiesAccruedFromLicensingAgreement" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.7.6" xlink:to="loc_LiabilitiesAccruedFromLicensingAgreement.74712.7.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborativeAndLicenseArrangementTable.70133.5.6" xlink:href="plx-20121231.xsd#plx_CollaborativeAndLicenseArrangementTable" xlink:type="locator" />
    <link:loc xlink:label="loc_StatementScenarioAxis.4951.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeAndLicenseArrangementTable.70133.5.6" xlink:to="loc_StatementScenarioAxis.4951.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeAndLicenseArrangementTable.70133.5.6" xlink:to="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.5.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40902 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals, Other) (Details)" xlink:role="http://www.protalix.com/role/SupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" xlink:type="extended">
    <link:loc xlink:label="loc_AccountsPayableAndAccrualsTable.70515.5.6" xlink:href="plx-20121231.xsd#plx_AccountsPayableAndAccrualsTable" xlink:type="locator" />
    <link:loc xlink:label="loc_AccountsPayableAndAccrualsAxis.70516.5.6" xlink:href="plx-20121231.xsd#plx_AccountsPayableAndAccrualsAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AccountsPayableAndAccrualsTable.70515.5.6" xlink:to="loc_AccountsPayableAndAccrualsAxis.70516.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_AccountsPayableAndAccrualsAxis.70516.8.6" xlink:href="plx-20121231.xsd#plx_AccountsPayableAndAccrualsAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_AccountsPayableAndAccrualsDomain.70517.8.6" xlink:href="plx-20121231.xsd#plx_AccountsPayableAndAccrualsDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AccountsPayableAndAccrualsAxis.70516.8.6" xlink:to="loc_AccountsPayableAndAccrualsDomain.70517.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_AccountsPayableAndAccrualsAxis.70516.6.6" xlink:href="plx-20121231.xsd#plx_AccountsPayableAndAccrualsAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_AccountsPayableAndAccrualsDomain.70517.6.6" xlink:href="plx-20121231.xsd#plx_AccountsPayableAndAccrualsDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AccountsPayableAndAccrualsAxis.70516.6.6" xlink:to="loc_AccountsPayableAndAccrualsDomain.70517.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_AccountsPayableAndAccrualsDomain.70517.7.6" xlink:href="plx-20121231.xsd#plx_AccountsPayableAndAccrualsDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_CollaborationOperationCurrentPortionMember.70518.7.6" xlink:href="plx-20121231.xsd#plx_CollaborationOperationCurrentPortionMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AccountsPayableAndAccrualsDomain.70517.7.6" xlink:to="loc_CollaborationOperationCurrentPortionMember.70518.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_PropertyAndEquipmentSuppliersMember.70519.7.6" xlink:href="plx-20121231.xsd#plx_PropertyAndEquipmentSuppliersMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AccountsPayableAndAccrualsDomain.70517.7.6" xlink:to="loc_PropertyAndEquipmentSuppliersMember.70519.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AccountsPayableAndAccrualsLineItems.70520.9.6" xlink:href="plx-20121231.xsd#plx_AccountsPayableAndAccrualsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_AccountsPayableAndAccrualsTable.70515.9.6" xlink:href="plx-20121231.xsd#plx_AccountsPayableAndAccrualsTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AccountsPayableAndAccrualsLineItems.70520.9.6" xlink:to="loc_AccountsPayableAndAccrualsTable.70515.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_AccountsPayableAndAccrualsLineItems.70520.7.6" xlink:href="plx-20121231.xsd#plx_AccountsPayableAndAccrualsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_EmployeeRelatedLiabilitiesCurrent.8812.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AccountsPayableAndAccrualsLineItems.70520.7.6" xlink:to="loc_EmployeeRelatedLiabilitiesCurrent.8812.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AccruedVacationCurrent.5530.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AccountsPayableAndAccrualsLineItems.70520.7.6" xlink:to="loc_AccruedVacationCurrent.5530.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AccruedLiabilitiesCurrent.5555.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AccountsPayableAndAccrualsLineItems.70520.7.6" xlink:to="loc_AccruedLiabilitiesCurrent.5555.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AccruedRoyaltiesCurrent.5572.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AccountsPayableAndAccrualsLineItems.70520.7.6" xlink:to="loc_AccruedRoyaltiesCurrent.5572.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AccountsPayableOtherCurrent.5442.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AccountsPayableAndAccrualsLineItems.70520.7.6" xlink:to="loc_AccountsPayableOtherCurrent.5442.7.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40704 - Disclosure - SHARE CAPITAL (Options Granted to Employees) (Details)" xlink:role="http://www.protalix.com/role/ShareCapitalOptionsGrantedToEmployeesDetails" xlink:type="extended">
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.8.6" xlink:to="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.6.6" xlink:to="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" />
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.5.6" xlink:to="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.9.6" xlink:to="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16369.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16369.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.16332.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.16332.7.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16356.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16356.7.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.16322.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.16322.7.6" order="11.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.16330.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.16330.7.6" order="12.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.16305.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.16305.7.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.16275.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.16275.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod.16341.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod.16341.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.16298.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.16298.7.6" order="9.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice.16315.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice.16315.7.6" order="10.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.14555.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ProceedsFromStockOptionsExercised.14555.7.6" order="13.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionsAndRestrictedStockGrantedToEmployeesMember.70546.7.6" xlink:href="plx-20121231.xsd#plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.7.6" xlink:to="loc_OptionsAndRestrictedStockGrantedToEmployeesMember.70546.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40705 - Disclosure - SHARE CAPITAL (Restricted Stock Granted to Employees) (Details)" xlink:role="http://www.protalix.com/role/ShareCapitalRestrictedStockGrantedToEmployeesDetails" xlink:type="extended">
    <link:loc xlink:label="loc_AwardTypeAxis.344.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AwardTypeAxis.344.8.6" xlink:to="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_AwardTypeAxis.344.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AwardTypeAxis.344.6.6" xlink:to="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.8.6" xlink:to="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.6.6" xlink:to="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" />
    <link:loc xlink:label="loc_AwardTypeAxis.344.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.5.6" xlink:to="loc_AwardTypeAxis.344.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.5.6" xlink:to="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.5.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.9.6" xlink:to="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.16281.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.16281.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.16300.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.16300.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.16252.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.16252.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable.73892.7.6" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable.73892.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_RestrictedStockMember.4416.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.7.6" xlink:to="loc_RestrictedStockMember.4416.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_EmployeesMember.68641.7.6" xlink:href="plx-20121231.xsd#plx_EmployeesMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.7.6" xlink:to="loc_EmployeesMember.68641.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40903 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Revenues) (Details)" xlink:role="http://www.protalix.com/role/SupplementaryFinancialStatementInformationRevenuesDetails" xlink:type="extended">
    <link:loc xlink:label="loc_SupplementalInformationTable.73896.5.6" xlink:href="plx-20121231.xsd#plx_SupplementalInformationTable" xlink:type="locator" />
    <link:loc xlink:label="loc_SupplementalInformationRevenueAxis.73897.5.6" xlink:href="plx-20121231.xsd#plx_SupplementalInformationRevenueAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SupplementalInformationTable.73896.5.6" xlink:to="loc_SupplementalInformationRevenueAxis.73897.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_SupplementalInformationRevenueAxis.73897.8.6" xlink:href="plx-20121231.xsd#plx_SupplementalInformationRevenueAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_SupplementalInformationRevenueDomain.73898.8.6" xlink:href="plx-20121231.xsd#plx_SupplementalInformationRevenueDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SupplementalInformationRevenueAxis.73897.8.6" xlink:to="loc_SupplementalInformationRevenueDomain.73898.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_SupplementalInformationRevenueAxis.73897.6.6" xlink:href="plx-20121231.xsd#plx_SupplementalInformationRevenueAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_SupplementalInformationRevenueDomain.73898.6.6" xlink:href="plx-20121231.xsd#plx_SupplementalInformationRevenueDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SupplementalInformationRevenueAxis.73897.6.6" xlink:to="loc_SupplementalInformationRevenueDomain.73898.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_SupplementalInformationRevenueDomain.73898.7.6" xlink:href="plx-20121231.xsd#plx_SupplementalInformationRevenueDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember.73899.7.6" xlink:href="plx-20121231.xsd#plx_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SupplementalInformationRevenueDomain.73898.7.6" xlink:to="loc_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember.73899.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_MilestonePaymentsMember.70480.7.6" xlink:href="plx-20121231.xsd#plx_MilestonePaymentsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SupplementalInformationRevenueDomain.73898.7.6" xlink:to="loc_MilestonePaymentsMember.70480.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SalesRevenueGoodsNetMember.4541.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SupplementalInformationRevenueDomain.73898.7.6" xlink:to="loc_SalesRevenueGoodsNetMember.4541.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SupplementalInformationRevenueLineItems.73901.9.6" xlink:href="plx-20121231.xsd#plx_SupplementalInformationRevenueLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_SupplementalInformationTable.73896.9.6" xlink:href="plx-20121231.xsd#plx_SupplementalInformationTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SupplementalInformationRevenueLineItems.73901.9.6" xlink:to="loc_SupplementalInformationTable.73896.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_SupplementalInformationRevenueLineItems.73901.7.6" xlink:href="plx-20121231.xsd#plx_SupplementalInformationRevenueLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_Revenues.15575.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SupplementalInformationRevenueLineItems.73901.7.6" xlink:to="loc_Revenues.15575.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>20
<FILENAME>plx-20121231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings-->
<!--produced on 2013-02-28 @ 11:25 AM-->
<link:linkbase xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-roles-2012-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/changeLabel2012" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-roles-2012-01-31.xsd#changeLabel2012" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/fragmentDocumentation" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-roles-2012-01-31.xsd#fragmentDocumentation" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/fragmentLabel" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-roles-2012-01-31.xsd#fragmentLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/deprecatedLabel" xlink:href="http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd#deprecatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/deprecatedDateLabel" xlink:href="http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd#deprecatedDateLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:label="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.394.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.394.11.7" xlink:to="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.138145.346487" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.138145.346487" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.138145.346487">Accounts payable and accruals:</link:label>
    <link:loc xlink:label="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.394.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.394.11.6" xlink:to="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.364.346486" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.364.346486" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.364.346486">Accounts Payable and Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:label="loc_AccountsPayableOtherCurrent.5442.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableOtherCurrent.5442.11.7" xlink:to="lab_AccountsPayableOtherCurrent.138148.346489" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableOtherCurrent.138148.346489" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableOtherCurrent.138148.346489">Other</link:label>
    <link:loc xlink:label="loc_AccountsPayableOtherCurrent.5442.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableOtherCurrent.5442.11.6" xlink:to="lab_AccountsPayableOtherCurrent.376.346488" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableOtherCurrent.376.346488" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableOtherCurrent.376.346488">Accounts Payable, Other, Current</link:label>
    <link:loc xlink:label="loc_AccountsPayableTradeCurrent.5457.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableTradeCurrent.5457.11.7" xlink:to="lab_AccountsPayableTradeCurrent.138147.346491" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableTradeCurrent.138147.346491" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableTradeCurrent.138147.346491">Trade</link:label>
    <link:loc xlink:label="loc_AccountsPayableTradeCurrent.5457.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableTradeCurrent.5457.11.6" xlink:to="lab_AccountsPayableTradeCurrent.402.346490" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableTradeCurrent.402.346490" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableTradeCurrent.402.346490">Accounts Payable, Trade, Current</link:label>
    <link:loc xlink:label="loc_AccountsReceivableNetCurrent.5451.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsReceivableNetCurrent.5451.11.7" xlink:to="lab_AccountsReceivableNetCurrent.138137.346493" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsReceivableNetCurrent.138137.346493" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccountsReceivableNetCurrent.138137.346493">Accounts receivable- Trade</link:label>
    <link:loc xlink:label="loc_AccountsReceivableNetCurrent.5451.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsReceivableNetCurrent.5451.11.6" xlink:to="lab_AccountsReceivableNetCurrent.390.346492" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsReceivableNetCurrent.390.346492" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsReceivableNetCurrent.390.346492">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:label="loc_Assets.5880.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Assets.5880.11.6" xlink:to="lab_Assets.1134.346496" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Assets.1134.346496" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_Assets.1134.346496">Assets</link:label>
    <link:loc xlink:label="loc_Assets.5880.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Assets.5880.11.9" xlink:to="lab_Assets.138141.346497" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Assets.138141.346497" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_Assets.138141.346497">Total assets</link:label>
    <link:loc xlink:label="loc_AssetsAbstract.595.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsAbstract.595.11.6" xlink:to="lab_AssetsAbstract.1105.346498" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsAbstract.1105.346498" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AssetsAbstract.1105.346498">Assets [Abstract]</link:label>
    <link:loc xlink:label="loc_AssetsAbstract.595.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsAbstract.595.11.7" xlink:to="lab_AssetsAbstract.138133.346499" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsAbstract.138133.346499" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AssetsAbstract.138133.346499">ASSETS</link:label>
    <link:loc xlink:label="loc_AssetsCurrent.5874.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsCurrent.5874.11.6" xlink:to="lab_AssetsCurrent.1123.346500" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsCurrent.1123.346500" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AssetsCurrent.1123.346500">Assets, Current</link:label>
    <link:loc xlink:label="loc_AssetsCurrent.5874.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsCurrent.5874.11.9" xlink:to="lab_AssetsCurrent.138142.346501" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsCurrent.138142.346501" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_AssetsCurrent.138142.346501">Total current assets</link:label>
    <link:loc xlink:label="loc_AssetsCurrentAbstract.592.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsCurrentAbstract.592.11.6" xlink:to="lab_AssetsCurrentAbstract.1099.346502" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsCurrentAbstract.1099.346502" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AssetsCurrentAbstract.1099.346502">Assets, Current [Abstract]</link:label>
    <link:loc xlink:label="loc_AssetsCurrentAbstract.592.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsCurrentAbstract.592.11.7" xlink:to="lab_AssetsCurrentAbstract.138132.346503" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsCurrentAbstract.138132.346503" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AssetsCurrentAbstract.138132.346503">CURRENT ASSETS:</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6556.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsAtCarryingValue.6556.11.7" xlink:to="lab_CashAndCashEquivalentsAtCarryingValue.138135.346505" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsAtCarryingValue.138135.346505" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsAtCarryingValue.138135.346505">Cash and cash equivalents</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6556.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsAtCarryingValue.6556.11.6" xlink:to="lab_CashAndCashEquivalentsAtCarryingValue.2187.346504" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsAtCarryingValue.2187.346504" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsAtCarryingValue.2187.346504">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:label="loc_CommitmentsAndContingencies.6842.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentsAndContingencies.6842.11.7" xlink:to="lab_CommitmentsAndContingencies.138162.346507" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommitmentsAndContingencies.138162.346507" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommitmentsAndContingencies.138162.346507">COMMITMENTS (Note 6)</link:label>
    <link:loc xlink:label="loc_CommitmentsAndContingencies.6842.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentsAndContingencies.6842.11.6" xlink:to="lab_CommitmentsAndContingencies.2677.346506" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommitmentsAndContingencies.2677.346506" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommitmentsAndContingencies.2677.346506">Commitments and Contingencies</link:label>
    <link:loc xlink:label="loc_DeferredRevenueCurrent.7671.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRevenueCurrent.7671.11.7" xlink:to="lab_DeferredRevenueCurrent.138149.346509" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRevenueCurrent.138149.346509" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRevenueCurrent.138149.346509">Deferred revenues</link:label>
    <link:loc xlink:label="loc_DeferredRevenueCurrent.7671.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRevenueCurrent.7671.11.6" xlink:to="lab_DeferredRevenueCurrent.3980.346508" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRevenueCurrent.3980.346508" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRevenueCurrent.3980.346508">Deferred Revenue, Current</link:label>
    <link:loc xlink:label="loc_DeferredRevenueNoncurrent.7662.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRevenueNoncurrent.7662.11.7" xlink:to="lab_DeferredRevenueNoncurrent.138153.346511" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRevenueNoncurrent.138153.346511" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRevenueNoncurrent.138153.346511">Deferred revenues</link:label>
    <link:loc xlink:label="loc_DeferredRevenueNoncurrent.7662.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRevenueNoncurrent.7662.11.6" xlink:to="lab_DeferredRevenueNoncurrent.3963.346510" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRevenueNoncurrent.3963.346510" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRevenueNoncurrent.3963.346510">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:label="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.7957.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.7957.11.7" xlink:to="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.138140.346513" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.138140.346513" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.138140.346513">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</link:label>
    <link:loc xlink:label="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.7957.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.7957.11.6" xlink:to="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.4362.346512" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.4362.346512" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.4362.346512">Defined Benefit Plan, Assets for Plan Benefits, Noncurrent</link:label>
    <link:loc xlink:label="loc_InventoryNet.11417.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryNet.11417.11.7" xlink:to="lab_InventoryNet.138139.346515" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryNet.138139.346515" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryNet.138139.346515">Inventories</link:label>
    <link:loc xlink:label="loc_InventoryNet.11417.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryNet.11417.11.6" xlink:to="lab_InventoryNet.9655.346514" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryNet.9655.346514" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryNet.9655.346514">Inventory, Net</link:label>
    <link:loc xlink:label="loc_Liabilities.11702.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Liabilities.11702.11.6" xlink:to="lab_Liabilities.10148.346516" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Liabilities.10148.346516" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_Liabilities.10148.346516">Liabilities</link:label>
    <link:loc xlink:label="loc_Liabilities.11702.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Liabilities.11702.11.9" xlink:to="lab_Liabilities.138159.346517" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Liabilities.138159.346517" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_Liabilities.138159.346517">Total liabilities</link:label>
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquity.11731.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAndStockholdersEquity.11731.11.6" xlink:to="lab_LiabilitiesAndStockholdersEquity.10196.346518" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAndStockholdersEquity.10196.346518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAndStockholdersEquity.10196.346518">Liabilities and Equity</link:label>
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquity.11731.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAndStockholdersEquity.11731.11.9" xlink:to="lab_LiabilitiesAndStockholdersEquity.138166.346519" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAndStockholdersEquity.138166.346519" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAndStockholdersEquity.138166.346519">Total liabilities net of capital deficiency</link:label>
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract.2940.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.2940.11.6" xlink:to="lab_LiabilitiesAndStockholdersEquityAbstract.10173.346520" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAndStockholdersEquityAbstract.10173.346520" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAndStockholdersEquityAbstract.10173.346520">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract.2940.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.2940.11.7" xlink:to="lab_LiabilitiesAndStockholdersEquityAbstract.138143.346521" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAndStockholdersEquityAbstract.138143.346521" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAndStockholdersEquityAbstract.138143.346521">LIABILITIES AND SHAREHOLDERS' EQUITY (NET OF CAPITAL DEFICIENCY)</link:label>
    <link:loc xlink:label="loc_LiabilitiesCurrent.11668.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesCurrent.11668.11.6" xlink:to="lab_LiabilitiesCurrent.10094.346522" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesCurrent.10094.346522" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesCurrent.10094.346522">Liabilities, Current</link:label>
    <link:loc xlink:label="loc_LiabilitiesCurrent.11668.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesCurrent.11668.11.9" xlink:to="lab_LiabilitiesCurrent.138151.346523" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesCurrent.138151.346523" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesCurrent.138151.346523">Total current liabilities</link:label>
    <link:loc xlink:label="loc_LiabilitiesCurrentAbstract.2935.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesCurrentAbstract.2935.11.6" xlink:to="lab_LiabilitiesCurrentAbstract.10147.346524" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesCurrentAbstract.10147.346524" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesCurrentAbstract.10147.346524">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:label="loc_LiabilitiesCurrentAbstract.2935.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesCurrentAbstract.2935.11.7" xlink:to="lab_LiabilitiesCurrentAbstract.138144.346525" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesCurrentAbstract.138144.346525" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesCurrentAbstract.138144.346525">CURRENT LIABILITIES:</link:label>
    <link:loc xlink:label="loc_LiabilitiesNoncurrent.11699.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesNoncurrent.11699.11.6" xlink:to="lab_LiabilitiesNoncurrent.10143.346526" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesNoncurrent.10143.346526" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesNoncurrent.10143.346526">Liabilities, Noncurrent</link:label>
    <link:loc xlink:label="loc_LiabilitiesNoncurrent.11699.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesNoncurrent.11699.11.9" xlink:to="lab_LiabilitiesNoncurrent.138158.346527" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesNoncurrent.138158.346527" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesNoncurrent.138158.346527">Total long term liabilities</link:label>
    <link:loc xlink:label="loc_LiabilitiesNoncurrentAbstract.2937.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesNoncurrentAbstract.2937.11.6" xlink:to="lab_LiabilitiesNoncurrentAbstract.10151.346528" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesNoncurrentAbstract.10151.346528" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesNoncurrentAbstract.10151.346528">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:label="loc_LiabilitiesNoncurrentAbstract.2937.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesNoncurrentAbstract.2937.11.7" xlink:to="lab_LiabilitiesNoncurrentAbstract.138152.346529" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesNoncurrentAbstract.138152.346529" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesNoncurrentAbstract.138152.346529">LONG TERM LIABILITIES:</link:label>
    <link:loc xlink:label="loc_LongTermDebtNoncurrent.12289.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LongTermDebtNoncurrent.12289.11.6" xlink:to="lab_LongTermDebtNoncurrent.11025.346530" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LongTermDebtNoncurrent.11025.346530" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LongTermDebtNoncurrent.11025.346530">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:label="loc_LongTermDebtNoncurrent.12289.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LongTermDebtNoncurrent.12289.11.7" xlink:to="lab_LongTermDebtNoncurrent.138155.346531" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LongTermDebtNoncurrent.138155.346531" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LongTermDebtNoncurrent.138155.346531">Liability in connection with collaboration operation</link:label>
    <link:loc xlink:label="loc_OtherReceivablesNetCurrent.13172.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherReceivablesNetCurrent.13172.11.6" xlink:to="lab_OtherReceivablesNetCurrent.12515.346532" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherReceivablesNetCurrent.12515.346532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherReceivablesNetCurrent.12515.346532">Other Receivables, Net, Current</link:label>
    <link:loc xlink:label="loc_OtherReceivablesNetCurrent.13172.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherReceivablesNetCurrent.13172.11.7" xlink:to="lab_OtherReceivablesNetCurrent.138138.346533" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherReceivablesNetCurrent.138138.346533" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherReceivablesNetCurrent.138138.346533">Other assets</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13885.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13885.11.6" xlink:to="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13684.346534" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13684.346534" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13684.346534">Pension and Other Postretirement and Postemployment Benefit Plans, Liabilities, Noncurrent</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13885.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13885.11.7" xlink:to="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.138157.346535" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.138157.346535" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.138157.346535">Liability for employee rights upon retirement</link:label>
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.14697.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyPlantAndEquipmentNet.14697.11.7" xlink:to="lab_PropertyPlantAndEquipmentNet.134116.346537" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PropertyPlantAndEquipmentNet.134116.346537" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PropertyPlantAndEquipmentNet.134116.346537">PROPERTY AND EQUIPMENT, NET</link:label>
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.14697.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyPlantAndEquipmentNet.14697.11.6" xlink:to="lab_PropertyPlantAndEquipmentNet.14913.346536" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PropertyPlantAndEquipmentNet.14913.346536" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PropertyPlantAndEquipmentNet.14913.346536">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:label="loc_StatementOfFinancialPositionAbstract.4958.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementOfFinancialPositionAbstract.4958.11.6" xlink:to="lab_StatementOfFinancialPositionAbstract.138129.346538" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementOfFinancialPositionAbstract.138129.346538" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementOfFinancialPositionAbstract.138129.346538">CONSOLIDATED BALANCE SHEETS [Abstract]</link:label>
    <link:loc xlink:label="loc_StockholdersEquity.16667.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquity.16667.11.6" xlink:to="lab_StockholdersEquity.18029.346539" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquity.18029.346539" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquity.18029.346539">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:label="loc_AdditionalPaidInCapitalCommonStock.5617.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdditionalPaidInCapitalCommonStock.5617.11.6" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl.346703" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl.346703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapitalCommonStock_lbl.346703">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:label="loc_AdditionalPaidInCapitalCommonStock.5617.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdditionalPaidInCapitalCommonStock.5617.11.7" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl.346704" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl.346704" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapitalCommonStock_lbl.346704">Additional paid-in capital</link:label>
    <link:loc xlink:label="loc_CommonStockValue.6874.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockValue.6874.11.6" xlink:to="us-gaap_CommonStockValue_lbl.346719" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_CommonStockValue_lbl.346719" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="us-gaap_CommonStockValue_lbl.346719">Common Stock Value</link:label>
    <link:loc xlink:label="loc_CommonStockValue.6874.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockValue.6874.11.7" xlink:to="us-gaap_CommonStockValue_lbl.346720" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_CommonStockValue_lbl.346720" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_CommonStockValue_lbl.346720">Common Stock, $0.001 par value: Authorized - as of December 31, 2011 and 2012, 150,000,000 shares; issued and outstanding - as of December 31, 2011 and 2012, 85,630,157 and 93,489,809 shares, respectively</link:label>
    <link:loc xlink:label="loc_RetainedEarningsAccumulatedDeficit.15457.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RetainedEarningsAccumulatedDeficit.15457.11.6" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl.346770" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl.346770" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl.346770">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:label="loc_RetainedEarningsAccumulatedDeficit.15457.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RetainedEarningsAccumulatedDeficit.15457.11.7" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl.346771" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl.346771" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl.346771">Accumulated deficit</link:label>
    <link:loc xlink:label="loc_StockholdersEquity.16667.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquity.16667.11.9" xlink:to="us-gaap_StockholdersEquity_lbl.346778" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_StockholdersEquity_lbl.346778" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl.346778">Total capital deficiency</link:label>
    <link:loc xlink:label="loc_StockholdersEquityAbstract.4986.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquityAbstract.4986.11.6" xlink:to="us-gaap_StockholdersEquityAbstract_lbl.346779" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract_lbl.346779" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract_lbl.346779">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:label="loc_StockholdersEquityAbstract.4986.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquityAbstract.4986.11.7" xlink:to="us-gaap_StockholdersEquityAbstract_lbl.346780" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract_lbl.346780" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract_lbl.346780">CAPITAL DEFICIENCY:</link:label>
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.11.7" xlink:to="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.139020.346612" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.139020.346612" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.139020.346612">Adjustments required to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.11.6" xlink:to="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.726.346611" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.726.346611" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.726.346611">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6556.11.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsAtCarryingValue.6556.11.10" xlink:to="lab_CashAndCashEquivalentsAtCarryingValue.139058.346613" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsAtCarryingValue.139058.346613" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsAtCarryingValue.139058.346613">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6556.11.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsAtCarryingValue.6556.11.11" xlink:to="lab_CashAndCashEquivalentsAtCarryingValue.139059.346614" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsAtCarryingValue.139059.346614" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsAtCarryingValue.139059.346614">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.11.9" xlink:to="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.139056.346616" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.139056.346616" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.139056.346616">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.11.6" xlink:to="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.2245.346615" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.2245.346615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.2245.346615">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:label="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.893.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.893.11.7" xlink:to="lab_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.139064.346618" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.139064.346618" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.139064.346618">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</link:label>
    <link:loc xlink:label="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.893.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.893.11.6" xlink:to="lab_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.2287.346617" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.2287.346617" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.2287.346617">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:label="loc_CashlessExerciseOfStockOptions.68634.11.6" xlink:href="plx-20121231.xsd#plx_CashlessExerciseOfStockOptions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashlessExerciseOfStockOptions.68634.11.6" xlink:to="lab_CashlessExerciseOfStockOptions.145608.346619" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashlessExerciseOfStockOptions.145608.346619" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CashlessExerciseOfStockOptions.145608.346619">Cashless Exercise Of Stock Options</link:label>
    <link:loc xlink:label="loc_CashlessExerciseOfStockOptions.68634.11.12" xlink:href="plx-20121231.xsd#plx_CashlessExerciseOfStockOptions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashlessExerciseOfStockOptions.68634.11.12" xlink:to="lab_CashlessExerciseOfStockOptions.145610.346621" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashlessExerciseOfStockOptions.145610.346621" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_CashlessExerciseOfStockOptions.145610.346621">Cashless exercise of stock options.</link:label>
    <link:loc xlink:label="loc_CashlessExerciseOfStockOptions.68634.11.7" xlink:href="plx-20121231.xsd#plx_CashlessExerciseOfStockOptions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashlessExerciseOfStockOptions.68634.11.7" xlink:to="lab_CashlessExerciseOfStockOptions.145611.346620" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashlessExerciseOfStockOptions.145611.346620" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashlessExerciseOfStockOptions.145611.346620">Exercise of options granted to employees</link:label>
    <link:loc xlink:label="loc_DepreciationAmortizationAndAssetImpairment.68637.11.6" xlink:href="plx-20121231.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DepreciationAmortizationAndAssetImpairment.68637.11.6" xlink:to="lab_DepreciationAmortizationAndAssetImpairment.139023.346622" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DepreciationAmortizationAndAssetImpairment.139023.346622" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DepreciationAmortizationAndAssetImpairment.139023.346622">Depreciation Amortization And Asset Impairment</link:label>
    <link:loc xlink:label="loc_DepreciationAmortizationAndAssetImpairment.68637.11.12" xlink:href="plx-20121231.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DepreciationAmortizationAndAssetImpairment.68637.11.12" xlink:to="lab_DepreciationAmortizationAndAssetImpairment.139026.346624" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DepreciationAmortizationAndAssetImpairment.139026.346624" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_DepreciationAmortizationAndAssetImpairment.139026.346624">The aggregate expense recognized in the current period that allocates the cost of tangible assets and intangible assets to periods that benefit from use of the assets. Also includes the charge against earnings resulting from the write down of assets from their carrying value to their fair value.</link:label>
    <link:loc xlink:label="loc_DepreciationAmortizationAndAssetImpairment.68637.11.7" xlink:href="plx-20121231.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DepreciationAmortizationAndAssetImpairment.68637.11.7" xlink:to="lab_DepreciationAmortizationAndAssetImpairment.139027.346623" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DepreciationAmortizationAndAssetImpairment.139027.346623" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DepreciationAmortizationAndAssetImpairment.139027.346623">Depreciation and write down of fixed assets</link:label>
    <link:loc xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents.8714.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectOfExchangeRateOnCashAndCashEquivalents.8714.11.7" xlink:to="lab_EffectOfExchangeRateOnCashAndCashEquivalents.139055.346626" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectOfExchangeRateOnCashAndCashEquivalents.139055.346626" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EffectOfExchangeRateOnCashAndCashEquivalents.139055.346626">EFFECT OF EXCHANGE RATE CHANGES ON CASH</link:label>
    <link:loc xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents.8714.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectOfExchangeRateOnCashAndCashEquivalents.8714.11.6" xlink:to="lab_EffectOfExchangeRateOnCashAndCashEquivalents.5445.346625" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectOfExchangeRateOnCashAndCashEquivalents.5445.346625" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EffectOfExchangeRateOnCashAndCashEquivalents.5445.346625">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossUnrealized.9966.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ForeignCurrencyTransactionGainLossUnrealized.9966.11.42" xlink:to="lab_ForeignCurrencyTransactionGainLossUnrealized.139028.346628" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ForeignCurrencyTransactionGainLossUnrealized.139028.346628" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_ForeignCurrencyTransactionGainLossUnrealized.139028.346628">Financial expenses (income), net (mainly exchange differences)</link:label>
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossUnrealized.9966.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ForeignCurrencyTransactionGainLossUnrealized.9966.11.6" xlink:to="lab_ForeignCurrencyTransactionGainLossUnrealized.7370.346627" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ForeignCurrencyTransactionGainLossUnrealized.7370.346627" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ForeignCurrencyTransactionGainLossUnrealized.7370.346627">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:label="loc_GainLossOnSaleOfPropertyPlantEquipment.10196.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GainLossOnSaleOfPropertyPlantEquipment.10196.11.6" xlink:to="lab_GainLossOnSaleOfPropertyPlantEquipment.7730.346629" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GainLossOnSaleOfPropertyPlantEquipment.7730.346629" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GainLossOnSaleOfPropertyPlantEquipment.7730.346629">Gain (Loss) on Sale of Property Plant Equipment</link:label>
    <link:loc xlink:label="loc_GainLossOnSaleOfPropertyPlantEquipment.10196.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GainLossOnSaleOfPropertyPlantEquipment.10196.11.42" xlink:to="lab_GainLossOnSaleOfPropertyPlantEquipment42.168198.346630" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GainLossOnSaleOfPropertyPlantEquipment42.168198.346630" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_GainLossOnSaleOfPropertyPlantEquipment42.168198.346630">Loss on sale of fixed assets</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.10871.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.10871.11.7" xlink:to="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.139038.346632" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.139038.346632" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.139038.346632">Increase (decrease) in accounts payable and accruals (including long term)</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.10871.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.10871.11.6" xlink:to="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.8810.346631" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.8810.346631" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.8810.346631">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsReceivable.10853.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInAccountsReceivable.10853.11.6" xlink:to="lab_IncreaseDecreaseInAccountsReceivable.8785.346633" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInAccountsReceivable.8785.346633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInAccountsReceivable.8785.346633">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsReceivable.10853.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInAccountsReceivable.10853.11.42" xlink:to="lab_IncreaseDecreaseInAccountsReceivable42.139035.346634" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInAccountsReceivable42.139035.346634" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInAccountsReceivable42.139035.346634">Decrease (increase) in accounts receivable and other assets</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInDeferredRevenue.10850.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInDeferredRevenue.10850.11.7" xlink:to="lab_IncreaseDecreaseInDeferredRevenue.139034.346636" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInDeferredRevenue.139034.346636" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInDeferredRevenue.139034.346636">Increase (decrease) in deferred revenues (including non-current portion)</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInDeferredRevenue.10850.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInDeferredRevenue.10850.11.6" xlink:to="lab_IncreaseDecreaseInDeferredRevenue.8782.346635" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInDeferredRevenue.8782.346635" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInDeferredRevenue.8782.346635">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInInventories.10936.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInInventories.10936.11.6" xlink:to="lab_IncreaseDecreaseInInventories.8903.346637" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInInventories.8903.346637" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInInventories.8903.346637">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInInventories.10936.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInInventories.10936.11.42" xlink:to="lab_IncreaseDecreaseInInventories42.139036.346638" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInInventories42.139036.346638" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInInventories42.139036.346638">Decrease (increase) in inventories</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.11.7" xlink:to="lab_IncreaseDecreaseInOperatingCapitalAbstract.139033.346640" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInOperatingCapitalAbstract.139033.346640" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInOperatingCapitalAbstract.139033.346640">Changes in operating assets and liabilities:</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.11.6" xlink:to="lab_IncreaseDecreaseInOperatingCapitalAbstract.8850.346639" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInOperatingCapitalAbstract.8850.346639" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInOperatingCapitalAbstract.8850.346639">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInRestrictedCash.11007.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInRestrictedCash.11007.11.6" xlink:to="lab_IncreaseDecreaseInRestrictedCash.9005" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInRestrictedCash.9005" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInRestrictedCash.9005">Increase (Decrease) in Restricted Cash</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInRestrictedCash.11007.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInRestrictedCash.11007.11.42" xlink:to="lab_IncreaseDecreaseInRestrictedCash.379569" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInRestrictedCash.379569" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInRestrictedCash.379569">Investment in restricted deposit</link:label>
    <link:loc xlink:label="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.68643.11.6" xlink:href="plx-20121231.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.68643.11.6" xlink:to="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139065.346641" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139065.346641" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139065.346641">Increase In Liabilities For Property Plant And Equipment</link:label>
    <link:loc xlink:label="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.68643.11.12" xlink:href="plx-20121231.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.68643.11.12" xlink:to="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139067.346643" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139067.346643" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139067.346643">Increase in liabilities for property, plant and equipment.</link:label>
    <link:loc xlink:label="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.68643.11.7" xlink:href="plx-20121231.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.68643.11.7" xlink:to="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139070.346642" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139070.346642" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139070.346642">Purchase of property and equipment</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivities.12740.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.12740.11.6" xlink:to="lab_NetCashProvidedByUsedInFinancingActivities.11796.346644" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInFinancingActivities.11796.346644" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInFinancingActivities.11796.346644">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivities.12740.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.12740.11.9" xlink:to="lab_NetCashProvidedByUsedInFinancingActivities.139054.346645" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInFinancingActivities.139054.346645" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInFinancingActivities.139054.346645">Net cash provided by financing activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.11.6" xlink:to="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.11763.346646" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.11763.346646" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.11763.346646">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.11.7" xlink:to="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.139046.346647" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.139046.346647" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.139046.346647">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivities.12731.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.12731.11.6" xlink:to="lab_NetCashProvidedByUsedInInvestingActivities.11776.346648" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInInvestingActivities.11776.346648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInInvestingActivities.11776.346648">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivities.12731.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.12731.11.9" xlink:to="lab_NetCashProvidedByUsedInInvestingActivities.139044.346649" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInInvestingActivities.139044.346649" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInInvestingActivities.139044.346649">Net cash used in investing activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.11.6" xlink:to="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.11840.346650" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.11840.346650" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.11840.346650">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.11.7" xlink:to="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.139040.346651" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.139040.346651" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.139040.346651">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivities.12778.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.11.6" xlink:to="lab_NetCashProvidedByUsedInOperatingActivities.11871.346652" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInOperatingActivities.11871.346652" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInOperatingActivities.11871.346652">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivities.12778.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.11.9" xlink:to="lab_NetCashProvidedByUsedInOperatingActivities.139039.346653" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInOperatingActivities.139039.346653" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInOperatingActivities.139039.346653">Net cash provided by (used in) operating activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3386.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3386.11.6" xlink:to="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract.11842.346654" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract.11842.346654" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract.11842.346654">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3386.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3386.11.7" xlink:to="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract7.138996.346655" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract7.138996.346655" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract7.138996.346655">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:loc xlink:label="loc_NetIncomeLoss.12771.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetIncomeLoss.12771.11.6" xlink:to="lab_NetIncomeLoss.11860.346656" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetIncomeLoss.11860.346656" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetIncomeLoss.11860.346656">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:label="loc_NetIncomeLoss.12771.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetIncomeLoss.12771.11.7" xlink:to="lab_NetIncomeLoss.138997.346657" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetIncomeLoss.138997.346657" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetIncomeLoss.138997.346657">Net loss</link:label>
    <link:loc xlink:label="loc_PaymentsForProceedsFromOtherInvestingActivities.13667.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsForProceedsFromOtherInvestingActivities.13667.11.6" xlink:to="lab_PaymentsForProceedsFromOtherInvestingActivities.13356.346658" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsForProceedsFromOtherInvestingActivities.13356.346658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsForProceedsFromOtherInvestingActivities.13356.346658">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:label="loc_PaymentsForProceedsFromOtherInvestingActivities.13667.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsForProceedsFromOtherInvestingActivities.13667.11.42" xlink:to="lab_PaymentsForProceedsFromOtherInvestingActivities.139042.346659" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsForProceedsFromOtherInvestingActivities.139042.346659" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsForProceedsFromOtherInvestingActivities.139042.346659">Amounts funded in respect of employee rights upon retirement, net</link:label>
    <link:loc xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment.13779.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsToAcquirePropertyPlantAndEquipment.13779.11.6" xlink:to="lab_PaymentsToAcquirePropertyPlantAndEquipment.13519.346660" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsToAcquirePropertyPlantAndEquipment.13519.346660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsToAcquirePropertyPlantAndEquipment.13519.346660">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment.13779.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsToAcquirePropertyPlantAndEquipment.13779.11.42" xlink:to="lab_PaymentsToAcquirePropertyPlantAndEquipment42.139041.346661" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsToAcquirePropertyPlantAndEquipment42.139041.346661" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsToAcquirePropertyPlantAndEquipment42.139041.346661">Purchase of property and equipment</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitContributions.13875.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementBenefitContributions.13875.11.6" xlink:to="lab_PensionAndOtherPostretirementBenefitContributions.13663.346662" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementBenefitContributions.13663.346662" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementBenefitContributions.13663.346662">Pension and Other Postretirement Benefit Contributions</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitContributions.13875.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementBenefitContributions.13875.11.42" xlink:to="lab_PensionAndOtherPostretirementBenefitContributions.139032.346663" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementBenefitContributions.139032.346663" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementBenefitContributions.139032.346663">Gain on amounts funded in respect of employee rights upon retirement</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitExpense.13882.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementBenefitExpense.13882.11.6" xlink:to="lab_PensionAndOtherPostretirementBenefitExpense.13676.346664" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementBenefitExpense.13676.346664" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementBenefitExpense.13676.346664">Pension and Other Postretirement Benefit Expense</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitExpense.13882.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementBenefitExpense.13882.11.7" xlink:to="lab_PensionAndOtherPostretirementBenefitExpense.139030.346665" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementBenefitExpense.139030.346665" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementBenefitExpense.139030.346665">Changes in accrued liability for employee rights upon retirement</link:label>
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.68650.11.6" xlink:href="plx-20121231.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.68650.11.6" xlink:to="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139047.346666" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139047.346666" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139047.346666">Proceeds From Issuance Of Common Stock Net Of Expenses</link:label>
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.68650.11.12" xlink:href="plx-20121231.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.68650.11.12" xlink:to="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139048.346668" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139048.346668" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139048.346668">Proceeds from issuance of common stock net of expenses.</link:label>
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.68650.11.7" xlink:href="plx-20121231.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.68650.11.7" xlink:to="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139050.346667" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139050.346667" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139050.346667">Issuance of shares, net of issuance cost</link:label>
    <link:loc xlink:label="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.14507.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.14507.11.7" xlink:to="lab_ProceedsFromSaleOfPropertyPlantAndEquipment.145607.346670" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromSaleOfPropertyPlantAndEquipment.145607.346670" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromSaleOfPropertyPlantAndEquipment.145607.346670">Proceeds from sale of property and equipment</link:label>
    <link:loc xlink:label="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.14507.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.14507.11.6" xlink:to="lab_ProceedsFromSaleOfPropertyPlantAndEquipment.14631.346669" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromSaleOfPropertyPlantAndEquipment.14631.346669" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromSaleOfPropertyPlantAndEquipment.14631.346669">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.14555.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromStockOptionsExercised.14555.11.8" xlink:to="lab_ProceedsFromStockOptionsExercised.139052.346672" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromStockOptionsExercised.139052.346672" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromStockOptionsExercised.139052.346672">Exercise of options</link:label>
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.14555.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromStockOptionsExercised.14555.11.6" xlink:to="lab_ProceedsFromStockOptionsExercised.14691.346671" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromStockOptionsExercised.14691.346671" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromStockOptionsExercised.14691.346671">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensation.16244.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensation.16244.11.6" xlink:to="lab_ShareBasedCompensation.17402.346673" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensation.17402.346673" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensation.17402.346673">Share-based Compensation</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensation.16244.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensation.16244.11.7" xlink:to="lab_ShareBasedCompensation7.138110.346674" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensation7.138110.346674" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensation7.138110.346674">Share based compensation</link:label>
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.4955.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.11.6" xlink:to="lab_StatementOfCashFlowsAbstract.138995.346675" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementOfCashFlowsAbstract.138995.346675" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementOfCashFlowsAbstract.138995.346675">CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]</link:label>
    <link:loc xlink:label="loc_SupplementalOfferingAndStockIssuanceCosts.68662.11.6" xlink:href="plx-20121231.xsd#plx_SupplementalOfferingAndStockIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementalOfferingAndStockIssuanceCosts.68662.11.6" xlink:to="lab_SupplementalOfferingAndStockIssuanceCosts.139071.346676" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementalOfferingAndStockIssuanceCosts.139071.346676" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SupplementalOfferingAndStockIssuanceCosts.139071.346676">Supplemental Offering And Stock Issuance Costs</link:label>
    <link:loc xlink:label="loc_SupplementalOfferingAndStockIssuanceCosts.68662.11.12" xlink:href="plx-20121231.xsd#plx_SupplementalOfferingAndStockIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementalOfferingAndStockIssuanceCosts.68662.11.12" xlink:to="lab_SupplementalOfferingAndStockIssuanceCosts.139073.346678" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementalOfferingAndStockIssuanceCosts.139073.346678" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_SupplementalOfferingAndStockIssuanceCosts.139073.346678">Supplemental offering and stock issuance costs.</link:label>
    <link:loc xlink:label="loc_SupplementalOfferingAndStockIssuanceCosts.68662.11.7" xlink:href="plx-20121231.xsd#plx_SupplementalOfferingAndStockIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementalOfferingAndStockIssuanceCosts.68662.11.7" xlink:to="lab_SupplementalOfferingAndStockIssuanceCosts.139074.346677" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementalOfferingAndStockIssuanceCosts.139074.346677" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SupplementalOfferingAndStockIssuanceCosts.139074.346677">Issuance cost not yet paid</link:label>
    <link:loc xlink:label="loc_AdditionalPaidInCapitalMember.461.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdditionalPaidInCapitalMember.461.11.6" xlink:to="lab_AdditionalPaidInCapitalMember.681.346576" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdditionalPaidInCapitalMember.681.346576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdditionalPaidInCapitalMember.681.346576">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:label="loc_CommonStockMember.1033.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockMember.1033.11.6" xlink:to="lab_CommonStockMember.2694.346579" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockMember.2694.346579" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockMember.2694.346579">Common Stock [Member]</link:label>
    <link:loc xlink:label="loc_EquityComponentDomain.1773.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EquityComponentDomain.1773.11.6" xlink:to="lab_EquityComponentDomain.5824.346580" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EquityComponentDomain.5824.346580" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EquityComponentDomain.5824.346580">Equity Component [Domain]</link:label>
    <link:loc xlink:label="loc_NetIncomeLoss.12771.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetIncomeLoss.12771.11.8" xlink:to="lab_NetIncomeLoss.138697.346581" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetIncomeLoss.138697.346581" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetIncomeLoss.138697.346581">Net Loss</link:label>
    <link:loc xlink:label="loc_RetainedEarningsMember.4458.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RetainedEarningsMember.4458.11.7" xlink:to="lab_RetainedEarningsMember.138685.346583" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RetainedEarningsMember.138685.346583" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_RetainedEarningsMember.138685.346583">Accumulated Deficit [Member]</link:label>
    <link:loc xlink:label="loc_RetainedEarningsMember.4458.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RetainedEarningsMember.4458.11.6" xlink:to="lab_RetainedEarningsMember.16154.346582" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RetainedEarningsMember.16154.346582" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RetainedEarningsMember.16154.346582">Retained Earnings [Member]</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.73695.11.6" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.73695.11.6" xlink:to="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.379542" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.379542" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.379542">Share Based Compensation Restricted Stock Awards Net Of Forfeitures</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.73695.11.12" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.73695.11.12" xlink:to="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.379547" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.379547" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.379547">Amount of recognized equity-based compensation during the period for restricted stock awards.</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.73697.11.6" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.73697.11.6" xlink:to="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.379549" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.379549" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.379549">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.73697.11.7" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.73697.11.7" xlink:to="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.379551" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.379551" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.379551">Share-based compensation related to restricted stock award, net of forfeitures (shares)</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.73697.11.12" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.73697.11.12" xlink:to="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.379550" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.379550" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.379550">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</link:label>
    <link:loc xlink:label="loc_SharesOutstanding.16423.11.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharesOutstanding.16423.11.10" xlink:to="lab_SharesOutstanding.138690.346585" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharesOutstanding.138690.346585" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US" id="lab_SharesOutstanding.138690.346585">Balance, shares</link:label>
    <link:loc xlink:label="loc_SharesOutstanding.16423.11.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharesOutstanding.16423.11.11" xlink:to="lab_SharesOutstanding.138702.346586" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharesOutstanding.138702.346586" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_SharesOutstanding.138702.346586">Balance, shares</link:label>
    <link:loc xlink:label="loc_SharesOutstanding.16423.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharesOutstanding.16423.11.6" xlink:to="lab_SharesOutstanding.17653.346584" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharesOutstanding.17653.346584" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SharesOutstanding.17653.346584">Shares, Outstanding</link:label>
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.4957.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementEquityComponentsAxis.4957.11.6" xlink:to="lab_StatementEquityComponentsAxis.17875.346587" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementEquityComponentsAxis.17875.346587" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementEquityComponentsAxis.17875.346587">Equity Components [Axis]</link:label>
    <link:loc xlink:label="loc_StatementOfStockholdersEquityAbstract.4954.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementOfStockholdersEquityAbstract.4954.11.6" xlink:to="lab_StatementOfStockholdersEquityAbstract.138674.346589" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementOfStockholdersEquityAbstract.138674.346589" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementOfStockholdersEquityAbstract.138674.346589">CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) [Abstract]</link:label>
    <link:loc xlink:label="loc_StatementTable.4950.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementTable.4950.11.6" xlink:to="lab_StatementTable.17867.346590" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementTable.17867.346590" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementTable.17867.346590">Statement [Table]</link:label>
    <link:loc xlink:label="loc_StockholdersEquity.16667.11.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquity.16667.11.10" xlink:to="lab_StockholdersEquity.138688.346591" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquity.138688.346591" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquity.138688.346591">Balance</link:label>
    <link:loc xlink:label="loc_StockholdersEquity.16667.11.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquity.16667.11.11" xlink:to="lab_StockholdersEquity.138700.346592" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquity.138700.346592" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquity.138700.346592">Balance</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.16628.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesNewIssues.16628.11.7" xlink:to="lab_StockIssuedDuringPeriodSharesNewIssues.138692.346596" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesNewIssues.138692.346596" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesNewIssues.138692.346596">Common stock issued for cash (net of issuance costs) (in shares)</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.16628.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesNewIssues.16628.11.6" xlink:to="lab_StockIssuedDuringPeriodSharesNewIssues.17977.346595" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesNewIssues.17977.346595" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesNewIssues.17977.346595">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.11.7" xlink:to="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.138106.346598" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.138106.346598" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.138106.346598">Exercised</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.11.6" xlink:to="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.17984.346597" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.17984.346597" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.17984.346597">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueNewIssues.16603.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueNewIssues.16603.11.7" xlink:to="lab_StockIssuedDuringPeriodValueNewIssues.138694.346602" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueNewIssues.138694.346602" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueNewIssues.138694.346602">Common stock issued for cash (net of issuance costs)</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueNewIssues.16603.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueNewIssues.16603.11.6" xlink:to="lab_StockIssuedDuringPeriodValueNewIssues.17939.346601" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueNewIssues.17939.346601" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueNewIssues.17939.346601">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueStockOptionsExercised.16599.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueStockOptionsExercised.16599.11.7" xlink:to="lab_StockIssuedDuringPeriodValueStockOptionsExercised.381597" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueStockOptionsExercised.381597" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueStockOptionsExercised.381597">Exercise of options granted to employees and non-employees</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueStockOptionsExercised.16599.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueStockOptionsExercised.16599.11.6" xlink:to="lab_StockIssuedDuringPeriodValueStockOptionsExercised.17935.346603" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueStockOptionsExercised.17935.346603" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueStockOptionsExercised.17935.346603">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.73695.11.7" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.73695.11.7" xlink:to="labShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.379548" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="labShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.379548" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="labShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.379548">Share-based compensation related to restricted stock award, net of forfeitures</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.5667.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.5667.11.6" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl.346706" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl.346706" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl.346706">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.5667.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.5667.11.7" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl.346707" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl.346707" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl.346707">Share-based compensation</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5652.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5652.11.6" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.735.346605" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.735.346605" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.735.346605">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5652.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5652.11.7" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts7.138770.346606" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts7.138770.346606" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts7.138770.346606">Common stock issued for cash, issuance costs</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.16252.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.16252.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.17413" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.17413" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.17413">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.16252.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.16252.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.139811" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.139811" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.139811">Restricted stock awards forfeited, share</link:label>
    <link:loc xlink:label="loc_CostOfRevenue.7176.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CostOfRevenue.7176.11.42" xlink:to="lab_CostOfRevenue.138492.346542" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CostOfRevenue.138492.346542" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_CostOfRevenue.138492.346542">COST OF REVENUES</link:label>
    <link:loc xlink:label="loc_CostOfRevenue.7176.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CostOfRevenue.7176.11.6" xlink:to="lab_CostOfRevenue.3224.346541" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CostOfRevenue.3224.346541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CostOfRevenue.3224.346541">Cost of Revenue</link:label>
    <link:loc xlink:label="loc_EarningsPerShareBasicAndDiluted.8698.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerShareBasicAndDiluted.8698.11.7" xlink:to="lab_EarningsPerShareBasicAndDiluted.167675.346546" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerShareBasicAndDiluted.167675.346546" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerShareBasicAndDiluted.167675.346546">NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED:</link:label>
    <link:loc xlink:label="loc_EarningsPerShareBasicAndDiluted.8698.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerShareBasicAndDiluted.8698.11.6" xlink:to="lab_EarningsPerShareBasicAndDiluted.5415.346545" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerShareBasicAndDiluted.5415.346545" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerShareBasicAndDiluted.5415.346545">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossBeforeTax.10004.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ForeignCurrencyTransactionGainLossBeforeTax.10004.11.7" xlink:to="lab_ForeignCurrencyTransactionGainLossBeforeTax.138517.346548" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ForeignCurrencyTransactionGainLossBeforeTax.138517.346548" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ForeignCurrencyTransactionGainLossBeforeTax.138517.346548">FINANCIAL INCOME - NET</link:label>
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossBeforeTax.10004.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ForeignCurrencyTransactionGainLossBeforeTax.10004.11.6" xlink:to="lab_ForeignCurrencyTransactionGainLossBeforeTax.7434.346547" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ForeignCurrencyTransactionGainLossBeforeTax.7434.346547" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ForeignCurrencyTransactionGainLossBeforeTax.7434.346547">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpense.10284.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GeneralAndAdministrativeExpense.10284.11.6" xlink:to="lab_GeneralAndAdministrativeExpense.7870.346549" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GeneralAndAdministrativeExpense.7870.346549" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GeneralAndAdministrativeExpense.7870.346549">General and Administrative Expense</link:label>
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpense.10284.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GeneralAndAdministrativeExpense.10284.11.42" xlink:to="lab_GeneralAndAdministrativeExpense42.138509.346550" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GeneralAndAdministrativeExpense42.138509.346550" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_GeneralAndAdministrativeExpense42.138509.346550">GENERAL AND ADMINISTRATIVE EXPENSES</link:label>
    <link:loc xlink:label="loc_GrantsAndReimbursementsReceivedOrReceivable.68642.11.6" xlink:href="plx-20121231.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrantsAndReimbursementsReceivedOrReceivable.68642.11.6" xlink:to="lab_GrantsAndReimbursementsReceivedOrReceivable.138496.346551" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrantsAndReimbursementsReceivedOrReceivable.138496.346551" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GrantsAndReimbursementsReceivedOrReceivable.138496.346551">Grants And Reimbursements Received Or Receivable</link:label>
    <link:loc xlink:label="loc_GrantsAndReimbursementsReceivedOrReceivable.68642.11.12" xlink:href="plx-20121231.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrantsAndReimbursementsReceivedOrReceivable.68642.11.12" xlink:to="lab_GrantsAndReimbursementsReceivedOrReceivable.138498.346553" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrantsAndReimbursementsReceivedOrReceivable.138498.346553" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_GrantsAndReimbursementsReceivedOrReceivable.138498.346553">Grants and reimbursements received or receivable from governmental institutions and collaboration partners for research and development expenses incurred.</link:label>
    <link:loc xlink:label="loc_GrantsAndReimbursementsReceivedOrReceivable.68642.11.7" xlink:href="plx-20121231.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrantsAndReimbursementsReceivedOrReceivable.68642.11.7" xlink:to="lab_GrantsAndReimbursementsReceivedOrReceivable.138500.346552" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrantsAndReimbursementsReceivedOrReceivable.138500.346552" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_GrantsAndReimbursementsReceivedOrReceivable.138500.346552">Less - grants and reimbursements</link:label>
    <link:loc xlink:label="loc_GrossProfit.10358.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrossProfit.10358.11.9" xlink:to="lab_GrossProfit.138487.346555" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrossProfit.138487.346555" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_GrossProfit.138487.346555">GROSS PROFIT</link:label>
    <link:loc xlink:label="loc_GrossProfit.10358.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrossProfit.10358.11.6" xlink:to="lab_GrossProfit.7981.346554" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrossProfit.7981.346554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GrossProfit.7981.346554">Gross Profit</link:label>
    <link:loc xlink:label="loc_IncomeStatementAbstract.2519.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeStatementAbstract.2519.11.6" xlink:to="lab_IncomeStatementAbstract.138470.346556" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeStatementAbstract.138470.346556" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncomeStatementAbstract.138470.346556">CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</link:label>
    <link:loc xlink:label="loc_NetIncomeLoss.12771.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetIncomeLoss.12771.11.9" xlink:to="lab_NetIncomeLoss.138521.346557" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetIncomeLoss.138521.346557" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetIncomeLoss.138521.346557">NET LOSS FOR THE YEAR</link:label>
    <link:loc xlink:label="loc_OperatingIncomeLoss.13080.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperatingIncomeLoss.13080.11.6" xlink:to="lab_OperatingIncomeLoss.12364.346558" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperatingIncomeLoss.12364.346558" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OperatingIncomeLoss.12364.346558">Operating Income (Loss)</link:label>
    <link:loc xlink:label="loc_OperatingIncomeLoss.13080.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperatingIncomeLoss.13080.11.9" xlink:to="lab_OperatingIncomeLoss.138511.346559" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperatingIncomeLoss.138511.346559" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_OperatingIncomeLoss.138511.346559">OPERATING LOSS</link:label>
    <link:loc xlink:label="loc_OtherGainsLosses.68648.11.6" xlink:href="plx-20121231.xsd#plx_OtherGainsLosses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherGainsLosses.68648.11.6" xlink:to="lab_OtherGainsLosses.138475.346560" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherGainsLosses.138475.346560" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherGainsLosses.138475.346560">Other Gains Losses</link:label>
    <link:loc xlink:label="loc_OtherGainsLosses.68648.11.12" xlink:href="plx-20121231.xsd#plx_OtherGainsLosses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherGainsLosses.68648.11.12" xlink:to="lab_OtherGainsLosses.138482.346562" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherGainsLosses.138482.346562" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_OtherGainsLosses.138482.346562">The Company's share in collaboration agreement.</link:label>
    <link:loc xlink:label="loc_OtherGainsLosses.68648.11.7" xlink:href="plx-20121231.xsd#plx_OtherGainsLosses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherGainsLosses.68648.11.7" xlink:to="lab_OtherGainsLosses.138484.346561" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherGainsLosses.138484.346561" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherGainsLosses.138484.346561">COMPANY'S SHARE IN COLLABORATION AGREEMENT</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpense.15293.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentExpense.15293.11.6" xlink:to="lab_ResearchAndDevelopmentExpense.15873.346563" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentExpense.15873.346563" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentExpense.15873.346563">Research and Development Expense</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpense.15293.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentExpense.15293.11.42" xlink:to="lab_ResearchAndDevelopmentExpense42.140375.346564" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentExpense42.140375.346564" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentExpense42.140375.346564">RESEARCH AND DEVELOPMENT EXPENSES</link:label>
    <link:loc xlink:label="loc_ResearchDevelopmentAndEngineeringExpenseNet.68652.11.6" xlink:href="plx-20121231.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchDevelopmentAndEngineeringExpenseNet.68652.11.6" xlink:to="lab_ResearchDevelopmentAndEngineeringExpenseNet.138504.346565" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchDevelopmentAndEngineeringExpenseNet.138504.346565" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ResearchDevelopmentAndEngineeringExpenseNet.138504.346565">Research Development And Engineering Expense Net</link:label>
    <link:loc xlink:label="loc_ResearchDevelopmentAndEngineeringExpenseNet.68652.11.12" xlink:href="plx-20121231.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchDevelopmentAndEngineeringExpenseNet.68652.11.12" xlink:to="lab_ResearchDevelopmentAndEngineeringExpenseNet.138505.346567" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchDevelopmentAndEngineeringExpenseNet.138505.346567" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ResearchDevelopmentAndEngineeringExpenseNet.138505.346567">Research and development expenses, net.</link:label>
    <link:loc xlink:label="loc_ResearchDevelopmentAndEngineeringExpenseNet.68652.11.45" xlink:href="plx-20121231.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchDevelopmentAndEngineeringExpenseNet.68652.11.45" xlink:to="lab_ResearchDevelopmentAndEngineeringExpenseNet.140370.346566" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchDevelopmentAndEngineeringExpenseNet.140370.346566" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US" id="lab_ResearchDevelopmentAndEngineeringExpenseNet.140370.346566">RESEARCH AND DEVELOPMENT EXPENSES, NET</link:label>
    <link:loc xlink:label="loc_Revenues.15575.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Revenues.15575.11.7" xlink:to="lab_Revenues.134146.346569" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Revenues.134146.346569" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_Revenues.134146.346569">REVENUES (see Note 9(c))</link:label>
    <link:loc xlink:label="loc_Revenues.15575.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Revenues.15575.11.6" xlink:to="lab_Revenues.16307.346568" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Revenues.16307.346568" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_Revenues.16307.346568">Revenues</link:label>
    <link:loc xlink:label="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.17395.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.17395.11.7" xlink:to="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.167681.346575" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.167681.346575" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.167681.346575">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE OF COMMON STOCK, BASIC AND DILUTED:</link:label>
    <link:loc xlink:label="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.17395.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.17395.11.6" xlink:to="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.19243.346574" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.19243.346574" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.19243.346574">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:label="loc_EntityCurrentReportingStatus.184.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityCurrentReportingStatus.184.11.6" xlink:to="dei_EntityCurrentReportingStatus_lbl.346735" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="dei_EntityCurrentReportingStatus_lbl.346735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="dei_EntityCurrentReportingStatus_lbl.346735">Entity Current Reporting Status</link:label>
    <link:loc xlink:label="loc_EntityPublicFloat.186.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityPublicFloat.186.11.6" xlink:to="dei_EntityPublicFloat_lbl.346740" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="dei_EntityPublicFloat_lbl.346740" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="dei_EntityPublicFloat_lbl.346740">Entity Public Float</link:label>
    <link:loc xlink:label="loc_EntityVoluntaryFilers.183.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityVoluntaryFilers.183.11.6" xlink:to="dei_EntityVoluntaryFilers_lbl.346743" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="dei_EntityVoluntaryFilers_lbl.346743" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="dei_EntityVoluntaryFilers_lbl.346743">Entity Voluntary Filers</link:label>
    <link:loc xlink:label="loc_EntityWellKnownSeasonedIssuer.182.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityWellKnownSeasonedIssuer.182.11.6" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl.346745" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl.346745" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="dei_EntityWellKnownSeasonedIssuer_lbl.346745">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:label="loc_AmendmentFlag.144.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AmendmentFlag.144.11.6" xlink:to="lab_AmendmentFlag.8.346679" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AmendmentFlag.8.346679" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AmendmentFlag.8.346679">Amendment Flag</link:label>
    <link:loc xlink:label="loc_CurrentFiscalYearEndDate.155.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CurrentFiscalYearEndDate.155.11.6" xlink:to="lab_CurrentFiscalYearEndDate.20.346680" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CurrentFiscalYearEndDate.20.346680" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CurrentFiscalYearEndDate.20.346680">Current Fiscal Year End Date</link:label>
    <link:loc xlink:label="loc_DocumentAndEntityInformationAbstract.68638.11.6" xlink:href="plx-20121231.xsd#plx_DocumentAndEntityInformationAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentAndEntityInformationAbstract.68638.11.6" xlink:to="lab_DocumentAndEntityInformationAbstract.138116.346681" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentAndEntityInformationAbstract.138116.346681" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentAndEntityInformationAbstract.138116.346681">Document And Entity Information [Abstract]</link:label>
    <link:loc xlink:label="loc_DocumentFiscalPeriodFocus.208.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentFiscalPeriodFocus.208.11.6" xlink:to="lab_DocumentFiscalPeriodFocus.123.346682" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentFiscalPeriodFocus.123.346682" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentFiscalPeriodFocus.123.346682">Document Fiscal Period Focus</link:label>
    <link:loc xlink:label="loc_DocumentFiscalYearFocus.207.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentFiscalYearFocus.207.11.6" xlink:to="lab_DocumentFiscalYearFocus.122.346683" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentFiscalYearFocus.122.346683" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentFiscalYearFocus.122.346683">Document Fiscal Year Focus</link:label>
    <link:loc xlink:label="loc_DocumentPeriodEndDate.161.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentPeriodEndDate.161.11.6" xlink:to="lab_DocumentPeriodEndDate.30.346684" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentPeriodEndDate.30.346684" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentPeriodEndDate.30.346684">Document Period End Date</link:label>
    <link:loc xlink:label="loc_DocumentType.212.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentType" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentType.212.11.6" xlink:to="lab_DocumentType.32.346685" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentType.32.346685" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentType.32.346685">Document Type</link:label>
    <link:loc xlink:label="loc_EntityCentralIndexKey.188.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityCentralIndexKey.188.11.6" xlink:to="lab_EntityCentralIndexKey.101.346686" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityCentralIndexKey.101.346686" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EntityCentralIndexKey.101.346686">Entity Central Index Key</link:label>
    <link:loc xlink:label="loc_EntityCommonStockSharesOutstanding.192.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityCommonStockSharesOutstanding.192.11.6" xlink:to="lab_EntityCommonStockSharesOutstanding.105.346687" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityCommonStockSharesOutstanding.105.346687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EntityCommonStockSharesOutstanding.105.346687">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:label="loc_EntityFilerCategory.185.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityFilerCategory.185.11.6" xlink:to="lab_EntityFilerCategory.98.346688" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityFilerCategory.98.346688" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EntityFilerCategory.98.346688">Entity Filer Category</link:label>
    <link:loc xlink:label="loc_EntityRegistrantName.187.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityRegistrantName.187.11.6" xlink:to="lab_EntityRegistrantName.100.346689" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityRegistrantName.100.346689" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EntityRegistrantName.100.346689">Entity Registrant Name</link:label>
    <link:loc xlink:label="loc_TradingSymbol.177.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_TradingSymbol" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TradingSymbol.177.11.6" xlink:to="lab_TradingSymbol.60.346690" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TradingSymbol.60.346690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_TradingSymbol.60.346690">Trading Symbol</link:label>
    <link:loc xlink:label="loc_InventoryDisclosureAbstract.2789.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryDisclosureAbstract.2789.11.6" xlink:to="lab_InventoryDisclosureAbstract.138059.346396" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryDisclosureAbstract.138059.346396" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryDisclosureAbstract.138059.346396">INVENTORIES [Abstract]</link:label>
    <link:loc xlink:label="loc_InventoryDisclosureTextBlock.11399.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryDisclosureTextBlock.11399.11.6" xlink:to="lab_InventoryDisclosureTextBlock.9626.346468" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryDisclosureTextBlock.9626.346468" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryDisclosureTextBlock.9626.346468">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_InventoryDisclosureTextBlock.11399.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryDisclosureTextBlock.11399.11.7" xlink:to="lab_InventoryDisclosureTextBlock7.138804.346469" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryDisclosureTextBlock7.138804.346469" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryDisclosureTextBlock7.138804.346469">INVENTORIES</link:label>
    <link:loc xlink:label="loc_ScheduleOfInventoryCurrentTableTextBlock.15772.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfInventoryCurrentTableTextBlock.15772.11.6" xlink:to="lab_ScheduleOfInventoryCurrentTableTextBlock.16610.346484" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfInventoryCurrentTableTextBlock.16610.346484" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfInventoryCurrentTableTextBlock.16610.346484">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleOfInventoryCurrentTableTextBlock.15772.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfInventoryCurrentTableTextBlock.15772.11.7" xlink:to="lab_ScheduleOfInventoryCurrentTableTextBlock7.138817.346485" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfInventoryCurrentTableTextBlock7.138817.346485" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfInventoryCurrentTableTextBlock7.138817.346485">Schedule of Inventory</link:label>
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.5816.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.5816.11.6" xlink:to="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.1005.346358" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.1005.346358" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.1005.346358">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.5816.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.5816.11.7" xlink:to="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.138029.346359" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.138029.346359" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.138029.346359">Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive</link:label>
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.11.6" xlink:to="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.1010.346360" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.1010.346360" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.1010.346360">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.559.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AntidilutiveSecuritiesNameDomain.559.11.6" xlink:to="lab_AntidilutiveSecuritiesNameDomain.1007.346361" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AntidilutiveSecuritiesNameDomain.1007.346361" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AntidilutiveSecuritiesNameDomain.1007.346361">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:label="loc_NumberOfSubsidiaries.68646.11.6" xlink:href="plx-20121231.xsd#plx_NumberOfSubsidiaries" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NumberOfSubsidiaries.68646.11.6" xlink:to="lab_NumberOfSubsidiaries.137996.346371" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NumberOfSubsidiaries.137996.346371" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NumberOfSubsidiaries.137996.346371">Number Of Subsidiaries</link:label>
    <link:loc xlink:label="loc_NumberOfSubsidiaries.68646.11.12" xlink:href="plx-20121231.xsd#plx_NumberOfSubsidiaries" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NumberOfSubsidiaries.68646.11.12" xlink:to="lab_NumberOfSubsidiaries.137997.346373" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NumberOfSubsidiaries.137997.346373" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_NumberOfSubsidiaries.137997.346373">Number of subsidiaries.</link:label>
    <link:loc xlink:label="loc_NumberOfSubsidiaries.68646.11.7" xlink:href="plx-20121231.xsd#plx_NumberOfSubsidiaries" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NumberOfSubsidiaries.68646.11.7" xlink:to="lab_NumberOfSubsidiaries.137998.346372" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NumberOfSubsidiaries.137998.346372" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NumberOfSubsidiaries.137998.346372">Number of Subsidiaries</link:label>
    <link:loc xlink:label="loc_SignificantAccountingPoliciesTable.68659.11.6" xlink:href="plx-20121231.xsd#plx_SignificantAccountingPoliciesTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SignificantAccountingPoliciesTable.68659.11.6" xlink:to="lab_SignificantAccountingPoliciesTable.137976.355733" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SignificantAccountingPoliciesTable.137976.355733" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SignificantAccountingPoliciesTable.137976.355733">Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:label="loc_SignificantAccountingPoliciesTable.68659.11.12" xlink:href="plx-20121231.xsd#plx_SignificantAccountingPoliciesTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SignificantAccountingPoliciesTable.68659.11.12" xlink:to="lab_SignificantAccountingPoliciesTable.137977.355734" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SignificantAccountingPoliciesTable.137977.355734" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_SignificantAccountingPoliciesTable.137977.355734">Significant Accounting Policies [Table].</link:label>
    <link:loc xlink:label="loc_StockOptionsAndRestrictedSharesMember.68661.11.6" xlink:href="plx-20121231.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockOptionsAndRestrictedSharesMember.68661.11.6" xlink:to="lab_StockOptionsAndRestrictedSharesMember.168199.346393" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockOptionsAndRestrictedSharesMember.168199.346393" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockOptionsAndRestrictedSharesMember.168199.346393">Stock Options And Restricted Shares [Member]</link:label>
    <link:loc xlink:label="loc_StockOptionsAndRestrictedSharesMember.68661.11.12" xlink:href="plx-20121231.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockOptionsAndRestrictedSharesMember.68661.11.12" xlink:to="lab_StockOptionsAndRestrictedSharesMember.168200.346395" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockOptionsAndRestrictedSharesMember.168200.346395" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_StockOptionsAndRestrictedSharesMember.168200.346395">Stock Options And Restricted Shares [Member].</link:label>
    <link:loc xlink:label="loc_StockOptionsAndRestrictedSharesMember.68661.11.7" xlink:href="plx-20121231.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockOptionsAndRestrictedSharesMember.68661.11.7" xlink:to="lab_StockOptionsAndRestrictedSharesMember.168201.346394" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockOptionsAndRestrictedSharesMember.168201.346394" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockOptionsAndRestrictedSharesMember.168201.346394">Options and Restricted Shares [Member]</link:label>
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.385.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountingPoliciesAbstract.385.11.6" xlink:to="lab_AccountingPoliciesAbstract.137967.346357" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountingPoliciesAbstract.137967.346357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountingPoliciesAbstract.137967.346357">SIGNIFICANT ACCOUNTING POLICIES [Abstract]</link:label>
    <link:loc xlink:label="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6085.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6085.11.7" xlink:to="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.138803.346467" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.138803.346467" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.138803.346467">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:label="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6085.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6085.11.6" xlink:to="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.1457.346466" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.1457.346466" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.1457.346466">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:label="loc_BasisOfAccountingPolicyPolicyTextBlock.6086.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BasisOfAccountingPolicyPolicyTextBlock.6086.11.6" xlink:to="lab_BasisOfAccountingPolicyPolicyTextBlock.1458.346475" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BasisOfAccountingPolicyPolicyTextBlock.1458.346475" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BasisOfAccountingPolicyPolicyTextBlock.1458.346475">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_BasisOfAccountingPolicyPolicyTextBlock.6086.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BasisOfAccountingPolicyPolicyTextBlock.6086.11.7" xlink:to="lab_BasisOfAccountingPolicyPolicyTextBlock7.134441.346476" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BasisOfAccountingPolicyPolicyTextBlock7.134441.346476" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_BasisOfAccountingPolicyPolicyTextBlock7.134441.346476">Basis of presentation</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsPolicyTextBlock.6571.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsPolicyTextBlock.6571.11.6" xlink:to="lab_CashAndCashEquivalentsPolicyTextBlock.2212" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsPolicyTextBlock.2212" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsPolicyTextBlock.2212">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsPolicyTextBlock.6571.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsPolicyTextBlock.6571.11.7" xlink:to="lab_CashAndCashEquivalentsPolicyTextBlock.350535" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsPolicyTextBlock.350535" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsPolicyTextBlock.350535">Cash equivalents</link:label>
    <link:loc xlink:label="loc_ConcentrationRiskCreditRisk.6940.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ConcentrationRiskCreditRisk.6940.11.6" xlink:to="lab_ConcentrationRiskCreditRisk.2862" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ConcentrationRiskCreditRisk.2862" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ConcentrationRiskCreditRisk.2862">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_ConcentrationRiskCreditRisk.6940.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ConcentrationRiskCreditRisk.6940.11.7" xlink:to="lab_ConcentrationRiskCreditRisk.350543" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ConcentrationRiskCreditRisk.350543" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ConcentrationRiskCreditRisk.350543">Concentration of credit risks and trade receivable</link:label>
    <link:loc xlink:label="loc_EarningsPerSharePolicyTextBlock.8704.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerSharePolicyTextBlock.8704.11.7" xlink:to="lab_EarningsPerSharePolicyTextBlock.138811.346478" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerSharePolicyTextBlock.138811.346478" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerSharePolicyTextBlock.138811.346478">Net Loss per share</link:label>
    <link:loc xlink:label="loc_EarningsPerSharePolicyTextBlock.8704.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerSharePolicyTextBlock.8704.11.6" xlink:to="lab_EarningsPerSharePolicyTextBlock.5427.346477" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerSharePolicyTextBlock.5427.346477" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerSharePolicyTextBlock.5427.346477">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock.10010.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock.10010.11.6" xlink:to="lab_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock.7448" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock.7448" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock.7448">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock.10010.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock.10010.11.7" xlink:to="lab_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock.350534" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock.350534" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock.350534">Functional currency</link:label>
    <link:loc xlink:label="loc_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock.10588.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock.10588.11.6" xlink:to="lab_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock.8351" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock.8351" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock.8351">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock.10588.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock.10588.11.7" xlink:to="lab_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock.350538" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock.350538" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock.350538">Impairment in value of long-lived assets</link:label>
    <link:loc xlink:label="loc_IncomeTaxPolicyTextBlock.10751.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeTaxPolicyTextBlock.10751.11.6" xlink:to="lab_IncomeTaxPolicyTextBlock.8637" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeTaxPolicyTextBlock.8637" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncomeTaxPolicyTextBlock.8637">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_IncomeTaxPolicyTextBlock.10751.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeTaxPolicyTextBlock.10751.11.7" xlink:to="lab_IncomeTaxPolicyTextBlock.350539" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeTaxPolicyTextBlock.350539" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncomeTaxPolicyTextBlock.350539">Income taxes</link:label>
    <link:loc xlink:label="loc_InventoryPolicyTextBlock.11360.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryPolicyTextBlock.11360.11.6" xlink:to="lab_InventoryPolicyTextBlock.9568" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryPolicyTextBlock.9568" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryPolicyTextBlock.9568">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_InventoryPolicyTextBlock.11360.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryPolicyTextBlock.11360.11.7" xlink:to="lab_InventoryPolicyTextBlock.350536" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryPolicyTextBlock.350536" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryPolicyTextBlock.350536">Inventories</link:label>
    <link:loc xlink:label="loc_NatureOfOperationsPolicyTextBlock.68645.11.12" xlink:href="plx-20121231.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NatureOfOperationsPolicyTextBlock.68645.11.12" xlink:to="lab_NatureOfOperationsPolicyTextBlock.381577" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NatureOfOperationsPolicyTextBlock.381577" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_NatureOfOperationsPolicyTextBlock.381577">Nature Of Operations Policy</link:label>
    <link:loc xlink:label="loc_NatureOfOperationsPolicyTextBlock.68645.11.6" xlink:href="plx-20121231.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NatureOfOperationsPolicyTextBlock.68645.11.6" xlink:to="lab_NatureOfOperationsPolicyTextBlock.138808.346479" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NatureOfOperationsPolicyTextBlock.138808.346479" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NatureOfOperationsPolicyTextBlock.138808.346479">Nature Of Operations [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_NatureOfOperationsPolicyTextBlock.68645.11.7" xlink:href="plx-20121231.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NatureOfOperationsPolicyTextBlock.68645.11.7" xlink:to="lab_NatureOfOperationsPolicyTextBlock.138810.346480" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NatureOfOperationsPolicyTextBlock.138810.346480" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NatureOfOperationsPolicyTextBlock.138810.346480">General</link:label>
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentPolicyTextBlock.14695.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyPlantAndEquipmentPolicyTextBlock.14695.11.6" xlink:to="lab_PropertyPlantAndEquipmentPolicyTextBlock.14908" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PropertyPlantAndEquipmentPolicyTextBlock.14908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PropertyPlantAndEquipmentPolicyTextBlock.14908">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentPolicyTextBlock.14695.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyPlantAndEquipmentPolicyTextBlock.14695.11.7" xlink:to="lab_PropertyPlantAndEquipmentPolicyTextBlock.350537" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PropertyPlantAndEquipmentPolicyTextBlock.350537" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PropertyPlantAndEquipmentPolicyTextBlock.350537">Property and equipment</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpensePolicy.15306.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentExpensePolicy.15306.11.6" xlink:to="lab_ResearchAndDevelopmentExpensePolicy.15898" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentExpensePolicy.15898" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentExpensePolicy.15898">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpensePolicy.15306.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentExpensePolicy.15306.11.7" xlink:to="lab_ResearchAndDevelopmentExpensePolicy.350541" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentExpensePolicy.350541" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentExpensePolicy.350541">Research and development costs</link:label>
    <link:loc xlink:label="loc_RevenueRecognitionPolicyTextBlock.15515.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RevenueRecognitionPolicyTextBlock.15515.11.6" xlink:to="lab_RevenueRecognitionPolicyTextBlock.16231" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RevenueRecognitionPolicyTextBlock.16231" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RevenueRecognitionPolicyTextBlock.16231">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_RevenueRecognitionPolicyTextBlock.15515.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RevenueRecognitionPolicyTextBlock.15515.11.7" xlink:to="lab_RevenueRecognitionPolicyTextBlock.350540" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RevenueRecognitionPolicyTextBlock.350540" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_RevenueRecognitionPolicyTextBlock.350540">Revenue Recognition</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationOptionAndIncentivePlansPolicy.16373.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationOptionAndIncentivePlansPolicy.16373.11.6" xlink:to="lab_ShareBasedCompensationOptionAndIncentivePlansPolicy.17588" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationOptionAndIncentivePlansPolicy.17588" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationOptionAndIncentivePlansPolicy.17588">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationOptionAndIncentivePlansPolicy.16373.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationOptionAndIncentivePlansPolicy.16373.11.7" xlink:to="lab_ShareBasedCompensationOptionAndIncentivePlansPolicy.350544" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationOptionAndIncentivePlansPolicy.350544" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationOptionAndIncentivePlansPolicy.350544">Share-based compensation</link:label>
    <link:loc xlink:label="loc_UseOfEstimates.17234.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" />
    <link:labelArc xlink:from="loc_UseOfEstimates.17234.11.6" xlink:to="lab_UseOfEstimates.18953" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_UseOfEstimates.18953" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_UseOfEstimates.18953">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_UseOfEstimates.17234.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" />
    <link:labelArc xlink:from="loc_UseOfEstimates.17234.11.7" xlink:to="lab_UseOfEstimates.350533" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_UseOfEstimates.350533" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_UseOfEstimates.350533">Use of estimates in the preparation of financial statements</link:label>
    <link:loc xlink:label="loc_ScheduleOfUsefulLifeTableTextBlock.70058.11.6" xlink:href="plx-20121231.xsd#plx_ScheduleOfUsefulLifeTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfUsefulLifeTableTextBlock.70058.11.6" xlink:to="lab_ScheduleOfUsefulLifeTableTextBlock.355226" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfUsefulLifeTableTextBlock.355226" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfUsefulLifeTableTextBlock.355226">Schedule Of Useful Life [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleOfUsefulLifeTableTextBlock.70058.11.7" xlink:href="plx-20121231.xsd#plx_ScheduleOfUsefulLifeTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfUsefulLifeTableTextBlock.70058.11.7" xlink:to="lab_ScheduleOfUsefulLifeTableTextBlock.355230" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfUsefulLifeTableTextBlock.355230" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfUsefulLifeTableTextBlock.355230">Schedule of Useful Life</link:label>
    <link:loc xlink:label="loc_ScheduleOfUsefulLifeTableTextBlock.70058.11.12" xlink:href="plx-20121231.xsd#plx_ScheduleOfUsefulLifeTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfUsefulLifeTableTextBlock.70058.11.12" xlink:to="lab_ScheduleOfUsefulLifeTableTextBlock.355228" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfUsefulLifeTableTextBlock.355228" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfUsefulLifeTableTextBlock.355228">Schedule Of Useful Life Table Text Block</link:label>
    <link:loc xlink:label="loc_AwardTypeAxis.344.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AwardTypeAxis.344.11.6" xlink:to="lab_AwardTypeAxis.250.346420" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AwardTypeAxis.250.346420" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AwardTypeAxis.250.346420">Award Type [Axis]</link:label>
    <link:loc xlink:label="loc_CommonStockSharesIssued.6875.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesIssued.6875.11.8" xlink:to="lab_CommonStockSharesIssued.138093.346423" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockSharesIssued.138093.346423" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockSharesIssued.138093.346423">Underwritten public offering, common stock issued and sold</link:label>
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.11.6" xlink:to="lab_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.3763.346424" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.3763.346424" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.3763.346424">Deferred Bonus and Profit Sharing Plan by Title of Individual [Axis]</link:label>
    <link:loc xlink:label="loc_EmployeesMember.68641.11.6" xlink:href="plx-20121231.xsd#plx_EmployeesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeesMember.68641.11.6" xlink:to="lab_EmployeesMember.145751.346428" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeesMember.145751.346428" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EmployeesMember.145751.346428">Employees [Member]</link:label>
    <link:loc xlink:label="loc_EmployeesMember.68641.11.12" xlink:href="plx-20121231.xsd#plx_EmployeesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeesMember.68641.11.12" xlink:to="lab_EmployeesMember.145753.346429" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeesMember.145753.346429" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_EmployeesMember.145753.346429">Employees [Member].</link:label>
    <link:loc xlink:label="loc_ExecutiveOfficerMember.1817.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ExecutiveOfficerMember.1817.11.6" xlink:to="lab_ExecutiveOfficerMember.5919.346430" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ExecutiveOfficerMember.5919.346430" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ExecutiveOfficerMember.5919.346430">Executive Officer [Member]</link:label>
    <link:loc xlink:label="loc_OfficersAndCertainEmployeesMember.70821.11.6" xlink:href="plx-20121231.xsd#plx_OfficersAndCertainEmployeesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OfficersAndCertainEmployeesMember.70821.11.6" xlink:to="lab_OfficersAndCertainEmployeesMember.360810" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OfficersAndCertainEmployeesMember.360810" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OfficersAndCertainEmployeesMember.360810">Officers And Certain Employees [Member]</link:label>
    <link:loc xlink:label="loc_OfficersAndCertainEmployeesMember.70821.11.12" xlink:href="plx-20121231.xsd#plx_OfficersAndCertainEmployeesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OfficersAndCertainEmployeesMember.70821.11.12" xlink:to="lab_OfficersAndCertainEmployeesMember.360811" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OfficersAndCertainEmployeesMember.360811" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_OfficersAndCertainEmployeesMember.360811">Officers And Certain Employees Member</link:label>
    <link:loc xlink:label="loc_OfficersAndDirectorsInPrivateTransactionMember.72242.11.6" xlink:href="plx-20121231.xsd#plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OfficersAndDirectorsInPrivateTransactionMember.72242.11.6" xlink:to="lab_OfficersAndDirectorsInPrivateTransactionMember.371147" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OfficersAndDirectorsInPrivateTransactionMember.371147" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OfficersAndDirectorsInPrivateTransactionMember.371147">Officers And Directors In Private Transaction [Member]</link:label>
    <link:loc xlink:label="loc_OfficersAndDirectorsInPrivateTransactionMember.72242.11.12" xlink:href="plx-20121231.xsd#plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OfficersAndDirectorsInPrivateTransactionMember.72242.11.12" xlink:to="lab_OfficersAndDirectorsInPrivateTransactionMember.371149" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OfficersAndDirectorsInPrivateTransactionMember.371149" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_OfficersAndDirectorsInPrivateTransactionMember.371149">Officers And Directors In Private Transaction [Member]</link:label>
    <link:loc xlink:label="loc_PaymentsOfStockIssuanceCosts.13770.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsOfStockIssuanceCosts.13770.11.6" xlink:to="lab_PaymentsOfStockIssuanceCosts.13507.346433" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsOfStockIssuanceCosts.13507.346433" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsOfStockIssuanceCosts.13507.346433">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:label="loc_PaymentsOfStockIssuanceCosts.13770.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsOfStockIssuanceCosts.13770.11.7" xlink:to="lab_PaymentsOfStockIssuanceCosts.138105.346434" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsOfStockIssuanceCosts.138105.346434" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsOfStockIssuanceCosts.138105.346434">Underwritten public offering, commissions and issuance costs</link:label>
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStock.14449.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromIssuanceOfCommonStock.14449.11.7" xlink:to="lab_ProceedsFromIssuanceOfCommonStock.138102.346438" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromIssuanceOfCommonStock.138102.346438" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromIssuanceOfCommonStock.138102.346438">Underwritten public offering, net proceeds from issuance</link:label>
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStock.14449.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromIssuanceOfCommonStock.14449.11.6" xlink:to="lab_ProceedsFromIssuanceOfCommonStock.14546.346437" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromIssuanceOfCommonStock.14546.346437" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromIssuanceOfCommonStock.14546.346437">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:label="loc_RestrictedStockMember.4416.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RestrictedStockMember.4416.11.6" xlink:to="lab_RestrictedStockMember.15961" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RestrictedStockMember.15961" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RestrictedStockMember.15961">Restricted Stock [Member]</link:label>
    <link:loc xlink:label="loc_SaleOfStockPricePerShare.15652.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SaleOfStockPricePerShare.15652.11.7" xlink:to="lab_SaleOfStockPricePerShare.138095.346441" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SaleOfStockPricePerShare.138095.346441" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SaleOfStockPricePerShare.138095.346441">Underwritten public offering, common stock price per share</link:label>
    <link:loc xlink:label="loc_SaleOfStockPricePerShare.15652.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SaleOfStockPricePerShare.15652.11.6" xlink:to="lab_SaleOfStockPricePerShare.16436.346440" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SaleOfStockPricePerShare.16436.346440" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SaleOfStockPricePerShare.16436.346440">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.11.6" xlink:to="lab_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.16890" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.16890" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.16890">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.16272.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.16272.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.360791" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.360791" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.360791">Vesting period</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.16272.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.16272.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.17443.346443" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.17443.346443" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.17443.346443">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.68656.11.6" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.68656.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.346450" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.346450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.346450">Share Based Compensation Arrangement By Share Based Payment Award Granted Contractual Term</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.68656.11.12" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.68656.11.12" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.145778.346452" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.145778.346452" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.145778.346452">Share based compensation arrangement by share based payment award granted contractual term.</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.68656.11.7" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.68656.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.145779.346451" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.145779.346451" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.145779.346451">Shares of common stock issued, lock up period</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.17450" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.17450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.17450">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.68657.11.6" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.68657.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.145760.346453" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.145760.346453" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.145760.346453">Share Based Compensation Arrangement By Share Based Payment Award Number Of Installments For Vesting Period</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.68657.11.12" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.68657.11.12" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.145764.346455" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.145764.346455" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.145764.346455">Share based compensation arrangement by share based payment award number of installments for vesting period.</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.68657.11.7" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.68657.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.145767.346454" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.145767.346454" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.145767.346454">Number of installments for vesting of stock</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.16337.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.16337.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.140091.346457" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.140091.346457" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.140091.346457">Shares of common stock approved for grant</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.16337.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.16337.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.17523.346456" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.17523.346456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.17523.346456">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.16333.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.16333.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.17518" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.17518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.17518">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.16333.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.16333.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.135580" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.135580" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.135580">Common stock available for issuance</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.16275.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.16275.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.17448" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.17448" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.17448">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.16275.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.16275.11.8" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross8.135601" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross8.135601" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross8.135601">Common stock shares granted</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.11.6" xlink:to="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.17586.346458" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.17586.346458" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.17586.346458">Award Type [Domain]</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.16378.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.16378.11.6" xlink:to="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.17594" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.17594" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.17594">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.16378.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.16378.11.7" xlink:to="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.358880" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.358880" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.358880">Exercise price</link:label>
    <link:loc xlink:label="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.11.6" xlink:to="lab_TitleOfIndividualWithRelationshipToEntityDomain.18500.346465" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TitleOfIndividualWithRelationshipToEntityDomain.18500.346465" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_TitleOfIndividualWithRelationshipToEntityDomain.18500.346465">Title of Individual with Relationship to Entity [Domain]</link:label>
    <link:loc xlink:label="loc_SubsequentEventsAbstract.5004.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SubsequentEventsAbstract.5004.11.6" xlink:to="lab_SubsequentEventsAbstract.138807.346472" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SubsequentEventsAbstract.138807.346472" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SubsequentEventsAbstract.138807.346472">SUBSEQUENT EVENTS [Abstract]</link:label>
    <link:loc xlink:label="loc_SubsequentEventsTextBlock.16697.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SubsequentEventsTextBlock.16697.11.7" xlink:to="lab_SubsequentEventsTextBlock.138806.346474" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SubsequentEventsTextBlock.138806.346474" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SubsequentEventsTextBlock.138806.346474">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:label="loc_SubsequentEventsTextBlock.16697.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SubsequentEventsTextBlock.16697.11.6" xlink:to="lab_SubsequentEventsTextBlock.18084.346473" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SubsequentEventsTextBlock.18084.346473" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SubsequentEventsTextBlock.18084.346473">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:label="loc_EmployeeMember.68640.11.6" xlink:href="plx-20121231.xsd#plx_EmployeeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeMember.68640.11.6" xlink:to="lab_EmployeeMember.140096.346404" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeMember.140096.346404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeMember.140096.346404">Employee [Member]</link:label>
    <link:loc xlink:label="loc_EmployeeMember.68640.11.12" xlink:href="plx-20121231.xsd#plx_EmployeeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeMember.68640.11.12" xlink:to="lab_EmployeeMember.140097.346406" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeMember.140097.346406" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeMember.140097.346406">Employee [Member].</link:label>
    <link:loc xlink:label="loc_EmployeeMember.68640.11.7" xlink:href="plx-20121231.xsd#plx_EmployeeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeMember.68640.11.7" xlink:to="lab_EmployeeMember.140327.346405" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeMember.140327.346405" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeMember.140327.346405">Certain Employee [Member]</link:label>
    <link:loc xlink:label="loc_OptionExerciseMember.68647.11.6" xlink:href="plx-20121231.xsd#plx_OptionExerciseMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OptionExerciseMember.68647.11.6" xlink:to="lab_OptionExerciseMember.140092.346407" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OptionExerciseMember.140092.346407" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OptionExerciseMember.140092.346407">Option Exercise [Member]</link:label>
    <link:loc xlink:label="loc_OptionExerciseMember.68647.11.12" xlink:href="plx-20121231.xsd#plx_OptionExerciseMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OptionExerciseMember.68647.11.12" xlink:to="lab_OptionExerciseMember.140093.346408" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OptionExerciseMember.140093.346408" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_OptionExerciseMember.140093.346408">Option Exercise [Member].</link:label>
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3555.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OptionIndexedToIssuersEquityEquityAxis.3555.11.6" xlink:to="lab_OptionIndexedToIssuersEquityEquityAxis.12418.346431" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OptionIndexedToIssuersEquityEquityAxis.12418.346431" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OptionIndexedToIssuersEquityEquityAxis.12418.346431">Option Indexed to Issuer's Equity [Axis]</link:label>
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3556.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OptionIndexedToIssuersEquityTypeDomain.3556.11.6" xlink:to="lab_OptionIndexedToIssuersEquityTypeDomain.12421.346432" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OptionIndexedToIssuersEquityTypeDomain.12421.346432" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OptionIndexedToIssuersEquityTypeDomain.12421.346432">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.11.8" xlink:to="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.140109.346409" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.140109.346409" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.140109.346409">Common Stock issued in connection with exercise of options</link:label>
    <link:loc xlink:label="loc_SubsequentEventLineItems.5006.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SubsequentEventLineItems.5006.11.6" xlink:to="lab_SubsequentEventLineItems.18100.346410" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SubsequentEventLineItems.18100.346410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SubsequentEventLineItems.18100.346410">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:label="loc_SubsequentEventTable.5008.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SubsequentEventTable.5008.11.6" xlink:to="lab_SubsequentEventTable.18108.346411" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SubsequentEventTable.18108.346411" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SubsequentEventTable.18108.346411">Subsequent Event [Table]</link:label>
    <link:loc xlink:label="loc_SubsequentEventTypeAxis.5007.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SubsequentEventTypeAxis.5007.11.6" xlink:to="lab_SubsequentEventTypeAxis.18104.346412" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SubsequentEventTypeAxis.18104.346412" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SubsequentEventTypeAxis.18104.346412">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:label="loc_SubsequentEventTypeDomain.5005.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SubsequentEventTypeDomain.5005.11.6" xlink:to="lab_SubsequentEventTypeDomain.18097.346413" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SubsequentEventTypeDomain.18097.346413" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SubsequentEventTypeDomain.18097.346413">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.6878.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockParOrStatedValuePerShare.6878.11.6" xlink:to="lab_CommonStockParOrStatedValuePerShare.2741.346607" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockParOrStatedValuePerShare.2741.346607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockParOrStatedValuePerShare.2741.346607">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.6878.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockParOrStatedValuePerShare.6878.11.7" xlink:to="lab_CommonStockParOrStatedValuePerShare7.134365.346367" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockParOrStatedValuePerShare7.134365.346367" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockParOrStatedValuePerShare7.134365.346367">Common stock, par value per share</link:label>
    <link:loc xlink:label="loc_CommonStockSharesAuthorized.6879.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesAuthorized.6879.11.6" xlink:to="lab_CommonStockSharesAuthorized.2742.346609" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockSharesAuthorized.2742.346609" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockSharesAuthorized.2742.346609">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:label="loc_CommonStockSharesIssued.6875.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesIssued.6875.11.6" xlink:to="lab_CommonStockSharesIssued.2734.346422" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockSharesIssued.2734.346422" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockSharesIssued.2734.346422">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:label="loc_StatementLineItems.4952.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementLineItems.4952.11.6" xlink:to="lab_StatementLineItems.17869.346588" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementLineItems.17869.346588" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementLineItems.17869.346588">Statement [Line Items]</link:label>
    <link:loc xlink:label="loc_CommonStockSharesAuthorized.6879.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesAuthorized.6879.11.7" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl.346715" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized_lbl.346715" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized_lbl.346715">Common Stock, Authorized</link:label>
    <link:loc xlink:label="loc_CommonStockSharesIssued.6875.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesIssued.6875.11.7" xlink:to="us-gaap_CommonStockSharesIssued_lbl.346716" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_CommonStockSharesIssued_lbl.346716" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued_lbl.346716">Common Stock, issued</link:label>
    <link:loc xlink:label="loc_CommonStockSharesOutstanding.6864.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesOutstanding.6864.11.6" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl.346717" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding_lbl.346717" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl.346717">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:label="loc_CommonStockSharesOutstanding.6864.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesOutstanding.6864.11.7" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl.346718" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding_lbl.346718" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl.346718">Common Stock, outstanding</link:label>
    <link:loc xlink:label="loc_StatementLineItems.4952.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementLineItems.4952.11.7" xlink:to="us-gaap_StatementLineItems_lbl.346773" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_StatementLineItems_lbl.346773" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_StatementLineItems_lbl.346773">Statement [Line Items]</link:label>
    <link:loc xlink:label="loc_CollaborativeAndLicenseArrangementDisclosure.68667.11.6" xlink:href="plx-20121231.xsd#plx_CollaborativeAndLicenseArrangementDisclosure" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeAndLicenseArrangementDisclosure.68667.11.6" xlink:to="lab_CollaborativeAndLicenseArrangementDisclosure.346756" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeAndLicenseArrangementDisclosure.346756" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeAndLicenseArrangementDisclosure.346756">LICENSE AND SUPPLY AGREEMENT [Abstract]</link:label>
    <link:loc xlink:label="loc_CollaborativeAndLicenseArrangementDisclosure.68667.11.12" xlink:href="plx-20121231.xsd#plx_CollaborativeAndLicenseArrangementDisclosure" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeAndLicenseArrangementDisclosure.68667.11.12" xlink:to="lab_CollaborativeAndLicenseArrangementDisclosure.346755" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeAndLicenseArrangementDisclosure.346755" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeAndLicenseArrangementDisclosure.346755">LICENSE AND SUPPLY AGREEMENT [Abstract]</link:label>
    <link:loc xlink:label="loc_CollaborativeAndLicenseArrangementDisclosureTextBlock.68665.11.6" xlink:href="plx-20121231.xsd#plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeAndLicenseArrangementDisclosureTextBlock.68665.11.6" xlink:to="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_lbl.346710" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_lbl.346710" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_lbl.346710">Collaborative And License Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_CollaborativeAndLicenseArrangementDisclosureTextBlock.68665.11.7" xlink:href="plx-20121231.xsd#plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeAndLicenseArrangementDisclosureTextBlock.68665.11.7" xlink:to="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_lbl.346711" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_lbl.346711" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_lbl.346711">LICENSE AND SUPPLY AGREEMENT</link:label>
    <link:loc xlink:label="loc_CollaborativeAndLicenseArrangementDisclosureTextBlock.68665.11.12" xlink:href="plx-20121231.xsd#plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeAndLicenseArrangementDisclosureTextBlock.68665.11.12" xlink:to="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_lbl.346709" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_lbl.346709" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_lbl.346709">Collaborative and License Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentAbstract.4105.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyPlantAndEquipmentAbstract.4105.11.6" xlink:to="lab_PropertyPlantAndEquipmentAbstract.350519" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PropertyPlantAndEquipmentAbstract.350519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PropertyPlantAndEquipmentAbstract.350519">PROPERTY AND EQUIPMENT [Abstract]</link:label>
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentDisclosureTextBlock.14703.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyPlantAndEquipmentDisclosureTextBlock.14703.11.6" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl.346764" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl.346764" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl.346764">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentDisclosureTextBlock.14703.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyPlantAndEquipmentDisclosureTextBlock.14703.11.7" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl.346765" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl.346765" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl.346765">PROPERTY AND EQUIPMENT</link:label>
    <link:loc xlink:label="loc_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract.1429.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract.1429.11.6" xlink:to="lab_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract.346793" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract.346793" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract.346793">LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT [Abstract]</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitsDisclosureTextBlock.13873.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementBenefitsDisclosureTextBlock.13873.11.6" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl.346760" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl.346760" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl.346760">Pension And Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitsDisclosureTextBlock.13873.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementBenefitsDisclosureTextBlock.13873.11.7" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl.346761" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl.346761" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl.346761">LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</link:label>
    <link:loc xlink:label="loc_CommitmentsAndContingenciesDisclosureAbstract.1025.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentsAndContingenciesDisclosureAbstract.1025.11.6" xlink:to="lab_CommitmentsAndContingenciesDisclosureAbstract.350521" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommitmentsAndContingenciesDisclosureAbstract.350521" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommitmentsAndContingenciesDisclosureAbstract.350521">COMMITMENTS [Abstract]</link:label>
    <link:loc xlink:label="loc_CommitmentsDisclosureTextBlock.6839.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentsDisclosureTextBlock.6839.11.6" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl.346712" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl.346712" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="us-gaap_CommitmentsDisclosureTextBlock_lbl.346712">Commitments Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_CommitmentsDisclosureTextBlock.6839.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentsDisclosureTextBlock.6839.11.7" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl.346713" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl.346713" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_CommitmentsDisclosureTextBlock_lbl.346713">COMMITMENTS</link:label>
    <link:loc xlink:label="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.11.6" xlink:to="lab_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.358825" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.358825" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.358825">SHARE CAPITAL [Abstract]</link:label>
    <link:loc xlink:label="loc_StockholdersEquityNoteDisclosureTextBlock.16673.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquityNoteDisclosureTextBlock.16673.11.7" xlink:to="lab_StockholdersEquityNoteDisclosureTextBlock.138805.346471" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquityNoteDisclosureTextBlock.138805.346471" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquityNoteDisclosureTextBlock.138805.346471">SHARE CAPITAL</link:label>
    <link:loc xlink:label="loc_StockholdersEquityNoteDisclosureTextBlock.16673.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquityNoteDisclosureTextBlock.16673.11.6" xlink:to="lab_StockholdersEquityNoteDisclosureTextBlock.18039.346470" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquityNoteDisclosureTextBlock.18039.346470" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquityNoteDisclosureTextBlock.18039.346470">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_IncomeTaxDisclosureAbstract.2523.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeTaxDisclosureAbstract.2523.11.6" xlink:to="lab_IncomeTaxDisclosureAbstract.350528" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeTaxDisclosureAbstract.350528" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncomeTaxDisclosureAbstract.350528">TAXES ON INCOME [Abstract]</link:label>
    <link:loc xlink:label="loc_IncomeTaxDisclosureTextBlock.10640.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeTaxDisclosureTextBlock.10640.11.6" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl.346749" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl.346749" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureTextBlock_lbl.346749">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_IncomeTaxDisclosureTextBlock.10640.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeTaxDisclosureTextBlock.10640.11.7" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl.346750" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl.346750" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureTextBlock_lbl.346750">TAXES ON INCOME</link:label>
    <link:loc xlink:label="loc_SupplementalInformationAbstract.73895.11.6" xlink:href="plx-20121231.xsd#plx_SupplementalInformationAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementalInformationAbstract.73895.11.6" xlink:to="lab_SupplementalInformationAbstract.381533" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementalInformationAbstract.381533" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SupplementalInformationAbstract.381533">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION [Abstract]</link:label>
    <link:loc xlink:label="loc_AdditionalFinancialInformationDisclosureTextBlock.5621.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdditionalFinancialInformationDisclosureTextBlock.5621.11.6" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl.346701" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl.346701" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl.346701">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_AdditionalFinancialInformationDisclosureTextBlock.5621.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdditionalFinancialInformationDisclosureTextBlock.5621.11.7" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl.346702" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl.346702" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl.346702">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:label>
    <link:loc xlink:label="loc_RelatedPartyTransactionsAbstract.4350.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RelatedPartyTransactionsAbstract.4350.11.6" xlink:to="lab_RelatedPartyTransactionsAbstract.350531" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RelatedPartyTransactionsAbstract.350531" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RelatedPartyTransactionsAbstract.350531">RELATED PARTY TRANSACTIONS [Abstract]</link:label>
    <link:loc xlink:label="loc_RelatedPartyTransactionsDisclosureTextBlock.15176.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RelatedPartyTransactionsDisclosureTextBlock.15176.11.6" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl.346768" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl.346768" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl.346768">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_RelatedPartyTransactionsDisclosureTextBlock.15176.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RelatedPartyTransactionsDisclosureTextBlock.15176.11.7" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl.346769" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl.346769" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl.346769">RELATED PARTY TRANSACTIONS</link:label>
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentTextBlock.14699.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyPlantAndEquipmentTextBlock.14699.11.6" xlink:to="lab_PropertyPlantAndEquipmentTextBlock.14924" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PropertyPlantAndEquipmentTextBlock.14924" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PropertyPlantAndEquipmentTextBlock.14924">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentTextBlock.14699.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyPlantAndEquipmentTextBlock.14699.11.7" xlink:to="lab_PropertyPlantAndEquipmentTextBlock.350520" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PropertyPlantAndEquipmentTextBlock.350520" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PropertyPlantAndEquipmentTextBlock.350520">Schedule of Property and Equipment</link:label>
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock.15869.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock.15869.11.6" xlink:to="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock.16754" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock.16754" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock.16754">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock.15869.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock.15869.11.7" xlink:to="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock.135281" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock.135281" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock.135281">Schedule of Stock-Based Compensation Expense in Statement of Operations</link:label>
    <link:loc xlink:label="loc_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock.73903.11.6" xlink:href="plx-20121231.xsd#plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock.73903.11.6" xlink:to="lab_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock.381552" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock.381552" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock.381552">Schedule Of Options And Restricted Stocks Granted [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock.73903.11.7" xlink:href="plx-20121231.xsd#plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock.73903.11.7" xlink:to="lab_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock.381554" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock.381554" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock.381554">Schedule of Options and Restricted Stocks Granted</link:label>
    <link:loc xlink:label="loc_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock.15821.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock.15821.11.6" xlink:to="lab_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock.16679" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock.16679" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock.16679">Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock.15821.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock.15821.11.7" xlink:to="lab_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock7.350524" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock7.350524" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock7.350524">Summary of Restricted Stock Activity - Options Granted to Employees</link:label>
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock.15939.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock.15939.11.6" xlink:to="lab_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock.16874" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock.16874" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock.16874">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock.15939.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock.15939.11.7" xlink:to="lab_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock.135270" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock.135270" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock.135270">Schedule of Information about Share Options Outstanding</link:label>
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock.15727.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock.15727.11.6" xlink:to="lab_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock.16559" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock.16559" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock.16559">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock.15727.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock.15727.11.7" xlink:to="lab_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock.350522" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock.350522" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock.350522">Summary of Stock Option Activity - Options Granted to Employees</link:label>
    <link:loc xlink:label="loc_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock.15935.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock.15935.11.6" xlink:to="lab_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock.16870" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock.16870" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock.16870">Schedule of Share-based Goods and Nonemployee Services Transaction by Supplier [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock.15935.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock.15935.11.7" xlink:to="lab_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock.1912301.350525" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock.1912301.350525" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock.1912301.350525">Schedule of Options Granted to Service Providers</link:label>
    <link:loc xlink:label="loc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.15758.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.15758.11.6" xlink:to="lab_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.16593" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.16593" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.16593">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.15758.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.15758.11.7" xlink:to="lab_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.350523" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.350523" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.350523">Schedule of Assumptions Used to Estimate Fair Value of Stock Option Award using Black-Scholes Valuation Model</link:label>
    <link:loc xlink:label="loc_SupplementaryBalanceSheetsInformationTableTextBlock.70103.11.6" xlink:href="plx-20121231.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementaryBalanceSheetsInformationTableTextBlock.70103.11.6" xlink:to="lab_SupplementaryBalanceSheetsInformationTableTextBlock.355617" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementaryBalanceSheetsInformationTableTextBlock.355617" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SupplementaryBalanceSheetsInformationTableTextBlock.355617">Supplementary Balance Sheets Information [Table Text Block]</link:label>
    <link:loc xlink:label="loc_SupplementaryBalanceSheetsInformationTableTextBlock.70103.11.7" xlink:href="plx-20121231.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementaryBalanceSheetsInformationTableTextBlock.70103.11.7" xlink:to="lab_SupplementaryBalanceSheetsInformationTableTextBlock.355621" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementaryBalanceSheetsInformationTableTextBlock.355621" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SupplementaryBalanceSheetsInformationTableTextBlock.355621">Supplemental Information, Balance Sheets</link:label>
    <link:loc xlink:label="loc_SupplementaryBalanceSheetsInformationTableTextBlock.70103.11.12" xlink:href="plx-20121231.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementaryBalanceSheetsInformationTableTextBlock.70103.11.12" xlink:to="lab_SupplementaryBalanceSheetsInformationTableTextBlock.355619" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementaryBalanceSheetsInformationTableTextBlock.355619" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_SupplementaryBalanceSheetsInformationTableTextBlock.355619">Supplementary Balance Sheets Information Table Text Block</link:label>
    <link:loc xlink:label="loc_SupplementaryIncomeStatementInformationTableTextBlock.73902.11.6" xlink:href="plx-20121231.xsd#plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementaryIncomeStatementInformationTableTextBlock.73902.11.6" xlink:to="lab_SupplementaryIncomeStatementInformationTableTextBlock.381547" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementaryIncomeStatementInformationTableTextBlock.381547" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SupplementaryIncomeStatementInformationTableTextBlock.381547">Supplementary Income Statement Information [Table Text Block]</link:label>
    <link:loc xlink:label="loc_SupplementaryIncomeStatementInformationTableTextBlock.73902.11.7" xlink:href="plx-20121231.xsd#plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementaryIncomeStatementInformationTableTextBlock.73902.11.7" xlink:to="lab_SupplementaryIncomeStatementInformationTableTextBlock.381549" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementaryIncomeStatementInformationTableTextBlock.381549" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SupplementaryIncomeStatementInformationTableTextBlock.381549">Supplemental Information, Income Statement</link:label>
    <link:loc xlink:label="loc_SupplementaryIncomeStatementInformationTableTextBlock.73902.11.12" xlink:href="plx-20121231.xsd#plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementaryIncomeStatementInformationTableTextBlock.73902.11.12" xlink:to="lab_SupplementaryIncomeStatementInformationTableTextBlock.381548" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementaryIncomeStatementInformationTableTextBlock.381548" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_SupplementaryIncomeStatementInformationTableTextBlock.381548">Supplementary Income Statement Information [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleOfRelatedPartyTransactionsTableTextBlock.15798.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfRelatedPartyTransactionsTableTextBlock.15798.11.6" xlink:to="lab_ScheduleOfRelatedPartyTransactionsTableTextBlock.16644" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfRelatedPartyTransactionsTableTextBlock.16644" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfRelatedPartyTransactionsTableTextBlock.16644">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleOfRelatedPartyTransactionsTableTextBlock.15798.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfRelatedPartyTransactionsTableTextBlock.15798.11.7" xlink:to="lab_ScheduleOfRelatedPartyTransactionsTableTextBlock.350532" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfRelatedPartyTransactionsTableTextBlock.350532" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfRelatedPartyTransactionsTableTextBlock.350532">Schedule of Related Party Transactions</link:label>
    <link:loc xlink:label="loc_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment.5600.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment.5600.11.6" xlink:to="lab_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment.627" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment.627" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment.627">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:label="loc_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment.5600.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment.5600.11.42" xlink:to="lab_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment.355758" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment.355758" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment.355758">Less - accumulated depreciation and amortization</link:label>
    <link:loc xlink:label="loc_AssetImpairmentCharges.5835.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetImpairmentCharges.5835.11.6" xlink:to="lab_AssetImpairmentCharges.1048" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetImpairmentCharges.1048" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AssetImpairmentCharges.1048">Asset Impairment Charges</link:label>
    <link:loc xlink:label="loc_AssetImpairmentCharges.5835.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetImpairmentCharges.5835.11.7" xlink:to="lab_AssetImpairmentCharges.134296" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetImpairmentCharges.134296" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AssetImpairmentCharges.134296">Impairment charges</link:label>
    <link:loc xlink:label="loc_EquipmentUnderConstructionMember.70136.11.6" xlink:href="plx-20121231.xsd#plx_EquipmentUnderConstructionMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EquipmentUnderConstructionMember.70136.11.6" xlink:to="lab_EquipmentUnderConstructionMember.355754" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EquipmentUnderConstructionMember.355754" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EquipmentUnderConstructionMember.355754">Equipment Under Construction [Member]</link:label>
    <link:loc xlink:label="loc_EquipmentUnderConstructionMember.70136.11.12" xlink:href="plx-20121231.xsd#plx_EquipmentUnderConstructionMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EquipmentUnderConstructionMember.70136.11.12" xlink:to="lab_EquipmentUnderConstructionMember.355755" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EquipmentUnderConstructionMember.355755" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_EquipmentUnderConstructionMember.355755">Equipment Under Construction [Member]</link:label>
    <link:loc xlink:label="loc_FurnitureAndComputerEquipmentMember.70134.11.6" xlink:href="plx-20121231.xsd#plx_FurnitureAndComputerEquipmentMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FurnitureAndComputerEquipmentMember.70134.11.6" xlink:to="lab_FurnitureAndComputerEquipmentMember.355751" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FurnitureAndComputerEquipmentMember.355751" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FurnitureAndComputerEquipmentMember.355751">Furniture And Computer Equipment [Member]</link:label>
    <link:loc xlink:label="loc_FurnitureAndComputerEquipmentMember.70134.11.12" xlink:href="plx-20121231.xsd#plx_FurnitureAndComputerEquipmentMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FurnitureAndComputerEquipmentMember.70134.11.12" xlink:to="lab_FurnitureAndComputerEquipmentMember.355752" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FurnitureAndComputerEquipmentMember.355752" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_FurnitureAndComputerEquipmentMember.355752">Furniture And Computer Equipment Member</link:label>
    <link:loc xlink:label="loc_LaboratoryEquipmentMember.70112.11.6" xlink:href="plx-20121231.xsd#plx_LaboratoryEquipmentMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LaboratoryEquipmentMember.70112.11.6" xlink:to="lab_LaboratoryEquipmentMember.355662" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LaboratoryEquipmentMember.355662" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LaboratoryEquipmentMember.355662">Laboratory Equipment [Member]</link:label>
    <link:loc xlink:label="loc_LaboratoryEquipmentMember.70112.11.12" xlink:href="plx-20121231.xsd#plx_LaboratoryEquipmentMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LaboratoryEquipmentMember.70112.11.12" xlink:to="lab_LaboratoryEquipmentMember.355663" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LaboratoryEquipmentMember.355663" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_LaboratoryEquipmentMember.355663">Laboratory Equipment [Member]</link:label>
    <link:loc xlink:label="loc_LeaseholdImprovementsMember.2905.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LeaseholdImprovementsMember.2905.11.6" xlink:to="lab_LeaseholdImprovementsMember.10019" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LeaseholdImprovementsMember.10019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LeaseholdImprovementsMember.10019">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentByTypeAxis.4117.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyPlantAndEquipmentByTypeAxis.4117.11.6" xlink:to="lab_PropertyPlantAndEquipmentByTypeAxis.14927" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PropertyPlantAndEquipmentByTypeAxis.14927" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PropertyPlantAndEquipmentByTypeAxis.14927">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentGross.14698.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyPlantAndEquipmentGross.14698.11.6" xlink:to="lab_PropertyPlantAndEquipmentGross.14920" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PropertyPlantAndEquipmentGross.14920" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PropertyPlantAndEquipmentGross.14920">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentLineItems.4115.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyPlantAndEquipmentLineItems.4115.11.6" xlink:to="lab_PropertyPlantAndEquipmentLineItems.14919" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PropertyPlantAndEquipmentLineItems.14919" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PropertyPlantAndEquipmentLineItems.14919">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.14697.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyPlantAndEquipmentNet.14697.11.9" xlink:to="lab_PropertyPlantAndEquipmentNet.14914" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PropertyPlantAndEquipmentNet.14914" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_PropertyPlantAndEquipmentNet.14914">Property, Plant and Equipment, Net, Total</link:label>
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentTypeDomain.4099.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyPlantAndEquipmentTypeDomain.4099.11.6" xlink:to="lab_PropertyPlantAndEquipmentTypeDomain.14865" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PropertyPlantAndEquipmentTypeDomain.14865" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PropertyPlantAndEquipmentTypeDomain.14865">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:label="loc_ScheduleOfPropertyPlantAndEquipmentTable.4693.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfPropertyPlantAndEquipmentTable.4693.11.6" xlink:to="lab_ScheduleOfPropertyPlantAndEquipmentTable.16928" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfPropertyPlantAndEquipmentTable.16928" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfPropertyPlantAndEquipmentTable.16928">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:label="loc_InventoryFinishedGoodsNetOfReserves.11388.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryFinishedGoodsNetOfReserves.11388.11.7" xlink:to="lab_InventoryFinishedGoodsNetOfReserves.134479.346398" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryFinishedGoodsNetOfReserves.134479.346398" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryFinishedGoodsNetOfReserves.134479.346398">Finished goods</link:label>
    <link:loc xlink:label="loc_InventoryFinishedGoodsNetOfReserves.11388.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryFinishedGoodsNetOfReserves.11388.11.6" xlink:to="lab_InventoryFinishedGoodsNetOfReserves.9609.346397" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryFinishedGoodsNetOfReserves.9609.346397" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryFinishedGoodsNetOfReserves.9609.346397">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:label="loc_InventoryNet.11417.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryNet.11417.11.9" xlink:to="lab_InventoryNet.138062.346399" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryNet.138062.346399" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryNet.138062.346399">Total inventory</link:label>
    <link:loc xlink:label="loc_InventoryRawMaterialsNetOfReserves.11392.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryRawMaterialsNetOfReserves.11392.11.6" xlink:to="lab_InventoryRawMaterialsNetOfReserves.9617.346400" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryRawMaterialsNetOfReserves.9617.346400" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryRawMaterialsNetOfReserves.9617.346400">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:label="loc_InventoryRawMaterialsNetOfReserves.11392.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryRawMaterialsNetOfReserves.11392.11.7" xlink:to="lab_InventoryRawMaterialsNetOfReserves7.134480.346401" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryRawMaterialsNetOfReserves7.134480.346401" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryRawMaterialsNetOfReserves7.134480.346401">Raw materials</link:label>
    <link:loc xlink:label="loc_InventoryWorkInProcessNetOfReserves.11424.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryWorkInProcessNetOfReserves.11424.11.7" xlink:to="lab_InventoryWorkInProcessNetOfReserves.134478.346403" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryWorkInProcessNetOfReserves.134478.346403" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryWorkInProcessNetOfReserves.134478.346403">Work in process</link:label>
    <link:loc xlink:label="loc_InventoryWorkInProcessNetOfReserves.11424.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryWorkInProcessNetOfReserves.11424.11.6" xlink:to="lab_InventoryWorkInProcessNetOfReserves.9665.346402" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryWorkInProcessNetOfReserves.9665.346402" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryWorkInProcessNetOfReserves.9665.346402">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:label="loc_InventoryWriteDown.11386.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryWriteDown" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryWriteDown.11386.11.6" xlink:to="lab_InventoryWriteDown.9607" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryWriteDown.9607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryWriteDown.9607">Inventory Write-down</link:label>
    <link:loc xlink:label="loc_InventoryWriteDown.11386.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryWriteDown" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryWriteDown.11386.11.7" xlink:to="lab_InventoryWriteDown.355761" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryWriteDown.355761" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryWriteDown.355761">Inventory write-down</link:label>
    <link:loc xlink:label="loc_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax.7817.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax.7817.11.6" xlink:to="lab_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax.4173" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax.4173" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax.4173">Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax</link:label>
    <link:loc xlink:label="loc_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax.7817.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax.7817.11.7" xlink:to="lab_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax.210978" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax.210978" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax.210978">Net (gain) or loss for the period</link:label>
    <link:loc xlink:label="loc_DefinedContributionPlanEmployerDiscretionaryContributionAmount.7821.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DefinedContributionPlanEmployerDiscretionaryContributionAmount.7821.11.6" xlink:to="lab_DefinedContributionPlanEmployerDiscretionaryContributionAmount.4177" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DefinedContributionPlanEmployerDiscretionaryContributionAmount.4177" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DefinedContributionPlanEmployerDiscretionaryContributionAmount.4177">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:label="loc_DefinedContributionPlanEmployerDiscretionaryContributionAmount.7821.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DefinedContributionPlanEmployerDiscretionaryContributionAmount.7821.11.7" xlink:to="lab_DefinedContributionPlanEmployerDiscretionaryContributionAmount.358635" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DefinedContributionPlanEmployerDiscretionaryContributionAmount.358635" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DefinedContributionPlanEmployerDiscretionaryContributionAmount.358635">Contributions</link:label>
    <link:loc xlink:label="loc_EmployeeSeveranceObligationPayment.70465.11.6" xlink:href="plx-20121231.xsd#plx_EmployeeSeveranceObligationPayment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeSeveranceObligationPayment.70465.11.6" xlink:to="lab_EmployeeSeveranceObligationPayment.358627" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeSeveranceObligationPayment.358627" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeSeveranceObligationPayment.358627">Employee Severance Obligation Payment</link:label>
    <link:loc xlink:label="loc_EmployeeSeveranceObligationPayment.70465.11.7" xlink:href="plx-20121231.xsd#plx_EmployeeSeveranceObligationPayment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeSeveranceObligationPayment.70465.11.7" xlink:to="lab_EmployeeSeveranceObligationPayment.358629" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeSeveranceObligationPayment.358629" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeSeveranceObligationPayment.358629">Employee severance obligation payments</link:label>
    <link:loc xlink:label="loc_EmployeeSeveranceObligationPayment.70465.11.12" xlink:href="plx-20121231.xsd#plx_EmployeeSeveranceObligationPayment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeSeveranceObligationPayment.70465.11.12" xlink:to="lab_EmployeeSeveranceObligationPayment.358628" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeSeveranceObligationPayment.358628" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeSeveranceObligationPayment.358628">Employee severance obligation payment.</link:label>
    <link:loc xlink:label="loc_ExpectedDefintedBenefitContributionDuringPeriod.70851.11.6" xlink:href="plx-20121231.xsd#plx_ExpectedDefintedBenefitContributionDuringPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ExpectedDefintedBenefitContributionDuringPeriod.70851.11.6" xlink:to="lab_ExpectedDefintedBenefitContributionDuringPeriod.361101" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ExpectedDefintedBenefitContributionDuringPeriod.361101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ExpectedDefintedBenefitContributionDuringPeriod.361101">Expected Definted Benefit Contribution During Period</link:label>
    <link:loc xlink:label="loc_ExpectedDefintedBenefitContributionDuringPeriod.70851.11.7" xlink:href="plx-20121231.xsd#plx_ExpectedDefintedBenefitContributionDuringPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ExpectedDefintedBenefitContributionDuringPeriod.70851.11.7" xlink:to="lab_ExpectedDefintedBenefitContributionDuringPeriod.361104" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ExpectedDefintedBenefitContributionDuringPeriod.361104" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ExpectedDefintedBenefitContributionDuringPeriod.361104">Expected contribution to one or more Contribution Plans</link:label>
    <link:loc xlink:label="loc_ExpectedDefintedBenefitContributionDuringPeriod.70851.11.12" xlink:href="plx-20121231.xsd#plx_ExpectedDefintedBenefitContributionDuringPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ExpectedDefintedBenefitContributionDuringPeriod.70851.11.12" xlink:to="lab_ExpectedDefintedBenefitContributionDuringPeriod.361102" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ExpectedDefintedBenefitContributionDuringPeriod.361102" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ExpectedDefintedBenefitContributionDuringPeriod.361102">Expected Definted Benefit Contribution During Period</link:label>
    <link:loc xlink:label="loc_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod.70852.11.6" xlink:href="plx-20121231.xsd#plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod.70852.11.6" xlink:to="lab_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod.361106" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod.361106" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod.361106">Expected Severance Liabilities Payments For Future Period</link:label>
    <link:loc xlink:label="loc_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod.70852.11.7" xlink:href="plx-20121231.xsd#plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod.70852.11.7" xlink:to="lab_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod.361111" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod.361111" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod.361111">Expected severance liabilities payments for fiscal year end 2013</link:label>
    <link:loc xlink:label="loc_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod.70852.11.12" xlink:href="plx-20121231.xsd#plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod.70852.11.12" xlink:to="lab_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod.361110" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod.361110" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod.361110">Expected severance liabilities payments for future period.</link:label>
    <link:loc xlink:label="loc_SeveranceCosts.16233.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SeveranceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SeveranceCosts.16233.11.6" xlink:to="lab_SeveranceCosts.17384" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SeveranceCosts.17384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SeveranceCosts.17384">Severance Costs</link:label>
    <link:loc xlink:label="loc_SeveranceCosts.16233.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SeveranceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SeveranceCosts.16233.11.7" xlink:to="lab_SeveranceCosts.140729" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SeveranceCosts.140729" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SeveranceCosts.140729">Severance expense</link:label>
    <link:loc xlink:label="loc_AccruedRoyaltiesCurrentAndNoncurrent.5534.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccruedRoyaltiesCurrentAndNoncurrent.5534.11.6" xlink:to="lab_AccruedRoyaltiesCurrentAndNoncurrent.525" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccruedRoyaltiesCurrentAndNoncurrent.525" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccruedRoyaltiesCurrentAndNoncurrent.525">Accrued Royalties</link:label>
    <link:loc xlink:label="loc_AccruedRoyaltiesCurrentAndNoncurrent.5534.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccruedRoyaltiesCurrentAndNoncurrent.5534.11.7" xlink:to="lab_AccruedRoyaltiesCurrentAndNoncurrent7.187410" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccruedRoyaltiesCurrentAndNoncurrent7.187410" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccruedRoyaltiesCurrentAndNoncurrent7.187410">Accrued royalties</link:label>
    <link:loc xlink:label="loc_AgreementMaintenanceFee.73724.11.6" xlink:href="plx-20121231.xsd#plx_AgreementMaintenanceFee" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AgreementMaintenanceFee.73724.11.6" xlink:to="lab_AgreementMaintenanceFee.379762" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AgreementMaintenanceFee.379762" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AgreementMaintenanceFee.379762">Agreement Maintenance Fee</link:label>
    <link:loc xlink:label="loc_AgreementMaintenanceFee.73724.11.7" xlink:href="plx-20121231.xsd#plx_AgreementMaintenanceFee" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AgreementMaintenanceFee.73724.11.7" xlink:to="lab_AgreementMaintenanceFee.379764" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AgreementMaintenanceFee.379764" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AgreementMaintenanceFee.379764">Agreement maintenance fee</link:label>
    <link:loc xlink:label="loc_AgreementMaintenanceFee.73724.11.12" xlink:href="plx-20121231.xsd#plx_AgreementMaintenanceFee" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AgreementMaintenanceFee.73724.11.12" xlink:to="lab_AgreementMaintenanceFee.379763" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AgreementMaintenanceFee.379763" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_AgreementMaintenanceFee.379763">Agreement maintenance fee</link:label>
    <link:loc xlink:label="loc_AnnualIncreaseToMaintenanceFee.73723.11.6" xlink:href="plx-20121231.xsd#plx_AnnualIncreaseToMaintenanceFee" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AnnualIncreaseToMaintenanceFee.73723.11.6" xlink:to="lab_AnnualIncreaseToMaintenanceFee.379759" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AnnualIncreaseToMaintenanceFee.379759" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AnnualIncreaseToMaintenanceFee.379759">Annual Increase To Maintenance Fee</link:label>
    <link:loc xlink:label="loc_AnnualIncreaseToMaintenanceFee.73723.11.7" xlink:href="plx-20121231.xsd#plx_AnnualIncreaseToMaintenanceFee" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AnnualIncreaseToMaintenanceFee.73723.11.7" xlink:to="lab_AnnualIncreaseToMaintenanceFee.379761" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AnnualIncreaseToMaintenanceFee.379761" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AnnualIncreaseToMaintenanceFee.379761">Annual increase to maintenance fee</link:label>
    <link:loc xlink:label="loc_AnnualIncreaseToMaintenanceFee.73723.11.12" xlink:href="plx-20121231.xsd#plx_AnnualIncreaseToMaintenanceFee" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AnnualIncreaseToMaintenanceFee.73723.11.12" xlink:to="lab_AnnualIncreaseToMaintenanceFee.379760" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AnnualIncreaseToMaintenanceFee.379760" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_AnnualIncreaseToMaintenanceFee.379760">Annual increase to maintenance fee.</link:label>
    <link:loc xlink:label="loc_CommitmentAmount.70485.11.6" xlink:href="plx-20121231.xsd#plx_CommitmentAmount" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentAmount.70485.11.6" xlink:to="lab_CommitmentAmount.358693" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommitmentAmount.358693" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommitmentAmount.358693">Commitment Amount</link:label>
    <link:loc xlink:label="loc_CommitmentAmount.70485.11.7" xlink:href="plx-20121231.xsd#plx_CommitmentAmount" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentAmount.70485.11.7" xlink:to="lab_CommitmentAmount.358695" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommitmentAmount.358695" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommitmentAmount.358695">Subcontracting commitment amount</link:label>
    <link:loc xlink:label="loc_CommitmentAmount.70485.11.12" xlink:href="plx-20121231.xsd#plx_CommitmentAmount" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentAmount.70485.11.12" xlink:to="lab_CommitmentAmount.358694" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommitmentAmount.358694" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_CommitmentAmount.358694">Commitment amount.</link:label>
    <link:loc xlink:label="loc_CommitmentsAndContingenciesAxis.70469.11.6" xlink:href="plx-20121231.xsd#plx_CommitmentsAndContingenciesAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentsAndContingenciesAxis.70469.11.6" xlink:to="lab_CommitmentsAndContingenciesAxis.358648" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommitmentsAndContingenciesAxis.358648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommitmentsAndContingenciesAxis.358648">Commitments And Contingencies [Axis]</link:label>
    <link:loc xlink:label="loc_CommitmentsAndContingenciesAxis.70469.11.12" xlink:href="plx-20121231.xsd#plx_CommitmentsAndContingenciesAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentsAndContingenciesAxis.70469.11.12" xlink:to="lab_CommitmentsAndContingenciesAxis.358649" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommitmentsAndContingenciesAxis.358649" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_CommitmentsAndContingenciesAxis.358649">Commitments And Contingencies Axis</link:label>
    <link:loc xlink:label="loc_CommitmentsAndContingenciesDomain.70470.11.6" xlink:href="plx-20121231.xsd#plx_CommitmentsAndContingenciesDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentsAndContingenciesDomain.70470.11.6" xlink:to="lab_CommitmentsAndContingenciesDomain.358650" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommitmentsAndContingenciesDomain.358650" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommitmentsAndContingenciesDomain.358650">Commitments And Contingencies [Domain]</link:label>
    <link:loc xlink:label="loc_CommitmentsAndContingenciesDomain.70470.11.12" xlink:href="plx-20121231.xsd#plx_CommitmentsAndContingenciesDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentsAndContingenciesDomain.70470.11.12" xlink:to="lab_CommitmentsAndContingenciesDomain.358651" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommitmentsAndContingenciesDomain.358651" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_CommitmentsAndContingenciesDomain.358651">Commitments And Contingencies [Domain]</link:label>
    <link:loc xlink:label="loc_CommitmentsAndContingenciesLineItems.70471.11.6" xlink:href="plx-20121231.xsd#plx_CommitmentsAndContingenciesLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.11.6" xlink:to="lab_CommitmentsAndContingenciesLineItems.358652" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommitmentsAndContingenciesLineItems.358652" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommitmentsAndContingenciesLineItems.358652">Commitments And Contingencies [Line Items]</link:label>
    <link:loc xlink:label="loc_CommitmentsAndContingenciesLineItems.70471.11.12" xlink:href="plx-20121231.xsd#plx_CommitmentsAndContingenciesLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.11.12" xlink:to="lab_CommitmentsAndContingenciesLineItems.358653" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommitmentsAndContingenciesLineItems.358653" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_CommitmentsAndContingenciesLineItems.358653">Commitments And Contingencies [Line Items]</link:label>
    <link:loc xlink:label="loc_CommitmentsAndContingenciesTable.70468.11.6" xlink:href="plx-20121231.xsd#plx_CommitmentsAndContingenciesTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentsAndContingenciesTable.70468.11.6" xlink:to="lab_CommitmentsAndContingenciesTable.358645" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommitmentsAndContingenciesTable.358645" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommitmentsAndContingenciesTable.358645">Commitments And Contingencies [Table]</link:label>
    <link:loc xlink:label="loc_CommitmentsAndContingenciesTable.70468.11.12" xlink:href="plx-20121231.xsd#plx_CommitmentsAndContingenciesTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentsAndContingenciesTable.70468.11.12" xlink:to="lab_CommitmentsAndContingenciesTable.358646" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommitmentsAndContingenciesTable.358646" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_CommitmentsAndContingenciesTable.358646">Commitments And Contingencies Table</link:label>
    <link:loc xlink:label="loc_ConsiderationForLicense.70492.11.6" xlink:href="plx-20121231.xsd#plx_ConsiderationForLicense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ConsiderationForLicense.70492.11.6" xlink:to="lab_ConsiderationForLicense.358715" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ConsiderationForLicense.358715" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ConsiderationForLicense.358715">Consideration For License</link:label>
    <link:loc xlink:label="loc_ConsiderationForLicense.70492.11.7" xlink:href="plx-20121231.xsd#plx_ConsiderationForLicense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ConsiderationForLicense.70492.11.7" xlink:to="lab_ConsiderationForLicense.358717" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ConsiderationForLicense.358717" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ConsiderationForLicense.358717">Consideration for license</link:label>
    <link:loc xlink:label="loc_ConsiderationForLicense.70492.11.12" xlink:href="plx-20121231.xsd#plx_ConsiderationForLicense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ConsiderationForLicense.70492.11.12" xlink:to="lab_ConsiderationForLicense.358716" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ConsiderationForLicense.358716" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ConsiderationForLicense.358716">Consideration for license.</link:label>
    <link:loc xlink:label="loc_FundingArrangementsMember.70476.11.6" xlink:href="plx-20121231.xsd#plx_FundingArrangementsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FundingArrangementsMember.70476.11.6" xlink:to="lab_FundingArrangementsMember.358672" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FundingArrangementsMember.358672" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FundingArrangementsMember.358672">Funding Arrangements [Member]</link:label>
    <link:loc xlink:label="loc_FundingArrangementsMember.70476.11.12" xlink:href="plx-20121231.xsd#plx_FundingArrangementsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FundingArrangementsMember.70476.11.12" xlink:to="lab_FundingArrangementsMember.358675" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FundingArrangementsMember.358675" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_FundingArrangementsMember.358675">Funding Arrangements Member</link:label>
    <link:loc xlink:label="loc_LeaseAgreementsMember.2904.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LeaseAgreementsMember.2904.11.6" xlink:to="lab_LeaseAgreementsMember.10014" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LeaseAgreementsMember.10014" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LeaseAgreementsMember.10014">Lease Agreements [Member]</link:label>
    <link:loc xlink:label="loc_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived.70474.11.6" xlink:href="plx-20121231.xsd#plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived.70474.11.6" xlink:to="lab_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived.358666" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived.358666" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived.358666">Maximum Aggregate Payments Of Royalties To Grant Received</link:label>
    <link:loc xlink:label="loc_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived.70474.11.7" xlink:href="plx-20121231.xsd#plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived.70474.11.7" xlink:to="lab_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived.358669" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived.358669" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived.358669">Percentage amount the aggregate amount of royalties that should not exceed grant received</link:label>
    <link:loc xlink:label="loc_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived.70474.11.12" xlink:href="plx-20121231.xsd#plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived.70474.11.12" xlink:to="lab_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived.358668" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived.358668" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived.358668">Percetnage aggregate royalties should not exceed grant amount</link:label>
    <link:loc xlink:label="loc_MaximumMember.3241.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MaximumMember.3241.11.6" xlink:to="lab_MaximumMember.11410" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MaximumMember.11410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_MaximumMember.11410">Maximum [Member]</link:label>
    <link:loc xlink:label="loc_MilestonePaymentsMember.70480.11.6" xlink:href="plx-20121231.xsd#plx_MilestonePaymentsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MilestonePaymentsMember.70480.11.6" xlink:to="lab_MilestonePaymentsMember.358682" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MilestonePaymentsMember.358682" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_MilestonePaymentsMember.358682">Milestone Payments [Member]</link:label>
    <link:loc xlink:label="loc_MilestonePaymentsMember.70480.11.12" xlink:href="plx-20121231.xsd#plx_MilestonePaymentsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MilestonePaymentsMember.70480.11.12" xlink:to="lab_MilestonePaymentsMember.358683" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MilestonePaymentsMember.358683" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_MilestonePaymentsMember.358683">Milestone Payments Member</link:label>
    <link:loc xlink:label="loc_MinimumMember.3248.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MinimumMember.3248.11.6" xlink:to="lab_MinimumMember.11450" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MinimumMember.11450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_MinimumMember.11450">Minimum [Member]</link:label>
    <link:loc xlink:label="loc_MonthlyRentLeaseExpense.70486.11.6" xlink:href="plx-20121231.xsd#plx_MonthlyRentLeaseExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MonthlyRentLeaseExpense.70486.11.6" xlink:to="lab_MonthlyRentLeaseExpense.358701" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MonthlyRentLeaseExpense.358701" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_MonthlyRentLeaseExpense.358701">Monthly Rent Lease Expense</link:label>
    <link:loc xlink:label="loc_MonthlyRentLeaseExpense.70486.11.7" xlink:href="plx-20121231.xsd#plx_MonthlyRentLeaseExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MonthlyRentLeaseExpense.70486.11.7" xlink:to="lab_MonthlyRentLeaseExpense.358703" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MonthlyRentLeaseExpense.358703" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_MonthlyRentLeaseExpense.358703">Monthly rent/lease expense</link:label>
    <link:loc xlink:label="loc_MonthlyRentLeaseExpense.70486.11.12" xlink:href="plx-20121231.xsd#plx_MonthlyRentLeaseExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MonthlyRentLeaseExpense.70486.11.12" xlink:to="lab_MonthlyRentLeaseExpense.358702" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MonthlyRentLeaseExpense.358702" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_MonthlyRentLeaseExpense.358702">Monthly rent/lease expense.</link:label>
    <link:loc xlink:label="loc_OCSMember.70473.11.6" xlink:href="plx-20121231.xsd#plx_OCSMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OCSMember.70473.11.6" xlink:to="lab_OCSMember.358663" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OCSMember.358663" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OCSMember.358663">OCS [Member]</link:label>
    <link:loc xlink:label="loc_OCSMember.70473.11.12" xlink:href="plx-20121231.xsd#plx_OCSMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OCSMember.70473.11.12" xlink:to="lab_OCSMember.358664" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OCSMember.358664" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_OCSMember.358664">OCS Member</link:label>
    <link:loc xlink:label="loc_OperatingLeasesFutureMinimumPaymentsDueCurrent.13089.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperatingLeasesFutureMinimumPaymentsDueCurrent.13089.11.6" xlink:to="lab_OperatingLeasesFutureMinimumPaymentsDueCurrent.12378" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperatingLeasesFutureMinimumPaymentsDueCurrent.12378" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OperatingLeasesFutureMinimumPaymentsDueCurrent.12378">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:label="loc_OperatingLeasesFutureMinimumPaymentsDueCurrent.13089.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperatingLeasesFutureMinimumPaymentsDueCurrent.13089.11.7" xlink:to="lab_OperatingLeasesFutureMinimumPaymentsDueCurrent7.358696" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperatingLeasesFutureMinimumPaymentsDueCurrent7.358696" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OperatingLeasesFutureMinimumPaymentsDueCurrent7.358696">Future minimum lease payments, 2013</link:label>
    <link:loc xlink:label="loc_OperatingLeasesFutureMinimumPaymentsDueInFourYears.13094.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperatingLeasesFutureMinimumPaymentsDueInFourYears.13094.11.6" xlink:to="lab_OperatingLeasesFutureMinimumPaymentsDueInFourYears.12385" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperatingLeasesFutureMinimumPaymentsDueInFourYears.12385" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OperatingLeasesFutureMinimumPaymentsDueInFourYears.12385">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:label="loc_OperatingLeasesFutureMinimumPaymentsDueInFourYears.13094.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperatingLeasesFutureMinimumPaymentsDueInFourYears.13094.11.7" xlink:to="lab_OperatingLeasesFutureMinimumPaymentsDueInFourYears.358699" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperatingLeasesFutureMinimumPaymentsDueInFourYears.358699" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OperatingLeasesFutureMinimumPaymentsDueInFourYears.358699">Future minimum lease payments, 2016</link:label>
    <link:loc xlink:label="loc_OperatingLeasesFutureMinimumPaymentsDueInThreeYears.13081.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperatingLeasesFutureMinimumPaymentsDueInThreeYears.13081.11.6" xlink:to="lab_OperatingLeasesFutureMinimumPaymentsDueInThreeYears.12366" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperatingLeasesFutureMinimumPaymentsDueInThreeYears.12366" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OperatingLeasesFutureMinimumPaymentsDueInThreeYears.12366">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:label="loc_OperatingLeasesFutureMinimumPaymentsDueInThreeYears.13081.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperatingLeasesFutureMinimumPaymentsDueInThreeYears.13081.11.7" xlink:to="lab_OperatingLeasesFutureMinimumPaymentsDueInThreeYears.358698" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperatingLeasesFutureMinimumPaymentsDueInThreeYears.358698" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OperatingLeasesFutureMinimumPaymentsDueInThreeYears.358698">Future minimum lease payments, 2015</link:label>
    <link:loc xlink:label="loc_OperatingLeasesFutureMinimumPaymentsDueInTwoYears.13087.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperatingLeasesFutureMinimumPaymentsDueInTwoYears.13087.11.6" xlink:to="lab_OperatingLeasesFutureMinimumPaymentsDueInTwoYears.12376" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperatingLeasesFutureMinimumPaymentsDueInTwoYears.12376" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OperatingLeasesFutureMinimumPaymentsDueInTwoYears.12376">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:label="loc_OperatingLeasesFutureMinimumPaymentsDueInTwoYears.13087.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperatingLeasesFutureMinimumPaymentsDueInTwoYears.13087.11.7" xlink:to="lab_OperatingLeasesFutureMinimumPaymentsDueInTwoYears.358697" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperatingLeasesFutureMinimumPaymentsDueInTwoYears.358697" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OperatingLeasesFutureMinimumPaymentsDueInTwoYears.358697">Future minimum lease payments, 2014</link:label>
    <link:loc xlink:label="loc_OperatingLeasesRentExpenseNet.13072.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperatingLeasesRentExpenseNet.13072.11.6" xlink:to="lab_OperatingLeasesRentExpenseNet.12348" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperatingLeasesRentExpenseNet.12348" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OperatingLeasesRentExpenseNet.12348">Operating Leases, Rent Expense, Net</link:label>
    <link:loc xlink:label="loc_OperatingLeasesRentExpenseNet.13072.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperatingLeasesRentExpenseNet.13072.11.7" xlink:to="lab_OperatingLeasesRentExpenseNet.358714" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperatingLeasesRentExpenseNet.358714" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OperatingLeasesRentExpenseNet.358714">Lease/rent expense</link:label>
    <link:loc xlink:label="loc_ProbableAggregateMilestonePaymentMember.70479.11.6" xlink:href="plx-20121231.xsd#plx_ProbableAggregateMilestonePaymentMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProbableAggregateMilestonePaymentMember.70479.11.6" xlink:to="lab_ProbableAggregateMilestonePaymentMember.358681" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProbableAggregateMilestonePaymentMember.358681" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProbableAggregateMilestonePaymentMember.358681">Probable Aggregate Milestone Payment [Member]</link:label>
    <link:loc xlink:label="loc_ProbableAggregateMilestonePaymentMember.70479.11.12" xlink:href="plx-20121231.xsd#plx_ProbableAggregateMilestonePaymentMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProbableAggregateMilestonePaymentMember.70479.11.12" xlink:to="lab_ProbableAggregateMilestonePaymentMember.361751" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProbableAggregateMilestonePaymentMember.361751" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ProbableAggregateMilestonePaymentMember.361751">Probable Aggregate Milestone Payment Member</link:label>
    <link:loc xlink:label="loc_ProductsManufacturedOutsideOfIsraelMember.70475.11.6" xlink:href="plx-20121231.xsd#plx_ProductsManufacturedOutsideOfIsraelMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProductsManufacturedOutsideOfIsraelMember.70475.11.6" xlink:to="lab_ProductsManufacturedOutsideOfIsraelMember.358670" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProductsManufacturedOutsideOfIsraelMember.358670" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProductsManufacturedOutsideOfIsraelMember.358670">Products Manufactured Outside Of Israel [Member]</link:label>
    <link:loc xlink:label="loc_ProductsManufacturedOutsideOfIsraelMember.70475.11.12" xlink:href="plx-20121231.xsd#plx_ProductsManufacturedOutsideOfIsraelMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProductsManufacturedOutsideOfIsraelMember.70475.11.12" xlink:to="lab_ProductsManufacturedOutsideOfIsraelMember.358671" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProductsManufacturedOutsideOfIsraelMember.358671" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ProductsManufacturedOutsideOfIsraelMember.358671">Products Manufactured Outside Of Israel Member</link:label>
    <link:loc xlink:label="loc_RangeAxis.4187.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RangeAxis.4187.11.6" xlink:to="lab_RangeAxis.15198" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RangeAxis.15198" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RangeAxis.15198">Range [Axis]</link:label>
    <link:loc xlink:label="loc_RangeMember.4188.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RangeMember.4188.11.6" xlink:to="lab_RangeMember.15199" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RangeMember.15199" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RangeMember.15199">Range [Domain]</link:label>
    <link:loc xlink:label="loc_ResearchAndLicenseAgreementsMember.70477.11.6" xlink:href="plx-20121231.xsd#plx_ResearchAndLicenseAgreementsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndLicenseAgreementsMember.70477.11.6" xlink:to="lab_ResearchAndLicenseAgreementsMember.358676" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndLicenseAgreementsMember.358676" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndLicenseAgreementsMember.358676">Research And License Agreements [Member]</link:label>
    <link:loc xlink:label="loc_ResearchAndLicenseAgreementsMember.70477.11.12" xlink:href="plx-20121231.xsd#plx_ResearchAndLicenseAgreementsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndLicenseAgreementsMember.70477.11.12" xlink:to="lab_ResearchAndLicenseAgreementsMember.358678" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndLicenseAgreementsMember.358678" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndLicenseAgreementsMember.358678">Research And License Agreements Member</link:label>
    <link:loc xlink:label="loc_RoyaltiesOnSaleOfProducts.70472.11.6" xlink:href="plx-20121231.xsd#plx_RoyaltiesOnSaleOfProducts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RoyaltiesOnSaleOfProducts.70472.11.6" xlink:to="lab_RoyaltiesOnSaleOfProducts.358654" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RoyaltiesOnSaleOfProducts.358654" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RoyaltiesOnSaleOfProducts.358654">Royalties On Sale Of Products</link:label>
    <link:loc xlink:label="loc_RoyaltiesOnSaleOfProducts.70472.11.7" xlink:href="plx-20121231.xsd#plx_RoyaltiesOnSaleOfProducts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RoyaltiesOnSaleOfProducts.70472.11.7" xlink:to="lab_RoyaltiesOnSaleOfProducts.358660" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RoyaltiesOnSaleOfProducts.358660" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_RoyaltiesOnSaleOfProducts.358660">Royalties based on sale of products developed from funded projects, percentage</link:label>
    <link:loc xlink:label="loc_RoyaltiesOnSaleOfProducts.70472.11.12" xlink:href="plx-20121231.xsd#plx_RoyaltiesOnSaleOfProducts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RoyaltiesOnSaleOfProducts.70472.11.12" xlink:to="lab_RoyaltiesOnSaleOfProducts.358656" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RoyaltiesOnSaleOfProducts.358656" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_RoyaltiesOnSaleOfProducts.358656">Percentage of royalties based on sale of products developed from projects funded.</link:label>
    <link:loc xlink:label="loc_RoyaltyExpense.15586.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RoyaltyExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RoyaltyExpense.15586.11.6" xlink:to="lab_RoyaltyExpense.16334" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RoyaltyExpense.16334" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RoyaltyExpense.16334">Royalty Expense</link:label>
    <link:loc xlink:label="loc_RoyaltyExpense.15586.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RoyaltyExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RoyaltyExpense.15586.11.7" xlink:to="lab_RoyaltyExpense7.148626" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RoyaltyExpense7.148626" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_RoyaltyExpense7.148626">Royalty expense included in cost of revenue</link:label>
    <link:loc xlink:label="loc_SecurityDeposit.16065.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SecurityDeposit.16065.11.6" xlink:to="lab_SecurityDeposit.17081" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SecurityDeposit.17081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SecurityDeposit.17081">Security Deposit</link:label>
    <link:loc xlink:label="loc_SecurityDeposit.16065.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SecurityDeposit.16065.11.7" xlink:to="lab_SecurityDeposit.150563" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SecurityDeposit.150563" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SecurityDeposit.150563">Cash deposited as bank guarantee</link:label>
    <link:loc xlink:label="loc_VehicleLeaseAndMaintenanceAgreementsMember.70487.11.6" xlink:href="plx-20121231.xsd#plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_VehicleLeaseAndMaintenanceAgreementsMember.70487.11.6" xlink:to="lab_VehicleLeaseAndMaintenanceAgreementsMember.358704" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_VehicleLeaseAndMaintenanceAgreementsMember.358704" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_VehicleLeaseAndMaintenanceAgreementsMember.358704">Vehicle Lease And Maintenance Agreements [Member]</link:label>
    <link:loc xlink:label="loc_VehicleLeaseAndMaintenanceAgreementsMember.70487.11.12" xlink:href="plx-20121231.xsd#plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_VehicleLeaseAndMaintenanceAgreementsMember.70487.11.12" xlink:to="lab_VehicleLeaseAndMaintenanceAgreementsMember.358705" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_VehicleLeaseAndMaintenanceAgreementsMember.358705" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_VehicleLeaseAndMaintenanceAgreementsMember.358705">Vehicle Lease and Maintenance Agreements Member</link:label>
    <link:loc xlink:label="loc_YissumAgreementMember.73722.11.6" xlink:href="plx-20121231.xsd#plx_YissumAgreementMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_YissumAgreementMember.73722.11.6" xlink:to="lab_YissumAgreementMember.379758" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_YissumAgreementMember.379758" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_YissumAgreementMember.379758">Yissum Agreement [Member]</link:label>
    <link:loc xlink:label="loc_GrantYearTwoThousandTenMember.70805.11.6" xlink:href="plx-20121231.xsd#plx_GrantYearTwoThousandTenMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrantYearTwoThousandTenMember.70805.11.6" xlink:to="lab_GrantYearTwoThousandTenMember.360749" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrantYearTwoThousandTenMember.360749" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GrantYearTwoThousandTenMember.360749">Grant Year Two Thousand Ten [Member]</link:label>
    <link:loc xlink:label="loc_GrantYearTwoThousandTenMember.70805.11.7" xlink:href="plx-20121231.xsd#plx_GrantYearTwoThousandTenMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrantYearTwoThousandTenMember.70805.11.7" xlink:to="lab_GrantYearTwoThousandTenMember.360752" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrantYearTwoThousandTenMember.360752" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_GrantYearTwoThousandTenMember.360752">2010 [Member]</link:label>
    <link:loc xlink:label="loc_GrantYearTwoThousandTenMember.70805.11.12" xlink:href="plx-20121231.xsd#plx_GrantYearTwoThousandTenMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrantYearTwoThousandTenMember.70805.11.12" xlink:to="lab_GrantYearTwoThousandTenMember.360751" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrantYearTwoThousandTenMember.360751" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_GrantYearTwoThousandTenMember.360751">Grant Year Two Thousand Ten [Member]</link:label>
    <link:loc xlink:label="loc_GrantYearTwoThousandTenSecondMember.70806.11.6" xlink:href="plx-20121231.xsd#plx_GrantYearTwoThousandTenSecondMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrantYearTwoThousandTenSecondMember.70806.11.6" xlink:to="lab_GrantYearTwoThousandTenSecondMember.360753" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrantYearTwoThousandTenSecondMember.360753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GrantYearTwoThousandTenSecondMember.360753">Grant Year Two Thousand Ten Second [Member]</link:label>
    <link:loc xlink:label="loc_GrantYearTwoThousandTenSecondMember.70806.11.7" xlink:href="plx-20121231.xsd#plx_GrantYearTwoThousandTenSecondMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrantYearTwoThousandTenSecondMember.70806.11.7" xlink:to="lab_GrantYearTwoThousandTenSecondMember.360755" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrantYearTwoThousandTenSecondMember.360755" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_GrantYearTwoThousandTenSecondMember.360755">2010 [Member]</link:label>
    <link:loc xlink:label="loc_GrantYearTwoThousandTenSecondMember.70806.11.12" xlink:href="plx-20121231.xsd#plx_GrantYearTwoThousandTenSecondMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrantYearTwoThousandTenSecondMember.70806.11.12" xlink:to="lab_GrantYearTwoThousandTenSecondMember.360754" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrantYearTwoThousandTenSecondMember.360754" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_GrantYearTwoThousandTenSecondMember.360754">Grant Year Two Thousand Ten Second [Member]</link:label>
    <link:loc xlink:label="loc_GrantYearTwoThousandTwelveMember.70807.11.6" xlink:href="plx-20121231.xsd#plx_GrantYearTwoThousandTwelveMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrantYearTwoThousandTwelveMember.70807.11.6" xlink:to="lab_GrantYearTwoThousandTwelveMember.360756" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrantYearTwoThousandTwelveMember.360756" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GrantYearTwoThousandTwelveMember.360756">Grant Year Two Thousand Twelve [Member]</link:label>
    <link:loc xlink:label="loc_GrantYearTwoThousandTwelveMember.70807.11.7" xlink:href="plx-20121231.xsd#plx_GrantYearTwoThousandTwelveMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrantYearTwoThousandTwelveMember.70807.11.7" xlink:to="lab_GrantYearTwoThousandTwelveMember.360758" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrantYearTwoThousandTwelveMember.360758" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_GrantYearTwoThousandTwelveMember.360758">2012 [Member]</link:label>
    <link:loc xlink:label="loc_GrantYearTwoThousandTwelveMember.70807.11.12" xlink:href="plx-20121231.xsd#plx_GrantYearTwoThousandTwelveMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrantYearTwoThousandTwelveMember.70807.11.12" xlink:to="lab_GrantYearTwoThousandTwelveMember.360757" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrantYearTwoThousandTwelveMember.360757" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_GrantYearTwoThousandTwelveMember.360757">Grant Year Two Thousand Twelve Member</link:label>
    <link:loc xlink:label="loc_GrantYearTwoThousandTwelveSecondMember.70808.11.6" xlink:href="plx-20121231.xsd#plx_GrantYearTwoThousandTwelveSecondMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrantYearTwoThousandTwelveSecondMember.70808.11.6" xlink:to="lab_GrantYearTwoThousandTwelveSecondMember.360762" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrantYearTwoThousandTwelveSecondMember.360762" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GrantYearTwoThousandTwelveSecondMember.360762">Grant Year Two Thousand Twelve Second [Member]</link:label>
    <link:loc xlink:label="loc_GrantYearTwoThousandTwelveSecondMember.70808.11.7" xlink:href="plx-20121231.xsd#plx_GrantYearTwoThousandTwelveSecondMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrantYearTwoThousandTwelveSecondMember.70808.11.7" xlink:to="lab_GrantYearTwoThousandTwelveSecondMember.360779" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrantYearTwoThousandTwelveSecondMember.360779" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_GrantYearTwoThousandTwelveSecondMember.360779">2012 [Member]</link:label>
    <link:loc xlink:label="loc_GrantYearTwoThousandTwelveSecondMember.70808.11.12" xlink:href="plx-20121231.xsd#plx_GrantYearTwoThousandTwelveSecondMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrantYearTwoThousandTwelveSecondMember.70808.11.12" xlink:to="lab_GrantYearTwoThousandTwelveSecondMember.360778" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrantYearTwoThousandTwelveSecondMember.360778" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_GrantYearTwoThousandTwelveSecondMember.360778">Grant Year Two Thousand Twelve Second [Member]</link:label>
    <link:loc xlink:label="loc_PlanNameAxis.3871.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PlanNameAxis.3871.11.6" xlink:to="lab_PlanNameAxis.13737" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PlanNameAxis.13737" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PlanNameAxis.13737">Plan Name [Axis]</link:label>
    <link:loc xlink:label="loc_PlanNameDomain.3870.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PlanNameDomain.3870.11.6" xlink:to="lab_PlanNameDomain.13729" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PlanNameDomain.13729" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PlanNameDomain.13729">Plan Name [Domain]</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.68656.11.8" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.68656.11.8" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.360792" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.360792" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.360792">Expiration period</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit.16365.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit.16365.11.6" xlink:to="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit.17569" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit.17569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit.17569">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit.16365.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit.16365.11.7" xlink:to="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit7.360790" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit7.360790" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit7.360790">Minimum exercise price</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.16378.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.16378.11.8" xlink:to="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.198908" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.198908" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.198908">Maximum exercise price</link:label>
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.8820.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.8820.11.6" xlink:to="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.5607" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.5607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.5607">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.8820.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.8820.11.7" xlink:to="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.135592" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.135592" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.135592">Unrecognized share-based compensation expense</link:label>
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1.8813.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1.8813.11.6" xlink:to="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1.5594" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1.5594" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1.5594">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1.8813.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1.8813.11.7" xlink:to="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1.134104" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1.134104" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1.134104">Unrecognized compensation cost, recognition period</link:label>
    <link:loc xlink:label="loc_ForfeitureRate.70802.11.6" xlink:href="plx-20121231.xsd#plx_ForfeitureRate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ForfeitureRate.70802.11.6" xlink:to="lab_ForfeitureRate.360737" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ForfeitureRate.360737" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ForfeitureRate.360737">Forfeiture Rate</link:label>
    <link:loc xlink:label="loc_ForfeitureRate.70802.11.7" xlink:href="plx-20121231.xsd#plx_ForfeitureRate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ForfeitureRate.70802.11.7" xlink:to="lab_ForfeitureRate.360739" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ForfeitureRate.360739" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ForfeitureRate.360739">Forfeiture rate</link:label>
    <link:loc xlink:label="loc_ForfeitureRate.70802.11.12" xlink:href="plx-20121231.xsd#plx_ForfeitureRate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ForfeitureRate.70802.11.12" xlink:to="lab_ForfeitureRate.360738" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ForfeitureRate.360738" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ForfeitureRate.360738">Forfeiture rate.</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.16324.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.16324.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.17508" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.17508" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.17508">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.16324.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.16324.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.134186" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.134186" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.134186">Dividend yield</link:label>
    <link:loc xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1.15604.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1.15604.11.6" xlink:to="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1.16361" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1.16361" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1.16361">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1.15604.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1.15604.11.7" xlink:to="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm17.134188" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm17.134188" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm17.134188">Expected life in years</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate.16318.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate.16318.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate.17502" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate.17502" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate.17502">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate.16318.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate.16318.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate.360736" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate.360736" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate.360736">Expected volatility</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.16317.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.16317.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.17501" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.17501" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.17501">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.16317.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.16317.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.134183" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.134183" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.134183">Risk free interest rate</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.68655.11.6" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.68655.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.145782.346447" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.145782.346447" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.145782.346447">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.68655.11.12" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.68655.11.12" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.145784.346449" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.145784.346449" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.145784.346449">Share based compensation arrangement by share based payment award grant date fair value.</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.68655.11.7" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.68655.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.145785.346448" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.145785.346448" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.145785.346448">Fair value of common stock at grant date</link:label>
    <link:loc xlink:label="loc_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember.70543.11.6" xlink:href="plx-20121231.xsd#plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember.70543.11.6" xlink:to="lab_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember.358891" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember.358891" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember.358891">Options Granted To Consultants Directors And Other Service Providers [Member]</link:label>
    <link:loc xlink:label="loc_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember.70543.11.12" xlink:href="plx-20121231.xsd#plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember.70543.11.12" xlink:to="lab_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember.358895" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember.358895" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember.358895">Options Granted To Consultants, Directors And Other Service Providers Member</link:label>
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.14555.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromStockOptionsExercised.14555.11.7" xlink:to="lab_ProceedsFromStockOptionsExercised.138107.346439" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromStockOptionsExercised.138107.346439" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromStockOptionsExercised.138107.346439">Cash proceeds from exercise of options</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.16332.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.16332.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.17517" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.17517" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.17517">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.16332.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.16332.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.358910" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.358910" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.358910">Exercisable at end of year</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.16322.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.16322.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.17506" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.17506" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.17506">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.16322.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.16322.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.358913" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.358913" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.358913">Exercisable at end of year</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.16330.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.16330.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.17514" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.17514" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.17514">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.16330.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.16330.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.358919" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.358919" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.358919">Intrinsic value of options exercised</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16369.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16369.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.17577" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.17577" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.17577">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16369.11.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16369.11.10" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.358903" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.358903" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.358903">Beginning Balance</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16369.11.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16369.11.11" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.358909" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.358909" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.358909">Ending Balance</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16356.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16356.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.17554" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.17554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.17554">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16356.11.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16356.11.10" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.358911" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.358911" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.358911">Weighted Average Exercise Price, Beginning Balance</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16356.11.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16356.11.11" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.358912" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.358912" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.358912">Weighted Average Exercise Price, Ending Balance</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.16305.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.16305.11.6" xlink:to="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.17487" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.17487" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.17487">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.16305.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.16305.11.7" xlink:to="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.134206" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.134206" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.134206">Exercised</link:label>
    <link:loc xlink:label="loc_FivePointZeroMember.70535.11.6" xlink:href="plx-20121231.xsd#plx_FivePointZeroMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FivePointZeroMember.70535.11.6" xlink:to="lab_FivePointZeroMember.358858" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FivePointZeroMember.358858" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FivePointZeroMember.358858">Five Point Zero [Member]</link:label>
    <link:loc xlink:label="loc_FivePointZeroMember.70535.11.7" xlink:href="plx-20121231.xsd#plx_FivePointZeroMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FivePointZeroMember.70535.11.7" xlink:to="lab_FivePointZeroMember.358861" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FivePointZeroMember.358861" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_FivePointZeroMember.358861">5.000 [Member]</link:label>
    <link:loc xlink:label="loc_FivePointZeroMember.70535.11.12" xlink:href="plx-20121231.xsd#plx_FivePointZeroMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FivePointZeroMember.70535.11.12" xlink:to="lab_FivePointZeroMember.358860" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FivePointZeroMember.358860" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_FivePointZeroMember.358860">Five Point Zero Member</link:label>
    <link:loc xlink:label="loc_NinePointSixSixMember.70539.11.6" xlink:href="plx-20121231.xsd#plx_NinePointSixSixMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NinePointSixSixMember.70539.11.6" xlink:to="lab_NinePointSixSixMember.358871" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NinePointSixSixMember.358871" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NinePointSixSixMember.358871">Nine Point Six Six [Member]</link:label>
    <link:loc xlink:label="loc_NinePointSixSixMember.70539.11.7" xlink:href="plx-20121231.xsd#plx_NinePointSixSixMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NinePointSixSixMember.70539.11.7" xlink:to="lab_NinePointSixSixMember.358873" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NinePointSixSixMember.358873" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NinePointSixSixMember.358873">9.660 [Member]</link:label>
    <link:loc xlink:label="loc_NinePointSixSixMember.70539.11.12" xlink:href="plx-20121231.xsd#plx_NinePointSixSixMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NinePointSixSixMember.70539.11.12" xlink:to="lab_NinePointSixSixMember.358872" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NinePointSixSixMember.358872" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_NinePointSixSixMember.358872">Nine Point Six Six [Member]</link:label>
    <link:loc xlink:label="loc_OneSixPointSevenMember.70540.11.6" xlink:href="plx-20121231.xsd#plx_OneSixPointSevenMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OneSixPointSevenMember.70540.11.6" xlink:to="lab_OneSixPointSevenMember.358875" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OneSixPointSevenMember.358875" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OneSixPointSevenMember.358875">One Six Point Seven [Member]</link:label>
    <link:loc xlink:label="loc_OneSixPointSevenMember.70540.11.7" xlink:href="plx-20121231.xsd#plx_OneSixPointSevenMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OneSixPointSevenMember.70540.11.7" xlink:to="lab_OneSixPointSevenMember.358877" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OneSixPointSevenMember.358877" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OneSixPointSevenMember.358877">16.700 [Member]</link:label>
    <link:loc xlink:label="loc_OneSixPointSevenMember.70540.11.12" xlink:href="plx-20121231.xsd#plx_OneSixPointSevenMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OneSixPointSevenMember.70540.11.12" xlink:to="lab_OneSixPointSevenMember.358876" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OneSixPointSevenMember.358876" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_OneSixPointSevenMember.358876">One Six Point Seven Member</link:label>
    <link:loc xlink:label="loc_OptionsAndRestrictedStockMember.70541.11.6" xlink:href="plx-20121231.xsd#plx_OptionsAndRestrictedStockMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OptionsAndRestrictedStockMember.70541.11.6" xlink:to="lab_OptionsAndRestrictedStockMember.358878" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OptionsAndRestrictedStockMember.358878" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OptionsAndRestrictedStockMember.358878">Options And Restricted Stock [Member]</link:label>
    <link:loc xlink:label="loc_OptionsAndRestrictedStockMember.70541.11.12" xlink:href="plx-20121231.xsd#plx_OptionsAndRestrictedStockMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OptionsAndRestrictedStockMember.70541.11.12" xlink:to="lab_OptionsAndRestrictedStockMember.358879" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OptionsAndRestrictedStockMember.358879" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_OptionsAndRestrictedStockMember.358879">Options And Restricted Stock [Member]</link:label>
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable.4676.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable.4676.11.6" xlink:to="lab_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable.16882" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable.16882" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable.16882">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</link:label>
    <link:loc xlink:label="loc_SevenPointFiveFiveMember.70538.11.6" xlink:href="plx-20121231.xsd#plx_SevenPointFiveFiveMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SevenPointFiveFiveMember.70538.11.6" xlink:to="lab_SevenPointFiveFiveMember.358868" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SevenPointFiveFiveMember.358868" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SevenPointFiveFiveMember.358868">Seven Point Five Five [Member]</link:label>
    <link:loc xlink:label="loc_SevenPointFiveFiveMember.70538.11.7" xlink:href="plx-20121231.xsd#plx_SevenPointFiveFiveMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SevenPointFiveFiveMember.70538.11.7" xlink:to="lab_SevenPointFiveFiveMember.358870" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SevenPointFiveFiveMember.358870" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SevenPointFiveFiveMember.358870">7.550 [Member]</link:label>
    <link:loc xlink:label="loc_SevenPointFiveFiveMember.70538.11.12" xlink:href="plx-20121231.xsd#plx_SevenPointFiveFiveMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SevenPointFiveFiveMember.70538.11.12" xlink:to="lab_SevenPointFiveFiveMember.358869" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SevenPointFiveFiveMember.358869" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_SevenPointFiveFiveMember.358869">Seven Point Five Five Member</link:label>
    <link:loc xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.15602.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.15602.11.6" xlink:to="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.16359" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.16359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.16359">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis.4870.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis.4870.11.6" xlink:to="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis.17542" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis.17542" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis.17542">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.11.6" xlink:to="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.17553" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.17553" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.17553">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:loc xlink:label="loc_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2.15607.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2.15607.11.6" xlink:to="lab_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2.16364" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2.16364" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2.16364">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:label="loc_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2.15607.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2.15607.11.7" xlink:to="lab_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2.358884" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2.358884" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2.358884">Weighted average remaining contractual life, exercisable</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems.4871.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems.4871.11.6" xlink:to="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems.17550" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems.17550" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems.17550">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.16348.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.16348.11.6" xlink:to="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.17539" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.17539" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.17539">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.16348.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.16348.11.7" xlink:to="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.358883" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.358883" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.358883">Number of options exercisable at end of year</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.16364.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.16364.11.6" xlink:to="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.17566" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.17566" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.17566">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.16364.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.16364.11.7" xlink:to="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.358881" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.358881" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.358881">Number of Options and restricted stock outstanding at end of year</link:label>
    <link:loc xlink:label="loc_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2.15612.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2.15612.11.6" xlink:to="lab_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2.16369" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2.16369" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2.16369">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:label="loc_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2.15612.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2.15612.11.7" xlink:to="lab_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2.358882" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2.358882" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2.358882">Weighted average remaining contractual life</link:label>
    <link:loc xlink:label="loc_SixPointEightOneZeroMember.70536.11.6" xlink:href="plx-20121231.xsd#plx_SixPointEightOneZeroMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SixPointEightOneZeroMember.70536.11.6" xlink:to="lab_SixPointEightOneZeroMember.358862" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SixPointEightOneZeroMember.358862" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SixPointEightOneZeroMember.358862">Six Point Eight One Zero [Member]</link:label>
    <link:loc xlink:label="loc_SixPointEightOneZeroMember.70536.11.7" xlink:href="plx-20121231.xsd#plx_SixPointEightOneZeroMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SixPointEightOneZeroMember.70536.11.7" xlink:to="lab_SixPointEightOneZeroMember.358864" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SixPointEightOneZeroMember.358864" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SixPointEightOneZeroMember.358864">6.810 [Member]</link:label>
    <link:loc xlink:label="loc_SixPointEightOneZeroMember.70536.11.12" xlink:href="plx-20121231.xsd#plx_SixPointEightOneZeroMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SixPointEightOneZeroMember.70536.11.12" xlink:to="lab_SixPointEightOneZeroMember.358863" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SixPointEightOneZeroMember.358863" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_SixPointEightOneZeroMember.358863">Six Point Eight One Zero Member</link:label>
    <link:loc xlink:label="loc_SixPointNineMember.70537.11.6" xlink:href="plx-20121231.xsd#plx_SixPointNineMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SixPointNineMember.70537.11.6" xlink:to="lab_SixPointNineMember.358865" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SixPointNineMember.358865" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SixPointNineMember.358865">Six Point Nine [Member]</link:label>
    <link:loc xlink:label="loc_SixPointNineMember.70537.11.7" xlink:href="plx-20121231.xsd#plx_SixPointNineMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SixPointNineMember.70537.11.7" xlink:to="lab_SixPointNineMember.358867" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SixPointNineMember.358867" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SixPointNineMember.358867">6.900 [Member]</link:label>
    <link:loc xlink:label="loc_SixPointNineMember.70537.11.12" xlink:href="plx-20121231.xsd#plx_SixPointNineMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SixPointNineMember.70537.11.12" xlink:to="lab_SixPointNineMember.358866" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SixPointNineMember.358866" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_SixPointNineMember.358866">Six Point Nine Member</link:label>
    <link:loc xlink:label="loc_ThreePointZeroTwoZeroMember.70534.11.6" xlink:href="plx-20121231.xsd#plx_ThreePointZeroTwoZeroMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ThreePointZeroTwoZeroMember.70534.11.6" xlink:to="lab_ThreePointZeroTwoZeroMember.358855" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ThreePointZeroTwoZeroMember.358855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ThreePointZeroTwoZeroMember.358855">Three Point Zero Two Zero [Member]</link:label>
    <link:loc xlink:label="loc_ThreePointZeroTwoZeroMember.70534.11.7" xlink:href="plx-20121231.xsd#plx_ThreePointZeroTwoZeroMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ThreePointZeroTwoZeroMember.70534.11.7" xlink:to="lab_ThreePointZeroTwoZeroMember.358857" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ThreePointZeroTwoZeroMember.358857" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ThreePointZeroTwoZeroMember.358857">3.020 [Member]</link:label>
    <link:loc xlink:label="loc_ThreePointZeroTwoZeroMember.70534.11.12" xlink:href="plx-20121231.xsd#plx_ThreePointZeroTwoZeroMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ThreePointZeroTwoZeroMember.70534.11.12" xlink:to="lab_ThreePointZeroTwoZeroMember.358856" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ThreePointZeroTwoZeroMember.358856" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ThreePointZeroTwoZeroMember.358856">Three Point Zero Two Zero Member</link:label>
    <link:loc xlink:label="loc_TwoPointSixFiveMember.70533.11.6" xlink:href="plx-20121231.xsd#plx_TwoPointSixFiveMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TwoPointSixFiveMember.70533.11.6" xlink:to="lab_TwoPointSixFiveMember.358852" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TwoPointSixFiveMember.358852" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_TwoPointSixFiveMember.358852">Two Point Six Five [Member]</link:label>
    <link:loc xlink:label="loc_TwoPointSixFiveMember.70533.11.7" xlink:href="plx-20121231.xsd#plx_TwoPointSixFiveMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TwoPointSixFiveMember.70533.11.7" xlink:to="lab_TwoPointSixFiveMember.358854" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TwoPointSixFiveMember.358854" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_TwoPointSixFiveMember.358854">2.650 [Member]</link:label>
    <link:loc xlink:label="loc_TwoPointSixFiveMember.70533.11.12" xlink:href="plx-20121231.xsd#plx_TwoPointSixFiveMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TwoPointSixFiveMember.70533.11.12" xlink:to="lab_TwoPointSixFiveMember.358853" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TwoPointSixFiveMember.358853" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_TwoPointSixFiveMember.358853">Two Point Six Five [Member]</link:label>
    <link:loc xlink:label="loc_TwoPointThreeFiveZeroMember.70532.11.6" xlink:href="plx-20121231.xsd#plx_TwoPointThreeFiveZeroMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TwoPointThreeFiveZeroMember.70532.11.6" xlink:to="lab_TwoPointThreeFiveZeroMember.358848" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TwoPointThreeFiveZeroMember.358848" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_TwoPointThreeFiveZeroMember.358848">Two Point Three Five Zero [Member]</link:label>
    <link:loc xlink:label="loc_TwoPointThreeFiveZeroMember.70532.11.7" xlink:href="plx-20121231.xsd#plx_TwoPointThreeFiveZeroMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TwoPointThreeFiveZeroMember.70532.11.7" xlink:to="lab_TwoPointThreeFiveZeroMember.358851" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TwoPointThreeFiveZeroMember.358851" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_TwoPointThreeFiveZeroMember.358851">2.350 [Member]</link:label>
    <link:loc xlink:label="loc_TwoPointThreeFiveZeroMember.70532.11.12" xlink:href="plx-20121231.xsd#plx_TwoPointThreeFiveZeroMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TwoPointThreeFiveZeroMember.70532.11.12" xlink:to="lab_TwoPointThreeFiveZeroMember.358850" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TwoPointThreeFiveZeroMember.358850" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_TwoPointThreeFiveZeroMember.358850">Two Point Three Five Zero [Member]</link:label>
    <link:loc xlink:label="loc_ZeroPointNineSevenTwoMember.70530.11.6" xlink:href="plx-20121231.xsd#plx_ZeroPointNineSevenTwoMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ZeroPointNineSevenTwoMember.70530.11.6" xlink:to="lab_ZeroPointNineSevenTwoMember.358843" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ZeroPointNineSevenTwoMember.358843" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ZeroPointNineSevenTwoMember.358843">Zero Point Nine Seven Two [Member]</link:label>
    <link:loc xlink:label="loc_ZeroPointNineSevenTwoMember.70530.11.7" xlink:href="plx-20121231.xsd#plx_ZeroPointNineSevenTwoMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ZeroPointNineSevenTwoMember.70530.11.7" xlink:to="lab_ZeroPointNineSevenTwoMember.358846" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ZeroPointNineSevenTwoMember.358846" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ZeroPointNineSevenTwoMember.358846">0.972 [Member]</link:label>
    <link:loc xlink:label="loc_ZeroPointNineSevenTwoMember.70530.11.12" xlink:href="plx-20121231.xsd#plx_ZeroPointNineSevenTwoMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ZeroPointNineSevenTwoMember.70530.11.12" xlink:to="lab_ZeroPointNineSevenTwoMember.358845" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ZeroPointNineSevenTwoMember.358845" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ZeroPointNineSevenTwoMember.358845">Zero Point Nine Seven Two [Member]</link:label>
    <link:loc xlink:label="loc_ZeroPointOneTwoZeroMember.70525.11.6" xlink:href="plx-20121231.xsd#plx_ZeroPointOneTwoZeroMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ZeroPointOneTwoZeroMember.70525.11.6" xlink:to="lab_ZeroPointOneTwoZeroMember.358832" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ZeroPointOneTwoZeroMember.358832" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ZeroPointOneTwoZeroMember.358832">Zero Point One Two Zero [Member]</link:label>
    <link:loc xlink:label="loc_ZeroPointOneTwoZeroMember.70525.11.7" xlink:href="plx-20121231.xsd#plx_ZeroPointOneTwoZeroMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ZeroPointOneTwoZeroMember.70525.11.7" xlink:to="lab_ZeroPointOneTwoZeroMember.358836" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ZeroPointOneTwoZeroMember.358836" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ZeroPointOneTwoZeroMember.358836">0.120 [Member]</link:label>
    <link:loc xlink:label="loc_ZeroPointOneTwoZeroMember.70525.11.12" xlink:href="plx-20121231.xsd#plx_ZeroPointOneTwoZeroMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ZeroPointOneTwoZeroMember.70525.11.12" xlink:to="lab_ZeroPointOneTwoZeroMember.358834" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ZeroPointOneTwoZeroMember.358834" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ZeroPointOneTwoZeroMember.358834">Zero Point One Two Zero Member</link:label>
    <link:loc xlink:label="loc_ZeroPointThreeNineNineMember.70527.11.6" xlink:href="plx-20121231.xsd#plx_ZeroPointThreeNineNineMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ZeroPointThreeNineNineMember.70527.11.6" xlink:to="lab_ZeroPointThreeNineNineMember.358837" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ZeroPointThreeNineNineMember.358837" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ZeroPointThreeNineNineMember.358837">Zero Point Three Nine Nine [Member]</link:label>
    <link:loc xlink:label="loc_ZeroPointThreeNineNineMember.70527.11.7" xlink:href="plx-20121231.xsd#plx_ZeroPointThreeNineNineMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ZeroPointThreeNineNineMember.70527.11.7" xlink:to="lab_ZeroPointThreeNineNineMember.358842" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ZeroPointThreeNineNineMember.358842" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ZeroPointThreeNineNineMember.358842">0.399 [Member]</link:label>
    <link:loc xlink:label="loc_ZeroPointThreeNineNineMember.70527.11.12" xlink:href="plx-20121231.xsd#plx_ZeroPointThreeNineNineMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ZeroPointThreeNineNineMember.70527.11.12" xlink:to="lab_ZeroPointThreeNineNineMember.358841" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ZeroPointThreeNineNineMember.358841" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ZeroPointThreeNineNineMember.358841">Zero Point Three Nine Nine [Member]</link:label>
    <link:loc xlink:label="loc_ZeroPointZeroZeroOneMember.70524.11.6" xlink:href="plx-20121231.xsd#plx_ZeroPointZeroZeroOneMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ZeroPointZeroZeroOneMember.70524.11.6" xlink:to="lab_ZeroPointZeroZeroOneMember.358829" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ZeroPointZeroZeroOneMember.358829" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ZeroPointZeroZeroOneMember.358829">Zero Point Zero Zero One [Member]</link:label>
    <link:loc xlink:label="loc_ZeroPointZeroZeroOneMember.70524.11.7" xlink:href="plx-20121231.xsd#plx_ZeroPointZeroZeroOneMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ZeroPointZeroZeroOneMember.70524.11.7" xlink:to="lab_ZeroPointZeroZeroOneMember.358831" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ZeroPointZeroZeroOneMember.358831" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ZeroPointZeroZeroOneMember.358831">0.001 [Member]</link:label>
    <link:loc xlink:label="loc_ZeroPointZeroZeroOneMember.70524.11.12" xlink:href="plx-20121231.xsd#plx_ZeroPointZeroZeroOneMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ZeroPointZeroZeroOneMember.70524.11.12" xlink:to="lab_ZeroPointZeroZeroOneMember.358830" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ZeroPointZeroZeroOneMember.358830" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ZeroPointZeroZeroOneMember.358830">Zero Point Zero Zero One [Member]</link:label>
    <link:loc xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.15602.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.15602.11.7" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.358885" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.358885" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.358885">Aggregate intrinsic value of the total outstanding and exercisable shares</link:label>
    <link:loc xlink:label="loc_AllocatedShareBasedCompensationExpense.5724.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AllocatedShareBasedCompensationExpense.5724.11.6" xlink:to="lab_AllocatedShareBasedCompensationExpense.852.346691" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AllocatedShareBasedCompensationExpense.852.346691" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AllocatedShareBasedCompensationExpense.852.346691">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:label="loc_CostOfSalesMember.1183.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfSalesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CostOfSalesMember.1183.11.6" xlink:to="lab_CostOfSalesMember.3160" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CostOfSalesMember.3160" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CostOfSalesMember.3160">Cost of Sales [Member]</link:label>
    <link:loc xlink:label="loc_CostOfSalesMember.1183.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfSalesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CostOfSalesMember.1183.11.7" xlink:to="lab_CostOfSalesMember7.381525" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CostOfSalesMember7.381525" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CostOfSalesMember7.381525">Cost of Revenues [Member]</link:label>
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1710.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1710.11.6" xlink:to="lab_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.5595" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.5595" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.5595">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.11.6" xlink:to="lab_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.5604" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.5604" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.5604">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]</link:label>
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpenseMember.2354.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GeneralAndAdministrativeExpenseMember.2354.11.6" xlink:to="lab_GeneralAndAdministrativeExpenseMember.7876.346697" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GeneralAndAdministrativeExpenseMember.7876.346697" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GeneralAndAdministrativeExpenseMember.7876.346697">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpenseMember.4381.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentExpenseMember.4381.11.6" xlink:to="lab_ResearchAndDevelopmentExpenseMember.15885.346698" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentExpenseMember.15885.346698" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentExpenseMember.15885.346698">Research and Development Expense [Member]</link:label>
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis.4617.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis.4617.11.6" xlink:to="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis.16736" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis.16736" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis.16736">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]</link:label>
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4618.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4618.11.6" xlink:to="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.16738" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.16738" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.16738">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:label="loc_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock.15803.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock.15803.11.6" xlink:to="lab_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock.16652" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock.16652" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock.16652">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock.15803.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock.15803.11.7" xlink:to="lab_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock.355237" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock.355237" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock.355237">Schedule of Deferred Tax Assets</link:label>
    <link:loc xlink:label="loc_ScheduleOfOpenTaxYearsTableTextBlock.70061.11.6" xlink:href="plx-20121231.xsd#plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfOpenTaxYearsTableTextBlock.70061.11.6" xlink:to="lab_ScheduleOfOpenTaxYearsTableTextBlock.355239" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfOpenTaxYearsTableTextBlock.355239" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfOpenTaxYearsTableTextBlock.355239">Schedule Of Open Tax Years [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleOfOpenTaxYearsTableTextBlock.70061.11.7" xlink:href="plx-20121231.xsd#plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfOpenTaxYearsTableTextBlock.70061.11.7" xlink:to="lab_ScheduleOfOpenTaxYearsTableTextBlock.355423" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfOpenTaxYearsTableTextBlock.355423" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfOpenTaxYearsTableTextBlock.355423">Schedule of Open Tax Years</link:label>
    <link:loc xlink:label="loc_ScheduleOfOpenTaxYearsTableTextBlock.70061.11.12" xlink:href="plx-20121231.xsd#plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfOpenTaxYearsTableTextBlock.70061.11.12" xlink:to="lab_ScheduleOfOpenTaxYearsTableTextBlock.355421" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfOpenTaxYearsTableTextBlock.355421" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfOpenTaxYearsTableTextBlock.355421">Schedule Of Open Tax Years Table Text Block</link:label>
    <link:loc xlink:label="loc_EntityDomain.99.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityDomain.99.11.6" xlink:to="dei_EntityDomain_lbl.346737" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="dei_EntityDomain_lbl.346737" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="dei_EntityDomain_lbl.346737">Entity [Domain]</link:label>
    <link:loc xlink:label="loc_LegalEntityAxis.136.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LegalEntityAxis.136.11.6" xlink:to="dei_LegalEntityAxis_lbl.346753" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="dei_LegalEntityAxis_lbl.346753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="dei_LegalEntityAxis_lbl.346753">Legal Entity [Axis]</link:label>
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateThereafter.70503.11.6" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectiveAdjustedIncomeTaxRateThereafter.70503.11.6" xlink:to="lab_EffectiveAdjustedIncomeTaxRateThereafter.358763" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectiveAdjustedIncomeTaxRateThereafter.358763" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EffectiveAdjustedIncomeTaxRateThereafter.358763">Effective Adjusted Income Tax Rate Thereafter</link:label>
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateThereafter.70503.11.7" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectiveAdjustedIncomeTaxRateThereafter.70503.11.7" xlink:to="lab_EffectiveAdjustedIncomeTaxRateThereafter.358765" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectiveAdjustedIncomeTaxRateThereafter.358765" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EffectiveAdjustedIncomeTaxRateThereafter.358765">Additional gradual decrease in tax rate, thereafter</link:label>
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateThereafter.70503.11.12" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectiveAdjustedIncomeTaxRateThereafter.70503.11.12" xlink:to="lab_EffectiveAdjustedIncomeTaxRateThereafter.358764" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectiveAdjustedIncomeTaxRateThereafter.358764" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_EffectiveAdjustedIncomeTaxRateThereafter.358764">Effective Adjusted Income Tax Rate Thereafter</link:label>
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateYearFive.70502.11.6" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectiveAdjustedIncomeTaxRateYearFive.70502.11.6" xlink:to="lab_EffectiveAdjustedIncomeTaxRateYearFive.358760" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectiveAdjustedIncomeTaxRateYearFive.358760" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EffectiveAdjustedIncomeTaxRateYearFive.358760">Effective Adjusted Income Tax Rate Year Five</link:label>
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateYearFive.70502.11.7" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectiveAdjustedIncomeTaxRateYearFive.70502.11.7" xlink:to="lab_EffectiveAdjustedIncomeTaxRateYearFive.358762" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectiveAdjustedIncomeTaxRateYearFive.358762" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EffectiveAdjustedIncomeTaxRateYearFive.358762">Additional gradual decrease in tax rate, 2016</link:label>
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateYearFive.70502.11.12" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectiveAdjustedIncomeTaxRateYearFive.70502.11.12" xlink:to="lab_EffectiveAdjustedIncomeTaxRateYearFive.358761" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectiveAdjustedIncomeTaxRateYearFive.358761" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_EffectiveAdjustedIncomeTaxRateYearFive.358761">Effective Adjusted Income Tax Rate Year Five</link:label>
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateYearFour.70501.11.6" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectiveAdjustedIncomeTaxRateYearFour.70501.11.6" xlink:to="lab_EffectiveAdjustedIncomeTaxRateYearFour.358756" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectiveAdjustedIncomeTaxRateYearFour.358756" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EffectiveAdjustedIncomeTaxRateYearFour.358756">Effective Adjusted Income Tax Rate Year Four</link:label>
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateYearFour.70501.11.7" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectiveAdjustedIncomeTaxRateYearFour.70501.11.7" xlink:to="lab_EffectiveAdjustedIncomeTaxRateYearFour.358758" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectiveAdjustedIncomeTaxRateYearFour.358758" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EffectiveAdjustedIncomeTaxRateYearFour.358758">Additional gradual decrease in tax rate, 2015</link:label>
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateYearFour.70501.11.12" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectiveAdjustedIncomeTaxRateYearFour.70501.11.12" xlink:to="lab_EffectiveAdjustedIncomeTaxRateYearFour.358757" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectiveAdjustedIncomeTaxRateYearFour.358757" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_EffectiveAdjustedIncomeTaxRateYearFour.358757">Additional gradual decrease in tax rate, 2015</link:label>
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateYearOne.70498.11.6" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectiveAdjustedIncomeTaxRateYearOne.70498.11.6" xlink:to="lab_EffectiveAdjustedIncomeTaxRateYearOne.358744" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectiveAdjustedIncomeTaxRateYearOne.358744" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EffectiveAdjustedIncomeTaxRateYearOne.358744">Effective Adjusted Income Tax Rate Year One</link:label>
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateYearOne.70498.11.7" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectiveAdjustedIncomeTaxRateYearOne.70498.11.7" xlink:to="lab_EffectiveAdjustedIncomeTaxRateYearOne.358746" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectiveAdjustedIncomeTaxRateYearOne.358746" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EffectiveAdjustedIncomeTaxRateYearOne.358746">Additional gradual decrease in tax rate, 2012</link:label>
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateYearOne.70498.11.12" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectiveAdjustedIncomeTaxRateYearOne.70498.11.12" xlink:to="lab_EffectiveAdjustedIncomeTaxRateYearOne.358745" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectiveAdjustedIncomeTaxRateYearOne.358745" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_EffectiveAdjustedIncomeTaxRateYearOne.358745">Effective Adjusted Income Tax Rate Year One</link:label>
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateYearThree.70500.11.6" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectiveAdjustedIncomeTaxRateYearThree.70500.11.6" xlink:to="lab_EffectiveAdjustedIncomeTaxRateYearThree.358753" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectiveAdjustedIncomeTaxRateYearThree.358753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EffectiveAdjustedIncomeTaxRateYearThree.358753">Effective Adjusted Income Tax Rate Year Three</link:label>
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateYearThree.70500.11.7" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectiveAdjustedIncomeTaxRateYearThree.70500.11.7" xlink:to="lab_EffectiveAdjustedIncomeTaxRateYearThree.358755" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectiveAdjustedIncomeTaxRateYearThree.358755" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EffectiveAdjustedIncomeTaxRateYearThree.358755">Additional gradual decrease in tax rate, 2014</link:label>
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateYearThree.70500.11.12" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectiveAdjustedIncomeTaxRateYearThree.70500.11.12" xlink:to="lab_EffectiveAdjustedIncomeTaxRateYearThree.358754" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectiveAdjustedIncomeTaxRateYearThree.358754" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_EffectiveAdjustedIncomeTaxRateYearThree.358754">Effective Adjusted Income Tax Rate Year Three</link:label>
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateYearTwo.70499.11.6" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectiveAdjustedIncomeTaxRateYearTwo.70499.11.6" xlink:to="lab_EffectiveAdjustedIncomeTaxRateYearTwo.358747" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectiveAdjustedIncomeTaxRateYearTwo.358747" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EffectiveAdjustedIncomeTaxRateYearTwo.358747">Effective Adjusted Income Tax Rate Year Two</link:label>
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateYearTwo.70499.11.7" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectiveAdjustedIncomeTaxRateYearTwo.70499.11.7" xlink:to="lab_EffectiveAdjustedIncomeTaxRateYearTwo.358751" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectiveAdjustedIncomeTaxRateYearTwo.358751" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EffectiveAdjustedIncomeTaxRateYearTwo.358751">Additional gradual decrease in tax rate, 2013</link:label>
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateYearTwo.70499.11.12" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectiveAdjustedIncomeTaxRateYearTwo.70499.11.12" xlink:to="lab_EffectiveAdjustedIncomeTaxRateYearTwo.358750" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectiveAdjustedIncomeTaxRateYearTwo.358750" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_EffectiveAdjustedIncomeTaxRateYearTwo.358750">Effective Adjusted Income Tax Rate Year Two</link:label>
    <link:loc xlink:label="loc_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate.8745.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate.8745.11.6" xlink:to="lab_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate.5495" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate.5495" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate.5495">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:label="loc_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate.8745.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate.8745.11.7" xlink:to="lab_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate.358738" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate.358738" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate.358738">Statutory income tax rate</link:label>
    <link:loc xlink:label="loc_IncomeTaxAuthorityAxis.2525.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeTaxAuthorityAxis.2525.11.6" xlink:to="lab_IncomeTaxAuthorityAxis.8458" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeTaxAuthorityAxis.8458" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncomeTaxAuthorityAxis.8458">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:label="loc_IncomeTaxAuthorityDomain.2535.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeTaxAuthorityDomain.2535.11.6" xlink:to="lab_IncomeTaxAuthorityDomain.8483" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeTaxAuthorityDomain.8483" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncomeTaxAuthorityDomain.8483">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:label="loc_IncomeTaxDisclosureLineItems.70495.11.6" xlink:href="plx-20121231.xsd#plx_IncomeTaxDisclosureLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeTaxDisclosureLineItems.70495.11.6" xlink:to="lab_IncomeTaxDisclosureLineItems.358736" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeTaxDisclosureLineItems.358736" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncomeTaxDisclosureLineItems.358736">Income Tax Disclosure [Line Items]</link:label>
    <link:loc xlink:label="loc_IncomeTaxDisclosureLineItems.70495.11.12" xlink:href="plx-20121231.xsd#plx_IncomeTaxDisclosureLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeTaxDisclosureLineItems.70495.11.12" xlink:to="lab_IncomeTaxDisclosureLineItems.358737" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeTaxDisclosureLineItems.358737" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_IncomeTaxDisclosureLineItems.358737">Income Tax Disclosure Line Items</link:label>
    <link:loc xlink:label="loc_IncomeTaxDisclosureTable.70493.11.6" xlink:href="plx-20121231.xsd#plx_IncomeTaxDisclosureTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeTaxDisclosureTable.70493.11.6" xlink:to="lab_IncomeTaxDisclosureTable.358725" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeTaxDisclosureTable.358725" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncomeTaxDisclosureTable.358725">Income Tax Disclosure [Table]</link:label>
    <link:loc xlink:label="loc_IncomeTaxDisclosureTable.70493.11.12" xlink:href="plx-20121231.xsd#plx_IncomeTaxDisclosureTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeTaxDisclosureTable.70493.11.12" xlink:to="lab_IncomeTaxDisclosureTable.358726" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeTaxDisclosureTable.358726" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_IncomeTaxDisclosureTable.358726">Income Tax Disclosure Table</link:label>
    <link:loc xlink:label="loc_OperatingLossCarryforwards.13067.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperatingLossCarryforwards.13067.11.6" xlink:to="lab_OperatingLossCarryforwards.12339" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperatingLossCarryforwards.12339" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OperatingLossCarryforwards.12339">Operating Loss Carryforwards</link:label>
    <link:loc xlink:label="loc_OperatingLossCarryforwards.13067.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperatingLossCarryforwards.13067.11.7" xlink:to="lab_OperatingLossCarryforwards.137244" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperatingLossCarryforwards.137244" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OperatingLossCarryforwards.137244">Net operating loss carry forwards</link:label>
    <link:loc xlink:label="loc_RestrictedAmountMember.70506.11.6" xlink:href="plx-20121231.xsd#plx_RestrictedAmountMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RestrictedAmountMember.70506.11.6" xlink:to="lab_RestrictedAmountMember.358772" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RestrictedAmountMember.358772" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RestrictedAmountMember.358772">Restricted Amount [Member]</link:label>
    <link:loc xlink:label="loc_RestrictedAmountMember.70506.11.12" xlink:href="plx-20121231.xsd#plx_RestrictedAmountMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RestrictedAmountMember.70506.11.12" xlink:to="lab_RestrictedAmountMember.358773" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RestrictedAmountMember.358773" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_RestrictedAmountMember.358773">Restricted Amount Member</link:label>
    <link:loc xlink:label="loc_SubsidiariesMember.5011.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsidiariesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SubsidiariesMember.5011.11.6" xlink:to="lab_SubsidiariesMember.18115" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SubsidiariesMember.18115" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SubsidiariesMember.18115">Subsidiaries [Member]</link:label>
    <link:loc xlink:label="loc_TaxBurdenDistributionLawMember.70504.11.6" xlink:href="plx-20121231.xsd#plx_TaxBurdenDistributionLawMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TaxBurdenDistributionLawMember.70504.11.6" xlink:to="lab_TaxBurdenDistributionLawMember.358766" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TaxBurdenDistributionLawMember.358766" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_TaxBurdenDistributionLawMember.358766">Tax Burden Distribution Law [Member]</link:label>
    <link:loc xlink:label="loc_TaxBurdenDistributionLawMember.70504.11.12" xlink:href="plx-20121231.xsd#plx_TaxBurdenDistributionLawMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TaxBurdenDistributionLawMember.70504.11.12" xlink:to="lab_TaxBurdenDistributionLawMember.358767" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TaxBurdenDistributionLawMember.358767" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_TaxBurdenDistributionLawMember.358767">Tax Burden Distribution Law Member</link:label>
    <link:loc xlink:label="loc_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal.70507.11.6" xlink:href="plx-20121231.xsd#plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal.70507.11.6" xlink:to="lab_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal.358774" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal.358774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal.358774">Tax Rate Assumption Related To Deferred Tax Difference Reversal</link:label>
    <link:loc xlink:label="loc_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal.70507.11.7" xlink:href="plx-20121231.xsd#plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal.70507.11.7" xlink:to="lab_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal.358776" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal.358776" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal.358776">Tax rates expected to be in effect when deferred tax asset differences reverse</link:label>
    <link:loc xlink:label="loc_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal.70507.11.12" xlink:href="plx-20121231.xsd#plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal.70507.11.12" xlink:to="lab_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal.358775" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal.358775" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal.358775">Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse.</link:label>
    <link:loc xlink:label="loc_TaxYearThereafterMember.70497.11.6" xlink:href="plx-20121231.xsd#plx_TaxYearThereafterMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TaxYearThereafterMember.70497.11.6" xlink:to="lab_TaxYearThereafterMember.358741" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TaxYearThereafterMember.358741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_TaxYearThereafterMember.358741">Tax Year Thereafter [Member]</link:label>
    <link:loc xlink:label="loc_TaxYearThereafterMember.70497.11.7" xlink:href="plx-20121231.xsd#plx_TaxYearThereafterMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TaxYearThereafterMember.70497.11.7" xlink:to="lab_TaxYearThereafterMember.358742" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TaxYearThereafterMember.358742" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_TaxYearThereafterMember.358742">Law for Amending the Israel Income Tax Ordinance, Tax Thereafter [Member]</link:label>
    <link:loc xlink:label="loc_TaxYearTwoThousandNineMember.70496.11.6" xlink:href="plx-20121231.xsd#plx_TaxYearTwoThousandNineMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TaxYearTwoThousandNineMember.70496.11.6" xlink:to="lab_TaxYearTwoThousandNineMember.358739" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TaxYearTwoThousandNineMember.358739" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_TaxYearTwoThousandNineMember.358739">Tax Year Two Thousand Nine [Member]</link:label>
    <link:loc xlink:label="loc_TaxYearTwoThousandNineMember.70496.11.7" xlink:href="plx-20121231.xsd#plx_TaxYearTwoThousandNineMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TaxYearTwoThousandNineMember.70496.11.7" xlink:to="lab_TaxYearTwoThousandNineMember.358740" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TaxYearTwoThousandNineMember.358740" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_TaxYearTwoThousandNineMember.358740">Law for Amending the Israel Income Tax Ordinance - 2009, Tax year [Member]</link:label>
    <link:loc xlink:label="loc_WithholdingTaxRateOnForeignIncome.70505.11.6" xlink:href="plx-20121231.xsd#plx_WithholdingTaxRateOnForeignIncome" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WithholdingTaxRateOnForeignIncome.70505.11.6" xlink:to="lab_WithholdingTaxRateOnForeignIncome.358768" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WithholdingTaxRateOnForeignIncome.358768" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_WithholdingTaxRateOnForeignIncome.358768">Withholding Tax Rate On Foreign Income</link:label>
    <link:loc xlink:label="loc_WithholdingTaxRateOnForeignIncome.70505.11.7" xlink:href="plx-20121231.xsd#plx_WithholdingTaxRateOnForeignIncome" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WithholdingTaxRateOnForeignIncome.70505.11.7" xlink:to="lab_WithholdingTaxRateOnForeignIncome.358771" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WithholdingTaxRateOnForeignIncome.358771" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_WithholdingTaxRateOnForeignIncome.358771">Withholding tax on the U.S. revenue source portion of the payments made to the Company for its share of Pfizer?s net profits</link:label>
    <link:loc xlink:label="loc_WithholdingTaxRateOnForeignIncome.70505.11.12" xlink:href="plx-20121231.xsd#plx_WithholdingTaxRateOnForeignIncome" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WithholdingTaxRateOnForeignIncome.70505.11.12" xlink:to="lab_WithholdingTaxRateOnForeignIncome.358770" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WithholdingTaxRateOnForeignIncome.358770" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_WithholdingTaxRateOnForeignIncome.358770">Withholding Tax Rate On Foreign Income</link:label>
    <link:loc xlink:label="loc_SubsidiariesMember.5011.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsidiariesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SubsidiariesMember.5011.11.7" xlink:to="SubsidiariesMember.358735" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="SubsidiariesMember.358735" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="SubsidiariesMember.358735">Protalix Ltd. [Member]</link:label>
    <link:loc xlink:label="loc_DeferredTaxAssetsDeferredIncome.7661.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredTaxAssetsDeferredIncome.7661.11.6" xlink:to="lab_DeferredTaxAssetsDeferredIncome.3962" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredTaxAssetsDeferredIncome.3962" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredTaxAssetsDeferredIncome.3962">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:label="loc_DeferredTaxAssetsDeferredIncome.7661.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredTaxAssetsDeferredIncome.7661.11.7" xlink:to="lab_DeferredTaxAssetsDeferredIncome.358722" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredTaxAssetsDeferredIncome.358722" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DeferredTaxAssetsDeferredIncome.358722">Deferred revenues</link:label>
    <link:loc xlink:label="loc_DeferredTaxAssetsInProcessResearchAndDevelopment.7627.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredTaxAssetsInProcessResearchAndDevelopment.7627.11.6" xlink:to="lab_DeferredTaxAssetsInProcessResearchAndDevelopment.3906" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredTaxAssetsInProcessResearchAndDevelopment.3906" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredTaxAssetsInProcessResearchAndDevelopment.3906">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:label="loc_DeferredTaxAssetsInProcessResearchAndDevelopment.7627.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredTaxAssetsInProcessResearchAndDevelopment.7627.11.7" xlink:to="lab_DeferredTaxAssetsInProcessResearchAndDevelopment.358718" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredTaxAssetsInProcessResearchAndDevelopment.358718" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DeferredTaxAssetsInProcessResearchAndDevelopment.358718">Research and development expenses</link:label>
    <link:loc xlink:label="loc_DeferredTaxAssetsNet.7623.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredTaxAssetsNet.7623.11.6" xlink:to="lab_DeferredTaxAssetsNet.3901" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredTaxAssetsNet.3901" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredTaxAssetsNet.3901">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:label="loc_DeferredTaxAssetsNet.7623.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredTaxAssetsNet.7623.11.9" xlink:to="lab_DeferredTaxAssetsNet.3902" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredTaxAssetsNet.3902" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_DeferredTaxAssetsNet.3902">Deferred Tax Assets, Net of Valuation Allowance, Total</link:label>
    <link:loc xlink:label="loc_DeferredTaxAssetsOperatingLossCarryforwards.7678.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredTaxAssetsOperatingLossCarryforwards.7678.11.6" xlink:to="lab_DeferredTaxAssetsOperatingLossCarryforwards.3989" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredTaxAssetsOperatingLossCarryforwards.3989" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredTaxAssetsOperatingLossCarryforwards.3989">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:label="loc_DeferredTaxAssetsOperatingLossCarryforwards.7678.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredTaxAssetsOperatingLossCarryforwards.7678.11.7" xlink:to="lab_DeferredTaxAssetsOperatingLossCarryforwards.358723" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredTaxAssetsOperatingLossCarryforwards.358723" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DeferredTaxAssetsOperatingLossCarryforwards.358723">Net operating loss carry forwards</link:label>
    <link:loc xlink:label="loc_DeferredTaxAssetsPropertyPlantAndEquipment.7500.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredTaxAssetsPropertyPlantAndEquipment.7500.11.6" xlink:to="lab_DeferredTaxAssetsPropertyPlantAndEquipment.3689" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredTaxAssetsPropertyPlantAndEquipment.3689" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredTaxAssetsPropertyPlantAndEquipment.3689">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:label="loc_DeferredTaxAssetsPropertyPlantAndEquipment.7500.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredTaxAssetsPropertyPlantAndEquipment.7500.11.7" xlink:to="lab_DeferredTaxAssetsPropertyPlantAndEquipment.358719" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredTaxAssetsPropertyPlantAndEquipment.358719" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DeferredTaxAssetsPropertyPlantAndEquipment.358719">Property and equipment</link:label>
    <link:loc xlink:label="loc_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits.7709.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits.7709.11.6" xlink:to="lab_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits.4028" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits.4028" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits.4028">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:loc xlink:label="loc_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits.7709.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits.7709.11.7" xlink:to="lab_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits.358720" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits.358720" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits.358720">Provision for vacation</link:label>
    <link:loc xlink:label="loc_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments.7710.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments.7710.11.6" xlink:to="lab_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments.4030" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments.4030" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments.4030">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Severance Payments</link:label>
    <link:loc xlink:label="loc_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments.7710.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments.7710.11.7" xlink:to="lab_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments.358721" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments.358721" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments.358721">Severance pay obligation</link:label>
    <link:loc xlink:label="loc_DeferredTaxAssetsValuationAllowance.7732.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredTaxAssetsValuationAllowance.7732.11.6" xlink:to="lab_DeferredTaxAssetsValuationAllowance.4058" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredTaxAssetsValuationAllowance.4058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredTaxAssetsValuationAllowance.4058">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:label="loc_DeferredTaxAssetsValuationAllowance.7732.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredTaxAssetsValuationAllowance.7732.11.42" xlink:to="lab_DeferredTaxAssetsValuationAllowance.358724" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredTaxAssetsValuationAllowance.358724" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_DeferredTaxAssetsValuationAllowance.358724">Valuation allowance</link:label>
    <link:loc xlink:label="loc_IL.17552.11.6" xlink:href="http://xbrl.sec.gov/country/2012/country-2012-01-31.xsd#country_IL" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IL.17552.11.6" xlink:to="lab_IL.358727" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IL.358727" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IL.358727">ISRAEL [Member]</link:label>
    <link:loc xlink:label="loc_IncomeTaxContingencyLineItems.2528.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeTaxContingencyLineItems.2528.11.6" xlink:to="lab_IncomeTaxContingencyLineItems.8469" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeTaxContingencyLineItems.8469" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncomeTaxContingencyLineItems.8469">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:label="loc_IncomeTaxContingencyTable.2508.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeTaxContingencyTable.2508.11.6" xlink:to="lab_IncomeTaxContingencyTable.8412" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeTaxContingencyTable.8412" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncomeTaxContingencyTable.8412">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:label="loc_NL.17619.11.6" xlink:href="http://xbrl.sec.gov/country/2012/country-2012-01-31.xsd#country_NL" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NL.17619.11.6" xlink:to="lab_NL.358729" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NL.358729" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NL.358729">NETHERLANDS [Member]</link:label>
    <link:loc xlink:label="loc_OpenTaxYear.13045.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OpenTaxYear.13045.11.6" xlink:to="lab_OpenTaxYear.12302" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OpenTaxYear.12302" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OpenTaxYear.12302">Open Tax Year</link:label>
    <link:loc xlink:label="loc_OpenTaxYear.13045.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OpenTaxYear.13045.11.7" xlink:to="lab_OpenTaxYear.358730" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OpenTaxYear.358730" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OpenTaxYear.358730">Open tax year</link:label>
    <link:loc xlink:label="loc_US.17690.11.6" xlink:href="http://xbrl.sec.gov/country/2012/country-2012-01-31.xsd#country_US" xlink:type="locator" />
    <link:labelArc xlink:from="loc_US.17690.11.6" xlink:to="lab_US.358728" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_US.358728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_US.358728">UNITED STATES [Member]</link:label>
    <link:loc xlink:label="loc_AccountsNotesAndLoansReceivableLineItems.410.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsNotesAndLoansReceivableLineItems.410.11.6" xlink:to="lab_AccountsNotesAndLoansReceivableLineItems.423" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsNotesAndLoansReceivableLineItems.423" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsNotesAndLoansReceivableLineItems.423">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:label="loc_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis.392.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis.392.11.6" xlink:to="lab_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis.354" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis.354" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis.354">Receivable Type [Axis]</link:label>
    <link:loc xlink:label="loc_DeferredCostMember.70510.11.6" xlink:href="plx-20121231.xsd#plx_DeferredCostMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredCostMember.70510.11.6" xlink:to="lab_DeferredCostMember.358788" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredCostMember.358788" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredCostMember.358788">Deferred Cost [Member]</link:label>
    <link:loc xlink:label="loc_DeferredCostMember.70510.11.12" xlink:href="plx-20121231.xsd#plx_DeferredCostMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredCostMember.70510.11.12" xlink:to="lab_DeferredCostMember.358789" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredCostMember.358789" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_DeferredCostMember.358789">Deferred Cost Member</link:label>
    <link:loc xlink:label="loc_InstitutionsMember.70511.11.6" xlink:href="plx-20121231.xsd#plx_InstitutionsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InstitutionsMember.70511.11.6" xlink:to="lab_InstitutionsMember.358790" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InstitutionsMember.358790" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InstitutionsMember.358790">Institutions [Member]</link:label>
    <link:loc xlink:label="loc_InstitutionsMember.70511.11.12" xlink:href="plx-20121231.xsd#plx_InstitutionsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InstitutionsMember.70511.11.12" xlink:to="lab_InstitutionsMember.358791" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InstitutionsMember.358791" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_InstitutionsMember.358791">Institutions Member</link:label>
    <link:loc xlink:label="loc_OtherReceivablesNetCurrent.13172.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherReceivablesNetCurrent.13172.11.8" xlink:to="lab_OtherReceivablesNetCurrent.189006" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherReceivablesNetCurrent.189006" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherReceivablesNetCurrent.189006">Other receivables</link:label>
    <link:loc xlink:label="loc_PrepaidExpenseCurrent.14246.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PrepaidExpenseCurrent.14246.11.6" xlink:to="lab_PrepaidExpenseCurrent.14227" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PrepaidExpenseCurrent.14227" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PrepaidExpenseCurrent.14227">Prepaid Expense, Current</link:label>
    <link:loc xlink:label="loc_PrepaidExpenseCurrent.14246.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PrepaidExpenseCurrent.14246.11.7" xlink:to="lab_PrepaidExpenseCurrent.134708" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PrepaidExpenseCurrent.134708" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PrepaidExpenseCurrent.134708">Prepaid expenses</link:label>
    <link:loc xlink:label="loc_ReceivableTypeDomain.4239.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ReceivableTypeDomain.4239.11.6" xlink:to="lab_ReceivableTypeDomain.15382" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ReceivableTypeDomain.15382" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ReceivableTypeDomain.15382">Receivable Type [Domain]</link:label>
    <link:loc xlink:label="loc_RestrictedDepositMember.70513.11.6" xlink:href="plx-20121231.xsd#plx_RestrictedDepositMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RestrictedDepositMember.70513.11.6" xlink:to="lab_RestrictedDepositMember.358794" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RestrictedDepositMember.358794" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RestrictedDepositMember.358794">Restricted Deposit [Member]</link:label>
    <link:loc xlink:label="loc_RestrictedDepositMember.70513.11.12" xlink:href="plx-20121231.xsd#plx_RestrictedDepositMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RestrictedDepositMember.70513.11.12" xlink:to="lab_RestrictedDepositMember.358795" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RestrictedDepositMember.358795" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_RestrictedDepositMember.358795">Restricted Deposit Member</link:label>
    <link:loc xlink:label="loc_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable.4698.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable.4698.11.6" xlink:to="lab_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable.16942" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable.16942" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable.16942">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:label="loc_StateOfIsraelMember.70512.11.6" xlink:href="plx-20121231.xsd#plx_StateOfIsraelMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StateOfIsraelMember.70512.11.6" xlink:to="lab_StateOfIsraelMember.358792" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StateOfIsraelMember.358792" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StateOfIsraelMember.358792">State Of Israel [Member]</link:label>
    <link:loc xlink:label="loc_StateOfIsraelMember.70512.11.12" xlink:href="plx-20121231.xsd#plx_StateOfIsraelMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StateOfIsraelMember.70512.11.12" xlink:to="lab_StateOfIsraelMember.358793" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StateOfIsraelMember.358793" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_StateOfIsraelMember.358793">State Of Israel Member</link:label>
    <link:loc xlink:label="loc_SundryMember.70514.11.6" xlink:href="plx-20121231.xsd#plx_SundryMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SundryMember.70514.11.6" xlink:to="lab_SundryMember.358797" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SundryMember.358797" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SundryMember.358797">Sundry [Member]</link:label>
    <link:loc xlink:label="loc_SundryMember.70514.11.12" xlink:href="plx-20121231.xsd#plx_SundryMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SundryMember.70514.11.12" xlink:to="lab_SundryMember.358798" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SundryMember.358798" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_SundryMember.358798">Sundry Member</link:label>
    <link:loc xlink:label="loc_CompensationToTheNon-executiveDirectorsMember.70522.11.6" xlink:href="plx-20121231.xsd#plx_CompensationToTheNon-executiveDirectorsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CompensationToTheNon-executiveDirectorsMember.70522.11.6" xlink:to="lab_CompensationToTheNon-executiveDirectorsMember.358818" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CompensationToTheNon-executiveDirectorsMember.358818" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CompensationToTheNon-executiveDirectorsMember.358818">Compensation To The Non -executiveDirectors [Member]</link:label>
    <link:loc xlink:label="loc_CompensationToTheNon-executiveDirectorsMember.70522.11.12" xlink:href="plx-20121231.xsd#plx_CompensationToTheNon-executiveDirectorsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CompensationToTheNon-executiveDirectorsMember.70522.11.12" xlink:to="lab_CompensationToTheNon-executiveDirectorsMember.358819" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CompensationToTheNon-executiveDirectorsMember.358819" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_CompensationToTheNon-executiveDirectorsMember.358819">Compensation To The Non-executive Directors Member</link:label>
    <link:loc xlink:label="loc_ManagementAndConsultingFeesToChairmanOfBoardMember.70521.11.6" xlink:href="plx-20121231.xsd#plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ManagementAndConsultingFeesToChairmanOfBoardMember.70521.11.6" xlink:to="lab_ManagementAndConsultingFeesToChairmanOfBoardMember.358816" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ManagementAndConsultingFeesToChairmanOfBoardMember.358816" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ManagementAndConsultingFeesToChairmanOfBoardMember.358816">Management And Consulting Fees To Chairman Of Board [Member]</link:label>
    <link:loc xlink:label="loc_ManagementAndConsultingFeesToChairmanOfBoardMember.70521.11.12" xlink:href="plx-20121231.xsd#plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ManagementAndConsultingFeesToChairmanOfBoardMember.70521.11.12" xlink:to="lab_ManagementAndConsultingFeesToChairmanOfBoardMember.358817" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ManagementAndConsultingFeesToChairmanOfBoardMember.358817" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ManagementAndConsultingFeesToChairmanOfBoardMember.358817">Management And Consulting Fees To Chairman Of Board [Member]</link:label>
    <link:loc xlink:label="loc_RelatedPartyDomain.4349.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RelatedPartyDomain.4349.11.6" xlink:to="lab_RelatedPartyDomain.15733" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RelatedPartyDomain.15733" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RelatedPartyDomain.15733">Related Party [Domain]</link:label>
    <link:loc xlink:label="loc_RelatedPartyTransactionAmountsOfTransaction.15187.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RelatedPartyTransactionAmountsOfTransaction.15187.11.6" xlink:to="lab_RelatedPartyTransactionAmountsOfTransaction.15735" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RelatedPartyTransactionAmountsOfTransaction.15735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RelatedPartyTransactionAmountsOfTransaction.15735">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:label="loc_RelatedPartyTransactionLineItems.4347.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RelatedPartyTransactionLineItems.4347.11.6" xlink:to="lab_RelatedPartyTransactionLineItems.15723" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RelatedPartyTransactionLineItems.15723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RelatedPartyTransactionLineItems.15723">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:label="loc_RelatedPartyTransactionsByRelatedPartyAxis.4351.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RelatedPartyTransactionsByRelatedPartyAxis.4351.11.6" xlink:to="lab_RelatedPartyTransactionsByRelatedPartyAxis.15743" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RelatedPartyTransactionsByRelatedPartyAxis.15743" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RelatedPartyTransactionsByRelatedPartyAxis.15743">Related Party [Axis]</link:label>
    <link:loc xlink:label="loc_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable.4689.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable.4689.11.6" xlink:to="lab_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable.16917" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable.16917" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable.16917">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:label="loc_ComputerEquipmentMember.1086.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ComputerEquipmentMember.1086.11.6" xlink:to="lab_ComputerEquipmentMember.2833" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ComputerEquipmentMember.2833" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ComputerEquipmentMember.2833">Computer Equipment [Member]</link:label>
    <link:loc xlink:label="loc_FurnitureAndFixturesMember.2275.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FurnitureAndFixturesMember.2275.11.6" xlink:to="lab_FurnitureAndFixturesMember.7585" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FurnitureAndFixturesMember.7585" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FurnitureAndFixturesMember.7585">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:label="loc_FurnitureAndFixturesMember.2275.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FurnitureAndFixturesMember.2275.11.7" xlink:to="lab_FurnitureAndFixturesMember.355665" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FurnitureAndFixturesMember.355665" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_FurnitureAndFixturesMember.355665">Furniture [Member]</link:label>
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentUsefulLife.14662.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyPlantAndEquipmentUsefulLife.14662.11.6" xlink:to="lab_PropertyPlantAndEquipmentUsefulLife.14857" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PropertyPlantAndEquipmentUsefulLife.14857" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PropertyPlantAndEquipmentUsefulLife.14857">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentUsefulLife.14662.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyPlantAndEquipmentUsefulLife.14662.11.7" xlink:to="lab_PropertyPlantAndEquipmentUsefulLife.355666" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PropertyPlantAndEquipmentUsefulLife.355666" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PropertyPlantAndEquipmentUsefulLife.355666">Property and equipment, useful life</link:label>
    <link:loc xlink:label="loc_AccruedLiabilitiesCurrentAndNoncurrent.5515.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccruedLiabilitiesCurrentAndNoncurrent.5515.11.6" xlink:to="lab_AccruedLiabilitiesCurrentAndNoncurrent.501" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccruedLiabilitiesCurrentAndNoncurrent.501" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccruedLiabilitiesCurrentAndNoncurrent.501">Accrued Liabilities</link:label>
    <link:loc xlink:label="loc_AccruedLiabilitiesCurrentAndNoncurrent.5515.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccruedLiabilitiesCurrentAndNoncurrent.5515.11.8" xlink:to="lab_AccruedLiabilitiesCurrentAndNoncurrent.361051" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccruedLiabilitiesCurrentAndNoncurrent.361051" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccruedLiabilitiesCurrentAndNoncurrent.361051">Accrued liabilities accrued related to the Collaboration Operation</link:label>
    <link:loc xlink:label="loc_CollaborationOperationMember.70846.11.6" xlink:href="plx-20121231.xsd#plx_CollaborationOperationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborationOperationMember.70846.11.6" xlink:to="lab_CollaborationOperationMember.361054" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborationOperationMember.361054" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CollaborationOperationMember.361054">Collaboration Operation [Member]</link:label>
    <link:loc xlink:label="loc_CollaborationOperationMember.70846.11.12" xlink:href="plx-20121231.xsd#plx_CollaborationOperationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborationOperationMember.70846.11.12" xlink:to="lab_CollaborationOperationMember.361055" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborationOperationMember.361055" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_CollaborationOperationMember.361055">Collaboration Operation Member</link:label>
    <link:loc xlink:label="loc_CollaborativeAndLicenseArrangementTable.70133.11.6" xlink:href="plx-20121231.xsd#plx_CollaborativeAndLicenseArrangementTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeAndLicenseArrangementTable.70133.11.6" xlink:to="lab_CollaborativeAndLicenseArrangementTable.355742" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeAndLicenseArrangementTable.355742" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeAndLicenseArrangementTable.355742">Collaborative And License Arrangement [Table]</link:label>
    <link:loc xlink:label="loc_CollaborativeAndLicenseArrangementTable.70133.11.12" xlink:href="plx-20121231.xsd#plx_CollaborativeAndLicenseArrangementTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeAndLicenseArrangementTable.70133.11.12" xlink:to="lab_CollaborativeAndLicenseArrangementTable.355746" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeAndLicenseArrangementTable.355746" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeAndLicenseArrangementTable.355746">Collaborative And License Arrangement Table</link:label>
    <link:loc xlink:label="loc_CollaborativeArrangementProfitSharePercentage.68635.11.6" xlink:href="plx-20121231.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeArrangementProfitSharePercentage.68635.11.6" xlink:to="lab_CollaborativeArrangementProfitSharePercentage.138005.346362" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeArrangementProfitSharePercentage.138005.346362" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeArrangementProfitSharePercentage.138005.346362">Collaborative Arrangement Profit Share Percentage</link:label>
    <link:loc xlink:label="loc_CollaborativeArrangementProfitSharePercentage.68635.11.12" xlink:href="plx-20121231.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeArrangementProfitSharePercentage.68635.11.12" xlink:to="lab_CollaborativeArrangementProfitSharePercentage.138007.346364" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeArrangementProfitSharePercentage.138007.346364" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeArrangementProfitSharePercentage.138007.346364">Collaborative arrangement profit sharing percentage.</link:label>
    <link:loc xlink:label="loc_CollaborativeArrangementProfitSharePercentage.68635.11.7" xlink:href="plx-20121231.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeArrangementProfitSharePercentage.68635.11.7" xlink:to="lab_CollaborativeArrangementProfitSharePercentage.138010.346363" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeArrangementProfitSharePercentage.138010.346363" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeArrangementProfitSharePercentage.138010.346363">Pfizer Agreement, future revenues and expense sharing percentage</link:label>
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.11.6" xlink:to="lab_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.2624.346365" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.2624.346365" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.2624.346365">Collaborative Arrangements and Non-collaborative Arrangements [Axis]</link:label>
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.11.6" xlink:to="lab_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.2617.346366" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.2617.346366" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.2617.346366">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]</link:label>
    <link:loc xlink:label="loc_LiabilitiesAccruedFromLicensingAgreement.74712.11.6" xlink:href="plx-20121231.xsd#plx_LiabilitiesAccruedFromLicensingAgreement" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAccruedFromLicensingAgreement.74712.11.6" xlink:to="lab_LiabilitiesAccruedFromLicensingAgreement.387654" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAccruedFromLicensingAgreement.387654" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAccruedFromLicensingAgreement.387654">Liabilities Accrued From Licensing Agreement</link:label>
    <link:loc xlink:label="loc_LiabilitiesAccruedFromLicensingAgreement.74712.11.7" xlink:href="plx-20121231.xsd#plx_LiabilitiesAccruedFromLicensingAgreement" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAccruedFromLicensingAgreement.74712.11.7" xlink:to="lab_LiabilitiesAccruedFromLicensingAgreement.388237" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAccruedFromLicensingAgreement.388237" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAccruedFromLicensingAgreement.388237">Accrued long term liabilities</link:label>
    <link:loc xlink:label="loc_LiabilitiesAccruedFromLicensingAgreement.74712.11.12" xlink:href="plx-20121231.xsd#plx_LiabilitiesAccruedFromLicensingAgreement" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAccruedFromLicensingAgreement.74712.11.12" xlink:to="lab_LiabilitiesAccruedFromLicensingAgreement.387655" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAccruedFromLicensingAgreement.387655" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAccruedFromLicensingAgreement.387655">Liabilities accrued from licensing agreement.</link:label>
    <link:loc xlink:label="loc_MilestonePayment.68644.11.6" xlink:href="plx-20121231.xsd#plx_MilestonePayment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MilestonePayment.68644.11.6" xlink:to="lab_MilestonePayment.138000.346368" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MilestonePayment.138000.346368" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_MilestonePayment.138000.346368">Milestone Payment</link:label>
    <link:loc xlink:label="loc_MilestonePayment.68644.11.12" xlink:href="plx-20121231.xsd#plx_MilestonePayment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MilestonePayment.68644.11.12" xlink:to="lab_MilestonePayment.138001.346370" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MilestonePayment.138001.346370" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_MilestonePayment.138001.346370">Milestone payment.</link:label>
    <link:loc xlink:label="loc_MilestonePayment.68644.11.7" xlink:href="plx-20121231.xsd#plx_MilestonePayment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MilestonePayment.68644.11.7" xlink:to="lab_MilestonePayment.138002.346369" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MilestonePayment.138002.346369" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_MilestonePayment.138002.346369">Milestone payment triggered</link:label>
    <link:loc xlink:label="loc_PfizerIncorporationMember.68649.11.6" xlink:href="plx-20121231.xsd#plx_PfizerIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PfizerIncorporationMember.68649.11.6" xlink:to="lab_PfizerIncorporationMember.137992.346374" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PfizerIncorporationMember.137992.346374" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PfizerIncorporationMember.137992.346374">Pfizer Incorporation [Member]</link:label>
    <link:loc xlink:label="loc_PfizerIncorporationMember.68649.11.12" xlink:href="plx-20121231.xsd#plx_PfizerIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PfizerIncorporationMember.68649.11.12" xlink:to="lab_PfizerIncorporationMember.137993.346376" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PfizerIncorporationMember.137993.346376" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_PfizerIncorporationMember.137993.346376">Pfizer Incorporation [Member].</link:label>
    <link:loc xlink:label="loc_PfizerIncorporationMember.68649.11.7" xlink:href="plx-20121231.xsd#plx_PfizerIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PfizerIncorporationMember.68649.11.7" xlink:to="lab_PfizerIncorporationMember.137994.346375" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PfizerIncorporationMember.137994.346375" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PfizerIncorporationMember.137994.346375">Pfizer Incorporation [Member]</link:label>
    <link:loc xlink:label="loc_ProceedsFromCollaborators.14370.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromCollaborators.14370.11.7" xlink:to="lab_ProceedsFromCollaborators.137999.346378" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromCollaborators.137999.346378" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromCollaborators.137999.346378">Pfizer Agreement, upfront payment received</link:label>
    <link:loc xlink:label="loc_ProceedsFromCollaborators.14370.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromCollaborators.14370.11.6" xlink:to="lab_ProceedsFromCollaborators.14422.346377" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromCollaborators.14422.346377" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromCollaborators.14422.346377">Proceeds from Collaborators</link:label>
    <link:loc xlink:label="loc_ProtalixBioTherapeuticsIncorporationMember.68651.11.6" xlink:href="plx-20121231.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProtalixBioTherapeuticsIncorporationMember.68651.11.6" xlink:to="lab_ProtalixBioTherapeuticsIncorporationMember.137989.346379" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProtalixBioTherapeuticsIncorporationMember.137989.346379" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProtalixBioTherapeuticsIncorporationMember.137989.346379">Protalix Bio Therapeutics Incorporation [Member]</link:label>
    <link:loc xlink:label="loc_ProtalixBioTherapeuticsIncorporationMember.68651.11.12" xlink:href="plx-20121231.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProtalixBioTherapeuticsIncorporationMember.68651.11.12" xlink:to="lab_ProtalixBioTherapeuticsIncorporationMember.137990.346381" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProtalixBioTherapeuticsIncorporationMember.137990.346381" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ProtalixBioTherapeuticsIncorporationMember.137990.346381">Protalix Bio Therapeutics Incorporation [Member].</link:label>
    <link:loc xlink:label="loc_ProtalixBioTherapeuticsIncorporationMember.68651.11.7" xlink:href="plx-20121231.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProtalixBioTherapeuticsIncorporationMember.68651.11.7" xlink:to="lab_ProtalixBioTherapeuticsIncorporationMember.137991.346380" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProtalixBioTherapeuticsIncorporationMember.137991.346380" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProtalixBioTherapeuticsIncorporationMember.137991.346380">Protalix Bio Therapeutics Incorporation [Member]</link:label>
    <link:loc xlink:label="loc_RevenueRecognizedOverDesignatedPeriod.73718.11.6" xlink:href="plx-20121231.xsd#plx_RevenueRecognizedOverDesignatedPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RevenueRecognizedOverDesignatedPeriod.73718.11.6" xlink:to="lab_RevenueRecognizedOverDesignatedPeriod.379730" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RevenueRecognizedOverDesignatedPeriod.379730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RevenueRecognizedOverDesignatedPeriod.379730">Revenue Recognized Over Designated Period</link:label>
    <link:loc xlink:label="loc_RevenueRecognizedOverDesignatedPeriod.73718.11.7" xlink:href="plx-20121231.xsd#plx_RevenueRecognizedOverDesignatedPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RevenueRecognizedOverDesignatedPeriod.73718.11.7" xlink:to="lab_RevenueRecognizedOverDesignatedPeriod.379732" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RevenueRecognizedOverDesignatedPeriod.379732" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_RevenueRecognizedOverDesignatedPeriod.379732">Revenue recognized over designated period of relationship</link:label>
    <link:loc xlink:label="loc_RevenueRecognizedOverDesignatedPeriod.73718.11.12" xlink:href="plx-20121231.xsd#plx_RevenueRecognizedOverDesignatedPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RevenueRecognizedOverDesignatedPeriod.73718.11.12" xlink:to="lab_RevenueRecognizedOverDesignatedPeriod.379731" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RevenueRecognizedOverDesignatedPeriod.379731" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_RevenueRecognizedOverDesignatedPeriod.379731">Revenue recognized over designated period.</link:label>
    <link:loc xlink:label="loc_RevenueRecognizedPeriod.73719.11.6" xlink:href="plx-20121231.xsd#plx_RevenueRecognizedPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RevenueRecognizedPeriod.73719.11.6" xlink:to="lab_RevenueRecognizedPeriod.379733" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RevenueRecognizedPeriod.379733" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RevenueRecognizedPeriod.379733">Revenue Recognized Period</link:label>
    <link:loc xlink:label="loc_RevenueRecognizedPeriod.73719.11.7" xlink:href="plx-20121231.xsd#plx_RevenueRecognizedPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RevenueRecognizedPeriod.73719.11.7" xlink:to="lab_RevenueRecognizedPeriod.379735" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RevenueRecognizedPeriod.379735" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_RevenueRecognizedPeriod.379735">Revenue recognition period</link:label>
    <link:loc xlink:label="loc_RevenueRecognizedPeriod.73719.11.12" xlink:href="plx-20121231.xsd#plx_RevenueRecognizedPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RevenueRecognizedPeriod.73719.11.12" xlink:to="lab_RevenueRecognizedPeriod.379734" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RevenueRecognizedPeriod.379734" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_RevenueRecognizedPeriod.379734">Revenue Recognized Period</link:label>
    <link:loc xlink:label="loc_ScenarioOneMember.68653.11.6" xlink:href="plx-20121231.xsd#plx_ScenarioOneMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioOneMember.68653.11.6" xlink:to="lab_ScenarioOneMember.137972.346382" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioOneMember.137972.346382" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioOneMember.137972.346382">Scenario One [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioOneMember.68653.11.12" xlink:href="plx-20121231.xsd#plx_ScenarioOneMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioOneMember.68653.11.12" xlink:to="lab_ScenarioOneMember.137973.346384" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioOneMember.137973.346384" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioOneMember.137973.346384">Scenario One [Member].</link:label>
    <link:loc xlink:label="loc_ScenarioOneMember.68653.11.7" xlink:href="plx-20121231.xsd#plx_ScenarioOneMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioOneMember.68653.11.7" xlink:to="lab_ScenarioOneMember.137974.346383" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioOneMember.137974.346383" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioOneMember.137974.346383">Upon each FDA and European Medicine Agency approval [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioTwoMember.68654.11.6" xlink:href="plx-20121231.xsd#plx_ScenarioTwoMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioTwoMember.68654.11.6" xlink:to="lab_ScenarioTwoMember.137969.346385" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioTwoMember.137969.346385" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioTwoMember.137969.346385">Scenario Two [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioTwoMember.68654.11.12" xlink:href="plx-20121231.xsd#plx_ScenarioTwoMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioTwoMember.68654.11.12" xlink:to="lab_ScenarioTwoMember.137970.346387" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioTwoMember.137970.346387" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioTwoMember.137970.346387">Scenario Two [Member].</link:label>
    <link:loc xlink:label="loc_ScenarioTwoMember.68654.11.7" xlink:href="plx-20121231.xsd#plx_ScenarioTwoMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioTwoMember.68654.11.7" xlink:to="lab_ScenarioTwoMember.137971.346386" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioTwoMember.137971.346386" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioTwoMember.137971.346386">Upon Filing of Pediatric Investigation Plan to EMA [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4553.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.11.6" xlink:to="lab_ScenarioUnspecifiedDomain.16504.346388" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioUnspecifiedDomain.16504.346388" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioUnspecifiedDomain.16504.346388">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.68658.11.6" xlink:href="plx-20121231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.11.6" xlink:to="lab_SignificantAccountingPoliciesLineItems.137995.346389" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SignificantAccountingPoliciesLineItems.137995.346389" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SignificantAccountingPoliciesLineItems.137995.346389">Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:label="loc_StatementScenarioAxis.4951.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementScenarioAxis.4951.11.6" xlink:to="lab_StatementScenarioAxis.17868.346392" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementScenarioAxis.17868.346392" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementScenarioAxis.17868.346392">Scenario [Axis]</link:label>
    <link:loc xlink:label="loc_UponFDAApprovalMember.70109.11.6" xlink:href="plx-20121231.xsd#plx_UponFDAApprovalMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_UponFDAApprovalMember.70109.11.6" xlink:to="lab_UponFDAApprovalMember.355649" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_UponFDAApprovalMember.355649" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_UponFDAApprovalMember.355649">Upon FDAApproval [Member]</link:label>
    <link:loc xlink:label="loc_UponFDAApprovalMember.70109.11.12" xlink:href="plx-20121231.xsd#plx_UponFDAApprovalMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_UponFDAApprovalMember.70109.11.12" xlink:to="lab_UponFDAApprovalMember.355650" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_UponFDAApprovalMember.355650" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_UponFDAApprovalMember.355650">Upon FDA approval Member</link:label>
    <link:loc xlink:label="loc_UponNearTermClinicalDevelopmentMilestonesMember.70110.11.6" xlink:href="plx-20121231.xsd#plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_UponNearTermClinicalDevelopmentMilestonesMember.70110.11.6" xlink:to="lab_UponNearTermClinicalDevelopmentMilestonesMember.355652" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_UponNearTermClinicalDevelopmentMilestonesMember.355652" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_UponNearTermClinicalDevelopmentMilestonesMember.355652">Upon Near Term Clinical Development Milestones [Member]</link:label>
    <link:loc xlink:label="loc_UponNearTermClinicalDevelopmentMilestonesMember.70110.11.12" xlink:href="plx-20121231.xsd#plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_UponNearTermClinicalDevelopmentMilestonesMember.70110.11.12" xlink:to="lab_UponNearTermClinicalDevelopmentMilestonesMember.355653" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_UponNearTermClinicalDevelopmentMilestonesMember.355653" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_UponNearTermClinicalDevelopmentMilestonesMember.355653">Upon Near Term Clinical Development Milestones Member</link:label>
    <link:loc xlink:label="loc_AccountsPayableAndAccrualsAxis.70516.11.6" xlink:href="plx-20121231.xsd#plx_AccountsPayableAndAccrualsAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableAndAccrualsAxis.70516.11.6" xlink:to="lab_AccountsPayableAndAccrualsAxis.358801" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableAndAccrualsAxis.358801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableAndAccrualsAxis.358801">Accounts Payable And Accruals [Axis]</link:label>
    <link:loc xlink:label="loc_AccountsPayableAndAccrualsAxis.70516.11.12" xlink:href="plx-20121231.xsd#plx_AccountsPayableAndAccrualsAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableAndAccrualsAxis.70516.11.12" xlink:to="lab_AccountsPayableAndAccrualsAxis.358802" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableAndAccrualsAxis.358802" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableAndAccrualsAxis.358802">Accounts Payable And Accruals Axis</link:label>
    <link:loc xlink:label="loc_AccountsPayableAndAccrualsDomain.70517.11.6" xlink:href="plx-20121231.xsd#plx_AccountsPayableAndAccrualsDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableAndAccrualsDomain.70517.11.6" xlink:to="lab_AccountsPayableAndAccrualsDomain.358803" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableAndAccrualsDomain.358803" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableAndAccrualsDomain.358803">Accounts Payable And Accruals [Domain]</link:label>
    <link:loc xlink:label="loc_AccountsPayableAndAccrualsLineItems.70520.11.6" xlink:href="plx-20121231.xsd#plx_AccountsPayableAndAccrualsLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableAndAccrualsLineItems.70520.11.6" xlink:to="lab_AccountsPayableAndAccrualsLineItems.358808" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableAndAccrualsLineItems.358808" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableAndAccrualsLineItems.358808">Accounts Payable And Accruals [Line Items]</link:label>
    <link:loc xlink:label="loc_AccountsPayableAndAccrualsLineItems.70520.11.12" xlink:href="plx-20121231.xsd#plx_AccountsPayableAndAccrualsLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableAndAccrualsLineItems.70520.11.12" xlink:to="lab_AccountsPayableAndAccrualsLineItems.358809" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableAndAccrualsLineItems.358809" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableAndAccrualsLineItems.358809">Accounts Payable And Accruals Line Items</link:label>
    <link:loc xlink:label="loc_AccountsPayableAndAccrualsTable.70515.11.6" xlink:href="plx-20121231.xsd#plx_AccountsPayableAndAccrualsTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableAndAccrualsTable.70515.11.6" xlink:to="lab_AccountsPayableAndAccrualsTable.358800" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableAndAccrualsTable.358800" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableAndAccrualsTable.358800">Accounts Payable And Accruals [Table]</link:label>
    <link:loc xlink:label="loc_AccountsPayableOtherCurrent.5442.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableOtherCurrent.5442.11.8" xlink:to="lab_AccountsPayableOtherCurrent8.358814" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableOtherCurrent8.358814" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableOtherCurrent8.358814">Accounts payable and accruals, other</link:label>
    <link:loc xlink:label="loc_AccruedLiabilitiesCurrent.5555.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccruedLiabilitiesCurrent.5555.11.6" xlink:to="lab_AccruedLiabilitiesCurrent.550" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccruedLiabilitiesCurrent.550" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccruedLiabilitiesCurrent.550">Accrued Liabilities, Current</link:label>
    <link:loc xlink:label="loc_AccruedLiabilitiesCurrent.5555.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccruedLiabilitiesCurrent.5555.11.7" xlink:to="lab_AccruedLiabilitiesCurrent.133963" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccruedLiabilitiesCurrent.133963" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccruedLiabilitiesCurrent.133963">Accrued expenses</link:label>
    <link:loc xlink:label="loc_AccruedRoyaltiesCurrent.5572.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccruedRoyaltiesCurrent.5572.11.6" xlink:to="lab_AccruedRoyaltiesCurrent.572" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccruedRoyaltiesCurrent.572" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccruedRoyaltiesCurrent.572">Accrued Royalties, Current</link:label>
    <link:loc xlink:label="loc_AccruedRoyaltiesCurrent.5572.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccruedRoyaltiesCurrent.5572.11.7" xlink:to="lab_AccruedRoyaltiesCurrent.358813" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccruedRoyaltiesCurrent.358813" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccruedRoyaltiesCurrent.358813">Royalties payable</link:label>
    <link:loc xlink:label="loc_AccruedVacationCurrent.5530.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccruedVacationCurrent.5530.11.6" xlink:to="lab_AccruedVacationCurrent.520" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccruedVacationCurrent.520" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccruedVacationCurrent.520">Accrued Vacation, Current</link:label>
    <link:loc xlink:label="loc_AccruedVacationCurrent.5530.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccruedVacationCurrent.5530.11.7" xlink:to="lab_AccruedVacationCurrent.358812" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccruedVacationCurrent.358812" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccruedVacationCurrent.358812">Provision for vacation</link:label>
    <link:loc xlink:label="loc_CollaborationOperationCurrentPortionMember.70518.11.6" xlink:href="plx-20121231.xsd#plx_CollaborationOperationCurrentPortionMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborationOperationCurrentPortionMember.70518.11.6" xlink:to="lab_CollaborationOperationCurrentPortionMember.358804" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborationOperationCurrentPortionMember.358804" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CollaborationOperationCurrentPortionMember.358804">Collaboration Operation Current Portion [Member]</link:label>
    <link:loc xlink:label="loc_CollaborationOperationCurrentPortionMember.70518.11.12" xlink:href="plx-20121231.xsd#plx_CollaborationOperationCurrentPortionMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborationOperationCurrentPortionMember.70518.11.12" xlink:to="lab_CollaborationOperationCurrentPortionMember.358805" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborationOperationCurrentPortionMember.358805" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_CollaborationOperationCurrentPortionMember.358805">Collaboration Operation Current Portion [Member]</link:label>
    <link:loc xlink:label="loc_EmployeeRelatedLiabilitiesCurrent.8812.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeRelatedLiabilitiesCurrent.8812.11.6" xlink:to="lab_EmployeeRelatedLiabilitiesCurrent.5592" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeRelatedLiabilitiesCurrent.5592" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeRelatedLiabilitiesCurrent.5592">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:label="loc_EmployeeRelatedLiabilitiesCurrent.8812.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeRelatedLiabilitiesCurrent.8812.11.7" xlink:to="lab_EmployeeRelatedLiabilitiesCurrent.358810" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeRelatedLiabilitiesCurrent.358810" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeRelatedLiabilitiesCurrent.358810">Payroll and related expenses</link:label>
    <link:loc xlink:label="loc_PropertyAndEquipmentSuppliersMember.70519.11.6" xlink:href="plx-20121231.xsd#plx_PropertyAndEquipmentSuppliersMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyAndEquipmentSuppliersMember.70519.11.6" xlink:to="lab_PropertyAndEquipmentSuppliersMember.358806" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PropertyAndEquipmentSuppliersMember.358806" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PropertyAndEquipmentSuppliersMember.358806">Property And Equipment Suppliers [Member]</link:label>
    <link:loc xlink:label="loc_PropertyAndEquipmentSuppliersMember.70519.11.12" xlink:href="plx-20121231.xsd#plx_PropertyAndEquipmentSuppliersMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyAndEquipmentSuppliersMember.70519.11.12" xlink:to="lab_PropertyAndEquipmentSuppliersMember.358807" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PropertyAndEquipmentSuppliersMember.358807" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_PropertyAndEquipmentSuppliersMember.358807">Property and Equipment Suppliers [Member]</link:label>
    <link:loc xlink:label="loc_OptionsAndRestrictedStockGrantedToEmployeesMember.70546.11.6" xlink:href="plx-20121231.xsd#plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OptionsAndRestrictedStockGrantedToEmployeesMember.70546.11.6" xlink:to="lab_OptionsAndRestrictedStockGrantedToEmployeesMember.358921" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OptionsAndRestrictedStockGrantedToEmployeesMember.358921" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OptionsAndRestrictedStockGrantedToEmployeesMember.358921">Options And Restricted Stock Granted To Employees [Member]</link:label>
    <link:loc xlink:label="loc_OptionsAndRestrictedStockGrantedToEmployeesMember.70546.11.12" xlink:href="plx-20121231.xsd#plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OptionsAndRestrictedStockGrantedToEmployeesMember.70546.11.12" xlink:to="lab_OptionsAndRestrictedStockGrantedToEmployeesMember.358922" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OptionsAndRestrictedStockGrantedToEmployeesMember.358922" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_OptionsAndRestrictedStockGrantedToEmployeesMember.358922">Options And Restricted Stock Granted To Employees Member</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod.16341.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod.16341.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod.17529" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod.17529" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod.17529">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice.16315.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice.16315.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice.17497" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice.17497" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice.17497">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.16275.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.16275.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.134193" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.134193" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.134193">Granted</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.16298.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.16298.11.6" xlink:to="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.17479" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.17479" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.17479">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.16298.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.16298.11.7" xlink:to="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.134205" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.134205" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.134205">Granted</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod.16341.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod.16341.11.7" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod.360263" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod.360263" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod.360263">Forfeited and Expired</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice.16315.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice.16315.11.7" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice.360724" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice.360724" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice.360724">Forfeited and Expired</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable.73892.11.6" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable.73892.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable.381508" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable.381508" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable.381508">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable.73892.11.7" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable.73892.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable.381510" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable.381510" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable.381510">Exercisable at end of year</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable.73892.11.12" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable.73892.11.12" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable.381509" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable.381509" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable.381509">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.16252.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.16252.11.8" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod8.381504" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod8.381504" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod8.381504">Forfeited</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.16300.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.16300.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.140098.346446" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.140098.346446" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.140098.346446">Granted</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.16300.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.16300.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.17481.346445" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.17481.346445" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.17481.346445">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.16281.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.16281.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.17456" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.17456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.17456">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.16281.11.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.16281.11.10" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.381145" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.381145" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.381145">Balance</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.16281.11.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.16281.11.11" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.381505" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.381505" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.381505">Balance</link:label>
    <link:loc xlink:label="loc_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember.73899.11.6" xlink:href="plx-20121231.xsd#plx_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember.73899.11.6" xlink:to="lab_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember.381540" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember.381540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember.381540">Deferred Revenue From License And Supply Agreement With Pzifer [Member]</link:label>
    <link:loc xlink:label="loc_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember.73899.11.12" xlink:href="plx-20121231.xsd#plx_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember.73899.11.12" xlink:to="lab_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember.381541" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember.381541" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember.381541">Deferred Revenue From License And Supply Agreement With Pzifer [Member]</link:label>
    <link:loc xlink:label="loc_SalesRevenueGoodsNetMember.4541.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SalesRevenueGoodsNetMember.4541.11.6" xlink:to="lab_SalesRevenueGoodsNetMember.16477" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SalesRevenueGoodsNetMember.16477" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SalesRevenueGoodsNetMember.16477">Sales Revenue, Goods, Net [Member]</link:label>
    <link:loc xlink:label="loc_SupplementalInformationRevenueAxis.73897.11.6" xlink:href="plx-20121231.xsd#plx_SupplementalInformationRevenueAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementalInformationRevenueAxis.73897.11.6" xlink:to="lab_SupplementalInformationRevenueAxis.381537" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementalInformationRevenueAxis.381537" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SupplementalInformationRevenueAxis.381537">Supplemental Information Revenue [Axis]</link:label>
    <link:loc xlink:label="loc_SupplementalInformationRevenueDomain.73898.11.6" xlink:href="plx-20121231.xsd#plx_SupplementalInformationRevenueDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementalInformationRevenueDomain.73898.11.6" xlink:to="lab_SupplementalInformationRevenueDomain.381539" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementalInformationRevenueDomain.381539" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SupplementalInformationRevenueDomain.381539">Supplemental Information Revenue [Domain]</link:label>
    <link:loc xlink:label="loc_SupplementalInformationRevenueLineItems.73901.11.6" xlink:href="plx-20121231.xsd#plx_SupplementalInformationRevenueLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementalInformationRevenueLineItems.73901.11.6" xlink:to="lab_SupplementalInformationRevenueLineItems.381545" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementalInformationRevenueLineItems.381545" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SupplementalInformationRevenueLineItems.381545">Supplemental Information Revenue [Line Items]</link:label>
    <link:loc xlink:label="loc_SupplementalInformationTable.73896.11.6" xlink:href="plx-20121231.xsd#plx_SupplementalInformationTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementalInformationTable.73896.11.6" xlink:to="lab_SupplementalInformationTable.381536" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementalInformationTable.381536" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SupplementalInformationTable.381536">Supplemental Information [Table]</link:label>
    <link:loc xlink:label="loc_SalesRevenueGoodsNetMember.4541.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SalesRevenueGoodsNetMember.4541.11.7" xlink:to="SalesRevenueGoodsNetMember.381544" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="SalesRevenueGoodsNetMember.381544" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="SalesRevenueGoodsNetMember.381544">Revenues from selling products [Member]</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>21
<FILENAME>plx-20121231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings-->
<!--produced on 2013-02-28 @ 11:25 AM-->
<link:linkbase xmlns:plx="http://www.protalix.com/20121231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef roleURI="http://www.protalix.com/role/ConsolidatedBalanceSheets" xlink:href="plx-20121231.xsd#plx-cbs" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="plx-20121231.xsd#plx-csocf" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiency" xlink:href="plx-20121231.xsd#plx-csocisecd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiencyParenthetical" xlink:href="plx-20121231.xsd#plx-csocisecdp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ConsolidatedStatementsOfOperations" xlink:href="plx-20121231.xsd#plx-csoo" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/DocumentAndEntityInformation" xlink:href="plx-20121231.xsd#plx-daei" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/Inventories" xlink:href="plx-20121231.xsd#plx-i" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesTables" xlink:href="plx-20121231.xsd#plx-it" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" xlink:href="plx-20121231.xsd#plx-sapd1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPolicies" xlink:href="plx-20121231.xsd#plx-sap" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesPolicy" xlink:href="plx-20121231.xsd#plx-sapp1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesTables" xlink:href="plx-20121231.xsd#plx-sapt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapitalNarrativeDetails" xlink:href="plx-20121231.xsd#plx-scnd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SubsequentEvents" xlink:href="plx-20121231.xsd#plx-se" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SubsequentEventsDetails" xlink:href="plx-20121231.xsd#plx-sed" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="plx-20121231.xsd#plx-cbsp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/LicenseAndSupplyAgreement" xlink:href="plx-20121231.xsd#plx-lasa" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/PropertyAndEquipment" xlink:href="plx-20121231.xsd#plx-pae" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/LiabilityForEmployeeRightsUponRetirement" xlink:href="plx-20121231.xsd#plx-lferur" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/Commitments" xlink:href="plx-20121231.xsd#plx-c" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapital" xlink:href="plx-20121231.xsd#plx-sc" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/TaxesOnIncome" xlink:href="plx-20121231.xsd#plx-toi" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformation" xlink:href="plx-20121231.xsd#plx-sfsi" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/RelatedPartyTransactions" xlink:href="plx-20121231.xsd#plx-rpt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/PropertyAndEquipmentTables" xlink:href="plx-20121231.xsd#plx-paet" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapitalTables" xlink:href="plx-20121231.xsd#plx-sct" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationTables" xlink:href="plx-20121231.xsd#plx-sfsit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/RelatedPartyTransactionsTables" xlink:href="plx-20121231.xsd#plx-rptt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/PropertyAndEquipmentDetails" xlink:href="plx-20121231.xsd#plx-paed" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesDetails" xlink:href="plx-20121231.xsd#plx-id" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/LiabilityForEmployeeRightsUponRetirementDetails" xlink:href="plx-20121231.xsd#plx-lferurd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CommitmentsDetails" xlink:href="plx-20121231.xsd#plx-cd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapitalSummaryOfOptionAndRestrictedStockGrantedToEmployeesDetails" xlink:href="plx-20121231.xsd#plx-scsooarsgted" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapitalFairValueAssumptionsOfOptionsGrantedDetails" xlink:href="plx-20121231.xsd#plx-scfvaoogd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapitalOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails" xlink:href="plx-20121231.xsd#plx-scogtcdaospd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapitalSummaryOfOutstandingAndRestrictedStocksDetails" xlink:href="plx-20121231.xsd#plx-scsooarsd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapitalShareBasedCompensationExpenseAllocationDetails" xlink:href="plx-20121231.xsd#plx-scsbcead" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/TaxesOnIncomeTables" xlink:href="plx-20121231.xsd#plx-toit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/TaxesOnIncomeNarrativeDetails" xlink:href="plx-20121231.xsd#plx-toind" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/TaxesOnIncomeDeferredIncomeTaxesDetails" xlink:href="plx-20121231.xsd#plx-toiditd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/TaxesOnIncomeOpenTaxYearsDetails" xlink:href="plx-20121231.xsd#plx-toiotyd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationAccountsReceivableOtherDetails" xlink:href="plx-20121231.xsd#plx-sfsiarod" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/RelatedPartyTransactionsDetails" xlink:href="plx-20121231.xsd#plx-rptd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" xlink:href="plx-20121231.xsd#plx-sapulopaed" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/LicenseAndSupplyAgreementDetails" xlink:href="plx-20121231.xsd#plx-lasad" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" xlink:href="plx-20121231.xsd#plx-sfsiapaaod" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapitalOptionsGrantedToEmployeesDetails" xlink:href="plx-20121231.xsd#plx-scogted" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/ShareCapitalRestrictedStockGrantedToEmployeesDetails" xlink:href="plx-20121231.xsd#plx-scrsgted" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SupplementaryFinancialStatementInformationRevenuesDetails" xlink:href="plx-20121231.xsd#plx-sfsird" xlink:type="simple" />
  <link:presentationLink xlink:title="002 - Statement - CONSOLIDATED BALANCE SHEETS" xlink:role="http://www.protalix.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:label="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.394.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_AccountsPayableTradeCurrent.5457.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.394.12.7" xlink:to="loc_AccountsPayableTradeCurrent.5457.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AccountsPayableOtherCurrent.5442.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.394.12.7" xlink:to="loc_AccountsPayableOtherCurrent.5442.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AssetsCurrentAbstract.592.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_AccountsReceivableNetCurrent.5451.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.592.12.7" xlink:to="loc_AccountsReceivableNetCurrent.5451.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OtherReceivablesNetCurrent.13172.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.592.12.7" xlink:to="loc_OtherReceivablesNetCurrent.13172.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6556.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.592.12.7" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue.6556.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_InventoryNet.11417.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.592.12.7" xlink:to="loc_InventoryNet.11417.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AssetsCurrentAbstract.592.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_AssetsCurrent.5874.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.592.12.9" xlink:to="loc_AssetsCurrent.5874.12.9" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_AssetsAbstract.595.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.595.12.7" xlink:to="loc_AssetsCurrentAbstract.592.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.7957.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.595.12.7" xlink:to="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.7957.12.7" order="2.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.14697.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.595.12.7" xlink:to="loc_PropertyPlantAndEquipmentNet.14697.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AssetsAbstract.595.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_Assets.5880.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.595.12.9" xlink:to="loc_Assets.5880.12.9" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_LiabilitiesCurrentAbstract.2935.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesCurrentAbstract.2935.12.7" xlink:to="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.394.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DeferredRevenueCurrent.7671.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesCurrentAbstract.2935.12.7" xlink:to="loc_DeferredRevenueCurrent.7671.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesCurrentAbstract.2935.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_LiabilitiesCurrent.11668.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesCurrentAbstract.2935.12.9" xlink:to="loc_LiabilitiesCurrent.11668.12.9" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_LiabilitiesNoncurrentAbstract.2937.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_DeferredRevenueNoncurrent.7662.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesNoncurrentAbstract.2937.12.7" xlink:to="loc_DeferredRevenueNoncurrent.7662.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LongTermDebtNoncurrent.12289.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesNoncurrentAbstract.2937.12.7" xlink:to="loc_LongTermDebtNoncurrent.12289.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13885.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesNoncurrentAbstract.2937.12.7" xlink:to="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13885.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.7" xlink:to="loc_LiabilitiesCurrentAbstract.2935.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.7" xlink:to="loc_LiabilitiesNoncurrentAbstract.2937.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_LiabilitiesNoncurrent.11699.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.9" xlink:to="loc_LiabilitiesNoncurrent.11699.12.9" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_Liabilities.11702.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.9" xlink:to="loc_Liabilities.11702.12.9" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_CommitmentsAndContingencies.6842.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.7" xlink:to="loc_CommitmentsAndContingencies.6842.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquity.11731.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.9" xlink:to="loc_LiabilitiesAndStockholdersEquity.11731.12.9" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_StockholdersEquityAbstract.4986.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.7" xlink:to="loc_StockholdersEquityAbstract.4986.12.7" order="6.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementOfFinancialPositionAbstract.4958.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfFinancialPositionAbstract.4958.12.7" xlink:to="loc_AssetsAbstract.595.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_StatementOfFinancialPositionAbstract.4958.12.7" xlink:to="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockholdersEquityAbstract.4986.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquity.16667.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StockholdersEquityAbstract.4986.12.9" xlink:to="loc_StockholdersEquity.16667.12.9" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_CommonStockValue.6874.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StockholdersEquityAbstract.4986.12.7" xlink:to="loc_CommonStockValue.6874.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AdditionalPaidInCapitalCommonStock.5617.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StockholdersEquityAbstract.4986.12.7" xlink:to="loc_AdditionalPaidInCapitalCommonStock.5617.12.7" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_RetainedEarningsAccumulatedDeficit.15457.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StockholdersEquityAbstract.4986.12.7" xlink:to="loc_RetainedEarningsAccumulatedDeficit.15457.12.7" order="2.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xlink:role="http://www.protalix.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensation.16244.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.12.7" xlink:to="loc_ShareBasedCompensation.16244.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DepreciationAmortizationAndAssetImpairment.68637.12.7" xlink:href="plx-20121231.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.12.7" xlink:to="loc_DepreciationAmortizationAndAssetImpairment.68637.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossUnrealized.9966.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.12.42" xlink:to="loc_ForeignCurrencyTransactionGainLossUnrealized.9966.12.42" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitExpense.13882.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.12.7" xlink:to="loc_PensionAndOtherPostretirementBenefitExpense.13882.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitContributions.13875.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.12.42" xlink:to="loc_PensionAndOtherPostretirementBenefitContributions.13875.12.42" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_GainLossOnSaleOfPropertyPlantEquipment.10196.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.12.42" xlink:to="loc_GainLossOnSaleOfPropertyPlantEquipment.10196.12.42" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.12.7" xlink:to="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.893.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.68643.12.7" xlink:href="plx-20121231.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.893.12.7" xlink:to="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.68643.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SupplementalOfferingAndStockIssuanceCosts.68662.12.7" xlink:href="plx-20121231.xsd#plx_SupplementalOfferingAndStockIssuanceCosts" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.893.12.7" xlink:to="loc_SupplementalOfferingAndStockIssuanceCosts.68662.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CashlessExerciseOfStockOptions.68634.12.7" xlink:href="plx-20121231.xsd#plx_CashlessExerciseOfStockOptions" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.893.12.7" xlink:to="loc_CashlessExerciseOfStockOptions.68634.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInDeferredRevenue.10850.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.12.7" xlink:to="loc_IncreaseDecreaseInDeferredRevenue.10850.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsReceivable.10853.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.12.42" xlink:to="loc_IncreaseDecreaseInAccountsReceivable.10853.12.42" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInInventories.10936.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.12.42" xlink:to="loc_IncreaseDecreaseInInventories.10936.12.42" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.10871.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.12.7" xlink:to="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.10871.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.68650.12.7" xlink:href="plx-20121231.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.12.7" xlink:to="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.68650.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.14555.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.12.8" xlink:to="loc_ProceedsFromStockOptionsExercised.14555.12.8" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivities.12740.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.12.9" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities.12740.12.9" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment.13779.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.12.42" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment.13779.12.42" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_PaymentsForProceedsFromOtherInvestingActivities.13667.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.12.42" xlink:to="loc_PaymentsForProceedsFromOtherInvestingActivities.13667.12.42" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.14507.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.12.7" xlink:to="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.14507.12.7" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivities.12731.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.12.9" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities.12731.12.9" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInRestrictedCash.11007.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.12.42" xlink:to="loc_IncreaseDecreaseInRestrictedCash.11007.12.42" order="1.87500" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3386.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NetIncomeLoss.12771.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3386.12.7" xlink:to="loc_NetIncomeLoss.12771.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3386.12.7" xlink:to="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3386.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivities.12778.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3386.12.9" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities.12778.12.9" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.4955.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.7" xlink:to="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3386.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.7" xlink:to="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.7" xlink:to="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents.8714.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.7" xlink:to="loc_EffectOfExchangeRateOnCashAndCashEquivalents.8714.12.7" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.4955.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.9" xlink:to="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.12.9" order="10.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.4955.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6556.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.10" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue.6556.12.10" order="11.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.4955.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6556.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.11" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue.6556.12.11" order="12.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.7" xlink:to="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.893.12.7" order="13.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="006 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY)" xlink:role="http://www.protalix.com/role/ConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiency" xlink:type="extended">
    <link:loc xlink:label="loc_EquityComponentDomain.1773.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_CommonStockMember.1033.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EquityComponentDomain.1773.12.6" xlink:to="loc_CommonStockMember.1033.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_AdditionalPaidInCapitalMember.461.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EquityComponentDomain.1773.12.6" xlink:to="loc_AdditionalPaidInCapitalMember.461.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EquityComponentDomain.1773.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_RetainedEarningsMember.4458.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EquityComponentDomain.1773.12.7" xlink:to="loc_RetainedEarningsMember.4458.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementTable.4950.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" />
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.4957.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementTable.4950.12.6" xlink:to="loc_StatementEquityComponentsAxis.4957.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementLineItems.4952.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementTable.4950.12.6" xlink:to="loc_StatementLineItems.4952.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementLineItems.4952.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.16628.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesNewIssues.16628.12.7" order="9.94289" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueNewIssues.16603.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.7" xlink:to="loc_StockIssuedDuringPeriodValueNewIssues.16603.12.7" order="9.94290" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.12.7" order="9.97188" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueStockOptionsExercised.16599.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.7" xlink:to="loc_StockIssuedDuringPeriodValueStockOptionsExercised.16599.12.7" order="9.95825" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementLineItems.4952.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_NetIncomeLoss.12771.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.8" xlink:to="loc_NetIncomeLoss.12771.12.8" order="10.21463" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.73695.12.7" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.7" xlink:to="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.73695.12.7" order="9.94352" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.73697.12.7" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.7" xlink:to="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.73697.12.7" order="9.94463" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementLineItems.4952.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_SharesOutstanding.16423.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.10" xlink:to="loc_SharesOutstanding.16423.12.10" order="9.94286" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_StatementLineItems.4952.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_SharesOutstanding.16423.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.11" xlink:to="loc_SharesOutstanding.16423.12.11" order="10.97188" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:label="loc_StockholdersEquity.16667.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.11" xlink:to="loc_StockholdersEquity.16667.12.11" order="10.45737" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:label="loc_StockholdersEquity.16667.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.10" xlink:to="loc_StockholdersEquity.16667.12.10" order="9.94287" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.5667.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.7" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.5667.12.7" order="9.94311" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementOfStockholdersEquityAbstract.4954.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfStockholdersEquityAbstract.4954.12.6" xlink:to="loc_StatementTable.4950.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_StatementEquityComponentsAxis.4957.12.6" xlink:to="loc_EquityComponentDomain.1773.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="007 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)" xlink:role="http://www.protalix.com/role/ConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiencyParenthetical" xlink:type="extended">
    <link:loc xlink:label="loc_StatementOfStockholdersEquityAbstract.4954.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5652.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfStockholdersEquityAbstract.4954.12.7" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5652.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.16252.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfStockholdersEquityAbstract.4954.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.16252.12.7" order="1.75000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" xlink:role="http://www.protalix.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:label="loc_IncomeStatementAbstract.2519.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_EarningsPerShareBasicAndDiluted.8698.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.7" xlink:to="loc_EarningsPerShareBasicAndDiluted.8698.12.7" order="12.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_Revenues.15575.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.7" xlink:to="loc_Revenues.15575.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OtherGainsLosses.68648.12.7" xlink:href="plx-20121231.xsd#plx_OtherGainsLosses" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.7" xlink:to="loc_OtherGainsLosses.68648.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncomeStatementAbstract.2519.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CostOfRevenue.7176.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.42" xlink:to="loc_CostOfRevenue.7176.12.42" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_IncomeStatementAbstract.2519.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_GrossProfit.10358.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.9" xlink:to="loc_GrossProfit.10358.12.9" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpense.15293.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.42" xlink:to="loc_ResearchAndDevelopmentExpense.15293.12.42" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_GrantsAndReimbursementsReceivedOrReceivable.68642.12.7" xlink:href="plx-20121231.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.7" xlink:to="loc_GrantsAndReimbursementsReceivedOrReceivable.68642.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncomeStatementAbstract.2519.12.45" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ResearchDevelopmentAndEngineeringExpenseNet.68652.12.45" xlink:href="plx-20121231.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.45" xlink:to="loc_ResearchDevelopmentAndEngineeringExpenseNet.68652.12.45" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpense.10284.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.42" xlink:to="loc_GeneralAndAdministrativeExpense.10284.12.42" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_OperatingIncomeLoss.13080.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.9" xlink:to="loc_OperatingIncomeLoss.13080.12.9" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossBeforeTax.10004.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.7" xlink:to="loc_ForeignCurrencyTransactionGainLossBeforeTax.10004.12.7" order="10.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetIncomeLoss.12771.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.9" xlink:to="loc_NetIncomeLoss.12771.12.9" order="11.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.17395.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.7" xlink:to="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.17395.12.7" order="13.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="001 - Document - Document and Entity Information" xlink:role="http://www.protalix.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:label="loc_DocumentAndEntityInformationAbstract.68638.12.6" xlink:href="plx-20121231.xsd#plx_DocumentAndEntityInformationAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_DocumentType.212.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentType" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.68638.12.6" xlink:to="loc_DocumentType.212.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_AmendmentFlag.144.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.68638.12.6" xlink:to="loc_AmendmentFlag.144.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_DocumentPeriodEndDate.161.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.68638.12.6" xlink:to="loc_DocumentPeriodEndDate.161.12.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_DocumentFiscalYearFocus.207.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.68638.12.6" xlink:to="loc_DocumentFiscalYearFocus.207.12.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_DocumentFiscalPeriodFocus.208.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.68638.12.6" xlink:to="loc_DocumentFiscalPeriodFocus.208.12.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_TradingSymbol.177.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_TradingSymbol" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.68638.12.6" xlink:to="loc_TradingSymbol.177.12.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EntityRegistrantName.187.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.68638.12.6" xlink:to="loc_EntityRegistrantName.187.12.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EntityCentralIndexKey.188.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.68638.12.6" xlink:to="loc_EntityCentralIndexKey.188.12.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_CurrentFiscalYearEndDate.155.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.68638.12.6" xlink:to="loc_CurrentFiscalYearEndDate.155.12.6" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EntityFilerCategory.185.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.68638.12.6" xlink:to="loc_EntityFilerCategory.185.12.6" order="13.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EntityCommonStockSharesOutstanding.192.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.68638.12.6" xlink:to="loc_EntityCommonStockSharesOutstanding.192.12.6" order="16.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EntityPublicFloat.186.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.68638.12.6" xlink:to="loc_EntityPublicFloat.186.12.6" order="17.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EntityWellKnownSeasonedIssuer.182.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.68638.12.6" xlink:to="loc_EntityWellKnownSeasonedIssuer.182.12.6" order="14.56250" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EntityVoluntaryFilers.183.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.68638.12.6" xlink:to="loc_EntityVoluntaryFilers.183.12.6" order="14.03125" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EntityCurrentReportingStatus.184.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.68638.12.6" xlink:to="loc_EntityCurrentReportingStatus.184.12.6" order="14.29688" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="104 - Disclosure - INVENTORIES" xlink:role="http://www.protalix.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:label="loc_InventoryDisclosureAbstract.2789.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_InventoryDisclosureTextBlock.11399.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2789.12.7" xlink:to="loc_InventoryDisclosureTextBlock.11399.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="304 - Disclosure - INVENTORIES (Tables)" xlink:role="http://www.protalix.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:label="loc_InventoryDisclosureAbstract.2789.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfInventoryCurrentTableTextBlock.15772.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2789.12.7" xlink:to="loc_ScheduleOfInventoryCurrentTableTextBlock.15772.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.385.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesTable.68659.12.6" xlink:href="plx-20121231.xsd#plx_SignificantAccountingPoliciesTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.6" xlink:to="loc_SignificantAccountingPoliciesTable.68659.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.559.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_StockOptionsAndRestrictedSharesMember.68661.12.7" xlink:href="plx-20121231.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AntidilutiveSecuritiesNameDomain.559.12.7" xlink:to="loc_StockOptionsAndRestrictedSharesMember.68661.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.559.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.12.6" xlink:to="loc_AntidilutiveSecuritiesNameDomain.559.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:type="locator" />
    <link:loc xlink:label="loc_ProtalixBioTherapeuticsIncorporationMember.68651.12.7" xlink:href="plx-20121231.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.12.7" xlink:to="loc_ProtalixBioTherapeuticsIncorporationMember.68651.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PfizerIncorporationMember.68649.12.7" xlink:href="plx-20121231.xsd#plx_PfizerIncorporationMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.12.7" xlink:to="loc_PfizerIncorporationMember.68649.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.12.6" xlink:to="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4553.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioTwoMember.68654.12.7" xlink:href="plx-20121231.xsd#plx_ScenarioTwoMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.12.7" xlink:to="loc_ScenarioTwoMember.68654.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScenarioOneMember.68653.12.7" xlink:href="plx-20121231.xsd#plx_ScenarioOneMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.12.7" xlink:to="loc_ScenarioOneMember.68653.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4553.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_UponFDAApprovalMember.70109.12.6" xlink:href="plx-20121231.xsd#plx_UponFDAApprovalMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.12.6" xlink:to="loc_UponFDAApprovalMember.70109.12.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_UponNearTermClinicalDevelopmentMilestonesMember.70110.12.6" xlink:href="plx-20121231.xsd#plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.12.6" xlink:to="loc_UponNearTermClinicalDevelopmentMilestonesMember.70110.12.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementScenarioAxis.4951.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementScenarioAxis.4951.12.6" xlink:to="loc_ScenarioUnspecifiedDomain.4553.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.68658.12.7" xlink:href="plx-20121231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_NumberOfSubsidiaries.68646.12.7" xlink:href="plx-20121231.xsd#plx_NumberOfSubsidiaries" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.12.7" xlink:to="loc_NumberOfSubsidiaries.68646.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ProceedsFromCollaborators.14370.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.12.7" xlink:to="loc_ProceedsFromCollaborators.14370.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_MilestonePayment.68644.12.7" xlink:href="plx-20121231.xsd#plx_MilestonePayment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.12.7" xlink:to="loc_MilestonePayment.68644.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CollaborativeArrangementProfitSharePercentage.68635.12.7" xlink:href="plx-20121231.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.12.7" xlink:to="loc_CollaborativeArrangementProfitSharePercentage.68635.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.6878.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.12.7" xlink:to="loc_CommonStockParOrStatedValuePerShare.6878.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.5816.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.12.7" xlink:to="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.5816.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesTable.68659.12.6" xlink:to="loc_StatementScenarioAxis.4951.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesTable.68659.12.6" xlink:to="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesTable.68659.12.6" xlink:to="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.12.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.68658.12.6" xlink:href="plx-20121231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesTable.68659.12.6" xlink:to="loc_SignificantAccountingPoliciesLineItems.68658.12.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" xlink:role="http://www.protalix.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.385.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6085.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.7" xlink:to="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6085.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesPolicy" xlink:type="extended">
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.385.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_BasisOfAccountingPolicyPolicyTextBlock.6086.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.7" xlink:to="loc_BasisOfAccountingPolicyPolicyTextBlock.6086.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EarningsPerSharePolicyTextBlock.8704.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.7" xlink:to="loc_EarningsPerSharePolicyTextBlock.8704.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_UseOfEstimates.17234.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.7" xlink:to="loc_UseOfEstimates.17234.12.7" order="2.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock.10010.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.7" xlink:to="loc_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock.10010.12.7" order="2.75000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsPolicyTextBlock.6571.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.7" xlink:to="loc_CashAndCashEquivalentsPolicyTextBlock.6571.12.7" order="2.87500" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_InventoryPolicyTextBlock.11360.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.7" xlink:to="loc_InventoryPolicyTextBlock.11360.12.7" order="2.93750" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentPolicyTextBlock.14695.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.7" xlink:to="loc_PropertyPlantAndEquipmentPolicyTextBlock.14695.12.7" order="2.96875" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock.10588.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.7" xlink:to="loc_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock.10588.12.7" order="2.98438" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncomeTaxPolicyTextBlock.10751.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.7" xlink:to="loc_IncomeTaxPolicyTextBlock.10751.12.7" order="2.99219" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_RevenueRecognitionPolicyTextBlock.15515.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.7" xlink:to="loc_RevenueRecognitionPolicyTextBlock.15515.12.7" order="2.99609" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpensePolicy.15306.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.7" xlink:to="loc_ResearchAndDevelopmentExpensePolicy.15306.12.7" order="2.99805" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ConcentrationRiskCreditRisk.6940.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.7" xlink:to="loc_ConcentrationRiskCreditRisk.6940.12.7" order="2.99951" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationOptionAndIncentivePlansPolicy.16373.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.7" xlink:to="loc_ShareBasedCompensationOptionAndIncentivePlansPolicy.16373.12.7" order="2.99976" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NatureOfOperationsPolicyTextBlock.68645.12.7" xlink:href="plx-20121231.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.7" xlink:to="loc_NatureOfOperationsPolicyTextBlock.68645.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.385.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfUsefulLifeTableTextBlock.70058.12.7" xlink:href="plx-20121231.xsd#plx_ScheduleOfUsefulLifeTableTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.7" xlink:to="loc_ScheduleOfUsefulLifeTableTextBlock.70058.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40701 - Disclosure - SHARE CAPITAL (Narrative) (Details)" xlink:role="http://www.protalix.com/role/ShareCapitalNarrativeDetails" xlink:type="extended">
    <link:loc xlink:label="loc_AwardTypeAxis.344.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AwardTypeAxis.344.12.6" xlink:to="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.12.6" xlink:to="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.6" xlink:to="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.12.6" xlink:to="loc_AwardTypeAxis.344.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.12.6" xlink:to="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.12.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.12.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_CommonStockSharesIssued.6875.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.8" xlink:to="loc_CommonStockSharesIssued.6875.12.8" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_SaleOfStockPricePerShare.15652.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_SaleOfStockPricePerShare.15652.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.16337.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.16337.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.16333.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.16333.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.16378.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.16378.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.68656.12.7" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.68656.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.68657.12.7" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.68657.12.7" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.16272.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.16272.12.7" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStock.14449.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_ProceedsFromIssuanceOfCommonStock.14449.12.7" order="2.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PaymentsOfStockIssuanceCosts.13770.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_PaymentsOfStockIssuanceCosts.13770.12.7" order="2.75000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.68655.12.7" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.68655.12.7" order="11.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.16275.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.8" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.16275.12.8" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_RestrictedStockMember.4416.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.12.6" xlink:to="loc_RestrictedStockMember.4416.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ExecutiveOfficerMember.1817.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.12.6" xlink:to="loc_ExecutiveOfficerMember.1817.12.6" order="1.62500" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EmployeesMember.68641.12.6" xlink:href="plx-20121231.xsd#plx_EmployeesMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.12.6" xlink:to="loc_EmployeesMember.68641.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_OfficersAndCertainEmployeesMember.70821.12.6" xlink:href="plx-20121231.xsd#plx_OfficersAndCertainEmployeesMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.12.6" xlink:to="loc_OfficersAndCertainEmployeesMember.70821.12.6" order="1.25000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_OfficersAndDirectorsInPrivateTransactionMember.72242.12.6" xlink:href="plx-20121231.xsd#plx_OfficersAndDirectorsInPrivateTransactionMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.12.6" xlink:to="loc_OfficersAndDirectorsInPrivateTransactionMember.72242.12.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="111 - Disclosure - SUBSEQUENT EVENTS" xlink:role="http://www.protalix.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:label="loc_SubsequentEventsAbstract.5004.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_SubsequentEventsTextBlock.16697.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SubsequentEventsAbstract.5004.12.7" xlink:to="loc_SubsequentEventsTextBlock.16697.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="41101 - Disclosure - SUBSEQUENT EVENTS (Details)" xlink:role="http://www.protalix.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3555.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3556.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_OptionIndexedToIssuersEquityEquityAxis.3555.12.6" xlink:to="loc_OptionIndexedToIssuersEquityTypeDomain.3556.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3556.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_EmployeeMember.68640.12.7" xlink:href="plx-20121231.xsd#plx_EmployeeMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_OptionIndexedToIssuersEquityTypeDomain.3556.12.7" xlink:to="loc_EmployeeMember.68640.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SubsequentEventsAbstract.5004.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_SubsequentEventTable.5008.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SubsequentEventsAbstract.5004.12.6" xlink:to="loc_SubsequentEventTable.5008.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_SubsequentEventTypeDomain.5005.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionExerciseMember.68647.12.6" xlink:href="plx-20121231.xsd#plx_OptionExerciseMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SubsequentEventTypeDomain.5005.12.6" xlink:to="loc_OptionExerciseMember.68647.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_SubsequentEventLineItems.5006.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SubsequentEventLineItems.5006.12.8" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.12.8" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_SubsequentEventLineItems.5006.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.14555.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SubsequentEventLineItems.5006.12.7" xlink:to="loc_ProceedsFromStockOptionsExercised.14555.12.7" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SubsequentEventTypeAxis.5007.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SubsequentEventTypeAxis.5007.12.6" xlink:to="loc_SubsequentEventTypeDomain.5005.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_SubsequentEventTable.5008.12.6" xlink:to="loc_SubsequentEventTypeAxis.5007.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_SubsequentEventLineItems.5006.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SubsequentEventTable.5008.12.6" xlink:to="loc_SubsequentEventLineItems.5006.12.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_SubsequentEventTable.5008.12.6" xlink:to="loc_OptionIndexedToIssuersEquityEquityAxis.3555.12.6" order="4.25000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xlink:role="http://www.protalix.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:label="loc_StatementLineItems.4952.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.6878.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.7" xlink:to="loc_CommonStockParOrStatedValuePerShare.6878.12.7" order="1.02000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CommonStockSharesAuthorized.6879.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.7" xlink:to="loc_CommonStockSharesAuthorized.6879.12.7" order="1.03000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CommonStockSharesIssued.6875.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.7" xlink:to="loc_CommonStockSharesIssued.6875.12.7" order="1.04000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CommonStockSharesOutstanding.6864.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.7" xlink:to="loc_CommonStockSharesOutstanding.6864.12.7" order="1.05000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementOfFinancialPositionAbstract.4958.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfFinancialPositionAbstract.4958.12.7" xlink:to="loc_StatementLineItems.4952.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="102 - Disclosure - LICENSE AND SUPPLY AGREEMENT" xlink:role="http://www.protalix.com/role/LicenseAndSupplyAgreement" xlink:type="extended">
    <link:loc xlink:label="loc_CollaborativeAndLicenseArrangementDisclosure.68667.12.7" xlink:href="plx-20121231.xsd#plx_CollaborativeAndLicenseArrangementDisclosure" xlink:type="locator" />
    <link:loc xlink:label="loc_CollaborativeAndLicenseArrangementDisclosureTextBlock.68665.12.7" xlink:href="plx-20121231.xsd#plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeAndLicenseArrangementDisclosure.68667.12.7" xlink:to="loc_CollaborativeAndLicenseArrangementDisclosureTextBlock.68665.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="103 - Disclosure - PROPERTY AND EQUIPMENT" xlink:role="http://www.protalix.com/role/PropertyAndEquipment" xlink:type="extended">
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentAbstract.4105.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentDisclosureTextBlock.14703.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PropertyPlantAndEquipmentAbstract.4105.12.7" xlink:to="loc_PropertyPlantAndEquipmentDisclosureTextBlock.14703.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="105 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT" xlink:role="http://www.protalix.com/role/LiabilityForEmployeeRightsUponRetirement" xlink:type="extended">
    <link:loc xlink:label="loc_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract.1429.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitsDisclosureTextBlock.13873.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract.1429.12.7" xlink:to="loc_PensionAndOtherPostretirementBenefitsDisclosureTextBlock.13873.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="106 - Disclosure - COMMITMENTS" xlink:role="http://www.protalix.com/role/Commitments" xlink:type="extended">
    <link:loc xlink:label="loc_CommitmentsAndContingenciesDisclosureAbstract.1025.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CommitmentsDisclosureTextBlock.6839.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesDisclosureAbstract.1025.12.7" xlink:to="loc_CommitmentsDisclosureTextBlock.6839.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="107 - Disclosure - SHARE CAPITAL" xlink:role="http://www.protalix.com/role/ShareCapital" xlink:type="extended">
    <link:loc xlink:label="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquityNoteDisclosureTextBlock.16673.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.7" xlink:to="loc_StockholdersEquityNoteDisclosureTextBlock.16673.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="108 - Disclosure - TAXES ON INCOME" xlink:role="http://www.protalix.com/role/TaxesOnIncome" xlink:type="extended">
    <link:loc xlink:label="loc_IncomeTaxDisclosureAbstract.2523.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_IncomeTaxDisclosureTextBlock.10640.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxDisclosureAbstract.2523.12.7" xlink:to="loc_IncomeTaxDisclosureTextBlock.10640.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="109 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION" xlink:role="http://www.protalix.com/role/SupplementaryFinancialStatementInformation" xlink:type="extended">
    <link:loc xlink:label="loc_SupplementalInformationAbstract.73895.12.7" xlink:href="plx-20121231.xsd#plx_SupplementalInformationAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_AdditionalFinancialInformationDisclosureTextBlock.5621.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SupplementalInformationAbstract.73895.12.7" xlink:to="loc_AdditionalFinancialInformationDisclosureTextBlock.5621.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="110 - Disclosure - RELATED PARTY TRANSACTIONS" xlink:role="http://www.protalix.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:label="loc_RelatedPartyTransactionsAbstract.4350.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_RelatedPartyTransactionsDisclosureTextBlock.15176.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RelatedPartyTransactionsAbstract.4350.12.7" xlink:to="loc_RelatedPartyTransactionsDisclosureTextBlock.15176.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="303 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" xlink:role="http://www.protalix.com/role/PropertyAndEquipmentTables" xlink:type="extended">
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentAbstract.4105.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentTextBlock.14699.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PropertyPlantAndEquipmentAbstract.4105.12.7" xlink:to="loc_PropertyPlantAndEquipmentTextBlock.14699.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="307 - Disclosure - SHARE CAPITAL (Tables)" xlink:role="http://www.protalix.com/role/ShareCapitalTables" xlink:type="extended">
    <link:loc xlink:label="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock.15727.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.7" xlink:to="loc_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock.15727.12.7" order="2.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.15758.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.7" xlink:to="loc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.15758.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock.15821.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.7" xlink:to="loc_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock.15821.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock.15935.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.7" xlink:to="loc_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock.15935.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock.15869.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.7" xlink:to="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock.15869.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock.15939.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.7" xlink:to="loc_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock.15939.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock.73903.12.7" xlink:href="plx-20121231.xsd#plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.7" xlink:to="loc_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock.73903.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="309 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)" xlink:role="http://www.protalix.com/role/SupplementaryFinancialStatementInformationTables" xlink:type="extended">
    <link:loc xlink:label="loc_SupplementalInformationAbstract.73895.12.7" xlink:href="plx-20121231.xsd#plx_SupplementalInformationAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_SupplementaryBalanceSheetsInformationTableTextBlock.70103.12.7" xlink:href="plx-20121231.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SupplementalInformationAbstract.73895.12.7" xlink:to="loc_SupplementaryBalanceSheetsInformationTableTextBlock.70103.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SupplementaryIncomeStatementInformationTableTextBlock.73902.12.7" xlink:href="plx-20121231.xsd#plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SupplementalInformationAbstract.73895.12.7" xlink:to="loc_SupplementaryIncomeStatementInformationTableTextBlock.73902.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="310 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)" xlink:role="http://www.protalix.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:label="loc_RelatedPartyTransactionsAbstract.4350.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfRelatedPartyTransactionsTableTextBlock.15798.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RelatedPartyTransactionsAbstract.4350.12.7" xlink:to="loc_ScheduleOfRelatedPartyTransactionsTableTextBlock.15798.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40301 - Disclosure - PROPERTY AND EQUIPMENT (Details)" xlink:role="http://www.protalix.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentTypeDomain.4099.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_LaboratoryEquipmentMember.70112.12.6" xlink:href="plx-20121231.xsd#plx_LaboratoryEquipmentMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PropertyPlantAndEquipmentTypeDomain.4099.12.6" xlink:to="loc_LaboratoryEquipmentMember.70112.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_FurnitureAndComputerEquipmentMember.70134.12.6" xlink:href="plx-20121231.xsd#plx_FurnitureAndComputerEquipmentMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PropertyPlantAndEquipmentTypeDomain.4099.12.6" xlink:to="loc_FurnitureAndComputerEquipmentMember.70134.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_LeaseholdImprovementsMember.2905.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PropertyPlantAndEquipmentTypeDomain.4099.12.6" xlink:to="loc_LeaseholdImprovementsMember.2905.12.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EquipmentUnderConstructionMember.70136.12.6" xlink:href="plx-20121231.xsd#plx_EquipmentUnderConstructionMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PropertyPlantAndEquipmentTypeDomain.4099.12.6" xlink:to="loc_EquipmentUnderConstructionMember.70136.12.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentAbstract.4105.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfPropertyPlantAndEquipmentTable.4693.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PropertyPlantAndEquipmentAbstract.4105.12.6" xlink:to="loc_ScheduleOfPropertyPlantAndEquipmentTable.4693.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentLineItems.4115.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentGross.14698.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PropertyPlantAndEquipmentLineItems.4115.12.6" xlink:to="loc_PropertyPlantAndEquipmentGross.14698.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentLineItems.4115.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment.5600.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PropertyPlantAndEquipmentLineItems.4115.12.42" xlink:to="loc_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment.5600.12.42" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentLineItems.4115.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.14697.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PropertyPlantAndEquipmentLineItems.4115.12.9" xlink:to="loc_PropertyPlantAndEquipmentNet.14697.12.9" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentLineItems.4115.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_DepreciationAmortizationAndAssetImpairment.68637.12.7" xlink:href="plx-20121231.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PropertyPlantAndEquipmentLineItems.4115.12.7" xlink:to="loc_DepreciationAmortizationAndAssetImpairment.68637.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AssetImpairmentCharges.5835.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PropertyPlantAndEquipmentLineItems.4115.12.7" xlink:to="loc_AssetImpairmentCharges.5835.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentByTypeAxis.4117.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PropertyPlantAndEquipmentByTypeAxis.4117.12.6" xlink:to="loc_PropertyPlantAndEquipmentTypeDomain.4099.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfPropertyPlantAndEquipmentTable.4693.12.6" xlink:to="loc_PropertyPlantAndEquipmentByTypeAxis.4117.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfPropertyPlantAndEquipmentTable.4693.12.6" xlink:to="loc_PropertyPlantAndEquipmentLineItems.4115.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40401 - Disclosure - INVENTORIES (Details)" xlink:role="http://www.protalix.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:label="loc_InventoryDisclosureAbstract.2789.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_InventoryRawMaterialsNetOfReserves.11392.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2789.12.7" xlink:to="loc_InventoryRawMaterialsNetOfReserves.11392.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_InventoryWorkInProcessNetOfReserves.11424.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2789.12.7" xlink:to="loc_InventoryWorkInProcessNetOfReserves.11424.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_InventoryFinishedGoodsNetOfReserves.11388.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2789.12.7" xlink:to="loc_InventoryFinishedGoodsNetOfReserves.11388.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_InventoryDisclosureAbstract.2789.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_InventoryNet.11417.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2789.12.9" xlink:to="loc_InventoryNet.11417.12.9" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_InventoryWriteDown.11386.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryWriteDown" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2789.12.7" xlink:to="loc_InventoryWriteDown.11386.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)" xlink:role="http://www.protalix.com/role/LiabilityForEmployeeRightsUponRetirementDetails" xlink:type="extended">
    <link:loc xlink:label="loc_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract.1429.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_EmployeeSeveranceObligationPayment.70465.12.7" xlink:href="plx-20121231.xsd#plx_EmployeeSeveranceObligationPayment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract.1429.12.7" xlink:to="loc_EmployeeSeveranceObligationPayment.70465.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SeveranceCosts.16233.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SeveranceCosts" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract.1429.12.7" xlink:to="loc_SeveranceCosts.16233.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax.7817.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract.1429.12.7" xlink:to="loc_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax.7817.12.7" order="4.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DefinedContributionPlanEmployerDiscretionaryContributionAmount.7821.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract.1429.12.7" xlink:to="loc_DefinedContributionPlanEmployerDiscretionaryContributionAmount.7821.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ExpectedDefintedBenefitContributionDuringPeriod.70851.12.7" xlink:href="plx-20121231.xsd#plx_ExpectedDefintedBenefitContributionDuringPeriod" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract.1429.12.7" xlink:to="loc_ExpectedDefintedBenefitContributionDuringPeriod.70851.12.7" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod.70852.12.7" xlink:href="plx-20121231.xsd#plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract.1429.12.7" xlink:to="loc_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod.70852.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40601 - Disclosure - COMMITMENTS (Details)" xlink:role="http://www.protalix.com/role/CommitmentsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_CommitmentsAndContingenciesDisclosureAbstract.1025.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CommitmentsAndContingenciesTable.70468.12.6" xlink:href="plx-20121231.xsd#plx_CommitmentsAndContingenciesTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesDisclosureAbstract.1025.12.6" xlink:to="loc_CommitmentsAndContingenciesTable.70468.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeAxis.4187.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4188.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeAxis.4187.12.6" xlink:to="loc_RangeMember.4188.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_MinimumMember.3248.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeMember.4188.12.6" xlink:to="loc_MinimumMember.3248.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_MaximumMember.3241.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeMember.4188.12.6" xlink:to="loc_MaximumMember.3241.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesTable.70468.12.6" xlink:to="loc_RangeAxis.4187.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_CommitmentsAndContingenciesAxis.70469.12.6" xlink:href="plx-20121231.xsd#plx_CommitmentsAndContingenciesAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesTable.70468.12.6" xlink:to="loc_CommitmentsAndContingenciesAxis.70469.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_CommitmentsAndContingenciesLineItems.70471.12.6" xlink:href="plx-20121231.xsd#plx_CommitmentsAndContingenciesLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesTable.70468.12.6" xlink:to="loc_CommitmentsAndContingenciesLineItems.70471.12.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_CommitmentsAndContingenciesDomain.70470.12.6" xlink:href="plx-20121231.xsd#plx_CommitmentsAndContingenciesDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesAxis.70469.12.6" xlink:to="loc_CommitmentsAndContingenciesDomain.70470.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_OCSMember.70473.12.6" xlink:href="plx-20121231.xsd#plx_OCSMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesDomain.70470.12.6" xlink:to="loc_OCSMember.70473.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ProductsManufacturedOutsideOfIsraelMember.70475.12.6" xlink:href="plx-20121231.xsd#plx_ProductsManufacturedOutsideOfIsraelMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesDomain.70470.12.6" xlink:to="loc_ProductsManufacturedOutsideOfIsraelMember.70475.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_FundingArrangementsMember.70476.12.6" xlink:href="plx-20121231.xsd#plx_FundingArrangementsMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesDomain.70470.12.6" xlink:to="loc_FundingArrangementsMember.70476.12.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ResearchAndLicenseAgreementsMember.70477.12.6" xlink:href="plx-20121231.xsd#plx_ResearchAndLicenseAgreementsMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesDomain.70470.12.6" xlink:to="loc_ResearchAndLicenseAgreementsMember.70477.12.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ProbableAggregateMilestonePaymentMember.70479.12.6" xlink:href="plx-20121231.xsd#plx_ProbableAggregateMilestonePaymentMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesDomain.70470.12.6" xlink:to="loc_ProbableAggregateMilestonePaymentMember.70479.12.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_MilestonePaymentsMember.70480.12.6" xlink:href="plx-20121231.xsd#plx_MilestonePaymentsMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesDomain.70470.12.6" xlink:to="loc_MilestonePaymentsMember.70480.12.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_VehicleLeaseAndMaintenanceAgreementsMember.70487.12.6" xlink:href="plx-20121231.xsd#plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesDomain.70470.12.6" xlink:to="loc_VehicleLeaseAndMaintenanceAgreementsMember.70487.12.6" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_LeaseAgreementsMember.2904.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesDomain.70470.12.6" xlink:to="loc_LeaseAgreementsMember.2904.12.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_YissumAgreementMember.73722.12.6" xlink:href="plx-20121231.xsd#plx_YissumAgreementMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesDomain.70470.12.6" xlink:to="loc_YissumAgreementMember.73722.12.6" order="10.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_CommitmentsAndContingenciesLineItems.70471.12.7" xlink:href="plx-20121231.xsd#plx_CommitmentsAndContingenciesLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_RoyaltiesOnSaleOfProducts.70472.12.7" xlink:href="plx-20121231.xsd#plx_RoyaltiesOnSaleOfProducts" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.12.7" xlink:to="loc_RoyaltiesOnSaleOfProducts.70472.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived.70474.12.7" xlink:href="plx-20121231.xsd#plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.12.7" xlink:to="loc_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived.70474.12.7" order="2.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_RoyaltyExpense.15586.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RoyaltyExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.12.7" xlink:to="loc_RoyaltyExpense.15586.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AccruedRoyaltiesCurrentAndNoncurrent.5534.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.12.7" xlink:to="loc_AccruedRoyaltiesCurrentAndNoncurrent.5534.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CommitmentAmount.70485.12.7" xlink:href="plx-20121231.xsd#plx_CommitmentAmount" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.12.7" xlink:to="loc_CommitmentAmount.70485.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OperatingLeasesRentExpenseNet.13072.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.12.7" xlink:to="loc_OperatingLeasesRentExpenseNet.13072.12.7" order="7.25000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SecurityDeposit.16065.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.12.7" xlink:to="loc_SecurityDeposit.16065.12.7" order="6.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OperatingLeasesFutureMinimumPaymentsDueCurrent.13089.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.12.7" xlink:to="loc_OperatingLeasesFutureMinimumPaymentsDueCurrent.13089.12.7" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OperatingLeasesFutureMinimumPaymentsDueInTwoYears.13087.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.12.7" xlink:to="loc_OperatingLeasesFutureMinimumPaymentsDueInTwoYears.13087.12.7" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OperatingLeasesFutureMinimumPaymentsDueInThreeYears.13081.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.12.7" xlink:to="loc_OperatingLeasesFutureMinimumPaymentsDueInThreeYears.13081.12.7" order="10.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OperatingLeasesFutureMinimumPaymentsDueInFourYears.13094.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.12.7" xlink:to="loc_OperatingLeasesFutureMinimumPaymentsDueInFourYears.13094.12.7" order="11.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_MonthlyRentLeaseExpense.70486.12.7" xlink:href="plx-20121231.xsd#plx_MonthlyRentLeaseExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.12.7" xlink:to="loc_MonthlyRentLeaseExpense.70486.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ConsiderationForLicense.70492.12.7" xlink:href="plx-20121231.xsd#plx_ConsiderationForLicense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.12.7" xlink:to="loc_ConsiderationForLicense.70492.12.7" order="13.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AnnualIncreaseToMaintenanceFee.73723.12.7" xlink:href="plx-20121231.xsd#plx_AnnualIncreaseToMaintenanceFee" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.12.7" xlink:to="loc_AnnualIncreaseToMaintenanceFee.73723.12.7" order="14.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AgreementMaintenanceFee.73724.12.7" xlink:href="plx-20121231.xsd#plx_AgreementMaintenanceFee" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesLineItems.70471.12.7" xlink:to="loc_AgreementMaintenanceFee.73724.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40702 - Disclosure - SHARE CAPITAL (Summary of Option and Restricted Stock Granted to Employees) (Details)" xlink:role="http://www.protalix.com/role/ShareCapitalSummaryOfOptionAndRestrictedStockGrantedToEmployeesDetails" xlink:type="extended">
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.12.6" xlink:to="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.6" xlink:to="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_PlanNameDomain.3870.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_GrantYearTwoThousandTenMember.70805.12.7" xlink:href="plx-20121231.xsd#plx_GrantYearTwoThousandTenMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PlanNameDomain.3870.12.7" xlink:to="loc_GrantYearTwoThousandTenMember.70805.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_GrantYearTwoThousandTenSecondMember.70806.12.7" xlink:href="plx-20121231.xsd#plx_GrantYearTwoThousandTenSecondMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PlanNameDomain.3870.12.7" xlink:to="loc_GrantYearTwoThousandTenSecondMember.70806.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_GrantYearTwoThousandTwelveMember.70807.12.7" xlink:href="plx-20121231.xsd#plx_GrantYearTwoThousandTwelveMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PlanNameDomain.3870.12.7" xlink:to="loc_GrantYearTwoThousandTwelveMember.70807.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_GrantYearTwoThousandTwelveSecondMember.70808.12.7" xlink:href="plx-20121231.xsd#plx_GrantYearTwoThousandTwelveSecondMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PlanNameDomain.3870.12.7" xlink:to="loc_GrantYearTwoThousandTwelveSecondMember.70808.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PlanNameAxis.3871.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_PlanNameDomain.3870.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PlanNameAxis.3871.12.6" xlink:to="loc_PlanNameDomain.3870.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.12.6" xlink:to="loc_PlanNameAxis.3871.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.12.6" xlink:to="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.12.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.16275.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.16275.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit.16365.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit.16365.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.16378.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.8" xlink:to="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.16378.12.8" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.16272.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.16272.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.68655.12.7" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.68655.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.68656.12.8" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.8" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.68656.12.8" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_EmployeesMember.68641.12.6" xlink:href="plx-20121231.xsd#plx_EmployeesMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.12.6" xlink:to="loc_EmployeesMember.68641.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40703 - Disclosure - SHARE CAPITAL (Fair Value Assumptions of Options Granted) (Details)" xlink:role="http://www.protalix.com/role/ShareCapitalFairValueAssumptionsOfOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:label="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.16324.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.16324.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate.16318.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate.16318.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.16317.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.16317.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1.15604.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.7" xlink:to="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1.15604.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ForfeitureRate.70802.12.7" xlink:href="plx-20121231.xsd#plx_ForfeitureRate" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.7" xlink:to="loc_ForfeitureRate.70802.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.8820.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.7" xlink:to="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.8820.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1.8813.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.7" xlink:to="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1.8813.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.68655.12.7" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.68655.12.7" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40706 - Disclosure - SHARE CAPITAL (Options Granted to Consultants, Directors and Other Service Providers) (Details)" xlink:role="http://www.protalix.com/role/ShareCapitalOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails" xlink:type="extended">
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.12.6" xlink:to="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.6" xlink:to="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.12.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.12.6" xlink:to="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16369.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.10" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16369.12.10" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16369.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.11" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16369.12.11" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.16332.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.16332.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16356.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.10" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16356.12.10" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.16305.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.16305.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16356.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.11" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16356.12.11" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.16322.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.16322.12.7" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.16330.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.16330.12.7" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.14555.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_ProceedsFromStockOptionsExercised.14555.12.7" order="11.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember.70543.12.6" xlink:href="plx-20121231.xsd#plx_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.12.6" xlink:to="loc_OptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersMember.70543.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40707 - Disclosure - SHARE CAPITAL (Summary of Outstanding and Restricted Stocks) (Details)" xlink:role="http://www.protalix.com/role/ShareCapitalSummaryOfOutstandingAndRestrictedStocksDetails" xlink:type="extended">
    <link:loc xlink:label="loc_AwardTypeAxis.344.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AwardTypeAxis.344.12.6" xlink:to="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable.4676.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.6" xlink:to="loc_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable.4676.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis.4870.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable.4676.12.6" xlink:to="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis.4870.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems.4871.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable.4676.12.6" xlink:to="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems.4871.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable.4676.12.6" xlink:to="loc_AwardTypeAxis.344.12.6" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis.4870.12.6" xlink:to="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems.4871.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.16378.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems.4871.12.7" xlink:to="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit.16378.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.16364.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems.4871.12.7" xlink:to="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions.16364.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2.15612.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems.4871.12.7" xlink:to="loc_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2.15612.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.16348.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems.4871.12.7" xlink:to="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions.16348.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2.15607.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems.4871.12.7" xlink:to="loc_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2.15607.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.15602.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems.4871.12.7" xlink:to="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.15602.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ZeroPointZeroZeroOneMember.70524.12.7" xlink:href="plx-20121231.xsd#plx_ZeroPointZeroZeroOneMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.12.7" xlink:to="loc_ZeroPointZeroZeroOneMember.70524.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ZeroPointOneTwoZeroMember.70525.12.7" xlink:href="plx-20121231.xsd#plx_ZeroPointOneTwoZeroMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.12.7" xlink:to="loc_ZeroPointOneTwoZeroMember.70525.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ZeroPointThreeNineNineMember.70527.12.7" xlink:href="plx-20121231.xsd#plx_ZeroPointThreeNineNineMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.12.7" xlink:to="loc_ZeroPointThreeNineNineMember.70527.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ZeroPointNineSevenTwoMember.70530.12.7" xlink:href="plx-20121231.xsd#plx_ZeroPointNineSevenTwoMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.12.7" xlink:to="loc_ZeroPointNineSevenTwoMember.70530.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_TwoPointThreeFiveZeroMember.70532.12.7" xlink:href="plx-20121231.xsd#plx_TwoPointThreeFiveZeroMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.12.7" xlink:to="loc_TwoPointThreeFiveZeroMember.70532.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_TwoPointSixFiveMember.70533.12.7" xlink:href="plx-20121231.xsd#plx_TwoPointSixFiveMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.12.7" xlink:to="loc_TwoPointSixFiveMember.70533.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ThreePointZeroTwoZeroMember.70534.12.7" xlink:href="plx-20121231.xsd#plx_ThreePointZeroTwoZeroMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.12.7" xlink:to="loc_ThreePointZeroTwoZeroMember.70534.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_FivePointZeroMember.70535.12.7" xlink:href="plx-20121231.xsd#plx_FivePointZeroMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.12.7" xlink:to="loc_FivePointZeroMember.70535.12.7" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SixPointEightOneZeroMember.70536.12.7" xlink:href="plx-20121231.xsd#plx_SixPointEightOneZeroMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.12.7" xlink:to="loc_SixPointEightOneZeroMember.70536.12.7" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SixPointNineMember.70537.12.7" xlink:href="plx-20121231.xsd#plx_SixPointNineMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.12.7" xlink:to="loc_SixPointNineMember.70537.12.7" order="10.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SevenPointFiveFiveMember.70538.12.7" xlink:href="plx-20121231.xsd#plx_SevenPointFiveFiveMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.12.7" xlink:to="loc_SevenPointFiveFiveMember.70538.12.7" order="11.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NinePointSixSixMember.70539.12.7" xlink:href="plx-20121231.xsd#plx_NinePointSixSixMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.12.7" xlink:to="loc_NinePointSixSixMember.70539.12.7" order="12.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OneSixPointSevenMember.70540.12.7" xlink:href="plx-20121231.xsd#plx_OneSixPointSevenMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain.4872.12.7" xlink:to="loc_OneSixPointSevenMember.70540.12.7" order="13.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OptionsAndRestrictedStockMember.70541.12.6" xlink:href="plx-20121231.xsd#plx_OptionsAndRestrictedStockMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.12.6" xlink:to="loc_OptionsAndRestrictedStockMember.70541.12.6" order="2.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_RestrictedStockMember.4416.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.12.6" xlink:to="loc_RestrictedStockMember.4416.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40708 - Disclosure - SHARE CAPITAL (Share Based Compensation Expense Allocation) (Details)" xlink:role="http://www.protalix.com/role/ShareCapitalShareBasedCompensationExpenseAllocationDetails" xlink:type="extended">
    <link:loc xlink:label="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4618.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.6" xlink:to="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4618.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1710.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_AllocatedShareBasedCompensationExpense.5724.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1710.12.6" xlink:to="loc_AllocatedShareBasedCompensationExpense.5724.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpenseMember.4381.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.12.6" xlink:to="loc_ResearchAndDevelopmentExpenseMember.4381.12.6" order="1.75000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpenseMember.2354.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.12.6" xlink:to="loc_GeneralAndAdministrativeExpenseMember.2354.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_CostOfSalesMember.1183.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfSalesMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.12.7" xlink:to="loc_CostOfSalesMember.1183.12.7" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis.4617.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis.4617.12.6" xlink:to="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4618.12.6" xlink:to="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis.4617.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4618.12.6" xlink:to="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1710.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="308 - Disclosure - TAXES ON INCOME (Tables)" xlink:role="http://www.protalix.com/role/TaxesOnIncomeTables" xlink:type="extended">
    <link:loc xlink:label="loc_IncomeTaxDisclosureAbstract.2523.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock.15803.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxDisclosureAbstract.2523.12.7" xlink:to="loc_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock.15803.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScheduleOfOpenTaxYearsTableTextBlock.70061.12.7" xlink:href="plx-20121231.xsd#plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxDisclosureAbstract.2523.12.7" xlink:to="loc_ScheduleOfOpenTaxYearsTableTextBlock.70061.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40801 - Disclosure - TAXES ON INCOME (Narrative) (Details)" xlink:role="http://www.protalix.com/role/TaxesOnIncomeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:label="loc_EntityDomain.99.12.7" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_SubsidiariesMember.5011.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsidiariesMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EntityDomain.99.12.7" xlink:to="loc_SubsidiariesMember.5011.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LegalEntityAxis.136.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_EntityDomain.99.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LegalEntityAxis.136.12.6" xlink:to="loc_EntityDomain.99.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeTaxDisclosureAbstract.2523.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_IncomeTaxDisclosureTable.70493.12.6" xlink:href="plx-20121231.xsd#plx_IncomeTaxDisclosureTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxDisclosureAbstract.2523.12.6" xlink:to="loc_IncomeTaxDisclosureTable.70493.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeTaxAuthorityAxis.2525.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_IncomeTaxAuthorityDomain.2535.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxAuthorityAxis.2525.12.6" xlink:to="loc_IncomeTaxAuthorityDomain.2535.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeTaxAuthorityDomain.2535.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_TaxYearThereafterMember.70497.12.7" xlink:href="plx-20121231.xsd#plx_TaxYearThereafterMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxAuthorityDomain.2535.12.7" xlink:to="loc_TaxYearThereafterMember.70497.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_TaxYearTwoThousandNineMember.70496.12.7" xlink:href="plx-20121231.xsd#plx_TaxYearTwoThousandNineMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxAuthorityDomain.2535.12.7" xlink:to="loc_TaxYearTwoThousandNineMember.70496.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_TaxBurdenDistributionLawMember.70504.12.6" xlink:href="plx-20121231.xsd#plx_TaxBurdenDistributionLawMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxAuthorityDomain.2535.12.6" xlink:to="loc_TaxBurdenDistributionLawMember.70504.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_RestrictedAmountMember.70506.12.6" xlink:href="plx-20121231.xsd#plx_RestrictedAmountMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxAuthorityDomain.2535.12.6" xlink:to="loc_RestrictedAmountMember.70506.12.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeAxis.4187.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4188.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeAxis.4187.12.6" xlink:to="loc_RangeMember.4188.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_MinimumMember.3248.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeMember.4188.12.6" xlink:to="loc_MinimumMember.3248.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_MaximumMember.3241.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeMember.4188.12.6" xlink:to="loc_MaximumMember.3241.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_IncomeTaxDisclosureTable.70493.12.6" xlink:to="loc_RangeAxis.4187.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_IncomeTaxDisclosureTable.70493.12.6" xlink:to="loc_LegalEntityAxis.136.12.6" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeTaxDisclosureLineItems.70495.12.6" xlink:href="plx-20121231.xsd#plx_IncomeTaxDisclosureLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxDisclosureTable.70493.12.6" xlink:to="loc_IncomeTaxDisclosureLineItems.70495.12.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_IncomeTaxDisclosureTable.70493.12.6" xlink:to="loc_IncomeTaxAuthorityAxis.2525.12.6" order="2.75000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeTaxDisclosureLineItems.70495.12.7" xlink:href="plx-20121231.xsd#plx_IncomeTaxDisclosureLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate.8745.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxDisclosureLineItems.70495.12.7" xlink:to="loc_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate.8745.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateYearOne.70498.12.7" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearOne" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxDisclosureLineItems.70495.12.7" xlink:to="loc_EffectiveAdjustedIncomeTaxRateYearOne.70498.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateYearTwo.70499.12.7" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearTwo" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxDisclosureLineItems.70495.12.7" xlink:to="loc_EffectiveAdjustedIncomeTaxRateYearTwo.70499.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateYearThree.70500.12.7" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearThree" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxDisclosureLineItems.70495.12.7" xlink:to="loc_EffectiveAdjustedIncomeTaxRateYearThree.70500.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateYearFour.70501.12.7" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearFour" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxDisclosureLineItems.70495.12.7" xlink:to="loc_EffectiveAdjustedIncomeTaxRateYearFour.70501.12.7" order="5.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateYearFive.70502.12.7" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateYearFive" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxDisclosureLineItems.70495.12.7" xlink:to="loc_EffectiveAdjustedIncomeTaxRateYearFive.70502.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EffectiveAdjustedIncomeTaxRateThereafter.70503.12.7" xlink:href="plx-20121231.xsd#plx_EffectiveAdjustedIncomeTaxRateThereafter" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxDisclosureLineItems.70495.12.7" xlink:to="loc_EffectiveAdjustedIncomeTaxRateThereafter.70503.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_WithholdingTaxRateOnForeignIncome.70505.12.7" xlink:href="plx-20121231.xsd#plx_WithholdingTaxRateOnForeignIncome" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxDisclosureLineItems.70495.12.7" xlink:to="loc_WithholdingTaxRateOnForeignIncome.70505.12.7" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OperatingLossCarryforwards.13067.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxDisclosureLineItems.70495.12.7" xlink:to="loc_OperatingLossCarryforwards.13067.12.7" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal.70507.12.7" xlink:href="plx-20121231.xsd#plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxDisclosureLineItems.70495.12.7" xlink:to="loc_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal.70507.12.7" order="10.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40802 - Disclosure - TAXES ON INCOME (Deferred Income Taxes) (Details)" xlink:role="http://www.protalix.com/role/TaxesOnIncomeDeferredIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:label="loc_IncomeTaxDisclosureAbstract.2523.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_DeferredTaxAssetsInProcessResearchAndDevelopment.7627.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxDisclosureAbstract.2523.12.7" xlink:to="loc_DeferredTaxAssetsInProcessResearchAndDevelopment.7627.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DeferredTaxAssetsPropertyPlantAndEquipment.7500.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxDisclosureAbstract.2523.12.7" xlink:to="loc_DeferredTaxAssetsPropertyPlantAndEquipment.7500.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits.7709.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxDisclosureAbstract.2523.12.7" xlink:to="loc_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits.7709.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments.7710.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxDisclosureAbstract.2523.12.7" xlink:to="loc_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments.7710.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DeferredTaxAssetsDeferredIncome.7661.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxDisclosureAbstract.2523.12.7" xlink:to="loc_DeferredTaxAssetsDeferredIncome.7661.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DeferredTaxAssetsOperatingLossCarryforwards.7678.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxDisclosureAbstract.2523.12.7" xlink:to="loc_DeferredTaxAssetsOperatingLossCarryforwards.7678.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncomeTaxDisclosureAbstract.2523.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_DeferredTaxAssetsValuationAllowance.7732.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxDisclosureAbstract.2523.12.42" xlink:to="loc_DeferredTaxAssetsValuationAllowance.7732.12.42" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_IncomeTaxDisclosureAbstract.2523.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_DeferredTaxAssetsNet.7623.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxDisclosureAbstract.2523.12.9" xlink:to="loc_DeferredTaxAssetsNet.7623.12.9" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40803 - Disclosure - TAXES ON INCOME (Open Tax Years) (Details)" xlink:role="http://www.protalix.com/role/TaxesOnIncomeOpenTaxYearsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_IncomeTaxContingencyTable.2508.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:type="locator" />
    <link:loc xlink:label="loc_IncomeTaxAuthorityAxis.2525.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxContingencyTable.2508.12.6" xlink:to="loc_IncomeTaxAuthorityAxis.2525.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeTaxContingencyLineItems.2528.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxContingencyTable.2508.12.6" xlink:to="loc_IncomeTaxContingencyLineItems.2528.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeAxis.4187.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxContingencyTable.2508.12.6" xlink:to="loc_RangeAxis.4187.12.6" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeTaxDisclosureAbstract.2523.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxDisclosureAbstract.2523.12.6" xlink:to="loc_IncomeTaxContingencyTable.2508.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeTaxAuthorityDomain.2535.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxAuthorityAxis.2525.12.6" xlink:to="loc_IncomeTaxAuthorityDomain.2535.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeTaxContingencyLineItems.2528.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_OpenTaxYear.13045.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxContingencyLineItems.2528.12.7" xlink:to="loc_OpenTaxYear.13045.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IL.17552.12.6" xlink:href="http://xbrl.sec.gov/country/2012/country-2012-01-31.xsd#country_IL" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxAuthorityDomain.2535.12.6" xlink:to="loc_IL.17552.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_US.17690.12.6" xlink:href="http://xbrl.sec.gov/country/2012/country-2012-01-31.xsd#country_US" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxAuthorityDomain.2535.12.6" xlink:to="loc_US.17690.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_NL.17619.12.6" xlink:href="http://xbrl.sec.gov/country/2012/country-2012-01-31.xsd#country_NL" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeTaxAuthorityDomain.2535.12.6" xlink:to="loc_NL.17619.12.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeMember.4188.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeAxis.4187.12.6" xlink:to="loc_RangeMember.4188.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_MinimumMember.3248.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeMember.4188.12.6" xlink:to="loc_MinimumMember.3248.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_MaximumMember.3241.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeMember.4188.12.6" xlink:to="loc_MaximumMember.3241.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40901 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Receivable, Other) (Details)" xlink:role="http://www.protalix.com/role/SupplementaryFinancialStatementInformationAccountsReceivableOtherDetails" xlink:type="extended">
    <link:loc xlink:label="loc_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis.392.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ReceivableTypeDomain.4239.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis.392.12.6" xlink:to="loc_ReceivableTypeDomain.4239.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_AccountsNotesAndLoansReceivableLineItems.410.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_PrepaidExpenseCurrent.14246.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountsNotesAndLoansReceivableLineItems.410.12.7" xlink:to="loc_PrepaidExpenseCurrent.14246.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AccountsNotesAndLoansReceivableLineItems.410.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_OtherReceivablesNetCurrent.13172.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountsNotesAndLoansReceivableLineItems.410.12.8" xlink:to="loc_OtherReceivablesNetCurrent.13172.12.8" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_DeferredCostMember.70510.12.6" xlink:href="plx-20121231.xsd#plx_DeferredCostMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ReceivableTypeDomain.4239.12.6" xlink:to="loc_DeferredCostMember.70510.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_InstitutionsMember.70511.12.6" xlink:href="plx-20121231.xsd#plx_InstitutionsMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ReceivableTypeDomain.4239.12.6" xlink:to="loc_InstitutionsMember.70511.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_StateOfIsraelMember.70512.12.6" xlink:href="plx-20121231.xsd#plx_StateOfIsraelMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ReceivableTypeDomain.4239.12.6" xlink:to="loc_StateOfIsraelMember.70512.12.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_RestrictedDepositMember.70513.12.6" xlink:href="plx-20121231.xsd#plx_RestrictedDepositMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ReceivableTypeDomain.4239.12.6" xlink:to="loc_RestrictedDepositMember.70513.12.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_SundryMember.70514.12.6" xlink:href="plx-20121231.xsd#plx_SundryMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ReceivableTypeDomain.4239.12.6" xlink:to="loc_SundryMember.70514.12.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable.4698.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable.4698.12.6" xlink:to="loc_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis.392.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_AccountsNotesAndLoansReceivableLineItems.410.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable.4698.12.6" xlink:to="loc_AccountsNotesAndLoansReceivableLineItems.410.12.6" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_SupplementalInformationAbstract.73895.12.6" xlink:href="plx-20121231.xsd#plx_SupplementalInformationAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SupplementalInformationAbstract.73895.12.6" xlink:to="loc_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable.4698.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="41001 - Disclosure - RELATED PARTY TRANSACTIONS (Details)" xlink:role="http://www.protalix.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_RelatedPartyTransactionLineItems.4347.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_RelatedPartyTransactionAmountsOfTransaction.15187.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RelatedPartyTransactionLineItems.4347.12.6" xlink:to="loc_RelatedPartyTransactionAmountsOfTransaction.15187.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_RelatedPartyDomain.4349.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ManagementAndConsultingFeesToChairmanOfBoardMember.70521.12.6" xlink:href="plx-20121231.xsd#plx_ManagementAndConsultingFeesToChairmanOfBoardMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RelatedPartyDomain.4349.12.6" xlink:to="loc_ManagementAndConsultingFeesToChairmanOfBoardMember.70521.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_CompensationToTheNon-executiveDirectorsMember.70522.12.6" xlink:href="plx-20121231.xsd#plx_CompensationToTheNon-executiveDirectorsMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RelatedPartyDomain.4349.12.6" xlink:to="loc_CompensationToTheNon-executiveDirectorsMember.70522.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_RelatedPartyTransactionsAbstract.4350.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable.4689.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RelatedPartyTransactionsAbstract.4350.12.6" xlink:to="loc_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable.4689.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_RelatedPartyTransactionsByRelatedPartyAxis.4351.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RelatedPartyTransactionsByRelatedPartyAxis.4351.12.6" xlink:to="loc_RelatedPartyDomain.4349.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable.4689.12.6" xlink:to="loc_RelatedPartyTransactionsByRelatedPartyAxis.4351.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable.4689.12.6" xlink:to="loc_RelatedPartyTransactionLineItems.4347.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Useful Lives of Property and Equipment) (Details)" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.385.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfPropertyPlantAndEquipmentTable.4693.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.6" xlink:to="loc_ScheduleOfPropertyPlantAndEquipmentTable.4693.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentTypeDomain.4099.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_FurnitureAndFixturesMember.2275.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PropertyPlantAndEquipmentTypeDomain.4099.12.7" xlink:to="loc_FurnitureAndFixturesMember.2275.12.7" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentTypeDomain.4099.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ComputerEquipmentMember.1086.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PropertyPlantAndEquipmentTypeDomain.4099.12.6" xlink:to="loc_ComputerEquipmentMember.1086.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_LaboratoryEquipmentMember.70112.12.6" xlink:href="plx-20121231.xsd#plx_LaboratoryEquipmentMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PropertyPlantAndEquipmentTypeDomain.4099.12.6" xlink:to="loc_LaboratoryEquipmentMember.70112.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentLineItems.4115.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentUsefulLife.14662.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PropertyPlantAndEquipmentLineItems.4115.12.7" xlink:to="loc_PropertyPlantAndEquipmentUsefulLife.14662.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentByTypeAxis.4117.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PropertyPlantAndEquipmentByTypeAxis.4117.12.6" xlink:to="loc_PropertyPlantAndEquipmentTypeDomain.4099.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeAxis.4187.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4188.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeAxis.4187.12.6" xlink:to="loc_RangeMember.4188.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_MinimumMember.3248.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeMember.4188.12.6" xlink:to="loc_MinimumMember.3248.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_MaximumMember.3241.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeMember.4188.12.6" xlink:to="loc_MaximumMember.3241.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfPropertyPlantAndEquipmentTable.4693.12.6" xlink:to="loc_PropertyPlantAndEquipmentByTypeAxis.4117.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfPropertyPlantAndEquipmentTable.4693.12.6" xlink:to="loc_RangeAxis.4187.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentLineItems.4115.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfPropertyPlantAndEquipmentTable.4693.12.6" xlink:to="loc_PropertyPlantAndEquipmentLineItems.4115.12.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40201 - Disclosure - LICENSE AND SUPPLY AGREEMENT (Details)" xlink:role="http://www.protalix.com/role/LicenseAndSupplyAgreementDetails" xlink:type="extended">
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:type="locator" />
    <link:loc xlink:label="loc_ProtalixBioTherapeuticsIncorporationMember.68651.12.7" xlink:href="plx-20121231.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.12.7" xlink:to="loc_ProtalixBioTherapeuticsIncorporationMember.68651.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PfizerIncorporationMember.68649.12.7" xlink:href="plx-20121231.xsd#plx_PfizerIncorporationMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.12.7" xlink:to="loc_PfizerIncorporationMember.68649.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:type="locator" />
    <link:loc xlink:label="loc_CollaborationOperationMember.70846.12.6" xlink:href="plx-20121231.xsd#plx_CollaborationOperationMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.12.6" xlink:to="loc_CollaborationOperationMember.70846.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.12.6" xlink:to="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4553.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioTwoMember.68654.12.7" xlink:href="plx-20121231.xsd#plx_ScenarioTwoMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.12.7" xlink:to="loc_ScenarioTwoMember.68654.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScenarioOneMember.68653.12.7" xlink:href="plx-20121231.xsd#plx_ScenarioOneMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.12.7" xlink:to="loc_ScenarioOneMember.68653.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4553.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_UponFDAApprovalMember.70109.12.6" xlink:href="plx-20121231.xsd#plx_UponFDAApprovalMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.12.6" xlink:to="loc_UponFDAApprovalMember.70109.12.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_UponNearTermClinicalDevelopmentMilestonesMember.70110.12.6" xlink:href="plx-20121231.xsd#plx_UponNearTermClinicalDevelopmentMilestonesMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.12.6" xlink:to="loc_UponNearTermClinicalDevelopmentMilestonesMember.70110.12.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementScenarioAxis.4951.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementScenarioAxis.4951.12.6" xlink:to="loc_ScenarioUnspecifiedDomain.4553.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.68658.12.7" xlink:href="plx-20121231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ProceedsFromCollaborators.14370.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.12.7" xlink:to="loc_ProceedsFromCollaborators.14370.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_MilestonePayment.68644.12.7" xlink:href="plx-20121231.xsd#plx_MilestonePayment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.12.7" xlink:to="loc_MilestonePayment.68644.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CollaborativeArrangementProfitSharePercentage.68635.12.7" xlink:href="plx-20121231.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.12.7" xlink:to="loc_CollaborativeArrangementProfitSharePercentage.68635.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.68658.12.8" xlink:href="plx-20121231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_AccruedLiabilitiesCurrentAndNoncurrent.5515.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.12.8" xlink:to="loc_AccruedLiabilitiesCurrentAndNoncurrent.5515.12.8" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_RevenueRecognizedOverDesignatedPeriod.73718.12.7" xlink:href="plx-20121231.xsd#plx_RevenueRecognizedOverDesignatedPeriod" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.12.7" xlink:to="loc_RevenueRecognizedOverDesignatedPeriod.73718.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_RevenueRecognizedPeriod.73719.12.7" xlink:href="plx-20121231.xsd#plx_RevenueRecognizedPeriod" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.12.7" xlink:to="loc_RevenueRecognizedPeriod.73719.12.7" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesAccruedFromLicensingAgreement.74712.12.7" xlink:href="plx-20121231.xsd#plx_LiabilitiesAccruedFromLicensingAgreement" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.68658.12.7" xlink:to="loc_LiabilitiesAccruedFromLicensingAgreement.74712.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CollaborativeAndLicenseArrangementDisclosure.68667.12.6" xlink:href="plx-20121231.xsd#plx_CollaborativeAndLicenseArrangementDisclosure" xlink:type="locator" />
    <link:loc xlink:label="loc_CollaborativeAndLicenseArrangementTable.70133.12.6" xlink:href="plx-20121231.xsd#plx_CollaborativeAndLicenseArrangementTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeAndLicenseArrangementDisclosure.68667.12.6" xlink:to="loc_CollaborativeAndLicenseArrangementTable.70133.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_CollaborativeAndLicenseArrangementTable.70133.12.6" xlink:to="loc_StatementScenarioAxis.4951.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_CollaborativeAndLicenseArrangementTable.70133.12.6" xlink:to="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.68658.12.6" xlink:href="plx-20121231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeAndLicenseArrangementTable.70133.12.6" xlink:to="loc_SignificantAccountingPoliciesLineItems.68658.12.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40902 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals, Other) (Details)" xlink:role="http://www.protalix.com/role/SupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" xlink:type="extended">
    <link:loc xlink:label="loc_AccountsPayableAndAccrualsTable.70515.12.6" xlink:href="plx-20121231.xsd#plx_AccountsPayableAndAccrualsTable" xlink:type="locator" />
    <link:loc xlink:label="loc_AccountsPayableAndAccrualsAxis.70516.12.6" xlink:href="plx-20121231.xsd#plx_AccountsPayableAndAccrualsAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountsPayableAndAccrualsTable.70515.12.6" xlink:to="loc_AccountsPayableAndAccrualsAxis.70516.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_AccountsPayableAndAccrualsLineItems.70520.12.6" xlink:href="plx-20121231.xsd#plx_AccountsPayableAndAccrualsLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountsPayableAndAccrualsTable.70515.12.6" xlink:to="loc_AccountsPayableAndAccrualsLineItems.70520.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_AccountsPayableAndAccrualsDomain.70517.12.6" xlink:href="plx-20121231.xsd#plx_AccountsPayableAndAccrualsDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountsPayableAndAccrualsAxis.70516.12.6" xlink:to="loc_AccountsPayableAndAccrualsDomain.70517.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborationOperationCurrentPortionMember.70518.12.6" xlink:href="plx-20121231.xsd#plx_CollaborationOperationCurrentPortionMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountsPayableAndAccrualsDomain.70517.12.6" xlink:to="loc_CollaborationOperationCurrentPortionMember.70518.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_PropertyAndEquipmentSuppliersMember.70519.12.6" xlink:href="plx-20121231.xsd#plx_PropertyAndEquipmentSuppliersMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountsPayableAndAccrualsDomain.70517.12.6" xlink:to="loc_PropertyAndEquipmentSuppliersMember.70519.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_AccountsPayableAndAccrualsLineItems.70520.12.7" xlink:href="plx-20121231.xsd#plx_AccountsPayableAndAccrualsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_EmployeeRelatedLiabilitiesCurrent.8812.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountsPayableAndAccrualsLineItems.70520.12.7" xlink:to="loc_EmployeeRelatedLiabilitiesCurrent.8812.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AccruedVacationCurrent.5530.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountsPayableAndAccrualsLineItems.70520.12.7" xlink:to="loc_AccruedVacationCurrent.5530.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AccruedLiabilitiesCurrent.5555.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountsPayableAndAccrualsLineItems.70520.12.7" xlink:to="loc_AccruedLiabilitiesCurrent.5555.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AccruedRoyaltiesCurrent.5572.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountsPayableAndAccrualsLineItems.70520.12.7" xlink:to="loc_AccruedRoyaltiesCurrent.5572.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AccountsPayableAndAccrualsLineItems.70520.12.8" xlink:href="plx-20121231.xsd#plx_AccountsPayableAndAccrualsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_AccountsPayableOtherCurrent.5442.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountsPayableAndAccrualsLineItems.70520.12.8" xlink:to="loc_AccountsPayableOtherCurrent.5442.12.8" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_SupplementalInformationAbstract.73895.12.6" xlink:href="plx-20121231.xsd#plx_SupplementalInformationAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SupplementalInformationAbstract.73895.12.6" xlink:to="loc_AccountsPayableAndAccrualsTable.70515.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40704 - Disclosure - SHARE CAPITAL (Options Granted to Employees) (Details)" xlink:role="http://www.protalix.com/role/ShareCapitalOptionsGrantedToEmployeesDetails" xlink:type="extended">
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.12.6" xlink:to="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.6" xlink:to="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.12.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.12.6" xlink:to="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16369.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.10" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16369.12.10" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.12.7" order="3.87500" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.16332.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.16332.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16356.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.10" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16356.12.10" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.16305.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.16305.12.7" order="7.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.16322.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.16322.12.7" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.16330.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.16330.12.7" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.16275.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.16275.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod.16341.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod.16341.12.7" order="3.75000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16369.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.11" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16369.12.11" order="3.93750" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16356.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.11" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16356.12.11" order="8.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.16298.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.16298.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice.16315.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice.16315.12.7" order="7.25000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.14555.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_ProceedsFromStockOptionsExercised.14555.12.7" order="11.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OptionsAndRestrictedStockGrantedToEmployeesMember.70546.12.6" xlink:href="plx-20121231.xsd#plx_OptionsAndRestrictedStockGrantedToEmployeesMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.12.6" xlink:to="loc_OptionsAndRestrictedStockGrantedToEmployeesMember.70546.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40705 - Disclosure - SHARE CAPITAL (Restricted Stock Granted to Employees) (Details)" xlink:role="http://www.protalix.com/role/ShareCapitalRestrictedStockGrantedToEmployeesDetails" xlink:type="extended">
    <link:loc xlink:label="loc_AwardTypeAxis.344.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AwardTypeAxis.344.12.6" xlink:to="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.12.6" xlink:to="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1556.12.6" xlink:to="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.12.6" xlink:to="loc_AwardTypeAxis.344.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.12.6" xlink:to="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4680.12.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.16281.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.10" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.16281.12.10" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.16300.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.16300.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.16252.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.8" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.16252.12.8" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.16281.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.11" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.16281.12.11" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable.73892.12.7" xlink:href="plx-20121231.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.4859.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable.73892.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_RestrictedStockMember.4416.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.12.6" xlink:to="loc_RestrictedStockMember.4416.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EmployeesMember.68641.12.6" xlink:href="plx-20121231.xsd#plx_EmployeesMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.12.6" xlink:to="loc_EmployeesMember.68641.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40903 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Revenues) (Details)" xlink:role="http://www.protalix.com/role/SupplementaryFinancialStatementInformationRevenuesDetails" xlink:type="extended">
    <link:loc xlink:label="loc_SupplementalInformationAbstract.73895.12.6" xlink:href="plx-20121231.xsd#plx_SupplementalInformationAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_SupplementalInformationTable.73896.12.6" xlink:href="plx-20121231.xsd#plx_SupplementalInformationTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SupplementalInformationAbstract.73895.12.6" xlink:to="loc_SupplementalInformationTable.73896.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_SupplementalInformationRevenueAxis.73897.12.6" xlink:href="plx-20121231.xsd#plx_SupplementalInformationRevenueAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SupplementalInformationTable.73896.12.6" xlink:to="loc_SupplementalInformationRevenueAxis.73897.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_SupplementalInformationRevenueLineItems.73901.12.6" xlink:href="plx-20121231.xsd#plx_SupplementalInformationRevenueLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SupplementalInformationTable.73896.12.6" xlink:to="loc_SupplementalInformationRevenueLineItems.73901.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_SupplementalInformationRevenueDomain.73898.12.6" xlink:href="plx-20121231.xsd#plx_SupplementalInformationRevenueDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SupplementalInformationRevenueAxis.73897.12.6" xlink:to="loc_SupplementalInformationRevenueDomain.73898.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember.73899.12.6" xlink:href="plx-20121231.xsd#plx_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SupplementalInformationRevenueDomain.73898.12.6" xlink:to="loc_DeferredRevenueFromLicenseAndSupplyAgreementWithPziferMember.73899.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_MilestonePaymentsMember.70480.12.6" xlink:href="plx-20121231.xsd#plx_MilestonePaymentsMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SupplementalInformationRevenueDomain.73898.12.6" xlink:to="loc_MilestonePaymentsMember.70480.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_SupplementalInformationRevenueDomain.73898.12.7" xlink:href="plx-20121231.xsd#plx_SupplementalInformationRevenueDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_SalesRevenueGoodsNetMember.4541.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SupplementalInformationRevenueDomain.73898.12.7" xlink:to="loc_SalesRevenueGoodsNetMember.4541.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_Revenues.15575.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SupplementalInformationRevenueLineItems.73901.12.6" xlink:to="loc_Revenues.15575.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EEXAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SHARE CAPITAL (Options Granted to Consultants, Directors and Other Service Providers) (Details) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of options</a></td>
        <td class="nump">$ 1,230<span></span></td>
        <td class="nump">$ 277<span></span></td>
        <td class="nump">$ 501<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Options Granted To Consultants Directors And Other Service Providers [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance</a></td>
        <td class="nump">1,238,692<span></span></td>
        <td class="nump">1,438,692<span></span></td>
        <td class="nump">1,438,692<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
        <td class="nump">326,267<span></span></td>
        <td class="nump">200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance</a></td>
        <td class="nump">912,425<span></span></td>
        <td class="nump">1,238,692<span></span></td>
        <td class="nump">1,438,692<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of year</a></td>
        <td class="nump">912,425<span></span></td>
        <td class="nump">1,235,567<span></span></td>
        <td class="nump">1,421,734<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
        <td class="nump">$ 5.385<span></span></td>
        <td class="nump">$ 4.697<span></span></td>
        <td class="nump">$ 4.697<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
        <td class="nump">$ 0.12<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
        <td class="nump">$ 7.259<span></span></td>
        <td class="nump">$ 5.385<span></span></td>
        <td class="nump">$ 4.697<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of year</a></td>
        <td class="nump">$ 7.259<span></span></td>
        <td class="nump">$ 5.385<span></span></td>
        <td class="nump">$ 4.653<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
        <td class="nump">2,300<span></span></td>
        <td class="nump">1,900<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of options</a></td>
        <td class="nump">$ 39<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph i<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(c), d(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(c)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total accumulated difference between fair values of underlying shares on dates of exercise and exercise price on options which were exercised (or share units converted) into shares during the reporting period under the plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph c(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(b)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(a)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(a)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EGDAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Management And Consulting Fees To Chairman Of Board [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party Transaction, Amounts of Transaction</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 6<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Compensation To The Non -executiveDirectors [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party Transaction, Amounts of Transaction</a></td>
        <td class="nump">$ 375<span></span></td>
        <td class="nump">$ 215<span></span></td>
        <td class="nump">$ 215<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of transactions with related party during the financial reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 57<br><br> -Paragraph 2<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionAmountsOfTransaction</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EQJAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals, Other) (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AccountsPayableAndAccrualsLineItems', window );"><strong>Accounts Payable And Accruals [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related expenses</a></td>
        <td class="nump">$ 1,748<span></span></td>
        <td class="nump">$ 1,108<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Provision for vacation</a></td>
        <td class="nump">1,453<span></span></td>
        <td class="nump">1,221<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
        <td class="nump">2,032<span></span></td>
        <td class="nump">2,327<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties payable</a></td>
        <td class="nump">1,560<span></span></td>
        <td class="nump">89<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Accounts payable and accruals, other</a></td>
        <td class="nump">11,051<span></span></td>
        <td class="nump">7,540<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Collaboration Operation Current Portion [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AccountsPayableAndAccrualsLineItems', window );"><strong>Accounts Payable And Accruals [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Accounts payable and accruals, other</a></td>
        <td class="nump">3,122<span></span></td>
        <td class="nump">1,322<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Property And Equipment Suppliers [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AccountsPayableAndAccrualsLineItems', window );"><strong>Accounts Payable And Accruals [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Accounts payable and accruals, other</a></td>
        <td class="nump">$ 1,136<span></span></td>
        <td class="nump">$ 1,473<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AccountsPayableAndAccrualsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_AccountsPayableAndAccrualsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, which are not elsewhere specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section A<br><br> -Paragraph 7<br><br> -Chapter 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableOtherCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section A<br><br> -Paragraph 7<br><br> -Chapter 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6911-107765<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section A<br><br> -Paragraph 8<br><br> -Chapter 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedRoyaltiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section A<br><br> -Paragraph 8<br><br> -Chapter 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 710<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 43<br><br> -Paragraph 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6911-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedVacationCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeRelatedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EP4AI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>COMMITMENTS (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentAmount', window );">Subcontracting commitment amount</a></td>
        <td class="nump">$ 1,300<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">OCS [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense included in cost of revenue</a></td>
        <td class="nump">1,500<span></span></td>
        <td class="nump">158<span></span></td>
        <td class="nump">769<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Research And License Agreements [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense included in cost of revenue</a></td>
        <td class="nump">674<span></span></td>
        <td class="nump">19<span></span></td>
        <td class="nump">115<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Probable Aggregate Milestone Payment [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense included in cost of revenue</a></td>
        <td class="nump">1,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Milestone Payments [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense included in cost of revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ConsiderationForLicense', window );">Consideration for license</a></td>
        <td class="nump">700<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Lease Agreements [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MonthlyRentLeaseExpense', window );">Monthly rent/lease expense</a></td>
        <td class="nump">82<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Cash deposited as bank guarantee</a></td>
        <td class="nump">298<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Lease/rent expense</a></td>
        <td class="nump">971<span></span></td>
        <td class="nump">994<span></span></td>
        <td class="nump">891<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Future minimum lease payments, 2013</a></td>
        <td class="nump">976<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Future minimum lease payments, 2014</a></td>
        <td class="nump">968<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Future minimum lease payments, 2015</a></td>
        <td class="nump">985<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">Future minimum lease payments, 2016</a></td>
        <td class="nump">823<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Vehicle Lease And Maintenance Agreements [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MonthlyRentLeaseExpense', window );">Monthly rent/lease expense</a></td>
        <td class="nump">49<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Future minimum lease payments, 2013</a></td>
        <td class="nump">526<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Future minimum lease payments, 2014</a></td>
        <td class="nump">385<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Future minimum lease payments, 2015</a></td>
        <td class="nump">175<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Yissum Agreement [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AgreementMaintenanceFee', window );">Agreement maintenance fee</a></td>
        <td class="nump">20<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived', window );">Percentage amount the aggregate amount of royalties that should not exceed grant received</a></td>
        <td class="nump">12.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum [Member] | OCS [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RoyaltiesOnSaleOfProducts', window );">Royalties based on sale of products developed from funded projects, percentage</a></td>
        <td class="nump">3.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member] | OCS [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RoyaltiesOnSaleOfProducts', window );">Royalties based on sale of products developed from funded projects, percentage</a></td>
        <td class="nump">6.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived', window );">Percentage amount the aggregate amount of royalties that should not exceed grant received</a></td>
        <td class="nump">100.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Accrued royalties</a></td>
        <td class="nump">$ 21,300<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member] | Products Manufactured Outside Of Israel [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RoyaltiesOnSaleOfProducts', window );">Royalties based on sale of products developed from funded projects, percentage</a></td>
        <td class="nump">300.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AgreementMaintenanceFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Agreement maintenance fee</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_AgreementMaintenanceFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommitmentAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Commitment amount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_CommitmentAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommitmentsAndContingenciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_CommitmentsAndContingenciesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ConsiderationForLicense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Consideration for license.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ConsiderationForLicense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percetnage aggregate royalties should not exceed grant amount</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_MaximumAggregatePaymentsOfRoyaltiesToGrantReceived</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MonthlyRentLeaseExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Monthly rent/lease expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_MonthlyRentLeaseExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RoyaltiesOnSaleOfProducts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of royalties based on sale of products developed from projects funded.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_RoyaltiesOnSaleOfProducts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph 5<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.15(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph a<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the next fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 13<br><br> -Paragraph 16<br><br> -Subparagraph b(i)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 13<br><br> -Paragraph 122<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the forth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 13<br><br> -Paragraph 16<br><br> -Subparagraph b(i)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 13<br><br> -Paragraph 122<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the third fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 13<br><br> -Paragraph 16<br><br> -Subparagraph b(i)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 13<br><br> -Paragraph 122<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the second fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 13<br><br> -Paragraph 16<br><br> -Subparagraph b(i)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 13<br><br> -Paragraph 122<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesRentExpenseNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RoyaltyExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.8,17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SecurityDeposit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementalInformationAbstract', window );"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementaryBalanceSheetsInformationTableTextBlock', window );">Supplemental Information, Balance Sheets</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-INDENT: -17.3pt; MARGIN: 0pt 0px 0pt 71.3pt; FONT: 10pt Times New Roman, Times, Serif">&nbsp;</p> <table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6">December 31,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt; FONT-STYLE: italic">(U.S. dollars in thousands)</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -26.45pt; PADDING-LEFT: 26.45pt; FONT-WEIGHT: bold"> a. Other assets:</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt; WIDTH: 74%"> Deferred costs*</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">1,558</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">89</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-LEFT: 45pt">Institutions</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">375</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">542</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt">State of Israel (see Note 6a)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,296</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">2,400</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt">Restricted deposit</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">208</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">298</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt">Prepaid expenses</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">235</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">251</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt">Sundry</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 165</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 106</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 3,837</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 3,686</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> * Manufacturing costs of inventory, paid by Pfizer, but not delivered.</p> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> <em>(U.S. dollars in thousands)</em></p> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 0.5in"><strong>b.</strong></td> <td style="TEXT-ALIGN: justify"><strong>Accounts payable and accruals - other:</strong></td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0"> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt; WIDTH: 74%"> Payroll and related expenses</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">1,108</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">1,748</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt">Provision for vacation</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,221</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,453</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt">Accrued expenses</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">2,327</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">2,032</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt">Royalties payable</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">89</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,560</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 52.2pt"> Liability in connection with collaboration operation- current portion</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,322</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">3,122</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; PADDING-LEFT: 45pt"> Property and equipment suppliers</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,473</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,136</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 7,540</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 11,051</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&nbsp;</p> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementaryIncomeStatementInformationTableTextBlock', window );">Supplemental Information, Income Statement</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="10">Year ended December 31,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2010</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-STYLE: italic">(U.S. dollars in thousands)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: right" colspan="2">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: right" colspan="2">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -28.85pt; PADDING-LEFT: 28.85pt; FONT-WEIGHT: bold"> c. Revenues:</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in; WIDTH: 61%"> Deferred revenues from the license and supply agreement with Pfizer</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">4,563</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">4,563</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">4,563</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 0.5in">Milestone payment (see note 2)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">25,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.5in"> Revenues from selling products</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 2,079</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 3,823</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 5,307</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -28.85pt; PADDING-LEFT: 28.85pt; FONT-WEIGHT: bold"> &nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 6,642</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 8,386</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 34,870</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_SupplementalInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementaryBalanceSheetsInformationTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Supplementary Balance Sheets Information Table Text Block</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_SupplementaryBalanceSheetsInformationTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementaryIncomeStatementInformationTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Supplementary Income Statement Information [Table Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_SupplementaryIncomeStatementInformationTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EDUAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>TAXES ON INCOME (Narrative) (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_WithholdingTaxRateOnForeignIncome', window );">Withholding tax on the U.S. revenue source portion of the payments made to the Company for its share of Pfizer?s net profits</a></td>
        <td class="nump">15.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
        <td class="nump">$ 72,500<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal', window );">Tax rates expected to be in effect when deferred tax asset differences reverse</a></td>
        <td class="text">39%, 25% and 0%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Law for Amending the Israel Income Tax Ordinance - 2009, Tax year [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
        <td class="nump">26.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Law for Amending the Israel Income Tax Ordinance, Tax Thereafter [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
        <td class="nump">25.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Restricted Amount [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
        <td class="nump">13,800<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Protalix Ltd. [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_EffectiveAdjustedIncomeTaxRateYearOne', window );">Additional gradual decrease in tax rate, 2012</a></td>
        <td class="nump">23.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_EffectiveAdjustedIncomeTaxRateYearTwo', window );">Additional gradual decrease in tax rate, 2013</a></td>
        <td class="nump">22.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_EffectiveAdjustedIncomeTaxRateYearThree', window );">Additional gradual decrease in tax rate, 2014</a></td>
        <td class="nump">21.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_EffectiveAdjustedIncomeTaxRateYearFour', window );">Additional gradual decrease in tax rate, 2015</a></td>
        <td class="nump">20.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_EffectiveAdjustedIncomeTaxRateYearFive', window );">Additional gradual decrease in tax rate, 2016</a></td>
        <td class="nump">18.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_EffectiveAdjustedIncomeTaxRateThereafter', window );">Additional gradual decrease in tax rate, thereafter</a></td>
        <td class="nump">18.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
        <td class="nump">$ 58,700<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Protalix Ltd. [Member] | Law for Amending the Israel Income Tax Ordinance, Tax Thereafter [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
        <td class="nump">25.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum [Member] | Protalix Ltd. [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
        <td class="nump">26.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
        <td class="nump">39.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member] | Protalix Ltd. [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
        <td class="nump">25.00%<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_EffectiveAdjustedIncomeTaxRateThereafter">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Effective Adjusted Income Tax Rate Thereafter</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_EffectiveAdjustedIncomeTaxRateThereafter</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_EffectiveAdjustedIncomeTaxRateYearFive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Effective Adjusted Income Tax Rate Year Five</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_EffectiveAdjustedIncomeTaxRateYearFive</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_EffectiveAdjustedIncomeTaxRateYearFour">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional gradual decrease in tax rate, 2015</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_EffectiveAdjustedIncomeTaxRateYearFour</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_EffectiveAdjustedIncomeTaxRateYearOne">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Effective Adjusted Income Tax Rate Year One</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_EffectiveAdjustedIncomeTaxRateYearOne</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_EffectiveAdjustedIncomeTaxRateYearThree">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Effective Adjusted Income Tax Rate Year Three</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_EffectiveAdjustedIncomeTaxRateYearThree</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_EffectiveAdjustedIncomeTaxRateYearTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Effective Adjusted Income Tax Rate Year Two</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_EffectiveAdjustedIncomeTaxRateYearTwo</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncomeTaxDisclosureLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_IncomeTaxDisclosureLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_WithholdingTaxRateOnForeignIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Withholding Tax Rate On Foreign Income</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_WithholdingTaxRateOnForeignIncome</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The domestic federal statutory tax rate applicable under enacted tax laws to the Company's pretax income from continuing operations for the period. The "statutory" tax rate is the regular tax rate if there are alternative tax systems.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 47<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6889476&amp;loc=d3e330036-122817<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of domestic, foreign and state and local operating loss carryforwards, before tax effects, available to reduce future taxable income under enacted tax laws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 48<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLossCarryforwards</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EJBAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SHARE CAPITAL (Options Granted to Employees) (Details) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of options</a></td>
        <td class="nump">$ 1,230<span></span></td>
        <td class="nump">$ 277<span></span></td>
        <td class="nump">$ 501<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Options And Restricted Stock Granted To Employees [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance</a></td>
        <td class="nump">6,141,030<span></span></td>
        <td class="nump">6,367,979<span></span></td>
        <td class="nump">5,366,729<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,444,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited and Expired</a></td>
        <td class="nump">25,858<span></span></td>
        <td class="nump">44,856<span></span></td>
        <td class="nump">13,441<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
        <td class="nump">861,593<span></span></td>
        <td class="nump">182,093<span></span></td>
        <td class="nump">429,309<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance</a></td>
        <td class="nump">5,253,579<span></span></td>
        <td class="nump">6,141,030<span></span></td>
        <td class="nump">6,367,979<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of year</a></td>
        <td class="nump">4,258,441<span></span></td>
        <td class="nump">4,647,834<span></span></td>
        <td class="nump">4,267,850<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
        <td class="nump">$ 3.563<span></span></td>
        <td class="nump">$ 3.576<span></span></td>
        <td class="nump">$ 2.476<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 7.076<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited and Expired</a></td>
        <td class="nump">$ 4.372<span></span></td>
        <td class="nump">$ 6.207<span></span></td>
        <td class="nump">$ 3.551<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
        <td class="nump">$ 1.346<span></span></td>
        <td class="nump">$ 1.652<span></span></td>
        <td class="nump">$ 1.602<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of year</a></td>
        <td class="nump">$ 3.201<span></span></td>
        <td class="nump">$ 2.581<span></span></td>
        <td class="nump">$ 2.183<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
        <td class="nump">$ 3.923<span></span></td>
        <td class="nump">$ 3.563<span></span></td>
        <td class="nump">$ 3.576<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
        <td class="nump">4,800<span></span></td>
        <td class="nump">1,300<span></span></td>
        <td class="nump">3,100<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of options</a></td>
        <td class="nump">$ 1,200<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph i<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(c), d(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(c)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total accumulated difference between fair values of underlying shares on dates of exercise and exercise price on options which were exercised (or share units converted) into shares during the reporting period under the plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph c(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price of options that were either forfeited or expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(b)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(a)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(a)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance on stock options awarded.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EFSAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Revenues) (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementalInformationRevenueLineItems', window );"><strong>Supplemental Information Revenue [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
        <td class="nump">$ 34,870<span></span></td>
        <td class="nump">$ 8,386<span></span></td>
        <td class="nump">$ 6,642<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Deferred Revenue From License And Supply Agreement With Pzifer [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementalInformationRevenueLineItems', window );"><strong>Supplemental Information Revenue [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
        <td class="nump">4,563<span></span></td>
        <td class="nump">4,563<span></span></td>
        <td class="nump">4,563<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Milestone Payments [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementalInformationRevenueLineItems', window );"><strong>Supplemental Information Revenue [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
        <td class="nump">25,000<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Revenues from selling products [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementalInformationRevenueLineItems', window );"><strong>Supplemental Information Revenue [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
        <td class="nump">$ 5,307<span></span></td>
        <td class="nump">$ 3,823<span></span></td>
        <td class="nump">$ 2,079<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalInformationRevenueLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_SupplementalInformationRevenueLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>LICENSE AND SUPPLY AGREEMENT<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeAndLicenseArrangementDisclosure', window );"><strong>LICENSE AND SUPPLY AGREEMENT [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock', window );">LICENSE AND SUPPLY AGREEMENT</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>NOTE 2 - LICENSE AND SUPPLY AGREEMENT</strong></p> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> On November 30, 2009, Protalix Ltd. and Pfizer entered into the Pfizer Agreement pursuant to which Pfizer was granted an exclusive, worldwide license to develop and commercialize taliglucerase alfa, except in Israel. Under the terms and conditions of the Pfizer Agreement, Protalix Ltd. retained the right to commercialize taliglucerase alfa in Israel. Under the Pfizer Agreement, Pfizer made an upfront payment to Protalix Ltd. of $60.0 million in connection with the execution of the agreement and shortly thereafter paid Protalix Ltd. an additional $5.0 million upon the Company&#39;s filing of a proposed pediatric investigation plan to the Pediatric Committee of the EMA. Protalix Ltd. received a $25.0 million milestone payment in connection with the approval of taliglucerase alfa by the FDA in May 2012. Protalix Ltd. is entitled to 40% of the results (profits or losses) earned on Pfizer&#39;s sales of taliglucerase alfa. Such result (profit or loss) will be calculated while, in addition to other adjustments, taking into account Protalix Ltd.&#39;s cost of goods sold and Pfizer&#39;s commercial expenses, with certain expenses capped or borne solely by one party ("Collaboration Operation"). Of the losses incurred by the Collaboration Operation through December 31, 2011, 40% will be deducted from the cash payments to be paid to the Company as its share in the profits from future years, if any. This deduction will be limited to a certain percentage of any quarterly profit. As of December 31, 2012, the Company accrued a liability in respect of these losses equal to $8.5 million, out of which $5.4 million is classified as a long term liability, and the remainder is included in accounts payable and accruals-other.</p> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> The Company has determined that the initial, non-refundable upfront license fee payment of $60.0 million together with the first $5.0 million payment will be recognized on a straight line basis as revenue over the estimated relationship period (approximately $4.6 million per year). The Company has estimated that the relationship period for its arrangement with Pfizer will be approximately 14 years (commencing upon the Company&#39;s receipt of the up-front license payment) based on the Company&#39;s last material patent relating to taliglucerase alfa to expire. The $25.0 million milestone payment received in connection with the FDA&#39;s approval of taliglucerase alfa in the United States was considered to be a substantive milestone for purposes of revenue recognition and, accordingly, was recorded as revenue during the period in which the milestone was achieved.</p> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> The Company&#39;s deliverables under this collaboration include an exclusive license to taliglucerase alfa as an enzyme replacement therapy for the treatment of Gaucher disease, certain research and development services as required under the Pfizer Agreement for taliglucerase alfa and manufacturing of taliglucerase alfa.</p> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> According to the terms and conditions of the Pfizer Agreement, the Company retained manufacturing rights and sells its products to Pfizer. In addition, Pfizer is required to reimburse the Company for certain costs it incurs in connection with certain development expenses for taliglucerase alfa. In connection with the payments received under the Pfizer Agreement, Protalix Ltd. is obligated to pay certain royalties. See Note 6a.</p> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeAndLicenseArrangementDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_CollaborativeAndLicenseArrangementDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaborative and License Arrangement Disclosure [Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_CollaborativeAndLicenseArrangementDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>32
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$
M7T)!3$%.0T5?4TA%1513/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0T].4T],241!5$5$7T)!3$%.0T5?4TA%15137U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$
M7U-4051%345.5%-?3T9?3U!%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].4T],241!5$5$7U-4051%345.5%]/1E]#2$%./"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!
M5$5$7U-4051%345.5%]/1E]#2$%.,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-BYH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-/3E-/3$E$051%1%]35$%414U%3E137T]&7T-!
M4SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970P-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-)1TY)
M1DE#04Y47T%#0T]53E1)3D=?4$],24-)13PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P."YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/DQ)0T5.4T5?04Y$7U-54%!,65]!1U)%14U%
M3E0\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y04D]0
M15)465]!3D1?15%525!-14Y4/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$P+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^24Y614Y43U))15,\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3$N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y,24%"24Q)5%E?1D]27T5-4$Q/645%7U))1TA4
M4U\\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,3(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#3TU-
M251-14Y44SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970Q,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E-(05)%7T-!4$E404P\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,30N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y405A%4U]/3E])3D-/344\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,34N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y355!03$5-14Y405)97T9)3D%.0TE!3%]35$%4
M14T\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,38N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y214Q!
M5$5$7U!!4E197U1204Y304-424].4SPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-RYH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/E-50E-%455%3E1?159%3E13/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#$X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4TE'3DE&24-!3E1?04-#3U5.
M5$E.1U]03TQ)0TE%,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q.2YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/E-)1TY)1DE#04Y47T%#0T]53E1)3D=?4$],24-)13(\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,C`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y04D]015)465]!3D1?
M15%525!-14Y47U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,2YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/DE.5D5.5$]224537U1A8FQE<SPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,BYH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/E-(05)%7T-!4$E404Q?5&%B;&5S/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#(S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^5$%815-?3TY?
M24Y#3TU%7U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R-"YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/E-54%!,14U%3E1!4EE?1DE.04Y#24%,7U-4051%33$\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,C4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y214Q!5$5$7U!!4E19
M7U1204Y304-424].4U]486(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C8N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y324=.249)0T%.5%]!0T-/54Y424Y'7U!/3$E#244S/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#(W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4TE'3DE&24-!
M3E1?04-#3U5.5$E.1U]03TQ)0TE%-#PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R."YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/DQ)0T5.4T5?04Y$7U-54%!,65]!1U)%14U%3E1?
M1#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970R.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E!23U!%
M4E197T%.1%]%455)4$U%3E1?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,"YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/DE.5D5.5$]224537T1E=&%I;',\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,S$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y,24%"24Q)5%E?1D]2
M7T5-4$Q/645%7U))1TA44U\Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T]-34E4345.5%-?1&5T86EL<SPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S
M,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-(05)%7T-!4$E404Q?3F%R<F%T
M:79E7T1E=&%I;#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-"YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/E-(05)%7T-!4$E404Q?4W5M;6%R>5]O9E]/<'1I;SPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970S-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-(05)%7T-!4$E404Q?1F%I
M<E]686QU95]!<W-U;3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-BYH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/E-(05)%7T-!4$E404Q?3W!T:6]N<U]'<F%N=&5D7SPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970S-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-(05)%7T-!4$E404Q?
M4F5S=')I8W1E9%]3=&]C:SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S."YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/E-(05)%7T-!4$E404Q?3W!T:6]N<U]'<F%N=&5D7S$\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,SDN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y32$%215]#05!)
M5$%,7U-U;6UA<GE?;V9?3W5T<W0\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-#`N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y32$%215]#05!)5$%,7U-H87)E7T)A<V5D7T-O;7`\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T-#$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y405A%4U]/
M3E])3D-/345?3F%R<F%T:79E7T1E=&$\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-#(N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y405A%4U]/3E])3D-/345?1&5F97)R961?26YC
M;VT\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T-#,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y405A%
M4U]/3E])3D-/345?3W!E;E]487A?665A<G,\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-#0N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y355!03$5-14Y405)97T9)3D%.0TE!3%]3
M5$%414TR/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#0U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M4U504$Q%345.5$%265]&24Y!3D-)04Q?4U1!5$5-,SPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T
M-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-54%!,14U%3E1!4EE?1DE.04Y#
M24%,7U-4051%330\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T-#<N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y214Q!5$5$7U!!4E197U1204Y304-424].4U]$970\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T-#@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y354)315%514Y47T5614Y4
M4U]$971A:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#0Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@/"]X.D5X8V5L5V]R:W-H965T<SX-"B`@/'@Z4W1Y
M;&5S:&5E="!(4F5F/3-$(E=O<FMS:&5E=',O<F5P;W)T+F-S<R(O/@T*("`\
M>#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0<F]T96-T
M4W1R=6-T=7)E/D9A;'-E/"]X.E!R;W1E8W13=')U8W1U<F4^#0H@(#QX.E!R
M;W1E8W17:6YD;W=S/D9A;'-E/"]X.E!R;W1E8W17:6YD;W=S/@T*(#PO>#I%
M>&-E;%=O<FMB;V]K/@T*/"]X;6P^/"%;96YD:69=+2T^#0H\+VAE860^#0H@
M(#QB;V1Y/@T*("`@/'`^5&AI<R!P86=E('-H;W5L9"!B92!O<&5N960@=VET
M:"!-:6-R;W-O9G0@17AC96P@6%`@;W(@;F5W97(N/"]P/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?96$S93$U-SE?-S4S8E\T
M-CAF7V$U,3E?8C<U834S.#$Q.65F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V5A,V4Q-3<Y7S<U,V)?-#8X9E]A-3$Y7V(W-6$U,S@Q,3EE9B]7
M;W)K<VAE971S+U-H965T,#$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5&54%%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/D1O8W5M96YT(&%N9"!%;G1I='D@26YF;W)M871I
M;VX@*%531"`D*3QB<CY);B!-:6QL:6]N<RP@97AC97!T(%-H87)E(&1A=&$L
M('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1F5B+B`Q-2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y*=6XN(#(Y+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1O8W5M96YT($%N9"!%;G1I='D@
M26YF;W)M871I;VX@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!4>7!E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XQ,"U+/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;65N9&UE;G0@1FQA9SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^9F%L<V4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT(%!E
M<FEO9"!%;F0@1&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M1&5C(#,Q+`T*"0DR,#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@665A<B!&;V-U<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,C`Q,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@
M1FES8V%L(%!E<FEO9"!&;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^1ED\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1R861I;F<@4WEM8F]L/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#Y03%@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!296=I<W1R86YT($YA;64\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/E!R;W1A;&EX($)I;U1H97)A<&5U
M=&EC<RP@26YC+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^16YT:71Y($-E;G1R86P@26YD97@@2V5Y/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XP,#`Q,#`V,C@Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT($9I
M<V-A;"!996%R($5N9"!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XM+3$R+3,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%;G1I='D@1FEL97(@0V%T96=O<GD\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/D%C8V5L97)A=&5D($9I;&5R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I
M='D@5F]L=6YT87)Y($9I;&5R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^3F\\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5N=&ET>2!#=7)R96YT(%)E<&]R=&EN9R!3=&%T=7,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/EEE<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%=E;&P@
M2VYO=VX@4V5A<V]N960@27-S=65R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#Y.;SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^16YT:71Y($-O;6UO;B!3=&]C:RP@4VAA<F5S($]U='-T
M86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,RPT.3<L
M.#`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%;G1I='D@4'5B;&EC($9L;V%T/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#,U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?96$S93$U-SE?-S4S8E\T-CAF7V$U,3E?8C<U834S.#$Q
M.65F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5A,V4Q-3<Y7S<U
M,V)?-#8X9E]A-3$Y7V(W-6$U,S@Q,3EE9B]7;W)K<VAE971S+U-H965T,#(N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5/0T%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-/
M3E-/3$E$051%1"!"04Q!3D-%(%-(14544R`H55-$("0I/&)R/DEN(%1H;W5S
M86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0U52
M4D5.5"!!4U-%5%,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-3(L,#,U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R-RPP,#$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U
M;G1S(')E8V5I=F%B;&4M(%1R861E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#0Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L,S<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!A<W-E=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,L-C@V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPX,S<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5N=&]R:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#`S.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L
M(&-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV,2PQ-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS,BPT.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D953D13($E.(%)%4U!%0U0@3T8@14U03$]9144@
M4DE'2%13(%503TX@4D5425)%345.5#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PR-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#`T,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4%)/4$525%D@04Y$($5154E0345.5"P@
M3D54/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-BPS,3`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."PR
M-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y4;W1A;"!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<X+#<R-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4Q+#@P-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT<R!P87EA8FQE(&%N
M9"!A8V-R=6%L<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5')A9&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4L,C8W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-2PP,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D]T:&5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,2PP-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XW+#4T,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@<F5V96YU97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/CDL-#,W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPQ,C$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R
M96YT(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-2PW-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ."PV.3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3$].1R!415)-($Q)04))3$E42453
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M969E<G)E9"!R979E;G5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-#@L.#@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-3`L.3(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y,:6%B:6QI='D@:6X@8V]N;F5C=&EO;B!W:71H
M(&-O;&QA8F]R871I;VX@;W!E<F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU+#0R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C8L-38V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,:6%B:6QI='D@9F]R(&5M<&QO>65E
M(')I9VAT<R!U<&]N(')E=&ER96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L,#$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PW,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!L;VYG('1E<FT@;&EA8FEL
M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4V+#,R.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4Y
M+#$X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E1O=&%L(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX,BPP.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XW-RPX.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-/34U)5$U%3E13("A.;W1E(#8I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0T%0251!3"!$149)0TE%3D-9.CPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@
M4W1O8VLL("0P+C`P,2!P87(@=F%L=64Z($%U=&AO<FEZ960@+2!A<R!O9B!$
M96-E;6)E<B`S,2P@,C`Q,2!A;F0@,C`Q,BP@,34P+#`P,"PP,#`@<VAA<F5S
M.R!I<W-U960@86YD(&]U='-T86YD:6YG("T@87,@;V8@1&5C96UB97(@,S$L
M(#(P,3$@86YD(#(P,3(L(#@U+#8S,"PQ-3<@86YD(#DS+#0X.2PX,#D@<VAA
M<F5S+"!R97-P96-T:79E;'D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/CDS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%D9&ET:6]N86P@<&%I9"UI;B!C87!I=&%L/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#`L,30U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30U+#@Q-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C=6UU
M;&%T960@9&5F:6-I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,3@S+#4Y-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@Q-S$L.3<W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-A<&ET86P@9&5F:6-I96YC>3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPS-3<I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C8L,#<W*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L(&QI86)I;&ET:65S(&YE="!O9B!C87!I=&%L(&1E9FEC:65N8WD\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-S@L-S(W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U,2PX
M,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5A
M,V4Q-3<Y7S<U,V)?-#8X9E]A-3$Y7V(W-6$U,S@Q,3EE9@T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B]E83-E,34W.5\W-3-B7S0V.&9?834Q.5]B
M-S5A-3,X,3$Y968O5V]R:W-H965T<R]3:&5E=#`S+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M,4=!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#3TY33TQ)1$%4140@0D%,
M04Y#12!32$5%5%,@*%!A<F5N=&AE=&EC86PI("A54T0@)"D\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM
M;VX@<W1O8VLL('!A<B!V86QU92!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@4W1O8VLL
M($%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U
M,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,34P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!3=&]C:RP@:7-S=65D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,RPT.#DL.#`Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#4L-C,P
M+#$U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]M;6]N(%-T;V-K+"!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.3,L-#@Y+#@P.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@U+#8S,"PQ-3<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5A,V4Q-3<Y7S<U
M,V)?-#8X9E]A-3$Y7V(W-6$U,S@Q,3EE9@T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B]E83-E,34W.5\W-3-B7S0V.&9?834Q.5]B-S5A-3,X,3$Y
M968O5V]R:W-H965T<R]3:&5E=#`T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%4U-!13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY#3TY33TQ)1$%4140@4U1!5$5-14Y44R!/
M1B!/4$52051)3TY3("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!E>&-E<'0@
M4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3`\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0T].
M4T],241!5$5$(%-4051%345.5%,@3T8@3U!%4D%424].4R!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)%
M5D5.5453("AS964@3F]T92`Y*&,I*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`S-"PX-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#@L,S@V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V+#8T,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0T]-4$%.62=3(%-(
M05)%($E.($-/3$Q!0D]2051)3TX@04=2145-14Y4/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@T-#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-2PT,3@I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PV,#(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-/4U0@3T8@4D56
M14Y515,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@L,30T*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L
M-3(U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#0L,S@S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D=23U-3(%!23T9)5#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C8L,C@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PT-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#@V,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4D5314%20T@@04Y$($1%
M5D5,3U!-14Y4($584$5.4T53/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@S-BPV-C4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,S<L.#$X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#,W+#8Y,2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE<W,@+2!G<F%N=',@86YD
M(')E:6UB=7)S96UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XW+#DW-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C8L-S<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-RPW-#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y215-%05)#2"!!3D0@1$5614Q/4$U%3E0@
M15A014Y315,L($Y%5#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,C@L-C@Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#,Q+#`T,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@R.2PY-3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'14Y%4D%,($%.1"!!1$U)3DE35%)!
M5$E612!%6%!%3E-%4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M.2PW-C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-BPY,S$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-BPX-S8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3U!%4D%424Y'($Q/4U,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$R+#$W,BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-BPU,S$I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,CDL.38V*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1DE.04Y#24%,($E.0T]-12`M($Y%5#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-34T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDV.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DY%5"!,3U-3($9/4B!42$4@645!4CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q,2PV,3@I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@S-BPU,CDI
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@R."PY.3@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.150@3$]34R!015(@4TA!4D4@3T8@0T]-34].(%-43T-+
M("T@0D%324,@04Y$($1)3%54140Z/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B0@*#`N,3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XD("@P+C0S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XS-BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=%24=(5$5$($%615)!
M1T4@3E5-0D52($]&(%-(05)%4R!/1B!#3TU-3TX@4U1/0TL@55-%1"!)3B!#
M3TU0551)3D<@3$]34R!015(@4TA!4D4@3T8@0T]-34].(%-43T-++"!"05-)
M0R!!3D0@1$E,551%1#H\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/CDP+#@T-2PY,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX-"PV-#4L,S8T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.#`L.38P+#,P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?96$S93$U-SE?-S4S8E\T-CAF
M7V$U,3E?8C<U834S.#$Q.65F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V5A,V4Q-3<Y7S<U,V)?-#8X9E]A-3$Y7V(W-6$U,S@Q,3EE9B]7;W)K
M<VAE971S+U-H965T,#4N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5/34%)/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,3X\<W1R;VYG/D-/3E-/3$E$051%1"!35$%414U%3E0@3T8@0TA!3D=%
M4R!)3B!32$%214A/3$1%4E,G($5154E462`H0T%0251!3"!$149)0TE%3D-9
M*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@97AC97!T(%-H87)E(&1A=&$\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y4;W1A;#QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y#;VUM;VX@4W1O8VL@
M6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^061D
M:71I;VYA;"!086ED+6EN($-A<&ET86P@6TUE;6)E<ET\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^06-C=6UU;&%T960@1&5F:6-I="!;365M
M8F5R73QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L
M86YC92!A="!$96,N(#,Q+"`R,#`Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#$U+#@X,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R,BPR-3(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$P-BPT-3`I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA
M;F-E+"!S:&%R97,@870@1&5C+B`S,2P@,C`P.3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.#`L.#0Q+#(S-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@8V]M<&5N
M<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(X,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M,C@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%>&5R8VES92!O9B!O<'1I;VYS(&=R86YT960@=&\@96UP;&]Y965S
M(&%N9"!N;VXM96UP;&]Y965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`W+#(S-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T
M($QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(X+#DY."D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@R."PY.3@I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E(&%T($1E
M8RX@,S$L(#(P,3`\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Q
M+#,R,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XX,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$R-"PP-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@Q,S4L-#0X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92P@<VAA<F5S(&%T($1E
M8RX@,S$L(#(P,3`\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@Q
M+#(T."PT-S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!I<W-U960@9F]R(&-A<V@@*&YE="!O
M9B!I<W-U86YC92!C;W-T<RD@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K(&ES<W5E
M9"!F;W(@8V%S:"`H;F5T(&]F(&ES<W5A;F-E(&-O<W1S*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C`L-3DP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#4X-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XX.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XX.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E(&]F(&]P=&EO;G,@9W)A
M;G1E9"!T;R!E;7!L;WEE97,@86YD(&YO;BUE;7!L;WEE97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.3@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X
M97)C:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S@Q+#8X
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3F5T($QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,V
M+#4R.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-BPU,CDI/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E
M(&%T($1E8RX@,S$L(#(P,3$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#(V+#`W-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$T-2PX,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q-S$L.3<W*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92P@<VAA<F5S
M(&%T($1E8RX@,S$L(#(P,3$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C@U+#8S,"PQ-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!I<W-U960@9F]R(&-A<V@@
M*&YE="!O9B!I<W-U86YC92!C;W-T<RD@*&EN('-H87)E<RD\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,3<U+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K
M(&ES<W5E9"!F;W(@8V%S:"`H;F5T(&]F(&ES<W5A;F-E(&-O<W1S*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4L,S@X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#,X,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT+#8Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-C$R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!C
M;VUP96YS871I;VX@<F5L871E9"!T;R!R97-T<FEC=&5D('-T;V-K(&%W87)D
M+"!N970@;V8@9F]R9F5I='5R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,L,3,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,L,3,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!C;VUP96YS871I;VX@
M<F5L871E9"!T;R!R97-T<FEC=&5D('-T;V-K(&%W87)D+"!N970@;V8@9F]R
M9F5I='5R97,@*'-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L-#DV+#<Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^17AE<F-I<V4@;V8@;W!T:6]N<R!G<F%N=&5D('1O
M(&5M<&QO>65E<R!A;F0@;F]N+65M<&QO>65E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PQ.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ.3@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C
M:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ.#<L.#8P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.970@3&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3$L
M-C$X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Q+#8Q."D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4@
M870@1&5C+B`S,2P@,C`Q,CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@S+#,U-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#DS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q.#`L,30U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q.#,L-3DU*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92P@
M<VAA<F5S(&%T($1E8RX@,S$L(#(P,3(\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/CDS+#0X.2PX,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7V5A,V4Q-3<Y7S<U,V)?-#8X9E]A-3$Y7V(W-6$U
M,S@Q,3EE9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E83-E,34W
M.5\W-3-B7S0V.&9?834Q.5]B-S5A-3,X,3$Y968O5V]R:W-H965T<R]3:&5E
M=#`V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%4D)!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@
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M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-/3E-/3$E$051%
M1"!35$%414U%3E0@3T8@0TA!3D=%4R!)3B!32$%214A/3$1%4E,G($5154E4
M62`H0T%0251!3"!$149)0TE%3D-9*2!;06)S=')A8W1=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!I
M<W-U960@9F]R(&-A<V@L(&ES<W5A;F-E(&-O<W1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$L-S@P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#0Q,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S=')I8W1E9"!S
M=&]C:R!A=V%R9',@9F]R9F5I=&5D+"!S:&%R93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,RPR,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7V5A,V4Q-3<Y7S<U,V)?-#8X9E]A-3$Y7V(W-6$U
M,S@Q,3EE9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E83-E,34W
M.5\W-3-B7S0V.&9?834Q.5]B-S5A-3,X,3$Y968O5V]R:W-H965T<R]3:&5E
M=#`W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%-C9!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY#3TY33TQ)1$%4140@4U1!5$5-14Y44R!/1B!#05-(($9,3U=3("A54T0@
M)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE
M9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY#05-(($9,3U=3($923TT@3U!%4D%424Y'($%#5$E6251)15,Z/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L
M;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$Q+#8Q."D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#,V+#4R.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B0@*#(X+#DY."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^061J=7-T;65N=',@<F5Q=6ER
M960@=&\@<F5C;VYC:6QE(&YE="!L;W-S('1O(&YE="!C87-H('!R;W9I9&5D
M(&)Y("AU<V5D(&EN*2!O<&5R871I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4@8F%S960@
M8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW
M+#<U,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C@X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L,C@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$97!R96-I871I;VX@86YD('=R:71E(&1O=VX@;V8@
M9FEX960@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M+#8Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L-C,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,RPQ,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D9I;F%N8VEA;"!E>'!E;G-E<R`H:6YC;VUE*2P@
M;F5T("AM86EN;'D@97AC:&%N9V4@9&EF9F5R96YC97,I/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q-S$I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S4P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-3DQ*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VAA;F=E<R!I;B!A
M8V-R=65D(&QI86)I;&ET>2!F;W(@96UP;&]Y964@<FEG:'1S('5P;VX@<F5T
M:7)E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y'86EN(&]N(&%M;W5N=',@9G5N9&5D(&EN(')E<W!E8W0@;V8@96UP
M;&]Y964@<FEG:'1S('5P;VX@<F5T:7)E;65N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,S8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,30I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,C8I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S(&]N('-A;&4@;V8@9FEX
M960@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S
M<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-H86YG97,@:6X@;W!E
M<F%T:6YG(&%S<V5T<R!A;F0@;&EA8FEL:71I97,Z/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8W)E87-E("AD96-R96%S
M92D@:6X@9&5F97)R960@<F5V96YU97,@*&EN8VQU9&EN9R!N;VXM8W5R<F5N
M="!P;W)T:6]N*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR
M.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@S+#`P-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@T+#4V,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D1E8W)E87-E("AI;F-R96%S92D@:6X@86-C;W5N
M=',@<F5C96EV86)L92!A;F0@;W1H97(@87-S971S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS+#@Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8L.#8P*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5C<F5A<V4@*&EN
M8W)E87-E*2!I;B!I;G9E;G1O<FEE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,RPW-C`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.3$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,2PQ.#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-R96%S92`H9&5C<F5A<V4I
M(&EN(&%C8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U86QS("AI;F-L=61I;F<@
M;&]N9R!T97)M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY
M-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV+#$T-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$L,#(Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('!R;W9I9&5D(&)Y("AU<V5D(&EN
M*2!O<&5R871I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-C,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,C,L-3<P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#,X+#0V-"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0T%32"!&3$]7
M4R!&4D]-($E.5D535$E.1R!!0U1)5DE42453.CPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S92!O9B!P<F]P97)T
M>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@R+#`V."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@U+#<P-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@W+#@U-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@<V%L92!O9B!P
M<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E<W1M96YT
M(&EN(')E<W1R:6-T960@9&5P;W-I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH.#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!;6]U;G1S(&9U;F1E9"!I;B!R97-P96-T(&]F(&5M
M<&QO>65E(')I9VAT<R!U<&]N(')E=&ER96UE;G0L(&YE=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,3,X*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$V-2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,S<I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@
M=7-E9"!I;B!I;G9E<W1I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,BPR.#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-2PX-C@I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-RPY.3(I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-!
M4T@@1DQ/5U,@1E)/32!&24Y!3D-)3D<@04-4259)5$E%4SH\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@
M<VAA<F5S+"!N970@;V8@:7-S=6%N8V4@8V]S=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C4L,S(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C`L-C4P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R
M8VES92!O9B!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#(S,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(W-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('!R;W9I9&5D(&)Y(&9I;F%N8VEN
M9R!A8W1I=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M-BPU-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR,"PY,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5&1D5#5"!/1B!%6$-(04Y'12!2051%($-(04Y'
M15,@3TX@0T%32#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,S@X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DY%5"!)3D-214%312`H1$5#4D5!4T4I($E.($-!4T@@04Y$
M($-!4T@@15%5259!3$5.5%,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(U+#`S-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#@L.#DY*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#0U+#,V-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)!3$%.0T4@3T8@0T%32"!!3D0@
M0T%32"!%455)5D%,14Y44R!!5"!"14=)3DY)3D<@3T8@645!4CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<L,#`Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S4L.3`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#$L,C8V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"
M04Q!3D-%($]&($-!4T@@04Y$($-!4T@@15%5259!3$5.5%,@050@14Y$($]&
M(%E%05(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4R+#`S-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W
M+#`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,U+#DP,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY355!03$5-14Y405)9($E.1D]234%424].
M($].($E.5D535$E.1R!!3D0@1DE.04Y#24Y'($%#5$E6251)15,@3D]4($E.
M5D],5DE.1R!#05-(($9,3U=3.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S92!O9B!P<F]P97)T>2!A;F0@97%U
M:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$S-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M-#<S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BPW,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DES<W5A;F-E(&-O<W0@;F]T('EE="!P86ED/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^17AE<F-I<V4@;V8@;W!T:6]N<R!G<F%N=&5D('1O(&5M<&QO>65E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`S,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?96$S93$U-SE?-S4S8E\T-CAF7V$U,3E?8C<U834S.#$Q.65F#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5A,V4Q-3<Y7S<U,V)?-#8X9E]A
M-3$Y7V(W-6$U,S@Q,3EE9B]7;W)K<VAE971S+U-H965T,#@N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY324=.249)0T%.5"!!
M0T-/54Y424Y'(%!/3$E#2453/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-)1TY)1DE#04Y4($%#0T]53E1)3D<@
M4$],24-)15,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y324=.249)0T%.5"!!0T-/54Y424Y'(%!/3$E#
M2453/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E0
M12!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I
M;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH
M=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X\9&EV/B`\9&EV/CPA+2U3=&%R
M=$9R86=M96YT+2T^(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P:6X[($U!
M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^(#QS=')O;F<^3D]412`Q("T@4TE'3DE&24-!3E0@04-#
M3U5.5$E.1R!03TQ)0TE%4SPO<W1R;VYG/CPO<#X@/'`@<W1Y;&4],T0G34%2
M1TE..B`P<'0@,'!X.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"=-
M05)'24XM5$]0.B`P<'0[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R('-T
M>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$
M5$@Z(#`N-6EN)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'
M2%0Z(&YO<FUA;#L@5TE$5$@Z(#`N,C5I;B<^82X\+W1D/B`\=&0^1V5N97)A
M;#PO=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T
M(#!P>#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX@)FYB<W`[/"]P/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/
M4#H@,'!T.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL93TS1"=6
M15)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`P+C<U
M:6XG/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@;F]R
M;6%L.R!724142#H@,"XR-6EN)SXQ+CPO=&0^(#QT9#Y/<&5R871I;VX\+W1D
M/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!&3TY4+5=%24=(5#H@;F]R;6%L
M.R!-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@5$585"U)3D1%3E0Z(#!I;B<^
M("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@1D].5"U714E'2%0Z(&YO<FUA;#L@34%2
M1TE..B`P<'0@,'!X(#!P="`Q:6X[(%1%6%0M24Y$14Y4.B`P:6XG/B!0<F]T
M86QI>"!":6]4:&5R87!E=71I8W,L($EN8RX@*&-O;&QE8W1I=F5L>2!W:71H
M(&ET<R!S=6)S:61I87)I97,L('1H92`B0V]M<&%N>2(I+"!A;F0@:71S('=H
M;VQL>2UO=VYE9"!S=6)S:61I87)Y+"!0<F]T86QI>"!,=&0N+"!A<F4@8FEO
M<&AA<FUA8V5U=&EC86P@8V]M<&%N:65S(&9O8W5S960@;VX@=&AE(&1E=F5L
M;W!M96YT(&%N9"!C;VUM97)C:6%L:7IA=&EO;B!O9B!R96-O;6)I;F%N="!T
M:&5R87!E=71I8R!P<F]T96EN<R!B87-E9"!O;B!T:&4@0V]M<&%N>28C,SD[
M<R!P<F]P<FEE=&%R>2!0<F]#96QL17@\<W5P/B9R96<[/"]S=7`^('!R;W1E
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M=&EV96QY(&AE<F5I;B!A<R!T:&4@(E-U8G-I9&EA<FEE<RXB/"]P/B`\<"!S
M='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(&)O;&0@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y
M;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@1D].5"U714E'2%0Z(&YO<FUA;#L@34%21TE..B`P<'0@,'!X(#!P="`Q
M:6X[(%1%6%0M24Y$14Y4.B`P:6XG/B!/;B!-87D@,2P@,C`Q,BP@=&AE(%4N
M4RX@1F]O9"!A;F0@1')U9R!!9&UI;FES=')A=&EO;B`H/&9O;G0@<W1Y;&4]
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M96-O;6)I;F%N="!F;W)M(&]F(&=L=6-O8V5R96)R;W-I9&%S92`H1T-$*2!T
M:&%T('1H92!#;VUP86YY(&1E=F5L;W!E9"!U<VEN9R!0<F]#96QL17@N(%1A
M;&EG;'5C97)A<V4@86QF82!W87,@86QS;R!A<'!R;W9E9"!B>2!T:&4@27-R
M865L:2!-:6YI<W1R>2!O9B!(96%L=&@@*'1H92`B27-R865L:2!-3T@B*2!I
M;B!397!T96UB97(@,C`Q,B!A;F0@<F5C96YT;'D@:6X@57)U9W5A>2X@5&%L
M:6=L=6-E<F%S92!A;&9A(&ES('1H92!F:7)S="!P;&%N="!C96QL+6)A<V5D
M(')E8V]M8FEN86YT('1H97)A<&5U=&EC('!R;W1E:6X@87!P<F]V960@8GD@
M96%C:"!O9B!T:&4@1D1!(&%N9"!T:&4@27-R865L:2!-3T@N/"]P/B`\<"!S
M='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(&)O;&0@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y
M;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P<'0@5&EM
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M86QI>"!,=&0N+"!M87)K971S($5,14Q94T\@:6X@27-R865L+CPO<#X@/'`@
M<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QP
M('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@4')O=&%L:7@@3'1D
M+B!G<F%N=&5D(%!F:7IE<B!A;B!E>&-L=7-I=F4L('=O<FQD=VED92!L:6-E
M;G-E('1O(&1E=F5L;W`@86YD(&-O;6UE<F-I86QI>F4@=&%L:6=L=6-E<F%S
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M(')E8V5I=F5D(&%N('5P9G)O;G0@<&%Y;65N="!O9B`D-C`N,"!M:6QL:6]N
M(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@97AE8W5T:6]N(&]F('1H92!09FEZ
M97(@06=R965M96YT(&%N9"!S:&]R=&QY('1H97)E869T97(@86X@861D:71I
M;VYA;"`D-2XP(&UI;&QI;VX@8VQI;FEC86P@9&5V96QO<&UE;G0M<F5L871E
M9"!M:6QE<W1O;F4@<&%Y;65N="X@5&AE($-O;7!A;GD@<F5C96EV960@86X@
M861D:71I;VYA;"`D,C4N,"!M:6QL:6]N(&UI;&5S=&]N92!P87EM96YT(&EN
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M;&EG;'5C97)A<V4@86QF82!O;B!A(#0P)2!A;F0@-C`E(&)A<VES+"!R97-P
M96-T:79E;'DL(&5X8V5P="!W:71H(')E<W!E8W0@=&\@=&AE('!R;V9I=',@
M;W(@;&]S<V5S(')E;&%T960@=&\@8V]M;65R8VEA;&EZ871I;VX@969F;W)T
M<R!I;B!)<W)A96PL('=H97)E('1H92!#;VUP86YY(')E=&%I;F5D(&5X8VQU
M<VEV92!M87)K971I;F<@<FEG:'1S+B`\9F]N="!S='EL93TS1"=#3TQ/4CH@
M8FQA8VLG/DEN(&-A;&-U;&%T:6YG('1H92!N970@<')O9FET<R!O<B!L;W-S
M97,@=6YD97(@=&AE(&%G<F5E;65N="P@=&AE<F4@87)E(&-E<G1A:6X@86=R
M965D('5P;VX@;&EM:71S(&]N('1H92!A;6]U;G1S('1H870@;6%Y(&)E(&1E
M9'5C=&5D(&9R;VT@9W)O<W,@<V%L97,@9F]R(&-E<G1A:6X@97AP96YS97,@
M86YD(&-O<W1S(&]F(&=O;V1S('-O;&0\+V9O;G0^+CPO<#X@/'`@<W1Y;&4]
M,T0G34%21TE..B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE
M/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@26X@1&5C96UB97(@,C`Q,BP@
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M;F<@8VQI;FEC86P@=')I86P@<&5R:6]D+CPO<#X@/'`@<W1Y;&4],T0G34%2
M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P
M="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
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M:6-I;F%L(%!R;V1U8W1S(&9O<B!(=6UA;B!5<V4@*$-(35`I($IU;F4@,C`Q
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M9B!T86QI9VQU8V5R87-E(&%L9F$N/"]P/B`\<"!S='EL93TS1"=-05)'24XZ
M(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G34%21TE.
M.B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B!);B!A9&1I=&EO;B!T;R!T86QI9VQU8V5R87-E
M(&%L9F$L('1H92!#;VUP86YY(&ES('=O<FMI;F<@;VX@=&AE(&1E=F5L;W!M
M96YT(&]F(&-E<G1A:6X@;W1H97(@<')O9'5C=',@=7-I;F<@4')O0V5L;$5X
M+CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q:6X[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S
M<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@0W5R
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M2G5L>2`Q,RP@,C`Q,"P@=&AE($-O;7!A;GD@86YN;W5N8V5D('1H870@=&AE
M($9R96YC:"!R96=U;&%T;W)Y(&%U=&AO<FET>2!H860@9W)A;G1E9"!A;B!!
M=71O<FES871I;VX@5&5M<&]R86ER92!D)B,S.3M5=&EL:7-A=&EO;B`H0515
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M=FES:6]N<R!I;B!"<F%Z:6P@86YD(&EN(&]T:&5R(&-O=6YT<FEE<RX\+W`^
M(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P
M/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^($]N($%U9W5S
M="`Q,"P@,C`Q,"P@4&9I>F5R(&5N=&5R960@:6YT;R!A('-H;W)T+71E<FT@
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M;V8@,C`Q,"!A;F0@=&AE(&9I<G-T('%U87)T97(@;V8@,C`Q,2P@=&AE($-O
M;7!A;GD@86YD(%!F:7IE<B!C;VUP;&5T960@=&AE('-U<'!L>2!O9B!P<F]D
M=6-T<R!D96QI=F5R86)L92!U;F1E<B!T:&4@<VAO<G0M=&5R;2!S=7!P;'D@
M86=R965M96YT+B!$=7)I;F<@,C`Q,2P@4&9I>F5R(')E8V]R9&5D(&%N(&%L
M;&]W86YC92!F;W(@<V%L97,@<F5T=7)N<R!I;B!C;VYN96-T:6]N('=I=&@@
M=&AE('-U<'!L>2!A9W)E96UE;G0@8F5C875S92!T:&4@0G)A>FEL:6%N($UI
M;FES=')Y(&]F($AE86QT:"!R97%U97-T960@=&AA="!09FEZ97(@8V]N<VED
M97(@=&AE(')E<&QA8V5M96YT(&]F(&-E<G1A:6X@=FEA;',@=&AA="!M:6=H
M="!E>'!I<F4@9'5R:6YG(#(P,3(N($1U<FEN9R!T:&4@=&AI<F0@<75A<G1E
M<B!O9B`R,#$R(')E<W5P<&QY(&9O<B!C97)T86EN('9I86QS('=A<R!C;VUP
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M92!09FEZ97(@06=R965M96YT+CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P
M<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"=-05)'
M24XM5$]0.B`P<'0[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE
M/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z
M(#`N-S5I;B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4
M.B!N;W)M86P[(%=)1%1(.B`P+C(U:6XG/C(N/"]T9#X@/'1D/DQI<75I9&ET
M>2!A;F0@1FEN86YC:6%L(%)E<V]U<F-E<SPO=&0^(#PO='(^(#PO=&%B;&4^
M(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P
M/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^($EN(&%D9&ET
M:6]N('1O('1H92!A<'!R;W9A;"!O9B!T86QI9VQU8V5R87-E(&%L9F$@8GD@
M=&AE($9$02!A;F0@=&AE($ES<F%E;&D@34](+"!S=6-C97-S9G5L(&-O;7!L
M971I;VX@;V8@=&AE($-O;7!A;GDF(S,Y.W,@9&5V96QO<&UE;G0@<')O9W)A
M;7,@86YD(&ET<R!T<F%N<VET:6]N('1O(&YO<FUA;"!O<&5R871I;VYS(&ES
M(&1E<&5N9&5N="!U<&]N(&]B=&%I;FEN9R!T:&4@9F]R96EG;B!R96=U;&%T
M;W)Y(&%P<')O=F%L<R!R97%U:7)E9"!T;R!S96QL(&ET<R!P<F]D=6-T<R!I
M;G1E<FYA=&EO;F%L;'DN($EN(&%C8V]R9&%N8V4@=VET:"!T:&4@=&5R;7,@
M86YD(&-O;F1I=&EO;G,@;V8@=&AE(%!F:7IE<B!!9W)E96UE;G0L('1H92!#
M;VUP86YY(')E8V5I=F5D(&$@)#(U+C`@;6EL;&EO;B!M:6QE<W1O;F4@<&%Y
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M;G1A;"!P97)I;V1S+CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X
M(#!P="`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P
M>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX@3V)T86EN:6YG(&UA<FME=&EN9R!A<'!R;W9A;"!W:71H(')E
M<W!E8W0@=&\@86YY('!R;V1U8W0@8V%N9&ED871E(&ES(&1I<F5C=&QY(&1E
M<&5N9&5N="!O;B!T:&4@0V]M<&%N>28C,SD[<R!A8FEL:71Y('1O(&EM<&QE
M;65N="!T:&4@;F5C97-S87)Y(')E9W5L871O<GD@<W1E<',@<F5Q=6ER960@
M=&\@;V)T86EN('-U8V@@87!P<F]V86P@:6X@=&AE(%5N:71E9"!3=&%T97,@
M86YD(&EN(&]T:&5R(&-O=6YT<FEE<RX@5&AE($-O;7!A;GD@8V%N;F]T(')E
M87-O;F%B;'D@<')E9&EC="!T:&4@;W5T8V]M92!O9B!T:&5S92!A8W1I=FET
M:65S+CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q:6X[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F
M;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@
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M(&UO;G1H<RX\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@
M,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX@)FYB<W`[/"]P/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T
M.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL93TS1"=615)424-!
M3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`P+C5I;B<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86P[(%=)
M1%1(.B`P+C(U:6XG/F(N/"]T9#X@/'1D/D)A<VES(&]F('!R97-E;G1A=&EO
M;CPO=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T
M(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ
M(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^(%1H92!#;VUP86YY)B,S.3MS(&9I;F%N8VEA
M;"!S=&%T96UE;G1S(&AA=F4@8F5E;B!P<F5P87)E9"!I;B!A8V-O<F1A;F-E
M('=I=&@@9V5N97)A;&QY(&%C8V5P=&5D(&%C8V]U;G1I;F<@<')I;F-I<&QE
M<R!I;B!T:&4@56YI=&5D(%-T871E<R`H(E4N4RX@1T%!4"(I+CPO<#X@/'`@
M<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^
M(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z(&)O;&0@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/
M5%1/33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I
M9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G
M/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N-6EN)SXF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;#L@5TE$5$@Z(#`N,C5I;B<^
M8RX\+W1D/B`\=&0^57-E(&]F(&5S=&EM871E<R!I;B!T:&4@<')E<&%R871I
M;VX@;V8@9FEN86YC:6%L('-T871E;65N=',\+W1D/B`\+W1R/B`\+W1A8FQE
M/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P
M.SPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[
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M/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\
M+W`^(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z(&)O
M;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T
M;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N-6EN)SXF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;#L@5TE$5$@Z(#`N,C5I
M;B<^9"X\+W1D/B`\=&0^1G5N8W1I;VYA;"!C=7)R96YC>3PO=&0^(#PO='(^
M(#PO=&%B;&4^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW
M-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T
M(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
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M;B!D;VQL87)S+CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P
M="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P
M>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
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M<R`H<W1A=&5D(&)E;&]W*2!R969L96-T960@:6X@=&AE('-T871E;65N=',@
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M97,L(&%S(&%P<')O<')I871E+CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P
M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX@)FYB<W`[/"]P/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@
M,'!T.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL93TS1"=615)4
M24-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`P+C5I;B<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86P[
M(%=)1%1(.B`P+C(U:6XG/F4N/"]T9#X@/'1D/D-A<V@@97%U:79A;&5N=',\
M+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P
M<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P
M<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
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M86QE;G1S+CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P
M+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P
M<'0[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)
M0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N-6EN)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;#L@
M5TE$5$@Z(#`N,C5I;B<^9BX\+W1D/B`\=&0^26YV96YT;W)I97,\+W1D/B`\
M+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T
M(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X
M(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B!);G9E;G1O<FEE<R!A<F4@=F%L=65D(&%T('1H92!L;W=E
M<B!O9B!C;W-T(&]R(&UA<FME="X@0V]S="!O9B!R87<@86YD('!A8VMA9VEN
M9R!M871E<FEA;',@86YD('!U<F-H87-E9"!P<F]D=6-T<R!I<R!D971E<FUI
M;F5D('5S:6YG('1H92`B;6]V:6YG(&%V97)A9V4B(&)A<VES+CPO<#X@/'`@
M<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^
M(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@0V]S="!O
M9B!F:6YI<VAE9"!P<F]D=6-T<R!T:&%T(&%R92!C87!I=&%L:7IE9"!I<R!D
M971E<FUI;F5D(&%S(&9O;&QO=W,Z('1H92!V86QU92!O9B!T:&4@<F%W(&%N
M9"!P86-K86=I;F<@;6%T97)I86QS(&-O;7!O;F5N="!I<R!D971E<FUI;F5D
M('!R:6UA<FEL>2!O;B!A('5S:6YG('1H92`B;6]V:6YG(&%V97)A9V4B(&)A
M<VES.R!T:&4@=F%L=64@;V8@=&AE(&QA8F]R(&%N9"!O=F5R:&5A9"!C;VUP
M;VYE;G0@:7,@9&5T97)M:6YE9"!O;B!A;B!A=F5R86=E(&)A<VES(&]V97(@
M=&AE('!R;V1U8W1I;VX@<&5R:6]D+CPO<#X@/'`@<W1Y;&4],T0G34%21TE.
M.B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!
M4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE
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M92!A;&9A(&]N($UA>2`Q+"`R,#$R+"!T:&4@0V]M<&%N>2!C87!I=&%L:7IE
M<R!M86YU9F%C='5R:6YG(&-O<W1S(&%S<V]C:6%T960@=VET:"!T86QI9VQU
M8V5R87-E(&%L9F$N/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@
M,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU4
M3U`Z(#!P=#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(@<W1Y;&4],T0G
M5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=724142#H@,"XU
M:6XG/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@;F]R
M;6%L.R!724142#H@,"XR-6EN)SYG+CPO=&0^(#QT9#Y0<F]P97)T>2!A;F0@
M97%U:7!M96YT/"]T9#X@/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@1D].5"U7
M14E'2%0Z(&YO<FUA;#L@34%21TE..B`P<'0@,'!X(#!P="`Q:6X[(%1%6%0M
M24Y$14Y4.B`M,"XR-6EN)SX@)FYB<W`[/"]P/B`\=&%B;&4@<W1Y;&4],T0G
M34%21TE.+51/4#H@,'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(@<W1Y;&4]
M,T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=724142#H@
M,"XW-6EN)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z
M(&YO<FUA;#L@5TE$5$@Z(#`N,C5I;B<^,2X\+W1D/B`\=&0^/&9O;G0@<W1Y
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M4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!415A4+4E.1$5.5#H@+3`N,C5I;B<^
M("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%2
M1TE.+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=.
M.B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N-S5I;B<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86P[(%=)1%1(.B`P
M+C(U:6XG/C(N/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M
M86PG/E1H92!#;VUP86YY)B,S.3MS(&%S<V5T<R!A<F4@9&5P<F5C:6%T960@
M8GD@=&AE('-T<F%I9VAT+6QI;F4@;65T:&]D(&]N('1H92!B87-I<R!O9B!T
M:&5I<B!E<W1I;6%T960@=7-E9G5L(&QI=F5S(&%S(&9O;&QO=W,Z/"]T9#X@
M/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&
M3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"=724142#H@-C4E.R!"3U)$
M15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM3$5&5#H@,2XU:6XG(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT<B!S='EL93TS1"=615)4
M24-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D(&YO=W)A<#TS1&YO=W)A<#XF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<@;F]W
M<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@
M8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/EEE87)S/"]T9#X@/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G(&YO=W)A<#TS1&YO=W)A<#XF
M;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/
M4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@.#4E)SY,
M86)O<F%T;W)Y(&5Q=6EP;65N=#PO=&0^(#QT9"!S='EL93TS1"=724142#H@
M,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@5TE$5$@Z(#$R)2<^-3PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!724142#H@,24G/B9N8G-P.SPO=&0^(#PO='(^
M(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!W:&ET93L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;2<^(#QT9#Y&=7)N:71U<F4\+W1D/B`\=&0^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)
M1TXZ(')I9VAT)SXQ,"TQ-3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=2
M3U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SY#;VUP
M=71E<B!E<75I<&UE;G0\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H="<^,SPO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S
M='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#DX+C8U<'0[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^
M(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@3&5A<V5H
M;VQD(&EM<')O=F5M96YT<R!A<F4@86UO<G1I>F5D(&)Y('1H92!S=')A:6=H
M="UL:6YE(&UE=&AO9"!O=F5R('1H92!E>'!E8W1E9"!L96%S92!T97)M+"!W
M:&EC:"!I<R!S:&]R=&5R('1H86X@=&AE(&5S=&EM871E9"!U<V5F=6P@;&EF
M92!O9B!T:&4@:6UP<F]V96UE;G1S+CPO<#X@/'`@<W1Y;&4],T0G34%21TE.
M.B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS
M1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R
M('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G
M5TE$5$@Z(#`N-6EN)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U7
M14E'2%0Z(&YO<FUA;#L@5TE$5$@Z(#`N,C5I;B<^:"X\+W1D/B`\=&0^26UP
M86ER;65N="!I;B!V86QU92!O9B!L;VYG+6QI=F5D(&%S<V5T<SH\+W1D/B`\
M+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T
M(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X
M(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B!4:&4@0V]M<&%N>2!T97-T<R!L;VYG+6QI=F5D(&%S<V5T
M<R!F;W(@:6UP86ER;65N="!I9B!A;B!I;F1I8V%T:6]N(&]F(&EM<&%I<FUE
M;G0@97AI<W1S+B!)9B!T:&4@<W5M(&]F(&5X<&5C=&5D(&9U='5R92!C87-H
M(&9L;W=S(&]F(&1E9FEN:71E(&QI9F4@87-S971S("AU;F1I<V-O=6YT960@
M86YD('=I=&AO=70@:6YT97)E<W0@8VAA<F=E<RD@:7,@;&5S<R!T:&%N('1H
M92!C87)R>6EN9R!A;6]U;G0@;V8@<W5C:"!A<W-E=',L('1H92!#;VUP86YY
M(')E8V]G;FEZ97,@86X@:6UP86ER;65N="!L;W-S+"!A;F0@=W)I=&5S(&1O
M=VX@=&AE(&%S<V5T<R!T;R!T:&5I<B!E<W1I;6%T960@9F%I<B!V86QU97,N
M/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N
M8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].
M5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-
M05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@=VED=&@],T0Q,#`E/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)
M1TXZ('1O<"<^(#QT9"!S='EL93TS1"=724142#H@,"XU:6XG/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L.R!724142#H@
M,"XR-6EN)SYI+CPO=&0^(#QT9#Y);F-O;64@=&%X97,\+W1D/B`\+W1R/B`\
M+W1A8FQE/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!&3TY4+5=%24=(5#H@;F]R;6%L.R!-05)'24XZ
M(#!P="`P<'@@,'!T(#$N,C5I;CL@5$585"U)3D1%3E0Z("TP+C5I;B<^("9N
M8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T
M;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N-S5I;B<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86P[(%=)1%1(.B`P+C(U
M:6XG/C$N/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86PG
M/D1E9F5R<F5D(&EN8V]M92!T87AE<SPO=&0^(#PO='(^(#PO=&%B;&4^(#QP
M('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\
M<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P
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M('1A>"!A<W-E=',N/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@
M,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X
M(#!P="`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
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M:6QI=&EE<RX\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@
M,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX@)FYB<W`[/"]P/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-
M05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@=VED=&@],T0Q,#`E/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)
M1TXZ('1O<"<^(#QT9"!S='EL93TS1"=724142#H@,"XW-6EN)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;#L@5TE$5$@Z
M(#`N,C5I;B<^,BX\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO
M<FUA;"<^56YC97)T86EN='D@:6X@:6YC;VUE('1A>&5S/"]T9#X@/"]T<CX@
M/"]T86)L93X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q:6X[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F
M;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@
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M86X@;F]T('1O(&)E('-U<W1A:6YE9"X\+W`^(#QP('-T>6QE/3-$)TU!4D=)
M3CH@,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\=&%B;&4@<W1Y;&4],T0G
M34%21TE.+51/4#H@,'!T.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S
M='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)
M1%1(.B`P+C5I;B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)
M1TA4.B!N;W)M86P[(%=)1%1(.B`P+C(U:6XG/FHN/"]T9#X@/'1D/E)E=F5N
M=64@4F5C;V=N:71I;VX\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS
M1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y
M;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@
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M8W1A8FEL:71Y(&ES(')E87-O;F%B;'D@87-S=7)E9"X\+W`^(#QP('-T>6QE
M/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\=&%B
M;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'0G
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E
M/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL
M93TS1"=724142#H@,"XW-6EN)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U714E'2%0Z(&YO<FUA;#L@5TE$5$@Z(#`N,C5I;B<^,2X\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;"<^4F5V96YU97,@9G)O
M;2!T:&4@;&EC96YS92!A;F0@<W5P<&QY(&%G<F5E;65N="!W:71H(%!F:7IE
M<CPO=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T
M(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P
M="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
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M.W,@<F5C96EP="!O9B!T:&4@=7`M9G)O;G0@;&EC96YS92!P87EM96YT('!A
M>6%B;&4@8GD@4&9I>F5R('5N9&5R('1H92!09FEZ97(@06=R965M96YT*2!B
M87-E9"!O;B!T:&4@9&%T92!T:&4@;&%S="!R96QE=F%N="!P871E;G0@97AP
M:7)E<RX@4V5E($YO=&4@,BX@5&AE($-O;7!A;GD@861J=7-T<R!T:&4@<&5R
M9F]R;6%N8V4@<&5R:6]D<RP@:68@87!P<F]P<FEA=&4L(&)A<V5D(&]N('1H
M92!A<'!L:6-A8FQE(&9A8W1S(&%N9"!C:7)C=6US=&%N8V5S+B!%86-H(&UI
M;&5S=&]N92!P87EM96YT('1H870@:7,@8V]N<VED97)E9"!T;R!B92!S=6)S
M=&%N=&EV92!F;W(@<'5R<&]S97,@;V8@<F5V96YU92!R96-O9VYI=&EO;B!I
M<R!R96-O<F1E9"!A<R!R979E;G5E(&1U<FEN9R!T:&4@<&5R:6]D(&1U<FEN
M9R!W:&EC:"!T:&4@;6EL97-T;VYE(&ES(&%C:&EE=F5D+CPO<#X@/'`@<W1Y
M;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QT86)L
M92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^
M(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE
M/3-$)U=)1%1(.B`P+C<U:6XG/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5=%24=(5#H@;F]R;6%L.R!724142#H@,"XR-6EN)SXR+CPO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L)SY2979E;G5E<R!F<F]M
M('-E;&QI;F<@<')O9'5C=',@=&\@4&9I>F5R/"]T9#X@/"]T<CX@/"]T86)L
M93X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\
M+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@5&AE($-O
M;7!A;GD@<F5C;V=N:7IE<R!R979E;G5E<R!F<F]M('!R;V1U8W1S('-O;&0@
M=&\@4&9I>F5R('5P;VX@9&5L:79E<GDL('=H96X@=&AE('-A;&5S('!R:6-E
M(&ES(&9I>&5D(&]R(&1E=&5R;6EN86)L92!A;F0@8V]L;&5C=&%B:6QI='D@
M:7,@<F5A<V]N86)L>2!A<W-U<F5D+CPO<#X@/'`@<W1Y;&4],T0G34%21TE.
M.B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"=-
M05)'24XM5$]0.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL93TS
M1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`P
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M>"`P<'0@,6EN.R!415A4+4E.1$5.5#H@,&EN)SX@)FYB<W`[/"]P/B`\<"!S
M='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!&3TY4+5=%24=(5#H@;F]R;6%L.R!-05)'24XZ(#!P="`P<'@@,'!T
M(#%I;CL@5$585"U)3D1%3E0Z(#!I;B<^(%5N9&5R('1H92!T97)M<R!A;F0@
M8V]N9&ET:6]N<R!O9B!T:&4@4&9I>F5R($%G<F5E;65N="P@=&AE($-O;7!A
M;GD@:7,@96YT:71L960@=&\@-#`E(&]F('1H92!P<F]F:71S(&]R(&QO<W,@
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M8V%L('EE87(@96YD:6YG($1E8V5M8F5R(#,Q+CPO<#X@/'`@<W1Y;&4],T0G
M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\=&%B;&4@<W1Y;&4],T0G34%2
M1TE.+51/4#H@,'!T.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL
M93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(
M.B`P+C5I;B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4
M.B!N;W)M86P[(%=)1%1(.B`P+C(U:6XG/FLN/"]T9#X@/'1D/E)E<V5A<F-H
M(&%N9"!D979E;&]P;65N="!C;W-T<SPO=&0^(#PO='(^(#PO=&%B;&4^(#QP
M('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P
M/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].
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M861E(&%N9"!,86)O<B`H=&AE(")/0U,B*2!A<F4@<F5C;V=N:7IE9"!W:&5N
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M;F-U<G)E9"X\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@
M,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@
M,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^(%)E:6UB=7)S96UE;G1S(')E8V5I=F5D(&9R;VT@4&9I>F5R
M(&%R92!R96-O9VYI>F5D('=H96X@=&AE(')E:6UB=7)S96UE;G1S(&)E8V]M
M92!R96-E:79A8FQE+"!P<F]V:61E9"!T:&5R92!I<R!R96%S;VYA8FQE(&%S
M<W5R86YC92!T:&%T('1H92!#;VUP86YY('=I;&P@8V]M<&QY('=I=&@@=&AE
M(&-O;F1I=&EO;G,@871T86-H960@=&\@=&AE(')E:6UB=7)S96UE;G1S(&%N
M9"!T:&5R92!I<R!R96%S;VYA8FQE(&%S<W5R86YC92!T:&4@<F5I;6)U<G-E
M;65N=',@=VEL;"!B92!R96-E:79E9"X@5&AE(')E:6UB=7)S96UE;G1S(&%R
M92!D961U8W1E9"!F<F]M('1H92!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@
M97AP96YS97,@87,@=&AE(&%P<&QI8V%B;&4@8V]S=',@87)E(&EN8W5R<F5D
M+CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F
M;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW
M-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
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M('1H92!P=7)C:&%S92!D871E+CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P
M<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)
M3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
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M=&AE(')E;&%T960@<V5R=FEC97,@87)E('!E<F9O<FUE9"X\+W`^(#QP('-T
M>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\
M=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!&3TY4.B!B;VQD(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U14
M3TTZ(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T
M:#TS1#$P,"4^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@
M/'1D('-T>6QE/3-$)U=)1%1(.B`P+C5I;B<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86P[(%=)1%1(.B`P+C(U:6XG/FPN
M/"]T9#X@/'1D/D-O;F-E;G1R871I;VX@;V8@8W)E9&ET(')I<VMS(&%N9"!T
M<F%D92!R96-E:79A8FQE/"]T9#X@/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4]
M,T0G34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QP('-T
M>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T
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M="!R:7-K(&]N('1H97-E(&EN<W1R=6UE;G1S+CPO<#X@/'`@<W1Y;&4],T0G
M34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE
M/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@/&9O;G0@<W1Y;&4],T0G
M0T],3U(Z(&)L86-K)SY4:&4@0V]M<&%N>28C,SD[<R!T<F%D93PO9F]N=#X@
M<F5C96EV86)L92`\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/G)E<')E
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M('!A>6UE;G0@;V8@=&AE(')E8V5I=F%B;&5S+CPO9F]N=#X\+W`^(#QP('-T
M>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\
M=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!&3TY4.B!B;VQD(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U14
M3TTZ(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T
M:#TS1#$P,"4^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@
M/'1D('-T>6QE/3-$)U=)1%1(.B`P+C5I;B<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86P[(%=)1%1(.B`P+C(U:6XG/FTN
M/"]T9#X@/'1D/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^(#PO='(^
M(#PO=&%B;&4^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW
M-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T
M(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
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M:7!A=&5D(&9U='5R92!C;VYD:71I;VYS+CPO<#X@/'`@<W1Y;&4],T0G34%2
M1TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$
M)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S
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M8V@N/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I
M;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P
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M9"X\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@
M)FYB<W`[/"]P/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!&
M3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL93TS1"=615)424-!3"U!
M3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`P+C5I;B<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86P[(%=)1%1(
M.B`P+C(U:6XG/FXN/"]T9#X@/'1D/DYE="!,;W-S('!E<B!S:&%R93PO=&0^
M(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P
M<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P
M<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^($)A<VEC(&%N9"!D:6QU=&5D(&QO<W,@<&5R('-H87)E
M("@B3%!3(BD@87)E(&-O;7!U=&5D(&)Y(&1I=FED:6YG(&YE="!L;W-S(&)Y
M('1H92!W96EG:'1E9"!A=F5R86=E(&YU;6)E<B!O9B!S:&%R97,@;V8@=&AE
M($-O;7!A;GDF(S,Y.W,@0V]M;6]N(%-T;V-K+"!P87(@=F%L=64@)#`N,#`Q
M('!E<B!S:&%R92`H=&AE(")#;VUM;VX@4W1O8VLB*2!O=71S=&%N9&EN9R!F
M;W(@96%C:"!P97)I;V0N/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P
M<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P
M<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B!$:6QU=&5D($Q04R!D;V5S(&YO="!I;F-L=61E
M(#<L-S8Q+#$V."P@-RPT-CDL,#@X(&%N9"`W+#(X,"PT-CD@/&9O;G0@<W1Y
M;&4],T0G0T],3U(Z(&)L86-K)SYS:&%R97,@;V8@0V]M;6]N(%-T;V-K('5N
M9&5R;'EI;F<@;W5T<W1A;F1I;F<@;W!T:6]N<R!A;F0@<F5S=')I8W1E9"!S
M:&%R97,@;V8@0V]M;6]N(%-T;V-K/"]F;VYT/B!F;W(@=&AE(&9I<V-A;"!Y
M96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,"P@,C`Q,2!A;F0@,C`Q,BP@
M<F5S<&5C=&EV96QY+"!B96-A=7-E('1H92!E9F9E8W0@=V]U;&0@8F4@86YT
M:2UD:6QU=&EV92X\+W`^(#PA+2U%;F1&<F%G;65N="TM/CPO9&EV/B`\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5A
M,V4Q-3<Y7S<U,V)?-#8X9E]A-3$Y7V(W-6$U,S@Q,3EE9@T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B]E83-E,34W.5\W-3-B7S0V.&9?834Q.5]B
M-S5A-3,X,3$Y968O5V]R:W-H965T<R]3:&5E=#`Y+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3$E#14Y312!!3D0@4U504$Q9
M($%'4D5%345.5#QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY,24-%3E-%($%.1"!355!03%D@04=2145-14Y4(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3$E#14Y312!!3D0@4U504$Q9($%'4D5%345.5#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),24,@
M(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T
M<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO
M;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A<G1&<F%G;65N="TM/B`\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!P="`P<'@[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`\
M<W1R;VYG/DY/5$4@,B`M($Q)0T5.4T4@04Y$(%-54%!,62!!1U)%14U%3E0\
M+W-T<F]N9SX\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@
M,"XU:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P
M<'0@,"XU:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B!/;B!.;W9E;6)E<B`S,"P@,C`P.2P@4')O=&%L:7@@3'1D+B!A
M;F0@4&9I>F5R(&5N=&5R960@:6YT;R!T:&4@4&9I>F5R($%G<F5E;65N="!P
M=7)S=6%N="!T;R!W:&EC:"!09FEZ97(@=V%S(&=R86YT960@86X@97AC;'5S
M:79E+"!W;W)L9'=I9&4@;&EC96YS92!T;R!D979E;&]P(&%N9"!C;VUM97)C
M:6%L:7IE('1A;&EG;'5C97)A<V4@86QF82P@97AC97!T(&EN($ES<F%E;"X@
M56YD97(@=&AE('1E<FUS(&%N9"!C;VYD:71I;VYS(&]F('1H92!09FEZ97(@
M06=R965M96YT+"!0<F]T86QI>"!,=&0N(')E=&%I;F5D('1H92!R:6=H="!T
M;R!C;VUM97)C:6%L:7IE('1A;&EG;'5C97)A<V4@86QF82!I;B!)<W)A96PN
M(%5N9&5R('1H92!09FEZ97(@06=R965M96YT+"!09FEZ97(@;6%D92!A;B!U
M<&9R;VYT('!A>6UE;G0@=&\@4')O=&%L:7@@3'1D+B!O9B`D-C`N,"!M:6QL
M:6]N(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@97AE8W5T:6]N(&]F('1H92!A
M9W)E96UE;G0@86YD('-H;W)T;'D@=&AE<F5A9G1E<B!P86ED(%!R;W1A;&EX
M($QT9"X@86X@861D:71I;VYA;"`D-2XP(&UI;&QI;VX@=7!O;B!T:&4@0V]M
M<&%N>28C,SD[<R!F:6QI;F<@;V8@82!P<F]P;W-E9"!P961I871R:6,@:6YV
M97-T:6=A=&EO;B!P;&%N('1O('1H92!0961I871R:6,@0V]M;6ET=&5E(&]F
M('1H92!%34$N(%!R;W1A;&EX($QT9"X@<F5C96EV960@82`D,C4N,"!M:6QL
M:6]N(&UI;&5S=&]N92!P87EM96YT(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@
M87!P<F]V86P@;V8@=&%L:6=L=6-E<F%S92!A;&9A(&)Y('1H92!&1$$@:6X@
M36%Y(#(P,3(N(%!R;W1A;&EX($QT9"X@:7,@96YT:71L960@=&\@-#`E(&]F
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M(&)Y(&]N92!P87)T>2`H(D-O;&QA8F]R871I;VX@3W!E<F%T:6]N(BDN($]F
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M=&5R;'D@<')O9FET+B!!<R!O9B!$96-E;6)E<B`S,2P@,C`Q,BP@=&AE($-O
M;7!A;GD@86-C<G5E9"!A(&QI86)I;&ET>2!I;B!R97-P96-T(&]F('1H97-E
M(&QO<W-E<R!E<75A;"!T;R`D."XU(&UI;&QI;VXL(&]U="!O9B!W:&EC:"`D
M-2XT(&UI;&QI;VX@:7,@8VQA<W-I9FEE9"!A<R!A(&QO;F<@=&5R;2!L:6%B
M:6QI='DL(&%N9"!T:&4@<F5M86EN9&5R(&ES(&EN8VQU9&5D(&EN(&%C8V]U
M;G1S('!A>6%B;&4@86YD(&%C8W)U86QS+6]T:&5R+CPO<#X@/'`@<W1Y;&4]
M,T0G34%21TE..B`P<'0@,'!X(#!P="`P+C5I;CL@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y
M;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P+C5I;CL@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^(%1H92!#;VUP86YY(&AA
M<R!D971E<FUI;F5D('1H870@=&AE(&EN:71I86PL(&YO;BUR969U;F1A8FQE
M('5P9G)O;G0@;&EC96YS92!F964@<&%Y;65N="!O9B`D-C`N,"!M:6QL:6]N
M('1O9V5T:&5R('=I=&@@=&AE(&9I<G-T("0U+C`@;6EL;&EO;B!P87EM96YT
M('=I;&P@8F4@<F5C;V=N:7IE9"!O;B!A('-T<F%I9VAT(&QI;F4@8F%S:7,@
M87,@<F5V96YU92!O=F5R('1H92!E<W1I;6%T960@<F5L871I;VYS:&EP('!E
M<FEO9"`H87!P<F]X:6UA=&5L>2`D-"XV(&UI;&QI;VX@<&5R('EE87(I+B!4
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M82!T;R!E>'!I<F4N(%1H92`D,C4N,"!M:6QL:6]N(&UI;&5S=&]N92!P87EM
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M979E9"X\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XU
M:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@
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M8V5R87-E(&%L9F$N/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@
M,'!T(#`N-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P
M<'@@,'!T(#`N-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX@06-C;W)D:6YG('1O('1H92!T97)M<R!A;F0@8V]N9&ET
M:6]N<R!O9B!T:&4@4&9I>F5R($%G<F5E;65N="P@=&AE($-O;7!A;GD@<F5T
M86EN960@;6%N=69A8W1U<FEN9R!R:6=H=',@86YD('-E;&QS(&ET<R!P<F]D
M=6-T<R!T;R!09FEZ97(N($EN(&%D9&ET:6]N+"!09FEZ97(@:7,@<F5Q=6ER
M960@=&\@<F5I;6)U<G-E('1H92!#;VUP86YY(&9O<B!C97)T86EN(&-O<W1S
M(&ET(&EN8W5R<R!I;B!C;VYN96-T:6]N('=I=&@@8V5R=&%I;B!D979E;&]P
M;65N="!E>'!E;G-E<R!F;W(@=&%L:6=L=6-E<F%S92!A;&9A+B!);B!C;VYN
M96-T:6]N('=I=&@@=&AE('!A>6UE;G1S(')E8V5I=F5D('5N9&5R('1H92!0
M9FEZ97(@06=R965M96YT+"!0<F]T86QI>"!,=&0N(&ES(&]B;&EG871E9"!T
M;R!P87D@8V5R=&%I;B!R;WEA;'1I97,N(%-E92!.;W1E(#9A+CPO<#X@/'`@
M<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P+C5I;CL@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@
M/"$M+45N9$9R86=M96YT+2T^/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?96$S93$U-SE?-S4S8E\T-CAF
M7V$U,3E?8C<U834S.#$Q.65F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V5A,V4Q-3<Y7S<U,V)?-#8X9E]A-3$Y7V(W-6$U,S@Q,3EE9B]7;W)K
M<VAE971S+U-H965T,3`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY04D]015)462!!3D0@15%525!-14Y4/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!23U!%4E19
M($%.1"!%455)4$U%3E0@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y04D]015)462!!3D0@15%525!-14Y4
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H
M=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA
M;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL
M,2UT<F%N<VET:6]N86PN9'1D(B`M+3X\9&EV/B`\9&EV/CPA+2U3=&%R=$9R
M86=M96YT+2T^(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)
M3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^(#QS=')O;F<^3D]412`S("T@4%)/4$525%D@04Y$($5154E0
M345.5#PO<W1R;VYG/CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X
M.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P
M<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL93TS1"=615)424-!3"U!
M3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`P+C5I;B<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86P[(%=)1%1(
M.B`P+C5I;B<^82X\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO
M<FUA;"<^0V]M<&]S:71I;VX@;V8@<')O<&5R='D@86YD(&5Q=6EP;65N="!G
M<F]U<&5D(&)Y(&UA:F]R(&-L87-S:69I8V%T:6]N<R!I<R!A<R!F;VQL;W=S
M.CPO=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T
M(#!P>#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX@)FYB<W`[/"]P/B`\=&%B;&4@<W1Y;&4],T0G5TE$5$@Z(#<P
M)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4Q%1E0Z(#%I;B<@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X@/'1R('-T>6QE/3-$
M)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B
M;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M5T5)
M1TA4.B!B;VQD)R!C;VQS<&%N/3-$-CY$96-E;6)E<B`S,2P\+W1D/B`\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O
M;&0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!
M3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M4$%$1$E.1RU"3U143TTZ(#%P="<@;F]W<F%P/3-$;F]W<F%P/B`H/&5M/E4N
M4RX@9&]L;&%R<R!I;B!T:&]U<V%N9',I/"]E;3X\+W1D/B`\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO
M=W)A<#TS1&YO=W)A<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W
M<F%P/C(P,3$\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P
M=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X@)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M
M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X]
M,T0R(&YO=W)A<#TS1&YO=W)A<#XR,#$R/"]T9#X@/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`]
M,T1N;W=R87`^("9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+
M1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)
M1%1(.B`W,"4G/DQA8F]R871O<GD@97%U:7!M96YT/"]T9#X@/'1D('-T>6QE
M/3-$)U=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#$R)2<^,3,L,#<Y/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#$R)2<^
M,30L-3`R/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)
M1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'
M4D]53D0M0T],3U(Z('=H:71E.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/D9U<FYI='5R92!A;F0@
M8V]M<'5T97(@97%U:7!M96YT/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C$L-3(R/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXQ+#@Q.#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\
M+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR
M-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SY,96%S96AO;&0@:6UP<F]V96UE;G1S/"]T
M9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G/C$S+#<P-3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%
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M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[
M(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R
M:6=H="<^(#$L,3$S/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,
M24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/B`S
M,CD\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.
M1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$
M)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#%P=#L@4$%$1$E.1RU,1494.B`W+C,U<'0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4
M+4%,24=..B!L969T)SXD/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/B`R.2PT
M,3D\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.
M1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G
M/B0\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T
M('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^(#,Q+#`Y-CPO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T
M)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#
M3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%
M.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@1D].5"U325I%.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#%P="<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T)SXF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q<'0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M1D].5"U325I%.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#%P="<^)FYB<W`[/"]T9#X@/"]T
M<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U
M+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@4$%$1$E.
M1RU,1494.B`Y<'0G/B!,97-S("T@86-C=6UU;&%T960@9&5P<F5C:6%T:6]N
M(&%N9"!A;6]R=&EZ871I;VX\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^("9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX@*#$Q+#$T.#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@
M,7!T)SXI/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!4
M15A4+4%,24=..B!R:6=H="<^("@Q-"PW.#8\+W1D/B`\=&0@<W1Y;&4],T0G
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M3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`Q."PR-S$\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"
M3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L
M969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@,38L,S$P/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]4
M5$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/"]T<CX@/"]T86)L93X@/'`@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P<'0@,'!X(#!P="`T
M+C-P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P
M=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M34%21TE.+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,
M24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N-6EN)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;#L@5TE$5$@Z
M(#`N,C5I;B<^8BX\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO
M<FUA;"<^1&5P<F5C:6%T:6]N(&%N9"!A;6]R=&EZ871I;VX@:6X@<F5S<&5C
M="!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT('1O=&%L960@87!P<F]X:6UA
M=&5L>2`D,RXQ(&UI;&QI;VXL("0S+C8@;6EL;&EO;B!A;F0@)#,N-R!M:6QL
M:6]N(&9O<B!T:&4@>65A<G,@96YD960@1&5C96UB97(@,S$L(#(P,3`L(#(P
M,3$@86YD(#(P,3(L(')E<W!E8W1I=F5L>2P@;W5T(&]F('=H:6-H('1H92!#
M;VUP86YY(')E8V]R9&5D(&$@=&]T86P@=W)I=&4@9&]W;B!O9B!A<'!R;WAI
M;6%T96QY("0T,RPP,#`L("0Q,"PP,#`@86YD("0P+"!R97-P96-T:79E;'DN
M/"]T9#X@/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@
M,'!X.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B`F;F)S<#L\+W`^(#PA+2U%;F1&<F%G;65N="TM/CPO9&EV/B`\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
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M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^24Y614Y43U))15,\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M24Y614Y43U))15,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y)3E9%3E1/4DE%4SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO
M+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO
M+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L
M+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A<G1&<F%G;65N="TM/B`\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!P="`P<'@[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`\<W1R
M;VYG/DY/5$4@-"`M($E.5D5.5$]22453/"]S=')O;F<^/"]P/B`\<"!S='EL
M93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'1A8FQE('-T
M>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R
M('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G
M5TE$5$@Z(#`N-6EN)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U7
M14E'2%0Z(&YO<FUA;#L@5TE$5$@Z(#`N,C5I;B<^82X\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;"<^26YV96YT;W)I97,@870@1&5C
M96UB97(F;F)S<#LS,2P@,C`Q,2!A;F0@,C`Q,B!C;VYS:7-T960@;V8@=&AE
M(&9O;&QO=VEN9SH\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=-
M05)'24XZ(#!P="`P<'@[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$
M)U=)1%1(.B`W,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU,
M1494.B`Q:6XG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT
M<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&YO
M=W)A<#TS1&YO=W)A<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N
M;W=R87`^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U7
M14E'2%0Z(&)O;&0G(&-O;'-P86X],T0V(&YO=W)A<#TS1&YO=W)A<#Y$96-E
M;6)E<B`S,2P\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P
M=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X@)FYB<W`[
M/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/
M5%1/33H@,7!T)R!N;W=R87`],T1N;W=R87`^("@\96T^52Y3+B!D;VQL87)S
M(&EN('1H;W5S86YD<RD\+V5M/CPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W
M<F%P/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M5T5)
M1TA4.B!B;VQD)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^,C`Q,3PO
M=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B`F;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O
M;&0G(&YO=W)A<#TS1&YO=W)A<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(@;F]W<F%P
M/3-$;F]W<F%P/C(P,3(\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#PO='(^
M(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR
M,#0I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`W,"4G/E)A=R!M871E<FEA;',\+W1D
M/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3(E)SXR-SD\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E
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M15A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,3DR/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S
M='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/D9I;FES:&5D(&=O;V1S
M/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M
M4TE:13H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4
M+5-)6D4Z(#%P="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-)6D4Z(#%P="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z
M(#%P="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S
M;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/B`Q+#<R.3PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T)SXF
M;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/
M4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SY4
M;W1A;"!I;G9E;G1O<GD\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@
M)#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P
M="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@,C<Y/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U
M8FQE.R!415A4+4%,24=..B!R:6=H="<^(#0L,#,Y/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^
M)FYB<W`[/"]T9#X@/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G34%21TE.
M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX@)FYB<W`[/"]P/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/
M4#H@,'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(@<W1Y;&4],T0G5D525$E#
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M,RPP,#`@86YD("0V.#0L,#`P(')E<W!E8W1I=F5L>2P@9F]R('=R:71E+61O
M=VX@;V8@:6YV96YT;W)Y('5N9&5R(&-O<W0@;V8@<F5V96YU97,N/"]T9#X@
M/"]T<CX@/"]T86)L93X@/"$M+45N9$9R86=M96YT+2T^/"]D:78^(#PO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?96$S
M93$U-SE?-S4S8E\T-CAF7V$U,3E?8C<U834S.#$Q.65F#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V5A,V4Q-3<Y7S<U,V)?-#8X9E]A-3$Y7V(W
M-6$U,S@Q,3EE9B]7;W)K<VAE971S+U-H965T,3(N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY,24%"24Q)5%D@1D]2($5-4$Q/
M645%(%))1TA44R!54$].(%)%5$E214U%3E0\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3$E!0DE,2519($9/4B!%
M35!,3UE%12!224=(5%,@55!/3B!2151)4D5-14Y4(%M!8G-T<F%C=%T\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3$E!0DE,
M2519($9/4B!%35!,3UE%12!224=(5%,@55!/3B!2151)4D5-14Y4/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!5
M0DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB
M(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N
M<VET:6]N86PN9'1D(B`M+3X\9&EV/B`\9&EV/CPA+2U3=&%R=$9R86=M96YT
M+2T^(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@,'!T
M(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^(#QS=')O;F<^3D]412`U("T@3$E!0DE,2519($9/4B!%35!,3UE%12!2
M24=(5%,@55!/3B!2151)4D5-14Y4/"]S=')O;F<^/"]P/B`\<"!S='EL93TS
M1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N-6EN.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL
M93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N-6EN.R!&3TY4.B`Q,'!T(%1I
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M/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N-6EN.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB
M<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N-6EN
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@
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M92!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,"P@,C`Q,2!A;F0@,C`Q
M,BP@=&AE($-O;7!A;GD@9&5P;W-I=&5D(&%P<')O>&EM871E;'D@)#$W-"PP
M,#`L("0Q.#$L,#`P(&%N9"`D,3<W+#`P,"P@<F5S<&5C=&EV96QY+"!W:71H
M(&EN<W5R86YC92!C;VUP86YI97,@:6X@8V]N;F5C=&EO;B!W:71H(&ET<R!S
M979E<F%N8V4@<&%Y;65N="!O8FQI9V%T:6]N<RX\+W`^(#QP('-T>6QE/3-$
M)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G34%21TE.
M.B`P<'0@,'!X(#!P="`P+C5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
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M8FQE(&EN<W5R86YC92!C;VUP86YI97,@*'1H92`B0V]N=')I8G5T:6]N(%!L
M86YS(BDN/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N
M-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T
M(#`N-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX@5&AE(&%M;W5N=',@;V8@<V5V97)A;F-E('!A>2!E>'!E;G-E<R!W
M97)E(&%P<')O>&EM871E;'D@)#$N,2!M:6QL:6]N+"`D.#$V+#`P,"!A;F0@
M)#$N,"!M:6QL:6]N(&9O<B!T:&4@>65A<G,@96YD960@1&5C96UB97(@,S$L
M(#(P,3`L(#(P,3$@86YD(#(P,3(L(')E<W!E8W1I=F5L>2P@;V8@=VAI8V@@
M87!P<F]X:6UA=&5L>2`D-3,Q+#`P,"`D-C0Q+#`P,"!A;F0@)#8W,"PP,#`@
M:6X@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$P+"`R,#$Q(&%N
M9"`R,#$R+"!R97-P96-T:79E;'DL('=E<F4@:6X@<F5S<&5C="!O9B!A($-O
M;G1R:6)U=&EO;B!0;&%N+B!'86EN(&]N(&%M;W5N=',@9G5N9&5D(&EN(')E
M<W!E8W0@;V8@96UP;&]Y964@<FEG:'1S('5P;VX@<F5T:7)E;65N="!T;W1A
M;&5D(&%P<')O>&EM871E;'D@)#(V+#`P,"P@)#$T+#`P,"!A;F0@)#,V+#`P
M,"!F;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$P+"`R,#$Q
M(&%N9"`R,#$R+"!R97-P96-T:79E;'DN/"]P/B`\<"!S='EL93TS1"=-05)'
M24XZ(#!P="`P<'@@,'!T(#`N-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-
M05)'24XZ(#!P="`P<'@@,'!T(#`N-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@5&AE($-O;7!A;GD@97AP96-T<R!T
M;R!C;VYT<FEB=71E(&%P<')O>&EM871E;'D@)#DV,RPP,#`@:6X@=&AE('EE
M87(@96YD:6YG($1E8V5M8F5R(#,Q+"`R,#$S('1O(&EN<W5R86YC92!C;VUP
M86YI97,@:6X@8V]N;F5C=&EO;B!W:71H(&ET<R!S979E<F%N8V4@;&EA8FEL
M:71I97,@9F]R(&ET<R!O<&5R871I;VYS(&9O<B!T:&%T('EE87(L(&%P<')O
M>&EM871E;'D@)#<W,RPP,#`@;V8@=VAI8V@@=VEL;"!B92!C;VYT<FEB=71E
M9"!T;R!O;F4@;W(@;6]R92!#;VYT<FEB=71I;VX@4&QA;G,N/"]P/B`\<"!S
M='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N-6EN.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@/'-T<F]N9SXF;F)S
M<#L\+W-T<F]N9SX\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P
M<'0@,"XU:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B!$=7)I;F<@=&AE(&9I=F4M>65A<B!P97)I;V0@9F]L;&]W:6YG
M($1E8V5M8F5R(#,Q+"`R,#$R+"!T:&4@0V]M<&%N>2!E>'!E8W1S('1O('!A
M>2!F=71U<F4@8F5N969I=',@=&\@-"!E;7!L;WEE97,@=7!O;B!T:&4@96UP
M;&]Y964F(S,Y.W,@;F]R;6%L(')E=&ER96UE;G0@86=E+B!4:&4@0V]M<&%N
M>2!A;G1I8VEP871E<R!T:&%T('1H92!B96YE9FET<R!P87EA8FQE('=I;&P@
M8F4@:6UM871E<FEA;"X\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P
M>"`P<'0@,"XU:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B`F;F)S<#L\+W`^(#PA+2U%;F1&<F%G;65N="TM/CPO9&EV
M/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
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M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0T]-34E4345.5%,\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^0T]-34E4345.5%,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#3TU-251-14Y44SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),24,@
M(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T
M<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO
M;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A<G1&<F%G;65N="TM/B`\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!P="`P<'@[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`\
M<W1R;VYG/DY/5$4@-B`M($-/34U)5$U%3E13/"]S=')O;F<^/"]P/B`\<"!S
M='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(&)O;&0@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'1A8FQE
M('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@8F]L9"`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P
M<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q
M,#`E/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S
M='EL93TS1"=724142#H@,"XU:6XG/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5=%24=(5#H@;F]R;6%L.R!724142#H@,"XR-6EN)SYA+CPO=&0^
M(#QT9#Y2;WEA;'1Y(&-O;6UI=&UE;G1S/"]T9#X@/"]T<CX@/"]T86)L93X@
M/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B!B;VQD(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QT
M86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P
M="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P
M,"4^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T
M>6QE/3-$)U=)1%1(.B`P+C<U:6XG/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
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M/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL
M93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^($EN('1H92!C87-E(&]F(&9A
M:6QU<F4@;V8@82!P<F]J96-T('1H870@=V%S('!A<G1L>2!F:6YA;F-E9"!A
M<R!D97-C<FEB960@86)O=F4L('1H92!#;VUP86YY(&ES(&YO="!O8FQI9V%T
M960@=&\@<&%Y(&%N>2!S=6-H(')O>6%L=&EE<R!O<B!R97!A>2!F=6YD:6YG
M(')E8V5I=F5D(&9R;VT@=&AE($]#4RX\+W`^(#QP('-T>6QE/3-$)TU!4D=)
M3CH@,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'
M24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
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M960@=&]T86P@86UO=6YT(&]F(')O>6%L=&EE<R`H<&]S<VEB;'D@=7`@=&\@
M,S`P)2!O9B!T:&4@9W)A;G0@86UO=6YT<R!P;'5S(&EN=&5R97-T*2P@9&5P
M96YD:6YG(&]N('1H92!M86YU9F%C='5R:6YG('9O;'5M92!T:&%T(&ES('!E
M<F9O<FUE9"!O=71S:61E('1H92!3=&%T92!O9B!)<W)A96PL(&%N9"P@<&]S
M<VEB;'DL(&%N(&EN8W)E87-E9"!R;WEA;'1Y(')A=&4N/"]P/B`\<"!S='EL
M93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y
M;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!2;WEA;'1Y(&5X<&5N<V5S
M('1O('1H92!/0U,@87)E(&EN8VQU9&5D(&EN('1H92!S=&%T96UE;G0@;V8@
M;W!E<F%T:6]N<R!A<R!A(&-O;7!O;F5N="!O9B!T:&4@8V]S="!O9B!R979E
M;G5E<R!A;F0@=V5R92!A<'!R;WAI;6%T96QY("0W-CDL,#`P+"`D,34X+#`P
M,"!A;F0@)#$N-2!M:6QL:6]N(&1U<FEN9R!T:&4@>65A<G,@96YD960@1&5C
M96UB97(F;F)S<#LS,2P@,C`Q,"P@,C`Q,2!A;F0@,C`Q,BP@<F5S<&5C=&EV
M96QY+CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q:6X[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F
M;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@
M070@1&5C96UB97(@,S$L(#(P,3(L('1H92!M87AI;75M(')O>6%L='D@86UO
M=6YT('!A>6%B;&4@8GD@=&AE($-O;7!A;GD@=6YD97(@=&AE<V4@9G5N9&EN
M9R!A<G)A;F=E;65N=',@:7,@87!P<F]X:6UA=&5L>2`D,C$N,R!M:6QL:6]N
M("AW:71H;W5T(&EN=&5R97-T+"!A<W-U;6EN9R`Q,#`E(&]F('1H92!F=6YD
M<R!A<F4@<&%Y86)L92DN/"]P/B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M,&EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS
M1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL
M93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(
M.B`P+C<U:6XG/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(
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M('=E<F4@87!P<F]X:6UA=&5L>2`D,3$U+#`P,"P@)#$Y+#`P,"!A;F0@)#8W
M-"PP,#`@9'5R:6YG('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B9N8G-P.S,Q
M+"`R,#$P+"`R,#$Q(&%N9"`R,#$R+"!R97-P96-T:79E;'DN/"]T9#X@/"]T
M<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4
M.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F
M;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@
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M>2`D,3`P+#`P,"!W87,@;6%D92!I;B!R97-P96-T(&]F('1H92!A9W)E96UE
M;G1S(&1U<FEN9R!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,"X@
M3F\@;6EL97-T;VYE('!A>6UE;G1S('=E<F4@;6%D92!D=7)I;F<@,C`Q,2!A
M;F0@,C`Q,BX\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@
M,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T
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M<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\
M+W`^(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z(&)O
M;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T
M;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N-6EN)SXF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;#L@5TE$5$@Z(#`N,C5I
M;B<^8BX\+W1D/B`\=&0^4W5B8V]N=')A8W1I;F<@06=R965M96YT<SPO=&0^
M(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P
M<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P
M<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
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M(#,Q+"`R,#$R+"!T;W1A;"!C;VUM:71M96YT<R!U;F1E<B!S86ED(&%G<F5E
M;65N=',@=V5R92!A<'!R;WAI;6%T96QY("0Q+C,@;6EL;&EO;BX\+W`^(#QP
M('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P
M/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!&3TY4.B!B;VQD
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"
M3U143TTZ(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W
M:61T:#TS1#$P,"4^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P
M)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`P+C5I;B<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86P[(%=)1%1(.B`P+C(U:6XG
M/F,N/"]T9#X@/'1D/DQE87-E($%G<F5E;65N=',\+W1D/B`\+W1R/B`\+W1A
M8FQE/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N
M8G-P.SPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P+C<U
M:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B!4:&4@0V]M<&%N>2!I<R!A('!A<G1Y('1O(&$@;G5M8F5R(&]F(&QE87-E
M(&%G<F5E;65N=',@9F]R(&ET<R!F86-I;&ET:65S+"!T:&4@;&%T97-T(&]F
M('=H:6-H(&5X<&ER97,@:6X@,C`Q-BX@5&AE($-O;7!A;GD@:&%S('1H92!O
M<'1I;VX@=&\@97AT96YD(&-E<G1A:6X@;V8@<W5C:"!A9W)E96UE;G1S(&]N
M('1H<F5E(&]C8V%S:6]N<R!F;W(@861D:71I;VYA;"!F:79E+7EE87(@<&5R
M:6]D<RP@9F]R(&$@=&]T86P@;V8@,34@861D:71I;VYA;"!Y96%R<RX@56YD
M97(@=&AE(&QE87-E<RP@=&AE(&%G9W)E9V%T92!M;VYT:&QY(')E;G1A;"!P
M87EM96YT<R!A<F4@87!P<F]X:6UA=&5L>2`D.#(L,#`P+B!!<R!O9B!$96-E
M;6)E<B`S,2P@,C`Q,BP@=&AE($-O;7!A;GD@<')O=FED960@8F%N:R!G=6%R
M86YT965S(&]F(&%P<')O>&EM871E;'D@)#(Y."PP,#`L(&EN('1H92!A9V=R
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M=W,Z(#(P,3,@+2`D.3<V+#`P,"P@,C`Q-"`M("0Y-C@L,#`P+"`R,#$U("T@
M)#DX-2PP,#`@86YD(#(P,38@+2`D.#(S+#`P,"X@3&5A<V4@97AP96YS97,@
M=&]T86QE9"`D.#DQ+#`P,"P@)#DY-"PP,#`@86YD("0Y-S$L,#`P(&9O<B!T
M:&4@>65A<G,@96YD960@1&5C96UB97(@,S$L(#(P,3`L(#(P,3$@86YD(#(P
M,3(L(')E<W!E8W1I=F5L>2X\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T
M(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\=&%B;&4@<W1Y;&4],T0G34%2
M1TE.+51/4#H@,'!T.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL
M93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(
M.B`P+C5I;B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4
M.B!N;W)M86P[(%=)1%1(.B`P+C(U:6XG/F0N/"]T9#X@/'1D/E9E:&EC;&4@
M3&5A<V4@86YD($UA:6YT96YA;F-E($%G<F5E;65N=',\+W1D/B`\+W1R/B`\
M+W1A8FQE/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I
M;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P
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M<R!A9V=R96=A=&4@87!P<F]X:6UA=&5L>2`D-#DL,#`P+B!4:&4@97AP96-T
M960@;&5A<V4@<&%Y;65N=',@9F]R('1H92!Y96%R<R!E;F1I;F<@1&5C96UB
M97(@,S$L(#(P,3,L(#(P,30@86YD(#(P,34@87)E(&%P<')O>&EM871E;'D@
M)#4R-BPP,#`L("0S.#4L,#`P(&%N9"`D,3<U+#`P,"P@<F5S<&5C=&EV96QY
M+CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F
M;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[(%=)
M1%1(.B`Q,#`E.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,#X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,
M24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N-6EN)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;#L@5TE$5$@Z
M(#`N,C5I;B<^92X\+W1D/B`\=&0^66ES<W5M($%G<F5E;65N=#PO=&0^(#PO
M='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($U!
M4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I
M;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M($]N($%U9W5S="`X+"`R,#`W+"!T:&4@0V]M<&%N>2!S:6=N960@86X@86=R
M965M96YT('=I=&@@=&AE(%EI<W-U;2!297-E87)C:"!A;F0@1&5V96QO<&UE
M;G0@0V]M<&%N>2P@=&AE('1E8VAN;VQO9WD@=')A;G-F97(@87)M(&]F('1H
M92!(96)R97<@56YI=F5R<VET>2!O9B!*97)U<V%L96TL($ES<F%E;"`H(EEI
M<W-U;2(I+"!A;F0@=&AE($)O>6-E(%1H;VUP<V]N($EN<W1I='5T92!F;W(@
M4&QA;G0@4F5S96%R8V@L(&%T($-O<FYE;&P@56YI=F5R<VET>2P@271H86-A
M+"!.97<@66]R:R`H(D)O>6-E(%1H;VUP<V]N(BDL('1O(&1E=F5L;W`@82!P
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M;VXM<F5F=6YD86)L92!I;FET:6%L(&UA:6YT96YA;F-E(&9E92!O9B`D,C`L
M,#`P+#PO9F]N=#X@8V]M;65N8VEN9R!O;B!T:&4@9F]U<G1H(&%N;FEV97)S
M87)Y(&]F('1H92!E>&5C=71I;VX@;V8@=&AE(&%G<F5E;65N="P@=VAI8V@@
M:7,@<W5B:F5C="!T;R!A(#$R)2!A;FYU86P@:6YC<F5A<V4N(#QF;VYT('-T
M>6QE/3-$)T-/3$]2.B!B;&%C:R<^26X@861D:71I;VXL/"]F;VYT/B!T:&4@
M0V]M<&%N>2!I<R!R97%U:7)E9"!T;R!M86ME(&-E<G1A:6X@;6EL97-T;VYE
M('!A>6UE;G1S(&5Q=6%L('1O('5P('1O("0W,#`L,#`P+"!I;B!T:&4@86=G
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M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?96$S93$U-SE?-S4S
M8E\T-CAF7V$U,3E?8C<U834S.#$Q.65F#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V5A,V4Q-3<Y7S<U,V)?-#8X9E]A-3$Y7V(W-6$U,S@Q,3EE
M9B]7;W)K<VAE971S+U-H965T,30N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY32$%212!#05!)5$%,/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-(05)%($-!4$E4
M04P@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y32$%212!#05!)5$%,/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$
M5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S
M+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M
M+3X\9&EV/B`\9&EV/CPA+2U3=&%R=$9R86=M96YT+2T^(#QP('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^(#QS=')O;F<^3D]4
M12`W("T@4TA!4D4@0T%0251!3#PO<W1R;VYG/CPO<#X@/'`@<W1Y;&4],T0G
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@1D].
M5"U714E'2%0Z(&YO<FUA;#L@34%21TE..B`P<'0@,'!X(#!P="`Q:6X[(%1%
M6%0M24Y$14Y4.B`M,"XU:6XG/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS
M1"=-05)'24XM5$]0.B`P<'0[(%=)1%1(.B`Q,#`E.R!&3TY4.B!B;VQD(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U14
M3TTZ(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X@/'1R
M('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G
M5TE$5$@Z(#`N-6EN)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U7
M14E'2%0Z(&YO<FUA;#L@5TE$5$@Z(#`N,C5I;B<^82X\+W1D/B`\=&0^4FEG
M:'1S(&]F('1H92!#;VUP86YY)B,S.3MS($-O;6UO;B!3=&]C:SPO=&0^(#PO
M='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@
M,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@
M,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^(%1H92!#;VUP86YY)B,S.3MS(&-O;6UO;B!S=&]C:R!I<R!L
M:7-T960@;VX@=&AE($Y94T4@34M4(&%N9"P@<VEN8V4@4V5P=&5M8F5R(#8L
M(#(P,3`L(&]N('1H92!496P@079I=B!3=&]C:R!%>&-H86YG92X@16%C:"!S
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M9',N/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!&3TY4+5=%24=(5#H@;F]R;6%L.R!-05)'24XZ
M(#!P="`P<'@@,'!T(#%I;CL@5$585"U)3D1%3E0Z("TP+C5I;B<^("9N8G-P
M.SPO<#X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@5TE$5$@Z
M(#$P,"4[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ
M('1O<"<^(#QT9"!S='EL93TS1"=724142#H@,"XU:6XG/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L.R!724142#H@,"XR
M-6EN)SYB+CPO=&0^(#QT9#Y3=&]C:R!B87-E9"!C;VUP96YS871I;VX\+W1D
M/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@
M,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@
M,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B!/;B!$96-E;6)E<B`Q-"P@,C`P-BP@=&AE($)O87)D
M(&]F($1I<F5C=&]R<R!A9&]P=&5D('1H92!0<F]T86QI>"!":6]4:&5R87!E
M=71I8W,L($EN8RX@,C`P-B!3=&]C:R!);F-E;G1I=F4@4&QA;B`H=&AE(")0
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M8FIE8W0@=&\@=&AE('1E<FUS('-T:7!U;&%T960@8GD@4V5C=&EO;G,@,3`R
M(&%N9"`Q,#)!(&]F('1H92!)<W)A96QI($EN8V]M92!487@@3W)D:6YA;F-E
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M4V5C=&EO;B`S*&DI(&]F('1H92!)<W)A96QI($EN8V]M92!487@@3W)D:6YA
M;F-E+CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P+C<U
M:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@
M,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX@07,@;V8@1&5C96UB97(@,S$L(#(P,3(L(#$W-BPY.#8@<VAA<F5S
M(&]F($-O;6UO;B!3=&]C:R!R96UA:6X@879A:6QA8FQE(&9O<B!G<F%N="!U
M;F1E<B!T:&4@4&QA;BX\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P
M>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P
M="`P<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^($9O<B!P=7)P;W-E<R!O9B!D971E<FUI;FEN9R!T
M:&4@9F%I<B!V86QU92!O9B!T:&4@;W!T:6]N<R!A;F0@<F5S=')I8W1E9"!S
M=&]C:R!G<F%N=&5D('1O(&5M<&QO>65E<R!A;F0@;F]N+65M<&QO>65E<RP@
M=&AE($-O;7!A;GDF(S,Y.W,@;6%N86=E;65N="!U<V5S('1H92!F86ER('9A
M;'5E(&]F('1H92!#;VUM;VX@4W1O8VLN/"]P/B`\<"!S='EL93TS1"=-05)'
M24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G
M34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!&<F]M($IA;G5A<GD@,2P@,C`Q
M,"!T:')O=6=H($1E8V5M8F5R(#,Q+"`R,#$R+"!T:&4@0V]M<&%N>2!G<F%N
M=&5D(&]P=&EO;G,@86YD('-H87)E<R!O9B!R97-T<FEC=&5D('-T;V-K('1O
M(&-E<G1A:6X@96UP;&]Y965S(&%N9"!N;VXM96UP;&]Y965S(&%S(&9O;&QO
M=W,Z/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I
M;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@
M1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(@<W1Y;&4],T0G5D525$E#04PM
M04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=724142#H@,"XW-6EN)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;#L@5TE$
M5$@Z(#`N,C5I;B<^,2X\+W1D/B`\=&0^3W!T:6]N<R!A;F0@<F5S=')I8W1E
M9"!S=&]C:R!G<F%N=&5D('1O(&5M<&QO>65E<SH\+W1D/B`\+W1R/B`\+W1A
M8FQE/B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3`N,C5I;CL@34%21TE.
M.B`P<'0@,'!X(#!P="`Q+C(U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS
M1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL
M93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(
M.B`Q:6XG/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=724142#H@,"XR-6EN
M)SYA*3PO=&0^(#QT9#Y"96QO=R!I<R!A('1A8FQE('-U;6UA<FEZ:6YG(&%L
M;"!O9B!T:&4@;W!T:6]N<R!A;F0@<F5S=')I8W1E9"!S=&]C:R!G<F%N=',@
M=&\@96UP;&]Y965S(&9O<B!E86-H(&]F('1H92!T:')E92!Y96%R<R!I;B!T
M:&4@=&AR964M>65A<B!P97)I;V0@96YD960@1&5C96UB97(@,S$L(#(P,3(Z
M/"]T9#X@/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@
M,'!X.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"=724142#H@.#`E
M.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM3$5&5#H@,2XR-6EN
M)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/B`\='(@<W1Y;&4]
M,T0G5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO
M=W)A<#Y996%R(&]F/&)R("\^(&=R86YT/"]T9#X@/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`]
M,T1N;W=R87`^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P
M/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4
M.B!B;VQD)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^3F\N(&]F(&]P
M=&EO;G,\8G(@+SX@;W(@<F5S=')I8W1E9#QB<B`O/B!S=&]C:R!G<F%N=&5D
M/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M
M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@
M8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=.
M.B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`^17AE<F-I<V4\8G(@+SX@<')I8V4@<F%N9V4\+W1D/B`\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z
M(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)R!N
M;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#Y697-T:6YG
M('!E<FEO9#PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T
M.R!&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B`F;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O
M;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^1F%I<B!V86QU93QB<B`O/B!A
M="!G<F%N=#QB<B`O/B`H52Y3+CQB<B`O/B!D;VQL87)S(&EN/&)R("\^('1H
M;W5S86YD<RD\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P
M=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X@)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M
M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X]
M,T0R(&YO=W)A<#TS1&YO=W)A<#Y%>'!I<F%T:6]N/&)R("\^('!E<FEO9#PO
M=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B`F;F)S<#L\+W1D/B`\+W1R
M/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L
M,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,3`E)SXR,#$P/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!7
M24142#H@,3`E)SXQ+#`Q-BPP,#`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!724142#H@,3`E)SXD-BXY,#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=724142#H@,24G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([(%=)1%1(.B`S-24G
M/C,@>65A<G,@8V]M;65N8VEN9SQB<B`O/B!U<&]N(&%C:&EE=F5M96YT(&]F
M(&$\8G(@+SX@8V5R=&%I;B!M:6QE<W1O;F4\+W1D/B`\=&0@<W1Y;&4],T0G
M5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!724142#H@,3`E)SXU+#8W,SPO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I
M9VAT.R!724142#H@,3`E)SXQ,"!Y96%R<SPO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!724142#H@,24G/B9N8G-P.SPO=&0^(#PO='(^
M(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!W:&ET93L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^,C`Q,#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF
M;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H="<^-#(X+#`P,#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^)#8N
M,S(M)#DN-C8\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97(G/C0@>65A<G,\+W1D/B`\=&0^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B0\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C(L,30W/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@
M<FEG:'0G/C$P('EE87)S/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/
M54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXR,#$R/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^
M(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M)SXT,#`L,#`P/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@8V5N=&5R)SYN+V$\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97(G/C,@
M>65A<G,\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B0\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0G/C(L,C@X/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0G/FXO83PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\+W1R
M/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G
M/C(P,3(\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$
M1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE
M9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^(#$L,3`P+#`P
M,#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-
M.B`Q<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^(&XO83PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M4$%$1$E.1RU"3U143TTZ(#%P="<^-"!Y96%R<SPO=&0^(#QT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@4$%$1$E.1RU"
M3U143TTZ(#%P="<^-BPR.3(\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@
M,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!0041$24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!R:6=H="<^(&XO
M83PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G
M0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF
M;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H="<^,BPY-#0L,#`P/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97(G/B9N8G-P
M.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\+W1R/B`\+W1A8FQE/B`\
M<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#$N,C5I;CL@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO
M<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q+C(U:6X[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!3970@
M9F]R=&@@8F5L;W<@87)E(&=R86YT<R!M861E(&)Y('1H92!#;VUP86YY('1O
M(&5M<&QO>65E<R`H:6YC;'5D:6YG(')E;&%T960@<&%R=&EE<RD@9'5R:6YG
M('1H92!T:')E92UY96%R('!E<FEO9"!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q
M,B`H<W5C:"!G<F%N=',@87!P96%R(&EN('1H92!T86)L92!A8F]V92DZ/"]P
M/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!&3TY4+5=%24=(5#H@;F]R;6%L.R!-05)'24XZ(#!P="`P
M<'@@,'!T(#$N-6EN.R!415A4+4E.1$5.5#H@+3`N,C5I;B<^("9N8G-P.SPO
M<#X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/
M33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H
M/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\
M=&0@<W1Y;&4],T0G5TE$5$@Z(#$N,C5I;B<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T-/3$]2.B!B;&%C:SL@1D].5"U714E'2%0Z(&YO<FUA;#L@5TE$
M5$@Z(#`N,C5I;B<^(#$N/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4
M.B!N;W)M86PG/DEN($9E8G)U87)Y(#(P,3`L('1H92!#;VUP86YY)B,S.3MS
M($)O87)D(&]F($1I<F5C=&]R<R!A<'!R;W9E9"!T:&4@9W)A;G0@;V8@;W!T
M:6]N<R!T;R!P=7)C:&%S92`Q+#`Q-BPP,#`@<VAA<F5S(&]F($-O;6UO;B!3
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M;6%N8V4@8V]N9&ET:6]N(&%C='5A;&QY(&]C8W5R<F5D+B`\9F]N="!S='EL
M93TS1"=#3TQ/4CH@8FQA8VLG/E5P;VX@=&AE($9$028C,SD[<SPO9F]N=#X@
M87!P<F]V86P@;V8@=&%L:6=L=6-E<F%S92!A;&9A(&]N($UA>2`Q+"`R,#$R
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M="!D871E+CPO9F]N=#X\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS
M1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!&
M3TY4+5=%24=(5#H@;F]R;6%L.R!-05)'24XZ(#!P="`P<'@@,'!T(#$N-6EN
M.R!415A4+4E.1$5.5#H@+3`N,C5I;B<^("9N8G-P.SPO<#X@/'1A8FQE('-T
M>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R
M('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G
M5TE$5$@Z(#$N,C5I;B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M5T5)1TA4.B!N;W)M86P[(%=)1%1(.B`P+C(U:6XG/C(N/"]T9#X@/'1D('-T
M>6QE/3-$)T-/3$]2.B!B;&%C:SL@1D].5"U714E'2%0Z(&YO<FUA;"<^26X@
M1F5B<G5A<GD@,C`Q,"P@=&AE($-O;7!A;GDF(S,Y.W,@0F]A<F0@;V8@1&ER
M96-T;W)S(&%P<')O=F5D('1H92!G<F%N="!O9B!O<'1I;VYS('1O('!U<F-H
M87-E(#$V,"PP,#`@<VAA<F5S(&]F($-O;6UO;B!3=&]C:R!W:71H(&%N(&5X
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M9R`W-24@=F5S="!I;B`Q,B!E<75A;"!T<F%N8VAE<R!O;B!A('%U87)T97)L
M>2!B87-I<R!F;W(@=&AR964@>65A<G,@=&AE<F5A9G1E<BX\+W1D/B`\+W1R
M/B`\+W1A8FQE/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!&3TY4+5=%24=(5#H@;F]R;6%L.R!-05)'
M24XZ(#!P="`P<'@@,'!T(#$N-6EN.R!415A4+4E.1$5.5#H@+3`N,C5I;B<^
M("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%2
M1TE.+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=.
M.B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$N,C5I;B<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T-/3$]2.B!B;&%C:SL@1D].5"U714E'2%0Z(&YO
M<FUA;#L@5TE$5$@Z(#`N,C5I;B<^(#,N/"]T9#X@/'1D/CQF;VYT('-T>6QE
M/3-$)T9/3E0M5T5)1TA4.B!N;W)M86PG/DEN(%-E<'1E;6)E<B`R,#$P+"!T
M:&4@0V]M<&%N>28C,SD[<R!";V%R9"!O9B!$:7)E8W1O<G,@87!P<F]V960@
M=&AE(&=R86YT(&]F(&]P=&EO;G,@=&\@<'5R8VAA<V4@,38P+#`P,"!S:&%R
M97,@;V8@0V]M;6]N(%-T;V-K('1O(&$@;F5W(&5X96-U=&EV92!O9F9I8V5R
M(&]F('1H92!#;VUP86YY('=I=&@@86X@97AE<F-I<V4@<')I8V4@97%U86P@
M=&\@)#<N-34@<&5R('-H87)E(&%N9"!O<'1I;VYS('1O('!U<F-H87-E(#0P
M+#`P,"!S:&%R97,@;V8@0V]M;6]N(%-T;V-K('1O(&$@;F5W(&5M<&QO>65E
M(&]F('1H92!#;VUP86YY('=I=&@@86X@97AE<F-I<V4@<')I8V4@97%U86P@
M=&\@)#8N,S(@<&5R('-H87)E+B!4:&4@;W!T:6]N<R!V97-T(&]V97(@82!F
M;W5R+7EE87(@<&5R:6]D+"!W:71H('1H92!F:7)S="`R-24@=F5S=&EN9R!O
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M9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[
M/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!&3TY4+5=%24=(5#H@;F]R;6%L.R!-05)'24XZ(#!P
M="`P<'@@,'!T(#$N-6EN.R!415A4+4E.1$5.5#H@+3`N,C5I;B<^("9N8G-P
M.SPO<#X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/
M5%1/33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I
M9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G
M/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$N,C5I;B<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T-/3$]2.B!B;&%C:SL@1D].5"U714E'2%0Z(&YO<FUA;#L@
M5TE$5$@Z(#`N,C5I;B<^(#0N/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)
M1TA4.B!N;W)M86PG/DEN($YO=F5M8F5R(#(P,3`L('1H92!#;VUP86YY)B,S
M.3MS($)O87)D(&]F($1I<F5C=&]R<R!A<'!R;W9E9"!T:&4@9W)A;G0@;V8@
M;W!T:6]N<R!T;R!P=7)C:&%S92`V."PP,#`@<VAA<F5S(&]F($-O;6UO;B!3
M=&]C:R!T;R!A(&YE=R!O9F9I8V5R(&]F('1H92!#;VUP86YY('=I=&@@86X@
M97AE<F-I<V4@<')I8V4@97%U86P@=&\@)#DN-C8@<&5R('-H87)E+B!4:&4@
M;W!T:6]N<R!V97-T(&]V97(@82!F;W5R+7EE87(@<&5R:6]D+"!W:71H('1H
M92!F:7)S="`R-24@=F5S=&EN9R!O;B!T:&4@9FER<W0@86YN:79E<G-A<GD@
M;V8@=&AE(&%P<&QI8V%B;&4@9&%T92!O9B!T:&4@9W)A;G0@86YD('1H92!R
M96UA:6YI;F<@-S4E('9E<W1I;F<@:6X@97%U86P@=')A;F-H97,@;VX@82!Q
M=6%R=&5R;'D@8F%S:7,@9F]R(&$@=&AR964M>65A<B!P97)I;V0@=&AE<F5A
M9G1E<BX@/&9O;G0@<W1Y;&4],T0G0T],3U(Z(&)L86-K)SY4:&4@;W!T:6]N
M<R!E>'!I<F4@;VX@=&AE('1E;G1H(&%N;FEV97)S87)Y(&]F('1H92!D871E
M(&]F(&=R86YT+"!U;FQE<W,@=&5R;6EN871E9"!E87)L:65R+CPO9F]N=#X\
M+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!&3TY4+5=%24=(5#H@;F]R
M;6%L.R!-05)'24XZ(#!P="`P<'@@,'!T(#$N-6EN.R!415A4+4E.1$5.5#H@
M+3`N,C5I;B<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU4
M3U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)
M0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$N,C5I;B<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86P[
M(%=)1%1(.B`P+C(U:6XG/C4N/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)
M1TA4.B!N;W)M86PG/DEN(%-E<'1E;6)E<B`R,#$P+"!T:&4@0V]M<&%N>28C
M,SD[<R!";V%R9"!O9B!$:7)E8W1O<G,@;6]D:69I960@=&AE('1E<FUS(&]F
M('1H92!O<'1I;VYS('!R979I;W5S;'D@9W)A;G1E9"!T;R!A;B!E>&5C=71I
M=F4@:6X@,C`P,2P@8GD@97AT96YD:6YG('1H92!L:69E(&]F('1H92!O<'1I
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M/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@1D].5"U714E'2%0Z(&YO<FUA;#L@
M34%21TE..B`P<'0@,'!X(#!P="`Q+C5I;CL@5$585"U)3D1%3E0Z("TP+C(U
M:6XG/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P
M<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL93TS1"=615)424-!3"U!
M3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`Q+C(U:6XG/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L.R!72414
M2#H@,"XR-6EN)SXV+CPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@
M;F]R;6%L)SY/;B!*=6QY(#$V+"`R,#$R+"!T:&4@0V]M<&%N>28C,SD[<R!"
M;V%R9"!O9B!$:7)E8W1O<G,@87!P<F]V960@=&AE(&=R86YT(&]F(#$L-3`P
M+#`P,"!S:&%R97,@;V8@<F5S=')I8W1E9"!#;VUM;VX@4W1O8VL@=&\@:71S
M(&]F9FEC97)S(&%N9"!C97)T86EN(&]T:&5R(&5M<&QO>65E<RX@3V8@<W5C
M:"!R97-T<FEC=&5D('-T;V-K+"`Q+#$P,"PP,#`@;V8@=&AE('-H87)E<R!W
M97)E(&ES<W5E9"!T;R!T:&4@0V]M<&%N>28C,SD[<R!N86UE9"!E>&5C=71I
M=F4@;V9F:6-E<G,@86YD('9E<W0@:6X@,38@97%U86PL('%U87)T97)L>2!I
M;F-R96UE;G1S(&]V97(@82!F;W5R+7EE87(@<&5R:6]D+"!C;VUM96YC:6YG
M('5P;VX@=&AE(&1A=&4@;V8@9W)A;G0L(&%N9"!A<F4@<W5B:F5C="!T;R!A
M(#(T+6UO;G1H(&QO8VLM=7`@<&5R:6]D+"!C;VUM96YC:6YG('5P;VX@=&AE
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M<R!S:&%L;"!V97-T+"!A;F0@=&AE(&QO8VLM=7`@<&5R:6]D<R!S:&%L;"!T
M97)M:6YA=&4L('-U8FIE8W0@=&\@8V5R=&%I;B!E>&-E<'1I;VYS+B!4:&4@
M<F5M86EN:6YG(#0P,"PP,#`@<VAA<F5S(&]F(')E<W1R:6-T960@0V]M;6]N
M(%-T;V-K('=E<F4@:7-S=65D('1O(&]T:&5R(&5M<&QO>65E<R!O9B!T:&4@
M0V]M<&%N>2!A;F0@=F5S="!I;B`Q,B!E<75A;"P@<75A<G1E<FQY(&EN8W)E
M;65N=',@;W9E<B!A('1H<F5E+7EE87(@<&5R:6]D+"!C;VUM96YC:6YG('5P
M;VX@=&AE(&1A=&4@;V8@9W)A;G0N(%1H92!#;VUP86YY(&5S=&EM871E9"!T
M:&4@9F%I<B!V86QU92!O9B!T:&4@<F5S=')I8W1E9"!S=&]C:R!O;B!T:&4@
M9&%T92!O9B!G<F%N="!T;R!B92!A<'!R;WAI;6%T96QY("0X+C8@;6EL;&EO
M;BX\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3`N,C5I;CL@34%21TE..B`P<'0@,'!X(#!P="`Q+C(U:6X[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\
M+W`^(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[(%=)1%1(.B`Q
M,#`E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@
M/'1D('-T>6QE/3-$)U=)1%1(.B`Q:6XG/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=724142#H@,"XR-6EN)SYB*3PO=&0^(#QT9#Y4:&4@9F%I<B!V86QU
M92!O9B!O<'1I;VYS(&%N9"!R97-T<FEC=&5D('-T;V-K(&=R86YT960@9'5R
M:6YG('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,"!A;F0@,C`Q
M,B!W97)E("0W+C@@;6EL;&EO;B!A;F0@)#@N-B!M:6QL:6]N(')E<W!E8W1I
M=F5L>2X@5&AE(&9A:7(@=F%L=64@;V8@96%C:"!O<'1I;VX@9W)A;G1E9"!I
M;B`R,#$P(&ES(&5S=&EM871E9"!O;B!T:&4@9&%T92!O9B!G<F%N="!U<VEN
M9R!T:&4@0FQA8VLM4V-H;VQE<R!O<'1I;VXM<')I8VEN9R!M;V1E;"P@=VET
M:"!T:&4@9F]L;&]W:6YG('=E:6=H=&5D(&%V97)A9V4@87-S=6UP=&EO;G,Z
M/"]T9#X@/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@
M,'!X.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"=724142#H@-3`E
M.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM3$5&5#H@,2XR-6EN
M)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/B`\='(@<W1Y;&4]
M,T0G5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=0041$
M24Y'+4Q%1E0Z(#!P>"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E
M<B<@8V]L<W!A;CTS1#(^,C`Q,#PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G
M0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!0041$24Y'+4)/5%1/33H@,BXU<'0[(%!!1$1)3D<M3$5&5#H@,'!X.R!7
M24142#H@.#<E)SX@1&EV:61E;F0@>6EE;&0\+W1D/B`\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!724142#H@,24G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B
M;&4[(%1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^("9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B
M;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E)SX@,#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@
M,BXU<'0[(%=)1%1(.B`Q)2<^("4\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G
M0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"
M3U143TTZ(#(N-7!T.R!0041$24Y'+4Q%1E0Z(#!P>"<^($5X<&5C=&5D('9O
M;&%T:6QI='D\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N
M-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T
M(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`W-3PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,BXU<'0G
M/B4\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@
M<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@
M,BXU<'0[(%!!1$1)3D<M3$5&5#H@,'!X)SX@4FES:RUF<F5E(&EN=&5R97-T
M(')A=&4\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O
M=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`S+C(S/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^
M)3PO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!W
M:&ET93L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[(%!!1$1)
M3D<M3$5&5#H@,'!X)SX@17AP96-T960@;&EF92`M(&EN('EE87)S/"]T9#X@
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O
M=6)L93L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(')I9VAT)SX@."XX/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@
M/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P
M="`Q+C(U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P
M>"`P<'0@,2XR-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX@5&AE(&5X<&5C=&5D('9O;&%T:6QI='D@:7,@8F%S960@
M;VX@=&AE(&AI<W1O<FEC86P@=F]L871I;&ET>2!O9B!T:&4@0V]M;6]N(%-T
M;V-K(&%N9"!T:&]S92!O9B!C;VUP87)A8FQE(&-O;7!A;FEE<RX@5&AE(')I
M<VLM9G)E92!I;G1E<F5S="!R871E(&%S<W5M<'1I;VX@:7,@8F%S960@;VX@
M;V)S97)V960@:6YT97)E<W0@<F%T97,@87!P<F]P<FEA=&4@9F]R('1H92!E
M>'!E8W1E9"!T97)M(&]F('1H92!S=&]C:R!O<'1I;VYS(&=R86YT960@:6X@
M9&]L;&%R('1E<FUS+B!4:&4@0V]M<&%N>28C,SD[<R!M86YA9V5M96YT('5S
M97,@=&AE(&-O;G1R86-T=6%L('1E<FT@;W(@:71S(&5X<&5C=&%T:6]N<RP@
M8F%S960@;VX@:&ES=&]R:6-A;"!I;F-I9&5N8V4@;V8@;W!T:6]N(&5X97)C
M:7-E<RP@87,@87!P;&EC86)L92`H9'5R:6YG(#(P,3`@+2!U<VEN9R!T:&4@
M<VEM<&QI9FEE9"!M971H;V0I+"!O9B!E86-H(&]P=&EO;B!A<R!I=',@97AP
M96-T960@;&EF92X@5&AE('!R92UV97-T:6YG(&9O<F9E:71U<F4@<F%T92!O
M9B!A<'!R;WAI;6%T96QY(#8N,24@:7,@97-T:6UA=&5D(&)A<V5D(&]N('!R
M92UV97-T:6YG(&9O<F9E:71U<F4@97AP97)I96YC92X\+W`^(#QP('-T>6QE
M/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,2XR-6EN.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S
M='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#$N,C5I;CL@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^(%1H92!F86ER('9A
M;'5E(&]F('1H92!R97-T<FEC=&5D('-T;V-K(&ES(&)A<V5D(&]N('1H92!#
M;VUP86YY)B,S.3MS('-H87)E('!R:6-E(&]N('1H92!.65-%($U+5"!O;B!T
M:&4@9W)A;G0@9&%T92X\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P
M>"`P<'0@,2XR-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P
M="`P<'@@,'!T(#$N,C5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^(%1H92!T;W1A;"!U;G)E8V]G;FEZ960@8V]M<&5N
M<V%T:6]N(&-O<W0@;V8@96UP;&]Y964@<W1O8VL@;W!T:6]N<R!A;F0@<F5S
M=')I8W1E9"!S=&]C:R!A="!$96-E;6)E<B`S,2P@,C`Q,B!I<R!A<'!R;WAI
M;6%T96QY("0W+C`@;6EL;&EO;B`H;F5T(&]F(&9O<F9E:71U<F4@<F%T92DN
M(%1H92!U;G)E8V]G;FEZ960@8V]M<&5N<V%T:6]N(&-O<W0@;V8@96UP;&]Y
M964@<W1O8VL@;W!T:6]N<R!I<R!E>'!E8W1E9"!T;R!B92!R96-O9VYI>F5D
M(&]V97(@82!W96EG:'1E9"!A=F5R86=E('!E<FEO9"!O9B`Q+C$@>65A<G,N
M/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#$N,C5I;CL@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N
M8G-P.SPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q+C(U
M:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B!4:&4@=&]T86P@8V%S:"!R96-E:79E9"!F<F]M(&5M<&QO>65E<R!A<R!A
M(')E<W5L="!O9B!E;7!L;WEE92!S=&]C:R!O<'1I;VX@97AE<F-I<V5S(&9O
M<B!T:&4@>65A<G,@96YD960@1&5C96UB97(@,S$L(#(P,3`L(#(P,3$@86YD
M(#(P,3(@=V%S(&%P<')O>&EM871E;'D@)#4P,2PP,#`L("0R-S<L,#`P(&%N
M9"`D,2XR(&UI;&QI;VXL(')E<W!E8W1I=F5L>2X@5&AE($-O;7!A;GD@9&ED
M(&YO="!R96%L:7IE(&%N>2!T87@@8F5N969I="!I;B!C;VYN96-T:6]N('=I
M=&@@=&AE<V4@97AE<F-I<V5S+CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P
M<'0@,'!X(#!P="`Q+C(U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)
M3CH@,'!T(#!P>"`P<'0@,2XR-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX@1'5R:6YG(#(P,3(L('1H92!#;VUP86YY
M(&ES<W5E9"`X-C$L-3DS('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@:6X@8V]N
M;F5C=&EO;B!W:71H('1H92!E>&5R8VES92!O9B`X-C$L-3DS(&]P=&EO;G,@
M8GD@8V5R=&%I;B!E;7!L;WEE97,@;V8@=&AE($-O;7!A;GDN(%1H92!#;VUP
M86YY(')E8V5I=F5D(&-A<V@@<')O8V5E9',@97%U86P@=&\@87!P<F]X:6UA
M=&5L>2`D,2XR(&UI;&QI;VX@:6X@8V]N;F5C=&EO;B!W:71H('-U8V@@97AE
M<F-I<V5S+CPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@1D].5"U714E'2%0Z(&YO<FUA;#L@34%2
M1TE..B`P<'0@,'!X(#!P="`Q:6X[(%1%6%0M24Y$14Y4.B`M,"XR-6EN)SX@
M)FYB<W`[/"]P/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!&
M3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL93TS1"=615)424-!3"U!
M3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`P+C<U:6XG/B9N8G-P
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M.B!N;W)M86P[($U!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!415A4+4E.1$5.
M5#H@,&EN)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!&3TY4+5=%24=(5#H@;F]R
M;6%L.R!-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@5$585"U)3D1%3E0Z(#!I
M;B<^($%S(&]F($1E8V5M8F5R(#,Q+"`R,#$R+"!T:&4@0V]M<&%N>2!H87,@
M<F5C;V=N:7IE9"!A;F0@<F5C;W)D960@86QL(&-O;7!E;G-A=&EO;B!C;W-T
M<R!R96QA=&5D('1O(&]U='-T86YD:6YG(&]P=&EO;G,@9F]R(&-O;G-U;'1A
M;G1S+"!D:7)E8W1O<G,@86YD(&]T:&5R('-E<G9I8V5S('!R;W9I9&5R<RX\
M+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[
M/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^($YO(&-A
M<V@@=V%S(')E8V5I=F5D(&9R;VT@8V]N<W5L=&%N=',@87,@82!R97-U;'0@
M;V8@8V]N<W5L=&%N="!S=&]C:R!O<'1I;VX@97AE<F-I<V5S(&9O<B!T:&4@
M>65A<G,@96YD960@1&5C96UB97(@,S$L(#(P,3`L(&%N9"`R,#$Q(&%N9"!A
M<'!R;WAI;6%T96QY("0S.2PP,#`@=V%S(')E8V5I=F5D(&1U<FEN9R!T:&4@
M>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,BX@5&AE($-O;7!A;GD@9&ED
M(&YO="!R96%L:7IE(&%N>2!T87@@8F5N969I=',@:6X@8V]N;F5C=&EO;B!W
M:71H('1H97-E(&5X97)C:7-E<RX\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@
M,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ
M(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^($1U<FEN9R`R,#$R+"!T:&4@0V]M<&%N>2!I<W-U
M960@,S(V+#(V-R!S:&%R97,@;V8@0V]M;6]N(%-T;V-K(&EN(&-O;FYE8W1I
M;VX@=VET:"!T:&4@97AE<F-I<V4@;V8@,S(V+#(V-R!O<'1I;VYS(&)Y(&-O
M;G-U;'1A;G1S(&]F('1H92!#;VUP86YY+B!4:&4@0V]M<&%N>2!R96-E:79E
M9"!C87-H('!R;V-E961S(&5Q=6%L('1O(&%P<')O>&EM871E;'D@)#,Y+#`P
M,"!I;B!C;VYN96-T:6]N('=I=&@@<W5C:"!E>&5R8VES92X\+W`^(#QP('-T
M>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[($9/3E0M5T5)1TA4.B!N;W)M86P[($U!4D=)3CH@,'!T(#!P>"`P<'0@
M,6EN.R!415A4+4E.1$5.5#H@+3`N,C5I;B<^("9N8G-P.SPO<#X@/'1A8FQE
M('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@
M/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4]
M,T0G5TE$5$@Z(#`N-S5I;B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M5T5)1TA4.B!N;W)M86P[(%=)1%1(.B`P+C(U:6XG/C,N/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86PG/D$@<W5M;6%R>2!O9B!S
M:&%R92!O<'1I;VX@<&QA;G,L(&%N9"!R96QA=&5D(&EN9F]R;6%T:6]N+"!U
M;F1E<B!A;&P@;V8@=&AE($-O;7!A;GDF(S,Y.W,@97%U:71Y(&EN8V5N=&EV
M92!P;&%N<R!F;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$P
M+"`R,#$Q(&%N9"`R,#$R(&%R92!A<R!F;VQL;W=S.CPO=&0^(#PO='(^(#PO
M=&%B;&4^(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,"XR-6EN.R!-05)'
M24XZ(#!P="`P<'@@,'!T(#$N,C5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE
M/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R('-T
M>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$
M5$@Z(#%I;B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`P+C(U
M:6XG/F$N/"]T9#X@/'1D/D]P=&EO;G,@9W)A;G1E9"!T;R!E;7!L;WEE97,Z
M/"]T9#X@/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@
M,'!X.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"=724142#H@,3`P
M)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,#X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG/B`\=&0@;F]W<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<@;F]W<F%P/3-$;F]W<F%P/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C
M96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,C(@;F]W<F%P
M/3-$;F]W<F%P/EEE87(@96YD960@1&5C96UB97(@,S$L/"]T9#X@/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD
M)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL
M93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS
M1&YO=W)A<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^
M("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z
M(&)O;&0G(&-O;'-P86X],T0V(&YO=W)A<#TS1&YO=W)A<#XR,#$P/"]T9#X@
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4
M.B!B;VQD)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<@
M;F]W<F%P/3-$;F]W<F%P/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT
M97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$-B!N;W=R87`],T1N
M;W=R87`^,C`Q,3PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B`F;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].
M5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X@)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A
M;CTS1#8@;F]W<F%P/3-$;F]W<F%P/C(P,3(\+W1D/B`\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A
M<#TS1&YO=W)A<#X@)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P
M/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0G
M(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X@
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)R!N
M;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`^(%=E:6=H=&5D/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A
M<#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0G
M(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@
M8F]L9"<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/E=E:6=H=&5D/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N
M;W=R87`^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B
M;VQD)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R
M87`^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L
M9"<@;F]W<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4
M.B!B;VQD)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^5V5I9VAT960\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS
M1&YO=W)A<#XF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#
M04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!N;W=R87`],T1N;W=R87`^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`]
M,T1N;W=R87`^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R(&YO=W)A
M<#TS1&YO=W)A<#Y.=6UB97(\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'
M2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/F%V
M97)A9V4\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0G(&YO
M=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U7
M14E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@
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M,B!N;W=R87`],T1N;W=R87`^879E<F%G93PO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W
M<F%P/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`^3G5M8F5R/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B
M;VQD)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'
M2%0Z(&)O;&0G(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#YA=F5R86=E
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`]
M,T1N;W=R87`^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)
M0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@;F]W<F%P/3-$;F]W<F%P/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P
M/3-$;F]W<F%P/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`^;V8\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z
M(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%
M24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/F5X97)C
M:7-E/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R
M87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)
M1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/'1D('-T
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M87`],T1N;W=R87`^97AE<F-I<V4\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U7
M14E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#XF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P
M/F]F/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R
M87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)
M1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G
M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#YE>&5R8VES93PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P
M/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'
M3CH@8F]T=&]M)SX@/'1D(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z
M(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(@;F]W
M<F%P/3-$;F]W<F%P/F]P=&EO;G,\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO
M=W)A<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^("9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O
M;&0G(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#YP<FEC93PO=&0^(#QT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@
M8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO
M=W)A<#TS1&YO=W)A<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W
M<F%P/F]P=&EO;G,\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X@)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/
M3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[
M(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P
M86X],T0R(&YO=W)A<#TS1&YO=W)A<#YP<FEC93PO=&0^(#QT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<@;F]W
M<F%P/3-$;F]W<F%P/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO
M=W)A<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%
M24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/F]P=&EO
M;G,\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].
M5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X@)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4
M.B!B;VQD)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R(&YO
M=W)A<#TS1&YO=W)A<#YP<FEC93PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W
M<F%P/B`F;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.
M1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!415A4+4E.
M1$5.5#H@+3`N,6EN.R!0041$24Y'+4Q%1E0Z(#`N,6EN.R!724142#H@-#`E
M)SX@3W5T<W1A;F1I;F<@870@8F5G:6YN:6YG(&]F('EE87(\+W1D/B`\=&0@
M<W1Y;&4],T0G5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`W)2<^-2PS-C8L
M-S(Y/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(
M.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(
M.B`Q)2<^)#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M5TE$5$@Z(#<E)SXR+C0W-CPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=7
M24142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#<E)SXV+#,V-RPY-SD\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXD/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@-R4G
M/C,N-3<V/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)
M1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)
M1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!724142#H@-R4G/C8L,30Q+#`S,#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B0\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`W)2<^,RXU-C,\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF
M;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/
M4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^0VAA;F=E<R!D=7)I;F<@=&AE('EE87(Z
M/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\
M+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$
M)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU,1494.B`P
M+C(U:6XG/D=R86YT960\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H="<^,2PT-#0L,#`P/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXW+C`W-CPO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\
M=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N
M8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO
M='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!W:&ET93L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!0041$24Y'+4Q%1E0Z(#`N,C5I;B<^1F]R9F5I=&5D(&%N9"!%
M>'!I<F5D/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0G/C$S+#0T,3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H="<^,RXU-3$\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C0T+#@U-CPO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\
M=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^
M-BXR,#<\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB
M<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0G/C(U+#@U.#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H="<^-"XS-S(\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE
M/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#%P=#L@4$%$1$E.1RU,1494.B`P+C(U:6XG/D5X97)C:7-E9"`H*BD\
M+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S
M;VQI9#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)
M1TXZ(')I9VAT)SX@-#(Y+#,P.3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@
M5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I
M9VAT)SX@,2XV,#(\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)
M1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^(#$X
M,BPP.3,\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$
M1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE
M9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^(#$N-C4R/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]4
M5$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P
M="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/B`X-C$L-3DS/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q
M<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI
M9#L@5$585"U!3$E'3CH@<FEG:'0G/B`Q+C,T-CPO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S
M<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@
M=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SY/=71S
M=&%N9&EN9R!A="!E;F0@;V8@>65A<CPO=&0^(#QT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#8L
M,S8W+#DW.3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0
M041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`S
M+C4W-CPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$
M24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)
M1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^
M(#8L,30Q+#`S,#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G
M/B`S+C4V,SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0
M041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H
M="<^(#4L,C4S+#4W.3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG
M:'0G/B`S+CDR,SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#PO='(^(#QT
M<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^17AE<F-I<V%B
M;&4@870@96YD(&]F('EE87(\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T
M)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`T+#(V-RPX
M-3`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.
M1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=.
M.B!L969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@,BXQ.#,\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"
M3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L
M969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`T+#8T
M-RPX,S0\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$
M1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,
M24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@,BXU
M.#$\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.
M1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=.
M.B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`T
M+#(U."PT-#$\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4
M+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@
M,RXR,#$\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$
M1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\+W1R/B`\+W1A8FQE
M/B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3`N,FEN.R!-05)'24XZ(#!P
M="`P<'@@,'!T(#@T+CDU<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"=-
M05)'24XM5$]0.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL93TS
M1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`W
M,"XU-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$T+C1P
M="<^*"HI/"]T9#X@/'1D/E1H92!T;W1A;"!I;G1R:6YS:6,@=F%L=64@;V8@
M;W!T:6]N<R!E>&5R8VES960@9'5R:6YG('1H92!Y96%R<R!E;F1E9"!$96-E
M;6)E<B`S,2P@,C`Q,"P@,C`Q,2!A;F0@,C`Q,BP@=V%S(&%P<')O>&EM871E
M;'D@)#,N,2!M:6QL:6]N+"`D,2XS(&UI;&QI;VX@86YD("0T+C@@;6EL;&EO
M;BP@<F5S<&5C=&EV96QY+CPO=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`M,"XR:6X[($U!4D=)3CH@,'!T(#!P>"`P<'0@
M.#0N.35P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z
M(#!P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@34%21TE.+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,
M+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#%I;B<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`P+C(U:6XG/F(N/"]T9#X@/'1D
M/E)E<W1R:6-T960@<W1O8VL@9W)A;G1E9"!T;R!E;7!L;WEE97,Z/"]T9#X@
M/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&
M3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"=724142#H@-3`E.R!"3U)$
M15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P(&%L:6=N/3-$8V5N=&5R/B`\='(@<W1Y;&4],T0G5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'
M2%0Z(&)O;&0G(&-O;'-P86X],T0U/EEE87(@96YD960@1&5C96UB97(@,S$L
M(#(P,3(\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97(G(&YO
M=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO
M=W)A<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%
M24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/DYU;6)E
M<B!O9CQB<B`O/B!297-T<FEC=&5D(%-H87)E<SPO=&0^(#QT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<@;F]W
M<F%P/3-$;F]W<F%P/B`F;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G
M0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97(G/D]U='-T86YD:6YG(&%T(&)E9VEN;FEN9R!O9B!Y96%R/"]T9#X@/'1D
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97(G
M(&-O;'-P86X],T0R/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\+W1R
M/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R)SY#:&%N9V5S(&1U<FEN9R!T:&4@>65A<CH\+W1D/B`\=&0^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO
M=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H
M,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@5TE$5$@Z(#DP)2<^1W)A;G1E
M9#PO=&0^(#QT9"!S='EL93TS1"=724142#H@,24G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z
M(#<E)SXQ+#4P,"PP,#`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4]
M,T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!0041$
M24Y'+4)/5%1/33H@,7!T.R!0041$24Y'+4Q%1E0Z(#$U+CDU<'0G/B!&;W)F
M96ET960\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%
M6%0M04Q)1TXZ(')I9VAT)SX@,RPR,#@\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T
M9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R
M,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!0041$24Y'+4)/5%1/33H@,BXU
M<'0G/D]U='-T86YD:6YG(&%T(&5N9"!O9B!Y96%R/"]T9#X@/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$58
M5"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I
M9VAT)SX@,2PT.38L-SDR/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/"]T
M<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SY%>&5R8VES86)L92!A
M="!E;F0@;V8@>65A<CPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#$P,BPP.#0\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U14
M3TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\
M+W`^(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U14
M3TTZ(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T
M:#TS1#$P,"4^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@
M/'1D('-T>6QE/3-$)U=)1%1(.B`Q:6XG/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=724142#H@,"XR-6EN)SYC+CPO=&0^(#QT9#Y/<'1I;VYS(&=R86YT
M960@=&\@8V]N<W5L=&%N=',L(&1I<F5C=&]R<RP@86YD(&]T:&5R('-E<G9I
M8V4@<')O=FED97)S.CPO=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$
M)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\=&%B;&4@<W1Y;&4]
M,T0G5TE$5$@Z(#$P,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT<B!S='EL93TS1"=615)4
M24-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS
M1#(R/EEE87(@96YD960@1&5C96UB97(@,S$L/"]T9#X@/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S
M<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4
M+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED
M.R!415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS
M<&%N/3-$-CXR,#$P/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z
M(&)O;&0G(&-O;'-P86X],T0V/C(P,3$\+W1D/B`\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#8^,C`Q,CPO=&0^(#QT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R/B`F;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O
M;&0G(&-O;'-P86X],T0R/B!796EG:'1E9#PO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS
M1#(^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L
M9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(^(%=E:6=H=&5D/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4
M.B!B;VQD)R!C;VQS<&%N/3-$,CX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N
M/3-$,CX@5V5I9VAT960\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z
M(&)O;&0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!
M3"U!3$E'3CH@8F]T=&]M)SX@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P
M86X],T0R/B!.=6UB97(\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z
M(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@
M8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R/B!A=F5R86=E
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M5T5)
M1TA4.B!B;VQD)R!C;VQS<&%N/3-$,CX@3G5M8F5R/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS
M<&%N/3-$,CX@879E<F%G93PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(
M5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4
M.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(^($YU;6)E
M<CPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%
M24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(^(&%V97)A9V4\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#PO='(^(#QT
M<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U7
M14E'2%0Z(&)O;&0G(&-O;'-P86X],T0R/B!O9CPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A
M;CTS1#(^(&5X97)C:7-E/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4
M.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z
M(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,CX@;V8\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z
M(&)O;&0G(&-O;'-P86X],T0R/B!E>&5R8VES93PO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A
M;CTS1#(^(&]F/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,CX@97AE<F-I<V4\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^
M(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(
M5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(^;W!T:6]N<SPO=&0^(#QT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q
M<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=.
M.B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,CYP<FEC
M93PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4
M+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED
M.R!415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS
M<&%N/3-$,CYO<'1I;VYS/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O
M;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'
M2%0Z(&)O;&0G(&-O;'-P86X],T0R/G!R:6-E/"]T9#X@/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].
M5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R/F]P=&EO;G,\+W1D
M/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'
M2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS
M1#(^<')I8V4\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P
M=#L@1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S
M='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`M,"XQ:6X[(%!!1$1)3D<M3$5&5#H@
M,"XQ:6X[(%=)1%1(.B`T,"4G/B!/=71S=&%N9&EN9R!A="!B96=I;FYI;F<@
M;V8@>65A<CPO=&0^(#QT9"!S='EL93TS1"=724142#H@,24G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M5TE$5$@Z(#<E)SXQ+#0S."PV.3(\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!724142#H@-R4G/C0N-CDW/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@-R4G
M/C$L-#,X+#8Y,CPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=724142#H@
M,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!724142#H@,24G/B0\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[(%=)1%1(.B`W)2<^-"XV.3<\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`W)2<^,2PR,S@L-CDR
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q
M)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q
M)2<^)#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$
M5$@Z(#<E)SXU+C,X-3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!724142#H@,24G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS
M1"="04-+1U)/54Y$+4-/3$]2.B!W:&ET93L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@,7!T.R!415A4+4E.1$5.5#H@+3`N,6EN.R!0041$24Y'+4Q%
M1E0Z(#`N,6EN)SX@0VAA;F=E<R!D=7)I;F<@=&AE('EE87(M($5X97)C:7-E
M9"`H*BD\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#%P="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX@)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M
M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T)SX@
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/B`F;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M
M0D]45$]-.B`Q<'0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^
M(#(P,"PP,#`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ
M(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^(#`N,#`Q
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M
M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T.R!0
M041$24Y'+4)/5%1/33H@,7!T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@
M<FEG:'0G/B`S,C8L,C8W/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4
M+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G
M/B`P+C$R/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!
M1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL
M93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U)3D1%3E0Z("TP
M+C%I;CL@4$%$1$E.1RU,1494.B`P+C%I;B<^($]U='-T86YD:6YG(&%T(&5N
M9"!O9B!Y96%R/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P
M="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@,2PT,S@L-CDR/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-
M.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^
M("0\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#0N-CDW/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R
M+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@
M5$585"U!3$E'3CH@<FEG:'0G/B`Q+#(S."PV.3(\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(')I9VAT)SX@-2XS.#4\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L
M93L@5$585"U!3$E'3CH@<FEG:'0G/B`Y,3(L-#(U/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE
M.R!415A4+4%,24=..B!R:6=H="<^(#<N,C4Y/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB
M<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z
M('=H:71E.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$58
M5"U)3D1%3E0Z("TP+C%I;CL@4$%$1$E.1RU,1494.B`P+C%I;B<^($5X97)C
M:7-A8FQE(&%T(&5N9"!O9B!Y96%R/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@
M;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@,2PT
M,C$L-S,T/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!
M1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!
M3$E'3CH@;&5F="<^("0\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#0N
M-C4S/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)
M3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N
M-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`Q+#(S-2PU-C<\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U14
M3TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T
M)SX@)#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R
M+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@-2XS.#4\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`Y,3(L-#(U/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]4
M5$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F
M="<^("0\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#<N,C4Y/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-
M.B`R+C5P="<^)FYB<W`[/"]T9#X@/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4]
M,T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QT86)L92!S='EL
M93TS1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S
M='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)
M1%1(.B`V,RXX<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=724142#H@
M,31P="<^*"HI/"]T9#X@/'1D/E1H92!T;W1A;"!I;G1R:6YS:6,@=F%L=64@
M;V8@;W!T:6]N<R!E>&5R8VES960@9'5R:6YG('1H92!Y96%R<R!E;F1E9"!$
M96-E;6)E<B`S,2P@,C`Q,"P@,C`Q,2!A;F0@,C`Q,BP@=V%S(&%P<')O>&EM
M871E;'D@)#`L("0Q+CD@;6EL;&EO;B!A;F0@)#(N,R!M:6QL:6]N+"!R97-P
M96-T:79E;'DN/"]T9#X@/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z("TP+C(U:6X[($U!4D=)3CH@,'!T(#!P>"`P<'0@,2XR-6EN
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@
M)FYB<W`[/"]P/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'
M24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@=VED=&@],T0Q,#`E/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ
M('1O<"<^(#QT9"!S='EL93TS1"=724142#H@,6EN)SXF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G5TE$5$@Z(#`N,C5I;B<^9"X\+W1D/B`\=&0^5&AE(&9O
M;&QO=VEN9R!T86)L97,@<W5M;6%R:7IE(&EN9F]R;6%T:6]N(&-O;F-E<FYI
M;F<@;W5T<W1A;F1I;F<@86YD(&5X97)C:7-A8FQE(&]P=&EO;G,@86YD(')E
M<W1R:6-T960@<W1O8VL@87,@;V8@1&5C96UB97(@,S$L(#(P,3(Z/"]T9#X@
M/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&
M3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"=724142#H@-S`E.R!"3U)$
M15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM3$5&5#H@,"XW-6EN)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/B`\='(@<W1Y;&4],T0G5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].
M5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0Q."!N;W=R87`],T1N;W=R87`^
M1&5C96UB97(@,S$L(#(P,3(\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A
M<#X@)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4
M.B!B;VQD)R!C;VQS<&%N/3-$,3`@;F]W<F%P/3-$;F]W<F%P/D]P=&EO;G,@
M86YD(')E<W1R:6-T960@<W1O8VL\8G(@+SX@;W5T<W1A;F1I;F<\+W1D/B`\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z
M(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)R!N
M;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0V(&YO=W)A<#TS1&YO
M=W)A<#Y/<'1I;VYS(&5X97)C:7-A8FQE(&%N9#QB<B`O/B!R97-T<FEC=&5D
M('-T;V-K('9E<W1E9#PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B`F
M;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O
M;&0G(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#Y%>&5R8VES93QB<B`O
M/B!P<FEC97,\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P
M=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X@)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M
M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X]
M,T0R(&YO=W)A<#TS1&YO=W)A<#Y.=6UB97(@;V8\8G(@+SX@3W!T:6]N<R!A
M;F0\8G(@+SX@<F5S=')I8W1E9"!S=&]C:SQB<B`O/B!O=71S=&%N9&EN9SQB
M<B`O/B!A="!E;F0@;V8\8G(@+SX@>65A<CPO=&0^(#QT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P
M/3-$;F]W<F%P/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A
M<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(
M5#H@8F]L9"<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/E=E:6=H=&5D
M/&)R("\^(&%V97)A9V4\8G(@+SX@<F5M86EN:6YG/&)R("\^(&-O;G1R86-T
M=6%L/&)R("\^(&QI9F4\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X@
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[
M($9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L
M:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O
M;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#Y.=6UB97(@;V8\8G(@+SX@;W!T
M:6]N<SQB<B`O/B!E>&5R8VES86)L92!A;F0\8G(@+SX@<F5S=')I8W1E9"!S
M=&]C:SQB<B`O/B!V97-T960@870@96YD(&]F/&)R("\^('EE87(\+W1D/B`\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z
M(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)R!N
M;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO
M=W)A<#Y796EG:'1E9#QB<B`O/B!A=F5R86=E/&)R("\^(')E;6%I;FEN9SQB
M<B`O/B!C;VYT<F%C='5A;#QB<B`O/B!L:69E/"]T9#X@/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R
M87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"="
M04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q."4G/FXO82`H
M4F5S=')I8W1E9"!3=&]C:RD\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q-R4G/C$L-#DV+#<Y,CPO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=724142#H@,24G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$
M5$@Z(#$W)2<^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B!N+V$\+W`^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#$W)2<^,3`R+#`X-#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=724142#H@,24G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$
M5$@Z(#$W)2<^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B!N+V$\+W`^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!724142#H@,24G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S
M='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!W:&ET93L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXD
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXP+C`P,3PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D
M/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M="<^-S$Y+#(P-SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H="<^,BXU-#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H="<^-S$Y+#(P-SPO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,BXU-#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\
M+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR
M-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SXD/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT)SXP+C$R,#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H="<^-#0W+#@U,#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,2XP-3PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\
M=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^
M-#0W+#@U,#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF
M;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H="<^,2XP-3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=2
M3U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H="<^,"XS.3D\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C(S+#`X-SPO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\
M=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^
M,2XY,CPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S
M<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H="<^,C,L,#@W/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT)SXQ+CDR/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS
M1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/B0\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C`N
M.3<R/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P
M.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT)SXY.38L,S4S/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT)SXS+C0T/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXY.38L,S4S/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXS+C0T
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M969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H="<^-#`L,#`P/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXU+C@R/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXT,"PP,#`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T
M9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G/C4N.#(\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],
M3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,BXV-3`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C0P,BPX.#(\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T
M9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G/C8N,34\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0G/C,Y-BPW-#0\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C8N,34\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T
M>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B0\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C,N,#(P/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^
M(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M)SXU,"PP,#`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0G/C4N,3`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0G/C4P+#`P,#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^-2XQ,#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\+W1R
M/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L
M,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SXD/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT)SXU+C`P,#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H="<^,2PW,#@L,#`P/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXU+C$P/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT
M9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXQ
M+#<P."PP,#`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0G/C4N,3`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'
M4D]53D0M0T],3U(Z('=H:71E.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B0\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C8N.#$P/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXQ-C`L,#`P/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^
M(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M)SXW+C$P/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N
M8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT)SXQ,3`L,#`P/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXW+C$P/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL
M93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/B0\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G
M/C8N.3`P/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N
M8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT)SXQ+#`P,RPP.#,\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C<N,34\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C$V."PP.#,\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@
M/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G
M/C<N,34\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB
M<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z
M('=H:71E.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/B0\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0G/C<N-34P/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXQ-C`L,#`P/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXW+C8V/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT
M9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXY
M,"PP,#`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB
M<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0G/C<N-C8\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]5
M3D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^.2XV-C`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C8X
M+#`P,#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S
M<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H="<^-RXX,SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H="<^,S0L,#`P/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D
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M6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+4)/5%1/33H@,7!T)SXQ-BXW,#`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"
M3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^(#,X-RPU-#(\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O
M;&ED.R!415A4+4%,24=..B!R:6=H="<^(#,N.3D\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4
M+4%,24=..B!R:6=H="<^(#,X-RPU-#(\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L
M:60[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=.
M.B!R:6=H="<^(#,N.3D\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/"]T<CX@
M/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P
M-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M
M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T
M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(')I9VAT)SX@-RPV-C(L-SDV/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!
M1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$
M24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)
M1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
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M=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T
M)SXF;F)S<#L\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=-05)'
M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T
M(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX@5&AE(&%G9W)E9V%T92!I;G1R:6YS:6,@=F%L=64@
M;V8@=&AE('1O=&%L(&]U='-T86YD:6YG(&%N9"!O9B!T;W1A;"!V97-T960@
M86YD(&5X97)C:7-A8FQE(&]P=&EO;G,@86YD(')E<W1R:6-T960@<W1O8VL@
M87,@;V8@1&5C96UB97(@,S$L(#(P,3(@:7,@87!P<F]X:6UA=&5L>2`D,3DN
M-R!M:6QL:6]N(&%N9"`D,3(N-"!M:6QL:6]N+"!R97-P96-T:79E;'DN/"]P
M/B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3(P+C$U<'0[($U!4D=)3CH@
M,'!T(#!P>"`P<'0@.3(N,35P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$
M)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE
M/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z
M(#<R<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=724142#H@,C`N,35P
M="<^92X\+W1D/B`\=&0^5&AE(&9O;&QO=VEN9R!T86)L92!I;&QU<W1R871E
M<R!T:&4@969F96-T(&]F('-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;B!O;B!T
M:&4@<W1A=&5M96YT(&]F(&]P97)A=&EO;G,Z/"]T9#X@/"]T<CX@/"]T86)L
M93X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B!B;VQD(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^
M(#QT86)L92!S='EL93TS1"=724142#H@-S`E.R!"3U)$15(M0T],3$%04T4Z
M(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!-05)'24XM3$5&5#H@,"XW-6EN)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97(G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&
M3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#$P/EEE87(@96YD
M960@1&5C96UB97(@,S$L/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\+W1R
M/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-464Q%.B!I=&%L
M:6,G/BA5+E,N(&1O;&QA<G,@:6X@=&AO=7-A;F1S*3PO=&0^(#QT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@
M8F]L9"<@8V]L<W!A;CTS1#(^,C`Q,#PO=&0^(#QT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)
M1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/
M3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,CXR,#$Q/"]T9#X@/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P
M=#L@1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R/C(P,3(\
M+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U7
M14E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"="
M04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%1%6%0M24Y$14Y4.B`M,3(N-G!T.R!0041$24Y'+4Q%1E0Z(#$R+C9P="<^
M($-O<W0@;V8@<F5V96YU97,\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@
M/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SXD/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXR,C`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T
M9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`M,3(N-G!T.R!0041$24Y'+4Q%
M1E0Z(#$R+C9P=#L@5TE$5$@Z(#8Q)2<^(%)E<V5A<F-H(&%N9"!D979E;&]P
M;65N="!E>'!E;G-E<SPO=&0^(#QT9"!S='EL93TS1"=724142#H@,24G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!72414
M2#H@,24G/B0\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M(%=)1%1(.B`Q,"4G/C8S,#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=7
M24142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!724142#H@,24G/B0\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/C0R,CPO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#$P)2<^-"PW
M-38\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z
M(#$E)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.
M1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@,7!T.R!415A4+4E.1$5.5#H@+3$R+C9P=#L@4$%$1$E.1RU,
M1494.B`Q,BXV<'0G/B!'96YE<F%L(&%N9"!A9&UI;FES=')A=&EV92!E>'!E
M;G-E<SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,7!T('-O;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$58
M5"U!3$E'3CH@<FEG:'0G/B`V-3(\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[
M(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R
M:6=H="<^(#0V-#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'
M3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX@,BPW
M-S4\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.
M1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$
M)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)SX@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P=#L@1D].
M5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`Q+#(X,CPO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/
M5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE
M9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`X.#8\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@
M)#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P
M="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@-RPW-3$\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N
M-7!T)SXF;F)S<#L\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!&3TY4
M+5=%24=(5#H@;F]R;6%L.R!-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@5$58
M5"U)3D1%3E0Z("TP+C5I;B<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$
M)TU!4D=)3BU43U`Z(#!P=#L@5TE$5$@Z(#$P,"4[($9/3E0Z(&)O;&0@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/
M33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/B`\='(@
M<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=7
M24142#H@,"XU:6XG/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%
M24=(5#H@;F]R;6%L.R!724142#H@,"XR.&EN)SYC+CPO=&0^(#QT9#Y0=6)L
M:6,@3V9F97)I;F=S/"]T9#X@/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@1D].
M5"U714E'2%0Z(&YO<FUA;#L@34%21TE..B`P<'0@,'!X(#!P="`W.'!T.R!4
M15A4+4E.1$5.5#H@+3(Q+C-P="<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE
M/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\
M='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS
M1"=724142#H@-38N-W!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U714E'2%0Z(&YO<FUA;#L@5TE$5$@Z(#(Q+C-P="<^,2X\+W1D/B`\=&0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;"<^3VX@36%R8V@@
M,C,L(#(P,3$L('1H92!#;VUP86YY(&ES<W5E9"!A;F0@<V]L9"`T+#`P,"PP
M,#`@<VAA<F5S(&]F($-O;6UO;B!3=&]C:R!I;B!A;B!U;F1E<G=R:71T96X@
M<'5B;&EC(&]F9F5R:6YG(&%T(&$@<')I8V4@=&\@=&AE('!U8FQI8R!O9B`D
M-2XU,"!P97(@<VAA<F4N(%1H92!N970@<')O8V5E9',@=&\@=&AE($-O;7!A
M;GD@=V5R92!A<'!R;WAI;6%T96QY("0R,"XV(&UI;&QI;VX@*&YE="!O9B!U
M;F1E<G=R:71I;F<@8V]M;6ES<VEO;G,@86YD(&ES<W5A;F-E(&-O<W1S(&]F
M("0Q+C0@;6EL;&EO;CPO9F]N=#XI/"]T9#X@/"]T<CX@/"]T86)L93X@/'`@
M<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@1D].5"U714E'2%0Z(&YO<FUA;#L@34%21TE..B`P<'0@,'!X(#!P
M="`W.'!T.R!415A4+4E.1$5.5#H@+3(Q+C-P="<^("9N8G-P.SPO<#X@/'1A
M8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!T
M)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P
M)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y
M;&4],T0G5TE$5$@Z(#4V+C=P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M5T5)1TA4.B!N;W)M86P[(%=)1%1(.B`R,2XS<'0G/C(N/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86PG/D]N($9E8G)U87)Y
M(#(R+"`R,#$R+"!T:&4@0V]M<&%N>2!I<W-U960@86YD('-O;&0@-2PQ-S4L
M,#`P('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@:6X@86X@=6YD97)W<FET=&5N
M('!U8FQI8R!O9F9E<FEN9R!A="!A('!R:6-E('1O('1H92!P=6)L:6,@;V8@
M)#4N,C4@<&5R('-H87)E+B!4:&4@;F5T('!R;V-E961S('1O('1H92!#;VUP
M86YY('=E<F4@87!P<F]X:6UA=&5L>2`D,C4N-"!M:6QL:6]N("AN970@;V8@
M=6YD97)W<FET:6YG(&-O;6UI<W-I;VYS(&%N9"!I<W-U86YC92!C;W-T<R!O
M9B`D,2XX(&UI;&QI;VXI+CPO=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE
M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\(2TM16YD1G)A
M9VUE;G0M+3X\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
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M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/E1!6$53($].($E.0T]-13QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY405A%4R!/3B!)3D-/344@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M05A%4R!/3B!)3D-/344\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q
M+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH
M=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/CQD:78^(#QD
M:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@/'-T<F]N9SY.3U1%(#@@+2!405A%
M4R!/3B!)3D-/344\+W-T<F]N9SX\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($9/3E0M5T5)1TA4
M.B!N;W)M86P[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!415A4+4E.
M1$5.5#H@+3`N,C5I;B<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)TU!
M4D=)3BU43U`Z(#!P=#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(@<W1Y
M;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=72414
M2#H@,"XU:6XG/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(
M5#H@;F]R;6%L.R!724142#H@,"XR-6EN)SYA+CPO=&0^(#QT9#Y4:&4@0V]M
M<&%N>3PO=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)TU!4D=)3CH@
M,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'
M24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^(%!R;W1A;&EX($)I;U1H97)A<&5U=&EC
M<RP@26YC+B!I<R!T87AE9"!A8V-O<F1I;F<@=&\@52Y3+B!T87@@;&%W<RX@
M5&AE($-O;7!A;GDF(S,Y.W,@:6YC;VUE(&ES+"!O<B!W:6QL(&)E+"!T87AE
M9"!I;B!T:&4@56YI=&5D(%-T871E<R!A="!T:&4@<F%T92!O9B!U<"!T;R`S
M.24N/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!&3TY4+5=%24=(5#H@;F]R;6%L.R!-05)'24XZ
M(#!P="`P<'@@,'!T(#%I;CL@5$585"U)3D1%3E0Z("TP+C5I;B<^("9N8G-P
M.SPO<#X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@5TE$5$@Z
M(#$P,"4[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ
M('1O<"<^(#QT9"!S='EL93TS1"=724142#H@,"XU:6XG/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L.R!724142#H@,"XR
M-6EN)SYB+CPO=&0^(#QT9#Y0<F]T86QI>"!,=&0N/"]T9#X@/"]T<CX@/"]T
M86)L93X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F
M;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW
M-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX@5&AE($ES<F%E;&D@4W5B<VED:6%R>2!I<R!T87AE9"!A8V-O<F1I;F<@
M=&\@27-R865L:2!T87@@;&%W<SH\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($9/3E0M5T5)1TA4
M.B!N;W)M86P[($U!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!415A4+4E.1$5.
M5#H@+3`N,C5I;B<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)TU!4D=)
M3BU43U`Z(#!P=#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(@<W1Y;&4]
M,T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=724142#H@
M,"XW-6EN)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z
M(&YO<FUA;#L@5TE$5$@Z(#`N,C5I;B<^,2X\+W1D/B`\=&0^365A<W5R96UE
M;G0@;V8@<F5S=6QT<R!F;W(@=&%X('!U<G!O<V5S/"]T9#X@/"]T<CX@/"]T
M86)L93X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q:6X[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S
M<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@4VEN
M8V4@,C`P."P@=&AE($-O;7!A;GD@:&%S(&UE87-U<F5D('1H92!R97-U;'1S
M(&]F('1H92!)<W)A96QI(%-U8G-I9&EA<GD@9F]R('1A>"!P=7)P;W-E<R!I
M;B!N;VUI;F%L('1E<FUS(&EN($Y)4RX@4'5R<W5A;G0@=&\@=&AE($ES<F%E
M;"!);F-O;64@5&%X($QA=R`H061J=7-T;65N=',@9F]R($EN9FQA=&EO;BDL
M(#$Y.#4@*'1H92`B061J=7-T;65N=',@3&%W(BDL('1H92!3=6)S:61I87)Y
M)B,S.3MS(')E<W5L=',@9F]R('1A>"!P=7)P;W-E<R!H879E(&)E96X@;65A
M<W5R960@=&AR;W5G:"`R,#`W(&]N(&$@<F5A;"!B87-I<RP@8F%S960@;VX@
M8VAA;F=E<R!I;B!T:&4@27-R865L(&-O;G-U;65R('!R:6-E(&EN9&5X+CPO
M<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@1D].5"U714E'2%0Z(&YO<FUA;#L@34%21TE..B`P<'0@
M,'!X(#!P="`Q:6X[(%1%6%0M24Y$14Y4.B`M,"XR-6EN)SX@)FYB<W`[/"]P
M/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!&3TY4.B!B;VQD
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"
M3U143TTZ(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W
M:61T:#TS1#$P,"4^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P
M)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`P+C<U:6XG/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L.R!724142#H@,"XR-6EN
M)SXR+CPO=&0^(#QT9#Y487@@<F%T97,\+W1D/B`\+W1R/B`\+W1A8FQE/B`\
M<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@
M/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!4:&4@:6YC;VUE
M(&]F('1H92!)<W)A96QI(%-U8G-I9&EA<GDL(&]T:&5R('1H86X@:6YC;VUE
M(&9R;VT@(D%P<')O=F5D($5N=&5R<')I<V5S+"(@:7,@=&%X960@:6X@27-R
M865L(&%T('1H92!R96=U;&%R(')A=&4N(%-E92`S(&)E;&]W+B!!8V-O<F1I
M;F<@=&\@=&AE('!R;W9I<VEO;G,@;V8@=&AE($QA=R!F;W(@06UE;F1I;F<@
M=&AE($ES<F%E;"!);F-O;64@5&%X($]R9&EN86YC92P@,C`P-2P@8V]R<&]R
M871E('1A>"!R871E<R!W:6QL(&)E(&=R861U86QL>2!L;W=E<F5D+"!R97-U
M;'1I;F<@:6X@82!C;W)P;W)A=&4@=&%X(')A=&4@9F]R(#(P,#D@86YD('1H
M97)E869T97(Z(#(P,#D@+2`R-B4@86YD(&9O<B`R,#$P(&%N9"!T:&5R96%F
M=&5R("T@,C4E+CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P
M="`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P
M<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX@3VX@2G5L>2`Q-"P@,C`P.2P@=&AE($ES<F%E;"!%8V]N;VUI8R!%
M9F9I8VEE;F-Y($QA=R`H3&5G:7-L871I;VX@06UE;F1M96YT<R!F;W(@07!P
M;'EI;F<@=&AE($5C;VYO;6EC(%!L86X@9F]R(#(P,#D@86YD(#(P,3`I+"`R
M,#`Y+"!B96-A;64@969F96-T:79E+"!S=&EP=6QA=&EN9RP@86UO;F<@;W1H
M97(@=&AI;F=S+"!A;B!A9&1I=&EO;F%L(&=R861U86P@9&5C<F5A<V4@:6X@
M=&%X(')A=&5S(&EN(#(P,3$@86YD('1H97)E869T97(L(&%S(&9O;&QO=W,Z
M(#(P,3$@+2`R-"4L(#(P,3(@+2`R,R4L(#(P,3,@+2`R,B4L(#(P,30@+2`R
M,24L(#(P,34@+2`R,"4@86YD(#(P,38@86YD('1H97)E869T97(@+2`Q."4N
M/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P
M.SPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q:6X[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!/;B!$
M96-E;6)E<B`U+"`R,#$Q+"!T:&4@(E1A>"!"=7)D96X@1&ES=')I8G5T:6]N
M($QA=R(@*&AE<F5I;F%F=&5R("T@=&AE(#(P,3$@86UE;F1M96YT*2!W87,@
M;V9F:6-I86QL>2!P=6)L:7-H960L(&1I<V-O;G1I;G5I;F<@82!P<F5V:6]U
M<VQY(&%P<')O=F5D(&=R861U86P@9&5C<F5A<V4@:6X@8V]R<&]R871E('1A
M>"!P<F]V:61E9"!I;B!T:&4@,C`P.2!A;65N9&UE;G0L(&%N9"!S971T:6YG
M('1H92!C;W)P;W)A=&4@=&%X(')A=&4@:6X@27-R865L(&9O<B`R,#$R(&%N
M9"!T:&5R96%F=&5R('1O(#(U)2X\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@
M,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ
M(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^($-A<&ET86P@9V%I;B!I<R!S=6)J96-T('1O(&-A
M<&ET86P@9V%I;B!T87@@86-C;W)D:6YG('1O(&-O<G!O<F%T92!T87@@<F%T
M92!I;B!T:&4@>65A<B!O9B!S96QL:6YG('1H92!A<W-E=',N/"]P/B`\<"!S
M='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!&3TY4+5=%24=(5#H@;F]R;6%L.R!-05)'24XZ(#!P="`P<'@@,'!T
M(#%I;CL@5$585"U)3D1%3E0Z("TP+C(U:6XG/B`F;F)S<#L\+W`^(#QT86)L
M92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z(&)O;&0@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@
M,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$
M,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@
M<W1Y;&4],T0G5TE$5$@Z(#`N-S5I;B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M5T5)1TA4.B!N;W)M86P[(%=)1%1(.B`P+C(U:6XG/C,N/"]T
M9#X@/'1D/E1H92!,87<@9F]R('1H92!%;F-O=7)A9V5M96YT(&]F($-A<&ET
M86P@26YV97-T;65N=',L(#$Y-3D@*'1H92`B16YC;W5R86=E;65N="!O9B!#
M87!I=&%L($EN=F5S=&UE;G1S($QA=R(I/"]T9#X@/"]T<CX@/"]T86)L93X@
M/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^
M(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@56YD97(@=&AE
M($5N8V]U<F%G96UE;G0@;V8@0V%P:71A;"!);G9E<W1M96YT<R!,87<L(&EN
M8VQU9&EN9R!!;65N9&UE;G0@3F\N(#8P('1O('1H92!%;F-O=7)A9V5M96YT
M(&]F($-A<&ET86P@26YV97-T;65N=',@3&%W(&%S('!U8FQI<VAE9"!I;B!!
M<')I;"`R,#`U+"!B>2!V:7)T=64@;V8@=&AE(")!<'!R;W9E9"!%;G1E<G!R
M:7-E(B!O<B`B0F5N969I=&5D($5N=&5R<')I<V4B('-T871U<R!T:&4@27-R
M865L:2!3=6)S:61I87)Y(&ES(&5N=&ET;&5D('1O('9A<FEO=7,@=&%X(&)E
M;F5F:71S(&%S(&9O;&QO=W,Z/"]P/B`\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3,W+C%P=#L@34%21TE..B`P<'0@,'!X(#!P="`Q+C5I;CL@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO
M<#X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/
M33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H
M/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\
M=&0@<W1Y;&4],T0G5TE$5$@Z(#<P+CEP="<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U=)1%1(.B`S-RXQ<'0G/F$N/"]T9#X@/'1D/CQS=')O;F<^4F5D
M=6-E9"!T87@@<F%T97,\+W-T<F]N9SX\+W1D/B`\+W1R/B`\+W1A8FQE/B`\
M<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#$N,C5I;CL@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO
M<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q+C(U:6X[($9/
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M;W0@96QA<'-E9"X\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P
M<'0@,2XR-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P
M<'@@,'!T(#$N,C5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^(%1H92!)<W)A96QI(%-U8G-I9&EA<GD@:&%S(&%N(")!
M<'!R;W9E9"!%;G1E<G!R:7-E(B!P;&%N('-I;F-E(#(P,#0@86YD(")"96YE
M9FET960@16YT97)P<FES92(@<&QA;B!S:6YC92`R,#`Y+B!4:&4@<&5R:6]D
M(&]F(&)E;F5F:71S(&EN(')E<W!E8W0@;V8@=&AE(&UA:6X@96YT97)P<FES
M92!O9B!T:&4@0V]M<&%N>2!H87,@;F]T('EE="!C;VUM96YC960N(%1H92!P
M97)I;V0@9'5R:6YG('=H:6-H('1H92!#;VUP86YY(&ES(&5N=&ET;&5D('1O
M(&)E;F5F:71S(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@0F5N969I=&5D($5N
M=&5R<')I<V4@97AP:7)E<R!I;B`R,#(Q+CPO<#X@/'`@<W1Y;&4],T0G34%2
M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P
M="`P<'@@,'!T(#$N,C5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
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M+CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q+C(U:6X[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F
M;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,2XR
M-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
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M<G)E;G1L>2`Q-24N/"]P/B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3`N
M,C5I;CL@34%21TE..B`P<'0@,'!X(#!P="`Q+C(U:6X[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QT
M86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P
M="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P
M,"4^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T
M>6QE/3-$)U=)1%1(.B`Q:6XG/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=7
M24142#H@,"XR-6EN)SYB+CPO=&0^(#QT9#X\<W1R;VYG/D%C8V5L97)A=&5D
M(&1E<')E8VEA=&EO;CPO<W1R;VYG/CPO=&0^(#PO='(^(#PO=&%B;&4^(#QP
M('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,2XR-6EN.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P
M/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#$N,C5I;CL@1D].
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M(&%N9"!T:&4@0F5N969I=&5D($5N=&5R<')I<V4N/"]P/B`\<"!S='EL93TS
M1"=415A4+4E.1$5.5#H@+3`N,C5I;CL@34%21TE..B`P<'0@,'!X(#!P="`Q
M+C(U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P
M<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL93TS1"=615)424-!3"U!
M3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`Q:6XG/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=724142#H@,"XR-6EN)SYC+CPO=&0^(#QT9#X\
M<W1R;VYG/D-O;F1I=&EO;G,@9F]R(&5N=&ET;&5M96YT('1O('1H92!B96YE
M9FET<SPO<W1R;VYG/CPO=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$
M)TU!4D=)3CH@,'!T(#!P>"`P<'0@,2XR-6EN.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL
M93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#$N,C5I;CL@1D].5#H@,3!P="!4
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M86P@=VET:"!R97-P96-T('1O(&ET<R`B07!P<F]V960@16YT97)P<FES92(@
M9G)O;2!T:&4@26YV97-T;65N="!#96YT97(N/"]P/B`\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@+3`N,C5I;CL@34%21TE..B`P<'0@,'!X(#!P="`Q+C(U
M:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!
M4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
M/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'
M3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`Q:6XG/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=724142#H@,"XR-6EN)SYD+CPO=&0^(#QT9#X\<W1R
M;VYG/D%M96YD;65N="!O9B!T:&4@3&%W(&9O<B!T:&4@16YC;W5R86=E;65N
M="!O9B!#87!I=&%L($EN=F5S=&UE;G1S+"`Q.34Y/"]S=')O;F<^/"]T9#X@
M/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P
M="`Q+C(U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P
M>"`P<'0@,2XR-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX@5&AE($5N8V]U<F%G96UE;G0@;V8@0V%P:71A;"!);G9E
M<W1M96YT<R!,87<@=V%S(&%M96YD960@87,@<&%R="!O9B!T:&4@16-O;F]M
M:6,@4&]L:6-Y($QA=R!F;W(@=&AE('EE87)S(#(P,3$M,C`Q,BP@=VAI8V@@
M=V%S('!A<W-E9"!B>2!T:&4@27-R865L:2!+;F5S<V5T(&]N($1E8V5M8F5R
M(#(Y+"`R,#$P("AT:&4@(D-A<&ET86P@26YV97-T;65N=',@3&%W($%M96YD
M;65N="(I+CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q
M+C(U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P
M<'0@,2XR-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX@5&AE($-A<&ET86P@26YV97-T;65N=',@3&%W($%M96YD;65N
M="!S971S(&%L=&5R;F%T:79E(&)E;F5F:70@=')A8VMS('1O('1H;W-E(&-U
M<G)E;G1L>2!I;B!E9F9E8W0@=6YD97(@=&AE('!R;W9I<VEO;G,@;V8@=&AE
M($5N8V]U<F%G96UE;G0@;V8@0V%P:71A;"!);G9E<W1M96YT<R!,87<N/"]P
M/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#$N,C5I;CL@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P
M.SPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q+C(U:6X[
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M;R!I=',@86UE;F1M96YT+CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@
M,'!X(#!P="`Q+C(U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@
M,'!T(#!P>"`P<'0@,2XR-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
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M(&QA=&5R('1H86X@=&%X('EE87(@,C`Q,BP@<')O=FED960@=&AA="!T:&4@
M;6EN:6UU;2!Q=6%L:69Y:6YG(&EN=F5S=&UE;G0@=V%S(&UA9&4@;F]T(&QA
M=&5R('1H86X@=&AE(&5N9"!O9B`R,#$P+B!/;B!E86-H('EE87(@9'5R:6YG
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M=&UE;G1S($%M96YD;65N="!A<'!L>2!T;R!T:&4@0V]M<&%N>2X\+W`^(#QP
M('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4]
M,T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M1D].5"U714E'2%0Z(&YO<FUA;#L@34%21TE..B`P<'0@,'!X(#!P="`Q:6X[
M(%1%6%0M24Y$14Y4.B`M,"XR-6EN)SX@)FYB<W`[/"]P/B`\=&%B;&4@<W1Y
M;&4],T0G34%21TE.+51/4#H@,'!T.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^
M(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE
M/3-$)U=)1%1(.B`P+C<U:6XG/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5=%24=(5#H@;F]R;6%L.R!724142#H@,"XR-6EN)SXT+CPO=&0^(#QT
M9#Y4:&4@3&%W(&9O<B!T:&4@16YC;W5R86=E;65N="!O9B!);F1U<W1R>2`H
M5&%X871I;VXI+"`Q.38Y.CPO=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE
M/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL
M93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^(%1H92!)<W)A96QI(%-U8G-I
M9&EA<GD@:7,@86X@(FEN9'5S=')I86P@8V]M<&%N>2PB(&%S(&1E9FEN960@
M=6YD97(@=&AE($QA=R!F;W(@=&AE($5N8V]U<F%G96UE;G0@;V8@26YD=7-T
M<GD@*%1A>&%T:6]N*2P@,3DV.2`H=&AE("),87<@9F]R('1H92!%;F-O=7)A
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M;F1U<W1R>2P@86YD(&AA<R!D;VYE('-O+CPO<#X@/'`@<W1Y;&4],T0G34%2
M1TE..B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!
M4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX@56YD97(@=&AE('!R;W9I<VEO;G,@;V8@
M=&AE($EN8V]M92!487@@4F5G=6QA=&EO;G,@(D%C8V5L97)A=&5D($1E<')E
M8VEA=&EO;B!I;B!R97-P96-T(&]F($5Q=6EP;65N="!A8W%U:7)E9"!D=7)I
M;F<@=&AE($1E9FEN960@4&5R:6]D(B`H5&5M<&]R87)Y($]R9&5R<RDL(&EN
M9'5S=')I86P@8V]M<&%N:65S('=H;W-E(&]P97)A=&EO;G,@87)E(&UO<W1L
M>2`B96QI9VEB;&4@;W!E<F%T:6]N<R(@87)E(&5N=&ET;&5D('1O(&-L86EM
M(&%C8V5L97)A=&5D(&1E<')E8VEA=&EO;B!A="!A(')A=&4@;V8@-3`E(&]N
M(&UA8VAI;F5R>2!A;F0@97%U:7!M96YT(&%C<75I<F5D(&9R;VT@2G5N92`Q
M+"`R,#`X('1O($UA>2`S,2P@,C`P.2X\+W`^(#QP('-T>6QE/3-$)T9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($9/3E0M5T5)
M1TA4.B!N;W)M86P[($U!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!415A4+4E.
M1$5.5#H@+3`N-6EN)SX@)FYB<W`[/"]P/B`\=&%B;&4@<W1Y;&4],T0G34%2
M1TE.+51/4#H@,'!T.R!724142#H@,3`P)3L@1D].5#H@8F]L9"`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P
M<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT<B!S='EL
M93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(
M.B`P+C5I;B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4
M.B!N;W)M86P[(%=)1%1(.B`P+C(U:6XG/F,N/"]T9#X@/'1D/E1A>"!L;W-S
M97,@8V%R<FEE9"!F;W)W87)D('1O(&9U='5R92!Y96%R<SPO=&0^(#PO='(^
M(#PO=&%B;&4^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW
M-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T
M(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^($%S(&]F($1E8V5M8F5R(#,Q+"`R,#$R+"!T:&4@0V]M<&%N>2!H
M860@86=G<F5G871E(&YE="!O<&5R871I;F<@;&]S<R`H3D],*2!C87)R>2UF
M;W)W87)D<R!E<75A;"!T;R!A<'!R;WAI;6%T96QY("0W,BXU(&UI;&QI;VX@
M=&AA="!A<F4@879A:6QA8FQE('1O(')E9'5C92!F=71U<F4@=&%X86)L92!I
M;F-O;64@87,@9F]L;&]W<SH\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($9/3E0M5T5)1TA4.B!N
M;W)M86P[($U!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!415A4+4E.1$5.5#H@
M+3`N,C5I;B<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU4
M3U`Z(#!P=#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(@<W1Y;&4],T0G
M5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=724142#H@,"XW
M-6EN)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO
M<FUA;#L@5TE$5$@Z(#`N,C5I;B<^,2X\+W1D/B`\=&0^5&AE($-O;7!A;GD\
M+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P
M<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@
M,'!X(#!P="`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B!4:&4@3D],(&-A<G)Y+69O<G=A<F0@;V8@=&AE($-O;7!A
M;GD@97%U86P@=&\@87!P<F]X:6UA=&5L>2`D,3,N."!M:6QL:6]N(&UA>2!B
M92!R97-T<FEC=&5D('5N9&5R(%-E8W1I;VX@,S@R(&]F('1H92!);G1E<FYA
M;"!2979E;G5E($-O9&4@*"))4D,B*2X@25)#(%-E8W1I;VX@,S@R(&%P<&QI
M97,@=VAE;F5V97(@82!C;W)P;W)A=&EO;B!W:71H($Y/3"!E>'!E<FEE;F-E
M<R!A;B!O=VYE<G-H:7`@8VAA;F=E+B!!<R!A(')E<W5L="!O9B!)4D,@4V5C
M=&EO;B`S.#(L('1H92!T87AA8FQE(&EN8V]M92!F;W(@86YY('!O<W0@8VAA
M;F=E('EE87(@=&AA="!M87D@8F4@;V9F<V5T(&)Y(&$@<')E+6-H86YG92!.
M3TP@;6%Y(&YO="!E>&-E960@=&AE(&=E;F5R86P@25)#(%-E8W1I;VX@,S@R
M(&QI;6ET871I;VXL('=H:6-H(&ES('1H92!F86ER(&UA<FME="!V86QU92!O
M9B!T:&4@<')E+6-H86YG92!E;G1I='D@;75L=&EP;&EE9"!B>2!T:&4@25)#
M(&QO;F<M=&5R;2!T87@@97AE;7!T(')A=&4N/"]P/B`\<"!S='EL93TS1"=&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!&3TY4
M+5=%24=(5#H@;F]R;6%L.R!-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@5$58
M5"U)3D1%3E0Z("TP+C(U:6XG/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS
M1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R
M('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G
M5TE$5$@Z(#`N-S5I;B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M5T5)1TA4.B!N;W)M86P[(%=)1%1(.B`P+C(U:6XG/C(N/"]T9#X@/'1D/E!R
M;W1A;&EX($QT9"X\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=-
M05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G
M34%21TE..B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!!="!$96-E;6)E<B`S,2P@,C`Q,BP@
M=&AE($ES<F%E;&D@4W5B<VED:6%R>2!H860@87!P<F]X:6UA=&5L>2`D-3@N
M-R!M:6QL:6]N(&]F($Y/3"!C87)R>2UF;W)W87)D<R!T:&%T(&%R92!A=F%I
M;&%B;&4@=&\@<F5D=6-E(&9U='5R92!T87AA8FQE(&EN8V]M92!W:71H(&YO
M(&QI;6ET960@<&5R:6]D(&]F('5S92X\+W`^(#QP('-T>6QE/3-$)T9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($9/3E0M5T5)
M1TA4.B!N;W)M86P[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!415A4
M+4E.1$5.5#H@+3`N,C5I;B<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$
M)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(@
M<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=7
M24142#H@,"XU:6XG/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%
M24=(5#H@;F]R;6%L.R!724142#H@,"XR-6EN)SYD+CPO=&0^(#QT9#Y$969E
M<G)E9"!I;F-O;64@=&%X97,Z/"]T9#X@/"]T<CX@/"]T86)L93X@/'`@<W1Y
M;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QP
M('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@5&AE(&-O;7!O
M;F5N=',@;V8@=&AE($-O;7!A;GDF(S,Y.W,@;F5T(&1E9F5R<F5D('1A>"!A
M<W-E=',@870@1&5C96UB97(@,S$L(#(P,3$@86YD(#(P,3(@=V5R92!A<R!F
M;VQL;W=S.CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P
M+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"=724142#H@-S`E.R!"
M3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM3$5&5#H@,6EN)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/B`\='(@<W1Y;&4],T0G5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z
M(&)O;&0G(&-O;'-P86X],T0V/D1E8V5M8F5R(#,Q+#PO=&0^(#QT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^
M)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@
M1D].5"U35%E,13H@:71A;&EC)SXH52Y3+B!D;VQL87)S(&EN('1H;W5S86YD
M<RD\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].
M5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R/C(P,3$\+W1D/B`\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z
M(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(^
M,C`Q,CPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&
M3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE
M/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VTG/B`\=&0^26X@<F5S<&5C="!O9CH\+W1D/B`\
M=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N
M8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'
M4D]53D0M0T],3U(Z('=H:71E.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M3$5&5#H@
M.7!T.R!724142#H@-S0E)SX@4F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&5X
M<&5N<V5S/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)3L@0T],3U(Z(&)L
M86-K)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@5TE$5$@Z(#$E.R!#3TQ/4CH@8FQA8VLG/B0\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4[($-/3$]2.B!B;&%C
M:R<^-"PQ,3D\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M5TE$5$@Z(#$E.R!#3TQ/4CH@8FQA8VLG/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=724142#H@,24[($-/3$]2.B!B;&%C:R<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@0T],3U(Z
M(&)L86-K)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[(%=)1%1(.B`Q,"4[($-/3$]2.B!B;&%C:R<^-BPP,#,\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E.R!#3TQ/
M4CH@8FQA8VLG/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+
M1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!
M1$1)3D<M3$5&5#H@.7!T)SY0<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X@
M/'1D('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($-/3$]2.B!B;&%C:R<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!#3TQ/4CH@
M8FQA8VLG/B@Q-#D\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@0T],3U(Z(&)L86-K)SXI/"]T9#X@/'1D('-T>6QE/3-$)T-/3$]2.B!B
M;&%C:R<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($-/3$]2.B!B;&%C:R<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!#3TQ/4CH@8FQA8VLG/B@V-#<\+W1D/B`\=&0@
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M<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($-/3$]2
M.B!B;&%C:R<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
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M86-K)SXS-C,\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M0T],3U(Z(&)L86-K)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G
M0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!0041$24Y'+4Q%1E0Z(#EP="<^4V5V97)A;F-E('!A>2!O8FQI9V%T:6]N
M/"]T9#X@/'1D('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($-/3$]2.B!B;&%C:R<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!#
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M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0T],3U(Z(&)L
M86-K)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.
M1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`Y<'0G
M/D1E9F5R<F5D(')E=F5N=65S/"]T9#X@/'1D('-T>6QE/3-$)T-/3$]2.B!B
M;&%C:R<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($-/3$]2.B!B;&%C:R<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!#3TQ/4CH@8FQA8VLG/C0L-S0V/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($-/3$]2.B!B;&%C:R<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($-/3$]2.B!B;&%C
M:R<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!#3TQ/4CH@8FQA8VLG/C$P+#0T.3PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!#3TQ/4CH@8FQA8VLG/B9N8G-P.SPO=&0^(#PO='(^
M(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR
M,#0I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M3$5&5#H@.7!T)SY.970@;W!E<F%T
M:6YG(&QO<W,@8V%R<GD@9F]R=V%R9',\+W1D/B`\=&0@<W1Y;&4],T0G0T],
M3U(Z(&)L86-K)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@0T],3U(Z(&)L86-K)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($-/3$]2.B!B;&%C:R<^-"PU-SD\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0T],3U(Z(&)L86-K
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0T],3U(Z(&)L86-K)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0T],3U(Z
M(&)L86-K)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($-/3$]2.B!B;&%C:R<^,34L,3<V/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($-/3$]2.B!B;&%C:R<^)FYB<W`[/"]T9#X@
M/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/E9A;'5A=&EO;B!A;&QO
M=V%N8V4\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%
M6%0M04Q)1TXZ(')I9VAT)SX@*#$S+#<V-#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T)SXI/"]T9#X@
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[
M(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R
M:6=H="<^("@S,2PU,S8\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^*3PO=&0^(#PO='(^(#QT<B!S
M='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@
M;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@+3PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/
M5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE
M9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^("T\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U14
M3TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL
M93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@
M<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!$969E<G)E9"!T
M87AE<R!A<F4@8V]M<'5T960@=7-I;F<@=&AE('1A>"!R871E<R!E>'!E8W1E
M9"!T;R!B92!I;B!E9F9E8W0@=VAE;B!T:&]S92!D:69F97)E;F-E<R!R979E
M<G-E+B!4:&4@0V]M<&%N>2!U<V5D('1A>"!R871E<R!O9B`S.24L(#(U)2!A
M;F0@,"4N/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\
M+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[($9/3E0M5T5)1TA4.B!N;W)M86P[($U!4D=)3CH@,'!T
M(#!P>"`P<'0@,6EN.R!415A4+4E.1$5.5#H@+3`N-6EN)SX@)FYB<W`[/"]P
M/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!724142#H@,3`P
M)3L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P
M)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`P+C5I;B<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86P[(%=)1%1(.B`P+C(U:6XG
M/F4N/"]T9#X@/'1D/E)E8V]N8VEL:6%T:6]N(&]F('1H92!T:&5O<F5T:6-A
M;"!T87@@97AP96YS92!T;R!A8W1U86P@=&%X(&5X<&5N<V4\+W1D/B`\+W1R
M/B`\+W1A8FQE/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N
M-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P
M="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
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M;G1Y(&]F('1H92!R96%L:7IA=&EO;B!O9B!S=6-H('1A>"!B96YE9FET<R`H
M<V5E(&%B;W9E*2X\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($9/3E0M5T5)1TA4.B!N;W)M86P[
M($U!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!415A4+4E.1$5.5#H@+3`N-6EN
M)SX@)FYB<W`[/"]P/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T
M.R!724142#H@,3`P)3L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT<B!S='EL93TS1"=615)424-!
M3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`P+C5I;B<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86P[(%=)
M1%1(.B`P+C(U:6XG/F8N/"]T9#X@/'1D/E1A>"!A<W-E<W-M96YT<SPO=&0^
M(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P
M<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P
M<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^($EN(&%C8V]R9&%N8V4@=VET:"!T:&4@26YC;VUE(%1A
M>"!/<F1I;F%N8V4L(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$R+"!A;&P@;V8@
M4')O=&%L:7@@3'1D+B8C,SD[<R!T87@@87-S97-S;65N=',@=&AR;W5G:"!T
M87@@>65A<B`R,#`X(&%R92!C;VYS:61E<F5D(&9I;F%L+CPO<#X@/'`@<W1Y
M;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QP
M('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@02!S=6UM87)Y
M(&]F(&]P96X@=&%X('EE87)S(&)Y(&UA:F]R(&IU<FES9&EC=&EO;B!I<R!P
M<F5S96YT960@8F5L;W<Z/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P
M<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)U=)1%1(
M.B`U,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`@86QI9VX],T1C96YT97(^(#QT<B!S='EL93TS
M1"="04-+1U)/54Y$+4-/3$]2.B!W:&ET93L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@
M<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`U,"4[($9/3E0M5T5)
M1TA4.B!B;VQD.R!415A4+41%0T]2051)3TXZ(&YO;F4G/B!*=7)I<V1I8W1I
M;VXZ/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[(%=)
M1%1(.B`Q)3L@1D].5"U714E'2%0Z(&)O;&0G/B`F;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P
M=#L@5TE$5$@Z(#$E.R!&3TY4+5=%24=(5#H@8F]L9"<^("9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%1%6%0M04Q)
M1TXZ(')I9VAT.R!724142#H@-#<E)SX@/'-T<F]N9SY996%R<SH\+W-T<F]N
M9SX\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.
M1RU"3U143TTZ(#%P=#L@5TE$5$@Z(#$E.R!&3TY4+5=%24=(5#H@8F]L9"<^
M("9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/
M3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/DES<F%E;#PO=&0^
M(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M5$585"U!3$E'3CH@<FEG:'0G/C(P,#DM,C`Q,CPO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y
M;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^56YI
M=&5D(%-T871E<R`H*BD\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXR,#`Y+3(P
M,3(\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[
M/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G
M8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^3F5T:&5R;&%N9',\+W1D/B`\
M=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%
M6%0M04Q)1TXZ(')I9VAT)SXR,#`Y+3(P,3(\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/"]T<CX@/"]T86)L93X@
M/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\
M+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@*"HI
M($EN8VQU9&5S(&9E9&5R86PL('-T871E(&%N9"!L;V-A;"`H;W(@<VEM:6QA
M<B!P<F]V:6YC:6%L(&IU<FES9&EC=&EO;G,I('1A>"!P;W-I=&EO;G,N/"]P
M/B`\(2TM16YD1G)A9VUE;G0M+3X\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/E-54%!,14U%3E1!4ED@1DE.04Y#24%,(%-4051%345.
M5"!)3D9/4DU!5$E/3CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY355!03$5-14Y405)9($9)3D%.0TE!3"!35$%4
M14U%3E0@24Y&3U)-051)3TX@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y355!03$5-14Y405)9($9)3D%.
M0TE!3"!35$%414U%3E0@24Y&3U)-051)3TX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O
M+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N
M=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B
M("TM/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@/'-T<F]N9SY.
M3U1%(#D@+2!355!03$5-14Y405)9($9)3D%.0TE!3"!35$%414U%3E0@24Y&
M3U)-051)3TX\+W-T<F]N9SX\+W`^(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,3<N,W!T.R!-05)'24XZ(#!P="`P<'@@,'!T(#<Q+C-P=#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^(#QS=')O;F<^
M0F%L86YC92!S:&5E=',Z/"]S=')O;F<^/"]P/B`\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@+3$W+C-P=#L@34%21TE..B`P<'0@,'!X(#!P="`W,2XS<'0[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B9N
M8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)U=)1%1(.B`W,"4[($)/4D1%4BU#
M3TQ,05!313H@8V]L;&%P<V4[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[($U!4D=)3BU,1494.B`P+C5I;B<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,#X@/'1R('-T>6QE/3-$)U9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O
M;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#8^1&5C
M96UB97(@,S$L/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q
M<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@
M<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-464Q%.B!I=&%L:6,G/BA5
M+E,N(&1O;&QA<G,@:6X@=&AO=7-A;F1S*3PO=&0^(#QT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S
M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@
M8V]L<W!A;CTS1#(^,C`Q,3PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B
M;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M5T5)
M1TA4.B!B;VQD)R!C;VQS<&%N/3-$,CXR,#$R/"]T9#X@/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S
M<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@
M<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!415A4+4E.1$5.5#H@+3(V
M+C0U<'0[(%!!1$1)3D<M3$5&5#H@,C8N-#5P=#L@1D].5"U714E'2%0Z(&)O
M;&0G/B!A+B!/=&AE<B!A<W-E=',Z/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO
M=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!W:&ET
M93L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!0041$24Y'+4Q%1E0Z(#0U<'0[(%=)1%1(.B`W-"4G
M/B!$969E<G)E9"!C;W-T<RH\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!724142#H@,3`E)SXQ+#4U.#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!724142#H@,24G/B0\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/C@Y/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)FYB<W`[/"]T
M9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R
M,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU,1494.B`T-7!T)SY);G-T:71U=&EO;G,\+W1D/B`\
M=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^
M,S<U/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P
M.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT)SXU-#(\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M
M0T],3U(Z('=H:71E.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M3$5&5#H@-#5P="<^
M4W1A=&4@;V8@27-R865L("AS964@3F]T92`V82D\+W1D/B`\=&0^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,2PR.38\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@
M/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G
M/C(L-#`P/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N
M8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2
M.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M3$5&5#H@
M-#5P="<^4F5S=')I8W1E9"!D97!O<VET/"]T9#X@/'1D/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C(P.#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P
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M97,\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H="<^,C,U/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT)SXR-3$\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!
M0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M4$%$1$E.1RU,1494.B`T-7!T)SY3=6YD<GD\+W1D/B`\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@
M;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX@,38U/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]4
M5$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P
M="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/B`Q,#8\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^
M)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],
M3U(Z('=H:71E.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@
M5$585"U!3$E'3CH@;&5F="<^("0\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H
M="<^(#,L.#,W/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$58
M5"U!3$E'3CH@;&5F="<^("0\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^
M(#,L-C@V/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!
M1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/"]T<CX@/"]T86)L
M93X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S
M='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N-6EN.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@*B!-86YU9F%C='5R
M:6YG(&-O<W1S(&]F(&EN=F5N=&]R>2P@<&%I9"!B>2!09FEZ97(L(&)U="!N
M;W0@9&5L:79E<F5D+CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X
M(#!P="`P+C5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@
M,'!X(#!P="`P+C5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^(#QE;3XH52Y3+B!D;VQL87)S(&EN('1H;W5S86YD<RD\
M+V5M/CPO<#X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M+4)/5%1/33H@,'!X)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M/B`\='(@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@5D525$E#04PM
M04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=724142#H@,"XU:6XG/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@
M,"XU:6XG/CQS=')O;F<^8BX\+W-T<F]N9SX\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@:G5S=&EF>2<^/'-T<F]N9SY!8V-O=6YT<R!P87EA8FQE
M(&%N9"!A8V-R=6%L<R`M(&]T:&5R.CPO<W1R;VYG/CPO=&0^(#PO='(^(#PO
M=&%B;&4^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@
M/'1A8FQE('-T>6QE/3-$)U=)1%1(.B`W,"4[($)/4D1%4BU#3TQ,05!313H@
M8V]L;&%P<V4[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[($U!4D=)3BU,1494.B`P+C5I;B<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,#X@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z
M(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`T
M-7!T.R!724142#H@-S0E)SX@4&%Y<F]L;"!A;F0@<F5L871E9"!E>'!E;G-E
M<SPO=&0^(#QT9"!S='EL93TS1"=724142#H@,24G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B0\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G
M/C$L,3`X/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)
M1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)
M1%1(.B`Q)2<^)#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@5TE$5$@Z(#$P)2<^,2PW-#@\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@
M<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M4$%$1$E.1RU,1494.B`T-7!T)SY0<F]V:7-I;VX@9F]R('9A8V%T:6]N/"]T
M9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G/C$L,C(Q/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT)SXQ+#0U,SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#
M2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0
M041$24Y'+4Q%1E0Z(#0U<'0G/D%C8W)U960@97AP96YS97,\+W1D/B`\=&0^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,BPS
M,C<\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[
M/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
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M='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C@Y/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXQ+#4V,#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\+W1R
M/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L
M,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!415A4+4E.1$5.5#H@+3`N,6EN.R!0041$24Y'
M+4Q%1E0Z(#4R+C)P="<^($QI86)I;&ET>2!I;B!C;VYN96-T:6]N('=I=&@@
M8V]L;&%B;W)A=&EO;B!O<&5R871I;VXM(&-U<G)E;G0@<&]R=&EO;CPO=&0^
M(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M)SXQ+#,R,CPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF
M;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H="<^,RPQ,C(\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'
M4D]53D0M0T],3U(Z('=H:71E.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-
M.B`Q<'0[(%!!1$1)3D<M3$5&5#H@-#5P="<^(%!R;W!E<G1Y(&%N9"!E<75I
M<&UE;G0@<W5P<&QI97)S/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T
M('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^(#$L-#<S/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@
M5$585"U!3$E'3CH@<FEG:'0G/B`Q+#$S-CPO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\
M+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B
M*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B
M;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@
M<FEG:'0G/B`W+#4T,#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG
M:'0G/B`Q,2PP-3$\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\+W1R/B`\
M+W1A8FQE/B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,&EN.R!-05)'24XZ
M(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X
M.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P
M<'0@,6EN.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B`\<W1R;VYG/E-T871E;65N=',@;V8@;W!E<F%T:6]N<SH\
M+W-T<F]N9SX\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].
M5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"=724142#H@-S`E.R!"3U)$15(M
M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!-05)'24XM3$5&5#H@,"XU:6XG(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT<B!S='EL93TS1"=615)424-!
M3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B
M;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0Q,#Y9
M96%R(&5N9&5D($1E8V5M8F5R(#,Q+#PO=&0^(#QT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T
M9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(
M5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(^,C`Q,#PO=&0^(#QT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[
M($9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C
M96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,CXR,#$Q/"]T
M9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)
M1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X]
M,T0R/C(P,3(\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P
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M<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT)R!C;VQS<&%N/3-$,CXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[
M/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H="<@8V]L<W!A;CTS1#(^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO
M=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H
M,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`M,C@N.#5P
M=#L@4$%$1$E.1RU,1494.B`R."XX-7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^
M(&,N(%)E=F5N=65S.CPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P
M.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!W
M:&ET93L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!415A4+4E.1$5.5#H@+3`N,6EN.R!0041$24Y'
M+4Q%1E0Z(#`N-FEN.R!724142#H@-C$E)SX@1&5F97)R960@<F5V96YU97,@
M9G)O;2!T:&4@;&EC96YS92!A;F0@<W5P<&QY(&%G<F5E;65N="!W:71H(%!F
M:7IE<CPO=&0^(#QT9"!S='EL93TS1"=724142#H@,24G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B0\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q
M,"4G/C0L-38S/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q
M)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%=)1%1(.B`Q)2<^)#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@5TE$5$@Z(#$P)2<^-"PU-C,\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E)SXT+#4V,SPO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B9N8G-P
M.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R
M9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M3$5&5#H@,"XU
M:6XG/DUI;&5S=&]N92!P87EM96YT("AS964@;F]T92`R*3PO=&0^(#QT9#XF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[
M/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H="<^,C4L,#`P/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS
M1"="04-+1U)/54Y$+4-/3$]2.B!W:&ET93L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@,7!T.R!0041$24Y'+4Q%1E0Z(#`N-6EN)SX@4F5V96YU97,@
M9G)O;2!S96QL:6YG('!R;V1U8W1S/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G
M/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^(#(L,#<Y/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-
M.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S
M;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/B`S+#@R,SPO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%
M6%0M04Q)1TXZ(')I9VAT)SX@-2PS,#<\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T
M9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R
M,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4E.1$5.5#H@+3(X
M+C@U<'0[(%!!1$1)3D<M3$5&5#H@,C@N.#5P=#L@1D].5"U714E'2%0Z(&)O
M;&0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@-BPV-#(\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N
M-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)#PO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B
M;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@."PS.#8\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(')I9VAT)SX@,S0L.#<P/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB
M<W`[/"]T9#X@/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF;F)S<#L\+W`^(#PA+2U%;F1&<F%G
M;65N="TM/CPO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M4D5,051%1"!005)462!44D%.4T%#5$E/3E,\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4D5,051%1"!005)462!4
M4D%.4T%#5$E/3E,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y214Q!5$5$(%!!4E19(%1204Y304-424].
M4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@
M:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N
M86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M
M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A<G1&
M<F%G;65N="TM/B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,&EN.R!-05)'
M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B`\<W1R;VYG/DY/5$4@,3`@+2!214Q!5$5$(%!!4E19(%12
M04Y304-424].4SPO<W1R;VYG/CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P
M<'0@,'!X.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"=724142#H@
M-S`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM3$5&5#H@,"XU
M:6XG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT<B!S='EL
M93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)T-/
M3$]2.B!B;'5E.R!&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B
M;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M5T5)
M1TA4.B!B;VQD)R!C;VQS<&%N/3-$,3`^665A<B9N8G-P.V5N9&5D)FYB<W`[
M1&5C96UB97(F;F)S<#LS,2P\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#PO
M='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P=#L@1D].5"U35%E,13H@
M:71A;&EC)SX@*%4N4RXF;F)S<#MD;VQL87)S)FYB<W`[:6XF;F)S<#MT:&]U
M<V%N9',I/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P
M=#L@1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R/C(P
M,3`\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!&
M3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R+C5P=#L@1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P
M="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O
M;&0G(&-O;'-P86X],T0R/C(P,3$\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#(N-7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P=#L@1D].5"U7
M14E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R/C(P,3(\+W1D/B`\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!&3TY4+5=%24=(
M5#H@8F]L9"<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'
M4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$
M1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4E.1$5.5#H@+3`N,C5I;CL@4$%$
M1$E.1RU,1494.B`P+C5I;CL@5TE$5$@Z(#8Q)2<^(#QS=')O;F<^82X\+W-T
M<F]N9SXF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#M-86YA9V5M96YT(&%N9"!C
M;VYS=6QT:6YG(&9E97,@=&\@=&AE($-H86ER;6%N(&]F('1H92!";V%R9#PO
M=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0[(%=)1%1(
M.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z
M(#$E)SX@)#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E
M)SX@-CPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$
M24Y'+4)/5%1/33H@,BXU<'0[(%=)1%1(.B`Q)2<^("9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0[(%=)1%1(.B`Q)2<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G
M/B`M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)
M3D<M0D]45$]-.B`R+C5P=#L@5TE$5$@Z(#$E)SX@)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5TE$5$@Z(#$E)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!724142#H@,24G/B`F
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#$P)2<^
M("T\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.
M1RU"3U143TTZ(#(N-7!T.R!724142#H@,24G/B`F;F)S<#L\+W1D/B`\+W1R
M/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4E.1$5.5#H@+3`N
M,C5I;CL@4$%$1$E.1RU,1494.B`P+C5I;B<^(#QS=')O;F<^8BX\+W-T<F]N
M9SXF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#M#;VUP96YS871I;VX@=&\@=&AE
M(&YO;BUE>&5C=71I=F4@9&ER96-T;W)S("AE>&-E<'0@=&AE($-H86ER;6%N
M(&]F('1H92!";V%R9"!I;B`R,#$P+"!A;F0@:6YC;'5D97,@=&AE(&EN=&5R
M:6T@0VAA:7)M86X@;V8@=&AE($)O87)D(&EN(#(P,3$@86YD(#(P,3(I/"]T
M9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T
M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,
M24=..B!R:6=H="<^(#(Q-3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B
M;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@
M<FEG:'0G/B`R,34\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!4
M15A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT
M)SX@,S<U/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!
M1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/"]T<CX@/"]T86)L
M93X@/"$M+45N9$9R86=M96YT+2T^/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?96$S93$U-SE?-S4S8E\T
M-CAF7V$U,3E?8C<U834S.#$Q.65F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V5A,V4Q-3<Y7S<U,V)?-#8X9E]A-3$Y7V(W-6$U,S@Q,3EE9B]7
M;W)K<VAE971S+U-H965T,3@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY354)315%514Y4($5614Y44SQB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY354)315%514Y4
M($5614Y44R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-50E-%455%3E0@159%3E13/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B
M+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P
M.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N
M86PN9'1D(B`M+3X\9&EV/B`\9&EV/CPA+2U3=&%R=$9R86=M96YT+2T^(#QP
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@,'!T(#!P>#L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^(#QS
M=')O;F<^3D]412`Q,2`M(%-50E-%455%3E0@159%3E13/"]S=')O;F<^/"]P
M/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!&3TY4+5=%24=(5#H@;F]R;6%L.R!-05)'24XZ(#!P="`P
M<'@@,'!T(#4V+C=P=#L@5$585"U)3D1%3E0Z("TR,"XW<'0G/B`F;F)S<#L\
M+W`^(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U14
M3TTZ(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T
M:#TS1#$P,"4^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@
M/'1D('-T>6QE/3-$)U=)1%1(.B`S-G!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;#L@5TE$5$@Z(#(P+C=P="<^82X\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;"<^1'5R:6YG
M($IA;G5A<GD@86YD($9E8G)U87)Y(#(P,3,L('1H92!#;VUP86YY(&ES<W5E
M9"!A('1O=&%L(&]F(#@L,#`P('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@:6X@
M8V]N;F5C=&EO;B!W:71H('1H92!E>&5R8VES92!O9B!O<'1I;VYS('1O('!U
M<F-H87-E(#@L,#`P('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@8GD@8V5R=&%I
M;B!E;7!L;WEE97,@;V8@=&AE($-O;7!A;GDN(%1H92!#;VUP86YY(')E8V5I
M=F5D(&%G9W)E9V%T92!C87-H('!R;V-E961S(&5Q=6%L('1O(&%P<')O>&EM
M871E;'D@)#$Y+#`P,"!I;B!C;VYN96-T:6]N('=I=&@@=&AE(&5X97)C:7-E
M(&]F('-U8V@@;W!T:6]N<RX\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL
M93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/"$M+45N9$9R
M86=M96YT+2T^/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?96$S93$U-SE?-S4S8E\T-CAF7V$U,3E?8C<U
M834S.#$Q.65F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5A,V4Q
M-3<Y7S<U,V)?-#8X9E]A-3$Y7V(W-6$U,S@Q,3EE9B]7;W)K<VAE971S+U-H
M965T,3DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5"3T%#/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/E-)1TY)1DE#04Y4($%#0T]53E1)3D<@4$],24-)15,@*%!O;&EC>2D\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4TE'3DE&24-!3E0@04-#3U5.5$E.1R!03TQ)0TE%4R!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A
M<VES(&]F('!R97-E;G1A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(
M5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O
M5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I
M=CX@/&1I=CX\(2TM4W1A<G1&<F%G;65N="TM/B`\=&%B;&4@<W1Y;&4],T0G
M34%21TE.+51/4#H@,'!T.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S
M='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)
M1%1(.B`P+C(U:6XG/B9N8G-P.SPO=&0^(#QT9#Y"87-I<R!O9B!P<F5S96YT
M871I;VX\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=-05)'24XZ
M(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G34%2
M1TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!4:&4@0V]M<&%N>28C,SD[<R!F:6YA
M;F-I86P@<W1A=&5M96YT<R!H879E(&)E96X@<')E<&%R960@:6X@86-C;W)D
M86YC92!W:71H(&=E;F5R86QL>2!A8V-E<'1E9"!A8V-O=6YT:6YG('!R:6YC
M:7!L97,@:6X@=&AE(%5N:71E9"!3=&%T97,@*")5+E,N($=!05`B*2X\+W`^
M(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[
M/"]P/B`\(2TM16YD1G)A9VUE;G0M+3X\+V1I=CX@/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5<V4@;V8@
M97-T:6UA=&5S(&EN('1H92!P<F5P87)A=&EO;B!O9B!F:6YA;F-I86P@<W1A
M=&5M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/
M0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N
M<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T14
M1"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM
M4W1A<G1&<F%G;65N="TM/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@
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M<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P
M+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P
M<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX@5&AE('!R97!A<F%T:6]N(&]F(&9I;F%N8VEA;"!S=&%T96UE
M;G1S(&EN(&-O;F9O<FUI='D@=VET:"!5+E,N($=!05`@<F5Q=6ER97,@;6%N
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M871E<RX\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW
M-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX@)FYB<W`[/"]P/B`\(2TM16YD1G)A9VUE;G0M+3X\+V1I=CX@/"]D:78^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y&=6YC=&EO;F%L(&-U<G)E;F-Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@
M6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R
M9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X\
M9&EV/B`\9&EV/CPA+2U3=&%R=$9R86=M96YT+2T^(#QT86)L92!S='EL93TS
M1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R
M('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G
M5TE$5$@Z(#`N,C5I;B<^)FYB<W`[/"]T9#X@/'1D/D9U;F-T:6]N86P@8W5R
M<F5N8WD\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=-05)'24XZ
M(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G34%2
M1TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!4:&4@9&]L;&%R(&ES('1H92!C=7)R
M96YC>2!O9B!T:&4@<')I;6%R>2!E8V]N;VUI8R!E;G9I<F]N;65N="!I;B!W
M:&EC:"!T:&4@;W!E<F%T:6]N<R!O9B!T:&4@0V]M<&%N>2!A;F0@:71S(%-U
M8G-I9&EA<FEE<R!A<F4@8V]N9'5C=&5D+B!-;W-T(&]F('1H92!#;VUP86YY
M)B,S.3MS(')E=F5N=65S(&%R92!D97)I=F5D(&EN(&1O;&QA<G,N($UO<W0@
M;V8@=&AE($-O;7!A;GDF(S,Y.W,@97AP96YS97,@86YD(&-A<&ET86P@97AP
M96YD:71U<F5S(&%R92!I;F-U<G)E9"!I;B!D;VQL87)S+"!A;F0@=&AE(&UA
M:F]R('-O=7)C92!O9B!T:&4@0V]M<&%N>28C,SD[<R!F:6YA;F-I;F<@:&%S
M(&)E96X@<')O=FED960@:6X@9&]L;&%R<RX\+W`^(#QP('-T>6QE/3-$)TU!
M4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS
M1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE
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M(&%V97)A9V4@<F%T97,[(&%N9"`H:6DI(&9O<B!O=&AE<B!I=&5M<R`H9&5R
M:79E9"!F<F]M(&YO;BUM;VYE=&%R>2!B86QA;F-E('-H965T(&ET96US('-U
M8V@@87,@9&5P<F5C:6%T:6]N(&%N9"!A;6]R=&EZ871I;VXL(&5T8RXI("T@
M:&ES=&]R:6-A;"!E>&-H86YG92!R871E<RX@0W5R<F5N8WD@=')A;G-A8W1I
M;VX@9V%I;G,@86YD(&QO<W-E<R!A<F4@8V%R<FEE9"!T;R!F:6YA;F-I86P@
M:6YC;VUE(&]R(&5X<&5N<V5S+"!A<R!A<'!R;W!R:6%T92X\+W`^(#PA+2U%
M;F1&<F%G;65N="TM/CPO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@97%U:79A;&5N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2U$3T-465!%(&AT
M;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L
M+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ
M+71R86YS:71I;VYA;"YD=&0B("TM/CQD:78^(#QD:78^/"$M+5-T87)T1G)A
M9VUE;G0M+3X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].
M5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-
M05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@=VED=&@],T0Q,#`E/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)
M1TXZ('1O<"<^(#QT9"!S='EL93TS1"=724142#H@,"XR-6EN)SXF;F)S<#L\
M+W1D/B`\=&0^0V%S:"!E<75I=F%L96YT<SPO=&0^(#PO='(^(#PO=&%B;&4^
M(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[
M/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@
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M(&]F(&-A<V@L('1O(&)E(&-A<V@@97%U:79A;&5N=',N/"]P/B`\<"!S='EL
M93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/"$M
M+45N9$9R86=M96YT+2T^/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV96YT;W)I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2U$3T-465!%(&AT;6P@
M4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%
M3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R
M86YS:71I;VYA;"YD=&0B("TM/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE
M;G0M+3X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@
M8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'
M24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@=VED=&@],T0Q,#`E/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ
M('1O<"<^(#QT9"!S='EL93TS1"=724142#H@,"XR-6EN)SXF;F)S<#L\+W1D
M/B`\=&0^26YV96YT;W)I97,\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL
M93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@
M<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!);G9E;G1O<FEE
M<R!A<F4@=F%L=65D(&%T('1H92!L;W=E<B!O9B!C;W-T(&]R(&UA<FME="X@
M0V]S="!O9B!R87<@86YD('!A8VMA9VEN9R!M871E<FEA;',@86YD('!U<F-H
M87-E9"!P<F]D=6-T<R!I<R!D971E<FUI;F5D('5S:6YG('1H92`B;6]V:6YG
M(&%V97)A9V4B(&)A<VES+CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@
M,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@
M,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX@0V]S="!O9B!F:6YI<VAE9"!P<F]D=6-T<R!T
M:&%T(&%R92!C87!I=&%L:7IE9"!I<R!D971E<FUI;F5D(&%S(&9O;&QO=W,Z
M('1H92!V86QU92!O9B!T:&4@<F%W(&%N9"!P86-K86=I;F<@;6%T97)I86QS
M(&-O;7!O;F5N="!I<R!D971E<FUI;F5D('!R:6UA<FEL>2!O;B!A('5S:6YG
M('1H92`B;6]V:6YG(&%V97)A9V4B(&)A<VES.R!T:&4@=F%L=64@;V8@=&AE
M(&QA8F]R(&%N9"!O=F5R:&5A9"!C;VUP;VYE;G0@:7,@9&5T97)M:6YE9"!O
M;B!A;B!A=F5R86=E(&)A<VES(&]V97(@=&AE('!R;V1U8W1I;VX@<&5R:6]D
M+CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F
M;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW
M-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
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M87!P<F]V86P@;V8@=&%L:6=L=6-E<F%S92!A;&9A(&]N($UA>2`Q+"`R,#$R
M+"!T:&4@0V]M<&%N>2!C87!I=&%L:7IE<R!M86YU9F%C='5R:6YG(&-O<W1S
M(&%S<V]C:6%T960@=VET:"!T86QI9VQU8V5R87-E(&%L9F$N/"]P/B`\<"!S
M='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@
M/"$M+45N9$9R86=M96YT+2T^/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@86YD
M(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M
M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4
M<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ
M+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\
M(2TM4W1A<G1&<F%G;65N="TM/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/
M4#H@,'!T.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL93TS1"=6
M15)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`P+C(U
M:6XG/B9N8G-P.SPO=&0^(#QT9#Y0<F]P97)T>2!A;F0@97%U:7!M96YT/"]T
M9#X@/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@1D].5"U714E'2%0Z(&YO<FUA
M;#L@34%21TE..B`P<'0@,'!X(#!P="`Q:6X[(%1%6%0M24Y$14Y4.B`M,"XR
M-6EN)SX@)FYB<W`[/"]P/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@
M,'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(@<W1Y;&4],T0G5D525$E#04PM
M04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=724142#H@,"XW-6EN)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;#L@5TE$
M5$@Z(#`N,C5I;B<^,2X\+W1D/B`\=&0^/&9O;G0@<W1Y;&4],T0G1D].5"U7
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M>"`P<'0@,6EN.R!415A4+4E.1$5.5#H@+3`N,C5I;B<^("9N8G-P.SPO<#X@
M/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@
M,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$
M,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@
M<W1Y;&4],T0G5TE$5$@Z(#`N-S5I;B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M5T5)1TA4.B!N;W)M86P[(%=)1%1(.B`P+C(U:6XG/C(N/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86PG/E1H92!#;VUP
M86YY)B,S.3MS(&%S<V5T<R!A<F4@9&5P<F5C:6%T960@8GD@=&AE('-T<F%I
M9VAT+6QI;F4@;65T:&]D(&]N('1H92!B87-I<R!O9B!T:&5I<B!E<W1I;6%T
M960@=7-E9G5L(&QI=F5S(&%S(&9O;&QO=W,Z/"]T9#X@/"]T<CX@/"]T86)L
M93X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B!B;VQD(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^
M(#QT86)L92!S='EL93TS1"=724142#H@-C4E.R!"3U)$15(M0T],3$%04T4Z
M(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!-05)'24XM3$5&5#H@,2XU:6XG(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@
M8F]T=&]M)SX@/'1D(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<@;F]W<F%P/3-$;F]W<F%P
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#(@
M;F]W<F%P/3-$;F]W<F%P/EEE87)S/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\
M+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR
M-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!724142#H@.#4E)SY,86)O<F%T;W)Y(&5Q
M=6EP;65N=#PO=&0^(#QT9"!S='EL93TS1"=724142#H@,24G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M5TE$5$@Z(#$R)2<^-3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!724142#H@,24G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS
M1"="04-+1U)/54Y$+4-/3$]2.B!W:&ET93L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<^(#QT9#Y&=7)N:71U<F4\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXQ
M,"TQ-3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S
M<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@
M<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SY#;VUP=71E<B!E<75I<&UE
M;G0\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H="<^,SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SXF;F)S<#L\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=-05)'
M24XZ(#!P="`P<'@@,'!T(#DX+C8U<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$
M)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S
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M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^26UP86ER;65N="!I;B!V86QU92!O9B!L;VYG+6QI=F5D(&%S<V5T<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M
M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO
M+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M
M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A<G1&<F%G
M;65N="TM/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!&3TY4
M.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!
M4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
M/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'
M3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`P+C(U:6XG/B9N8G-P.SPO
M=&0^(#QT9#Y);7!A:7)M96YT(&EN('9A;'5E(&]F(&QO;F<M;&EV960@87-S
M971S.CPO=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)TU!4D=)3CH@
M,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'
M24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@
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M86ER('9A;'5E<RX\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P
M<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX@)FYB<W`[/"]P/B`\(2TM16YD1G)A9VUE;G0M+3X\+V1I=CX@
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y);F-O;64@=&%X97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!8
M2%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G
M+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/CQD
M:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'1A8FQE('-T>6QE/3-$
M)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(@
M<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9#Y);F-O;64@=&%X
M97,\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!&3TY4+5=%24=(5#H@
M;F]R;6%L.R!-05)'24XZ(#!P="`P<'@@,'!T(#$N,C5I;CL@5$585"U)3D1%
M3E0Z("TP+C5I;B<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)TU!4D=)
M3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%
M4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N-S5I
M;B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M
M86P[(%=)1%1(.B`P+C(U:6XG/C$N/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M5T5)1TA4.B!N;W)M86PG/D1E9F5R<F5D(&EN8V]M92!T87AE<SPO=&0^(#PO
M='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@
M,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T
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M=&\@:71S(&1E9F5R<F5D('1A>"!A<W-E=',N/"]P/B`\<"!S='EL93TS1"=-
M05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G
M34%21TE..B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W
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M87-S971S(&%N9"!L:6%B:6QI=&EE<RX\+W`^(#QP('-T>6QE/3-$)TU!4D=)
M3CH@,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\=&%B;&4@<W1Y;&4],T0G
M34%21TE.+51/4#H@,'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(@<W1Y;&4]
M,T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=724142#H@
M,"XW-6EN)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z
M(&YO<FUA;#L@5TE$5$@Z(#`N,C5I;B<^,BX\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U714E'2%0Z(&YO<FUA;"<^56YC97)T86EN='D@:6X@:6YC;VUE('1A
M>&5S/"]T9#X@/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G34%21TE..B`P
M<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@
M,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
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M(&UO<F4@;&EK96QY('1H86X@;F]T('1O(&)E('-U<W1A:6YE9"X\+W`^(#PA
M+2U%;F1&<F%G;65N="TM/CPO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5N=64@4F5C;V=N
M:71I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2U$3T-4
M65!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I
M=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O
M>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/CQD:78^(#QD:78^/"$M+5-T
M87)T1G)A9VUE;G0M+3X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P
M="`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P
M<'0[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)
M0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N-6EN)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;#L@
M5TE$5$@Z(#`N,C5I;B<^:BX\+W1D/B`\=&0^4F5V96YU92!296-O9VYI=&EO
M;CPO=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T
M(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ
M(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
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M<F5A<V]N86)L>2!A<W-U<F5D+CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P
M<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"=-
M05)'24XM5$]0.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL93TS
M1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`P
M+C<U:6XG/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@
M;F]R;6%L.R!724142#H@,"XR-6EN)SXQ+CPO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5=%24=(5#H@;F]R;6%L)SY2979E;G5E<R!F<F]M('1H92!L:6-E;G-E
M(&%N9"!S=7!P;'D@86=R965M96YT('=I=&@@4&9I>F5R/"]T9#X@/"]T<CX@
M/"]T86)L93X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q:6X[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F
M;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@
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M8V5R87-E(&%L9F$L('1H92!N;VXM<F5F=6YD86)L92P@=7`M9G)O;G0@;&EC
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M92`R+B!4:&4@0V]M<&%N>2!A9&IU<W1S('1H92!P97)F;W)M86YC92!P97)I
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M:6QE<W1O;F4@:7,@86-H:65V960N/"]P/B`\<"!S='EL93TS1"=-05)'24XZ
M(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)TU!
M4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$
M)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N
M-S5I;B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N
M;W)M86P[(%=)1%1(.B`P+C(U:6XG/C(N/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M5T5)1TA4.B!N;W)M86PG/E)E=F5N=65S(&9R;VT@<V5L;&EN9R!P<F]D
M=6-T<R!T;R!09FEZ97(\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS
M1"=-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4]
M,T0G34%21TE..B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!4:&4@0V]M<&%N>2!R96-O9VYI
M>F5S(')E=F5N=65S(&9R;VT@<')O9'5C=',@<V]L9"!T;R!09FEZ97(@=7!O
M;B!D96QI=F5R>2P@=VAE;B!T:&4@<V%L97,@<')I8V4@:7,@9FEX960@;W(@
M9&5T97)M:6YA8FQE(&%N9"!C;VQL96-T86)I;&ET>2!I<R!R96%S;VYA8FQY
M(&%S<W5R960N/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T
M(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P
M=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M34%21TE.+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,
M24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N-S5I;B<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86P[(%=)1%1(
M.B`P+C(U:6XG/C,N/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N
M;W)M86PG/D-O;7!A;GDF(S,Y.W,@<VAA<F4@:6X@=&AE(&-O;&QA8F]R871I
M;VX@86=R965M96YT/"]T9#X@/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@1D].
M5"U714E'2%0Z(&YO<FUA;#L@34%21TE..B`P<'0@,'!X(#!P="`Q:6X[(%1%
M6%0M24Y$14Y4.B`P:6XG/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)T9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($9/3E0M5T5)
M1TA4.B!N;W)M86P[($U!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!415A4+4E.
M1$5.5#H@,&EN)SX@56YD97(@=&AE('1E<FUS(&%N9"!C;VYD:71I;VYS(&]F
M('1H92!09FEZ97(@06=R965M96YT+"!T:&4@0V]M<&%N>2!I<R!E;G1I=&QE
M9"!T;R`T,"4@;V8@=&AE('!R;V9I=',@;W(@;&]S<R!F<F]M('-A;&5S(&]F
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M(&)A<V5D(&]N('1H92!F:7-C86P@>65A<B!E;F1I;F<@3F]V96UB97(@,S`L
M('=H:6QE(&9I;F%N8VEA;"!I;F9O<FUA=&EO;B!F;W(@=&AE(%4N4RX@96YT
M:71Y(&ES(&EN8VQU9&5D(&)A<V5D(&]N('1H92!F:7-C86P@>65A<B!E;F1I
M;F<@1&5C96UB97(@,S$N/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P
M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B`F;F)S<#L\+W`^(#PA+2U%;F1&<F%G;65N="TM/CPO9&EV/B`\+V1I=CX\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)E<V5A<F-H(&%N9"!D979E;&]P;65N="!C;W-T<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO
M+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO
M+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L
M+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A<G1&<F%G;65N="TM/B`\=&%B
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M=&%B;&4^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@
M)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N
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M=7-T<GDL(%1R861E(&%N9"!,86)O<B`H=&AE(")/0U,B*2!A<F4@<F5C;V=N
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M<W1S(&%R92!I;F-U<G)E9"X\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T
M(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ
M(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
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M(&EN8W5R<F5D+CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P
M="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P
M>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
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M(&-O<W1S(&%T('1H92!P=7)C:&%S92!D871E+CPO<#X@/'`@<W1Y;&4],T0G
M34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE
M/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I
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M+W`^(#PA+2U%;F1&<F%G;65N="TM/CPO9&EV/B`\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;F-E;G1R
M871I;VX@;V8@8W)E9&ET(')I<VMS(&%N9"!T<F%D92!R96-E:79A8FQE/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL
M(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O
M14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT
M<F%N<VET:6]N86PN9'1D(B`M+3X\9&EV/B`\9&EV/CPA+2U3=&%R=$9R86=M
M96YT+2T^(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z
M(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%2
M1TE.+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=.
M.B!T;W`G/B`\=&0^0V]N8V5N=')A=&EO;B!O9B!C<F5D:70@<FES:W,@86YD
M('1R861E(')E8V5I=F%B;&4\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL
M93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@
M<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P
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M9&ET(')I<VL@;VX@=&AE<V4@:6YS=')U;65N=',N/"]P/B`\<"!S='EL93TS
M1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y
M;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`\9F]N="!S='EL93TS
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M.W,@<&%Y;65N="!O9B!T:&4@<F5C96EV86)L97,N/"]F;VYT/CPO<#X@/'`@
M<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^
M(#PA+2U%;F1&<F%G;65N="TM/CPO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D
M(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N
M,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT
M;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I
M=CX\(2TM4W1A<G1&<F%G;65N="TM/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.
M+51/4#H@,'!T.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL93TS
M1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`P
M+C(U:6XG/B9N8G-P.SPO=&0^(#QT9#Y3:&%R92UB87-E9"!C;VUP96YS871I
M;VX\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=-05)'24XZ(#!P
M="`P<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G34%21TE.
M.B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
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M;F-E(&%N9"!A;G1I8VEP871E9"!F=71U<F4@8V]N9&ET:6]N<RX\+W`^(#QP
M('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P
M/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].
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M(&%W87)D(&%P<')O86-H+CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@
M,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@
M,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
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M:'0M;&EN92!M971H;V0N/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P
M<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^("9N8G-P.SPO<#X@/"$M+45N9$9R86=M96YT+2T^/"]D
M:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F5T($QO<W,@<&5R('-H87)E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O
M5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O
M=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN
M9'1D(B`M+3X\9&EV/B`\9&EV/CPA+2U3=&%R=$9R86=M96YT+2T^(#QT86)L
M92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z(&)O;&0@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@
M,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$
M,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@
M<W1Y;&4],T0G5TE$5$@Z(#`N,C5I;B<^)FYB<W`[/"]T9#X@/'1D/DYE="!,
M;W-S('!E<B!S:&%R93PO=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$
M)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL
M93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^($)A<VEC(&%N9"!D:6QU
M=&5D(&QO<W,@<&5R('-H87)E("@B3%!3(BD@87)E(&-O;7!U=&5D(&)Y(&1I
M=FED:6YG(&YE="!L;W-S(&)Y('1H92!W96EG:'1E9"!A=F5R86=E(&YU;6)E
M<B!O9B!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S,Y.W,@0V]M;6]N(%-T;V-K
M+"!P87(@=F%L=64@)#`N,#`Q('!E<B!S:&%R92`H=&AE(")#;VUM;VX@4W1O
M8VLB*2!O=71S=&%N9&EN9R!F;W(@96%C:"!P97)I;V0N/"]P/B`\<"!S='EL
M93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@
M<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!$:6QU=&5D($Q0
M4R!D;V5S(&YO="!I;F-L=61E(#<L-S8Q+#$V."P@-RPT-CDL,#@X(&%N9"`W
M+#(X,"PT-CD@/&9O;G0@<W1Y;&4],T0G0T],3U(Z(&)L86-K)SYS:&%R97,@
M;V8@0V]M;6]N(%-T;V-K('5N9&5R;'EI;F<@;W5T<W1A;F1I;F<@;W!T:6]N
M<R!A;F0@<F5S=')I8W1E9"!S:&%R97,@;V8@0V]M;6]N(%-T;V-K/"]F;VYT
M/B!F;W(@=&AE(&9I<V-A;"!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q
M,"P@,C`Q,2!A;F0@,C`Q,BP@<F5S<&5C=&EV96QY+"!B96-A=7-E('1H92!E
M9F9E8W0@=V]U;&0@8F4@86YT:2UD:6QU=&EV92X\+W`^(#PA+2U%;F1&<F%G
M;65N="TM/CPO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M4TE'3DE&24-!3E0@04-#3U5.5$E.1R!03TQ)0TE%4R`H5&%B;&5S*3QB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3
M24=.249)0T%.5"!!0T-/54Y424Y'(%!/3$E#2453(%M!8G-T<F%C=%T\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U
M;&4@;V8@57-E9G5L($QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-
M3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12
M+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/CQD:78^
M(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'1A8FQE('-T>6QE/3-$)U=)
M1%1(.B`V-24[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU,1494
M.B`P+CEI;B<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X@/'1R
M('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@;F]W<F%P
M/3-$;F]W<F%P/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,7!T)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!
M3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^665A
M<G,\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<@;F]W
M<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"="
M04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%=)1%1(.B`X-24G/DQA8F]R871O<GD@97%U:7!M96YT/"]T9#X@/'1D('-T
M>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3(E)SXU/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)FYB
M<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z
M('=H:71E.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D/D9U<FYI='5R
M93PO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@5$585"U!3$E'3CH@<FEG:'0G/C$P+3$U/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S
M='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/D-O;7!U=&5R(&5Q=6EP;65N=#PO=&0^(#QT9#XF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXS/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^
M(#PO=&%B;&4^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@.3@N
M-C5P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^("9N8G-P.SPO<#X@/"$M+45N9$9R86=M96YT+2T^/"]D:78^(#PO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?96$S
M93$U-SE?-S4S8E\T-CAF7V$U,3E?8C<U834S.#$Q.65F#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V5A,V4Q-3<Y7S<U,V)?-#8X9E]A-3$Y7V(W
M-6$U,S@Q,3EE9B]7;W)K<VAE971S+U-H965T,C$N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY04D]015)462!!3D0@15%525!-
M14Y4("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E!23U!%4E19($%.1"!%455)4$U%3E0@6T%B<W1R
M86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y38VAE9'5L92!O9B!0<F]P97)T>2!A;F0@17%U:7!M96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)
M0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H
M='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET
M:6]N86PN9'1D(B`M+3X\9&EV/B`\9&EV/CPA+2U3=&%R=$9R86=M96YT+2T^
M(#QT86)L92!S='EL93TS1"=724142#H@-S`E.R!"3U)$15(M0T],3$%04T4Z
M(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!-05)'24XM3$5&5#H@,6EN)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X]
M,T0V/D1E8V5M8F5R(#,Q+#PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/"]T
M<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,7!T
M)R!N;W=R87`],T1N;W=R87`^("@\96T^52Y3+B!D;VQL87)S(&EN('1H;W5S
M86YD<RD\+V5M/CPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B`F;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T
M('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD
M)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^,C`Q,3PO=&0^(#QT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<@;F]W<F%P/3-$;F]W<F%P/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A
M<#TS1&YO=W)A<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P
M/C(P,3(\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@
M1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X@)FYB<W`[/"]T
M9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R
M,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#<P)2<^3&%B;W)A=&]R
M>2!E<75I<&UE;G0\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z
M(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!7
M24142#H@,3(E)SXQ,RPP-SD\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!724142#H@,3(E)SXQ-"PU,#(\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D
M/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^1G5R;FET=7)E(&%N9"!C;VUP=71E<B!E<75I<&UE;G0\
M+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H="<^,2PU,C(\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0G/C$L.#$X/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"="
M04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/DQE87-E:&]L9"!I;7!R;W9E;65N=',\+W1D/B`\=&0^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,3,L-S`U/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXQ-"PT
M-#<\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[
M/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H
M:71E.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/D5Q=6EP;65N
M="!U;F1E<B!C;VYS=')U8W1I;VX\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^
M("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX@,2PQ,3,\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O
M;&ED.R!415A4+4%,24=..B!R:6=H="<^(#,R.3PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S
M<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@
M<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!0041$24Y'+4Q%1E0Z
M(#<N,S5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/B0\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED
M.R!415A4+4%,24=..B!R:6=H="<^(#(Y+#0Q.3PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P
M="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^)#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ
M(')I9VAT)SX@,S$L,#DV/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#PO='(^
M(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!W:&ET93L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;2<^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#%P="<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#%P
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4TE:13H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-)6D4Z(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#%P="<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4TE:13H@,7!T)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#
M2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0
M041$24Y'+4)/5%1/33H@,7!T.R!0041$24Y'+4Q%1E0Z(#EP="<^($QE<W,@
M+2!A8V-U;75L871E9"!D97!R96-I871I;VX@86YD(&%M;W)T:7IA=&EO;CPO
M=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O
M;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'
M3CH@<FEG:'0G/B`H,3$L,30X/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/BD\+W1D/B`\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!
M3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX@
M*#$T+#<X-CPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0
M041$24Y'+4)/5%1/33H@,7!T)SXI/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$
M)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)SX@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!4
M15A4+4%,24=..B!R:6=H="<^(#$X+#(W,3PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R
M+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`D/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$58
M5"U!3$E'3CH@<FEG:'0G/B`Q-BPS,3`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\
M+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M,&EN.R!-05)'24XZ(#!P="`P<'@@,'!T(#0N,W!T.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\(2TM
M16YD1G)A9VUE;G0M+3X\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/DE.5D5.5$]22453("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DE.5D5.5$]22453(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4V-H961U;&4@;V8@26YV96YT;W)Y/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#
M+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W
M+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D
M(B`M+3X\9&EV/B`\9&EV/CPA+2U3=&%R=$9R86=M96YT+2T^(#QT86)L92!S
M='EL93TS1"=724142#H@-S`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-
M05)'24XM3$5&5#H@,6EN)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B
M;VQD)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<@;F]W
M<F%P/3-$;F]W<F%P/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([
M($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$-B!N;W=R87`],T1N;W=R
M87`^1&5C96UB97(@,S$L/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^
M("9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'
M3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$
M1$E.1RU"3U143TTZ(#%P="<@;F]W<F%P/3-$;F]W<F%P/B`H/&5M/E4N4RX@
M9&]L;&%R<R!I;B!T:&]U<V%N9',I/"]E;3X\+W1D/B`\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A
M<#TS1&YO=W)A<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P
M/C(P,3$\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@
M1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X@)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)
M1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R
M(&YO=W)A<#TS1&YO=W)A<#XR,#$R/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D
M/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P
M-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!724142#H@-S`E)SY287<@;6%T97)I
M86QS/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#$R
M)2<^,C<Y/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)
M1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)
M1%1(.B`Q)2<^)#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@5TE$5$@Z(#$R)2<^,BPQ,3@\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@
M<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M5V]R:R!I;B!P<F]G<F5S<SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C$Y,CPO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\+W1R
M/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L
M,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T)SY&:6YI<VAE
M9"!G;V]D<SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T
M.R!&3TY4+5-)6D4Z(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U325I%.B`Q<'0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R
M:6=H=#L@1D].5"U325I%.B`Q<'0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].
M5"U325I%.B`Q<'0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^
M("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX@,2PW,CD\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#%P="<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]5
M3D0M0T],3U(Z('=H:71E.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R
M+C5P="<^5&]T86P@:6YV96YT;W)Y/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@
M;&5F="<^("0\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#(W.3PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/
M33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G
M/B`D/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N
M-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`T+#`S.3PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@
M,BXU<'0G/B9N8G-P.SPO=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$
M)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/"$M+45N9$9R86=M96YT+2T^
M/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?96$S93$U-SE?-S4S8E\T-CAF7V$U,3E?8C<U834S.#$Q.65F
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5A,V4Q-3<Y7S<U,V)?
M-#8X9E]A-3$Y7V(W-6$U,S@Q,3EE9B]7;W)K<VAE971S+U-H965T,C,N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5(1D%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-(05)%
M($-!4$E404P@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4TA!4D4@0T%0251!3"!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C
M:&5D=6QE(&]F($]P=&EO;G,@86YD(%)E<W1R:6-T960@4W1O8VMS($=R86YT
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2U$3T-465!%
M(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO
M;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT
M;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/CQD:78^(#QD:78^(#QT86)L92!S
M='EL93TS1"=724142#H@.#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-
M05)'24XM3$5&5#H@,2XR-6EN)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P/CPA+2U3=&%R=$9R86=M96YT+2T^(#QT<B!S='EL93TS1"=615)4
M24-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/EEE
M87(@;V8\8G(@+SX@9W)A;G0\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A
M<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q
M<'0[($9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^("9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@
M<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G
M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#Y.;RX@;V8@;W!T:6]N<SQB
M<B`O/B!O<B!R97-T<FEC=&5D/&)R("\^('-T;V-K(&=R86YT960\+W1D/B`\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z
M(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)R!N
M;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO
M=W)A<#Y%>&5R8VES93QB<B`O/B!P<FEC92!R86YG93PO=&0^(#QT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<@
M;F]W<F%P/3-$;F]W<F%P/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS
M1&YO=W)A<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P/E9E<W1I;F<@<&5R:6]D
M/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M
M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X]
M,T0R(&YO=W)A<#TS1&YO=W)A<#Y&86ER('9A;'5E/&)R("\^(&%T(&=R86YT
M/&)R("\^("A5+E,N/&)R("\^(&1O;&QA<G,@:6X\8G(@+SX@=&AO=7-A;F1S
M*3PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4
M+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B`F;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z
M(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(@;F]W
M<F%P/3-$;F]W<F%P/D5X<&ER871I;VX\8G(@+SX@<&5R:6]D/"]T9#X@/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B
M;VQD)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#PO='(^(#QT<B!S
M='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q,"4G/C(P,3`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q
M,"4G/C$L,#$V+#`P,#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=72414
M2#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([(%=)1%1(.B`Q,"4G/B0V+CDP/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@5TE$5$@Z(#,U)2<^,R!Y96%R
M<R!C;VUM96YC:6YG/&)R("\^('5P;VX@86-H:65V96UE;G0@;V8@83QB<B`O
M/B!C97)T86EN(&UI;&5S=&]N93PO=&0^(#QT9"!S='EL93TS1"=724142#H@
M,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!724142#H@,24G/B0\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[(%=)1%1(.B`Q,"4G/C4L-C<S/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0[(%=)
M1%1(.B`Q,"4G/C$P('EE87)S/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T
M>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXR,#$P
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO
M=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT)SXT,C@L,#`P/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@8V5N=&5R)SXD-BXS,BTD.2XV
M-CPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\
M+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<B<^-"!Y96%R<SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^)#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H="<^,BPQ-#<\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<^
M,3`@>65A<G,\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],
M3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/C(P,3(\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C0P,"PP
M,#`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[
M/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!415A4+4%,24=..B!C96YT97(G/FXO83PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<B<^,R!Y96%R<SPO
M=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<^)#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^
M,BPR.#@\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB
M<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<^;B]A/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S
M='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!W:&ET93L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0
M041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^,C`Q,CPO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/
M5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^("9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX@,2PQ,#`L,#`P/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-
M.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@
M5$585"U!3$E'3CH@8V5N=&5R)SX@;B]A/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!0041$24Y'
M+4)/5%1/33H@,7!T)SXT('EE87)S/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T)SXD/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+4)/5%1/33H@
M,7!T)SXV+#(Y,CPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)
M3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SX@;B]A/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-
M.B`Q<'0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/
M54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO
M=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT)SXR+#DT-"PP,#`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<B<^)FYB<W`[/"]T9#X@
M/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF
M;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#PA+2U%;F1&<F%G;65N="TM
M/CPO=&%B;&4^(#PO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F($%S<W5M<'1I
M;VYS(%5S960@=&\@17-T:6UA=&4@1F%I<B!686QU92!O9B!3=&]C:R!/<'1I
M;VX@07=A<F0@=7-I;F<@0FQA8VLM4V-H;VQE<R!686QU871I;VX@36]D96P\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2U$3T-465!%(&AT
M;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L
M+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ
M+71R86YS:71I;VYA;"YD=&0B("TM/CQD:78^(#QD:78^/"$M+5-T87)T1G)A
M9VUE;G0M+3X@/'1A8FQE('-T>6QE/3-$)U=)1%1(.B`U,"4[($)/4D1%4BU#
M3TQ,05!313H@8V]L;&%P<V4[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[($U!4D=)3BU,1494.B`Q+C(U:6XG(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT<B!S='EL93TS1"=615)424-!
M3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U!!1$1)3D<M3$5&5#H@
M,'!X)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N
M/3-$,CXR,#$P/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q
M<'0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$
M+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M
M0D]45$]-.B`R+C5P=#L@4$%$1$E.1RU,1494.B`P<'@[(%=)1%1(.B`X-R4G
M/B!$:79I9&5N9"!Y:65L9#PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,BXU<'0[(%=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!
M3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!
M3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/B`P/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5TE$
M5$@Z(#$E)SX@)3PO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$
M+4-/3$]2.B!W:&ET93L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,BXU
M<'0[(%!!1$1)3D<M3$5&5#H@,'!X)SX@17AP96-T960@=F]L871I;&ET>3PO
M=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P
M="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!4
M15A4+4%,24=..B!R:6=H="<^(#<U/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)3PO=&0^(#PO
M='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U
M-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@4$%$
M1$E.1RU,1494.B`P<'@G/B!2:7-K+69R964@:6YT97)E<W0@<F%T93PO=&0^
M(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4
M+4%,24=..B!R:6=H="<^(#,N,C,\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXE/"]T9#X@/"]T
M<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@4$%$1$E.1RU,1494.B`P
M<'@G/B!%>'!E8W1E9"!L:69E("T@:6X@>65A<G,\+W1D/B`\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4
M+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG
M:'0G/B`X+C@\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\+W1R/B`\+W1A
M8FQE/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#$N,C5I;CL@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N
M8G-P.SPO<#X@/"$M+45N9$9R86=M96YT+2T^/"]D:78^(#PO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5M
M;6%R>2!O9B!3=&]C:R!/<'1I;VX@06-T:79I='D@+2!/<'1I;VYS($=R86YT
M960@=&\@16UP;&]Y965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@
M,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X
M:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X\9&EV/B`\
M9&EV/CPA+2U3=&%R=$9R86=M96YT+2T^(#QT86)L92!S='EL93TS1"=-05)'
M24XM5$]0.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL93TS1"=6
M15)424-!3"U!3$E'3CH@=&]P)SX@/'1D/B9N8G-P.SPO=&0^(#PO='(^(#PO
M=&%B;&4^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@8F]L
M9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[
M/"]P/B`\=&%B;&4@<W1Y;&4],T0G5TE$5$@Z(#$P,"4[($)/4D1%4BU#3TQ,
M05!313H@8V]L;&%P<V4[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^
M(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D(&YO
M=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO
M=W)A<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%
M24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(R(&YO=W)A<#TS1&YO=W)A<#Y996%R
M(&5N9&5D($1E8V5M8F5R(#,Q+#PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W
M<F%P/B`F;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^("9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4
M+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B`F;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!4
M15A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N
M/3-$-B!N;W=R87`],T1N;W=R87`^,C`Q,#PO=&0^(#QT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P
M/3-$;F]W<F%P/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A
M<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(
M5#H@8F]L9"<@8V]L<W!A;CTS1#8@;F]W<F%P/3-$;F]W<F%P/C(P,3$\+W1D
M/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'
M2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X@)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD
M)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0V(&YO=W)A<#TS
M1&YO=W)A<#XR,#$R/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^("9N
M8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@
M8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].
M5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X@)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R
M87`^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD
M)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<@
M;F]W<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/B!7
M96EG:'1E9#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<@
M;F]W<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B
M;VQD)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R
M87`^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD
M)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%
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M8F]L9"<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/B`F;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO
M=W)A<#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O
M;&0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A
M;CTS1#(@;F]W<F%P/3-$;F]W<F%P/E=E:6=H=&5D/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^)FYB<W`[
M/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG/B`\=&0@;F]W<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^3G5M
M8F5R/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R
M87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)
M1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G
M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#YA=F5R86=E/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)R!N
M;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R
M(&YO=W)A<#TS1&YO=W)A<#Y.=6UB97(\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A
M<#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W
M<F%P/F%V97)A9V4\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O
M;&0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(
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M<&%N/3-$,B!N;W=R87`],T1N;W=R87`^879E<F%G93PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B9N8G-P
M.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T
M=&]M)SX@/'1D(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/F]F
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`]
M,T1N;W=R87`^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4
M.B!B;VQD)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/'1D('-T>6QE
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M;W=R87`],T1N;W=R87`^;V8\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'
M2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/F5X
M97)C:7-E/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)R!N
M;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/'1D
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M;W=R87`],T1N;W=R87`^97AE<F-I<V4\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\
M+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT
M9"!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`]
M,T1N;W=R87`^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].
M5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#YO
M<'1I;VYS/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[
M($9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B`F;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4
M+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$
M,B!N;W=R87`],T1N;W=R87`^<')I8V4\+W1D/B`\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS
M1&YO=W)A<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^
M("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z
M(&)O;&0G(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#YO<'1I;VYS/"]T
M9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)
M1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<@;F]W<F%P/3-$;F]W<F%P/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C
M96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`^<')I8V4\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X@
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[
M($9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L
M:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O
M;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#YO<'1I;VYS/"]T9#X@/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD
M)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P
M/3-$;F]W<F%P/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/
M3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^
M<')I8V4\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@
M1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X@)FYB<W`[/"]T
M9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R
M,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5$585"U)3D1%3E0Z("TP+C%I;CL@
M4$%$1$E.1RU,1494.B`P+C%I;CL@5TE$5$@Z(#0P)2<^($]U='-T86YD:6YG
M(&%T(&)E9VEN;FEN9R!O9B!Y96%R/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(
M.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!724142#H@-R4G/C4L,S8V+#<R.3PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B0\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`W)2<^,BXT
M-S8\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z
M(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z
M(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[(%=)1%1(.B`W)2<^-BPS-C<L.3<Y/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#<E)SXS+C4W-CPO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=724142#H@,24G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z
M(#<E)SXV+#$T,2PP,S`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5TE$
M5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!724142#H@-R4G/C,N-38S/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/"]T
M<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/D-H86YG97,@9'5R:6YG('1H92!Y96%R.CPO=&0^(#QT9#XF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T
M9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D
M/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/
M3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)SX@/'1D('-T>6QE/3-$)U!!1$1)3D<M3$5&5#H@,"XR-6EN)SY'<F%N=&5D
M/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0G/C$L-#0T+#`P,#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H="<^-RXP-S8\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P
M.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4]
M,T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.
M1RU,1494.B`P+C(U:6XG/D9O<F9E:71E9"!A;F0@17AP:7)E9#PO=&0^(#QT
M9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXQ
M,RPT-#$\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB
M<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0G/C,N-34Q/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT)SXT-"PX-38\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C8N,C`W/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXR-2PX
M-3@\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[
M/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0G/C0N,S<R/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$
M+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)SX@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[(%!!1$1)
M3D<M3$5&5#H@,"XR-6EN)SY%>&5R8VES960@*"HI/"]T9#X@/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)
M1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^(#0R
M.2PS,#D\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$
M1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE
M9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^(#$N-C`R/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]4
M5$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P
M="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/B`Q.#(L,#DS/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q
M<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI
M9#L@5$585"U!3$E'3CH@<FEG:'0G/B`Q+C8U,CPO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P
M="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M
M04Q)1TXZ(')I9VAT)SX@.#8Q+#4Y,SPO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI
M9#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ
M(')I9VAT)SX@,2XS-#8\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/"]T<CX@
M/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^3W5T<W1A;F1I;F<@870@96YD
M(&]F('EE87(\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N
M-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T
M(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`V+#,V-RPY-SD\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@
M)#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P
M="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@,RXU-S8\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N
M-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N
M-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`V+#$T,2PP,S`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U14
M3TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T
M)SX@)#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R
M+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@,RXU-C,\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`U+#(U,RPU-SD\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"
M3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L
M969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@,RXY,C,\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U14
M3TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#
M2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0
M041$24Y'+4)/5%1/33H@,BXU<'0G/D5X97)C:7-A8FQE(&%T(&5N9"!O9B!Y
M96%R/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B
M;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@-"PR-C<L.#4P/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U
M8FQE.R!415A4+4%,24=..B!R:6=H="<^(#(N,3@S/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@-"PV-#<L.#,T/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R
M+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@
M9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#(N-3@Q/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P
M="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@-"PR-3@L-#0Q/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-
M.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^
M("0\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#,N,C`Q/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R
M+C5P="<^)FYB<W`[/"]T9#X@/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z("TP+C)I;CL@34%21TE..B`P<'0@,'!X(#!P="`X-"XY
M-7!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX@)FYB<W`[/"]P/B`\(2TM16YD1G)A9VUE;G0M+3X\+V1I=CX@/"]D:78^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3=6UM87)Y(&]F(%)E<W1R:6-T960@4W1O8VL@06-T:79I='D@+2!/<'1I
M;VYS($=R86YT960@=&\@16UP;&]Y965S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$
M5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S
M+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M
M+3X\9&EV/B`\9&EV/CPA+2U3=&%R=$9R86=M96YT+2T^(#QT86)L92!S='EL
M93TS1"=724142#H@-3`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/B`\='(@<W1Y;&4],T0G5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].
M5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0U/EEE87(@96YD960@1&5C96UB
M97(@,S$L(#(P,3(\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97(G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A
M<#TS1&YO=W)A<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P
M/DYU;6)E<B!O9CQB<B`O/B!297-T<FEC=&5D(%-H87)E<SPO=&0^(#QT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<@;F]W<F%P/3-$;F]W<F%P/B`F;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y
M;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97(G/D]U='-T86YD:6YG(&%T(&)E9VEN;FEN9R!O9B!Y96%R/"]T
M9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97(G(&-O;'-P86X],T0R/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D
M/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R)SY#:&%N9V5S(&1U<FEN9R!T:&4@>65A<CH\+W1D/B`\
M=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N
M8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2
M.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@5TE$5$@Z(#DP)2<^
M1W)A;G1E9#PO=&0^(#QT9"!S='EL93TS1"=724142#H@,24G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M5TE$5$@Z(#<E)SXQ+#4P,"PP,#`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@
M<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!0041$24Y'+4)/5%1/33H@,7!T.R!0041$24Y'+4Q%1E0Z(#$U+CDU<'0G
M/B!&;W)F96ET960\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L
M:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX@,RPR,#@\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB
M<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z
M(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!0041$24Y'+4)/5%1/
M33H@,BXU<'0G/D]U='-T86YD:6YG(&%T(&5N9"!O9B!Y96%R/"]T9#X@/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L
M93L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)
M1TXZ(')I9VAT)SX@,2PT.38L-SDR/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T
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M15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE
M9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#$P,BPP
M.#0\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.
M1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\+W1R/B`\+W1A8FQE/B`\
M<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!-05)'24XZ(#!P="`P<'@[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F
M;F)S<#L\+W`^(#PA+2U%;F1&<F%G;65N="TM/CPO9&EV/B`\+V1I=CX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C
M:&5D=6QE(&]F($]P=&EO;G,@1W)A;G1E9"!T;R!397)V:6-E(%!R;W9I9&5R
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@
M:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N
M86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M
M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A<G1&
M<F%G;65N="TM/B`\=&%B;&4@<W1Y;&4],T0G5TE$5$@Z(#$P,"4[($)/4D1%
M4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(
M5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(R/EEE87(@96YD960@1&5C96UB
M97(@,S$L/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[
M($9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y
M;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M
M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([
M($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$-CXR,#$P/"]T9#X@/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B
M;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0V/C(P
M,3$\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].
M5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI
M9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L
M<W!A;CTS1#8^,C`Q,CPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/"]T<CX@
M/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y
M;&4],T0G1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O
M;'-P86X],T0R/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'
M2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(
M5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R/B!796EG
M:'1E9#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(^("9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@
M8V]L<W!A;CTS1#(^(%=E:6=H=&5D/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U7
M14E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,CX@
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,CX@5V5I9VAT960\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#PO
M='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R/B!.=6UB97(\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O
M;&0G(&-O;'-P86X],T0R/B!A=F5R86=E/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$
M,CX@3G5M8F5R/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,CX@879E<F%G93PO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@
M8F]L9"<@8V]L<W!A;CTS1#(^($YU;6)E<CPO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS
M1#(^(&%V97)A9V4\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O
M;&0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!
M3$E'3CH@8F]T=&]M)SX@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X]
M,T0R/B!O9CPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(^(&5X97)C:7-E/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B
M;VQD)R!C;VQS<&%N/3-$,CX@;V8\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U7
M14E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%
M24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R/B!E
M>&5R8VES93PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(^(&]F/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C
M;VQS<&%N/3-$,CX@97AE<F-I<V4\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U7
M14E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=6
M15)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A
M;CTS1#(^;W!T:6]N<SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4
M.B!B;VQD)R!C;VQS<&%N/3-$,CYP<FEC93PO=&0^(#QT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M
M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([
M($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,CYO<'1I;VYS/"]T9#X@
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4
M.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R
M/G!R:6-E/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[
M($9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@
M<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G
M(&-O;'-P86X],T0R/F]P=&EO;G,\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(
M5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(^<')I8V4\+W1D/B`\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G
M/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/
M3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4
M.B`M,"XQ:6X[(%!!1$1)3D<M3$5&5#H@,"XQ:6X[(%=)1%1(.B`T,"4G/B!/
M=71S=&%N9&EN9R!A="!B96=I;FYI;F<@;V8@>65A<CPO=&0^(#QT9"!S='EL
M93TS1"=724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#<E)SXQ+#0S."PV.3(\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E
M)SXD/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!72414
M2#H@-R4G/C0N-CDW/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(
M.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!724142#H@-R4G/C$L-#,X+#8Y,CPO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B0\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`W)2<^-"XV
M.3<\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z
M(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z
M(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[(%=)1%1(.B`W)2<^,2PR,S@L-CDR/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#<E)SXU+C,X-3PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B9N8G-P
M.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!W
M:&ET93L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!415A4+4E.1$5.5#H@+3`N,6EN.R!0041$24Y'
M+4Q%1E0Z(#`N,6EN)SX@0VAA;F=E<R!D=7)I;F<@=&AE('EE87(M($5X97)C
M:7-E9"`H*BD\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C(P,"PP,#`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T
M9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G/C`N,#`Q/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT)SXS,C8L,C8W/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXP+C$R/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S
M='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U)3D1%3E0Z
M("TP+C%I;CL@4$%$1$E.1RU,1494.B`P+C%I;B<^($]U='-T86YD:6YG(&%T
M(&5N9"!O9B!Y96%R/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@
M5$585"U!3$E'3CH@<FEG:'0G/B`Q+#0S."PV.3(\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(')I9VAT)SX@-"XV.3<\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$
M1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=.
M.B!R:6=H="<^(#$L,C,X+#8Y,CPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'
M3CH@<FEG:'0G/B`U+C,X-3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/
M33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@
M.3$R+#0R-3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0
M041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`W
M+C(U.3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$
M24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL
M93TS1"="04-+1U)/54Y$+4-/3$]2.B!W:&ET93L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$
M24Y'+4)/5%1/33H@,BXU<'0[(%1%6%0M24Y$14Y4.B`M,"XQ:6X[(%!!1$1)
M3D<M3$5&5#H@,"XQ:6XG/B!%>&5R8VES86)L92!A="!E;F0@;V8@>65A<CPO
M=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I
M9VAT)SX@,2PT,C$L-S,T/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L
M93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R
M:6=H="<^(#0N-C4S/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R
M+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`Q+#(S
M-2PU-C<\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$
M1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,
M24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@-2XS
M.#4\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.
M1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#DQ,BPT,C4\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@
M)#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P
M="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@-RXR-3D\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N
M-7!T)SXF;F)S<#L\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=-
M05)'24XZ(#!P="`P<'@[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/"$M+45N9$9R86=M96YT
M+2T^/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@26YF;W)M871I;VX@86)O
M=70@4VAA<F4@3W!T:6]N<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S
M0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W
M=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T
M9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A<G1&<F%G;65N="TM/B`\=&%B;&4@
M<W1Y;&4],T0G5TE$5$@Z(#<P)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S
M93L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M34%21TE.+4Q%1E0Z(#`N-S5I;B<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,#X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED
M.R!415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS
M<&%N/3-$,3@@;F]W<F%P/3-$;F]W<F%P/D1E8V5M8F5R(#,Q+"`R,#$R/"]T
M9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)
M1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#PO='(^
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M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R
M87`^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B`F;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T
M('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD
M)R!C;VQS<&%N/3-$-B!N;W=R87`],T1N;W=R87`^3W!T:6]N<R!E>&5R8VES
M86)L92!A;F0\8G(@+SX@<F5S=')I8W1E9"!S=&]C:R!V97-T960\+W1D/B`\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z
M(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X@)FYB<W`[/"]T9#X@/"]T<CX@/'1R
M('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=.
M.B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`^17AE<F-I<V4\8G(@+SX@<')I8V5S/"]T9#X@/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD
M)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P
M/3-$;F]W<F%P/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/
M3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^
M3G5M8F5R(&]F/&)R("\^($]P=&EO;G,@86YD/&)R("\^(')E<W1R:6-T960@
M<W1O8VL\8G(@+SX@;W5T<W1A;F1I;F<\8G(@+SX@870@96YD(&]F/&)R("\^
M('EE87(\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@
M1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X@)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)
M1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R
M(&YO=W)A<#TS1&YO=W)A<#Y796EG:'1E9#QB<B`O/B!A=F5R86=E/&)R("\^
M(')E;6%I;FEN9SQB<B`O/B!C;VYT<F%C='5A;#QB<B`O/B!L:69E/"]T9#X@
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4
M.B!B;VQD)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<@
M;F]W<F%P/3-$;F]W<F%P/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT
M97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`^3G5M8F5R(&]F/&)R("\^(&]P=&EO;G,\8G(@+SX@97AE<F-I<V%B
M;&4@86YD/&)R("\^(')E<W1R:6-T960@<W1O8VL\8G(@+SX@=F5S=&5D(&%T
M(&5N9"!O9CQB<B`O/B!Y96%R/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R
M87`^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B`F;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T
M('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD
M)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^5V5I9VAT960\8G(@+SX@
M879E<F%G93QB<B`O/B!R96UA:6YI;F<\8G(@+SX@8V]N=')A8W1U86P\8G(@
M+SX@;&EF93PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T
M.R!&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B`F;F)S<#L\
M+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B
M*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ
M(')I9VAT.R!724142#H@,3@E)SYN+V$@*%)E<W1R:6-T960@4W1O8VLI/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!7
M24142#H@,3<E)SXQ+#0Y-BPW.3(\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q-R4G/B`\<"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@;B]A/"]P/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M(%=)1%1(.B`Q-R4G/C$P,BPP.#0\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q-R4G/B`\<"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@;B]A/"]P/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E
M)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#
M3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^)#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H="<^,"XP,#$\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C<Q.2PR,#<\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C(N-30\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T
M9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G/C<Q.2PR,#<\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0G/C(N-30\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!
M0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M)#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,"XQ,C`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T
M9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G/C0T-RPX-3`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0G/C$N,#4\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C0T-RPX-3`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C$N,#4\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@
M/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/B0\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G/C`N,SDY/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT)SXR,RPP.#<\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C$N.3(\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C(S+#`X-SPO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\
M=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^
M,2XY,CPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S
M<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@
M<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXD/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXP+CDW,CPO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^.3DV+#,U,SPO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\
M=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^
M,RXT-#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S
M<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H="<^.3DV+#,U,SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H="<^,RXT-#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4]
M,T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,BXS-3`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C0P
M+#`P,#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S
M<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H="<^-2XX,CPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H="<^-#`L,#`P/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXU+C@R/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT
M<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B0\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0G/C(N-C4P/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT)SXT,#(L.#@R/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXV+C$U/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXS.38L-S0T
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO
M=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT)SXV+C$U/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/
M3$]2.B!W:&ET93L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SXD/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT)SXS+C`R,#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^-3`L,#`P/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXU+C$P/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^
M(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M)SXU,"PP,#`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0G/C4N,3`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'
M4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^-2XP,#`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@
M/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G
M/C$L-S`X+#`P,#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H="<^-2XQ,#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H="<^,2PW,#@L,#`P/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[
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M)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H="<^,38P+#`P,#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^-RXQ,#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,3$P+#`P,#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D
M/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M="<^-RXQ,#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF
M;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/
M4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXD/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXV+CDP,#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,2PP,#,L,#@S
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO
M=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT)SXW+C$U/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT)SXQ-C@L,#@S/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T
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M/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M="<^,38P+#`P,#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H="<^-RXV-CPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H="<^.3`L,#`P/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXW+C8V/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO
M='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U
M-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/B0\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0G/CDN-C8P/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXV."PP,#`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C<N.#,\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C,T
M+#`P,#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S
M<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H="<^-RXX,SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.
M1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P
M="<^)#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@4$%$
M1$E.1RU"3U143TTZ(#%P="<^,38N-S`P/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O
M;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'
M3CH@<FEG:'0G/B`S.#<L-30R/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!4
M15A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG
M:'0G/B`S+CDY/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=.
M.B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/B`S.#<L
M-30R/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)
M3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T
M)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/B`S+CDY/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-
M.B`Q<'0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/
M54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)
M3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#<L
M-C8R+#<Y-CPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0
M041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,BXU<'0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O
M=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`U+#(W,BPY-3`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N
M-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M0D]45$]-.B`R
M+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/"]T<CX@
M/"]T86)L93X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P
M/B`\(2TM16YD1G)A9VUE;G0M+3X\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O
M9B!3=&]C:RU"87-E9"!#;VUP96YS871I;VX@17AP96YS92!I;B!3=&%T96UE
M;G0@;V8@3W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,
M(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O
M>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@
M/&1I=CX\(2TM4W1A<G1&<F%G;65N="TM/B`\=&%B;&4@<W1Y;&4],T0G5TE$
M5$@Z(#<P)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4Q%1E0Z
M(#`N-S5I;B<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X@/'1R
M('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O
M;&0G(&-O;'-P86X],T0Q,#Y996%R(&5N9&5D($1E8V5M8F5R(#,Q+#PO=&0^
M(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(
M5#H@8F]L9"<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)
M0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#%P=#L@1D].5"U35%E,13H@:71A;&EC)SXH52Y3+B!D;VQL87)S(&EN
M('1H;W5S86YD<RD\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R/C(P
M,3`\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].
M5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI
M9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L
M<W!A;CTS1#(^,C`Q,3PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4
M.B!B;VQD)R!C;VQS<&%N/3-$,CXR,#$R/"]T9#X@/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\
M+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B
M*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!415A4+4E.1$5.5#H@+3$R+C9P
M=#L@4$%$1$E.1RU,1494.B`Q,BXV<'0G/B!#;W-T(&]F(')E=F5N=65S/"]T
M9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@
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M1$5.5#H@+3$R+C9P=#L@4$%$1$E.1RU,1494.B`Q,BXV<'0[(%=)1%1(.B`V
M,24G/B!297-E87)C:"!A;F0@9&5V96QO<&UE;G0@97AP96YS97,\+W1D/B`\
M=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E)SXV,S`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXD
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@
M,3`E)SXT,C(\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/C0L-S4V/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/"]T
M<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U
M+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U)
M3D1%3E0Z("TQ,BXV<'0[(%!!1$1)3D<M3$5&5#H@,3(N-G!T)SX@1V5N97)A
M;"!A;F0@861M:6YI<W1R871I=F4@97AP96YS97,\+W1D/B`\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'
M3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX@-C4R
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M
M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T)SX@
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/B`T-C0\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q
M<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED
M.R!415A4+4%,24=..B!R:6=H="<^(#(L-S<U/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P
M.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!W
M:&ET93L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,BXU<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(')I9VAT)SX@,2PR.#(\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(')I9VAT)SX@.#@V/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O
M=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=.
M.B!R:6=H="<^(#<L-S4Q/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/"]T
M<CX@/"]T86)L93X@/"$M+45N9$9R86=M96YT+2T^/"]D:78^(#PO9&EV/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?96$S93$U
M-SE?-S4S8E\T-CAF7V$U,3E?8C<U834S.#$Q.65F#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+V5A,V4Q-3<Y7S<U,V)?-#8X9E]A-3$Y7V(W-6$U
M,S@Q,3EE9B]7;W)K<VAE971S+U-H965T,C0N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4R1CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY405A%4R!/3B!)3D-/344@*%1A8FQE
M<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^5$%815,@3TX@24Y#3TU%(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@1&5F
M97)R960@5&%X($%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,
M(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O
M>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@
M/&1I=CX\(2TM4W1A<G1&<F%G;65N="TM/B`\=&%B;&4@<W1Y;&4],T0G5TE$
M5$@Z(#<P)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4Q%1E0Z
M(#%I;B<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X@/'1R('-T
M>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)
M1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/
M3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$-CY$96-E;6)E<B`S,2P\+W1D
M/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'
M2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)4
M24-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`Q<'0[($9/3E0M4U193$4Z(&ET86QI8R<^*%4N4RX@9&]L;&%R<R!I
M;B!T:&]U<V%N9',I/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,
M24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,CXR
M,#$Q/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/
M3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L
M:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O
M;'-P86X],T0R/C(P,3(\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#PO='(^
M(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR
M,#0I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D/DEN(')E<W!E8W0@
M;V8Z/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
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M($-/3$]2.B!B;&%C:R<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@0T],3U(Z(&)L86-K)SXD/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E.R!#
M3TQ/4CH@8FQA8VLG/C0L,3$Y/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@0T],3U(Z(&)L86-K)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E.R!#3TQ/4CH@8FQA8VLG/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@
M,24[($-/3$]2.B!B;&%C:R<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E.R!#3TQ/4CH@8FQA8VLG/C8L
M,#`S/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(
M.B`Q)3L@0T],3U(Z(&)L86-K)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y
M;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D52
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M15A4+4%,24=..B!R:6=H=#L@0T],3U(Z(&)L86-K)SXS,#4\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0T],3U(Z(&)L86-K)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G0T],3U(Z(&)L86-K)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0T],3U(Z(&)L86-K
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($-/3$]2.B!B;&%C:R<^,S8S/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($-/3$]2.B!B;&%C:R<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R
M('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`Y<'0G/E-E=F5R86YC92!P87D@
M;V)L:6=A=&EO;CPO=&0^(#QT9"!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!#3TQ/
M4CH@8FQA8VLG/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@0T],3U(Z(&)L86-K)SXQ-C0\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@0T],3U(Z(&)L86-K)SXF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G0T],3U(Z(&)L86-K)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0T],3U(Z(&)L86-K)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($-/3$]2.B!B
M;&%C:R<^,3DR/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($-/3$]2.B!B;&%C:R<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$
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M24=..B!R:6=H=#L@0T],3U(Z(&)L86-K)SXQ,"PT-#D\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0T],3U(Z(&)L86-K)SXF;F)S<#L\
M+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B
M*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4Q%1E0Z(#EP="<^
M3F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y(&9O<G=A<F1S/"]T9#X@/'1D('-T
M>6QE/3-$)T-/3$]2.B!B;&%C:R<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($-/3$]2.B!B;&%C:R<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!#3TQ/4CH@8FQA8VLG
M/C0L-3<Y/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($-/
M3$]2.B!B;&%C:R<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T-/3$]2.B!B
M;&%C:R<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($-/3$]2.B!B;&%C:R<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%
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M5$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T
M('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^("@Q,RPW-C0\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P
M="<^*3PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,7!T('-O;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$58
M5"U!3$E'3CH@<FEG:'0G/B`H,S$L-3,V/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/BD\+W1D/B`\
M+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR
M-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R
M:6=H="<^("T\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4
M+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG
M:'0G/B`M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!
M1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/"]T<CX@/"]T86)L
M93X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S
M<#L\+W`^(#PA+2U%;F1&<F%G;65N="TM/CPO9&EV/B`\+V1I=CX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D
M=6QE(&]F($]P96X@5&%X(%EE87)S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@
M6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R
M9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X\
M9&EV/B`\9&EV/CPA+2U3=&%R=$9R86=M96YT+2T^(#QT86)L92!S='EL93TS
M1"=724142#H@-3`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$8V5N=&5R/B`\='(@
M<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T.R!724142#H@-3`E.R!&
M3TY4+5=%24=(5#H@8F]L9#L@5$585"U$14-/4D%424]..B!N;VYE)SX@2G5R
M:7-D:6-T:6]N.CPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,7!T.R!724142#H@,24[($9/3E0M5T5)1TA4.B!B;VQD)SX@)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]4
M5$]-.B`Q<'0[(%=)1%1(.B`Q)3L@1D].5"U714E'2%0Z(&)O;&0G/B`F;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T
M('-O;&ED.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R!4
M15A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#0W)2<^(#QS=')O;F<^665A<G,Z
M/"]S=')O;F<^/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%=)1%1(.B`Q)3L@1D].5"U714E'2%0Z
M(&)O;&0G/B`F;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=2
M3U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SY)<W)A
M96P\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXR,#`Y+3(P,3(\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/"]T<CX@
M/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/E5N:71E9"!3=&%T97,@*"HI/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<^
M,C`P.2TR,#$R/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/
M3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/DYE=&AE<FQA;F1S
M/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!415A4+4%,24=..B!R:6=H="<^,C`P.2TR,#$R/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#PO
M=&%B;&4^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@
M)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N
M-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^("@J*2!);F-L=61E<R!F961E<F%L+"!S=&%T92!A;F0@;&]C86P@*&]R
M('-I;6EL87(@<')O=FEN8VEA;"!J=7)I<V1I8W1I;VYS*2!T87@@<&]S:71I
M;VYS+CPO<#X@/"$M+45N9$9R86=M96YT+2T^/"]D:78^(#PO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?96$S93$U-SE?
M-S4S8E\T-CAF7V$U,3E?8C<U834S.#$Q.65F#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V5A,V4Q-3<Y7S<U,V)?-#8X9E]A-3$Y7V(W-6$U,S@Q
M,3EE9B]7;W)K<VAE971S+U-H965T,C4N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4R1CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY355!03$5-14Y405)9($9)3D%.0TE!3"!3
M5$%414U%3E0@24Y&3U)-051)3TX@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4U504$Q%345.5$%2
M62!&24Y!3D-)04P@4U1!5$5-14Y4($E.1D]234%424].(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5P
M<&QE;65N=&%L($EN9F]R;6%T:6]N+"!"86QA;F-E(%-H965T<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),
M24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B
M:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I
M=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A<G1&<F%G;65N="TM
M/B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$W+C-P=#L@34%21TE..B`P
M<'0@,'!X(#!P="`W,2XS<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)U=)
M1%1(.B`W,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU,1494
M.B`P+C5I;B<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X@/'1R
M('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4]
M,T0G1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P
M="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L
M9"<@8V]L<W!A;CTS1#8^1&5C96UB97(@,S$L/"]T9#X@/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S
M<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4
M+5-464Q%.B!I=&%L:6,G/BA5+E,N(&1O;&QA<G,@:6X@=&AO=7-A;F1S*3PO
M=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(^,C`Q,3PO=&0^(#QT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q
M<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=.
M.B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,CXR,#$R
M/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M
M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G
M0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!415A4+4E.1$5.5#H@+3(V+C0U<'0[(%!!1$1)3D<M3$5&5#H@,C8N-#5P
M=#L@1D].5"U714E'2%0Z(&)O;&0G/B!A+B!/=&AE<B!A<W-E=',Z/"]T9#X@
M/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF
M;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+
M1U)/54Y$+4-/3$]2.B!W:&ET93L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4Q%1E0Z
M(#0U<'0[(%=)1%1(.B`W-"4G/B!$969E<G)E9"!C;W-T<RH\+W1D/B`\=&0@
M<W1Y;&4],T0G5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E)SXQ+#4U.#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=724142#H@,24G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B0\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q
M,"4G/C@Y/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)
M1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'
M4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU,1494.B`T-7!T)SY)
M;G-T:71U=&EO;G,\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H="<^,S<U/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXU-#(\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T
M>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!
M1$1)3D<M3$5&5#H@-#5P="<^4W1A=&4@;V8@27-R865L("AS964@3F]T92`V
M82D\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H="<^,2PR.38\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0G/C(L-#`P/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS
M1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M3$5&5#H@-#5P="<^4F5S=')I8W1E9"!D97!O<VET/"]T
M9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G/C(P.#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF
M;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
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M<'0G/E!R97!A:60@97AP96YS97,\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,C,U/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXR-3$\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/"]T
M<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U
M+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`T-7!T)SY3=6YD<GD\
M+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S
M;VQI9#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)
M1TXZ(')I9VAT)SX@,38U/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4
M+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G
M/B`Q,#8\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$
M1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE
M/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M)SX@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE
M.R!415A4+4%,24=..B!R:6=H="<^(#,L.#,W/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!4
M15A4+4%,24=..B!R:6=H="<^(#,L-C@V/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[
M/"]T9#X@/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@
M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T
M(#`N-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX@*B!-86YU9F%C='5R:6YG(&-O<W1S(&]F(&EN=F5N=&]R>2P@<&%I
M9"!B>2!09FEZ97(L(&)U="!N;W0@9&5L:79E<F5D+CPO<#X@/'`@<W1Y;&4]
M,T0G34%21TE..B`P<'0@,'!X(#!P="`P+C5I;CL@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y
M;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P+C5I;CL@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^(#QE;3XH52Y3+B!D;VQL
M87)S(&EN('1H;W5S86YD<RD\+V5M/CPO<#X@/'1A8FQE('-T>6QE/3-$)TU!
M4D=)3BU43U`Z(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!X)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P/B`\='(@<W1Y;&4],T0G5$585"U!3$E'3CH@
M:G5S=&EF>3L@5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=7
M24142#H@,"XU:6XG/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!724142#H@,"XU:6XG/CQS=')O;F<^8BX\+W-T<F]N9SX\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>2<^/'-T<F]N
M9SY!8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R=6%L<R`M(&]T:&5R.CPO<W1R
M;VYG/CPO=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)TU!4D=)3CH@
M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)U=)1%1(.B`W,"4[
M($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU,1494.B`P+C5I;B<@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X@/'1R('-T>6QE/3-$
M)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@4$%$1$E.1RU,1494.B`T-7!T.R!724142#H@-S0E)SX@4&%Y<F]L;"!A
M;F0@<F5L871E9"!E>'!E;G-E<SPO=&0^(#QT9"!S='EL93TS1"=724142#H@
M,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!724142#H@,24G/B0\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[(%=)1%1(.B`Q,"4G/C$L,3`X/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#$P)2<^,2PW-#@\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF;F)S
M<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@
M=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`T-7!T)SY0<F]V:7-I
M;VX@9F]R('9A8V%T:6]N/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0G/C$L,C(Q/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXQ+#0U,SPO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\+W1R
M/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L
M,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!0041$24Y'+4Q%1E0Z(#0U<'0G/D%C8W)U960@
M97AP96YS97,\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H="<^,BPS,C<\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
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M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C@Y
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO
M=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT)SXQ+#4V,#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#
M3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!415A4+4E.1$5.
M5#H@+3`N,6EN.R!0041$24Y'+4Q%1E0Z(#4R+C)P="<^($QI86)I;&ET>2!I
M;B!C;VYN96-T:6]N('=I=&@@8V]L;&%B;W)A=&EO;B!O<&5R871I;VXM(&-U
M<G)E;G0@<&]R=&EO;CPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT)SXQ+#,R,CPO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,RPQ,C(\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/"]T<CX@
M/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%!!1$1)3D<M3$5&5#H@-#5P="<^
M(%!R;W!E<G1Y(&%N9"!E<75I<&UE;G0@<W5P<&QI97)S/"]T9#X@/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M
M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^
M(#$L-#<S/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!
M1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L
M969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/B`Q+#$S-CPO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/
M5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#
M2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU
M<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`D/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O
M=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`W+#4T,#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,BXU<'0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU
M<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`D/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L
M93L@5$585"U!3$E'3CH@<FEG:'0G/B`Q,2PP-3$\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF
M;F)S<#L\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@,&EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B9N8G-P.SPO<#X@/'`@<W1Y;&4]
M,T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#PA+2U%;F1&<F%G
M;65N="TM/CPO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U<'!L96UE;G1A;"!);F9O<FUA=&EO
M;BP@26YC;VUE(%-T871E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(
M5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O
M5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I
M=CX@/&1I=CX\(2TM4W1A<G1&<F%G;65N="TM/B`\=&%B;&4@<W1Y;&4],T0G
M5TE$5$@Z(#<P)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4Q%
M1E0Z(#`N-6EN)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/B`\
M='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL
M93TS1"=&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B
M;VQD)R!C;VQS<&%N/3-$,3`^665A<B!E;F1E9"!$96-E;6)E<B`S,2P\+W1D
M/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'
M2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)4
M24-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4
M.B!B;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R
M/C(P,3`\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@
M1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S
M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@
M8V]L<W!A;CTS1#(^,C`Q,3PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B
M;VQD)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M5T5)
M1TA4.B!B;VQD)R!C;VQS<&%N/3-$,CXR,#$R/"]T9#X@/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S
M<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<^(#QT9"!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,G/BA5+E,N
M(&1O;&QA<G,@:6X@=&AO=7-A;F1S*3PO=&0^(#QT9#XF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,CXF
M;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@8V]L<W!A;CTS1#(^)FYB
M<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G(&-O;'-P86X],T0R/B9N8G-P
M.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#
M2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!4
M15A4+4E.1$5.5#H@+3(X+C@U<'0[(%!!1$1)3D<M3$5&5#H@,C@N.#5P=#L@
M1D].5"U714E'2%0Z(&)O;&0G/B!C+B!2979E;G5E<SH\+W1D/B`\=&0^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO
M=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G
M0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5$585"U)3D1%
M3E0Z("TP+C%I;CL@4$%$1$E.1RU,1494.B`P+C9I;CL@5TE$5$@Z(#8Q)2<^
M($1E9F5R<F5D(')E=F5N=65S(&9R;VT@=&AE(&QI8V5N<V4@86YD('-U<'!L
M>2!A9W)E96UE;G0@=VET:"!09FEZ97(\+W1D/B`\=&0@<W1Y;&4],T0G5TE$
M5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!724142#H@,3`E)SXT+#4V,SPO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B0\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/C0L-38S/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^
M)#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z
M(#$P)2<^-"PU-C,\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G
M0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!0041$24Y'+4Q%1E0Z(#`N-6EN)SY-:6QE<W1O;F4@<&%Y;65N="`H<V5E
M(&YO=&4@,BD\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C(U+#`P,#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D
M/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@4$%$1$E.1RU,1494
M.B`P+C5I;B<^(%)E=F5N=65S(&9R;VT@<V5L;&EN9R!P<F]D=6-T<SPO=&0^
M(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED
M.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@
M<FEG:'0G/B`R+#`W.3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!
M3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX@
M,RPX,C,\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$
M1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE
M9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^(#4L,S`W/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]4
M5$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+
M1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P
M=#L@5$585"U)3D1%3E0Z("TR."XX-7!T.R!0041$24Y'+4Q%1E0Z(#(X+C@U
M<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$58
M5"U!3$E'3CH@;&5F="<^("0\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^
M(#8L-C0R/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!
M1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!
M3$E'3CH@;&5F="<^("0\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#@L
M,S@V/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)
M3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'
M3CH@;&5F="<^("0\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#,T+#@W
M,#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#PO='(^(#PO=&%B;&4^(#PA
M+2U%;F1&<F%G;65N="TM/CPO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
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M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^4D5,051%1"!005)462!44D%.4T%#5$E/3E,@*%1A8FQE<RD\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4D5,051%1"!005)462!44D%.4T%#5$E/3E,@6T%B<W1R86-T73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L
M92!O9B!296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO
M+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO
M+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L
M+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A<G1&<F%G;65N="TM/B`\=&%B
M;&4@<W1Y;&4],T0G5TE$5$@Z(#<P)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL
M87!S93L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@34%21TE.+4Q%1E0Z(#`N-6EN)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<^(#QT9"!S='EL93TS1"=#3TQ/4CH@8FQU93L@1D].5"U714E'2%0Z(&)O
M;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#$P/EEE
M87(@96YD960@1&5C96UB97(@,S$L/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF;F)S<#L\+W1D
M/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;2<^
M(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0[($9/3E0M4U19
M3$4Z(&ET86QI8R<^*%4N4RX@9&]L;&%R<R!I;B!T:&]U<V%N9',I/"]T9#X@
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P=#L@1D].5"U714E'
M2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R/C(P,3`\+W1D/B`\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!&3TY4+5=%24=(5#H@
M8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R+C5P=#L@1D].5"U714E'2%0Z(&)O;&0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X]
M,T0R/C(P,3$\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N
M-7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P=#L@1D].5"U714E'2%0Z(&)O;&0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'
M2%0Z(&)O;&0G(&-O;'-P86X],T0R/C(P,3(\+W1D/B`\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)FYB
M<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z
M(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#(N-7!T.R!415A4+4E.1$5.5#H@+3`N,C5I;CL@4$%$1$E.1RU,1494.B`P
M+C5I;CL@5TE$5$@Z(#8Q)2<^(#QS=')O;F<^82X\+W-T<F]N9SX@36%N86=E
M;65N="!A;F0@8V]N<W5L=&EN9R!F965S('1O('1H92!#:&%I<FUA;B!O9B!T
M:&4@0F]A<F0\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N
M-7!T.R!724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE
M9G0[(%=)1%1(.B`Q)2<^("0\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@
M5TE$5$@Z(#$P)2<^(#8\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!724142#H@,24G/B`F;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!7
M24142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[(%=)
M1%1(.B`Q)2<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!7
M24142#H@,3`E)SX@+3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[(%=)1%1(.B`Q)2<^("9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0[(%=)
M1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@5TE$
M5$@Z(#$E)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[(%=)
M1%1(.B`Q,"4G/B`M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5TE$5$@Z(#$E)SX@)FYB<W`[
M/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H
M:71E.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U)
M3D1%3E0Z("TP+C(U:6X[(%!!1$1)3D<M3$5&5#H@,"XU:6XG/B`\<W1R;VYG
M/F(N/"]S=')O;F<^($-O;7!E;G-A=&EO;B!T;R!T:&4@;F]N+65X96-U=&EV
M92!D:7)E8W1O<G,@*&5X8V5P="!T:&4@0VAA:7)M86X@;V8@=&AE($)O87)D
M(&EN(#(P,3`L(&%N9"!I;F-L=61E<R!T:&4@:6YT97)I;2!#:&%I<FUA;B!O
M9B!T:&4@0F]A<F0@:6X@,C`Q,2!A;F0@,C`Q,BD\+W1D/B`\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4
M+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@
M,C$U/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)
M3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'
M3CH@;&5F="<^("0\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#(Q-3PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/
M5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE
M9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`S-S4\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#(N-7!T)SXF;F)S<#L\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS
M1"=415A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^
M(#PA+2U%;F1&<F%G;65N="TM/CPO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
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M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%4#-!1SX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY324=.249)0T%.5"!!0T-/54Y424Y'(%!/3$E#2453
M("A$971A:6QS*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@97AC97!T(%-H
M87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$P/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-I9VYI
M9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O
M9B!3=6)S:61I87)I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!F:7IE<B!!9W)E96UE;G0L('5P9G)O;G0@<&%Y;65N="!R96-E:79E
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;6UO;B!S=&]C:RP@<&%R('9A;'5E('!E<B!S:&%R93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@=&\@
M<'5R8VAA<V4@8V]M;6]N('-T;V-K(&YO="!I;F-L=61E9"!I;B!D:6QU=&5D
M($Q04R!B96-A=7-E('1H92!E9F9E8W0@=V]U;&0@8F4@86YT:2UD:6QU=&EV
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPW-C$L,38X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPT
M-CDL,#@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-RPR.#`L-#8Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F]T86QI>"!":6\@5&AE<F%P975T:6-S($EN
M8V]R<&]R871I;VX@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC
M:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y09FEZ97(@06=R965M96YT+"!F=71U<F4@<F5V96YU
M97,@86YD(&5X<&5N<V4@<VAA<FEN9R!P97)C96YT86=E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!F:7IE<B!);F-O<G!O<F%T
M:6]N(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4&9I>F5R($%G<F5E;65N="P@9G5T=7)E(')E=F5N=65S(&%N9"!E
M>'!E;G-E('-H87)I;F<@<&5R8V5N=&%G93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y5<&]N($9I;&EN9R!O9B!0961I871R:6,@
M26YV97-T:6=A=&EO;B!0;&%N('1O($5-02!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-I9VYI9FEC86YT($%C
M8V]U;G1I;F<@4&]L:6-I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!F:7IE<B!!9W)E96UE;G0L
M('5P9G)O;G0@<&%Y;65N="!R96-E:79E9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E5P;VX@96%C:"!&1$$@86YD($5U<F]P96%N
M($UE9&EC:6YE($%G96YC>2!A<'!R;W9A;"!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-I9VYI9FEC86YT($%C
M8V]U;G1I;F<@4&]L:6-I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI;&5S=&]N92!P87EM96YT
M('1R:6=G97)E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y5<&]N($9$04%P<')O=F%L(%M-96UB97)=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VEG;FEF:6-A;G0@06-C;W5N
M=&EN9R!0;VQI8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EL97-T;VYE('!A>6UE;G0@=')I
M9V=E<F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E5P;VX@3F5A<B!497)M($-L:6YI8V%L($1E=F5L;W!M96YT($UI;&5S=&]N
M97,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y-:6QE<W1O;F4@<&%Y;65N="!T<FEG9V5R960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@."PS,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7V5A,V4Q-3<Y7S<U,V)?-#8X9E]A-3$Y
M7V(W-6$U,S@Q,3EE9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E
M83-E,34W.5\W-3-B7S0V.&9?834Q.5]B-S5A-3,X,3$Y968O5V]R:W-H965T
M<R]3:&5E=#(X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%6D)!13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY324=.249)0T%.5"!!0T-/54Y424Y'(%!/3$E#2453("A5<V5F
M=6P@3&EV97,@;V8@4')O<&5R='D@86YD($5Q=6EP;65N="D@*$1E=&%I;',I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,86)O
M<F%T;W)Y($5Q=6EP;65N="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U
M:7!M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT+"!U<V5F
M=6P@;&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-2!Y96%R
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1G5R;FET=7)E(%M-96UB97)=('P@36EN:6UU;2!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y
M+"!0;&%N="!A;F0@17%U:7!M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@
M97%U:7!M96YT+"!U<V5F=6P@;&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^,3`@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D9U<FYI='5R92!;365M8F5R72!\($UA>&EM
M=6T@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY0<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')O<&5R='D@86YD(&5Q=6EP;65N="P@=7-E9G5L(&QI9F4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/C$U('EE87)S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUP=71E<B!%
M<75I<&UE;G0@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY0<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')O<&5R='D@86YD(&5Q=6EP;65N="P@=7-E9G5L(&QI9F4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C,@>65A<G,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
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M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%1$-!1SX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY,24-%3E-%($%.1"!355!03%D@04=2145-
M14Y4("A$971A:6QS*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S
M(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O
M;&EC:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y09FEZ97(@06=R965M96YT+"!U<&9R;VYT('!A
M>6UE;G0@<F5C96EV960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-C`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y2979E;G5E(')E8V]G;FEZ960@;W9E<B!D97-I9VYA=&5D
M('!E<FEO9"!O9B!R96QA=&EO;G-H:7`\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0L-C`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y2979E;G5E(')E8V]G;FET:6]N('!E<FEO9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,30@>65A<G,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W1A
M;&EX($)I;R!4:&5R87!E=71I8W,@26YC;W)P;W)A=&EO;B!;365M8F5R73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-I9VYI
M9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!F:7IE<B!!
M9W)E96UE;G0L(&9U='5R92!R979E;G5E<R!A;F0@97AP96YS92!S:&%R:6YG
M('!E<F-E;G1A9V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P
M+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]L;&%B;W)A=&EO;B!/<&5R871I;VX@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:6=N:69I8V%N
M="!!8V-O=6YT:6YG(%!O;&EC:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&QI86)I
M;&ET:65S(&%C8W)U960@<F5L871E9"!T;R!T:&4@0V]L;&%B;W)A=&EO;B!/
M<&5R871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L-3`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!8V-R=65D(&QO;F<@=&5R;2!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-2PT,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!F:7IE<B!);F-O<G!O<F%T:6]N
M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4&9I>F5R($%G<F5E;65N="P@9G5T=7)E(')E=F5N=65S(&%N9"!E>'!E
M;G-E('-H87)I;F<@<&5R8V5N=&%G93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y5<&]N($9I;&EN9R!O9B!0961I871R:6,@26YV
M97-T:6=A=&EO;B!0;&%N('1O($5-02!;365M8F5R73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-I9VYI9FEC86YT($%C8V]U
M;G1I;F<@4&]L:6-I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!F:7IE<B!!9W)E96UE;G0L('5P
M9G)O;G0@<&%Y;65N="!R96-E:79E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E5P;VX@96%C:"!&1$$@86YD($5U<F]P96%N($UE
M9&EC:6YE($%G96YC>2!A<'!R;W9A;"!;365M8F5R73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-I9VYI9FEC86YT($%C8V]U
M;G1I;F<@4&]L:6-I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI;&5S=&]N92!P87EM96YT('1R
M:6=G97)E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y5<&]N($9$04%P<')O=F%L(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VEG;FEF:6-A;G0@06-C;W5N=&EN
M9R!0;VQI8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^36EL97-T;VYE('!A>6UE;G0@=')I9V=E
M<F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5P
M;VX@3F5A<B!497)M($-L:6YI8V%L($1E=F5L;W!M96YT($UI;&5S=&]N97,@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y-:6QE<W1O;F4@<&%Y;65N="!T<FEG9V5R960\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@."PS,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
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M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%3$=!1SX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY04D]015)462!!3D0@15%525!-14Y4("A$971A:6QS*2`H55-$("0I
M/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3`\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT+"!'<F]S<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S,2PP.38\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(Y+#0Q.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5S<R`M
M(&%C8W5M=6QA=&5D(&1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-"PW.#8I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3$L,30X*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT+"!.970L(%1O=&%L/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-BPS,3`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."PR-S$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E
M<')E8VEA=&EO;B!A;F0@=W)I=&4@9&]W;B!O9B!F:7AE9"!A<W-E=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-CDR/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPV,S$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#$S,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M26UP86ER;65N="!C:&%R9V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3&%B;W)A=&]R>2!%<75I<&UE;G0@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0<F]P97)T
M>2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='DL(%!L
M86YT(&%N9"!%<75I<&UE;G0L($=R;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-"PU,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,RPP-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9U<FYI='5R92!!;F0@0V]M<'5T
M97(@17%U:7!M96YT(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE
M;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT+"!'
M<F]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX,3@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4R
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3&5A<V5H;VQD($EM<')O=F5M96YT<R!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N
M="!A;F0@17%U:7!M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2P@4&QA;G0@86YD
M($5Q=6EP;65N="P@1W)O<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$T+#0T-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$S+#<P-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^17%U:7!M96YT(%5N9&5R($-O;G-T<G5C=&EO
M;B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="P@1W)O<W,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S(Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#$Q,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?96$S93$U-SE?-S4S
M8E\T-CAF7V$U,3E?8C<U834S.#$Q.65F#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V5A,V4Q-3<Y7S<U,V)?-#8X9E]A-3$Y7V(W-6$U,S@Q,3EE
M9B]7;W)K<VAE971S+U-H965T,S$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5(2$%#/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/DE.5D5.5$]22453("A$971A:6QS*2`H55-$
M("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I
M960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/DE.5D5.5$]22453(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F%W(&UA=&5R:6%L<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#$Q.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C<Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y7;W)K(&EN
M('!R;V-E<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N
M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1FEN:7-H960@9V]O9',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L-S(Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@:6YV96YT
M;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#`S.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M26YV96YT;W)Y('=R:71E+61O=VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-C@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`S-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
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M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%34]!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY,
M24%"24Q)5%D@1D]2($5-4$Q/645%(%))1TA44R!54$].(%)%5$E214U%3E0@
M*$1E=&%I;',I("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H
M97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY,24%"24Q)5%D@1D]2($5-4$Q/645%(%))
M1TA44R!54$].(%)%5$E214U%3E0@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;7!L;WEE92!S979E<F%N
M8V4@;V)L:6=A=&EO;B!P87EM96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,3<T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3979E<F%N8V4@97AP96YS93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,38\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]N=')I8G5T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-C<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-C0Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-3,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.970@*&=A:6XI(&]R(&QO<W,@9F]R('1H92!P97)I;V0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T
M960@<V5V97)A;F-E(&QI86)I;&ET:65S('!A>6UE;G1S(&9O<B!F:7-C86P@
M>65A<B!E;F0@,C`Q,SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.38S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%>'!E8W1E9"!C;VYT<FEB=71I;VX@=&\@;VYE(&]R(&UO<F4@0V]N
M=')I8G5T:6]N(%!L86YS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#<W,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?96$S93$U-SE?-S4S8E\T-CAF7V$U,3E?8C<U834S.#$Q.65F#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5A,V4Q-3<Y7S<U,V)?-#8X9E]A
M-3$Y7V(W-6$U,S@Q,3EE9B]7;W)K<VAE971S+U-H965T,S,N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$50-$%)/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-/34U)5$U%3E13
M("A$971A:6QS*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T
M:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3`\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N=',@06YD($-O;G1I;F=E
M;F-I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-U8F-O;G1R86-T:6YG(&-O;6UI=&UE;G0@86UO
M=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,S`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/
M0U,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY#;VUM:71M96YT<R!!;F0@0V]N=&EN9V5N8VEE<R!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F]Y86QT>2!E>'!E;G-E(&EN8VQU9&5D(&EN(&-O<W0@;V8@<F5V96YU
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-CD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)E<V5A<F-H($%N9"!,:6-E;G-E($%G<F5E;65N=',@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M
M96YT<R!!;F0@0V]N=&EN9V5N8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F]Y86QT>2!E>'!E
M;G-E(&EN8VQU9&5D(&EN(&-O<W0@;V8@<F5V96YU93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-C<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,34\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V)A8FQE($%G9W)E9V%T
M92!-:6QE<W1O;F4@4&%Y;65N="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;6UI=&UE;G1S($%N9"!#;VYT
M:6YG96YC:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y2;WEA;'1Y(&5X<&5N<V4@:6YC;'5D960@
M:6X@8V]S="!O9B!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^36EL97-T;VYE(%!A>6UE;G1S(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N
M=',@06YD($-O;G1I;F=E;F-I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)O>6%L='D@97AP96YS
M92!I;F-L=61E9"!I;B!C;W-T(&]F(')E=F5N=64\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]N<VED97)A=&EO;B!F;W(@;&EC96YS
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,96%S92!!
M9W)E96UE;G1S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N=',@06YD($-O;G1I;F=E;F-I97,@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DUO;G1H;'D@<F5N="]L96%S92!E>'!E;G-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!D97!O<VET960@87,@
M8F%N:R!G=6%R86YT964\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3&5A<V4O<F5N="!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XY-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XY.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XX.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9U='5R92!M:6YI;75M(&QE87-E('!A
M>6UE;G1S+"`R,#$S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY
M-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D9U='5R92!M:6YI;75M(&QE87-E('!A>6UE;G1S+"`R,#$T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-C@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9U='5R92!M:6YI;75M
M(&QE87-E('!A>6UE;G1S+"`R,#$U/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XY.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D9U='5R92!M:6YI;75M(&QE87-E('!A>6UE;G1S+"`R
M,#$V/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,C,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9E:&EC
M;&4@3&5A<V4@06YD($UA:6YT96YA;F-E($%G<F5E;65N=',@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM
M:71M96YT<R!!;F0@0V]N=&EN9V5N8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36]N=&AL>2!R
M96YT+VQE87-E(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y&=71U<F4@;6EN:6UU;2!L96%S92!P87EM96YT<RP@,C`Q,SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3(V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&=71U<F4@;6EN
M:6UU;2!L96%S92!P87EM96YT<RP@,C`Q-#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S@U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y&=71U<F4@;6EN:6UU;2!L96%S92!P87EM96YT
M<RP@,C`Q-3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y9
M:7-S=6T@06=R965M96YT(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N=',@06YD($-O;G1I;F=E
M;F-I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%G<F5E;65N="!M86EN=&5N86YC92!F964\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E(&%M
M;W5N="!T:&4@86=G<F5G871E(&%M;W5N="!O9B!R;WEA;'1I97,@=&AA="!S
M:&]U;&0@;F]T(&5X8V5E9"!G<F%N="!R96-E:79E9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3(N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6YI;75M(%M-96UB97)=('P@
M3T-3(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^0V]M;6ET;65N=',@06YD($-O;G1I;F=E;F-I97,@6TQI;F4@
M271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E)O>6%L=&EE<R!B87-E9"!O;B!S86QE(&]F('!R;V1U8W1S(&1E=F5L
M;W!E9"!F<F]M(&9U;F1E9"!P<F]J96-T<RP@<&5R8V5N=&%G93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RXP,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA>&EM=6T@6TUE;6)E
M<ET@?"!/0U,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#;VUM:71M96YT<R!!;F0@0V]N=&EN9V5N8VEE<R!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4F]Y86QT:65S(&)A<V5D(&]N('-A;&4@;V8@<')O9'5C=',@
M9&5V96QO<&5D(&9R;VT@9G5N9&5D('!R;VIE8W1S+"!P97)C96YT86=E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+C`P)3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G
M92!A;6]U;G0@=&AE(&%G9W)E9V%T92!A;6]U;G0@;V8@<F]Y86QT:65S('1H
M870@<VAO=6QD(&YO="!E>&-E960@9W)A;G0@<F5C96EV960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"XP,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@<F]Y86QT
M:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(Q+#,P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M36%X:6UU;2!;365M8F5R72!\(%!R;V1U8W1S($UA;G5F86-T=7)E9"!/=71S
M:61E($]F($ES<F%E;"!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D-O;6UI=&UE;G1S($%N9"!#;VYT:6YG96YC
M:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y2;WEA;'1I97,@8F%S960@;VX@<V%L92!O9B!P<F]D
M=6-T<R!D979E;&]P960@9G)O;2!F=6YD960@<')O:F5C=',L('!E<F-E;G1A
M9V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P,"XP,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
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M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%5DU"23X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY32$%212!#05!)5$%,("A.87)R871I
M=F4I("A$971A:6QS*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@97AC97!T
M(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^
M,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$-3XQ($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0S/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D9E8BX@
M,CDL(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R
M+B`R,RP@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIU;BX@,3<L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^2G5N+B`Q-BP@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y&96(N(#(R+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,#QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y&96(N(#(X+"`R,#$P/&)R/D]F9FEC97)S($%N9"!#97)T
M86EN($5M<&QO>65E<R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y.;W8N(#,P+"`R,#$P/&)R/D5X96-U=&EV92!/9F9I8V5R
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,3`\8G(^17AE8W5T:79E($]F9FEC97(@6TUE;6)E<ET\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1F5B+B`R."P@,C`Q,#QB
M<CY%>&5C=71I=F4@3V9F:6-E<B!;365M8F5R73QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$P/&)R/D5M<&QO>65E<R!;
M365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$R/&)R/D5M<&QO>65E<R!;365M8F5R73QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y*=6PN(#$V+"`R,#$R/&)R/E)E<W1R:6-T
M960@4W1O8VL@6TUE;6)E<ET\8G(^3V9F:6-E<G,@06YD($-E<G1A:6X@16UP
M;&]Y965S(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;"X@,38L(#(P,3(\8G(^4F5S=')I8W1E9"!3=&]C:R!;365M8F5R
M73QB<CY%;7!L;WEE97,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^2G5L+B`Q-BP@,C`Q,CQB<CY297-T<FEC=&5D(%-T;V-K
M(%M-96UB97)=/&)R/D]F9FEC97)S($%N9"!$:7)E8W1O<G,@26X@4')I=F%T
M92!4<F%N<V%C=&EO;B!;365M8F5R73QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I
M;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^56YD97)W<FET=&5N('!U8FQI8R!O9F9E<FEN9RP@8V]M;6]N
M('-T;V-K(&ES<W5E9"!A;F0@<V]L9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.3,L-#@Y+#@P.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,3<U+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@U+#8S,"PQ
M-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y5;F1E<G=R:71T96X@<'5B;&EC(&]F9F5R:6YG+"!C;VUM
M;VX@<W1O8VL@<')I8V4@<&5R('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#4N-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-2XR-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YD97)W<FET=&5N('!U8FQI8R!O
M9F9E<FEN9RP@;F5T('!R;V-E961S(&9R;VT@:7-S=6%N8V4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C4L-#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,"PV,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N9&5R
M=W)I='1E;B!P=6)L:6,@;V9F97)I;F<L(&-O;6UI<W-I;VYS(&%N9"!I<W-U
M86YC92!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#0P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!A<'!R;W9E9"!F;W(@
M9W)A;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q+#,T,2PV
M-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XY+#<T,2PV-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#`Q-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV."PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-C`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]M;6]N('-T;V-K('-H87)E<R!G<F%N=&5D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#DT-"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;6UO;B!S=&]C:R!A=F%I;&%B;&4@9F]R(&ES<W5A;F-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-S8L.3@V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!P<FEC
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V+CD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#DN-C8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#<N-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#8N.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-H87)E<R!O9B!C;VUM;VX@<W1O8VL@:7-S=65D+"!L
M;V-K('5P('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M,C0@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.=6UB97(@;V8@:6YS=&%L;&UE;G1S(&9O<B!V97-T:6YG
M(&]F('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y697-T:6YG('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^-"!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/C0@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XT('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-"!Y96%R<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!V86QU92!O
M9B!C;VUM;VX@<W1O8VL@870@9W)A;G0@9&%T93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`X+#8P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-RPX,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@L-C`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
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M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15<V044^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0Q/CQS=')O;F<^4TA!4D4@0T%0251!3"`H4W5M;6%R>2!O9B!/
M<'1I;VX@86YD(%)E<W1R:6-T960@4W1O8VL@1W)A;G1E9"!T;R!%;7!L;WEE
M97,I("A$971A:6QS*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@97AC97!T
M(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$P/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L
M(#(P,3`\8G(^16UP;&]Y965S(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^16UP;&]Y965S(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3(\8G(^,C`Q,"!;365M8F5R73QB<CY%;7!L;WEE97,@6TUE;6)E
M<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,CQB<CXR,#$P(%M-96UB97)=/&)R/D5M<&QO>65E<R!;365M8F5R73QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R
M/&)R/C(P,3(@6TUE;6)E<ET\8G(^16UP;&]Y965S(%M-96UB97)=/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^
M,C`Q,B!;365M8F5R73QB<CY%;7!L;WEE97,@6TUE;6)E<ET\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S
M960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A
M>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R86YT960\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L.30T+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#$V+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0R."PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PQ,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y-:6YI;75M(&5X97)C:7-E('!R:6-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8N,S(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8N,S(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA>&EM=6T@
M97AE<F-I<V4@<')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-BXY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Y+C8V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y697-T:6YG('!E<FEO9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^-"!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/C,@>65A<G,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XT('EE87)S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,R!Y96%R<SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C0@
M>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D9A:7(@=F%L=64@;V8@8V]M;6]N('-T;V-K(&%T(&=R86YT(&1A
M=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@."PV,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<L
M.#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`U+#8W,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,BPQ-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#(L,C@X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V+#(Y,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP:7)A=&EO;B!P
M97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C$P('EE87)S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M,3`@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
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M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%,DY!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY32$%212!#05!)
M5$%,("A&86ER(%9A;'5E($%S<W5M<'1I;VYS(&]F($]P=&EO;G,@1W)A;G1E
M9"D@*$1E=&%I;',I("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@
M;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3`\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4TA!4D4@0T%0251!3"!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1I
M=FED96YD('EI96QD/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^17AP96-T960@=F]L871I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-S4N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y2:7-K(&9R964@:6YT97)E<W0@<F%T93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RXR,R4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D
M(&QI9F4@:6X@>65A<G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/C@@>65A<G,@.2!M;VYT:',@,3@@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F]R9F5I='5R92!R871E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+C$P)3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YR96-O9VYI
M>F5D('-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;G)E8V]G;FEZ960@
M8V]M<&5N<V%T:6]N(&-O<W0L(')E8V]G;FET:6]N('!E<FEO9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,2!Y96%R(#$@;6]N=&@@-B!D87ES
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y&86ER('9A;'5E(&]F(&-O;6UO;B!S=&]C:R!A="!G<F%N="!D871E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@L-C`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W+#@P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?96$S93$U
M-SE?-S4S8E\T-CAF7V$U,3E?8C<U834S.#$Q.65F#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+V5A,V4Q-3<Y7S<U,V)?-#8X9E]A-3$Y7V(W-6$U
M,S@Q,3EE9B]7;W)K<VAE971S+U-H965T,S<N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5*0D%'
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-(05)%($-!4$E404P@*$]P=&EO
M;G,@1W)A;G1E9"!T;R!%;7!L;WEE97,I("A$971A:6QS*2`H55-$("0I/&)R
M/DEN(%1H;W5S86YD<RP@97AC97!T(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE
M<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$P/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!
M<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#87-H('!R;V-E961S(&9R;VT@97AE<F-I<V4@;V8@;W!T:6]N<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#(S,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C<W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U
M,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D]P=&EO;G,@06YD(%)E<W1R:6-T960@4W1O8VL@1W)A;G1E9"!4;R!%
M;7!L;WEE97,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG
M96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0F5G:6YN:6YG($)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C8L,30Q+#`S,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C8L,S8W+#DW.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,S8V+#<R.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)A;G1E9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT-#0L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&;W)F96ET
M960@86YD($5X<&ER960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(U+#@U.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C0T+#@U-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$S+#0T,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V5D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XX-C$L-3DS/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@R+#`Y,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0R.2PS,#D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN
M9R!"86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#(U
M,RPU-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV+#$T,2PP,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XV+#,V-RPY-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-A8FQE(&%T(&5N9"!O
M9B!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#(U."PT
M-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT+#8T-RPX,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT+#(V-RPX-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@17AE<F-I
M<V4@4')I8V4L($)E9VEN;FEN9R!"86QA;F-E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#,N-38S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+C4W-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BXT-S8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R86YT960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M-RXP-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D9O<F9E:71E9"!A;F0@17AP:7)E9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`T+C,W,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-BXR,#<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,N-34Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XS-#8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N
M-C4R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q+C8P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^17AE<F-I<V%B;&4@870@96YD(&]F('EE87(\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RXR,#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N-3@Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+C$X
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5V5I9VAT960@079E<F%G92!%>&5R8VES92!0<FEC92P@16YD:6YG($)A
M;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RXY,C,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#,N-38S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`S+C4W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^26YT<FEN<VEC('9A;'5E(&]F(&]P=&EO;G,@97AE
M<F-I<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#@P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M,S`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,RPQ,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-A<V@@<')O8V5E9',@9G)O;2!E>&5R8VES92!O9B!O<'1I
M;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,C`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E83-E,34W
M.5\W-3-B7S0V.&9?834Q.5]B-S5A-3,X,3$Y968-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO96$S93$U-SE?-S4S8E\T-CAF7V$U,3E?8C<U834S
M.#$Q.65F+U=O<FMS:&5E=',O4VAE970S."YH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15I+04,^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^4TA!4D4@0T%0251!3"`H4F5S=')I
M8W1E9"!3=&]C:R!'<F%N=&5D('1O($5M<&QO>65E<RD@*$1E=&%I;',I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R
M92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&;W)F96ET960\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,C`X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D
M(%-T;V-K(%M-96UB97)=('P@16UP;&]Y965S(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@
M0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE
M;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)A;G1E9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&;W)F96ET960\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,C`X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0Y-BPW.3(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C
M:7-A8FQE(&%T(&5N9"!O9B!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,#(L,#@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P1458044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4TA!
M4D4@0T%0251!3"`H3W!T:6]N<R!'<F%N=&5D('1O($-O;G-U;'1A;G1S+"!$
M:7)E8W1O<G,@86YD($]T:&5R(%-E<G9I8V4@4')O=FED97)S*2`H1&5T86EL
M<RD@*%531"`D*3QB<CY);B!4:&]U<V%N9',L(&5X8V5P="!3:&%R92!D871A
M+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,#QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#
M;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N
M="!!=V%R9"!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V%S:"!P<F]C965D<R!F<F]M(&5X97)C:7-E
M(&]F(&]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,2PR,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#(W-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-3`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS($=R86YT960@5&\@0V]N<W5L=&%N
M=',@1&ER96-T;W)S($%N9"!/=&AE<B!397)V:6-E(%!R;W9I9&5R<R!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R
M92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"96=I;FYI;F<@0F%L
M86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR,S@L-CDR
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PT,S@L-CDR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PT,S@L-CDR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES960\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,R-BPR-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;F1I;F<@0F%L86YC
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3$R+#0R-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C,X
M+#8Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L-#,X+#8Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^17AE<F-I<V%B;&4@870@96YD(&]F('EE87(\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDQ,BPT,C4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(S-2PU-C<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#0R,2PW,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4L($)E
M9VEN;FEN9R!"86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#4N,S@U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`T+C8Y-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-"XV.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C$R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@
M079E<F%G92!%>&5R8VES92!0<FEC92P@16YD:6YG($)A;&%N8V4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-RXR-3D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4N,S@U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+C8Y
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^17AE<F-I<V%B;&4@870@96YD(&]F('EE87(\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-RXR-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4N,S@U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+C8U,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT<FEN
M<VEC('9A;'5E(&]F(&]P=&EO;G,@97AE<F-I<V5D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+#,P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.3`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!P<F]C965D<R!F
M<F]M(&5X97)C:7-E(&]F(&]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
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M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%639#23X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY32$%2
M12!#05!)5$%,("A3=6UM87)Y(&]F($]U='-T86YD:6YG(&%N9"!297-T<FEC
M=&5D(%-T;V-K<RD@*$1E=&%I;',I("A54T0@)"D\8G(^26X@5&AO=7-A;F1S
M+"!E>&-E<'0@4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES92!S<&5C:69I
M960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY3:&%R92UB87-E9"!#;VUP96YS871I;VXL(%-H87)E<R!!=71H;W)I>F5D
M('5N9&5R(%-T;V-K($]P=&EO;B!0;&%N<RP@17AE<F-I<V4@4')I8V4@4F%N
M9V4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%G9W)E9V%T92!I;G1R:6YS:6,@=F%L=64@;V8@=&AE
M('1O=&%L(&]U='-T86YD:6YG(&%N9"!E>&5R8VES86)L92!S:&%R97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3DL-S`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC
M=&5D(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N+"!3:&%R
M97,@075T:&]R:7IE9"!U;F1E<B!3=&]C:R!/<'1I;VX@4&QA;G,L($5X97)C
M:7-E(%!R:6-E(%)A;F=E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@3W!T:6]N<R!A
M;F0@<F5S=')I8W1E9"!S=&]C:R!O=71S=&%N9&EN9R!A="!E;F0@;V8@>65A
M<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT.38L-SDR/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y7
M96EG:'1E9"!A=F5R86=E(')E;6%I;FEN9R!C;VYT<F%C='5A;"!L:69E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XP('EE87)S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@
M;V8@;W!T:6]N<R!E>&5R8VES86)L92!A="!E;F0@;V8@>65A<CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`R+#`X-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@879E
M<F%G92!R96UA:6YI;F<@8V]N=')A8W1U86P@;&EF92P@97AE<F-I<V%B;&4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C`@>65A<G,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%G9W)E
M9V%T92!I;G1R:6YS:6,@=F%L=64@;V8@=&AE('1O=&%L(&]U='-T86YD:6YG
M(&%N9"!E>&5R8VES86)L92!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,3(L-#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS($%N9"!297-T<FEC=&5D(%-T
M;V-K(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N+"!3:&%R97,@075T
M:&]R:7IE9"!U;F1E<B!3=&]C:R!/<'1I;VX@4&QA;G,L($5X97)C:7-E(%!R
M:6-E(%)A;F=E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@3W!T:6]N<R!A;F0@<F5S
M=')I8W1E9"!S=&]C:R!O=71S=&%N9&EN9R!A="!E;F0@;V8@>65A<CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPV-C(L-SDV/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@
M;V8@;W!T:6]N<R!E>&5R8VES86)L92!A="!E;F0@;V8@>65A<CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PR-S(L.34P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XP+C`P,2!;365M
M8F5R72!\($]P=&EO;G,@06YD(%)E<W1R:6-T960@4W1O8VL@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R
M92UB87-E9"!#;VUP96YS871I;VXL(%-H87)E<R!!=71H;W)I>F5D('5N9&5R
M(%-T;V-K($]P=&EO;B!0;&%N<RP@17AE<F-I<V4@4')I8V4@4F%N9V4@6TQI
M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5X97)C:7-E('!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@3W!T:6]N<R!A;F0@<F5S=')I
M8W1E9"!S=&]C:R!O=71S=&%N9&EN9R!A="!E;F0@;V8@>65A<CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S$Y+#(P-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@879E
M<F%G92!R96UA:6YI;F<@8V]N=')A8W1U86P@;&EF93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^,B!Y96%R<R`V(&UO;G1H<R`Q-2!D87ES/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M=6UB97(@;V8@;W!T:6]N<R!E>&5R8VES86)L92!A="!E;F0@;V8@>65A<CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S$Y+#(P-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT
M960@879E<F%G92!R96UA:6YI;F<@8V]N=')A8W1U86P@;&EF92P@97AE<F-I
M<V%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C(@>65A<G,@
M-B!M;VYT:',@,34@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^,"XQ,C`@6TUE;6)E<ET@?"!/<'1I;VYS($%N
M9"!297-T<FEC=&5D(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T
M:6]N+"!3:&%R97,@075T:&]R:7IE9"!U;F1E<B!3=&]C:R!/<'1I;VX@4&QA
M;G,L($5X97)C:7-E(%!R:6-E(%)A;F=E(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!P
M<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C$R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M=6UB97(@;V8@3W!T:6]N<R!A;F0@<F5S=')I8W1E9"!S=&]C:R!O=71S=&%N
M9&EN9R!A="!E;F0@;V8@>65A<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-#0W+#@U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5V5I9VAT960@879E<F%G92!R96UA:6YI;F<@8V]N
M=')A8W1U86P@;&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M,2!Y96%R(#$X(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!O<'1I;VYS(&5X97)C:7-A8FQE
M(&%T(&5N9"!O9B!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT-#<L.#4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E(')E;6%I;FEN9R!C;VYT<F%C
M='5A;"!L:69E+"!E>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^,2!Y96%R(#$X(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C`N,SDY(%M-96UB97)=('P@3W!T
M:6]N<R!!;F0@4F5S=')I8W1E9"!3=&]C:R!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O
M;7!E;G-A=&EO;BP@4VAA<F5S($%U=&AO<FEZ960@=6YD97(@4W1O8VL@3W!T
M:6]N(%!L86YS+"!%>&5R8VES92!0<FEC92!286YG92!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE
M<F-I<V4@<')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,"XS.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYU;6)E<B!O9B!/<'1I;VYS(&%N9"!R97-T<FEC=&5D('-T;V-K
M(&]U='-T86YD:6YG(&%T(&5N9"!O9B!Y96%R/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,RPP.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D(&%V97)A9V4@<F5M86EN
M:6YG(&-O;G1R86-T=6%L(&QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/C$@>65A<B`Q,2!M;VYT:',@,2!D87D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!O<'1I
M;VYS(&5X97)C:7-A8FQE(&%T(&5N9"!O9B!Y96%R/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR,RPP.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D(&%V97)A9V4@<F5M
M86EN:6YG(&-O;G1R86-T=6%L(&QI9F4L(&5X97)C:7-A8FQE/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ('EE87(@,3$@;6]N=&AS(#$@9&%Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#XP+CDW,B!;365M8F5R72!\($]P=&EO;G,@06YD(%)E<W1R:6-T960@4W1O
M8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VXL(%-H87)E<R!!=71H
M;W)I>F5D('5N9&5R(%-T;V-K($]P=&EO;B!0;&%N<RP@17AE<F-I<V4@4')I
M8V4@4F%N9V4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E('!R:6-E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N.3<R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@3W!T:6]N
M<R!A;F0@<F5S=')I8W1E9"!S=&]C:R!O=71S=&%N9&EN9R!A="!E;F0@;V8@
M>65A<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3DV+#,U,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5V5I9VAT960@879E<F%G92!R96UA:6YI;F<@8V]N=')A8W1U86P@;&EF93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,R!Y96%R<R`U(&UO;G1H
M<R`Y(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYU;6)E<B!O9B!O<'1I;VYS(&5X97)C:7-A8FQE(&%T(&5N
M9"!O9B!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY.38L
M,S4S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y796EG:'1E9"!A=F5R86=E(')E;6%I;FEN9R!C;VYT<F%C='5A;"!L
M:69E+"!E>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^,R!Y96%R<R`U(&UO;G1H<R`Y(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(N,S4P(%M-96UB97)=('P@
M3W!T:6]N<R!!;F0@4F5S=')I8W1E9"!3=&]C:R!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D
M($-O;7!E;G-A=&EO;BP@4VAA<F5S($%U=&AO<FEZ960@=6YD97(@4W1O8VL@
M3W!T:6]N(%!L86YS+"!%>&5R8VES92!0<FEC92!286YG92!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M17AE<F-I<V4@<')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,BXS-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3G5M8F5R(&]F($]P=&EO;G,@86YD(')E<W1R:6-T960@<W1O
M8VL@;W5T<W1A;F1I;F<@870@96YD(&]F('EE87(\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@879E<F%G92!R96UA
M:6YI;F<@8V]N=')A8W1U86P@;&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^-2!Y96%R<R`Y(&UO;G1H<R`R-B!D87ES/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@
M;W!T:6]N<R!E>&5R8VES86)L92!A="!E;F0@;V8@>65A<CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E
M(')E;6%I;FEN9R!C;VYT<F%C='5A;"!L:69E+"!E>&5R8VES86)L93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-2!Y96%R<R`Y(&UO;G1H<R`R
M-B!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#XR+C8U,"!;365M8F5R72!\($]P=&EO;G,@06YD(%)E<W1R:6-T
M960@4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VXL(%-H87)E
M<R!!=71H;W)I>F5D('5N9&5R(%-T;V-K($]P=&EO;B!0;&%N<RP@17AE<F-I
M<V4@4')I8V4@4F%N9V4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E('!R:6-E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N-C4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!/
M<'1I;VYS(&%N9"!R97-T<FEC=&5D('-T;V-K(&]U='-T86YD:6YG(&%T(&5N
M9"!O9B!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,#(L
M.#@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y796EG:'1E9"!A=F5R86=E(')E;6%I;FEN9R!C;VYT<F%C='5A;"!L
M:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XV('EE87)S(#$@
M;6]N=&@@,C0@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(&]P=&EO;G,@97AE<F-I<V%B;&4@
M870@96YD(&]F('EE87(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,Y-BPW-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E=E:6=H=&5D(&%V97)A9V4@<F5M86EN:6YG(&-O;G1R86-T
M=6%L(&QI9F4L(&5X97)C:7-A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XV('EE87)S(#$@;6]N=&@@,C0@9&%Y<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,RXP,C`@6TUE;6)E
M<ET@?"!/<'1I;VYS($%N9"!297-T<FEC=&5D(%-T;V-K(%M-96UB97)=/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M
M8F%S960@0V]M<&5N<V%T:6]N+"!3:&%R97,@075T:&]R:7IE9"!U;F1E<B!3
M=&]C:R!/<'1I;VX@4&QA;G,L($5X97)C:7-E(%!R:6-E(%)A;F=E(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%>&5R8VES92!P<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`S+C`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@3W!T:6]N<R!A;F0@<F5S=')I8W1E
M9"!S=&]C:R!O=71S=&%N9&EN9R!A="!E;F0@;V8@>65A<CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E
M(')E;6%I;FEN9R!C;VYT<F%C='5A;"!L:69E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XU('EE87)S(#$@;6]N=&@@-B!D87ES/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@
M;V8@;W!T:6]N<R!E>&5R8VES86)L92!A="!E;F0@;V8@>65A<CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R
M86=E(')E;6%I;FEN9R!C;VYT<F%C='5A;"!L:69E+"!E>&5R8VES86)L93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-2!Y96%R<R`Q(&UO;G1H
M(#8@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^-2XP,#`@6TUE;6)E<ET@?"!/<'1I;VYS($%N9"!297-T<FEC
M=&5D(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N+"!3:&%R
M97,@075T:&]R:7IE9"!U;F1E<B!3=&]C:R!/<'1I;VX@4&QA;G,L($5X97)C
M:7-E(%!R:6-E(%)A;F=E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!P<FEC93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@3W!T
M:6]N<R!A;F0@<F5S=')I8W1E9"!S=&]C:R!O=71S=&%N9&EN9R!A="!E;F0@
M;V8@>65A<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW,#@L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y796EG:'1E9"!A=F5R86=E(')E;6%I;FEN9R!C;VYT<F%C='5A;"!L
M:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XU('EE87)S(#$@
M;6]N=&@@-B!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@;W!T:6]N<R!E>&5R8VES86)L92!A
M="!E;F0@;V8@>65A<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PW,#@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E(')E;6%I;FEN9R!C;VYT<F%C
M='5A;"!L:69E+"!E>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^-2!Y96%R<R`Q(&UO;G1H(#8@9&%Y<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^-BXX,3`@6TUE;6)E
M<ET@?"!/<'1I;VYS($%N9"!297-T<FEC=&5D(%-T;V-K(%M-96UB97)=/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M
M8F%S960@0V]M<&5N<V%T:6]N+"!3:&%R97,@075T:&]R:7IE9"!U;F1E<B!3
M=&]C:R!/<'1I;VX@4&QA;G,L($5X97)C:7-E(%!R:6-E(%)A;F=E(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%>&5R8VES92!P<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`V+C@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@3W!T:6]N<R!A;F0@<F5S=')I8W1E
M9"!S=&]C:R!O=71S=&%N9&EN9R!A="!E;F0@;V8@>65A<CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,38P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@879E<F%G
M92!R96UA:6YI;F<@8V]N=')A8W1U86P@;&EF93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^-R!Y96%R<R`Q(&UO;G1H(#8@9&%Y<SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R
M(&]F(&]P=&EO;G,@97AE<F-I<V%B;&4@870@96YD(&]F('EE87(\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D(&%V
M97)A9V4@<F5M86EN:6YG(&-O;G1R86-T=6%L(&QI9F4L(&5X97)C:7-A8FQE
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XW('EE87)S(#$@;6]N
M=&@@-B!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#XV+CDP,"!;365M8F5R72!\($]P=&EO;G,@06YD(%)E<W1R
M:6-T960@4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VXL(%-H
M87)E<R!!=71H;W)I>F5D('5N9&5R(%-T;V-K($]P=&EO;B!0;&%N<RP@17AE
M<F-I<V4@4')I8V4@4F%N9V4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E('!R:6-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8N.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F
M($]P=&EO;G,@86YD(')E<W1R:6-T960@<W1O8VL@;W5T<W1A;F1I;F<@870@
M96YD(&]F('EE87(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M,#`S+#`X,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5V5I9VAT960@879E<F%G92!R96UA:6YI;F<@8V]N=')A8W1U
M86P@;&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-R!Y96%R
M<R`Q(&UO;G1H(#(T(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!O<'1I;VYS(&5X97)C:7-A
M8FQE(&%T(&5N9"!O9B!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-C@L,#@S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E(')E;6%I;FEN9R!C;VYT
M<F%C='5A;"!L:69E+"!E>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^-R!Y96%R<R`Q(&UO;G1H(#(T(&1A>7,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C<N-34P(%M-
M96UB97)=('P@3W!T:6]N<R!!;F0@4F5S=')I8W1E9"!3=&]C:R!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H
M87)E+6)A<V5D($-O;7!E;G-A=&EO;BP@4VAA<F5S($%U=&AO<FEZ960@=6YD
M97(@4W1O8VL@3W!T:6]N(%!L86YS+"!%>&5R8VES92!0<FEC92!286YG92!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^17AE<F-I<V4@<')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-RXU-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F($]P=&EO;G,@86YD(')E<W1R
M:6-T960@<W1O8VL@;W5T<W1A;F1I;F<@870@96YD(&]F('EE87(\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D(&%V
M97)A9V4@<F5M86EN:6YG(&-O;G1R86-T=6%L(&QI9F4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/C<@>65A<G,@-R!M;VYT:',@,C@@9&%Y<SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3G5M8F5R(&]F(&]P=&EO;G,@97AE<F-I<V%B;&4@870@96YD(&]F('EE87(\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDP+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT
M960@879E<F%G92!R96UA:6YI;F<@8V]N=')A8W1U86P@;&EF92P@97AE<F-I
M<V%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C<@>65A<G,@
M-R!M;VYT:',@,C@@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^.2XV-C`@6TUE;6)E<ET@?"!/<'1I;VYS($%N
M9"!297-T<FEC=&5D(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T
M:6]N+"!3:&%R97,@075T:&]R:7IE9"!U;F1E<B!3=&]C:R!/<'1I;VX@4&QA
M;G,L($5X97)C:7-E(%!R:6-E(%)A;F=E(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!P
M<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Y+C8V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M=6UB97(@;V8@3W!T:6]N<R!A;F0@<F5S=')I8W1E9"!S=&]C:R!O=71S=&%N
M9&EN9R!A="!E;F0@;V8@>65A<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-C@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E(')E;6%I;FEN9R!C;VYT
M<F%C='5A;"!L:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XW
M('EE87)S(#D@;6]N=&AS(#(Y(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!O<'1I;VYS(&5X
M97)C:7-A8FQE(&%T(&5N9"!O9B!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D(&%V97)A9V4@<F5M86EN:6YG
M(&-O;G1R86-T=6%L(&QI9F4L(&5X97)C:7-A8FQE/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XW('EE87)S(#D@;6]N=&AS(#(Y(&1A>7,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C$V
M+C<P,"!;365M8F5R72!\($]P=&EO;G,@06YD(%)E<W1R:6-T960@4W1O8VL@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VXL(%-H87)E<R!!=71H;W)I
M>F5D('5N9&5R(%-T;V-K($]P=&EO;B!0;&%N<RP@17AE<F-I<V4@4')I8V4@
M4F%N9V4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E('!R:6-E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$V+C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!/<'1I;VYS(&%N
M9"!R97-T<FEC=&5D('-T;V-K(&]U='-T86YD:6YG(&%T(&5N9"!O9B!Y96%R
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.#<L-30R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG
M:'1E9"!A=F5R86=E(')E;6%I;FEN9R!C;VYT<F%C='5A;"!L:69E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XS('EE87)S(#$Q(&UO;G1H<R`R
M-R!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.=6UB97(@;V8@;W!T:6]N<R!E>&5R8VES86)L92!A="!E;F0@
M;V8@>65A<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S@W+#4T
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5V5I9VAT960@879E<F%G92!R96UA:6YI;F<@8V]N=')A8W1U86P@;&EF
M92P@97AE<F-I<V%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/C,@>65A<G,@,3$@;6]N=&AS(#(W(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
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M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%1E-!13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY32$%212!#05!)5$%,("A3:&%R92!"87-E9"!#;VUP96YS871I
M;VX@17AP96YS92!!;&QO8V%T:6]N*2`H1&5T86EL<RD@*%531"`D*3QB<CY)
M;B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^
M,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$P/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D5M
M<&QO>65E(%-E<G9I8V4@4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N+"!!;&QO
M8V%T:6]N(&]F(%)E8V]G;FEZ960@4&5R:6]D($-O<W1S(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M;&QO8V%T960@4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($5X<&5N<V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-RPW-3$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@X-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PR
M.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O<W0@;V8@4F5V96YU97,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%;7!L;WEE92!397)V:6-E(%-H
M87)E+6)A<V5D($-O;7!E;G-A=&EO;BP@06QL;V-A=&EO;B!O9B!296-O9VYI
M>F5D(%!E<FEO9"!#;W-T<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06QL;V-A=&5D(%-H87)E+6)A
M<V5D($-O;7!E;G-A=&EO;B!%>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!$979E;&]P;65N="!%>'!E
M;G-E(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^16UP;&]Y964@4V5R=FEC92!3:&%R92UB87-E9"!#;VUP96YS
M871I;VXL($%L;&]C871I;VX@;V8@4F5C;V=N:7IE9"!097)I;V0@0V]S=',@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%L;&]C871E9"!3:&%R92UB87-E9"!#;VUP96YS871I;VX@
M17AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PW-38\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D=E;F5R86P@86YD($%D;6EN:7-T<F%T:79E($5X<&5N<V4@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY%;7!L;WEE92!397)V:6-E(%-H87)E+6)A<V5D($-O;7!E;G-A=&EO;BP@
M06QL;V-A=&EO;B!O9B!296-O9VYI>F5D(%!E<FEO9"!#;W-T<R!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^06QL;V-A=&5D(%-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!%>'!E;G-E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L-S<U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T-C0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#8U,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M96$S93$U-SE?-S4S8E\T-CAF7V$U,3E?8C<U834S.#$Q.65F#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5A,V4Q-3<Y7S<U,V)?-#8X9E]A-3$Y
M7V(W-6$U,S@Q,3EE9B]7;W)K<VAE971S+U-H965T-#(N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5$54%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E1!6$53($].($E.0T]-
M12`H3F%R<F%T:79E*2`H1&5T86EL<RD@*%531"`D*3QB<CY);B!4:&]U<V%N
M9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^26YC;VUE(%1A>"!$:7-C
M;&]S=7)E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y7:71H:&]L9&EN9R!T87@@;VX@=&AE(%4N4RX@
M<F5V96YU92!S;W5R8V4@<&]R=&EO;B!O9B!T:&4@<&%Y;65N=',@;6%D92!T
M;R!T:&4@0V]M<&%N>2!F;W(@:71S('-H87)E(&]F(%!F:7IE<C]S(&YE="!P
M<F]F:71S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2XP,"4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYE="!O<&5R871I;F<@;&]S<R!C87)R>2!F;W)W87)D<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W,BPU,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1A>"!R871E<R!E>'!E
M8W1E9"!T;R!B92!I;B!E9F9E8W0@=VAE;B!D969E<G)E9"!T87@@87-S970@
M9&EF9F5R96YC97,@<F5V97)S93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^,SDE+"`R-24@86YD(#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,87<@9F]R($%M96YD:6YG('1H92!)
M<W)A96P@26YC;VUE(%1A>"!/<F1I;F%N8V4@+2`R,#`Y+"!487@@>65A<B!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/DEN8V]M92!487@@1&ES8VQO<W5R92!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1A='5T;W)Y
M(&EN8V]M92!T87@@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C8N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y,87<@9F]R($%M96YD:6YG('1H92!)<W)A96P@26YC;VUE
M(%1A>"!/<F1I;F%N8V4L(%1A>"!4:&5R96%F=&5R(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^26YC;VUE(%1A
M>"!$:7-C;&]S=7)E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&%T=71O<GD@:6YC;VUE('1A>"!R
M871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2XP,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E
M<W1R:6-T960@06UO=6YT(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^26YC;VUE(%1A>"!$:7-C;&]S=7)E(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.970@;W!E<F%T:6YG(&QO<W,@8V%R<GD@9F]R=V%R9',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S+#@P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O=&%L:7@@
M3'1D+B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/DEN8V]M92!487@@1&ES8VQO<W5R92!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D
M:71I;VYA;"!G<F%D=6%L(&1E8W)E87-E(&EN('1A>"!R871E+"`R,#$R/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,RXP,"4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D9&ET:6]N
M86P@9W)A9'5A;"!D96-R96%S92!I;B!T87@@<F%T92P@,C`Q,SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C(N,#`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L(&=R
M861U86P@9&5C<F5A<V4@:6X@=&%X(')A=&4L(#(P,30\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(Q+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!G<F%D=6%L
M(&1E8W)E87-E(&EN('1A>"!R871E+"`R,#$U/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@9W)A9'5A;"!D96-R
M96%S92!I;B!T87@@<F%T92P@,C`Q-CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3@N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L(&=R861U86P@9&5C<F5A<V4@
M:6X@=&%X(')A=&4L('1H97)E869T97(\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$X+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y(&9O
M<G=A<F1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4X+#<P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')O=&%L:7@@3'1D+B!;365M8F5R72!\($QA=R!F;W(@06UE;F1I;F<@
M=&AE($ES<F%E;"!);F-O;64@5&%X($]R9&EN86YC92P@5&%X(%1H97)E869T
M97(@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY);F-O;64@5&%X($1I<V-L;W-U<F4@6TQI;F4@271E;7-=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T871U
M=&]R>2!I;F-O;64@=&%X(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(U+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^36EN:6UU;2!;365M8F5R72!\(%!R;W1A;&EX($QT
M9"X@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY);F-O;64@5&%X($1I<V-L;W-U<F4@6TQI;F4@271E;7-=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T871U
M=&]R>2!I;F-O;64@=&%X(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(V+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^36%X:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN8V]M92!487@@1&ES8VQO
M<W5R92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4W1A='5T;W)Y(&EN8V]M92!T87@@<F%T93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SDN,#`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-87AI;75M(%M-
M96UB97)=('P@4')O=&%L:7@@3'1D+B!;365M8F5R73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN8V]M92!487@@1&ES8VQO
M<W5R92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4W1A='5T;W)Y(&EN8V]M92!T87@@<F%T93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4N,#`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P139-04,^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0Q/CQS=')O;F<^5$%815,@3TX@24Y#3TU%("A$969E<G)E9"!);F-O
M;64@5&%X97,I("A$971A:6QS*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@
M=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^5$%815,@3TX@
M24Y#3TU%(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&5X<&5N
M<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8L,#`S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T
M+#$Q.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')O<&5R='D@86YD(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-C0W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$T.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W9I<VEO;B!F;W(@=F%C871I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,V,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5V
M97)A;F-E('!A>2!O8FQI9V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E=F5N=65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PT-#D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#<T-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&]P97)A=&EN
M9R!L;W-S(&-A<G)Y(&9O<G=A<F1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-2PQ-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT+#4W.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5F%L=6%T:6]N(&%L;&]W86YC93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S$L-3,V*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$S+#<V-"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M969E<G)E9"!487@@07-S971S+"!.970@;V8@5F%L=6%T:6]N($%L;&]W86YC
M92P@5&]T86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?96$S93$U-SE?-S4S8E\T-CAF7V$U,3E?8C<U834S
M.#$Q.65F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5A,V4Q-3<Y
M7S<U,V)?-#8X9E]A-3$Y7V(W-6$U,S@Q,3EE9B]7;W)K<VAE971S+U-H965T
M-#0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$504$%%/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/E1!6$53($].($E.0T]-12`H3W!E;B!487@@665A<G,I("A$971A:6QS*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^25-2045,
M(%M-96UB97)=('P@36EN:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN8V]M92!487@@0V]N=&EN9V5N
M8WD@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D]P96X@=&%X('EE87(\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/C(P,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DE34D%%3"!;365M8F5R72!\($UA>&EM=6T@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY);F-O;64@5&%X($-O;G1I;F=E;F-Y(%M,:6YE($ET96US73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<&5N('1A
M>"!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XR,#$R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5
M3DE4140@4U1!5$53(%M-96UB97)=('P@36EN:6UU;2!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN8V]M92!4
M87@@0V]N=&EN9V5N8WD@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P96X@=&%X('EE87(\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/C(P,#D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5.251%1"!35$%415,@
M6TUE;6)E<ET@?"!-87AI;75M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^26YC;VUE(%1A>"!#;VYT:6YG96YC
M>2!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3W!E;B!T87@@>65A<CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^,C`Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3D542$523$%.1%,@6TUE;6)E<ET@?"!-:6YI
M;75M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^26YC;VUE(%1A>"!#;VYT:6YG96YC>2!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!E
M;B!T87@@>65A<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,C`P
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3D542$523$%.1%,@6TUE;6)E<ET@?"!-87AI;75M(%M-96UB97)=/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^26YC;VUE
M(%1A>"!#;VYT:6YG96YC>2!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!E;B!T87@@>65A<CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,C`Q,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?96$S93$U-SE?-S4S8E\T-CAF
M7V$U,3E?8C<U834S.#$Q.65F#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V5A,V4Q-3<Y7S<U,V)?-#8X9E]A-3$Y7V(W-6$U,S@Q,3EE9B]7;W)K
M<VAE971S+U-H965T-#4N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4T,T%%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,3X\<W1R;VYG/E-54%!,14U%3E1!4ED@1DE.04Y#24%,(%-4051%345.
M5"!)3D9/4DU!5$E/3B`H06-C;W5N=',@4F5C96EV86)L92P@3W1H97(I("A$
M971A:6QS*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R
M=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C;W5N=',L($YO=&5S+"!,;V%N
M<R!A;F0@1FEN86YC:6YG(%)E8V5I=F%B;&4@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@
M97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C4Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`R,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D]T:&5R(')E8V5I=F%B;&5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS+#8X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,L.#,W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!#;W-T(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C
M;W5N=',L($YO=&5S+"!,;V%N<R!A;F0@1FEN86YC:6YG(%)E8V5I=F%B;&4@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D]T:&5R(')E8V5I=F%B;&5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XX.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L-34X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G-T:71U=&EO;G,@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O
M=6YT<RP@3F]T97,L($QO86YS(&%N9"!&:6YA;F-I;F<@4F5C96EV86)L92!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3W1H97(@<F5C96EV86)L97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4T,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4W1A=&4@3V8@27-R865L(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C
M;W5N=',L($YO=&5S+"!,;V%N<R!A;F0@1FEN86YC:6YG(%)E8V5I=F%B;&4@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D]T:&5R(')E8V5I=F%B;&5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR+#0P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L,CDV/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D($1E<&]S:70@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY!8V-O=6YT<RP@3F]T97,L($QO86YS(&%N9"!&:6YA;F-I;F<@4F5C
M96EV86)L92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3W1H97(@<F5C96EV86)L97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5N9')Y(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C
M;W5N=',L($YO=&5S+"!,;V%N<R!A;F0@1FEN86YC:6YG(%)E8V5I=F%B;&4@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D]T:&5R(')E8V5I=F%B;&5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,38U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
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M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P15%*044^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS
M=')O;F<^4U504$Q%345.5$%262!&24Y!3D-)04P@4U1!5$5-14Y4($E.1D]2
M34%424].("A!8V-O=6YT<R!087EA8FQE(&%N9"!!8V-R=6%L<RP@3W1H97(I
M("A$971A:6QS*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T
M:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C;W5N=',@4&%Y86)L92!!
M;F0@06-C<G5A;',@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!A>7)O;&P@86YD(')E;&%T960@97AP
M96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PW-#@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$L,3`X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<F]V:7-I;VX@9F]R('9A8V%T:6]N/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#0U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C(Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&5X<&5N<V5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`S,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,S(W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M;WEA;'1I97,@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PU-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XX.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06-C;W5N=',@<&%Y86)L92!A;F0@86-C<G5A;',L(&]T
M:&5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PP-3$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#4T
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]L;&%B;W)A=&EO;B!/<&5R871I;VX@0W5R<F5N="!0;W)T:6]N(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^06-C;W5N=',@4&%Y86)L92!!;F0@06-C<G5A;',@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C
M8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U86QS+"!O=&AE<CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ,C(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,R,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@06YD
M($5Q=6EP;65N="!3=7!P;&EE<G,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT<R!087EA8FQE($%N
M9"!!8V-R=6%L<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<&%Y86)L92!A;F0@86-C
M<G5A;',L(&]T:&5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$L,3,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q+#0W,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?96$S93$U-SE?-S4S8E\T-CAF7V$U,3E?8C<U834S.#$Q.65F
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5A,V4Q-3<Y7S<U,V)?
M-#8X9E]A-3$Y7V(W-6$U,S@Q,3EE9B]7;W)K<VAE971S+U-H965T-#<N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5&4T%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-54%!,
M14U%3E1!4ED@1DE.04Y#24%,(%-4051%345.5"!)3D9/4DU!5$E/3B`H4F5V
M96YU97,I("A$971A:6QS*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL
M97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3`\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5P<&QE;65N=&%L($EN9F]R
M;6%T:6]N(%)E=F5N=64@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5N=65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#,T+#@W,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@."PS.#8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8L-C0R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M969E<G)E9"!2979E;G5E($9R;VT@3&EC96YS92!!;F0@4W5P<&QY($%G<F5E
M;65N="!7:71H(%!Z:69E<B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U<'!L96UE;G1A;"!);F9O<FUA=&EO
M;B!2979E;G5E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y2979E;G5E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-"PU-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT+#4V,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-38S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6QE<W1O;F4@4&%Y
M;65N=',@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY3=7!P;&5M96YT86P@26YF;W)M871I;VX@4F5V96YU92!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4F5V96YU97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V96YU97,@
M9G)O;2!S96QL:6YG('!R;V1U8W1S(%M-96UB97)=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5P<&QE;65N=&%L($EN9F]R
M;6%T:6]N(%)E=F5N=64@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5N=65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#4L,S`W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#@R,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPP-SD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5A,V4Q-3<Y
M7S<U,V)?-#8X9E]A-3$Y7V(W-6$U,S@Q,3EE9@T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B]E83-E,34W.5\W-3-B7S0V.&9?834Q.5]B-S5A-3,X
M,3$Y968O5V]R:W-H965T<R]3:&5E=#0X+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%1T1!13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY214Q!5$5$(%!!4E19(%1204Y304-4
M24].4R`H1&5T86EL<RD@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S
M<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$P/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y-86YA9V5M96YT($%N9"!#;VYS=6QT:6YG($9E
M97,@5&\@0VAA:7)M86X@3V8@0F]A<F0@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY296QA=&5D(%!A<G1Y(%1R
M86YS86-T:6]N(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N
M+"!!;6]U;G1S(&]F(%1R86YS86-T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;7!E
M;G-A=&EO;B!4;R!4:&4@3F]N("UE>&5C=71I=F5$:7)E8W1O<G,@6TUE;6)E
M<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY2
M96QA=&5D(%!A<G1Y(%1R86YS86-T:6]N(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296QA=&5D(%!A
M<G1Y(%1R86YS86-T:6]N+"!!;6]U;G1S(&]F(%1R86YS86-T:6]N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,W-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C$U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,34\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
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M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%5DE!0SX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY354)315%514Y4($5614Y44R`H1&5T
M86EL<RD@*%531"`D*3QB<CY);B!4:&]U<V%N9',L(&5X8V5P="!3:&%R92!D
M871A+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$P
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D9E8BX@,C@L(#(P
M,3,\8G(^3W!T:6]N($5X97)C:7-E(%M-96UB97)=/&)R/D-E<G1A:6X@16UP
M;&]Y964@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4W5B<V5Q=65N="!%=F5N="!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M
M;6]N(%-T;V-K(&ES<W5E9"!I;B!C;VYN96-T:6]N('=I=&@@97AE<F-I<V4@
M;V8@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-A<V@@<')O8V5E9',@9G)O;2!E>&5R8VES92!O9B!O<'1I;VYS/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,C,P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R-S<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4P
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
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M.D9I;&4@2%)E9CTS1")3:&5E=#`R+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970P,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#0N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`U+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970P-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,#<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`X
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P.2YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,3`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#$Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q
M,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3,N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$T+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970Q-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,38N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$W+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970Q."YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,3DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#(P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,2YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C(N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#(S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970R-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C4N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(V+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970R-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,C@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(Y+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S,"YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,S$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#,R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S,RYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S0N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#,U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970S-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S<N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,X+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970S.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T-#`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0Q+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T,BYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T-#,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#0T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T-2YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#8N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#0W+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970T."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#DN
M:'1M;"(O/@T*/"]X;6P^#0HM+2TM+2T]7TYE>'1087)T7V5A,V4Q-3<Y7S<U
=,V)?-#8X9E]A-3$Y7V(W-6$U,S@Q,3EE9BTM#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E6MAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>TAXES ON INCOME (Deferred Income Taxes) (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development expenses</a></td>
        <td class="nump">$ 6,003<span></span></td>
        <td class="nump">$ 4,119<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property and equipment</a></td>
        <td class="num">(647)<span></span></td>
        <td class="num">(149)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Provision for vacation</a></td>
        <td class="nump">363<span></span></td>
        <td class="nump">305<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments', window );">Severance pay obligation</a></td>
        <td class="nump">192<span></span></td>
        <td class="nump">164<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenues</a></td>
        <td class="nump">10,449<span></span></td>
        <td class="nump">4,746<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
        <td class="nump">15,176<span></span></td>
        <td class="nump">4,579<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
        <td class="num">(31,536)<span></span></td>
        <td class="num">(13,764)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred Tax Assets, Net of Valuation Allowance, Total</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 11<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6969291&amp;loc=d3e28680-109314<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsDeferredIncome</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 11<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6969291&amp;loc=d3e28680-109314<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6969291&amp;loc=d3e28680-109314<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43, 289<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 11<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6969291&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from severance costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 11<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6969291&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43-49<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 17<br><br> -Subparagraph e<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsValuationAllowance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EDCAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>LICENSE AND SUPPLY AGREEMENT (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Pfizer Agreement, upfront payment received</a></td>
        <td class="nump">$ 60,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RevenueRecognizedOverDesignatedPeriod', window );">Revenue recognized over designated period of relationship</a></td>
        <td class="nump">4,600<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RevenueRecognizedPeriod', window );">Revenue recognition period</a></td>
        <td class="text">14 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Protalix Bio Therapeutics Incorporation [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementProfitSharePercentage', window );">Pfizer Agreement, future revenues and expense sharing percentage</a></td>
        <td class="nump">40.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Collaboration Operation [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities accrued related to the Collaboration Operation</a></td>
        <td class="nump">8,500<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_LiabilitiesAccruedFromLicensingAgreement', window );">Accrued long term liabilities</a></td>
        <td class="nump">5,400<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Pfizer Incorporation [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementProfitSharePercentage', window );">Pfizer Agreement, future revenues and expense sharing percentage</a></td>
        <td class="nump">60.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Upon Filing of Pediatric Investigation Plan to EMA [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Pfizer Agreement, upfront payment received</a></td>
        <td class="nump">5,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Upon each FDA and European Medicine Agency approval [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MilestonePayment', window );">Milestone payment triggered</a></td>
        <td class="nump">25,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Upon FDAApproval [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MilestonePayment', window );">Milestone payment triggered</a></td>
        <td class="nump">25,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Upon Near Term Clinical Development Milestones [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MilestonePayment', window );">Milestone payment triggered</a></td>
        <td class="nump">$ 8,300<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementProfitSharePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaborative arrangement profit sharing percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_CollaborativeArrangementProfitSharePercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_LiabilitiesAccruedFromLicensingAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Liabilities accrued from licensing agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_LiabilitiesAccruedFromLicensingAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MilestonePayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Milestone payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_MilestonePayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenueRecognizedOverDesignatedPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue recognized over designated period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_RevenueRecognizedOverDesignatedPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenueRecognizedPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue Recognized Period</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_RevenueRecognizedPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_SignificantAccountingPoliciesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph 5<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.15(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph a<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received from collaborators during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 27<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromCollaborators</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EZBAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Useful Lives of Property and Equipment) (Details)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Laboratory Equipment [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
        <td class="text">5 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Furniture [Member] | Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
        <td class="text">10 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Furniture [Member] | Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
        <td class="text">15 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Computer Equipment [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
        <td class="text">3 years<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentUsefulLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EPPAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>TAXES ON INCOME (Open Tax Years) (Details)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">ISRAEL [Member] | Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
        <td class="text">2009<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">ISRAEL [Member] | Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
        <td class="text">2012<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">UNITED STATES [Member] | Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
        <td class="text">2009<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">UNITED STATES [Member] | Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
        <td class="text">2012<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">NETHERLANDS [Member] | Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
        <td class="text">2009<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">NETHERLANDS [Member] | Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
        <td class="text">2012<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxContingencyLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tax year that remains open to examination under enacted tax laws, in CCYY format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OpenTaxYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELGAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
        <td class="nump">$ 31,096<span></span></td>
        <td class="nump">$ 29,419<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less - accumulated depreciation and amortization</a></td>
        <td class="num">(14,786)<span></span></td>
        <td class="num">(11,148)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net, Total</a></td>
        <td class="nump">16,310<span></span></td>
        <td class="nump">18,271<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DepreciationAmortizationAndAssetImpairment', window );">Depreciation and write down of fixed assets</a></td>
        <td class="nump">3,692<span></span></td>
        <td class="nump">3,631<span></span></td>
        <td class="nump">3,133<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">10<span></span></td>
        <td class="nump">43<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Laboratory Equipment [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
        <td class="nump">14,502<span></span></td>
        <td class="nump">13,079<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Furniture And Computer Equipment [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
        <td class="nump">1,818<span></span></td>
        <td class="nump">1,522<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Leasehold Improvements [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
        <td class="nump">14,447<span></span></td>
        <td class="nump">13,705<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Equipment Under Construction [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
        <td class="nump">$ 329<span></span></td>
        <td class="nump">$ 1,113<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DepreciationAmortizationAndAssetImpairment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets and intangible assets to periods that benefit from use of the assets. Also includes the charge against earnings resulting from the write down of assets from their carrying value to their fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_DepreciationAmortizationAndAssetImpairment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 45, 46, 47<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2420-110228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetImpairmentCharges</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross amount of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -Subparagraph b, c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EHHAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INVENTORIES (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
        <td class="nump">$ 2,118<span></span></td>
        <td class="nump">$ 279<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
        <td class="nump">192<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
        <td class="nump">1,729<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
        <td class="nump">4,039<span></span></td>
        <td class="nump">279<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
        <td class="nump">$ 684<span></span></td>
        <td class="nump">$ 363<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section BB<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386940&amp;loc=d3e100047-122729<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryFinishedGoodsNetOfReserves</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386940&amp;loc=d3e100047-122729<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section BB<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryRawMaterialsNetOfReserves</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386940&amp;loc=d3e100047-122729<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section BB<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryWorkInProcessNetOfReserves</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br> -Number 6<br><br> -Paragraph 86<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section 7<br><br> -Paragraph 14<br><br> -Chapter 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386783&amp;loc=d3e4542-108314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryWriteDown</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES</strong></p> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">a.</td> <td>General</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">1.</td> <td>Operation</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: 0in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: 0in"> Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the "Company"), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#39;s proprietary ProCellEx<sup>&reg;</sup> protein expression system ("ProCellEx"). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency ("EMA") application process in the European Union. The Company&#39;s two subsidiaries are referred to collectively herein as the "Subsidiaries."</p> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: 0in"> On May 1, 2012, the U.S. Food and Drug Administration (<font style="TEXT-TRANSFORM: uppercase">"</font>FDA<font style="TEXT-TRANSFORM: uppercase">"</font>) approved taliglucerase alfa for injection, the Company&#39;s first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the "Israeli MOH") in September 2012 and recently in Uruguay. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by each of the FDA and the Israeli MOH.</p> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO&trade; by Pfizer Inc. (<font style="TEXT-TRANSFORM: uppercase">"</font>Pfizer<font style="TEXT-TRANSFORM: uppercase">"</font>), the Company&#39;s commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the <font style="TEXT-TRANSFORM: uppercase">"</font>Pfizer Agreement<font style="TEXT-TRANSFORM: uppercase">"</font>). The Company, through Protalix Ltd., markets ELELYSO in Israel.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel. The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company received an additional $25.0 million milestone payment in connection with the FDA&#39;s approval of taliglucerase alfa in the United States, which was considered to be a substantive milestone for purposes of revenue recognition, and, accordingly, was recorded as revenue during the period in which the milestone was achieved. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel, where the Company retained exclusive marketing rights. <font style="COLOR: black">In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold</font>.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> In December 2012, Protalix Ltd. entered into a Clinical Development Agreement with Pfizer under which Protalix Ltd. will continue to manage, administer and sponsor current, ongoing clinical trials relating to taliglucerase alfa. According to the terms of the agreement, Protalix Ltd. was eligible to receive a payment of $8.3 million upon the achievement of certain near-term clinical development goals. The goals were achieved, and the payment made, in December 2012. The Company evaluated the terms of the agreement and the nature of the payment made by Pfizer and concluded that the amount received represents an upfront funding of the anticipated costs of the Company&#39;s ongoing clinical trials relating to taliglucerase alfa. Accordingly, the amount was deferred upon receipt and will be recognized as a reduction of research and development expenses over the ongoing clinical trial period.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> The Company is cooperating with Pfizer to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed for Brazil and other countries. The European Commission (EC) issued a Commission Decision refusing the marketing authorization for taliglucerase alfa in the European Union. This decision is an endorsement of the EMA&#39;s Committee for Medicinal Products for Human Use (CHMP) June 2012 opinion recommending against the marketing authorization of taliglucerase alfa. While the CHMP gave a positive risk-benefit assessment for taliglucerase alfa, its recommendation was based solely on the orphan market exclusivity granted to VPRIV<sup>&reg;</sup>, Shire plc&#39;s Gaucher disease treatment. It was not based on the safety and efficacy profile of taliglucerase alfa.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States and Israel. In addition, patients are being treated globally through the Company&#39;s clinical trials and related studies, compassionate use programs, special access agreements, named patient provisions and other programs designed to ensure that treatments are available to Gaucher patients in light of recent shortages of approved treatments. On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d&#39;Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease. An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations to hospitals. Notwithstanding the EC&#39;s decision not to approve the market authorization of taliglucerase alfa in the EU, the Company, together with Pfizer, will continue to supply taliglucerase alfa as required by physicians under the ATU process for as long as it is authorized by the French regulatory authorities. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in Brazil and in other countries.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> On August 10, 2010, Pfizer entered into a short-term supply agreement with the Ministry of Health of Brazil pursuant to which the Company and Pfizer have provided taliglucerase alfa to the Brazilian Ministry of Health for the treatment of Gaucher patients. During the remainder of 2010 and the first quarter of 2011, the Company and Pfizer completed the supply of products deliverable under the short-term supply agreement. During 2011, Pfizer recorded an allowance for sales returns in connection with the supply agreement because the Brazilian Ministry of Health requested that Pfizer consider the replacement of certain vials that might expire during 2012. During the third quarter of 2012 resupply for certain vials was completed. Revenue, net of allowance for sales returns, generated from the Brazilian Ministry of Health was recorded by Pfizer, and the Company recorded its share of such revenues in accordance with the terms and conditions of the Pfizer Agreement.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">2.</td> <td>Liquidity and Financial Resources</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> In addition to the approval of taliglucerase alfa by the FDA and the Israeli MOH, successful completion of the Company&#39;s development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. In accordance with the terms and conditions of the Pfizer Agreement, the Company received a $25.0 million milestone payment in connection with the FDA&#39;s approval of taliglucerase alfa in the United States. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all and the Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Obtaining marketing approval with respect to any product candidate is directly dependent on the Company&#39;s ability to implement the necessary regulatory steps required to obtain such approval in the United States and in other countries. The Company cannot reasonably predict the outcome of these activities.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">b.</td> <td>Basis of presentation</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> The Company&#39;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP").</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">c.</td> <td>Use of estimates in the preparation of financial statements</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">d.</td> <td>Functional currency</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> The dollar is the currency of the primary economic environment in which the operations of the Company and its Subsidiaries are conducted. Most of the Company&#39;s revenues are derived in dollars. Most of the Company&#39;s expenses and capital expenditures are incurred in dollars, and the major source of the Company&#39;s financing has been provided in dollars.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below) reflected in the statements of operations, the following exchange rates are used: (i) for transactions - exchange rates at the transaction dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.) - historical exchange rates. Currency transaction gains and losses are carried to financial income or expenses, as appropriate.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">e.</td> <td>Cash equivalents</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> The Company considers all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">f.</td> <td>Inventories</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Inventories are valued at the lower of cost or market. Cost of raw and packaging materials and purchased products is determined using the "moving average" basis.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Cost of finished products that are capitalized is determined as follows: the value of the raw and packaging materials component is determined primarily on a using the "moving average" basis; the value of the labor and overhead component is determined on an average basis over the production period.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Prior to the FDA&#39;s approval of taliglucerase alfa, manufacturing costs related to taliglucerase alfa were not capitalized; rather, such costs were expensed as research and development expenses. Effective as of the FDA approval of taliglucerase alfa on May 1, 2012, the Company capitalizes manufacturing costs associated with taliglucerase alfa.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">g.</td> <td>Property and equipment</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">1.</td> <td><font style="FONT-WEIGHT: normal">Property and equipment are stated at cost, net of accumulated depreciation and amortization.</font> </td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">2.</td> <td style="FONT-WEIGHT: normal">The Company&#39;s assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="WIDTH: 65%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1.5in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Years</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 85%">Laboratory equipment</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">5</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td>Furniture</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">10-15</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Computer equipment</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">3</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 98.65pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Leasehold improvements are amortized by the straight-line method over the expected lease term, which is shorter than the estimated useful life of the improvements.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">h.</td> <td>Impairment in value of long-lived assets:</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> The Company tests long-lived assets for impairment if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted and without interest charges) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their estimated fair values.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">i.</td> <td>Income taxes</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1.25in; TEXT-INDENT: -0.5in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">1.</td> <td style="FONT-WEIGHT: normal">Deferred income taxes</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> The guidance prohibits the recognition of deferred tax liabilities or assets that arise from differences between the financial reporting and tax bases of assets and liabilities that are measured from the local currency into dollars using historical exchange rates, and that result from changes in exchange rates or indexing for tax purposes. Consequently, the above mentioned differences with respect to Protalix Ltd. were not reflected in the computation of deferred tax assets and liabilities.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">2.</td> <td style="FONT-WEIGHT: normal">Uncertainty in income taxes</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Tax benefits recognized in the financial statements are those that the Company&#39;s management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit the Company&#39;s management deems more likely than not to be sustained.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">j.</td> <td>Revenue Recognition</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> The Company recognizes revenue when the earnings process is complete, which is when revenue is realized or realizable and earned, there is persuasive evidence a revenue arrangement exists, delivery of goods or services has occurred, the sales price is fixed or determinable and collectability is reasonably assured.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">1.</td> <td style="FONT-WEIGHT: normal">Revenues from the license and supply agreement with Pfizer</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> The Company recognizes revenue from milestone payments received pursuant to the Pfizer Agreement in accordance with guidance regarding revenue recognition and accounting for revenue arrangements with multiple deliverables. As the arrangement with Pfizer requires the Company&#39;s continued involvement with respect to the proposed commercialization of taliglucerase alfa, the non-refundable, up-front license payment the Company received from Pfizer was deferred and recognized over the related performance period. The Company estimated the performance period of 14 years (commencing upon the date of the Company&#39;s receipt of the up-front license payment payable by Pfizer under the Pfizer Agreement) based on the date the last relevant patent expires. See Note 2. The Company adjusts the performance periods, if appropriate, based on the applicable facts and circumstances. Each milestone payment that is considered to be substantive for purposes of revenue recognition is recorded as revenue during the period during which the milestone is achieved.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">2.</td> <td style="FONT-WEIGHT: normal">Revenues from selling products to Pfizer</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> The Company recognizes revenues from products sold to Pfizer upon delivery, when the sales price is fixed or determinable and collectability is reasonably assured.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">3.</td> <td style="FONT-WEIGHT: normal">Company&#39;s share in the collaboration agreement</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: 0in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: 0in"> Under the terms and conditions of the Pfizer Agreement, the Company is entitled to 40% of the profits or loss from sales of taliglucerase alfa, and related expenses incurred, except with respect to sales in Israel, where the Company retained exclusive marketing rights. Since Pfizer bears most of the risks and rewards relating to the agreement, the Company&#39;s share in the profits and loss in the agreement is recognized on a net basis. The Company recognizes its share of net profit or loss from the Pfizer Agreement based on reports it receives from Pfizer summarizing the results of the collaborative activities under the agreement for the applicable period. Under the terms of the Pfizer Agreement, for its subsidiaries operating outside the United States, financial information is included based on the fiscal year ending November 30, while financial information for the U.S. entity is included based on the fiscal year ending December 31.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">k.</td> <td>Research and development costs</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment and supplies for research and development activities. Grants received by the Israeli Subsidiary from the Office of the Chief Scientist of Israel&#39;s Ministry of Industry, Trade and Labor (the "OCS") are recognized when the grant becomes receivable, provided there is reasonable assurance that the Company or the Subsidiary will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Reimbursements received from Pfizer are recognized when the reimbursements become receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the reimbursements and there is reasonable assurance the reimbursements will be received. The reimbursements are deducted from the research and development expenses as the applicable costs are incurred.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> In connection with purchases of assets, amounts assigned to intangible assets to be used in a particular research and development project that have no alternative future use are charged to research and development costs at the purchase date.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are consumed or the related services are performed.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">l.</td> <td>Concentration of credit risks and trade receivable</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits. The Company deposits these instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> <font style="COLOR: black">The Company&#39;s trade</font> receivable <font style="COLOR: black">represents mainly amounts to be received from Pfizer, as the Company currently receives most of its revenues from Pfizer. The Company does not require Pfizer to post collateral with respect to the receivables. The Company performs periodic credit evaluations of Pfizer&#39;s financial condition and believes there is no significant risk with respect to Pfizer&#39;s payment of the receivables.</font></p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">m.</td> <td>Share-based compensation</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> The Company accounts for employee&#39;s share-based payment awards classified as equity awards using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period, net of estimated forfeitures. The Company estimates forfeitures based on historical experience and anticipated future conditions.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> The Company elected to recognize compensation cost for an award with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> When stock options are granted as consideration for services provided by consultants and other non-employees, the grant is accounted for based on the fair value of the stock options issued. Options granted is measured on a final basis at the end of the related service period and is recognized over the related service period using the straight-line method.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">n.</td> <td>Net Loss per share</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Basic and diluted loss per share ("LPS") are computed by dividing net loss by the weighted average number of shares of the Company&#39;s Common Stock, par value $0.001 per share (the "Common Stock") outstanding for each period.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Diluted LPS does not include 7,761,168, 7,469,088 and 7,280,469 <font style="COLOR: black">shares of Common Stock underlying outstanding options and restricted shares of Common Stock</font> for the fiscal years ended December 31, 2010, 2011 and 2012, respectively, because the effect would be anti-dilutive.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EMOAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract', window );"><strong>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_EmployeeSeveranceObligationPayment', window );">Employee severance obligation payments</a></td>
        <td class="nump">$ 177<span></span></td>
        <td class="nump">$ 181<span></span></td>
        <td class="nump">$ 174<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts', window );">Severance expense</a></td>
        <td class="nump">1,000<span></span></td>
        <td class="nump">816<span></span></td>
        <td class="nump">1,100<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Contributions</a></td>
        <td class="nump">670<span></span></td>
        <td class="nump">641<span></span></td>
        <td class="nump">531<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax', window );">Net (gain) or loss for the period</a></td>
        <td class="nump">36<span></span></td>
        <td class="nump">14<span></span></td>
        <td class="nump">26<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod', window );">Expected severance liabilities payments for fiscal year end 2013</a></td>
        <td class="nump">963<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ExpectedDefintedBenefitContributionDuringPeriod', window );">Expected contribution to one or more Contribution Plans</a></td>
        <td class="nump">$ 773<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_EmployeeSeveranceObligationPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Employee severance obligation payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_EmployeeSeveranceObligationPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ExpectedDefintedBenefitContributionDuringPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected Definted Benefit Contribution During Period</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ExpectedDefintedBenefitContributionDuringPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected severance liabilities payments for future period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Before tax amount, net of reclassification adjustments, of the (increase) decrease in the value of the projected benefit obligation and the increase (decrease) in the value of the plan assets resulting from experience different from that assumed or from a change in an actuarial assumption that has not been recognized in net periodic benefit cost.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915506&amp;loc=d3e1928-114920<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10A<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=SL7669646-108580<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The charge against earnings in the period for known and estimated costs of termination benefits provided to current employees that are involuntarily terminated under a benefit arrangement associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination or a discontinued operation as defined by generally accepted accounting principles and costs associated with one-time termination benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)(10)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915506&amp;loc=d3e1928-114920<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 146<br><br> -Paragraph 8-13, 20<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.P.4(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394695&amp;loc=d3e140904-122747<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5-8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 112<br><br> -Paragraph 7<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section P<br><br> -Subsection 3, 4<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 5.P.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394695&amp;loc=d3e140864-122747<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS146-1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SeveranceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EY6CI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SHARE CAPITAL (Summary of Outstanding and Restricted Stocks) (Details) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of the total outstanding and exercisable shares</a></td>
        <td class="nump">$ 19,700<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Restricted Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump">1,496,792<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
        <td class="text">0 years<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump">102,084<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
        <td class="text">0 years<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of the total outstanding and exercisable shares</a></td>
        <td class="nump">$ 12,400<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Options And Restricted Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump">7,662,796<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump">5,272,950<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">0.001 [Member] | Options And Restricted Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump">719,207<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
        <td class="text">2 years 6 months 15 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump">719,207<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
        <td class="text">2 years 6 months 15 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">0.120 [Member] | Options And Restricted Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="nump">$ 0.12<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump">447,850<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
        <td class="text">1 year 18 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump">447,850<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
        <td class="text">1 year 18 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">0.399 [Member] | Options And Restricted Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="nump">$ 0.399<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump">23,087<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
        <td class="text">1 year 11 months 1 day<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump">23,087<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
        <td class="text">1 year 11 months 1 day<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">0.972 [Member] | Options And Restricted Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="nump">$ 0.972<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump">996,353<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
        <td class="text">3 years 5 months 9 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump">996,353<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
        <td class="text">3 years 5 months 9 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">2.350 [Member] | Options And Restricted Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="nump">$ 2.35<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump">40,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
        <td class="text">5 years 9 months 26 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump">40,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
        <td class="text">5 years 9 months 26 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">2.650 [Member] | Options And Restricted Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="nump">$ 2.65<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump">402,882<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
        <td class="text">6 years 1 month 24 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump">396,744<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
        <td class="text">6 years 1 month 24 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">3.020 [Member] | Options And Restricted Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="nump">$ 3.02<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump">50,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
        <td class="text">5 years 1 month 6 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump">50,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
        <td class="text">5 years 1 month 6 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">5.000 [Member] | Options And Restricted Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="nump">$ 5.0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump">1,708,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
        <td class="text">5 years 1 month 6 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump">1,708,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
        <td class="text">5 years 1 month 6 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">6.810 [Member] | Options And Restricted Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="nump">$ 6.81<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump">160,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
        <td class="text">7 years 1 month 6 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump">110,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
        <td class="text">7 years 1 month 6 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">6.900 [Member] | Options And Restricted Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="nump">$ 6.9<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump">1,003,083<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
        <td class="text">7 years 1 month 24 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump">168,083<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
        <td class="text">7 years 1 month 24 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">7.550 [Member] | Options And Restricted Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="nump">$ 7.55<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump">160,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
        <td class="text">7 years 7 months 28 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump">90,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
        <td class="text">7 years 7 months 28 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">9.660 [Member] | Options And Restricted Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="nump">$ 9.66<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump">68,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
        <td class="text">7 years 9 months 29 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump">34,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
        <td class="text">7 years 9 months 29 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">16.700 [Member] | Options And Restricted Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="nump">$ 16.7<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options and restricted stock outstanding at end of year</a></td>
        <td class="nump">387,542<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
        <td class="text">3 years 11 months 27 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable at end of year</a></td>
        <td class="nump">387,542<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, exercisable</a></td>
        <td class="text">3 years 11 months 27 days<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(c)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(a, b)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EOCAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 52,035<span></span></td>
        <td class="nump">$ 27,001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable- Trade</a></td>
        <td class="nump">1,410<span></span></td>
        <td class="nump">1,374<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other assets</a></td>
        <td class="nump">3,686<span></span></td>
        <td class="nump">3,837<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
        <td class="nump">4,039<span></span></td>
        <td class="nump">279<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">61,170<span></span></td>
        <td class="nump">32,491<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</a></td>
        <td class="nump">1,247<span></span></td>
        <td class="nump">1,043<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">PROPERTY AND EQUIPMENT, NET</a></td>
        <td class="nump">16,310<span></span></td>
        <td class="nump">18,271<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">78,727<span></span></td>
        <td class="nump">51,805<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
        <td class="nump">5,267<span></span></td>
        <td class="nump">5,032<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
        <td class="nump">11,051<span></span></td>
        <td class="nump">7,540<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenues</a></td>
        <td class="nump">9,437<span></span></td>
        <td class="nump">6,121<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">25,755<span></span></td>
        <td class="nump">18,693<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenues</a></td>
        <td class="nump">48,888<span></span></td>
        <td class="nump">50,923<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Liability in connection with collaboration operation</a></td>
        <td class="nump">5,425<span></span></td>
        <td class="nump">6,566<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
        <td class="nump">2,016<span></span></td>
        <td class="nump">1,700<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
        <td class="nump">56,329<span></span></td>
        <td class="nump">59,189<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">82,084<span></span></td>
        <td class="nump">77,882<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS (Note 6)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>CAPITAL DEFICIENCY:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.001 par value: Authorized - as of December 31, 2011 and 2012, 150,000,000 shares; issued and outstanding - as of December 31, 2011 and 2012, 85,630,157 and 93,489,809 shares, respectively</a></td>
        <td class="nump">93<span></span></td>
        <td class="nump">86<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
        <td class="nump">180,145<span></span></td>
        <td class="nump">145,814<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(183,595)<span></span></td>
        <td class="num">(171,977)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total capital deficiency</a></td>
        <td class="num">(3,357)<span></span></td>
        <td class="num">(26,077)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities net of capital deficiency</a></td>
        <td class="nump">$ 78,727<span></span></td>
        <td class="nump">$ 51,805<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, which are not elsewhere specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableOtherCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableTradeCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapitalCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 5<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7, 8<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7, 8<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 48<br><br><br><br> -Paragraph 6<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount for overfunded plans recognized in the balance sheet as a noncurrent asset associated with a defined benefit pension plan or other postretirement defined benefit plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915240&amp;loc=d3e1703-114919<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 132R<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915506&amp;loc=d3e1928-114920<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22, 23, 24, 25, 26, 27<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of other receivables, net, due within one year of the balance sheet date (or one operating cycle, if longer) from third parties or arising from transactions not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherReceivablesNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This represents the noncurrent liability recognized in the balance sheet that is associated with the defined benefit pension plans and other postretirement and postemployment benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 132R<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915506&amp;loc=d3e1928-114920<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915240&amp;loc=d3e1703-114919<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915506&amp;loc=d3e2417-114920<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915506&amp;loc=d3e2410-114920<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 132R<br><br><br><br> -Paragraph 6<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph b, c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E43AE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Receivable, Other) (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
        <td class="nump">$ 251<span></span></td>
        <td class="nump">$ 235<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
        <td class="nump">3,686<span></span></td>
        <td class="nump">3,837<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Deferred Cost [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
        <td class="nump">89<span></span></td>
        <td class="nump">1,558<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Institutions [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
        <td class="nump">542<span></span></td>
        <td class="nump">375<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">State Of Israel [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
        <td class="nump">2,400<span></span></td>
        <td class="nump">1,296<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Restricted Deposit [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
        <td class="nump">298<span></span></td>
        <td class="nump">208<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Sundry [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
        <td class="nump">$ 106<span></span></td>
        <td class="nump">$ 165<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsNotesAndLoansReceivableLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of other receivables, net, due within one year of the balance sheet date (or one operating cycle, if longer) from third parties or arising from transactions not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherReceivablesNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6787-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386993&amp;loc=d3e5879-108316<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section A<br><br> -Paragraph 4<br><br> -Chapter 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Assets<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>44
<FILENAME>0001144204-13-012065-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-13-012065-xbrl.zip
M4$L#!!0````(`!.$7$(H1J/`#MH``'81"P`0`!P`<&QX+3(P,3(Q,C,Q+GAM
M;%54"0`#]<PO4?7,+U%U>`L``00E#@``!#D!``#L76MWVT:2_;[G['_HX3IS
M[#DD!8!O.?8,+5*.-I*H(]%)O-]`H$EB!@08-*!'?OU6=>-)`B0@DJ!D>R:)
M)*`?MVY75U>_"C__\W%ADGOJ,,.V/E3DNE0AU-)LW;!F'RI?[FK]N[.+BPIA
MKFKIJFE;]$/%LBO__/C?__7SWVJU,X>J+M7)Y(G\9EBN.J/DW#`A+ZO5_"1+
MQ]8]#=+8%E$DN5&3E)K2)?\BLGRJM$C_2J1\G#@F`2P6.]5LSW*=IP^5N>LN
M3T].\%6=4:T^L^]/_)<G4)12D^1:0Z[XV:#:_X1Y'AX>ZCR?[<P@K=0XP=<3
ME=$@^=)\3*0&G*YJ&H]US5[PTF4E*AN+,C84;EA(D!86_CAW%V8B_4.#IY9[
MO=X)?QLF7<.=2(IO@Z0Z-=))@1<IA'BL-E/599AEJK()+]E_D9+%8'93D3N;
M)!4I@@R6MTA/K+O.B?NTI">0@CJ&YF?(PR&H`R$_H^"G3)O3A7I+IX03<8HE
M?J@P8[$TD6O^;.[0Z8<*-&<M:+7Z(],KY$24`]R<]A?4TN%?]]Q49\30/U02
M3^J=;JM;EZ+_5XAF6RY]=&^QZ*EC+VH!5_"/:XN_X!^H:S4OY/XX54U&?SY9
MJSI"=.8Y#CXTF*::7ZGJ#"U]`%V)@\MZN7><-?%.(,VJ-0(]L#5O$2:Y@6:U
M]7-XQCCJS+=[AWW^52#.K#$+,DJ5!3A\MW>X^#H-<%CC.EPA2UPG4M\<!&I<
M)U)K78<[AFZ90(D/]@Y.EFJ_)F%A-1&:H>4:[M,9/'=4\\+2Z>.O](G#2GVS
M=WR2),F2U%:Z/GFIM:[!M1<+V[IS;>T_=W/5H6SDN7RPA4$TCGU#LGI/[DK9
M@JBL9D]KP=`KM]:28P;/,D3J+Z+X"M&I9BS`CGVH@&B]1K/7Z4J]A&`;(*U)
M*6S++5W:C@OO[US5]7OAI@1[;Z*OE"5$2*UU%3QX--0Y`\6?V4Y<GQ+/]PZU
MKVD4RN?N%:\I#CQ1]2K>&V]B&MJY::MN#&WL*6A`IY=#80!LNZ;TUI*O*,P@
MKBRU=N5CH]63^/_BD&/UKP*^I3.#02>QW&MU06.8DR_V3O&-[_*13X8]G@/7
M2^JYAL:JY,+2ZG'P22"K^'^S37!*54<T2URM5][L78)K.XYRI;95F+]3T_S5
MLA^L.ZHR\.3U"\8\ZL3@9J0X,.R,6B/X8T=%HW+WM)C8)H>;>+)_O;C\0^!+
M5"/P@)]YVI\YE.+X<Z7"I(=:Z+6>4Z&X&>]$/9U&1U'J':G9[NV`-;64S/[8
MP%&=]\4-T"/9SE0V-RECPT?J:`:CHRFW\*.E"Q-$H=J;DZ2TQB,S3BT#YD.N
MX]$=&V=%4'\.Q8RT&13(+9_\<75YQV<1M6B2=K)?>=L;1M]`0#DAH!P*F,R[
MK24;<MB2FU'M64!YNX!20D`I$E`N(F"ON'RV::H3&P9*XY[V+?W2T*C%:-\!
M:SWCJCX`;]NTF>?0,8#^9$(I0NSGY-R[L?F[Z;[_6ZTV&)V-O]X,"2X-D)LO
MGRXOSDBE=G+R>^/LY&0P'I`_?AE?71(@DX!5LIB!-*CFR<GPND)2=']\*Y89
M9,SL_UIS8SGKN@N3Y%KM[S/W/6+0C7O\E<1^]Z&!5^2XYXXZ0TI$!IYJ29C[
M9,)\?#S\8UR[N!X,K\>G1#*L]^2J?_OYXAK^6+KP[^-[<C["=S+^/386E)%K
M^D!N[85J5<6#*KF#.<:T$I8.PZUMS?#/Z]%X2!12(\#)\/IN2/K7`W+WY>;F
M\BOI?[X=#J^@8LQR$N7A?R[7H:X`$S_K+<1<$**Z6+ZW)FQY^*I&%KFV[^EB
M`F-U0ZH2,&N]*@F=ETM7KQ-PN\G-U/@+DD`C40><1K#O-G'G-'@>FGZR]!SF
M@2]#(,'#W-#F09('E9$9>CF07;4(?=1,CT'GJ)('VS'U!T.GQ!2]!//J])Z:
M]I)7KL%L`#LJ0/H+7L*/F>EIX%-!4M6<JE4LC8+`AD4NF*-2LTZ^P)S(X1`!
M\8+YY<`$0I@F>YH*?U5TA[HPE@%B3.P8LSF7:QN>=!PI=8DG"Q5$!TJ\)?1P
MI%!]XE1"34DT`/H-VG2R,$P3Q,!Z0":+:B@4>3#<.:^)/E+-XX]\,=6P>9`&
M-H<9B?F$;QRJ3H$?J-+0UUJ=J+KN=VCRIA6KUEO"?[!<F*8M5>N)Z^O_-'KO
M&9GR%5JL5R5+QU[:#,A;4MU07<?0`/`]9:XQ4SFZI0F5!(H4IL&YG^&ZX//X
MZ(=7_?I:NV@4=`<TB;Q1XM#@)U0`CE[(8@9'ZA+@W8-D6,EZ"TXX/>1\T,<"
MKM0G7%]65F$8#'N$X9JH(39I2C\%F&'*ZIDN(V^AEJD!O]@.`6O/*'M'J.I8
M8LU:*$",/J8"_'1(=7+G06\2!0?E!L6^`\%,DTPHT513\TP^LX/N9T+W,J*&
M1)`V-CL\^;?'7"0([(&K_H>O"&"G5C6^"IX4-(90LYF+`&>VK0->V]1C]B&1
M+N@CH(Y+[-50$6<?9,).%3X&R,LE\N$0&#"AY:!0"NH)32#:T7&?R-OXB`J"
MC)94_%9Y5R<CP;G@%\30<.JM!VV8D1'>.;8WFY,!Z)*P?S+:/QG^BPT9$*I3
MW=.03AQ^>8$:>`^!>C&D=$)%!_)5V>\5!`P>MCS#!0QL!7P7J`,O;.JY,/R3
M)U`((,>`/F,]U<EX#FHE:A4:*W"8!O0*H6=JR"$(`Q:3[XW8/#OYTP.^J`/\
MB:KJI,\5:E5*I9K$JFG@/V-_,@UU`IT8.(?R0=N6T'-\K68AQQ2J,1'*FVZ]
M%72^*K$]GE38?3`9S<A203.;*F/&U,!:&%8$PRDWSE&55:Y+HO\L0#XTG09O
M4=/3^;`3Z"?#!E`G)N4Y.'KP\VI<N>O?T@`]CC727$7%0,K\,4EU.5D&.+W0
MT:K$LJV:0Z>>I7-J@@$E&%:G-#*+:V.):\\H-PVAB9P:#O3UA.4/<@=*"7;8
MGEG0];DY4PFN8_!1$D8!2B8J@]8#T`X,YI8'.GKOCX4X""RXD7*HR;LCFQM+
M5&?#ULE;;IP?>0I0Y#?->CM"`"5@AWE77Z,F*C1D)JWT*1@:[()JY(L+F0-'
MQ9<M"4)NBGY*WG++9FEH,3<,A'R$6@8]!U+6DFWA,_D.21+LI9<#G<8EB,%!
M4[J$7Z`0(19V'SMM\(*G8%P-APJ.MHV0X6":,53"(!@#M&7@].W<%XL;*UST
M!`U'WP]*9N#C.<*$(;^$>1.<->,4*08+VP>\2'0=N.4*E,?7-8X-.GV5FP('
MUU!,,!P/7,WP@;`O02[=<SA1:'M%^P-"8:#P650M%J!J<P/RZ=^J!8DUHTY-
MH-U!.\%@UBR<5+32B='2M[P)ASWNI:<H`-((J:V_0+F@%<#'TT0?<_DJZ!-O
M7^Z7X_Y^8(L^J^#<``8=9N-05#4<X6`$@FX'K85VWI\4\$R,.O<`Q+<O?WH&
M:I:7Z6V+:E/@0K%`G#=5-5>H2KKW]2UI1#_H.(''4FR*%/<;P@E2DD,^51(E
M,FJ:PA$2IS6$RR1*K9.+R#D-YT-&K$$AJ4.-Q01FE311,39GH"/HDV(5PO5C
M:78L2!K7H-`!35<-#B[-'H:N7V@XL]5N=4()LMD3$R=`0C@H*U)U^TDU78,R
M</5AI+ZV74K:Q]2\O]5J0TM/KL[P)/'UG.`/?V7M.>M>60MN4:8;[LORK<";
MR.5=7VC;D@,7R=KU=K?=DNN]7L8Z>6R+*EQ9:T.RE&S1:N,-R!-?;Y0K'Z5Z
M,XV3+1#+YZ+9>Q87J]FV<-'>D0M<$\"$_06?G@IQDP_WO7RZ<3%9;DC1SL<J
MDCAPX?7PX?3<=OS^X.-/?>=OYTC-KK3[=DY:*9O$ZB2D2L47"3>@2S"!!G\/
M@CNN\9?XW=+[,$UT+\!4&XY8A<$#'+F3E]J2C79/"67.C[$<&DK<_FG'-H!>
M'`VE;1(UY$9C)QJ&TRDZ#&#=^!(;U2\LF#'2L?IX"X/^.%ISY5OC.1,+N]N"
MUJW+C78Q6[V>*]M4*VBJY:Z0/B^XO++S,VDX@=@N>9#T!<H=0"LDM>WE:>\@
M:5E2\X%9R2TT("LB],C*V]*0LM2&5AIY909D140>SQV:5VB>MERQY;QB<VR%
M!'^P\XK]8)<K=&[]!F0QD1=+TWZB]([B(HFET9&8M8'QOPDVEE#>K<G*=4H[
MG7#LV@[M,-*6Y['(7?GXTI;FF,B=YO.D?<0='*H/Z!1/9>F?J`6_N>#<NXXQ
MX=O$`[YH<^,OCZ+HQ?*4JN.=3N2?%<2Y3DI(X*6_!650YC/(8,9SSC?H4H@I
MD*]4<GKM=7(*8(T(@A=3:N";V^"60/)18)`SQ,JRWQF2K)KN!IINJ>T/6,F:
M(Y"?\3@)`V?\-E@BY$+=^LMR(T?\QO?"4(("Z<M5Z5ZG'39;`9!E,5&>26]W
M.JT7S41IYK[#S?TN3("#X^!>RH45Z_C0E6X<>TD=]^G&A$*AS.&?GK$,1[W"
MN<IU<,#U"UDI#/48W)3H#C5C(^/KX*:TWJ1T8N?4=^`FEJ$O3LR<`TZQ,`IN
M1K3;B)3D32S&QH[4;;:+K\2G9-M$1*L96^#-"S"2_TI]-!;>HC^#5[B'%?@1
MH^EML'DUMKFUN@T/%0`3Q;,%G(!.^\O7#:4IUYMRMU.$F\SLV:X'7@84]!1'
M?3RBMEW^R*1H\WV/]'4R90_\!.<NXC.NU8?!3H@L]>K-7DO>;"FV;(2L%[+1
M8+2D6$=9!?8L.7#_L+&K'&F%E"P'4"E+>VB/M4(VR=%MY!,#<,S-IUMX>(DF
M?BBV^(4TZ>^B[;;.7K;;UDK9)%8SNI.2`6\/LBD]J;FS:&F%;&PP);]DUQZ>
M3!U-[[P),W1#=0PJ+@^EO3B@OYDR%/BF+@U(A'^$1YL^JX;%+OTCR(!]]6&I
M?G*MV8S\Y%4DQ8&7Y\366C!&[Q-Y:2XF$*[D``Y.ID:ISM#3PKNH?/5N&KOO
M?DW=T708'$U"L8IE*57/E%9#B9JK&-!R.2E/A16IW9)>!R<KG2/'7=KG]I6=
M[]+>^N=`!]$!/IRB63/#HA27>'VY0$9.1H'TY?:8;KL;#?H%4)9%1:D7CIN-
M%TU%>>L3/?"$=Z6"'WB_#6]DC.ZI,Z#,F%EXV#2VB9$K9:F=@CLKD?0YX&V0
M>Y.DAY'MXXW<_)H!?@UN,#4>67>J"?;Y)C@5S0%GO0UG*?$%C6[&>DC>N4I6
M65OF_Y)_?"(3[&&DS5K]>8ZT^9:"A+3M\J1M[5':C+(VSG;R-RP.U;J'[T9@
MBL;J(YZ@8&/<@4@&0LB3\$?<@S"5RS>F_!/^OU\,QK^<DI;TTWOR:70[&-[6
MSD:7E_V;N^&IN*BS9+3`:7^BX5V,I:KQ`)R2^'N)]R_\O_$.A/6AHO%K_E&X
M!-<)$'WJG_WZ^7;TY7J`2$:WIWB5R@4,OPUOQQ=G_<M:__+B\_4IF=BN:R]B
M1>AA$4*03Z/Q>'0%"4T5-$4&[,PV#?T]X0$?_%),.H7\<1I0UMKOPXO/OXRQ
M$C/(,!B>C6[[XXL1Y+)LBXJ:_]=S#*8;_/[&*;^LX.HID&[Z@\'%]><0$Z`)
M:Y73*DV]-Y%:]+HT!ZQL&[6\Z+N+_QL*;<EFTP?,;_&$X)J=G](B:/#^?)H6
M(N-8A)RX3B[5=6:3MXK4K"JM5A5^OBNBQ:MB\#0BYL.Z[)R19RA+)6_&M89=
M:T5>%`;WX*9S;Q#R4EW82J3B2%XJ??N/=S^H+D&KK_FU<%.U=/:]\GW"A^6\
M5_`Z)=[^?$Y=T'$P""%>[&5D2O&&CUG%*-RNB*8`+IEJDK<V*)FQ,$S5P9N;
M]X;%@WG\.S:DLG?$51_)TA;^#UN]JOB,^X-YW,5T+Y0CX$=D&(:1P8-ON.;%
M/HN80UM<TT*YOR=_-=,K[>[)*PT">M4NA^>8H:Z`2F]U5?.XTJ&1/(QS*KSD
M-/\$60#L%LX@P1M]<#!0NOA9"5PF8D^QZHE#3C@.'AJKH(N:4G-*;;E<QT.7
M7PZQUS8/DF6+[IS@%ZR9$_;MQ!N&'3T(3?:C!79K@2"B8H+A);!.";_K^X/?
M+?RF5/\;!K:Q9G[\DE<OX18-.E<-A]RKII?4(=6-3&3X\.V7^ET]\43'\8>'
M@$@\=N>VQ]"#39DR_%#`8AU\:8@;X<DN?A3=/,:<*+8VD7L2DUV&]),_?9&E
MYV3/#V&?H)]71G(U*9!<KDIRNRI)W[SX09=;D?]-N]Y[T;*OX&ZT1#$-/QQ:
M%`TM80]X9#0_G%80XTE-I`BBWH01N,ILO#>[J&RKVNXT7G*3/;?6[6LMZ]U7
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M)-5[.4\>K0R!.8:WE'W-Y[HFSRVK^/YPKH-,!3W.8NB/NL';];>Z+D7`>OQ`
M-PU"`F4+??R=QI6=&L7?M3H$@+TO1>"OYYYC\6A_1QB\<B\OU^0"A+Y`+>=I
M\&,J'L8BWZ#71_(7"FRP%F"WR$'N7K?>;@7'5([S-97MGD+,^<!O9WS"CXEA
MJU*+B4CUT2<V/CU%2?S`.?T'U>%ASMRG"PM<'4_$;\+S_N.Y:OF.D'^F+PR9
M6$I-(D!5LRFWZXUFDW]P!`,_R[UU=R@KME5FYMA59,3)5L-_28K4];_=4HJL
M>VA$[ID.5)?B\;G?\/3<;DVU7E[TO1B?RH[4E5KU1K<CYV^2#=DW1JUKQT(;
M[E&FUTM\>S?BVSF)5^1FYP?Q<>8ZNQ'?R4N\TNW^(#[.7'<WXKLYB6\KL:\!
M?9_$9ZX[%`SJG1(4+A[GXWLDMY>#W"B&3#+YUHC1W>^9W&ZKU2SL+DJ=&F3@
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M;Z/=+"!)C%ION32YK57-T73*`YOV+5%"$+[XS&9^],3<J5,4+D=<X^?JW\YQ
MC0_'0HE?[8I-@?,"+(6!5Q3?.B:7\_1)-3'!W9Q2EUU84]M9\'Z6=IBH>+X?
MIXO6-X#YGO+%]6"(6[TUN5-OX,YOVK8P3(H;A7>%,S>%TXXW=0X364FJYPVL
M5/QX4_STQ%JHQCT&QSC<6:?-L3#:O.8!U2AZ_Z0A5P\L2OJ1D/PMD0WB;OSU
M$M3)`/MI:#PKCZ(2BYRRSV@IQVHP);A8))<FPFMA9,.]B@.J[J'/["4-N-*N
M-UOQ"Q3"!(:/,V+*JG7"CVD0E3$805-"!G\[IZ>_)5F.<"-2*)30IF#<;OH!
MD@<4_%*'ZM#YP!']1YEG17<*;")76ZT"EV]?1F"3G23N]HYY*G87"[BNASP5
M+DO"=#N,?_@B>GRCL[^SLD<3HM5\A6&ST^P5S\=C:&-0)A&SG+QEE))K&YZU
MU6.$U<XX9EU5>L>.V;*7FWO-/=[:.XY_E:%'T<H?T2D/!/UR6)=>52")#"%Z
M^Q/B^%;GQJ%+U=`)];]!]W)H;GP#(Y32VC#9?<U&YLZS=.>IT+3U%<?T:!>Z
MJ?4C%DK`FU3`4SAD^(/"YG,5BE)O[="(Q7*GDLV+(+KM34R:U9(;IET%RXRU
M8:/:;12(1K?>BM\S=>WN3AT@C_#/N$I7UH=0GO$=E'^0*_7_VWO3YL:1)$'T
M^YKM?\!JJ\8RUT@F#IY94V6FE)35FLF4]"1E===\@\B@B"X08./0T;_^N4<$
M3@(D``(\8[>GDB*!B/`S/#S\L/PIQL?A+2+SUN"9R+!>B(7YOBV)FBM/[]+=
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M9\\V/$T]@O+O6DNI$8S=5L[.5642&$_`4<!Y:,^'M9@D%V-[#=)44=_]<^&V
MNN4:ZPCG=U0(7-L3]W<=02W"G3MH];H;574_7=0I2DLN<Q/:G"L\88#(:'UL
MYC<K[0D.QL<(U]T4L"N?G9*3$G-MC>TYH6%+^$V)I)BB;XJTF$A8#L`-*[)2
MSA2&&-I.G%@3,I$.*$/E:*D2)EJLV+]/-/5$)./L1S).22G=,&6LB@<@HP#Y
MIAZ*ZHZ(8UO%/KCCU&%GF)6A%7R=DZ$U[DCWY(58/A'960*6[<.R10]B`?>U
MW.GCET%;#"6=?^9P49'P\`(ZFDB@P/%VC3H:J7OQ7=*?'<)Z=%-/-XMTRD?8
MGEVI=UN]_L$UXQ80[P?$^W`!'@6'?3=,XGJV1?!&DPHDS<JR,"M+W9^D++%#
M["<L:J_6YG#[=5<624EH_[%-S26FB<&["\>>^&/O5*[*U)8\*)6[+*[*HAP#
M55PR5L%<KZ7)&V5G[/$E8TW'TU.[:^NW^F72XL4U982Z84MK/F'G.%&G=5O#
M0>.WXRMN>#>]"2UZ)1G=A3[J;_?P]+GK^O,%*[E)H_X?[>"P#T]<&E@0D5AC
M@C:2X^HFO0VM^&[M]Z':Z.>6I/9^ILX'^6>&EXJ+BS#S=\.;S4`!@Q'(Q[JU
MOMH.,9XMAF:*@[5/U=OZ)%UY6CW[3>XH/0;RVK4PX'RW_:SKB\]!4L\="W.E
M!:HN>-0A@K;B]Z;[N2B*W&/EG@LLME:H!@6@BLJ9)A]?VTBEUY5W`E2_,P!\
M#NE_^^5(EOGBZE+)JKHCRA4',D7!TD`JVHZ`9)0<5:7DTHNKA5#K[Y"2Q8#,
MH&0Y(+N\`^"F0#XZ^H2L`#+^>]/JLZ?V!ZN`BJ^E5J":U)X]65LI<^N!NB=C
M8KS@LS?$RX(JZX'&M[JNDKTI9"VF9KB:))>B#;K5X<*,K2!OPB!N"JCL7YNF
ME)K!@-DKJ0V<)@FD:NJ2DM@(G'-K<F-;XR*P)1X-]K5AM]\9C4;EJ)?QVLJV
M:CUY2=H*+#$3`V&B6`8YT[\UKD5Z_4RXTNNH!9`FN7(XJ@V,7'Y<^6#`C6`7
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MH/"\'\FEB3^9Y8>VO\:#+D$DLBQ$1Y9#(YA(`MFS)!#1D45$#AY#G+SHR'),
ML=ZB(\LV)%YT9-DG?47?$QU9MEH,3W1DV0'614>6?=,ZHB-+HT"(CBQ'D/<@
M.K*(CBPG&VHO.K*(CBPEJ\Z)CBRB(XOHR"(ZLHB.+*(CR_Y#+#JR[.9L+#JR
M[/LA7W1D:1H,T9%E.Y@6'5GV0]$D0T)$1Y9#Y$/1D45T9!'.;]&1Y=3<N:(C
MB^C(LF\=65;ZFY7(VUQN-C/NP`R+%%$_?&AF%4[CJ`'^@_9-BE0-T:9D+ZDB
MVI2(#)4]SU`1;4I*G<Z/;17[X*,2;4KVTPLE8*E%=$2;DBW=,XNF'0+BO<Y>
M6W?+)]J4"%A$FQ+1ID2T*1%M2O8;<Z)-B6A3DF()T:9$M"DYP38EV[_V+-D8
MI7(9P[PJB'>Z,;FV+O0%.H$O[/G<MAZ\Y;*'>8\U7G-S*"O=7K(NY-I%-0AK
MHR4PN[VATMT05DRLH9?/CW;.RP\SW2%/NDLF,`S&*>NLB<R_?,,%BQ]X]L48
MDSM@77MR3\;VLT5'^4,W?<(QU>PDK/YEMZ]TNJ,(@Q4*:"X/L0K]\'2J"GK#
M<!XGZ?I9>,\BG9(@720T?;DTZ8;INKR"<E4HIQ2DG)R@G!Q13BE-.44="J&K
M15_65VM8:,FM:,FU!%NI((OW'1"ZL1[=N)9>*]5BB7K\^Z\1T?"\=EV?3/"_
M6*KZ@M8=*$R,G`&VJLF4P5`NC^B<E>\7$K>G79:;/-6'1!/.K9@53IG[2YJY
MKUB.)4-7H4?YN4(;4CMGHX/%\A@K]\Q!+Z6#"ZVW>73T,T$I;ZR71$>ZQ>"^
M8$,IBHW5!G`Y;/0U>2^Q`8RN:KWNIJ*2,<;*1D&#06\OT='/!*6TJ)1$1[??
MW4]L*$6QL5)42F*CW]M/Q;$]FP6D0]E+%.SP/+,O&-CA"6%/4`"\K"A#;=,M
M(V.,E5N&6L,&:GG&Q#!]SWB!P]+8=VC#Q*NWL>E/R.0KK!J'\#TZPNWT2G<L
MPWIVX4!%)SF?8\DJAJPZ1FI2I^`L;AR',JJ5OJ+TAS$<U@'%OJ.X,9V5B>)N
M?R0/3P[%32G%3!2K0^Q+V2R*L:G*]7RA&PZ><2_@N6?"S^R9/VW5/(AKP<S5
M;`[,%ET+*;7>%$!;V[>[6C6`8@"X3=^W#X:#=/-D.F^!937:(ET9RKV"RTJT
M5(U_TS3N8`\=9/!L3FO?]6MM$J&:VATI1=<*-I3AWDYY94Y0D7>V:8S?V7^3
MC3*+/2JZ8T;!3?GU9KV2J?\916>]M0GXTJLQ\6:8<LYS,M9DE*XK-JL6J3:+
M'RFG8(6$!>SD@)/,6HL5ZKCRRL&#+58IKC+7XXQ(:'WHUCN=]O]JHU]<:1H$
M<\&$816)F?Y"I"="+$350L?\+\/"DKBV,Z%M0FEZUS.QB*.;F/<U'I,%5E/5
M0RF$-PT8=V$2GM1+I!^@'>`96JW"E3Z<T<3?W\_/[\X^EJP'72NJ*\;#%=,[
MF6KM+L9_Y];DP7BVC*DQQB["R='`=LQ4=I4&$"JP^:#+5&$6VB!8P0;!H,FN
MOX)6NWF4SB\N;G_</%[?_"[=W0*RKJ\>*(=MI4Y+P2+21[`ME*E!G@C!MS"F
MU8R5(0\W&+V3O;'\SA1A#5N)(.DJD@X:H*F20]/;H(I2%:H6+V"4N<K<2E%I
M=574B-CN>NX<&\M[O$E?#!N,#D=?$-\SQC#)M37N2!^PT!-6"7TA8#I02\(`
MF\/UGUQC8NB.@<M!>^&,6RMG'ULTR1R?>IW!R^]M^]4BD^B5]U8TZ3=OTH'G
M'3!@#'L!1]RY/J;S@XDSI@-B]=NI/?9=&,)FILF$P&)L5C\2IX('Y\1!L\CX
M-R]>.I4<`E\_H;WDX4L!7)@OZ!'#<B4:#A,,N6QJP7-@%!'8D]YQN1<@+%=O
M=,/P%R%7.^29D9%_&8R.%9YAUZ>UPMUW%RPUL*#"4<""`N0"$<$*HT6;5%D>
MI9"")<;G:*-9M*%!'BKA$#>!7VF&O_Y*[67\?$/P)1/KLL3&_=+Y`Y"=4?D5
M7[GRL4"G;DG?R01,$0O0?@XVX_@=5G[U_?SLHZ1CI4Y6\QSA'`-\@;$8O@Q6
MHVUU<JQ7[]5.,`ZENQ/4+/!L*<%K``!B4G<9>SW$7NR<[633W9&$W@)-]'=)
M:4EHXC%IH];X5]N>4`&X=/QGZ7PR-RP#[!)&H0^XXJF-)59CUM/C_?G-P]?;
M>]@3_`4HS3$(`9V%812?Q[^^7IYO\CKE%<=^0:H"YSV;_A@$$*M/F%.=%L\W
MK'\R!FSEB-_4<%PO&F:"$/)4WQ;R!/`:L?[]/D<&6IB@-*@V8((.+`M[U4<Z
M$94,L-3:'G'FDN<0G08?H:#H$]_TI`6@BQZCJ"3H*!M3@XH>,-NS9?-3J/>^
M(&`<_J[[8Q3'B>$2``@X?1D^>$&/JX]60A>A7..`^!+(D$.>')AC@F]_^/WB
M\B.L6/?B2`G4':S(=_&L%NJ1S-E?$3FF:T>X>WJGP[$NJ(;TG7').R[B;T0W
M`>H/5,+"!V[_!M)N)!64HO)&'%B@R:3UHW\`37S]/0\'.":C(M`'`$=SH\V4
M[AK=G%@ZT<>S0*T!6])5),"Y_5O1\^AN2D46/O%G8O&)(,GGNO,7\=C!?OEP
M'NT!3PZBQ])!+*Z^77W[\^&6+A]TPH3\$O5XXEO[)B(>58NIK"3R1']Y.U_`
MP=#"UE0ZW9=?C$F$"H+7-2YL&:M+W#RQPM-/Q'M%3TERK\5?.&:H*&R.&-@[
M^<P;H2BQDR*^'-M_GJ7-)\8=;D!RQ`R3CE*.F@HLNS792)+K&;@<V9^C&K>"
M@`E:TJOMF!,XRD3\`(8%5Z%+UB+)VI\B<4K3DO5&<T"K&VB&>3,;WJ'YJ6X,
MZ7&:23-4Q_@^-7!TR5V0,7I_8"H:AH#LO98IP<S4'3RGT56!8;FP+=>@E?R9
M><R6BPXBP_)IG^+(0B93^-WC3RU!"ZL%](`:24@C73;J>N.%VJ#`I5,'F3@H
M4`,*^2>\KI/FAFDB##E6)7DC8S\PR;-0RJ1U!BLTZ38%&_348T35P^A@Z:=>
M;*JQ"3L8'A!B4+:##E'S="V=)#GB,,7'5^,3+(V1!QV:29'>8KL6C(:@9BCS
M#-7=PBHJL+_AICU&FDX(-X6?"#(+V+P>\#IJMVA12,B%[RR`^5QVTJ%U4>BN
MR@/WZ1&LQ7W`P#<F*(]71E+X`L%WP]<FK#,@KFU!$P!PI6Q9^%TT+[4LQC,#
MWILPK$;JE6ME=]EZ<?&J/%YAC/YJ$?K.%$^)`(YINV[8Y`N@+WS*R\`S_*!+
M7?EG^E(?_GU"-VR+BDUPN&BAQ@#KAJV+_Q),G%H72:QL>16!?(4*`(D*9$Q@
M(=09T7;%M#:BGFF0SM*VPVM>T`1YJ@?AT`A\/_9A-0'),A"9L`CT2'=1Z:)G
M+D`7+B=03#ZH$]"6<SH&XU)]SIKL47+.X?3QA`1!ZQN>I_5WGAVDF:N;7`$%
M8P:]C3C->+O)9SBJN%AF9)+8X(YF@P+*A"68V2DMJ<QI55-JM-!=X")089<Q
M)C_/JL?'2<GD,3GF*ZBK4.<C;\+:]&=0Y#H_"5(U"MH5=PND$+N[;0&-GVW:
M##18A><8V#R1LCEE+#MSIS@/U$D@*7BF"GT.,4Y+K1/T!ECJSP;Z-^%-KH/Q
MD!3;388=+53`E"'IF$S=!`\%/&81W6$'NJR]`)@-H&$:BGZ47BGC<]75"H\0
MP?1SL(ZI7R1!PN3&04"Q^TP)Y`(>#FSIG@\S\M_CT\1L<"8?%@LVBO0FD[QH
MHX+C+;L_<N/[\!38`@D1+`&88&PLZ/I"F<NVKC<FOOG>BB\4J3L)?#B4<'3I
M"X8-RJ-/X=[T;[;UZ/`WZI+050>':0?X&]](F"Z!+H'#(%-GV:OG&U?9<^#>
M:9$XPQEH$?#N``!P8@.U)?N)"D*TAX3&1[:91V^$(WN'7CLR%QR@_)]@`;@3
M@](#Y(;'>""=8^/[8.TZP9X7<P7&[Y^G8"M,Z`J^./J_#=:[D_DOPQF96(4.
M0RQ583!'Z8>KBX\`-J9]H8J,?@"Q9&T7'3)E+A!JF.2L+1\!V9Y*PZ6Q+W0"
M@SN6)K;CAEJ'OO8];NG1M7D>8;88=Y@"6N]X+3KZ]=_\.4Z#?IV+OWV_^RC]
MEP]&%/6DV`O#8O!0<X*)LOX,%'6]E;!E6CP=Z>\SP^3V!LPD/>M,N]IX!_N"
M)Q3WK_83L0A8"2!^(%`NA2T;4RWJN@^7QB9&*6>^&]C#T3O+%;3M+&9ZP(>A
M<8,-QH)#&C#K'W?WUW^L<YV#(,P,4)H+<QS#=,K?%CGP.M(UTSW8J3KARG?U
M*0G:3$WQGGW\SBPDD^3@[XB,D$#&L[5X\HP'S`Z'Y;_H-K)\L1+;;ID$!X46
ME[R0QX*^F-X+G<+T9HJZX"CGD0D__.4<.Z+3`3MU9/OKD#4#7T&,9BNG?3;M
M)QJ]$_B`<GQGJ5T]WCS9]?P)O:ZC%VM4M<+W0$YZY`%YG<-OU#\![V.0D.M&
MM@W\A&[%2;!&=N)SZ080:?E@'.`DUWBVF/C#%N[3XQ!:.('\,ACU%]TP=6X7
M!K(>8L'`4PD<C?AU'FT7AYX"_9D=?*-+AG#4#MZ6_)</>%(T>E\B)WE>MRS8
MB,9Q@^LK$'V,A\!G/%?9SGN@<SUT@TQ"109J[MR'WPV6)R(]DOG"=G3469.0
M`C\\PPP>^'#^^.-C"T]E_%$8^GQIJX(-HI6W9P6.G<2UQ=(5Q#DL[/%'X'*/
MP3$G8U#.ACN7Z.TIOP?@\'+7?[AE(1$?F.KD]W[T1/$7UB&VVHF+&#=)MSB]
MOCHLXFQ&4!Q@'-]`-XK_!.:"-&-36H2>@PW,16?[+RX?_6&O;B83\$%C1X<(
M(7GB^$0`>6N,!';61_`1>0&=<PR%.V[%YY`*'6;4!G(QD8#R%Y/39[1=+78\
M"%U^+@(SLUV:[@Y8N+$]!`2=/:&;[^HB)M>AA8+;G1=>[L2,A2*60@C;CX14
MP!_V,V'7S)&9V5H^8'*O>L;`U)_T+]]P&)\M9N\NV$2Z%7=%()6#>V/$(KR#
M-W/XKT$I$$"PQ*L9LDDMR83RS`+7#0Z]YCO7I^'U09;"86O-58$HRKE*$%`;
M,WK#73.R>X]EF[Q%/?CL@Z6*RI6I6'XP27DYJ+)FY_3LE@-(XHSK2/C$4;GP
M':S_0%D^<DE&RCSTD-,S2$3;95;@'@LVKH%A#LOSKE2W`9-TI,O(8>J0.1A(
MR#3P)*(B=`&PF\]_^;KCA;\JZ;TH7#[NR"8)O`L<633VF6OG"3%![SE4Y482
MM0+!X3+9O.%%0N#_M9C"I8H5X6:./(=XOL.8.<O?O7RK1L8ZV@]K48O*@;A>
ML.^&8#.7-\=E=(\?,SY?J!W#_)#4&"!O"[KGAN"I"9)X<(J8I!"OHHN!K3WN
MJF1#,]\[QW_89:9%/:MH9.2CJ<6#JD.?Z%HT)'SPH2LH\DC%KBG8,S36BGK0
M81#7I[J05T'/B/&.7%/<N<1T8^@-2E^^[$PGB5C'];&.:DZLXS<#]MF)P8^X
M87E78%S7]AW8LNI*DMCG32A]U$5_Y.KKM\"BR`XA::%PX78_]<U`&\1N+9</
M6O&C<GCJ">(>H_AW7!PC<:S3IT1=3@OLW`AO4Y\I\^<%.@Q-5S@^)>P>#EW,
MSD*##-B:SAAN%`9NP9;._'SF.[.1-E03K;1NXE>H.[LVA3-/=#>*EAIS1>,`
MP"GTO@H/N,$A(+'ILEL`]$&;2,+8!2I\-P'<XIF8V[JPNU+L1J1K209L"=24
M7U+:-.H*7=9(!QC!L,#X3*R3^K,!V7!`R-UC,VB>L)J#>*@8U:4Q'ALFU+<0
MW>8:3NS*,\ZOH;_\B&S24'PR/.+I.UZDU1+FJ$R"6(WQJ!`)9VYXL$ZC+^@A
MV4!M$80?@MF`I,*S?HR28/DLDI++'?AT2P]7FNLMRCA.)"X+QNC7P$LCW06Y
M?S(10/1*LR79O@<J+;B/0L%"GF!GJ&/A@"^!"QCE@A_Z`"TNI3S;%\,H`L/C
M'JVX]#[!3D`5@^&%MU:!AP.-?$JN^.`8U6BE8FTBQ(;:`50O"]BA!_M0YR14
M`3T->_"C[@9,]`984*4Y'+YGL%`T'JDWP;+1@>\SAPA0'5?Y#/)M,0LY6#LR
M`W6SQ.Y\\,H0589A.TR_X6D*\`A;Q#06&^!;3(718]P8.8KI*IX_2.'28Z'&
M+R1V3>>LO\M+8AU5M46"S8S\E5@P,VT`:[$0E21FA`&[O_E73SGVJTCL%8F]
M0J*J2-0X1Z+PCAFW%!?4.24JIS3CFM`?G,5CIR5W!1#"S7+,TD#SCDI8*"&!
M!>?R4"MF]/%KD@C]=(N$77J^X+Y^W)KUZ91P>PQ6`2<+E%,>98=N)E8R!5\U
M#3T([66;Y21LUT(=8]0A_TS-C<R7)'ZQ1<U:?J3+!#4P4;+6$YV)\!X]V.`G
M<=<GOD15#`N^D<['G@\3H*O-]%RZM4\,@-H)G&,8+1UB2>B:O=8UDQQ=\]6W
MQD$0$36$Q^^GI4,FMFGJ3G#;&N`@C/5S@+OAP$=`2NVY,9:(]6(XMA6X0Z)+
MC)@[*.ED"KU(#^E42?34T`C<CO3==KU\YU0DO.@HA_6_,-.!K=U=]WHRA)?5
MY$X>6'!<ZMYP$@-'CNRY_D_TEM.#5_Y$D84?7I_&TWN"Y>Y04S3!1.@<U%FP
M'<M)TDVTYO#X9#P;U&T'1$/VL70O@0F*=VXVH[KVN)\G>#%0X!TX#O,Q,5K6
MMMJ<:SF[!@Q%_90FGP339/@T+,)G!B<\&'G,#WW!N9>\853!,^P`=+/#LRO.
M``<REBR-SX9_!+`EP^\Q==6)K\M+XX1Y.\!0G8.)2K<LS-TR[=>/&`1H!N=3
M=BL5[6C`:7%?'?.EX@4.PI-:.#WLNF3R6?I@\%S1^"K:2\][_'(P?$AB+C<\
MO./=7/#D+Q2"#P8?-0%*((QT1TR@C6-*<F>$>/QQYAVBSF('[Z19[*5%-VK8
M>]E5?TLBWKCS$18<(UAR[4%,)P9UQ)9/`PZ9]<#2!JB2T1U0./1`'AD-(.O4
M@>3$CO$Z=]V"RH,YMAY[*_;PM7LXR=G#+]`MAI;LBVZ>WB$@])GRRV>7.O.C
MJ_06R-'S#'2P22_:@/=?B!MX#-G^;;"H_?C]^Y-N_85RBC&W/)<\U,IS3`=@
MICG="AU"N/^*INQ0SWYP?1P8[0O8.6%3I&EY>'IP:#]XU*(>2+C'XN@Q*@)F
MFCCZ*]Z?.#26C^H'6EA!GQ@FA1.TDQ=D7_QEV:]6W-)')VF+IYR-4YPAC/2]
M%O!ICH!?`\4MW`KJNPS>?]F.`4WY'Q-V0B,)=KA7%@XRIJ:OPR^*8&?DIC#(
M$!4=8(B_]&=VE022'4;1!@(YB=VUXLZ,TD\S^Z+,A+,YV+!X`\6L@C,6"WQD
M9FR`MRG>!,SB:`D5%C\ZT("^)*YTE]ME[F>*,4JKX)RPBA)X-0\6D^6E!F3G
M+H,E)NAK:?'+\JRF_F2SI"P,V)R!\LR=C!IAH<W'`KW##"6.!EJVH%16TH'0
M_2ZX0"I[DX_91)8_!=N3.9%8GEH\Z3>CF`GA^UZ,E7Y!FW:&45/4/&;#T`>Y
M;<JSF]?<0W6D*^J1HYF(X1F<AH>L#DBP,\KQ1/>PP3+=3&AUU[71CL_/(Q`[
M[E[ON,\Y.^X=!HL[0=H1&%"+H/;'7E:C:\=`VHP?#H05MEF,$#_%T_@SACO+
MYQFZ<W*/!^RCJ#>B6-3QV)_[3&&N]`FPE059]I+@PV/FPZQ`T76\EWT+'=PG
M4:\Q9Z\H&0/C/3`"NVUB3L^<>#,[3+I\"B[UF4,RN.5!JYA@2"5&K[MQLZ^&
M<TF#Y5<YDON]GW^1OMS>7U[=MR]NOWT[OWNX^DRK%.H+EU1@O6]77_$%NC.M
M8[T"W/9D>YX]3S`<G.X=??'K&?NW,*O=G5]>7M_\'LJ&@K)1<2R.L&`H6KX$
M!\3486/"-0"'8$Q31K"V-:+"^O5,S9SV3[#EEHZR=:X^SGX1OK^<7_SW[_>W
M/VXNV[P6B_/\]$&5NRVUUVO!OQ]_D0K0)%[YBS]EDJD7RO*PQW3+-SR"L(#!
M7!-B2:<H/Q<F3.X"*HY!Z]9$@ZALE%X3"RA*G]>9X9$B1&%WF8Y%+[1R]O$*
M*"VGVQ^N_^>*Z8^D5%#$,AM#;BLE$+J'7$Z?87V4,$,LGZ\;1WDVAK5&L%O&
MM38:=OJ],I;,]@_]WS`,=(;[K#&GB:>Q%&YF=JXS$P+W2!A<:K)Z#M3ASKWJ
M+G.HTR=U7MUQV9"8ABZ;^%K$N7FOS\VS/$]UV-\*;W-#AQRMV&NR+!-JD]9A
M+QZ(@RU^1^41]!HM88.54(ZA;HH.2<.:!.6Y,3\D^CG(M6=QWI+KSX,(=%;.
MS:?5JNC=SY0FX<.O$X*.78\P@>/3?L"J4RZ-+2437M\)`],]EG8$BY7&K$T9
M%O)A-UNA*./%\CMUQ8;9.OQ^&\=>RC%BY:)H/9X8*'A1S:),7AV#YKO@;19-
M_V)+9([)Q!%D"B\SUA):8K^UA)%[GT7##SS]K=J%5A.^#+KJ97>&\&8TX%5;
MY\VX#.K/&1LRRJ%E/86`4XBYXR:ZD<1B-/\.;L)R@H6Y@98HH173G6QO@.&Q
MF!;-;.3&%POM)33(+"A@G(PTCF4AT+!`&.-)YS5K<Q83JUO**LS1H`5X$9M;
M=!+@1F%S+#22'C#BM[#X#(O<"G<Z%N1@6!P65J:&Q27'P<'P28=6UI%8U4?J
M8@WK`!A6F$W(-LIH31PL(UZF?-KBR`VK6KZ2H*I15$>'X-,P>HO70IECXJII
M_$5HR2>=%W[!FU671V)AU$I`BXPUA'E@M/HBNSI;+DT=+E,'4L,+6?"F\R<-
MS\V:\6A2"1%'S[[!4FP`03/CB29USQ(EEI=H'^=C6MV&V2/L,MP`%J,Q/NO%
M)@JL+RHUX87[',Y4M/A0&$Z$!8>B2.TU49[)H,$@F%?W>$@_&Y4]0@-+4P&2
MM*W'!(Q-&)5527H+ZU1CG(7E8A$05F"-BO@35C!"LP[02?MM1*A)\URJHBP)
MPZ%2L:#CJ&%SGG"FL+?7*80G;`=4N=7X8?'2+AYM4')JUL`CZ@I6YM.-5]PU
MTBHFG@-$ZR/8;E"?+_->*);M-"$8F!PF*V=O4W2;=7V7U3QOQ8P+,IZQ^H1S
M6+;'L]BC`V%B];0`#J_)Y++]//P==\A`V?$.428]>'K!,T5!*0+!7NN($S\S
M_C/GS,CK.$GWT99]FCZDF"\E:/G`[5ZP.G4'JV:X43^WJ!96S"U+GP]>-MS0
MGF0)_[05`O(IC6.`$5'D64$!-(0)EG"C'0\"&Y?6_V:#Z8Z#%D3,3=4*:IV]
M1WT#,)6(."\&6@9HM=ICEGK$[`A6DVL!-@R=<&J\L94%)Z%P;;R]7%"Z@P$2
M%,R@915*BOH./$0'(NC[XAFX#S+A(HMX59>H6/G+DS`85JL)BK.EJDZQQD#Q
M\HQ9A:,RRQ4$)ZNHJ5%&`QL6T10Y$*94TRSI#'Y0F,/I!&L<Q,LD8I$H9AC$
M=4R\C'Z8S)UM*43=E`SKQ39?8@,L-XS!0T[A%C5,;6'V%Q:TMR:XW);D+]JL
MMT/`H4$5K<SB6Y0V')!$"P;>I2^P_<*+MR#0%O0Q)K>SPRW/W([S0>3[H:`M
M/8T@*5WI'2,RL#LL%HFG*9RA>R.>=YZ5F\JZ0_`'<J&&?ZDZC!IFY/?E^IAT
M7]$%,)/0Q3.B25YT.J+'`X"1ZAT0!(*%=XF4:O6A3_[IN_S`OPP_+P$69;ZU
MDI/''%<8_<N3:`UG[,^Q#MB81AYC#:_E<FFLA$]&)ZAX'Z@"W9_8SE:DTQ/_
M)JO;DQ%K]K3/YN\);XA5CLC)#1'K!_*JR#QWPQ;;GY-`48@:;%X5X8>IN\!4
M;44F]>ZL42%Y6Y,\K8+D+6^%K+!OZ+DT31;_1\V?>/O0?;CN/)R&]C]",Z%Z
MC5,01G1+>R;;@K&;8%C@(]FTD*E1*O,YMEZ\!4=862,HGI';B)`-N7E/P0<#
M31<.[1,UVN:QXA_8&BCH$O(*YGBJ#]@LW4`PPZ!+<'&`GJ"H0/!]=,0R$JY)
MFJV'V0TL13)/)2?*8$<M#Y-4R#R!A+89NU:AY1VY$>TFC&C7GV,&87A=&I0Q
MXHB*B>=+O(!F5JO%L)!\S!8,3.TT=^:R(PWQ0;#C56"B?F"V[Z&-N%S1K94H
MVT"-U\`F-()F<PF#=6JXZ)!%@U[BK:AN,*H.^^!I,O4"F21GT`!06B&+2LQ[
MJ8G"AGN:(@I([)]O]:]<WVI.<B7-<CP=-^MJ/-"[E7A.:E@QB6])H/&\>.;R
ME#I+L2:TB<FM3^B!<$#5V$ZXBZ%.TM'O\0%KTIKO656D4SV@/K;P(!H6E(LE
MF@4>L*"'=&[.;*Q>L/2[HR=\0#SJ-ZBE'A:M>H^4\BVV88M<`G"HG$H/8^RF
M8;"=B+T<VU/BK1.NK8F/GUM8.6G";&>:*<%ZM9_=7CR<?>05+\)])33':5<?
M[%-ASTFP:N9OB;J%!*[JT/XFL2*[2PV-N<J+`<K[Y,S1EQC6\8Z9'+KGP5&:
MA)V-V9IXJ:R54P?/QMIH4JSSYJ;T-YJ;'N_,RW>O-2TU^:U9;(N*F#9@U"-+
M7;\GQOS)YYT=W6Q?6AX?.<EW&4/5PD]EN2>UDF)LE'HIFY_2(SOIGL^"L_+;
M4:2U<%`O)!:XTPK+[F#WO:`]'I86MUASY"B&^8G5)J,.=&FA.YZ!7;]7J&C@
MOG^R^J+`7K1P,)8*-WDS"/0;LD@^6B$(`^9HG/:$-55;O8LQ=@W@H=[5(R/?
MC6U%GGA)G[PP?V]PWX%[X_)%),5T($B46'0+M9CC%M_A*"^PK7)9B[GPH[2:
MJ+((\]F&"H0MB1>&A.,+6T'<UQ^NE=8-9*[L_;_B/'&CV\RKVF9;F"T;E2\>
M8XL'+W:$]ZA]%.U)IV.(?XV=3L%6])G<4DE9V'CK8]"JFF!3_S,HPARFV-BT
M"WL>9N-V.A92I^-@I%*\WEO2;Q%6@6-Q2_$5T9V!EY?C?<,2*S<\GY>NC,S[
MP++&&5E0)JN]B%61>(NSA0T[+1C(IC$/(E7C!=X8-+`_LQK2O`4*7O)DSKX<
M)8PA4;B].P:AO5-IJ1LV*J\<R=P\M+7(F&]QJ.QLPALTL^8:/+:9KH3M/3@2
M;H4&-FK&+2>&>=M:QN"1;3PX;+Q4",^_I2GS*^HT4$&GJPM+?$12OWY0A_`:
MLF[`9@&W,,LCRS!N!69=6.HH;*P9NM,"QR(+X(M?HK`Q4F(2,`>_AX]UMU_@
M0-3CYM&>(UF7[A'`*?'C^YS+]TMC'`I`&-Q.Q8+?<V7U8`BM;U:?-^@,$YK9
M8%K%F99RZU+$<GKXX)8W\+S&UI\@I=B=]WEWGN?LS@_HG6XS?R<>YN`HI)]N
MS&&X"]".97"TM=\)2=\9<&P%<J&S^X>QB8>CJ<%<9J@:L$(2^RU*[J&NCS8-
M](C2.WDN$U,'L:\QTS1CPD2YY^2UA$[S3OF)-AY#`\MQ,2N66]9<QX0%FF*)
M4[8S):Q:>G9\C1M_)'*4)](Q@AV7G0C`BD$#))ZR&WH)CFQ?3"#,#).W0@HE
M1(R5]*0]M"S&*;S^+NYL`:%B#A5^1$83ZADWTHF$!7Z1LUSTL_C88C=D-.RI
M8_(>KUFI<D'H6=M>L`V#SD_#@_3Q[,C(\G?TA@%_CL$XX[U-\&09=$[7H]"E
MZ'HH/(.&_K&G]X0G.RKWCA%Q@;+@">&ABY-K%'ZR3MXK)22=QF`DEFBXKH\N
MKEO^=]CH/99#0.\AI[1:,RMEQ<_8Q)I$&W;B4!T<QVFWAN2=9CKD+O5&Q%Q9
MI3+$Z7RO]W\K9_^_@0W@&UY%+_`N&7>;T]GYL:/;F!WX#)-FX9H)3$@?SK[=
M!9<T8:;N$[8'`HV`PH#;)WV'WR:Q#%E4*;S(KN73:^)@)T_W3(F9%O#-'*3Y
M`55`"UVG7#7\)'=D68DOBMX>Q1^'%>*UNJ>SR^FPV^I1UO&]Y*0"RD1'L:"P
M_:`UZ"LMI3]LP<=N?]22AT-*X$%+'<KXS?I39D2H.(Y9O(3Y'L0P!,@.]Q,:
MBA(6N<\>)'GT#8(08O$%&+Z#6TTLOH"6ZY7I?Q4Z"ZO>&V]+TDKTLP]RQ&W?
MG-!FH&!_M2F#P\-I9O@_[?:5-?D*O(JF9;L='N2`Q2.IYW_\YR??;3_K^N(S
M[85X.[V+=4(\MR8/T=GR/`R!OT,?CT'<1_+F?3$!";_][_\E2?\9C(0]'>!5
M_.<JJM]_[EWPJBM_4"$P)D"H(D]V!L->OR-'__^,QL/#W/=D^NN9[K;M:1LQ
MV(;_:<K2X_B";QGLZ1\/EV?2A(S![C7=7\_:VMEO/576>K(L1Z@HM*S&81X4
M@%F)8!Z4@5D=@`+:0YA'!6"6(YA'96#6>B-9WC^8^^IZF.51"'/R\74P#Q6U
MWV\&YCNZ$UWSOKR@W>B_*T#/?@').,S'`+KLF'#+"O[/LU.B/BR##K4G:]T"
MZ,A>ZG:QTI?78T5)8"52!LEWUV&E/1R.1H>"%64]5N0$5B)UD7QW+5:Z/:V0
M[&R`%GI7$NZBJ_"1?+)NH?F-VPV7MQ>/?]Y=23-O;DIW/[Y\N[Z0SMJ?/OU=
MN_CTZ?+Q4OK'WQZ_?Y,`CZQU'&^/_>G3U<V9=#;SO,7G3Y]>7U\[KUK'=IX_
M/=Y_>L.Q%'R9?VQ[L3<[$V]R)D4V2MQ$X9_YTAX\W?&21LU1GA/5(@=%>@<K
M.F>)SEE[WSFKXF&DD!9,J5@XE!F,POAFT)F8-IBDBC7_]XP3QIMK?+8,\]<S
MS_')Q@>.M[EIN9]AS%\SE"28=\JG?WS_]C">D;G>QAMFC/DYDS[5"N"@/(#%
M3Q=U`W@9MIE.[8XK'Q';XK*,IQ.3EG*8JL0)@/JRK6?J:[Q]O)+Z4ENZN/W^
M_?KQ.TSS0$4Z>J2@]FFPA<(1F`4-N(_UO(P*^UTWO7=:08#+6@VVQ?;)>R"4
MW9?R)'&K"ONG/)G&<]`.;:&_2PYE"UKCCT6]W%X\X%T5+==#)C'K!_,%J?43
MI"OS0-,@BJ=($"J+:,48%XR%Q>1$&GF,(6\M],P_L]2/**_CXJ$CG?.VR,8\
MEK#`&[(%@42T51O6%\(*[O')4U=K/(C9I14MT&A+I$$?>3;Z=5`FVZ6$G.J&
MZ;.$1ST9W8W(0<*`A<I"EIA).R'NV#&>\`\LK+B4T(KX7&(P&G^'5;@C3J-1
MS/@;,@$KSQ(/!PL(WS`VMH;VG(3,`/CE8C,<`:TXRJ:2]C.BM/\S"[7FM4ML
MJY!LAFS/Q"ZX!*.3L&-3&(KNSG1>UA7SAE&RP@3;9RRH@^5(4$D&8$2E]:+;
M])">'WCW==.P_B*3CR#NI@_(2==T^2_=\G7G/:((O4N1E594]1W/618\9=*H
MUNAZ_MOUE]O[#K(VZG+6K=Q(W-Q%T8-AVT7`8]0[D61AC142PGMVBZH1KG/B
M.;$T&3;*+:-E=:.L%QIP&!,"/)=2#Q)^YV'MXA!O$94_P!'5-;`Z@[_`5[48
MGGE*%S\;(AY#Y'S$BF8+GO`:1(TD>D.^V*8_)V'YES!0?S5`-!`X6%(K"83#
MS0FG;*[&/DMJ8".%B4:Q/9'G%K&L8RX2895+Q!K/G*97C!CY$_5V#1.\>1_@
M('"5-AG`78PRYAL-V@+:_S3`ZU!9;DD_*;TA?J)/_J1T>E@]Q\2XEUBAG:S;
MR`ACA:XECX:`8"JD+V1Y_]2Y#OCUYR'?<O&+U8"*JXPPY=[-T=.&FR::JG2T
MD#P?TETK6M30F.,X<>6)8[MQA?XQEQ3UG_B$%5[)"M^P&2)E'6I=L<P05DXX
M:3V'%02#8@UNO*S#VKB(Z+4E$RTTSY(!#DN'`=@G7G363(65WJ9FA$$M")YR
MQI08KZ\;V`:Q(0+18K(4JR4?+8^F:OS+9SNR'IL12WZS9'5,F]&?F06$,3QA
M(12.HZ@K>&=9?6=4SG"WJ<@5I1<H\E&DQ_N#+OVC"1V^3Z?Y9NQH&B^573*&
MBI;IVLN'D+#H7(OS35#\GH6%AL8OW^]9(*A#SZ91)%@X*>/Y\*5<+L.PH8"G
MP[Q<?@,0)HK9X2.Q6&MLI!23F''"*YS.`\FHGQDM:8U>X47].1XC,<X8,Y#G
M*%PIQ>P=.=S_J$`$S_$7655##^%*I_K$<UB"DPI\@,6XL;[W0!7'Y<?5*%J/
MBD[J`*!GE#ZTITL+!LE$.<33[ASS&I-M-U($34EK7OA71[K)I`A5#W06/E!"
ME(_&`+M!H)>1QV+A6:4Z7J2.AF_33&\L=!'(`F#6-)#>L8=0C)B<LN(#6&(D
MH03"IU$53S%C40_WU12C\.[``26GAD/SP(*BJN%!&K5)>H?)+,2$.0%KI@QL
M07P1.YX9419H<F(WF'G%A'M=K^_$7>]/>9E;4:$=9+RP!->)7NZC,B#T7#1A
M[6)@+VS'$113''2O<[%;$B9-!F6'>*)'1M&B6#D[+UVWC#W,A90I%+K1T[IG
M&56.#+H+8>VD2")3!3%H1?N@2R&S.R<TWRK:N3/:0\0<,U'=)%I,&M[*.K]2
MAU'LXH8K!E<W)@ED99F@T:E4Y'WLM?88YV@/VAGWY)5&\M0<-P!9F]^8&`1U
M#>,UR5`6\0:('=R8RYN7Z4;1!SGK+Q<EP)=XTAV:)F\>B2N0H+EH-#%UO6(`
MD3T>ZRX]0-*<06Z7@@Q/X:C6IN9C6.J;/L%%'`N?]^+/<^,V.OM38-TE:QT#
MEFB>O(7#A$:GOJP/ABK:O*N433S1/4RHPPBJ9U^G>6W<3DFYOT9#=M1=OBU`
M#4_&/J\M.O7-*>BCP":GE4[9<8TBS$^"FG"!T*1;YGX`<X^Z\]A#L;X!W.^.
MO</01N1JV`+B4>1SDRR:):IWR5#+,@J1L`N'S`V79&%1#^Q(]S-B39/:TD^C
M09\A`+[HTB_ZP_"+'OUBV`N=`,AP^-U0U1@]F)3'',]`2(#CI^%(X2Z$T:@;
M^1!&`_IUF)E2/25%[`I[O2LLWTRSCW\0T&&`/,8W2-KOV)6,T-O:D]\MDN8E
M-Q^I;F;:UPRQ-H]A+;6'O#`4NWR[8'&;SU@DC=8S8<*&802PJO!9?(J.SHL$
M\"(FH8IF,T]1B4;Z.Z5+NR.F$_#]5#?[1,6PA."GBMU2F=>X-N*2W\O:$'HJ
MUUL_:3']]),RX*[+P]`57'!0D+>A./935Y`<7?$GYJ?/(Z5012?0ZR<.FDFF
M7G;1]*:T1).SWUK2N?_L@V4XI%$'@Z0-Q,LHZE:ZB1,^Q#&;J-)[&3LB\D%:
M//IC/+-LTWY^9X5!IK08Z#RP4?Y&GAQ8)QQ9L3<PUB2!'_Z+.#ZZAN8M?JZ5
M/IRQ2<\^!NU3B?3%?@?U]3B#V5PP0J]YI2WF@;XS,7`@6&(+7;`7MF,!0\?F
M@N&]F3[66Q17?]K.7S!1<EB<$'N[,O!8R!`<CXE'S\=T$I027@)%'Q,@W7AF
M8^$!UV/EZC^<7\RN/K*"!E@:RC8)*SKYHCN&'E=K/BW*%5/=\,^"^![/`L>I
M9^\F^@O&V!+6&.N\JAF[V:%>!.D)+&PR93U_T)NLSYG/WWG6+7C?=A<S4()!
MS1:LT#&FL1`.T3WFY[]+M9_*N7>8Z;%:K[2L2U`N_]5VS,DKCDK+Y2>\\+';
MOX@UXA"P=D+\SB`Z%/`N0[SZ*3.;XS7U$<D\]_Q;X,)\#"=`,DYY<^>B:.WP
M\J.IPAO42F<S+-W#K+VD7+JCX;($ZTC>32:YL!5T->'YU.LO0RT>.-1*]</B
MOE@S80),"77=_*32JX%6<B6QL*6@,(CM.QZ*/1,DG=63IKG=;\#:88.N).N$
M70]CET"ZI*@_!R%.09A-9SUX\7N/U)UNDB#QD*2Y_A<)>2_CLB*\DV5A2#\-
MV$U)UN&.QF_1?@RLE5-PK@M]=>'P//,^O!^.];4`KHK"_VCE-L=_CH=CI<(S
M0OV;P=_!A72@J\/*`^$E@83I[J9$#'[WQWT*2;\^K0E$OPY?2U$Q1KQ(C#/:
M@;B$E@YB*W:(L>2'JYI,LS)I8CD'P[9H98,[W;EUJ$-T0I."[XCSP/IK\$2,
M-<_5F[<?C!I/T]3.?I.QDD82U#7+:A3>^G+VFX>7_NJ>^][,=EAOYB2<Z=]K
MKL-`1X]#)Y_]IO1D.9VCG[^@6B&KL=I"XY!=TRI2V5"QW[9`JY'6'8Z&\F@%
M0&PMM0#3,'D`?`V.O8,M`#/L=0M4?,`D-;6MJDN/%P"F!T?RU9Q6%RPC52D"
MB]*6M;:J+3U>`);N6JFICRZ];J?;5?H=K=OM](?]KM)1-&6TFD:#-KQ`7Y7S
M7UX%(Y8:Z-8"XVVLA%$FH+$']D,_Q!94,VR[5Q=%8(L5BTE]V73-HY&6QW!9
M]5^*KKC)BD7#?JD5QZJHWQON7Q>T[#)^XHO/_5WD$!_+I0M^%(T*1*,"T:A@
MAY<QHE%!7&Y$HX+C:U10V2F7:X*D;1G7NYWR7NG<>HE]L]7Z>4.EFRJ?%U]*
MV75OK\*=TE/3)^)-UKVU&G1=;9@VU'/7?<E;=O$?+W@X`0*0_5/C9XRN-D@L
M/GL9-4#1Y+FCKZC*IE#<V-8X'Y#HUZ8ITAW"_UL%3+24VN!IDC8]>:1JF\#S
MJ+^=TSZ'P1?7%NVE&8<JYYFF::7(W>XH$[:<!34"89/4ZPZZ_1H!O+;N6)A]
M$,!P;DWB$1:9$*]YJ6DB`_S9_%MT@3O"2:-LH2AK^'XSG&!WA$RXX8?#*`18
M&J3]+_VWM/+;(-H:&UG0VM1P/F&=ES(AS7^^<47=4P9K]%C^XK:*A4:EMC=8
M([65D0#"#J]Z[S0\#43]*NP:GXF#W,>;9H1VOYMM[ZY?VA8QT"03M)5U)DM5
M#,"'X+LKEOEP$>NZ!0-](1:9H@\E$R.%7V^:1[3^FOV^\$KW"&%-LI0F]_8,
M80\TTA0VL;L@"&XS#"Z-U_B&-5)K0NG2T@\*QTVRK=+O[@C'?P3^VG-,.Z.A
MJIFX6WZN<=VG]+0UAM+RHAJ%ME$.T`;K>*``M(9%`D[`+?.<73G<APW^KJU;
M=+`C[SADAN5J7@@[+:.5!>;_[[IAX<<O!*PM`E,'^*E_Y*UZHI<YJ7Z`#IT:
M6_2O+W&ZH,82-;9V:Z#N@VQ0#??5=O"/8"];]AN7>ZMQRTA=/L&56^'.T-+H
M5B9WETXM-:`%.U0XQA,-G\#7KEB[70=S%!Q"@YB<]_A#C&WC.*HXQ%9WJOY`
MSD)>Q:7O'R:WM\OTNTLW<<>%R:WM$#VM.4Q>Z8YE6,]ND']"._*BAYXW>454
MK7FF0?G,2JM1SWYKRQU%B_"Q9GU-`-R4&.4#W-TQP`UQ>S[`6K\F@+/Z]JUY
M1H05'TM8<?6.?:(ON^C+?E!$$WW9]Z`O^YJ-);53T06%IW<XJ-_K'L&#OH4E
M[IBWT?M*L#J#B<G"OF<[[XF'V6ZV^3ALU]+4KM+I*L/!!OM>QABQ[=Y?VNKA
MC5C660V@[#F.>\"N8+[V$5'#$%$5$)TWT!ILJ_U3Q;92%[:5$MCNG22V!W)W
M-`#@U=ZFZ$Z/)/`=PW<2.151G36(P'(*R_TZL)P>9/>:^G9Z]3:>85\6?.+6
MRN[D'$-GL1>VZK)5U.0U0)F%;A<GVW.^MK54ZL`>(V5[?M3AJ"Z<,%<KR!]M
M/_K-T)]X2>IX"LS:IQJ_(1MT4URP;D6-@=GHC9<BUP(FG*5?C#$)/(SH88^"
M?&YLZP4+'D[.:13L(Q9RCO^.N5XWMO<G\:*+V@1Z:A^]:>X9I(NY-`;)ELAQ
M1[T^7VV'?X7/*<W2*'/*VKW+=\J?RO?^Y18HE0E/DGSP(S&>+29IXW?JQ]9I
M^XWL"(X2SV_5K.CUDF$R)=:Y381LSZ90#P(=6[,F1OWAMA#RPW*(;H8[2ID7
MMFN)#Y22*(D6NEV<;-,2[\F'@I3M6>*CYAG%!2.>_FFR@AA9U\"5WQ87Q.*"
M^*MOC7GI[C%GH-.Y(<9R-!,L7^-@M1@O[(@Q#BME!RW6T$5ESXVQ1*P7P[$M
ME@EG\6K9L5X]O&A-O`)/4%'^P7]RC8FATY9N[,[9PKYMV(WC.R_)DWUY'/7R
MA;>">M0P.UN[N^[UL'$/+?ZL+PSLPQ3K!Q>V'4;@XP-'1?SG^C^Q]9#M.V.2
M/Q&OS&,]TVI43X1849>FV'*/Z\8ZKF]9'2+=Q,0*X`/'>`:,8"6R"4'VL6@I
ML0@3K+DZJ_&$406TXIGAA"\&]9XZTI=@3&SA:5MMSK6<70.&\KBN#YK+!-/X
MM*7PS'`]&!DOHRDC<.\'X8ZCH)<VT!EGF-L6ZYY`&]$$?P2PI5JO2%_Y6WQ=
M7AHGK*.AX9&Y*WV@#:UIO2;[]2,,-#59%YETOVLWV?"ZQ:O:!SU24PM'!/AP
M.OPL?3`^LMOW^"K:2\^S^G*QAVC'5Y=V3>7Q'?3)7R@$'PP^:@*41''X!-HX
MIB1W1C!5GC[.>K)A[7@@^IBW6J4-%.:VXQG_IE^T).*-.Q]AP3&")=?>D8+-
M/K'\9S`S&+IYM3>J9'0'%`XMXA:O(D<K<F`D"=<-K%;=@K7-P$N#>B()*MLF
M20,I,*!NK0?=)+?31$YO,C6YV*,9IL^*$@6;'C!JJ5?0!`ZV>()(GC.+K7`+
M"%!*,T'5PT,]3$`LO!L#V3F?8)M!EU9S>R$\H9,!O_J9K1ZF1X-4]OF:Q34!
M[1:S!4:I(/==0+NU\V]_F"I"4@Y:!^03Y')J<)&-_MXJAZI]=9CT;<164F;)
MVTQ]3"5'55WQ%EFEKQ1;\36<*0P'M?,MYH`L;%<W;Z??;.OY&QI:O*1'AA>D
MRHO"`2(<(!'?X/F#!65CXV9@G+;)>J91UOE\6FZ1L.PV<>$<MH0-UL<ZAKHI
MMI:+NK+1\L+1S^0--@/LU,8\!]A*#1X(VX?ROLECW9U)4^Q<C+].,$$,SDV2
M:4Q),.T''Z9P:>EJ6M^:-;>W?20>=E7%>L0SW7DF[D=TZ9C$I>7%V<$2CT(T
MPIL=JZ,NV73L9)<X)[@M="E@$2AXM&)^D5?'P./BQ'[EC<?8$EG=8SC%8\^^
M.2L>#B\SUMJI\Z/B&:Z*9DTI]2""*Z,7&%/>*QX02CJGY>CUS>45\H6,+))B
MGRH%SL%<`YK2K*';QRMI*+6EQ_-_7#U(MS?2]<W%[?<KRA_18WFL7'1JMLBE
MWK&K)"$!>#NFYD4?[PUZ\^HYO7GC5>U/9O<#J]333>--^F+8CU$/4G@(M%2'
M7A3H;[2)[-AV)KRMZ8_.0P>_ETS]-5GG/N8>YUXW`X:"W?/5,$WI"9N3TN&X
M\_,';GD3B3;5"WV4Z/3#W8IUO-1&/^?N(@V(GI(E=YN*G6B)#6\]Y8A=R('?
MO,G2(\<K>"@T01.5\*[L/4?@@@<#F?N\:XDXP9UHT(!,*#DR\9WH:!4&G3G`
MTO?-H"4WL,#"=[!7C5N7M"C;$I4*$ST8>*^DRO)PN='WG*%IPEN7,"3Q^]H,
MV4JCCUTOSNG=(^L7#%_<7#\L-QOG#=]Y:7<,<_NFOTH?SB?_]%W6]Y<.?FU-
MV?W.QY:DC(8]GMX<?PS>H]W;X?MH98G+[VQ2`[POA%TRQZ!V;/]YAL@98%\B
M7<*`&^E)=W'39;W4X6MVEQ9T0PI@P0Y2_AR[+CL&%O6S)N1MYQNM4"NUJ!4U
MS\(%AJ)7JJ>@.'"##6Y^\U1"B]]O4Z<)?YA>;I^=X^4P>H"NT-,",H*WQF?1
M]ARV0`NM5O+L8S``XK<#ZR"2QN[\.])Y?"MG<3;VB^'&HV=0G:#(G\\)2\7/
MUCJW.`Q>E6$*O=QK@12#>J`&LQ?0-C"UI6='G_@T'@-604!AM+AVH3T^45TL
MOTT7`4./@E@8T"A30,!G]F5;4OL_TY_8<XJ<>@Z?Z.4;[(?&0[>6]%\^(%#I
M4H2/6G&Z7`514E?3J3$V:(`"W1:^D6>#7_0S@D8[!+`5*[N`XX0#X$5M$O.(
MVH_!G%@081[40C!>@/BN9RQ\G,%Z;J%_#VLW<$;&2@;HL9-09?%8-\X)>$T!
M=**]ZV+\`G^$]1@B2M(0"19^XGYF#P!MNS_3X@TJ?M;89PT_J^QS%S\K[',/
M/\L_!^#TESE%&1X5IX1U+GJLP`5CEC.4VR^^,X&=^Q(O"7EE+VH)2!\0'R#2
M'"/X`J-%P#8?I5<=M01R&)7EA?]D&NX,I9GZABU@`I^Z>3&VZL6P?1=;YP7J
M*XOT2;&/QZRQ^9$'@_F9\]<EGA=P;8;2B)0A5PMJFMB@^(Y)+USPL$*,0<(]
M(6SA:8<1A_0GQ%#B()>-/$0K5DRA/GHP-P)4,Q^[L,J.PRK35O@=@_V?;@NP
MW_L8D!<<_P)NNZ;)7W0SP?-%;\3/%T5>8`>/4[#[?F!MH\*(1+RT>,DE%+MP
MOY9N[([4EP.3K>A8N&N&*AIE^QQL1Y-;:T_OTHOA>'YHD6:9F6?H+CWC)5Y3
MOV"PJ._FG6^QB2UL!Y[)`B!?=`=W`ZIIGH)F%+%-/8\.2?'7!AT%93B3.ITZ
MG6Q%=,A!J(^!W!G!I$75!W^+(7KE#47RWNJ>3'SL>^PE3G6I"ZLZA)VJL"W)
M>Z6Y^`DI$9Z,,I(A7=+$=YBUI,AMNN>RPG)8$F].6#B_O[!C>W(B[X%$`TT-
MQ_4DGN)$I8SR;WCM0>E"WLA\`494:&31[M\LQ^#-F/OS8'J05S8+:T8=J[[&
MJ_$55D!A:VQ37[BD7,6\_2=UCML<@88S3[8^7>#QR@W\B%UJF^8HV.2C(W:W
MQ4F$_=7#GCY6V%69JW+L61UGCU1:3$"5=^(%K(:9,+'A.6-&O!:\FE+K\36`
M^6\1%@Y/.SWC:UF`8?")X01G/54IRA3[S`G7N7Y>L,9=\B^?]0%?Z._8EIY6
MN228F^&S;N`Y*J/LCLRI1G,K0GE'>C"JME">`X=,[)2@TZ>YFN$!.I/@=(AG
MN\@BH6W-@_BD\"4W>`T/^[%[4\8^K%YBY#*&XZ!IC*E^FND3%@?$,8!,29]A
M2S\ZA7$=>4("6RYQ"&-"P;@H><,PQ_*G2W1#.9O!2892/:(AO1+GF6M!YM@"
MTUQ8=!CU^@6MEN;ZA`1K"2:C$6;P&RN+FM4('LNS+F@,J<OJ=]+W>7OZ\V>'
MT)V!J93T(ME!TPVRH-"CM>(TGG7^RS,`:R7_T5B`2HG38_&;\J3Y=SX&$#!;
M##12/,7J9*W`_!OU^/8Y-G5CCDZ93.11KV=HK('I%0QHLF,BKW&+EM\4-@Y>
MYS:>N$=#/?4@SK*5LA2>?(-*):Q\#@\9%N$YAR3,Z,&LOL#HRS)@@R35K/U(
MB/2>BO2XD$A?V!;;J=AE`6=;RA5\NPB,/R'D"2&/IW_G(PTDW1V#A871-4\@
M5BG/+3XQ]<VI$3E@QQ%!@BN72#BI2G!\DP0%LY]]GMT9\P!1'SC=KJ/T<LQW
M<_PPYY?YZG4S=`"BMC"FQA@>#(YV]+[.BMSZT4$C"#-W*#C4E-`-$P/,^3(S
M5")U1,\78`8$IP8W#FLKB;6Y_HY6T!CO'4V3!Z(G`QB"9QQ48PY3M`Z9^OS!
M*`(]/G"+':UMDZ;FPN>%[H#"I$L*XML[>5H=-#9A$?HTT=?$H'5&=9YG'""5
M#A=H8$[E;",_/`-$)VKI@B):J-4]5:O+`8.9EE+HTTW=MI?SMI^TSBWL?L+K
M2GI[2+-GJ$P':(_NNVGZ1((,S)"B:8*L)P`_R-(AW)A)%.B"_[8(&EAX_@HO
M7M41:S`0M)7(66+(#V<?C^RP2R.QUT$MT<0=W03%9M&,U4`C8WF%\5\\I\=V
M2>RXB+XMUHHA.GHN1[$499(CQ'JX6SX[.LW6XK9'EI4>A>CXEFG,C:`:"`S<
MHE_]19([<&Q,:AL`1J-Q22Q`*9`:/GPP.`I9VN'=22[;G>EAU%`P%_,Z8;D5
MZK6FH_[+UTUC^L[98(Q)88ZA(TL%IR,PBZ)V(',LU</V=<Y2P1OHYG!A?;2`
M"O?+!+^QZ="DB8U;6`,!+FPGV.K#0(8CX[GHEC.>=+6!3"9]7ZE#LZ<#2^J3
M%V`-+!3#ATY>++Z`V4FM$K_T!6P.R6`DSS#YO<LD;3Z&'E9:8H:VURO+*HG4
ME5!J=+P>Y=)&F&OU+(C.("9SMY])EBWA:8#'#B(JZ#-L\\JX[C$L>MW#Y8>%
MX(5F)FYSU"N(WMCXL!'HN*]U,,R(.A?H7#'?\Q)2O"S`D#H`%04B6EH6<J+-
M`EW'[REO98L=.)[0[O\K[OYF`67I8U;$&LEA.M*Y%6(4?Z,.ZZ)+`A8U'$Q<
MQ>I%,'B2F(1764*$EATYM<J=W96(^)Z#BN_I5HWON;8F/IPKWJ4/C_I;E#_0
M']66A;_/\3KY;EN\T#48;M#DX9=@K;.XQH\VFVHHYD>%0B_#<4$Z9W7-XH'`
MZ[W-R0IHM,,;#<:<Q*K0I1S`!JTO$(".1<1>#.^=;G9)3U2VVXFAI1!4S"^%
M]],3V\*[JZ.)TORQXJ@2"ZJ_CV'P+'ZK<ADG6]*/'Q7@TL?<Y17;C7FW7XF5
M7C\#IB-SO'$$_KAU8$WNQY:TQ-AH9[]2&SE67!.M9+2A85<Z`TY[-E`-1[^?
MT0>*7V\@\^EA@FU/_AF/SWD7$2%DU#'V7SXP!VW@)P]QHN_Z.V_H)X]V'J$J
M$G1KV+_R[BA01GB)Q:"\(B@5;$!`RRRR:B;4?U/7=K7_V;OG5)&D.UNJZ11%
ML("?GT%#H\#A_3V77%`3M-'JAYO;;Q]9H98V1ZF+`HCYB#9S8;_1HBH@_C\-
MU$X/CA&F28UE--Y1]A.VM4,C`@.2I"+2"D1^"H/SH`S.O.SAV#GH5`Q($*2D
M'*7C[_*D2M$ZPU"JPENL,/B2V5$/_(BJ#=7(?J#N4Q.L!Q;S<V%/L,?R]?T%
MFHGP3^(M&H!%-W@XJ,.!-99\%P;O(0Q8),K!5#)6B<E^A7W9G1D+GL1+[4^=
MI_%1(RXY3RLXB<<%GWK_``4+F]6+PL*ZU']`E0B'V9Y.T=D!!B7-(VKSYW!-
M^`0-*'T;$YYK_<QJ'RZ!21V./)""A[.R:'5:$VJN.W_!'&'5,6:9A7-1,^9=
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M'M-;VZS9$*^`$.O7L_X9D[R(;1H&)2Z^9?"]?A$/CW]^`Y;!FQ=C3%_]0`/F
M@Y8=]-[.]EV0"'<I2?5@"*8R0P9$>VL@'`I&U)VP[I?SB__^_?[VQ\TEZJW;
M^\^2\_ST096[+;77:\&_'W^1BJF3Z[CW=VG?*ZYRX@@TR;1XDFC\10<34RJ]
M66C*XX&E*%?`4=4C15@A;QV_2`$7LZUM%',J#[K<V+LG+IRZ,3/`0J_\"S'M
M!:\7S;K2Y,,=^*=A'^9+IJ)9&6^1QSMKQ)]*D"[F.\\:JMM2E%%=ZRH1([HE
M3%7B]C4HZ[=D66M^@4UJS!)B<L;/^+1A3?("*A\'-5&V+G(NC?-!Z99B^J4!
M5MA`>P][OSNH%_9=:O&`/=GM,76EONCC*,_N($FDR;W&U['W..B7TK$'JE@?
M\*Z!-N9;Z.^2_60:SP?.NTJ_>_*\JXQ6'*>VPKN-J=K0SQ@T@3U<*G5;@VY?
M\*K<ZFYH#!V&JKU9#N^@MRY!K,Q!<W)OT!0)#P<+2J^E#)H2Z!THWIB_C;[X
MAV[Z/$@0;R'0:L@'-F^0NIV,H9,G?6.Q\<B1XTGZH&BM03F[(@_^<L[K`T:9
MIK1Z6BEI*(RR;6CU]&+43J\$.39[.Q/E=`AI8OM/)JF=GOF#QTC:WH28`G_-
MX^]X;]<O8S?F02-W>[[P:02>NYQ@%K92I.7P8LG)&%['$TTG!GSEL$@Z/$PX
M;BI#C*991&/:4VPUU<(RU=0-*1>N5GVXB5\B;+Z&D!F2$S)S3\:V-39,0X\7
M@8/_LQWB&6.,1J61C*S=-4:FCCT_^>WI:(#'H(*F$V`-$V0],@?Y]EX)8:FP
MM/RQ9SOO45&[5)AO4)HF[)40EKY+I`%11^[4-TT:C)JR>M/%/>-9SC05)G&N
M8SVY6'K$Q`]37'T8R/$`(N\]6",K%1MR`RW"F!C\@TL(2YG-KTLA5,,!J8;I
MBHP:#`QS79J`?#IBCL4X:3L$*F=AR=KL#C=Z7HX-5JK`"IF)R.`H!L]+8E<*
MVF3%<O3E(3<R+->8$)KCAD6D=MFNN(DD)6P]/<<P85:@,"I3X$HT=_^?H`7_
MZ3N&.S%8#+^!Q0^)2V@%$-J]:-]B$7LUQ2*N#]8%UGJV?CUC84Y9"J8&[TS9
M<WVH9'J!6DT$2?$7+J\N;N_/'Z]O;U`Y683-_%\Q0F=$,*T,QXJ%&&1'9A4Z
M6Q7R"=0UV3K4LKC$Z_^Y8MR2C\W,T(WN(!;!'=4$^Q-EBR$WOU#85A&R"Q<Y
M?88E*V3O?XU&ERT1-ON\CGG+[=61B?L:;4:?2;9._O#_,CR/`M6U<_4-P<HW
M)L8IGRJ^C\LB!<%!\]/T)UB'@TPPK;%%#YJLTK)IXTG]`QA*0;$R>HBT:!&V
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MB-1?W4X"7!C+U%D]@<:N5<X+N%&SLB*-6*\%8QJT+`_;;[T2VH$%T1#F*1/:
MQ@?=0ZQ1UMQVL,[I7YCZ3$LFTH)_F-_LTL[/3N`MHK3(6`,MCLB:X`3-O";)
MBZ)9O"6$GN\VSJHTGC'CT9370AP]^P;SY0&"9L:3X;G<U3VVGRTC<'4GL!#G
M8R0/(P-/2:>-U=#'OEYL'$+[ZY20FC#M?4YT-*1B;9^8F<?J'8^QW#'0+TA.
M9*(R,US/=NB]#7GC%2NHV`1U_74OJ,O!+@GH(S2U,?D\*W8_(6\X*JW.AF:C
M[X#E2$!V+\!V#)I7L;1_5D03K15`)Q;TBJ$FS7,)GRC+*T;>=LB4U\/D%5*9
M'M`S"92-O9VQK;`#2M?-6&<'_(A=3AG6R5D#C_%+-ZZJ_AW)1J1BZ#&072*@
MVF`[8%0W=RG['^8+"BQ.")G3M'\3=(V7LTW9K+N8BZ3`IF^1<4'&,XOJFCDL
M&_8,JFRC-AJ)U3L37N*;]?%(7"GB#ADH.]WE];D=T$M>5/2]&"A%(*C[S)LZ
MK"Z==VD1S4O>V?S:.F>&E'NGOR.CGEL3^,;QR>1;;!/@I^$*K]9]5@8KSF"O
M_GBX/,,.[6!,FNZO9VWM[#=U-!C(LIQ`2H4U[QYE?7D]RI0$RI009<EWUZ&L
MKW2/!&7*>I3)"93)$<J4,BAK*[(ZVB+.[FG7'E97:"6&H@>W*G5MM:L51$>T
MPF:!WY[\M+7A2-DWZ+<F"GW`5NW`!P?QH$A@-N2II[;*\8HZ7$?SU/*:@GF;
MC"[+O3T!>GNJOMOKK]-M)8'&'@H6'HIS-[S8$UOE:FVP5IAC2ZL;SBUR,E78
M.X-S:\RK*,-U9DH).._#^JX7NCO+`37YT%:Y=[B.ILFUI<%E>'C/N##DH.8_
M(*X#EYT.B9LK.:._8VD_1R)DZ.;V\4KJ2FWI^N8/F.+V_OKJ(2N`J'@>0L%+
MRM-QNS7@==,K>-WBZC56#S):U7)A2!J@ZJ+?EM]@L`J1@*<Z:F\VR#`'6CDR
M*SQF19T[RWYU],6O9^S?XK&)!4O>51Z__DJ464NIM3)E25@W+56Y%$F5E9V:
MN:8/.!"94S?ZZA*6[*'CX0(U<RFUE+L\&4G*Q>$A%\C,#V>.M@'Z_+W^*F&\
M!'8]*E+M<(,R$,DQJE4T5-G+:KGB%^57OV_PMN"XU03$VPV0_KOM_$6[RCOV
MLT/<7<3K'G_1UE*EJ/921>65I?AJ6*R5WK-MKRK>LZ+H-3,O&BSSD3E1,V4_
MJD]5,,FEZO!'559%:0W44IM->>AW6&DH*G+QB%%*M`$R]405I^Z6*H6LV#^K
M%P@I:4<<9(F51A#7;<E:XZC;P'\B?&V-^MJ>JD2Z1\U8:<HWL2:TH6M>"Y86
M'7=J6UXP\E+QMGB9B2#LBBX,WZ)+2S5BTOI:2Y9E.L=/_6&7_L%C-8T7@N&=
M&+7UZH"B;4_L5QJ)&>I$'N,]QJ9M\'U0#[-,"ZS*X5?Y%P0Y=PV!L?0[VDHW
MQ+N=8K%[YR6\2%K['-X>]/-O'G2W;4]3EPW],G<JRF`IT&7MFAH%=I!<^YMK
M?+8,\]<SS_%)#NS1+6'R[678W^:FY7Z&,7_-N#Q195GY](_OWQ[&,S+7VX;E
M>AC"?29]R@$82ULF((,OFJ97%U1^-KU@\I+K'!189W'<IN+T!J67F9V?E_VC
MN)`KM4GN<7[>TDZI%MDJ\6/LWJ@&H^5`\G(3EV4.84U#)Q(/O3;M5]@;85MD
MVV/06A2S)_AVJ;_2?1?(^9?^C*9`Z'=DW_O.>$:CK6'+GOAC%BH=SPD+\Z/.
MYICO^RSI6$K]&=3DD^X:Y=(A]A_=`=ZF@=<C1$N8-#/6%[1_%XV43^`JUKF.
M8BS1X'45)<*.>JD!%PYH6,<`(PH3K-;2XI?E64W]B7:]G4@V/#HC^B1W,IS"
M"D9D`]*7@HIAB`9,DV$=+X^,[G<`DQ/4+/MZ>1[+`*#6+""5U4`SC6?3'P..
M7"+IYE1O88:`/\6:==321D'$=`13YPF$RZ]$Z4@Q5OH%DZ)FQ&FQ>FAL&/H@
MKX%'V<M9USJI(UV%%=_T,/<2`%H#!E+_N_XN9?9OCY;I9D*KNZX]-BC`K)35
MTO"[Y)9-K?\UR1?\J7O]]7L@SRMLX=S'FK8C54499AMHN4MJ$-*=6*)E`<6+
MDVOKSK''Q%T%:?YSC1_F1FHVJ/E+:A36`SK+_1V]#9?H;$C"%WR]U4#'_K";
M0\=@.=6AV%X0KK845[T:BG2>4"K%K$G!&:IR"N6Y23QK5MFD)AL,AD.U]"K/
MK<F#!QO5#,Z`Q'&O_N4;F-Z:7'KF0TUC?3`<J(,\>#)7U!"031*M!_MLKQX@
M+V@:OI<&BW_=N,70&_1R`>%KV&#I3=)`&?9'6M6EW]C6.'OUT2]-X[[7UU)N
MVLQE;`Q#HX(P2B<K%('!MIX?X41Z29Z\-!"9/S5.B:Z:$H+,9=0`19.TZ/?Z
M_=)0@'F':15WO.3+E_<?<`J]MKZRL@#6\SD>,Z.-L?CCVTT@[_=ZR9-/\85N
M#Q_;L])4>93:A/<2'UM+J>K)2I/80"/8]0IC(^/Q+2=^J\-^$7QD+'1[^-AB
M8F%OV"^D/7:+C^UESPY&*9]#S?BX#5H'%L-'QN/;/;EKO2+8R%CF]K"Q16E1
MM=Y`WG^$;$]<M&&WWZT+(:P>T#=LJ<EACK[9[BZA*'UE22U&BRF[\FV6/.CW
M4B>KS5:^/592AZ-1C3@'BG>[^)]1=)2HP#,98VR9<PI"L9)_RD)1/Q<5A&(E
M+Y6%HGZ.4F1-2ZU@Q25`(0;+&+*!>X%"G%8-NI6,MS?0*16A6\F0^P(=B@7*
M6*V,N3SBKOBR$FRK]>&>P*94@VVUEMP&;&#.68_Z&_;!H9#%_N::<M#KJ1VU
MI_8ZFMH%_E2&@XI;<.Y0OV$#C$BYQ]:PT6*5^A:K)!:KJ/4LMC^2Z\)LSE`U
M8C8^PX:8S1FJ3LPJH]HPFSU4G9B-S;`I9K.'*H%9=KA+Z;N,[[=\CE.50=*=
MD[&D36#9[LE.4QJ%98MGO=$H=6%3')9O6!O+_4H;,7PW+&/NS^_T=UJ]^=(G
M\8O9<J^PJ[.!W`7FA__V1]F8R+MQRWQQI6->S<%`H=7N!#EP)NQ6P4W6>ZM0
M,QIL'377UE?;=VA?OS+HB;VV710-5:T*BF+KK8BFQYE#2`4\1>]M6]#`)*N&
MJFC).\;5UN1NN#-,O=I5\,3?VC9':97QQ!>\0RQMC9=2]XKUXN@>'K]B.0%!
M-N#*)YCIN`[V0M9G^<TLQVK+6F?=0/>SUUO:3"T-]*B[0Z"5PD"OM&=+[\FC
M&B@-AN^%[CCO4]MYU9U)6M;3/S<>TTK#P[*A2J^E5I!ZP(,=1>N7@VOYK94F
M^'"P&^`&<D_NLQ-WR9UJ^;V5IH\VK`H@)FM%!?`Q%R)Q>LC]N6F&U/JI`)[\
MI=0(49/!B]I0&VP?(LJ$BMS11FII'DR_MEHI[H):16%+T:PD;$HZ]'*+E%.J
M44XI#EVOJ^Z*=$6`RR!=">"T]*%P>Y13JU%.+0Z<VDUK_>V1K@AT&:0K`9VB
MCG:P`S#::=5HIY6@W6@'*F50&+@,TI4!3MZ9ONQ6HURW!%_*.S%,B@*70;DR
MP/6KZ<O@:/_5=FA6+9FX7^'L15_/BPTN^<Y6KY2811WAH>1:=X&<[=U1I9GD
M$)"SO=XV*2N_%N3<3FF^Y;7K^ABG<4'K5<0QD?5`9]CK=@L)C!H7&/A+'2V]
MNSY7,66+K%I9G4".5*4`;8&P6ISQX2]56WIW+9!I@ZL\D(_V^?A?ON$08`8X
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MY]65=(\U^!^D'W>W-]+]U>/U_=5W6`FM,5FZDRDOA[G%VJD5IGJ<$>G:=71B
M&M*#_^0:$T-WWK&XK$/HV86609WK?Q%)EUR"]67AI"\MV!%'\A>V)4T,=VZX
M+JM.JEL2,P\)P9+&]`%6I5:G!6CAD<A\Q,Y68S@9Z?BOX8S].<O(<3MT88GY
M))/;E^]!I==@'E?Z\$2K(-/)3&(]>S.<!TL;&O`REEMEY70]XGK2'&1L9KY+
ML&`$M2W9%F%?QNK&\A^QM0'1QS/>?X%-./G(\,.Z)V#QU5B]U=@83S`&+MZ=
M$>*YO!5"6,Z)#Q[@BG8*<1D(D?;HG%%$1*#')];!M)E*AL<JS0**:&UQW6,K
M3LPN30!V7B08U@&ZR/8M+/E:I0ST_G-T`E]3G[;-P"9JH'PD5*NL*C*OGLT:
M5H!F9IR&!6/1XPK$>7IG?.9B47+#G5&6A:<73.'3D5U6-1=F,,:TB.Z$+&Q0
MC+R7)F$/,7[6YXAU(+++Q`I_PF?<:,5!I7##&IL^7W89[OI*EV1808N.2-[6
M\)@;`QT7D#VI[KHP64?ZF_V*LMGBT_)"U<\.H2.RZN2N__1/7`$`&LBX:<P-
MC^H!H!D6)Z93OH-^>9>>8$[<4Z;$X5H'EV"_6L1Q9\8BJ(9L`/>^&!,?M$T(
M%VU`,K,!A">VVT:(9[+!:4(F'>G:"ONIN#D-5>2EMBKQ>LKA6.E.*<J`-D=I
MP:>A$O5,408#]G6R:0KEFHCMQG1TZNFWT`JP"*O7S1X#C"[K7AMX\IDALZ@`
M[['8`EWT,2HV"B.K1`U8#UPKL3TCQF;TL8"YPNT@22_<NU!I/ON@T2/I3+R:
M10=D*EP1E5BTRQS;-%%COC/]"M0'WJ4J-V1$&`I5,ZU%[A)8.TEL5#%!RA%%
MJB:"E5/=99K8J,<T@/P3IKOPI[R=D4(5B#XL@JZ4UB0/UZA/83O&78,AAFI"
M[K#$#>*)S'1S&DA;\%8GI58!,8[/M%-,T3!5%FW+P<8;Z#VFB5NQVN:13$1D
MI7L5Z@=>9]TA4Q.>*:X+Z03+\X8#,IU%N8N1E2X4^%)_)H&*CW-0`$:@]H$Q
MDOAW#/<O5YKI+ZB`"+`3\.R+C;SQGJ738IR3Q7@?:(^`^/E>HOZULX]'MT\'
M!*+&6ARC045\IK[3BK:C2'/#-`$SH&R'2C^F;.%,PW^B`EQ>U2>U-"SL=68P
M:8\OH:<Q#?]3OQM3]?V!3/\PJNPQJ>V!4",@+EVZM,03'>EW5%]HUR59O90!
M`'SIZ>;RAJ;V@_VL&\&H,6QOCMRC8^9`72#OTIXC-M,O2+`E'A[QMFHQ5D$L
M8EN&-!HU'*F2I1`W*I%@^*O-0J31+\IH".<%G+V57N%@P%88BL`KR!5::1%0
M5*/AZ0E[U]@.66;0;1PM$@?\%,VW>&B/->N;`H.W*4E9NQ7>6":+N"GC,L8[
MJ`:G-(\HL&KIU]W8_LH.U]D&!FLC&)=RV-V2]H5N>6#O+W"W97R`0X5S!>?)
M@.S&/&AYLT/)K=@.I*J'+N4D=,A"-R;<@1B/8LO\I?&[TEXR(2=S$1M#T&BS
MCU3]Q4(01,%$%R!5>/#4/9MG#>;^NM5[B[XLIR]5\]95(W#]8;_7Q=HXR@8P
M9@VRNO[NYI`&X4.W4U!,<]NB,45+$&<^M=58+[6W%`>U;GW-`+W-V"]5[M<'
M]`-8F;?3-4$^Q9_/$.I-RX*MP$LME:6:Q<8VZY#GL<2:56X5'4IIYJAZ+5D_
M<Z`DW2ZHH7[U1IRQ@3[C)1QD/;7=B'%:J2./%[*6UQ3,6V3^]*WSSD#>69W]
M'8$\["DCM%&Z<D?K]7KTXZ`#1LB*XF!:`@$:W?R';"1YU5BK6[?M`S:HK`[D
M7E?K*)JR2=6'K$%6QEWL%_S].N!/#[):ZZTPBHIA('O7R@TQ*?&"""O935B)
M)K6EN_O;NZO[QS^E\YM+Z>K_^W%]5SU^I&0[\#6>DR*-QP^DYWB1EN/!2PA8
M^^]7&-;SF?O$?I&61N(M;HN.0-]!+YK-6)7&!'`)I=YN$EJMSX[M+]BMX5S_
MI^U(8U-W76.*P0(L.-6-=YZNH35Z@VS#\3:0?_Y%^G)[?WEUW[ZX_?;M_.[A
MZC/H&#CM+UQ2@9F^77W%%X`8ZUBI`/<\V9YGS^,,5)17[LXO+Z]O?@]Y6PDD
M(R0_XK0PZW$,!:,]F3HH<QA3<FW3F/PB49W$%ST&7B%.UFR(5T"(]>M9G\X<
M=R`W#$J<^<K@.R$Y#]?_<\68X1<I8U5G(%*OCK[X]8S]R\;Y@`.1.7[^T7GH
M2!/D+8>'U-B^"S+F?J1+9`]MC(C,5>R"R&KF4O"PLCL8CP:'ZK9AS):@+^<7
M__W[_>V/FTM4G[?WGR7G^>F#*G=;:J_7@G\__B(5E[(X=DPR]<+M;<!WVV^!
M#_8]VI?R$<%?5GXNK.=R%\#'^*G8J_1N.GI792\K6DL>C*I/7@2`?0.YV^K)
M*UBU.LA%V?%U9GAD$QZDSWSU'3A"X?TEFD1X;>UCY-$*'JR*_DITH\AG"&_U
MU!+X7CO;SL`8*L/:9MN%ZF+J"LL)8HMER9B#4?W"0OWV!\M::R#WCH!;NJUN
M=[!U=ME8M61;D?AB=%7``OS&<+SR')]&QY3:^!NQ\$,<UFX21325E):B:&5V
MCDV@/RK,:6HI(Z,\[-O0IYE&;/`E.V0/.EIOGVF\PG*J2%EUU.HJ#1/WJ!"&
MH:VC_GY(0^'MHBB.XSZ)$J19AKF&@;CYO^LE[7K^O4');D[K!93VB"]=^D9<
M5VIC]H4_]\T@W<PA8X,E5^)!2Y_;CF?\6S\AL^>#`H9/M\39)U]E?3P9E'5;
M@V$M6GX)98V=!=(K4#N;V#+EWL[$,QU"FMC^DTGRB%AV@\X?,V[H#UOJ8(5+
M>#WU3AAW_9:FR$WCKLC-W=I;:?IOMZ.5N:(5]\#E[X'58*BG"A?!EZMVX%0F
M5LXM<4X"EI9(=-,Z_3"WC:5B=0;U)KOY7I3M$\]*B2H.L)5*KPYH;I"S5WKU
MG5IU5PO2QN0H;4S.2O[:IXONJIDE)0)S"L8`_>X$G0Q7/Q)4?U84M=-5E)S>
MX_GEGY??6UW$JR<O1?VN6%T#P`Z*`[M4#KHDL)H\6`IQVRZPE+):MQIEE]Y;
M7<-6&>X!88O!NDS8<K#VU!TS,>U1UJM`UHS75LMKM[L4IKQMLA8%-475LJ!J
M2P5I=R.M_8K2FGYO9>BMNF/%-"@.:H:PE@%5411MUV3-#:/=O-63(J<Z?>R`
ME.O!JYS;.>HN1\EO#E[0)6_5`TU33NG35M5%0%MJA;<Q8(T6`QZJ@Z4\CTT!
MNZ,EG@J&LZ<>%J'LI<[M!4]">W%X5XN<WO%CP"O)(W.5\V-QYT:FMR#+-Z.@
MTR;AQFG'0#L)+\R@`3>,DN&&"61D"@I@G4LFFV=H`2C7H]<FN@>:Q/5:DD58
M<9VB5RIL9;B(&+\)/CQ./E0KN`,?,RN4L<*)E`-#]F)I(>AH<V&O0`=UVS2P
M%BGQ9G985Y16Z.0ER0P'BU%23]L$JTA.?5,RC1=R>#DD_5XS.234*=Q(%DE6
MZ'?5B)"J8Y6/E%\;%D^[D3>Y^IW&P`][^Q$#7S$.(A497B+L=(=!X?@QC/W.
MV<>;C'==2CO*"8"5VTI]<;P["Y>^V-^X^A*1J#5<IF:91:-AI]^K\?)T3:6S
M08529]GA[M10X&;G.C/AA1<S9;7CX&D3AZ1%UUO\,@\,"'<&@]$G=2NH:ITV
M)*8DK+(<6TNZW%O=-V6I,W]!MT)!AX)P):QQ)8B<7I'3*W)Z&R6RR.D5.;TB
MIU?D](J<7I'36QH,D=.[!2R+G%Z1T[NOF1HBIU?D](J<7I'3NYDHB)S>`C`?
M>@*K0,E>F+PBI[<&C25R>D5.[XGEI8J<7I'3NQ>YBV7O8G_0"^1O>'^\\C(V
M>BZHW;XZG:]@[?:E07Z[Z_U9`,QH.0W#J<C#5?DRA<!<'N.W.VVOH%35`<_:
MTM3N$#X-5W1E6`EKWDB_W2GR_H*LU`:RD@!Y(UZ^)]2DO-/A)1I_H%/?V3EK
M%WH[C7U'02_Q?-A_087U:O&.89MV8<H:LX%^.\WBII\-1P'<K.Q2<QRX43+A
M*-V_9CTRECOS1<)48LT[$"JU`'+62E%ZD)4)B8/>(:"GGPU9)4$J@QY5.0ST
M*(71LU:T]@D]6>U95Z$GZWD1`UCAO%)#9QQ%EMK2_=6W\\>K2SAX87^<Q_OS
MFX?SB\?KVYL'>CK9I_8XS<9$R@WFJ/`GN3/FR?3))M&.>QX\J<AA!DLT/2U]
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M=ESI`WD;$Z!AKE;&E!U63A3UN6&-37^"BASS!G$C-N8KWXL*D)8U0@_T<E(M
MDV<L;G4%XC9&G#9H''$K[L(K7D>7<.2E/88NT9WQ[-R:7)(78MKT1NSJ#34>
MX3["%4_4[15<[63O]_MI1^F*M=4-:%]>#^A*KWEQ0`?ILK+;!519#^A*_W<)
M0/LCI1%`66+\>G#9<\*YG>W,/;Q:>?@Q(#BUE281R6G5LJ7,J:KU,:J5K-AF
M>8S5>*!E,@B3@@G6P`)CU'<<_,P]#8;K20NP2'7',-]I!7[BN+9E$;,EN?X3
M2HBC,[LWYIS0L03'A[EN6/`26*UC?(/=R+T:WDP:FX9EC'53\AP#%,''EC0%
M9C"!@7'YL8)S,*3K+Q8F?$]+]#MYX.!>]T+?[TB_.W1^L,<)6.9A]8]KU]&)
M:4@/_I-K3`S=>9=0J.EOM].I,0ZK=US,##*5'L8&C(P(@*_9R[&"9-\!`CA'
M4)Q<6Q,?/[=0@B<LMY-F&$L?<+BSVXN'LX\4U]@)X-FB-4E>9X05$GG&Y4I/
M\`M2DZT:6;"%W0Y>#.P;`(_!RP;^J@/VJ7CJ+FSI&'N`)4F\1+\!WLL@!NBK
M89HTW=1\9Q3`WX$J$ZHS@':>IX]G.),=6Q/"L6[JX%DZPQ,)L=Z1'L/?X&V`
MPJ?%54*4YY*2\R.MR88/ZDC_,9TX8MJ`4=/%50Y>7(WYD^^XO(I-R,(4:W=3
M8!PGEX^<Y+N,H6KAI[+<DUI),39*O93-3^F1:3E`P5D%YKI>UL(+'Y"D(SZP
M@"<ML-C"5`F?HM9UC6>+T=2P0*,_&YQF6(<1O@3:^+AK@'K7I048$L;8-_45
M*AJX[Y_8QH6RUTQ_00^*I)L><2R=NE"F/LV,AU$I(6!MSC-;0.Z8G&R,70-X
MI`F<@XZ,?#>VY9"I;TV8Y$Q>J-PL]'<F"+@W/MOVQ$7=[Q+G!78SEV$Z$"1*
M++J%8B8PR@O\P5%>8%OELC8EH7D0E=<*2VB!<6#8DTB!L"518J)A,&<K8#+*
M4G7"M>)#\#HL:KXL>Y5/Q&NM_O1QP@.;A4RN=,<"6]0]CY**+@E8"(;'3Q/K
M'FNZA'I;&6J]4?H@O&Y5#0+;9%GUMC)01H/!AL"^$,LG]VS?1!V855=][5/B
MD%A,R2DU:M,#/XVF@J(::;OVSYQZWYR?I1A#G\[1-U9(.K*7T0!E.`GM9L)5
M"!HH8TPF!2N5&KO$([$"D/3YX&5FR)IL]W/X9[8U8\5T&)%,6I'1BX=F7W?1
MR"%H@>/>K8>#Z0X()K_A)V]PJ@0X)@3K4K/CY?+&#E:.9(^9G=IBI2UUDR`$
M>(J%":?&&UO9A&`=2\,*UX;A=V"%Z4]XW'Y/6.3OS"+?K>DK*JJ7KNR_8HBS
MF!9PHQ,2[&G4$QSZ5X#TSPYA+$C/!NRL69>RJ',[J'NB-6J"XFQN@'1YMA6S
MN,.C.9PZ0+9I$TJ*6WY*/P_QB0>D,3:`I"8[Q>ZS;["_'/*L.\A_X7Q.I*J9
ME0VOPH&,AOM03;.D,UPVYAR#@D!I!:H#J>-VI'-^U(WIF!B!8;Q_^8;#;Y^7
MR^ZC<6/`?'C,>['-E]@`05=.#C9VYK3QB`&J<TZ<L4$U(@4#O6KPU[/ICV%9
MR';F5&^%=^C1N:8E^8LV(!RF"#B4XSO=3G/9*_*JN\GC2<Q%$IY/@E,'/VBP
M,Q0]LW02?!#5]N6GFM33")+2Y<U"/U"(+=0JL'[>=0"/H*$[<0FM%(*%%SR0
M"S7\2]7ATWL`)BOCE,5G'['3`0G;'M`%4%G770\!)R\Z'='CGA"D>@<$@<#9
M$AY5DQC0)__T\6B=#3](D,'[EL*6H^,^F9@\YEB9PA&2^X8-!VQTEB\%,U_I
ML*\N"18[.](=&&Q5=E!ES@;7?\)WF:<`)`'D#AF..B^RA(?N;$'?U4B>)[Z#
MA(J=5ODW4=O6:%$P!JS2("\E]\1MF[\GO"%6:3&2W!!=`!H9`)@9/8G4N26V
MOP2*0M2X>,X*\</476"JMB*3>G?6J)"\K4F>5D'REK="=\:<[OQ.P31995YJ
M_@1;6Q4YW$J3*'EM@Z@=K>=':":@P(5WL\&%#;<[TB9$*V%F&=@'W3,\DVW!
M7?GGX#U0!U/#HT=2$[ME,C5*93['UF,&&3.^PEN8X*:E)?&(R;1=R88$WF"W
MKU3!."1E"S(_(`YA^O2$/=>=OP@UF&E$%QHY!IHN'-HG:K3-;3<TOQS#_<OE
M2WP%<]QE2Z5F`C-N]4P,Y7%Q@!X<D>*'?Q\=L;AM$IBG>(."?=1HJZI.GDK&
M(=D\L&Y\G,V3I$+F"22TS1RRL!T/APJ,:#=A1+O^'&_Z_QU82$`+.%6$_!(3
M3\!S[&X@LDHC&*?<TQ^S!0-3.\V=N>R(8U"P@YMLG`PK.##JV+Z'-B)]^0>8
M?0#D`[:G`UF:PB9CX2$$D$^-U\`FY.&VDZ3!.C5<#$=`@QZ8GA[(;K#,+FTJ
M(%,O$-JRF8,&@-*J_%1BWDM-%.M>4'2KVW7EF[5^\DSGNQOWL;O;#1OL#@=R
MZ@*!+:/82K<7]S?4ANDJ"Z46NK6XO7Z_JVZP4*S2H`U'(_K?C>H798VR:N'=
M7E_;C!4*+WQU`85M+UPIOO#5I0VVO'!:T*,[E#=GE:Q15A9EP!O6#7DE:\[-
MB]BL!:2F*C;YK%01KC5%,W8+%W!)M]=5-F:TK$%6\5E/D]/7VR79K.BR5[)5
MV65K0W5#A51TV2NYINRR57DP*K)L^UTWO?=$U'SBJU`U#33\;W^TF6I:'F5E
MK_E>6C,EUE8>E'[.(JHHI[*@#.N%1"D.R3IU5`Z207]4*R2<O0:UL-?2*"NM
MNT&W">XJ!,E:[BH%B5(O23AS%0)D+7.5`R1=(:H>YAK5PEQ+HZR$9,FJJH4H
M0[D.HBR/LAZ48I`\Z":YG3YX<#Z^0]?X'7$>F-\(8,K[L3/L==7DJ2PGDE!6
MVZJZ]'@2@&#4.!@JV!\=M1?!D+>4.J`9J4H1:(!"6EO5EAY?#XV"T)0'!L/7
M?7SRDM\A/^IOYS36^=R:?#/8!85!W$=T9"6#!BN^*T()LR]:1$-5T5!U@V)?
MRHI27Q_6-$X]1()5*5BU(0B'@I'-6YM68=UZZE3AQVLKO`RSIY^S(WQWT"6O
MD2F/!Y8=E,@).^)$?6Z[/Z_)_PUN8?/A#HL"_2*%]3!!-"OC+59F*&/$:NUA
MY:RANBVE7'.S32'=+J8J]H]:B;)^2Y9+-4FLML#=5O9+-HX*6@&PB/WU3:!K
MHFQ=Y%P:YX/2+<7T2P.LL('V'O9^F;:M16#?I18/V//%<(/X@A=]O*9YV;Z3
M2"O3(+CB.O8>!_U2.O9`%>L#P>P#GIXLV4^F\7S@O*OTNR?/N\JH1#OX1GBW
M,54;N.W"H.?#I5*W->B6*G9[G+PJM[H;&D.'H6IOB!<+AZ11H&/=P<)&MD,C
M60^7AMU6;]`4"0\'"TJOI0R:$N@=%O,-^J3^H9L^#_8W3?L5K89\8(^LV:S6
M&I2S*TZ^/Z^FM'K:;OOS;J+5#[*^;E.%S-GHFQ<O%_C;59GB;5:%J)BG4/%J
M/B\VX&J^,.UW0AY8'0X:1_`%LSOBY>'/82-CSIK;Z7V8Y'-'4U\NL%Q97O1`
MS:.+^()(*+;9G&S0>'>RY0O18[FZC74DDV@C,DE$(AP,\:KT%#N12`01FW%,
ML1GY%E:R.8VB=OJ+)=\-^Y:-=\&SD/,=CU5]$OL7%R%@"0<N$^O`!$9=H5/W
M-SZEN#@L-\^K(W"EC@",C8)36&R%5H)X5?J5[1F\7;743=$^P+MQ2$UP^=(K
MY9TJNHC]:(BI++=?6[_#_4XLXN@F*V4WF;.F":Q^Q'I!/BKO9;]72BPV@?VH
M\-:MQTE^<GA36X/-NIBMA[XQ4V(['9:;=_XVTIQ.::G#C53)0?C-&T'=<+AY
M)^"31-P`3)L53HQ];8G8F',][X;@VH*#O&<[[Q=8V<SR5J8+KGY8^.\C1CN"
M_,!\YWVFQ\RR7QU]\>L9^[>XL5#0>59Y_/KS#;.64JO7OR2LFUX#,(__]?]<
M,>[+MJLRU_0!!R)S_+SF>H`]=#Q<H&8NI1;'^<E(4BX.C]/5'FT#]/E[_57"
MBNVTG^3^N\I4]K):+L1Q'UQEF\';4I3A+CUD&SNUZ3-_MYV_4"LO'/O9(:ZX
MMFD"EE()!WNIHO(<*E_1"XKM,FECGRK:F9L7#;JG,B=JQEU5?:J"/NNJPQ^5
M.U!I#=12F\T>N0/+N!<>;8_69^9'Z]-PSY2T(X1?*[Q<:,E:XZBK$$.[/X&S
MJYU4>7ZP>U;K_TYWO'?J1=)IW^'5Y;.*O23\8KOPB[&VE8UZQL+,)9\<<03<
M486XQN_E&@IRW?CJK^3FT%2D:S-7F/N*F!)^N]-"3`EG7$4X]N.LRQ>?#!=B
MS:/2X4)T:UD.`,097<^QK6?\4V>M4:(OI.^ZI?.&EKR[$?:JH7TR"7&#SCT7
M,]W`UH5!CYDOMNY,2M.@O!NM@IF;GJ9NBW<I7DW:_#)\:<T;".QND-Q4?MXR
MMC?/U1/8WE-L[]KS44+19BG7IR7E&H^*"%0I]NHE;V3LT^C-B>&0,9P+7>D#
M[]Z6JV[1]$-CB;6!XWVQ6&M9`[=.8[[R/86^AGMG6;/Q0)T2JK)1W-[I>G,$
MXBHB3MLL4K0N)UA"B<FHP/;6+5;,5Y7G'J/A9T_I\+-[`AK8&,.PM%S]N35)
M?8,]#MUSUG;Q?:4KK?X)A-MMI=NM5Y/;K5D76]W.K-XJ7Y:4==S=U`.5D?N>
M%?9R.@$^-S[%MSW%R9\<Z1-=2237$E4%E6Z9ZX^B:\X+$:N#<.M[V/:-]E;5
M/>F)/!N61=O%3FG?U654%.68+.9+N7BJ!U)LY0P10Q.8W-8S***)[P3M?A$[
M1UUG?C=<&1XD1_QP^CML1R":^6#M6X;C@`VBM'JRW)+E1O)9M\C_.7$BJ2S&
M7F<4F+725]N9$F,ES8XJ6D0#MB\5J-=<M$C=LIA_>$EM'&#1Y&\9.SX%-EM5
M3&EU1_W6H%S%WTT/A5N7^6B!5V_$&1LN->M/F_"RVI*'&^7;UNH+2,RTM[Z`
M^@_;*_T&2VEKS,(_][V9[6#"V@\XBCETBML%_GYGPNGWRSOG<D+;X-VC\;?2
M>]#`-,*'L-*'<,`EZ6J/DAFNS0O+="_L>W)8`]%$61`P@73IQ8D3N0)<%-:$
MG\".3)[=.4H.S1&3G;,8X)S$C0EKDD!WFA;2"WQ1\E!QA%R<[=D*-I($!A>X
MJVS=FW6XO%K&:1C3&BNY=I4&";\/[>C$M^5L:D&\K*7\G:#!3I(TTK'GSC-)
MT6VN&U::,&AQ.?K8\W4S\;UI3,O5WA>D*2A7-I.KQ'=E=HG$CVS'$.(EQ&O_
M+F&J.IZ72B:LB.\:LF&M3[KT(7[+A8*R(CYH/Y.I-ZP[&+KE*[CKC@?\?+\1
M?WY#QQ&P6LIC='HXKN`8/![@#Y_!MEL>H71Y8[DCRR6JBVUXT=[8A?5`&<'V
M6:(1[;X"HG9Z)41]7Z$0Y-@7F["J5E!J+'N^,^IUNX/6L'<$@"B=,BV<]Q4*
M08Z#-!"T48DR#?M*,E4#(_H(-B2E4V-M)D&-?:+&(9D'H\$1<.%HU&]I/>WP
M`=$ZW2,X-`AR'*!YH':T8[#HNB5CJ_<5CEZG3'^"?85"4..@S0.UTS\.G:"V
MAL<@3OU.F>3L?85"PXNV8[!S:B7'GIL'6D<^!D=B[V@VI%5UTPX&"D&-0S8/
M>IVCH)[2&LA#P8C[`X4@R$&:"/W.\"BXKW\DN]+@.)2!(LAQR$9"OS,Z!NHI
MP(1XUW4$7NW!47@1E/Y0D./03(1!IW<,#L4C,A'Z)>H7[RL4(T&-0[801@#V
M$5"O?R1'UD'G&'95K2NHL3OK(+^65;G6EWFC*/W.H%P%M4TJBQU75;+AH-7K
M;E25ZG1QURD302L0)YCN()ANC[K=5-\MZQRPC@4>96V[0:O?5UN#T>9-;[:$
M1\%VQ\!VH&X&:FM4QG4DV&X+"SSHIJQ-%6@L67<R&KI$5XH*PXBZD9$8Q.M&
M\C*/C[=WE$<K5(@,)`;>6%L@4GHU)MX,:P[*L;H(^?7C/'L1MZ8:$T>LC+.Y
M3&85Y$1(][FKQZDTOL@NU-14"]TM%U,LB(U3*<J575RS7*_=4R]LEHO#$FUY
M!0YS<'AP-8<;5C#%AJHXTII:?;M?X/9`C=<E/!Q`2^_U>[#F?8/^,"E_0M)\
M*&2NO),<"899>=Y3Y*U8_=I3`UT0_01!%T07FTA#"&8EUT^-K4BL&<>IP2XH
M?FJP"XH?Q]YQ:$[''&Z,^H<(WVUU--+640*)@A?W`(V"%P4O[@L:=\*+NXG;
MI=]<WUQ>8=A&6^XHAI5N^\Z_Y!$@W2#4)=4;_(D\&Q;V?EK?*'K?NIKPIB:]
MEM;OMP9JJ?CL?>CI4BX+)PFTVND.2L7_[@/`M9"[#^0>M$:#DR*WUNF=++F5
MKM*2M5)1Q_L`_8;D[I=(.-S7]DD7,XS)=:6)[^`&X\T(W6$^+T-6%>G5^:PR
MG=>^*&`1L`A83A&6;1P%TC:^VC,L^MSOCFYEQESL"+]*J]L]FO1_N8SUM:]@
M".D5L!P@+#NHE[&D7+_:SI08M%VY-9&NWA:&LT^J5@-=>P1M1^'8TSL",&#;
M&_:.8+_H=XZCZ6@/R#$\?#BZ':W&-F';M%43#O=<'1MD\TZD#__O8SZ<1U56
MI*N.6IHLRME4P9W2Z<NBF$TES`W5ECPJY6`4N(NXKB>XK@KFAGVEU1-<5Y'K
MM.Y&Y7[JJS_50%G"J,I)ZG*:P&%K[;7T41;;J73+>9!%BU;<DU5'7^G[TH-$
M7=,L6.'F]2#QV!0+EKO#/4C4-<N"<.3L::V>T()567"D-LZ"^U:WDKL1:!&D
MDS8A`-5@0@P/IU[??@F/VE'*%/T^4-0US8+]+K"@5J+-[('BL2$6[`U+W(<<
M*.H:UX*]8;GKL0/%8T,FA"HWCKHB)1/I3+&`=Q5CVU-U%.F_PVYGU"M30C*3
M"YLO<;JV5NCZ$J:_V_;$/;<F-[9%Y@O3?B<$('HQQL2E53[U,0[_Y?W!7RQ,
M@SCKJYE6'E$4-HVDXP#K;];@,RV87=.$"[9@Z4V<I:E2FU7.2!M>I%;'[9Z3
MJL^N[>LHE'EL&-F\[.6Q863S(I;-BFYUE%5_L[1N+&Z('Q`X5:K0[2TP@C;[
M"XR@34,Z=&]15+XHV]Z"4J'*VM["(LBRE[`(LIR0:BQ7<&QOP:A206QO@1$T
MV3]@!$VVYRL[%J<'PWE=Q:*."BGUE'XZ*I0(/A%\(OADC_E$5(XK9HXT5EM*
M:76U8:L_*I7/<^BUI;J=_JA$5N]^`"S(+<A=GMSJZ9&[U]&&O28`WF)Z6-$=
MBHV64V2N+:W))Z]*K>H,6IE!UKXH8-F\2H0L'T>Q*KDCEXG8W%<P-+6/^0N'
M#PBHJL.JVE$PIK>LGMY^:F_=<=W5HZ@K69XB"#V,X2]KP^X2=?O$=14,8,%U
M8?)I65-:<!V.,U+45E<]&,3M%\\-.FJO\63G75?Z*&LY;#^C=W^D"2P'56D-
M1`9E9<NA=S!)O/O$=:K6:_7*'+\$UPG+05@.)V0YY"7JIG)R@]1&O`^5]BD9
MMW*JZ_J\W#O]'9=W_JH[DWB>[Q^ZZ=/DWW/7]>?LNV3.;VYB;O4A169N)`X9
MF;F]FA)S@V1T;KXJK*[M5K)UN<&\>-LD!*/!>(NEX(K2J9V'Y!5=HDIXQS;D
M=W32I?%B3/`8\VX0<T6>3<X,Y6\<*VQ5Z6D:*],1313$F6Q>L&AI\3_OWQDX
M6WJQMP`98Z.!%]L$Q6X:WOO>&3#-FH&#FBS`RC3?C9I@H]T;[E_MJ4.(9*#J
M)*XG.;I7(A+M*%A`Z]15M^X`!=\TID1J`_VIBZM$7.91D'[8*=&J86NG&/HO
ML^GVL;!0]=-!ZC!#QKX#.\XE6=A@=K/32/([/!+T.^I([G8&<K<_RCY5Z&[;
MGJ8.$GUX+.L]WS+82S\>+L^D"1D;<]UT?SUK:V>_J:.A+,LQX).+2:\>L_.L
M,;FP7<_EBX]_5?=1:.72%9G^O_C:XVLIO_2^O'[I2F+I2KCTY+OKECY4^O6N
M7%F_<CFQ<CE:N5(*Z4H9I&<6YF(@9/ZT5?X9#'I*$I3,-6T.TA;Y:MC?#D3;
MXS=UJ-8$TKGC8"`CZO$O[]FJG?[G#[`)#>OY#G88>Z*L0$2U`1F?]H?]KM)1
M-&4$VGHHHT-[H%3D^/RQ?KO3_ER'NFI0'#K"^S4BO!]'>%<@/!/A@QH1/A`<
MOA[APQH1/A0<GD3XL-<==)2A,F`X6K<1JO&-$/Y2AVP$.6,,@6"&X)Y2`L&C
M!()';4UF(P@$KT"P6AS!2M*44SB"58'@U1P<TZ/563ACD+U'\=6_?,-[O[9<
MS_'Q2_?6FQ'G<:9;W',2-OR]MMC,FU&@_'Q-GC5QB6[\*`,4TU1Y6`/)R@-Z
M8A3M=A4PR+O=E-A4H&[N2*=.Z=]A",_=$IF3D^T+C95>V@^V)01LB\8WMO4"
M&P.9L.)R#1,Y-1OS9A>B<IXCO#)ANZ/^8*1N@[`IH$^&LH-\XKRYQF?+,'\]
M@^%(#J$CYVAO4([0;W/3<C_#'+]FA$>ILJQ\^L?W;WC],]?;AH7)=&-8Q*>:
M"/-5-QR\+R*QNZ+@3C((6+G7/;(908K.TJ`7]\YW2$JJZE"412'+(-?3^NF>
MRDSW2)QY[,C0R/!U$^BWN^&?H^_*\#)%BD86OP61^2,,WVE6:)+S;%%L5!";
MSJ#7L.0DP6N0;AAX\]4AY)J'W31#M:Q9MDBS+M),UE2M(:IE@5<3S=C^S(,>
MW'/?F]F.\6^RH7F?-RKZ/WOY-(E9=7*_#1M\^O$"EMQH`)9!KP[YR0/B8#'?
M+XSYP=+C16QH11.HST']$"]4U%4^P9`"L:L"/*IFO;>.$'(ZT$30(:3#&N=W
M'ADR7EM'A7Y-KH)C(T(O$YMY1`A<XK(@0JU$T$H0(;SYT2H1H3\4-,@1A'4W
M17F2D/7>&BITA21D4Z$;.9.2FVV^B31@QBF\*N>_O#5?\G8I\J(;)L8Z?[4=
MZJ.NE3#IP0._[GJS->$&+F6V#OJC8;]^,J1!J<E!=1L<Y,/B'7`J=`S+-<;T
MV+BA@VKM\"DG?2FR++^U.@BTFR4AC4!U5,2I35R623(:[)(D5:1R>9XZ+D#R
M1F48'<B]KE9D5T_1(>N]=>X.D!*UCB-W'D0'2X9!<3*D[I8JD$%1M5ZO/Q!T
M6*;#J#@=(N]K;U21#EU5&6A=08<\M=2OJ);2[ZT[;*B](>SV@@YY>JD0'3+T
M4EDZ]+N#H9"'?+U4B`X9>JFT//3AY3H.>UNG0]"W]ISU:`S*O]]A)Y>ZJ;-J
MKB9-JSOBT"7&J8:Y@EC\J1&:K0+T)"C9E'660TE:.DY0L@E*-F7?Y5"2EIX4
ME&Q.N]9O(>904NO`0(*2S6G7^FW,'$JJG=Y04+)![5J_E9I+265X)-J5A,'S
MC[:GFTGO8IUD7#D1RSA8MT,62EI8XPY9+O*BU77!5`+>XR9E/YL*I4M[E"6E
M,A*DK)N42F%2K@P1+4M*0<3Z5>NJ[;&P:EWAT5DB8G<HY+$9U5J$E&M5:QE2
M*F*7;$BU%B'E6M5:AI3:4I6R@R,E3^[U,8#$FER]+0R'CE!3VFW16;:G6K.<
MY6H/7JV/BFNA/582;DFE9MYW=(>].F*J3IZ$VU&EF5?I6JT7N/M&PL:=/!NM
M8&L*.-?+K@WJR(:O`Q>",9*,L1VUGL,8_8XJUQCF)!BC3L;8RF:1>YO3ZVUS
MN]@>8R0KL?SNV*Y;"[DSQMWQCM_M=FL]/V5`>,BDV5H!WY6$8D70Z\KP/!5*
M-53Y=RVENFI-R6^G0JB&*@:O)U3-OJ.C)U1#E8;7Z[ZZO7Q'3:GJY\:R*::L
MKXBP(/)I,^SU>K%T457MJNN+&`[:2B\D4)AXBE51<D=:6Z?CT`3HUO>P+!MV
M=ZPQ*GQIU(-/WEJ"Z&#)L.WDK6&_EN*/1T>'+2=O"3IDTZ&O%J:#/(K\`*J@
M0R/;PY:2Z'IJ3^L-:DQ`.1XZ;#6)KJ]T%5FKT6`Z'CIL-8FNK_4'(R$/^?M#
M$3ID[0]E]9+6[P_4@Z1#XW<X!><Z_&3&@H">!"4/.YE14'*7R8RC&F_3!26C
MN_"F3DR"DKO9)[>8ECJJI9"WH.2NTU*U3J\O*-G@/KFUM%2@Y*#&<&)!R?0^
M6?_),3?!N+O_E'3+YH5L3M!:I]Q:TG$6D6D#$Z6,][A6V$^/U-M)2LZ19WBJ
M5!$/0>LZQ'HW20%*1^N6T=V"UG7(]6[B_)5.OR=T^/9HO<O0?:"U?"RT3L8B
M-4_HXO/E2_2*]I>U"OAV&F$>-H5V*8>#CESJ;%0?Y$5(S`8]MR;7P!:69[R0
M.U.WW#O;-,;O*TBU\KW`'I%7X[IP._;?_L/T?OD_[?;E[<7CGW=7TLR;F]+=
MCR_?KB^DL_:G3W_7+CY]NGR\E/[QM\?OWR0@E?0(6'(-7*-N?OIT=7,F94C'
MX_VG-QQ+P9?YQ[87>[,S\29G4KO]'\_>+[B&B?&"'Z789[ZT!T]WO*]``B07
M>X$^Y6&5+,GUWDWRZ]GW\_O?KV_:C[=WGR5Y`4]\O;UY_"P]V>9$4N`+Z=&8
M$U>Z(:_2O3W7K1;[HB4]`*VGOTC\_2^WCX^WW^D0@%ABFNY"'\-9&:]QZ=\+
M?3()_GXU)M[LUS-%EG\^BU;E!$OZX^K^\?KB_%O[_-OU[S>?)<]>Q!Z;!(_]
M_?KR\6\P8T?M&19]X#_T^>(7Z\E=4`Q\\B:QM_`C99OV$_(-$#]BG/33GSPG
M]AFQ%?ZY2.*-`@S_]\;^[0Q@*0$*UV./0Y5<]:+)N1YG1$*1T:UW21^/;1_$
M5IK:CD3F"]-^)X0NYO]JHU]<R8UA:\%D7M)1Z%UI;.JN:TP-^$5W)4)[-`>_
M^2Z06?)@HF?4"NT)]N&<ZH8CO=#R('/BS>Q)ARXE]K4]S9R0<KX^IEI&,ES)
M(6/[V:)M>F!FW9+(&Y(1W@=E0V=U<#D@+,#AQ'E!Y;Z@6JDE6<3#:8CK@28$
M_82`!ZE_G01J@D?<^",26YEM23/#]6S09KI)IW<,`@H'%@-K`K4S-A9L=!]?
M0RTSH:+K=IJG[ZYXB9BTV2N(:D2AA(C!'ZY'.0UH1CD%M(`W`VR:[R&A(E0!
M)75/FB&)D8TF,#1V^4;.<L%LF/B@P")&`TZ&!3@4ZXR](EKA[W/?](R%2=HV
MW2'X_/IBX=CZ>'9D9/G[C%@PJCW^2V+@`@X=+HQ,:@#-KC$A+,V5TH03P)4`
M(]CH&O#W3A\#Q.'.3GG;QL[KDF5;[4!9P,2AG*-P<HW")"M)@J2DXS?))1JN
MZQ/0"MR@")<+H\Z)[H(@T:%T:6K`'HACXWP>'8G@XJ9<^$W*!4G1I\M/*H^8
MNLA\(V(N%U00VC-MT[!"[;5#EH&-_<J:)+=U^DC<$`C^6&?CK329BK0J8F%;
M42>P'Q8PU@.2E@U-ATM8@/=H5,;*=7**IXS&>S@:&!;0X`*,-`<V`%\WL?.W
MNJ*OT=;7$KG)%-Z7K:=V.]WA8!-G6>90O]VI?_:_*[VUS=6WC@/!)!68I%<?
MD_3B3*+\J0P%BQP%BPSJ8Y%!BD64[XI@DF-@$DVNC4GB0_UVI_W9^SX2/'(4
M/*+6QR-JG$=Z?XZ^JWW!)$?!)%I]3*+%F:3_I_)=[0HF.0HFJ<]JU7I)3:)\
M%XKD.'BDON.OUA4\<IP\TJ^/1_IQ'AD('CD:'JGO^*L-TCPB#)(C89)A?4PR
M3#+)X+LJ'&G'P22C^IADE&02./\*)\E1,$FW/D=:-^5(4V"_&0@N.5`N"2O?
M50\:6QKBMSOYST/@AZ7+XHJ+^F:_$H=],N:&MR*`KYX)=E25-R=#"1Y>&_%<
M#]S'1,)AKZ<4+BXJM^51/#X6_M)D-L2ZXJ+'3#16X.9VNJP4ZJ=?_EQ17KV2
MKTA7I=6G7EM;R6R@CGIK*VC5#N:)T''U?IA'QN6WUM4%E%5YV!5$;%H85P4L
MK9?)]-MKB#I01@4ZN@BBUD'4O*N:8D3M%2=JMPLC"'6[%:+F^42+$750G*BJ
M)@^%H&Z#IKD1/(5HFGA[707P45_KK:U1(XA:!U'S0FZ*$54MH7V+E-<7-*V#
MIGD1,L5HJA6GJ3;J#[K"]MT*43>R?;42MF]/".JV:+J1Z:N5,'T5]`4*JFZ'
MJGDQ(\6HVB]!546(ZK:(NM&!1BMQH%'Z0WDHC-^M$#4O**,848<E3C1"4+=%
MT[P8BF(T'94P?HLT=1,TK8&FN2$/A6C:+>%YT(:#7K>IZ[2=$C56$[1QHB[/
M=?S._&683Y*HQ^7,%T0]/F>^H.D1.O,%48_/F2]HNEUG?E=6A\.F;5]!U.-S
MY@N:'J,S7U!UR\[\OA#5;1%U>\Y\6=::]^8+JF[7FR]$=7M$W9H[OR_VU"W1
M],C<^8*H32?*#/I]=3!:VP1`T+$:';>5*-,=]0>CO9#&NG)8ER?;7?IP];4<
M3VG@ZC@03'(BI8$%BVR510ZS-+!@DFTRR6&6!A8\LE4>.<S2P())MLHDAUD:
M6##)5IGD(,N^"A[9*H\<9/EHP2-;Y9&#+`TL>&2K/'*8I8$%DVR520ZS-+!@
MDJTRR6&6!A9,LDTF.=32P()+&N:2`RL-7"L_U'7!_&.Q:+:N;&J"[=W*KJDQ
MJYW]!D_)2D,7]RFPCYR"S5R9KJ\2+'>4IB(O3HN`S5QH%A%!;302%-R<@@W=
M-A:AX&@@9+`."C9S%[A>B:H=K2<(6`,!F[FG*T+`OB!@'01LY@YM/0&UCBQ4
M:!T$;.:":PT!E;/?>IVF<BQ.BW[-7#X5Z38R%`?!.@C8S,W0>@'L=\0IH@[Z
M-7-ILUX`!YV>,&'J(&`S%RKK"3CJ])O*9#HI`C9TV;%>@RK]3E,UJHZ=@*GF
M=+T:&]WU"C>Z$YM@?13<6:M"H46KD'#8ZPX0UVK!5H5JHE6AVE:';`@Y<Q`A
M=HW13!DJ@TU)EC&&..XU1+*>4H)D^0U!JY!,'!`JDDPM3C)%B9,,_F(D4RN2
M;*>;F1N+MHCP'/^69?PK,OK:1[U!N3(!&:^M*QBJ=8>CH9S>*N(KJ@S&H#`8
M2@3&H!(8`+XF*[WT4:$6,$:%P9`C,$;5P%#4[K"[='%9!QA]M2@8H!0#,/IJ
M-3#D85=1M1+40-&:V29(F7OU+]_PWAD<2U\'C"Z7DXO$"['%7\87WM;.?FMK
M6F^0+$VTM(8-ECXHL/24+!1?NMJ7!PVN?51@[2D!*+YV1=%4K;&U4S9>L_8T
MUQ=>N](;#IM;>E-[P1(8HP9A:&@C6()AV&^2_1O9!99A4)H4@T:V@&W"@!64
M^DH%<5A^:Z50#V6EVVM2(@I"D1*(DE!T>T.EVZ1,%(0B)1(EH5"[<K<Y*(#!
MBT&1%HJR4*AJ3VU4+KH8?%Y>,)9?6[U5#[7>J%G1*`A(6C;*`C)01LT:3$4!
M28M'64"T7K<[;%1`B@&R)"%E`9'[W70-]=*`W-@>N33<L6F[OD,>88U?3'@F
M![Z<IP.O>8[16,CC'G_[M_\PO5_^3[M]>7OQ^.?=E33SYJ9T]^/+M^L+Z:S]
MZ=/?M8M/GRX?+Z5__.WQ^S=)Z<C2HZ-;KH'>!MW\].GJYDPZFWG>XO.G3Z^O
MKYU7K6,[SY\>[S^]X5@*OLP_MKW8FYV)-SF3VNW_>/9^P35,C!?\*,4^\Z4]
M>+KC?77TYSFQ//8"?6HAN=Z[27X]>[SZQV/[^N;RZN;QLR0;UB_2]_/[WZ]O
MX(^%!__W]HOT]19_4_#O1V-.7.F&O$KW]ERW6NR+EO1`'&-Z%H[N>HYM/>.?
M-[>/5])`:DL/?SN_OY(NSN^N'\^_X3.?HH?HGXOEM16=F"VQ_?>KZ]__!B]8
MM@/LMP0(_5=!"!,PM^5.S[#XVO7YXA?KR5VDE^1AI[%@66S<]N/M'1W[%^GO
MUY>/?\.%RC\'V'H"=BRT<C[8E]O'Q]OO=#Q@2F*:[D(?PXD:3][T[X4^F?"_
MHU4YP9+^N+I_O+XX_]8^_W;].X#LV8O88Y/@,;[0".(4P-XDXZ5,W(8CJ<%0
M>F=Y"/QXCVE'KF1/)6]&)/3'Z=8[G??_:J-?7/QF;EL2%>+T")\\)_89:;#,
M)%E4ECN#'A*Z).?F4;^!N1XS<3%FN'`]JMI<R31<CTPD^`IQ=_/GPY7T_;\?
M)=V:M"37L,8$AEQX!,MV2OV6A)M.*WCZD9C2^8OQPC`K7;V-9^C#[$A7^G@F
MN>BZ0:+$T8]3@IHP/!,F]6P8B4@OH$H[=+E<P^)+]&UWZ74<$O2^G1C$(6-B
MO!`)])(Q(=;$E5YGQ"(OL.2ICW_B6R9YUDWS7=)?=,-$.K?H4PBI9$QQ1S'A
ML8GT]$YA^V+KS@2GOS1@>,]VW([T0/%A`*OA!^K0;<593IKI+K"O%PV&7X:K
MZ@@E=`1*Z"E'"3'^I,F5*&3AE<#I*)Q;2[H$2:2J0NFBKI#[K1QADO2)O4#%
M@S_?.;:GF\:;],6P00TX^H+XGC&&T:^M<8>.P\4?_D;!!UG'FQ3I`[Y]AA_/
M/C(-0K]^!3'4P1J9,,7V7SXH&65`E9>*^@*DUR%`*#JY14L2)U5.0DF&"@-L
M4-!.]*4%3H/&G#1J#;I*J]_K!:_#^(K2TA)?LK4]@WGEX?`V2Y?%1Z]=1R>F
M(9'YPK3?";P?34)A`7WI^D__!*SAX_BU1YPY?.D9"]_4/::Q'N!W.J0BJU2C
MP;_GP888S`'(L^>@M?4WZ=8!(=,!F5Q7LQ7Q%69,Z>B`B/',=D%A<@7)=5Y+
M(@;\Z01+H"NP$W\66DB++GOA.ZZ/:TC`BN,3>YK4M093M:#3[5>V#8#.->8P
M#A#?DL@;2B"1IK`6#R:"D1>P?)<-HL]MWP(]#GPP,3SV>D0"'$%Z@AUD:G@M
MY!;3IU<DP5O`P[:#S`4/NCIH^O?@:=P9<HP0?3RF;^.`,(*[0/S&F('B/KV2
M)#/`C@6XIG^2-[X!!;A]M9V_V@9#+%\,54.PP5H(Q%2BQ)H01*EA15L^H_E$
MQSWX*R`K())E6^UP(0QK?$=G\RZ6N3.@N?;!^%B(^9K72=O4?^=4=X0J4%.8
MQFF![NFW1L-^GDWCT#SYF)Y!GF5D2=+_R/"%W!:()2(EX$T4-01YJAN.]**;
M/@F8*9`55!6`2<\QQB@R3$]G"A`^F<')R^():]2?"1YA)1_7D[V`.-V.C1JX
MF_V7;OFHSACKR@"S8_O/LRRFCNOB`/5Q^D3,OD0IU-7$\9#I5U`*M>O41O7N
M?MXAJE>;Q,U;P:#S)][LUS.TNNLPB0<-V,1*CDU\6U9>/U>QEM/''+67X6-B
MIR+^VQ99XR"X0BG!$AENF8_9U/]"0';11-`ECBE_/M<=X]_4EC+-XEK=32IU
MW!\)-5O9`*"E")'>B>Z$]A?]JHU?20M`LCV1V'%@29%5XK@<_V5!-5"&JSBV
MAWCB_G)[?WEUW[ZX_?;M_.[AZC/8=Z:I+UQ2@=>^77W%%Q@1:SB(/]F>9\^S
M6(RO.F#N)Q./$@HLU+5-8\*=%'P4/-P1)^7F0*RB%QU7:&$D'BBB5S@C_GK&
M_J63_HF4MJ<X]9,C?:+KH*R3S\AWYY>7US>_ARM3`J%-S9PQ6YIX.QE_.XB]
ML3NQ4TH"OR"%D;@F?DDH>$&!S2@0A(LF,+S`V%')07>KP.\:_&9,_P?P+>Y"
M;&\X>`C7<-#7\!R3X"'=BU1D^.6''YV'3N*;">XR=&=-?.W-;-^%+=O-V/T%
M`Y83\(7AA+[B2,1WPIMQ\R?:[K^<7_SW[_>W/VXNT?RXO?\L.<]/'U2YVU)[
MO1;\^_$7J;A)$$>;2::QFX6?"YNA^6-P@QC/KU5>+[Z$.A==;0P'+SZ7(%=:
MLM)OR?+1@Q^(7`K^G_J=T5[#GEJWUF/#:/P(@[</Q$)C/*$/_(5M27#J,<@+
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M')XW7JY!N5W:E3M9YXW2;ZFC@U`)NV;JF#)HG*</Q@2.D-+(UK\C2UAMC;K=
M0[.%]YPLL3U!H.G08*F:G%!S8%4#<ST0#^.&O)GT1,.2,)*9QQ;-]0E)1;4G
MXXT^1"'@#F$Q]PO=\0SB?I0FOA/$JQ:..9(^N/YX%DRO+Q;X2A"X1*-_]"?[
MA7S,#7ML(F&HT\M*&5(WS1DZI"BX"-HBHL6W9GJPR$'T<JR<E!4JF;!5DF/0
MEZXMZ2MY<FAD+DO`RXYASDJS62P<8*5)+-0_F8"R\)WQ#'-APEO#G##U5L"A
M^O.S0YY!"EI!ED9&QN7,(%/IZHV,?9JM<SN=&F.0``SQ"VZI;/8=B_N+A"V9
MQ<DR'F@^!XN"X9$OY%^^;N+\]+(/Y8TMFV7:!/"]$->3X$D'=B3S7;(Q(U#/
MD-/HQHW=LN$"OEZ>Q[,W*!YU%K.HF\:SZ</:$6^Z.=4[\61+R7.('J0VZ:]`
M$AK*#%--D:36F+19EECP&Z9:/@.6<%[=8_E%T<.8/SZA2=D82FG[GFM,2`[:
M,=7<L<T6?D"-11>Q<LA7GK$(T#WQ'"?/,%>\P-KX(3+'8]]QR*1#F7@*,V<)
M!N7?'YDXI7*`[U%)6(U@3%;YK@=QZ>K:&9/AZ2YFJ),)S=MYMEC\*<ME64[7
M"Q*'4LL+]#YP'-7=G,,ZTD/>./$WB/,"3!OR`'Q+<\=PC9AX@S"'LHE?\O0@
ME)Q05'DD/D=CA*\)E<2U&'DE#@D1$&3_Z#SQ)P%K%9M`;$A[L"$5W(+4%3O0
MVCUMB_M17UZQ&Q79%X9*M"_@5[ID`:E)N"GQ#2BUXR1W$(*Q623(E?/@;(.S
M6O"ZXR+X_-V$%+=`B9K$=266SD2U`&PVID$<-OC4<&!?4GL_IR/@Z7[%YV(/
MK9N+;IY,9?!FJ](`QJ4#P1X+MB;'"#P\GB$>087'MD107`8+J(\'T=.$2WT*
MCRSQBM`&!Z(-JIFG6DXF3WI_6:$:HGH1N](-A65]O1;!.LTQ+8+2EK6@;L'U
M<"NW@I&KJ2N-7&[:3FW?B5NVL8SA2.F\\.#G=8H&Z&$:8RH^@<Z)*).O=V@Q
M6:NPWLFRQV/Z9[UETZ2Z7C:,0HNP!M=)O7E#0OT>OOKM5O,.W(#X-ZMQ^\-"
M"JZJFL5`,J'?]D&_"5/O\'1-0>W2JZ9<*MMS<WMB3`VN75@EE]1Y9^&0%\/V
M7?,]G@W.%`4WW$#25%E66NB@)V_`\9/`W6X:TZ7"$,Q[!>OL=Z1S+R$+;#5C
MG57MRD@_IAZ2J8^^+11S]&S%O7K++C5XG+G/6$$AC,D'C1`6%^+NTD3]B,CE
MQP8`!4%P`%X<!D$#?>L\`W=:A&'CB43U9F!(6(;%RZR$JB\.FBM.;$<NQOT*
M8GR+5;"`L95^1OF.*C:"TNK)Z3-/+'<_;1T8M#QCS-\?7@+0VE&A][\CW4Z9
M@S5="*`5168%PL1GIG)KN*[/Y"4;,$M'K^O2>9`M)O26]-FNWHIMY*%HN_DV
M2-;U06H+QFGP`!FKEJ1+:K<-6`(AQLJQ;7^Q<L"8M1)8(3@'H.P:'IX8\!FK
M&^(\O@?BX,'#)@6`%8QZ"5*&I`M:I1%_N`CN"["0%6(=M31>,TS(E-:(XB^S
MXE-15;6$_ES/`$GBY)("!H)1$;A6:'XE,1,\$UHRK3A"PYHR06TL7G<M,N&Z
MA7DVQ50I-DW;MPDF4HLPT9)-6("+DOL1\L`\O&=:+E6T5$DC:TB^P5`9?Z/#
MP6I_&G;ZF$-F`@HK[29[6I`EHWSEOE:NW*P@RU-.09;')48I5%`K%N+`W,/9
M80TR'87&-U#I^6G0&09L1'^*\U7LBLOD+O?DRDBZ+"'31G0>K"$;<G\F6_MN
ML.(O>(YJ/XQGMHER2P=LX_$3'P##B9CQ,R0M-X6_O!(,L\%+6I!7';2E#KI@
MSK!U&"5C>H=;,B:(HV0S`K;V+A2=![G%,_OIU=K*O,7#"`]=#F-5.[UXX&Q(
ME5"C#@?<6+[DI8ZE=X.8)4H7\!G*I]=FTHR.)DUL'X1B.8,@/4WU9(+\>;(3
M>Z6-<@HR<23]7)5E&LADR>,3-MK5&^I[T*@OM@G&J6EX[R49I$FN:)85V.B#
MWL;TIP-5IOENU`0;[=YP_VI/\8K90-6)QK(#6_:)L8#644N5.6B`"78G^-1A
MUT8KKF1:S5&0?M@ID82YBO*G&+W]2$M>+VT@>!)@H7?\%#`SX.CBH.<C_E1&
M\5[N8+!=PNN]+W2'&M'THV4$-=N=;+45.PXDUF`_8:P?/:K$GN9.-#AUX*LL
MV"8&#W6Z!,X4=E1/U00'D6%5N)@;O9/3VR.KAC$-"65!FWPBAWKCV.S,9=R*
M`(@AT+#&:,R-8P?%\`+/9=Z@R"7U@1\2Z?FL'3M_N<8<'J+7`',"")]\;*6/
M=S!2M"*N)QB("X>T`V<7H&U*#,_',$9^UDNZ+?H=Y>?DT3"$*F<<G-$Q2-E*
MY(<A+@4\0FGI6>8H%O7";FO3+6*6Z\<?'Q(];$PA^58L<#81Y#NV7>I4#0-[
MDO*;Z5;1O8R,$,--.^$&'3ETEGRP")TF)0.\YT7EY1DQH8MNFH(`8>:H7'*$
M\"MLO`/H*&PG/UK"CW5W%G07XC';J2X10%W?S,=QI#!#M;_2A4;_J\0<:?H2
M7_1D!7W8+>DG=3"@WFSJ6P-0`W9I93C7`J_QQ)C0>'^'Z":0F38HPO880<N(
M[!M&ET2`'!FQ+\-]2TWW%Z'._V%?:?5&6E[D2\Z-;!CH`L\'(P12]_2>4?T^
M*P8Y6$G(@)0=@1G&A$S<*'HFQ2`Q3LA:'KWG64_-;?6DJND^^-0K\&<%]=.+
MW^7N,L`0J+-TVHMF$MSSLBLW=L_%\U60U="?YU3S>&^%@^2UW+.C]>0V@XGK
M&.P7%]MRF;D0]!8RS>7-W(VG%6$N&)"1!L0$R@5WF6P"+]/7C0A<3JEO3:.7
MG^C&9EKRE6$VMG''L)+>NJ.?-MR\^;[--O"46M9&=+-.+"QULY:7+UQJ"W=K
MW\/WF-SK=F]-[;?4_F"#W3L8(;Y[QSBIQGV;,\BZ+?M8=NP3WJRSDFS617"=
M\^XI[V&GPG@C-KY]!YN#8=',71;JR'J(Q0)VEH_YA'?R#KLKTC&K'5EHFDRJ
M<]-QQ(\<$-]NV-"GN#&Y6>>FK0=%L-B?&J(B&@J`R*C57S'L8;_[(*QHXK.L
M9K8-=_9-6K4+LW)M28ZRZ44_<RFE0V4$#K-PJ`@<;HS#%5413U+!%!NJXDAK
M>N'L?H';`_7O_&KEL`"MI^?1SHFS4^@/D_(G),V'0N;*.\F18/C&QT/"*?(6
MOXX_1=`%T4\0=$%TL8DTA&#6-OK4V(K$V@J?&NR"XJ<&NZ#X<>P=A^9TS.%&
M=I&V.S"/`XTT+ET@4?#B'J!1\*+@Q7U!XTYX<3=)R.E0(1JQEDI$95_R")!N
M$%YS&XN>U3WIB3P;%BT29$]IP%,^_G;?^#Y97V`0]%#7^OW60!TUNXX]Z1S/
M@58[W4&)%M3[`7`MY.X#N0>MT>"DR*UU>B=+;J6KM&2M5`V1?8!^0W+W2]5+
M*+K\K15+H,^P@GMN.MQ_*622?:R"].I\5IG.:U\4L`A8!"RG",LVC@)I&S\,
M7O^=!:?O#7Z55O=8>LP..G(9ZVM?P1#2*V`Y0%AV4.!K2;E^905(>*[R%>U&
ML4>J5@-=NR(B_E"8!XX]O2,``[:]8>\(]HM^1Y4'AP^&V@-RE*A!MZ]P=#O:
M8$7*QA[;J@F'>ZZ.O>*7]A/IP__+*.2]8M#"B"US#5%#?<2<D6/%$;OJJ*7)
MI5R9F\!_5+A3.GVYA#P(S$68&ZHM>;110=;3Q5VGWQ-<5P5SO!Z8P%TEKM.Z
MI>Y_FJNYWU0=9?IJZG(:2^JOO98^RJK)E6XY-\/$CO"XXIYLDWKC)>]+#Q)U
M3;-@A9O7@\1C4RQ8[@[W(%'7+`O"D;.GM7I""U9EP5%=;1?V+?XM?Z7<C4"+
M()VT"='%^GVM84_H[TKH4SO*4.CO35FPWP46U+I'C\>&6+`W+'$?<J"H:UP+
M]H;EKL<.%(\-F1"JW#CJ*M7&S"N-.>QV1KTR92LSN?`(:V,.Y$ZO#",&,:7=
M3I>_E7DO@Q^CSA&&Y3F&Y1KCY5ZK)+S?*=I8-55BM975%D+K*%+8_^$GI:-)
MB=:KW:@7:ZH]A&#"PRO0^I13H/4^KX7OX55JK:M][7JZZJ;Q;/UZQENZ%J!L
M_OFL[O2N'ITDIRRJE%6ZL/[2@I53V(\CEX[5G9%8_8`G1_I$5Q(3M`=:6G[;
M:-BVMR$F'>43YXIR3!;SI3HL5X]'V<J]3@Q-IYCTL1NN#--^1GQGS@T!3V_"
M>Y;CI;1ZLEPN5'S/4IX"@A2(>%)ZU#1D(X9QI:7TZ.'>8VO`]ANU@]V_WO%Y
MI!>7VLM1#*WNJ-\:C#:*GZGS3J(1F1=7$<N$E]66/&S<"USX")^8*>>()\[L
M]9S9Q_O7H4^T7RD<KUWWJ;<)RZ5@YY45+H6&P=K4.5$S;O><5'TZ<RU]4HX-
M(YMW/3DVC&S>PZ19T:V.LNIOEG<`%C8!#PB<*DT(]A8809O]!4;0IB$=NK<H
M*E^3?V]!J5!D?V]A$6392U@$64Y(-9:K-[^W8%0I(+^WP`B:[!\P@B;;\Y4=
MB].#X;RN6N%'A91Z*G\?%4H$GP@^$7RRQWPB&@<4,T<:##OK:L-6OUPXRJ&7
M%N]V^J,21=WV`V!!;D'N\N163X_<O8XV[#4!\`ZK`]'-M>BVQ:;(B4%O2WM8
M8S`_QK7)0-QJC"KJ<9T$^G;#DFKY'(!#06CCN),[\F9IVON*N=VPHJ;VL7C*
M,2)T"ZRX*BCK$#,\5@2DES5,1"I(E`I2WCH793G"JB9ECW6[1%W=J]F$ZRJ<
M"077A>7XRIXN#Q)US;+@2%%;7?7XL=@(`PXZ:J_Q6I"[+H1<UJ8068:13:$J
MK8&H-E?9IN@=3,'#_;(I>JW>9J?%T^4Z85,(F^*T;(K=9R4?<C)Z7^L,JQ0Q
MW.,2AC(M7#B2$H4+U:B281.%"WMYE0L5_ILH@I#BH(V*($QRBB`@UTUMT[1?
M*3<ALES)]>=SW3'^38`5I[8#;()<,;:M,7%8P$W<BPC,0F(G@(!5\7LG7181
M>`^X>:F8WF$441C45$,A9*;@)#5`*C5:6*'N(#5EF%DW;VV5Q-(1;+54Y]LA
MGN1,"&Y7R`@N*"QW&!.T;:-R>^/7GYN_"N=Q70683:![25^]P!<E:Z,=(1=G
M%^B\BJ5>A!BD<:M;+\IYN+Q:IO9I3&NLY-I5&B3\/G34);XMY[03Q,M:2CQ_
M/4)WE+@9H]M<-ZPT8<#,\AQ][/FZF?C>-*:;!X2?.&FRY2J6@!!^5V:72/S(
M=@PA7D*\]J^6=-408PKHP_7_7+'3388G*QIUR(:U/NG2AWBQ;A24%0&O^QD)
MO5D<N!+%_9>O.GH\X&<X@I+/;UC_$E@M=7@_/1Q7J&]Z/,`?/H-M[<:?/E,F
MOX.^4#*X=RUIJ[)/=9ZA;PZ4$6R?):Y)]Q40M=,K(>K["H4@Q[[8A%6U@J*6
M2);85^IUNR5[E.XK($I'+G$#OZ]0"'(<I(&@C4J$,.PKR50-C.@CV)"43IFS
MYKY"(:AQX.;!:'`$7#@:]5M:F;#4?05$ZW2/X-`@R'&`YH':T8[!HNN63`_?
M5SAZG>$1*&9!C8,V#]1._SAT@MH:'H,X]3O*$7@/-+QH.P8[IU9R[+EYH'7D
M8W`D]HYF0UK5^.I@H!#4.&3SH-<Y"NHIK8$\%(RX/U`(@ARDB=#O#(^"^_I'
MLBL-CD,9*((<AVPD]#NC8Z">`DR(=UU'X-4>'(470>D/!3D.S408='K'X%`\
M(A.AWS]\*$:"&H=L(8P`[".@7O](CJR#SC'LJEI74&-WUD%^P>9R?2OR1E'Z
MG8$H`E^M:OEPT.IU&RZ^?:RXZY2)H!6($TQW$$RW1Z7RJ^^6=0Y8QP*/LH;D
MH-7OJZW!J,0QY;@JP`JVVP7;@;H9J*U1&=>18+LM+'"#"H`;%__+FX#]2\OU
ME9T+ZRSJS\\.>=8]DE7ATPO+?Z:+*^*/](>@M$P-!1<E8ZD(J#+J#*1$!5!%
M[72E%25`,Q!&:1^6^53ECD+KR6?A<:3R'T6A3_Y84&92+5]>EF.:OD:*E_J4
M@+@^<`RP@$LYD$RG0&-D&7>F.Z3]I&.MV;$]7Q#+965`X7_X)+"H1^;$\EAY
M6N+07UU1R;/A2IYQ[<J**&UR=-FGQM<*P\R?1'<RBADW#-:F)1?S%_'P^.<W
M8"X#-+@QIJ]^^-%YZ(!=`MSFN+`7@#S9O@LJURW7$72?B,>ZEF/!Z:V!<"@8
M65$YY40QLGE9X'UT.B1M'S">^@LOW36'?<O&N[!=NGDZY(58?E;1U*H6]X;W
M`HU,*6"IG"E58W+$%F]IBHM#6">KSPME2??$!2M@/*/GD`G(AVDOJ*U)WM`0
M755@>$_:H2O\)-#72CD6]J$HVT;P=M53JW(8`-X:]$JY+NNN#=>L!UU9;@NW
M?H?[G5AP+C2I%.N3N6$9]*QIO)`"@GQ4%RW]GKB@JH*W;G^C7GHGBS>U-1AL
MU(ZKOIN]TJ9$3D_*^HY%A]PL3&FI9;+-#_3*IQ'4#8<'<[6X7X@;@&E3HOQK
M<_<]Q=VR"65A80LK,Z?;&%[E).T:N1,TS:IZV1":ANAF+N7+KG3]D*&&R]TX
M1!`78<Y,W$8=QX9\J''.-<0=\)HQEFZG4X(=[)8LP!TQPF"X;.&J2D=;9&_6
MY>Z=FJ1^O9=/O7YG4$)1K>*%&/:4'%[`3U,;SO7YP]'W;RWI._4'J!KK9]BB
M=U`7]GRA6^^2X;H^OQAU$=,T/A?_C]UBT2M0>'9N6ZP/`?K<=4ORK0EQ7AW#
M\X@E+1A;VIPML8&'SKH9`<;H;.$3TD^]3D^6%L1AXW?H[:Y%/'C>'A,R<8-7
M@@6^$H>D[UM5N=,/[UL_X-LP<K@D7,(8E@R@A9>["*9NP8+&MNM1H'Y2HAM:
MBF%$)B)LZ2+A&*7JA`5*S1"H`D+TE3PYONZ\2ZK:XNU`5\E1KZ4,>LW*D=K;
M6(YZD0QL($?#8(R/E?J;-GJ%_7_:[2MK\M71G]$)VFX'JO/3Q'B)5L;_^,]/
MOMM^UO7%9TJC&:R`..[5OWS#>[^Q/7)IN&/3=GV'/)(W[XL)S_SVO_^7)/UG
MXK5KR@J7M,GL'2S1GCQ0%@``Z$^N9$Q^/2OV:&<P[`T[BJQIG>ZH-^C([/^?
MT5X\L(9[,OWU;.K8\S:R9%M6\'^>S?Z"_VD*&T'.&L.W##;`#S;KF30A8V`.
MTT59_JT''`P,G$+*VB4WCY%^)C19&%$2&%%"C/3E2ACIRO3_-8@1^B-O5G<5
M-BQ>BYW,UW;).XHR1"P7Q%3F\G>'M9WQES94^L/>@2)-*8HT.8$T.4*:4E$H
M!ZIVD$@;]I11IS_L=^6.UNOUZ,<!F,?R(!]Y6@)Y\)?:5H=L)'G56&N0."RN
MUO8*A51!#>1>5^LH&L5!51V7-<@Z<57[:G]PF&CK9T-<6LE50)M:9A/=,[1Q
M;NO7P6WI0=:):%_IC;3#1%L_&^)*W%82;<I0E0\6;4IAM*W<5"N@K:N.-'G4
M.-K^P!C^0L>`Y)/;LFTOXVAI:W`H*J*ZDFMM&A%;,5>7$-'=/T0`/;O`[QLR
MQ/(0J]"@]K2AMG^HZ&?!49HE2J)"[L%K>X<*2E1Y`X9(O+V.%PH9TEOGA;4(
M6,D&Q1$@]T:%;+OMZX4N_B?!RF^N\=DRS%_//,<G5?3$\I!)W+S-3<O]#-/\
M>C;SO,7G3Y]>7U\[KUK'=IX_@1&L?/K']V\/XQF9ZVW#PKRU,:SCTS940R5L
MK%85.\=&:=LK_ZV=61=*8>'9T.2J%UF[L4`.%5F9CK("\K>!W^P@Y6_KMIRB
MC(IOW_O%4[LP]PX664I!9*T4N'+(ZBG%[:*]0M;VK&>0OM%AXFB+!O;!HDA9
MCZ*5XE8818<L:4=Y2JE_IQ.GER);7"4LK=[RMH,E_\DE__*)Y5V]P'_<,-2&
M82/OU[KWJM]X]-#E[<7CGW=7TLR;F]+=CR_?KB^DL_:G3W_7+CY]NGR\E/[Q
MM\?OWR3`C_3HZ)9K(#%T\].GJYLS*0,-C_>?WG`L!5_F']M>[,W.Q)N<25&D
M4CQ0B7_F2WOP=,=+AC:M*"DC8[CVIF5_8'37<VSK&?^\N7V\DA1%:DL//[X\
M7/U_/V`>Z>H/^.\#C:J*GDP%9349-LF"!I<")^4PE/`$`B>U?EUADQ':]`IA
MDTQ?2?^E6S1R$@,(HS!*6=&R0RB#6DY3:;@F@!($W,*Z2O#=J^'-6!D>K@99
M;1U6WLFSI87OC&<Z?+URS*=W((SCZ3`VF2],^YVPAV++9)&6P9H=,B;&"ZXZ
M+%`UUMU9%(4)N@I@@04LE8RBZR@`A.N/9P$DQQ-?F:?&DWO!#Y?<3J]<CZ*-
MN3F37PFM?RS)%/CQ!^-X$A&<%<Q:.&2A.[R&UE2:&A98#@;(55A)JU(J3'TE
MZK9=#J\`0KAJF8(V-KQWIEIH\:3?S\_O0&_]RS=0`\(D^C,K1@9*:J[_16+H
MI\GGH)7G@1Z=84@ZJW.&=(%5V`ZMJS>W?8O%@\/SQ&.OFH;^9)C`X`@!/C\)
MXZ?Q2114X!V<.OLE#("GKZ%:Y5HX$U1\+V\]08D87ON/I<Y+$[8S12_A7PMJ
M6'>D\[&'2AO0XYL>HN@=5HY!^1+J$RPYY<:PE%O0;POL55'[)G5H4N7^G6#V
M(IF<OQ`8EMSX6$7L=DH#/6ZC\HI?=-<8GUN32\/T/7Y2J?9JDTZFK,B6D3SL
M]D:R$J&CVKIWC[;&_$Z9X6?=?K>G];M'@+:F?%'9@;6COJS%'5*;H.WMR3&-
MSS@ELX7XE/3'\.<YT5'%_L;^8I;N?WY*_D9'^Q0-ES/\9<[0AFMW567P&9ZH
M-O(=/+IRV6"ODXI#$X>B)34\*$%C0OAWB=>``EB"TW;"'\O"2]_XM&K$V'27
MQ++GL(NMG'`=[=(S+@\:_!J#.P]W7``H^C:,,T_B'/8DL#W22(#EP/=3`W/7
MT!=$$MXBEXP[S_;+IXOK_S[[#8Y(8$[VU:$2K#UZ.3VL2^@FF,;I!);QMC"-
ML>%]9Q4Q)["_6IC2]NM9()/,A79M3>#@-7FTJ;<M2/QB_SU_,]S0P46'#5>-
M?P8>KOXG]N/9;POS[?,5/T.RB?_S4^9Z*BTX=7YZ?%^02BMD@`>NPV+K#$B1
M1'CP;8+FG#3,L%HB&!YD+L$"^2WBMW#L\+?42P0T8O0*,F4T\23V0O!M;.K@
M*\[NZR0`#(Y!6^F%!@?^U0<)`*9'5RA\UKK=SD!5NVH86GNH_'_^JCN32DP4
MC'`?5L^FGI3Z.?Z2@`'ND,E%K*#RN0,G:'9Z^3N<;T!^4=F![7[U-C9]W$7I
M3O`%*S'?Z>_TL`!;ZIT-:R4>G'_PFR_$(E/#<[^\/QJ>"89Q-$PUD9I.C3%H
M#[IW.W!4LAWWVKISC!?@3NHLT*FW9X?"QEF[C+!Q_M^QL,E#51'")H0M2]@N
MF.,VV'-=(5^EY0N-.2%?0KZ6+5@A32EI4N.^*+1#1R!-($*IZX2M2]#FN%9+
MFN$<_`9QO2*-4AN.1O2_@QWB?".MA5+VX"\6)I5?W;RF+GNJ$>Z9Z[J2X`8:
MAH_Q%;#Y#79*RR6@,^A\[^?/#@G5S=V_#7AAMU)>]@#(F6%'G`<G/S!(N_W1
M(7,>WGX;7K"77`0W,F.#N)78[D^\Q)^'G"7XJ3`_+:?H'A@['9QMP^/F8)Z4
MO?<[+-9#/^">6#^'QL>:X.,=\''(M:#%\>(:_G)#!Q0LXM:;$>>!."]@!MPY
M-MX*.(*Q2S&VPKU0O2X<FH>#@V;OZJ?DE;JS@:N.4*+BDLAN/L]];V8[QK_)
MY`=6+8R%0]^9N@42%MQLW&$5Q7N4W6K@6N3!>+NS#<M[0(-:B$TEL=%&0FQ.
M26QN#(LPH3'>X']":JI)S5!(S2E)#=UAJ-A\-5X(_I\0G&J",Q""<U*"PTTT
MW':$R%03F;X0F5,4F2N,2853SO\0QQ:B4TUT>D)T3DETT#"CLB-DIKK,=(7,
MG)+,/,X<$@G-XZLM9*>Z[&A"=DY*=E[MP)<F?`+5I4854G.*4D-W'I0;L>-4
MEQUQZWE2LH.B$CK4J%<:I$G(3B79484O^C1EAVX\*$#"*UU=>(1K[32%Y]8B
MPDFPD>0(!]MI2@Y^P/^[%9M.*=%1U4Y7ZRF''KQ\3TS`VN0.\/T>RSD'1HO_
M4HG%XLS]:#_.R(UMM<D;&?L>'*_#B&/!=66X3A%<MYKKOH=UZEB>$D:X&];S
M5T+<1_MBIAO.7+=NIU]LV"P$ZQ5GO>YHT%'1P#YPUKNVQO:</.IO?*>MR&8P
MP)]$=T"K.42?>B(CLAPO]04O+?/2*VR2MN_JUD2X`$HRU'`@4FS3;/4'F1EC
MDWPC.LWE_JZ#M4^P*"H)TVZ%\56*R61102#+XC),.#';%@D2&053E60JH;D$
M1]7'48.1X*@T1]TY]A/6=C\/NB^D64QP6!D.$];6$H?=$Q=L^/$,!@OJYP@K
MJQ)S]3AS:6I7Z725X4$6#&Y(B4W\,;"3;OE3?>SY#IE@(7!8^>WTVG5T8M9_
M65'MBB%X^[O^9LS]N1"`,@*@10(P%`(0$X#;BX>]8W##$@R^`8,+#;_O#"XT
M>'4&%_9Q>=86/(0\I"@J:$;E8'V-@?H`FQ5PY+UC]`K>R&*3C`4M;O9>.53G
MF_YDTZXI[^%H@K7*L):,S7D//HC@(>CK]@#';1V058F9?BQLZP9OWX@SOS#!
MFAOKYB5Y(:;-&"OP$XE#?!D6DT>"Q1(L]O7R_!P;N[[H!<_H@I%H^ZA>5S!2
MR$C!RR*[IB03:8*)EIA(!/R68Z*@X<E`'LK#CC8<*(?,2P=3M+AD:>U29Q,X
MD]SH\VJ'$%I%.16V]?A*S!?R0("]1&QI5=D:"-D2LI4G6T*J*DI57TB5D*H,
MJ2*6V*XV$JR>$"PA6)F")42J@D@=^!']6&5)<*G<Z<D*,FD_E0QW:*PZ(<;G
M;^09V(^NM')@`':6-R:&[AA-*&21IK<W['[086B'P>TB!FUGK'VX`6@GP=HB
M^JP<:W?["MYU'7S<4'C7A2$^WCO:T[9%+>.JK'0^F1AHCNOFG6Y,KJT+?6%X
MXC:^!&MAN2B1`)NC1'63N'R0WVU[XMX0$916G+6Z\(]06UF,=4\\W;#(Y$IW
M+,-Z%N?U$DRE]&EYNZ1[Z5!9JWIYNXB5&BYL)[Q?)R!-!ZZA=R1&@H6`A;2A
M@@>4P]_E81T3'_50H$AXN_3LRI[GIFF/Z:?;Z3T9V\\6UO>\HTB^`#U'R]XM
M;,?[!AO])FP9)*#'XM>OWG`9(FZB,),F7$*'S*3"\;)5OE%'<E=D_66Q$BM`
M)HIAE&<I#;,?Q'[9S'[Y.YPI'#@_6)/SR=RP###J="Q,+';,LFRJ#GHL5_6@
M;PJ;RE@-QOWJ.Y:!-5M@S*_&&W[:O^L6<9.X`>\?[E6BX'UA\9;F?670'\DL
M#.HH%'\-(4=CV[<\Y_WSCX<]XFNATS?AZ\-7ZL?*UT)?E^9K923T=19?WWS;
M([X6^GH3OA;Z>E_Y6NCKLGS=ZZE"7V?Q]?4^\;70UYOPM=#7^\K70E^7Y&ME
MJ(GKFJ:N:W"DVRD-LQ4L69@EY6%?E!%=R57SA>\11Q02K<!;FB9BMO.X:FY;
M(CJP%#_%_O\...GH<`W+T2)<T[]4K3-2%>70<<TA*X-K#GZ#N%;BN`[XNH\8
MQHRID<B;RHC"#](%^!A?`9M!ZR1K0N=[#\/&,'?@[M_&=*<9_$IY*5<:E_(5
MG"?WNGU15F6;B26W"]K''.9)90G0&D%D\FCO0^K)`?*Q)OAX!WP<<NT%_.&;
M'OSE7L*48\]V<!&WWHPXW#D`1S28D#B"L<LPMJIVNMKAEZ:^)R9@#?@3SNB/
MP#2N/J8,A*Z?Z)=*K!B7E4?[<49N;*M-WLC8QVC=D!L%UY7A.D5PW9H6Q+JE
M,Z7,\B!0^X$J_@H;-VC#F6Z`_6O=3K_8NK/+VID'QWJBB?K^M[P^/*82#8D/
MIB'Q`3*7Z.:W9]W\#HR'1$VNPZG)=6BL)6IR'4Q-KD-C+5&3ZP!J<AT:4XD2
M,"=8`N;`F%24\MC_4AZ'QE*BE,=)EO(X,#85,7U['M-W8/QTZ'%F>X9KN:W$
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MR3RQ`V-3D2>VYWEB!\9/!YTGMC^XUMVV/47T:A@9J?0Z(V5XB&EXAN5B4,IO
M$23AX/R7VC`5:T+0IV&=`U45-EW:C?NGX;K^/#3HMJO88MR0ZIG0.#?(PVZ_
M,QH=+"]$FY)IZD\VLW9BH6G('3>V-<[Y.1Y]43'*)QP8+#L@#/UP.NPC(G5%
MI.X^<*&(LQ5QMGO(EDI'ZW;I)[G3'0X.FCG/7W5G4JD7W4J]58P=2AUY,QTP
M]%N7=S#]-YG\L(`9Z0K8TK#Q'LC'U1MQQH8+[`H\6ZV_*`77(@_&VYUM6-X#
MWKN=)--K(\'TI\3T-X9%&,L;;_"_T^3YH>#Y4^)YJMTITW^%HR7^WVFR_4"P
M_4FQ/3=N4.6?)L/W!<.?(L-?&<\S#ZS[_R&.?9J,WQ.,?TJ,CR8-Y?S3Y?BN
MX/A3XOC'F4,BEG]\M4^7\S7!^2?%^:]VX+\YW9.L*GC^%'F>:GWD^M/5]N*.
MZJ0X'QD]=.)0/R;(PDEROBJ\EZ?)^53I(_N?K!]3%>Z<TV3]6XN<\M%6%4Z=
MT^1[_(#_=WN*"O_`XR-WRO%'P0?*B/ZW?ZB<@'0\'X]MW_+<._U=?S*QZ#9\
MX_BZ62V$_\ZQ`<7>.XR#.7(T4YS6X3!.*UA5&0K6*)3=<>$[#BSNSG9.+-=#
MZ7:TD7JH_!%N(IQ';FR/N-]LG>X(7PU+M\:&]7Q/QL1X0>;!A.S@<^4]Y\&W
M)L[[*?&()GBD?'U";HU<DH7M!NLZ#791!;N452F8T7\[O78=G6RY0-QN6441
MK%*25:Z!*H;GTV//*7&*+#BE8D\C+$5S0IPB]SLJNL`/G%6NK;$])X_Z&_>F
M56P>$!DBYW-DO=-AA.Y0U,U>8H<_R,P8FX25.K,FWW4#4(GJ9V>%SW;*(F'U
M:TWM*IVN,AP(1BE9`[N,3JOFZ@_>_JZ_&7-_?CKLJ6!"BG+X9?4";RS>_GAQ
ME^R7]\K&33@&O6+"6@6>XX]/RWFG8!2[X(_L%`??L>"8Y!"J#><+WR-...X)
ML8BB"A;)89%O[!K`=MY/CC'ZPWY/$37"JM<(`W[T=--X^V)@&T!'7Q#?,\8N
M'MJ<A7U:%<.`F;HCP4P;,-/4^#=Q3I9W%%;G:R`/Y6%'&PZ40^:A@RGW5;*D
M7*G-&C;I&WU>;5>F]<?^)+KS^`JJU?9=W9H\OA+SA3P0X*@M=[C<&\D8",D0
MDI$G&2<J$WTA$T(F,F2"6">]5?2$6`BQR!2+4Q&(GJR@/!QLV.N$&)^_D6?@
M;;K2ZCT"_2?7F!BZ8YQ.Y6C1CW2O^Y'ND#%$R\?];/FX2Y90^C2'*F9!'3!C
M5$^EBO58;#9M\%@MNR.2A0/7CCL2@L-G`'4$)T=Q5[RF/^C,-B?7\X5COYQ6
ML)QH&[N7;6-WQQ"BF^;^==/<'3<<<+/&YC$E#]I@6PU[O6[<SAK(0U6<.<29
M(Q9S/9T:8T*[;%V``0-'\GTXA5#NW;ITB!.YD([].Y$W+@O]MCKJC)3!Z-#W
M5`I)LYB"D^H0>Y4>/J:40<.80OW:[1T#IAJ5/K6MJH@I]>`QA9`TABDELOT'
M'=$Q6'0,SN1"I>%S5087BH[!HF/P_K&EJ,]W(/7Y=L`:HC[?0=7GVP&'B/I\
M!U:?;P<\(NKS'6Y]OAVPBZC/=YCU^7;`*J(^WT'6Y]L!IXCZ?`=9GV_KG"**
M&N5SQ!X6-=H!?XBB1H=5U&C[+"**&N6RR#X5-=HR8XC,KT/)_-HV8XC,K[W/
M_-HZ2X@X,Q%GMJ=Q9EN6!9'XLT8V]BOQ9\O<(?(\]CK/8\O<<,!1<<UC2M;:
MJM89J<J!QP]R2!K#E!SQU$C$#XKXP6PNE!N6UPPN%/&#(GYPS]A2.+4.Q:FU
M;<803JV]=VIMF27$46VOCVI;YH8#/H!L`5-*6Y,QZ5A#N1DJ`V'Y;<OR"Q9[
M]4;&/K92X&GONY1+Y(8&N4T><6Y#[DK>.`AV.PF7/N>!;?&8T&@GKM$:YS:U
MK0XQ57I(72?Q2C:"W4ZT5`SGBFUQG=!QIZ[CFN0V4*#!::JOBDL*<4F1R84!
MEVR3"\4EA;BDV#.V%)<4!W))L77&$)<4^WY)L6V6$)<4^WQ)L6UN.-Q+BAHP
MQ;Z!#_\_4$L#!!0````(`!.$7$(AKN59+PX``.&G```4`!P`<&QX+3(P,3(Q
M,C,Q7V-A;"YX;6Q55`D``_7,+U'US"]1=7@+``$$)0X```0Y`0``W5W=<^(X
M$G^_JOL??.S+[0,$\\W4SNTQ"9FE*A,X(+.[3U?"%D2UQF(E.PG[UU]+V,0$
M&V3'(O;-0T(\POKUA[I;K9;TT\\O:\=XPHP3ZGZNF+5ZQ<"N16WBKCY7'F;5
MP>QZ-*H8W$.NC1SJXL\5EU9^_M??__;3/ZK5:X:1AVUCL36^$]=#*VS<$@>^
MRZO5H,F&4=NWH`UUC4;=;%;KC6JC9_S;,,U/C;8Q^+9K"5_ZXY/XL4`<&P#*
MY9\VSLOGRJ/G;3Y=73T_/]?@51YRR$O-HNLK>%?#;#3-2M#X9<$<V]NW%W_6
M*%M!NWK[:O>?^Z:BGX,W/S=E6[/?[U_)_]TWY22N(;S4O/KMV]W,>L1K5"6N
MX(^%X5N<?.+RX1VUD">9&OEZ%%7S:D]N8@OQ5S5L5A6/JF:CVC1K+]P.(1X1
M$]])!;AL&#L^,^K@*5X:XO?#=)3,9-'@ZIJZG#K$%I+^@AQ!Z.P18X\#`OFZ
M1X:7GRL@K6HH%('O!_'`6NQ;>=L-*`\GZXT#C+K*!<[,@Y]K['I\O+Q&_/'6
MH<]*L#BUEA<!!K@>D;O"?.3.'A'#C]2Q8;0-__2)M[U&&P(ON<%+8A$8=EM%
MZ(1CRRX@_`FT<+U'[!$+.6EHV5Q*2<8;S.2P5-02FC>P&VKY`LO`M8>N!TP<
MN4O*UA*3`B0;89(WI)'[!(`H(UB%*3J[GZ.%HP;"RQO%C*Q<`GJ,0#2617V0
MC;N:@`J!9O,;["'BJ`#C:&.;%\6F!NJBD.1O%5L&P#:7Y9:RA@&T_'5,6-#`
M:-XC)@S1$TZA6Y:;N]&?^0N.__1A``[%*%2"@76#2,$2K-4-'D0[J9W;@N<^
M[.Z(A5V.P7G,_,W&V0Y6#$O7IH#'01SEC6?"*#A4;RN\&80$&T4H&Y2[#MT1
MM("9A[>]I6P(+Z-;C*=D]>CQAPUUIR`UILRH)68^RU^OUFOBK14'F:73]BC9
MFKP!S-$+YF-W!)/+-59`X-'<(PTY9J06(+:])2Z,;8*<?7B8+A+C2YX[P"EV
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M<P/3`^EYAB\;.5-PG"`/G0KUPL(H=]`'$:"R#X(X,'<?=(`DPTP<,.4_%3\`
M=8/!=C-LA\QZ26.P`)Y-/+T`QZ!>\.!WC-*,9$!&O:V&+(9J0!9DA/@46Y@\
M"1V4MBG%X(!`#3&:.PE)L9HZ,@C6\F?LJ5S:`\=+W[F#D0-NZGUA'4<;WZ$Z
M@KO$C$F*,`KQ_(UA>I6=H*W05Z`$GC`?.3R+ZFX0RE]Y3X4$F0(NJCO6RC4\
MU!0:*FO(%,,$QD^%&51!96)@(<?R'=G)'?P=MB>>`U^HUQM&U=@#@L_7X_O9
M^&YT,Y@/;XPO@[O!_?70F/TR',YG85^"M/>N-^_PXA</NS;P7>(-$4.X$[1R
MT`([GROPX+\04,/7KWTF,KBU=J_;JIFM6N>04='"@27B"[F$[O/J"J&-K#:X
MPH['PR>2I]6Z&2S&_Q`\/NSJ$+",Q"@+.7P2L5C,AI$N?@ES^H0<,=T:>-<0
MK&S!!LMY0JW3;G>T4:($08G"B!8-6$CLDM&UDG0\FI$EE,$T0]:TB'\5XQF+
MV?3N0<78,`)3?F\+>EPQ?`[HJ;1<K^E1Q*PC;3VLK0A:7'$Q<1!?KA(8"X<\
M@39*$C^.3.ZQMV=*JVWJ4]D3/5]0OJH,",3:+(=8I8]^)8E':#*;9K>A3:K)
M'5]0IHK4!R)ME4.D8;YP"]343+-E=K4),=K5!<662&$@J$8Y!+6C%LCLU37[
M^_QD<XQV;Q^39%<N/R>JQ5P([+`+'[P)A'<[PFXI$W\$S_D]=:V`U&Z_K6^$
MI89S"5&_BT?E&J-AWD#0Y463!]+TM#I]?:(_U?4EI*Q,>KDBGG`=B^"]L3+-
M3J>G38[''6:?=[U)MLP9LG$D!M6GC"<ZSD,7E83R-A(_PX1R^9TW1,G(])6H
MEKY`_$3''RW9)":4RX6$:R5!&BRDI]OIZILSQ_=Y<7F>)[VTOB,2W`#]_?XE
MW$?**$]%&Z,Q6J>CS\HD=INS3IX42X):QO.@7.[CCKJK.6;K&[SPHCQH-'H:
M53.VTX^0J`+YY7(:$^SR7:60=((3RCVV+[&"I^(!EHM!XD%D)L836-?L]=KZ
MIBKYHOT(#=+)\-(Z.>!7MZ[/*41ZREGD,<#WIN*L8A36\N=-?UP`5RXS&2%&
ME%"(M?*#+:""#TU]8?:Y[K.':7&D=#H=?1/\C.#555)5/J&>GN'`_\$@3<N1
MI/%=+O<2*<\6R^54UFQA5U1LU3H]C8F.$QU_L*HKLJ1<IGDJJGU<;`\1<\6)
M&P/+\M>^K"+<[<@'OZ,U97D>0!YB5S+4H:!3\J2P-BX^@VG;9-?_!!%[Y`:E
M;$*YJ2O95&MW-"Y&G^__XO).QY)RC>\($4%ID\ZZM;>]75R4I\@MG`/^Z>HM
M_7?PMWKA9.]4X>1L#K^^#>_G,V-\:UP/9K\8MW?C7[.64)X\(R=U*65\%=X$
M@PS$9@6&$<<W>/>[UFEK3(ZE09)]GC!<+K'EC9?#%TL>A#,%9H[=^+YKO:ZI
M;X2F09+'Z'V?I,-AG95_Y7+-HJX-:`GVMME?M@]<[-T1=51<Q)H#RR-/P<2B
MH7/"K`ZD."J2D7GE\N8)1`;G4;TELJNO6D(=2.$UY!SS"A<V9-&08.?'6R);
M^DH:U8$47D/.,:]<A<<3)-=&^)P.+&`5PXD59#6SV>WJ"[W4@>2A(>]RKOOE
MIVR\2PI#JL76$%$HRJB%L<UO@8]RQ2V67TV=*>^4:`JG*UFXF&11BJHP$?IF
M8'I?-_+&C(M6NZZU&E<527$4)2/WRA68O/7"(_=U]ZS@8<TTZQH5XUSWA=&&
M5'Q*FKV4P$Z,./?%IMSQ,I*S`PZ*2;X\=$0LJG3:<0%JW&;DE._6*&ZU4#MN
M\*=D2;F2&P=63A`6;/$?OF`FCF^VA6UK:RQ^.M=_(57B/*?*E<"(/V:H9G8:
M+7TYS_A.-<I;+1^S+Z$XSY-`R)UR"/D&;QBVR(YK:\H\\A<*#E23NYE&ZPTB
M3,8S8,^:<4X_UL2KO[<PLLW(BD#>W7+(^V119E"#&7@P67"IKW@D!9+"J$A6
M[@4ZTBN'CAR'M<<G-=3,>J_=O.`4X!A"8;0B-;\"=>B79"IP3%_D`%4@K-_4
M=R;-R;X+K`%)'`HG`O72RC[A=#)L'Q13UGL:]^)E`U5@;4G-TU"-2C*AO*4,
M\+F[ZG@K>MSA5T3<.\KY@PNL<,A?,&/J]SOZ[$D:)(51F*SL2\HZ%M36J$17
MHI27D84O9]DBQNI^T!ZL.#R%49CW<;)D*QK'YO3-;E09>^E;/3_;?V'4(AVG
M`C5HE\/%`(-VYQ0+<RAYH+7FZK6OPD@WF0/ERCZ'/FWLQJRP19;7ZF9?7YR@
M!J(PLL_`L^*M1[VWQKJE7F,]G@RG@_D(&N108WU\Q63J(NNO#(0'0EN*_2KU
M9EM?-6"DI^PUTN'YPS6SW=88@(7=Y#',3G/X=3M1#&'E,I\RXA/V@`N#L%N'
M;,7I4VS>_NVW+\?ZD[C+M7)V#?'V>!G&5%VSJ_',YFA7EQ-6(H4EFW(6.VJ,
M']]A8!`%WJQK//$TIL><`I^3O-\;AC,$E\L\G\_E?,%+:#-'+S#^(*CYP%38
M'LDEQ9V5085U$6?XHC:>]X%^@GDNUR"88HZA[>,-.!"';O;7HZ^(BS$#7@2+
MJ.)<5%%&%;<*'1N^I'AQ'CJ=3G99J2[>3.WT7`:[P!5'+&+8:^(2[NUNV]HO
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M^;KVU,:^R#<YG08\1<_?P-(P@APN]QF)R(4]R8,+FWU]9=KG`>0QT,[(Y>B:
M*C5NE"NDWA/W*V5_C%RYM8@?4==JZ)L[*R#X"&$K\J-PIE1-VK<B)_"([:^4
MVL>ZW-/G/A40?(2T%?E1N!W5[W6</7FY[H'CG`]^`Y<YO@</>CW^-A3.<U>N
M9>PR3X:\H/W'3$XUY>7SJ3UM^$IXV>Y:+"'^;J>A+R,4UV-VQWOT-G%&X4[)
M'8<^B[V_M6ZWJ?]^CQ,`\AB>:G)Z>\^'(E=*-ILYHFZ?Z14Y7GGM\)*R9\1L
M+F[<T6>:4P`I@`ZH<:E<[OF(R$,3*:ZUT7_75$+G!1!Y,C<*YY?3B1D^A,^"
MS&]THS?,Y<.K.&?X";0>[%UX=A#8/5-?NBQ'H`50GWRX7*ZSW+(S`6BNZSO:
M+3NN,BE2E(?EVMAP1'-R'KG;UIBP5\=1`+U0XE'93NIX0^,^)1*_QBRXI?46
M[51H"J`3*?A5N#,]$I,+P7^('PO$,3SY'U!+`P04````"``3A%Q":BO0HN0T
M``#R9P,`%``<`'!L>"TR,#$R,3(S,5]D968N>&UL550)``/US"]1]<PO475X
M"P`!!"4.```$.0$``.1=77?B.).^WW/V/[!Y+W;F(@G?D#[3^RXAI(=S$F`"
MZ7?[:H]CB^`=8S.6G83Y]5N2/S`@@VQ+6*3GHB>=!JF>JD=2E50J_?;/CZ55
M>4,N-AW[ZT7MJGI10;;N&*;]^O7B>7K9F_:'PXL*]C3;T"S'1E\O;.?BG__U
M[__VVW]<7O9=I'G(J+RL*]]-V]->4>7>M."[^/(R_,C*=0Q?A\\X=J5>K34N
MJ_7+>K?RWY5:[4N]5>D]!I^$+_WYA?SQHF%4`:%L_&5E?7R]6'C>ZLOU]?O[
M^Q4TY6F6^7&E.\MK:*M>JS=J%^&'/UY<R_#BSY._7CGN*WRNVKH._C'^*.EG
MJ^7W!OUL[>;FYIK^:_Q1;+(^"(W6KO_G\6&J+]!2NS1MHA\=P;>P^0737SXX
MNN91I2:^GI2J<1W#3?T$^=ME]+%+\JO+6OVR4;OZP$8DXAX8=B<7H.5*)="S
MZUCH"<TKY/_/3\-T)9,/7/<=&SN6:1!+WVH6`3I=(.1AD(`VMW#1_.L%6.LR
M,@J1[Q_D%_I+_"EOO0+R8'.YLD!1UT+$F7KPYQ+9'A[/^QI>W%O..Y=8V-'G
M)Q$,Y%IH]BO"0WNZT%RT<"P#1MO@+]_TUGUM94(C=VANZB8,NS6GZ"9&NJ&@
M^!/XA.TMD&?JFI4%R^I4)!FOD$N')2=+'-&"W3FZ3V3IV<;`]D")0WONN$LJ
M$X=(AH9,T2(-[3<0R'%-Q*,4F=W/M!>+3PA/M!13\]4V@<<:F$;7'1]L8[].
M@$+`;'R'/,VT>`3#VLJHG50V/J%.*A+]/\]<!H*M3JLM;H:!:.(Y1F;0<-(<
M:2Z9B-Y0!F[IMO!)?^J_8/27#P-P0$8AEQA(MA`95(*D+H-;WD[FQ>T%"Q]V
M#Z:.;(Q@\9CZJY6U[KVZB"YM'/)8&M9$RS-Q'5A0O359S<`E6'&*LM*$<^C!
MU%X@\O#6]XX[@,:<-4)/YNO"P\\KQWX"J[G<BIHCUW?%\VJY-+TEYR#39<X]
M7'.-:`%FV@?"8WL(P>42<4C@.<(]#3IF*`LT=WUOVC"V3<V*W<-LGAB>8^$"
M/B&+3#LPTWCKF:O96--Y?557_'+%&MS<ZR<,<:GK)_]"KHN7@YM'_%("FX3+
MF48G;JF`5"=A%?^"#[02ON(G`A!^04SA8O"N8/PR!@N9!`\I7LGX91&_7Y&<
M#:;^<@ECD<3WA.'`K2>$/=?4:?COZ']^`_K#SS,GTFP6)Y/L`V@N?O7$<R\)
MXEXSW>^:Y:,>QOZ2`L$1(AP"R"+U_$USG%>I(F\+-W.(\^Q;GD:H`735851A
M,,88W&9WBMPW<%]A_+^99`\I"Q3GU=,-S<&K$['(]^B&-P2.^U3*P1RY4I.?
M;S4(A6!@KB`\H"O/X&-%(P7+"O>A,TG]HB--N-!;'B#W&@1^H/`U:$N2')$X
MR"0^%-\2Z@[!W.TB(U+61Y8)"\0S3$^N@&.@%_SB!]*RC&20S/'6$G8Q>!VR
M<$<(/R$=F6^$@W1NRC`XP%'37$<XA#1?C5\R<-;$*_;07MHS1G/?>H"1`\M4
M,;<.:RO?<F0X=ZD[)AG<*`V+GPRS4W:BK0E?`0G\QO4U"^>A[DK3Q)/WD$N0
MR^%R9/M:0MU#2:XA-T.>$`0P?B:9@0H\@8'FZI'0X8])N>.#9M/VK@US>1U^
MYEJS=O:84DZGHX-Y<K+=HL(EOBE<*MOQ>KD%V_ZR<-D6T*"K^R_H$GX+$];>
M'A2WH`=:$BYUW,.EX2PU,Z_(:<V(EY<V?[E$RQ?DYA66U89,S:*Y!B%5<=5N
MMY,N,7S0M$TRKSS`7Z./FYX%GZ]6VY7+2CP'P<_]\6@Z?AC>]6:#N\IT!O][
M'(QFE?%]I?][;_1M,*T,1Y7I[[VGP>_CA[O!T_0_*X,_GH>S'Y5?^KW)<-9[
MJ-P-[H?]X6#4__%K)!W1P>FR+0)=H`\/V0;,XU07D38@?`H_96DOR/IZ`;_X
MW[`]"+<<F[@2E!)7M4ZG<=6Y:C--1<TTU_`+M96/+U\U;463F*Z1Y>'H-W2J
MOJS6PAR??X2_9O>X+3\-]!PW,N9!`&0+Q['ITO=(B7Q5JS:D";_7&Y?@&Q[V
MW`C"W'6664S@.<?Q.BY0A*:^D?\N*BO7=%QH&]A^4?$Q".A0EV9S;A(.TISS
M30`:/L)EJ9YAF$'O$\V$<#`D<8BBV:[),MK!CD]N0$XUA+:LJVG+)^*?V<@8
M:*Y-<B0CZ9NMKBPKLKL\N?F.(@\-UU#3</'Z0G>MKIHWK>I52X[!MKO*/\/'
M[>P8"O<^3$P0=*0C8/4L@'E'C!%1CE<!$J?_HZYX9OZ!1X:&\",%4+^ZD6S!
MN#L!/$Q82[;8_$.'DVGI:M]CVR[,77H%#OH7W7(P,KY>>*Z/-K]T;`^\T$$0
M]8-WCEZ#E!6!G-P+L(MR4-+")9:#X/<-,?:1<>>[9`<3@4(->M8V0N_T7_!5
MK=VN2G.!N4202%G&FIQ9*R&5FZJNT4PX-`S$6WCJTKPM/AF4,/,!O<1V;IV1
MG2EMZ;^%&]"##UA[39AD`5KKYJ:,@<T41PGK\VDK)$+G#`=\&K9VHUG*X%>7
M"ISZBKF@Y*0P0EYP+/W@8)C+ZIV.M'V1K:Y.:\%4E*%QNHH.5&:"RLX)7.]=
M<PU8C[SQ_-YQY\CT?*#E5:?1OFGMFY)UJ%6DGQ./1#$*B:U^T_Q<5@^F)`JU
M(]_V06]GPX!]Y80\N`$>--L-)7F`$QEUL*HTZ_("K=WN2C!L&MJ$H>K=MG*&
M(IS;.C`CZW^;,0(%^DM;_97@#Z7BW;)51S5;]8S_\W&0@CUS4LY&*!5?]N<8
M@(I-#T7IN-0)?$*Z\QIHE88&5RV)AI<M_&EI=$)3)#C9J-54XR3'AGM;U1.'
MK*?\DH#D/^7GI#.7:2)F'\,O\^#\8$:00$9V/PLC)0$ID9'=3(SLRC[^/YQ(
ME:#D;]<[^&$-^9,SOZI9K55KE<O*G8G)"1'X^R3=:OAM-+P?]GNC6:77[X^?
M1[/AZ%ME,GX@:5/3RB]AWF>6[*DLY2XRIT?UH#7#M'QRJ6**=!],`*V.M"4*
M+=9J2=N//=9WP5.D<(ML^U80]?G#E(9VM\W*R6$'K3PM"AAL6>VQY2%G0:QX
M*A53#8,/W?*!U_>@+C*S^!YUSL;S*%<%W+(@7%^S&Z`S5JM=E>442!0[_V#@
MHM1)%9)QB.<9,5*H$L<1W!I5WN^2K3U)OL[Y#K23*N2L!AK#B>37J!+NY)$\
M;@O^Y@3W5WNN2W+?Z58$+-<CQ]93_CEYP3!<Q6]NI!V,"A,R_RB:A`[PK>G,
M%LC55@C,KV-RFN:NG*`BX,:=:?$Z</S-"A@JTFP=#8Q\2E+;YYO,S;^1FP*A
MR8A"V'9.:^4LS,JC`K43YP7HB*X(-S?2G%)!(N:?XL3R2%TMJ33P6*3:7#D2
M;@_E'7^1*I7DTWZR<:JNEI0<IXQP0((]U(\;ICJR-9#JV<8KI)MS$QEA\--L
MM>3E9J3U6F!3-FQR]NXD7%-&*,/>@-W]MHB3#6[5QMNLAS"H[5Y'HH]ME!"=
M0:"#ZH^_7:KZF1C4]HM)8<#[NUYOM7*=M_@V;*=:J_)&-LP62C'#42QJ7Q$E
MXH^0YLZ0N^S#/Y(BT7?H#5D.+87T:%H(>XX=GYH`L%HU@Y$RM%V:^7+B5_U>
M47A2'>DD.J&N24]G2?98?(E,L:4L$(76>L[D@8,FV9W?#^%7/K(Z`%EV"LM)
M6"@+1#DL9(09//C/(&XXE#;R$.=*$@>JNW_-F^T$<C59@'A'GP.AXMZ($%?8
MQ?.<:H[)E@GSY[FBGD5MG"&*9':.?.*9C.?D"133,#52A)SNR[<Y!60U<&H&
MLJZJ'<&E=EPU<1T=(0,'Y\_1!I#CXJM:L]%AN.UB5JO4;A4P*)=*U`[1XAAD
MHJW)I$7YR+M5M/ME!4QR"(_:,57:GBN0;&YZ-+-C@EP=T1=%":P&[QW03"TK
M8,/<F@@-W%+5P'&]O8GFCEWJ*P=5!Z+4'0#3D5:(@Z-_)8R?14NAQ=MJ6KQ@
M(E=O2=1WU>K6&(Z/$NE]@80*L$:TIA6O\L$;RNQ5LY,9OF7=HY%=:B_S'DT!
MBJ8H?:\26HH6SJ'>GNRL5$ET*#N!61ZI3F(0B3&I,&:*3(:0Q,)39MC(8YQP
M14N,C;.PJ]CMQ`[C=B*I[5Z):KG_$K^F]&N^>XD<3R1GOX]("JG,X%O4(HVF
MM/3&K8X*.!+,ZC!)$MZN-Y\)HW_:]T8`VYA8FIVXU=#L=J3AEB&P@/%_T.Z'
M2_$(4[;R)XO[2I)UFTCUP2'K#/)<!@?KU%*NLM4_\(S>X4N!_R_36PQMPWPS
M#5^S`G\4?(P]E1"O8>)@SXU?<;U%-IB'Z&]&%M?Q?-,,-4BM49-V5Z$L4/D'
M_5YS1$;Z9!YQM!;F:N8,P+OSUM$5OEI-6K69C+((&*K*D#":%O*;0_GEL%Q=
M2UJ"?I(!+TE[/]N`9_@!^<VA_A(_U1?(\`F\_-Y.^.I#NROO71A14N8?D_L>
MHZQ]S,R1PK%L9ED6CO<GV:HYAQW%<N<:20Q2>L$KFZP*6%R1S=!B&PUIVM^<
MX3:[\@J=%1<O_TJ02%P(2H$%SPJ09`5&HH[PE(YDGR)&G'A#,S(\4A2E^/T^
MC4Y$-$/%#4K4!FDIM59;XMM/*;VJ;6L>7:F=]II;.7&V+^5XS_<6@.IO^H!(
MHR&O@+AH<17GETSKJ)TO*@KZFV9:Q#6Z=]QO\%V/:D#N4P02I/XY:'K(5FJG
M0K(UL#OZGFW`D*BP2@Y)XJ>7Z`+R1#3VO`)WEO[T8"Y-J@5Y:;,R)3]'UHJW
MF>+)EGD53$<H^9;MN9KN0<!'[H'3[!K>BTR"^SY'N@E1]#F^!99A=1C:V-,L
MBVY`P-+P'6$O?LJ.JJ'8BU&")/FD[,MJA/C!DL_%1?K'%N@:S/'UCKR`6*"D
MGY2:1VP2;;-4/QD5=S0JZV7U$O<:!>^'R]+028_G3C,\684%)!@C&IKG7W\@
M>4>:;/1JM@Z:2NP!7]6:35;18?'7QYG=*\2M(S?,CVHO(HVB5\VC([)P/SB"
MTW>P1X[!.A)K"!SH67'[<^I,[2(#Q2*[.\U#]YKI!B__$4^ZV./'N?I5FR:2
M%!Q-*)_M:"9\OHF"QT,[<(V_N?0!<7"/I1W72A#XD_*2ST)JUWN0=T^@+'K*
MNI3!5-_.P]]AB<QF4UXQ!&:/IQA@(H@0#;EC:E,[MR)73JTD.LA(<6:"'GP@
MG5["'L_GIH[<T&:UKCQL["X%<+VH`>-738_I1&T>#Y8KRUFCY'N03=X'E':^
MJY)1TE&IG<03DHAD9_:1ZT%SNU`ZU6Z=UT!'6U/(9)F0QV.JWE+;B'>FBW12
M:`]<0]=\@_@E46,@PE6O-QF'#\<LRM&TFN;-J)/2=PP*%5VHL9Z$?KZ=#OYX
M'HQFE<%W^#/G(]#^"T9_^>"!#=Z(:U:TSD(0R8"AT0<R9@[-=75Q\&AW\&=P
M/:(%0;>DRYE\(N3W7PZU3YS7D,,`L5T&Q(T(`@9N3G/&XS6KJI2_&YI%(9+N
M(JK$[Q(@EL9OQIW(S*I2_RID%DB2HC6!UC\8K23<>MYG6+:_*IF`!]2]&Z+L
M0U$[8-QQ.Q)(P167MR&=UFO1R3+*_TR8@3<'C=6`B$TX;@5OSV7I2-0.>7?P
M;O;J`6Y;6L9'2J<%,EUVS$;S)``"XR4-.4-"5/X)KSGBHY/#P#_/^Q0'%7.:
M>4\$3Z/C>63<^6Z<;Q<DRR>RX^/,>'+3J-V0=Y:361[I)&>=#Q;2FMI9W<G4
MG10HS18KE4%\XI,R]LZD$\43I??]B:!R;K4JK<I62I_B5M<=I^AT,,0]0,9I
MEK1EEJ4!Y?=@#H*65<'QQ%P\'8S3<)%56))#`^KOEZ0[KK*J0.7UV+./I1,A
M$%CEB<<8!_BW`_T<WBG(LH,IR9X"-Z0%FC>S8N+Z!^*/@T]5G;U:;9"3P>CY
M#?BY/QY-QP_#N]YL<%>Y[3WT1OU!9?K[8$#."R<0=]C>`GGDI>8LIX9]<&(=
MRS3(6T6WFD5RM*<+A#R\U6+N0\08P,;%;MY(K#6SUUW^^?0G>?7JN($*/7`%
M,VY=P2!HKY13HI`*8)!VJ^=`OZ49\X`"-D9LG(,1S[MP60'C'2A$UCP'PXU]
M#WN:32H3TH.*DUDOT7'))F2K8&/'DA+;BKTPT]A/=IH\C2>#I]F/2F]T5QG\
M\3R</)+$ISP93Q/7`6<,O#_;(&[@BFB^:-93U"9)6O>2#2>"VF;U1N:USV/]
MYW=I'J)W?M=QLW$N9:W&FW.8VHJ`$91'_=&0XD*G]F'ZO>^";F"@D*Q7^@8:
M<AE@6*<O3%-QM%>RT3(B5OOH^@%I&"T<RQ@N8;9Z"Z[(A"#J-_*R(0[T6_:8
MY-)(Z2F]AY.,(KRT8!@)F#W7WTI.!G[R%L8ZUEC)]LJ"5>TJDZE:2/AFM5I+
M5C;&\>X+[/3&=3O231V6Y;AIR*^1<E@(F81.-^5^B1-N57V:!!5>M9W:DQ4P
M`E+;#F]:@S6E[<L=[ON$=&>G*7#J16U'JJ?K_M*WR/[B'5JY2#?I_2+XV4)4
M;;;16SJN9_Y-?Y\*FSP'+*TXBR@ARZ6,!%6K[<ZE(A@ACXX0:7>7#_6LZ+RQ
MHQ.U7;XD?Y.<)13&&'D0@VBF2\G:[K99I>R9+CM_L^4:,1]\M4N1[`C>7VCN
M*\)7K6Y#FM_"[K+D2?J8&M2NH9Z*_'8=YVHT);[YQ]&_!%]T-]P^-3BA*6%Y
M3'AT=6%JZ#1)BT42Q;AU(2D-50TZGQI<.71F9-YFT]!I\AZ+Y.!FVB*1_B"F
M@-VD8H-6$D)1@Y;WO<&,QCQ*;J::%$FK+'9(W=X_I.Z/'Q^'L\?<M3C(Z;[I
MT<..H@?2].614.U=:1Y2W$O^`4:;B*JVU;I=J:(*.RQ)5V]<EXZ)2WTO90>9
MI.5:!G%DBBJ+.`P_@8U+>7]@3VQ912LSFH,I["-8:.DO0W$;]:8T<;=Z$L6?
M%#5'#$I#IW82RZ/VL2TUHSR=()LD>SJ535+0J7V@DG!(:**-35Y60;9N(ASX
M@YUJL\VXZ,3<$#W66,&E8#.I2G+%LZU9ARF37;%;R\,.5D7\Z;Q4HF@(8,93
M\%F95+I],N"4./9/;+8]GUV:V;(*&6ZL@)B=:G$QA6TD958K![WVH:H?;?#I
M8<^S5Y->A<4\,;T8P4<FJ,K')+QH^`YTQ1B.*>BX/XT3)9L=QF/4[,IAT;?D
M,B9-5?$]6Y;P:L<:$]<Q?-W#CYKMS\D3JBXRR$T:TR!%BK&K(2L!B??Y'>Y6
MR[57+O!JQRGW/KT!E7QB(@&!-\DZM95R[<4%3NWDJ2>$$7QV`=`?3!UF=M1[
M==$>%M[4FN/-E6NQ;'#5SHZ"V>*%1#R]5X#PJGGHT;00]AP;A0^W)``QKK>E
M390\;98^368%KG92U*[\"2IV>7V@E#;*M10',+43G;ZCA:E;B-YZ`O"/T)Z'
M;%)4@S5O='FG2?YFR[5?/OBA23MJFC0`LRM^_:8J[9(ZL\=R#7M,"6H7M/QA
M8NPO8_$C!C8Z==XKS\P6RC7)45"*/Y)^`/I#G`]+T-?V;[!EC>H?Q%0#XMA'
M+BRJJ#MS^=3+L7NTA_;3W)?+H++"^TP"&/GDK#7+@[;&]E0+,[[H=@"5D7=F
M2VWEM!QDQ5X\^-2.EL.SXCCPV#R*'8.;.?2IV">D(_,-&10;;W6'[,V7;M1B
M&E';^0\0K`<?Y*54=%5KM;KR7GS=ZJMTLZ9#5]NY[^DZ+$]&S+V^[Y*JAZ"!
MD6/KP5^N6BUYU>YY!"C=NAFUI'8PL%%%;^GX(#B)1'D/!G:_7+II#J%1NPS]
M(R!=6.LG<O^-1)?1W$$`\.[SI[11NE4XL"D>G4T1C&ORBB=:.=CTKFKM:EO>
M8T[;G95NO@/@([,I>APZ7B%7(U@I[3`A8,@]>I&[467%!:)*1Q_HNG23<BLF
M,K"BYZ,[..Y]<N@;I@E'OO2=C\(5F@#K2BM5F$T6U2B00741)Q2-,CF!#>W9
MN_,#:2ZFV*15N<@LSKDP@ZW`B!R*GOKR8P,.H`TZ:3G[.00Z(X(PE1A11-'C
M9&YT]X[OQN!NI,7$V>4Y'X(P51CQ0]%]+5(%TC0H0`<`N&$F#-'&#>\V<TH;
MI1N.`YO:N2`]V_8U:VCK+F'>S$F<N=\C1,\#>;-0#S=5NJGXD:J=XK@YLMT'
MP+OSG])&^38ZCJWT)+EBQ0(ZU?INL8#I[[VG0:7?FPQGO8?*+U-_N=3<=<69
M5X*'BRJ:;52>$/9<4_>04:%%_ROTD`/^YCF5Z.EO_&NN8@/T_8"^MC+A]V'G
MXWG0-9APTS'M-^QVYL2=%BU0<(?F"$(F6KT;YLZ@Y-@FQ?5?IK<8VH;Y9AHP
M?`<?NN63)%@J]"T,9"-:'T'6B0.R(L]TZ3=OD0VF\/#M>D:T/YYOFJ%W'VJ-
MFK2B2F6!RG\<O-<<D?$)651TO#!78'(8S-XZ>IE/8KVMC+((F+:4(6$T$^8W
MA_IWO<I5MJ3J$#_)B)>DO9]MQ#-NW.4WA_+7[T@QJ)&VC(J;-;JLJW:"RF1M
M=95_<%`_AT3:LW=GMG!\#$[8#&U>,>BR7N-@^MH'6Q)`Y"/*C>C%#4CM"WLI
M,*9(=VPC`8;W")BCO=)ME`9.[3B5">8=66\H@83W!L.QQDJV40HLM;,+TY'L
M$8Y1%2FCF10:4`<AEKZ]P+60!N\5=SLU:46!$QWE7T195I(LL+@*KX=4'5\-
M3`.H?A"VCT]605YI5)(LL$0JL:H"IP%4WKO?U(S=1$<I414$17L15.]=<XVH
MJ&RW*K]"<$$IBW-XPP-9M8*S#CG>HL"B#;Q+_AW-G$,YLW+W$2012.G-K++)
MJH#%SZ%@W%'UIVE_<T[8[+9NI+T_6%B\_`N!8(Y*?Z'Q%"OFD5$MGDS[3SR*
M,\:GN=,J2N^R,O_+',1Y^PZ.UC'=F\!#>X+`SD;XP&*[SBHR5K*RT@56:&2S
M[F'(M9#:VZ]L\/2WN.=["Q#U;V309YII8D>`F3CB>/`!'H")T<0U=43+##\X
M[\@-?C*7]$9+0^)U'HF2GR-AQ=M,[7UIH5IX7JUVM="15N-?IN0_$7,/V$SM
M[?G<"J9_?$>8)$L&JTV-KC32;MN)E/0<F5G<)FJG=>=&37V>.\U#]YKI?M<L
M'Y''7EN\R0X"^_VDM#JL8+4KE!0#C6@ZN$L*#?]_>]?6G3BNK/\*C_.P=P[F
MSB.Y]6&M-+`2>L^9\^8&D7@?8N?8)MW,K]^2\0TLV[*ELLO$:TW/2I-&JOJJ
M))7J)GV_)O:[Q[AHHH;BN:]9NS*!QMU0I502'-`9"9&3R&4Z3*7WTQ&HM'AO
M'G&7Q<5W%:BUK`@"'<[@JO84,]D:CE%.#8?O0(@7:;!*L</>91Z%?]#OVF1#
M)>-XM1U+]XW8G1=B?U(+N+.RK4]64J:@FB/NQV`U&S$:0@IFYM:;WY\^G+TM
MZVA:7*PMZTCL96B4L"WK:,LZ,*_XMJRC+>LH?AUL$[_$EB2"C)$OMC.V.4*-
M2)YK<X2JVES;'*$V1ZC-$6I:CA![C<_5O5??%@?/B\:B^/B@2B,7T:H&R`_*
ME`[R["`6A)\[SH%L[P]V&.$\!>QC$?HP.K^EO(W@^I@7IP>Y:DGAV\3\'/%E
MX[/,CL-HV?3QI3JDD8M<\R"E<Z7I-\G]_$]BO+ZY9#O[)+;^2LYRE!@@O+`U
M#G459.*ZE;B$)!N>SY-Z[;@X9\)TYCQ<>/U-*M)PI;PT7-'!Y'JEF4;)4RP/
M$-XCCCBV<D$F&J[AZB6).\5)$2#1BE^S%)"YZ=)KAF-L3BF%S&8#Z[%5!0=?
M0JF%98C[2:R5;6T(V3J/%/J4N^U@R$LA5M3M(&]ZW+I4"#W<;W)]R>Q-F22[
ML/_4<"#:95U^.D0YHFJQ:WQ:Z;A`:_#HALOM#ZZT%W@T5[(AN'2BZ"DX1K]U
M:OXR&$"E'YY-!!C32;VR1028VXMV3X/)&(QO"((5["&9<I>_'PN!C3^I,HD2
M4*H>^M4!Q'=C5@<GMQ`8[,8G(`K5']\>DQ7(0:[&>%175J(<Z:K7;VEJ/.T=
ML%Z&4#BJI[>"!$/%BJF@"E]`>$U(*$QNFT!Z5_RX1*DQ*7B%HA[B%368LE=J
MAL/O5*K!2Y(2&0X]A."ET0OF%52K@B`=5A(2PW\1`L.ZTGO%M2UW?.`U<;D+
M7^U420S_S4XE^_$8S%BKMEA$EF2X`A(5%F5-52457([!=H(BZBE:?J),E%=>
MDZ)&0$UH'JAB_U!)SRF5^"R4Y,?^O)H)N+J":IA`OJ5`-VP4DVX3JQI*`M)V
M';T.Q<[O1(JUOHOQ^U,1"LEE?9&)^4P8P?37%WWG>C?:<*3!YM?6SV1#UTC]
MP,6UHXF519*G92RS.79:#IIQ3J0ST=#E4*UT&U!MI&I_2`)19'_@O1"+\/0H
MSV1#ETO]P,6UHP'%3`G`DLGC/_-+8,Y+!#0/@XKM*Q5T7XO2JY9A$RN7%,0D
MFF#PR)8)_"^QK95%I<)^8'^69O1B^+#'\8!QT__3A\&VIE($'"PH,3QJ3^D7
MDRFE??W+XR+&@NB;":FC-%6B66C@=IN$+*RIO,B"G@KL3XP+CC6:+5/.0$T5
M:PXFN-V[(1>,^!?R24RJHA$3O&+9;,$FQVFJ7+,1P>V8H21'NOEH?)+S78?7
M58@KUHQQ&B96041P.R`")EZ,WXR%&/FB99+<$1HJRE04<%][/0T,3;R$1<!K
M)L<79?HX31.H&"*X;X%,%4,>8L2+FKN<[S=,C#D(X&[60#<3C_8'YF6CEOH%
M#\+/<:4.TS!ABN&!N^]"P,.Y8=X7O:PDO]Y0&?+Y#WP(7:3"8Z:W1S[;5RX.
M>DXPD"_"E$&:)D@!+`)Q(O4),1T,K#;Z7XQ^3MMFKBRY(S1,D+DH!%)$Z@BB
M!T&PJ7@Z&6LV(NHIX`_1,#GFXQ`($JG?AP^6BA)Y=-TQ)?L1\-?!*7J5;/L2
M4P31IRISQ@);&8J%?=&[2`0:W%$,/OF#@0;6X_@JY)\'6^V1#MEN5).\;E0,
MR8X'92>.=^?A-_N9=&9[3XKT(P7-J+BB]6>*)I)M1A4\6NLW&TM1J'"ZY>Z9
M;*Q7DQVXIT:.=Y;C.D]A.H$VUL#>WE%,JXI*,S4D!55)V@2^P$PAQ0HV,&CU
M2Q:4P4CL:NK(0`0"=*JBV0_\.<@V<].^&8YY62^*VK,(D8!UQ7*LC<*8UFY^
M5+"NGLF'9;L,/-]6H^B!M1F&(;G\*J/V)Z%POU&+]9Y>S??6!]LV?44(K-'^
M!*Q>56!^-.LK5U%B1GT!4''?Z[X1D]CZGK(RV[Y3B.EUA6+T2<ZYZ?6'8+NP
M$`7-4Y*BP.+>BAGOR]V+OB=!2V5-FW#2+-2H1&*VYHD_"S#`QFDJG*&*S?[;
M8P3:J9O-2!N#M0`#)K[\20RI?T!@UFC,B/9!K$A%@U4-+L0&M%BK!'NHEF%?
M<GL``O.+;P^<?FS@0L3?D@W.9PC>8[MJ+V^-VVM#L"RUO5:[-_`5%,J%GB%-
M)(VWY>*)DZYV&4]<S_[GX:6S7'3FB[OE]X?.'PO=/MVDR\4+U_IOXBS-N4D_
M(>%8TB'!^$-&4TX25QQCAVQN7JW/_]H2X[2VZ`^72XI^=#:HQ(YR^.D86T.W
MC?`J.NQJ<!WJ$M.IN+RGPQLNM2PV<?O@GLBKOC^QZ"UJK3_*OM*)*M#%P!+6
MZ07^2J@KK-[9.I*#8FBC\5C!?^WB<9=IU]>N(TJHJT!'>'8\CQ7TMO?I2*/G
MFY_?Z?/88V750!XB_I3E=2@YGB^$'BN<J8P)9?HF*))`[P38Q[]39?$,Y(FH
M5@TK8Z(2->1L?P+L-W`SC/,`9/M*B9#+!AWK+Z+;ZS=B$WWG$CO,&QY,12NW
M4L8`T:L4D,/:UGQV<)OJ`0._K/6;=7!T<WM63C:8BI9&9@U4IV3R&,,=IJ9<
MW!XHA>8]B[<;/P^>HT'_%67;=X4+RC.'JDE$@LSA[K(2Y<3/WJV#Z<;H%UT]
M_"'J$$H^,[A[H\0>F=$F8&%Y!:\3>4,$R57:9`)*JC)]2H<W5"`N7_C-_`O.
M@(QB",6!)!5*<3A6.I\O](9Y@FRHS-."XN`2^YU*Z/WP[I/;[\'UW3Z;297^
MI,`<:%`:=[A-\._Z[W.JP4(99S-5)9,4[G#;W:'9%(7N3H%1=G/H)\/-7*,N
M;1#)K3_:1(&BWBK?A!8'\NP8N.`122RX<$`C4T"0`0W50DEEK@EO)F=Y"X&6
MD(0#5[7H<KD/=^+Q$+\(([:?PNHQQOHP630KNB<_R=?^Y4BE-&FJ*FR+P9?0
MG`RNKJ;F50`B,5<.C(8]['9DPQ)[PN&?=9>PG"IS8^R-4[:5^TBVK$;GQ=7=
M`QWY>/:/;R;C`5R=H#Q]U>@YQT15BRUNPS;D=;;]]\%QR?:,#>8Q7YJG!2[:
MA$UHQ/IE*\HO;E=S/CN/UN'DK15M4"0V)&(!7G*,VS^=S\_ZE^7!(=HY3VA$
MQ/*[X!=WCVX!=EB[8T\?17OF"8Z)6827/./NT2VPI]!?>OR(MM(7&Q*Q""\Y
MQMV..YN?*!W#XTBT>[[HH$BER.<:=U_N/PWW[<W:LV=4?2Z6YJ-E$^/5+VCP
M6!&]>N6.5IOD"O&)N^WV\H.P$A/S]<ERG#O=MH\[RV:-!)E7L#L">[DR?=[:
MI"H&!?).W+X^SASG\.Z1\4SVK.72VKHG.V+;]"<&"]UZ;&)NZ+7XD]B.OO<4
MMD#&7IDY:A.L`DSJ;]@M6[G6SZU<H_IO=B@2'69`.`K*U]B`?N*>(UO!%DJ>
M/:%*UR@5U/'DONP-NV#5MZFS*G`N7U/X(E<H1<,7J&.##8[;"@LJ,V[;T.A@
M6V6$KKRCK3)JJ!JV548-2&;D;?N1O4PY!VM.G3FS`IWDGV,5,J,\EB\DHH1R
M9N!P?;'\=(B@"^;4:G'L7L0\"W!A_-A$U:@JWZO"8Q9W7/U*RC/G3S?:>#CD
M1#UXF8L;5B!D'T\$^W^YI-7_F(X,<B+G5#.=\X,[#_S'"Z5U-,WIE%\&^Q\O
M=6!_S@_NY;M@>C+2!/L<%<%^48O>G_.#.Z>EK=AK*_94*$Y;L==6[+45>VW%
M7ENQ=Z45>W(!S6FR%>?+C]7JZ>'[PV(]>_ZK\SA?S!9W\]E3YV4]6WL?=^:+
MQ^7S]]EZOEQT_IAM/*/.Z3R3#3$^F??D'YVE^T;LDB_]'3X^3OX3W3X^&J9N
M;HQ3@KGWX=S<6?;[*?O<GSF:V)M6-D0:#+NP7.(\6;KWKJ=/B/D:3<:ZM`8_
MK^DDWJ'0G_:@#"`9NB1.Z;.Q@G<P>_V<[I`R;PDE)U2PQE5*->H*DHD-?EM1
M&A0@DPV;JD-9IDA5G6?49F.#WKH]PX3"X<$2,17Y7P=PC[2*TE!>@Z-&Y*(Z
M$#0VGU;POFHAFE2O@P(R3[9U+XOFU<2."D$)]8XG^/)9V>1#-[;^VVUW!]NF
M`KC1!KT!V//GW"FKUGW.=2<7BMKO/=FA0781B-AU%L0->>AKXYQ(CD2D,'5>
M!#(5`P6Y6SS5#@%[VK2DC<8E/TB49L]\1#T$>7LF-V,\^745W@\12`,=RF8`
MMX-J;CJNX7K]-)T8[:(EP<FO5PU^-@.X=V3/@;/<S1U;)_L8\:*EA)SO5PU_
M#@O8-\Z@@^D]^;`<([YZ14L!4\:H6@X"K."N=G\YF%O[&*-:M%MQ_(N5:W\*
MT;@KTZ7N<.#OIZF_$<.X^8"``'?SB3X2)Z<;P0I1`S.2RAVIL)+638:5GA^>
M9NN'^\YJ]KS^J[-^GBU>9G<LA/12*DSDUQZN=-L]KFV*M;[Q["+9Z$_*N+'+
M57\PAO*5Y4VNPC.8!AS3RMAO?$V?3.']@@4H4G+H%11PTAU8#L*K<0:*(0AV
M'X=:(BDCGQK^.\M=[+,;;<B2?ZIED4=(9>N!:X:7P@OW-37.5&`0]P>`WJ7+
MZ21RHG13?_7V"VIVW-'MZ+!GY06/A#AKZ^Y--^QWW5SN;BW=WD9F?$_4_5%\
M>,7*F2*.*$%'AGW<GJOXZ\%K:_U&%I;Y3_*;;`[>J[:&3384VIA/J"?J5BDT
M<K4"+<UT<W:8=./AE&':'VIP:3:B9*@Y4>/"KH`E9<D4$N+B'90)&/`G"15%
M`"Q9ICZ%K8"EVA26F^R3`0/Z5!^)>QJXPT_U55?)@H5JO*)VP8KZ\F2$GG.U
MR4;P&AQW7:W;2^2#S[\MYH_SN]EBW9G=W2U_+-;SQ;?.:ODTOYL_O'3^^.&0
MW6'?>:)6F=.Q=IV5;5%RW6-'-[>=A_\_&!_,*B^9#6Z\FL;.V.C4K#^Y5ZE-
MO[+VQL8@SFEB;][E+IB56O_AG++.P&#,U5[WKA7AP/%X29?7DUA5=E#N_.6W
MB2?]IV6S?WT,APUM:4TX+ILZBH)%70;^\&T6$>YPW_H>#S;%ABY"+XSPF_T4
MW'9ZO3%8_7SZM#6+5`@/P.9:BB[R!Y?8ESJI=2=@*88I<]8LS'PD<%_C4WF/
M.4XUC?,`#_#)H,`1'ME2Z0(.`J&<9WQ4V\S91$"J<;HHDS$A8:BN)@PD"EO5
MMI&"%9`Z=F!Q[LB--AB-P/*(!0BH4/&Y^>&%$&KH7GY[#/,S*!!@73@$Y@?0
MY<M#NFKFE-:\E1%AKBYS$<+OL!7&`LBMB4.=JV:N'G7F>&^+(83>G=LV0FH;
M(:E0G+814ML(J6V$U#9":ALA76DC)(4^+?`XL`*?EISI#\2A*M-?--A;4)BY
M)C(7)B2!W2M[2T5:B!E/JT!L0M7%X'O)XIFG^=W#XN6A,UO<G_JS_=69?7M^
M.+5C*Q-7?S(VK+$#1=OKMW:<O=J$J`B9WUG[_2GTREYDM&TF)#8NJX5:6.8F
MY=?Q+`O_:)E..661JD)BBHB4VJD]D=P:++75UC_(P34V#NMI;']X4UNF#\1H
M,AJ*9FF+#ZM@"8/).K9/EP`)MW6XVAE_$SN%!5ZE`5_.::,T0JPB$.`NIX]A
M9)G^BY<A%^/NA-<Q*"4!/WV@)LA2%`C<UP,%,'F6R!3.\:R(Q/(GEEI5PHL2
MIK7'4RK.RE,ECVJ<NA*^.960`KGGKVR=XD4)Y3KEQ$\`Y%&-#UTF^/)"KY<Z
MI>J'Z7R0C;$SR#8(/0Z'G'Y#JAQL*;/*),.=AES_LF(W#>&&/9??5N(X$84V
MRE++X`'W;2D@?6F2&.FB#:L2WZX5?BX/N.WB'Q^6^7@_FWU\V-:G'C4]T[JB
M%U7N"+6((9<7W#=.1OZ"Z/::V.]W])?&1M_?DT^RMT[IT\:>.*YEDJ@@6A/N
M*UEP[-K$5Y)_Y-W@@J<M`DQ./NTI7"DM=T;Y(S)%EE!,2)WU.=HI))++_3V+
M?_0WJPR6@:X`U6HA%!/U:"'GFB'"?P/N#5GUGD]A6CHSH#B9+GPC4&A(J4C.
MAI"M\T@%%]WU+-NYT0;],5@[_-1I56A>22G$XC;YD."^>(3VQ$H_LC7HA29$
MKWV77T8@DBQ^<-]!TOPG5,EVAOORIMMD1>P->S#LE3"V>$]+Y\5>\D=&(,/2
M2."^V12")5%N6,N>?RX)<QND4\3<=U[N"KV$]#DED@+:F#IFU7K(J7HLP?UE
ME^C&5CU2P"BME&7]I[&G"!/'?T/#]^;Z#VH,AW"5CV(D(-BO"F.%^Z+^3#Z)
M>2#/9&-17/XFV^4G>VW2H2AY/6$(I79[,^Z/-5'35&A$!((LS+DOR'%#!!EC
M0-2OF3(&1F$EN?/%,\$IGMA^X>\@[!YQ.F0H%&&JXLUX,!;O4R,X*`(!EN'?
ME^@(IT2+&0R)Y&5P<ZFH1PRJ/J"T1ZQ(@+L`_&<OWV1`T80,>951?B#Y5YDZ
M`JPQRM&^BLS^*:>[7LG7UE?ZD4G`Z['GG1+ZWJGXW76?!"K1@`"E[Z\GAP]T
MCMT7Q`Z)G+'*'P[I`WMJRV@<2=.H:#$7!O3R09M\)IMP``AQDP@308FL((E^
M*(<1R>F!4)!(Y2^-BT*:KUA)/O$W&A!"(1$%QZA8LD16JUB<4'P1/M$W(A!D
M1NS^JT1H>89UK`+$]_2M+/NL'F0H[!L3'Q94W]*@SJY_R>,>=^R3UTK9,P\-
M$G]O0]A7)C!>K3(LR"_N<&DZ#)'KB3V6TA4,2PF,!W$NQ4U364)5Q<U*09M_
M-"58O9H6H>*`R1YB"G3QX?UC;QT)\5O\)Z-6-Y,)S]VLQO>3.WNE^LO9)(O`
M@WZ'9$[U?^F;^%E],QSVP9*U^%/6+=)<('#GC:2&ERD'P^JC[TBDF0D'[@"[
MS\&S==3WY_2/P?;=E#F1"#,#"MSOKE\P[SF&0QX&`TAQILV+0*0"D-0>R)6+
M<(R[@T2$X[]GSP^=N]EJOIX]=?Y8>N0[G6^V3BW7;<>U.H%IX92,7+#$QSO]
MPZ"?^Z/[@Z^M<&C9J,0]V1$JJVW\5<I8X.I/PWV;FUOCT]A2=7CXO=D?MH;Y
MZI%VJSOLQ:AC$/]:68YK$]>PO6_>$I,BZCJWQS4#<;F+AO%\75I?`ZM5KXNI
M\D9Z8CA&HV>2,K&_&1]4Y";5QN#=NB%@V_:"M"C8?]`H8;"GE1<'?K=^O6`#
M5<U]D14/A-Y76_&<"$MY<:"/MT0=*2/\4G"GL"4PGOW2[6WXKF07OHFL))7E
MEV2]2@F$*^J=4;25JFK%#58]`HDW(<4D%_XT]*/KXV`RG(*]J29-GD0VK5H=
M!7]UKHK--6=5JU>FY+-UZH1Q-4$K5;A#];BJ<Q&7G=MWRRP/KN/J)CL;%H?3
M<Y^C_@@?5&GD(EK5O#Y3D-+!'=*39?WA-S4`#(=M:1'K?3`OM7)RKULQ,Z53
MN\.\JAWS3V*\OKED._LDMOY*?%#(RC8VA`$R!'M!NB(FKEN)2T@2=Q6MPE6=
M!TBO"3OQUU7M$I(,;@M(,V`5(4*<N7FJOEZSH.7<=&W#=(S-O_3]P8,#+N.H
M"@Z^A%8+RS!0::PFLFMM_F_N.`>RO3_8K"+=8\J#P/%^><'WEC(WZH.]P5.<
M'N3J)H4O[DR[\EZBM+64=TYTP?+WJN4%N<[6)E?<'4ADCPXO_2C$Y)MM.0YE
MOC>N3ZF+$]QPS963$.X\65GF'RU[1PSW0`\F5O+T^\,X5:V%>+"5"O=J+3CY
MUZVZA:2'.TM8^OPY7\8YAT]O"O8X=H6,-%RY823JJ_FTH6HNN^+SK"ZX7I2U
MLM;PI5"5U`/'1!?GZH@W"T^Y)P\`Z[ERI\>M9870"S0!J9NA5&XID%I`I/IR
MF?;E19?X,W%<NG;IBO8$F:QAB5H1"#\O6WAT!=HN*\9`M:60J;W#AFP=U3"G
MCBK"I..!`E10E0N]=+LW+YF,?LO+]^P/P)Z</)L(,`<JU<*-"#"WJ[UN+O1W
M$CS1,AF#\0U!L(I:RBRYRU\GA,#&7X241`FHM`7]ZH!Z1JPIJX/W\!@LV.@+
M=M"40WZ9.I2V)C>Q4M$H85N3V];D8E[Q;4UN6Y-;W'7>UN0*=E),&(Q`O!:_
M*-1=O)H"31,*2A'4W7ZQ\ZYN944@<21/;;25UB5=,&VE=5MIW59:-WP1EYV;
M-3!WCW.3;OT'3ZN\/H/K-]WTPVD+R_PDCDNV82EE;X(OU:\H&XAV`96I(#+2
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M/_SA6'7?D[&A.+`[B#?U<?9JDS`G8/6W0;\0E$%1-D3?YI69"%Q'T\1RF2PA
MBQ+NV]AW8T]ODY9)@MR.L-IM,!%].35EC-HE*,!;[=>4['U%IPSXS'ZSK*VS
M(&YPVQ\"]E!)G;9VD0HA@CQ\DPE`Y((=]Z==3?!Y:L$QE9LI\:N,%*7*LFW*
M@IMCFR08O9X\F4*(J3!?%*ACX/2XT89#N,9GP2R5ZR77YYODN/;#*\W'YG_.
M_O=3=PC]Y#]02P,$%`````@`$X1<0M'N(L%0GP``VHX)`!0`'`!P;'@M,C`Q
M,C$R,S%?;&%B+GAM;%54"0`#]<PO4?7,+U%U>`L``00E#@``!#D!``#M_6ES
MXTJ:)HA^'[/Y#W[SCEEEFBF4!'?6=*&'(3%.REHAJB7%R3[WV%@91+HD=%*`
M"@`5H?SUUQ=L)!R`+W"',TZV=65&BKX\K^-Y%]]>_V___<?K#KS#*/;#X#_^
MY)P/_@1@L`FW?O#\'W_Z=O]I>7]Q=?4G$"=>L/5V80#_XT]!^*?_[OZ?_\=_
M^_]\^G0102^!6_#X`7[U@\1[AN"+OT-UXT^?TB)O4;C=;U"9,`##@3/Z-!A^
M&L[!_P,<Y]^'$[#\2DNB2O_X=_P?CUX,`0(5Q/_^XS':;9/_^--+DKS]^U__
MBO_G>1@]_W4X&$S^2G_\4U845\U+?O_^_?S[B)1U%HO%7\FO>='89Q5$C3I_
M_5]?K^\W+_#5^^0'6.0-1+5B_]]C\L?K<.,E9)Q*U<NH1G_-):@M@?_7IZS8
M)_RG3\[PT\@Y_Q%O,X@58=B=_`D-'`!TZ*)P!^_@$\#__>WN*J_]Y,6/I.8^
M_O3L>6]_Q07^NO,>X>ZOW@\_OH1/WGZ'QY$T\Q+!I\,!KS2`/N+PKW"7Q/@O
MN+7X$_[3IX&32O'_9;2;?+PAYL3^Z]L.#>E?%8%O7KS@&5[C?^.N.P5?TW:W
M`CQ%WO,K#)++<+/'_TUHU:D8C3WH$8:,F18A#EH6!W^L00N*?@O?(KC!]JL>
M^4'5710=U\0*O,`*[$P)XIHV-6"^1/^A`W>EW<ZP!_!99K#3:L>(6:UU#?46
M1GZX704=8V8WJP?\?>)%#9HI#[_:<-<"/(2)M^L6>K7)KD'?P(Y'^[C!SD<9
MQ7["AJ1EE"M-=@A:8GB3*D[>,24>[AK]*RV)6VR(S*A7I,%FJ67X(X'!%FYI
MP):W'6[24J27__@3^L-_+C>;<!\D\:WWX3WNX#+8HK]$>V3H?.\1A=:)#^.+
M?10AK[A\C)/(VR3GH\7XW''.9[*^%__EV/6F?Y;!<RC[#@?-890-Z\'`+J-L
M!)ZB\+6[`4A"U);W*-66,YH[X\GY:#P=SU&#8;2%$9H8_0F\(:L7^<G'?_P)
MS9'V,1(M?,-!E9?3R(LV+?Q(2_QU$Z*IQ5OR:5=E(2K"'*LCJG0C'3^IDQJ=
MCF`<[B,R3WK=(71XV@B#3]_N_P3\;5<XW:P)\$;;`&@V"CS<BK>+__V__;48
M&JT:-OVC:]BT"PT;3<?TPTY_.O4JBR;@,(RI50E?H5.W)9U*FP"E-LY`V@KX
M/6OG_U72N'7R`J.TS?/)>#PTY;S*'7>J0LT2U>C*025B[^;TVRQ.22V:I.C#
MNS3@<<EOW5/7A%<P2]TV,W]0:32;TA&>GRQORR(8-MMU."KF^0R0HKDU5N+Q
M0^1M8?'5)S-3)KC<<:<\;I:HAL<'E8BQF)'Q7SBG1.4F*?HPP0UX7/);]]0U
M88+-4K?-!!]4&@^&=(0')\O;L@B&37`=#H8))D453?`=W$#_';=W`Y/29W>T
MVV!6S]TPF4^F8RHS:V&#,4H-QN@DZ,PCAE$[S`&HX':4%_X$%*QS(P.TFN>>
M6%UKH)FU1HL!'?KAZ5*Z+(,I$]T&I.!Q4?(,H+*R1CJ.81*?3^;S@3[BDCX4
M*5J#,R<C_=UQ1G3!9V'Y6AL#KG:*5?MTZ=^4*+,X$<HLZBB#`W:'CHCE^Q],
MP`*>MF8S6(`[!UV[9'<9>-(<RI=I)XN)9NO3T4Y",^Q#9A5[.\Z`[NPL+%\Q
M:H!MQC@Q^TZ-E/QJ//.CZ9EX:.=:=6YQ-'`XZAW1H;-\7;T1N)GY0Q,$=WE_
MOWJXE^%:'CK/9QJW4<M==4&U6M2'5,OG5\Z0C-5D8/DB3#UJ,T:-U75JTY2"
M]N/OI3$0T\BRFK#L8#EU2(?-\D7J)MP&@S0V@C16VZ0[V_(QV_$.^V2A<4^0
MU6.')*P5@LG%PD\,%@LZKI8O;K2C-VH!F1".+:%BF%?S935&>^;H61/[L8Z2
MC5+%MWQ!F0>_P4BP&8E[\>WN;G7S`&A@*'@*[\*+7Y;!%O_7ZK_V_KNW0SW%
MR^3"BZ(//WC^U=OMX?ET,IEJXRL7!#7^2DJ9$9JO.ODL$_I9)E837$H>(X27
M0>;BTN34W`;_`Q;U=*J"ELC".E6HA!Y\U8?.?$8_S_@G4(0#:72')N*0"OZ3
M?Y1JG0$O`5E%0&H*JD3X^NHGKP0!PA0&"6H(!AL?QN?3N<83HPT=*])?1**<
M]`V5L"V:IL[8[G5Z`2G,V'IN/.[%^NO7JX>O*,JY!W^^"1,(IG_IGLEZ3'J?
M3*Z:[X9*P^DLM2EV;U)RRZ#=5',"<4L%J9TN%Q7C\25\@F@VL+V#[S#8Y\>E
M9M.9OG-+[#[5V,LK1T;<FO)D-2F=M-N]K\`G@!'#RP7%S4J!B!;KEJA:;&T/
M1*U8V)KRH\5\0(?6[LU6'OBZ[2H'AH*=:2')+8NCKF[0$.8?>*HOO*WMME.N
M-DE30]=2%6P.)G1GR+%[BX-;ACZL:RV:C@TLXV.;L+'FJ-MF:4M51HMI.LQV
M[P%S2F#8WM;`8)C<HJ0P=?T`;C_#`/TCN46@Z$+WES#"_R/]>UPFP4+CW2AA
M.,I45Y6^I`*"39$@C[I1Q^Y=&&793%E[)93NEV\WE_?@Z@;<K>YO5Q</8/T%
MK+[>7J]_6ZW`W=4O?WNX!]]NU_CWAZN[%5X#,:5LNOS':2@;R]\(-C4>I6M8
MCMT[\HJ2&?!/"O#<M#I(RP%<YPRDIS>?PHC\(?LUEO=J5P%RBXB;'S<0GZH:
M._H\5KDK-?UH`9UQ_[`8WGZC"P6.W1N=3;"-N(<&`&[VF_`:(/N;:;'6NHE6
M,;('Q1;3"=WE=>S>1JP'K=LTUO:<L^N#7,,2(U@IZPSZ2+.!OMEDJ2<U>C5#
MSMAU4&J0YB29.';O=]2#ULVNVI[=TB\=4$O+$6&]U*J<#SXHA1=Z4D-O]YYP
M`VH!_RA_-KB^__1D\*X#HBV#[7T2;O[Q$N[0AXCQ`8GD`W_*D;ZMB+;N.Z,D
MKW`,GM94'3B+*?T*=F]5"$IBT%ARP"E;4+(G3`OIXKAN"]LKQYML<4U5?+PD
M_19V;QN+BF+::O.`JIIR$,`$A$]@X[WY^*<MFGIO?!AL.E:`_,CT<#'6ETB`
M%X5>?:B7E5<M2A<AD&J1KS>T>P-%4J*^70$;5HU+D+YY(DP8+4M5EBI'986+
M_YOA]?OTH]F]+RXKDI&5,4EP[O75\O/5]=7#U>H>+&\NP?W?EG>KOZVO+U=W
M]_\&5O_SV]7#;^#/-RNRD7*QO+UZ6%Z#R]67JXNKU<W%;X+'1JLY?!%YIM.Y
M"5_2R?$E+@$8.I`7'@P68SKX=N]AM&(W:/29`,KF7?*T4M/'U!WA:V=C4Q1?
M/J(X<>B(VKU[W0[>=*3.AG%T`;N+Y9;CZXK#Q4A?&AU=R?E%Y*DG;#G0H]E7
M)T.[MS*X93!O3ME`F&:UBYBY[K/KCI)-T[@I$F;=/!ZG'LWNG5]^(4Q'N\UP
M\MO<I3A7\$IWJ:_RL2-GNEB8,,-=G=SA%8-!VW+Y03YY.)E=OEKX!FUN'89#
M<RM[5*;EV^J.90U1M"FB/3X63K=6AR>S6UB/WW1<6XLD6W8.@V>`3/=K)\%M
MT5O9D>H[@-/8M0;VUDO52.)R;)9-+DYF][!5C%[L+AM+G?WM(N)M8('NH+<?
M;C>%OJP/@<T+/5<Z/)E=PW8Y3`?`K8C<Z_7-+^!A=?=5)0I&9O\!6?U+^)B4
M7<1P.-<8!C,[5:0RKR`YB6LJ.(,A/1XXLGQ3CP>_=I/,`<+%A3Z1T`(7.P.K
M'YO=?HMSK63K$%^]9!_)1!PM'UV//>Z!O5437%,!6XATY"W?=>,2P(S1Y8&2
M1Q0?P`\`&H(`;O``@N]^\H+^]PZU%$8>^5/X!NF_Q-A,7DPK'H:(#YY#<6;Z
MCA?7=ZS&:B&!,F8W51I.G/2#V+W+QBV#;OO,"X0^-EEZE216>9:$Y[MK,<U]
M$KEBHALKS='_IX-O]P8=OQ!&3#4WG)30,IF2;V$0HR%?!EO2QFV(HF^8^!'$
MF8G07_$?X.O;+OS`?RA=MXMKEUOF^G;V.D:KIB?ZARY3KNY[FL[I[L+([IU'
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M2_!Y>;V\N5B!^[^M5@_WTOO@K%N,T^E4GVGO^KXLEP`%L:N%YX-LB.W>W&[%
MKI^RS0#<<H%_RZ[Q+9,D\A_W"5[>`TD(;CWQ^?=RN_7IV-]Z_O8JN*#W9W%^
M\3`@O9Y/IAK3`;7WK\9A&?DPI?GQ_>?N<8>_T\SB-Z@DI=%)>SE(;E$<X/+@
M*@!I#4"K`%)'FQ+H>5_-'B68J2J!O4O"DM)HGX7*X2IKPALJ_PEOM=,:XN^8
MI.VG+S7I?,SWN#<U8K=C+]/XN'0^G!9G[.#";L).-P%PRZ97]E4HYG?4]A24
M`0XR36GM,%J<%X,+NS$SV83B@(AGX/\:G`\&#C*/$7C'1?\=+/?)"QK8?\(M
M^`2\&&>,N80;^/H((S!RS@!BC$-603!USH`S&9P-!N3_0/R"PNOX_P9^'.]1
M=5PHW"=Q@OZ!S^?Q-#>?G$U'@S-G,B-_7(S.QO/%V7RP2!L_`^@_WO!AJ7>X
M$TQ<<P<3#R>E77E1@/#$R\UF_[K?H:GP]I+DPD%SWLE88QKF=@!J>B8E8%GU
MVAO(J32S7QD%I3'A(L0@N5EQD)4'I0H@K:%/";2X%IN4@.E_1+Z1O:=B):4Q
MYJ/$<+EEWF]E>-^T4J?EZJ/)I<8%B\?5"L6(VKMDSHE>@*=R%Q[Y<&29/!13
MZC5D8AHOYOJ>/M:5&4Q$GF;*9O6*0;=_(LHIA8EX@P_*P=JY:@8\CF^O):[H
MD<O,,()CZ.?VQ]"<4A@+&_CPN-4<=((W&9?;_[V/Z>NQ#^$=Q./I[^`-3*Z"
M3?@*K\,8_1T__7T;A>_^%FX_?WR+X?8J6-/;.L'S$L]1::J]G"]S?2D?=0!6
M75(W,(39WJJ6SIS18C`DKT9-+7],R(3XVG7<D"!NJ0\0061$\/MZ28C^G79'
M,B7O4%?XK_C?&]0A^NBT1_#X`?Z,/OH6^,%?LMMYP3/P\HXMLC6:=J3_2+:F
M<HY#2V>SX902U-XE!2.RZSY'HEN``^N"S$?>!3XJ"&@GX,^XF[_@GW%/X+9L
M6;YEEB7O$!0]2D?EN)]EL,7_A<.F=V^'`2Z3"R^*/E`?Z;[,9$("VN(!U$XW
ME7@P*.XT28J9J39??>Q/:,JCJ>7O>4K)PZ^"B*%^N+U/O"B1<_<R^-SL\"')
M-7W_-W+4G/P#GS?_=7F]NGFX!\L'\'GUR]7-S=7-+[CD;ZOEG5:5<?X8*N,H
MJ,R"?D)[S[](RR.J,JM@JUUA<G3<"K-"?^]056Z)J,CE1="+X26D_XVH-->7
M<%`$B0Z]X96Y67MJ6B&?-8TT[+[KH2*6]J5]18`N?N?@ZN;B;K6\7X$_7Z[H
MO_Z"WY.N52\#^J3G,)K=^E29FPFU,AR.)_2KVGW%5EXHW;,I:60NF?C@(S[D
M'Z7*9X!6!UE]I&)I"X+OB."6O^S"[_AB+OHG?IPU)A.X8)O>>BE/YB[]>+,+
MXWT$\VG=?#'2=\).$9RZLG4Z-&7]4VH8V]KIF-+$WEUJ':(:65_M&+1[_^WV
M]GJ%[_@N[WY#'O#+^N[K\N%J?0/0_[^Z^75U_X`G8-@E?KFZ05$H^5\7#U>_
MTM>$;M;8E_ZZOOX5_T"\YI?K]=]%$T]VQ6=M/O3T59WI:I4:'@[G,THDNR_D
M=RNH"9?<&5KJIG%S-'\-_E]YB\1]YVV65RF+5I46+'<PCE<_8+3Q8[A^(EN_
M:T*%^'PZGXY85S#>=C^(&CK#5`G1'UK:4E<O(9QE]6FHZ(PGTT&ZYF7OD1=Q
M04S0GQN-FY4&67&P?DKO:*0U]+"VV$^UG+8%4`'>.G2OU?*7&L4$X>?M-MSL
M\?8/R=FJ@[\%JH*_,.-O^`1BPM\PK:&'P+,3X2]S@M(VO@X=7WM/9XD+8FQR
MP0W)794HFY(5/$=>D-#3&%F:+$$+?`G?(KCQB?(M7\,H\?])_QULESA]Y]7K
MF^='6#\)25B7?9ADYF]7C=A*^#.2"S1"SL:,Z$>Q^XR3O%"Z8PYI9&ZY)BA7
M!:@N()5!45N_)G#%)3:K0C5>$?TX=)W?\A<CY84R%<=((W0?7B#PGI\C^.PE
M$`4V;S!`3@(?SGL.R+54/P`)*I,]PD-W5-&?O`1X.T(R-`4E)<(XP=XE00!]
MG`&&)G`F\U8_./XK\CFTJ9BV]9CF<L6$Q!^=M/22%3\'RUT<HF;PZQ-9?R]>
M](S!>WZ`>H;9I3TT7/L=F3&3MG#1[XA.$&S#[P%N-D60_>I'8)/NY]);N1@;
M_?L3&C3Z-\'`3D:9>((\FXU!)?@3)25=!['\U6-YH8P$A=+P#ITCUME#I7GR
M?^!+YA(YV5=/3W"3K)]6/Y#&!L_P#EF,=<#>RSJ?SQQ]>19$D*CICYK,F0()
MM4*VS>F.G^7O@*J(942)%`"ZJR]?5A</^&#/ZG]=_&UY\\L*W"T?5H#^^QYO
MU.!]%P,JI&5WQ7(5JLS-A%J9C-,M<\M??I872O?<3!J92VMB3Y/5!;@R"`-0
M>WA!3(F^A!'TGP/ZYLCFXR'R@M@C[T#]@B)(?$;\6Q!!;X>CWO/%8DI.8(Z'
M.K1(!(J:%BD*G:F14#,DL*"K_I:_D*HB%H<J+:@J!61N)7D$50&BFV>;S>9U
M,?BS3^Y$_.6,W+3Z\RMJ8_>!?DY5;NLC-<0=P5CP^(\4T;2X*,N5J^*BA%J9
MC6;I?H3=N_CR0NEV4=+(W+0FR*J"4EV`*Z<WC<Y`T8*8$F4(UL$]\G#KIX/,
MZ7D>=/Q<\D*?_O"!4-,<:4$SI>%L8#8;I=_/[EU]&7%T*XH$)K>D!3ARPQ5Q
M2)=53;/ZYY7U:H>>V,U&]:@&;'PMC(?GSG3N+&C(8/FCR;(B&0K4).&YN`[6
ME3C5%?F%MN,CX%?!<K,)]_B(N/>!<[+C1<#-)MHC$8N'E!"+T.Q9VYJ;'"@U
M]>EL(#)MDFT0A>.C]$O;O=O;C8!&%N<Z@>H6UQVVV74'O-/EI4V!-]H667;P
M<&O>CDZ>TM?/=R'Z#_PNNN`T296:6B*^4]312D0HV>!\GA[PLOS-]2[$TQTQ
M=H#19=Q#PHJ9-01N2XJ9ME5^^+,K;2S>*<:4F^B[KL`#09>F-0K9KE>EZO/9
MG"[E6OXDMK@P_>E,#:)6#2GJZ50&/9,KV[2A.K'BJ8^#?!QNI-_,[L--<@(9
MFE1)@7.STB1@8P1W45Z79LV7?FZ^"N\2/L$H@ML[^`Z#/662OC2$K?UWK2OM
MXM7K2:4N_FCT;J/E;VD*R]+31*@95=V<9YO60FI!JAW,<X(P^)0?_</'B<)`
M><932R)#`59?.L(16AW718Y_2+^?W2<2!"4Q'U0UP:F+J+(Z(*VDRGM\E3-`
MW*+SV,5(WQ9.8]]=\[U9K'JNE^O-D:&BG\/N;4T!*<QSO`Y*';]+Y;50V]04
MP32W>28%I8I9?$K/W%O^?K*@)+U-`YI0U<7_?G=\S[.%IF\B%M?YIXZ^I/O\
M.+K6`WYYZU6BM@WR]:BU&MN]!2DO5$\S`DYX[@4Y_A5C+2FEV"[N[^R*%5;!
M7#$27#(4$EFC.QRQ4FT;<SRW(';/[@,NLB*9CZ*X<-6%5$46Z>P1:-F,+%5@
M=Q`UY&^0$\7GH!%Q!@-]CR>V==^UDK0*5Z\;1U47@\&IS969$IAG/@M&'=&+
MLN14OBYNFYI"]$-NGHG$4=W1;#&9GIJIKY&AM\D#&X]+4VWA4UJ8X5'!\"U\
M"V/1)Q"S;J^"TO;TES`Z.!>V#+;%<;[I?#IF;30S;P(+-]\-J56D.28Y?ULD
M#2+=WQF?QC$-:=E,F7U9@(5#N`K*!R\`:N/XG"_.JB%YUE>!;UQ9-4Y'?:HY
M-B0_(;WJ/3Z-`QK2LO'KCUK&#56@A1XA7U.:7H,GI$=O:2-GX(TH$IZ"P[PA
M8YK$DY'B=!2I=HE*[!.F%X+&IW&@5UHVHPM6LBC=6]3!BT>SQ61*<Z@M8LIR
M`Q,<$AZ_1L5(Y8KL\FRL;]>:'XB:/BD)G"F22"/.;$$7ZL=V'XN2EDEW`"<+
MS,4OHI$;].P'T%BIA?4KCY9G:6Q6GLJ;-"*-X%0C]#S/V.XU+GFA!/R._'LT
MTO"($I&\W.7W29]RU?&TJTZ^'#T:H4E9_^ZGFUV3+N075ZAB-\R93=/-,+M/
M(BK+9H]W8@.4\5+2>RP*K-.ROW]"6E>93,E\>&1:QVE\8O>Q+W7AC$RGE&&Z
MQ9,PX,O=^BOS%1G!`P`UH(J7,@Z"I)&^6X[\0+1H%9_`+>K$;,29S=(O:/?9
M,FF9>G):K<#:G%7Q=DO'4ZI&+IF<4EFA/+Q3*F8CV/ZEX;W=VZKR0O4YI6J'
M5TRI]E1OR#G-],DC[6I3"FSFQJ=3#7A,:5&]_.+*5(KHYV.Z1CNQ^SRGLFSV
M>"8V0!D/U?5TBH=U)J=3-FH=[W2J\<-CLYI^>;L/2:@+U^=TBA]F93I5>J*S
MX^E4?O#T,$":S4W[-`80+5K%)W"+.C$;<7"&&?(%[=[BE9:I)Z?5"JS-616'
MJSN>3C5RR>1TR@KEX9U.,1O!UTH6](/:?=!(7J@^IU/M\-@[5'_>9TI4NMZC
M78G*88Z^FSWB>$SI5+W\XJIU$-_3J^N3DSQ!P2^;/7Z*#5#&7W4]N>)AG<G)
ME8U:QSNY:FAKAJSL?)$>IIF<Y-D+$>GZG%X)X*S,K]:WJ[NE\OSJBCR1@//R
MDJ!(ZXY4T9>R>C3"+E&_7,Z93]/9JO7G'FIA&W`3=7T3#T!_S+*>+Y,D\A_W
M"<DNEH3@UHMD3J&R/J8N.ZZ9@RSS6RZ'59H>BY]8?PJ@'K<IDUF+@'!QA_XN
MQK5;[P,?DTY/76\@W,9?T!==XYQX[,V;Z53?M6-!-&I\51<]8[1X2Z-)ZL7L
MWK)7$TRW959"YV:UR8V;/V<-D&=A4>Q.<D*J;^!+<TS/S>?3T*_JO6CQIA:#
M;*)F][:^HF0<*M;%'6HUE.[RE29>?=H'6[K'C_I\2]_[@Z]ON_`#0A#YSR^H
MT/XMQ+\G?@1QG^2E,CFE>PB7F__:HW::[A/-9@OM[JP=2#>:)B7PL8YQ-3)Q
MZ(KCU.X-?FF93+DN46"%UT)SB[1J?NWZC-Z[/B,WX"0O7LM02:^OLE%YZCU4
M>RMIOKHQW?>:VKU5KR*68=\D`;'S^Z.W,(CI:^O$-=Z&<5)XLL\P@$]^<A$&
M=(D`%223N)F^@V?">!15J0/Q<X62:&N:7B29VKUSKRJ:=N>DAL]-ZQ-%HA.I
MPR9`V@8X:,28IFER5R>C:@SG)='88C"B`?[4[HU^9=E,N3%%G/3M3:QU"I.M
M[G5P15^>QNR;#WOU<RD2_6I7+[*(OA6M3-,;)U.[]_OEA;+!GS&1\7NRM+H!
M_=&R"V2W_E1VD,1:05:2[MA-[=ZX5Y#*R.Z3/+YR?FDO?;0ORWGU0=;?N_5+
MI27*JSC>>^CCK)\NPM?7,+A/PLT_;F"R?DJAQCA#%//]&6:^*[&V%95%58Y<
M7\0:(I-DNK$XM?M<@)I@VOV."CHWWY'"U4%6'ZR?`&T!D"8`WO9%?\M:,:,I
M7#D63T%5JMD593X:?5=X:OE>KI)@_+JBEE=1"66A,Y@9P,]T!DU\-E1G8J(S
M`:23H:P5,TK#DT[Q%'2F&HZ)?[,TE?[4[A,_:H*9"<I4(+I7)0V)7SS4WUFF
M'+GR;%"<)Z\@]]X.X6G84AE/:#)T/?,:?B3=Z9*XR"Q%XFAE.J#1PLSR35AY
MJ8RKD!B^(W\3H\J=[23)$$K/VIK5.M0XUVEO93I*-P,M/R4D+93).8X0LB/=
MN4]UI].S#&5LV!>NR5>,5S]@M/%CN,4TFI`]D;EVS6'UWZ&^<(K'U!)V71PI
MT-V%F>7;J:*R\.O$.XP>PT[\"@<N-_L!ZP$=4X7I?`LC]+N*7@G?[!9JZDX7
MU#K-+#^3(RB*41?0CN?8\),9>5H%Y'7$B'^/YRZ?/50/S7SP5(<L/IP[T^%X
MK(WM[$[5*,XM2,;KN@JS\2`U+'9OSW/AU\U@'A`N*?3I$9<"Y6+=,E7+-+@/
MIE8FM^P*Y$ZGX]`EB9G=.]R<$AB9M/)AH:0%E+0;>=(F7D+VX=9/^,KNEUWX
MO;AF/5YHC"B:>E;DKY!,.8F;:I$+>?2EK)G=6\TB8F@WOOQ8W(OUS?WZ^NIR
M^;"Z!/</Z+^^KFX>[L'Z"RC=!9?-L7"_?WO;$2C>;OWT!"-\J278D@@E6RF]
M"..$K(5/6:>9F&OZW,TJ$EH!?4YO[C;(0SQI3&?W'K&T3-J)+PG,+5<$64WR
MVAX-IO-5?5);NPYP;0;;JP35+6#!#T,//L_LWOV5ELG4QJ\LP$-M"#-MP,N&
M=+/W8"-+=*]7@D\\V[SV:D,U;!?[+C2O\\SN?5UIF<R$]I+HBMU<S'00A`GX
M@`EX\WS!U93E=NO3[W.+ZEX%Z5OV7^'K(XS.QU-]&7$:>U;3!3&A,O8WUYK.
MB5.>6!X!\0NA.^3A1N(6)0$N^LD/0%H8_$Z+"P;WI2,1:7?.8,1Z;KL;)E>Z
M4V,O!_J,LM6BP^EB3`?6[EW.%N2ZR=G<O7MPZE*.@W@?,_G`"S9A@,S[9?CJ
M^7B9<::/A\PNU;C(*47&1W;QR7Q(AW9N]^$5#O2Z>=D.P:5%0%X&_$Y+B2>9
M9&7PTK(YKC_Q6&73NY(^:TK39TWF=F_X->(VM)G=A(&D'KL63CUV!Q-$4;A=
M>5&`0MPX"\7&D[FVG1!VGVKTXY4CHV%->3RF\PD=4[OW[/@$,#)7XH+B+C>;
M_>M^AR_G@DOXY&_\1-*#MWQK+2Z\!\Y6G'C=.$^=2>J%[#XCQ(5?MR/G`>%F
MA4!62I*I[`W".Q@GD;]!BD#BV.5W+]K&Y(CXES!Z@GZR1W*<ST;3!6M/C[V6
M)=^1CAUH60F;MZGY6AW-%I.QW8K0A7C]',<0PIAN?'^NG-8`13/I5(XVE-VC
M*[75@[[Q;:6<M,(QMEM4/[?EB\T=B&=L$T8=:YKL$9]AC>`F?`[\?T)Z"R+Y
M^%0]B`*V>[)?D[Q`\`;1M]N2^^!1H:5T%\<CG8KNWLB+0ZI2VK*N5G2MF+2[
MWM2S5MH.=#1MF]##[O7'[H2TV$,>(NW"3P+:9&^JR;7A^M.H)N>Y2E$N6/YD
M9'="FMG"[0KNP:GC`[\90;J>D80USC*_R?M44M4_TUN^?^E-675'N)9I:Z?1
M;ID:=N^:="?D"42^AXC[]:CQ>I_$B1=L44Q][DS'0[(GYPP.E:[#6P7E#CO0
MNC;\!UIT6!AO20SH,IKEAZ_;L/-SGLZ8[A,O2A0<50,6][.WPT>*SM+T$-U1
MTCEQ2CI<E)S1"T23N=TGA%JQBU)R%4BF06U#HHV0^JX(&N$C>\9^6'8VG8SH
M.)[`/:L&Z$9FU_7]4P\?GX%2"<G[5$='.^+E#S_&EX_T9?-H[%J1G6)25:Y4
M,:LY,YRUFHR\Y<N\`F)H)S`_ELK1(?Q$+2HENMM87.(BL>U+N$-?*J:-EZ_5
M:;R.S0.A(X:+2<FX/-A0'0=@LW0_V/+U4AEYC'%?`%3-O4)RK?!ORYM?5O?@
MZ@;<_VUYM_K;^OIR=7?_;V#U/[]=/?P&_GRQO+UZ6%Z#R]67JXNKU<W%;W^1
MOX"887_`SX=B(K'RTG:L+J2OCO2B!G=%`6@Y9(BF]!#9PO+EC";<Q@C-Z-S-
M?P2_DY^%"7>L(2BB3%_AT[1H4.E1E7H\$A0$K);&1\7F=$`M7P-O!6]RX:`-
M3#91ZY"0>I8,3!*RNFC`',;9@"[`+"P_2]0*WMRR01L4!3KB:W5P>TG.*=Q2
MO2$3P!OXG?P4XP\\U'=FF0]$!ZR5$?2`R!P-X-5%NIBSL'Q)3$H@,[N+,M"R
M^TO%I6A(C]ILO/@%_)F5]3?^"_BS'P"Y+4-!0FF*<>W3'$90S-?`;#%+XS[+
MMS=DY-$?1(N#<HML&OC>`#VG1NN=@6P-$-6E)417HIL`U631FTY'&G.$"0/2
MJ#>\`\"E0W6Y-^?.8$J_M>6I.Y2%Z]\K\<!T99,_*C#)O-NQ3)7$W%%-8[/%
MG*ZE+6Q?HU>4K5<WQ0&P-DDE6$81?H*++!4]?H!RN?0!97H<Y2Q+Q7J6YV(E
MSW91()THYJ_>;@\/(J/!R+1;.\2@1?U:Q6S1N./Z.)JGN5X&)[`L("I/GRZJ
M$9G4O$FKGICT63WJ":]G.JX_6XP6]..=P'*NH#@]^9\F3(VS)%*Q\TD2:;4N
MKIDL%KTX$W-QG9#X/,K#;@O%YB<:SW$(U;N[:83'>@D"/*,`+CWPG[V6&I,T
MAT$8?,K_8DS!C'LANQ1,R#O51NXCFMIX8'>^#U71^O1:'/AX/!@MHN65"JX[
M!L7]:<VWW3HXH-J9A*EJ*5]*MGIYKPOI3'BS#G!V?)E--*GI_]['"5[HB!_"
MFCR4!-]C5<;_VONQG\![&+W[&TA-PQV]W(X+$!MQ/DDW^34E1M6+7DWMS8\M
M-@VFQN8_=X\[["MF`WMWK'L9"YU^O0^!W%)GX"$$1SEHP561@[;H\OB.7]HI
M2'M-`PE0ZI?&%)9:+RWSYG]9K^K5??,$MW<NW\M8:`^:^I"J-L328&Z*6==A
M5OK)=,)Z&\>@*:E!9L!,<(])D6!>H=59-HFU^T109S+J7DCH"NA!()%4`XDB
MF?T9*"\^G"D]W=,)0?OS__8J;64Q7:55\D3?;$:?Z+-X1M&YG$:6W+M$W+CS
M>W:TY=O%2F#IC,;GCZ)(>CZ#K*W0L^U709Q$)-E)O$Y>8/3PX@7IVF2Z[()$
M"VBT@%_DU.B/#4JB8VG2U)`W9__1A&(V=BS?6#`_&MKW(HR+U,69K_02>*EW
M0+H'">J_.!&60Y`^$=:'$AI\4OE?=J\F8C**8K28.Y:?_>EA.,P<>3`OF'O'
MW#&*LZTB/*TB5YA$WPN+D_73'7R'P1Z>SYS9%!-[/-1A3`[Z4E/W-MC%*V'E
M<BCP':=7Q2S/7]^(FX/B"TKQ`#[C#4<YDC=A<"_6]R1QQ-WJU]7-M]5]%ZS3
M]$*=9M(Q7J8K%QL-TP>LQG;;Z@;4NH/)^JY=_!/>#T]_%'R'+GU:!!G2S!K[
MFV6PO?1W>Z05Y_/I0M]UYI;.U9@H+%G^2EU+16<ZFZ99D\9V+]H(2F(D+!##
MY-ZL'L#U^OX>W*[N:-H=DHIG_?7K^@;</ZPO_@?X!#XO[Z\NP/+F$EQ>77][
M6%W^NQXET/,LHPU*4'VJL:4BLCSI1[)[PT%(#MU&7`2,FS_ZA$K3"?L9(!7(
M2=^TBAC/4>`,_>?@8A]%,-A\/*!0//8V^/O\XOD!?K;O,T2A,GSP?IP[@\%`
MWQ5C`21J"J`F<J8-0JV,YA.'WARW^[BABE1&7(4\/O?+U<WRYN)J>0VN;I"S
M6"$G@3R)`6W1XB+LUI:*[Q!I938>I9&LO6=2E&32[5-D@;EI19#5!*6J`-<%
M?\:U_W(&'DD#`+4@ID"_P`!&W@XYN.7VU0]\G`@Q\=_AZ@=>#D+3Y<%PKD]I
M6GI74Q1QT3+E:*LYF]-M1]M?2!*20[<2B(!QT\(DC#HL#M+RFFBN9\70#IY7
MEQ5;JHZ'Q&</R.U1VQ\Q$9;%T/*C*"[WE]7-Z@Y%17BNO+S\>G5S=?]PMWRX
M^G4%5O_K=G5S+[I*^0N^BA@C`'?0?WW<HUB/+-G?P0U$.+;KB/Z+Y"N=SJ=C
MUO$#YL4E@885*:XD0<YV@5;(,C'-=6/Y6UL*4FDW^=+07%H5H+K@L#+(:H-U
M!(KZ!C2"ZRTLNU6B^KZ5\">B&6,G=I]449"*7R?47K"2AYCI!HZ-HD/=B#+=
M(&^R9O4!9@UX#M]A%!#`.^`'<>(G>WH_%C>T"7<(51C1HRAO7I0@KQ5GC[M"
M-/0OI-P6OL-=^$9.HT#JP7#"H0V>H&P%WWN5HC#/A5J[E;"R<B5(A4F:)G=B
M]]:O@E1&5J[D\;G7,([!)YKB@:6'HFJ`IO"W4?CD)RA6'TW(8O]"RS2DZ$F5
M]TV0"UZ72B$3-J=K?Q.[=R,:4`OP,D165I:7=?V[O]R17;:[]9<KP752Y@?3
MLZ2CE6.,F+XH-5O,'3I6=C^858M9?SS.[M@E/P#ZBQBQKH)-^`KS=RWR%UN&
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M/4<VM7M;K0VZ=G/7W+]++[Z1`H"6Z(I17.O]IBA57;EG#LR<WFR8VKTTV`;=
MU!I\"P[WX062*YI>\/%O,;V5A*]2'JZ5>\\1)/,6P=7O^F_-L\1MBG>5Q6KV
MF-'@8VKW3FD;="/+SBT@T"SWZ^WRYK=_NT]/TE_=@(OU]?7R\YK.<,'RE[L5
MF?F*T>TNW<7!1YF+/9S\C,ADN-"7K;ZQ;S7FBHJ5T;BMWGQ&'Y"?VKW1*2*&
M;D\M@,6]*^\IEDK+G>[B)(&>LUW]D[MZKJNQ(MZ%'`]&60QE]UJYH"0<'._B
M3)<8*O=N=;]:WEW\C5Y_6OVZNE[?DA?+Y<YS9;V7ND9`5L&S'T"(TV&G0&Y@
M@ATY,YT,,Z@0:+@;8LM)<,QRGE;(#F[J9>W>?U20RI2%%X=6&/RRL<>GNTJU
M,^,/4'T#&L$UO[-;):JS0N%/E%HINW<!%*0R-9>4AW@8#+$.6)%TZH+32RD^
M%1<L3U8E"A&D5`([;KKE.+5[[U9!*N$@Z4%^/5@>9GO4="9^7S#-OX!FW9/)
MC/5`1U=S`MJ-*O]KP1;<SHJ,QLZ8'I^>VKU340?9R.I+3>=NEOX%_#F&*/X(
M$P@6?][\17#/K/K!-"VGZ&$7(\#.BDQ'`WH,;6KW]FP-8OV!,:M;-_NS&(O^
M#OWG%V1UE^\P\I[AS?[U$4;K)Y)>8+U/X@2%"<AP5I)RS$;,)X>ZX9P<*#6&
M=C80&9]E&YS.INEAN9G=<\=N!#1BB3N!ZOY]=?7+W_!YL.6OJ[OE+RMP\^WK
MY]4=/A-&EL_O*YEHOMVCTF11_>OMMWP7NCYUS9ERYAI5&FOQ(:>HSQ7_)-O@
M8CBF2]$SNQ<_.Y%/M^_K`J2;-0+25@!M!J=,HZ^I@U)3RCEV5D&"/C--JI#<
MP;<PPB=6\`'4/7+AK?D.8K@Y?P[?_[J%/E4X](]C/4-_:NQ&39.$!,#:T@8G
M?Y1D9*^#$Y)!)^M%@+BT8)K!(P%Y44#+RA#W=O^X\S=?=J&'YLSSMI238FPM
MM=T%19N@'O*R5#(?O[&]1Z/:@9MA8$WO&>WHSX#\+D.U7\/=/DB\Z..+OT.Q
M'OJ&;:<$Q.AVU'X7E&N#?$B[H]+%&-J[[\\'W@S]&A!D%,R+`%I&AH9_A[O=
M_PC"[\$]].(PH"^!P`A]V[:G,L3H6--/%[3D%>&0GC6UBG$^!7?-(X09NG(@
MR6B+BP)2%F2%Z;-/D>`S3Z\PV.)E[R\[[_G<&7<57!ZTJT;09HCY*TH'I4@V
M@NG,[J7F.LBZIT0U_;KYWP'^03#5.`T@O_CQQMO]!KUHA>927H*/`;6M$O!2
MJJX+-79Q`\_SCM=5&-*WGN;V1H6\\'43D`.#F\U(:"&`2X$5GE&C<F+4O$PW
MSLG&7D+>A7@*HU?ZED1VF7,ZGXZX+VKPM*C&2DG,&4>YJCNCN>-,Z8#;?3):
M1AS=');`Y&9UTI-%"7TE*:\F?3DX:Y?J"GW0Y`OZ6XP4JBV5`J_UK>VC&Z*W
M0S_F=K4&TE$ZU'9?+^$3P!1_&U$4C$W-</K^."FHPE%LSK///-/"T+R'+OE9
M#YO-SJ*\,QS20;5WXLX+WRPSF1@JO"3A@0(K*:_ST&_J=,S)@_:[860SY&,^
M'I8>I7&6W?M+K=A-,;$.0$'#U"ZJ!:@/"-<YBC0[YAYNMAO*,0$>,XT4&J6J
M:N_Z3Q-D4[PZZK>@$_Y!:L\058Z\W56PA3_^!_PX=^9=A7_,]CO9)6R!G+\F
MPRX]<.CHV7T:MAV\;LJU(LAW`FD10,H`5$B*A^2M:_(T-MT?+VV/XZWU;DG9
MT%DG#!41YHBNC57I&?OIW.[+#8*2&"(R)YR<U?3Q=5+AC'%F0X;D9+_H`GG[
MYS#"=JNK=4Y&ZUW0N!GN(6\/R]+<OM.YW6=K6Y";X65=]QD/R>\@*R##NCOX
M3'+T!\F-]XKB_GE7TV=6\UWPK@7P(?&."P_26-ONC9Q6[&;(5P\@HU]1`N`B
M8OQ[B#QL*N\_7A_#W;DSZXIX!^VJ,:X98D:UPU)3.DH+N[=M:C'KIE9=QV[Z
M`Z"_B*9E?4=A)K*`EWZ\V87Q/H)%0M/97&=JUMJ.U9@G)%&1HK6^DC.:#R;D
MU971PN[)C8`4NLG*#\6]NOEU=?.POKM:R2=E973W`'\DG]%O_T`??+0P2N2\
MZ\Z9W"14`Y>+:HOID.R"C2V_G\4O1`],9B-Q\Y*@*`I^QX4!*:V%TUHN<?7-
MZ<J%K*9J,VQ0YC2%Q-CR.ZU"<O`S6^%ZE0BBLJD6X_+]Y@5N]SNX?LK[2X^5
M/.!W,TH4F,QF;8M2\KSFA:'&<05A,[[S-S&=.B02'%N^A20ID6[K+@?+S:KA
M>T=YQ;/\\L;OI#*0-OWB#-+B!FQ5EXI[X&V"&C3ZM/38\BTQ:9F,N`U9=&S-
M$3PI'23^%E_G\]_A/=SLT6?S8;SZL=GMMW#[!1$+YV+=T_P\ZZ>5%P5H>AS?
MPH@L-R]?PWV0G$_F3MN-*'G-Z02BFEII&J7\E'<GS3L#ND,PLCR;OP9I=7NV
M[B&[Y29!T2;(&J7O!Y::Q4J>-8Q/9M#]GC-`&^]3Z[7XRY].ZRN.MB-2C>:#
M(5T`LORU!"WR&G'0.I"[ZS?Z$&@2@C?4_XL70["A&[HQWM`%09C@1SZI-?`#
ML*6W[L'U[3UXA!L/?5.0O$``GY[@)@'?P_UNBWX`'D+[*8-KU"Y\_F`WL/SA
MQ^>3J;['=33B[M6$"`UH1W:EL4]G0"=N(\L?T#`V!I9''MR"U,8CO^.B@E-N
M=I]X;_8R?/7\X'PRT;>'T-:Y#H5N$*U9*TL5470XHU_#[FM+8H+THQ\U:.I(
M?D;.#8#?:171-PRSW#O[QQ@U[D5^^I0':T;,O'C':D&-I9R8\G<*6<6=T6RQ
M(!LRHYG=C.2!KYN''!C<-+W2^@F42W7)-J[LVJ;I5LV773]85%5G=E\GXH'/
MSS>U#-@<6-PBK5=<+M4E\7A>3S+-N\J$NWZLYG2L[+YAR0/?R'28`TB)<_*V
M[MY_#OPG?X,FM,O-!L^A46A[&^[\#6J*+(V3#.2L4)))P/;V%#=?9/#FVR[M
ME?$0SY`[F4QF([LMI+@PVO<F11&YI1J@J`*R.NF^I.AFI`!%N)RY39RN.GK>
M49_14;=\UUU8&%-!@#`R7G(+Q@CD(DJZKKD,MG<P3B)_D\`MO9KR%6*?@/G"
MO(G,YC=/DXH4ET2=DYRKOC.=.XOTH*;EQEM&'NWV6P*42RJ!;*$=IR<IZF77
MI7ZG547MN!AG^$RY=51G&'3>SS"DUS1&"\L/ALC(8\RL2X`3XKQ>\\XS)[2/
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M6N75@0N"FC9(2ID_0<!5?3AT[#ZF(2*&;L<@@,7%A4C(1/Y1*MZ=6Q`CB!:O
M8)T:5'P"7_719#"Q^-E`<4&,>``A2%0C8%%.D.QX#''64?P1[OSX'Q<1W/H)
M_M?Y=#'6=QFFH6-%8HM(E-.YH=)P/K7<EK>"UV[!VQ"X!R4`_N$,T$+I_^C,
M>G-\?CTVNT]"5^US0R5L.2Q^Q)`7OAE;W`[DB-LH!-]08D>H$-WR0[]M(8C@
M!B(K_;@3S2]^=%WJV!/,9X.Q-EJW=*Y&;6')\HRE+15)"HIT<F1WG@%!28R0
M7@R3>P,3<!W&,7B#$8AQ!3W\UA*'6,'O:D;>EHJ3\9"N*\_LWG\3DD-WE"("
MQF4EL>@J1OD21M!_#FCZ'(0@\H+8VV0G2LC_W!%G4@GZG0&^#:M+%Z1QJ6E)
ME\.1*9!\F[/QV&Z/H2J:;C53Q.>F]4'6`"BW0,*I<ALV*:66`.QTE;(2M<FW
M218[[#ZQJ"Z<D=A.&:;[91]LZ$B#3=J*8)K;US?/C_")XW5TZ<=O8>SMUD_7
M8?!\[;_#[3*.876YRQE,6A]44DA_*P%)3;\Z&H0\7:Y,<_/1Q.X[\PI2Z?9R
M\M#<HBH:>Y!5Q@L'N/HG4A_0!KJ+.=7XIB?G](DI735'M4QSQ(S:'6$JR67$
MBZD@+.N?'X!W;[<GN4EW6/EV1/D\4E\T>?LF?(4/WH\J?V83?3OF==TJ*@J_
M,$7"]IHJ\^G([D6*%N3:/4EC]R[]&:#?.W0&K9]7TR,#_7"5\;A`315B(NQ.
M4-F*W8P!;D&1T3;Q?H@FU,AS1%>^IS/2F)VQKEM5<G(+4WGYXKC*8G(J3[BP
MD>LWI$W=NZ6L_=W9T;:OJ_>Q%L-4K7^DA6D%[#X#VHK=D!UM1I&S5CP'FY?L
M([A^6K_!B+V@@W-03?@3LK6UI\8^*;AYSJS6RJ,Y?DO":D+R"\'/3,6T;;R(
M7%H2)PTLRJ965AMKN9)66D/::CK+UKKD.E]Z%\+NF%18%MVA@"@@-H&5XP,!
M?G#E)K2&S=6LA5P#GKVG9'=:;F%9C$0*HJC<7V"`2@J^#GL;A:C]Y.-VAV\V
M!EM\`/D->Y#J-:WI0M^=7EX8:H17$#;CO4`3BX'=LS=1473;<$$\;E8>3>]P
M#7)2(*_3W9Q/G#1:YH"V:DC%,W`W068\=H?HPK(8\0RBJ')-(2H"L])B:G`'
M8X@&#E]4N83O<!>2-E8_WF`0IR?KSIW):*#O6CD'`C7RRXF8\9ZO]GQAMU,0
MD$*W/^"'XF9%"<%+A4%:NCMO(,01+8[`+C6HF'^>VN0BA=TG443$,&+T!0`=
MJL.VI`Z;,!;=YKY#U8,]O(.;\#GP\3>IA`*3B:-O9M#:ORK9Q<4KJ-Y:=XJF
M\Y;SG%,&_=:>#XB;%@2EDEV:=VXZ:#+NMK"=8=C;ZA+S8_=2#[\0AHPZ)QP6
MZP73Y)*'U[P8;O'3;,AIT+?9WM+\5E?D2J/_#O&D(LZ\/'ZI19MEET"DQOYN
MAB#/P"O3VFPRMSO^5Y!*MX>0A^:2JI\><5U0KGR6IJ0F@5+>`%E/ZNZBB1+M
MM'B9T]*\:NYKB=:(';7[0HF*6$:\E0+``PW<E&J+J=*W&*Z?5G'BOWH)?MUI
M-ASINRE\V)F:`K0"S[A]7'"^F-B=N8$-6+<O8/;JHK^2]^BSOW<W+ZC[?EK,
MLPGB58SJ44&R='Q2S,L0&S&%[+XS`L+L!WS?`#^&_A;!-Z_(%_+D!UZP\;T=
MB!-4[%4\C=/]Y@5N]SL$`G7YM-]=^T^0/(Y4NEP[&$Q8%^C8+UZTMJ<8`,C@
MS?U]>^719#(<VGW^4$`*[9$T-Q0W*XI/RM#"`)=.G^)2"(H%",'U9(M%!*X&
MK'SC/;)[[41`"C/A*#>>@L7A`8OU49;O:2V+.,MX5(O32%B^GL$O!3]I%1_0
MXH94:WV/C:_@0T+?O6C[@.`N?_@H=AGKFT(=]*1&YF;0^0M!!Z6&$WHZ;FBW
M8:T'K3L0J.W9);\`_!/X'?\HG)7Q]34,R--9],VKJSC>P^WY=#XCNPMS'6RK
MZ52-=]R2%)D8V16<T7RPH(^U#.V>6'%*P$_.=Q@]AO(9&7G0N-\"-)[?T3@F
M,`!O^T<TWT?>_@E&Y`F!#6D$3;=0*\`G#9`UWSC<;<68?0E1F]'A$M@RBA!R
M,H_[NY^\7`5;_]W?[KW=ZL=FM]\B!,72V:WW0>9[RV![&\9)!!,_(C4_PP`^
M^4G\^>/!3[!W*)HAVNF,'-:;XMVH3E]2J>FF/=\B4_[>$(UFTU07[%[DMF.`
M=/M5*Z1T,Q3@<QCL:2:UVRA$U4E^0_+@$$(/'C\`:0Q/CHKFI-S^ZO5M%W[`
M\ONE8^Y'M8\JJYF&=B1YZLVCDO@)IPE-=FKYW*8%N6Z2-W?OYC]+/G=:^P6Y
MYM9FR%2=-3,')55)N^_TM2`W-3MNAL%@E>!ST:L?<+/'NY3KIR=_`Z.LF[DS
MTY=SF-FG(B<YY<B)R2X_63CD9?JQY8N///"U&[QV#&Y>!J2%)*U?6AM'`!<P
M2CP_.%:,V6`^Y/:MK<VID5$&;4;,]KJCZ6#NV$U/?B%TDY0;B9N5!$O\O!(M
M"U2]M@`3N/RX/<2M^GK.H;;[`#B_$*8B`&Y$;0RFI:7Y>XGF7!M$IO@JN(W\
M=R^!I>2Y&3N&P_%0P@ASM-T9L>7D8)"<IZ'1S''&=E_JE)3(H.$6@'6H`WE%
M-)$':=5R.G5UHRY$)E$+;ZU6--I^[J]E]_Q/4J(>O((`/"/JD:W6K9_(+@7>
MG_#0![G`E^W.G=%LIB^)85/7:JHB*%1^^[^YVF1`7URQ_&BA@!2ZW0(_%#<K
MBA=R26&0E087XA<_^0B@)]=%SZRNYK1HKH:F4Q/Z%>S>?!$1@Y_7*IDL^`%Q
M;/#Z<>QG3\;X&?,EKCS?1N$&PFW\!=$F@[1^*NU#GSOC\7BA,]5+<_^*.B`A
M7BFY2UM=_-6&]*O9O7TB+(L9E1!$U:(7`4S0R-,F`>9`KAG:=$)7@C!+=(*5
M$JRU[F0\I1_,[JFQJ"C:@Q\Q/.[M`=/SZ`?%0[0.#8N$,[XDD;])X)943N<7
MX[&C-=-1M4LU@G-*4<KBPBCN3!93NU<S&W'K9FM3YV[Q8QJ;R\TU[SU\ZH.T
M@":P&YB];8FZF4Z&^FX,UW2K>$"=7YC\5'IM%7P<D$:+EJ<6XA7!2+C!"4;D
M>.4;;D?V;>!V2NC)1=$3OZMWW6JK(`]''9WE*58X)=!MC/E@N+A8OEYR!DC1
MX@E@V0M"[)ORI1.`\>>/RFD_>A@?W^PX'T_G^M8,.X.IJ!SZ1JMZA4FU"V<Z
M7UBN=EW+JEU!.P9\<,FO+N$+*+>*3[Z6"Z8M`WKWA=YP[2372ZG3.DG(?_R*
M+XX'S\C\^.'6P0G/9AI#N@ZA*EH"O8/6G#9&LIO1=#!;6!YGZI#73%"J`;F;
M_AD'INCO-JBUP:QJ/X]:<^9AD^UF-A[3P\9CNW<H-4JMW?%K@UZ;YZWL]AN]
M_EGJ_#-C<6O26/R"2B2X5I!$WB;9>[L'&+WBVP83UEHC.Z=`MYWW9`&X1T+9
M"-3TA`DUL3S@UR2RM>K?C)OJ/OC<K/N?4]U/RQU&_&D'H-0#P%U8HOY\.47^
M$/K/R%;2<5?XVM&,/A<V&?ZA[,"1Y*;.]^D5([4.U?R3P#N,#.)2N;?4.GC$
M.CRGUF%3L@X)[LD2\\"5)>L/81VZF_DW<8O>^9K\I&L`?)+;O1K`)0.U#.3,
M)"-)R!G`Z97`_LWLLL&U'\"K!+[&Y^/Y1-^A&G5\/5F`AO%1UOFB;32W_%GG
M`!4AK8WZCY&JS_'![[A-0!HUM;Q_L\=G/7"ZCCCQ=CNR_?`EC`X6,X@#8UU"
M[]:5\T#I2:TE1TE9Y;GZQ6YC2A.D69Z2V^@X6&LX)(3I8`V!]HKS-9;[!:CC
M?M84Q51*[Q+#3V-Y.EQ^X&?IF+)T\D<W/<4X6+\T(2%4!PL5`35!:$+CETW0
M$S)![P=[H*96+L242^LZQD]C@KI;X^`G*;UI.+'[CIO1<;![_4-"(O>FW7B@
MWV+Q:Q3*4M!UFN4^>4&$^R=.`#L=C5@6H^>UD3J\/9L5CN'KS)14^QH/!@N:
M&G!B]PTH[;*?ALEHD:)NT=1[>XO"=Q218'M!-DRL,1)V+:">G)'H?K&EVM=L
M,J1'>2:6O^2C673KEU2:\7=Q"JL(0U)+4W36CT5Y]_P=/@^.XB>RK40TP_3;
MN.JP[;`O'(/9M9FI=CF;.';G)]`M^JF8F1K\>LQ,UAF)8'[I+X*I5Q&K9SNG
M9F^TS7VJ78XFD_E/NIO,*_M)S7WJI'`O#F8\!P9#+K>*-&+Z]'),X.%D>&1%
MYY<HC&-R7V)B7WA2C[@G2R$TA,I&HJFWV7C\D\8C[5);&XJT0N\B"DD[.:/Q
M!GDTF':$_X*ZLLB::'FW[8]E32H/QFGH;8Z=U73PDYY-Y9&;WZ(H/4ZG4X;#
M0".F$Y3T%'K')J'V@GWQ0&2PQ8]%W7BO\#)\]?S@?#R?Z7LX5`=BS3:ADS'D
MM@DRO:%Y\YQF/IF<>*2A+GWO$8>R"`=/M-("G9QF/5[<)9F?2'H<:K,PIGCU
M`T8;/X8D7\X=ENG;VQN,R+^N_5>?3+%G<\/VH1OH.NR$MD%M-AA==3N;+$[Q
MU$>WXO=C,CJ5H7:V<E;=9P%[W%.:K)#V1=Z+1/.4K+LT71;IY@R0+NG_`*13
M&ZV1P=73/XXUXEQ%[:C;T60^/\F5U([E[W$UM5M)W-R>D-218F:C\@XN?ESW
M#NX(SOC%?WL(5T&"R)'&4!-'XT./@F#4=%M9\DQ;11MRYI,!O3,QM?LTNII@
MNOV]$CJ7]63S=]0`*+<`DA#0-F2G"/O'&/[7'LU-5N]XTK)\C,E=VG,$1>/L
MOZ9715_(+4ONQNIJ."-DM^BAV9GEV2$X1=`>W/+A<.^_?;Y?_<]OJYL'L/H5
M_><]^#TKJDC=!_@C^;PC.>.GTX7&@\-U_7;+WB9QZOA;JH-'G2XES"R?V?'*
M8"8<XD13Y7'GY#5B><V1M]7XENK,!W-Z86IF^45<3A%,&]\:'&Y1#M""X'=<
M%)"R@N8W>X8U?05A.I^.62FMF=>[#NNJ4:\51_Y`^F%!<N"=ZO/`;@O9#%PW
MMQI[=[-?)5^[J/MX7/>43;"H>A.8-1XTO!G8?:J]&3@_C=3NVC:BJ-))\`IK
MW6?DN7-J@DZ5"*XZ'*-A.AQV3[V;@1N)U1HAN,?/A<L^C4R&.5O`*GU/[D0N
MK!;4V,6)*7_*F%6<*!Y]9&Y@]XT]'OBZG2`'!C?=0LG7.G7PC>_!;<.$8SR>
M73M<]!+1P.[C"3SP3?E+#BRUS!-TGK29JV`+?\#M0XA?UT/&>?5?>_1MZ'\N
M?_CQ^6@RT7?PF`]#%VP6E_.0W:WUG>'8H?E)1W:?TY.2QXS%%0.5*4):"R^.
MTWK_%@-:!_R.:TF99#84?#HG7;Y'?-'W8B0?!GUZT20GCUZ4ZJ-/-J07S4=V
M+ZU+R=.G7M2!:M>+,Z5C9MG3WG![N8_RS"-T#[FT:9QO&.-KY]/16-]Y<V%`
MBJN?70Q`OBPJT=AXX`QHPMO!PFJ54A>.7[_4SGVK`LT.=]^7D@WCBQ]H&`.X
M(>I(=G-A%K2%3X!^'-'K((=KO]=Y.M7)8*#/']7UVNDV0H,L-9L(10UG[J2;
MZ8[E1XGX)#"\A5`#H[*#H))K][!'^M0?^M`:#Q4S>NR4L#4RU)`U?=P0C2^-
M8!V[IPD<Z`V3E`&!05"I9QZ/.L*G]?%T`WU:8WNS6:?=,K16DCJ29A7P,-.=
M1,?NL)U/`--49:*HLI6&X1*35$9_V;'`P4#C1?&Z;CMG;9TT#;S-S]5E6TS.
M21TGJ!6A!^ZR<-2Q5VH22<-E^IRW%ZVC^\1+X/97;[<O7O:>SC7>..(`H,9I
M*0DS=O-4'L[&9,H_M7Q#1U@6W7P7!70PMSL#J`X:;D!K`5)-]H5Y$8YH.=QH
ME194=LLY*J.@9C0>32?X6XVF)Z\(%7&,[*Q+`#NXS'X&WI!.O!--P'?&8B5-
MJ&0C1/S0]V920\>=,;]=(@;C*Y6021I2DV3WHA^W#`;M?".0(_M>N3FIR&2Z
MK(B_N;ZXO*;3CAE<)TDM>],*P]F(SH&&=D\EN?`;9RT#!).Q9W271S27"+;U
MKP=+@./%1.-[]I7^5#=CVO$7>RV5LLYL/B6+^).YW8=46K%KGR6V`'#S`@J+
MQ#Q.4W<@;#X,.`A\.1#]Y^YQAX=]YMA[:%14#.V!KB"@(Q.K*QHP0V83T0`?
MB6FE8J#M/4,O(D)_Y*V".2*N+Q$35'I9[Y,X\8*M'SR3<Z#FXMA2SQW3MU&F
M1@Z7:A8#;^_2@[`<.B,)43"'YRK2J5FIK`9BFS')9HG-9YR9W\#>L%A8CO[,
M=`VB(UL=RO*Z81*DYTZ\N4D<D[G5\OFH6GR%F!.],98VX^AH/K=#_RN,O,1_
MQPD0K_T-#&)8RIMXZ<>;71COR3[`=,I]S4JD954#JR1#L3@FT`S^!I:_FB0E
MC_[%,W%0[O75Q>KF?@66-Y?@_MOM[?5O8/G+W6KU%6=[D$U7(L<:K@M?ME._
M>D%,_+/8N[`A+0\_]]6ND,F`ZU\'BAP6F$>LG1)E7>@H^4E74F'ED!:AB"+M
M/>[<C7`Z748G"-V#%@!J`J1M'+P94;2BD(5%D7L\>1%.3Z-F'6N4O>>RNQ%.
M^P2C$YB-+LFHUG0>E-FA-H=AFOHWL_A82C?"F0C@.D%ZY)$\G1[I-@K?8)1\
MX!3!"0*++YB^D<</LHR08T?C@?36[M543$*Z;,[37G4T&4P<>Y5&3`C=,WMN
M).[MW?IV=??P&W$<J__Y[>I6:1)3VS'+N#KCV4#?*\(B4#3QGD_H\EJM2%.Y
M$9O:FZ)/62X3VVNRX-RL(GD:(B&3F;RN9H?12"TMVQBVZQ-S[T/NT]J[GJ8L
ME[']$EF$-1Y)3&TNX9,?X%<;@B3R'_?D5084T>%'J(+M.GF!T6V(_!M,_(A$
M=^3)A@)8D9][/-1WF+XCD&JZIFVDLLBNJPXP/1;V;E?J$%5WE-@Q7O?Z:OGY
MZOH*J>Z7]1U8?;V]7O^V6H&[JU_^]G`/OMVN;\#=ZN'J3FV=O!'B9Q@@H9*8
MZ2E&\YG&<%,2EJ*K[&XP#MRF9+.%(;=WH;U3&8V$IQT`==-&2(Q*F@&'[8"L
MH8[B5F5>ZHEA3U1)V;&M,B_L7;OO5$9S,6\':,6\J/B)3C\A#[`BC-CO^\$S
M##8^9(9T@Z'>.WC<4-3/?"I(7;ZOQ]\,7E\;VJM?\@+I/Y0D@<J]6'_]>O7P
M5>G-I%+/[*V@D=Z+U?5]=\9_+KF.3SW7URUV(.V]JBHAB8F@CA^.6RK:U;D(
M+D)H.]K?,]%KC_?S?`][5R`D)#$6&/%C*EMRP36_O.'U4_FY5O(D)%[EB).8
MW"]X+#TZ7WJ*3V>&:C5LBBM\'8]+OK"GUBY^_G9H[T)[AQ)J7\;K!*9[_[?E
MW0I<+&^O'I;7\@]/XLLY+^%NFR?>O@D3R)S<3J<:9_K<.%3OXLB+>Y#4FJ\-
M_,SBA+Y89_?<0EHF[2Y)!=VACFA7#$TI16Q5#$8&$NXVYH,1S2X^LW?A644D
MW3Y$$I=;KO=OV3LBN&HW,Y6K8!.^P@?O!V/J/YP,]6E)0\=J>B$D4:8(397(
M"HB]UXYYX>LF.`<&]V'YOU;W8'T#KF[0+&0E'0,Q^BKISX#]%JPVWG9DT`6%
M*L^MFZKF<[^QO6<[A>4PL8#$"\:E!0$JJ<TF,XB@):COF]W,E2.N#S&Q-RP1
MEL/8JA$OHF/#+9H<_NUM1W;HO-U5\!1&KV3VG'N'V6B^X+YAV=*88DPMC+3(
M_]Y<<S1W)B-[ES9%1-`>*?/A<,DE++)'N[S[#7RYNEG>7%PMK\']P_*!'H"Z
MNOFROONZ?+A"Q)4--9;;K4\_RQ<_\(*-?P"*9<PFTZ&C+?P0AJ.F$!U(7[;D
MPLT5UXCL78WI1C@3$8T20K>H#?+JH%2_F^!'GG%:`J*3T3=FY*3PP>W?;U83
MSEB,I013S,F):5JZ>W'K1<G'0^0%L4<>!BSV+<9HVJ[-D;7UKJ9'XK)E@5QK
M3;R68?F3RMPRZ`[E>(&X=ZMKQ.=+<+O$]U(>[I8W]\L+3&GYPT9U?3/GGQ-G
MIF]O6@")'M;SB5QV'`(M%4<K[5TC517+1'`FB<U-ZP%2$91K=A.029%*2RQF
MMQXQ`S"ICVK_.JVL6,:"+DF`#7ZHHUO%Y6NUTX6^XZ[M`!1O7,@(V)J+HEQY
M,;3WTKV8$+JC+&XD^77ZL_0^O7=PGYZ^50NZOTK/X(39"_0]D+YR"(FC,MDF
MM7<?0U`*(P>-^/&X]YL7N-WOR%OW>5Z)`PT0W-9(VUL_K5[?=N$'A/<P>O<W
MD!P%_(R/`I8/"RYWA&[H7^NG.[@)GP/\?,<M1%^8GB`LQQ3X(1MMYY-TX5;<
M>S$XG/FNC;X^I[.)W?Y+N^S:]XDT"W!@,+(N0-H'??OA$SGP"\K=G(&B(URQ
MZ`K0O@#I3-G9&E`7/<>&_[#6IWHL65^?H\EP;O<:I7[AC<0?VL4XL$+D,.BG
MSQ6C`U8_WD@^13\`Q3L)J,(:13FD1"QK7=9O=,4VV-[!.(G\#9I6$QCQ+VA>
MC?X'L6,%[-EHP4PYQS[,(=M-5\JN+EU5F47;Q.<9)O9NMW4CG+E@0!)AH6=K
MK#9T`17G\BA:H>H7@[2=#EVX-`UY,FB?KI(U>$RIKWPJ`;FL<(8]GB3,`X^6
M:9K7I&FR:E7<R3N\M7<`M@K_6^`G\7*3^.^('D<RH&A.X^DNG="[TF8C@UI5
M>!W=3J<S>_=:3(EOSC-KD^$P1JZ=F!_;%Z;1`:0[D/77H9/7J3B:I^I_3&O4
M$'YTW^V,KE.?2HBB<P`,AS$:17'O]Z^O7O1!%P*/#$UN8C[E45`VLTC"?,%1
M>N+.7H`X?F/\6X#(1O!0#"0#Z>>/U0\8;?P8WB+$\`X_T5#6CX7&/$WZ!>C4
M])@9X!H#I*7SZ7QV4D9(XR`8#HWT2<(9(*7O61<=@CWN,;57M$]R<B`^`X\?
M(.L7D(X!Z;GK>$FK?IF(FO[0!JPM@M+2^6@RM#U'A;E1Z".6TBC/@2$KWSWR
M'L-]0@U8'DVMI=\O;Y.G@%X_B9@-68]'&[(QK0`UVQ"9`>*V$1R-3R>3DUK9
M41"R]R"%%REO$%(*-E"<H6LA1HFS_00.)Z34XHZ_O7$RISZ5?5)E*>UPW-QX
MRRL=!],%8ZL<OX3A%N]%W80!/#R*$9=N`'S^(.D%?!@=AJOZ\K!WBK5[#>]R
MV)J47:$?-(4]O7A>6=X^_+HJZ%H73QHF^RVEIK.SE''YUAI>6,B:U^+S.R"\
M,??_<]D)KJ!`H9^%,QP-'.J1[,Y[K%?PWD*'SD1@'A$IA0W9(>S;*'SW<69,
M=;.09FU>?O>B;3GL^=7;[>G1S3C>O]*_5:/>R=QH_"`/MGO#T.G`-5D&E8ZF
M$\M?-M0C<!\QA#+JVB`B;1F0IBL+!7G[H-2!E@BB"\8;"R%^-E/!%40H=$0\
MT!_*5F02]Q8VJ&,_,!EE]?\6I^L,<>*_>@D$7SP_(J8"5E<J</_H`_O!,S(5
MWN8?GU"K2-RX9%J^AENXD\Y^&7U\]M"HX,LA$"9Q:?_B^`3TP!&X1"'>@:)J
M=R(1(W,F=VNCR63JS.Q64@6QM+MM>6SN05V05@:T]L&.G++G56$9U[V(D]*;
MJM^3_(B6OYFH(I89#R8/L*P\!ZDSSXX4R:"F%,_Q_32J4HBD[&,LWT16$(M?
M5[;A9D_ZP*V9\S4+`5]S[&H4](>F1,\OT3;0;;08#*5B--XN.E0A!:F8.L3=
M'K[S-3ZA2$U8,*.QFBBZ(PU*'ZHH;HAKB]?$^28<L9V$%C5';6*?\X1\D;!@
MYB,W48@-L=NQ6AG5&_'X[204IR6&$_MZ]B:F51>LESA.%*51/Y2O,-8E`:TN
M+2],;-_QP>EJU5U:^.JZ.F]3T^GX5&X.B8ED;AM-"-?!JG=#&NC^-$KS+I?=
M&M6P4\79%,F.?RHG7@5E,KS;)(:.4[,$7[;9(/^[)VU=PK<(;GSZ`@A$GI'L
M<@7;Y6L8)?X_R=]K,YN>3Z8#?>]R=(523>OTC56FC)WU,!W:O;S1K:"Z76&G
M:-U2:Z#<W!G(&R2'4LM-GH&C+-EG*DF".R?R>/@OK9<8K,[5?C3!)U+^&)J?
MR<JA_`NJ_`%\QMW*>>VN<;O7,([!)^"5K,&VU##1;Z_4HJ"*QS%,KE[?/#_"
MO5Z\>-$SC,\G<XV72MA]*FH?IQRY*K'+.P/+UUL:<6OW;PV=N^1'4/P*TI\[
MY:.>9Q+-\[$RO:H;VM%XN)B>)"-3Y$:F2LT8W!(I-S*DS(TRN?M_@29/2;0G
MLZBO\/411GCW?L1Z@HVYGMW6FAKQ)+!F'&RM2ER2W:MDW#+HMI6\0-SB"1M2
M$I2+@M]I8<$U+WX.<&W`V$+8ZK8*WR#;?9V*6P93FR6\@'0P]\L^"OQD'T$4
M"N.[W'OD%/)N2GP8\QI;C@;5Z"N'.",P3VTRW':?>Q010[?A%<#BYF5)LO2L
M=/E5,?TLYC+!=M&X:HBY!]WN#0$1,4R98P%,[7RFY<78C$+R,,)D^F`0PN$^
M15C;C!IQ1=!E;*VO@P]O3NWF:#MXW1:V%8%;E%"VI1S?E\N"]D>_JK5L&4"[
M+_"U@S=E&5N1=,I#Z,7P)=QMKU[?HO"='/V)T^Z&BX&^U=*&CA6I*R)13MV&
M2LY@8/F=`P[TVHUG*P0W+P+*921Y6[O!\/GC`6%>_O#C\['CZ$OWR`%`C<=2
M$K8^;%NJC-\?MGN;7$`*W?SFA]+\H/,9P,7![[A"5Y3_)0KCF+QRK._(9'/G
MFIA>)U@KR[.*BU-]N?E`@-ZX74;11FM2MB-"7_L!O$K@*S%P^D*0]OXU\;I!
MOE9J%W71=[$\+N$7HC>*'R-IICGX'9<'I$)7UOL&)L3$$4>^,,ISU+4FAK.%
M:B4WK;9P[-Z,XX$OL#\<)MY.;G^8`TB;V48E44B"(71$9QS>7(:OGA^<CP<+
M?6_2<`#0Q.TF"5L97JKLC.=3N_?P!*3HS8!7H/#%W[2*]*6+>CCX[/HYLGRL
M5$%=W[5H1J%&?WE9JU<K6EIPIHNAW<?31$71K0V">`ZN3K0$.*2>H%Y<!>^H
M;AA]?/$#/WY)DXXBUX+O>,0P>L>'EIS17-_](PX$:NH@)V*F"ERU1^/Q;'$^
M&D]'"[NU04(:@7!(_KB<."XW*PF><5&-K-?B">QB?<4!\-1>3`?IU[![*5)8
M%MTN0!20FU<X`SGK21TR"4A?PR3U)-6`3#J<L:-O(EONJB-BLT%7&$R*C>:#
MZ9".I]WK+DVPC4Q,&P"X9+()_*R$)-GNO.]?/>0K?&]7M4<+UNF-CBE8"Z`C
M8HH(6*%K?>7%%%$=?8KQP.Z5<5%1C)E;/CQE:XMJ@+Q*5\:6@QYZ`VT+^%\?
M9M=6GI$`<#Z@W\GNTZ<2TI@-L[EQN5@%7K.BDHS_>QC]XPI?+-S`N,*(\7"L
MG_+U"#KBO)"(%=(WU<:SGCG]''8?PY*0QBSIN7&YN"2*<]`8D[(:::\WTK&"
M]O6Q3D/MQ70ZH9_#[K.OPK(8BW8X`97#G8SV::6N`IZ_HR\&+\/O`5EP8-U*
M[)KV68==L;Q!@"JI\\)H#G\B*R/'F,V1]+#C@HR`_/)IBW[JCG6:8PS]K&N(
M(/+"^.;%]$3"XRIJPQ'!<?\E`GZ7).`E?/(#N/T,`_2/!&_4+%_#?9#$=W`3
M/@?XP?:K8)V\X(N,KV\1?(%![+]#FL3Q.B2V^A?/#_`_/\.G,((/WH_SV5SC
M@5@MD-6TP-`H9GJDI[NQ,[,[9-<IMFX?HA&[F[8-TL;)=NL92-L'10<X6")=
M@(,^LHRL?\9M_X6&4;BK_`^/I#^`.K3)MFAQCW\XVU+QT7JZ&SJ#Q<SNS6:]
M@AN)%+2*X&*[\.=G]/-?T&<$.U0&H"(`-0?>(/J:6RGK<!$&2>0_[DDR+X0X
M?10^NO3C340R?GG11[D0%0D1>.CH#C$DL76B[YV-RY%BR[:+7(W=T\-.Y#,4
M!BB!S/U]N4#J]+.&P$%+AR5I6[THJTZ??<K*6N>%9=L=3>;3D=U'?CN2T*1?
M5<3JEG\2S:"6OZC^#B/\$-;Z<><_TPR8]`'5\]E@/&5=86*GI&IM3TTOI/#F
M6:G:*^,AM?Q.J8`4NKT./Q0W*PKRLJ`HG#W"K8^[/`]!V<3=BN'F'6J[SW4)
M2&'$`//C*0@<YP0."P*_T=(:K2]?1D"+*,S("L@YVG;/YP6DX.>P8F9`;DA\
M-#X7I/&/-[@A>;51.)/DZP3EL.1R'_G!\RV9SB.*S">L.3:;TF*-*_);69*<
MZX(MC::.8_EQ+EF1M$<A<KC<K![(*N8+W0?36EH7W$HL14G3B2M<.0G%J`8R
M,E_+[NO4LB*9"7'DP!7:L2DK0Q*",(!XG?85;]U45HI$`R!96O%%0R>A(8PX
M2>:3V7U`3%8D8Q&4'#Z#/B2/[:Y][]'?^8D/XS2XB[^$T9<]3B]:XA9W_D^)
M#KK1%#6)CI5%I#7R]>Q^O4%%+%,!EP2V0F&*=:!2[6PA*`:H/J`-F-<:D>CK
M-+2F-@H3_83.:4Q19,0R&HU)`"Q4IYBZ[TJJDRU!D<WS)S_>>#OP`;T(P&`+
M$']'!C5(*#P[#16J#].$OZ7=%Q=5Q#(=KDE@%%,CZH'H,13!5;$<VT48)_&Y
M,QV.-*;4.>A,34U:@>?Y<8X*SD9SNR?J;,"ZPR5FKVX1_Y`_=\,M/4]C&^!6
M]5GKHX+CP<SRO:T:Q$;""G;?)8Y!9/2"&`H_,QOMX?8N_/!VV#9>[*,(DB1-
M-VC`Z/\XGTR8C_YT]H)L*P(U0LK)6'KXE:/VT.X3,_Q"Z+:4W$C<M"3(BVID
MMIZW+>UB=O7=2X[:LW-G/AM;'LZ*"6+$6@M!RJD>25+].8+DH8*O'EZ@#+`[
M^`+A^6PT8]Z]9D[5:AI1)"@WLIR4-35&L\7,\M>!VJ!K-ZW-_;OY[Z!4`*`2
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MKHG'<FSWI3->$<QYQT8<)5K&`!4$!R6E'H_E_OR"YJ]/IC89QX;QM7O1A5<$
M\Z:S$4\+97'1S@B;/O>&>#`;=&!;NW@L4`8M!VG3NGB,)W9/<?F%Z-'&'B)I
ML[)23P0*$$'5TAKFK9"U+8^TW6N(_$)88'$/$9DF\'7^5C(F!?<5=)X6M;&X
M"3,'CXOJ9,SM/B0A)$>/9K@"IHW(U[*/;HL10]4@]\)F(;-\-/*GLH;)(8<%
MQKD"J@]:TV=?\12)]>RD**,[>$=8`BL'D6E5,O<XE<74%AEZM,<'0-I(*_,^
M,#\'5$VP4<(*F=[2(-M]=9I;!@M,[@&@%N:2LJ*\#6(??2B"^TL87?L;?`T$
M,X#YQ&0-6YF-J)*4%UE!378--'@SQW8;V@Q=O^EL[-\]^)U<O4]+=,PVOIW.
M/MC&V/=L&#*[$X2V03>T"]H(XHAR^*[M3@OE./UQ'YQC>=^&0;/=Z39#-^=K
M&W'4\TYPW_3+/M@BU[R,(H2"G":.O\+71QB1B2WK=3<F\VJ;4>.>"+J,?/5U
M<'@RLWOEJ!V\;A_;BL!-2X!R$?`[+20X'^'XOER&KS_Z58U?RP#:'>&U@S=E
M`%N1L'E(RXBQ\!J?JLQO4V3=#!<#?1?"F5VJD953BHRF[.+.8.#8?82I$;=N
MX]C4N4M^!,6ODC;QJ_?#?]V_+I]10\]>`K,\,.NG_*+M0_@+HGQR!S?0?X=;
M8HVX[\"*MZ_&RT[DR5@KT1@V%U.[@TX%J70S7AZ:FU8%>=TB*][ZJ<AX@.\'
MD09`UH(Y?>&9R)^2OE2F_[*?S^ZC60I2&5DTD,?GWD+4-(J9GF%Z#I:\'^?E
M*I3^,7PJ\BB@$EX"XI=PO]N"($P`_+&!<`N>B5)%QI6**V(_):VJQOBR']CN
MP[D*4IF:%<A#I)J5!$2S<G4JE*A.?V3N-*0HL_G*<*SO)<:#KCI1D3K41]S/
M8E_']L0Y3+R&PJ:#3O.`2')>X.]@G(1!SOEB*6+.??JVIA%%XG`CRSE44P/K
MZMSN%;HVZ-J9U=R_F_]>1-N:^,;GYWLA',-C-PV;W<>OVJ`;\[W-.%C,DUF-
M^^H'AVZ(=7ZJ(^=9[DJ5DHVH"QH&AW[!\ML$3+SZ35RU4S?]HZPQ"X/D9?=Q
MAUA)ENE6-(\HL1C<FUPUC2@2AQM9SJ&:&GAKT/*GM]J@:V=6<_]N^CO`!0!=
MSUW)9)QM_:A<"T^]T*VZA-0T9I9[SA;H9A:#FD'DG,/9,O^Z(YR3RG+<^F7Y
MXK5>2,>(UYI&S?(90@MT8_%:,XX&X@F>(5E?W)>VQ;F3Q>75U,C5U'O&IJ(,
M60VRVVI5P>IVBY4>7?07R4B+\3FX#(\^-E2-RY&\=F]X5\&:,B"5G@DM9.9T
MZS=R4BUX)H8HIN^9I!%]-EF\W,,T@?2Y,QK,6<DZNIGUB8%1I*.JX#EE!1L:
MCF9V;S;(":3=$LJ@<O-:=,X0GV5/OF63UGQ!!-4]`S?P1P(>OL/=.RJ!G;!@
M1@994FEY`.`4M*DRIQ%K:$:S%-E]AD16)"-S($EP;JI&KZD:T2`U>]GJ3.(U
M.$X@5\$7)-)OT(MBS**%OH.`XH",J%#S``BJT4%CP]'<[B.P\D)9XIRJR/@=
MU!GV4,#'EZ?V$2!MF%.P/OV3%0HFZZ?*C1'3:??Q+06I;/)6#'P<#FNJ29\>
MD-+`G$]S?2=.)!`9TJC&(1!6J7)KPY'E)X@5I++&:U6@2;@MTH96O\4B6;^.
MRPH]DW==I=:(%?TIEBV88MGEO*H`.;S71)=6?0\+0LTL\%TI'E,:52^^N#[E
M;0U'LY_%:QW)9(_/.@0FX[&^AWK]585:/7NKOC5+P5-E;1%[:7?R#'FA+/-2
M1_`X?-1829/P=GFZ4WX#R1KRC)5A2(O6'/;=J8:TBE6C#<?UAB/+,\QSX3?L
M/Y@@&+Z"'#M+"^)M(L%K)YR?W(3][X');7;]J!Y)I&+YSC^7`'W8:S84>@/^
MKW@+1^X(VVT4/N+D</GUKN,CYZ6C'=R/>7`VJL91>>096WE;(*?M[3[E*RJ*
M;FLLB,?-RI=NKE?N-DB>CA+F"=?9*3LI7CUWQ?TAIL[,\FSUHJ*8.K,EB(N/
MZS)'OE##V_TFB;]ZP?[)V^"@?;O>)SAIV?KI*HX\N"L1AOOQ0>YFE<DNC;[$
M=LXV2$8CNR\"B0MCP*J+(7*S&J!<!:1U<$X26DO>M(M2AM>X6\IXIH$7^2;6
MFWA!80P:>3%DW-27L?1W./L:>8)J[&A<N\^[4>-Y`]J,Q4419^)8OA]5P:K;
M[!YWZ)(_2#V%1VJF1$4?0]\]WU)''9"G#O$!?;++JVB,[#Z,PT!KA$('768D
MDGHHZ0[&$,G[L@RV:9;<2H8^[+)8EHGI<-O;4R21#-Z<7.V5B<VW>^-/0`KM
M9.2&XF9%R9L&:6'U?(\B=.`*&&WB;S5$Y!UOR]TNOQ2F@D)^2*U$EHH"LTQ:
MZ^#>VZ$X-`LY"1FX'^FH;4:1LP+H<J;6UB'/2MF]=]`.7KMA;4/@%BE`UP'`
M9?!$)"O5.?MX4B[TQ[[*[E7S\$WM7BUJ!V]DUZH51HF"CUZ,9L1A`&),Q/`)
M#6HZ9=["=[@+W]"O^(N"IWVP1?]&/_]ON,%'#M[RE)V=<Y;/W_=&6H9W;U9Z
MRZ/25O#&?'D;DG*>V(-<L-PTSOB;\EDPY0,%^)&EE'`F$V8:I8ZF[P>==<'J
M!N"'3"X*3D>C4_#XQX#->/FC7E.S^B&7/*GN$VDYMV*"6S6^/2N()DKC^71X
M"K:Q"MF@'Z]TGM,L/6P"_&"SVV/G[`=@$\8T338R>\%>D(+W<+/'PW\)W\+8
M3Q"M!U/6%F4W'#SJ38V$[=`S%E9*S@:6'RRI0:S;QK&[=;,_@_3O'5%,BYDS
M0[&*H:N4G`PFEF=?JH-LQ-#5=.Y>>/$+"N#('Y%Y\W"<%_P#/.\]G*,<"EJW
M7^&+O]E!^IA-L/WJ^:B-P$.#QUK(8V[I,2<B_.VJ\4\)?T9-@49(PC2[@S\)
M:71;37%(;EHES;R)%R=+M=17VF5XPS4#MYGXU3FZZ(>Q.UV'A#2F9O'BT(XT
MP*O7`)DE^M_\.,9O9Z2-9$P9S8;<R_/,)M1(S8LJHR^[_&BVF$WLWC-J!J[;
M'#?V[M)?"X))6ECR\@J^K_7P/7QX"?<Q8O`##'*;-!]P'_1L;$J-<:(H,^8U
MUQM-![.QW6<]^`30S40N%"Y]$@X7(U=DLX(`E=1+3IY]HO[)69EJM8_JQ.ZT
MR7P"&)F&<4%Q$2L&>JG(%7SVS\5JB,DQ@':O-/$)8"J0Y$)CSF+>0S3&VQ(+
MN%_0X&A0"V-;$+?0]J`V&6V[E[!$Q.C)V;.P-!*85C#!8P7_WQ./>6.!ZJ#;
M/;47$://N(`%2$-TP/[X*C%"3WSECA>J`VOW*JR(&#W'#BQ,A@TP28!>X@;W
M/D-;:QJHW(RUD<;EJF2@[=[HYY:AE\B!`:2>M33#OF[&2L<+/3"6+U*H#++=
MZZK<,O07(S#0X`!AJ)V<\M%!#^SDC`LJ@VEW)C9N&7J-"!B`V@RKS!94?=^5
M4)%U'520OIKC6Q[<[4RN1&+3$URGK9>DOS"!!:>-TYJB7#9)U"*'_L@M$$54
MOL'L!'?(ZB7I.:)@8=(35[")H!A=],=@D4BC.LBG&@XS)>D_ZF#!TFJG;Q'`
M&^^59K$8S6?ZWLHH]Z3&\&;,>?Z=<BEG-!O9'1JSX.J.%QA]NOAO`/]1*HU)
MUB)-7H$_SD`[H6A?W5"J#O<QJ=)R:,R&=CMQ-F!3Q#KHM4PMJ>0F]R]>!#_C
M2WT7X2N^Y4*L[S**<,(4;(T_?Q1%TGQ]R^]>M"4&%-<*D@CG>_)V#S!Z/9_B
MZX/X,\\Y7'?'G:O15?](Y+<6.NX)^[2%W9,Z72+S*]T[C!Y#Z7L3>N"[JQ]O
M?D3:PK>\_7#;A?*2O\;+??*"./!/N/T6(%K<)^'F'VM"`FPRXM4/&&W\&-Y&
M_@:2[$C7X7<8T7_YK^36S4CGG32-T'78`6V#VFP4NNIV-IG:[5--B*_;0QN0
MP26M?:*W\,N]G`':#R@Z`OCB?01(5X#V!4AG9R#K#I#^`.GF#)`NZ?\`I%,;
MK9&>ZXM_<&M4O5BIL=L9=7]V9Y@Q,P!&UO>,B.)F#U#!S+2\X3H]6I!O;V_'
M9)_-&3,3"RW($72++$C[H&JQ()5N%_/%P.YE4B/R]SK]Z586]ZOW0]F`K%[?
M=N$'A/<P>D>5V;AOPN`=QFA61F9H\4.8>+OR[Q=AG-R$R6\PN8.;\#G`LIW/
MYT-]JV[:8*M9#H.CF5D-?5U.D)^RVF#H%EWW[$<S?C=K'Z0=@/JI4-X+H-V<
M`=+102F`NT(E$_`!$U#T9IO!T3+?^<,:G,I$1U^7SF@RL7Q55K_P1B8XVL5P
MOP51_D<0E^S.IFQ1I-ZDTP;^EBPH?PFC]$^X'(K3Y\[H].(8IBR6VAK.<==N
M@-@X$)_MON/2RWB<;&S4()2I@.D,4!#@*8Q`"<9)F,'3BJY^'C-H+@YCXW!&
M8\?RE&L]C<AI1VR-LAV&<0>A&\[F>@:BHI+4?CSJ]PGZ^.VS.R^!Y#@H=^:K
MP[IJ2MV*(].ZHX)X+=_R(WTUB'4[<':W;O%G@/_>#5MXCNV;8$O%1K,&P>Y3
M!36(C=@X=M]ERD2=48;KH+P)SE0/OK.&P>Z=FQK$_*11.\C.[OZ8-X+O*4@?
M8/OB^=&OWFX/ESB!'_DP,<Z3OD%^^=)_][<PV!*<SG0T'!L^+M8A_I[.CBH,
MK_)I4OZ^9Y.3W&S5,`;]'"'K7I#:<V2@U!=X_#A8,\B>:R<=G@'<)2!]@E*G
M9R#K%F3]2L1&!A7*X(&R/Z*]XCQ:UFG?:+HWMSL+BKE!Z/&(F09QW-RF?/AP
M)W-<_K$=Y:,(2GR>'\6]D^E`<_2C!7@'9L34@![8#TV=3D=3N_.&ZA?>2(2C
M4P(CH0WNT#[CHR^4^8,:'W;PHJ73&75Q)S#/TBR^N8!%KR!N;BQV_A-^.PY\
M0"\2?'=82V#U:[A#S>P0L;)0W6$E0[)X)G0H@85SH=8AUCH;.NX=3?GM/HAF
M<!1.<@6'*8J10*?HV995G#K5.IUUG).U7F;6<HYZ)QL@?\#5G)IA.-WU'+9`
M19CTGO_>HY6Y\^-_?(D@O`K0\,$XR16`E3W:0AO#PF^1A>$<7BWVA=TW<J4G
ML.1C8@Q.*C)J$$1G7(2[!;A?D'7<=UC4K%'V!T4G;;#T!D3LOO'J@MWO`YD;
MA-,+AIK$<8EU><+6Q<^LB_@9,6FX)%?5)>HOQTURF'&_J-EAQST9`*X1Z":+
MVV$OSG@RFP_/1^/I>&SW^5N-4EL;?[1"IQ$'^-P<<7Q.(XZTW$'$`6@^6MQ)
M*?:P0/&Y3I;^W)I?/=/:.9/&E$EV'Z;6*+6IL[7Z1$A-`)U,'%PM\0XG'7&I
MW%MJ`CQB`IZ)"=AB$_"$3<`[Z<8"&\!S(>'G-@'=Q?EU1)I0(IW`]J\>J>V.
MY%OQNU]RC07A$S8`KTCU8Y)ZT4M*JBVFSC214IQFD7T(+]#_V.\2]+_B2S^"
M&Z08\3+8KI,7&*5WZ6ZC$)^0B^+\38+)F'7CGZG%ZOVI*:\6>3.=[:#QT60^
M7]B]7-BAE+H#\NZ@NFE3(&T+/(2@U!K(FP.H/4`:!-FM^+Q)R=<>NN0L5[3]
M,REI-;;NBA1V/SW<H92F8N?N(+=HZQFGNLJ\#X=J;R#<QE\0FTNI"O,TA5OL
MUYE1;T?O:[3UKZ::,N+ESW"TUQW-G<&,A#R6W_L5EL5(^"F*RKWPXA<TN+06
MP)^YR(Z)HDPZR*9.%!Z"]1YW\&9/M-J9CD:L-`<];S;5X>UI>BDP?,J3S/J^
M9A/G)UU?;I/9VM7E%N!=[&:OBV-]>2=G@'9CC?6P:ZOZY*Q'=TM4M7VA\&WA
MG&+:_BZ$MGN!J@V^6_H%+TCA&Y0H@L`W$GHS`'^'_O,+3N_T#B/O&1YD"B?W
MAT\BJ&B2PAIC(3C4&DQ(,X+99/"3GO"5&XD3"E8XQ-$7PF2=@[3WHX>-+#=M
MMD<\/Y%ITQD=-2(@_O<G/:XG.12G%DGQ"&5;?`7CJX#FPB1I,Z^")/*#V-^D
M>Y=HTJ#O-1,3(EAA?D0'N6/;T]+];.+8G>#6Y#"<2$#%(XN.:`K&^'XZ[3G+
M_9UW;O0LHI2&V1Q(_31F3%<(U=P]\:]V;S89'8=3"IZX)'(+.Y,?GTHWMO+-
MKDZ>Q>:'O]XG<>(%6S]X+E99IPMK`Z8*WG[-"L_P=65#&'W-)K.?>XNK5F;;
M@YPZX)U&-*5.^MGB:J!_L8_P+_.A-G[Z[`=V2X.?>\&F7FA^"T*?Q[A/O"CI
M)\:H%<+]#)_]($!_!Y\]U+7I9>`F_CK_TO]NQD^S_O_<$XYZH47U?Q5LK=)^
M-)U8D3_VKOIMVQ*3Z2E,)^S=`9(?:@VFHVT/=/)S+\0*CL0)35,XQ-$W>;%J
M<UM8WZR?Z_Q$MDWKO*A]^]/N"W&FA^(TYU`\HKDM%ND,V#/UXE0<VR=D/Y.1
MTCEY:Z?O3YH`67(H3G&BQR-8NXG2.C^,13?&VE1GP,J^9<A*=2J,9F.E>^"Y
M35;'0&;C^8EO9FD9D-ZGD#JDXII)QDHG>\Q.*34I93^G??YE#25.`'4,9#0>
MGOH]$3TC8L>I("VR92>K10\!??'?X6WH!\G_#T9AD79DQ)W.E-&`FMKR(<K?
MS6:4QODS)G:G"&N"K=MK-_3MXM\`^1'@7R5S_31^0IXT>69)53'8=2-D^:N'
M3;"-F+X&`.[D?#`8Z.`35S(HLX2JIFNJ'1F[[XDWP>9GE%I"I08,%7,ED^OH
MQ@]H^_?^#_3_2]^2=925R2YF$VK\XD65$8Q='H_3S&ZCU0Q<MR]L[-W%OZ;T
M0C^2_Y,S8"U?D\<EFN=8Q2TV#);=)P&;@1MQC8T0W,7Y="KK'%N^(I=[-$^N
MJHML&"&[-R6:@9MRDXTHNK-DZP"BRK0C^`Z#4J9*UE59=F9.9AMJ=./&E2?0
M9%<@`V9Y4LQFY+I=9G/W+OJ9T"LE&RZAB6H\7K,/JE7\9M.(V;UMT8+<B.=L
MQN`Z4S3RLKZS[5/R)1KN@6.,A,`-PV3W8G`+<E,.M!D&TZ[)3#?31=YEL+V#
M<1+Y^$U/DN6T](D=P43T=8TI<E`8Z5%RZMJ:9$SM7J#E%4&[M^7#D>>*QIF@
MBY*`%%7+V-[^_472L?=,U=I$ZLT#;/=%%UX1C%E2/CPZ.'N_>8';_0ZNG]C;
M<.2O\7*?O*!/^$^X_1:@KUI*,GV+!(H_?QQLL=WAC;L'G++H?#R=:;R0HA6[
MXEZZX7'-M\[U]NM,YW.[%Q?,#(!N+V9$"C?K!>?&J#LD=$9_048G[PSL<6^I
MV:']`=+A&3Y$='CT!Y!>P>^D7U';A&-&$C[B;0O\?Z5%L3GW\Z$UK2CJ-S^V
M7#7KJI#-&;NCNU;LVA6B!8!+)QATLD%VN<A_2#K%UH_+]71=3\2K'J=J&KN9
MW1NJK=B-+*FTH7!GYY.)[)I*^Q?E>RRU)[HQGC%MU%6[IP:MV$W-"=J`U!@\
MF146XN`?V^]2/#:?O\,>_C`7%R+'9#K0G&Y="_`.#M*:&M"#0[.:.IV.)I:K
MK7;AM0<XNB70ERU=0T9/Z?G-\H<?GX^13S9\OTD)<`?61O<(-A_-5^O,F4W&
MEB\JZ)/:B%W1`MUES_1Q"=$(6!YC%>%E^.KY`6:PZ7=>E`#W9@/X1[`#&U#;
M&4YZ8O>9.(U26VP#6J#7!A5BRX9L2T)[DK$EE3A*4M92F).&/D=7B^X@AN@'
MSQ<A"H*\3;+W=@\P>AV20'UF>.9C7$H=TR0;/E7SG*H'A-/1]`1R?=DS4OW,
MUOH25Z,5/ICJ%?._RH7O'"(H8008Y(F;;WVWPON7\B<SW^Q[Y!8@Q$NV\W_9
M;Y&A,K.M8Y?019(A+[6J46Y5-R6KNO.?D%V&17\]SK:O_0!>)?"5+!FQCF%:
M..'.,5LTYVX81RW3[J(_/)&S?`]8J^`G-?D^1J]U_HT[`Z2W/M?S:![N]5/5
MON+H=\PZ!V2AS:F7PB(C)#346LQ2$X+99'0"FY#F1N*D#%>K.%KGL+1W?,R1
M,9NUW+893$OV1[=MG(G(ND=`)@!_H.T/CJ$P-P$T)Y1;V*$PO<I1FL5I>-]9
M49)2DMR2KDS'IQ5R5:6PT"QQ#;56L\1",)M,[;X*:W@D3C+DJA7'4,A5ZM^B
MD*M)X4XGY#IYVV8FY&(@("[9[DQ?IH?B=$.N>J%*(5=V>Q:5`U%Q>S8F)BTL
M&2GE.*RK+86J6"*;8H[I@_?&I;1H_[+33Z5E_U(%(7XHTWY3:<](G=3Q$V5Q
MM<:1C.CQ5(Z?=&$3[#]^\B_S??RI;#/?)!0Z@0L6%@W5Z1T_41=:Y/B)H%5-
MTX2M</OK`!ZE`&=EB&%?<:YM1]&4B.#+M;N^$KFB:[G"M:/7'L2T0G"+_'&D
M$,`YY12>6>#YSER9'7KD8=7+M`RCY><.V]&;L<6M.-SI^=R1SO'`\67YLCST
M2#U&IH>64;-\2[,=/3_W%+,]M$*IMX52*1_2_G":Z])G9EU8:J1A4;\;^C7B
M.69=J3`9)+NS4#>@-N5IJUV76$4RGJM9-];7$_&G)MA4ZS^/!\?N1-,-J(WZ
MRVK_R$\NI/-+-WTY(?]H@DKU_O!X5"S?1*]';=K_52$<6R@9;_>`"%,\B?3P
M/3R*;E@'6ICL:FA(C69B"#.Z-=4B#]39[1%YX.MVC1P87%*F_&H6*J8R#>7Z
MV#Q^LU\Z5CQIZUC:[5)YX!OQK1Q`W-'Y8"CK9+F^+I>W[9>`5?_;.G)V.V(>
M^*8\,@>6!L,HY:6_A]E[3$=Y)D?<_IG5A"(3.5'E%&26)R-F]XIP,W#M?KBI
M=Q?SJGB,2R&S;\O7Y'*ZQCE6=;3U@V7W:F\S<#/.M0F".SR?2N?Q;?F*?`[5
M.+D83K1^A.Q>SVT&;LQQ-J'HWI(1'XS;.8J06(?_&BG':*@;XO$A/&8?JQ8>
MQ+'=B?)YX)ORI0T82CRD01QAHLJ<EN=CB[C7?NA8ZVKKQG)B]Q%R'OA&W6X#
M$!>?1%%UOHU?5\@%]T/`>G=<.W)V)^_@@6_:-3=@Z=PPXJKYTC;)V8]Z*'UU
M[D>`&QI2XZ48PHR63;6(D[$[5N2!K]M/<V!P"?-*VQ_TU0=,4HUTY/'3_=*Q
MXJ=;Q]+NE3\>^$;\-`<0=W"^F`UU\H_+3_=+P*J?;ATYNS?C>.";\M,<6/09
MQG4`*_L-PXFPESYNIB-.<J"K$+)2!X_AR.[5Z';PQKQS'8(R!?%A/,5=88Y/
M+.27C1.PWB>S1_!$/'(M>+/^N`X&\L:.]$XPQU<5\\7&2=?@A]DC9O<&23MX
MXSZX#DFM^9/9^\U[(Y-N[-`/#]P-N4\F-[74$1OY,%;XR*I&QM+N8S%<^(TY
MXP8094+2M1L2&"J<:^;[XD)>N2=6UOOFN@&U_$4N+OQF/70#$N2D1XN%5A:*
M^>F>:-C@K6M'S^X-%B[\QGUV`QB-5A+_`__?^N##<Q^NKF^G(VKRX*OPLEH)
M#^30[G0H'.B->>Q:"&4FDG^2_UAKY:&0K^Z!A_5^FCV,HQ.QCO7HS?KH6AS(
M0P\&CD;FB?GG'JC7X)MK1LWNC6<.],;]<BV4KFTA.[5(MR^0&TQ-],=XTOW`
M^&OLD.1[L7<WRH#DVIV.?AG<Y?-S!)^]!`(_?W_]'1?!B2N3%PB2,/%VAXDM
M@^U!PO&8I!H2LRS+'5$=N&4G\ES]P/^$YY,9,_#OQDCP85!3>%DY,^?)67\^
M&9Z/QM/IPNY`3D(:W1,,<4AN7@7492P$:34QG;@(XV3]=._M8)RZ=<>9LRXM
M=4/_2G=J3.=`GY&Z6G3D3.T.`^L@ZZ9G3;\N_CNVT.07R>BN_HMIB<F,\:TR
M^ZT4G9V/YLYD:&_PTH+:R&RWOO^<?7?XM,Q>FH"KU[==^`'A/8S>_0UD6^#4
MVJ)_K9_NX"9\#G`ZPUN(/M<6XXBO2X_9.:QSL-W0MV.P:N37/G*9ZG3=T62R
ML%OK]`BLVTUH0>UFK8*TV=IXYPP4;5.[D+4.:/.`M*_P%F0W`M[!MS!*,(C+
M$.<DQ;QGG<FSR6(<8[;!<+2/8[?VH]+?9#JP^P2.5KE/PYJPP7=N5,X`[0@0
MV_([[4O0NOP"`QAYNV6P76Y?_<"/DPAU^P[3:5P:7PY'$WV+$5P0U'1?4LI,
ME?FJS^:S*9TIVWT>24(:W6HG#LE-JY`EN<-*V1*$9&A^!V.(!O,%@;E$0?XN
M?,-KBX=(QF@ZH$T?.`"H:8.4A)DN\%1V\%5`^J7LOFPN+HQN31!&Y&8UB":4
MZBBJP?WF!6[W.[A^ZL8G?OXHO.+RAQ^?CZ<.ZTQJ1[M@FM$K[H49']L\OZ;N
MGIWIS/)["::&0+>E,"2'F_5#'O_N/()]_#@,8G'//5NJ![RUAU5H?C+FB4"V
MRR;5C*(N0T2[PY2U.^+0*O>IF9PR>*UV!OQ.NI(V+)?P"481W#YX/Y9Q#),8
MA6?7OO?H[_S$AU2.!_@C^8RJ_0/'9P-]FY>2J+JR#JI#434`@BU.IY;G@524
MS)P2R\`[4-.L`8!:`+0),@LI-9)J'L#M`-*0:274<\KN))6P^G2#9(NCR61H
M^:T[5=&,;#0K@FQ31EE-6R/_BEKY#7K1<<^SP6#*6OIBOR7!T6)7*B&$N<K_
MANIDL.V^KB(DASD'TPZF8/`:OR^.$Y`@]I(*'7H.'FYP/;-C&9\;['GST(^'
M=B<7$Y+#L*5N1W1@E@])K9/!?,_[6$9AQA-`W"-M]XE?(3GX.:SX3)``J";;
M?&R:!8^T!`GZ4NG>^&+1,E6.X>;\.7S_ZQ;Z-$!'_SB.R]&?#EI5/"K2@`_3
M]+BW_]P][O!^S,SBF+@1L\Z0H*ECE_X@>7;A&CY[.]H"7;!F/H0L0Z6CEM78
MU`8S8]11N7R<+$X:WP9;-Z\:^G;);R`CF,2^PNKI"6[P@8+E]G_OXP1NKX)-
M^`J1$;SS$OCP`B/H/27T!BASO8_I@'E;5;1@\MCS\VN\38PF\YGE#]4*RZ+]
MG)D@(#>O`+(:@%8A3AE7`D4MW3SGF2O9RO/*G$GL4UA^A%M4%B-S)U%4[G*[
M]>DX@N?(V^[1?V_A!I6*\5U-D"#&1ZCF&;ZE:8CR7),K6SE?G62)?1++#QR+
MRF)JLB4*K#\CCR=U.$\_H0SWPS=\;>HD>P-N/J;G#9!/8/=%3$%)^@UACN'P
M<!O7(<]%Z*6V>O32#[4%(Y?#+V#WEKF@)!9$+<>8^&,6Q+6I7H)W$*OTPW#1
M..7P(]B]'"PHB1TQRC&L?JTXDH5PA7O_F:]-[1QGXQ:@.&X`?P'+7U\6E,2"
M`*4$AY_:J))>:G<4H!BGMDR`DG\!NX_M"DIB2X!2PB04H$ST$KRK`,4XPZ4"
ME/PCV+LY*"&)10%*"5:_+%\'.)@=+U@71R0YCIK437$V:GZ"X_IX^,>GO$QX
M+$C_P4D)#7=L@NIHY70WD8EI3DO$)?G@GWK$71;$DJBD!$G(7`^U4KNCF,0T
MMV4BDOP#G/)FYK$@]L0C)51]&F[R-@4)7;E?2.9L5#?!ZY#S,YRV0&+"4SZ8
M4A6E_[#D``\WOTDMS0SO)CCI@^$2`4KI,YRZ%3\4Q9(@Y0"44)@RUDSSC@*5
M/G@N$ZR4/L2ISR\/1;$G8#G`U;-)_QZ2V)9U)T"6Z-]#[31GHA;@.*I/(L93
M7R$L"V)!J%*@X6?U]U`KISL*4@QS6B9`20=_<NK;\F5!;`E."DA"H<E(*[6[
M"DP,<ULJ*,D^P*F?&"P+8E%`4J`R8+@/NL<)A(*-O_-I!J/D"]SB-*/W2-8]
M(N''0>%SO,BC+XFV.L".%*G+$:HHF4+CD['M*?4[$])8-*6*M*2PQWIZV-H9
M\!*0-@CR%H\K]:?36O(&_50Z71\5*C2.[;[E.?RZ%--L1*D.V"TTU:>:FD68
M8IJ:-[[<)R_D\Y*[T</)4)]#9?>IID^\<F0J4E-^/K;\`%PC;MW.J:ESM^0P
M\I^E[GM7>TDS0`PG(Y.D["*#!;\L]<1,:\S'<[OWT%J0FR=GN?L:>DKEN\A[
MNO3CS2Z,]Q&\SM\MPO-9%DN9L_"FECHB'A_&"OM8U8CKL?L@#A=^8TQL`%'F
M8U%,X7DJO@_.M3;4-RNK*T'M(VKWBCT7?E/K/CQ@:NA9L%.9G#3G-/[FW"E;
MZEKIG)-UV!KH2*O@T;/\3<]6[#U8QP,`=991)G-X^[>5-8A&B,=E"$N#=W*^
M^1![CP;P`$@-`TD9,?ZMW]!,/O&#Y^LPCB^\*/IX"J/O7K3%V<<&4WWO[M1W
MK,99(8$RTC95&HXL3^G;#EZWP6Q%X.8E`"X"#LIT3U@M"[)]$K:R?MI8:3:T
M_((-!WHCJYWM.-P;F(`P)^\.DW>#"P(Y]M[!.(G\30*WR]=P'R39>X6#R8"5
MD9+IZ]EMJ)&0&U?I<3]6!>R?9G9G$&E!KMM6-G?O%C\#^KO\VY2-'Y0KJNR#
M:=6(LFG$[%YO;$%N*IILAL&@'"T@F(%\_QC[6]^+?!BG'4P&CKZW3ZO]J?&2
M!W^>>+Q:UID[CMW3ZGK0NDU>;<]N^1=)0X>F0)_W:-2#2_RLK_^XQX-\[7TO
MV176@]1,>]?<EAJ_A'%F9&NI2/+MV#VMYI1`-PWY8+AX3DW+@7)!@$IJIBB7
M3[:!HU4?S3.V=B^`<TI@RF?SP6DDJXP73\]P+.-X_TJ^QQW<H?^]?0A+STY=
M^D_HWQ`-^AU\1[,O;T>HP5HKJJ.P3"?*W.Y(LA+GI5HD<9?=$W15T0R8<A5\
M;G[0L&@!I$V`A_#P@;2B&9"U8UBG>&Z"G*9.5=:UE#ZL]5&0DFA&5L0401+%
MPD?\8@!_O$$RITQ"\$@NF$!RMA!\?T'.:IMI&#X3Z.$G",$V;S4&$6E7<"M#
MF8V\\=<)*AHS8I/_TG;/=%5%,QCCJ>!T+TM*A)3&BR#8A*]O>ZQU^QBO5R<O
MQ:G;-I5,7L(8LK3P7%@-Z57A+/U\/GL8+T1"1%8CREK$B:RD),P:Y*ZHW=<5
MVZ`;"-&:^B>>(KT=GI60GUXW?U;.^*D'PK'BG_I1LWM?I0VZJ?BE"82+Y\5/
M8026R&IO,PMY%4<>DJATIF(=H1\]-"AGY']V1M'OX<-+N(^]8'OC![#$!N[-
MOZ:6NB$K)\9CQC*KD;-Z=I^>X,)ORE@V@2A9S.\AR,H!7%`K*T6L9U^LK+6C
MM0,ZMOL^-A=^HQ:U"8FP606?``*WH-;U`W-:CL%_]Y.7EW"'NTR#Z77P)8R@
M_QS0;LD,B/NR0VMS:ER609L1NKTN61*V^VH8OQ"Z#2XW$K=4LKB?O`Y`6CJE
MMS;:\EA?>VA;L<-\XSRS>RK%+X01B\P-YX"[>!D@#(AA_G9^?TXF]\$>`MH=
M>`LCL@H>/I$B;]X'7M>(P:NWA7B]`/_Q(GQ]\P)R]`WXZ+?X!2\YH!JW3_X_
M8?3?8Q#`!'V^\`G]JDTCN%;I[%&)ZLH;Y_>S.T#A%\+4:AHW(BTFO>'XD);3
MR`://QT8=48Y,C^Q=T6X`;%V<UW?MWL;A8FW\W^`ZV1[+AG^EI:)EW@/)<[^
MD!FAZ53?`;R6SM7H*"Q99ES;*HX6EC]PR">`[OB8"X5[L$].RYT5F^<R9I3W
MNVNQJ58PNA)"MWX*?"7LQ#F=BF`D?.8$4Y`[C90%(]I*-U<!,OD;&,=W,(9H
M[%Z6P?82-;T+WW#0@P@PU'?;3A1-QUP7EKV6_&TMC18#NX^!2$IDW.!SP6)[
M`#\`:5V0509XJ;I4W9`NF7$3=NI2NR-I_<3($CIVKRA*R]2/J^%$YQZHS;8H
M0(YP!+&R+[J!A">LO!::=`3UV+$>,&6HY3HNC4R6W0N-#:B-V_^\:[:-)_=B
MG\"OWFY/EFO`<K<+O^.]G0ZIN?@)J+G@I>:)A?`%:@%3BI<\.C*E>?^B_#P#
M#QB&(DT;KH[/IC/6LYZ:V*LK+8&2Q+5<;VADM)C;?5)$7!CC1KL-$5M7NDO.
M(4,:,S&Z36K2'IDW?4>\/&'WM7<9<?J)Q]N!=9T`I`(!30A0Z\G'+4*<H.G`
MZK_V?CJ18[_'J$E!:G%TK!\"\M:J1WT;H^FI.9$V68S[D!9`;!>254+_PM7(
MO#6OJ%U#S+@0>S2DW8$T?$2\Q/#SZ$@J33_NHQ67FY4@"@$[4@A\*RC]VXJN
M!^&3.>B_:7K^8/L9!A"?P3F?S0:L]_$T*0@WKHX51F$\:A6(O\WQ8'AB:Z2B
MLAEW08(`V2X)_SO_(6WF#)0;(DJ9-65<)\TXK=/1R7:GQM\F"=[M/D#7@73]
M.#UAG-@)OOLQ5CA\<O3=VY"2IA3N'M]BQ0M_M^F95L0XQ^#$2AYH7RK),6+J
M.EKM9#P8_:PJ6R>LO9ZU!G$GKO8,Y*V#K/G^K8%E_O@$K$&''KO:"7$>)[9=
MVX&XEOOT6N!NH=)OW@<('W?^<Q=N/M_`R_?O$/U&0W/NNPJ@8T7DD;!6P1B5
MQP/+'XCC%\*X>ZQ#PG9[W1]^:.#">/C3TWU<N2K%4YL8(+O3Z8F(P<'Y!>5\
M`)]QMJ".7$`])+?@N2?'\ZOK<V<VF;19[1ANSI_#=S3F^R")/BB+T_]Q3.#T
MSZAI-7XRH>5OV5S3,;`[<VD)I6Z#673E7MW?+5?7DA>7\O=M+L(`[ZO"8/-Q
MG;_P-9P,]1V@:>Q:D4MB4E5>3&)6FX^G=N_6\,#7SLMV#.4GDTJENGC/L-0<
M?:5I.!F8)7"7;WVU2]-$7%IE/G;L/L[8!KT/PI;ZKR6KS!-S-]C%39VVC4`9
M[WNCZ'V9T#)ZW:3.QF[S5T*IFS1%5^[-ZN%OJ[OKY<WEO:0+7J/I_0/-[8/?
MF1KK>[>ZU),:6YHAEY[&*DH-1Y:?JV:@U4VC:I?X>;:`&!O\QPYXI.L!-HT\
M8CVQEI<BE_;MWIQ@P36RF,CHF/(I27-[B?'IVSUV"8NV#3H9;X51J_"&"2VC
M"_J1&&>[U]Y**'6;F:(K]]O-U</J$MP_+!]6LOYJN2&?,;X)$Q@O@^UUZ`7Q
M'=Q`_QW'1$6T/]:XN<L+0HUGTJ)F7.1OP/*3Y&*"Z&:T$!HW*WT&2/DS0(J3
MC=`O)`LB/D]>U%:8B![@(KT@<'D?11>?/XI_/R"AES]\?"]$WV:*"K`.54AU
M2)AJ)=SHQ.XU:G7AC*J?#$*WI&WX!_`[_DDRY])%&)?>KF3Z'&9FNFK];C98
M&O$<[Z>4"F,?/;<[:&E`;6J'L-IUL26(?U-,X,7Z>%QY#DVRJ9K)L&YT[%ZQ
M:4#-3R>U7(7U$(YH)?.&VU40)WY"WH&+2]^0E0F.R:EJ?=6590X\Q9IRI3`>
MF87=D^\&U/I7DNNZ=LL_26_4U7\[+@-EDDQ5`U4W.':?*VM`;<I`U4,X9)6,
M?5HG+S`J0C&<R>%BCTQ>D)P[(V=&8N_Y(;4Z6D"L[5AQ/5%$H'QYL:'2?#&P
M/(L9!WI^JK[#Z#&47GYL1>*2(B`JRHCQ]3:";YZ?'XS,&A\/QZQ76[JA*K-/
M-9;RBI$1M+:\Y<=A&G'K]L9-G;OICZ43\O3W3NFH9>O%/!TKVS$UY4?CV<#N
MV6LS<"-;-(T0<EK*Y98[7&NY#%\]/\`+H/KN';-Z5.,BGPP9$YFEG<EH;O=.
M<Q-LW6:QH>_JHAS]67"B<@?QZ^?X=<M+^!;&?GGU@I7FD#E9J6E$E5R\R`J"
ML6N0"-SN5>0VZ/J)UMB_6_P.T@*2$^/6K\HU.^Z'<-5Y<N.PV?NT`P]T4S/F
M%APLYLE,GN\W+W"[W\'U$^]V"#U6.)XN]!U)E02E1O/.1B)3`MD&G>G"\J=9
M%273;;35X+E9=9SO4WC37>9`[7V"'Q=ZHN\;EHPK:R.=:?89#2CJ`A>BG.B,
MTL1,6<[B!MC:*5K?MTM^`^NG[,%+N8"B\1-R!1-F654-(FK'R.XS1DVP304/
M#1@J])**&O;!-OHH?<(QMZDJU51D4S.&G$7E8F0,[%YN9.+5;HX8G;KTC[+F
MA_EU^.R.9HHP+$U%?+N7`)EXC=D61N<95V1L23DSQ$/X\`)OPN`3_`$W^\1_
MAY=^!#?HFY<V9X?<<9%0TVI44Y4BHZ)8.VCXYY:_J"(GD&Z#)X7*/<A`]!`"
M5`_-"P+`J"EI-B5IQ&57[=>&JF66^$YV'Q:3$\B4;9="5Z<61450J(6,A_CJ
M!=XSQ%*AV?M%&,3[';[!^@7"^"&\>/'\Z-4+UD^?0R_:EBC%?4!-O'TU[>A$
MGDQ#)!HCW\WN\R`*4NEV'?+0W*(J0'5!41G@VEAULOIX?D9:D/0C*A3C<B:G
MI#-5MR+[#>V>.BI(9<K!R$,TJ#QW<(<3(=UZ4?*1;=Z/QCH/(!SWI[IAUXZ_
MV*FKE'4FLY'=2VSUH/7O!]?T[*:_`/*3]*&#HO6'R$,AU89DT'HE>Q#KI]+?
M4+?.7-_[O@)(NN.JN,@L%K>W,AO9O@4M+(U)WO-!.E*(4H$SD%;#&VREOW>B
M*]?%I=G1V+A^7'=S85M<MA9%*&JBCV/Y'6U>$7JB_#&.>IXKW,"NZ3O&5U&+
M7\A%U/%HPIKH:J4Y`X<6PG/)VT)]5AOHRXU/4@D:A.E)'>H1'4=$$G>CBX,<
M?+UG!W+F^F)U*4A='4Q2&H7JL221YISIPO+9KY)<VC=8%<`='$BJ]3;Q&7C\
M./I9ZC027LW=)S#*'Q]+Y^'.8*[O?E)-I^J[$%R2E'<;6!6&<\LGQ,W`36RF
MU?;N9K\6[S=*+LM\V4>!G^PC2,[P_<#_RG8BAL.9OGR#]?VJT5-$GHRA#75F
MD[G=T]I6[+IYV@;`S0ND!SQI$7UTU7*WKD>Z5B[9-=0932;3Z<D2-D//3UF%
MZW;M.$K,E2-K[<NCWV+XM-]=^T\H&AE/I_IR>W$@4..OG(C%=5&>VO.)W3&R
M@!2ZC3$_%+?Q,>@S0"L`7$,CZ37=@[:)](P[TNVUB06R^S"!B!A&#+H`H)H7
MG\_PP&+6[X19O]QLHCW<7OO>H[_S$Q_&Z05N!.0&#7=ZFWLR<?2%U'P8U*@O
M*V<I.R-7_8'=R7]$Q-!M\P6PN&E94"JLE>=:,@19R/-*XB#.^J.I,YC\%%3/
M).%GNU)"(3%4.>]W17G@I7^+TM6])`3)"P07X0YU$$;TX.4:N0F)%Q(/&LG;
MR(]0S9E)B6K.%]>WI+J0)X2Q6,YKJ$;&V^[D!USX]2_NM8-P:Y@H?0B>YW-S
MGGGOEY.L$^UMXVGWH@@7?GY2JIY7;P=32TZYRTIY6^]X.>;:W^`<1\LH0O#(
MX42Z<S,;."/N-#&<C7;&5T'D#.8VMH!F+C/+$QB(BF+0R/+@<0_*D^.P:0U0
MJB*[_2?($U$[;!'%&ZUS^X>P>]5#5)0>;#8/+DZNDSHJ3"_:NHW")S^Y?_$B
M>`N1+$C09W@^G4]'K`41#KJW--TEZ<6E8#._K1UG-!\,)N>C\70T/253+RB7
M6;LO!NY8,4K*0*L#4A\4#1A1#PEW8*-^M+D&KF\UH]_J9&:9XG+UXS3$0!XI
MBE=2E#>J*#&JCR\2O15-&-&5V4^A*I5M(_&/Y0SHQ[+]E)6"7$8VEE00NK=/
M_C]A!);/$81TC^EI3XX41/`=!GM(TYZE67T9.M.-RL3ILFC-S^43C^2P\6*A
M[[!O1QCU:*7J0+5IJVC[P^EP3+ET,@M8W<G;5Z"H`KH^@*2:CE,X;.J+R!SH
M[T",='%OL6"E'+-&[3M>8>YXL#I4_>P$X-1)XZU36A3I3.(34'\&;"4#<'#W
M0/*^<VE/--WV_(+83Y=W4&R11R+GL_&,/QLJ;ZMJVJF`/5,_[B9&\]G4\KU*
M85ETJXPH(+=4`62;\+@*R.L4H;%NFO-,#&VE>64Z*/`EYL.1W0=HA64Q,NT3
M154<,@D1JU''K^7C)KK)S;5":"N[J^N"8H;&[KF1L"RFUO]$@1U8\^SX%/[N
MB.B9-??R2H*YM?P=C),P@+?>!ZD^G4_'W`F0CVNK$9@#2Y[SZK@H625-EW_L
MSB':!EUW+-'2OYO_#M("71&*+Q6;(48QTJ@QQ\4AXS*S^X7=-NBF#%L+CA*U
MWM("77&+)\8T1:U*S,@>EB'5.+LSO+9!-Q(1MH"HT@HDD?_\#".X%;Q#138-
MKH)-&+V%!\?O\,=E+<TSB5;;C!KC1-#EEYYJZSBCV6)!QW!F]VR<6P;=GI,7
M2+;Y=%!2]BYK^T?G\JO]<;+J:5O&<43'T>ZU5VX93/E>7D#-Y!1TR!R?G\<S
M]T?.ZBW1YF&D^TTSNR>^W#(8\=Z\:#JUFE&X@7`;XWEUL2\01O&Y,T:1J,XK
MT.Q^%8DL($[ING-='3SL"SKL=D^5N64P0V1.-(RS)_LW]#'Q$:TT/HW((WO"
MX6D[#71EL^B)U:S,%;5UQL,T`K-[U9U7!.W1+!\.-RM'5QP/2@K3-_%V_H_/
M/GZ,(_+>X#[Q-W&-?V8F`F5'#]SM*O-5'G^)P+R-8*LR3ZV*W:L$\D(9(+D<
M,C>K"5!54*[;58`BS"6^>9[%RL"8"8I]G@5=I9[;?7-?7BAC<T59A,):(3J?
ME&`5UP338JU@1>Y"7X>NK\_MWJ*0%\I4;"\'3[.?N*.GU>_@)GP.T*QBNWZ'
MT26,_>>`I->%Z#MOSV>CF<-ZP)ZI"UQ-JJF!+.HB^SE/??0=9B.[62\FB.Y@
M2`B-FY8&17&`RX.B`J`UM#*:Q[K;Q^B*31<8>KMOH(H)8L1V"T'*:1T5M`XQ
MK;<%K=](#9R@G.0HPF>"7_PWK33GBNWMXWDUHA?X&'9'\6*"F(K<A5#Q<UTP
M3*^@*/&">Y>\II&.^5N+K):PY3&T^PIG&W3C\<1A_ZP(HI.(X?B;2L4(1MC6
M'@>4A\SN7<4VZ/WX^D,0QQ:/S+S>='!.SF$;(1V'4RZ/FMV'?]J@]^9X#W%T
M9>ON-S#P4+5U`$OK1-S)URK5U:C&@Z9XB>FX+%XHF=%]I+G=DYI6[+H]:1L`
M-RL`4`G)I:2&C\EES,QQJVK`:L:''FJ:VVW!6K&;,F%M0-@D$YP:-'Q6GC#-
M',DJH5G-\-#S27.[9P*MV(T$9VTHW&]O*!R#WN8%?+E<TI<O]OA%``_G+]WZ
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M!PE2F=MPAT)-&%^C<).\9T^,&??Y";XV%9DJBSOG+5\#Y"P+3<([M_N(J9Q`
MVCDM@\HMU0)%-9#5`[_CFH!4%>4["FG(E8-,B4B>O/&">9BZ(UO-ZE*1_7Q2
MY%QG%G=F\^F<#/G"\L5'#OC:>=R.H8AJ97(EXH@%S?F7Z:P^?UG&&7#O%S.;
M4",:+ZJ,:>SR^''#L=W6LQFX;G8U]IX&L\7/DJ%JR[?DFIJ;IUAUBEX_6!.[
MSSHV`S<U.6]$D7.M6%Z4>3<)MW(#O>@!1J\7Z$?DR7>7\!WN0O*<:9Z.(BZ^
MML.ZG5?+08'&U=FI)DF9MB(MD2]BMV.6%<F$.97`1<F/*P)<$V150:DN*"HK
MF&$I1G$;:/N5@VW4A3^9W5M.LB*9=`02^$2U1,9_I'.^^-;[P`\]+8,M20/H
M[6A:\]E@XG"_4]K<EIH"".,LO<+;5'$TF<_M?VB:1P+=IIX/AIL5`VDY\K!8
M5E)JOL;[Z;FLM@T<K=IDGK&U.T#AE,"4Q>6#TT)67+0KJJ;+RY@#,W5[VL4.
MA`36=KJF5<GXVATS<,O0GUT]!-)F6:4V)>H[O\Y7C!$/AMQ31HX&==&V"7$[
M<XO:9+SMWD<3$:,__E:PM%'X6G:O08@4BG%"'SP6B1B.1MWNQ6`1,?J/'2J8
M6@A=\+DK.F?O+$\<[B=S6QK3Q>(ZI.T$SEXI1B-L]RHSKPC]6>`#'&W65^91
M\Z.NU\D+C"[V480S(T_&8_*RP_R0I-UL]39TW"FCFR6J(7.YTIP,OV/WO0`N
M_/PT?H?18RA[XHP'2T'EMY3*^`"WEU+Y#(2XDC"3\5L6I><M\J^._I^V(PNU
MW2JSF%>:$H=KJUAOAYN0&S"_#=WG3P*5?C\#:8FN*:HED6QO%*T<YZVOXHQ&
M"\L?.6X'ST]4A0.]K3!RPJ8/$HO'KKCV7?CA[0X_ZHSUT&"G%#WNM!."MDMR
M1,]JA9GU:[?UN`U93V;G.17S7]4L9^VGU&DWS9*RSF96*I!(ZB0L9BUTD_:R
M#H2;_Y"%HE+,_-7;D,6*XG..].709O?9"2];Y3BB9:7\\"1"329L0Y:2U7=N
M*+,?U>QDW5?4:29-LK'.2!Z7)SI^$KZ[#KE)$UF#`6<E??=C?`GL*8S`>UI*
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M&+K-LP`6-RM+3C;DI4%>7/Z%)'Y.\#Z-9!&-F8\A\0VZW7F:1,0P%6,+8"KX
M['7*YS7Y*C%"<`=CG*P'&?C[)-S\XY?("]"_'\+,5Y2H,N:^!R3<O!K5NY`F
MX[UX6^A3+89V7R"2%TJW;9=&YJ8UB:$OZ@)2&:2UP4,(\OKF587+$9R.KE2=
MA.37LWM6*B^4*0<BC5!":62NE-Z_>!'\[,5P>Q&^XDD#$7,9H?:?26*7SQ]%
MD5OZ"O'RNQ=M4WA?PN@)^LD>#07VD3_>?+JD%%\%::)S9SH::\PBI!N_F@KW
M,;QY>B/]?<\F0[NO+!@;`]W.UY0@+FGETR-N!I2[`J6^P.,'*)=+^P.DPS.0
M=GD&2IW2H+CH%OB!W#L'NL?A[]!_?D&F=?D.(^\9KG[`:./'\!:97XB5C7F7
MXT1L69-LEMLYP<]BS`8VXYJ-%W;/N:T8GY.WG1Q"FK>K9R"#!5)<(`,&"#*S
MAI=$K/F(_1*%<8ST=CC3=Q1>`^)^C23?$'9E^IB]H5AS8?<Y5)UB&]GYT2B`
MFTX;.];\6`A1BR<?+ECGP0Q9A.XDT6PIM`XYMP7I$L5L/#OQJ63WH]%[8-2Y
M2%QA4,P;!]'N^PMY=&AA/Z'0']KPB8=.7:(8C8>6GX'L8SCL"+6Z%TQ3"-;=
M,K*54[&?9Y7^P-;H[W<T'0PMOFIM;@"TVQ-CHKAI213DY&L_UMD3ON7:T[0U
M/_TJNED;U8@)<7XVM/=JE!V#<_JVC4?,7NT>/LZ7?%P%<1*1PR`QR73T\.(%
MJ8@I9)I';31?L*ZYL%\%,P&I)[.D.&K**]E"_8_FSL3R3*)F!Z+WU:<NI:$+
M3^!S\_[;YW3=*2UWL.X$:+>@U"\@'0/<<[8H!4I]6VV;N!Z#_9=MJALU\[;)
M\OM39@?"CN6A+D5R2W\#7@(@BG'")_`!/5,G.N4T@N_I\G\9DMIAZR'*.?&-
MMDX'PM1!<*-2_9&CG7R:6%I\'4[T)3<V*(FM%HYGR/6;N0J*.54'>Y>/>AL/
M?J.GE!VZ#]F*92);#-+A)B%>9AWH2]!F2@Q;35'K8.NW0\<0QH/!@KR&/1[;
MG4B@KR$Y\<E<HW"&]_NE]<.N"RT_N3$RN,)]#&$VGCN4FR=^YDC/B)SNFG>3
M6%U</JF=#R:E^6#U2*8M=N\F#-YAC`SQS9[<LD83E+F%MY)%Y;#5\K4/MW[3
M5\$P&T_^J`%8S5B<KKEC"V30T.4`T#_W!O,NR*M>L6_R+U-G=KS-V[K1W''^
ML!%>W6#P6[LW$KO<)UZ4V#;;K!'._>PA(,8N]2IHA?,O*]3/>/=BA2:G?K>E
M\\$0M4*K8'L"-@B+)F>#+N$3C"*XO8/O,-C#+TA9KOT-3E^[#+8D>>+'\CF"
M!/'?_>3E]I\^JI`E/!O-%]SI:%5Z4M/[CF7,-%FI6?S1QG:?*>I$/MUSG"Y`
MNEDC(&T%X&9`V@Y)`4=;`GE3`+<%:&.2Z1*[8277`:!35[WJ<1WUSVYW'M).
MY#-UN*8+L/WHX+VW@W':X2]AN(UO8)+B&D]TYDVL[5<QPA60)P](Z^LXT_',
M\@Q:K>"U+[*U(7!)B8S69X`4.@.HF"QIL1X0#?!V5\%3&+T2M4T[6/[P8V(Y
M9]QW8%K;4R2E#-Z<G>V5L04964Y3?BFT\Y4;BELN"DIE<Q/].R[>*7LOPU?/
M#P@?N!^FXVE1)X-K,?-Q.*U.!MWRH\$B<O3+XT,P'$RF%3KE\K4?P*L$OF+S
MMABP@@D).N>-ZF1T$W(^4A<MD/C.\E4H05'ZI78%#P>[<1U`*G7#\(?\.@7W
M2Q=-+6GA<AW&%@(_Y"?Y1Y9O5_/@[XFJ!R#J^?D[*=?]G$W/V=[^YFR'*2'J
MRQ.#8.^!>P[DV@^CMF-PTU]C@+\1B.$.M?Z,1C+<[C=)P^,HY3\@@_L/],?L
M3^@_\&D'])?_/U!+`P04````"``3A%Q"83+@<.-,```XTP0`%``<`'!L>"TR
M,#$R,3(S,5]P<F4N>&UL550)``/US"]1]<PO475X"P`!!"4.```$.0$``.Q=
M6W?BN)9^G[7F/S`Y#]/S$((!<^G5-6>HA%2S3CHP@>J>?IKE&$$\;6S:LE.A
M?_ULR1<,V$8RDFU<IQ^Z4A21]O[V5=+6UD]__]B8C7?D8,.V/MTHS=9-`UFZ
MO32L]:>;K_/;T?Q^,KEI8%>SEIII6^C3C67?_/T___5??OJWV]M[!VDN6C9>
M=XU?#<O5UJCQ:)CPN_CV-OC*UK&7G@[?L:U&NZ5T;EOMV_:@\5\-1?FQK39&
MO_C?A%_ZXT?ROU<-HP809>$?M^;'IYLWU]W^>'?W[=NW)@SE:J;QT=3MS1V,
MU5;:'>4F^/+'JV,NW>C[Y*]-VUG#]UKJG?^/T5?)/`<C?^O0[RK#X?"._FOT
M56PD?1$&5>[^YY>GN?Z&-MJM81%\=`2_A8T?,?WPR=8UEX(:^_4X59V[B-W4
M;Y"_W89?NR4?W2KMVX[2_,#+D,039I(GN0&4&PT?9\<VT0M:-<B?7U\FZ2"3
M+]S=VQ:V36-))/U9,PFC\S>$7`P4T.'>'+3Z=`/2N@V%0NC[&_E`?XV^Y>ZV
MH#S8V&Q-`.I."#ES%_Z_09:+IZM[#;\]FO8W)K*PK:\*(0SH>M.L-<(3:_ZF
M.>C--I=@;>,_/</=W6M;`P9Y0"M#-\#L=HRD&QCIRPJ2/X-O6.X;<@U=,WEX
MV1:E)-,M<JA9,FJ)+9JP!UOW""TC:SFV7`!Q8JUL9T-I8B!IJ2%#-$D3ZQT(
MLAT#L8`B<_J%]FJR$>&*IF)NK"T#]%@#T>BZ[8%LK/4,5`@T&S\@5S-,%L*P
MMETJA=+&1E2A)-$_67P9$+8M%BUF#0/2Q.L8\:"!TWS6'.*(WA&';NF6<*<_
M]UXQ^M,#`QP3*V0B`\DF@@,2)#4,'F0[W,'M%0LWNR=#1Q9&$#SFWG9K[D9K
M!]'0QD"/J6%--#TSQX:`ZNY(-(.48,M(RE83KD-/AO8**P]W]V@[8QC,WB'T
M8JS?7/QU:ULO(#6'&:@5<CQ'O%YM-H:[830R7:;O8?(UH@E8:!\(3ZT)+"XW
MB($"UQ:>:5";H5J@.;M'PP+;-C0S2@_Y,C&\PL()?$$F<3O@:=S=PM$LK.FL
MN:HC/EPE&3=S_`03EQH_V0.Y+IX.9CUBIQ*T23B=:>K$3!4H52%:Q1[P0:V$
M1_S8`H2=$$,X&:P1C)U&/Y!)R)"B2,9.B_C]BK@WF'N;#=@B6=\3#0?=>D'8
M=0R=+O]M_8\OH/[P\\(.D>5),LD^@.;@M2M>]^),/&J&\ZMF>FB$L;>AC."0
M(QPPP$/UZEVS[;54D@^)6]@D>?9,5R.J`>JJ@U5A$,84TF9GCIQW2%_!_M\-
MLH?$PXJ]=O6E9N-M05KDN73#&Q:.IZJ40W/D4DU^_JS!4@@,<PO+`QIYQA];
MNE(PS6`?FHOJ5QUIPHD^R`"98Q#D@<)CT`$E.5;B0)/XI?@!40\(?+>#EB%8
M'SP."\A;&JY<`J>@7O#![TCCL62@S'9W$G8Q6!.R8$<(OR`=&>]$!ZEOXC`.
M2-0TQQ;.0EJNQDX9)&OB@<W:2_N*T<HSG\!R($Q=EM9A;>N9MHSD+G7'A".-
MTK!X9\BOLC-M1_05.(%/'$\S<1[5W6J:>.7-2@ER)5RV[%Q+:'HH*35DUI`7
M!`L8CXMF4`66A<'609@00&9Y@@_"7S!<$WZCU6HW;AL11?#S_?1Y/GV:/(P6
MXX?&Y]'3Z/E^W)C_/!XOYN%DA+=+#YQ]@M&'BZPE`$\)#DF&?"?XEJF](O/3
M#7SPORDVA);AH@O<V;WGD`W>T2MH!CC?9F?8;2KM9O\0SGAYP4K#K_2@W<.W
M:TW;TIJ$.V2Z./R$(G_;4H(C^[\%'^>AYY!WFM793B@M'N8ANBQ1,'A3[:K]
MHKB,3\S$35S[1D[(V<JQ-^*DZMI<(-D.+%UHG0SY[Z:Q=0S;@34[&,--P\/`
MBTW]WWZ357/T$Y4_K-`(OG&WI0<,M_J;81Z9)GR#3!7DA$^^:%/'HX.YL,)"
M])MY=(1&ECW[W791.A*?N.HZD@92H"/MVND(QN"#C\%2AQ*5(VG&RQWA/OE_
M1F[,R!7I6IXTLQ@U9Y+-L2*?`Z*NFDPM=\\\CG&O=)2^/(5.G[@$+6!$(5""
M3MV4@-0+0C@@?Y`5Z[MFDAWMD7NO.<X.EKET*[;94]6>-'5@(J$$S>"&IJYI
M47@TM`/;:"I*5Y&7+,>G*D'DJ9P&HNW63;29\`RO(9N)#]=4!_UN,93+5\[A
M2;Z2QFJ@G&KUE9/L<?`J9PP757*.S:6.;,)-I3Y1J@D.JJY!A=3+6VCY&5GP
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M!T-Y2ITX:9DZP`!#76/S#%G8OQ9!S_QF-F`5W2>!3\D'B%:^D0]BFRTX$>NF
MTAD,Y.7[@JDM4^=D`G\]D3AW(DFJ=DEYYD'7D1CJW58103F3"M':Q<ER>M:6
MM%:I080K%,IL4_^G`080REX276Z`["D_6>P,AT5P)2]"<4HM4_$/\/@.=C:!
MWWY+7@U`;*;J2?V`][H>K<=N+Y,2)YM>:4(6N=#4[`TD5CIG3%R1)((1FD`S
M>M77#+%QCYA'1RDMX%7/7YQ'*5"50?55A<^)9`#7'0[D%8Q6?AW"!DSD06I6
MF!%KFQE=V(,EOD'QWN.@#B0JR'D*A*A*/E8/#\T3JCR^@Q7J9<CE,=&Z;FLR
M.!LID5K&8C0ID/9ZO7Z!3`CR"^PR20\:![S7==5)TFW;HLP'%RJ"PF9IRX_X
M;$5).W&5D<9V#=Q_<NG;<FGX=,\T8SFQ@BX$,2B::D_BY9+S\Y>F#GS01`I2
ML\SQA;1NL-!RK#D6>3YAI.O>QJ,M8?SVZFY3D7I7_SP!I6D()S977/7]T]T)
MB$_P`4=#CD%60X[Y`O[X9?R\F#>FCXW[T?SGQN/3]+>\K3DR'U_@;]&Q_#\/
M^YM/"_L%Z38DQO1>LM]OZLG&\#F9)F@@M_R\^XI)@ZR@I;^U'NFN\>YGQI%.
M#>2=$,H@^(+\,;$+'.11[:Z\G")Y4C'5UT6H0Y2`G@>OKIG)`X+A80E*Y;"Q
M'=?X2PM::-)%^F2SU0R'R`'RM%YB%5Q2AR&.<:]/77)B5M=EN$SLN^WZN^Y'
MVT'&VO+K-O1X][\OD/<08KY:#H(X_!=:-H?#7D\>,#RD5-YN]Q"%AIL;Z>J7
M>@Q]T[70FJ1F@DH#@X*TH)<LK3Z3=S[*04GE58^O$#`#YNO9^Q)8D1K@00Z@
M'>/5H_TD"2I]59[GXR:H\CIXZOXN!+WZ%2%YG6#H_:?67#/1OIDMO5T<72UN
M*BUE*#'XLE%QA7J7!][J%YGD53:`&'(,C!Z0_V<,U&#O<W^&UU/DU1*PTU%Y
ME4OH9I0'XT#G^M75N?R=SLCF'*GJA!])JR?L^F\;!"?0<7`?#*R;-O8<%&$T
M&':D]D"[A+C\ZZY02296[%"=-!9)ZRU!5O/=)"02=T"XAQ=B9L)E?6Q2^="J
MZ_99K$FW.5W!/#[4])AC@K%'>E??0YY%"BB3;UTFZ@[SL-76F7SHU'6?C,!L
M(HS''\@ASQY/5Q2(H&$^W2I,VJI/5)#LL:JM%1PX5'_?)6]?R>/\Y.B&,B3#
M`U7>V=79^85HT"69;GHFEX547<-,#B3EK%$%+QH8F3WM5TVEWBF2SU,:RK*1
MTP4V/V+5C['BEM>Q]QT!A&&G4/.(35YE?4G%J/H16)RBL'3U(F8DL9U5/J(J
M'*VY,:WKB0?IKI^PNY602N\[QG5Z\KIL\-.3/Z+#)#I"2_P(RA:N^Z:K6(DG
M$#-=!>=?=`60F/LFKH3XQA9B*2)$&6MDFA>:NB:[%\`[J).EQ%?%X5IYV52Z
MJBJ/U[/SEVU`@RP#.H]8]?/>P&;>D?-J%V0U4NX7%6DU[',!NWV)34O8"2G;
MCDXN8>7$L/KK@WR7LU+@V.^")D$[D%B@PD_0!5%(VP4'M2/]3\]P4/HAC]+I
M]X<2RW*8*9%I4'Q2CR)33A2KG]?E+C8,$/&/#:.P3:N1$C`&6();H'*5BY&<
MZFI8+CRKGPKE5;,+,"YRJ2W'=<?3X=-JJT.OTU5;4I\*8:6D;,O*7)7SH%C7
MZZD78%MDGBW%HMCG(HFQQ`91[(24;4^LBXMS&-9U<7&Z3?X".#B&#F&.X-14
ME%9+8N)S;OZR]8?EQ"H+L<@-#_IJ-?5&<&J352,+H,HK(N:GYR)'O*\5)GY"
MXCG<P5PRS8%+<C%WFH)$]=>.%_?/$@FDY*+TZB^QA*:#+"(H,C.2Y848YZ*&
M*>_-('9"RO9?K.G@.0SKF@[&.@)&?53BG0#E[4QDS2Q$:_A8X]>/)!?_'<1`
MH;`R[I!4__IGM6!E+`>IZZ6S\6J%=%JZHK]IUAJ]`+13BP!%>HO#'V0'[5TS
M2>X%ZS1%7I<B'DI*='IY`0L4:%@W!6)"45)KU`NC8NKUGU-)SA"(:WF\O='L
MJ0-YCY#P4%*<09QDB7D!"^-_J_H6(2%/5%K7;A(C"*>.LX/(&?2'5=6>/,Z8
M:"C."O9,9IM!%DBA`50_`]Y28P9@'%>T&2BU-0,IG%7-#)0+S4#9FT'UM]]\
M,QA;R0<!<M)-@==[0Z"O8&-&0LO='E/+7=IQ]^?1\Y?QO#%Y;LQ_'KV,?YX^
M/8Q?YO_>&/_WU\GB]\8/]Z/99#%Z:CR,'R?WD_'S_>__$;*<MS<OZ`1=3>")
M1;N<'O1>#N[U^%V424>\0X`YNO<&X]F;K6W!K`_V1C.LIM+O4QWI25G6)4UY
M@1/>7[GX!6U>D0.AM"./^I/IA/A61C$DM.(_Y;G$;;3\'?4#-KH]19KD,F<N
M0XJL4)1X&L6R7Y3)M)R-(;$>Y+A/?2B`KL3WGI+G+$`+SW;I/^7^>HYO<FY4
M+>@]>\BX6M*<S^%<^74U&N=(RGCT86#"0E\^"TE3BUUAI`AD_^X0(PC5#H41
M&Y"=H@G\2&EORQ=@-%\Y4DMDM]I!+H-VN>>[?*)*H3WHVH66#Q[IY.7OQ-)5
M!7Y&W^@_8?)R5UOF^X8L1(C5QPQ9';Q@QH=-=&PS[+8'PSI%PT0HZ/;,`1(M
M>8D=$PU549(,9.(Z,JQ5QI1A+BF7N'O)W?$*<"OR[L$+<S'G,=NK4E\9#&JO
M2M2HTE!1A\-27$^E%8D1L;T>J8.V6B<]2D502J,-D9E92CFXK&8H@@OC69`_
M4_@^B!_ZMY5NKU-AQ>3N[)'\.MG^_@LUVM$WS5EBVBSHT796R'`]P+W9[_2&
M2>6CR5V'\T]4O!<3!$HLQ>JH[0JK#:\_RX^/GU)0E)B?>[MXNFM2H`2`8FI4
M;>\C+BQ*+C02L6-!Y33U7.QJUA(R'<ADNNV.1.*/)Y2MU:?50F=X/MAUZ%58
M3R^K#$I`2FX]D&1ME4-\X=IZ4M1SAN=]4E?U56MV!4_ZRO6@'(,LV/W^++*T
M]7C&$B1^ANN]R+MJO]/_CD0N*9P6+O+3D'2&ZX.85'V)<\:D@RO&*:4:U`V^
MGN:B`!8V7#1'SKNA(W^?AMQ27EMT%+_D40V@E/_(N03J"T_[BQ1'?&U)?%ME
M%3O_S9Q3VXY7GG;EGT%GD2"Z7)F'V9/3ZI-3[<J<5#,CP%8K$MUG.U?%5GI5
MQ>6UOWVIM;^-'V:4C3?D&KIF%EP+?#!W[L)@/O.1?<G]0E^1/\#OSUP.WSU3
M>Q*K/RZAK`3?F2]6,R!;@X8`''N\(\<A1D[?=-[MOQ+T"J4[FKX`)A8(P*/P
MTHZA"W`.P=E?L-E)KK'[:0YD[&V9=4K%<5(%Q2Y+<)$AD+9HUV4(E\?J+E.L
MGI-@/9V-7T:+"7SATI"+IZN@:\G)LXP<0=0_\XP&W;_#HRKR*AE2)LT?*,/*
M<%#,4+L-?60M'PS3`\R:@]Y07N'@F<F%>`5F,44I,CLBUW.9D3.(!<\XXJ:B
MJGUYG8[":<H1="*3=4U+:$SZ`HL]3*HT_$>+NDF6G7B2?/S;Y0@LDX>ZMO4[
MAY*T9K1BXPS)_Z>K\'G8OM*7^.#CP5R%J.II;]QT?JM_X^J"QQLS49+2-T>X
MIGYQP+G,''MEN.3FK2JO661LID*T]*293QJKU_/<(U^OGA?`#V8A+2L>P#)-
MFSX6$+SC!VE`>RCQ]>+,R4OR4AR`5+_38%ZW]056^"X&"%Z0L7GU(#K31:+_
M2C-:3IW8>\TDXTC:<4G,FC@&+B>ARLMYH`N]ZNJ"I%Q+O8H(%EIUS*3)XRC6
MVK`0(I<+`@-_1BY]N[2=Q%NB1G.,7(Q'4],\&C?OU6_Y>>C?%GRA[PNRD*.9
MY*GGY<:P#`*D"T8>^?I6>]"5%_S.3%]2^.,")5"0P;4H",?>0-C".7Z-H],:
MR'N2,V'&<C+@<ZQ?3Q]7/G?P:#O(6%OW'DQ@Z;L%)`(8@`).R/X*@>$S6L%W
M%MH'6$&K)>\@F(.2<I*DO%!=4<=3[H<FDNY[R7I/H6P7D<[N];3TY/0.OX'"
MOT$(&;V#=URC9X]T#9JNZ'%(K"[\^&1$Z7<2[[6)485\1)7C,P0`^'WW;U0:
MMXT'6_>"8^'H1\"M,;;@:[O&Q`*ONZ$C<!P(AR/118%+S^U/AN$^"LX:-%(6
M6&UT!@FUEXD++981\R\0P]$7\)O-MG*N*Q%&>G-MO]\MD>&;*_QP;*7PT<&P
M0NPN)ZZA%::P67J)8W;E&E"\)%0_FMJZJ73/E>NR"N=@W"I()XW1RI3@9IK.
M++QH\@!!H:F<;6W):T,'XU=!7.<8+_%8BT-LCP;6-?-WI#F/\`ENMEOG>NKQ
M"NYHABJ)+IWY$@]\N(7G*V#(05)$O5Q\L3FJ)\!D`$H\GV$0(:R:2<([WVU>
M;9/<-Q`DMH-QJR"J-$9+/#)AJ0*DG+Z@-=T"M=QG;0.^?2!*2DG#5T%89]@N
M\4B`66;W,(JCF1-8J7S\`^V`>E$>,7'\ZD@MG?$2-^I9"J'H/F(L%D>IE/\F
MA`#)I4U1!>$QL%_BGCNSV3T:)G+N@>ZU[1#=$R6ZA-&K(+5LIO=;56IU)19[
M5B&AP<50U![(^<FJ(T]&2$+Q5CIWF7FOIJ$_FK;F@F;VA$HS-G9UA)?,<"BK
M2N<LOR'3_(=E?[/F2,.VY5\2).^<#,1:8<H\U9'A>2!">7:;:J^M5E2>O]JF
M!U`Y?H#`0/ZY)WKXY'@T?G7DE\[X7FZMCE)P2U;VD.CG8B]H:SND!H(<<'F$
M"U%[SEG35$>*9V'8"[,][!7<\4K,@9I"+UKNWXN#OTR>?QT_+Z8ODS'/?4KR
M(IT%@C*.[P!Q79STQ]@EO%_7[@]D7IY,G3C_65K"H`L`XS/\VQ]-1>E(;&N=
M-;6@<V\.285&Q0S(%5^UN]0>.YGVV/B!]J7!/+U%8H;I__(_S9-R,]??T-(S
MT705#1_X>PI33#/5?E]B+P5&,LHSVUQ`?<<FW&TI?I5*W(CGDR_/D\?)_>AY
MT1C=WT^_/B\FSU\:L^D3:1\$AOU`'F0SN2Q[;JPM8V7H&J0YNFY#PDF>![!-
MTA$(!^/E-O;3$2--Z9S=U+J@"4[JM!=8>A9.B_`.BSID+<$Y/YX08^600&2J
M?)Q6O-X%J%^2^C?C'<V1[CGT:6-R$A,T)U-5>2'GW.07:&/LT0YZP2IJ84YW
MVH*'&$%,?@$%4SMWEB'%Z"2O3`ZZBG)Q?<41)(=:CS]TTP//_`A0DRY#GB^#
MZ>JDZ<@N>0#:W4_MR7O+4B+=^8V)51\+1(331^2S.#GJ$A7@L:-:[1!R;YOP
M-]N_NQ5KV$5<T+-MZ2G_'+O)$7JFX5#>11=A5.:WHUF07'XV[,4;<K0M`N'K
MF)2W.UO;;XBU]]$J<V1B'U>(L<B3=V@:.8&J:S";K8R_D)/"?3<I/4M6D[1A
MKD4KF&"H:R,B`?C2<#0<RHO5@FC,[V&%*V%58:J6X28JUKX5DWB95#LAFNO(
MTH"BKQ;>(MU8&6@9I'1=597XPF_:M)=LW_I#+K[9L7B;E*0E+YF/?UV(PG+`
MN]]=S>*CKGE#R/740C&NDQ0P4WK1KY<MO60^ZAKPSP,EYQ4)\5[DZ]:V'A]&
MH^W6L=\U,Y!AOZ6TF'>#$X<H2!]/(MIY?JI]&XO0_XPT9X&<S3W\(WG,(-:P
MYQ?#1-BUK6C#$#A3DK:\4B7%,7B9,LR+0;6O:T7WY$-4PB=)SMV1%/":1'Q*
M,9)E8^8X4F0J0L63QZS3I:?H,2<2`9G[![.-F=_!1PT6O%=L+`V-E$'017F/
ME<*D$<0H4%XXH_XCYWBK:_8X<VP=H27V=[_#19I-ZBR[G7Y+VC(F==YJZ`,;
M+'5-2J.X&+S`02V!>3UX_-O5D&@F3]5O%RUV.]%O1TQ/M6;(T0GP:UK/T$EJ
M+90H9:ZAJZ$"^=&XGE[-O/H174Z::<[4H8G8DC[G&)YZ`@Y]>8^3,!!0%=WA
M0JKZC9Q+J;@8;0CT376@).6,E2BN\$FLAM()1[L&/:4O`CVM0O'DS=*TA6AE
M5I5282BF4*8R/:BD8BG^X*W:VXZ\3N_B*F&^G0VY[H.?]])W&2^_]<9;H"^J
M+%]B/;Z<Q$1"/3YI;HJGJUE<JZUEMA)'ETQZ+8G<7D)9037_)_F6*#2O>+/P
M4G?0SG%?AV*Y$W9=QQ_NG]XATN>CH7?^_P\T5]YRC(V&DBV>`Z&Z[OD>)_''
M$`SZ$M\G.#-Y6=K!@4E==Y"_8@0+/.P:&U@9XZ;2;W?DJ<'A9&5)/8/ER/B+
M[\$E5<KISV^092K]JTDAQL<FH+1:BKQ3PMQTE:4[8H",U.SZ7JO//F[0,'D%
MD?PQ_M,SWC63;(2<!%NUGW0I1M"!`PL)96D/-SZ1H@R(IM1'4:+N""=6HG1Z
M\MQ-VK1EZ0,3#)$.##O]@IN7R:Y,V2+'W<U,S>\]!19!J_9.P.CV)+Z(PTI&
M63J2"Z:]SO3`<]1'9R:;K68XA/NI\V#@K8TU<[IZLJWU$WEK=80Q.O6G2DL=
MR#OASD-2:?[F4OCV>C7H=HKMX5;`F[4+[>.4^7[B#5Y1\2AYVO+B$0,,>QT8
MMI5A?73@!4$P]M`+TNVU91`.3E!0545>(#H[?UE:P0=,3#UZK?]O[VJ?$\>9
M_+_"Q[VJNQSFG8\D(;-4$>"`S#YSWQP0B6^)S6.;3-B__B3Y%5NR95NR98>J
MW:D,&23UKUNM5JM?&B4>"5W>'4`@#MVV.$\KPPJJ$Y%LX(2$9-1ND'WR8.@H
MO-!):U]KUM\/<"+-1C_=#<8]<3>;A(DKN^RR81$2A7%?:8XH.)$RJ@7V*)8&
M[@,GF.;D/CK.,#C0ZD)VO>5MD4%W*#"S./N*JI*=HN"%A6HX:(Y0+53[;(+E
MP>VX37`SHJAWYACOU.&JXG\V.K_Q<WPWQW-\]KJXZ4%3MV"=J^JO+Q8XG(]S
M[0`B=5^'[7:&A+_4\2K3S]DH_<8;M-<>$K;HGY/UM/4P6<VVDWGKCX5J.O&A
M_Y&OMBTZ+!_4DP8_]X<J7-/VMVKN4<]?')S:3>V@6V`GAF<JL/F()D,X(/?^
M$OP;-TD,SQTL0-\C@R)4O*\W&HHC7,2*^2B$1-XGVVC\`)<F%)\H;H^N6J'0
M_I=FO\_TO?:I[<_JT8FL1UTQHGB@5^.5`;4ML#43?_,>Z."@(?"V2(.@2N+>
M,)@=2E<15_JK*JKR;_O8<&B-:^`^PK]KIZTQQ0U*O'*<BI+6D#,_?!D7PV6S
MRB.(?O?6_"R1?,_[9_CR$(8;TX8X8-D6!O;U"EC/F%+Z_;26:@5V;J&U\;!Y
M\Y\'3MI%;S`25Y&9VS+Y[%G.@A0WRSDR0YH]F5X_2)@H^HES%,NH/JENXC&2
MX4"2/(4N#7H:\G,_Q:PW$EBLO?CZ^*3JB9=5OIRH/->O+*D;U5CJ*.]VD2:^
MN(?H'E5\Z`LCF#(IG[TC@-F$4ADTL&KC\/L$YJM1_%DO%[`E/O*5LXLV*E;6
MN(:*J>V"PBE*?]`7V!:.,JUL&RGN16?!JZGY:+F!]4OY8=TS.=OO$(]_H/Y1
M!MWN4+Z-15NO_.(IE$--3:CCA=JGJAV1\?IDF#_@=VT,7MG!(<67_6VD/)%?
M32T71@8ONN]?=$A]J*L=CMJ9?@%SIUD`GWQK!/;+Z01,_--<^]`P@`(KTXE<
M>DV%7@#?&E"0C*^6Q[H!?4O'OMRS>D2URW')(.8RRYPGKZFT\@';%=#A34`C
MQ]I,MVSU>,3>-7BF_006CA`"$)\]1I!D:O,55Y:E-%=X,S/"%>71393#<297
M>"GP<.J([%#/<:G-E>PTOKB"/&Z:((>+SB.?J:KOG`=@SYUZI_1ZQ$Z0_&OR
M$^>77N2R(=C4:B[>"ZGK._2`P&$#=TIW*+*M0\+4\DL/*VY-K<]2S)!^5&WP
MI&HF+HJ.+0_F1!..$TLO9:)`]M[4Y']4*TLJ':^$A7&S9KIC2OPP#<O"YH2X
MEUL!*Y9-K&.OOJ*Y5)L6')F?C-?0TC6UG0WV^-AQ6]'U>HJX:%#BE.6(&)<T
MBU!>>3)TT@0G$CD__0([7"-_>3AH.V"ZZU=&`F/0R7-RX7WA6'N_[F8J+CY?
M!YVR"Y^Q\/7C=#0NP&\KB9)127T9B;90Y,N2<2:!,FF"7(D\<44)A8T^`-.&
M5$9I&;9''68NI0XG%]^R4>_OKD[I]YMLG'S43+!#;?F@W6!JG]`V#E7<]`CK
M='J='&QE&%M:'F?%I?)XZ,)=*)1X$NW+_6;Z/R_3Q;8U_0G_S-1WXOQJ@7^?
MX7Q35($Q?YIL="`_1P-N+'%UE&FS%@C=BXP8JNTT&(P%1E71YN5CK#)SQ[_E
M,.%0F_!6`?GL"JDA3'0KYLMCCV!?-(7=N7A"O0N^P'YKX"AETT+U,^V+\Z>3
MQ=-W7"Q"K'&V->3?MTGCH[N6>Z9T1:8>LJV!RX;.RU+_",T,E]P7S(ST"%'A
M'-F?>-D*W4A([QN)=RV.YEQ>R*,W+`(Y-3Y6BAE)8K+81!M)3FX9I('4YTX(
M#?PRD-E90K&,8L3+K2BCJP\V*B1!W/%/G;;HB>]%88:T",FE2+X#$T80(51)
M(%\?R`G4R.UTBE`\]Y]1(,$#<<]/E%D+:#;O/1SL'\^F'Y;C!`2'(H#]Z%^4
MRS%PVN:((3'S@D1(<`(_@X["A9"K3?AI]D3)-"C+\"=PV!KAD",*/WM]8B0$
M_Z"M"@4_,10K'9?&QJ;&CSRG"W:[+>Z)CS*IJ#.<3!#-+B0>^M(8AUG))YOX
M";1'P9*&\GQ*N@SYS::DA7*0"$"%R7LB2<_N2_-#=*IZ-BSJO(83(F\U_#4.
M58$_/RP7F^5\]CC93A];]Y/Y9/$P;6W^G$Z1#WN%U_0.;&VG'K-XLA_@.6@<
MM3TJYG6O'E&0Z>8=H-XZX1'S/SIY!`3BVAN+++`0FR^_.16*U89@+$T\]AY'
M._KE#P8C@7F?#`O@HX<8F$2HJ,("2G"F=!IE3,4*RX1*!T#RQ25&)$Q<I2PD
M@1#(0+?9,A`I+E0._WE68BK"^SCQ`=][S>;[\FQ;MJJCVH#8(5@>\T,S5R\!
M%!@",6A8AHJ'U?+PI.G0<-+4X\JP<-<Q_XT"HB>P+@3#"OB*1292`[]CDE#5
M^"6Q<*18NQ,-3YG/'J:+S;0U63RV-B^KU?Q7:_)C/9T^3Q?;#%;]7-NA=F83
M?;\YGT['R^3-!)@%N0WY!^,(_V8X'1O@N-X,031]0`?:_0/FG/LL(Q<QYMEG
MN6K=,V#.',LU!9?]69`Y@48OBM&WWLS=Z&9>K9>KZ7K["^_FZ?^\S%89M['7
M4#G<2SGW#J9V9PXTN-*NH'EU\6`'ZM`D<55ZP[:XVF19EL)EZ^?@:FJ[[C38
MOO4N[\>/[,G];#Z#V_QIN6Y-GU?SY:_IM+6>_?ASNVF]K):+UGJZG:VSG^'J
MJW:$L#X9IA>)M=;>WFWKY83J[WNUQG,KA$=P@`:94W)(>STC@E=0WVNX;^'2
M?@?F=5%S7%,K(#VH\=_KB/-W<%ID`>62-)M7YYVX8[HC@1TR\RZ+B](1)CF^
M:N(!^K=64X.HFGI8/C_/ML\9LT_0)5^S<;)L@:N#/P;*^3)P_SZ@H^Y]))EH
M=\1ZSYB74NSEP)V&;#%WQ3J(Z7-SNFX48FC8@<2&TK?>R</$EHQ9DE:0E\YM
MOIC?:.#3#TB,K5!58RGD`WTWCGO_47IAV(!X/,&KM\#"R*SKX&,$<):$JS#%
MS&C6N/9\<14QBJJ([>1?TTT+WCQF"WCN3S,HB:WZ!:RE/M/A)R"WEG"^#L<B
MG`>=?D?<%DB8./_^)@P:$L(V.<E'&#U\=W$F3GE;E!F0;WUPC^.YIZO5'+L!
M)NM?K:?98K)XF$WFK<UVLL4?P^WZM%P_3[:SY2++P8Y\_/AJI)H7_X'&?W:9
MZ0?#_,#+S!_'$TQQ#(WGB\JP.QJSEUA+'BS_1IWL]YHC3CX*H?%)PMH?.)4F
MQ#1NS[H<3E&%65GEMPPL`M]W/H"5=G2KKZ=S'*>WFB#__W8]66PF#VA;9[E\
MNY;42C7M2ZAH1OZ;.&W`P%?<[8L[R])FS[_O:2,3CZ>^,A1W!<FP$BZ;/3M'
M@WIE^3#[QD=ZE_6)K_4'#FC.5%*"]-;GC')[\6.G+/Q@-1@+K4^=L@!I7_?(
M$'WK;9WL8LNSF\.^MH*[^.9Q(UQ'4OKMAK/\)O!<^T05+Q`;PF?:L".P6%3A
M!<KMH^.+?U.KWY-@"M>9#<.$4B@</EK6^</Y+`Z9R&A2KHNMG?ARXDN-K\%9
M1/DUNN,CY8^AP1'YY$77;+HN&`ETPXA<>IW$7!S/&ML@E:`G?AC&'CU[+PP=
MN%%9&V!^:CM@A:[1]Q?LAM.`&49LW!5WV^*ZUCJ)-4>NU*:P?VXYGEZ#0RF1
M?\0<AS\M#VNP,]YTE-+G5(O!7+O2`@.!'>)%K;LF\BV26XUM=YIV-6'I''M_
MB?>.O58990B]*`)J(OVE\*^Q[:Y]&+UK>,RZL]R>LQ'#;M@=$Q,DR$^Y>:>I
MB0P6`>];NU2+!3_D<KDR1T$4=,C6(Q;B"HZKRBY1)$+2VU8R;/WL$U0<WU`4
MDAIO:'91<6*[J-OF6M61"OFD"POK%#*)2RY8:NP,+'P"9(F)R:/N:?$+!95[
M4T-D`I,F$;@KI_:XC,<&MN54'"Q3"+T:'QN%6["TN_$6++28F1Q]6$A!,T5[
ML=`#)X)ZH;VV$S@AI.8DPP+RZX&Y4^#!,"_^L'[7-45A;DY&'49LV$L2"[R]
MRD:AW,5.G\ZFKMDH%E_'SH\SW)H$:KJDEA1$?C$,6#WGLE(M=\'].5`M@/*8
M9A]0<7TZ'6==*CIC@9T<$B:NGL>,J%3>!3"YSX]',78^HA*JMGF^:F@(I914
ME)C<^2=EM.J9EHG>"A_1BD2.QB(JRSW;>5KX=%[C,LN]P;@KKF`VXRI*#H^-
M5]/.@9;<-@.5CGE0=D]1*A#M.9?.%N2Q?YB&9>%`9G&=K9(G%RO(";Q+#?2.
M8R.WP90!A%ZG;A(\V>W.'V?L.W@$4!QVFI-4!TY'@*5"WT\^#-/6_L&?4Y=R
MUQ^TV^(@X+7,LG=%@(:?S"@"</D#W<:.8T0';XAR]C>`#%B/Z[;WJ&,O@(WU
MX[!\LN#49>^1,?/)$<6E/G%QR$$H1.C+S2+C(/1AI1=6=$CO61:PX?U;U4RL
MX0:C09>Y7"_[N&7+=\QKGQ."IH8$16A^>%?--V#=]4<"HY+)<U8N&>E0-#4\
MDHK:_<7O"09A$]<1CF$!8L4CB=#TY%FBMTP:QT!J,$1N'U$J,F18;\A0[O"5
M7\6+/^WVXD^[L\7/Z6*[7,^FFUSON3,==8.#0`"KZ#.N-]2%5-AJ.!(7OYTP
M<7YKSA]TK?Y^AC<[4U./%C3344""!<Q/>'@I2G<LKK%:^@*X:.U,7`O*D64"
MI\;Q&&PR\I=A_CW3<==;*X9#KR.N/Q'#"B20$D9X:AR\QR8F3YJN6>]N[EQL
MNXS$!7\QK$`",6&$1WZ78$$Q20!/B,M,[/F)75M*3Q'G\@M/59H8QWQ[5(*;
MZLL+U#ND!M[1?NMXFXJK?1.?4`*E12:^QAZMXM>4?OR:DJEE2ZZ+#&OSEJ*W
MG%L/%Z9X+3^/^A.8*.MG^7K4WIQW/R<I\&[8[K%W>DL?CXLJ$-YF)2,N3;TX
M^>3CA-$[9=#I"BS2?S59/>0D`:"FWI)<3-U>0PBQR8=QUFTK*+$PTS&V*%+9
M!.\(\$_@I(G-#7RQ_*%J.OKQ'AP,$Y5+OQN.%'$UYX0LN1X"*IQ;OM7<L`IU
M),Y`]-R#P40\,'&XC&I>PO_(@1<B)+!N5[&UU4IP.>!?GWM=-@F=?IW`#@=Q
M0:1L?X^'P7@\FYK^YE2\@0;+J$^22;(AEVWP>LA4$<1<*1HU58I\2\:[H&G`
M\NJ"P*O:TQFE'X5P84YPSS%!O:0I+W*N1`UK*%'%?0^#N.\AU(<QEV<AW#6O
MH/,@7Q\_(5$AY3=FC$[CO.ZCZRXIDX#2\#UY-"X;O""3",T6TRF7)FJ#R$1<
MS<L--!F)"U3RI\DO;G@(-T4.KE5<BDIH(BY"EP"QWS^$3)O<HO.LZ=K'^<-=
M=K?3$\>2JZGX,84F31Y;J!1*SACUZWK9BCC&A*<JD3$T"BN/!.-P$M$.SRME
M$=4G<DMD`K68$$0LJ09(5DN!6\!K`?9DH54:<<W*M;D?A@G)&9+T2U;6S3-E
M:53#/S+5<I=72#)YG=AK1$N;`P<S5-,IP#Z*OF#@'H%<N;7F\F'CEX3H#4EE
M!H@L\K\F_,I$DQ^/&60"Y`9]91K[\\ZVGE7]?("W0'@AW"_/MJ7MP?(PLTP5
M'$,TD2[Q1*8P#ULYT_(!(/=)]G36]Q"!B6DBVRE<)@?1P%Q<ACI,Y4QC(U#N
MDPI%A,)_^PZ)GVL[H%M@\F:"&#$D)P616^GC5<ZVC"1+7PWH%=E6DS=(`\J8
M?]:.P+(-';BN[1!%S,8^XZ"5<S(/\15&$C*Y=ZX)"`GDB-E<I`Q2.;M8B*LP
M:Y6!/3_!N[8[`EP"#I+_K*+G252GG:A"B*Y=(L?8QZV<B3DA</DZEI.O#C71
M]7?&;5)Y2HXU#J7C;BH0%3ZO,_#QEX9:'/KK]^2P.^PPUX4E#E$Y7]()\RYX
M;3DYD\W!PQ*OP,VM1;:+C8MZ1!$"2WVCNDG5^(:&%\D<5$$=1K1$)8'J&\),
M-#8U9MI]SO!M1\\H61Y\7+8&[I&S!CN@?8(]AH64>TJVPC*/+X-,%$2EJ7V0
M'>(O*)0(WA=1WR6!>5G7D\D@%0GD-S5[=++;F6>P]Z7^X6RBQ3@=.G?.7^[Z
M_:ZX7'26%<@@'%F1:FJ<;P"C%]L,[S_,&5G1;\O`V42*:IR2F?P`=`*FBG#"
M=R%K#1?BZCV<B-QM$ZT_/EL^<6X9)((='#]JMM-OE'AL`%1ID(Y'<#(L#=(\
M:!/3+GGEVEW-)H,()`'@>^\:9OY%Q-X)%7<#U3P+^?$,W),/[0.!Y9FR+48&
MD2D`7U/3.1@AF>G;W\8OH)H61D5<ZF7F]=1(KB@@5NB2ED2TH`"!`!=Q>9`Y
M5E0O\2(#6:5+5@X)>S+.IH_+6-Q5.?N":B5?9!@]\6J>9Q8"^7Z\H,L%1L9S
M.Z';)\GK1G:_D@>1@>\L]#6U>C-JO:7ML=P;4*Y--P('T4ZL_4GQE1`'D8&W
M+/1Y&[=Y/E-=/Z,>U3L3B?76"`4'/`&`GRN9F[,GCR4#JS-0ZW&\<3[/X$4Z
M3CSS2QEE$"EXS$!?C0L(%<\/'[8[T?SPS9^3];3U,%G-MI-YZX_-^>-#-2\M
MX]!:8AQ:JKYOK8%EFQI*RV]M;&/W=PN_*<*_V4;+*^IE_4>N_/+-.P3M03UI
M\'-W\N7!F1J*0#`QGM>==FOXDW(H:(=9@NKT0-7O2J8?(OR79K_/]+WVJ>VA
M]IA^[8YG%$2,%WT/]<C>L_S@6J\+'[A5,*S[RQ:AOSP$P^#\#*6KB&OI7!55
M^2,X8L.A->+FYW#IUKMV@CR'VL"^N,$W?9$](S(NAHOJDT<0/6U:@"5RYZ\$
M^F]Y",.-:4,<L&P+`_MZ!:Q?\Z#?)Z5#<-JYA=:6?_\%_2@"D:*((I2DF-A-
M?JOFWFM808Q]YMWNM>`R^>Q9SH(4;Q;+D1ER[TE4)VBA?GC-;KHC)[123!NT
MJ[GR[QELC2!/S_:WL7TWSA8TE;8@Z%$]:C/'$R0.Q456TP#V9(^=J*:&&E(0
MV("=H>]#.#`[MQ@&E('%5`)K?&7*SNC?X/@)0B`P-RI,&ZUZ%M-(:VI0(!V$
MF*B3FH]DY+)<VSF9S*8&]7F0X8L-!$Q<59_P3/DM"`J+A:Z8XYTU&6X_[Y-*
MI#0F*7NW/NZWHRA*42QO&`48R>`CD;N*0RKT-.0#]WIOU!?GF"R^/BZ*JP19
MY<L)N<M2<*153%QN.5+'%QOG#<3"UITUTYU2QS],P\(-,88"HYCYKYC/IA4@
M985W*R.7FNHK(>.&/[4F9_L=$OD/V+_HD'K\@.?`A8N"3[^`N=,LL#*U'<`%
M&^?&;V`Z/VD?.%:]*S)87^#2:RKO`OC65-\11^:,I%+BPHZ\G,+U<CI%A6LX
M*ADV/DN732F,A"J%)+[5QN'X"<Q7HQ2U@/_X"2S;[Y.B8`-"7/8BSZ7*)MK\
M[+LTOC35DYH;,&P)/ZHV>%(U\Z=Z/(.[P6C09WX)Y3AQ<Z4R!>2F)GL7P\OM
M6H3JM:K'+3`_,&8#@BTA0#!CD\LFG(S6`!^P:Y,OD=D`\`-3W5<W2#6QMT1B
MGU^>]>4*!U9&F_>2**O\D8)':'0W)30:Z=H65K:M":KOYGA^@DAIRXN*+AX(
M[:OUT$1>5+3ESE(X\IE/\)J85IQ514'FU7DDAOE]$='&@UQ9PZ6C:Q`QU:)B
MFYYU_3*%3?(SIW)Q[WNY=`NB^--`!\X1PN/AJ)!";B3>!=<4?+]]D,#!FX^7
M`<>U9OW]9`(P@V<WE`O;1U%<E1#AZ_\^NR"5>[5Q:>;9`Z_I*+YFT27H/@BO
M#OU!6[`I)&3A\DN]>'XUU>WY9)@'H*'*'GB'HYA9YCH'U]^56DH2R&RJ[]!S
M7VR`^:GM`/ET6!CZ)]3NP''[6UMT1P__'@&^,.Q?`-53-MYT]!YV-QIUQ.4J
M"5NVU/)9"K-JXX241=*=]R^H.]R/T+]3(*(*J4R(Y.)/I.5[[HE4MOK%81NV
M46YOG+)>P=C>-^M8"Y+'0\4@Y:$B\AR!BK2@0E?GHXV"5/\3?M>$9KUA6KBV
MR])^!V;+U2JME6D@?Z?)H9K+]7/%U@BMP5_!1-_C^=WI_=EO95UN95VXPW<K
MZU*0)94_\][*NMS*NMS*NM2HK,LM'Y%)XNJ:CUA]%JP$R,IPQ'\;+:"T:ZP&
MA"2(+L^V!2]52*869QR9A_*O9`2+MF#90F$#V'BEAZ;PJ#:A1"?L*MS8JFE7
MDBHG5Y@$C\V/\JAFEG4&^\>SZ>>8.#E7H20K/\%J#R5G(+"-8?8%R;9[XU[(
M8AC?HIO2%:;2N'TI4.'+!59M#F6ES$-9J5%$EW,H3_5]"7O_6E.B>U$`75?"
M7%7:>F63;NX%29(YU-3P+8XJX2^@O;VCA_1/8*IOX"K!'6'I^/BDOV$ED2';
M)A!Z[V+G9VTBX,3<QJANL(B5[%<[2D.66`6[I(W"E1C9]DOV0T,<;YL:3%>^
M!I+]>E"G'2+TTL#.S]H$T%5[E4@#M%.+"T:=]H?(:P<S-YO:-)P3EL%AC*-Y
M9[IM:KJE[9RP2'2K$Y=]4`8)WV5/L/.QQN&MR=7N36,'P-YZ@FRC^-U[?6(4
M-:<*^&GS2R^*V1!L;,OI(I'%?C>,?J_+6I>G^'Q<)(M;*1_.^%4>?,(CJ'Z8
MH3%J<`<@=D?EV@DUF"O>#K5PF+P3W@2_Y72=Z/6$!=I=S23P78[JX0@6H.\C
M'4EZHZ$XPD6LF(LV2>9]<9<2&^"5ZXY;2#GGD'(GKB*E7O#])5XQV`NS'(K#
M3.S::QU\SH]M<F]ISM1CY=D3V;=+P()+B5GGK0<X5"EG86!CI9?0MR%TX138
M*D_,FK^K##.RL3$)&J)80#-__?W?;_S^#ZSQ3CTV/\?;3REF@)#M'N?:MSZR
M:M`;JBX==>2'LKR..OSEL]PN.]^N0'%.`)W@V"L_J^L=Q]'@99?JYD[%;8LP
M<KC1:3ZOG+",8QB)\E@#9)S`7T>Z?W10]5!%</Q.]536=[=5C]V5A-0F^4:&
MLRL4=!72;+V:V'1T*NJ[FTKF<*/3>7AIICB&63136W"9_NJIK.]NJQZ[*PFI
M3?Y06:T`XK'!U\&/3FGYLHU#'@MOT)[ASL?OE1'$QYDKO[66P05/1.]_@6FL
M#$VWT0_H_Z4.@I!"8FLT8D@F?1SY]B2-R=Z&9,2DJ?X\GWQ(]O8W!B!$/7-1
M;>HP-1:(1$2:ZK'RJ=]";H,%/-#0_R$`2*9XLD@01JJQ5*3ATE3GB0\`HGL#
M/H$.-T=`/S$/*EDNX@/56"Q24&FJDP!2&^R*)^T37*M+8E4:HE0D#%0_J6!%
MI:F758_^C?:%J`]13FI6DR@/5T/45Q+H2#3UIH9EWS>L8X84L8HB61+H`]50
M'AA1J4W1@JPM_N`F\,D/T<U\T2`,4#\I2$.AL4GYVA<F>XH<N_!Z%2&?U-*>
MW,*).D[]9($1DZ:FI7OD7]^FNLRWS/CWZRL"%`P\UU.[<;Q']R5,.5*($?N(
M](!.E@#**#64`Q8\&EM7`$F_9RO#_T*DDZJ/$T6!.$3]Y"`="4\(&N=^A`>@
MIPWQ;@@5/&!V,)''J)\8,&#AR4'CO(WN:V>\ZD((!%+27%(%$=I@`B6#=VV$
M2`T1)GC\EPHI<ZK(Z^_U%'%YZ$T1@E3H*D]#Y%$:9I16&@;AV<*`ML*HMZ9?
MZ&?0FAPQ-^%''"K#$!GLSA1,5+B!ZJWR1?RRX*>J,O7B#IBQ/$2[;>,U>AFJ
MRJB$@A<<E\Q%48FO<R&(27)G6_(A>NY'D2E#15QI"\Z+S;^SW3G`/E&[WO6'
M'8$5LIC6P&7O"1<2/\D^,Z[?87>MP<DP;02?:U]!_/J2;[+HFO/O-6@S`HCW
M.S0S'^&=\FB<D&9W1<&S(+LC<?5(&!8@T2Y+%Y:0,9X%6'^G#?L2[K0?0`>F
M>H2T3/8?FJZA8]_6/L$U.9UN7YQ"9EI"+24E,[B57^.JU,I"@K)ET\IHN.5A
MHQZ!5^%544:D4!D^Y,>FJ\,^BKE'$T&KL)"0V"<SSA>L^TL`N%-&9Q`I6RSS
MA3BZ>CY.O-(A]B1:_$DDC8%?-A,HWAY1?HLDGM]X0.:!P'MQY19444=X-^X&
MWT[^-=VTEHO6;/&P?)ZV_L#P9O)L;]4O8"WUF0X_<2KVY7=9>X-\!8OTW86=
M?D><,9,P,0]G\Z-[F,,))I8%;/3F-M?45^VHV1IP9'H+<;J'7_O[3NF/VN)(
MS;DJ+J=B)O[&U6I^&)N:>!=@LX3:#>+R"ZAF%(AANST@%=HC!T(QC"B#+##2
M6^,,N^+OGJ.VDJKP%ZKI>`[RO6M>:7]_K*)/EU<]4,:DR*VP+K3`[N[-^/SO
M/=`<-0A_B&H_^-'5J`6T^OG5TO:::FK^E;'?5@06LHS-Q^>BG0"QO]L226VJ
M3IV#-_7HP(.M;J6;]@[.*H"1D?/+((%Y'):7>7^DR5@:DK[13B1'FBM.;E-5
MB/M#B*E*&-2Y:`W;O3%SDRW:**79"S')8J*K)H+FAH:Z>ZGC5A$0*V-7<W(0
M+W\\=[-WW'2EDJC@J-M8V1*3Q`0(ZB:($0K$WLSS,)%(AWMKV+X#$Z@':!SX
MX:Z],7/&$&400:)%`]I/"&4@J:DE)3S:?QO;=^-LJ?K^*@.J-V9."$P:J6+&
MIA+75&,<`G!_AK3IC^B)6WL]X[NN^CL(46^3P@=H_$T8JQP.Q\Z%#`16[H!F
MC,&??!AGW0X10+H_$3E$'J,BSC`05&%!%A:.!&U-E)&X]]AL/<GH*_7BFY21
MN&#JT$1<I"H!8E^,R+3);>L]:[KV<?YPE]WM],2QY&HJ?DRA29/'%BJ%DC-&
M_;I>MK@@RZNI2F0,C4)ICK\<G@J:,^5*243UB#22*(!@NFM0[NYM!%+G?K``
M(I?DSF!UELTSI4$(X`HS==(8/B)!H'IV?$TD9=PU&Q-9+L2%193\>'$X@!UZ
M)?2'7ZLV0'$X^DX[:@XK[2>P1P'.&\C:,QSY<O6/[T;#GL#`WN(+%+6!DQCI
MOZ;PQ;>IG@4?ILG^_\X6O.5=(8"\+DO=41/,1628AI1"-)AIKG'\1$'N;W\;
M&`GFNC%,0\K-_2C-32TXRX`$*K&(?3W,%6,8!Y5<`F)T-[6\;#H63\;9<?<Q
M!\^QC2FW!,2H]@6@85DP#%#`7V(HF`M0LXTIN0!$J6YJ<>%D*(+'5`P&<\UI
MUE'E%0(*Y4VM)OR79K^_&T?4[](%8*D_&2;0WMRP5HP"\Z4Y=;@J&9^-UJ96
M$%Z>`(I3UM_FAF4]J*9Y.1@FJIV%_)#M@;@^@?2)JQ0*1CB:6CS8W0@3RSI_
MG$+UB[9&*-_D48,J$ZYQ!];@$XZO'O%.R1(OE&>2*L6"!RYUKCK,(_^BDYI_
MX6'9<KC4P@D5''(QO'%]Y@.K:%9&L[+S8LED,WUE&CM@6>0J+'?#`;%M%:>"
M>!E74UI(=4PM%,&MJ;[D&"80$7BHVA=4A=.&>$S_?=9<-,@>)4%21%V'1/+#
MA%53_=`Q-!":[F=N+9^KS'5]?P]T<-!L>'(/VVF9<1PEB7E=$DE6+BR;&B>=
M'QU4-]Q4H8GGE?"$<"DE*K'\"ZVC+":BW=0'F1A<U^8KM"&(&>R"!.YZ<HF$
MB(Y*4U]I8A`D."N&@R'IJ5Z0D)3OR\DA,&QH-=7!SX)AKU/?&^M/]7CV"QK]
M1F<&/"N<OJ!BR&)806G"'U!(E?X4?.1_T!@[8J^#-^1XXROXX_K*_0)@KX(X
M,D@SEB;8XU2YCM!?GV<:Y+'D[F/MIOI84:T@Y%AMX6I!')RKX>)#W+RJ#X:.
M3FJ@[RY.B'*GWQ:7=D.=-O\^K5FE`N:]FLZ8S*'CU>=T,,MB\%0$R2A7'N=B
M\B%R\#,-#VERDXALE3(15`"[DK.HZI)/5(\R0F++]23QO"8J]%;JI@&E;A+U
MOMBW[MSG("WDR;-845"/P.RIT$S"SH$$7H2"FH@$-_4)>C:_4X;]?H>Q%N`.
M5;0P+PY;W;]$.>I^#(<6I$;2*G!$:));9[QLX&('X[16:WD8\+*IB`$1FN2V
M<A=(6@8*:S7,+`Q85+4#(C15^#9]J^)RJ^)RJ^)RJ^)2^RHNQ5W.XWA9]<W+
M:C6?/D\7V\GZ5^MIMI@L'F:3>6NSG6SQQZW9XFFY?IYL9\M%ZX_)#I\L5FL-
M=D#[1#?<_VPM[7=@YNPN?3Z=CK@WN&I>GC1=U7>:D]N//YSI!\/\<!CJSAQ,
MC*<MZL3VAET8-K#FAHJ[RKL+T=^"R5!+&^_G+9P$*]WN.,UJ+="2M<#"\M^V
MKL?R6K!WNFFV29&.F/$9N>QVKIP-2NLEXR.W]KZ"!+4@0:@$)`67TY[`*#G6
M1>07XI4)3JKF1ZN=383;G=+K]$@55?E019R3OQQG89HGL^EP--6UD!6Z43WE
M'1^$P8CHE=WG<E<9=H211I^X$LD?126?$9C:A.A_`O/5R!.$B'K#!55@%9*K
MAYC\%_\^'T.<R<J(1I%0B)#[R)WI%C2_<6UD*[1XTK6)4LDL^OT*.)!"1.4W
MH^2V1^@RL3S,+%,%Q]#J2:8[N;%8?(`*>)!&AN0>-K\D]2,X&986WLC,75HH
M@U3`#!9RI*DT2=X59WUO7D++9BY&'_YF%?N`MO`*$PDR]3MDO9=Z_6+'XGR?
M.1?%A>O<`/$$@]-]7VYS(JM)+-XU5?1&4ZV<L$$H=R16R(=Z##M,O:"E87?$
M7MPY93`^+,V\X'@7U=S"4+FQ6MB-K[3C;OSU=#[93A];J\EZ^ZNU74\6F\D#
M<MEO<KGEW8(I*]6T+UL3@@O9@HS_HMYVRKBA/=?M"0SS3)F]B-N<.++3?L5:
M'D*?W2E]H:&L["OA9+QEY6A@0^?#3.X#.DR59\IV>R*?3Z+SY9?B9U57W[!>
MAKKT`6[W\Q'%K3T!8&V-AW=5@XI:7Q[N#=7<!P9XA]F7D7U\[B)*8TGP^EL(
M`KEE,YRWOS6V[V!AZ/\%OL#NC%M?:R;807A#'IX.LX\DT]"E<S4_X95;"WF.
M'<NWI'K=OKAK0-KL^1518.;1YD"7N-!O7"-O)$[/YEJ2R!,V@<EQ:SDGC'*K
M,S:BG.BX;E]<H!+[.H3*`PO9)-LKKCRE83N[;Z"0GDBQ2%.0O:&5;OE7?HP6
MCYU3XB4Q-[,?B]G3[&&RV+8F#P_+E\5VMOC16BWGLX?9%-Z\7RQP.!];<VAD
M6"WCT/(*QK54?=_RJ\7EC)S3WG3MH.U0Z3G'%P+MU)5QU'8:L)R)\;S+@S=K
MN$(=I["YT)3^<=0=B<L6HT_+P]B@UO/SG4CBLAI95\$SL(*%>W%;@ATE:30C
M)4J,1D?H%:I-[*+#*V0L=0'YI?KI;.J:C7)7D5OT"_WDW6\ZG:&X)#KZO%PD
M-Q?3/!EFPZ1"9[_08+@LT`E1<4+E'5WQSQ`1?U"7L4I[1&KBS8<BRJ2E2SK1
MX9&"1N4F62([H5@;)H+M$B5AV%;80W>HPU3/(C8*:WJ$ABX!BB+NL$F?OT@0
M.65LS[8^@#NE-QB0.BP)IBY8@5@Q3N!B$%N>#:6F1II3<;B_^#$F$$1Q[WX,
M"Q`K+$F$IDH+66'*K?RDK$U$7^DMO5D>T;FE-\O*F%MZ<^6,87=C9_77I1Y#
MY#-,&I$5CTQ2';KJ):/H':1<PRO;':1"J2<"57DZ2?$7FTX\3'(^>Y@N-M/6
M9/'H5#[XU9K\6$^=0@=Y7F'FV@XEU4(X<5#K9?)F`L#C@>7!.!X=#P%J=FJ:
M:&/BIAIPJH6A[RB_#K_FN3I^/.X)NZ)R6V6A>SKFR;V&`GM,]03.MK:S4,4B
M\X2G-G07B<%HT&?NB,T^+I?]+8[?H?V?!ZC&WM@/VC_`I%#?([WZD,6$-DQ=
MI(()AJ:VEN*.KZ!GALJU;&@)AN[V9O$E9=@>]4B/+)1(4?I(<NX9PNL*(QAR
M6\X<@,)7A;'`-T-.:Y1%L(AX$<2*F^!*<W>EA-X`784K>M&M$]AI!PWL/2]P
MOR^N*R]UVB)!1,Z0V]]&R(8B&=[DK+OHUSG=&9GA#<)\DNAHJBWH4;W408AJ
MD@`F<L__>M7<(]-1FS(W.;E'!TI0Q!YW+?)R,O2GQ\GD=#*-3S6H\J&T22<L
M41:)0Y0DC_$JS*GT5.YF2N7'`JCF%I@?#_"7VDX]AAJ$/VM'8-F&#H+,(86]
MME+&P:OD85X,)"^!XE49]5!Q'-]C@:DBQ"GY<):-F.A)D2@(DAN/20'P@4\;
MG8"DIA?DDYQIS$+.RAT`>^L)\BTP]PW3NE-ZW:&XFIO4>?G(7EY.A%R3#+`T
MU7[Q5:C;-QM[WIBO#M%OR\'11)J^FS<1BO=!LS?O<&DK8.X0\&\`(=(EA4:F
M><W2AY9#!/*CT=1>\5DA'4EP8L%!S3.$0U-?M:-FPT'="JJN4\HMI]KO.R_'
MHBKH,JRA$JF/E9S-CE>%=>L$5Y]=PVN"?@9KL#,@JO^`_?(3%>RW(,8X<Q1`
M2O=WP^Y083;0F(:40_]EIU[^MM[Y]%X,B1#MS`^ME$$DY36!POHTN\[&W9"J
M<Y4?,N.=P!@(HQ\1<S?L#152M@0Y<X=Q5#GXGPL#5R`&31.(:\-/WWLQ4H$)
M&,1D(4P'I.!Y!BLX>60N;]V469Q(NV%;Z3+7+F8<5,!#968&D`UX-ARD<1D5
MQXC&Y*N"W$D>MV^$!?^G<;E#)[(>&$R55_G=Y$H0_NP`5/[4PZ-_6KP&3,[^
M:2OU@B#&E6"PR:`>K9([J;E+@/SW%L"UHUI\>$^H^L1P?.*F2!FLD%^#,C!6
M1&B1S"%MR6-QV;'908V6NV8@5)H#*R/'`GV#2C<R/\`R#"@M[\@DRWUHTJEQ
MGQX1$,QW@;31!+..HB72.4>@5>Y]1XYV=;V:*\.\BGWM*\SV#ONX@EE)E;[D
M>-]4!.1F*ZDJ'+8A-!"NA$OL2DY+F$D;L&I&9J6YKOJ4<#JP^-QX'8C$U4X_
M3D?C`H!;-C+^0'(W&A'=@WS>D%*G%RR;22SQQ#,31$V-Q77]IS_575C+WO7[
M7:$M:0ES2B`1Z6`T-2B&^HX*B>^+JRA%G58>84B&I*FQ-2[Q:^.B'J])'XH[
M-"B3RB,+27`T-8HF$W`L(31"S9[(X-C#YC.KUQ/7FSEAXO+EEQ0FPP)+<V-C
MOE'3MBS^K\IO7,4?"8;M7NR1X,_)>MIZF*QFV\F\]<<2DV"U?IBJ#NW\EFVT
M/-/?RNG\1]&4#^I)@Y^[H[N#;PU_Z**._:`/=]!-)_1D])=FO\_TO?:I[2%O
MIU^[XWFOZ6]X:?>JA3H%7+PWP94!I0;8FHF_>0]T<-!LZ_ZR12`N#\$PV,VF
M=(E>"#YZLBJJ\A\IL>'0&O&=$?']73M!GNM0'+W.'GV1=2<S+H:+*I)'$#T5
M5X`E<GL)`S6V/(3A=ET4#Q`^"P/[>@6L=R@H_;ZXZMO%UI9__P6EN`*1HH@B
ME*28V$U^J^;>[ZTBKCT7MV7RV;.<!2G>EX(C,^3>DZF$TN@,#//>J"^P55KA
M]?$Q6,5M4U_XN'*B<MM7(F1E..*_C190VC56`WS!<2]/R[-MV:J.9&IQ=CIG
M#+H#&<&B+9B/"A4A8X65)QN/:O,^=L*I(AM;->T,[B-^G!%38JG*S6\;N[]G
MEG4&^\>SB>)2'831?!;^I2M!TR]@[C2X`"@Y@ZZX*JG9%R3;[HU7&BJ&L?]*
M-1KVI=Z<63-\"^HT%RUD&P4ZK2ON@8O[>N477*$<:NJ;&\>S^B^@O;W#&__D
M$YCJ&_#TP\K4=@!AZ=SSI;>RDLB0;1,(M;W8^5F;QSPQ%AGU*APY*:V9[ARF
M:<BVQ87!E$N,;/LE^Z$ACK=^38"&=2/E>`ZG8=FIA?W4[`TB@)M-K:?`"<M`
MUVP-'+)APVN:I>U^JL<S!E)@/&T9)'R7/<'.1W=#C&\;XAI('`GCH_C#-"P+
MXB:R";J`%3=>W-.XU-3`YJ*X/1GF`>"N]NBQ:_IUTIST-!]*I"-ZI+9'<LAZ
MZOH;+_G9..CO`^0YO>T#HK]#D4K0)7_/E`NLVKQG*@)]:B0>^?M^W(4[7^)]
M[WC/IOI>9O>R[$)?)V^`T*W`SD_?'R"[ITS$!DES0%Y;URF@=L:D>JR2>);9
M*9%MG_!W*^?D:E/KS`HWQ-.4D2*O2Z$0;?7?2:5QWM];G69=S\(M.BCQ/3V1
MB?FI\TLOH]D0],(7Y8]?S"A(+M5PFZV!9</]`W<5AB.>L!A4Y&%O+YMY>"YR
M4S@ESQ.28NA4'K'.(WNVGY(]&P#3PL@(2J--Q;]PG4R<!@&_A?,.NCUQ_:.O
M9A+HA**:J\$"]/WJJ.H+]0-X[<9&0W&$BU@QG^()B;PO?C]@`[QR=7%+-[^E
MF]_2S6_IYK=T\UNZ^2W=O/H]*4'B+\TRNF$D97)T]<GJMQ()WZ]$@J3MXH6D
M[-10[/B"@RIUVY>9#A75&4LB+A:X?5=UUUFV,/1/8,%3W0^;Z(P4"4',2HAL
M'FV.:63%>'I+[<_Z!B&%_$NM1*Z?TG$*EH3Y$1G)D$V#\'NW+<+/II9,Y\@H
M(16)FZDXW-`!L`_)6J<OKJYSB93(ICYB5:2KXFIM<E&REZ6^1>'+=861"\3:
M7V'XA2H7XVEM"L64&<V?"FDH31S7FV?N)E_*DF03]A*M;1IC:E/R):.I'0D.
M<D.Q>CUBSU@^.ILX93DBQR6NQQ/"5.BD>>DA<CX:?C<8#7H*@>E$-21UZ&$2
M996_]O#HW=TMV+M[#3Z!?LX=6\C<G]N;IVB`H70M9K*L<NN?)<RAOTDC\5&4
MN5O@,!,IM_*CD.$*K-,2&1+#W,,Y?3R1?*.)6`K3:-36F76!\3CLCMO,YQGC
MH/(RD4QWY:==`4YZ/9`A(,R=N%E&%,G#9/W!QDD"W7)O2"^(QUT_R@J::SMH
M?2-C&M-ZF;R9P(_H6?VCP2]X21^03.;&W$5F*H'M5(F-ACL51DIN@7C6CO!J
M9.C`"\_R$WQZQ+!-(J\I@\C`1A;ZFJ1YF?Q2O#0O>;TJ1-P=ZX=A[*T%L+W[
M=E]D22CJO!7(8=P+QH1*;9YX,GNNG,LE"G$>DFY_O+Q5SC0E,#S)=@V<3@2J
M*S\.Z$X-]S?H#Q2@#C_Y?U!+`P04````"``3A%Q"6?O82CP3``!\Z@``$``<
M`'!L>"TR,#$R,3(S,2YX<V155`D``_7,+U'US"]1=7@+``$$)0X```0Y`0``
M[5UM<^(ZEOZ^5?,?O/FR/55#$Y+;MV^G;M]90J";*H(9(#W3^Z5+V#)HQTB^
MDIW`_?5[)-M@_`(V<2;*CJOZ!>PC<Q[I\3E'TI'TZU\W:]=XQ%P01C]?=-Y?
M7AB86LPF=/GYXF'6ZLYZP^&%(7Q$;>0RBC]?4';QU]_^]!^__F>KU>,8^=@V
M%EOC&Z$^6F)C0%PH*UJM2,3CS`XLD&'4N+KL7+<NKUI7OQC_;70Z-U<?C.Y]
M*+D1]HVP5GB-#!_Q)?;':(V%ARSXP97O>S?M]M/3TWMXFH]<LGEOL74;'G?5
MN;KN@,HN7F/J#QA?WV$'!:[_^>+W``0=@NT+`S!2<>.YFS+/"H4W"^[:_DY>
M?GW/^!+D+C^TPYM)47+PY*3T=9M067L6CN4IHS18YQ>P?=[VMQYN@U`+I#`G
MUJ[<Z4*'!:!.#PH\7<=*==K_N!_-5'5?0.T;AJI_1"G4B`],4-?BJYY'J,.B
M2W`1VO>?-_*?!1)XBAUCHZYPYN(CM2!OMRWD6H&K?F*T?\!%](05Q\[G"VBF
M5MP:/Z#`>P`32TB4GR\$67LNCJ\A;F5^.D+:^?3I4UM)M:&Q/<Q]@D4[5GU7
M3?+"\>*Q:$;R$./^R>U:JLO&#J&D?&V!_+]Q;;EH@=UR%06B_\85Y7$LP%I6
M>`VAQ/^+^I(:SD%Y0WYXF`Z+_8&JJ!Y;KXDO/8NX,(@=5HI558N=#K$6^]?Z
MM\[EST;+N"/"<ID(.(8O/?/^?CB_[X_GLU_;:?GTHP*!;9/^ICZGC&M4.)(X
M5O#0S)0OE^91^9*[5[5\$2`EYA":X.)BT=6XD9_;]E0PE]@ROKE%KG3@LQ7&
M!TQ8B#JY<'EY!<T_@_I4P8RBPGAFCH9WW7G_SKCMCKKC7M^8?>WW&VIH28T)
M`C7\%?8)5/@!3[QZB7)=GBC&NP.M_MP0YS6)L_,G=]A'Q$T:$[M.BOQT^?-E
MYXAG,=Y%"C1\T,20[%YG83H])%8#ESTEZ2&8Y=1K1'XY9D1F<_@OI(HY,'K=
MV5=C,#+_WO@=W>@";%DANL1B2&<KL/0KYMJ8B_[O`?&W/>01>,@=U*9%0-/M
M(:&(P/6:G4L5SIXFE>+4U^[X2W]F#,?@J;K3_E=S=->?SO[+Z/_M83C_;KSK
M=2?#>7=DW/4'P]ZP/^Y];XS5VV9?47P44['F*.GCBW*Q":PTYR8X4M/#7"$^
M]*2L7I[]5-Z1FI/^M#L?@D!#E]>CRQVS`ME676KWJ0^6:D@=QM<*[)XH-L*D
M7J*HB#SZ[>1'1&TC5,1(:-(PY/48,J2/@(UQ@A.6HU8V=)39..B?#<??P$Z8
MTV&_L0YZM'VFETYJ[J7_E.VE)UC0]-(UX\,<+=P#B^#728?KHR;!>!?^>L.%
M5^3"B%B8"@R!PRSP/'?;77*LPKX])UPD4+V.XBK-BM&PUQ_/^D9W#/'EPV0R
M^FYTOTS[*LQLV*$A.S)^1)*D9E=RE74EQWC2^!8]&(,6Q(7`?\!X?^VY;(OQ
ME"Q7OGCP&)UBG_"T>0$%`UZO@?F0)4[W=CB2(Q\#<VKT[R<C\WN_;TR'7[Y"
M/_9A8HZ-:7\^G#86YXWP)VN`%(UJ-D$?\DQ0!28U-DD'3DW"')VM'!WY/2#>
MH?WQ$*[7^%RG*3.9RE$R8(QT6W(`=M)8&?T8D;$H0(R:S<EUUISD<Z.Q&[JR
M)-UA!I+4W&4N:3Z:WK,&#)EB5\[03!"P9,X1%<A*3<YPKU9Z=#J7:7I,^R,U
M+S/I2H[,I]WQK-MK9F0T94;&RP!!ZO4RG<NLERGF2.-I=&9+VML`6>KU-E7,
M2>-Q-&#*C"PI<8B%J-^U+!90G]#EA+DR(25!%(%J33WI9$W*;/AE/!P,>UT(
M1;J]GODPG@_'7XR).9+Y)(WOT94C&0<$5+$[]?9SJM.E<4/:$T?]OSW@C5<K
M;W+&^T^R)E2J(8VNI$D',$":FKO+U3G31#%Z<^9!8"<``(]8F$ZID3I@5>"R
M^L?K<F:J3[(KU-Y0ZAO,,6(`84Y<#.'/C</3@H<RQ3O*ZD[0J>85L1\S))(I
MV4:4@MVTOQ[M/T"$?T-N@+M"!&M/];]EPK7Z\`4ZY=!!SUH>RWE$C"UK-CP?
MLZ/`!YPQWDEM#:6ND=!7&IQ(8R-2N;$TVC%MC+A,XG_$.72BM3,I&R`=,FFG
M3<,4[9AR:'WF3"X+"5P?R?6VA&/+9UQ`9&3Z*\QGF#\2"T.\\4CDDJ4<<K&E
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M8]4\^7/*FC53/:_/AV`A\.\!X.L_'NX[*>K-N^]D![H>;F?]OSW(9-G^MV;[
M2;UXD'4[-7N;3EX62IH1C<_0@QN>%VYX#KY_0"BB%H%8)MZ!)G<S$^&(FK>O
M^)1ERV0R4NNXNM/OQF`X[HY[0W`K^YV6AN.!.;U7^]\T_'D+_(FR#<0$;65H
M`/$Q7.$!<H4:<\X:)6`9\A!B-4?"GW(BX2IL,][%2(P(B@J48S!_"8?0FY#X
MC=)SBBU,'F6S'J$EKY^4.0[S/%+N`314?)M4G&((TX*\X0'@7MWKK#_EY#M4
M8UZL;L.S-\:SS!@!T*OF48+G!7;-*((&?)JC#18F'5*X@O=D\5G-?8#,;,R\
M^X_^S``6#,<]\[[?<$`3#MS)'^?8#K^I6QE/!>RP2<VK*R]_R4;N*8Y(#Q0J
M9X3:&4J]QC/IQZ+B3#S@3MVI>+]DP^L,<YID/(W98GH8PI7-=XQRLNN`,,S?
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MW^`G%2GI^1)*^,<4B$XS5QI\OBB>@^UNR#Y,_G%*CA+7E3<^7_@\@'`%+83/
MD>7'W]4QYC<>N"%FS]4!OW;`HRP"$8`P\0/Y[0MG@??Y(O3@-S8!5>7A\4,?
MKR^,\&3@\%$R"9$NY77YN+,0WK$U(K0,QECR!5"2&Y+`%I[>?F.KWWL6.(BC
ML7Q`J39,"+\XQ-J:3_6BRJ"+!%^&HBN0Y%:PP,^A:+R3^SVTNH_E!`T>X"2V
M(H$TIO"'%^&QL0``+U3OMIXV6S,P+8AORR`"&B,7>MP<0R]DS@J!G9#+QY=$
M$G:X_++O%[Q<LKWDM-=I%/*D3.BHB_X&BA"!34=E/$?+V/8H3LGIVDH])O5B
MX8_L3C/KJ>C&GX";@F_W>+W`/(&U0AGMS&6^\N4@O@50C]+LQ>=$<"[/3E1[
MM.Q&HW)!EBBEFU>HHOT<;_Q;%]['\\`GBI^V1N<UM1__1"W(4WZQ=`%]_>,A
MA+WB$\X<XJM%#I/0J*-E(?*3Q5[9U^Q.[^ZN91R3A)&^<\*?@#.U7\NA[(X@
M!Z;UF-I*"GK*!*>Z$R<%]>U/'%$]W:$H(:JA-RG4.:=+44Y:/^]1J'7&>)Z2
MU-EJ[A<HS]E\A<>,MO`&6X&:9(\W^<A&/Y6*:4A@>,/M*&@;,![YNR3``@%=
MP_0X@Z7'A)]NK;Q[VC5)K&24%SK@;%UXF-G?B;^:_$&@0!'4\YZB8:5X\"J1
M,-5\+3M.?X2?J=T5`OO#M8<(/S@>YT>5,MJR^<CQR-VH41*(2TGKYF#ZC@-6
M4D:=]O\&PD]DQDV1C\&F<HP</TGN\B5>-TP]KJ?,>AG`S;*X]O+:HV)!Z=;:
MR^N.RJ25FDJ)ZXYION*X$JJH@/:XGE@E5%+\E3%%NT&D'7GZNG:N.59P!I$&
ME^[27+ADJ7YQ@K:'+KF,K*ZN>+==1U$+Z1OE[S9O?J`0RLN0'A2Q\D9S3TOJ
M!V[C84OM<.O(Z1#[%E/XY,ON)R<+]5MW@0Q%)DJG!-:J!;5E9@1D]U;%1Y'*
MLP_"UTI`UVT0^($:Q,NMA4J%=:T)&1Y-&+3F_V#.TMS.O:D=G:&N'4QD94OG
ME-`^=?UUO=4@"#<$VX\39\SB$1']*CW@5-6M&K=:>P%T'G:F,`NLA+!V$-7&
M4T)MJT76BX"+L$G"Y<[8-OE^X?,>:J5"V@ZT*Q11F#=?L4`@:L]QQO>=$-.S
M1;/ZSK#%J%T2W*'PVX#XA-W'3)A\6O(-@:O0A#GRV@'==;?V\\0YLR/'I70;
MM,K1-C4;4BRA[RQ(G%LTI(DH$"*/^"B8B8O"T<7,8>0_SBBJK<,8TMU#,V%-
MWCWMWKA1.)//^+8PBCDBHA^</:-4FB*V]_,9,L2,)S(2Z$J7.)N$U<+KRAR\
M1Q2%87,XERI/'`#-!QB+.>NMY,P%HJ9SRQ#/>(ISRFK7Z/=H0];!NKN$MI*)
MXG%GU'2F;(M<V;1SIGQB'(XF*Z!ZV=?M4-T3%PL?Z)$9,\O>T;7WG=8T8SL+
M!?0C'Z/^RMU.X<I(>K5HR_($E"(!71MGC&2756ZO'$WF1\=BYB3\E1#5(;EO
M#-&A&L^9D0W\29.MX+9V5!L'4C'3D=N,$IL@GCP.^4?^W=JK/[I"?;S$O(32
M9F^6KN_$)>WJV'0<</WJQ*$>!*-0J'`TOX2HSO!V*4=#.N'D44Z'[T]E/X*U
M5#G]@%,,KW;XELM$EPS`@OOZ`5&K'^(E$1D8N7<U!2'*;-V?C[!2T;<#OS18
MW:&==9I;`?IG/4N_"I+:?@%9,6)")!UX]HZVPQX3A_P!WI]:C'LL?[7/$1'M
MV@18LU"+&^->8+K[D0%7MH".4"V,;2$'.89"!"JUPI'YV(PJRS+&ONE$?11Q
M@+A2.5T[-X###BSH3R(:.-`0T'VQY2%`8#1,9R@XPFY.8Y<MHF-S9XX65SF]
M),?>EA+6$:+:F.J6R*QZCCP,S[?$<>-4H8QV@"$4P(A;J\2BLWB0,M.D962U
M!7@'@;C+O%V>\A+ZZ5C.3T1F9HS]+-)2A72U3OLH+UR3EM.<N?=U;,)(T3OL
M,4&.($D):`A%K8N88HLM*<0TMODH=ZL79$GEIB3I+*F2XMJ&=AG]3P(\#NG9
MNL>%RN@>#]F;=(9<\,ZQZTYH7RQ2_TAEI7']&<@A^"V39GKU.;>T>TUB'>=/
MF72ZG%L:JK_"=N"&8]F['5#5-'S.N'<Y:1V&OI.:%HPE[#K8)<!6?(1>-?`@
ML!.X(^+@TU"+9;7`)&VP&JR4J:KR;^:=*Y30[]7+/:TXD0UZN]V+1/WK[A/B
MJI,B5Z[)S/-PTE:.H,Q7B$9$C<9!#[-M_D4_5_<D<92?(S43+UFIZDV^@U!E
M@`C_AMR@CJK+>^BY,?@+9U,\#R-6B]GEZQ0@=X[YNJ[*RWGPZ\=;9T.*YRKE
MRX1<-UXZ\`V\2L[RBQ?^F9>J1VR1-7+/KL:4BU6`A!IEVR?XBU.55/(AVO9&
MGH%*%:VG@N)'O1!3RAMUZ$02AU@R/S+<ED_26&9<Y&\C4E9>MY39HWJGDF?+
MR.J;1AO/.??)<N5#]RYO-=(Q&?V"N4A9F5-3!"1Y3S\`\ORNHJF`W)L:0MCO
MDGC85U.&)@NJE+A^,`-J\VT&S<%5#97>'1KG'MVAXZ2@=D8[7^%HN/!PG[(R
MLOIN579<^_1N9>6DWPI1([7S@HVR!=X(<=-QQE$IC2.,A-ZFXZBI,+FQDS3Z
M\42^W.6JH"5/%-&WXY`\G/,VU&>VPM@7Z<;+&P8\I[`6XX))Q<-E987GD9["
M7;ZX#LCG:',;<!O3.R)VFS*,T%,Z/#@EIYT=CO:>Z<)[M_9"@^HBE0X7;]RF
M%@XZT3E/TMQR@=P#Q.<]X*5ZNV4M5S2MLM^D*Z<M\P5T;,34<MR\_M%Q*?U`
MR0V>=MMD@-9YG=>C0OI!>F+Q0I"\296"V]K"4)4O-<UMF6-"VD%Z\!@=W'6[
MGL?9(\ITS`MN:PEC+-]QS-<]EU!B(3>1L;1+(\UTTBL7U`[Z-[PBEHO5&CB(
M)A-'4A2GKU4IHQU@N5GJBKER:YO(!YMR7UQ,ENDSOG^4$'W=1:??B0P?]N>E
MI-JIX+9V32)-W&X(4DV1YZ2K'!72%Y))<8$//B*B+QSEEF0+Y$5*QZ7T!24_
MR+\Y.5['9%X34'CL:WA2&GS]/U!+`0(>`Q0````(`!.$7$(H1J/`#MH``'81
M"P`0`!@```````$```"D@0````!P;'@M,C`Q,C$R,S$N>&UL550%``/US"]1
M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`$X1<0B&NY5DO#@``X:<``!0`
M&````````0```*2!6-H``'!L>"TR,#$R,3(S,5]C86PN>&UL550%``/US"]1
M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`$X1<0FHKT*+D-```\F<#`!0`
M&````````0```*2!U>@``'!L>"TR,#$R,3(S,5]D968N>&UL550%``/US"]1
M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`$X1<0M'N(L%0GP``VHX)`!0`
M&````````0```*2!!QX!`'!L>"TR,#$R,3(S,5]L86(N>&UL550%``/US"]1
M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`$X1<0F$RX'#C3```.-,$`!0`
M&````````0```*2!I;T!`'!L>"TR,#$R,3(S,5]P<F4N>&UL550%``/US"]1
M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`$X1<0EG[V$H\$P``?.H``!``
M&````````0```*2!U@H"`'!L>"TR,#$R,3(S,2YX<V155`4``_7,+U%U>`L`
A`00E#@``!#D!``!02P4&``````8`!@`4`@``7!X"````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ERBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Common stock issued for cash, issuance costs</a></td>
        <td class="nump">$ 1,780<span></span></td>
        <td class="nump">$ 1,410<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock awards forfeited, share</a></td>
        <td class="nump">3,208<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Direct costs (e.g., legal and accounting fees) associated with issuing stock that is deducted from additional paid in capital. Also includes any direct costs associated with stock issues under a shelf registration.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Technical Practice Aid (TPA)<br><br> -Number 4110<br><br> -Paragraph 1, 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(2)(e)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfStockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EW6AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SHARE CAPITAL (Summary of Option and Restricted Stock Granted to Employees) (Details) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="5">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2010

</div>
          <div>Employees [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Employees [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>2010 [Member]

</div>
          <div>Employees [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>2010 [Member]

</div>
          <div>Employees [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>2012 [Member]

</div>
          <div>Employees [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>2012 [Member]

</div>
          <div>Employees [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,944,000<span></span></td>
        <td class="nump">1,016,000<span></span></td>
        <td class="nump">428,000<span></span></td>
        <td class="nump">400,000<span></span></td>
        <td class="nump">1,100,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Minimum exercise price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6.32<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6.32<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Maximum exercise price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6.9<span></span></td>
        <td class="nump">$ 9.66<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">4 years<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value of common stock at grant date</a></td>
        <td class="nump">$ 8,600<span></span></td>
        <td class="nump">$ 7,800<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5,673<span></span></td>
        <td class="nump">$ 2,147<span></span></td>
        <td class="nump">$ 2,288<span></span></td>
        <td class="nump">$ 6,292<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm', window );">Expiration period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award grant date fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award granted contractual term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap">December 31,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> (<em>U.S. dollars in thousands)</em></td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 70%">Raw materials</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">279</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">2,118</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Work in progress</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">192</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">Finished goods</td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 1pt"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 1pt"> &nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 1pt"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,729</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">Total inventory</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 279</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4,039</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 2<br><br> -Paragraph 6<br><br> -Subparagraph a,b,c<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfInventoryCurrentTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E2NAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SHARE CAPITAL (Fair Value Assumptions of Options Granted) (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE CAPITAL [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">75.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3.23%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">8 years 9 months 18 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ForfeitureRate', window );">Forfeiture rate</a></td>
        <td class="nump">6.10%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share-based compensation expense</a></td>
        <td class="nump">$ 7,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, recognition period</a></td>
        <td class="text">1 year 1 month 6 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value of common stock at grant date</a></td>
        <td class="nump">$ 8,600<span></span></td>
        <td class="nump">$ 7,800<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ForfeitureRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Forfeiture rate.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ForfeitureRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award grant date fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the aggregate unrecognized cost of equity-based awards made to employees under equity-based compensation awards that have yet to vest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph h<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph e(2)(c)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6793087&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph e(2)(b)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph e(2)(d)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>TAXES ON INCOME (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6">December 31,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt; FONT-STYLE: italic">(U.S. dollars in thousands)</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td>In respect of:</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt; WIDTH: 74%"> Research and development expenses</td> <td style="WIDTH: 1%; COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; COLOR: black">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%; COLOR: black">4,119</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; COLOR: black">&nbsp;</td> <td style="WIDTH: 1%; COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 10%; COLOR: black">6,003</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; COLOR: black">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt">Property and equipment</td> <td style="COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: right; COLOR: black">(149</td> <td style="TEXT-ALIGN: left; COLOR: black">)</td> <td style="COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: right; COLOR: black">(647</td> <td style="TEXT-ALIGN: left; COLOR: black">)</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt">Provision for vacation</td> <td style="COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: right; COLOR: black">305</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> <td style="COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: right; COLOR: black">363</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt">Severance pay obligation</td> <td style="COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: right; COLOR: black">164</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> <td style="COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: right; COLOR: black">192</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt">Deferred revenues</td> <td style="COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: right; COLOR: black">4,746</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> <td style="COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: right; COLOR: black">10,449</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt">Net operating loss carry forwards</td> <td style="COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: right; COLOR: black">4,579</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> <td style="COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: right; COLOR: black">15,176</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">Valuation allowance</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (13,764</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">)</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (31,536</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">)</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ScheduleOfOpenTaxYearsTableTextBlock', window );">Schedule of Open Tax Years</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; WIDTH: 50%; FONT-WEIGHT: bold; TEXT-DECORATION: none"> Jurisdiction:</td> <td style="PADDING-BOTTOM: 1pt; WIDTH: 1%; FONT-WEIGHT: bold"> &nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%; FONT-WEIGHT: bold"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: right; WIDTH: 47%"> <strong>Years:</strong></td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%; FONT-WEIGHT: bold"> &nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Israel</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">2009-2012</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">United States (*)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">2009-2012</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Netherlands</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">2009-2012</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> (*) Includes federal, state and local (or similar provincial jurisdictions) tax positions.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ScheduleOfOpenTaxYearsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Schedule Of Open Tax Years Table Text Block</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ScheduleOfOpenTaxYearsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E66AG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (11,618)<span></span></td>
        <td class="num">$ (36,529)<span></span></td>
        <td class="num">$ (28,998)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
        <td class="nump">7,751<span></span></td>
        <td class="nump">886<span></span></td>
        <td class="nump">1,282<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DepreciationAmortizationAndAssetImpairment', window );">Depreciation and write down of fixed assets</a></td>
        <td class="nump">3,692<span></span></td>
        <td class="nump">3,631<span></span></td>
        <td class="nump">3,133<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial expenses (income), net (mainly exchange differences)</a></td>
        <td class="num">(171)<span></span></td>
        <td class="nump">350<span></span></td>
        <td class="num">(591)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
        <td class="nump">276<span></span></td>
        <td class="nump">155<span></span></td>
        <td class="nump">377<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitContributions', window );">Gain on amounts funded in respect of employee rights upon retirement</a></td>
        <td class="num">(36)<span></span></td>
        <td class="num">(14)<span></span></td>
        <td class="num">(26)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on sale of fixed assets</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">8<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Increase (decrease) in deferred revenues (including non-current portion)</a></td>
        <td class="nump">1,281<span></span></td>
        <td class="num">(3,005)<span></span></td>
        <td class="num">(4,563)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease (increase) in accounts receivable and other assets</a></td>
        <td class="nump">243<span></span></td>
        <td class="nump">3,891<span></span></td>
        <td class="num">(6,860)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (increase) in inventories</a></td>
        <td class="num">(3,760)<span></span></td>
        <td class="nump">910<span></span></td>
        <td class="num">(1,189)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable and accruals (including long term)</a></td>
        <td class="nump">2,977<span></span></td>
        <td class="nump">6,147<span></span></td>
        <td class="num">(1,029)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
        <td class="nump">635<span></span></td>
        <td class="num">(23,570)<span></span></td>
        <td class="num">(38,464)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num">(2,068)<span></span></td>
        <td class="num">(5,705)<span></span></td>
        <td class="num">(7,855)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Investment in restricted deposit</a></td>
        <td class="num">(80)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts funded in respect of employee rights upon retirement, net</a></td>
        <td class="num">(138)<span></span></td>
        <td class="num">(165)<span></span></td>
        <td class="num">(137)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
        <td class="num">(2,286)<span></span></td>
        <td class="num">(5,868)<span></span></td>
        <td class="num">(7,992)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses', window );">Issuance of shares, net of issuance cost</a></td>
        <td class="nump">25,328<span></span></td>
        <td class="nump">20,650<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of options</a></td>
        <td class="nump">1,230<span></span></td>
        <td class="nump">277<span></span></td>
        <td class="nump">501<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">26,558<span></span></td>
        <td class="nump">20,927<span></span></td>
        <td class="nump">501<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH</a></td>
        <td class="nump">127<span></span></td>
        <td class="num">(388)<span></span></td>
        <td class="nump">589<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
        <td class="nump">25,034<span></span></td>
        <td class="num">(8,899)<span></span></td>
        <td class="num">(45,366)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR</a></td>
        <td class="nump">27,001<span></span></td>
        <td class="nump">35,900<span></span></td>
        <td class="nump">81,266<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR</a></td>
        <td class="nump">52,035<span></span></td>
        <td class="nump">27,001<span></span></td>
        <td class="nump">35,900<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="nump">1,136<span></span></td>
        <td class="nump">1,473<span></span></td>
        <td class="nump">2,720<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementalOfferingAndStockIssuanceCosts', window );">Issuance cost not yet paid</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">60<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CashlessExerciseOfStockOptions', window );">Exercise of options granted to employees</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 31<span></span></td>
        <td class="nump">$ 9<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CashlessExerciseOfStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cashless exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_CashlessExerciseOfStockOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DepreciationAmortizationAndAssetImpairment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets and intangible assets to periods that benefit from use of the assets. Also includes the charge against earnings resulting from the write down of assets from their carrying value to their fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_DepreciationAmortizationAndAssetImpairment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase in liabilities for property, plant and equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from issuance of common stock net of expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalOfferingAndStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Supplemental offering and stock issuance costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_SupplementalOfferingAndStockIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The effect of exchange rate changes on cash balances held in foreign currencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 25<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate unrealized foreign currency transaction gain (loss) (pretax) included in determining net income for the reporting period. Represents the aggregate of gains (losses) on transactions that are unsettled as of the balance sheet date, which is therefore an adjustment to reconcile income (loss) from continuing operations to net cash provided by or used in continuing operations. Excludes foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting entity's financial statements. For certain entities, primarily banks, that are dealers in foreign exchange, foreign currency transaction gains (losses) may be disclosed as dealer gains (losses).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 52<br><br> -Paragraph 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ForeignCurrencyTransactionGainLossUnrealized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfPropertyPlantEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInInventories</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15, 16, 17<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInRestrictedCash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash outflow or inflow from other investing activities. This element is used when there is not a more specific and appropriate element in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3095-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3098-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForProceedsFromOtherInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitContributions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementBenefitContributions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of pension and other (such as medical, dental and life insurance) postretirement benefit costs recognized during the period for (1) defined benefit plans (periodic benefit costs include the following components: service cost, interest cost, expected return on plan assets, gain (loss) on assets, prior service cost or credit, transition asset or obligation, and gain (loss) due to settlements or curtailments) and for (2) defined contribution plans (to the extent that a plan's defined contributions to an individual's account are to be made for periods in which that individual renders services, the net cost for a period is the contribution called for in that period; if a plan calls for contributions for periods after an individual retires or terminates, the estimated cost is accrued during the employee's service period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 70<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6414718&amp;loc=d3e28014-114942<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph h<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5, 11<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementBenefitExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph i<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E1GAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Authorized</a></td>
        <td class="nump">150,000,000<span></span></td>
        <td class="nump">150,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, issued</a></td>
        <td class="nump">93,489,809<span></span></td>
        <td class="nump">85,630,157<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, outstanding</a></td>
        <td class="nump">93,489,809<span></span></td>
        <td class="nump">85,630,157<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 129<br><br><br><br> -Paragraph 4<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>NOTE 10 - RELATED PARTY TRANSACTIONS</strong></p> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="COLOR: blue; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="10">Year&nbsp;ended&nbsp;December&nbsp;31,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt; FONT-STYLE: italic"> (U.S.&nbsp;dollars&nbsp;in&nbsp;thousands)</td> <td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2010</td> <td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2011</td> <td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2012</td> <td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -0.25in; PADDING-LEFT: 0.5in; WIDTH: 61%"> <strong>a.</strong>&nbsp;&nbsp;&nbsp;&nbsp;Management and consulting fees to the Chairman of the Board</td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"> 6</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> &nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> &nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -0.25in; PADDING-LEFT: 0.5in"> <strong>b.</strong>&nbsp;&nbsp;&nbsp;&nbsp;Compensation to the non-executive directors (except the Chairman of the Board in 2010, and includes the interim Chairman of the Board in 2011 and 2012)</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 215</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 215</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 375</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 57<br><br> -Paragraph 1-4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph b<br><br> -Article 3A<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EFUAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information (USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Feb. 15, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 29, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-K<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Dec. 31,
         2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">FY<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">PLX<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">Protalix BioTherapeutics, Inc.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001006281<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well Known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">93,497,809<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 359<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityPublicFloat</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityVoluntaryFilers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_TradingSymbol</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>NOTE 11 - SUBSEQUENT EVENTS</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 56.7pt; TEXT-INDENT: -20.7pt"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 36pt">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 20.7pt">a.</td> <td style="FONT-WEIGHT: normal">During January and February 2013, the Company issued a total of 8,000 shares of Common Stock in connection with the exercise of options to purchase 8,000 shares of Common Stock by certain employees of the Company. The Company received aggregate cash proceeds equal to approximately $19,000 in connection with the exercise of such options.</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ESSAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUES (see Note 9(c))</a></td>
        <td class="nump">$ 34,870<span></span></td>
        <td class="nump">$ 8,386<span></span></td>
        <td class="nump">$ 6,642<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_OtherGainsLosses', window );">COMPANY'S SHARE IN COLLABORATION AGREEMENT</a></td>
        <td class="num">(446)<span></span></td>
        <td class="num">(5,418)<span></span></td>
        <td class="nump">4,602<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF REVENUES</a></td>
        <td class="num">(8,144)<span></span></td>
        <td class="num">(1,525)<span></span></td>
        <td class="num">(4,383)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
        <td class="nump">26,280<span></span></td>
        <td class="nump">1,443<span></span></td>
        <td class="nump">6,861<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
        <td class="num">(36,665)<span></span></td>
        <td class="num">(37,818)<span></span></td>
        <td class="num">(37,691)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GrantsAndReimbursementsReceivedOrReceivable', window );">Less - grants and reimbursements</a></td>
        <td class="nump">7,976<span></span></td>
        <td class="nump">6,775<span></span></td>
        <td class="nump">7,740<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ResearchDevelopmentAndEngineeringExpenseNet', window );">RESEARCH AND DEVELOPMENT EXPENSES, NET</a></td>
        <td class="num">(28,689)<span></span></td>
        <td class="num">(31,043)<span></span></td>
        <td class="num">(29,951)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
        <td class="num">(9,763)<span></span></td>
        <td class="num">(6,931)<span></span></td>
        <td class="num">(6,876)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
        <td class="num">(12,172)<span></span></td>
        <td class="num">(36,531)<span></span></td>
        <td class="num">(29,966)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">FINANCIAL INCOME - NET</a></td>
        <td class="nump">554<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="nump">968<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS FOR THE YEAR</a></td>
        <td class="num">$ (11,618)<span></span></td>
        <td class="num">$ (36,529)<span></span></td>
        <td class="num">$ (28,998)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED:</a></td>
        <td class="num">$ (0.13)<span></span></td>
        <td class="num">$ (0.43)<span></span></td>
        <td class="num">$ (0.36)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE OF COMMON STOCK, BASIC AND DILUTED:</a></td>
        <td class="nump">90,845,901<span></span></td>
        <td class="nump">84,645,364<span></span></td>
        <td class="nump">80,960,300<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GrantsAndReimbursementsReceivedOrReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Grants and reimbursements received or receivable from governmental institutions and collaboration partners for research and development expenses incurred.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_GrantsAndReimbursementsReceivedOrReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_OtherGainsLosses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The Company's share in collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_OtherGainsLosses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ResearchDevelopmentAndEngineeringExpenseNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research and development expenses, net.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ResearchDevelopmentAndEngineeringExpenseNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 2<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate foreign currency transaction gain (loss) (both realized and unrealized) included in determining net income for the reporting period. Excludes foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements. For certain enterprises, primarily banks, that are dealers in foreign exchange, foreign currency transaction gains (losses) may be disclosed as dealer gains (losses).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 52<br><br> -Paragraph 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1,2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GrossProfit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeStatementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract', window );"><strong>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>NOTE 5 - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</strong></p> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> The Israeli Subsidiary is required to make a severance payment upon dismissal of an employee or upon termination of employment in certain circumstances. The severance pay liability to the employees (based upon length of service and the latest monthly salary - one month&#39;s salary for each year employed) is recorded on the Company&#39;s balance sheets under "Liability for employee rights upon retirement." The liability is recorded as if it were payable at each balance sheet date on an undiscounted basis.</p> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> The liability is funded in part from the purchase of insurance policies or by the establishment of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities are included in the Company&#39;s balance sheets under "Funds in respect of employee rights upon retirement." These policies are the Company&#39;s assets. However, under labor agreements and subject to certain limitations, any policy may be transferred to the ownership of the individual employee for whose benefit the funds were deposited. In the years ended December 31, 2010, 2011 and 2012, the Company deposited approximately $174,000, $181,000 and $177,000, respectively, with insurance companies in connection with its severance payment obligations.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> In accordance with the current employment agreements with certain employees, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee&#39;s rights upon retirement. The Company is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in the Company&#39;s balance sheets, as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies (the "Contribution Plans").</p> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> The amounts of severance pay expenses were approximately $1.1 million, $816,000 and $1.0 million for the years ended December 31, 2010, 2011 and 2012, respectively, of which approximately $531,000 $641,000 and $670,000 in the years ended December 31, 2010, 2011 and 2012, respectively, were in respect of a Contribution Plan. Gain on amounts funded in respect of employee rights upon retirement totaled approximately $26,000, $14,000 and $36,000 for the years ended December 31, 2010, 2011 and 2012, respectively.</p> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> The Company expects to contribute approximately $963,000 in the year ending December 31, 2013 to insurance companies in connection with its severance liabilities for its operations for that year, approximately $773,000 of which will be contributed to one or more Contribution Plans.</p> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> <strong>&nbsp;</strong></p> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> During the five-year period following December 31, 2012, the Company expects to pay future benefits to 4 employees upon the employee&#39;s normal retirement age. The Company anticipates that the benefits payable will be immaterial.</p> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for pension and other postretirement benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 158<br><br> -Paragraph 7, 21, 22<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS106-2<br><br> -Paragraph 20, 21, 22<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Implementation Guide (Q and A)<br><br> -Number FAS88<br><br> -Paragraph 63<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 106<br><br> -Paragraph 518<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 8<br><br> -Subparagraph m<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 87<br><br> -Paragraph 264<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 30<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 03-2<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph h<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph q<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INVENTORIES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>NOTE 4 - INVENTORIES</strong></p> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">a.</td> <td style="FONT-WEIGHT: normal">Inventories at December&nbsp;31, 2011 and 2012 consisted of the following:</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap">December 31,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> (<em>U.S. dollars in thousands)</em></td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 70%">Raw materials</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">279</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">2,118</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Work in progress</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">192</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">Finished goods</td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 1pt"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 1pt"> &nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 1pt"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,729</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">Total inventory</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 279</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4,039</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">b.</td> <td style="FONT-WEIGHT: normal">During the year ended December 31, 2011 and 2012, <font style="COLOR: black">the Company recorded</font> approximately $363,000 and $684,000 respectively, for write-down of inventory under cost of revenues.</td> </tr> </table> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a, b, c<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section A<br><br> -Paragraph 9<br><br> -Chapter 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EHFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SHARE CAPITAL (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE CAPITAL [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock', window );">Schedule of Options and Restricted Stocks Granted</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div> <table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1.25in" cellspacing="0" cellpadding="0"><!--StartFragment--> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Year of<br /> grant</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">No. of options<br /> or restricted<br /> stock granted</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Exercise<br /> price range</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap">Vesting period</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Fair value<br /> at grant<br /> (U.S.<br /> dollars in<br /> thousands)</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Expiration<br /> period</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 10%">2010</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">1,016,000</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: center; WIDTH: 10%">$6.90</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: center; WIDTH: 35%">3 years commencing<br /> upon achievement of a<br /> certain milestone</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">5,673</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">10 years</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: left">2010</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">428,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center">$6.32-$9.66</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center">4 years</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">2,147</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">10 years</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: left">2012</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">400,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center">n/a</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center">3 years</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">2,288</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">n/a</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">2012</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,100,000</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> n/a</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt">4 years</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">$</td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt">6,292</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: right"> n/a</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">2,944,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <!--EndFragment--></table> </div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Estimate Fair Value of Stock Option Award using Black-Scholes Valuation Model</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1.25in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-LEFT: 0px">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2010</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px; WIDTH: 87%"> Dividend yield</td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"> 0</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> %</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px"> Expected volatility</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 75</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">%</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px"> Risk-free interest rate</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 3.23</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">%</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px"> Expected life - in years</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 8.8</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity - Options Granted to Employees</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td>&nbsp;</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="22" nowrap="nowrap">Year ended December 31,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap">2010</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"> &nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"> Weighted</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Weighted</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"> &nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Weighted</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Number</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">average</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Number</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">average</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Number</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">average</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">of</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">exercise</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">of</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">exercise</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">of</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">exercise</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">options</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">price</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">options</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">price</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">options</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">price</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in; WIDTH: 40%"> Outstanding at beginning of year</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 7%">5,366,729</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 7%">2.476</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 7%">6,367,979</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 7%">3.576</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 7%">6,141,030</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 7%">3.563</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Changes during the year:</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-LEFT: 0.25in">Granted</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,444,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">7.076</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 0.25in">Forfeited and Expired</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">13,441</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">3.551</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">44,856</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">6.207</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">25,858</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">4.372</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.25in">Exercised (*)</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 429,309</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1.602</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 182,093</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1.652</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 861,593</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1.346</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">Outstanding at end of year</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 6,367,979</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 3.576</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 6,141,030</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 3.563</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 5,253,579</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 3.923</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">Exercisable at end of year</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4,267,850</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2.183</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4,647,834</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2.581</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4,258,441</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 3.201</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <p style="TEXT-INDENT: -0.2in; MARGIN: 0pt 0px 0pt 84.95pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Activity - Options Granted to Employees</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="5">Year ended December 31, 2012</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center" nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Number of<br /> Restricted Shares</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center">Outstanding at beginning of year</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center">Changes during the year:</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center; WIDTH: 90%">Granted</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 7%">1,500,000</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt; PADDING-LEFT: 15.95pt"> Forfeited</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 3,208</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2.5pt">Outstanding at end of year</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,496,792</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2.5pt">Exercisable at end of year</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 102,084</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock', window );">Schedule of Options Granted to Service Providers</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="22">Year ended December 31,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6">2010</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> &nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Weighted</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> &nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Weighted</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> &nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Weighted</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Number</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> average</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Number</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> average</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Number</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> average</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> of</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> exercise</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> of</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> exercise</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> of</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> exercise</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">options</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">price</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">options</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">price</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">options</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">price</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in; WIDTH: 40%"> Outstanding at beginning of year</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 7%">1,438,692</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 7%">4.697</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 7%">1,438,692</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 7%">4.697</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 7%">1,238,692</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 7%">5.385</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in"> Changes during the year- Exercised (*)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">200,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">0.001</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">326,267</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">0.12</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in"> Outstanding at end of year</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,438,692</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4.697</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,238,692</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 5.385</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 912,425</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 7.259</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in"> Exercisable at end of year</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,421,734</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4.653</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,235,567</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 5.385</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 912,425</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 7.259</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Information about Share Options Outstanding</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="18" nowrap="nowrap">December 31, 2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="10" nowrap="nowrap">Options and restricted stock<br /> outstanding</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap">Options exercisable and<br /> restricted stock vested</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Exercise<br /> prices</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Number of<br /> Options and<br /> restricted stock<br /> outstanding<br /> at end of<br /> year</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Weighted<br /> average<br /> remaining<br /> contractual<br /> life</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Number of<br /> options<br /> exercisable and<br /> restricted stock<br /> vested at end of<br /> year</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Weighted<br /> average<br /> remaining<br /> contractual<br /> life</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 18%">n/a (Restricted Stock)</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 17%">1,496,792</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 17%"> <p style="TEXT-ALIGN: right; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> n/a</p> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 17%">102,084</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 17%"> <p style="TEXT-ALIGN: right; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> n/a</p> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">0.001</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">719,207</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">2.54</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">719,207</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">2.54</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">0.120</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">447,850</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1.05</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">447,850</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1.05</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">0.399</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">23,087</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1.92</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">23,087</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1.92</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">0.972</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">996,353</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">3.44</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">996,353</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">3.44</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">2.350</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">40,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">5.82</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">40,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">5.82</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">2.650</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">402,882</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">6.15</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">396,744</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">6.15</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">3.020</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">50,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">5.10</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">50,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">5.10</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">5.000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,708,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">5.10</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,708,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">5.10</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">6.810</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">160,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">7.10</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">110,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">7.10</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">6.900</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,003,083</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">7.15</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">168,083</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">7.15</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">7.550</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">160,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">7.66</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">90,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">7.66</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">9.660</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">68,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">7.83</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">34,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">7.83</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">$</td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt">16.700</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 387,542</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 3.99</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 387,542</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 3.99</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 7,662,796</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 5,272,950</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense in Statement of Operations</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="10">Year ended December 31,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt; FONT-STYLE: italic">(U.S. dollars in thousands)</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2010</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -12.6pt; PADDING-LEFT: 12.6pt"> Cost of revenues</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">220</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -12.6pt; PADDING-LEFT: 12.6pt; WIDTH: 61%"> Research and development expenses</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">630</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">422</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">4,756</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -12.6pt; PADDING-LEFT: 12.6pt"> General and administrative expenses</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 652</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 464</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 2,775</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,282</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 886</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 7,751</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ScheduleOfOptionsAndRestrictedStocksGrantedTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph g(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6793087&amp;loc=d3e301413-122809<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph f<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of each transaction in which an entity acquires goods or services other than employee services in exchange for equity securities of the company, including the purpose of the transaction, identification and quantity of the securities issued, the accounting made, disclosure of amounts by which report lines were affected, and noncash effects on the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 65<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EBOAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policy)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in">&nbsp;</td> <td>Basis of presentation</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> The Company&#39;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP").</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates in the preparation of financial statements</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td>Use of estimates in the preparation of financial statements</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional currency</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in">&nbsp;</td> <td>Functional currency</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> The dollar is the currency of the primary economic environment in which the operations of the Company and its Subsidiaries are conducted. Most of the Company&#39;s revenues are derived in dollars. Most of the Company&#39;s expenses and capital expenditures are incurred in dollars, and the major source of the Company&#39;s financing has been provided in dollars.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below) reflected in the statements of operations, the following exchange rates are used: (i) for transactions - exchange rates at the transaction dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.) - historical exchange rates. Currency transaction gains and losses are carried to financial income or expenses, as appropriate.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash equivalents</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in">&nbsp;</td> <td>Cash equivalents</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> The Company considers all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in">&nbsp;</td> <td>Inventories</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Inventories are valued at the lower of cost or market. Cost of raw and packaging materials and purchased products is determined using the "moving average" basis.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Cost of finished products that are capitalized is determined as follows: the value of the raw and packaging materials component is determined primarily on a using the "moving average" basis; the value of the labor and overhead component is determined on an average basis over the production period.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Prior to the FDA&#39;s approval of taliglucerase alfa, manufacturing costs related to taliglucerase alfa were not capitalized; rather, such costs were expensed as research and development expenses. Effective as of the FDA approval of taliglucerase alfa on May 1, 2012, the Company capitalizes manufacturing costs associated with taliglucerase alfa.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in">&nbsp;</td> <td>Property and equipment</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">1.</td> <td><font style="FONT-WEIGHT: normal">Property and equipment are stated at cost, net of accumulated depreciation and amortization.</font> </td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">2.</td> <td style="FONT-WEIGHT: normal">The Company&#39;s assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="WIDTH: 65%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1.5in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Years</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 85%">Laboratory equipment</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">5</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td>Furniture</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">10-15</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Computer equipment</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">3</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 98.65pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Leasehold improvements are amortized by the straight-line method over the expected lease term, which is shorter than the estimated useful life of the improvements.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment in value of long-lived assets</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in">&nbsp;</td> <td>Impairment in value of long-lived assets:</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> The Company tests long-lived assets for impairment if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted and without interest charges) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their estimated fair values.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td>Income taxes</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1.25in; TEXT-INDENT: -0.5in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">1.</td> <td style="FONT-WEIGHT: normal">Deferred income taxes</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> The guidance prohibits the recognition of deferred tax liabilities or assets that arise from differences between the financial reporting and tax bases of assets and liabilities that are measured from the local currency into dollars using historical exchange rates, and that result from changes in exchange rates or indexing for tax purposes. Consequently, the above mentioned differences with respect to Protalix Ltd. were not reflected in the computation of deferred tax assets and liabilities.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">2.</td> <td style="FONT-WEIGHT: normal">Uncertainty in income taxes</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Tax benefits recognized in the financial statements are those that the Company&#39;s management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit the Company&#39;s management deems more likely than not to be sustained.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">j.</td> <td>Revenue Recognition</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> The Company recognizes revenue when the earnings process is complete, which is when revenue is realized or realizable and earned, there is persuasive evidence a revenue arrangement exists, delivery of goods or services has occurred, the sales price is fixed or determinable and collectability is reasonably assured.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">1.</td> <td style="FONT-WEIGHT: normal">Revenues from the license and supply agreement with Pfizer</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> The Company recognizes revenue from milestone payments received pursuant to the Pfizer Agreement in accordance with guidance regarding revenue recognition and accounting for revenue arrangements with multiple deliverables. As the arrangement with Pfizer requires the Company&#39;s continued involvement with respect to the proposed commercialization of taliglucerase alfa, the non-refundable, up-front license payment the Company received from Pfizer was deferred and recognized over the related performance period. The Company estimated the performance period of 14 years (commencing upon the date of the Company&#39;s receipt of the up-front license payment payable by Pfizer under the Pfizer Agreement) based on the date the last relevant patent expires. See Note 2. The Company adjusts the performance periods, if appropriate, based on the applicable facts and circumstances. Each milestone payment that is considered to be substantive for purposes of revenue recognition is recorded as revenue during the period during which the milestone is achieved.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">2.</td> <td style="FONT-WEIGHT: normal">Revenues from selling products to Pfizer</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> The Company recognizes revenues from products sold to Pfizer upon delivery, when the sales price is fixed or determinable and collectability is reasonably assured.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">3.</td> <td style="FONT-WEIGHT: normal">Company&#39;s share in the collaboration agreement</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: 0in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: 0in"> Under the terms and conditions of the Pfizer Agreement, the Company is entitled to 40% of the profits or loss from sales of taliglucerase alfa, and related expenses incurred, except with respect to sales in Israel, where the Company retained exclusive marketing rights. Since Pfizer bears most of the risks and rewards relating to the agreement, the Company&#39;s share in the profits and loss in the agreement is recognized on a net basis. The Company recognizes its share of net profit or loss from the Pfizer Agreement based on reports it receives from Pfizer summarizing the results of the collaborative activities under the agreement for the applicable period. Under the terms of the Pfizer Agreement, for its subsidiaries operating outside the United States, financial information is included based on the fiscal year ending November 30, while financial information for the U.S. entity is included based on the fiscal year ending December 31.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development costs</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td>Research and development costs</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment and supplies for research and development activities. Grants received by the Israeli Subsidiary from the Office of the Chief Scientist of Israel&#39;s Ministry of Industry, Trade and Labor (the "OCS") are recognized when the grant becomes receivable, provided there is reasonable assurance that the Company or the Subsidiary will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Reimbursements received from Pfizer are recognized when the reimbursements become receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the reimbursements and there is reasonable assurance the reimbursements will be received. The reimbursements are deducted from the research and development expenses as the applicable costs are incurred.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> In connection with purchases of assets, amounts assigned to intangible assets to be used in a particular research and development project that have no alternative future use are charged to research and development costs at the purchase date.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are consumed or the related services are performed.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risks and trade receivable</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td>Concentration of credit risks and trade receivable</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits. The Company deposits these instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> <font style="COLOR: black">The Company&#39;s trade</font> receivable <font style="COLOR: black">represents mainly amounts to be received from Pfizer, as the Company currently receives most of its revenues from Pfizer. The Company does not require Pfizer to post collateral with respect to the receivables. The Company performs periodic credit evaluations of Pfizer&#39;s financial condition and believes there is no significant risk with respect to Pfizer&#39;s payment of the receivables.</font></p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based compensation</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in">&nbsp;</td> <td>Share-based compensation</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> The Company accounts for employee&#39;s share-based payment awards classified as equity awards using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period, net of estimated forfeitures. The Company estimates forfeitures based on historical experience and anticipated future conditions.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> The Company elected to recognize compensation cost for an award with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> When stock options are granted as consideration for services provided by consultants and other non-employees, the grant is accounted for based on the fair value of the stock options issued. Options granted is measured on a final basis at the end of the related service period and is recognized over the related service period using the straight-line method.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per share</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in">&nbsp;</td> <td>Net Loss per share</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Basic and diluted loss per share ("LPS") are computed by dividing net loss by the weighted average number of shares of the Company&#39;s Common Stock, par value $0.001 per share (the "Common Stock") outstanding for each period.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Diluted LPS does not include 7,761,168, 7,469,088 and 7,280,469 <font style="COLOR: black">shares of Common Stock underlying outstanding options and restricted shares of Common Stock</font> for the fiscal years ended December 31, 2010, 2011 and 2012, respectively, because the effect would be anti-dilutive.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfAccountingPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 8, 9, 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Technical Practice Aid (TPA)<br><br> -Number 2110<br><br> -Paragraph 6<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122427<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for credit risk.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61044-112788<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number SOP94-6-1<br><br> -Paragraph 7, 11<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 113<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14537-108613<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 825<br><br> -Section 55<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6487554&amp;loc=d3e32600-158583<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15A<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 01-6<br><br> -Paragraph 14<br><br> -Subparagraph m<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7491637&amp;loc=d3e13537-108611<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7491637&amp;loc=d3e13531-108611<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61082-112788<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConcentrationRiskCreditRisk</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 6, 8-16, 60<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144384<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 30<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2175892<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 52<br><br> -Paragraph 5, 7-20, 80<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2175856<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2175826<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 7-15, 26, 30-37<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section CC<br><br> -Subsection 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 48<br><br> -Paragraph 20<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32247-109318<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 4<br><br> -Paragraph 11<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 6-34, 43, 47, 49<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32280-109318<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144749<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144681<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2126999<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 206<br><br> -Paragraph b<br><br> -Subparagraph i, ii<br><br> -Chapter 2<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Paragraph 3, 5-10, 15, 16, 17<br><br> -Chapter 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 81-1<br><br> -Paragraph 69-75<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386783&amp;loc=d3e4556-108314<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section A<br><br> -Paragraph 9<br><br> -Chapter 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386783&amp;loc=d3e4492-108314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for property, plant and equipment which may include the basis of such assets, depreciation methods used and estimated useful lives, the entity's capitalization policy, including its accounting treatment for costs incurred for repairs and maintenance activities, whether such asset balances include capitalized interest and the method by which such is calculated, how disposals of such assets are accounted for and how impairment of such assets is assessed and recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 34<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section C<br><br> -Paragraph 5<br><br> -Chapter 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 7<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 8, 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 6<br><br> -Paragraph 5, 6, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 42<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2127266<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpensePolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 8, 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2228939<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 06-11<br><br> -Paragraph 7<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 94-6<br><br> -Paragraph 11, 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>TAXES ON INCOME<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES ON INCOME</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>NOTE 8 - TAXES ON INCOME</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 0.75in; TEXT-INDENT: -0.25in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">a.</td> <td>The Company</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Protalix BioTherapeutics, Inc. is taxed according to U.S. tax laws. The Company&#39;s income is, or will be, taxed in the United States at the rate of up to 39%.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.5in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">b.</td> <td>Protalix Ltd.</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> The Israeli Subsidiary is taxed according to Israeli tax laws:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">1.</td> <td>Measurement of results for tax purposes</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Since 2008, the Company has measured the results of the Israeli Subsidiary for tax purposes in nominal terms in NIS. Pursuant to the Israel Income Tax Law (Adjustments for Inflation), 1985 (the "Adjustments Law"), the Subsidiary&#39;s results for tax purposes have been measured through 2007 on a real basis, based on changes in the Israel consumer price index.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">2.</td> <td>Tax rates</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> The income of the Israeli Subsidiary, other than income from "Approved Enterprises," is taxed in Israel at the regular rate. See 3 below. According to the provisions of the Law for Amending the Israel Income Tax Ordinance, 2005, corporate tax rates will be gradually lowered, resulting in a corporate tax rate for 2009 and thereafter: 2009 - 26% and for 2010 and thereafter - 25%.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> On July 14, 2009, the Israel Economic Efficiency Law (Legislation Amendments for Applying the Economic Plan for 2009 and 2010), 2009, became effective, stipulating, among other things, an additional gradual decrease in tax rates in 2011 and thereafter, as follows: 2011 - 24%, 2012 - 23%, 2013 - 22%, 2014 - 21%, 2015 - 20% and 2016 and thereafter - 18%.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> On December 5, 2011, the "Tax Burden Distribution Law" (hereinafter - the 2011 amendment) was officially published, discontinuing a previously approved gradual decrease in corporate tax provided in the 2009 amendment, and setting the corporate tax rate in Israel for 2012 and thereafter to 25%.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Capital gain is subject to capital gain tax according to corporate tax rate in the year of selling the assets.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">3.</td> <td>The Law for the Encouragement of Capital Investments, 1959 (the "Encouragement of Capital Investments Law")</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Under the Encouragement of Capital Investments Law, including Amendment No. 60 to the Encouragement of Capital Investments Law as published in April 2005, by virtue of the "Approved Enterprise" or "Benefited Enterprise" status the Israeli Subsidiary is entitled to various tax benefits as follows:</p> <p style="TEXT-INDENT: -37.1pt; MARGIN: 0pt 0px 0pt 1.5in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 70.9pt">&nbsp;</td> <td style="WIDTH: 37.1pt">a.</td> <td><strong>Reduced tax rates</strong></td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> Income derived from the Approved Enterprise during a 10-year period commencing upon the year in which the enterprise first realizes taxable income is tax exempt, provided that the maximum period to which it is restricted by the Encouragement of Capital Investments Law has not elapsed.</p> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> The Israeli Subsidiary has an "Approved Enterprise" plan since 2004 and "Benefited Enterprise" plan since 2009. The period of benefits in respect of the main enterprise of the Company has not yet commenced. The period during which the Company is entitled to benefits in connection with the Benefited Enterprise expires in 2021.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> If the Israeli Subsidiary subsequently pays a dividend out of income derived from the "Approved Enterprise" or "Benefited Enterprise" during the tax exemption period, it will be subject to a tax on the amount distributed, including any company tax on these amounts, at the rate which would have been applicable had such income not been exempted.</p> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> In addition to the corporate taxes in Israel, the Company might be subject to a withholding tax on the U.S. revenue source portion of the payments made to the Company for its share of Pfizer&#39;s net profits under the Pfizer Agreement. The withholding tax rate is currently 15%.</p> <p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 1in">&nbsp;</td> <td style="WIDTH: 0.25in">b.</td> <td><strong>Accelerated depreciation</strong></td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> The Israeli Subsidiary is entitled to claim accelerated depreciation, as provided by Israeli law, in the first five years of operation of each asset, in respect of buildings, machinery and equipment used by the Approved Enterprise and the Benefited Enterprise.</p> <p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 1in">&nbsp;</td> <td style="WIDTH: 0.25in">c.</td> <td><strong>Conditions for entitlement to the benefits</strong></td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> The Israeli Subsidiary&#39;s entitlement to the benefits described above is subject to its fulfilling the conditions stipulated by the law, rules and regulations published thereunder, and the instruments of approval for the specific investment in an approved enterprise. If there is any failure by the Israeli Subsidiary to comply with these conditions, the benefits may be cancelled and the Subsidiary may be required to refund the amount of the benefits, in whole or in part, with interest. The Israeli Subsidiary received a final implementation approval with respect to its "Approved Enterprise" from the Investment Center.</p> <p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 1in">&nbsp;</td> <td style="WIDTH: 0.25in">d.</td> <td><strong>Amendment of the Law for the Encouragement of Capital Investments, 1959</strong></td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> The Encouragement of Capital Investments Law was amended as part of the Economic Policy Law for the years 2011-2012, which was passed by the Israeli Knesset on December 29, 2010 (the "Capital Investments Law Amendment").</p> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> The Capital Investments Law Amendment sets alternative benefit tracks to those currently in effect under the provisions of the Encouragement of Capital Investments Law.</p> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> The benefits granted to the Benefited Enterprises will be unlimited in time, unlike the benefits granted to special Benefited enterprises, which will be limited for a 10-year period. The benefits shall be granted to companies that will qualify under criteria set in the law; for the most part, those criteria are similar to the criteria that were set in the Encouragement of Capital Investments Law prior to its amendment.</p> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> Under the transitional provisions of the Encouragement of Capital Investments Law, the Company is entitled to take advantage of the tax benefits available under the Encouragement of Capital Investments Law prior to its amendment until the end of the benefits period, as defined in the Encouragement of Capital Investments Law. The Company will be allowed to set the "year of election" no later than tax year 2012, provided that the minimum qualifying investment was made not later than the end of 2010. On each year during the benefits period, the Company will be able to elect that the Capital Investments Amendment apply to the Company, thereby making the tax rates described above available to the Company. An election to have the Capital Investments Amendment apply is irrecoverable. The Company elected not to have the Capital Investments Amendment apply to the Company.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">4.</td> <td>The Law for the Encouragement of Industry (Taxation), 1969:</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> The Israeli Subsidiary is an "industrial company," as defined under the Law for the Encouragement of Industry (Taxation), 1969 (the "Law for the Encouragement of Industry"). As such, the Israeli Subsidiary is entitled to claim depreciation at increased rates for equipment used in industrial activity, as stipulated by regulations published under Law for the Encouragement of Industry, and has done so.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Under the provisions of the Income Tax Regulations "Accelerated Depreciation in respect of Equipment acquired during the Defined Period" (Temporary Orders), industrial companies whose operations are mostly "eligible operations" are entitled to claim accelerated depreciation at a rate of 50% on machinery and equipment acquired from June 1, 2008 to May 31, 2009.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.5in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">c.</td> <td>Tax losses carried forward to future years</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> As of December 31, 2012, the Company had aggregate net operating loss (NOL) carry-forwards equal to approximately $72.5 million that are available to reduce future taxable income as follows:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">1.</td> <td>The Company</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> The NOL carry-forward of the Company equal to approximately $13.8 million may be restricted under Section 382 of the Internal Revenue Code ("IRC"). IRC Section 382 applies whenever a corporation with NOL experiences an ownership change. As a result of IRC Section 382, the taxable income for any post change year that may be offset by a pre-change NOL may not exceed the general IRC Section 382 limitation, which is the fair market value of the pre-change entity multiplied by the IRC long-term tax exempt rate.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">2.</td> <td>Protalix Ltd.</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> At December 31, 2012, the Israeli Subsidiary had approximately $58.7 million of NOL carry-forwards that are available to reduce future taxable income with no limited period of use.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 0.75in; TEXT-INDENT: -0.25in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">d.</td> <td>Deferred income taxes:</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> The components of the Company&#39;s net deferred tax assets at December 31, 2011 and 2012 were as follows:</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6">December 31,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt; FONT-STYLE: italic">(U.S. dollars in thousands)</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td>In respect of:</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt; WIDTH: 74%"> Research and development expenses</td> <td style="WIDTH: 1%; COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; COLOR: black">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%; COLOR: black">4,119</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; COLOR: black">&nbsp;</td> <td style="WIDTH: 1%; COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 10%; COLOR: black">6,003</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; COLOR: black">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt">Property and equipment</td> <td style="COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: right; COLOR: black">(149</td> <td style="TEXT-ALIGN: left; COLOR: black">)</td> <td style="COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: right; COLOR: black">(647</td> <td style="TEXT-ALIGN: left; COLOR: black">)</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt">Provision for vacation</td> <td style="COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: right; COLOR: black">305</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> <td style="COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: right; COLOR: black">363</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt">Severance pay obligation</td> <td style="COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: right; COLOR: black">164</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> <td style="COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: right; COLOR: black">192</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt">Deferred revenues</td> <td style="COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: right; COLOR: black">4,746</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> <td style="COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: right; COLOR: black">10,449</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt">Net operating loss carry forwards</td> <td style="COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: right; COLOR: black">4,579</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> <td style="COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> <td style="TEXT-ALIGN: right; COLOR: black">15,176</td> <td style="TEXT-ALIGN: left; COLOR: black">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">Valuation allowance</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (13,764</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">)</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (31,536</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">)</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse. The Company used tax rates of 39%, 25% and 0%.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.5in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">e.</td> <td>Reconciliation of the theoretical tax expense to actual tax expense</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> The main reconciling item between the statutory tax rate of the Company and the effective rate is the provision for full valuation allowance in respect of tax benefits from carry forward tax losses due to the uncertainty of the realization of such tax benefits (see above).</p> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.5in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">f.</td> <td>Tax assessments</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> In accordance with the Income Tax Ordinance, as of December 31, 2012, all of Protalix Ltd.&#39;s tax assessments through tax year 2008 are considered final.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> A summary of open tax years by major jurisdiction is presented below:</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; WIDTH: 50%; FONT-WEIGHT: bold; TEXT-DECORATION: none"> Jurisdiction:</td> <td style="PADDING-BOTTOM: 1pt; WIDTH: 1%; FONT-WEIGHT: bold"> &nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%; FONT-WEIGHT: bold"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: right; WIDTH: 47%"> <strong>Years:</strong></td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%; FONT-WEIGHT: bold"> &nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Israel</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">2009-2012</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">United States (*)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">2009-2012</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Netherlands</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">2009-2012</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> (*) Includes federal, state and local (or similar provincial jurisdictions) tax positions.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 136, 172<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43, 44, 45, 46, 47, 48, 49<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>COMMITMENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">COMMITMENTS</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>NOTE 6 - COMMITMENTS</strong></p> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">a.</td> <td>Royalty commitments</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">1.</td> <td style="FONT-WEIGHT: normal">The Company is obligated to pay royalties to the OCS on proceeds from the sale of products developed from research and development activities that were funded, partially, by grants from the OCS. At the time the grants were received, successful development of the related projects was not assured.</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> In the case of failure of a project that was partly financed as described above, the Company is not obligated to pay any such royalties or repay funding received from the OCS.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Under the terms of the funding arrangements with the OCS, royalties of 3% to 6% are payable on the sale of products developed from projects funded by the OCS, which payments shall not exceed, in the aggregate, 100% of the amount of the grant received (dollar linked), plus, commencing upon January&nbsp;1, 2001, interest at annual rate based on LIBOR. In addition, if the Company receives approval to manufacture products developed with government grants outside the State of Israel, it will be required to pay an increased total amount of royalties (possibly up to 300% of the grant amounts plus interest), depending on the manufacturing volume that is performed outside the State of Israel, and, possibly, an increased royalty rate.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Royalty expenses to the OCS are included in the statement of operations as a component of the cost of revenues and were approximately $769,000, $158,000 and $1.5 million during the years ended December&nbsp;31, 2010, 2011 and 2012, respectively.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> At December 31, 2012, the maximum royalty amount payable by the Company under these funding arrangements is approximately $21.3 million (without interest, assuming 100% of the funds are payable).</p> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">2.</td> <td style="FONT-WEIGHT: normal">The Company is a party to certain research and license agreements. Under the <font style="COLOR: black">agreements, the Company is obligated</font> to pay royalties at varying rates from its future revenues. The aggregate royalties payable under all of the agreements is equal to a varying range of percentages of net sales of licensed products. Royalty expenses under the agreements are included in the statement of operations as a component of the cost of revenues and were approximately $115,000, $19,000 and $674,000 during the years ended December&nbsp;31, 2010, 2011 and 2012, respectively.</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Under each agreement, the Company is also obligated to pay milestone, licensing and other payments to the counterparties of the agreement. The payments under the agreements are for varying amounts and are subject to varying conditions. If all of the contingencies with respect to milestone payments under the research and license agreements are met, the aggregate milestone payments payable would be approximately $1.0 million and would be payable, if at all, as the Company&#39;s projects progress over the course of a number of years. In addition, a milestone payment of approximately $100,000 was made in respect of the agreements during the year ended December 31, 2010. No milestone payments were made during 2011 and 2012.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> None of the agreements has a fixed termination date. Subject to earlier termination for other reasons, each agreement terminates after a certain number of years following the first commercial sale of any licensed product under the agreement or after a certain number of years without the initiation of commercial sales of any product under the agreement.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">b.</td> <td>Subcontracting Agreements</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> The Company has entered into sub-contracting agreements with several clinical providers and consultants in Israel, the United States and certain other countries in connection with its primary product development process and with expenditure of the company&#39;s manufacturing facilities. As of December 31, 2012, total commitments under said agreements were approximately $1.3 million.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">c.</td> <td>Lease Agreements</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> The Company is a party to a number of lease agreements for its facilities, the latest of which expires in 2016. The Company has the option to extend certain of such agreements on three occasions for additional five-year periods, for a total of 15 additional years. Under the leases, the aggregate monthly rental payments are approximately $82,000. As of December 31, 2012, the Company provided bank guarantees of approximately $298,000, in the aggregate, to secure the fulfillment of its obligations under the lease agreements. The future minimum lease payments required in each of the next five years under the operating leases for such premises are approximately as follows: 2013 - $976,000, 2014 - $968,000, 2015 - $985,000 and 2016 - $823,000. Lease expenses totaled $891,000, $994,000 and $971,000 for the years ended December 31, 2010, 2011 and 2012, respectively.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">d.</td> <td>Vehicle Lease and Maintenance Agreements</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> The Company entered into several three-year lease and maintenance agreements for vehicles which are regularly amended as new vehicles are leased. The current monthly lease fees aggregate approximately $49,000. The expected lease payments for the years ending December 31, 2013, 2014 and 2015 are approximately $526,000, $385,000 and $175,000, respectively.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">e.</td> <td>Yissum Agreement</td> </tr> </table> <p style="TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> On August 8, 2007, the Company signed an agreement with the Yissum Research and Development Company, the technology transfer arm of the Hebrew University of Jerusalem, Israel ("Yissum"), and the Boyce Thompson Institute for Plant Research, at Cornell University, Ithaca, New York ("Boyce Thompson"), to develop a proprietary plant cell-based acetylcholinesterase (AChE) and its molecular variants for the use in several therapeutic and prophylactic indications, including a biodefense program and organophosphate-based pesticide treatment. Pursuant to the agreement, the Company has received an exclusive worldwide right and license to certain technology, including patents and additional patent applications relating to AChE (the "Licensed Technology"), for all therapeutic and prophylactic indications. In consideration for the license, the Company is <font style="COLOR: black">obligated to pay Yissum and</font> Boyce Thompson, collectively, <font style="COLOR: black">an annual, non-refundable initial maintenance fee of $20,000,</font> commencing on the fourth anniversary of the execution of the agreement, which is subject to a 12% annual increase. <font style="COLOR: black">In addition,</font> the Company is required to make certain milestone payments equal to up to $700,000, in the aggregate, upon its achievement of clinical milestones and royalties from sales derived from any drugs developed by the Company with the Licensed Technology. The agreement does not terminate until either party to the agreement elect to terminate the agreement, subject to certain terms and conditions set forth therein.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 17<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.(a)(19))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 25<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SHARE CAPITAL<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE CAPITAL [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHARE CAPITAL</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>NOTE 7 - SHARE CAPITAL</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.5in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">a.</td> <td>Rights of the Company&#39;s Common Stock</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> The Company&#39;s common stock is listed on the NYSE MKT and, since September 6, 2010, on the Tel Aviv Stock Exchange. Each share of Common Stock is entitled to one vote. The holders of shares of Common Stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. Since its inception, the Company has not declared any dividends.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.5in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">b.</td> <td>Stock based compensation</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> On December 14, 2006, the Board of Directors adopted the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan (the "Plan"). The Plan was amended on June 17, 2012 to increase the number of shares of common stock available under the plan from 9,741,655 shares to 11,341,655 shares. The grant of options to Israeli employees under the Plan is subject to the terms stipulated by Sections 102 and 102A of the Israeli Income Tax Ordinance. Each option grant is subject to the track chosen by the Company, either Section 102 or Section 102A of the Israeli Income Tax Ordinance, and pursuant to the terms thereof, the Company is not allowed to claim, as an expense for tax purposes, the amounts credited to employees as a benefit, including amounts recorded as salary benefits in the Company&#39;s accounts, in respect of options granted to employees under the Plan, with the exception of the work-income benefit component, if any, determined on the grant date. For Israeli non-employees, the share option plan is subject to Section 3(i) of the Israeli Income Tax Ordinance.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> As of December 31, 2012, 176,986 shares of Common Stock remain available for grant under the Plan.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> For purposes of determining the fair value of the options and restricted stock granted to employees and non-employees, the Company&#39;s management uses the fair value of the Common Stock.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> From January 1, 2010 through December 31, 2012, the Company granted options and shares of restricted stock to certain employees and non-employees as follows:</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">1.</td> <td>Options and restricted stock granted to employees:</td> </tr> </table> <p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 1in">&nbsp;</td> <td style="WIDTH: 0.25in">a)</td> <td>Below is a table summarizing all of the options and restricted stock grants to employees for each of the three years in the three-year period ended December 31, 2012:</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1.25in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Year of<br /> grant</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">No. of options<br /> or restricted<br /> stock granted</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Exercise<br /> price range</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap">Vesting period</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Fair value<br /> at grant<br /> (U.S.<br /> dollars in<br /> thousands)</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Expiration<br /> period</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 10%">2010</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">1,016,000</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: center; WIDTH: 10%">$6.90</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: center; WIDTH: 35%">3 years commencing<br /> upon achievement of a<br /> certain milestone</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">5,673</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">10 years</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: left">2010</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">428,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center">$6.32-$9.66</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center">4 years</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">2,147</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">10 years</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: left">2012</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">400,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center">n/a</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center">3 years</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">2,288</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">n/a</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">2012</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,100,000</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> n/a</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt">4 years</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">$</td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt">6,292</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: right"> n/a</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">2,944,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> Set forth below are grants made by the Company to employees (including related parties) during the three-year period ended December 31, 2012 (such grants appear in the table above):</p> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1.5in; TEXT-INDENT: -0.25in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 1.25in">&nbsp;</td> <td style="COLOR: black; FONT-WEIGHT: normal; WIDTH: 0.25in"> 1.</td> <td style="FONT-WEIGHT: normal">In February 2010, the Company&#39;s Board of Directors approved the grant of options to purchase 1,016,000 shares of Common Stock, in the aggregate, to the Company&#39;s Chief Executive Officer and certain officers and employees of the Company with an exercise price equal to $6.90 per share. The options vest quarterly over a three-year period commencing upon the FDA&#39;s approval of taliglucerase alfa. The Company treated the awards as performance-based awards and, given that the performance condition is outside the Company&#39;s control, concluded that the performance condition was not probable until the performance condition actually occurred. <font style="COLOR: black">Upon the FDA&#39;s</font> approval of taliglucerase alfa on May 1, 2012<font style="COLOR: black">, the Company started recognizing share based compensation expenses</font> related to such options. Share based compensation related to services performed from the date of grant of the respective options through the FDA approval date, <font style="COLOR: black">were recognized on that date.</font></td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1.5in; TEXT-INDENT: -0.25in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 1.25in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">2.</td> <td style="COLOR: black; FONT-WEIGHT: normal">In February 2010, the Company&#39;s Board of Directors approved the grant of options to purchase 160,000 shares of Common Stock with an exercise price equal to $6.81 per share to a new executive officer of the Company. The options expire on the tenth anniversary of the date of grant, unless terminated earlier. The first 25% of the options vest on the first anniversary of the date of grant and the remaining 75% vest in 12 equal tranches on a quarterly basis for three years thereafter.</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1.5in; TEXT-INDENT: -0.25in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 1.25in">&nbsp;</td> <td style="COLOR: black; FONT-WEIGHT: normal; WIDTH: 0.25in"> 3.</td> <td><font style="FONT-WEIGHT: normal">In September 2010, the Company&#39;s Board of Directors approved the grant of options to purchase 160,000 shares of Common Stock to a new executive officer of the Company with an exercise price equal to $7.55 per share and options to purchase 40,000 shares of Common Stock to a new employee of the Company with an exercise price equal to $6.32 per share. The options vest over a four-year period, with the first 25% vesting on the first anniversary of the applicable date of the grant and the remaining 75% vesting in equal tranches on a quarterly basis for a three-year period thereafter. <font style="COLOR: black">The options expire on the tenth anniversary of the date of grant, unless terminated earlier.</font></font> </td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1.5in; TEXT-INDENT: -0.25in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 1.25in">&nbsp;</td> <td style="COLOR: black; FONT-WEIGHT: normal; WIDTH: 0.25in"> 4.</td> <td style="FONT-WEIGHT: normal">In November 2010, the Company&#39;s Board of Directors approved the grant of options to purchase 68,000 shares of Common Stock to a new officer of the Company with an exercise price equal to $9.66 per share. The options vest over a four-year period, with the first 25% vesting on the first anniversary of the applicable date of the grant and the remaining 75% vesting in equal tranches on a quarterly basis for a three-year period thereafter. <font style="COLOR: black">The options expire on the tenth anniversary of the date of grant, unless terminated earlier.</font></td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1.5in; TEXT-INDENT: -0.25in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 1.25in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">5.</td> <td style="FONT-WEIGHT: normal">In September 2010, the Company&#39;s Board of Directors modified the terms of the options previously granted to an executive in 2001, by extending the life of the options until 2016. At the date of modification, all of the options were fully vested. The Company concluded that there was no incremental increase in the value of the awards and therefore no accounting charges need to be recorded in connection with the modifications.</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1.5in; TEXT-INDENT: -0.25in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 1.25in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">6.</td> <td style="FONT-WEIGHT: normal">On July 16, 2012, the Company&#39;s Board of Directors approved the grant of 1,500,000 shares of restricted Common Stock to its officers and certain other employees. Of such restricted stock, 1,100,000 of the shares were issued to the Company&#39;s named executive officers and vest in 16 equal, quarterly increments over a four-year period, commencing upon the date of grant, and are subject to a 24-month lock-up period, commencing upon the applicable vesting dates. Immediately and automatically in the event of a Change in Control, as such term is defined in the Plan, as amended, all of the shares of restricted Common Stock issued to the named executive officers shall vest, and the lock-up periods shall terminate, subject to certain exceptions. The remaining 400,000 shares of restricted Common Stock were issued to other employees of the Company and vest in 12 equal, quarterly increments over a three-year period, commencing upon the date of grant. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $8.6 million.</td> </tr> </table> <p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 1in">&nbsp;</td> <td style="WIDTH: 0.25in">b)</td> <td>The fair value of options and restricted stock granted during the years ended December 31, 2010 and 2012 were $7.8 million and $8.6 million respectively. The fair value of each option granted in 2010 is estimated on the date of grant using the Black-Scholes option-pricing model, with the following weighted average assumptions:</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1.25in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-LEFT: 0px">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2010</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px; WIDTH: 87%"> Dividend yield</td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"> 0</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> %</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px"> Expected volatility</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 75</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">%</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px"> Risk-free interest rate</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 3.23</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">%</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px"> Expected life - in years</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 8.8</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> The expected volatility is based on the historical volatility of the Common Stock and those of comparable companies. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term of the stock options granted in dollar terms. The Company&#39;s management uses the contractual term or its expectations, based on historical incidence of option exercises, as applicable (during 2010 - using the simplified method), of each option as its expected life. The pre-vesting forfeiture rate of approximately 6.1% is estimated based on pre-vesting forfeiture experience.</p> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> The fair value of the restricted stock is based on the Company&#39;s share price on the NYSE MKT on the grant date.</p> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> The total unrecognized compensation cost of employee stock options and restricted stock at December 31, 2012 is approximately $7.0 million (net of forfeiture rate). The unrecognized compensation cost of employee stock options is expected to be recognized over a weighted average period of 1.1 years.</p> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> The total cash received from employees as a result of employee stock option exercises for the years ended December 31, 2010, 2011 and 2012 was approximately $501,000, $277,000 and $1.2 million, respectively. The Company did not realize any tax benefit in connection with these exercises.</p> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> During 2012, the Company issued 861,593 shares of Common Stock in connection with the exercise of 861,593 options by certain employees of the Company. The Company received cash proceeds equal to approximately $1.2 million in connection with such exercises.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">2.</td> <td>Options granted to consultants, directors, and other service providers:</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: 0in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: 0in"> As of December 31, 2012, the Company has recognized and recorded all compensation costs related to outstanding options for consultants, directors and other services providers.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> No cash was received from consultants as a result of consultant stock option exercises for the years ended December 31, 2010, and 2011 and approximately $39,000 was received during the year ended December 31, 2012. The Company did not realize any tax benefits in connection with these exercises.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> During 2012, the Company issued 326,267 shares of Common Stock in connection with the exercise of 326,267 options by consultants of the Company. The Company received cash proceeds equal to approximately $39,000 in connection with such exercise.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">3.</td> <td style="FONT-WEIGHT: normal">A summary of share option plans, and related information, under all of the Company&#39;s equity incentive plans for the years ended December 31, 2010, 2011 and 2012 are as follows:</td> </tr> </table> <p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 1in">&nbsp;</td> <td style="WIDTH: 0.25in">a.</td> <td>Options granted to employees:</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="22" nowrap="nowrap">Year ended December 31,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap">2010</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"> &nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"> Weighted</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Weighted</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"> &nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Weighted</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Number</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">average</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Number</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">average</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Number</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">average</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">of</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">exercise</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">of</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">exercise</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">of</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">exercise</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">options</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">price</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">options</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">price</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">options</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">price</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in; WIDTH: 40%"> Outstanding at beginning of year</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 7%">5,366,729</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 7%">2.476</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 7%">6,367,979</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 7%">3.576</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 7%">6,141,030</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 7%">3.563</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Changes during the year:</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-LEFT: 0.25in">Granted</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,444,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">7.076</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 0.25in">Forfeited and Expired</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">13,441</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">3.551</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">44,856</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">6.207</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">25,858</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">4.372</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.25in">Exercised (*)</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 429,309</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1.602</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 182,093</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1.652</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 861,593</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1.346</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">Outstanding at end of year</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 6,367,979</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 3.576</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 6,141,030</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 3.563</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 5,253,579</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 3.923</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">Exercisable at end of year</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4,267,850</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2.183</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4,647,834</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2.581</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4,258,441</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 3.201</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <p style="TEXT-INDENT: -0.2in; MARGIN: 0pt 0px 0pt 84.95pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 70.55pt">&nbsp;</td> <td style="WIDTH: 14.4pt">(*)</td> <td>The total intrinsic value of options exercised during the years ended December 31, 2010, 2011 and 2012, was approximately $3.1 million, $1.3 million and $4.8 million, respectively.</td> </tr> </table> <p style="TEXT-INDENT: -0.2in; MARGIN: 0pt 0px 0pt 84.95pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 1in">&nbsp;</td> <td style="WIDTH: 0.25in">b.</td> <td>Restricted stock granted to employees:</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="5">Year ended December 31, 2012</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center" nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Number of<br /> Restricted Shares</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center">Outstanding at beginning of year</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center">Changes during the year:</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center; WIDTH: 90%">Granted</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 7%">1,500,000</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt; PADDING-LEFT: 15.95pt"> Forfeited</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 3,208</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2.5pt">Outstanding at end of year</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,496,792</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2.5pt">Exercisable at end of year</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 102,084</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <p style="TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 1in">&nbsp;</td> <td style="WIDTH: 0.25in">c.</td> <td>Options granted to consultants, directors, and other service providers:</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="22">Year ended December 31,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6">2010</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> &nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Weighted</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> &nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Weighted</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> &nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Weighted</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Number</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> average</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Number</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> average</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Number</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> average</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> of</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> exercise</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> of</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> exercise</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> of</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> exercise</td> <td style="FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">options</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">price</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">options</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">price</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">options</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">price</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in; WIDTH: 40%"> Outstanding at beginning of year</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 7%">1,438,692</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 7%">4.697</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 7%">1,438,692</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 7%">4.697</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 7%">1,238,692</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 7%">5.385</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in"> Changes during the year- Exercised (*)</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> &nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> &nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 200,000</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 0.001</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 326,267</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 0.12</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in"> Outstanding at end of year</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,438,692</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4.697</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,238,692</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 5.385</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 912,425</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 7.259</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in"> Exercisable at end of year</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,421,734</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4.653</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,235,567</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 5.385</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 912,425</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 7.259</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 63.8pt">&nbsp;</td> <td style="WIDTH: 14pt">(*)</td> <td>The total intrinsic value of options exercised during the years ended December 31, 2010, 2011 and 2012, was approximately $0, $1.9 million and $2.3 million, respectively.</td> </tr> </table> <p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1.25in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 1in">&nbsp;</td> <td style="WIDTH: 0.25in">d.</td> <td>The following tables summarize information concerning outstanding and exercisable options and restricted stock as of December 31, 2012:</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="18" nowrap="nowrap">December 31, 2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="10" nowrap="nowrap">Options and restricted stock<br /> outstanding</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap">Options exercisable and<br /> restricted stock vested</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Exercise<br /> prices</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Number of<br /> Options and<br /> restricted stock<br /> outstanding<br /> at end of<br /> year</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Weighted<br /> average<br /> remaining<br /> contractual<br /> life</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Number of<br /> options<br /> exercisable and<br /> restricted stock<br /> vested at end of<br /> year</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Weighted<br /> average<br /> remaining<br /> contractual<br /> life</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 18%">n/a (Restricted Stock)</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 17%">1,496,792</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 17%"> <p style="TEXT-ALIGN: right; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> n/a</p> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 17%">102,084</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 17%"> <p style="TEXT-ALIGN: right; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> n/a</p> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">0.001</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">719,207</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">2.54</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">719,207</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">2.54</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">0.120</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">447,850</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1.05</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">447,850</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1.05</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">0.399</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">23,087</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1.92</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">23,087</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1.92</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">0.972</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">996,353</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">3.44</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">996,353</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">3.44</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">2.350</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">40,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">5.82</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">40,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">5.82</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">2.650</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">402,882</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">6.15</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">396,744</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">6.15</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">3.020</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">50,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">5.10</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">50,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">5.10</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">5.000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,708,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">5.10</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,708,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">5.10</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">6.810</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">160,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">7.10</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">110,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">7.10</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">6.900</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,003,083</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">7.15</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">168,083</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">7.15</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">7.550</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">160,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">7.66</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">90,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">7.66</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">9.660</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">68,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">7.83</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">34,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">7.83</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">$</td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt">16.700</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 387,542</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 3.99</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 387,542</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 3.99</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 7,662,796</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 5,272,950</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> The aggregate intrinsic value of the total outstanding and of total vested and exercisable options and restricted stock as of December 31, 2012 is approximately $19.7 million and $12.4 million, respectively.</p> <p style="TEXT-INDENT: -20.15pt; MARGIN: 0pt 0px 0pt 92.15pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 72pt">&nbsp;</td> <td style="WIDTH: 20.15pt">e.</td> <td>The following table illustrates the effect of share-based compensation on the statement of operations:</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="10">Year ended December 31,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt; FONT-STYLE: italic">(U.S. dollars in thousands)</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2010</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -12.6pt; PADDING-LEFT: 12.6pt"> Cost of revenues</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">220</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -12.6pt; PADDING-LEFT: 12.6pt; WIDTH: 61%"> Research and development expenses</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">630</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">422</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">4,756</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -12.6pt; PADDING-LEFT: 12.6pt"> General and administrative expenses</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 652</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 464</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 2,775</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,282</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 886</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 7,751</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.5in"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.28in">c.</td> <td>Public Offerings</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 78pt; TEXT-INDENT: -21.3pt"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 56.7pt">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 21.3pt">1.</td> <td><font style="FONT-WEIGHT: normal">On March 23, 2011, the Company issued and sold 4,000,000 shares of Common Stock in an underwritten public offering at a price to the public of $5.50 per share. The net proceeds to the Company were approximately $20.6 million (net of underwriting commissions and issuance costs of $1.4 million</font>)</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px 0pt 78pt; TEXT-INDENT: -21.3pt"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 56.7pt">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 21.3pt">2.</td> <td style="FONT-WEIGHT: normal">On February 22, 2012, the Company issued and sold 5,175,000 shares of Common Stock in an underwritten public offering at a price to the public of $5.25 per share. The net proceeds to the Company were approximately $25.4 million (net of underwriting commissions and issuance costs of $1.8 million).</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section B<br><br> -Paragraph 7, 11A<br><br> -Chapter 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementalInformationAbstract', window );"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>NOTE 9 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</strong></p> <p style="TEXT-INDENT: -17.3pt; MARGIN: 0pt 0px 0pt 71.3pt; FONT: 10pt Times New Roman, Times, Serif"> <strong>Balance sheets:</strong></p> <p style="TEXT-INDENT: -17.3pt; MARGIN: 0pt 0px 0pt 71.3pt; FONT: 10pt Times New Roman, Times, Serif">&nbsp;</p> <table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6">December 31,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt; FONT-STYLE: italic">(U.S. dollars in thousands)</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -26.45pt; PADDING-LEFT: 26.45pt; FONT-WEIGHT: bold"> a. Other assets:</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt; WIDTH: 74%"> Deferred costs*</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">1,558</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">89</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-LEFT: 45pt">Institutions</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">375</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">542</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt">State of Israel (see Note 6a)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,296</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">2,400</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt">Restricted deposit</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">208</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">298</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt">Prepaid expenses</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">235</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">251</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt">Sundry</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 165</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 106</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 3,837</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 3,686</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> * Manufacturing costs of inventory, paid by Pfizer, but not delivered.</p> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> <em>(U.S. dollars in thousands)</em></p> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 0.5in"><strong>b.</strong></td> <td style="TEXT-ALIGN: justify"><strong>Accounts payable and accruals - other:</strong></td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0"> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt; WIDTH: 74%"> Payroll and related expenses</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">1,108</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">1,748</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt">Provision for vacation</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,221</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,453</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt">Accrued expenses</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">2,327</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">2,032</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt">Royalties payable</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">89</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,560</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 52.2pt"> Liability in connection with collaboration operation- current portion</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,322</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">3,122</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; PADDING-LEFT: 45pt"> Property and equipment suppliers</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,473</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,136</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 7,540</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 11,051</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&nbsp;</p> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: bold 10pt Times New Roman, Times, Serif"> <strong>Statements of operations:</strong></p> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif">&nbsp;</p> <table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="10">Year ended December 31,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2010</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-STYLE: italic">(U.S. dollars in thousands)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: right" colspan="2">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: right" colspan="2">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -28.85pt; PADDING-LEFT: 28.85pt; FONT-WEIGHT: bold"> c. Revenues:</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in; WIDTH: 61%"> Deferred revenues from the license and supply agreement with Pfizer</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">4,563</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">4,563</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">4,563</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 0.5in">Milestone payment (see note 2)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">25,000</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.5in"> Revenues from selling products</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 2,079</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 3,823</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 5,307</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -28.85pt; PADDING-LEFT: 28.85pt; FONT-WEIGHT: bold"> &nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 6,642</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 8,386</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 34,870</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_SupplementalInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalFinancialInformationDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EVMBI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SHARE CAPITAL (Narrative) (Details) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="5">1 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="3">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Feb. 29, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 23, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 17, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 16, 2012</div>
        </th>
        <th class="th">
          <div>Feb. 22, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2010

</div>
          <div>Officers And Certain Employees [Member]</div>
        </th>
        <th class="th">
          <div>Nov. 30, 2010

</div>
          <div>Executive Officer [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2010

</div>
          <div>Executive Officer [Member]</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2010

</div>
          <div>Executive Officer [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2010

</div>
          <div>Employees [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Employees [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 16, 2012

</div>
          <div>Restricted Stock [Member]

</div>
          <div>Officers And Certain Employees [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 16, 2012

</div>
          <div>Restricted Stock [Member]

</div>
          <div>Employees [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 16, 2012

</div>
          <div>Restricted Stock [Member]

</div>
          <div>Officers And Directors In Private Transaction [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Underwritten public offering, common stock issued and sold</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,000,000<span></span></td>
        <td class="nump">93,489,809<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,175,000<span></span></td>
        <td class="nump">85,630,157<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Underwritten public offering, common stock price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5.5<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5.25<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Underwritten public offering, net proceeds from issuance</a></td>
        <td class="nump">$ 25,400<span></span></td>
        <td class="nump">$ 20,600<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwritten public offering, commissions and issuance costs</a></td>
        <td class="nump">1,800<span></span></td>
        <td class="nump">1,400<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock approved for grant</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">11,341,655<span></span></td>
        <td class="nump">9,741,655<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,016,000<span></span></td>
        <td class="nump">68,000<span></span></td>
        <td class="nump">160,000<span></span></td>
        <td class="nump">160,000<span></span></td>
        <td class="nump">40,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Common stock shares granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,944,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,100,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock available for issuance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">176,986<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6.9<span></span></td>
        <td class="nump">$ 9.66<span></span></td>
        <td class="nump">$ 7.55<span></span></td>
        <td class="nump">$ 6.81<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm', window );">Shares of common stock issued, lock up period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">24 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod', window );">Number of installments for vesting of stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">16<span></span></td>
        <td class="nump">12<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value of common stock at grant date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 8,600<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 7,800<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 8,600<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award grant date fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award granted contractual term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award number of installments for vesting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:decimalItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for cost incurred directly with the issuance of an equity security.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18, 19, 20<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsOfStockIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section H<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockPricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6">December 31,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> (<em>U.S. dollars in thousands)</em></td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 70%">Laboratory equipment</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">13,079</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">14,502</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Furniture and computer equipment</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,522</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,818</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Leasehold improvements</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">13,705</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">14,447</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">Equipment under construction</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,113</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 329</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 7.35pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">$</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 29,419</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">$</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 31,096</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td style="FONT-SIZE: 1pt">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 1pt">&nbsp;</td> <td style="TEXT-ALIGN: right; FONT-SIZE: 1pt">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 1pt">&nbsp;</td> <td style="FONT-SIZE: 1pt">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 1pt">&nbsp;</td> <td style="TEXT-ALIGN: right; FONT-SIZE: 1pt">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt"> Less - accumulated depreciation and amortization</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (11,148</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">)</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (14,786</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">)</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 18,271</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 16,310</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 4.3pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the useful life and salvage value of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Party Transactions</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="COLOR: blue; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="10">Year ended December 31,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt; FONT-STYLE: italic">(U.S. dollars in thousands)</td> <td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2010</td> <td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2011</td> <td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2012</td> <td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -0.25in; PADDING-LEFT: 0.5in; WIDTH: 61%"> <strong>a.</strong> Management and consulting fees to the Chairman of the Board</td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"> 6</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> &nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> &nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -0.25in; PADDING-LEFT: 0.5in"> <strong>b.</strong> Compensation to the non-executive directors (except the Chairman of the Board in 2010, and includes the interim Chairman of the Board in 2011 and 2012)</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 215</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 215</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 375</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EVIAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1">2 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2013

</div>
          <div>Option Exercise [Member]

</div>
          <div>Certain Employee [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common Stock issued in connection with exercise of options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of options</a></td>
        <td class="nump">$ 1,230<span></span></td>
        <td class="nump">$ 277<span></span></td>
        <td class="nump">$ 501<span></span></td>
        <td class="nump">$ 19<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph i<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EFSAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SHARE CAPITAL (Share Based Compensation Expense Allocation) (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
        <td class="nump">$ 7,751<span></span></td>
        <td class="nump">$ 886<span></span></td>
        <td class="nump">$ 1,282<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Cost of Revenues [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
        <td class="nump">220<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Research and Development Expense [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
        <td class="nump">4,756<span></span></td>
        <td class="nump">422<span></span></td>
        <td class="nump">630<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">General and Administrative Expense [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
        <td class="nump">$ 2,775<span></span></td>
        <td class="nump">$ 464<span></span></td>
        <td class="nump">$ 652<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph g(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6793087&amp;loc=d3e301413-122809<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EOMAI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) (USD $)<br>In Thousands, except Share data</strong></div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
        <th class="th">
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Additional Paid-in Capital [Member]</div>
        </th>
        <th class="th">
          <div>Accumulated Deficit [Member]</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2009</a></td>
        <td class="nump">$ 15,883<span></span></td>
        <td class="nump">$ 81<span></span></td>
        <td class="nump">$ 122,252<span></span></td>
        <td class="num">$ (106,450)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2009</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">80,841,237<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
        <td class="nump">1,282<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,282<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees and non-employees</a></td>
        <td class="nump">510<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">510<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">407,235<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
        <td class="num">(28,998)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(28,998)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2010</a></td>
        <td class="num">(11,323)<span></span></td>
        <td class="nump">81<span></span></td>
        <td class="nump">124,044<span></span></td>
        <td class="num">(135,448)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2010</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">81,248,472<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued for cash (net of issuance costs) (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for cash (net of issuance costs)</a></td>
        <td class="nump">20,590<span></span></td>
        <td class="nump">4<span></span></td>
        <td class="nump">20,586<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
        <td class="nump">886<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">886<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees and non-employees</a></td>
        <td class="nump">299<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="nump">298<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">381,685<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
        <td class="num">(36,529)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(36,529)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2011</a></td>
        <td class="num">(26,077)<span></span></td>
        <td class="nump">86<span></span></td>
        <td class="nump">145,814<span></span></td>
        <td class="num">(171,977)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2011</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">85,630,157<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued for cash (net of issuance costs) (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,175,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for cash (net of issuance costs)</a></td>
        <td class="nump">25,388<span></span></td>
        <td class="nump">5<span></span></td>
        <td class="nump">25,383<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
        <td class="nump">4,612<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,612<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock award, net of forfeitures</a></td>
        <td class="nump">3,139<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="nump">3,138<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock award, net of forfeitures (shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,496,792<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees and non-employees</a></td>
        <td class="nump">1,199<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="nump">1,198<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,187,860<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
        <td class="num">(11,618)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(11,618)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2012</a></td>
        <td class="num">$ (3,357)<span></span></td>
        <td class="nump">$ 93<span></span></td>
        <td class="nump">$ 180,145<span></span></td>
        <td class="num">$ (183,595)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2012</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">93,489,809<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of recognized equity-based compensation during the period for restricted stock awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6576910&amp;loc=d3e11178-113907<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A91<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6576910&amp;loc=d3e11149-113907<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 39<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued and outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A3<br><br> -Appendix A<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued as a result of the exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>NOTE 3 - PROPERTY AND EQUIPMENT</strong></p> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.5in">a.</td> <td style="FONT-WEIGHT: normal">Composition of property and equipment grouped by major classifications is as follows:</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6">December 31,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt" nowrap="nowrap"> (<em>U.S. dollars in thousands)</em></td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 70%">Laboratory equipment</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">13,079</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">14,502</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Furniture and computer equipment</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,522</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">1,818</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Leasehold improvements</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">13,705</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">14,447</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">Equipment under construction</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,113</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 329</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 7.35pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">$</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 29,419</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">$</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 31,096</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td style="FONT-SIZE: 1pt">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 1pt">&nbsp;</td> <td style="TEXT-ALIGN: right; FONT-SIZE: 1pt">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 1pt">&nbsp;</td> <td style="FONT-SIZE: 1pt">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 1pt">&nbsp;</td> <td style="TEXT-ALIGN: right; FONT-SIZE: 1pt">&nbsp;</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt"> Less - accumulated depreciation and amortization</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (11,148</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">)</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (14,786</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">)</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 18,271</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 16,310</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 4.3pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="FONT-WEIGHT: normal; WIDTH: 0.25in">b.</td> <td style="FONT-WEIGHT: normal">Depreciation and amortization in respect of property and equipment totaled approximately $3.1 million, $3.6 million and $3.7 million for the years ended December 31, 2010, 2011 and 2012, respectively, out of which the Company recorded a total write down of approximately $43,000, $10,000 and $0, respectively.</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EP3AG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NumberOfSubsidiaries', window );">Number of Subsidiaries</a></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Pfizer Agreement, upfront payment received</a></td>
        <td class="nump">$ 60,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive</a></td>
        <td class="nump">7,761,168<span></span></td>
        <td class="nump">7,469,088<span></span></td>
        <td class="nump">7,280,469<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Protalix Bio Therapeutics Incorporation [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementProfitSharePercentage', window );">Pfizer Agreement, future revenues and expense sharing percentage</a></td>
        <td class="nump">40.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Pfizer Incorporation [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementProfitSharePercentage', window );">Pfizer Agreement, future revenues and expense sharing percentage</a></td>
        <td class="nump">60.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Upon Filing of Pediatric Investigation Plan to EMA [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Pfizer Agreement, upfront payment received</a></td>
        <td class="nump">5,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Upon each FDA and European Medicine Agency approval [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MilestonePayment', window );">Milestone payment triggered</a></td>
        <td class="nump">25,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Upon FDAApproval [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MilestonePayment', window );">Milestone payment triggered</a></td>
        <td class="nump">25,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Upon Near Term Clinical Development Milestones [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MilestonePayment', window );">Milestone payment triggered</a></td>
        <td class="nump">$ 8,300<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementProfitSharePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaborative arrangement profit sharing percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_CollaborativeArrangementProfitSharePercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MilestonePayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Milestone payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_MilestonePayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NumberOfSubsidiaries">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of subsidiaries.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_NumberOfSubsidiaries</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_SignificantAccountingPoliciesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 171<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 13, 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received from collaborators during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 27<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromCollaborators</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>197</ContextCount>
  <ElementCount>227</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>75</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>006 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiency</Role>
      <ShortName>CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>007 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiencyParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>102 - Disclosure - LICENSE AND SUPPLY AGREEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/LicenseAndSupplyAgreement</Role>
      <ShortName>LICENSE AND SUPPLY AGREEMENT</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>103 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>104 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/Inventories</Role>
      <ShortName>INVENTORIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>105 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/LiabilityForEmployeeRightsUponRetirement</Role>
      <ShortName>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>106 - Disclosure - COMMITMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/Commitments</Role>
      <ShortName>COMMITMENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>107 - Disclosure - SHARE CAPITAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ShareCapital</Role>
      <ShortName>SHARE CAPITAL</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>108 - Disclosure - TAXES ON INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/TaxesOnIncome</Role>
      <ShortName>TAXES ON INCOME</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>109 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SupplementaryFinancialStatementInformation</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>110 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>111 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPoliciesPolicy</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policy)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>303 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>304 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/InventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>307 - Disclosure - SHARE CAPITAL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ShareCapitalTables</Role>
      <ShortName>SHARE CAPITAL (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>308 - Disclosure - TAXES ON INCOME (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/TaxesOnIncomeTables</Role>
      <ShortName>TAXES ON INCOME (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>309 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SupplementaryFinancialStatementInformationTables</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>310 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Useful Lives of Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPoliciesUsefulLivesOfPropertyAndEquipmentDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Useful Lives of Property and Equipment) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40201 - Disclosure - LICENSE AND SUPPLY AGREEMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/LicenseAndSupplyAgreementDetails</Role>
      <ShortName>LICENSE AND SUPPLY AGREEMENT (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40301 - Disclosure - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40401 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/InventoriesDetails</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/LiabilityForEmployeeRightsUponRetirementDetails</Role>
      <ShortName>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40601 - Disclosure - COMMITMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CommitmentsDetails</Role>
      <ShortName>COMMITMENTS (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40701 - Disclosure - SHARE CAPITAL (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ShareCapitalNarrativeDetails</Role>
      <ShortName>SHARE CAPITAL (Narrative) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40702 - Disclosure - SHARE CAPITAL (Summary of Option and Restricted Stock Granted to Employees) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ShareCapitalSummaryOfOptionAndRestrictedStockGrantedToEmployeesDetails</Role>
      <ShortName>SHARE CAPITAL (Summary of Option and Restricted Stock Granted to Employees) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40703 - Disclosure - SHARE CAPITAL (Fair Value Assumptions of Options Granted) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ShareCapitalFairValueAssumptionsOfOptionsGrantedDetails</Role>
      <ShortName>SHARE CAPITAL (Fair Value Assumptions of Options Granted) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40704 - Disclosure - SHARE CAPITAL (Options Granted to Employees) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ShareCapitalOptionsGrantedToEmployeesDetails</Role>
      <ShortName>SHARE CAPITAL (Options Granted to Employees) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40705 - Disclosure - SHARE CAPITAL (Restricted Stock Granted to Employees) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ShareCapitalRestrictedStockGrantedToEmployeesDetails</Role>
      <ShortName>SHARE CAPITAL (Restricted Stock Granted to Employees) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40706 - Disclosure - SHARE CAPITAL (Options Granted to Consultants, Directors and Other Service Providers) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ShareCapitalOptionsGrantedToConsultantsDirectorsAndOtherServiceProvidersDetails</Role>
      <ShortName>SHARE CAPITAL (Options Granted to Consultants, Directors and Other Service Providers) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40707 - Disclosure - SHARE CAPITAL (Summary of Outstanding and Restricted Stocks) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ShareCapitalSummaryOfOutstandingAndRestrictedStocksDetails</Role>
      <ShortName>SHARE CAPITAL (Summary of Outstanding and Restricted Stocks) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40708 - Disclosure - SHARE CAPITAL (Share Based Compensation Expense Allocation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/ShareCapitalShareBasedCompensationExpenseAllocationDetails</Role>
      <ShortName>SHARE CAPITAL (Share Based Compensation Expense Allocation) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40801 - Disclosure - TAXES ON INCOME (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/TaxesOnIncomeNarrativeDetails</Role>
      <ShortName>TAXES ON INCOME (Narrative) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40802 - Disclosure - TAXES ON INCOME (Deferred Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/TaxesOnIncomeDeferredIncomeTaxesDetails</Role>
      <ShortName>TAXES ON INCOME (Deferred Income Taxes) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40803 - Disclosure - TAXES ON INCOME (Open Tax Years) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/TaxesOnIncomeOpenTaxYearsDetails</Role>
      <ShortName>TAXES ON INCOME (Open Tax Years) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40901 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Receivable, Other) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SupplementaryFinancialStatementInformationAccountsReceivableOtherDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Receivable, Other) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40902 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals, Other) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals, Other) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40903 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Revenues) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SupplementaryFinancialStatementInformationRevenuesDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Revenues) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>41001 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41101 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element us-gaap_CommonStockSharesIssued had a mix of decimals attribute values: -3 0.</Log>
    <Log type="Info">Element us-gaap_SaleOfStockPricePerShare had a mix of decimals attribute values: 1 2.</Log>
    <Log type="Info">Element us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit had a mix of decimals attribute values: 1 2 3.</Log>
    <Log type="Info">Process Flow-Through: 002 - Statement - CONSOLIDATED BALANCE SHEETS</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2010'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2009'</Log>
    <Log type="Info">Process Flow-Through: 003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Feb. 22, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 23, 2011'</Log>
    <Log type="Info">Process Flow-Through: 004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</Log>
    <Log type="Info">Process Flow-Through: 007 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</Log>
  </Logs>
  <InputFiles>
    <File>plx-20121231.xml</File>
    <File>plx-20121231.xsd</File>
    <File>plx-20121231_cal.xml</File>
    <File>plx-20121231_def.xml</File>
    <File>plx-20121231_lab.xml</File>
    <File>plx-20121231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EZKAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SHARE CAPITAL (Restricted Stock Granted to Employees) (Details)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
        <td class="nump">3,208<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Restricted Stock [Member] | Employees [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
        <td class="nump">1,500,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
        <td class="nump">3,208<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance</a></td>
        <td class="nump">1,496,792<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable', window );">Exercisable at end of year</a></td>
        <td class="nump">102,084<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(2)(e)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(2)(c)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(2)(b)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(2)(a)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ScheduleOfUsefulLifeTableTextBlock', window );">Schedule of Useful Life</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="WIDTH: 65%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.9in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Years</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 85%">Laboratory equipment</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">5</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td>Furniture</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">10-15</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Computer equipment</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">3</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 98.65pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ScheduleOfUsefulLifeTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Schedule Of Useful Life Table Text Block</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ScheduleOfUsefulLifeTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
